[
  {
    "id": 0,
    "text": "复盘 2021年以来 CXO板块走势（以 CRO指数（8841421.WI）来代表），自 2021年 10月开始板块进入下行周期，其最初的导火索源自于投融资数据月度间波动，此后行业因素和估值成为持续扰动 CXO板块的重要因素。当前，我们认为 CXO板块的压制因素正在边际缓和。基于当前旺盛的订单需求，产能快速扩张的趋势，CXO仍是医药板块中具备高业绩确定性和成长性的赛道。",
    "labels": [
      [
        "T0",
        "行业需求",
        147,
        149,
        "需求"
      ],
      [
        "T1",
        "时间范围",
        3,
        10,
        "2021年以来"
      ],
      [
        "T2",
        "行业",
        11,
        14,
        "CXO"
      ],
      [
        "T3",
        "时间范围",
        43,
        56,
        "自 2021年 10月开始"
      ],
      [
        "T4",
        "行业",
        102,
        105,
        "CXO"
      ],
      [
        "T5",
        "行业",
        121,
        124,
        "CXO"
      ],
      [
        "T6",
        "产能",
        150,
        152,
        "产能"
      ],
      [
        "T7",
        "行业",
        160,
        163,
        "CXO"
      ],
      [
        "T8",
        "投融资情况",
        75,
        80,
        "投融资数据"
      ],
      [
        "T9",
        "时间范围",
        113,
        115,
        "当前"
      ],
      [
        "T10",
        "属性值",
        142,
        144,
        "旺盛"
      ],
      [
        "T11",
        "时间范围",
        140,
        142,
        "当前"
      ],
      [
        "T12",
        "属性值",
        152,
        156,
        "快速扩张"
      ],
      [
        "T13",
        "属性值",
        172,
        182,
        "高业绩确定性和成长性"
      ],
      [
        "T14",
        "行业",
        165,
        167,
        "医药"
      ]
    ]
  },
  {
    "id": 1,
    "text": "再聚焦于投融资数据，根据动脉网数据，2013-2018年全球医疗健康产业投融资数据呈现较快增长趋势，流动性收紧并未对其增长趋势带来太大扰动。分析其原因，我们认为这可能源于流动性收紧更多是调控市场的手段，影响投融资数据的核心是经济状态。回顾来看，2015和 2018年美国经济都处于扩张期的顶端， 2015年和 2018年是 2008年金融危机之后以及 2020年新冠疫情之前，美国经济增长排名前二的年份，分别为 2.7%和 2.9%。因此，在当前疫情复苏的大环境下，2022全球医疗健康领域投融资数据的增长趋势虽然仍有待观察，但不必过度悲观。并且，对于 biotech来说，获得融资后尽快投入研发是其保证自身发展的主要动力，因此即使短期投融数据出现一定程度的波动，对 CXO行业景气度请务必阅读正文之后的信息披露和重要声明",
    "labels": [
      [
        "T0",
        "投融资情况",
        36,
        41,
        "投融资数据"
      ],
      [
        "T1",
        "时间范围",
        18,
        28,
        "2013-2018年"
      ],
      [
        "T2",
        "地点范围",
        28,
        30,
        "全球"
      ],
      [
        "T3",
        "行业",
        30,
        34,
        "医疗健康"
      ],
      [
        "T4",
        "属性值",
        43,
        47,
        "较快增长"
      ],
      [
        "T5",
        "投融资情况",
        4,
        9,
        "投融资数据"
      ],
      [
        "T6",
        "时间范围",
        148,
        153,
        "2015年"
      ],
      [
        "T7",
        "时间范围",
        155,
        160,
        "2018年"
      ],
      [
        "T8",
        "投融资情况",
        103,
        108,
        "投融资数据"
      ],
      [
        "T9",
        "时间范围",
        122,
        126,
        "2015"
      ],
      [
        "T10",
        "时间范围",
        128,
        133,
        "2018年"
      ],
      [
        "T11",
        "时间范围",
        233,
        237,
        "2022"
      ],
      [
        "T12",
        "地点范围",
        237,
        239,
        "全球"
      ],
      [
        "T13",
        "行业",
        239,
        243,
        "医疗健康"
      ],
      [
        "T14",
        "投融资情况",
        245,
        250,
        "投融资数据"
      ],
      [
        "T15",
        "行业",
        277,
        284,
        "biotech"
      ],
      [
        "T16",
        "行业",
        334,
        337,
        "CXO"
      ],
      [
        "T17",
        "时间范围",
        162,
        173,
        "2008年金融危机之后"
      ],
      [
        "T18",
        "时间范围",
        176,
        187,
        "2020年新冠疫情之前"
      ],
      [
        "T19",
        "属性值",
        258,
        270,
        "有待观察，但不必过度悲观"
      ],
      [
        "T20",
        "投融资情况",
        318,
        322,
        "投融数据"
      ],
      [
        "T21",
        "地点范围",
        133,
        135,
        "美国"
      ],
      [
        "T22",
        "地点范围",
        188,
        190,
        "美国"
      ],
      [
        "T23",
        "时间范围",
        221,
        223,
        "当前"
      ]
    ]
  },
  {
    "id": 2,
    "text": "1970年代-1980年代初，当代定义的 CRO行业初具雏形。这一阶段美国卫生支出持续较快增长，推动新药研发需求的持续上行。而随之而来的是药物研发竞争的加剧，对新药研发的质量和效率要求不断提高，为 CRO行业的诞生和发展提供土壤。1980年代-1990年代初，CRO行业处于成长初期阶段，彼时 CRO主要作用是填补药企在内部研发产能饱和时承接外溢出来的研发需求，是一个补位者的角色，其订单需求存在较大的不确定性。这一阶段 CRO公司主要承接非核心研发项目，但随着研发外包趋势的提升，CRO的角色正逐渐转变，药企也开始重视 CRO的作用，可以将新药研发成本由永久性内部资源成本转变成由需求驱动的临时可变成本。这一时期，昆泰、PPD等 CRO龙头陆续成立，CRO企业的业务类型由临床前服务延伸到临床服务。",
    "labels": [
      [
        "T0",
        "行业公司",
        157,
        159,
        "药企"
      ],
      [
        "T1",
        "公司",
        308,
        310,
        "昆泰"
      ],
      [
        "T2",
        "公司",
        311,
        314,
        "PPD"
      ],
      [
        "T3",
        "行业",
        316,
        319,
        "CRO"
      ],
      [
        "T4",
        "龙头企业",
        319,
        321,
        "龙头"
      ],
      [
        "T5",
        "时间范围",
        0,
        14,
        "1970年代-1980年代初"
      ],
      [
        "T6",
        "行业",
        21,
        24,
        "CRO"
      ],
      [
        "T7",
        "行业",
        99,
        102,
        "CRO"
      ],
      [
        "T8",
        "时间范围",
        115,
        129,
        "1980年代-1990年代初"
      ],
      [
        "T9",
        "行业",
        130,
        133,
        "CRO"
      ],
      [
        "T10",
        "行业公司",
        253,
        255,
        "药企"
      ],
      [
        "T11",
        "行业",
        69,
        73,
        "药物研发"
      ],
      [
        "T12",
        "竞争格局",
        73,
        75,
        "竞争"
      ],
      [
        "T13",
        "属性值",
        76,
        78,
        "加剧"
      ],
      [
        "T14",
        "行业",
        50,
        54,
        "新药研发"
      ],
      [
        "T15",
        "行业需求",
        54,
        56,
        "需求"
      ],
      [
        "T16",
        "属性值",
        57,
        61,
        "持续上行"
      ],
      [
        "T17",
        "行业",
        147,
        150,
        "CRO"
      ],
      [
        "T18",
        "行业需求",
        194,
        196,
        "需求"
      ],
      [
        "T19",
        "属性值",
        196,
        205,
        "存在较大的不确定性"
      ],
      [
        "T20",
        "行业公司",
        211,
        216,
        "CRO公司"
      ],
      [
        "T21",
        "行业",
        241,
        244,
        "CRO"
      ],
      [
        "T22",
        "行业",
        261,
        264,
        "CRO"
      ],
      [
        "T23",
        "行业公司",
        326,
        331,
        "CRO企业"
      ],
      [
        "T24",
        "属性值",
        336,
        349,
        "由临床前服务延伸到临床服务"
      ],
      [
        "T25",
        "地点范围",
        35,
        37,
        "美国"
      ]
    ]
  },
  {
    "id": 3,
    "text": "以 Charles River员工数及 Lonza固定资产增长率为例来分析海外 CXO公司的产能情况，可以看到 2015年后两家公司加快产能投入，反映出全球 CXO行业处在较好的景气度。但其增速和稳定性远不及国内 CXO公司，间接体现出基于海外订单往中国转移趋势，国内 CXO行业拥有更高的景气度。同时，从人效指标来看，以 Charles River人均收入为例，可以看到仍有提升的空间。",
    "labels": [
      [
        "T0",
        "公司",
        2,
        15,
        "Charles River"
      ],
      [
        "T1",
        "公司",
        20,
        25,
        "Lonza"
      ],
      [
        "T2",
        "地点范围",
        37,
        39,
        "海外"
      ],
      [
        "T3",
        "时间范围",
        56,
        62,
        "2015年后"
      ],
      [
        "T4",
        "行业",
        79,
        82,
        "CXO"
      ],
      [
        "T5",
        "地点范围",
        76,
        78,
        "全球"
      ],
      [
        "T6",
        "地点范围",
        104,
        106,
        "国内"
      ],
      [
        "T7",
        "公司",
        162,
        175,
        "Charles River"
      ],
      [
        "T8",
        "人均收入",
        175,
        179,
        "人均收入"
      ],
      [
        "T9",
        "固定资产",
        25,
        29,
        "固定资产"
      ],
      [
        "T10",
        "产能",
        46,
        48,
        "产能"
      ],
      [
        "T11",
        "行业公司",
        40,
        45,
        "CXO公司"
      ],
      [
        "T12",
        "员工数量",
        15,
        18,
        "员工数"
      ],
      [
        "T13",
        "产能",
        68,
        70,
        "产能"
      ],
      [
        "T14",
        "行业公司",
        107,
        112,
        "CXO公司"
      ],
      [
        "T15",
        "地点范围",
        132,
        134,
        "国内"
      ],
      [
        "T16",
        "行业",
        135,
        138,
        "CXO"
      ],
      [
        "T17",
        "属性值",
        120,
        129,
        "海外订单往中国转移"
      ],
      [
        "T18",
        "行业趋势",
        129,
        131,
        "趋势"
      ],
      [
        "T19",
        "属性值",
        187,
        193,
        "有提升的空间"
      ]
    ]
  },
  {
    "id": 4,
    "text": "这一轮上行周期结束时点基本在 2021Q3末左右，此后海外 CXO板块和国内 CXO板块纷纷进入下行周期。分析来看，我们认为海外和国内 CXO板块的下行在逻辑上存在一定的差异。海外头部 CXO公司股价的下行，我们认为一方面源于疫情进入复苏阶段后部分公司业绩增速开始有所回落（季度业绩数据变化）； 另一方面，流动性收紧悲观预期、全球地缘政治局势变化等因素影响纳斯达克指数，纳斯达克指数整体趋势向下，而可以看到图 24中所列举海外 CXO头部公司走势整体与纳斯达克指数趋同。反观国内 CXO板块，其下行主要源于行业因素和板块估值等因素，业绩、订单等经营层面数据仍保持较好的增长趋势。",
    "labels": [
      [
        "T0",
        "时间范围",
        15,
        22,
        "2021Q3末"
      ],
      [
        "T1",
        "地点范围",
        27,
        29,
        "海外"
      ],
      [
        "T2",
        "行业",
        30,
        33,
        "CXO"
      ],
      [
        "T3",
        "地点范围",
        36,
        38,
        "国内"
      ],
      [
        "T4",
        "行业",
        39,
        42,
        "CXO"
      ],
      [
        "T5",
        "地点范围",
        62,
        64,
        "海外"
      ],
      [
        "T6",
        "地点范围",
        65,
        67,
        "国内"
      ],
      [
        "T7",
        "地点范围",
        88,
        90,
        "海外"
      ],
      [
        "T8",
        "龙头企业",
        90,
        92,
        "头部"
      ],
      [
        "T9",
        "属性值",
        128,
        136,
        "增速开始有所回落"
      ],
      [
        "T10",
        "业绩",
        126,
        128,
        "业绩"
      ],
      [
        "T11",
        "行业",
        68,
        71,
        "CXO"
      ],
      [
        "T12",
        "行业公司",
        93,
        98,
        "CXO公司"
      ],
      [
        "T13",
        "业绩",
        139,
        141,
        "业绩"
      ],
      [
        "T14",
        "地点范围",
        163,
        165,
        "全球"
      ],
      [
        "T15",
        "地点范围",
        211,
        213,
        "海外"
      ],
      [
        "T16",
        "行业公司",
        214,
        221,
        "CXO头部公司"
      ],
      [
        "T17",
        "地点范围",
        237,
        239,
        "国内"
      ],
      [
        "T18",
        "行业",
        240,
        243,
        "CXO"
      ],
      [
        "T19",
        "业绩",
        266,
        268,
        "业绩"
      ],
      [
        "T20",
        "在手订单",
        269,
        271,
        "订单"
      ],
      [
        "T21",
        "属性值",
        279,
        288,
        "保持较好的增长趋势"
      ],
      [
        "T22",
        "属性值",
        44,
        52,
        "纷纷进入下行周期"
      ]
    ]
  },
  {
    "id": 5,
    "text": "但如果从销售额角度分析，当前我国小分子 CDMO行业占全球市场份额相对不高。基于沙利文的全球小分子 CDMO市场规模和中国小分子 CDMO市场规模， 估计 2021年中国小分子 CDMO行业的全球市占率约为 11.3%。从全球创新药市场规模来测算，根据沙利文数据 2021年全球创新药市场规模为 9787亿美元，假设其中小分子药物占比为 70%；假设 CDMO占比创新药销售收入的 15%；假设当前 CDMO的渗透率为 45%，则计算得到全球小分子 CDMO市场规模约为 462 亿美元。对比沙利文 2021年中国小分子 CDMO市场规模，估计 2021年中国小分子 CDMO的全球市占率约为 10.3%。",
    "labels": [
      [
        "T0",
        "行业",
        16,
        24,
        "小分子 CDMO"
      ],
      [
        "T1",
        "地点范围",
        14,
        16,
        "我国"
      ],
      [
        "T2",
        "地点范围",
        27,
        29,
        "全球"
      ],
      [
        "T3",
        "市场份额",
        29,
        33,
        "市场份额"
      ],
      [
        "T4",
        "属性值",
        33,
        37,
        "相对不高"
      ],
      [
        "T5",
        "地点范围",
        44,
        46,
        "全球"
      ],
      [
        "T6",
        "行业",
        46,
        54,
        "小分子 CDMO"
      ],
      [
        "T7",
        "市场规模",
        54,
        58,
        "市场规模"
      ],
      [
        "T8",
        "地点范围",
        59,
        61,
        "中国"
      ],
      [
        "T9",
        "行业",
        61,
        69,
        "小分子 CDMO"
      ],
      [
        "T10",
        "市场规模",
        69,
        73,
        "市场规模"
      ],
      [
        "T11",
        "时间范围",
        78,
        83,
        "2021年"
      ],
      [
        "T12",
        "地点范围",
        83,
        85,
        "中国"
      ],
      [
        "T13",
        "行业",
        85,
        93,
        "小分子 CDMO"
      ],
      [
        "T14",
        "地点范围",
        96,
        98,
        "全球"
      ],
      [
        "T15",
        "属性值",
        104,
        109,
        "11.3%"
      ],
      [
        "T16",
        "地点范围",
        111,
        113,
        "全球"
      ],
      [
        "T17",
        "行业",
        113,
        116,
        "创新药"
      ],
      [
        "T18",
        "市场规模",
        116,
        120,
        "市场规模"
      ],
      [
        "T19",
        "时间范围",
        132,
        137,
        "2021年"
      ],
      [
        "T20",
        "地点范围",
        137,
        139,
        "全球"
      ],
      [
        "T21",
        "行业",
        139,
        142,
        "创新药"
      ],
      [
        "T22",
        "市场规模",
        142,
        146,
        "市场规模"
      ],
      [
        "T23",
        "属性值",
        148,
        155,
        "9787亿美元"
      ],
      [
        "T24",
        "地点范围",
        219,
        221,
        "全球"
      ],
      [
        "T25",
        "行业",
        221,
        229,
        "小分子 CDMO"
      ],
      [
        "T26",
        "市场规模",
        229,
        233,
        "市场规模"
      ],
      [
        "T27",
        "地点范围",
        255,
        257,
        "中国"
      ],
      [
        "T28",
        "行业",
        257,
        265,
        "小分子 CDMO"
      ],
      [
        "T29",
        "市场规模",
        265,
        269,
        "市场规模"
      ],
      [
        "T30",
        "时间范围",
        273,
        278,
        "2021年"
      ],
      [
        "T31",
        "地点范围",
        278,
        280,
        "中国"
      ],
      [
        "T32",
        "行业",
        280,
        288,
        "小分子 CDMO"
      ],
      [
        "T33",
        "地点范围",
        289,
        291,
        "全球"
      ],
      [
        "T34",
        "市场份额",
        291,
        294,
        "市占率"
      ],
      [
        "T35",
        "时间范围",
        12,
        14,
        "当前"
      ],
      [
        "T36",
        "市场份额",
        98,
        101,
        "市占率"
      ],
      [
        "T37",
        "行业",
        160,
        165,
        "小分子药物"
      ],
      [
        "T38",
        "行业",
        176,
        180,
        "CDMO"
      ],
      [
        "T39",
        "时间范围",
        197,
        199,
        "当前"
      ],
      [
        "T40",
        "行业",
        200,
        204,
        "CDMO"
      ],
      [
        "T41",
        "时间范围",
        250,
        255,
        "2021年"
      ],
      [
        "T42",
        "属性值",
        294,
        302,
        "约为 10.3%"
      ],
      [
        "T43",
        "行业",
        182,
        185,
        "创新药"
      ],
      [
        "T44",
        "营业收入",
        187,
        189,
        "收入"
      ],
      [
        "T45",
        "属性值",
        233,
        243,
        "约为 462 亿美元"
      ]
    ]
  },
  {
    "id": 6,
    "text": "同时，行业因素和估值等是前期扰动 CXO板块的重要因素，当前我们认为其对板块的压制正在边际缓和。一方面，复盘海外市场来看，我们认为海外流动性收紧（联储收紧）对全球投融资数据、CXO公司业绩及股价表现并不会产生太强的负面影响。另一方面，从估值角度来看，随着前期板块下跌消化估值溢价，当前 CXO板块估值处在相对低位水平。此外，虽然短期新冠小分子药物重磅订单催化我国小分子 CDMO行业产能快速释放，但根据我们分析和测算行业需求后续仍有较大提升空间，且全球订单向中国转移和集中的趋势可持续。",
    "labels": [
      [
        "T0",
        "投融资情况",
        81,
        86,
        "投融资数据"
      ],
      [
        "T1",
        "地点范围",
        79,
        81,
        "全球"
      ],
      [
        "T2",
        "行业公司",
        87,
        92,
        "CXO公司"
      ],
      [
        "T3",
        "业绩",
        92,
        94,
        "业绩"
      ],
      [
        "T4",
        "产能",
        191,
        193,
        "产能"
      ],
      [
        "T5",
        "属性值",
        193,
        197,
        "快速释放"
      ],
      [
        "T6",
        "地点范围",
        179,
        181,
        "我国"
      ],
      [
        "T7",
        "行业",
        181,
        189,
        "小分子 CDMO"
      ],
      [
        "T8",
        "行业",
        17,
        20,
        "CXO"
      ],
      [
        "T9",
        "地点范围",
        54,
        56,
        "海外"
      ],
      [
        "T10",
        "地点范围",
        65,
        67,
        "海外"
      ],
      [
        "T11",
        "行业",
        143,
        146,
        "CXO"
      ],
      [
        "T12",
        "时间范围",
        164,
        166,
        "短期"
      ],
      [
        "T13",
        "属性值",
        215,
        222,
        "有较大提升空间"
      ],
      [
        "T14",
        "行业需求",
        208,
        212,
        "行业需求"
      ],
      [
        "T15",
        "属性值",
        224,
        236,
        "全球订单向中国转移和集中"
      ]
    ]
  },
  {
    "id": 7,
    "text": "CRO/CDMO公司的业务为订单驱动型，若客户订单发生非常大的变化或订单结构出现较大变化，可能会对相关公司的业绩产生影响。",
    "labels": [
      [
        "T0",
        "行业公司",
        0,
        10,
        "CRO/CDMO公司"
      ],
      [
        "T1",
        "业绩",
        54,
        56,
        "业绩"
      ]
    ]
  },
  {
    "id": 8,
    "text": "根据辉瑞 Paxlovid 的临床数据， 新冠口服特效药能够大幅降低住院率及死亡率， 同时具备成本低、临床可及性高等优点，在新冠病毒或与人类共存的大趋势下有望成为大单品。例如，2021 年 11 月，辉瑞发布公告称已经与美国政府签订了采购订单，美国政府将采购 1000 万个疗程、共计 52.9 亿美元的 Paxlovid。 生产环节借助 CDMO 供应商的力量，有利于保障药品大规模商业化阶段的稳定供应。国内 CXO 企业凭借工艺开发、稳定供应的优势，整体在新冠小分子药 CDMO 领域的全球市占率较高。例如，凯莱英在疫情期间承担两个小分子抗病毒创新药物研发生产工作， 11 月 16 日公告与美国某大型药企签订价值 4.8 亿美元的供货合同， 11 月 28 日公告子公司吉林凯莱英新签订约 27.20 亿人民币的供货合同。",
    "labels": [
      [
        "T0",
        "公司",
        2,
        4,
        "辉瑞"
      ],
      [
        "T1",
        "时间范围",
        88,
        99,
        "2021 年 11 月"
      ],
      [
        "T2",
        "公司",
        100,
        102,
        "辉瑞"
      ],
      [
        "T3",
        "地点范围",
        203,
        205,
        "国内"
      ],
      [
        "T4",
        "行业公司",
        206,
        212,
        "CXO 企业"
      ],
      [
        "T5",
        "行业",
        230,
        241,
        "新冠小分子药 CDMO"
      ],
      [
        "T6",
        "地点范围",
        245,
        247,
        "全球"
      ],
      [
        "T7",
        "市场份额",
        247,
        250,
        "市占率"
      ],
      [
        "T8",
        "属性值",
        250,
        252,
        "较高"
      ],
      [
        "T9",
        "公司",
        256,
        259,
        "凯莱英"
      ],
      [
        "T10",
        "时间范围",
        286,
        295,
        "11 月 16 日"
      ],
      [
        "T11",
        "属性值",
        310,
        317,
        "4.8 亿美元"
      ],
      [
        "T12",
        "时间范围",
        324,
        333,
        "11 月 28 日"
      ],
      [
        "T13",
        "公司",
        338,
        343,
        "吉林凯莱英"
      ],
      [
        "T14",
        "属性值",
        348,
        358,
        "27.20 亿人民币"
      ],
      [
        "T15",
        "地点范围",
        122,
        124,
        "美国"
      ],
      [
        "T16",
        "地点范围",
        110,
        112,
        "美国"
      ],
      [
        "T17",
        "行业公司",
        170,
        178,
        "CDMO 供应商"
      ],
      [
        "T18",
        "地点范围",
        298,
        300,
        "美国"
      ],
      [
        "T19",
        "行业公司",
        303,
        305,
        "药企"
      ]
    ]
  },
  {
    "id": 9,
    "text": "公司服务主要包括：1）自体和异体细胞疗法生产服务；2）用于基因治疗的病毒载体生产（拥有最高 250L 病毒载体生产）；3）其他技术，如 CRISPR/Cas9、 溶瘤病毒、NK 和外泌体。公司在中国地区主要提供质粒及病毒 CDMO 服务，在美国地区主要提供病毒及细胞 CDMO 服务。",
    "labels": [
      [
        "T0",
        "地点范围",
        97,
        101,
        "中国地区"
      ],
      [
        "T1",
        "地点范围",
        120,
        124,
        "美国地区"
      ]
    ]
  },
  {
    "id": 10,
    "text": "CGT 前景巨大，市场规模高速增长。以上多重因素，将催使全球及我国 CGT 市场快速增长。根据弗若斯特沙利文的统计，2016-2020 年，全球 CGT 市场规模从 0.5 亿美元增长至 20.8 亿美元，CAGR 达到 154%；2025 年，全球 CGT 市场规模预计将突破 300 亿美元，2020-2025E 的 CAGR 将达到 71%。中国市场虽起步晚，但后续势头强劲。2016-2020 年，中国 CGT 市场规模从 0.02 亿美元增长至 0.03 亿美元，CAGR 为 12%。到 2025 年，中国 CGT 市场规模预计将飞速发展至 25.9 亿美元，2020-2025E 年的 CAGR 将达到惊人的 287%。",
    "labels": [
      [
        "T0",
        "地点范围",
        31,
        33,
        "我国"
      ],
      [
        "T1",
        "行业",
        34,
        37,
        "CGT"
      ],
      [
        "T2",
        "属性值",
        40,
        44,
        "快速增长"
      ],
      [
        "T3",
        "地点范围",
        70,
        72,
        "全球"
      ],
      [
        "T4",
        "行业",
        73,
        76,
        "CGT"
      ],
      [
        "T5",
        "市场规模",
        77,
        81,
        "市场规模"
      ],
      [
        "T6",
        "CAGR",
        103,
        107,
        "CAGR"
      ],
      [
        "T7",
        "属性值",
        111,
        115,
        "154%"
      ],
      [
        "T8",
        "时间范围",
        116,
        122,
        "2025 年"
      ],
      [
        "T9",
        "地点范围",
        123,
        125,
        "全球"
      ],
      [
        "T10",
        "行业",
        126,
        129,
        "CGT"
      ],
      [
        "T11",
        "市场规模",
        130,
        134,
        "市场规模"
      ],
      [
        "T12",
        "属性值",
        137,
        147,
        "突破 300 亿美元"
      ],
      [
        "T13",
        "时间范围",
        148,
        158,
        "2020-2025E"
      ],
      [
        "T14",
        "CAGR",
        161,
        165,
        "CAGR"
      ],
      [
        "T15",
        "属性值",
        170,
        173,
        "71%"
      ],
      [
        "T16",
        "时间范围",
        191,
        202,
        "2016-2020 年"
      ],
      [
        "T17",
        "地点范围",
        203,
        205,
        "中国"
      ],
      [
        "T18",
        "行业",
        206,
        209,
        "CGT"
      ],
      [
        "T19",
        "市场规模",
        210,
        214,
        "市场规模"
      ],
      [
        "T20",
        "CAGR",
        237,
        241,
        "CAGR"
      ],
      [
        "T21",
        "属性值",
        244,
        247,
        "12%"
      ],
      [
        "T22",
        "时间范围",
        248,
        256,
        "到 2025 年"
      ],
      [
        "T23",
        "行业",
        260,
        263,
        "CGT"
      ],
      [
        "T24",
        "市场规模",
        264,
        268,
        "市场规模"
      ],
      [
        "T25",
        "地点范围",
        257,
        259,
        "中国"
      ],
      [
        "T26",
        "属性值",
        277,
        285,
        "25.9 亿美元"
      ],
      [
        "T27",
        "时间范围",
        286,
        298,
        "2020-2025E 年"
      ],
      [
        "T28",
        "属性值",
        312,
        316,
        "287%"
      ],
      [
        "T29",
        "行业",
        0,
        3,
        "CGT"
      ],
      [
        "T30",
        "属性值",
        13,
        17,
        "高速增长"
      ],
      [
        "T31",
        "市场规模",
        9,
        13,
        "市场规模"
      ],
      [
        "T32",
        "地点范围",
        28,
        30,
        "全球"
      ],
      [
        "T33",
        "地点范围",
        174,
        176,
        "中国"
      ],
      [
        "T34",
        "属性值",
        214,
        236,
        "从 0.02 亿美元增长至 0.03 亿美元"
      ],
      [
        "T35",
        "CAGR",
        300,
        304,
        "CAGR"
      ],
      [
        "T36",
        "属性值",
        83,
        90,
        "0.5 亿美元"
      ],
      [
        "T37",
        "属性值",
        94,
        102,
        "20.8 亿美元"
      ],
      [
        "T38",
        "时间范围",
        58,
        62,
        "2016"
      ],
      [
        "T39",
        "时间范围",
        63,
        69,
        "2020 年"
      ],
      [
        "T40",
        "时间连接词",
        62,
        63,
        "-"
      ]
    ]
  },
  {
    "id": 11,
    "text": "中国药物研发支出增速高于全球平均，药物发现有望爆发。2019年中国药物研发开支约 211亿美元，同比增长 21.3%，占全球比重为 11.6%。过去五年年复合增长率为 19.1%，未来五年有望维持 17.7%的复合增长率，高于全球平均水",
    "labels": [
      [
        "T0",
        "地点范围",
        0,
        2,
        "中国"
      ],
      [
        "T1",
        "属性值",
        8,
        16,
        "增速高于全球平均"
      ],
      [
        "T2",
        "时间范围",
        26,
        31,
        "2019年"
      ],
      [
        "T3",
        "地点范围",
        31,
        33,
        "中国"
      ],
      [
        "T4",
        "研发费用",
        4,
        8,
        "研发支出"
      ],
      [
        "T5",
        "行业",
        2,
        4,
        "药物"
      ],
      [
        "T6",
        "研发费用",
        35,
        39,
        "研发开支"
      ],
      [
        "T7",
        "行业",
        33,
        35,
        "药物"
      ],
      [
        "T8",
        "时间范围",
        72,
        76,
        "过去五年"
      ],
      [
        "T9",
        "CAGR",
        76,
        82,
        "年复合增长率"
      ],
      [
        "T10",
        "属性值",
        84,
        89,
        "19.1%"
      ],
      [
        "T11",
        "时间范围",
        90,
        94,
        "未来五年"
      ],
      [
        "T12",
        "属性值",
        99,
        104,
        "17.7%"
      ],
      [
        "T13",
        "CAGR",
        105,
        110,
        "复合增长率"
      ],
      [
        "T14",
        "地点范围",
        113,
        115,
        "全球"
      ],
      [
        "T15",
        "地点范围",
        60,
        62,
        "全球"
      ],
      [
        "T16",
        "行业",
        17,
        21,
        "药物发现"
      ],
      [
        "T17",
        "属性值",
        39,
        58,
        "约 211亿美元，同比增长 21.3%"
      ]
    ]
  },
  {
    "id": 12,
    "text": "我国 CAR-T 产品尽管未进入医保，但已有多地政府推出惠民保，可一定程度缓解患者经济负担。部分商业保险也已可报销 CAR-T 治疗费用，且保费低廉。此外公司也与医院积极协商，考虑分期付款等方式，提高患者支付意愿。随着支付体系的进一步成熟，CGT 药物对患者经济负担将会减小，从而促进患者使用意愿，推动 CGT 商业化进一步成熟。",
    "labels": [
      [
        "T0",
        "地点范围",
        0,
        2,
        "我国"
      ],
      [
        "T1",
        "行业",
        152,
        155,
        "CGT"
      ]
    ]
  },
  {
    "id": 14,
    "text": "亿元，同比增长 41.42%。 CRO业务收入 5.64亿元 (其中 J-STAR团队收入 2.13亿元， 中国团队收入 3.51亿元)，同比增长 14.90%。",
    "labels": [
      [
        "T0",
        "行业",
        16,
        19,
        "CRO"
      ],
      [
        "T1",
        "营业收入",
        21,
        23,
        "收入"
      ],
      [
        "T2",
        "营业收入",
        43,
        45,
        "收入"
      ],
      [
        "T3",
        "营业收入",
        58,
        60,
        "收入"
      ],
      [
        "T4",
        "地点范围",
        54,
        56,
        "中国"
      ]
    ]
  },
  {
    "id": 15,
    "text": "口药物发现CRO行业飞速发展，2019年全球药物发现CRO的市场规模为129亿美元，近五年年复合增速为10.8%，略高于CRO行业整体增速9%。中国药物发现CRO市场规模14亿美元，近五年年复合增速为33.4%，已进入高速发展时期。2018年药物发现阶段CR4是25.3%，其中中国企业药明康德和康龙化成分别排第2、3位，已经占据龙头地位",
    "labels": [
      [
        "T0",
        "时间范围",
        15,
        20,
        "2019年"
      ],
      [
        "T1",
        "地点范围",
        20,
        22,
        "全球"
      ],
      [
        "T2",
        "行业",
        22,
        29,
        "药物发现CRO"
      ],
      [
        "T3",
        "市场规模",
        30,
        34,
        "市场规模"
      ],
      [
        "T4",
        "属性值",
        35,
        41,
        "129亿美元"
      ],
      [
        "T5",
        "属性值",
        51,
        56,
        "10.8%"
      ],
      [
        "T6",
        "时间范围",
        42,
        45,
        "近五年"
      ],
      [
        "T7",
        "属性值",
        69,
        71,
        "9%"
      ],
      [
        "T8",
        "地点范围",
        72,
        74,
        "中国"
      ],
      [
        "T9",
        "地点范围",
        139,
        141,
        "中国"
      ],
      [
        "T10",
        "行业",
        74,
        81,
        "药物发现CRO"
      ],
      [
        "T11",
        "公司",
        143,
        147,
        "药明康德"
      ],
      [
        "T12",
        "公司",
        148,
        152,
        "康龙化成"
      ],
      [
        "T13",
        "属性值",
        100,
        105,
        "33.4%"
      ],
      [
        "T14",
        "属性值",
        85,
        90,
        "14亿美元"
      ],
      [
        "T15",
        "市场规模",
        81,
        85,
        "市场规模"
      ],
      [
        "T16",
        "时间范围",
        91,
        94,
        "近五年"
      ],
      [
        "T17",
        "时间范围",
        116,
        121,
        "2018年"
      ],
      [
        "T18",
        "行业",
        1,
        8,
        "药物发现CRO"
      ],
      [
        "T19",
        "CAGR",
        45,
        50,
        "年复合增速"
      ],
      [
        "T20",
        "行业",
        60,
        63,
        "CRO"
      ],
      [
        "T21",
        "CAGR",
        94,
        99,
        "年复合增速"
      ],
      [
        "T22",
        "龙头企业",
        165,
        167,
        "龙头"
      ],
      [
        "T23",
        "行业",
        121,
        125,
        "药物发现"
      ]
    ]
  },
  {
    "id": 16,
    "text": "公司投资评级： 买入：预期未来 6个月个股涨跌幅相对大盘在 15%以上； 增持：预期未来 6个月个股涨跌幅相对大盘介于 5%与 15%之间； 中性：预期未来 6个月个股涨跌幅相对大盘介于-5%与 5%之间； 减持：预期未来 6个月个股涨跌幅相对大盘介于-15%与-5%之间； 卖出：预期未来 6个月个股涨跌幅相对大盘在-15%以下。 行业投资评级： 增持：预期未来 6个月内，行业指数相对强于大盘 5%以上； 中性：预期未来 6个月内，行业指数相对大盘-5%与 5%； 减持：预期未来 6个月内，行业指数相对弱于大盘 5%以上。",
    "labels": [
      [
        "T0",
        "时间范围",
        13,
        19,
        "未来 6个月"
      ],
      [
        "T1",
        "时间范围",
        42,
        48,
        "未来 6个月"
      ],
      [
        "T2",
        "时间范围",
        76,
        82,
        "未来 6个月"
      ],
      [
        "T3",
        "时间范围",
        109,
        115,
        "未来 6个月"
      ],
      [
        "T4",
        "时间范围",
        143,
        149,
        "未来 6个月"
      ],
      [
        "T5",
        "时间范围",
        180,
        187,
        "未来 6个月内"
      ],
      [
        "T6",
        "时间范围",
        210,
        217,
        "未来 6个月内"
      ],
      [
        "T7",
        "时间范围",
        240,
        247,
        "未来 6个月内"
      ]
    ]
  },
  {
    "id": 17,
    "text": " 2020年年报：全年实现营业收入、归母净利润、扣非归母净利润分别为31.50亿元、7.22亿元、6.44 亿元，同比增长28.04%、30.37%、31.79%； 剔除汇率差异，营业收入同比增长28.92%。",
    "labels": [
      [
        "T0",
        "时间范围",
        2,
        7,
        "2020年"
      ],
      [
        "T1",
        "时间范围",
        10,
        12,
        "全年"
      ],
      [
        "T2",
        "营业收入",
        14,
        18,
        "营业收入"
      ],
      [
        "T3",
        "归母净利润",
        19,
        24,
        "归母净利润"
      ],
      [
        "T4",
        "扣非净利润",
        25,
        32,
        "扣非归母净利润"
      ],
      [
        "T5",
        "营业收入",
        91,
        95,
        "营业收入"
      ]
    ]
  },
  {
    "id": 18,
    "text": "跨国药企研发投入",
    "labels": [
      [
        "T0",
        "研发费用",
        4,
        8,
        "研发投入"
      ],
      [
        "T1",
        "行业公司",
        0,
        4,
        "跨国药企"
      ]
    ]
  },
  {
    "id": 19,
    "text": "以领先的结晶技术和复杂高端制剂技术作为切入点，启动了中美两地制剂 CDMO业务的战略布局。 2021年， J-STAR成功获得首个制剂服务项目订单，标志着制剂 CDMO业务正式开启中美两地协同，为全球客户提供“原料药+制剂”一体化服务的新篇章。 预计公司 2021-2023年 EPS分别为 0.94\\1.64\\1.91，对应公司 1月 26日收盘价 77.40元，2021-2023年 PE分别为 82.4\\47.1\\40.5倍，给予“增持”评级。",
    "labels": [
      [
        "T0",
        "时间范围",
        46,
        51,
        "2021年"
      ],
      [
        "T1",
        "公司",
        53,
        59,
        "J-STAR"
      ],
      [
        "T2",
        "行业",
        77,
        84,
        "制剂 CDMO"
      ],
      [
        "T3",
        "行业",
        30,
        37,
        "制剂 CDMO"
      ],
      [
        "T4",
        "地点范围",
        90,
        94,
        "中美两地"
      ],
      [
        "T5",
        "地点范围",
        26,
        30,
        "中美两地"
      ],
      [
        "T6",
        "时间范围",
        128,
        138,
        "2021-2023年"
      ],
      [
        "T7",
        "行业",
        65,
        69,
        "制剂服务"
      ],
      [
        "T8",
        "地点范围",
        98,
        100,
        "全球"
      ],
      [
        "T9",
        "时间范围",
        166,
        172,
        "1月 26日"
      ],
      [
        "T10",
        "时间范围",
        183,
        193,
        "2021-2023年"
      ],
      [
        "T11",
        "PE",
        194,
        196,
        "PE"
      ],
      [
        "T12",
        "属性值",
        200,
        215,
        "82.4\\47.1\\40.5倍"
      ]
    ]
  },
  {
    "id": 21,
    "text": "考虑到全球研发依然处于高景气度且向中国转移趋势不变，以及叠加国内研发高β爆发中，维持前期对国内CXO高景气度的判断。",
    "labels": [
      [
        "T0",
        "地点范围",
        3,
        5,
        "全球"
      ],
      [
        "T1",
        "地点范围",
        17,
        19,
        "中国"
      ],
      [
        "T2",
        "地点范围",
        45,
        47,
        "国内"
      ],
      [
        "T3",
        "行业",
        47,
        50,
        "CXO"
      ],
      [
        "T4",
        "地点范围",
        30,
        32,
        "国内"
      ]
    ]
  },
  {
    "id": 22,
    "text": "临床前 CRO业务是公司的主要收入来源，结构持续优化推动毛利率持续提升。公司临床前 CRO服务分为实验室化学、生物科学（安评已纳入其中），实验室化学业务是公司的起始及核心业务。2015年至今，实验室服务收入占比维持在 63-74%区间，是公司主要收入来源业务。随着项目经验及客户的不断累积，公司的临床前 CRO业务发展愈加成熟，毛利率由 2015年的 24.97%快速提升至 2019年的 40.26%。我们认为预计未来随着高毛利率生物科学业务占比的提升，临床前 CRO利润率将进一步优化。",
    "labels": [
      [
        "T0",
        "行业",
        0,
        7,
        "临床前 CRO"
      ],
      [
        "T1",
        "毛利",
        28,
        31,
        "毛利率"
      ],
      [
        "T2",
        "行业",
        38,
        45,
        "临床前 CRO"
      ],
      [
        "T3",
        "时间范围",
        88,
        95,
        "2015年至今"
      ],
      [
        "T4",
        "营收占比",
        101,
        105,
        "收入占比"
      ],
      [
        "T5",
        "毛利",
        164,
        167,
        "毛利率"
      ],
      [
        "T6",
        "时间范围",
        169,
        174,
        "2015年"
      ],
      [
        "T7",
        "地点范围",
        188,
        193,
        "2019年"
      ],
      [
        "T8",
        "营业收入",
        15,
        17,
        "收入"
      ],
      [
        "T9",
        "行业",
        49,
        54,
        "实验室化学"
      ],
      [
        "T10",
        "行业",
        55,
        59,
        "生物科学"
      ],
      [
        "T11",
        "行业",
        60,
        62,
        "安评"
      ],
      [
        "T12",
        "行业",
        69,
        74,
        "实验室化学"
      ],
      [
        "T13",
        "行业",
        96,
        101,
        "实验室服务"
      ],
      [
        "T14",
        "营业收入",
        123,
        125,
        "收入"
      ],
      [
        "T15",
        "行业",
        148,
        155,
        "临床前 CRO"
      ],
      [
        "T16",
        "毛利",
        213,
        216,
        "毛利率"
      ],
      [
        "T17",
        "行业",
        216,
        220,
        "生物科学"
      ],
      [
        "T18",
        "行业",
        228,
        235,
        "临床前 CRO"
      ],
      [
        "T19",
        "利润",
        235,
        238,
        "利润率"
      ],
      [
        "T20",
        "行业公司",
        145,
        147,
        "公司"
      ]
    ]
  },
  {
    "id": 23,
    "text": "但是从2021年10月份开始CXO股价受到月度投融资YOY波动影响出现调整，我们预计主要是因为CXO高估值背景下，市场对于未来收入/利润增速变化趋势，短期订单",
    "labels": [
      [
        "T0",
        "时间范围",
        2,
        14,
        "从2021年10月份开始"
      ],
      [
        "T1",
        "行业",
        14,
        17,
        "CXO"
      ],
      [
        "T2",
        "投融资情况",
        23,
        26,
        "投融资"
      ],
      [
        "T3",
        "行业",
        47,
        50,
        "CXO"
      ],
      [
        "T4",
        "营业收入",
        63,
        65,
        "收入"
      ],
      [
        "T5",
        "利润",
        66,
        68,
        "利润"
      ]
    ]
  },
  {
    "id": 24,
    "text": "行业处于早期发展阶段，国内龙头有望与全球龙头同台竞技。CGT外包服务领域全球龙头主要包括：Lonza、 Catalent、 Oxford BioMedica、药明康德等。国内提供 CGT服务的 CXO公司仍相对较少，且多数处于发展初期，考虑到全球市场仍处于早期快速发展阶段，国内企业有望快速成长，扩大市场份额，国内主要从事 CGT外包服务的企业包括：药明生基、金斯瑞生物科技、博腾生物、和元生物等。",
    "labels": [
      [
        "T0",
        "地点范围",
        11,
        13,
        "国内"
      ],
      [
        "T1",
        "龙头企业",
        13,
        15,
        "龙头"
      ],
      [
        "T2",
        "龙头企业",
        20,
        22,
        "龙头"
      ],
      [
        "T3",
        "地点范围",
        18,
        20,
        "全球"
      ],
      [
        "T4",
        "地点范围",
        36,
        38,
        "全球"
      ],
      [
        "T5",
        "龙头企业",
        38,
        40,
        "龙头"
      ],
      [
        "T6",
        "公司",
        45,
        50,
        "Lonza"
      ],
      [
        "T7",
        "公司",
        52,
        60,
        "Catalent"
      ],
      [
        "T8",
        "公司",
        62,
        78,
        "Oxford BioMedica"
      ],
      [
        "T9",
        "公司",
        79,
        83,
        "药明康德"
      ],
      [
        "T10",
        "地点范围",
        85,
        87,
        "国内"
      ],
      [
        "T11",
        "地点范围",
        155,
        157,
        "国内"
      ],
      [
        "T12",
        "行业",
        162,
        167,
        "CGT外包"
      ],
      [
        "T13",
        "公司",
        175,
        179,
        "药明生基"
      ],
      [
        "T14",
        "公司",
        180,
        187,
        "金斯瑞生物科技"
      ],
      [
        "T15",
        "公司",
        188,
        192,
        "博腾生物"
      ],
      [
        "T16",
        "公司",
        193,
        197,
        "和元生物"
      ],
      [
        "T17",
        "行业",
        27,
        34,
        "CGT外包服务"
      ],
      [
        "T18",
        "行业",
        90,
        93,
        "CGT"
      ],
      [
        "T19",
        "行业公司",
        97,
        102,
        "CXO公司"
      ],
      [
        "T20",
        "地点范围",
        121,
        123,
        "全球"
      ],
      [
        "T21",
        "地点范围",
        137,
        139,
        "国内"
      ],
      [
        "T22",
        "属性值",
        148,
        150,
        "扩大"
      ],
      [
        "T23",
        "市场份额",
        150,
        154,
        "市场份额"
      ]
    ]
  },
  {
    "id": 25,
    "text": "1）需求端：全球医疗健康领域投融资和研发管线数的持续增长，以及中小药企研发管线占比提升对外包率提高的促进，将共同保障 2021-2025 年 CXO 需求端景气持续。此外，我们预计 2022 年，前期受新冠影响而推迟的研发管线有望恢复进展。",
    "labels": [
      [
        "T0",
        "投融资情况",
        14,
        17,
        "投融资"
      ],
      [
        "T1",
        "行业",
        8,
        12,
        "医疗健康"
      ],
      [
        "T2",
        "地点范围",
        6,
        8,
        "全球"
      ],
      [
        "T3",
        "属性值",
        24,
        28,
        "持续增长"
      ],
      [
        "T4",
        "时间范围",
        59,
        70,
        "2021-2025 年"
      ],
      [
        "T5",
        "行业",
        71,
        74,
        "CXO"
      ],
      [
        "T6",
        "时间范围",
        91,
        97,
        "2022 年"
      ],
      [
        "T7",
        "行业需求",
        2,
        5,
        "需求端"
      ],
      [
        "T8",
        "行业需求",
        75,
        78,
        "需求端"
      ],
      [
        "T9",
        "属性值",
        78,
        82,
        "景气持续"
      ],
      [
        "T10",
        "行业公司",
        31,
        35,
        "中小药企"
      ]
    ]
  },
  {
    "id": 26,
    "text": "综合对比收入规模及 CAGR，端到端/平台型企业的成长性持续性更强，药明康德小分子 CDMO 业务的 2020 年收入 53 亿元， 2018-2020 年收入 CAGR 为 40%。 而转型兑现期企业的成长性强，九洲药业创新药 CDMO 业务的 2018-2020 年收入 CAGR 为 55%。对于由临床前 CRO 向 CDMO 拓展的企业，转型基础是来自长尾客户的临床早期订单储备、创新药的早期创新工艺研发等。对于由仿制药 API 向 CDMO 拓展的企业，转型基础是 cGMP 规模化产能、EHS 体系和规范市场供应经验等。 上述两类企业转型时都需要加强 CMC 能力， 包括合成工艺开发、 生产质量控制这两大类技术服务， 来更好的满足制药企业对于生产工艺对于经济性、环保性的要求。",
    "labels": [
      [
        "T0",
        "CAGR",
        10,
        14,
        "CAGR"
      ],
      [
        "T1",
        "行业公司",
        15,
        24,
        "端到端/平台型企业"
      ],
      [
        "T2",
        "属性值",
        25,
        33,
        "成长性持续性更强"
      ],
      [
        "T3",
        "公司",
        34,
        38,
        "药明康德"
      ],
      [
        "T4",
        "时间范围",
        67,
        78,
        "2018-2020 年"
      ],
      [
        "T5",
        "属性值",
        60,
        65,
        "53 亿元"
      ],
      [
        "T6",
        "属性值",
        88,
        91,
        "40%"
      ],
      [
        "T7",
        "CAGR",
        81,
        85,
        "CAGR"
      ],
      [
        "T8",
        "公司",
        107,
        111,
        "九洲药业"
      ],
      [
        "T9",
        "行业",
        111,
        119,
        "创新药 CDMO"
      ],
      [
        "T10",
        "时间范围",
        124,
        135,
        "2018-2020 年"
      ],
      [
        "T11",
        "CAGR",
        138,
        142,
        "CAGR"
      ],
      [
        "T12",
        "属性值",
        145,
        148,
        "55%"
      ],
      [
        "T13",
        "营业收入",
        135,
        137,
        "收入"
      ],
      [
        "T14",
        "营业收入",
        4,
        6,
        "收入"
      ],
      [
        "T15",
        "营业收入",
        57,
        59,
        "收入"
      ],
      [
        "T16",
        "营业收入",
        78,
        80,
        "收入"
      ],
      [
        "T17",
        "时间范围",
        51,
        57,
        "2020 年"
      ],
      [
        "T18",
        "行业",
        38,
        46,
        "小分子 CDMO"
      ],
      [
        "T19",
        "行业",
        152,
        159,
        "临床前 CRO"
      ],
      [
        "T20",
        "行业",
        162,
        166,
        "CDMO"
      ],
      [
        "T21",
        "行业",
        211,
        218,
        "仿制药 API"
      ],
      [
        "T22",
        "行业",
        221,
        225,
        "CDMO"
      ],
      [
        "T23",
        "行业公司",
        322,
        326,
        "制药企业"
      ]
    ]
  },
  {
    "id": 28,
    "text": "加码投资CDMO 富士胶片1亿美元收购Atara细胞疗法图表工厂。日本富士胶片公司宣布将以1亿美元的价格收购Atara Biotherapeutics旗下的一家细胞疗法工厂，该工厂位于加利福尼亚州千橡市的90000平方英尺的场地设施，包括生产同种异体T 细胞和CAR-T免疫疗法。通过此次收购，富士胶片可以将其 CDMO产品扩展到细胞疗法领域。未来，公司将通过提供稳定的高质量生物制药，进一步推进建立未满足医疗需求的产品线。",
    "labels": [
      [
        "T0",
        "地点范围",
        34,
        36,
        "日本"
      ],
      [
        "T1",
        "公司",
        36,
        40,
        "富士胶片"
      ],
      [
        "T2",
        "公司",
        55,
        76,
        "Atara Biotherapeutics"
      ],
      [
        "T3",
        "公司",
        148,
        152,
        "富士胶片"
      ],
      [
        "T4",
        "行业",
        157,
        161,
        "CDMO"
      ],
      [
        "T5",
        "行业",
        166,
        170,
        "细胞疗法"
      ],
      [
        "T6",
        "行业",
        5,
        9,
        "CDMO"
      ],
      [
        "T7",
        "公司",
        10,
        14,
        "富士胶片"
      ],
      [
        "T8",
        "公司",
        20,
        25,
        "Atara"
      ],
      [
        "T9",
        "地点范围",
        93,
        102,
        "加利福尼亚州千橡市"
      ],
      [
        "T10",
        "行业",
        204,
        206,
        "医疗"
      ],
      [
        "T11",
        "行业需求",
        206,
        208,
        "需求"
      ]
    ]
  },
  {
    "id": 29,
    "text": "业绩逐季恢复，整体加速增长。10家CXO公司2020年收入（29.2%），归母净利润（69.9%），整体维持高速增长。2020Q4收入（32.1%），归母净利润（87%），四季度收入端继续加速，利润端增速提升主要与龙头企业投资收益等增长有关。10家CXO公司2021Q1收入（56.5%）、归母净利润（209.5%），受益于低基数以及充足的订单，2021年一季度CXO企业业绩仍然保持高增长。  CDMO业务增长持续加速，盈利能力保持较高水平。CDMO行业空间较大，CDMO业务整体呈现出加速增长态势。从盈利能力角度来看，大部分企业的CDMO业务毛利率均在40%以上，其中九洲药业、凯莱英毛利率较高 ，康龙化成进入时间较晚，毛利率仍有较大提升空间。",
    "labels": [
      [
        "T0",
        "行业公司",
        15,
        23,
        "10家CXO公司"
      ],
      [
        "T1",
        "时间范围",
        23,
        28,
        "2020年"
      ],
      [
        "T2",
        "营业收入",
        28,
        30,
        "收入"
      ],
      [
        "T3",
        "属性值",
        31,
        36,
        "29.2%"
      ],
      [
        "T4",
        "属性值",
        44,
        49,
        "69.9%"
      ],
      [
        "T5",
        "归母净利润",
        38,
        43,
        "归母净利润"
      ],
      [
        "T6",
        "时间范围",
        60,
        66,
        "2020Q4"
      ],
      [
        "T7",
        "营业收入",
        66,
        68,
        "收入"
      ],
      [
        "T8",
        "属性值",
        69,
        74,
        "32.1%"
      ],
      [
        "T9",
        "属性值",
        82,
        85,
        "87%"
      ],
      [
        "T10",
        "属性值",
        139,
        144,
        "56.5%"
      ],
      [
        "T11",
        "属性值",
        152,
        158,
        "209.5%"
      ],
      [
        "T12",
        "毛利",
        275,
        278,
        "毛利率"
      ],
      [
        "T13",
        "时间范围",
        130,
        136,
        "2021Q1"
      ],
      [
        "T14",
        "营业收入",
        136,
        138,
        "收入"
      ],
      [
        "T15",
        "归母净利润",
        146,
        151,
        "归母净利润"
      ],
      [
        "T16",
        "时间范围",
        174,
        182,
        "2021年一季度"
      ],
      [
        "T17",
        "行业公司",
        182,
        187,
        "CXO企业"
      ],
      [
        "T18",
        "业绩",
        187,
        189,
        "业绩"
      ],
      [
        "T19",
        "行业",
        200,
        204,
        "CDMO"
      ],
      [
        "T20",
        "行业",
        224,
        228,
        "CDMO"
      ],
      [
        "T21",
        "行业",
        269,
        273,
        "CDMO"
      ],
      [
        "T22",
        "公司",
        288,
        292,
        "九洲药业"
      ],
      [
        "T23",
        "公司",
        293,
        296,
        "凯莱英"
      ],
      [
        "T24",
        "毛利",
        296,
        299,
        "毛利率"
      ],
      [
        "T25",
        "属性值",
        299,
        301,
        "较高"
      ],
      [
        "T26",
        "公司",
        303,
        307,
        "康龙化成"
      ],
      [
        "T27",
        "毛利",
        314,
        317,
        "毛利率"
      ],
      [
        "T28",
        "业绩",
        1,
        3,
        "业绩"
      ],
      [
        "T29",
        "属性值",
        55,
        59,
        "高速增长"
      ],
      [
        "T30",
        "归母净利润",
        76,
        81,
        "归母净利润"
      ],
      [
        "T31",
        "时间范围",
        87,
        90,
        "四季度"
      ],
      [
        "T32",
        "营业收入",
        90,
        93,
        "收入端"
      ],
      [
        "T33",
        "属性值",
        95,
        97,
        "加速"
      ],
      [
        "T34",
        "利润",
        98,
        101,
        "利润端"
      ],
      [
        "T35",
        "龙头企业",
        108,
        112,
        "龙头企业"
      ],
      [
        "T36",
        "行业公司",
        122,
        130,
        "10家CXO公司"
      ],
      [
        "T37",
        "属性值",
        193,
        196,
        "高增长"
      ],
      [
        "T38",
        "行业",
        235,
        239,
        "CDMO"
      ],
      [
        "T39",
        "属性值",
        318,
        325,
        "有较大提升空间"
      ],
      [
        "T40",
        "行业公司",
        263,
        268,
        "大部分企业"
      ],
      [
        "T41",
        "属性值",
        280,
        285,
        "40%以上"
      ]
    ]
  },
  {
    "id": 30,
    "text": "CDMO：景气度无虞，竞争力提升——医药外包行业系列深度报告之四（2021-12-02） 疫情常态化之下， 新冠治疗药物投资价值几何？ ——创新药研究系列五之新冠治疗药物篇 （2021-10-11） “API+”：全球产业大转移，褪去周期迎成长 ——医药外包行业系列深度报告之三 （2020-07-09） 内资药企需求高增长，助力 CRO 产业第三波浪潮——医药外包行业系列深度报告之二 （2019-06-13） 中国制药产业大破大立，开启 CRO 行业黄金发展期——CRO 行业深度报告（2018-12-25）",
    "labels": [
      [
        "T0",
        "行业",
        234,
        237,
        "CRO"
      ],
      [
        "T1",
        "行业",
        221,
        224,
        "CRO"
      ],
      [
        "T2",
        "行业",
        166,
        169,
        "CRO"
      ],
      [
        "T3",
        "行业",
        179,
        183,
        "医药外包"
      ],
      [
        "T4",
        "行业",
        0,
        4,
        "CDMO"
      ],
      [
        "T5",
        "行业",
        18,
        22,
        "医药外包"
      ],
      [
        "T6",
        "时间范围",
        33,
        43,
        "2021-12-02"
      ],
      [
        "T7",
        "行业",
        70,
        73,
        "创新药"
      ],
      [
        "T8",
        "时间范围",
        88,
        98,
        "2021-10-11"
      ],
      [
        "T9",
        "地点范围",
        107,
        109,
        "全球"
      ],
      [
        "T10",
        "行业",
        125,
        129,
        "医药外包"
      ],
      [
        "T11",
        "时间范围",
        141,
        151,
        "2020-07-09"
      ],
      [
        "T12",
        "行业公司",
        155,
        157,
        "药企"
      ],
      [
        "T13",
        "时间范围",
        195,
        205,
        "2019-06-13"
      ],
      [
        "T14",
        "地点范围",
        207,
        209,
        "中国"
      ],
      [
        "T15",
        "行业",
        209,
        211,
        "制药"
      ],
      [
        "T16",
        "时间范围",
        245,
        255,
        "2018-12-25"
      ]
    ]
  },
  {
    "id": 31,
    "text": "中性测算下 2030年收入规模有望达到 2131亿元，经调整 Non-IFRS净利润达到 501亿元。基于以上假设测算，公司 2030年 CRO和 CDMO业务收入分别达到 1499亿元和 631亿元，2020~2030年 CAGR分别为 29.6%和 28.2%。 对应总收入体量达到 2131亿元（2020~2030年 CAGR为 29.1%），按照 23.5% 的经调整 Non-IFRS净利率计算， 2030年经调整 Non-IFRS净利润约为 501亿元（2020~2030年 CAGR为 30.2%）。",
    "labels": [
      [
        "T0",
        "假设情形",
        0,
        4,
        "中性测算"
      ],
      [
        "T1",
        "时间范围",
        6,
        11,
        "2030年"
      ],
      [
        "T2",
        "时间范围",
        63,
        68,
        "2030年"
      ],
      [
        "T3",
        "行业",
        69,
        72,
        "CRO"
      ],
      [
        "T4",
        "行业",
        74,
        78,
        "CDMO"
      ],
      [
        "T5",
        "营业收入",
        80,
        82,
        "收入"
      ],
      [
        "T6",
        "时间范围",
        101,
        111,
        "2020~2030年"
      ],
      [
        "T7",
        "CAGR",
        112,
        116,
        "CAGR"
      ],
      [
        "T8",
        "时间范围",
        151,
        161,
        "2020~2030年"
      ],
      [
        "T9",
        "CAGR",
        162,
        166,
        "CAGR"
      ],
      [
        "T10",
        "CAGR",
        244,
        248,
        "CAGR"
      ],
      [
        "T11",
        "时间范围",
        233,
        243,
        "2020~2030年"
      ],
      [
        "T12",
        "时间范围",
        204,
        209,
        "2030年"
      ],
      [
        "T13",
        "归母净利润",
        39,
        42,
        "净利润"
      ],
      [
        "T14",
        "营业收入",
        11,
        13,
        "收入"
      ],
      [
        "T15",
        "营业收入",
        136,
        139,
        "总收入"
      ],
      [
        "T16",
        "归母净利润",
        197,
        200,
        "净利率"
      ],
      [
        "T17",
        "归母净利润",
        221,
        224,
        "净利润"
      ]
    ]
  },
  {
    "id": 32,
    "text": " 全年 CXO的高景气，分版块来看，我们预计： ① 药物发现 CRO板块，保持平稳增长； ② 临床前 CRO板块，保持高景气； ③ 小分子 CDMO板块，国内外项目持续放量，加速成长； ④ 临床 CRO板块，行业高景气叠加临床试验推进节奏的恢复，实现高增长； ⑤ 大分子 CDMO板块，国内外临床阶段项目逐渐恢复，对应早期项目推进速度恢复正常，对于该细分领域龙头药明生物而言，2021年是商业化兑现的元年，我们预计会新增 5-8个商业化项目，拉动公司和板块快速增长； ⑥ 部分海外实验室，逐渐恢复正常状态。（对应药明美国、方达美国等业务）",
    "labels": [
      [
        "T0",
        "行业",
        5,
        8,
        "CXO"
      ],
      [
        "T1",
        "行业",
        27,
        35,
        "药物发现 CRO"
      ],
      [
        "T2",
        "行业",
        48,
        55,
        "临床前 CRO"
      ],
      [
        "T3",
        "行业",
        67,
        75,
        "小分子 CDMO"
      ],
      [
        "T4",
        "行业",
        96,
        102,
        "临床 CRO"
      ],
      [
        "T5",
        "行业",
        133,
        141,
        "大分子 CDMO"
      ],
      [
        "T6",
        "时间范围",
        189,
        194,
        "2021年"
      ],
      [
        "T7",
        "公司",
        182,
        186,
        "药明生物"
      ],
      [
        "T8",
        "龙头企业",
        180,
        182,
        "龙头"
      ],
      [
        "T9",
        "地点范围",
        144,
        147,
        "国内外"
      ],
      [
        "T10",
        "地点范围",
        239,
        241,
        "海外"
      ],
      [
        "T11",
        "公司",
        257,
        261,
        "药明美国"
      ],
      [
        "T12",
        "公司",
        262,
        266,
        "方达美国"
      ]
    ]
  },
  {
    "id": 33,
    "text": "医疗健康产业融资方兴未艾，CXO发展动能充足。从全球季度医疗健康领域融资规模来看，2021Q4全球融资总额 322.73亿美元，同比增长 27.5%，全球融资事件 887 起，同比增长 37.1%，仍处于历史较高位置。中国融资趋势与全球一致，持续升温， 2021年 Q4国内融资总额 90.3亿美元，同比增长 13.8%，融资事件数 425起，同比增长 54.5%，环比增长 9.8%，再创历史新高。医疗健康产业融资的持续升温保障了 CXO的后续充足动能。",
    "labels": [
      [
        "T0",
        "行业",
        0,
        4,
        "医疗健康"
      ],
      [
        "T1",
        "行业",
        13,
        16,
        "CXO"
      ],
      [
        "T2",
        "地点范围",
        24,
        26,
        "全球"
      ],
      [
        "T3",
        "时间范围",
        26,
        28,
        "季度"
      ],
      [
        "T4",
        "行业",
        28,
        32,
        "医疗健康"
      ],
      [
        "T5",
        "投融资情况",
        34,
        38,
        "融资规模"
      ],
      [
        "T6",
        "时间范围",
        41,
        47,
        "2021Q4"
      ],
      [
        "T7",
        "地点范围",
        47,
        49,
        "全球"
      ],
      [
        "T8",
        "投融资金额",
        49,
        53,
        "融资总额"
      ],
      [
        "T9",
        "地点范围",
        109,
        111,
        "中国"
      ],
      [
        "T10",
        "地点范围",
        116,
        118,
        "全球"
      ],
      [
        "T11",
        "时间范围",
        127,
        135,
        "2021年 Q4"
      ],
      [
        "T12",
        "地点范围",
        135,
        137,
        "国内"
      ],
      [
        "T13",
        "投融资金额",
        137,
        141,
        "融资总额"
      ],
      [
        "T14",
        "投融资事件数",
        161,
        166,
        "融资事件数"
      ],
      [
        "T15",
        "行业",
        200,
        204,
        "医疗健康"
      ],
      [
        "T16",
        "行业",
        217,
        220,
        "CXO"
      ],
      [
        "T17",
        "投融资情况",
        6,
        8,
        "融资"
      ],
      [
        "T18",
        "属性值",
        8,
        12,
        "方兴未艾"
      ],
      [
        "T19",
        "属性值",
        54,
        74,
        "322.73亿美元，同比增长 27.5%"
      ],
      [
        "T20",
        "地点范围",
        75,
        77,
        "全球"
      ],
      [
        "T21",
        "投融资事件数",
        77,
        81,
        "融资事件"
      ],
      [
        "T22",
        "属性值",
        82,
        98,
        "887 起，同比增长 37.1%"
      ],
      [
        "T23",
        "属性值",
        121,
        125,
        "持续升温"
      ],
      [
        "T24",
        "投融资情况",
        111,
        113,
        "融资"
      ],
      [
        "T25",
        "属性值",
        142,
        160,
        "90.3亿美元，同比增长 13.8%"
      ],
      [
        "T26",
        "属性值",
        167,
        192,
        "425起，同比增长 54.5%，环比增长 9.8%"
      ],
      [
        "T27",
        "投融资情况",
        206,
        208,
        "融资"
      ],
      [
        "T28",
        "属性值",
        209,
        213,
        "持续升温"
      ]
    ]
  },
  {
    "id": 34,
    "text": "公司经历了四个发展阶段：1）2000-2007年：进入国际药物发现和临床前服务领域；2） 2008-2011年：业务拓展至医疗器械检测和临床服务业务领域（收购美国 AppTech），同时加强其在 CRO/CMO行业的领导地位；3）2011-2015年：通过多元化投资捕捉行业未来增长趋势和长期发展机会（细胞&基因治疗，人工智能和风险投资等）； 4） 2015年至今： 完成私有化从美股退市，并于 2018年 5月在 A股上市。公司不断做广做深新药研发全产业链服务，持续完善医药健康生态系统，未来有望进击全球医药外包服务行业顶级企业。",
    "labels": [
      [
        "T0",
        "时间范围",
        14,
        24,
        "2000-2007年"
      ],
      [
        "T1",
        "时间范围",
        45,
        55,
        "2008-2011年"
      ],
      [
        "T2",
        "时间范围",
        115,
        125,
        "2011-2015年"
      ],
      [
        "T3",
        "时间范围",
        175,
        182,
        "2015年至今"
      ],
      [
        "T4",
        "时间范围",
        198,
        206,
        "2018年 5月"
      ],
      [
        "T5",
        "行业",
        27,
        33,
        "国际药物发现"
      ],
      [
        "T6",
        "行业",
        34,
        39,
        "临床前服务"
      ],
      [
        "T7",
        "行业",
        61,
        67,
        "医疗器械检测"
      ],
      [
        "T8",
        "行业",
        68,
        72,
        "临床服务"
      ],
      [
        "T9",
        "地点范围",
        79,
        81,
        "美国"
      ],
      [
        "T10",
        "公司",
        82,
        89,
        "AppTech"
      ],
      [
        "T11",
        "行业",
        98,
        105,
        "CRO/CMO"
      ],
      [
        "T12",
        "行业",
        151,
        158,
        "细胞&基因治疗"
      ],
      [
        "T13",
        "行业",
        159,
        163,
        "人工智能"
      ],
      [
        "T14",
        "行业",
        221,
        229,
        "新药研发全产业链"
      ],
      [
        "T15",
        "行业",
        236,
        240,
        "医药健康"
      ],
      [
        "T16",
        "地点范围",
        251,
        253,
        "全球"
      ],
      [
        "T17",
        "行业",
        253,
        259,
        "医药外包服务"
      ]
    ]
  },
  {
    "id": 35,
    "text": "制剂工艺研发与生产：与实验室部门协同，提供全流程的研发和生产支持。合全药业的制剂工艺研发和生产能够提供从早期处方前研发到处方研发，到商业化制剂生产，及先进给药技术研发、微生物催化增强技术开发等服务。  在处方前阶段，合全药业的创新药临床申报处方前研究一体化平台（IEPP） 通过与药明康德实验室业务的药物化学、药代动力、药理、毒理和生物分析等团队合作，进行全面的快速评估和优化，节约时间与成本，支撑新药快速从临床前推进到临床阶段。  临床处方研发阶段，公司能够提供多种剂型的开发、稳定性注册批次生产、 稳定性评估、工艺优化和验证、工艺放大到商业化生产、关键步骤的控制、 批量生产等服务，支持药物临床进展并快速推进到市场。  在商业化生产阶段，公司已通过美国、中国、欧盟、日本、加拿大、瑞士、 澳大利亚和新西兰等多国 GMP认证，且储备了充足的产能，包括：上海外高桥地 4万 5千平方英尺的 cGMP商业化和中试生产车间，用于固体口服制剂的生产；位于无锡的占地 14英亩的金山基地，包含一个公斤级实验室、两个中试车间和一个商业化车间，反应釜体积从 5L至 20,000L，还包含一个 cGMP的高活性原料药生产设施、质量控制实验室、仓库和溶剂罐区。",
    "labels": [
      [
        "T0",
        "公司",
        141,
        145,
        "药明康德"
      ],
      [
        "T1",
        "公司",
        33,
        37,
        "合全药业"
      ],
      [
        "T2",
        "公司",
        109,
        113,
        "合全药业"
      ],
      [
        "T3",
        "地点范围",
        329,
        331,
        "美国"
      ],
      [
        "T4",
        "地点范围",
        332,
        334,
        "中国"
      ],
      [
        "T5",
        "地点范围",
        335,
        337,
        "欧盟"
      ],
      [
        "T6",
        "地点范围",
        338,
        340,
        "日本"
      ],
      [
        "T7",
        "地点范围",
        341,
        344,
        "加拿大"
      ],
      [
        "T8",
        "地点范围",
        345,
        347,
        "瑞士"
      ],
      [
        "T9",
        "地点范围",
        349,
        353,
        "澳大利亚"
      ],
      [
        "T10",
        "地点范围",
        354,
        357,
        "新西兰"
      ],
      [
        "T11",
        "地点范围",
        380,
        382,
        "上海"
      ],
      [
        "T12",
        "地点范围",
        427,
        429,
        "无锡"
      ]
    ]
  },
  {
    "id": 36,
    "text": "自主开发也是国内创新药走向国际的重要途径。自 2017年中国正式成为国际人用药品注册技术协调会 （ICH）会员之后，创新药的中美双报和同步开发成为焦点，越来越多本土创新企业开始尝试国际多中心临床研究，将自己的产品通过自行申报的方式出海，利用研发成本优势进军海外市场。据医药魔方不完全统计，2017年之后中美双报的临床获批数量较 2017年前翻了近 10倍。2019年 11月 14日，FDA宣布加速批",
    "labels": [
      [
        "T0",
        "时间范围",
        23,
        28,
        "2017年"
      ],
      [
        "T1",
        "地点范围",
        28,
        30,
        "中国"
      ],
      [
        "T2",
        "新药获批数",
        156,
        162,
        "临床获批数量"
      ],
      [
        "T3",
        "时间范围",
        164,
        170,
        "2017年前"
      ],
      [
        "T4",
        "属性值",
        170,
        177,
        "翻了近 10倍"
      ],
      [
        "T5",
        "时间范围",
        144,
        151,
        "2017年之后"
      ],
      [
        "T6",
        "地点范围",
        6,
        8,
        "国内"
      ],
      [
        "T7",
        "行业",
        8,
        11,
        "创新药"
      ],
      [
        "T8",
        "行业",
        58,
        61,
        "创新药"
      ],
      [
        "T9",
        "地点范围",
        62,
        63,
        "中"
      ],
      [
        "T10",
        "地点范围",
        63,
        64,
        "美"
      ],
      [
        "T11",
        "行业公司",
        82,
        86,
        "创新企业"
      ],
      [
        "T12",
        "地点范围",
        80,
        82,
        "本土"
      ],
      [
        "T13",
        "地点范围",
        151,
        152,
        "中"
      ],
      [
        "T14",
        "地点范围",
        152,
        153,
        "美"
      ],
      [
        "T15",
        "时间范围",
        178,
        191,
        "2019年 11月 14日"
      ]
    ]
  },
  {
    "id": 37,
    "text": "综上，通过观察重点企业 CDMO 业务 III 期项目数量，以及单个项目金额的边际变化， 我们认为中期来看， 商业化订单放量+订单附加值提升， 将成为国内 CDMO 的重要成长驱动。",
    "labels": [
      [
        "T0",
        "行业",
        12,
        16,
        "CDMO"
      ],
      [
        "T1",
        "地点范围",
        75,
        77,
        "国内"
      ],
      [
        "T2",
        "行业",
        78,
        82,
        "CDMO"
      ]
    ]
  },
  {
    "id": 38,
    "text": "➢ 考虑IPO及二级市场融资，2021年全球Biotech公司融资总额高速增长。根据Nature Biotecnology统计的六种融资方式 （IPO，增发，风险投资，债券融资，私募股权和合伙）， 2021年全球Biotech公司融资总额为2273亿美元，同比2020 年下降25.33%，2017-2021 CAGR为12.22%，整体保持增长趋势。 ➢ 在上述六种融资方式中，合伙、债权融资以及增发三种模式在2017-2021年间占比较大。IPO方面，融资总额保持增长， 其中亚太地区IPO总额增长明显，同比增长31%；一级市场风投方面，Biotech公司的融资额也保持增加，同比增长8.52%。",
    "labels": [
      [
        "T0",
        "时间范围",
        15,
        20,
        "2021年"
      ],
      [
        "T1",
        "地点范围",
        20,
        22,
        "全球"
      ],
      [
        "T2",
        "地点范围",
        104,
        106,
        "全球"
      ],
      [
        "T3",
        "时间范围",
        99,
        104,
        "2021年"
      ],
      [
        "T4",
        "投融资金额",
        115,
        119,
        "融资总额"
      ],
      [
        "T5",
        "属性值",
        120,
        127,
        "2273亿美元"
      ],
      [
        "T6",
        "时间范围",
        130,
        136,
        "2020 年"
      ],
      [
        "T7",
        "属性值",
        136,
        144,
        "下降25.33%"
      ],
      [
        "T8",
        "时间范围",
        145,
        154,
        "2017-2021"
      ],
      [
        "T9",
        "CAGR",
        155,
        159,
        "CAGR"
      ],
      [
        "T10",
        "属性值",
        160,
        166,
        "12.22%"
      ],
      [
        "T11",
        "投融资情况",
        12,
        14,
        "融资"
      ],
      [
        "T12",
        "行业公司",
        22,
        31,
        "Biotech公司"
      ],
      [
        "T13",
        "投融资金额",
        31,
        35,
        "融资总额"
      ],
      [
        "T14",
        "属性值",
        35,
        39,
        "高速增长"
      ],
      [
        "T15",
        "行业公司",
        106,
        115,
        "Biotech公司"
      ],
      [
        "T16",
        "属性值",
        171,
        175,
        "增长趋势"
      ],
      [
        "T17",
        "时间范围",
        206,
        216,
        "2017-2021年"
      ],
      [
        "T18",
        "投融资金额",
        228,
        232,
        "融资总额"
      ],
      [
        "T19",
        "地点范围",
        240,
        244,
        "亚太地区"
      ],
      [
        "T20",
        "行业公司",
        271,
        280,
        "Biotech公司"
      ],
      [
        "T21",
        "属性值",
        287,
        299,
        "增加，同比增长8.52%"
      ],
      [
        "T22",
        "投融资金额",
        281,
        284,
        "融资额"
      ]
    ]
  },
  {
    "id": 40,
    "text": "康龙化成2016-2020年通过并购快速搭建海外与中国一站式临床服务平台，2021年预计通过收购完成CGT疗法的CDMO业务布局",
    "labels": [
      [
        "T0",
        "公司",
        0,
        4,
        "康龙化成"
      ],
      [
        "T1",
        "时间范围",
        4,
        14,
        "2016-2020年"
      ],
      [
        "T2",
        "时间范围",
        37,
        42,
        "2021年"
      ],
      [
        "T3",
        "行业",
        50,
        60,
        "CGT疗法的CDMO"
      ],
      [
        "T4",
        "行业",
        27,
        34,
        "一站式临床服务"
      ]
    ]
  },
  {
    "id": 41,
    "text": "迈瑞医疗：疫情后预计医院建设投入将加大，对医疗设备的需求随之加大；并且， 国家有望进一步出台政策，鼓励支持国产高端设备的技术研发，提高相关设备的自主可控能力。公司是具备创新属性的器械龙头，业绩高增长，行业优势明显。 恒瑞医药：随着医改的持续推进，具有创新属性的药品龙头稀缺性将愈发凸显。 公司是国内创新药的标杆，并积极布局创新药的国际化战略。 药明康德：医药研发/生产外包行业（CXO）成长性强、确定性高，是医药板块最为优质的细分赛道之一。药明康德作为本土CXO中当之无愧的龙头企业，凭借高素质的研发团队、稀缺的全产业链平台、前沿的技术能力布局构建了强大的竞争力，从而能够打开丰富的订单流量入口，保持高度的客户粘性，并跟随分子成长实现业务体量的持续增长。 惠泰医疗：国产电生理产品龙头，冠脉通路排名第三。公司已完成电生理、冠脉介入、外周介入、神经介入等四大创新赛道布局。作为国产创新器械先行者，由 “专精特新”成功转向平台化发展，2021年海外业务营收增速 35%，出海前景广阔。 东方生物：经此新冠一“疫”，奠定 POCT龙头地位，积极补强其它 IVD领域， 国内外市场双轮驱动，持续成长可期。 华大基因：华大因源新冠抗原检测试剂已获得自测资质，公司作为基因测序龙头公司，加大研发创新，借助新冠打开 IVD 全球化之路。",
    "labels": [
      [
        "T0",
        "时间范围",
        5,
        8,
        "疫情后"
      ],
      [
        "T1",
        "地点范围",
        147,
        149,
        "国内"
      ],
      [
        "T2",
        "行业",
        149,
        152,
        "创新药"
      ],
      [
        "T3",
        "龙头企业",
        153,
        155,
        "标杆"
      ],
      [
        "T4",
        "公司",
        172,
        176,
        "药明康德"
      ],
      [
        "T5",
        "龙头企业",
        237,
        241,
        "龙头企业"
      ],
      [
        "T6",
        "公司",
        220,
        224,
        "药明康德"
      ],
      [
        "T7",
        "地点范围",
        226,
        228,
        "本土"
      ],
      [
        "T8",
        "行业",
        228,
        231,
        "CXO"
      ],
      [
        "T9",
        "时间范围",
        415,
        420,
        "2021年"
      ],
      [
        "T10",
        "地点范围",
        420,
        422,
        "海外"
      ],
      [
        "T11",
        "属性值",
        429,
        432,
        "35%"
      ],
      [
        "T12",
        "公司",
        328,
        332,
        "惠泰医疗"
      ],
      [
        "T13",
        "公司",
        441,
        445,
        "东方生物"
      ],
      [
        "T14",
        "公司",
        499,
        503,
        "华大基因"
      ],
      [
        "T15",
        "行业",
        458,
        462,
        "POCT"
      ],
      [
        "T16",
        "龙头企业",
        462,
        464,
        "龙头"
      ],
      [
        "T17",
        "公司",
        0,
        4,
        "迈瑞医疗"
      ],
      [
        "T18",
        "行业",
        21,
        25,
        "医疗设备"
      ],
      [
        "T19",
        "行业需求",
        26,
        28,
        "需求"
      ],
      [
        "T20",
        "属性值",
        30,
        32,
        "加大"
      ],
      [
        "T21",
        "行业",
        89,
        91,
        "器械"
      ],
      [
        "T22",
        "龙头企业",
        91,
        93,
        "龙头"
      ],
      [
        "T23",
        "业绩",
        94,
        96,
        "业绩"
      ],
      [
        "T24",
        "属性值",
        96,
        99,
        "高增长"
      ],
      [
        "T25",
        "公司",
        108,
        112,
        "恒瑞医药"
      ],
      [
        "T26",
        "行业",
        130,
        132,
        "药品"
      ],
      [
        "T27",
        "龙头企业",
        132,
        134,
        "龙头"
      ],
      [
        "T28",
        "行业",
        161,
        164,
        "创新药"
      ],
      [
        "T29",
        "行业",
        204,
        206,
        "医药"
      ],
      [
        "T30",
        "行业",
        177,
        193,
        "医药研发/生产外包行业（CXO）"
      ],
      [
        "T31",
        "属性值",
        322,
        326,
        "持续增长"
      ],
      [
        "T32",
        "龙头企业",
        340,
        342,
        "龙头"
      ],
      [
        "T33",
        "行业",
        343,
        347,
        "冠脉通路"
      ],
      [
        "T34",
        "行业",
        357,
        360,
        "电生理"
      ],
      [
        "T35",
        "行业",
        361,
        365,
        "冠脉介入"
      ],
      [
        "T36",
        "行业",
        366,
        370,
        "外周介入"
      ],
      [
        "T37",
        "行业",
        371,
        375,
        "神经介入"
      ],
      [
        "T38",
        "行业",
        387,
        393,
        "国产创新器械"
      ],
      [
        "T39",
        "营业收入",
        424,
        426,
        "营收"
      ],
      [
        "T40",
        "行业",
        474,
        477,
        "IVD"
      ],
      [
        "T41",
        "地点范围",
        481,
        484,
        "国内外"
      ],
      [
        "T42",
        "行业",
        528,
        532,
        "基因测序"
      ],
      [
        "T43",
        "龙头企业",
        532,
        536,
        "龙头公司"
      ],
      [
        "T44",
        "行业",
        551,
        554,
        "IVD"
      ],
      [
        "T45",
        "行业",
        335,
        338,
        "电生理"
      ]
    ]
  },
  {
    "id": 42,
    "text": "已经积累了近50万行业研究样本，完成近10,000多个独 、医学服务、医疗外包领域着手，研究内容覆盖整个行业的发展周期，伴随着行业中企业的创立， 期，研究院的各行业研究员探索和评估行业中多变的产业模式，企业的商业模式和运营模式，以专研发的算法，结合行业交叉的大数据，以多元化的调研方法，挖掘定量数据背后的逻辑，分析定性状，前瞻性地预测行业未来的发展趋势，在研究院的每一份研究报告中，完整地呈现行业的过去， 及数据会随着行业发展、技术革新、竞争格局变化、政策法规颁布、市场调研深入，保持不断更新层面阅读行业，为每一个行业的报告阅读者提供值得品鉴的研究报告",
    "labels": [
      [
        "T0",
        "行业",
        35,
        39,
        "医疗外包"
      ],
      [
        "T1",
        "行业",
        30,
        34,
        "医学服务"
      ]
    ]
  },
  {
    "id": 43,
    "text": "整体看，我们认为CXO板块是医药行业中能持续兑现高增长业绩的优异子版块，2021年在全球新冠大流行背景下，中国CXO企业尤其CDMO公司，以准时、高质量交付的口碑获海外药企的高度认可，进一步奠定其在全球供应链体系中不可或缺的战略地",
    "labels": [
      [
        "T0",
        "行业",
        8,
        11,
        "CXO"
      ],
      [
        "T1",
        "行业",
        14,
        16,
        "医药"
      ],
      [
        "T2",
        "时间范围",
        36,
        41,
        "2021年"
      ],
      [
        "T3",
        "地点范围",
        53,
        55,
        "中国"
      ],
      [
        "T4",
        "行业公司",
        55,
        60,
        "CXO企业"
      ],
      [
        "T5",
        "行业公司",
        62,
        68,
        "CDMO公司"
      ],
      [
        "T6",
        "属性值",
        24,
        27,
        "高增长"
      ],
      [
        "T7",
        "地点范围",
        82,
        84,
        "海外"
      ],
      [
        "T8",
        "行业公司",
        84,
        86,
        "药企"
      ],
      [
        "T9",
        "地点范围",
        99,
        101,
        "全球"
      ],
      [
        "T10",
        "业绩",
        27,
        29,
        "业绩"
      ]
    ]
  },
  {
    "id": 44,
    "text": "规模效应显现，毛利率和净利率水平持续提升。随着收入规模的上升、经营效率的不断提高，2014年到 2020年 Q1-Q3公司毛利率由 25.09%增长到 37.74%，净利率由 2.66%上升到 21.37%。2019年 Q2以来，公司毛利率稳步提升，目前已经十分接近国内龙头企业药明康德的水平。我们认为，扣除公允价值变动损益（Zentalis Pharmaceu ticals的股权投资）带来的增厚，以 2020年 Q1-Q3扣非归母净利率 16.89%来估算主营业务的盈利水平，公司与龙头相比还具有一定成长空间。",
    "labels": [
      [
        "T0",
        "毛利",
        7,
        10,
        "毛利率"
      ],
      [
        "T1",
        "归母净利润",
        11,
        14,
        "净利率"
      ],
      [
        "T2",
        "时间范围",
        41,
        59,
        "2014年到 2020年 Q1-Q3"
      ],
      [
        "T3",
        "毛利",
        61,
        64,
        "毛利率"
      ],
      [
        "T4",
        "归母净利润",
        83,
        86,
        "净利率"
      ],
      [
        "T5",
        "时间范围",
        104,
        114,
        "2019年 Q2以来"
      ],
      [
        "T6",
        "地点范围",
        133,
        135,
        "国内"
      ],
      [
        "T7",
        "龙头企业",
        135,
        139,
        "龙头企业"
      ],
      [
        "T8",
        "公司",
        139,
        143,
        "药明康德"
      ],
      [
        "T9",
        "公司",
        163,
        188,
        "Zentalis Pharmaceu ticals"
      ],
      [
        "T10",
        "扣非净利润",
        213,
        220,
        "扣非归母净利率"
      ],
      [
        "T11",
        "主营业务",
        230,
        234,
        "主营业务"
      ],
      [
        "T12",
        "时间范围",
        202,
        213,
        "2020年 Q1-Q3"
      ],
      [
        "T13",
        "营业收入",
        23,
        25,
        "收入"
      ],
      [
        "T14",
        "毛利",
        117,
        120,
        "毛利率"
      ],
      [
        "T15",
        "时间范围",
        125,
        127,
        "目前"
      ],
      [
        "T16",
        "龙头企业",
        243,
        245,
        "龙头"
      ]
    ]
  },
  {
    "id": 45,
    "text": "、各自媒体公开发布创造者、颠覆者、领航者，知识共享、 政府及园区、金融及投资机构、顶流财经媒体担任计划首席科创辅导官首席新媒体造势官首席生态合作官",
    "labels": []
  },
  {
    "id": 46,
    "text": " CXO行业产能转移不及预期风险；  CXO企业订单不及预期风险；  CXO企业订单波动风险；  汇率波动风险；  其他医药行业政策风险等。",
    "labels": [
      [
        "T0",
        "行业",
        2,
        5,
        "CXO"
      ],
      [
        "T1",
        "行业公司",
        21,
        26,
        "CXO企业"
      ],
      [
        "T2",
        "行业公司",
        38,
        43,
        "CXO企业"
      ],
      [
        "T3",
        "产能",
        7,
        9,
        "产能"
      ],
      [
        "T4",
        "在手订单",
        26,
        28,
        "订单"
      ],
      [
        "T5",
        "在手订单",
        43,
        45,
        "订单"
      ],
      [
        "T6",
        "行业",
        65,
        67,
        "医药"
      ]
    ]
  },
  {
    "id": 48,
    "text": "我国在 2019 年底也推出《GMP 附录-细胞治疗产品》征求意见稿，针对操作人员、原辅料及质量控制等各生产步骤均作出详细要求，进一步提高 CGT 生产的工艺要求。CDMO 公司具有丰富的审查应对经验，及成熟的生产质控体系，可以帮助中小企业规避审查风险，防止因为生产不规范造成的上市延误。",
    "labels": [
      [
        "T0",
        "地点范围",
        0,
        2,
        "我国"
      ],
      [
        "T1",
        "时间范围",
        4,
        11,
        "2019 年底"
      ],
      [
        "T2",
        "行业公司",
        82,
        89,
        "CDMO 公司"
      ],
      [
        "T3",
        "行业",
        70,
        73,
        "CGT"
      ]
    ]
  },
  {
    "id": 49,
    "text": "根据医药魔方数据，2022年2月化学创新药IND申请数量为71个，同比增长61%；生物创新药IND申请数量为52个，同比增长33%，可以看到，国内创新申报延续火热趋势。",
    "labels": [
      [
        "T0",
        "时间范围",
        9,
        16,
        "2022年2月"
      ],
      [
        "T1",
        "行业",
        41,
        46,
        "生物创新药"
      ],
      [
        "T2",
        "IND申报数",
        46,
        53,
        "IND申请数量"
      ],
      [
        "T3",
        "行业",
        16,
        21,
        "化学创新药"
      ],
      [
        "T4",
        "IND申报数",
        21,
        28,
        "IND申请数量"
      ],
      [
        "T5",
        "属性值",
        29,
        40,
        "71个，同比增长61%"
      ],
      [
        "T6",
        "属性值",
        54,
        65,
        "52个，同比增长33%"
      ],
      [
        "T7",
        "地点范围",
        71,
        73,
        "国内"
      ],
      [
        "T8",
        "行业",
        73,
        75,
        "创新"
      ],
      [
        "T9",
        "IND申报数",
        75,
        77,
        "申报"
      ],
      [
        "T10",
        "属性值",
        79,
        81,
        "火热"
      ]
    ]
  },
  {
    "id": 50,
    "text": "1月 18日，优时比（UCB）公司宣布了抗 IL-17A/F抗体 Bimzelx（bimekizumab） 的一项 3期临床试验的积极中期分析结果。试验达到其主要终点和所有重要次要终点，表明 bimekizumab能有效改善活动性非放射学中轴型脊柱关节炎 （nr-axSpA）成人患者的临床症状。这项试验与该药在强直性脊柱炎患者中开展的另一项试验，共同证明了 bimekizumab在整个疾病谱系中的治疗潜力。基于获得的数据，优时比计划在今年第三季度提交 bimekizumab治疗中轴型脊柱关节炎（axSpA）的监管申请。",
    "labels": [
      [
        "T0",
        "时间范围",
        0,
        6,
        "1月 18日"
      ],
      [
        "T1",
        "公司",
        7,
        15,
        "优时比（UCB）"
      ],
      [
        "T2",
        "时间范围",
        219,
        225,
        "今年第三季度"
      ]
    ]
  },
  {
    "id": 51,
    "text": " 2020年CDMO板块营业收入同比增速：九洲药业70.8%>普洛药业46.1%>药明康德40.8%>康龙化成 35.5%>博腾股份32.6%>凯莱英28.0%。  2018-2020期间，CDMO业务在综合CXO的收入占比持续提升。2020年，CDMO业务占比：凯莱英 100%>博腾股份97.2%>九洲药业48.9%>药明康德31.9%>康龙化成23.8%>普洛药业13.4%。",
    "labels": [
      [
        "T0",
        "时间范围",
        2,
        7,
        "2020年"
      ],
      [
        "T1",
        "收入增速",
        13,
        21,
        "营业收入同比增速"
      ],
      [
        "T2",
        "公司",
        22,
        26,
        "九洲药业"
      ],
      [
        "T3",
        "公司",
        32,
        36,
        "普洛药业"
      ],
      [
        "T4",
        "公司",
        42,
        46,
        "药明康德"
      ],
      [
        "T5",
        "公司",
        52,
        56,
        "康龙化成"
      ],
      [
        "T6",
        "公司",
        63,
        67,
        "博腾股份"
      ],
      [
        "T7",
        "公司",
        73,
        76,
        "凯莱英"
      ],
      [
        "T8",
        "时间范围",
        85,
        96,
        "2018-2020期间"
      ],
      [
        "T9",
        "行业",
        97,
        101,
        "CDMO"
      ],
      [
        "T10",
        "行业",
        104,
        109,
        "综合CXO"
      ],
      [
        "T11",
        "营收占比",
        110,
        114,
        "收入占比"
      ],
      [
        "T12",
        "属性值",
        114,
        118,
        "持续提升"
      ],
      [
        "T13",
        "属性值",
        26,
        31,
        "70.8%"
      ],
      [
        "T14",
        "属性值",
        36,
        41,
        "46.1%"
      ],
      [
        "T15",
        "属性值",
        46,
        51,
        "40.8%"
      ],
      [
        "T16",
        "属性值",
        57,
        62,
        "35.5%"
      ],
      [
        "T17",
        "属性值",
        67,
        72,
        "32.6%"
      ],
      [
        "T18",
        "属性值",
        76,
        81,
        "28.0%"
      ],
      [
        "T19",
        "公司",
        134,
        137,
        "凯莱英"
      ],
      [
        "T20",
        "公司",
        143,
        147,
        "博腾股份"
      ],
      [
        "T21",
        "公司",
        153,
        157,
        "九洲药业"
      ],
      [
        "T22",
        "公司",
        163,
        167,
        "药明康德"
      ],
      [
        "T23",
        "公司",
        173,
        177,
        "康龙化成"
      ],
      [
        "T24",
        "公司",
        183,
        187,
        "普洛药业"
      ],
      [
        "T25",
        "时间范围",
        119,
        124,
        "2020年"
      ],
      [
        "T26",
        "行业",
        125,
        129,
        "CDMO"
      ],
      [
        "T27",
        "行业",
        7,
        11,
        "CDMO"
      ],
      [
        "T28",
        "属性值",
        138,
        142,
        "100%"
      ],
      [
        "T29",
        "属性值",
        147,
        152,
        "97.2%"
      ],
      [
        "T30",
        "属性值",
        157,
        162,
        "48.9%"
      ],
      [
        "T31",
        "属性值",
        167,
        172,
        "31.9%"
      ],
      [
        "T32",
        "属性值",
        177,
        182,
        "23.8%"
      ],
      [
        "T33",
        "属性值",
        187,
        192,
        "13.4%"
      ]
    ]
  },
  {
    "id": 52,
    "text": "公司凭借其强大的数据资源与丰富的研发经验，与国内客户建立起以成功为导向的收益共享型合作关系。公司为客户提供一站式研发服务，收入模式主要包括：1）服务费：提供传统临床前试验服务的一次性收费（整体 pre-IND的服务打包，参考板块平均利润率水平， 预计 DDSU净利率约 30-40%）；2）里程碑收费：达到里程碑条件或药物授权后的一次性收费（净利率 100%）； 3）专利费：药品成功上市后的持续性收费，约为每年销售额的 3-5% （净利率 100%）。",
    "labels": [
      [
        "T0",
        "地点范围",
        22,
        24,
        "国内"
      ],
      [
        "T1",
        "行业公司",
        46,
        48,
        "公司"
      ],
      [
        "T2",
        "营业收入",
        61,
        63,
        "收入"
      ],
      [
        "T3",
        "利润",
        116,
        119,
        "利润率"
      ],
      [
        "T4",
        "归母净利润",
        130,
        133,
        "净利率"
      ],
      [
        "T5",
        "归母净利润",
        171,
        174,
        "净利率"
      ],
      [
        "T6",
        "归母净利润",
        217,
        220,
        "净利率"
      ]
    ]
  },
  {
    "id": 53,
    "text": "概览标签：康龙化成、药明康德、泰格医药、CXO、凯莱英",
    "labels": [
      [
        "T0",
        "公司",
        5,
        9,
        "康龙化成"
      ],
      [
        "T1",
        "公司",
        10,
        14,
        "药明康德"
      ],
      [
        "T2",
        "公司",
        15,
        19,
        "泰格医药"
      ],
      [
        "T3",
        "行业",
        20,
        23,
        "CXO"
      ],
      [
        "T4",
        "公司",
        24,
        27,
        "凯莱英"
      ]
    ]
  },
  {
    "id": 54,
    "text": "龙头效应显著，公司临床前 CRO收入保持高速稳定增长。公司 2015-2019年临床前 CRO收入 CAGR达 30.07%，为国内四家综合临床前 CRO（药明康德、康龙化成、 美迪西、睿智医药）之首。我们认为药企在选择长期合作伙伴时会更倾向于选择口碑佳、 技术强的龙头企业，叠加持续高涨的行业景气度，预计公司临床前 CRO收入将继续高增长。",
    "labels": [
      [
        "T0",
        "行业",
        9,
        16,
        "临床前 CRO"
      ],
      [
        "T1",
        "营业收入",
        16,
        18,
        "收入"
      ],
      [
        "T2",
        "时间范围",
        30,
        40,
        "2015-2019年"
      ],
      [
        "T3",
        "行业",
        40,
        47,
        "临床前 CRO"
      ],
      [
        "T4",
        "营业收入",
        47,
        49,
        "收入"
      ],
      [
        "T5",
        "CAGR",
        50,
        54,
        "CAGR"
      ],
      [
        "T6",
        "地点范围",
        64,
        66,
        "国内"
      ],
      [
        "T7",
        "行业公司",
        105,
        107,
        "药企"
      ],
      [
        "T8",
        "龙头企业",
        133,
        137,
        "龙头企业"
      ],
      [
        "T9",
        "行业",
        155,
        162,
        "临床前 CRO"
      ],
      [
        "T10",
        "营业收入",
        162,
        164,
        "收入"
      ],
      [
        "T11",
        "行业",
        68,
        77,
        "综合临床前 CRO"
      ],
      [
        "T12",
        "公司",
        78,
        82,
        "药明康德"
      ],
      [
        "T13",
        "公司",
        83,
        87,
        "康龙化成"
      ],
      [
        "T14",
        "公司",
        89,
        92,
        "美迪西"
      ],
      [
        "T15",
        "公司",
        93,
        97,
        "睿智医药"
      ]
    ]
  },
  {
    "id": 57,
    "text": "重庆博腾制药科技股份有限公司成立于 2005 年，深耕业务十五载，现已立足于国内领先的 CDMO，为全球制药公司、新药研发机构等提供从临床前到临床试验直至药品上市全生命周期所需的化学原料药、化学制剂及生物药的 CDMO服务。一方面得益于 CDMO行业的高景气发展，另一方面公司不断提升核心竞争力，客户、产品管线不断壮大，公司实现了自深度战略转型以来连续九个季度强劲的财务表现。",
    "labels": [
      [
        "T0",
        "地点范围",
        38,
        40,
        "国内"
      ],
      [
        "T1",
        "行业",
        44,
        48,
        "CDMO"
      ],
      [
        "T2",
        "地点范围",
        50,
        52,
        "全球"
      ],
      [
        "T3",
        "行业公司",
        52,
        56,
        "制药公司"
      ],
      [
        "T4",
        "行业公司",
        57,
        63,
        "新药研发机构"
      ],
      [
        "T5",
        "行业",
        119,
        123,
        "CDMO"
      ],
      [
        "T6",
        "公司",
        0,
        14,
        "重庆博腾制药科技股份有限公司"
      ],
      [
        "T7",
        "时间范围",
        18,
        24,
        "2005 年"
      ],
      [
        "T8",
        "行业",
        105,
        109,
        "CDMO"
      ],
      [
        "T9",
        "属性值",
        180,
        182,
        "强劲"
      ],
      [
        "T10",
        "财务情况",
        183,
        185,
        "财务"
      ],
      [
        "T11",
        "时间范围",
        165,
        174,
        "自深度战略转型以来"
      ]
    ]
  },
  {
    "id": 59,
    "text": "对于临床 CRO细分行业而言，大量新药研发项目进入后期临床开发阶段， 临床 CRO需求激增。此外，从全球竞争力角度，我们预计未来 3年，中国临床 CRO头部企业将会持续通过产能扩张、海外并购方式推进全球化布局，全球多中心临床订单承接能力将出现拐点式变化，中国临床 CRO 产业的全球竞争力将显著提升。",
    "labels": [
      [
        "T0",
        "行业",
        2,
        8,
        "临床 CRO"
      ],
      [
        "T1",
        "行业",
        35,
        41,
        "临床 CRO"
      ],
      [
        "T2",
        "地点范围",
        50,
        52,
        "全球"
      ],
      [
        "T3",
        "时间范围",
        62,
        67,
        "未来 3年"
      ],
      [
        "T4",
        "地点范围",
        68,
        70,
        "中国"
      ],
      [
        "T5",
        "行业",
        70,
        76,
        "临床 CRO"
      ],
      [
        "T6",
        "龙头企业",
        76,
        80,
        "头部企业"
      ],
      [
        "T7",
        "地点范围",
        127,
        129,
        "中国"
      ],
      [
        "T8",
        "地点范围",
        105,
        107,
        "全球"
      ],
      [
        "T9",
        "行业",
        129,
        135,
        "临床 CRO"
      ],
      [
        "T10",
        "属性值",
        43,
        45,
        "激增"
      ],
      [
        "T11",
        "行业需求",
        41,
        43,
        "需求"
      ],
      [
        "T12",
        "产能",
        86,
        88,
        "产能"
      ],
      [
        "T13",
        "地点范围",
        91,
        93,
        "海外"
      ],
      [
        "T14",
        "行业",
        139,
        141,
        "全球"
      ]
    ]
  },
  {
    "id": 60,
    "text": "医药生物市盈率（TTM，整体法，剔除负值）31.05x，全部A股（申万A股指数） 市盈率16.85x。分板块来看，化学制药32.74x，生物制品29.80x，医疗服务55.11x， 医疗器械21.69x，医药商业18.43x，中药34.65x",
    "labels": [
      [
        "T0",
        "行业",
        0,
        4,
        "医药生物"
      ],
      [
        "T1",
        "PE",
        4,
        7,
        "市盈率"
      ],
      [
        "T2",
        "属性值",
        21,
        27,
        "31.05x"
      ],
      [
        "T3",
        "属性值",
        61,
        67,
        "32.74x"
      ],
      [
        "T4",
        "属性值",
        72,
        78,
        "29.80x"
      ],
      [
        "T5",
        "属性值",
        83,
        89,
        "55.11x"
      ],
      [
        "T6",
        "属性值",
        95,
        101,
        "21.69x"
      ],
      [
        "T7",
        "属性值",
        106,
        112,
        "18.43x"
      ],
      [
        "T8",
        "属性值",
        115,
        121,
        "34.65x"
      ],
      [
        "T9",
        "行业",
        57,
        61,
        "化学制药"
      ],
      [
        "T10",
        "行业",
        68,
        72,
        "生物制品"
      ],
      [
        "T11",
        "行业",
        79,
        83,
        "医疗服务"
      ],
      [
        "T12",
        "行业",
        91,
        95,
        "医疗器械"
      ],
      [
        "T13",
        "行业",
        102,
        106,
        "医药商业"
      ],
      [
        "T14",
        "行业",
        113,
        115,
        "中药"
      ],
      [
        "T15",
        "PE",
        41,
        44,
        "市盈率"
      ]
    ]
  },
  {
    "id": 61,
    "text": "“让天下没有难做的药，难治的病”，这是药明康德的愿景，也是医药人共同的期盼。",
    "labels": [
      [
        "T0",
        "公司",
        19,
        23,
        "药明康德"
      ],
      [
        "T1",
        "行业",
        29,
        31,
        "医药"
      ]
    ]
  },
  {
    "id": 62,
    "text": "CGT CDMO 渗透率高，显著受益于 CGT 发展。相较于小分子及大分子，CGT 药物的研发生产高度依赖外包。截至 2020 年，Pharma's Almanac 及 JP Morgan 的数据统计显示，CGT 行业的外包率在 65%以上，远高于传统生物制剂约 35% 的外包率。CRB 公司通过对近 150 家 CGT 企业调研发现，77%的企业与 CDMO 公司进行研发生产合作，仅有 23%的企业选择完全内部生产。CGT 研发生产高度依赖外包的特性， 导致 CGT CDMO 市场的发展与 CGT 市场的发展高度相关。",
    "labels": [
      [
        "T0",
        "行业",
        0,
        8,
        "CGT CDMO"
      ],
      [
        "T1",
        "行业",
        20,
        23,
        "CGT"
      ],
      [
        "T2",
        "行业",
        30,
        37,
        "小分子及大分子"
      ],
      [
        "T3",
        "行业",
        38,
        44,
        "CGT 药物"
      ],
      [
        "T4",
        "时间范围",
        56,
        65,
        "截至 2020 年"
      ],
      [
        "T5",
        "行业",
        103,
        106,
        "CGT"
      ],
      [
        "T6",
        "属性值",
        115,
        120,
        "65%以上"
      ],
      [
        "T7",
        "行业",
        124,
        130,
        "传统生物制剂"
      ],
      [
        "T8",
        "外包率",
        137,
        140,
        "外包率"
      ],
      [
        "T9",
        "外包率",
        110,
        113,
        "外包率"
      ],
      [
        "T10",
        "行业公司",
        177,
        184,
        "CDMO 公司"
      ],
      [
        "T11",
        "行业",
        233,
        241,
        "CGT CDMO"
      ],
      [
        "T12",
        "行业",
        249,
        252,
        "CGT"
      ],
      [
        "T13",
        "属性值",
        130,
        135,
        "约 35%"
      ],
      [
        "T14",
        "行业",
        211,
        214,
        "CGT"
      ],
      [
        "T15",
        "属性值",
        215,
        225,
        "研发生产高度依赖外包"
      ],
      [
        "T16",
        "属性值",
        45,
        55,
        "研发生产高度依赖外包"
      ],
      [
        "T17",
        "行业公司",
        150,
        164,
        "近 150 家 CGT 企业"
      ]
    ]
  },
  {
    "id": 63,
    "text": "康龙化成属于CRO+CDMO共同布局的公司，主要服务有临床研究服务、CMC服务和实验室；2017-2020年，凯莱英与泰格医药毛利率略高于药明康德与康龙化成",
    "labels": [
      [
        "T0",
        "公司",
        0,
        4,
        "康龙化成"
      ],
      [
        "T1",
        "时间范围",
        44,
        54,
        "2017-2020年"
      ],
      [
        "T2",
        "公司",
        55,
        58,
        "凯莱英"
      ],
      [
        "T3",
        "公司",
        59,
        63,
        "泰格医药"
      ],
      [
        "T4",
        "毛利",
        63,
        66,
        "毛利率"
      ],
      [
        "T5",
        "公司",
        69,
        73,
        "药明康德"
      ],
      [
        "T6",
        "公司",
        74,
        78,
        "康龙化成"
      ],
      [
        "T7",
        "主营业务",
        22,
        26,
        "主要服务"
      ],
      [
        "T8",
        "属性值",
        27,
        43,
        "临床研究服务、CMC服务和实验室"
      ],
      [
        "T9",
        "行业",
        6,
        9,
        "CRO"
      ],
      [
        "T10",
        "行业",
        10,
        14,
        "CDMO"
      ]
    ]
  },
  {
    "id": 65,
    "text": "2）外包前置化：细胞基因治疗产品较传统小分子化药和大分子生物药更复杂，操作和检测难度大；以全球首款上市CAR-T产品为例，诺华从立项到商业化生产，都跟CDMO合作紧密。",
    "labels": [
      [
        "T0",
        "行业",
        75,
        79,
        "CDMO"
      ],
      [
        "T1",
        "公司",
        61,
        63,
        "诺华"
      ]
    ]
  },
  {
    "id": 66,
    "text": "国产生物科研试剂市占率及集中度将不断提升。由于发展时间尚短，国产技术和品牌实力弱于国际巨头，我国生物科研试剂主要市场仍被外资企业占据，另与欧美等发达国家相比，国产市场集中度处于较低水平，产品种类与企业众多、规模较小且较为分散。未来随着国内生物行业的快速发展，技术水平的不断提升，国产生物科研试剂市场占有率或将不断提高，同时行业市场集中度也将持续提升，建议关注国产优质上市公司义翘神州、百普赛斯、诺唯赞等。",
    "labels": [
      [
        "T0",
        "市场集中度",
        81,
        86,
        "市场集中度"
      ],
      [
        "T1",
        "地点范围",
        79,
        81,
        "国产"
      ],
      [
        "T2",
        "地点范围",
        69,
        76,
        "欧美等发达国家"
      ],
      [
        "T3",
        "地点范围",
        117,
        119,
        "国内"
      ],
      [
        "T4",
        "行业",
        119,
        121,
        "生物"
      ],
      [
        "T5",
        "市场集中度",
        163,
        168,
        "市场集中度"
      ],
      [
        "T6",
        "公司",
        187,
        191,
        "义翘神州"
      ],
      [
        "T7",
        "公司",
        192,
        196,
        "百普赛斯"
      ],
      [
        "T8",
        "公司",
        197,
        200,
        "诺唯赞"
      ],
      [
        "T9",
        "行业",
        0,
        8,
        "国产生物科研试剂"
      ],
      [
        "T10",
        "市场份额",
        8,
        11,
        "市占率"
      ],
      [
        "T11",
        "市场集中度",
        12,
        15,
        "集中度"
      ],
      [
        "T12",
        "地点范围",
        46,
        48,
        "我国"
      ],
      [
        "T13",
        "行业",
        48,
        54,
        "生物科研试剂"
      ],
      [
        "T14",
        "时间范围",
        113,
        115,
        "未来"
      ],
      [
        "T15",
        "行业",
        139,
        147,
        "国产生物科研试剂"
      ],
      [
        "T16",
        "市场份额",
        147,
        152,
        "市场占有率"
      ],
      [
        "T17",
        "属性值",
        170,
        174,
        "持续提升"
      ],
      [
        "T18",
        "属性值",
        16,
        20,
        "不断提升"
      ],
      [
        "T19",
        "属性值",
        88,
        92,
        "较低水平"
      ],
      [
        "T20",
        "属性值",
        154,
        158,
        "不断提高"
      ]
    ]
  },
  {
    "id": 67,
    "text": "◼ 技术：主要业务涵盖片剂、胶囊、多颗粒给药系、颗粒剂、注射剂等。目前正在推进制剂技术平台的搭建，包括复杂制剂技术、增溶技术等，其中重庆实验室和上海张江研发中心已投入使用，美国制剂实验室也在积极建设中。2021年 5月，位于重庆两江新区的商业化生产基地一期项目已开工建设，。2021年 3月，博腾药业与 AI 制剂研发公司剂泰医药宣布战略合作，积极探索 AI在 CDMO领域的应用。 ◼ 订单：博腾药业作为承接制剂 CDMO业务的主体，积极与公司多个现有的原料药 CDMO客户及潜在有需求客户开展互动，持续积累潜在项目储备。2020年博腾药业签订了 3个订单（订单金额约 1,900万元），并启动首个项目的前期研发工作， 2021年一季度客户数量达到 9家。",
    "labels": [
      [
        "T0",
        "主营业务",
        5,
        9,
        "主要业务"
      ],
      [
        "T1",
        "时间范围",
        101,
        109,
        "2021年 5月"
      ],
      [
        "T2",
        "地点范围",
        112,
        118,
        "重庆两江新区"
      ],
      [
        "T3",
        "时间范围",
        137,
        145,
        "2021年 3月"
      ],
      [
        "T4",
        "公司",
        146,
        150,
        "博腾药业"
      ],
      [
        "T5",
        "公司",
        161,
        165,
        "剂泰医药"
      ],
      [
        "T6",
        "公司",
        197,
        201,
        "博腾药业"
      ],
      [
        "T7",
        "行业",
        205,
        212,
        "制剂 CDMO"
      ],
      [
        "T8",
        "行业",
        228,
        236,
        "原料药 CDMO"
      ],
      [
        "T9",
        "时间范围",
        262,
        267,
        "2020年"
      ],
      [
        "T10",
        "公司",
        267,
        271,
        "博腾药业"
      ],
      [
        "T11",
        "时间范围",
        311,
        319,
        "2021年一季度"
      ],
      [
        "T12",
        "客户数量",
        319,
        323,
        "客户数量"
      ],
      [
        "T13",
        "属性值",
        326,
        328,
        "9家"
      ],
      [
        "T14",
        "地点范围",
        86,
        88,
        "美国"
      ],
      [
        "T15",
        "地点范围",
        66,
        68,
        "重庆"
      ],
      [
        "T16",
        "行业",
        152,
        159,
        "AI 制剂研发"
      ],
      [
        "T17",
        "行业",
        181,
        185,
        "CDMO"
      ],
      [
        "T18",
        "属性值",
        275,
        277,
        "3个"
      ],
      [
        "T19",
        "属性值",
        284,
        293,
        "约 1,900万元"
      ]
    ]
  },
  {
    "id": 68,
    "text": "药企研发投入持续提升，CXO需求不减。根据 Pharmaprojects数据，全球药物研发支出由 2012年的 1361亿美元提升至 2020年的 1878亿美元，复合增速达 4.11%。 持续加大研发投入的同时，新药管线与 IND申请/受理数量也持续走高，根据 Statista 数据，在研新药数量也由 2010年的 9737个提高到 2021年的 18582个，复合增速达 4.76%。",
    "labels": [
      [
        "T0",
        "行业公司",
        0,
        2,
        "药企"
      ],
      [
        "T1",
        "研发费用",
        2,
        6,
        "研发投入"
      ],
      [
        "T2",
        "属性值",
        6,
        10,
        "持续提升"
      ],
      [
        "T3",
        "行业",
        11,
        14,
        "CXO"
      ],
      [
        "T4",
        "地点范围",
        39,
        41,
        "全球"
      ],
      [
        "T5",
        "时间范围",
        49,
        54,
        "2012年"
      ],
      [
        "T6",
        "属性值",
        56,
        63,
        "1361亿美元"
      ],
      [
        "T7",
        "属性值",
        74,
        81,
        "1878亿美元"
      ],
      [
        "T8",
        "属性值",
        88,
        93,
        "4.11%"
      ],
      [
        "T9",
        "CAGR",
        82,
        86,
        "复合增速"
      ],
      [
        "T10",
        "时间范围",
        67,
        72,
        "2020年"
      ],
      [
        "T11",
        "时间范围",
        153,
        158,
        "2010年"
      ],
      [
        "T12",
        "时间范围",
        169,
        174,
        "2021年"
      ],
      [
        "T13",
        "CAGR",
        183,
        187,
        "复合增速"
      ],
      [
        "T14",
        "属性值",
        16,
        18,
        "不减"
      ],
      [
        "T15",
        "行业需求",
        14,
        16,
        "需求"
      ],
      [
        "T16",
        "行业",
        41,
        43,
        "药物"
      ],
      [
        "T17",
        "研发费用",
        43,
        47,
        "研发支出"
      ],
      [
        "T18",
        "研发费用",
        99,
        103,
        "研发投入"
      ],
      [
        "T19",
        "属性值",
        95,
        99,
        "持续加大"
      ],
      [
        "T20",
        "IND申报数",
        113,
        118,
        "IND申请"
      ],
      [
        "T21",
        "属性值",
        124,
        128,
        "持续走高"
      ]
    ]
  },
  {
    "id": 69,
    "text": "综上，随着国内 CXO行业全球化一体化布局的加速，整个板块有望迎来业绩加速成长的新拐点，带来估值和市值天花板的再一轮刷新，继续强力推荐 CXO赛道，建议积极关注小分子 CDMO创新药项目管线储备最深厚的一体化 CRO/CDMO外包服务龙头药明康德；CDMO核心技术优势明显、客户结构优秀、储备品种丰富的凯莱英；与诺华深度战略绑定重磅药 API生产服务，并有数个国内 MAH项目即将报产的九洲药业；围绕“做强 CDMO”发展战略，向“注册中间体+原料药”模式转变的普洛药业；国内创新药临床 CRO 龙头，新签和在手订单充沛，有望通过国际化拓展打开成长天花板的泰格医药；基于分子砌块研发制造双轮驱动，大规模生产项目或已进入放量阶段的药石科技。",
    "labels": [
      [
        "T0",
        "地点范围",
        5,
        7,
        "国内"
      ],
      [
        "T1",
        "行业",
        8,
        11,
        "CXO"
      ],
      [
        "T2",
        "行业",
        80,
        91,
        "小分子 CDMO创新药"
      ],
      [
        "T3",
        "龙头企业",
        117,
        119,
        "龙头"
      ],
      [
        "T4",
        "公司",
        119,
        123,
        "药明康德"
      ],
      [
        "T5",
        "属性值",
        13,
        21,
        "全球化一体化布局"
      ],
      [
        "T6",
        "业绩",
        33,
        35,
        "业绩"
      ],
      [
        "T7",
        "属性值",
        35,
        39,
        "加速成长"
      ],
      [
        "T8",
        "市值",
        49,
        51,
        "市值"
      ],
      [
        "T9",
        "行业",
        68,
        71,
        "CXO"
      ],
      [
        "T10",
        "行业",
        101,
        117,
        "一体化 CRO/CDMO外包服务"
      ],
      [
        "T11",
        "行业",
        124,
        128,
        "CDMO"
      ],
      [
        "T12",
        "公司",
        151,
        154,
        "凯莱英"
      ],
      [
        "T13",
        "公司",
        156,
        158,
        "诺华"
      ],
      [
        "T14",
        "行业",
        164,
        173,
        "重磅药 API生产"
      ],
      [
        "T15",
        "公司",
        193,
        197,
        "九洲药业"
      ],
      [
        "T16",
        "公司",
        231,
        235,
        "普洛药业"
      ],
      [
        "T17",
        "地点范围",
        236,
        238,
        "国内"
      ],
      [
        "T18",
        "行业",
        238,
        247,
        "创新药临床 CRO"
      ],
      [
        "T19",
        "龙头企业",
        248,
        250,
        "龙头"
      ],
      [
        "T20",
        "在手订单",
        254,
        258,
        "在手订单"
      ],
      [
        "T21",
        "公司",
        278,
        282,
        "泰格医药"
      ],
      [
        "T22",
        "属性值",
        258,
        260,
        "充沛"
      ],
      [
        "T23",
        "公司",
        314,
        318,
        "药石科技"
      ],
      [
        "T24",
        "属性值",
        215,
        226,
        "“注册中间体+原料药”"
      ]
    ]
  },
  {
    "id": 71,
    "text": "1）市场认为细胞基因治疗药物售价高，难以依靠医保报销，受众群体小，市场规模受限，CGT CDMO 天花板低。我们认为随着 CGT 技术突破及 CGT 生产工艺突破，以及国产化原材料替代，CGT 生产成本将大幅下降，尤其是病毒载体制备成本最多可以降低 80%。此外商业保险以及新的支付模式，可支持对 CGT 药物保险覆盖，提高 CGT 药物可及性。CGT 药物渗透率的进一步提升将推动其规模化生产，可以有效助力 CGT CDMO 快速发展。",
    "labels": [
      [
        "T0",
        "行业",
        6,
        14,
        "细胞基因治疗药物"
      ],
      [
        "T1",
        "市场规模",
        33,
        37,
        "市场规模"
      ],
      [
        "T2",
        "行业",
        40,
        48,
        "CGT CDMO"
      ],
      [
        "T3",
        "属性值",
        37,
        39,
        "受限"
      ],
      [
        "T4",
        "属性值",
        49,
        53,
        "天花板低"
      ],
      [
        "T5",
        "行业",
        205,
        213,
        "CGT CDMO"
      ],
      [
        "T6",
        "行业",
        61,
        64,
        "CGT"
      ],
      [
        "T7",
        "行业",
        71,
        74,
        "CGT"
      ],
      [
        "T8",
        "行业",
        93,
        96,
        "CGT"
      ],
      [
        "T9",
        "行业",
        149,
        155,
        "CGT 药物"
      ],
      [
        "T10",
        "行业",
        163,
        169,
        "CGT 药物"
      ],
      [
        "T11",
        "行业",
        173,
        179,
        "CGT 药物"
      ]
    ]
  },
  {
    "id": 72,
    "text": "❑ 培育 CGT和制剂 CDMO新业务，蓄势中长期发力。2020年两大业务合计减少净利润 4247万元，未来 2-3年有望迎来快速增长。2020年，生物 CDMO共签订 5个订单（约 5600万元），2021年一季度服务客户 7家；2020年签订 3 个订单（约 1900万元），并启动首个项目的前期研发工作，2021年一季度服务客户 9家。",
    "labels": [
      [
        "T0",
        "时间范围",
        28,
        33,
        "2020年"
      ],
      [
        "T1",
        "时间范围",
        52,
        59,
        "未来 2-3年"
      ],
      [
        "T2",
        "时间范围",
        68,
        73,
        "2020年"
      ],
      [
        "T3",
        "时间范围",
        100,
        108,
        "2021年一季度"
      ],
      [
        "T4",
        "时间范围",
        116,
        121,
        "2020年"
      ],
      [
        "T5",
        "属性值",
        124,
        127,
        "3 个"
      ],
      [
        "T6",
        "属性值",
        113,
        115,
        "7家"
      ],
      [
        "T7",
        "属性值",
        85,
        87,
        "5个"
      ],
      [
        "T8",
        "属性值",
        90,
        98,
        "约 5600万元"
      ],
      [
        "T9",
        "属性值",
        130,
        138,
        "约 1900万元"
      ],
      [
        "T10",
        "行业",
        74,
        81,
        "生物 CDMO"
      ],
      [
        "T11",
        "时间范围",
        155,
        163,
        "2021年一季度"
      ],
      [
        "T12",
        "属性值",
        168,
        170,
        "9家"
      ],
      [
        "T13",
        "行业",
        5,
        8,
        "CGT"
      ],
      [
        "T14",
        "行业",
        9,
        16,
        "制剂 CDMO"
      ],
      [
        "T15",
        "归母净利润",
        41,
        44,
        "净利润"
      ]
    ]
  },
  {
    "id": 73,
    "text": "另一方面，从估值角度来看，随着前期板块下跌消化估值溢价，当前 CXO板块估值处在相对低位水平，匹配业绩增速我们认为短期具备一定估值弹性。此外， 基于新冠小分子药物重磅订单，CDMO 赛道 2022年的业绩增长相对具备更强弹性。虽然这些重磅订单催化我国小分子 CDMO行业产能快速释放，但根据我们分析和测算行业需求后续仍有较大提升空间，且全球订单向中国转移和集中的趋势可持续。（详见近期深度报告《知往鉴今，放眼全球，论我国 CXO赛道发展趋势》）",
    "labels": [
      [
        "T0",
        "业绩",
        49,
        51,
        "业绩"
      ],
      [
        "T1",
        "行业",
        74,
        81,
        "新冠小分子药物"
      ],
      [
        "T2",
        "行业",
        86,
        90,
        "CDMO"
      ],
      [
        "T3",
        "时间范围",
        94,
        99,
        "2022年"
      ],
      [
        "T4",
        "业绩",
        100,
        102,
        "业绩"
      ],
      [
        "T5",
        "地点范围",
        123,
        125,
        "我国"
      ],
      [
        "T6",
        "行业",
        125,
        133,
        "小分子 CDMO"
      ],
      [
        "T7",
        "产能",
        135,
        137,
        "产能"
      ],
      [
        "T8",
        "属性值",
        137,
        141,
        "快速释放"
      ],
      [
        "T9",
        "行业",
        31,
        34,
        "CXO"
      ],
      [
        "T10",
        "行业需求",
        152,
        156,
        "行业需求"
      ],
      [
        "T11",
        "属性值",
        159,
        166,
        "有较大提升空间"
      ],
      [
        "T12",
        "属性值",
        168,
        180,
        "全球订单向中国转移和集中"
      ],
      [
        "T13",
        "地点范围",
        208,
        210,
        "我国"
      ],
      [
        "T14",
        "行业",
        211,
        214,
        "CXO"
      ],
      [
        "T15",
        "地点范围",
        204,
        206,
        "全球"
      ],
      [
        "T16",
        "属性值",
        108,
        112,
        "更强弹性"
      ]
    ]
  },
  {
    "id": 74,
    "text": "2020年年初至 2021年前三季度，CXO板块公司股价走势一路向好，近期股价波动的原因之一为市场对于美国制裁中国生物科技股的忧虑。我们认为国内龙头 CXO 公司已与美国龙头药企合作多年，且承接大批小分子新冠药物订单，若美国药企更换 CXO服务商需付出高成本，承担高风险，因此国内 CXO龙头受美国制裁的可能性不高。随着 CXO板块公司年报相继发布，业绩整体略好于预期，增强了市场信心。",
    "labels": [
      [
        "T0",
        "时间范围",
        -1,
        18,
        ""
      ],
      [
        "T1",
        "行业公司",
        19,
        26,
        "CXO板块公司"
      ],
      [
        "T2",
        "龙头企业",
        72,
        74,
        "龙头"
      ],
      [
        "T3",
        "行业公司",
        75,
        81,
        "CXO 公司"
      ],
      [
        "T4",
        "龙头企业",
        85,
        87,
        "龙头"
      ],
      [
        "T5",
        "行业公司",
        87,
        89,
        "药企"
      ],
      [
        "T6",
        "地点范围",
        83,
        85,
        "美国"
      ],
      [
        "T7",
        "地点范围",
        70,
        72,
        "国内"
      ],
      [
        "T8",
        "行业",
        99,
        106,
        "小分子新冠药物"
      ],
      [
        "T9",
        "地点范围",
        110,
        112,
        "美国"
      ],
      [
        "T10",
        "行业公司",
        112,
        114,
        "药企"
      ],
      [
        "T11",
        "地点范围",
        138,
        140,
        "国内"
      ],
      [
        "T12",
        "地点范围",
        147,
        149,
        "美国"
      ],
      [
        "T13",
        "地点范围",
        51,
        53,
        "美国"
      ],
      [
        "T14",
        "地点范围",
        55,
        57,
        "中国"
      ],
      [
        "T15",
        "行业公司",
        57,
        62,
        "生物科技股"
      ],
      [
        "T16",
        "行业公司",
        117,
        123,
        "CXO服务商"
      ],
      [
        "T17",
        "行业公司",
        161,
        168,
        "CXO板块公司"
      ],
      [
        "T18",
        "业绩",
        175,
        177,
        "业绩"
      ],
      [
        "T19",
        "属性值",
        179,
        184,
        "略好于预期"
      ],
      [
        "T20",
        "行业公司",
        141,
        146,
        "CXO龙头"
      ]
    ]
  },
  {
    "id": 75,
    "text": "金斯瑞生物科技于 2020 年打造金斯瑞蓬勃生物品牌子公司，金斯瑞蓬勃生物主营大分子及 CGT CDMO 业务， 并在 2021 年获得高瓴资本 1.5 亿美元 A 轮融资， 此后迅速扩大产能，快速提升订单承接能力。公司 CGT CDMO 业务涵盖质粒、 病毒（AAV 和 LV）的端到端一站式服务。由于公司提供实验室研究级别质粒历史悠久，扩张至工业规模生产后依旧保持高质量，是国内 GMP 质粒生产龙头。 公司累计帮助客户完成超过 50 批次 GMP 质粒生产，提供的质粒具有菌库溯源清晰、适用性强、生产工艺优秀、质粒性质稳定等优点。",
    "labels": [
      [
        "T0",
        "公司",
        0,
        7,
        "金斯瑞生物科技"
      ],
      [
        "T1",
        "时间范围",
        9,
        15,
        "2020 年"
      ],
      [
        "T2",
        "公司",
        30,
        37,
        "金斯瑞蓬勃生物"
      ],
      [
        "T3",
        "行业公司",
        17,
        29,
        "金斯瑞蓬勃生物品牌子公司"
      ],
      [
        "T4",
        "主营业务",
        37,
        39,
        "主营"
      ],
      [
        "T5",
        "时间范围",
        60,
        66,
        "2021 年"
      ],
      [
        "T6",
        "公司",
        68,
        72,
        "高瓴资本"
      ],
      [
        "T7",
        "产能",
        94,
        96,
        "产能"
      ],
      [
        "T8",
        "行业",
        111,
        119,
        "CGT CDMO"
      ],
      [
        "T9",
        "行业",
        192,
        200,
        "GMP 质粒生产"
      ],
      [
        "T10",
        "地点范围",
        189,
        191,
        "国内"
      ],
      [
        "T11",
        "龙头企业",
        200,
        202,
        "龙头"
      ],
      [
        "T12",
        "属性值",
        73,
        86,
        "1.5 亿美元 A 轮融资"
      ],
      [
        "T13",
        "属性值",
        90,
        94,
        "迅速扩大"
      ],
      [
        "T14",
        "时间范围",
        88,
        90,
        "此后"
      ],
      [
        "T15",
        "属性值",
        39,
        52,
        "大分子及 CGT CDMO"
      ]
    ]
  },
  {
    "id": 76,
    "text": "重点公司CDMO业务固定资产规模均呈现快速增长，且单位固定资产产值呈现提升过程中：2018-2020年药明康德的CDMO业务、药明生物、凯莱英固定资产原值规模均呈现高速增长中，且考虑到产品升级、技术平台进步以及规模效应下，其单位固定资产产值也呈现逐渐提升中； 核心CXO公司2020年以来呈现明显加速：2020年以来，药明康德、康龙化成、凯莱英、博腾股份等公司资本开支呈现明显加速的趋势。展望未来3年，受益于全球产业链“转移”和国内行业的高景气度，我们判断未来资本开支将继续呈现高强度。",
    "labels": [
      [
        "T0",
        "行业",
        5,
        9,
        "CDMO"
      ],
      [
        "T1",
        "时间范围",
        42,
        52,
        "2018-2020年"
      ],
      [
        "T2",
        "公司",
        52,
        56,
        "药明康德"
      ],
      [
        "T3",
        "行业",
        57,
        61,
        "CDMO"
      ],
      [
        "T4",
        "公司",
        64,
        68,
        "药明生物"
      ],
      [
        "T5",
        "公司",
        69,
        72,
        "凯莱英"
      ],
      [
        "T6",
        "固定资产",
        72,
        76,
        "固定资产"
      ],
      [
        "T7",
        "时间范围",
        153,
        160,
        "2020年以来"
      ],
      [
        "T8",
        "时间范围",
        139,
        146,
        "2020年以来"
      ],
      [
        "T9",
        "公司",
        161,
        165,
        "药明康德"
      ],
      [
        "T10",
        "公司",
        166,
        170,
        "康龙化成"
      ],
      [
        "T11",
        "公司",
        171,
        174,
        "凯莱英"
      ],
      [
        "T12",
        "公司",
        175,
        179,
        "博腾股份"
      ],
      [
        "T13",
        "时间范围",
        198,
        202,
        "未来3年"
      ],
      [
        "T14",
        "行业公司",
        132,
        139,
        "核心CXO公司"
      ],
      [
        "T15",
        "固定资产",
        11,
        15,
        "固定资产"
      ],
      [
        "T16",
        "属性值",
        83,
        87,
        "高速增长"
      ],
      [
        "T17",
        "CAPEX资本开支",
        232,
        236,
        "资本开支"
      ],
      [
        "T18",
        "属性值",
        241,
        244,
        "高强度"
      ],
      [
        "T19",
        "CAPEX资本开支",
        182,
        186,
        "资本开支"
      ],
      [
        "T20",
        "属性值",
        188,
        192,
        "明显加速"
      ]
    ]
  },
  {
    "id": 77,
    "text": "2）市场认为国内 CGT 市场尚不成熟，获批药物少、CDMO 空间较小，布局尚早。我们认为，由于 CGT 生产工艺壁垒高，客户粘性大，临床 III 期工艺确认完成后，后续更换成本高昂。现阶段与临床早期 CGT 项目达成合作的 CDMO 公司具有较高投资价值，一旦药物上市，获取商业化订单销售放量的确定性高。",
    "labels": [
      [
        "T0",
        "地点范围",
        6,
        8,
        "国内"
      ],
      [
        "T1",
        "行业",
        9,
        12,
        "CGT"
      ],
      [
        "T2",
        "行业",
        26,
        30,
        "CDMO"
      ],
      [
        "T3",
        "行业",
        49,
        52,
        "CGT"
      ],
      [
        "T4",
        "行业公司",
        113,
        120,
        "CDMO 公司"
      ]
    ]
  },
  {
    "id": 78,
    "text": "从收入端来看，国内主要 CXO企业，尤其是小分子创新药 CDMO企业近年来已开始呈现出高速增长态势。我们认为，资本热潮下叠加国内 MAH制度试行至今，众多临床前项目需求有望继续传导到临床 CRO和 CDMO公司的后期阶段项目，国内 CXO企业作为全球竞争市场的参与者，凭借国内工程师红利和制造业的比较优势，全球份额不断提升， 而 2020年初爆发的新冠疫情，国内控制相对较好，导致海外订单需求阶段性向中国转移加速，加速行业爆发式增长趋势，前两年已经不错的行业增长进一步提速，带来可观的业绩弹性——如药明康德、泰格医药、博腾股份、药石科技、昭衍新药等公司 2020年利润端（体现产能利用和经营效率）在 2019年的基础上进一步加速（凯莱英、九洲药业暂未披露 2020年年报）。",
    "labels": [
      [
        "T0",
        "地点范围",
        7,
        9,
        "国内"
      ],
      [
        "T1",
        "行业公司",
        21,
        34,
        "小分子创新药 CDMO企业"
      ],
      [
        "T2",
        "地点范围",
        113,
        115,
        "国内"
      ],
      [
        "T3",
        "行业公司",
        116,
        121,
        "CXO企业"
      ],
      [
        "T4",
        "地点范围",
        123,
        125,
        "全球"
      ],
      [
        "T5",
        "地点范围",
        153,
        155,
        "全球"
      ],
      [
        "T6",
        "市场份额",
        155,
        157,
        "份额"
      ],
      [
        "T7",
        "属性值",
        157,
        161,
        "不断提升"
      ],
      [
        "T8",
        "时间范围",
        165,
        171,
        "2020年初"
      ],
      [
        "T9",
        "公司",
        249,
        253,
        "药明康德"
      ],
      [
        "T10",
        "公司",
        254,
        258,
        "泰格医药"
      ],
      [
        "T11",
        "公司",
        259,
        263,
        "博腾股份"
      ],
      [
        "T12",
        "公司",
        264,
        268,
        "药石科技"
      ],
      [
        "T13",
        "公司",
        269,
        273,
        "昭衍新药"
      ],
      [
        "T14",
        "时间范围",
        277,
        282,
        "2020年"
      ],
      [
        "T15",
        "时间范围",
        300,
        305,
        "2019年"
      ],
      [
        "T16",
        "公司",
        315,
        318,
        "凯莱英"
      ],
      [
        "T17",
        "公司",
        319,
        323,
        "九洲药业"
      ],
      [
        "T18",
        "营业收入",
        1,
        4,
        "收入端"
      ],
      [
        "T19",
        "行业公司",
        12,
        17,
        "CXO企业"
      ],
      [
        "T20",
        "时间范围",
        34,
        37,
        "近年来"
      ],
      [
        "T21",
        "属性值",
        43,
        47,
        "高速增长"
      ],
      [
        "T22",
        "行业",
        91,
        97,
        "临床 CRO"
      ],
      [
        "T23",
        "行业",
        99,
        103,
        "CDMO"
      ],
      [
        "T24",
        "行业",
        77,
        80,
        "临床前"
      ],
      [
        "T25",
        "地点范围",
        136,
        138,
        "国内"
      ],
      [
        "T26",
        "行业",
        144,
        147,
        "制造业"
      ],
      [
        "T27",
        "地点范围",
        179,
        181,
        "国内"
      ],
      [
        "T28",
        "地点范围",
        190,
        192,
        "海外"
      ],
      [
        "T29",
        "属性值",
        196,
        206,
        "阶段性向中国转移加速"
      ],
      [
        "T30",
        "行业需求",
        194,
        196,
        "需求"
      ],
      [
        "T31",
        "属性值",
        211,
        216,
        "爆发式增长"
      ],
      [
        "T32",
        "时间范围",
        219,
        222,
        "前两年"
      ],
      [
        "T33",
        "业绩",
        242,
        244,
        "业绩"
      ],
      [
        "T34",
        "属性值",
        239,
        241,
        "可观"
      ],
      [
        "T35",
        "利润",
        282,
        285,
        "利润端"
      ],
      [
        "T36",
        "时间范围",
        328,
        333,
        "2020年"
      ],
      [
        "T37",
        "属性值",
        309,
        314,
        "进一步加速"
      ]
    ]
  },
  {
    "id": 79,
    "text": " CDMO：合全药业持续加大产能建设，原料药、制剂、包装一体化生产服务能力进一步提升。行业景气度维持较高水平，漏斗效应下有望维持稳健增长，预计未来三年增速有望维持在 30~40%的水平。",
    "labels": [
      [
        "T0",
        "行业",
        2,
        6,
        "CDMO"
      ],
      [
        "T1",
        "公司",
        7,
        11,
        "合全药业"
      ],
      [
        "T2",
        "时间范围",
        72,
        76,
        "未来三年"
      ],
      [
        "T3",
        "属性值",
        11,
        15,
        "持续加大"
      ]
    ]
  },
  {
    "id": 80,
    "text": "员工总数保持稳健增长，收入增速高于人员增长体现为人效提升。我们预计公司员工招聘计划通常与订单规模增长具有一定相关性。考虑到 CRO商业模式轻资产、重人才，CDMO模式相对重资产，预计人员增长水平与 CRO类业务相关性更强。2016年以来公司员工数量持续保持 20%~30%的较高增速。截止 2020年末，公司员工总数达到 26411人，同比增加 21%。而员工数量增速略低于公司的收入端增速，这也体现为人均创收水平的持续提升。",
    "labels": [
      [
        "T0",
        "员工数量",
        0,
        4,
        "员工总数"
      ],
      [
        "T1",
        "收入增速",
        11,
        15,
        "收入增速"
      ],
      [
        "T2",
        "时间范围",
        111,
        118,
        "2016年以来"
      ],
      [
        "T3",
        "员工数量",
        120,
        124,
        "员工数量"
      ],
      [
        "T4",
        "时间范围",
        142,
        151,
        "截止 2020年末"
      ],
      [
        "T5",
        "员工数量",
        154,
        158,
        "员工总数"
      ],
      [
        "T6",
        "行业",
        62,
        65,
        "CRO"
      ],
      [
        "T7",
        "属性值",
        69,
        76,
        "轻资产、重人才"
      ],
      [
        "T8",
        "行业",
        77,
        81,
        "CDMO"
      ],
      [
        "T9",
        "属性值",
        83,
        88,
        "相对重资产"
      ],
      [
        "T10",
        "行业",
        99,
        102,
        "CRO"
      ],
      [
        "T11",
        "员工数量",
        178,
        182,
        "员工数量"
      ],
      [
        "T12",
        "收入增速",
        190,
        195,
        "收入端增速"
      ],
      [
        "T13",
        "人均收入",
        201,
        205,
        "人均创收"
      ]
    ]
  },
  {
    "id": 81,
    "text": "CMC业务高速增长，产能释放及利用率提升带来盈利能力的改善。临床前 CRO导流叠加公司产能的释放，CMC前期项目储备充沛，中后期项目占比逐步提升。随着订单数量和质量的持续提升，公司 CMC收入由 2015年的 2.96亿元提升至 2019年的 9. 02亿元，CAGR达 32.14%。与合全药业、凯莱英等一线企业相比，公司毛利率水平较低，主要原因是公司为了加快布局 C(D)MO业务，提前进行了产能和人员布局，导致 C MC业务的直接人工和制造费用（固定资产折旧）成本占比较高，2017年占收入比例达到了 55.34%。随着产能逐步释放及利用率进一步提升，2019年、2020H1 CMC业务毛利率分别同比提升了 5.99pct、8.26pct，预计随着收入规模的扩大及产能利用率的提升，未来公司 CMC业务利润增速将持续超出收入增速。",
    "labels": [
      [
        "T0",
        "行业",
        0,
        3,
        "CMC"
      ],
      [
        "T1",
        "行业",
        30,
        37,
        "临床前 CRO"
      ],
      [
        "T2",
        "行业",
        91,
        94,
        "CMC"
      ],
      [
        "T3",
        "营业收入",
        94,
        96,
        "收入"
      ],
      [
        "T4",
        "时间范围",
        98,
        103,
        "2015年"
      ],
      [
        "T5",
        "时间范围",
        115,
        120,
        "2019年"
      ],
      [
        "T6",
        "CAGR",
        130,
        134,
        "CAGR"
      ],
      [
        "T7",
        "公司",
        144,
        148,
        "合全药业"
      ],
      [
        "T8",
        "公司",
        149,
        152,
        "凯莱英"
      ],
      [
        "T9",
        "龙头企业",
        153,
        157,
        "一线企业"
      ],
      [
        "T10",
        "毛利",
        162,
        165,
        "毛利率"
      ],
      [
        "T11",
        "行业",
        184,
        190,
        "C(D)MO"
      ],
      [
        "T12",
        "行业",
        209,
        213,
        "C MC"
      ],
      [
        "T13",
        "时间范围",
        240,
        245,
        "2017年"
      ],
      [
        "T14",
        "时间范围",
        279,
        291,
        "2019年、2020H1"
      ],
      [
        "T15",
        "毛利",
        297,
        300,
        "毛利率"
      ],
      [
        "T16",
        "行业",
        292,
        295,
        "CMC"
      ],
      [
        "T17",
        "产能",
        10,
        12,
        "产能"
      ],
      [
        "T18",
        "产能",
        43,
        45,
        "产能"
      ],
      [
        "T19",
        "行业",
        49,
        52,
        "CMC"
      ],
      [
        "T20",
        "产能",
        198,
        200,
        "产能"
      ],
      [
        "T21",
        "营业收入",
        246,
        248,
        "收入"
      ],
      [
        "T22",
        "营业收入",
        328,
        330,
        "收入"
      ],
      [
        "T23",
        "产能",
        336,
        338,
        "产能"
      ],
      [
        "T24",
        "行业",
        350,
        353,
        "CMC"
      ],
      [
        "T25",
        "利润",
        355,
        357,
        "利润"
      ],
      [
        "T26",
        "收入增速",
        364,
        368,
        "收入增速"
      ]
    ]
  },
  {
    "id": 83,
    "text": " 建议关注：药明康德；泰格医药；康龙化成；博腾股份；凯莱英。  风险提示：核心客户流失的风险；大品种终端销售额迅速下降的风险；订单执行不力的风险等。",
    "labels": [
      [
        "T0",
        "公司",
        7,
        11,
        "药明康德"
      ],
      [
        "T1",
        "公司",
        12,
        16,
        "泰格医药"
      ],
      [
        "T2",
        "公司",
        17,
        21,
        "康龙化成"
      ],
      [
        "T3",
        "公司",
        22,
        26,
        "博腾股份"
      ],
      [
        "T4",
        "公司",
        27,
        30,
        "凯莱英"
      ]
    ]
  },
  {
    "id": 84,
    "text": "用率也将稳步提升，预计未来几年毛利率有望稳步提高。尽管 2021年 Q1美国区实验室业务仍受疫情影响收入和毛利均有所下滑，但预计全年仍有望保持正增长的可能。",
    "labels": [
      [
        "T0",
        "时间范围",
        11,
        15,
        "未来几年"
      ],
      [
        "T1",
        "毛利",
        15,
        18,
        "毛利率"
      ],
      [
        "T2",
        "时间范围",
        28,
        36,
        "2021年 Q1"
      ],
      [
        "T3",
        "地点范围",
        36,
        39,
        "美国区"
      ],
      [
        "T4",
        "行业",
        39,
        42,
        "实验室"
      ],
      [
        "T5",
        "营业收入",
        50,
        52,
        "收入"
      ],
      [
        "T6",
        "毛利",
        53,
        55,
        "毛利"
      ]
    ]
  },
  {
    "id": 85,
    "text": "国内企业单个 CDMO 项目金额呈提高趋势。同时，过去几年凯莱英、博腾股份和九洲药业的单个 CDMO 项目金额呈现持续提高的趋势。值得注意的是，除了凯莱英是因为订单结构的原因，博腾股份和九洲药业的 III 期及商业化项目数占比呈下降趋势，即这两家公司单笔金额较小的早期项目增长更快。我们认为，这提示了以博腾股份为代表的 CMO 转型 CDMO 的公司， 以及以九洲药业为代表的特色原料药转 CDMO 公司，其单个 CDMO 项目金额的提高与项目附加值的提高相关，背后原因是其在全球创新药产业链参与度的提升。",
    "labels": [
      [
        "T0",
        "公司",
        29,
        32,
        "凯莱英"
      ],
      [
        "T1",
        "时间范围",
        25,
        29,
        "过去几年"
      ],
      [
        "T2",
        "公司",
        33,
        37,
        "博腾股份"
      ],
      [
        "T3",
        "公司",
        38,
        42,
        "九洲药业"
      ],
      [
        "T4",
        "公司",
        74,
        77,
        "凯莱英"
      ],
      [
        "T5",
        "公司",
        151,
        155,
        "博腾股份"
      ],
      [
        "T6",
        "公司",
        180,
        184,
        "九洲药业"
      ],
      [
        "T7",
        "地点范围",
        0,
        2,
        "国内"
      ],
      [
        "T8",
        "行业",
        7,
        11,
        "CDMO"
      ],
      [
        "T9",
        "行业",
        46,
        50,
        "CDMO"
      ],
      [
        "T10",
        "公司",
        88,
        92,
        "博腾股份"
      ],
      [
        "T11",
        "公司",
        93,
        97,
        "九洲药业"
      ],
      [
        "T12",
        "行业",
        160,
        163,
        "CMO"
      ],
      [
        "T13",
        "行业",
        167,
        171,
        "CDMO"
      ],
      [
        "T14",
        "行业",
        188,
        193,
        "特色原料药"
      ],
      [
        "T15",
        "行业",
        195,
        199,
        "CDMO"
      ],
      [
        "T16",
        "行业",
        207,
        211,
        "CDMO"
      ],
      [
        "T17",
        "地点范围",
        238,
        240,
        "全球"
      ],
      [
        "T18",
        "行业",
        240,
        246,
        "创新药产业链"
      ]
    ]
  },
  {
    "id": 86,
    "text": "公司在 A股与 H股上市，其中 A股总股本占比约 87.4%。公司于 2018年 5月和 12月先后在上交所和港交所上市。截止 2021年 7月 6日，公司总股本 29.51 亿股，其中 A股占比 86.9%，港股占比 13.1%。A股中流通股占比 99.3%，限售股占比 0.7%。 李革等 4人为公司实际控制人，合计控制公司 25.16%股权。公司无控股股东， Ge Li（李革）及 Ning Zhao（赵宁）、刘晓钟、张朝晖四人签署一致行动协议， 为公司的实际控制人。根据公司 2021年 6月 21日股东权益变动公告， 公司实控人及一致行动人合计持有股权比例 25.1596%。",
    "labels": [
      [
        "T0",
        "时间范围",
        35,
        48,
        "2018年 5月和 12月"
      ],
      [
        "T1",
        "时间范围",
        61,
        75,
        "截止 2021年 7月 6日"
      ],
      [
        "T2",
        "公司",
        242,
        254,
        "2021年 6月 21日"
      ]
    ]
  },
  {
    "id": 88,
    "text": "比最少，每年以2%的速度增加，2025年预计大分子CDMO/CMO行业占比2.6%，临床前外包行业占比3.8%，发现外包行业占比8.5%，临床外包行业占比28%，小分子CDMO行业占比58%",
    "labels": [
      [
        "T0",
        "时间范围",
        15,
        20,
        "2025年"
      ],
      [
        "T1",
        "行业",
        22,
        33,
        "大分子CDMO/CMO"
      ],
      [
        "T2",
        "行业",
        42,
        47,
        "临床前外包"
      ],
      [
        "T3",
        "行业",
        81,
        88,
        "小分子CDMO"
      ],
      [
        "T4",
        "行业",
        69,
        73,
        "临床外包"
      ],
      [
        "T5",
        "行业",
        56,
        60,
        "发现外包"
      ]
    ]
  },
  {
    "id": 89,
    "text": "订单方面，公司 2020年共服务 API产品 92个（中国客户产品数 59个），累计服务 API项目 230余个，同时也完成了第一个杨森地瑞那韦的创新药原料药商业化订单（地瑞那韦原料药相关产品三代工艺的技术转移和 WHO的认证工作仍在积极进行中），并有 6个 API项目即将或已经进入工艺验证阶段，未来将成为公司一个重要的业绩增长点。",
    "labels": [
      [
        "T0",
        "时间范围",
        8,
        13,
        "2020年"
      ],
      [
        "T1",
        "地点范围",
        27,
        29,
        "中国"
      ],
      [
        "T2",
        "行业",
        45,
        48,
        "API"
      ],
      [
        "T3",
        "行业",
        17,
        20,
        "API"
      ],
      [
        "T4",
        "业绩",
        161,
        163,
        "业绩"
      ]
    ]
  },
  {
    "id": 91,
    "text": "PROTAC使小分子药物存在调控原本不可成药靶点的可能性。PROTAC机制不需要药物直接抑制目标蛋白的功能活性，而是将泛素“标记”在目标蛋白上， 进而使其被蛋白酶体降解，理论上能够靶向作用到几乎所有的靶点蛋白。同时整个过程类似于催化反应，只需要较少的药物量即可能完成调控，对 PROTAC 分子本身的药物活性要求可能并不需要很高。",
    "labels": []
  },
  {
    "id": 92,
    "text": "同比增长 150.14%。公司运营平稳，2021 年上半年实现经营活动现金流 0.81 亿元，同比增长 0.53%。",
    "labels": [
      [
        "T0",
        "时间范围",
        20,
        29,
        "2021 年上半年"
      ],
      [
        "T1",
        "现金流",
        35,
        38,
        "现金流"
      ]
    ]
  },
  {
    "id": 93,
    "text": "的时间窗（ph2 对照或者单臂注册临床试验同理）。创新药的时间窗是有限的， 在 FIC注册临床试验尚未读出之前，快速跟随者（fast-follow）策略通常总是有效的；但在读出之后， SOC/治疗范式将会升级，此后较慢的跟随者采用相同的注册临床策略可能存在较大的不确定性。以美国为例，跟随者时间窗从 FIC 新药启动 ph3，到临床指南更新（通常在 FDA批准前后），通常只有 2-3年， FIC 新药撞线后时间窗关闭。从全球角度看，挤进时间窗内的快速跟随者（fast-follow） 通常只有 3-5家，竞争格局较好。较慢的跟随者，需要做头对头对照证明非劣效（me-too）或优效（me-better），或选择差异化适应症（me-different）才能获批。 政策利好综合实力强的大型药企、研发效率高且进度领先的 Biotech。对于研发型企业来说，未来预计将迎来以下变化：  竞争格局变好：从与数量不确定的竞争对手博弈，变成可预期的有限家数博弈；  商业回报提高：整体价格水平上浮，每一家的销量市场份额提升，预计巅峰销售额增加；  竞争更加残酷：对策略、布局、效率、速度、进度的要求缺一不可；跟随者提速，FIC新药也需要提速；  适应症可拓宽：原本投入产出性价比不高的适应症（如罕见肿瘤、早期肿瘤辅助/新辅助）变得具有投资吸引力对于 CXO行业来说，重复性订单数量可能下降，但项目结构有望优化，利好能力全面、效率较高的 CXO龙头。CXO行业未来预计将迎来以下变化：  客户数量可能减少：尾部玩家难以进入跟随者时间窗，逐步被淘汰，头部玩家加大研发投入，立项方向更偏向 FIC新药，对研发效率要求更高，外包渗透率持续提升；  订单结构有望优化：订单中低质量重复性项目预计将逐步中止，更多高质量、高价值量的新药项目将成为主要的订单来源；  单个订单金额有望提升：三期临床竞争将更加激烈，少数几家进度较快、 具有竞争优势的客户对效率的要求进一步提升，导致单个订单价值量提升。 整体来看，医药行业研发投入仍将持续加大、对研发效率的要求持续提升、外包渗透率持续提高的长期逻辑并未发生改变。新药研发竞争格局有望向头部集中，研发型企业的立项、布局更加多元、更加前瞻。“去伪存真”之后，创新药行业将有更多“真创新”企业在 CXO的帮助下加速对海外医药龙头的追赶。 研发立项扎堆热门靶点问题有望缓解，政策引导药企向原创新药方向发展利于行业长期成长。从政策修改的初衷来看，当前国内创新药行业存在着热门靶点扎堆的问题，政策希望通过减少重复研发、无序竞争，引导创新药企业开发临床效果更佳、真正对患者有价值的创新药。诚然，这一过程中部分 CXO企业可能面临客户需求有所下降的风险，但只要上游 Biotech投融资和行业研发投入维持较高强度，原本被重复研发项目占用的资金有望进入潜在“me-better”或 “first-in-class”项目中。而考虑到未来对新药上市速度、研发效率的需求将进一步提升，外包渗透率有望继续提高，而研发经验丰富、具有端到端能力的头部 CXO有望获取更高的市场份额。",
    "labels": [
      [
        "T0",
        "行业",
        574,
        577,
        "CXO"
      ],
      [
        "T1",
        "新签订单",
        582,
        589,
        "重复性订单数量"
      ],
      [
        "T2",
        "行业",
        617,
        620,
        "CXO"
      ],
      [
        "T3",
        "龙头企业",
        620,
        622,
        "龙头"
      ],
      [
        "T4",
        "行业",
        623,
        626,
        "CXO"
      ],
      [
        "T5",
        "公司",
        1143,
        1150,
        "Biotech"
      ],
      [
        "T6",
        "行业公司",
        1116,
        1121,
        "CXO企业"
      ],
      [
        "T7",
        "投融资情况",
        1150,
        1153,
        "投融资"
      ],
      [
        "T8",
        "研发费用",
        1154,
        1160,
        "行业研发投入"
      ],
      [
        "T9",
        "时间范围",
        628,
        630,
        "未来"
      ],
      [
        "T10",
        "客户数量",
        643,
        647,
        "客户数量"
      ],
      [
        "T11",
        "属性值",
        647,
        651,
        "可能减少"
      ],
      [
        "T12",
        "研发费用",
        679,
        683,
        "研发投入"
      ],
      [
        "T13",
        "行业",
        850,
        852,
        "医药"
      ],
      [
        "T14",
        "研发费用",
        854,
        858,
        "研发投入"
      ],
      [
        "T15",
        "属性值",
        860,
        864,
        "持续加大"
      ],
      [
        "T16",
        "行业",
        899,
        903,
        "新药研发"
      ],
      [
        "T17",
        "竞争格局",
        903,
        907,
        "竞争格局"
      ],
      [
        "T18",
        "属性值",
        909,
        914,
        "向头部集中"
      ],
      [
        "T19",
        "行业",
        945,
        948,
        "创新药"
      ],
      [
        "T20",
        "行业",
        963,
        966,
        "CXO"
      ],
      [
        "T21",
        "地点范围",
        973,
        975,
        "海外"
      ],
      [
        "T22",
        "行业",
        975,
        977,
        "医药"
      ],
      [
        "T23",
        "行业公司",
        1005,
        1007,
        "药企"
      ],
      [
        "T24",
        "行业",
        1008,
        1012,
        "原创新药"
      ],
      [
        "T25",
        "地点范围",
        1038,
        1040,
        "国内"
      ],
      [
        "T26",
        "时间范围",
        1036,
        1038,
        "当前"
      ],
      [
        "T27",
        "行业",
        1040,
        1043,
        "创新药"
      ],
      [
        "T28",
        "行业公司",
        1078,
        1083,
        "创新药企业"
      ]
    ]
  },
  {
    "id": 94,
    "text": "截至 2022.1.19，全球新冠疫苗每百人接种量 124.69剂次，中国 204.69剂次， 美国 160.20剂次，德国 192.05剂次，法国 197.90剂次，英国 200.72剂次， 意大利 203.29剂次，印度 114.85剂次。",
    "labels": [
      [
        "T0",
        "时间范围",
        0,
        12,
        "截至 2022.1.19"
      ],
      [
        "T1",
        "地点范围",
        13,
        15,
        "全球"
      ],
      [
        "T2",
        "地点范围",
        35,
        37,
        "中国"
      ],
      [
        "T3",
        "地点范围",
        48,
        50,
        "美国"
      ],
      [
        "T4",
        "地点范围",
        60,
        62,
        "德国"
      ],
      [
        "T5",
        "地点范围",
        72,
        74,
        "法国"
      ],
      [
        "T6",
        "地点范围",
        84,
        86,
        "英国"
      ],
      [
        "T7",
        "地点范围",
        97,
        100,
        "意大利"
      ],
      [
        "T8",
        "地点范围",
        110,
        112,
        "印度"
      ]
    ]
  },
  {
    "id": 95,
    "text": "病毒是细胞基因治疗中最重要也是最常用的基因载体。 根据基因药物杂志文章统计，在 1989-2017 年处于研发阶段的基因细胞治疗产品中，病毒载体占比高达",
    "labels": [
      [
        "T0",
        "时间范围",
        40,
        51,
        "1989-2017 年"
      ],
      [
        "T1",
        "行业",
        58,
        64,
        "基因细胞治疗"
      ]
    ]
  },
  {
    "id": 96,
    "text": "公司的股权结构相对分散。截至 9M19，创始人李革博士，赵宁博士，刘晓钟先生、张朝晖先生及其一致行动人持有公司 27.76%的投票权，此外公司投资者多为海内外知名机构。",
    "labels": [
      [
        "T0",
        "时间范围",
        12,
        19,
        "截至 9M19"
      ],
      [
        "T1",
        "地点范围",
        76,
        79,
        "海内外"
      ]
    ]
  },
  {
    "id": 97,
    "text": "康龙化成主要业务是实验室服务，实验室服务主要进行实验室化学、生物科学、安全性评价，其中实验室化学是实验室服务的主要业务",
    "labels": [
      [
        "T0",
        "公司",
        0,
        4,
        "康龙化成"
      ],
      [
        "T1",
        "主营业务",
        4,
        8,
        "主要业务"
      ],
      [
        "T2",
        "属性值",
        9,
        14,
        "实验室服务"
      ]
    ]
  },
  {
    "id": 98,
    "text": "本周（2022.3.28-2022.4.1）、年初至今医药指数涨幅分别为 0.0%、-12.6%，相对沪指的超额收益分别为-2.2%、2.8%；本周医疗器械、中药、服务等股价较为强势，商业、 化药及生物制品等股价较弱；本周涨幅居前振东制药（+38.58%）、瑞康医药（+33.33%）、 太安堂（+20.63%），跌幅居前凯因科技（-23.11%）、奥翔药业（-23.05%）、亚太药业（- 22.40%）。涨跌表现特点：小市值公司股价跌幅较为明显，机构重仓大市值股价较为平稳，尤其是医疗服务等；中西新冠治疗、抗原检测出现一定程度回落；中药及原料药回调明显。",
    "labels": [
      [
        "T0",
        "时间范围",
        0,
        22,
        "本周（2022.3.28-2022.4.1）"
      ],
      [
        "T1",
        "时间范围",
        23,
        27,
        "年初至今"
      ],
      [
        "T2",
        "时间范围",
        72,
        74,
        "本周"
      ],
      [
        "T3",
        "行业",
        74,
        78,
        "医疗器械"
      ],
      [
        "T4",
        "行业",
        79,
        81,
        "中药"
      ],
      [
        "T5",
        "行业",
        82,
        84,
        "服务"
      ],
      [
        "T6",
        "行业",
        92,
        94,
        "商业"
      ],
      [
        "T7",
        "行业",
        96,
        98,
        "化药"
      ],
      [
        "T8",
        "行业",
        99,
        103,
        "生物制品"
      ],
      [
        "T9",
        "时间范围",
        109,
        111,
        "本周"
      ],
      [
        "T10",
        "公司",
        115,
        119,
        "振东制药"
      ],
      [
        "T11",
        "公司",
        129,
        133,
        "瑞康医药"
      ],
      [
        "T12",
        "公司",
        144,
        147,
        "太安堂"
      ],
      [
        "T13",
        "公司",
        161,
        165,
        "凯因科技"
      ],
      [
        "T14",
        "公司",
        175,
        179,
        "奥翔药业"
      ],
      [
        "T15",
        "公司",
        189,
        193,
        "亚太药业"
      ],
      [
        "T16",
        "行业",
        242,
        246,
        "医疗服务"
      ],
      [
        "T17",
        "市值",
        212,
        214,
        "市值"
      ],
      [
        "T18",
        "行业",
        248,
        254,
        "中西新冠治疗"
      ],
      [
        "T19",
        "行业",
        255,
        259,
        "抗原检测"
      ],
      [
        "T20",
        "行业",
        268,
        270,
        "中药"
      ],
      [
        "T21",
        "行业",
        271,
        274,
        "原料药"
      ]
    ]
  },
  {
    "id": 99,
    "text": "所有的新药最终都需要通过安全性和有效性验证后，方可申请上市销售，临床试验连接早期研发和商业化阶段，其变化和发展对新药研发具有重要影响，临床 CRO 行业的发展一定程度上代表了中国 CRO 行业的发展。从 20 世纪 90 年代至今，我国临床 CRO 行业可分为三个发展阶段。",
    "labels": [
      [
        "T0",
        "行业",
        67,
        73,
        "临床 CRO"
      ],
      [
        "T1",
        "地点范围",
        87,
        89,
        "中国"
      ],
      [
        "T2",
        "行业",
        90,
        93,
        "CRO"
      ],
      [
        "T3",
        "时间范围",
        100,
        115,
        "从 20 世纪 90 年代至今"
      ],
      [
        "T4",
        "地点范围",
        116,
        118,
        "我国"
      ],
      [
        "T5",
        "行业",
        118,
        124,
        "临床 CRO"
      ]
    ]
  },
  {
    "id": 100,
    "text": "团队规模持续扩张下人均创收持续提升。CRO行业为人才密集型行业，尤其对于高素质人才需求量巨大。国内大量的生物医药专业人才基数带来巨大的工程师红利，为国内 CRO企业在全球市场承接外包订单带来较强的竞争力。药明康德近年来员工规模持续扩张，年增长率在 20%以上。在团队规模扩大的同时， 人均创收与人均创利均持续提升。2020年公司人均创收达到 62.6万元。",
    "labels": [
      [
        "T0",
        "人均收入",
        9,
        13,
        "人均创收"
      ],
      [
        "T1",
        "行业",
        18,
        21,
        "CRO"
      ],
      [
        "T2",
        "地点范围",
        47,
        49,
        "国内"
      ],
      [
        "T3",
        "行业",
        52,
        56,
        "生物医药"
      ],
      [
        "T4",
        "地点范围",
        74,
        76,
        "国内"
      ],
      [
        "T5",
        "行业公司",
        77,
        82,
        "CRO企业"
      ],
      [
        "T6",
        "公司",
        102,
        106,
        "药明康德"
      ],
      [
        "T7",
        "人均收入",
        142,
        146,
        "人均创收"
      ],
      [
        "T8",
        "人均利润",
        147,
        151,
        "人均创利"
      ],
      [
        "T9",
        "属性值",
        152,
        156,
        "持续提升"
      ],
      [
        "T10",
        "时间范围",
        157,
        162,
        "2020年"
      ],
      [
        "T11",
        "人均收入",
        164,
        168,
        "人均创收"
      ],
      [
        "T12",
        "属性值",
        171,
        177,
        "62.6万元"
      ],
      [
        "T13",
        "地点范围",
        83,
        85,
        "全球"
      ],
      [
        "T14",
        "属性值",
        24,
        29,
        "人才密集型"
      ],
      [
        "T15",
        "员工数量",
        109,
        113,
        "员工规模"
      ],
      [
        "T16",
        "时间范围",
        106,
        109,
        "近年来"
      ],
      [
        "T17",
        "属性值",
        113,
        117,
        "持续扩张"
      ],
      [
        "T18",
        "属性值",
        124,
        129,
        "20%以上"
      ],
      [
        "T19",
        "CAGR",
        118,
        122,
        "年增长率"
      ]
    ]
  },
  {
    "id": 101,
    "text": "根据医药魔方数据，2022年第一季度，海外医药融资总额约130.88亿美金，同比上涨8.46%，融资事件数达到174起；国内融资总额约39.16亿美金，同比上涨 2.84%，融资事件数达到115起。",
    "labels": [
      [
        "T0",
        "时间范围",
        9,
        18,
        "2022年第一季度"
      ],
      [
        "T1",
        "地点范围",
        19,
        21,
        "海外"
      ],
      [
        "T2",
        "行业",
        21,
        23,
        "医药"
      ],
      [
        "T3",
        "投融资金额",
        23,
        27,
        "融资总额"
      ],
      [
        "T4",
        "投融资事件数",
        48,
        52,
        "融资事件"
      ],
      [
        "T5",
        "属性值",
        55,
        59,
        "174起"
      ],
      [
        "T6",
        "地点范围",
        60,
        62,
        "国内"
      ],
      [
        "T7",
        "投融资金额",
        62,
        66,
        "融资总额"
      ],
      [
        "T8",
        "属性值",
        94,
        98,
        "115起"
      ],
      [
        "T9",
        "属性值",
        27,
        47,
        "约130.88亿美金，同比上涨8.46%"
      ],
      [
        "T10",
        "投融资事件数",
        87,
        92,
        "融资事件数"
      ],
      [
        "T11",
        "属性值",
        66,
        86,
        "约39.16亿美金，同比上涨 2.84%"
      ]
    ]
  },
  {
    "id": 102,
    "text": "市值管理提升市场关注管理企业市值",
    "labels": [
      [
        "T0",
        "市值",
        0,
        2,
        "市值"
      ],
      [
        "T1",
        "市值",
        14,
        16,
        "市值"
      ]
    ]
  },
  {
    "id": 103,
    "text": "CXO板块将在 Q1季报窗口期表现靓丽，尤其在辉瑞口服新冠产业链受益更为明显的个股，建议重点关注凯莱英、药明康德等；CXO板块中 2023年增长更为确定个股在下半年表现将更为明显，重点关注百诚医药、九洲药业等；如果看更长周期，药明康德、 凯莱英等第一梯队个股将仍有全球较强竞争力。将是国内新冠疫苗续贯接种将是大概率、 且可能持续多年，获批用于续冠智飞重复蛋白及康希诺腺病毒疫苗应该享受一定估值。 基本面、筹码结构、估值体系等多因素支持医药板块见底。从基本面看，每年医保基金支出约 10%增长、行业增长有保障，医药十四五规划相对于十二五，医药产业从民生产业提升至民生、国家安全性战略性产业，医药地位明显上升。另外结合一季报，主流医药公司都较好；从估值上看，医药板块经历近三个季度快速下跌后企稳，其 PE（ttm） 估值约 29倍，再次回到 2018年底部；从筹码结构看，公募基金对医药持仓也处于近十年低点，当前约 7%，处于极低配置水平。",
    "labels": [
      [
        "T0",
        "行业",
        0,
        3,
        "CXO"
      ],
      [
        "T1",
        "时间范围",
        8,
        10,
        "Q1"
      ],
      [
        "T2",
        "公司",
        23,
        25,
        "辉瑞"
      ],
      [
        "T3",
        "公司",
        48,
        51,
        "凯莱英"
      ],
      [
        "T4",
        "公司",
        52,
        56,
        "药明康德"
      ],
      [
        "T5",
        "行业",
        58,
        61,
        "CXO"
      ],
      [
        "T6",
        "时间范围",
        65,
        70,
        "2023年"
      ],
      [
        "T7",
        "时间范围",
        79,
        82,
        "下半年"
      ],
      [
        "T8",
        "公司",
        94,
        98,
        "百诚医药"
      ],
      [
        "T9",
        "公司",
        99,
        103,
        "九洲药业"
      ],
      [
        "T10",
        "公司",
        113,
        117,
        "药明康德"
      ],
      [
        "T11",
        "公司",
        119,
        122,
        "凯莱英"
      ],
      [
        "T12",
        "地点范围",
        142,
        144,
        "国内"
      ],
      [
        "T13",
        "行业",
        217,
        219,
        "医药"
      ],
      [
        "T14",
        "行业",
        268,
        270,
        "医药"
      ],
      [
        "T15",
        "行业",
        294,
        296,
        "医药"
      ],
      [
        "T16",
        "行业",
        327,
        329,
        "医药"
      ],
      [
        "T17",
        "PE",
        348,
        350,
        "PE"
      ],
      [
        "T18",
        "属性值",
        358,
        363,
        "约 29倍"
      ],
      [
        "T19",
        "时间范围",
        369,
        374,
        "2018年"
      ],
      [
        "T20",
        "时间范围",
        396,
        399,
        "近十年"
      ],
      [
        "T21",
        "行业公司",
        313,
        317,
        "医药公司"
      ],
      [
        "T22",
        "地点范围",
        132,
        134,
        "全球"
      ],
      [
        "T23",
        "时间范围",
        333,
        338,
        "近三个季度"
      ]
    ]
  },
  {
    "id": 104,
    "text": "制剂工艺研发与生产：与实验室部门协同，提供全流程的研发和生产支持。合全药业的制剂工艺研发和生产能够提供从早期处方前研发到处方研发，到商业化制剂生产，及先进给药技术研发、微生物催化增强技术开发等服务。",
    "labels": [
      [
        "T0",
        "公司",
        33,
        37,
        "合全药业"
      ]
    ]
  },
  {
    "id": 105,
    "text": "口药明康德CDMO业务收入最高，综合来看CDMO营业收入药明康德>凯莱英>博腾股份〉康龙化成凯莱英的CDMO毛利率最高，综合来看CDMO毛利率凯莱英>药明康德>博腾股份>康龙化成。药明康德订单数量较多，但凯莱英单订单经济附加值大，可能会导致凯莱依CDMO业务毛利率>药明康德，但凯莱英CDMO营业收入<药明康德口康龙化成CMC服务（小分子CDMO）正处于产能扩张阶段，所以CDMO毛利率、营业收入较低，预计2021年CMC业务产能释放，营业收入以及毛利率将会迎来较大提升。康龙化成2019年中国团队完成及在研CMC项目568个，其中临床前项目485个，临床I期54个，临床=期20个，临床=期9个。2020年CMC服务中国团队完成及在研临床前项目487个，临床-=期202个，临床=期47个，商业化阶段3个，2021迎来临床I期和商业化产能释放口以临床前CRO业务为基础，业务协同效应加速CMC服务营业收入。在创新药研发起始阶段，药物发现业务长期积累的技术能力和客户资源，拓宽了CMC业务的客户群体。2018年，77%的CMC服务收入来源于实验室服务的协同效应，药物安全评价实验中有60%的API生产工作由CMC部门完成。2019年，药物安全评价与CMC业务客户重合度进一步提升至68%。",
    "labels": [
      [
        "T0",
        "公司",
        1,
        5,
        "药明康德"
      ],
      [
        "T1",
        "行业",
        5,
        9,
        "CDMO"
      ],
      [
        "T2",
        "营业收入",
        11,
        13,
        "收入"
      ],
      [
        "T3",
        "行业",
        20,
        24,
        "CDMO"
      ],
      [
        "T4",
        "营业收入",
        24,
        28,
        "营业收入"
      ],
      [
        "T5",
        "公司",
        28,
        32,
        "药明康德"
      ],
      [
        "T6",
        "公司",
        33,
        36,
        "凯莱英"
      ],
      [
        "T7",
        "公司",
        37,
        41,
        "博腾股份"
      ],
      [
        "T8",
        "公司",
        42,
        46,
        "康龙化成"
      ],
      [
        "T9",
        "公司",
        46,
        49,
        "凯莱英"
      ],
      [
        "T10",
        "公司",
        50,
        54,
        "CDMO"
      ],
      [
        "T11",
        "毛利",
        54,
        57,
        "毛利率"
      ],
      [
        "T12",
        "行业",
        64,
        68,
        "CDMO"
      ],
      [
        "T13",
        "毛利",
        68,
        71,
        "毛利率"
      ],
      [
        "T14",
        "公司",
        71,
        74,
        "凯莱英"
      ],
      [
        "T15",
        "公司",
        75,
        79,
        "药明康德"
      ],
      [
        "T16",
        "公司",
        80,
        84,
        "博腾股份"
      ],
      [
        "T17",
        "公司",
        85,
        89,
        "康龙化成"
      ],
      [
        "T18",
        "公司",
        90,
        94,
        "药明康德"
      ],
      [
        "T19",
        "在手订单",
        94,
        98,
        "订单数量"
      ],
      [
        "T20",
        "公司",
        102,
        105,
        "凯莱英"
      ],
      [
        "T21",
        "行业",
        123,
        127,
        "CDMO"
      ],
      [
        "T22",
        "毛利",
        129,
        132,
        "毛利率"
      ],
      [
        "T23",
        "公司",
        133,
        137,
        "药明康德"
      ],
      [
        "T24",
        "公司",
        139,
        142,
        "凯莱英"
      ],
      [
        "T25",
        "行业",
        142,
        146,
        "CDMO"
      ],
      [
        "T26",
        "营业收入",
        146,
        150,
        "营业收入"
      ],
      [
        "T27",
        "公司",
        151,
        155,
        "药明康德"
      ],
      [
        "T28",
        "公司",
        156,
        160,
        "康龙化成"
      ],
      [
        "T29",
        "行业",
        160,
        163,
        "CMC"
      ],
      [
        "T30",
        "行业",
        186,
        190,
        "CDMO"
      ],
      [
        "T31",
        "毛利",
        190,
        193,
        "毛利率"
      ],
      [
        "T32",
        "营业收入",
        194,
        198,
        "营业收入"
      ],
      [
        "T33",
        "属性值",
        198,
        200,
        "较低"
      ],
      [
        "T34",
        "时间范围",
        203,
        208,
        "2021年"
      ],
      [
        "T35",
        "行业",
        208,
        211,
        "CMC"
      ],
      [
        "T36",
        "营业收入",
        218,
        222,
        "营业收入"
      ],
      [
        "T37",
        "毛利",
        224,
        227,
        "毛利率"
      ],
      [
        "T38",
        "属性值",
        231,
        235,
        "较大提升"
      ],
      [
        "T39",
        "公司",
        236,
        240,
        "康龙化成"
      ],
      [
        "T40",
        "时间范围",
        240,
        245,
        "2019年"
      ],
      [
        "T41",
        "时间范围",
        354,
        358,
        "2021"
      ],
      [
        "T42",
        "行业",
        374,
        380,
        "临床前CRO"
      ],
      [
        "T43",
        "营业收入",
        399,
        403,
        "营业收入"
      ],
      [
        "T44",
        "时间范围",
        450,
        455,
        "2018年"
      ],
      [
        "T45",
        "时间范围",
        511,
        516,
        "2019年"
      ],
      [
        "T46",
        "时间范围",
        299,
        304,
        "2020年"
      ],
      [
        "T47",
        "属性值",
        98,
        100,
        "较多"
      ],
      [
        "T48",
        "公司",
        120,
        123,
        "凯莱依"
      ],
      [
        "T49",
        "产能",
        177,
        179,
        "产能"
      ],
      [
        "T50",
        "属性值",
        179,
        181,
        "扩张"
      ],
      [
        "T51",
        "属性值",
        215,
        217,
        "释放"
      ],
      [
        "T52",
        "产能",
        213,
        215,
        "产能"
      ],
      [
        "T53",
        "行业",
        394,
        397,
        "CMC"
      ]
    ]
  },
  {
    "id": 106,
    "text": "五大板块，所投资企业均为所投资企业中，Unity B 证交所上市。通过投资，公司业务板块间协同效应加强，利于公司把握昀新产业动向，",
    "labels": [
      [
        "T0",
        "公司",
        19,
        26,
        "Unity B"
      ]
    ]
  },
  {
    "id": 107,
    "text": "2、产业化：公司目前拥有近1000㎡的中试平台，近7000㎡的GMP生产平台，GMP产能规模已达国外同类企业水平。募投项目建成后，将新增近10倍产能。",
    "labels": [
      [
        "T0",
        "产能",
        72,
        74,
        "产能"
      ],
      [
        "T1",
        "产能",
        42,
        46,
        "产能规模"
      ]
    ]
  },
  {
    "id": 109,
    "text": "公司搭建起覆盖全产业链的药物研发一站式服务平台，赋能全球新药研发。 考虑到：1）公司小分子 CMO/CDMO商业化项目加速落地推动业务快速增长；2）临床 CRO与细胞&基因疗法 CDMO高速增长；3）“长尾客户” 和中国客户日益增加的研发需求；公司业绩有望提速发展，远超行业平均水平。我们预计公司 19/20/21三年收入有望实现 27.4%的年复合增速，对应 EPS 为 1.24/1.48/2.00 元，分部估值法下 2020 年合理估值为 1791.06-1935.76亿元，对应目标价 108.48-117.24元，给予买入评级。",
    "labels": [
      [
        "T0",
        "业绩",
        124,
        126,
        "业绩"
      ],
      [
        "T1",
        "行业",
        42,
        54,
        "小分子 CMO/CDMO"
      ],
      [
        "T2",
        "营业收入",
        159,
        161,
        "收入"
      ],
      [
        "T3",
        "CAGR",
        172,
        177,
        "年复合增速"
      ],
      [
        "T4",
        "时间范围",
        211,
        217,
        "2020 年"
      ],
      [
        "T5",
        "时间范围",
        149,
        159,
        "19/20/21三年"
      ],
      [
        "T6",
        "行业",
        74,
        83,
        "临床 CRO与细胞"
      ],
      [
        "T7",
        "行业",
        84,
        93,
        "基因疗法 CDMO"
      ]
    ]
  },
  {
    "id": 110,
    "text": "公司深耕电生理与血管介入领域，在研管线丰富。（1）电生理：公司 2019 年市占率为 3.6%，排名国产品牌第一。2021年 1月公司三维标测系统与磁定位冷盐水射频消融导管顺利完成注册，以此为契机实现产品升级，进军三维市场。我国电生理市场进口替代空间广阔，预计随着三维产品上市，市占率有望加速提升。（2）血管介入：冠脉产品线覆盖全面，积极拓展外周与神经介入领域。公司冠脉通路产品线布局全面，并且产品性能可与泰尔茂、美敦力等外资品牌竞争。随着我国 PCI手术渗透率进一步提升以及进口替代趋势推进，预计公司将显著获益。公司 2019年进入外周介入领域，并积极布局神经介入领域， 未来将成为新的增长引擎。（3）产线布局丰富，研发投入持续。公司 2019 年研发投入 7042.27万元，占营业收入的 17.43%。公司在研发和生产领域拥有丰富的技术积累和人才储备，具备独立生产导管、导丝等产品的高端生产制造能力。",
    "labels": [
      [
        "T0",
        "时间范围",
        32,
        38,
        "2019 年"
      ],
      [
        "T1",
        "市场份额",
        38,
        41,
        "市占率"
      ],
      [
        "T2",
        "行业",
        25,
        28,
        "电生理"
      ],
      [
        "T3",
        "行业",
        4,
        7,
        "电生理"
      ],
      [
        "T4",
        "行业",
        8,
        12,
        "血管介入"
      ],
      [
        "T5",
        "时间范围",
        57,
        65,
        "2021年 1月"
      ],
      [
        "T6",
        "市场份额",
        139,
        142,
        "市占率"
      ],
      [
        "T7",
        "行业",
        114,
        117,
        "电生理"
      ],
      [
        "T8",
        "行业",
        152,
        156,
        "血管介入"
      ],
      [
        "T9",
        "公司",
        203,
        206,
        "泰尔茂"
      ],
      [
        "T10",
        "公司",
        207,
        210,
        "美敦力"
      ],
      [
        "T11",
        "时间范围",
        260,
        265,
        "2019年"
      ],
      [
        "T12",
        "行业",
        267,
        271,
        "外周介入"
      ],
      [
        "T13",
        "行业",
        279,
        283,
        "神经介入"
      ],
      [
        "T14",
        "时间范围",
        319,
        325,
        "2019 年"
      ],
      [
        "T15",
        "研发费用",
        325,
        329,
        "研发投入"
      ],
      [
        "T16",
        "营业收入",
        341,
        345,
        "营业收入"
      ],
      [
        "T17",
        "地点范围",
        112,
        114,
        "我国"
      ]
    ]
  },
  {
    "id": 112,
    "text": "口一体化医药研发服务平台是公司最重要的核心竞争力之一。凭借一体化研发服务平台，一方面公司可以提供一体化研究服务，另一方面不同的业务之间可以互相导流。口药明康德、康龙化成、药明生物、泰格医药都属于全球TOP20CXO企业的中国企业，其中只有药明康德与康龙化成布局了药物发现、临床前、临床试验、CDMO业务，形成一站式服务平台。一站式服务平台指在新药研发生产中，CXO企业可以提供一体化或一揽子课题研究服务。一站式服务平台，减少CXO企业的获客成本，增强客户黏性。一体化的服务平台积累的经验和优势，帮助康龙化成对于新药研发的理解更为深刻，能够更好的帮助客户缩短新药研发所需时间和降低风险。口CRO+CDMO一体化是重要发展趋势，CRO企业可以通过前端研发业务向后端CDMO业务导流，实现收入和利润的放大。CDMO企业也可以布局CRO业务带动CDMO业务发展。从整体来看，属于第一梯队的药明康德已经实现了CRO+CDMO全产业链布局，属于第二梯队的康龙化成通过并购、自有投资也发展了一体化服务平台，实现了CRO+CDMO全产业链布局。2020年，公司有超过90%的收入来自重复客户，药物发现阶段的生物科学收入中有超过80%来自实验室化学的现有客户，CMC服务的收入中有77%来自于实验室服务的现有客户。口药明康德主要布局生物大分子CRO+CDMO，康龙化成主要布局小分子CDMO+CRO，业务竞争并不激烈，市场风险较低",
    "labels": [
      [
        "T0",
        "公司",
        75,
        79,
        "药明康德"
      ],
      [
        "T1",
        "公司",
        80,
        84,
        "康龙化成"
      ],
      [
        "T2",
        "公司",
        85,
        89,
        "药明生物"
      ],
      [
        "T3",
        "公司",
        90,
        94,
        "泰格医药"
      ],
      [
        "T4",
        "行业公司",
        104,
        109,
        "CXO企业"
      ],
      [
        "T5",
        "公司",
        119,
        123,
        "药明康德"
      ],
      [
        "T6",
        "公司",
        124,
        128,
        "康龙化成"
      ],
      [
        "T7",
        "行业",
        131,
        135,
        "药物发现"
      ],
      [
        "T8",
        "行业",
        136,
        139,
        "临床前"
      ],
      [
        "T9",
        "行业",
        140,
        144,
        "临床试验"
      ],
      [
        "T10",
        "行业",
        145,
        149,
        "CDMO"
      ],
      [
        "T11",
        "行业公司",
        179,
        184,
        "CXO企业"
      ],
      [
        "T12",
        "行业公司",
        212,
        217,
        "CXO企业"
      ],
      [
        "T13",
        "公司",
        249,
        253,
        "康龙化成"
      ],
      [
        "T14",
        "行业公司",
        312,
        317,
        "CRO企业"
      ],
      [
        "T15",
        "行业公司",
        350,
        356,
        "CDMO企业"
      ],
      [
        "T16",
        "公司",
        390,
        394,
        "药明康德"
      ],
      [
        "T17",
        "公司",
        421,
        425,
        "康龙化成"
      ],
      [
        "T18",
        "时间范围",
        464,
        469,
        "2020年"
      ],
      [
        "T19",
        "公司",
        549,
        553,
        "药明康德"
      ],
      [
        "T20",
        "公司",
        571,
        575,
        "康龙化成"
      ],
      [
        "T21",
        "行业",
        566,
        570,
        "CDMO"
      ],
      [
        "T22",
        "行业",
        579,
        586,
        "小分子CDMO"
      ],
      [
        "T23",
        "行业",
        587,
        590,
        "CRO"
      ],
      [
        "T24",
        "行业",
        449,
        452,
        "CRO"
      ],
      [
        "T25",
        "行业",
        453,
        457,
        "CDMO"
      ],
      [
        "T26",
        "行业",
        330,
        334,
        "CDMO"
      ],
      [
        "T27",
        "行业",
        361,
        364,
        "CRO"
      ],
      [
        "T28",
        "行业",
        368,
        372,
        "CDMO"
      ],
      [
        "T29",
        "行业",
        399,
        402,
        "CRO"
      ],
      [
        "T30",
        "行业",
        403,
        407,
        "CDMO"
      ],
      [
        "T31",
        "地点范围",
        97,
        99,
        "全球"
      ],
      [
        "T32",
        "地点范围",
        110,
        112,
        "中国"
      ],
      [
        "T33",
        "属性值",
        293,
        304,
        "CRO+CDMO一体化"
      ],
      [
        "T34",
        "营业收入",
        341,
        343,
        "收入"
      ],
      [
        "T35",
        "利润",
        344,
        346,
        "利润"
      ],
      [
        "T36",
        "行业",
        521,
        524,
        "CMC"
      ],
      [
        "T37",
        "营业收入",
        527,
        529,
        "收入"
      ],
      [
        "T38",
        "营业收入",
        499,
        501,
        "收入"
      ],
      [
        "T39",
        "行业",
        557,
        565,
        "生物大分子CRO"
      ]
    ]
  },
  {
    "id": 113,
    "text": "➢ 业绩维持高增长，前瞻性预案降低疫情影响：公司Q1收入剔除汇率影响后同比+78.47%，非经常性损益主要为所投资标的公允价值变动，在疫情影响下保持高速增长。3月底上海疫情爆发，公司第一时间启动业务连续性预案，1）安排员工驻场保证生产；2）充分利用公司强大产业链和供应链优势，保证原料供给充足。充分的预案准备保证公司2022上半年业绩稳定性。 ➢ 常规化学业务高增速，新分子业务加速放量：2022一季度公司化学业务实现收入61.18亿元（+102.1% ），其中R端收入17.45亿（+46.6%），D&M端收入43.73亿（+138.1%），受益于新冠订单交付，化学业务实现翻倍增长。公司常规业务仍保持高增速，剔除新冠业务后常规业务增速达到52.3%。公司 2022Q1 完成9万个定制化合物，化学药工艺研发和生产管线共增加217 个新分子。截至2022年3月底， 化学业务新药分子1808个，其中III期项目49个，获批项目42个。寡核苷酸和多肽药物的D&M 客户达到 86 个（+72%），分子数达121个（+98%）。 ➢ 依托WIND一体化凭条，测试业务保持稳定增长：2022一季度公司测试业务收入12.79亿元（31.7%）。 拆分来看，实验室分析及测试服务收入9.71亿元（+39.9%），通过WIND 服务平台，发挥一体化优势 ，2022Q1签署订单47个，其中安评业务订单饱满，收入同比增速达到53%。临床CRO&SMO业务收入 3.70亿元（+15.2%），保持平稳增长，其中CRO完成4个临床申请，SMO团队加速建设（人数+26%） ，2022Q1赋能4 个创新药获批上市。 ➢ 生物和ATU业务增长动能强，DDSU业务短期受到影响：其余业务除DDSU受到CDE提升临床质量政策的影响，实现收入2.41亿元（-21.6%）外，生物学业务和ATU业务分别实现收入5.33亿元（+26.2%）和 2.99亿元（37.0%），均保持良好增长态势。其中ATU业务结构不断改善，拥有的74个项目中，II期和 III期项目分别为7个和8个；生物业务新分子种类及生物药相关收入同比增长110%，成为重要增长点。 ➢ 盈利预测与投资评级：我们维持公司2022-2024年归母净利润为86.33/104.06/132.20亿元，同比增速为 69%/21%/27%；当前市值对应2022-2024年PE分别为34/28/22倍，公司作为CRO平台化龙头，业绩高确定性，估值性价比凸显，维持“买入”评级。 ➢ 风险提示：产能扩张不及预期，汇兑损益风险，新冠订单不及预期等。",
    "labels": [
      [
        "T0",
        "业绩",
        2,
        4,
        "业绩"
      ],
      [
        "T1",
        "时间范围",
        24,
        26,
        "Q1"
      ],
      [
        "T2",
        "营业收入",
        26,
        28,
        "收入"
      ],
      [
        "T3",
        "时间范围",
        79,
        82,
        "3月底"
      ],
      [
        "T4",
        "时间范围",
        159,
        165,
        "022上半年"
      ],
      [
        "T5",
        "业绩",
        165,
        167,
        "业绩"
      ],
      [
        "T6",
        "时间范围",
        194,
        201,
        "2022一季度"
      ],
      [
        "T7",
        "营业收入",
        209,
        211,
        "收入"
      ],
      [
        "T8",
        "时间范围",
        330,
        336,
        "2022Q1"
      ],
      [
        "T9",
        "时间范围",
        372,
        382,
        "截至2022年3月底"
      ],
      [
        "T10",
        "时间范围",
        489,
        496,
        "2022一季度"
      ],
      [
        "T11",
        "营业收入",
        502,
        504,
        "收入"
      ],
      [
        "T12",
        "时间范围",
        573,
        579,
        "2022Q1"
      ],
      [
        "T13",
        "新签订单",
        581,
        583,
        "订单"
      ],
      [
        "T14",
        "行业",
        610,
        619,
        "临床CRO&SMO"
      ],
      [
        "T15",
        "营业收入",
        621,
        623,
        "收入"
      ],
      [
        "T16",
        "行业",
        648,
        651,
        "CRO"
      ],
      [
        "T17",
        "时间范围",
        679,
        685,
        "2022Q1"
      ],
      [
        "T18",
        "营业收入",
        756,
        758,
        "收入"
      ],
      [
        "T19",
        "营业收入",
        789,
        791,
        "收入"
      ],
      [
        "T20",
        "营业收入",
        890,
        892,
        "收入"
      ],
      [
        "T21",
        "时间范围",
        928,
        938,
        "2022-2024年"
      ],
      [
        "T22",
        "归母净利润",
        938,
        943,
        "归母净利润"
      ],
      [
        "T23",
        "时间范围",
        990,
        1000,
        "2022-2024年"
      ],
      [
        "T24",
        "PE",
        1000,
        1002,
        "PE"
      ],
      [
        "T25",
        "龙头企业",
        1025,
        1027,
        "龙头"
      ],
      [
        "T26",
        "业绩",
        1028,
        1030,
        "业绩"
      ],
      [
        "T27",
        "行业",
        589,
        591,
        "安评"
      ],
      [
        "T28",
        "行业",
        1019,
        1025,
        "CRO平台化"
      ]
    ]
  },
  {
    "id": 114,
    "text": "公司核心业务 2016-2018年实现 25%的稳步增长：1）中国实验室业务增长稳定（1H19 收入占比约为 51%）；2）CMO/CDMO业务与临床 CRO业务快速发展，两大高增长业务奠定公司的成长基石。2016-1H19公司整体毛利率略有下降，系低毛利的大临床业务快速扩张所致，未来随着临床 CRO板块毛利率的提升（发展高毛利数统业务、提升人效），公司整体毛利率有望逐步提升。",
    "labels": [
      [
        "T0",
        "时间范围",
        8,
        17,
        "016-2018年"
      ],
      [
        "T1",
        "行业",
        62,
        70,
        "CMO/CDMO"
      ],
      [
        "T2",
        "时间范围",
        103,
        112,
        "2016-1H19"
      ],
      [
        "T3",
        "毛利",
        116,
        119,
        "毛利率"
      ],
      [
        "T4",
        "行业",
        145,
        151,
        "临床 CRO"
      ],
      [
        "T5",
        "毛利",
        153,
        156,
        "毛利率"
      ],
      [
        "T6",
        "毛利",
        180,
        183,
        "毛利率"
      ],
      [
        "T7",
        "时间范围",
        43,
        47,
        "1H19"
      ],
      [
        "T8",
        "营收占比",
        48,
        52,
        "收入占比"
      ],
      [
        "T9",
        "行业",
        33,
        36,
        "实验室"
      ],
      [
        "T10",
        "行业",
        73,
        79,
        "临床 CRO"
      ],
      [
        "T11",
        "地点范围",
        31,
        33,
        "中国"
      ],
      [
        "T12",
        "时间范围",
        141,
        143,
        "未来"
      ],
      [
        "T13",
        "毛利",
        163,
        165,
        "毛利"
      ]
    ]
  },
  {
    "id": 117,
    "text": "口实验室服务是康龙化成的明星业务。在收入结构方面，康龙化成实验室服务占据最大比重，在收入增速方面，实验室服务稳定增长，说明实验室服务是康龙化成的明星业务。CMC服务增速人人2017年开始下降,对营业收入的贡献也开始降低，说明CMC业务增长缓慢，原因在于2020年疫情影响导致工厂停工，2021年预计有较大提升。康龙化成2016年、2017年通过先后收购（Uotient、celeron布局临床研究服务，2018、2019年临床研究服务保持稳定增长，由营业入结构及增速看出，临床研究服务是康龙化成潜在发展业务",
    "labels": [
      [
        "T0",
        "属性值",
        1,
        6,
        "实验室服务"
      ],
      [
        "T1",
        "公司",
        7,
        11,
        "康龙化成"
      ],
      [
        "T2",
        "公司",
        25,
        29,
        "康龙化成"
      ],
      [
        "T3",
        "行业",
        29,
        34,
        "实验室服务"
      ],
      [
        "T4",
        "属性值",
        36,
        40,
        "最大比重"
      ],
      [
        "T5",
        "收入增速",
        42,
        46,
        "收入增速"
      ],
      [
        "T6",
        "行业",
        49,
        54,
        "实验室服务"
      ],
      [
        "T7",
        "属性值",
        54,
        58,
        "稳定增长"
      ],
      [
        "T8",
        "属性值",
        61,
        66,
        "实验室服务"
      ],
      [
        "T9",
        "公司",
        67,
        71,
        "康龙化成"
      ],
      [
        "T10",
        "时间范围",
        86,
        91,
        "2017年"
      ],
      [
        "T11",
        "营业收入",
        97,
        101,
        "营业收入"
      ],
      [
        "T12",
        "行业",
        112,
        115,
        "CMC"
      ],
      [
        "T13",
        "时间范围",
        126,
        131,
        "2020年"
      ],
      [
        "T14",
        "时间范围",
        142,
        147,
        "2021年"
      ],
      [
        "T15",
        "公司",
        155,
        159,
        "康龙化成"
      ],
      [
        "T16",
        "公司",
        177,
        184,
        "Uotient"
      ],
      [
        "T17",
        "公司",
        185,
        192,
        "celeron"
      ],
      [
        "T18",
        "时间范围",
        201,
        211,
        "2018、2019年"
      ],
      [
        "T19",
        "公司",
        243,
        247,
        "康龙化成"
      ],
      [
        "T20",
        "营业收入",
        18,
        20,
        "收入"
      ],
      [
        "T21",
        "时间范围",
        159,
        164,
        "2016年"
      ],
      [
        "T22",
        "时间范围",
        165,
        170,
        "2017年"
      ],
      [
        "T23",
        "行业",
        236,
        242,
        "临床研究服务"
      ],
      [
        "T24",
        "营业收入",
        225,
        228,
        "营业入"
      ],
      [
        "T25",
        "行业",
        211,
        217,
        "临床研究服务"
      ],
      [
        "T26",
        "行业",
        194,
        200,
        "临床研究服务"
      ],
      [
        "T27",
        "行业",
        77,
        82,
        "CMC服务"
      ]
    ]
  },
  {
    "id": 118,
    "text": "公司对医药健康产业诸多企业进行了投资布局，目前投资收益较为稳定。若被投企业公允价值或净资产发生较大变化，可能导致公司归母净利润出现较大波动。",
    "labels": [
      [
        "T0",
        "行业",
        3,
        7,
        "医药健康"
      ],
      [
        "T1",
        "归母净利润",
        58,
        63,
        "归母净利润"
      ]
    ]
  },
  {
    "id": 119,
    "text": "依据国家统计局数据，2021年 1-11月医药制造业规模以上企业实现营业收入 2.61万亿元，同比增长 20.90%，与 2019年同期相比增长 20.83%，两年复合增长率为 9.92%；实现利润总额 5403.50亿元，同比增长 70.80%，与 2019年同期相比增长 90.08%，两年复合增长率为 37.87%。国内疫情控制良好，医药工业数据实现恢复性增长。",
    "labels": [
      [
        "T0",
        "时间范围",
        10,
        21,
        "2021年 1-11月"
      ],
      [
        "T1",
        "行业公司",
        21,
        32,
        "医药制造业规模以上企业"
      ],
      [
        "T2",
        "营业收入",
        34,
        38,
        "营业收入"
      ],
      [
        "T3",
        "属性值",
        39,
        46,
        "2.61万亿元"
      ],
      [
        "T4",
        "属性值",
        52,
        58,
        "20.90%"
      ],
      [
        "T5",
        "CAGR",
        82,
        87,
        "复合增长率"
      ],
      [
        "T6",
        "属性值",
        89,
        94,
        "9.92%"
      ],
      [
        "T7",
        "利润",
        97,
        99,
        "利润"
      ],
      [
        "T8",
        "属性值",
        102,
        111,
        "5403.50亿元"
      ],
      [
        "T9",
        "属性值",
        117,
        123,
        "70.80%"
      ],
      [
        "T10",
        "CAGR",
        147,
        152,
        "复合增长率"
      ],
      [
        "T11",
        "属性值",
        154,
        160,
        "37.87%"
      ],
      [
        "T12",
        "地点范围",
        161,
        163,
        "国内"
      ],
      [
        "T13",
        "行业",
        170,
        174,
        "医药工业"
      ],
      [
        "T14",
        "属性值",
        73,
        79,
        "20.83%"
      ],
      [
        "T15",
        "属性值",
        138,
        144,
        "90.08%"
      ],
      [
        "T16",
        "时间范围",
        80,
        82,
        "两年"
      ],
      [
        "T17",
        "时间范围",
        145,
        147,
        "两年"
      ],
      [
        "T18",
        "时间范围",
        61,
        66,
        "2019年"
      ],
      [
        "T19",
        "时间范围",
        126,
        131,
        "2019年"
      ]
    ]
  },
  {
    "id": 122,
    "text": "行业龙头，稳步向前。药明康德为全球临床前 CRO行业领导者（2018年全球市场份额： 5.3%；中国市场份额 14.8%），公司临床前 CRO板块主要包含两部分业务：1）中国实验室业务（小分子药物研发）；2）美实验室业务（细胞&基因疗法和医疗器械检测服务）。公司临床前 CRO业务发展稳健（2016-2018年收入 CAGR=23%），超行业平均水平。",
    "labels": [
      [
        "T0",
        "龙头企业",
        2,
        4,
        "龙头"
      ],
      [
        "T1",
        "公司",
        10,
        14,
        "药明康德"
      ],
      [
        "T2",
        "行业",
        17,
        24,
        "临床前 CRO"
      ],
      [
        "T3",
        "时间范围",
        30,
        35,
        "2018年"
      ],
      [
        "T4",
        "地点范围",
        35,
        37,
        "全球"
      ],
      [
        "T5",
        "市场份额",
        37,
        41,
        "市场份额"
      ],
      [
        "T6",
        "属性值",
        43,
        47,
        "5.3%"
      ],
      [
        "T7",
        "地点范围",
        48,
        50,
        "中国"
      ],
      [
        "T8",
        "市场份额",
        50,
        54,
        "市场份额"
      ],
      [
        "T9",
        "属性值",
        55,
        60,
        "14.8%"
      ],
      [
        "T10",
        "行业",
        64,
        71,
        "临床前 CRO"
      ],
      [
        "T11",
        "属性值",
        85,
        101,
        "中国实验室业务（小分子药物研发）"
      ],
      [
        "T12",
        "属性值",
        104,
        128,
        "美实验室业务（细胞&基因疗法和医疗器械检测服务）"
      ],
      [
        "T13",
        "行业",
        131,
        138,
        "临床前 CRO"
      ],
      [
        "T14",
        "时间范围",
        145,
        155,
        "2016-2018年"
      ],
      [
        "T15",
        "营业收入",
        155,
        157,
        "收入"
      ],
      [
        "T16",
        "CAGR",
        158,
        162,
        "CAGR"
      ],
      [
        "T17",
        "属性值",
        163,
        166,
        "23%"
      ],
      [
        "T18",
        "地点范围",
        15,
        17,
        "全球"
      ]
    ]
  },
  {
    "id": 123,
    "text": "➢ 相对于行业先行指标，公司指标更为即时： 我们认为，CXO公司应主要关注以下指标： 1）短期收入转化及产业链地位看，预收账款+合同负债； 2）需求端看，在手订单数量； 3）供给端看，人员扩张与扩产计划的推进。 ➢ 另外结合公司产能排期、临床试验基地排期，募资情况，以及财务方面收入、净利润增速等指标，同步高位则预示高景气度，周转率/人均产出/单位固定资产产出在产能快速释放过程中可能阶段性降低，但会很快回升。",
    "labels": [
      [
        "T0",
        "行业公司",
        27,
        32,
        "CXO公司"
      ],
      [
        "T1",
        "合同负债",
        64,
        68,
        "合同负债"
      ],
      [
        "T2",
        "在手订单",
        77,
        81,
        "在手订单"
      ],
      [
        "T3",
        "行业需求",
        72,
        75,
        "需求端"
      ],
      [
        "T4",
        "行业供给",
        87,
        90,
        "供给端"
      ],
      [
        "T5",
        "归母净利润增速",
        142,
        147,
        "净利润增速"
      ],
      [
        "T6",
        "营业收入",
        139,
        141,
        "收入"
      ]
    ]
  },
  {
    "id": 124,
    "text": "◼ Clients：公司是强生、吉利德、GSK、BI、辉瑞、罗氏等 big pharma战略合作伙伴，具备做深大客户、做广中小客户的基础。",
    "labels": [
      [
        "T0",
        "公司",
        13,
        15,
        "强生"
      ],
      [
        "T1",
        "公司",
        16,
        19,
        "吉利德"
      ],
      [
        "T2",
        "公司",
        20,
        23,
        "GSK"
      ],
      [
        "T3",
        "公司",
        24,
        26,
        "BI"
      ],
      [
        "T4",
        "公司",
        27,
        29,
        "辉瑞"
      ],
      [
        "T5",
        "公司",
        30,
        32,
        "罗氏"
      ],
      [
        "T6",
        "行业",
        34,
        44,
        "big pharma"
      ]
    ]
  },
  {
    "id": 125,
    "text": "2.1 全球研发投入保持稳健增长，FDA批准新药数量维持较高水平全球研发投入保持稳健增长。2008年金融危机对全球医药研发造成较大冲击，研发投入增速降至1% ，2011年开始，增速逐步企稳回升，2020年全球医药研发投入同比增速已经接近2%。从绝对值来看 ，全球医药行业研发投入从2010年的1090亿美元增长到2020年的1506亿美元，复合增长率为 1.79%，预计2020-2025年全球医药研发仍将以2-4%的速度稳步增长。 海外医药生物PEVC融资额依然保持在较高水平。从一级市场来看，海外医药生物PEVC融资情况经过 2016年的低谷之后快速爆发，2017-2018年持续保持较快增长，2019年保持平稳，2020年融资金额达到2851亿美元，同比有所回升。",
    "labels": [
      [
        "T0",
        "地点范围",
        4,
        6,
        "全球"
      ],
      [
        "T1",
        "研发费用",
        6,
        10,
        "研发投入"
      ],
      [
        "T2",
        "FDA新药获批数",
        17,
        26,
        "FDA批准新药数量"
      ],
      [
        "T3",
        "研发费用",
        34,
        38,
        "研发投入"
      ],
      [
        "T4",
        "地点范围",
        55,
        57,
        "全球"
      ],
      [
        "T5",
        "研发费用",
        68,
        72,
        "研发投入"
      ],
      [
        "T6",
        "时间范围",
        97,
        102,
        "2020年"
      ],
      [
        "T7",
        "属性值",
        88,
        96,
        "增速逐步企稳回升"
      ],
      [
        "T8",
        "行业",
        131,
        133,
        "医药"
      ],
      [
        "T9",
        "研发费用",
        135,
        139,
        "研发投入"
      ],
      [
        "T10",
        "时间范围",
        140,
        145,
        "2010年"
      ],
      [
        "T11",
        "属性值",
        146,
        153,
        "1090亿美元"
      ],
      [
        "T12",
        "时间范围",
        156,
        161,
        "2020年"
      ],
      [
        "T13",
        "属性值",
        162,
        169,
        "1506亿美元"
      ],
      [
        "T14",
        "CAGR",
        170,
        175,
        "复合增长率"
      ],
      [
        "T15",
        "属性值",
        177,
        182,
        "1.79%"
      ],
      [
        "T16",
        "时间范围",
        185,
        195,
        "2020-2025年"
      ],
      [
        "T17",
        "地点范围",
        217,
        219,
        "海外"
      ],
      [
        "T18",
        "投融资金额",
        227,
        230,
        "融资额"
      ],
      [
        "T19",
        "地点范围",
        248,
        250,
        "海外"
      ],
      [
        "T20",
        "投融资情况",
        258,
        262,
        "融资情况"
      ],
      [
        "T21",
        "时间范围",
        265,
        270,
        "2016年"
      ],
      [
        "T22",
        "属性值",
        271,
        273,
        "低谷"
      ],
      [
        "T23",
        "时间范围",
        280,
        290,
        "2017-2018年"
      ],
      [
        "T24",
        "投融资金额",
        314,
        318,
        "融资金额"
      ],
      [
        "T25",
        "时间范围",
        309,
        314,
        "2020年"
      ],
      [
        "T26",
        "时间范围",
        299,
        304,
        "2019年"
      ],
      [
        "T27",
        "属性值",
        72,
        78,
        "增速降至1%"
      ],
      [
        "T28",
        "属性值",
        110,
        120,
        "同比增速已经接近2%"
      ],
      [
        "T29",
        "地点范围",
        102,
        104,
        "全球"
      ],
      [
        "T30",
        "地点范围",
        129,
        131,
        "全球"
      ],
      [
        "T31",
        "地点范围",
        32,
        34,
        "全球"
      ],
      [
        "T32",
        "时间范围",
        45,
        50,
        "2008年"
      ],
      [
        "T33",
        "行业",
        57,
        61,
        "医药研发"
      ],
      [
        "T34",
        "时间范围",
        80,
        87,
        "2011年开始"
      ],
      [
        "T35",
        "地点范围",
        195,
        197,
        "全球"
      ],
      [
        "T36",
        "行业",
        197,
        201,
        "医药研发"
      ],
      [
        "T37",
        "属性值",
        203,
        215,
        "以2-4%的速度稳步增长"
      ],
      [
        "T38",
        "行业",
        219,
        223,
        "医药生物"
      ],
      [
        "T39",
        "属性值",
        235,
        239,
        "较高水平"
      ],
      [
        "T40",
        "行业",
        250,
        254,
        "医药生物"
      ],
      [
        "T41",
        "属性值",
        275,
        279,
        "快速爆发"
      ],
      [
        "T42",
        "属性值",
        294,
        298,
        "较快增长"
      ],
      [
        "T43",
        "属性值",
        306,
        308,
        "平稳"
      ],
      [
        "T44",
        "属性值",
        320,
        334,
        "2851亿美元，同比有所回升"
      ],
      [
        "T45",
        "行业",
        104,
        106,
        "医药"
      ],
      [
        "T46",
        "研发费用",
        106,
        110,
        "研发投入"
      ]
    ]
  },
  {
    "id": 126,
    "text": "中国CXO企业收入和利润增速远超行业平均增速，2021年创历史新高。根据弗若斯特沙利文的数据，2017-2021年全球CR(D)MO市场规模年均复合增长率为11.4%，中国为26%。根据我们测算，2021年，19家中国CXO企业实现收入713亿元，同比增长46%；实现归母净利润175亿元，同比增长71%； 2017-2021年，收入年均复合增长率为32.5%，利润为56.5%，远超行业平均增速。",
    "labels": [
      [
        "T0",
        "行业公司",
        2,
        7,
        "CXO企业"
      ],
      [
        "T1",
        "收入增速",
        7,
        9,
        "收入"
      ],
      [
        "T2",
        "地点范围",
        0,
        2,
        "中国"
      ],
      [
        "T3",
        "时间范围",
        23,
        28,
        "2021年"
      ],
      [
        "T4",
        "时间范围",
        47,
        57,
        "2017-2021年"
      ],
      [
        "T5",
        "地点范围",
        57,
        59,
        "全球"
      ],
      [
        "T6",
        "行业",
        59,
        66,
        "CR(D)MO"
      ],
      [
        "T7",
        "CAGR",
        70,
        77,
        "年均复合增长率"
      ],
      [
        "T8",
        "市场规模",
        66,
        70,
        "市场规模"
      ],
      [
        "T9",
        "属性值",
        78,
        83,
        "11.4%"
      ],
      [
        "T10",
        "地点范围",
        84,
        86,
        "中国"
      ],
      [
        "T11",
        "属性值",
        87,
        90,
        "26%"
      ],
      [
        "T12",
        "时间范围",
        98,
        103,
        "2021年"
      ],
      [
        "T13",
        "行业公司",
        104,
        114,
        "19家中国CXO企业"
      ],
      [
        "T14",
        "营业收入",
        116,
        118,
        "收入"
      ],
      [
        "T15",
        "属性值",
        118,
        123,
        "713亿元"
      ],
      [
        "T16",
        "属性值",
        128,
        131,
        "46%"
      ],
      [
        "T17",
        "归母净利润",
        134,
        139,
        "归母净利润"
      ],
      [
        "T18",
        "时间范围",
        154,
        164,
        "2017-2021年"
      ],
      [
        "T19",
        "营业收入",
        165,
        167,
        "收入"
      ],
      [
        "T20",
        "CAGR",
        167,
        174,
        "年均复合增长率"
      ],
      [
        "T21",
        "属性值",
        175,
        180,
        "32.5%"
      ],
      [
        "T22",
        "利润",
        181,
        183,
        "利润"
      ],
      [
        "T23",
        "属性值",
        184,
        189,
        "56.5%"
      ],
      [
        "T24",
        "利润",
        10,
        12,
        "利润"
      ],
      [
        "T25",
        "属性值",
        139,
        152,
        "175亿元，同比增长71%"
      ],
      [
        "T26",
        "属性值",
        14,
        22,
        "远超行业平均增速"
      ]
    ]
  },
  {
    "id": 127,
    "text": "CXO板块大部分股价表现相对较好，跑赢医药板块指数。2020年初至今，CXO板块公司普遍取得相对较好的股价表现，其中博腾股份、昭衍新药、康龙化成和九洲药业等股价涨幅超过200%，药石科技、药明康德、凯莱英等涨幅也都超过100%，博济医药和睿智医药表现相对一般。",
    "labels": [
      [
        "T0",
        "行业",
        19,
        21,
        "医药"
      ],
      [
        "T1",
        "时间范围",
        26,
        34,
        "2020年初至今"
      ],
      [
        "T2",
        "行业公司",
        35,
        42,
        "CXO板块公司"
      ],
      [
        "T3",
        "公司",
        58,
        62,
        "博腾股份"
      ],
      [
        "T4",
        "公司",
        63,
        67,
        "昭衍新药"
      ],
      [
        "T5",
        "公司",
        68,
        72,
        "康龙化成"
      ],
      [
        "T6",
        "公司",
        73,
        77,
        "九洲药业"
      ],
      [
        "T7",
        "公司",
        89,
        93,
        "药石科技"
      ],
      [
        "T8",
        "公司",
        94,
        98,
        "药明康德"
      ],
      [
        "T9",
        "公司",
        99,
        102,
        "凯莱英"
      ],
      [
        "T10",
        "公司",
        114,
        118,
        "博济医药"
      ],
      [
        "T11",
        "公司",
        119,
        123,
        "睿智医药"
      ],
      [
        "T12",
        "行业",
        0,
        3,
        "CXO"
      ]
    ]
  },
  {
    "id": 128,
    "text": "随着公司产能的释放，公司 CMC服务能力进一步提升，订单数量和质量持续提高。 公司 2019年国内团队完成及在研 CMC项目 568个，其中临床前项目 485个，临床 I 期 54个，临床 II期 20个，临床 III期 9个。2020年 H1公司完成在研项目 463个，其中临床前项目 292个，临床 I期和和 II期 134个，临床 III期 35个，商业化阶段 2个。 公司在 CMC项目上取得许多突破，反映了公司 C(D)MO产能建设成果。",
    "labels": [
      [
        "T0",
        "时间范围",
        114,
        119,
        "2020年"
      ],
      [
        "T1",
        "产能",
        4,
        6,
        "产能"
      ],
      [
        "T2",
        "行业",
        13,
        16,
        "CMC"
      ],
      [
        "T3",
        "时间范围",
        42,
        47,
        "2019年"
      ],
      [
        "T4",
        "地点范围",
        47,
        49,
        "国内"
      ],
      [
        "T5",
        "在手订单",
        26,
        28,
        "订单"
      ],
      [
        "T6",
        "行业",
        192,
        195,
        "CMC"
      ],
      [
        "T7",
        "行业",
        211,
        217,
        "C(D)MO"
      ],
      [
        "T8",
        "产能",
        217,
        219,
        "产能"
      ]
    ]
  },
  {
    "id": 129,
    "text": "◆ 盈利预测与估值：我们预计公司2022-2024年营业收入分别为6.53/10.54/13.70亿元，同比增速分别为74.5%/61.3%/30.0%， 2022-2024年归母净利润分别为2.16/3.14/4.17亿元，同比增速分别为94.5%/45.2%/33.0%，P/E估值分别为40X/28X/21X，维持“买入”评级。 ◆ 风险提示：药物研发失败风险；市场竞争加剧风险；仿制药一致性评价业务增速放缓或减少的风险；制药企业仿制药研发投入下降风险等",
    "labels": [
      [
        "T0",
        "时间范围",
        16,
        26,
        "2022-2024年"
      ],
      [
        "T1",
        "营业收入",
        26,
        30,
        "营业收入"
      ],
      [
        "T2",
        "时间范围",
        78,
        88,
        "2022-2024年"
      ],
      [
        "T3",
        "归母净利润",
        88,
        93,
        "归母净利润"
      ],
      [
        "T4",
        "PE",
        138,
        141,
        "P/E"
      ]
    ]
  },
  {
    "id": 130,
    "text": "截至 2022年 2月 11日，医药指数市盈率为 29.25，环比上周下跌 0.55个单位，低于历史均值 11.62个单位；沪深 300指数市盈率为 13.36，医药指数的估值溢价率为 118.9%，环比上周下降 9.2个百分点，低于历史均值 72.8个百分点。",
    "labels": [
      [
        "T0",
        "时间范围",
        0,
        15,
        "截至 2022年 2月 11日"
      ],
      [
        "T1",
        "行业",
        16,
        18,
        "医药"
      ],
      [
        "T2",
        "PE",
        20,
        23,
        "市盈率"
      ],
      [
        "T3",
        "属性值",
        25,
        30,
        "29.25"
      ],
      [
        "T4",
        "PE",
        70,
        73,
        "市盈率"
      ],
      [
        "T5",
        "行业",
        81,
        83,
        "医药"
      ]
    ]
  },
  {
    "id": 131,
    "text": "➢ 国内CXO细分赛道市场规模空间广阔，其中各细分赛道的龙头公司药明康德、昭衍新药、泰格医药、药明生物、和元生物等将持续提升市占率，拥有较为好的发展前景。",
    "labels": [
      [
        "T0",
        "地点范围",
        2,
        4,
        "国内"
      ],
      [
        "T1",
        "市场规模",
        11,
        15,
        "市场规模"
      ],
      [
        "T2",
        "属性值",
        15,
        19,
        "空间广阔"
      ],
      [
        "T3",
        "龙头企业",
        28,
        32,
        "龙头公司"
      ],
      [
        "T4",
        "公司",
        32,
        36,
        "药明康德"
      ],
      [
        "T5",
        "公司",
        37,
        41,
        "昭衍新药"
      ],
      [
        "T6",
        "公司",
        42,
        46,
        "泰格医药"
      ],
      [
        "T7",
        "公司",
        47,
        51,
        "药明生物"
      ],
      [
        "T8",
        "公司",
        52,
        56,
        "和元生物"
      ],
      [
        "T9",
        "市场份额",
        62,
        65,
        "市占率"
      ],
      [
        "T10",
        "属性值",
        58,
        62,
        "持续提升"
      ],
      [
        "T11",
        "行业",
        4,
        7,
        "CXO"
      ]
    ]
  },
  {
    "id": 132,
    "text": "建议关注：1）研发管线丰富的龙头药企恒瑞医药、复星医药、中国生物制药等；2） 直接受益创新审评和进口替代的国产中高端医疗器械龙头迈瑞医疗、大博医疗、安图生物和消费级医疗器械三诺生物等；3）“卖水者”逻辑下的药明康德、泰格医药、凯莱英、九",
    "labels": [
      [
        "T0",
        "行业公司",
        16,
        18,
        "药企"
      ],
      [
        "T1",
        "龙头企业",
        14,
        16,
        "龙头"
      ],
      [
        "T2",
        "公司",
        18,
        22,
        "恒瑞医药"
      ],
      [
        "T3",
        "公司",
        23,
        27,
        "复星医药"
      ],
      [
        "T4",
        "公司",
        28,
        34,
        "中国生物制药"
      ],
      [
        "T5",
        "龙头企业",
        62,
        64,
        "龙头"
      ],
      [
        "T6",
        "公司",
        64,
        68,
        "迈瑞医疗"
      ],
      [
        "T7",
        "公司",
        69,
        73,
        "大博医疗"
      ],
      [
        "T8",
        "公司",
        74,
        78,
        "安图生物"
      ],
      [
        "T9",
        "公司",
        86,
        90,
        "三诺生物"
      ],
      [
        "T10",
        "公司",
        103,
        107,
        "药明康德"
      ],
      [
        "T11",
        "公司",
        108,
        112,
        "泰格医药"
      ],
      [
        "T12",
        "公司",
        113,
        116,
        "凯莱英"
      ],
      [
        "T13",
        "行业",
        53,
        62,
        "国产中高端医疗器械"
      ],
      [
        "T14",
        "行业",
        79,
        86,
        "消费级医疗器械"
      ]
    ]
  },
  {
    "id": 133,
    "text": "1、《中药行业专题报告：国家药监局、医保局先后强支持， 优质中药迎战略性机遇！》 2022-02-09 2、《医药工业“十四五”发布，发展动力强劲，把握战略机遇期》2022-02-06",
    "labels": [
      [
        "T0",
        "时间范围",
        41,
        51,
        "2022-02-09"
      ],
      [
        "T1",
        "行业",
        55,
        57,
        "医药"
      ],
      [
        "T2",
        "时间范围",
        82,
        92,
        "2022-02-06"
      ],
      [
        "T3",
        "行业",
        3,
        5,
        "中药"
      ]
    ]
  },
  {
    "id": 136,
    "text": " 2月 10日，阿斯利康针对贝塔变种的新冠疫苗在去年进入临床试验第 2/3 阶段。由于贝塔变种在最具威胁的变体名单排名不断下降，阿斯利康放弃这款名为 AZD2816的候选疫苗。  2月 10日，人福医药发布公告称，其控股子公司宜昌人福收到 NMPA核准签发的氨酚羟考酮缓释片的《药物临床试验批准通知书》，用于治疗中至重度疼痛。  2月 9日，Gamida Cell宣布，已启动向美国 FDA滚动递交干细胞/骨髓移植产品 omidubicel的生物制品许可申请。Omidubicel作为一种潜在挽救生命的治疗药物，用于治疗需要干细胞移植的血癌患者。该公司有望在 2022年第二季度完成 BLA提交。  2月 9日，CelerisTx宣布与德国默克达成一项研究合作协议，利用 CelerisTx 基于图形的人工智能技术平台，发现和设计新型小分子结合剂和双功能蛋白降解剂。  2月 9日，红细胞成熟剂——注射用罗特西普，获得 NMPA批准上市，用于治疗需要定期输注红细胞且红细胞输注≤15 单位/24 周的β-地中海贫血成人患者。注射用罗特西普的获批上市，将为β-地中海贫血成人患者带来治疗新选择，有望减轻输血依赖型β-地中海贫血患者的输血负担，降低因输血导致的铁过载风险，同时缓解血源紧张的现状。  2月 9日，康宁杰瑞两款 1类新药获得临床试验默示许可，分别为：1）抗 PD-L1/OX40 双特异性抗体 KN052 注射液，拟开发用于治疗晚期实体瘤患者；2）重组人源化 PD-L1/CTLA-4双特异性单域抗体 Fc融合蛋白注射液，拟开发用于联合阿昔替尼治疗晚期非小细胞肺癌患者。  2月 9日，齐鲁制药他达拉非口溶膜获批，目前国内市场上共有四款国产口溶膜获批上市。他达拉非口溶膜是齐鲁获批的第三个口溶膜产品。  2月 9日，基石药业申报的艾伏尼布片已在中国获批，适应症为复发性或难治性急性髓系白血病。  2月 9日，GSK旗下注射用贝利尤单抗的新适应症上市申请已获得批准。贝利尤单抗是首个获批用于治疗系统性狼疮和成人活动性狼疮性肾炎的药物。  2 月 9 日，远大医药申报的钇[90Y]树脂微球已在中国获批。钇[90Y]树脂微球可用于晚期肝癌的介入式核放射治疗。  2 月 9 日，华兰生物的四价流感病毒裂解疫苗获批上市，用于 6 个月至 3 岁以下人群预防相关型别的流感病毒引起的流行性感冒。  2月 8日，优瑞科生物宣布，FDA已授予在研 T细胞疗法 ET140203和 ECT204 治疗肝细胞癌的孤儿药资格。这两款 T细胞候选产品均基于其专有 ARTEMIS 技术平台开发，靶向特异性肝癌抗原。优瑞科生物目前正在 3项 1/2期临床",
    "labels": [
      [
        "T0",
        "时间范围",
        2,
        8,
        "2月 10日"
      ],
      [
        "T1",
        "公司",
        9,
        13,
        "阿斯利康"
      ],
      [
        "T2",
        "公司",
        65,
        69,
        "阿斯利康"
      ],
      [
        "T3",
        "时间范围",
        92,
        98,
        "2月 10日"
      ],
      [
        "T4",
        "公司",
        99,
        103,
        "人福医药"
      ],
      [
        "T5",
        "公司",
        115,
        119,
        "宜昌人福"
      ],
      [
        "T6",
        "时间范围",
        168,
        173,
        "2月 9日"
      ],
      [
        "T7",
        "公司",
        174,
        185,
        "Gamida Cell"
      ],
      [
        "T8",
        "时间范围",
        283,
        291,
        "2022年第二季"
      ],
      [
        "T9",
        "时间范围",
        304,
        309,
        "2月 9日"
      ],
      [
        "T10",
        "公司",
        310,
        319,
        "CelerisTx"
      ],
      [
        "T11",
        "公司",
        322,
        327,
        "德国默克达"
      ],
      [
        "T12",
        "公司",
        340,
        349,
        "CelerisTx"
      ],
      [
        "T13",
        "时间范围",
        390,
        395,
        "2月 9日"
      ],
      [
        "T14",
        "时间范围",
        554,
        559,
        "2月 9日"
      ],
      [
        "T15",
        "公司",
        560,
        564,
        "康宁杰瑞"
      ],
      [
        "T16",
        "时间范围",
        699,
        704,
        "2月 9日"
      ],
      [
        "T17",
        "公司",
        705,
        709,
        "齐鲁制药"
      ],
      [
        "T18",
        "时间范围",
        719,
        721,
        "目前"
      ],
      [
        "T19",
        "地点范围",
        721,
        723,
        "国内"
      ],
      [
        "T20",
        "时间范围",
        765,
        770,
        "2月 9日"
      ],
      [
        "T21",
        "公司",
        771,
        775,
        "基石药业"
      ],
      [
        "T22",
        "地点范围",
        785,
        787,
        "中国"
      ],
      [
        "T23",
        "时间范围",
        812,
        817,
        "2月 9日"
      ],
      [
        "T24",
        "公司",
        818,
        821,
        "GSK"
      ],
      [
        "T25",
        "时间范围",
        883,
        890,
        "2 月 9 日"
      ],
      [
        "T26",
        "公司",
        891,
        895,
        "远大医药"
      ],
      [
        "T27",
        "时间范围",
        945,
        952,
        "2 月 9 日"
      ],
      [
        "T28",
        "公司",
        953,
        957,
        "华兰生物"
      ],
      [
        "T29",
        "时间范围",
        1012,
        1017,
        "2月 8日"
      ],
      [
        "T30",
        "公司",
        1018,
        1023,
        "优瑞科生物"
      ],
      [
        "T31",
        "公司",
        1114,
        1119,
        "优瑞科生物"
      ],
      [
        "T32",
        "时间范围",
        1119,
        1121,
        "目前"
      ]
    ]
  },
  {
    "id": 137,
    "text": "小结：2021 年前三季度，国内 CXO 企业在扩产提速的前提下，固定资产利用效率处于较高水平，显示订单饱满。结合对订单结构的分析，我们认为中期来看， 商业化订单放量+订单附加值提升，将成为国内 CDMO 的重要成长驱动。",
    "labels": [
      [
        "T0",
        "时间范围",
        3,
        13,
        "2021 年前三季度"
      ],
      [
        "T1",
        "地点范围",
        14,
        16,
        "国内"
      ],
      [
        "T2",
        "行业公司",
        17,
        23,
        "CXO 企业"
      ],
      [
        "T3",
        "地点范围",
        95,
        97,
        "国内"
      ],
      [
        "T4",
        "行业",
        98,
        102,
        "CDMO"
      ],
      [
        "T5",
        "属性值",
        24,
        28,
        "扩产提速"
      ],
      [
        "T6",
        "固定资产",
        33,
        37,
        "固定资产"
      ],
      [
        "T7",
        "属性值",
        52,
        54,
        "饱满"
      ],
      [
        "T8",
        "在手订单",
        50,
        52,
        "订单"
      ],
      [
        "T9",
        "在手订单",
        58,
        60,
        "订单"
      ],
      [
        "T10",
        "属性值",
        86,
        91,
        "附加值提升"
      ],
      [
        "T11",
        "在手订单",
        84,
        86,
        "订单"
      ],
      [
        "T12",
        "时间范围",
        70,
        72,
        "中期"
      ],
      [
        "T13",
        "属性值",
        81,
        83,
        "放量"
      ],
      [
        "T14",
        "行业",
        76,
        79,
        "商业化"
      ],
      [
        "T15",
        "在手订单",
        79,
        81,
        "订单"
      ]
    ]
  },
  {
    "id": 138,
    "text": "不断有早期项目转化为临床及商业化项目，从而带来收入规模的持续扩大。截止 2021年一季度末，合全药业的商业化生产项目数量达到 28个，三期临床项目达到 46个。",
    "labels": [
      [
        "T0",
        "时间范围",
        33,
        45,
        "截止 2021年一季度末"
      ],
      [
        "T1",
        "公司",
        46,
        50,
        "合全药业"
      ],
      [
        "T2",
        "营业收入",
        23,
        25,
        "收入"
      ]
    ]
  },
  {
    "id": 139,
    "text": "国内创新药IND受理情况 国内PEVC投融资情况及IPO情况 国内Biotech企业和大药企研发投入",
    "labels": [
      [
        "T0",
        "地点范围",
        1,
        3,
        "国内"
      ],
      [
        "T1",
        "地点范围",
        15,
        17,
        "国内"
      ],
      [
        "T2",
        "投融资情况",
        21,
        26,
        "投融资情况"
      ],
      [
        "T3",
        "地点范围",
        34,
        36,
        "国内"
      ],
      [
        "T4",
        "研发费用",
        49,
        53,
        "研发投入"
      ],
      [
        "T5",
        "行业公司",
        36,
        45,
        "Biotech企业"
      ],
      [
        "T6",
        "行业公司",
        46,
        49,
        "大药企"
      ]
    ]
  },
  {
    "id": 141,
    "text": "通过复盘2011-2021年首次登录A/H上市的本土CXO企业股价表现，我们发现分年度看其与全球投融资短期（如月度和年度）同比增速变化趋势一致性并不强，但是拉长维度看与全球中长期（3-5年）创新药研发投入持续增加趋势一致性较强。我们预计可能是投资者对于整个创新药行业中长期蓬勃向上发展趋势以及CXO中长期订单高景气的乐观预期。",
    "labels": [
      [
        "T0",
        "行业公司",
        26,
        31,
        "CXO企业"
      ],
      [
        "T1",
        "时间范围",
        4,
        14,
        "2011-2021年"
      ],
      [
        "T2",
        "行业",
        95,
        98,
        "创新药"
      ],
      [
        "T3",
        "研发费用",
        98,
        102,
        "研发投入"
      ],
      [
        "T4",
        "属性值",
        102,
        106,
        "持续增加"
      ],
      [
        "T5",
        "行业",
        146,
        149,
        "CXO"
      ],
      [
        "T6",
        "行业",
        128,
        131,
        "创新药"
      ],
      [
        "T7",
        "地点范围",
        24,
        26,
        "本土"
      ],
      [
        "T8",
        "投融资情况",
        48,
        51,
        "投融资"
      ],
      [
        "T9",
        "地点范围",
        46,
        48,
        "全球"
      ],
      [
        "T10",
        "时间范围",
        51,
        53,
        "短期"
      ],
      [
        "T11",
        "地点范围",
        84,
        86,
        "全球"
      ],
      [
        "T12",
        "时间范围",
        86,
        89,
        "中长期"
      ],
      [
        "T13",
        "时间范围",
        149,
        152,
        "中长期"
      ],
      [
        "T14",
        "属性值",
        154,
        157,
        "高景气"
      ],
      [
        "T15",
        "假设情形",
        158,
        162,
        "乐观预期"
      ],
      [
        "T16",
        "在手订单",
        152,
        154,
        "订单"
      ],
      [
        "T17",
        "时间范围",
        133,
        136,
        "中长期"
      ],
      [
        "T18",
        "属性值",
        136,
        142,
        "蓬勃向上发展"
      ]
    ]
  },
  {
    "id": 143,
    "text": "“聚焦+放大”打开成长空间。药石科技是全球领先的药物分子砌块供应商，通过“聚焦+放大”打开了成长空间。（1）聚焦：基于分子砌块优势，强化药物发现业务。基于分子砌块库优势，延伸并强化药物发现服务业务，建设基于碎片分子片段的药物发现（FBDD）技术、DNA 编码化合物库（DEL）技术、超大容量特色虚拟化合物库筛选技术等多个关键药物发现技术平台；（2）放大：中间体→原料药→制剂，全产业链布局促进分子砌块产品的放量。建设符合 FDA 标准的制剂 CDMO 产能，将公司服务阶段从中间体、API，延伸到制剂，提高价值量的同时，将进一步绑定客户。",
    "labels": [
      [
        "T0",
        "公司",
        14,
        18,
        "药石科技"
      ],
      [
        "T1",
        "行业",
        177,
        180,
        "中间体"
      ],
      [
        "T2",
        "行业",
        181,
        184,
        "原料药"
      ],
      [
        "T3",
        "行业",
        185,
        187,
        "制剂"
      ],
      [
        "T4",
        "行业",
        237,
        240,
        "中间体"
      ],
      [
        "T5",
        "行业",
        241,
        244,
        "API"
      ],
      [
        "T6",
        "行业",
        248,
        250,
        "制剂"
      ],
      [
        "T7",
        "地点范围",
        19,
        21,
        "全球"
      ],
      [
        "T8",
        "行业",
        24,
        30,
        "药物分子砌块"
      ],
      [
        "T9",
        "行业",
        68,
        72,
        "药物发现"
      ],
      [
        "T10",
        "行业",
        90,
        96,
        "药物发现服务"
      ],
      [
        "T11",
        "行业",
        218,
        225,
        "制剂 CDMO"
      ],
      [
        "T12",
        "产能",
        226,
        228,
        "产能"
      ]
    ]
  },
  {
    "id": 144,
    "text": "◼ 流量：通过 CRO业务提高客户/分子覆盖率，在全球获取更多的客户及订单，以及在全球分子管线中覆盖更多的分子。",
    "labels": [
      [
        "T0",
        "行业",
        8,
        11,
        "CRO"
      ],
      [
        "T1",
        "地点范围",
        25,
        27,
        "全球"
      ]
    ]
  },
  {
    "id": 146,
    "text": "根据2月6日收盘价，部分重点 CXO个股动态市盈率已到历史平均值之下。药明生物动态PE 为100x（历史平均PE 206x） ＞康龙化成动态PE为66x（历史平均PE 95x）＞泰格医药动态PE为44x（历史平均PE 76x）。我们认为，在基本面逻辑没有变化的情况下，CXO 板块迎来适配区。",
    "labels": [
      [
        "T0",
        "公司",
        35,
        39,
        "药明生物"
      ],
      [
        "T1",
        "PE",
        41,
        43,
        "PE"
      ],
      [
        "T2",
        "属性值",
        45,
        49,
        "100x"
      ],
      [
        "T3",
        "公司",
        64,
        68,
        "康龙化成"
      ],
      [
        "T4",
        "PE",
        70,
        72,
        "PE"
      ],
      [
        "T5",
        "属性值",
        73,
        76,
        "66x"
      ],
      [
        "T6",
        "属性值",
        98,
        101,
        "44x"
      ],
      [
        "T7",
        "PE",
        95,
        97,
        "PE"
      ],
      [
        "T8",
        "公司",
        89,
        93,
        "泰格医药"
      ],
      [
        "T9",
        "行业",
        134,
        137,
        "CXO"
      ],
      [
        "T10",
        "PE",
        22,
        25,
        "市盈率"
      ],
      [
        "T11",
        "属性值",
        27,
        34,
        "历史平均值之下"
      ],
      [
        "T12",
        "行业公司",
        15,
        20,
        "CXO个股"
      ],
      [
        "T13",
        "时间范围",
        2,
        6,
        "2月6日"
      ],
      [
        "T14",
        "属性值",
        57,
        61,
        "206x"
      ],
      [
        "T15",
        "时间范围",
        50,
        52,
        "历史"
      ],
      [
        "T16",
        "PE",
        54,
        56,
        "PE"
      ],
      [
        "T17",
        "属性值",
        84,
        87,
        "95x"
      ],
      [
        "T18",
        "时间范围",
        77,
        79,
        "历史"
      ],
      [
        "T19",
        "属性值",
        109,
        112,
        "76x"
      ],
      [
        "T20",
        "时间范围",
        102,
        104,
        "历史"
      ]
    ]
  },
  {
    "id": 148,
    "text": "美国证券交易所IPO融资金额和数量处于历史高位，为全球研发支出提供弹性：自2020Q2开始，在美国证券交易所IPO单季度数量达到30-50家、金额达到60亿美金，处于历史以来的高点上、为美国Biotech的研发支出呈现高速增长提供支撑。",
    "labels": [
      [
        "T0",
        "投融资金额",
        11,
        15,
        "融资金额"
      ],
      [
        "T1",
        "行业",
        96,
        103,
        "Biotech"
      ],
      [
        "T2",
        "地点范围",
        94,
        96,
        "美国"
      ],
      [
        "T3",
        "时间范围",
        37,
        46,
        "自2020Q2开始"
      ],
      [
        "T4",
        "研发费用",
        104,
        108,
        "研发支出"
      ],
      [
        "T5",
        "属性值",
        110,
        114,
        "高速增长"
      ],
      [
        "T6",
        "地点范围",
        26,
        28,
        "全球"
      ],
      [
        "T7",
        "研发费用",
        28,
        32,
        "研发支出"
      ],
      [
        "T8",
        "地点范围",
        48,
        50,
        "美国"
      ],
      [
        "T9",
        "地点范围",
        1,
        3,
        "美国"
      ]
    ]
  },
  {
    "id": 149,
    "text": "若药品研发企业无药品生产资质，则无法获得药品批文，进而无法上市销售药品研发企业只能贱卖研发成果给具有药品生产资质的药品生产企业。药品生产企业在获得药制度实施前，制药企业需要耗费大量时间",
    "labels": [
      [
        "T0",
        "行业公司",
        1,
        7,
        "药品研发企业"
      ],
      [
        "T1",
        "行业公司",
        33,
        39,
        "药品研发企业"
      ],
      [
        "T2",
        "行业公司",
        57,
        63,
        "药品生产企业"
      ],
      [
        "T3",
        "行业公司",
        64,
        70,
        "药品生产企业"
      ],
      [
        "T4",
        "行业公司",
        80,
        84,
        "制药企业"
      ]
    ]
  },
  {
    "id": 150,
    "text": "CGT 发展历经三十余年发展，逐步迈入商业化的黄金时期。我们认为多重因素刺激 CGT 市场快速发展：1）技术成熟，商业化产品数量快速增加；2）单药售价高，易产生重磅炸弹；3）治疗效果好，患者接受意愿高，市占率有望快速提升；4）上游审批加速，下游保险支持，提高药物可及性。",
    "labels": [
      [
        "T0",
        "行业",
        39,
        42,
        "CGT"
      ],
      [
        "T1",
        "市场份额",
        101,
        104,
        "市占率"
      ],
      [
        "T2",
        "属性值",
        106,
        110,
        "快速提升"
      ]
    ]
  },
  {
    "id": 151,
    "text": "中国实验室主要提供小分子药物发现和检测业务，2016-2018年销售收入实现 25.1%的复合增长，我们预计未来三年公司该业务仍将保持稳健增长，基于：1）公司逐步与中国大型制药企业和初创型生物科技公司建立起紧密的合作关系，持续进行新客户的开发；2） 高毛利的 DDSU业务逐步进入收获期，有望从服务费用走向后期里程碑款及销售分成的新阶段（已有 54个项目拿到 CTA，其中进度最快的项目已进入 3期关键性临床）；3）新扩充业务与产能于 2019年起逐步投产（安评业务领衔增长，在国内动物房及评价产能瓶颈时期加大市场供应）。",
    "labels": [
      [
        "T0",
        "行业",
        9,
        19,
        "小分子药物发现和检测"
      ],
      [
        "T1",
        "时间范围",
        22,
        32,
        "2016-2018年"
      ],
      [
        "T2",
        "时间范围",
        54,
        58,
        "未来三年"
      ],
      [
        "T3",
        "毛利",
        126,
        128,
        "毛利"
      ],
      [
        "T4",
        "时间范围",
        218,
        223,
        "2019年"
      ],
      [
        "T5",
        "地点范围",
        239,
        241,
        "国内"
      ],
      [
        "T6",
        "地点范围",
        0,
        2,
        "中国"
      ],
      [
        "T7",
        "营业收入",
        34,
        36,
        "收入"
      ],
      [
        "T8",
        "地点范围",
        82,
        84,
        "中国"
      ],
      [
        "T9",
        "行业公司",
        86,
        90,
        "制药企业"
      ],
      [
        "T10",
        "行业公司",
        94,
        100,
        "生物科技公司"
      ],
      [
        "T11",
        "行业",
        130,
        134,
        "DDSU"
      ],
      [
        "T12",
        "产能",
        214,
        216,
        "产能"
      ],
      [
        "T13",
        "行业",
        229,
        231,
        "安评"
      ],
      [
        "T14",
        "产能",
        247,
        249,
        "产能"
      ]
    ]
  },
  {
    "id": 153,
    "text": "同比其他公司康龙化成临床研究服务毛利率较低，但康临床研究服务对康龙化成的营业收入影响最小，龙化成打通SMO与CRO的桥梁，利润空间较大",
    "labels": [
      [
        "T0",
        "公司",
        6,
        10,
        "康龙化成"
      ],
      [
        "T1",
        "毛利",
        16,
        19,
        "毛利率"
      ],
      [
        "T2",
        "属性值",
        19,
        21,
        "较低"
      ],
      [
        "T3",
        "公司",
        31,
        35,
        "康龙化成"
      ],
      [
        "T4",
        "营业收入",
        36,
        40,
        "营业收入"
      ],
      [
        "T5",
        "利润",
        61,
        63,
        "利润"
      ],
      [
        "T6",
        "属性值",
        63,
        67,
        "空间较大"
      ],
      [
        "T7",
        "行业",
        10,
        16,
        "临床研究服务"
      ],
      [
        "T8",
        "行业",
        24,
        30,
        "临床研究服务"
      ],
      [
        "T9",
        "行业",
        50,
        53,
        "SMO"
      ],
      [
        "T10",
        "行业",
        54,
        57,
        "CRO"
      ],
      [
        "T11",
        "公司",
        45,
        48,
        "龙化成"
      ]
    ]
  },
  {
    "id": 154,
    "text": "药物发现：主要过程为通过高通量方法筛选化合物，再优化化合物的分子结构、合成路线等，经过初步的有效性及成药性研究后，获得先导化合物，再经过深入研究及优化，获得候选化合物。",
    "labels": [
      [
        "T0",
        "行业",
        0,
        4,
        "药物发现"
      ]
    ]
  },
  {
    "id": 155,
    "text": "达到 34.9%。中国 CGT CDMO 市场规模则可能在全球范围内增速最快，预计到 2025 年，达到 107 亿人民币，2020-2025 年 CAGR 高达 51.5%。",
    "labels": [
      [
        "T0",
        "行业",
        12,
        20,
        "CGT CDMO"
      ],
      [
        "T1",
        "地点范围",
        9,
        11,
        "中国"
      ],
      [
        "T2",
        "市场规模",
        21,
        25,
        "市场规模"
      ],
      [
        "T3",
        "属性值",
        36,
        38,
        "最快"
      ],
      [
        "T4",
        "时间范围",
        43,
        49,
        "2025 年"
      ],
      [
        "T5",
        "属性值",
        53,
        61,
        "107 亿人民币"
      ],
      [
        "T6",
        "CAGR",
        74,
        78,
        "CAGR"
      ],
      [
        "T7",
        "属性值",
        82,
        87,
        "51.5%"
      ],
      [
        "T8",
        "地点范围",
        29,
        31,
        "全球"
      ],
      [
        "T9",
        "时间范围",
        62,
        73,
        "2020-2025 年"
      ]
    ]
  },
  {
    "id": 156,
    "text": "分别同比增长 41%/30%/29%，现价对应 21-23 年 PE 为 123/95/73 倍（暂不考虑港股上市摊薄），维持“买入”评级。",
    "labels": [
      [
        "T0",
        "时间范围",
        24,
        31,
        "21-23 年"
      ],
      [
        "T1",
        "PE",
        32,
        34,
        "PE"
      ]
    ]
  },
  {
    "id": 157,
    "text": "1月 21日，Alnylam Pharmaceuticals宣布，在研 RNAi疗法 vutrisiran的一项 3期试验获得积极结果。在第 9个月时达到其主要终点后，试验在 18个月时达到了其所有次要终点，与安慰剂相比，遗传性转甲状腺素蛋白淀粉样变性多发性神经病（hATTR-PN）成人患者表现出神经病变损害、生活质量（QoL）、步态速度、营养状况和总体残疾等多种指标的显著改善。并且，vutrisiran组患者的血清 TTR降低相对另一款获批 RNAi疗法 patisiran，达到了非劣效性标准。 Vutrisiran已被美国 FDA授予快速通道资格，PDUFA目标日期为 2022年 4月 14日。",
    "labels": [
      [
        "T0",
        "公司",
        7,
        30,
        "Alnylam Pharmaceuticals"
      ],
      [
        "T1",
        "时间范围",
        290,
        302,
        "2022年 4月 14日"
      ],
      [
        "T2",
        "时间范围",
        0,
        6,
        "1月 21日"
      ]
    ]
  },
  {
    "id": 158,
    "text": "CXO 全领域发展多面手。康龙化成是我国唯一一家集小分子、大分子、CGT CDMO 于一体的公司，致力于为各类药物提供端到端服务。公司以小分子化合物实验室服务起家，横向扩展至大分子及 CGT 药物开发服务，纵向扩展至商业化生产，目前已完成小分子药物的一体化开发生产布局，而大分子及 CGT 相关业务正处于起步阶段。",
    "labels": [
      [
        "T0",
        "行业",
        0,
        3,
        "CXO"
      ],
      [
        "T1",
        "公司",
        13,
        17,
        "康龙化成"
      ],
      [
        "T2",
        "地点范围",
        18,
        20,
        "我国"
      ],
      [
        "T3",
        "属性值",
        24,
        45,
        "集小分子、大分子、CGT CDMO 于一体"
      ],
      [
        "T4",
        "行业",
        68,
        79,
        "小分子化合物实验室服务"
      ],
      [
        "T5",
        "行业",
        87,
        102,
        "大分子及 CGT 药物开发服务"
      ],
      [
        "T6",
        "行业",
        119,
        124,
        "小分子药物"
      ],
      [
        "T7",
        "行业",
        136,
        144,
        "大分子及 CGT"
      ]
    ]
  },
  {
    "id": 160,
    "text": "截至 2021 年 12 月， 全球范围内共有 19 款 CGT 产品获批在售。 根据 FDA 推测， 2020 至 2025 年 CGT 药物将迎来收获期，每年将会有 10-20 个药物获批上市， 至 2025 年全球范围将有 50 款以上 CGT 产品上市。快速增加的上市产品数将迅速打开 CGT 市场规模。",
    "labels": [
      [
        "T0",
        "时间范围",
        0,
        14,
        "截至 2021 年 12 月"
      ],
      [
        "T1",
        "地点范围",
        16,
        18,
        "全球"
      ],
      [
        "T2",
        "时间范围",
        52,
        65,
        "2020 至 2025 年"
      ],
      [
        "T3",
        "行业",
        122,
        125,
        "CGT"
      ],
      [
        "T4",
        "行业",
        147,
        150,
        "CGT"
      ],
      [
        "T5",
        "市场规模",
        151,
        155,
        "市场规模"
      ],
      [
        "T6",
        "行业",
        29,
        32,
        "CGT"
      ],
      [
        "T7",
        "行业",
        66,
        72,
        "CGT 药物"
      ],
      [
        "T8",
        "地点范围",
        108,
        110,
        "全球"
      ],
      [
        "T9",
        "属性值",
        142,
        146,
        "迅速打开"
      ],
      [
        "T10",
        "时间范围",
        102,
        108,
        "2025 年"
      ]
    ]
  },
  {
    "id": 161,
    "text": "成本优势带来全球产业链再分工，订单向亚太地区转移趋势持续。综合以上人力成本、患者招募便利程度、临床试验进度等优势，全球 CRO行业供给分布中，亚太地区承担了主要的供给作用。全球 CRO行业上游需求主要来自北美与西欧地区，占比合计达到了 74%，而 CRO服务的供给则主要由北美和亚太地区提供。其中亚太地区供给份额超出需求份额 10个百分点。",
    "labels": [
      [
        "T0",
        "地点范围",
        57,
        59,
        "全球"
      ],
      [
        "T1",
        "行业",
        60,
        63,
        "CRO"
      ],
      [
        "T2",
        "行业",
        89,
        92,
        "CRO"
      ],
      [
        "T3",
        "行业需求",
        96,
        98,
        "需求"
      ],
      [
        "T4",
        "地点范围",
        6,
        8,
        "全球"
      ],
      [
        "T5",
        "地点范围",
        71,
        75,
        "亚太地区"
      ],
      [
        "T6",
        "行业供给",
        65,
        67,
        "供给"
      ],
      [
        "T7",
        "地点范围",
        86,
        88,
        "全球"
      ],
      [
        "T8",
        "属性值",
        98,
        109,
        "主要来自北美与西欧地区"
      ],
      [
        "T9",
        "行业",
        124,
        129,
        "CRO服务"
      ],
      [
        "T10",
        "行业供给",
        130,
        132,
        "供给"
      ],
      [
        "T11",
        "属性值",
        133,
        145,
        "主要由北美和亚太地区提供"
      ],
      [
        "T12",
        "地点范围",
        148,
        152,
        "亚太地区"
      ],
      [
        "T13",
        "行业供给",
        152,
        154,
        "供给"
      ],
      [
        "T14",
        "行业需求",
        158,
        160,
        "需求"
      ]
    ]
  },
  {
    "id": 162,
    "text": "从行业大环境来看，海外订单向亚太区转移趋势持续，国内创新药研发保持较高景气度。尽管 2019年归母净利润受投资标的公允价值变动影响存在一定波动，2020年疫情对美国区实验室和临床 CRO业务带来一定负面影响，但中国区实验室和 CDMO业务增长提速。综合来看，未来受疫情影响业务有望陆续恢复，高景气度带来的订单需求有望持续，随着产能利用率和营运效率持续改善， 公司整体盈利能力也有望进一步提升。",
    "labels": [
      [
        "T0",
        "行业",
        26,
        31,
        "创新药研发"
      ],
      [
        "T1",
        "属性值",
        33,
        38,
        "较高景气度"
      ],
      [
        "T2",
        "地点范围",
        24,
        26,
        "国内"
      ],
      [
        "T3",
        "时间范围",
        42,
        47,
        "2019年"
      ],
      [
        "T4",
        "归母净利润",
        47,
        52,
        "归母净利润"
      ],
      [
        "T5",
        "属性值",
        65,
        71,
        "存在一定波动"
      ],
      [
        "T6",
        "时间范围",
        72,
        77,
        "2020年"
      ],
      [
        "T7",
        "行业",
        87,
        93,
        "临床 CRO"
      ],
      [
        "T8",
        "行业",
        113,
        117,
        "CDMO"
      ],
      [
        "T9",
        "属性值",
        119,
        123,
        "增长提速"
      ],
      [
        "T10",
        "属性值",
        9,
        19,
        "海外订单向亚太区转移"
      ],
      [
        "T11",
        "地点范围",
        80,
        83,
        "美国区"
      ],
      [
        "T12",
        "行业",
        83,
        86,
        "实验室"
      ],
      [
        "T13",
        "地点范围",
        105,
        108,
        "中国区"
      ],
      [
        "T14",
        "行业",
        108,
        111,
        "实验室"
      ],
      [
        "T15",
        "行业需求",
        154,
        156,
        "需求"
      ],
      [
        "T16",
        "时间范围",
        129,
        131,
        "未来"
      ]
    ]
  },
  {
    "id": 163,
    "text": "临床 CRO为 CRO市场中规模最大的业务子单元，2018年其全球份额为 65.6%（中国份额为 55.4%）。公司从战略角度出发，近年来加速发展临床 CRO业务，2016-2018年实现了 68.4%的高速增长，我们认为此高速增长态势有望持续，基于：1）中国临床 CRO 市场高速增长（2018-2022E CAGR=24.3%），且中高端市场的集中度仍在提升；2）公司快速扩展团队（截至 9M19人数已达 3000），正处于以老带新的发展阶段，人均产出有较大的提升空间；3）持续的收并购扩大国际市场版图（如 2018年收购美国临床 CRO公司 RPG）并开始发展高毛利的数据统计业务（2019年收购美国数统公司 Pharmapace）。",
    "labels": [
      [
        "T0",
        "行业",
        0,
        6,
        "临床 CRO"
      ],
      [
        "T1",
        "行业",
        8,
        11,
        "CRO"
      ],
      [
        "T2",
        "时间范围",
        25,
        30,
        "2018年"
      ],
      [
        "T3",
        "地点范围",
        31,
        33,
        "全球"
      ],
      [
        "T4",
        "市场份额",
        33,
        35,
        "份额"
      ],
      [
        "T5",
        "属性值",
        37,
        42,
        "65.6%"
      ],
      [
        "T6",
        "地点范围",
        43,
        45,
        "中国"
      ],
      [
        "T7",
        "市场份额",
        45,
        47,
        "份额"
      ],
      [
        "T8",
        "属性值",
        49,
        54,
        "55.4%"
      ],
      [
        "T9",
        "行业",
        73,
        79,
        "临床 CRO"
      ],
      [
        "T10",
        "时间范围",
        82,
        92,
        "2016-2018年"
      ],
      [
        "T11",
        "地点范围",
        128,
        130,
        "中国"
      ],
      [
        "T12",
        "行业",
        130,
        136,
        "临床 CRO"
      ],
      [
        "T13",
        "时间范围",
        144,
        154,
        "2018-2022E"
      ],
      [
        "T14",
        "CAGR",
        155,
        159,
        "CAGR"
      ],
      [
        "T15",
        "属性值",
        160,
        165,
        "24.3%"
      ],
      [
        "T16",
        "市场集中度",
        174,
        177,
        "集中度"
      ],
      [
        "T17",
        "时间范围",
        193,
        200,
        "截至 9M19"
      ],
      [
        "T18",
        "公司",
        274,
        277,
        "RPG"
      ],
      [
        "T19",
        "毛利",
        284,
        286,
        "毛利"
      ],
      [
        "T20",
        "行业",
        287,
        291,
        "数据统计"
      ],
      [
        "T21",
        "时间范围",
        294,
        299,
        "2019年"
      ],
      [
        "T22",
        "公司",
        308,
        318,
        "Pharmapace"
      ],
      [
        "T23",
        "时间范围",
        256,
        261,
        "2018年"
      ],
      [
        "T24",
        "属性值",
        139,
        143,
        "高速增长"
      ],
      [
        "T25",
        "属性值",
        179,
        181,
        "提升"
      ],
      [
        "T26",
        "属性值",
        16,
        18,
        "最大"
      ],
      [
        "T27",
        "行业",
        168,
        171,
        "中高端"
      ],
      [
        "T28",
        "地点范围",
        263,
        265,
        "美国"
      ],
      [
        "T29",
        "地点范围",
        301,
        303,
        "美国"
      ],
      [
        "T30",
        "行业",
        303,
        305,
        "数统"
      ],
      [
        "T31",
        "行业",
        265,
        271,
        "临床 CRO"
      ]
    ]
  },
  {
    "id": 164,
    "text": "2020年投融资兑现研发投入586亿美金，强劲增长。从测算结果看：全球创新药 Biotech企业融资主要方式为PE/VC、IPO以及上市后的定增配股等方式（MNC一般依靠商业化品种销售实现研发资金的积累），2020年和2021年全球Biotech年化研发投入金额预计分别为586亿和790亿美元，同比增速分别为48%和35%，依然维持强劲的增长势头。考虑到募集资金研发投入周期，意味着2022-2023年Biotech研发投入较高绝对值是有保障的。",
    "labels": [
      [
        "T0",
        "时间范围",
        0,
        5,
        "2020年"
      ],
      [
        "T1",
        "研发费用",
        10,
        14,
        "研发投入"
      ],
      [
        "T2",
        "地点范围",
        33,
        35,
        "全球"
      ],
      [
        "T3",
        "行业公司",
        35,
        48,
        "创新药 Biotech企业"
      ],
      [
        "T4",
        "投融资情况",
        48,
        50,
        "融资"
      ],
      [
        "T5",
        "时间范围",
        103,
        108,
        "2020年"
      ],
      [
        "T6",
        "时间范围",
        109,
        114,
        "2021年"
      ],
      [
        "T7",
        "地点范围",
        114,
        116,
        "全球"
      ],
      [
        "T8",
        "行业",
        116,
        123,
        "Biotech"
      ],
      [
        "T9",
        "研发费用",
        125,
        129,
        "研发投入"
      ],
      [
        "T10",
        "属性值",
        136,
        140,
        "586亿"
      ],
      [
        "T11",
        "属性值",
        141,
        147,
        "790亿美元"
      ],
      [
        "T12",
        "时间范围",
        192,
        202,
        "2022-2023年"
      ],
      [
        "T13",
        "行业",
        202,
        209,
        "Biotech"
      ],
      [
        "T14",
        "研发费用",
        209,
        213,
        "研发投入"
      ],
      [
        "T15",
        "属性值",
        213,
        218,
        "较高绝对值"
      ],
      [
        "T16",
        "投融资情况",
        5,
        8,
        "投融资"
      ]
    ]
  },
  {
    "id": 166,
    "text": "➢ 医药行业明显调整，市值相比高位出现回落，截至2022年3月31日，医药行业总市值约7.5万亿元，占全部A股的市值从2011年的 4.1%提升至8.70%，相比2022年2月的8.01%略有提升。 ➢ 2021年四季度公募基金重仓医药行业的比例为11.00%，如果扣除主动医药基金及指数基金，重仓比例为7.07%，环比有所下降， 仍远低于2014峰值持仓比例20%。",
    "labels": [
      [
        "T0",
        "行业",
        2,
        4,
        "医药"
      ],
      [
        "T1",
        "时间范围",
        22,
        34,
        "截至2022年3月31日"
      ],
      [
        "T2",
        "行业",
        35,
        37,
        "医药"
      ],
      [
        "T3",
        "时间范围",
        59,
        64,
        "2011年"
      ],
      [
        "T4",
        "时间范围",
        81,
        88,
        "2022年2月"
      ],
      [
        "T5",
        "时间范围",
        102,
        110,
        "2021年四季度"
      ],
      [
        "T6",
        "行业",
        116,
        118,
        "医药"
      ],
      [
        "T7",
        "时间范围",
        170,
        174,
        "2014"
      ],
      [
        "T8",
        "市值",
        11,
        13,
        "市值"
      ],
      [
        "T9",
        "属性值",
        17,
        21,
        "出现回落"
      ],
      [
        "T10",
        "市值",
        40,
        42,
        "市值"
      ],
      [
        "T11",
        "属性值",
        42,
        49,
        "约7.5万亿元"
      ],
      [
        "T12",
        "市值",
        56,
        58,
        "市值"
      ]
    ]
  },
  {
    "id": 167,
    "text": "➢ 我国科研服务行业仍由外资品牌占据主要市场份额，一方面，是因为外资品牌发展较早，积累了深厚的客户资源，形成品牌壁垒；另一方面，外资企业研发实力相对较强，并掌握了许多关键技术，形成技术壁垒。 ➢ 近年来，国产企业逐渐崛起，部分企业也突破了卡脖子技术，迎来新一波进口替代浪潮。例如纳微科技的色谱填料、奥浦迈的培养基、诺唯赞/义翘神州/菲鹏生物等企业的酶/抗原抗体等主流产品，可逐渐媲美进口品牌，外加具有价格与本土优势以及政策支持引导，国产替代值得期待。",
    "labels": [
      [
        "T0",
        "行业",
        4,
        8,
        "科研服务"
      ],
      [
        "T1",
        "市场份额",
        20,
        24,
        "市场份额"
      ],
      [
        "T2",
        "公司",
        139,
        143,
        "纳微科技"
      ],
      [
        "T3",
        "公司",
        149,
        152,
        "奥浦迈"
      ],
      [
        "T4",
        "公司",
        157,
        160,
        "诺唯赞"
      ],
      [
        "T5",
        "公司",
        161,
        165,
        "义翘神州"
      ],
      [
        "T6",
        "公司",
        166,
        170,
        "菲鹏生物"
      ],
      [
        "T7",
        "地点范围",
        2,
        4,
        "我国"
      ],
      [
        "T8",
        "属性值",
        11,
        20,
        "由外资品牌占据主要"
      ],
      [
        "T9",
        "时间范围",
        98,
        101,
        "近年来"
      ],
      [
        "T10",
        "行业",
        216,
        220,
        "国产替代"
      ]
    ]
  },
  {
    "id": 168,
    "text": "中国 CRO行业起步较晚，第一家 CRO 公司是由 MDS 在 1996年投资成立的临床 CRO 公司，本土第一家 CRO公司在 1997年成立，这期间，凯莱英、药明康德陆续成立，2003版 GCP 的出台直接推动了国内 CRO 行业的发展。在我国 CRO 行业 25 年的发展过程中，诞生了多个优秀的本土 CRO公司，推动我国新药创新快速发展。",
    "labels": [
      [
        "T0",
        "行业",
        3,
        6,
        "CRO"
      ],
      [
        "T1",
        "地点范围",
        0,
        2,
        "中国"
      ],
      [
        "T2",
        "行业公司",
        58,
        63,
        "CRO公司"
      ],
      [
        "T3",
        "公司",
        77,
        80,
        "凯莱英"
      ],
      [
        "T4",
        "公司",
        81,
        85,
        "药明康德"
      ],
      [
        "T5",
        "地点范围",
        108,
        110,
        "国内"
      ],
      [
        "T6",
        "行业",
        111,
        114,
        "CRO"
      ],
      [
        "T7",
        "行业",
        125,
        128,
        "CRO"
      ],
      [
        "T8",
        "行业公司",
        154,
        159,
        "CRO公司"
      ],
      [
        "T9",
        "时间范围",
        32,
        37,
        "1996年"
      ],
      [
        "T10",
        "时间范围",
        65,
        70,
        "1997年"
      ],
      [
        "T11",
        "公司",
        26,
        29,
        "MDS"
      ],
      [
        "T12",
        "地点范围",
        52,
        54,
        "本土"
      ],
      [
        "T13",
        "行业公司",
        42,
        51,
        "临床 CRO 公司"
      ],
      [
        "T14",
        "行业公司",
        17,
        23,
        "CRO 公司"
      ],
      [
        "T15",
        "行业",
        151,
        153,
        "本土"
      ],
      [
        "T16",
        "地点范围",
        162,
        164,
        "我国"
      ],
      [
        "T17",
        "行业",
        164,
        166,
        "新药"
      ]
    ]
  },
  {
    "id": 169,
    "text": "泰格医药近几年营业收入和净利润均处于增长状态， 2021年上半年实现营业收入 20.56亿元，同比增长 41.62%，归母净利润 12.55 亿元，同比增长 25.65%，扣非归母净利润 5.43 亿元，同比增长 79.10%，公司营收及盈利能力高速恢复。得益于营业收入增加，应收账款回款良好以及预收款增加，2021 年上半年公司实现经营活动现金流 4.84 亿元，同比大增 120.10%。",
    "labels": [
      [
        "T0",
        "公司",
        0,
        4,
        "泰格医药"
      ],
      [
        "T1",
        "时间范围",
        4,
        7,
        "近几年"
      ],
      [
        "T2",
        "营业收入",
        7,
        11,
        "营业收入"
      ],
      [
        "T3",
        "归母净利润",
        12,
        15,
        "净利润"
      ],
      [
        "T4",
        "属性值",
        18,
        20,
        "增长"
      ],
      [
        "T5",
        "时间范围",
        24,
        32,
        "2021年上半年"
      ],
      [
        "T6",
        "营业收入",
        34,
        38,
        "营业收入"
      ],
      [
        "T7",
        "属性值",
        39,
        46,
        "20.56亿元"
      ],
      [
        "T8",
        "属性值",
        52,
        58,
        "41.62%"
      ],
      [
        "T9",
        "归母净利润",
        59,
        64,
        "归母净利润"
      ],
      [
        "T10",
        "扣非净利润",
        86,
        93,
        "扣非归母净利润"
      ],
      [
        "T11",
        "营业收入",
        116,
        118,
        "营收"
      ],
      [
        "T12",
        "营业收入",
        131,
        135,
        "营业收入"
      ],
      [
        "T13",
        "时间范围",
        154,
        163,
        "2021 年上半年"
      ],
      [
        "T14",
        "属性值",
        65,
        85,
        "12.55 亿元，同比增长 25.65%"
      ],
      [
        "T15",
        "属性值",
        94,
        113,
        "5.43 亿元，同比增长 79.10%"
      ],
      [
        "T16",
        "属性值",
        175,
        195,
        "4.84 亿元，同比大增 120.10%"
      ],
      [
        "T17",
        "现金流",
        171,
        174,
        "现金流"
      ]
    ]
  },
  {
    "id": 170,
    "text": "中性假设：药明康德全球 CRO市占率提升至 15%， CDMO市占率提升至 5%。 2019年 LabCorp与 IQVIA收入规模分别为 116亿美元和 111亿美元，对应全球 CRO市场份额为 18.5%和 17.7%，Lonza、Catalent收入规模为 47.4亿美元和 30.9亿美元，对应全球 CDMO市场份额为 6.46%和 4.21%。药明康德在 2030年有望进入全球 CXO行业第一梯队，中性假设下我们认为公司 CRO份额有望提升到 15%，CDMO份额达到 5%。",
    "labels": [
      [
        "T0",
        "公司",
        5,
        9,
        "药明康德"
      ],
      [
        "T1",
        "行业",
        12,
        15,
        "CRO"
      ],
      [
        "T2",
        "市场份额",
        15,
        18,
        "市占率"
      ],
      [
        "T3",
        "属性值",
        22,
        25,
        "15%"
      ],
      [
        "T4",
        "行业",
        27,
        31,
        "CDMO"
      ],
      [
        "T5",
        "市场份额",
        31,
        34,
        "市占率"
      ],
      [
        "T6",
        "属性值",
        38,
        40,
        "5%"
      ],
      [
        "T7",
        "时间范围",
        42,
        47,
        "2019年"
      ],
      [
        "T8",
        "公司",
        57,
        62,
        "IQVIA"
      ],
      [
        "T9",
        "营业收入",
        62,
        64,
        "收入"
      ],
      [
        "T10",
        "属性值",
        70,
        76,
        "116亿美元"
      ],
      [
        "T11",
        "行业",
        90,
        93,
        "CRO"
      ],
      [
        "T12",
        "市场份额",
        93,
        97,
        "市场份额"
      ],
      [
        "T13",
        "属性值",
        99,
        104,
        "18.5%"
      ],
      [
        "T14",
        "属性值",
        106,
        111,
        "17.7%"
      ],
      [
        "T15",
        "公司",
        112,
        117,
        "Lonza"
      ],
      [
        "T16",
        "公司",
        118,
        126,
        "Catalent"
      ],
      [
        "T17",
        "营业收入",
        126,
        128,
        "收入"
      ],
      [
        "T18",
        "属性值",
        132,
        139,
        "47.4亿美元"
      ],
      [
        "T19",
        "属性值",
        141,
        148,
        "30.9亿美元"
      ],
      [
        "T20",
        "行业",
        154,
        158,
        "CDMO"
      ],
      [
        "T21",
        "属性值",
        164,
        169,
        "6.46%"
      ],
      [
        "T22",
        "属性值",
        171,
        176,
        "4.21%"
      ],
      [
        "T23",
        "市场份额",
        158,
        162,
        "市场份额"
      ],
      [
        "T24",
        "公司",
        177,
        181,
        "药明康德"
      ],
      [
        "T25",
        "时间范围",
        183,
        188,
        "2030年"
      ],
      [
        "T26",
        "行业",
        195,
        198,
        "CXO"
      ],
      [
        "T27",
        "行业",
        217,
        220,
        "CRO"
      ],
      [
        "T28",
        "属性值",
        228,
        231,
        "15%"
      ],
      [
        "T29",
        "行业",
        232,
        236,
        "CDMO"
      ],
      [
        "T30",
        "属性值",
        241,
        243,
        "5%"
      ],
      [
        "T31",
        "地点范围",
        192,
        194,
        "全球"
      ],
      [
        "T32",
        "假设情形",
        0,
        4,
        "中性假设"
      ],
      [
        "T33",
        "地点范围",
        9,
        11,
        "全球"
      ],
      [
        "T34",
        "公司",
        48,
        55,
        "LabCorp"
      ],
      [
        "T35",
        "属性值",
        78,
        84,
        "111亿美元"
      ],
      [
        "T36",
        "地点范围",
        87,
        89,
        "全球"
      ],
      [
        "T37",
        "地点范围",
        151,
        153,
        "全球"
      ],
      [
        "T38",
        "假设情形",
        205,
        209,
        "中性假设"
      ]
    ]
  },
  {
    "id": 171,
    "text": "公司不断扩增产能以满足订单增长需求，截至 2021年底，公司在手订单金额约 29 亿元，较去年同期增长 70.59%。昭衍（苏州）于 2021年启动约 7500平米的动物房装修工程，已于 2021年年底完工并投入使用。苏州昭衍计划 2022年完成 II期 2万平米的设施建设，公司预计 2022年下半年正式投入使用；子公司昭衍易创计划租赁 9000平米实验室，开展药物筛选、药效学试验；无锡昭衍 3000平米的试验设施预计 2022年下半年投入使用。公司人员增长快速，2021年公司研发技术人员 1590人，同比增长 46%。在公司订单充足的前提下、产能释放有望形成规模效应，同时公司不断拓展的业务之间有望发挥协同作用，进一步带动订单增长。另外公司通过收购 Biomere进一步提升海外影响力，国际业务快速推进有望为公司打开新的成长天花板。",
    "labels": [
      [
        "T0",
        "时间范围",
        18,
        27,
        "截至 2021年底"
      ],
      [
        "T1",
        "在手订单",
        30,
        34,
        "在手订单"
      ],
      [
        "T2",
        "公司",
        161,
        165,
        "昭衍易创"
      ],
      [
        "T3",
        "时间范围",
        234,
        239,
        "2021年"
      ],
      [
        "T4",
        "公司",
        329,
        336,
        "Biomere"
      ],
      [
        "T5",
        "在手订单",
        266,
        268,
        "订单"
      ],
      [
        "T6",
        "时间范围",
        67,
        72,
        "2021年"
      ],
      [
        "T7",
        "时间范围",
        94,
        101,
        "2021年年底"
      ],
      [
        "T8",
        "公司",
        109,
        113,
        "苏州昭衍"
      ],
      [
        "T9",
        "公司",
        59,
        65,
        "昭衍（苏州）"
      ],
      [
        "T10",
        "时间范围",
        116,
        121,
        "2022年"
      ],
      [
        "T11",
        "时间范围",
        143,
        151,
        "2022年下半年"
      ],
      [
        "T12",
        "公司",
        193,
        197,
        "无锡昭衍"
      ],
      [
        "T13",
        "时间范围",
        212,
        220,
        "2022年下半年"
      ],
      [
        "T14",
        "产能",
        275,
        277,
        "产能"
      ]
    ]
  },
  {
    "id": 172,
    "text": "（2）随着公司对外并购和资源整合，临床 CRO业务拓展迅速、毛利率逐步提升。 2020-2022年的临床 CRO收入增速为 30%、40%、40%，毛利率分别为 25%、27%、 30%。",
    "labels": [
      [
        "T0",
        "行业",
        17,
        23,
        "临床 CRO"
      ],
      [
        "T1",
        "毛利",
        30,
        33,
        "毛利率"
      ],
      [
        "T2",
        "时间范围",
        39,
        49,
        "2020-2022年"
      ],
      [
        "T3",
        "行业",
        50,
        56,
        "临床 CRO"
      ],
      [
        "T4",
        "毛利",
        74,
        77,
        "毛利率"
      ],
      [
        "T5",
        "营业收入",
        56,
        58,
        "收入"
      ]
    ]
  },
  {
    "id": 174,
    "text": "海外个股表现来看，近1个月跌幅排名前3 的分别是：Catalent（-4.25%）＞ Samsung Biologics（-1.43%）＞Lonza （-0.16%）；近1年涨幅排名前3的分别是：ICON（31.73%）＞IQVIA",
    "labels": [
      [
        "T0",
        "公司",
        25,
        33,
        "Catalent"
      ],
      [
        "T1",
        "公司",
        43,
        60,
        "Samsung Biologics"
      ],
      [
        "T2",
        "公司",
        69,
        74,
        "Lonza"
      ],
      [
        "T3",
        "公司",
        98,
        102,
        "ICON"
      ],
      [
        "T4",
        "公司",
        111,
        116,
        "IQVIA"
      ],
      [
        "T5",
        "时间范围",
        9,
        13,
        "近1个月"
      ],
      [
        "T6",
        "时间范围",
        84,
        87,
        "近1年"
      ],
      [
        "T7",
        "地点范围",
        0,
        2,
        "海外"
      ]
    ]
  },
  {
    "id": 175,
    "text": "CAR-T疗法商业化面临多项挑战。尽管 CAR-T在临床上的安全性及有效性已得到验证，但由于其制造流程复杂性、生产周期较长及缺乏标准化的监管，目前仍然是一种高度个性化的疗法，国内产业化面临着监管（产业链、运输等）、患者支付可及性、生产标准化、治疗控制、临床有效性等多个挑战。未来随着行业监管日趋完善，技术水平的不断提升，国内细胞免疫治疗行业的产业化进程将逐步开启。国内研发火热，靶点与适应症重复性较高，未来市场竞争激烈，我们建议关注研究进展较快、临床数据优异、产业化程度较高及商业化能力较强的企业，如复星医药等。",
    "labels": [
      [
        "T0",
        "地点范围",
        87,
        89,
        "国内"
      ],
      [
        "T1",
        "地点范围",
        160,
        162,
        "国内"
      ],
      [
        "T2",
        "行业",
        162,
        168,
        "细胞免疫治疗"
      ],
      [
        "T3",
        "地点范围",
        182,
        184,
        "国内"
      ],
      [
        "T4",
        "公司",
        250,
        254,
        "复星医药"
      ],
      [
        "T5",
        "属性值",
        171,
        174,
        "产业化"
      ],
      [
        "T6",
        "时间范围",
        201,
        203,
        "未来"
      ]
    ]
  },
  {
    "id": 176,
    "text": "业绩期逐渐来临，有望驱动板块上行。近期随着年报及一季报季到来，业绩有望成为板块向上的重要催化剂。随着我国需求端稳中有增，叠加企业新产品进入放量期、新建产能陆续投产，部分企业有望于 2022年一季度实现同比/环比较快增长，建议重点关注一季报业绩有望高增长的细分领域和相关公司，我们预计以下",
    "labels": [
      [
        "T0",
        "业绩",
        31,
        33,
        "业绩"
      ],
      [
        "T1",
        "行业需求",
        52,
        54,
        "需求"
      ],
      [
        "T2",
        "地点范围",
        50,
        52,
        "我国"
      ],
      [
        "T3",
        "时间范围",
        90,
        98,
        "2022年一季度"
      ],
      [
        "T4",
        "业绩",
        119,
        121,
        "业绩"
      ]
    ]
  },
  {
    "id": 177,
    "text": "专注于药物发现研究服务， 企业或者生物科技公 NDA 获批上市及生产销售 CSO 注册 IV期临床上市临床试验监察、数据管理、统计分析注册申报服务上市后监测阶段便可开始与药企供支持，覆盖了药学产，集中于生产环节，不涉 www.leadleo.com",
    "labels": [
      [
        "T0",
        "行业",
        3,
        11,
        "药物发现研究服务"
      ],
      [
        "T1",
        "行业",
        17,
        21,
        "生物科技"
      ],
      [
        "T2",
        "行业公司",
        85,
        87,
        "药企"
      ]
    ]
  },
  {
    "id": 178,
    "text": "板块如“CXO、生命科学上游、疫苗、眼科、部分器械上游、部分品牌中药和部分原料药”的相关公司一季报有望实现较快增长。",
    "labels": [
      [
        "T0",
        "行业",
        4,
        7,
        "CXO"
      ],
      [
        "T1",
        "行业",
        15,
        17,
        "疫苗"
      ],
      [
        "T2",
        "行业",
        18,
        20,
        "眼科"
      ],
      [
        "T3",
        "行业",
        37,
        40,
        "原料药"
      ],
      [
        "T4",
        "行业",
        23,
        27,
        "器械上游"
      ],
      [
        "T5",
        "行业",
        8,
        14,
        "生命科学上游"
      ],
      [
        "T6",
        "行业",
        30,
        34,
        "品牌中药"
      ]
    ]
  },
  {
    "id": 179,
    "text": " 临床试验服务：主要覆盖临床试验方案设计和咨询、临床法规申报、项目管理、I至 IV期临床试验监察及管理、临床统计和数统编程等业务。公司临床试验服务主要通过康德弘翼（2016年 2月并表）、上海杰诚（2016年 2月并表）、WuXi Clinical（2018年 7月并表）、Pharmapace（2019年 5 月并表）等子公司开展。",
    "labels": [
      [
        "T0",
        "公司",
        78,
        82,
        "康德弘翼"
      ],
      [
        "T1",
        "公司",
        95,
        99,
        "上海杰诚"
      ],
      [
        "T2",
        "公司",
        112,
        125,
        "WuXi Clinical"
      ],
      [
        "T3",
        "公司",
        138,
        148,
        "Pharmapace"
      ],
      [
        "T4",
        "时间范围",
        83,
        91,
        "2016年 2月"
      ],
      [
        "T5",
        "时间范围",
        100,
        108,
        "2016年 2月"
      ],
      [
        "T6",
        "时间范围",
        126,
        134,
        "2018年 7月"
      ],
      [
        "T7",
        "时间范围",
        149,
        158,
        "2019年 5 月"
      ],
      [
        "T8",
        "行业",
        2,
        8,
        "临床试验服务"
      ]
    ]
  },
  {
    "id": 180,
    "text": "由于 CDMO偏向于重资产行业，因此相比于员工数和人效，固定资产是反映公司产能及产出更为重要的指标。可以看到，近两年 A股 CRO/CDMO公司的固定资产均保持稳定较快增长，凯莱英作为 CDMO的龙头公司之一，其固定资产较快增长成为公司业绩快速增长的重要基础。在“收入/固定资产”方面，CDMO企业近年整体维持稳中有升状态，博腾股份基于战略调整 2018-2020年上升趋势明显。",
    "labels": [
      [
        "T0",
        "行业",
        3,
        7,
        "CDMO"
      ],
      [
        "T1",
        "行业公司",
        62,
        72,
        "CRO/CDMO公司"
      ],
      [
        "T2",
        "固定资产",
        73,
        77,
        "固定资产"
      ],
      [
        "T3",
        "属性值",
        80,
        86,
        "稳定较快增长"
      ],
      [
        "T4",
        "公司",
        87,
        90,
        "凯莱英"
      ],
      [
        "T5",
        "行业",
        93,
        97,
        "CDMO"
      ],
      [
        "T6",
        "龙头企业",
        98,
        102,
        "龙头公司"
      ],
      [
        "T7",
        "固定资产",
        106,
        110,
        "固定资产"
      ],
      [
        "T8",
        "属性值",
        110,
        114,
        "较快增长"
      ],
      [
        "T9",
        "业绩",
        118,
        120,
        "业绩"
      ],
      [
        "T10",
        "属性值",
        120,
        124,
        "快速增长"
      ],
      [
        "T11",
        "行业公司",
        143,
        149,
        "CDMO企业"
      ],
      [
        "T12",
        "公司",
        162,
        166,
        "博腾股份"
      ],
      [
        "T13",
        "时间范围",
        173,
        183,
        "2018-2020年"
      ],
      [
        "T14",
        "固定资产",
        28,
        32,
        "固定资产"
      ],
      [
        "T15",
        "时间范围",
        55,
        58,
        "近两年"
      ],
      [
        "T16",
        "属性值",
        10,
        13,
        "重资产"
      ],
      [
        "T17",
        "产能",
        37,
        39,
        "产能"
      ],
      [
        "T18",
        "时间范围",
        149,
        151,
        "近年"
      ],
      [
        "T19",
        "属性值",
        155,
        159,
        "稳中有升"
      ],
      [
        "T20",
        "营业收入",
        132,
        134,
        "收入"
      ],
      [
        "T21",
        "固定资产",
        135,
        139,
        "固定资产"
      ]
    ]
  },
  {
    "id": 181,
    "text": "SMO业务地位稳固，CDS业务快速发展。公司的 SMO业务已经处于国内领先地位，团队人数国内第一。CDS 业务通过自建+并购持续拓展产能，逐步构建全球多中心服务能力，随着越来越多的全球多中心临床试验在中国开展，公司有望抓住行业发展机遇，借助全产业链平台的客户导流和转化优势，实现临床 CRO业务的高速发展。2020年受疫情影响该部分业务收入增速及毛利率均受到一过性冲击，预计 2021年起收入增速及毛利率均有望提升，内生增速恢复到 30%以上。",
    "labels": [
      [
        "T0",
        "行业",
        -1,
        3,
        ""
      ],
      [
        "T1",
        "行业",
        10,
        13,
        "CDS"
      ],
      [
        "T2",
        "行业",
        24,
        27,
        "SMO"
      ],
      [
        "T3",
        "行业",
        139,
        145,
        "临床 CRO"
      ],
      [
        "T4",
        "时间范围",
        153,
        158,
        "2020年"
      ],
      [
        "T5",
        "毛利",
        173,
        176,
        "毛利率"
      ],
      [
        "T6",
        "收入增速",
        168,
        172,
        "收入增速"
      ],
      [
        "T7",
        "时间范围",
        188,
        193,
        "2021年"
      ],
      [
        "T8",
        "收入增速",
        194,
        198,
        "收入增速"
      ],
      [
        "T9",
        "毛利",
        199,
        202,
        "毛利率"
      ],
      [
        "T10",
        "地点范围",
        44,
        46,
        "国内"
      ],
      [
        "T11",
        "员工数量",
        40,
        44,
        "团队人数"
      ],
      [
        "T12",
        "行业",
        49,
        52,
        "CDS"
      ],
      [
        "T13",
        "地点范围",
        73,
        75,
        "全球"
      ]
    ]
  },
  {
    "id": 182,
    "text": "中国医药CXO行业发展趋势——特色化技术 O中特色技术要求较高，药物发现阶段是新药研发流程中昀前端的环节，企业需要发展特色技术，以 DELT 难度和经济价值最高的乏，药物发现的成本 ELT技术具有较较高的高通量筛选，也药物筛选（SBD",
    "labels": [
      [
        "T0",
        "行业",
        2,
        7,
        "医药CXO"
      ],
      [
        "T1",
        "地点范围",
        0,
        2,
        "中国"
      ],
      [
        "T2",
        "属性值",
        15,
        20,
        "特色化技术"
      ],
      [
        "T3",
        "行业趋势",
        7,
        13,
        "行业发展趋势"
      ]
    ]
  },
  {
    "id": 183,
    "text": "近期，随着 4月一季报的发布，CXO赛道再次表现出其优秀的成长性和较强的业绩确定性。",
    "labels": [
      [
        "T0",
        "行业",
        15,
        18,
        "CXO"
      ],
      [
        "T1",
        "时间范围",
        6,
        8,
        "4月"
      ],
      [
        "T2",
        "时间范围",
        0,
        2,
        "近期"
      ],
      [
        "T3",
        "属性值",
        26,
        41,
        "优秀的成长性和较强的业绩确定性"
      ]
    ]
  },
  {
    "id": 184,
    "text": "预计公司 2021~2023年归母净利润达到 39.59/53.66/71.68亿元，同比增长 34/36/34%，对应当前股价 PE为 118/87/65X。结合绝对估值和相对估值法，给予目标估值 5300~6000亿元，维持“买入”评级。",
    "labels": [
      [
        "T0",
        "归母净利润",
        15,
        20,
        "归母净利润"
      ],
      [
        "T1",
        "PE",
        65,
        67,
        "PE"
      ],
      [
        "T2",
        "时间范围",
        5,
        15,
        "2021~2023年"
      ]
    ]
  },
  {
    "id": 185,
    "text": "CGT CDMO 提供的服务贯穿药物开发的全流程，囊括从临床前研发至商业化生产。与传统药物相比，细胞基因治疗的外包服务更注重活体开发过程，如质粒、 病毒、细胞的生产及纯化。因为开发工艺深度影响最终产品，因此细胞基因质粒产品开发有“过程即产品（process is the product）”这一说法。",
    "labels": [
      [
        "T0",
        "行业",
        0,
        8,
        "CGT CDMO"
      ],
      [
        "T1",
        "行业",
        48,
        59,
        "细胞基因治疗的外包服务"
      ],
      [
        "T2",
        "行业",
        41,
        45,
        "传统药物"
      ],
      [
        "T3",
        "属性值",
        59,
        68,
        "更注重活体开发过程"
      ]
    ]
  },
  {
    "id": 186,
    "text": " 核心CXO公司CDMO业务均保持高速增长：在疫情对CDMO业务略有冲击的情况下，CDMO业务继续保持高速增长。  核心CDMO公司管线数量继续呈现高速增长：CDMO企业服务的管线数量在过去3年中均呈现高速增长，例如药明康德、凯莱英、博腾股份、九洲药业、康龙化成2020年合计管线数量同比增速分别为25%/25%/17%/31%/30%。",
    "labels": [
      [
        "T0",
        "行业公司",
        2,
        9,
        "核心CXO公司"
      ],
      [
        "T1",
        "行业",
        9,
        13,
        "CDMO"
      ],
      [
        "T2",
        "行业",
        27,
        31,
        "CDMO"
      ],
      [
        "T3",
        "行业",
        42,
        46,
        "CDMO"
      ],
      [
        "T4",
        "行业公司",
        60,
        68,
        "核心CDMO公司"
      ],
      [
        "T5",
        "行业公司",
        81,
        87,
        "CDMO企业"
      ],
      [
        "T6",
        "时间范围",
        95,
        99,
        "过去3年"
      ],
      [
        "T7",
        "公司",
        110,
        114,
        "药明康德"
      ],
      [
        "T8",
        "公司",
        115,
        118,
        "凯莱英"
      ],
      [
        "T9",
        "公司",
        119,
        123,
        "博腾股份"
      ],
      [
        "T10",
        "公司",
        124,
        128,
        "九洲药业"
      ],
      [
        "T11",
        "公司",
        129,
        133,
        "康龙化成"
      ],
      [
        "T12",
        "时间范围",
        133,
        138,
        "2020年"
      ],
      [
        "T13",
        "属性值",
        18,
        22,
        "高速增长"
      ],
      [
        "T14",
        "属性值",
        52,
        56,
        "高速增长"
      ]
    ]
  },
  {
    "id": 187,
    "text": "四大核心业务，全产业链覆盖：1）中国实验室服务：提供从小分子药物发现（靶标筛选、 先导化合物合成及优化）到药物检测（DMPK/ADME、毒理学、生化分析）的一站式服务； 2）美国实验室服务：提供细胞&基因疗法服务（开发、测试与 cGMP生产）及医疗器械测试服务；3）临床研究服务：提供药物开发服务（I-IV期临床试验、数据分析、医学写作等）及现场管理服务；4）CMO/CDMO 服务：提供中间体、原料药以及制剂产品的工艺开发和商业化生产服务（制剂产品的生产主要于临床阶段）。",
    "labels": [
      [
        "T0",
        "行业",
        27,
        34,
        "小分子药物发现"
      ],
      [
        "T1",
        "行业",
        53,
        57,
        "药物检测"
      ],
      [
        "T2",
        "地点范围",
        16,
        18,
        "中国"
      ],
      [
        "T3",
        "地点范围",
        87,
        89,
        "美国"
      ],
      [
        "T4",
        "行业",
        18,
        23,
        "实验室服务"
      ],
      [
        "T5",
        "行业",
        89,
        94,
        "实验室服务"
      ],
      [
        "T6",
        "行业",
        133,
        139,
        "临床研究服务"
      ],
      [
        "T7",
        "行业",
        180,
        191,
        "CMO/CDMO 服务"
      ]
    ]
  },
  {
    "id": 188,
    "text": "我们认为，中国CXO企业能持续兑现高成长业绩得益于：",
    "labels": [
      [
        "T0",
        "行业公司",
        7,
        12,
        "CXO企业"
      ],
      [
        "T1",
        "地点范围",
        5,
        7,
        "中国"
      ],
      [
        "T2",
        "业绩",
        20,
        22,
        "业绩"
      ],
      [
        "T3",
        "属性值",
        17,
        20,
        "高成长"
      ]
    ]
  },
  {
    "id": 189,
    "text": "从项目数量来看，近几年CDMO企业项目数总量明显快速增加，最多的合全药业已经突破1300个， 凯莱英2020年项目总量也达到686个，其次九洲药业为494个，博腾股份为359个，合全药业和凯莱英在项目总量上体现出了明显的龙头优势。",
    "labels": [
      [
        "T0",
        "时间范围",
        8,
        11,
        "近几年"
      ],
      [
        "T1",
        "行业公司",
        11,
        17,
        "CDMO企业"
      ],
      [
        "T2",
        "公司",
        32,
        36,
        "合全药业"
      ],
      [
        "T3",
        "公司",
        47,
        50,
        "凯莱英"
      ],
      [
        "T4",
        "公司",
        50,
        55,
        "2020年"
      ],
      [
        "T5",
        "公司",
        69,
        73,
        "九洲药业"
      ],
      [
        "T6",
        "公司",
        79,
        83,
        "博腾股份"
      ],
      [
        "T7",
        "公司",
        89,
        93,
        "合全药业"
      ],
      [
        "T8",
        "公司",
        94,
        97,
        "凯莱英"
      ],
      [
        "T9",
        "龙头企业",
        110,
        112,
        "龙头"
      ]
    ]
  },
  {
    "id": 190,
    "text": "根据已披露2021年年度业绩预告来看，各 CXO公司业绩表现优异。",
    "labels": [
      [
        "T0",
        "行业公司",
        21,
        26,
        "CXO公司"
      ],
      [
        "T1",
        "时间范围",
        5,
        10,
        "2021年"
      ],
      [
        "T2",
        "业绩",
        26,
        28,
        "业绩"
      ],
      [
        "T3",
        "属性值",
        28,
        32,
        "表现优异"
      ],
      [
        "T4",
        "业绩",
        12,
        14,
        "业绩"
      ]
    ]
  },
  {
    "id": 192,
    "text": " 需求旺盛，资本支出加速： 国金医药大数据中心统计了 CXO板块中 21家代表性 CXO上市公司（以 CXO为主营业务）的历年资本开支情况，近 5 年来产业需求旺盛，资本支出逐渐加速。上述公司 2015-2020年资本开支分别为 32/38/45/73/98/153亿元，2016-2020年分别同比增长 18%/17%/ 63%/34%/56%。",
    "labels": [
      [
        "T0",
        "行业",
        28,
        31,
        "CXO"
      ],
      [
        "T1",
        "行业",
        52,
        55,
        "CXO"
      ],
      [
        "T2",
        "时间范围",
        71,
        76,
        "近 5 年"
      ],
      [
        "T3",
        "属性值",
        81,
        83,
        "旺盛"
      ],
      [
        "T4",
        "时间范围",
        98,
        108,
        "2015-2020年"
      ],
      [
        "T5",
        "时间范围",
        137,
        147,
        "2016-2020年"
      ],
      [
        "T6",
        "行业需求",
        2,
        4,
        "需求"
      ],
      [
        "T7",
        "CAPEX资本开支",
        7,
        11,
        "资本支出"
      ],
      [
        "T8",
        "行业公司",
        35,
        49,
        "21家代表性 CXO上市公司"
      ],
      [
        "T9",
        "主营业务",
        56,
        60,
        "主营业务"
      ],
      [
        "T10",
        "CAPEX资本开支",
        64,
        68,
        "资本开支"
      ],
      [
        "T11",
        "行业需求",
        77,
        81,
        "产业需求"
      ],
      [
        "T12",
        "属性值",
        88,
        92,
        "逐渐加速"
      ],
      [
        "T13",
        "CAPEX资本开支",
        84,
        88,
        "资本支出"
      ],
      [
        "T14",
        "CAPEX资本开支",
        108,
        112,
        "资本开支"
      ],
      [
        "T15",
        "属性值",
        116,
        136,
        "32/38/45/73/98/153亿元"
      ],
      [
        "T16",
        "属性值",
        149,
        174,
        "同比增长 18%/17%/ 63%/34%/56%"
      ],
      [
        "T17",
        "属性值",
        11,
        13,
        "加速"
      ],
      [
        "T18",
        "属性值",
        4,
        6,
        "旺盛"
      ]
    ]
  },
  {
    "id": 193,
    "text": "对比来看，2020年药明康德、泰格医药和康龙化成汇兑损益金额达到亿元，相对较大，其他CXO企业汇兑损益也都在千万级别，对业绩影响相对较大，后续需重点关注。",
    "labels": [
      [
        "T0",
        "时间范围",
        5,
        10,
        "2020年"
      ],
      [
        "T1",
        "公司",
        10,
        14,
        "药明康德"
      ],
      [
        "T2",
        "公司",
        15,
        19,
        "泰格医药"
      ],
      [
        "T3",
        "公司",
        20,
        24,
        "康龙化成"
      ],
      [
        "T4",
        "行业公司",
        42,
        47,
        "CXO企业"
      ],
      [
        "T5",
        "业绩",
        60,
        62,
        "业绩"
      ]
    ]
  },
  {
    "id": 194,
    "text": "注：药明康德的数据是除去长尾客户的收入；凯莱英的数据是除去大型制药公司的收入； 博腾股份的数据是除去前十大客户的其他客户收入； 康龙化成、九洲药业、普洛药业是除去前五大客户的其他客户的收入。",
    "labels": [
      [
        "T0",
        "公司",
        2,
        6,
        "药明康德"
      ],
      [
        "T1",
        "公司",
        20,
        23,
        "凯莱英"
      ],
      [
        "T2",
        "营业收入",
        17,
        19,
        "收入"
      ],
      [
        "T3",
        "营业收入",
        36,
        38,
        "收入"
      ],
      [
        "T4",
        "营业收入",
        60,
        62,
        "收入"
      ],
      [
        "T5",
        "营业收入",
        92,
        94,
        "收入"
      ],
      [
        "T6",
        "公司",
        40,
        44,
        "博腾股份"
      ],
      [
        "T7",
        "公司",
        64,
        68,
        "康龙化成"
      ],
      [
        "T8",
        "公司",
        69,
        73,
        "九洲药业"
      ],
      [
        "T9",
        "公司",
        74,
        78,
        "普洛药业"
      ],
      [
        "T10",
        "行业公司",
        31,
        35,
        "制药公司"
      ]
    ]
  },
  {
    "id": 195,
    "text": "一体化悬浮培养平台，相比传统的贴壁培养，悬浮培养将进一步提高细胞和基因治疗产品研发和生产效率。公司于 2020年 5月推出 CAR-T细胞治疗一体化封闭式生产平台，有助于加快客户 CGT项目的研发、生产时间表。",
    "labels": [
      [
        "T0",
        "时间范围",
        51,
        59,
        "2020年 5月"
      ]
    ]
  },
  {
    "id": 196,
    "text": "金赛道中的好公司，2020年目标市值 1791.06-1935.76亿元。我们认为公司作为行业内领先的一站式研发服务平台，未来三年业绩迎来多点催化：1）CMO/CDMO 板块项目由前至后的持续转化；2）临床 CRO业务的规模扩张与人效提升；3）DDSU业务进入里程碑与专利费收入时代，2019E-2021E营业收入增速预为 31.0%/26.6%/24.8%，归母净利润增速为-9.2%/18.8%/35.7%。公司归母净利润受股权投资公允价值变动影响较大（9M19 公允价值变动损失 1.32亿元 vs 9M18 公允价值变动收益 5.9 亿元），我们以经调整的 non-IFRS口径净利润为基础，采用分部估值法给予公司目标市值 1791.06-1935.76亿元。",
    "labels": [
      [
        "T0",
        "时间范围",
        9,
        14,
        "2020年"
      ],
      [
        "T1",
        "时间范围",
        61,
        65,
        "未来三年"
      ],
      [
        "T2",
        "行业",
        101,
        107,
        "临床 CRO"
      ],
      [
        "T3",
        "时间范围",
        142,
        153,
        "2019E-2021E"
      ],
      [
        "T4",
        "归母净利润增速",
        180,
        187,
        "归母净利润增速"
      ],
      [
        "T5",
        "归母净利润",
        208,
        213,
        "归母净利润"
      ],
      [
        "T6",
        "市值",
        16,
        18,
        "市值"
      ],
      [
        "T7",
        "业绩",
        65,
        67,
        "业绩"
      ],
      [
        "T8",
        "行业",
        76,
        84,
        "CMO/CDMO"
      ],
      [
        "T9",
        "行业",
        122,
        126,
        "DDSU"
      ],
      [
        "T10",
        "营业收入",
        153,
        157,
        "营业收入"
      ]
    ]
  },
  {
    "id": 197,
    "text": "资产负债率较低，总体偿债能力较强。2020年末公司资产负债率为 29%，较上年末有较大下降，主要由于 2020年 9月公司完成了非公开发行募资，净资产有较大提升。公司流动比率处于较高水平，净资产/带息债务也有显著提升， 总体偿债能力较强。",
    "labels": [
      [
        "T0",
        "时间范围",
        17,
        23,
        "2020年末"
      ],
      [
        "T1",
        "时间范围",
        51,
        59,
        "2020年 9月"
      ]
    ]
  },
  {
    "id": 198,
    "text": "全球临床阶段 CRO市场规模超过 400亿美元，中国市场增速较快。2019年全球临床 CRO市场规模达到 406亿美元，同比增长 7.1%。按照不同地区划分的临床 CRO市场中，美国市场占比过半，达到 209亿美元，中国市场规模约 37 亿美元。但未来 5年中国临床 CRO市场有望保持 30%的年复合增长，到 2024 年预计将达到 137亿美元。",
    "labels": [
      [
        "T0",
        "地点范围",
        0,
        2,
        "全球"
      ],
      [
        "T1",
        "行业",
        2,
        10,
        "临床阶段 CRO"
      ],
      [
        "T2",
        "市场规模",
        10,
        14,
        "市场规模"
      ],
      [
        "T3",
        "属性值",
        14,
        23,
        "超过 400亿美元"
      ],
      [
        "T4",
        "属性值",
        30,
        32,
        "较快"
      ],
      [
        "T5",
        "地点范围",
        24,
        26,
        "中国"
      ],
      [
        "T6",
        "时间范围",
        33,
        38,
        "2019年"
      ],
      [
        "T7",
        "地点范围",
        38,
        40,
        "全球"
      ],
      [
        "T8",
        "行业",
        40,
        46,
        "临床 CRO"
      ],
      [
        "T9",
        "市场规模",
        46,
        50,
        "市场规模"
      ],
      [
        "T10",
        "行业",
        79,
        85,
        "临床 CRO"
      ],
      [
        "T11",
        "地点范围",
        89,
        91,
        "美国"
      ],
      [
        "T12",
        "属性值",
        101,
        107,
        "209亿美元"
      ],
      [
        "T13",
        "地点范围",
        108,
        110,
        "中国"
      ],
      [
        "T14",
        "市场规模",
        110,
        114,
        "市场规模"
      ],
      [
        "T15",
        "属性值",
        114,
        122,
        "约 37 亿美元"
      ],
      [
        "T16",
        "时间范围",
        124,
        129,
        "未来 5年"
      ],
      [
        "T17",
        "地点范围",
        129,
        131,
        "中国"
      ],
      [
        "T18",
        "行业",
        131,
        137,
        "临床 CRO"
      ],
      [
        "T19",
        "CAGR",
        148,
        153,
        "年复合增长"
      ],
      [
        "T20",
        "时间范围",
        156,
        160,
        "2024"
      ],
      [
        "T21",
        "属性值",
        168,
        174,
        "137亿美元"
      ],
      [
        "T22",
        "属性值",
        53,
        69,
        "406亿美元，同比增长 7.1%"
      ],
      [
        "T23",
        "属性值",
        144,
        147,
        "30%"
      ]
    ]
  },
  {
    "id": 199,
    "text": "整合 HitS药物发现平台：密切把握行业药物研发趋势，通过自主建设和外延并购方式，较早布局 DEL、SBDD等药物发现平台，建设 PROTAC技术平台赋能长尾客户。2020年公司通过整合 DEL、蛋白生产和基于蛋白质结构的药物发现平台建立起一体化的靶标到命中化合物发现平台（HitS），已赋能超过 500家全球客户。更多分析详见上文“中国区实验室服务：中流砥柱”章节。",
    "labels": [
      [
        "T0",
        "时间范围",
        82,
        87,
        "2020年"
      ],
      [
        "T1",
        "地点范围",
        153,
        155,
        "全球"
      ],
      [
        "T2",
        "地点范围",
        167,
        170,
        "中国区"
      ]
    ]
  },
  {
    "id": 200,
    "text": "本人具有中国证券业协会授予的证券投资咨询执业资格，以勤勉的职业态度，独立、客观地出具本报告。本报告所采用的数据和信息均来自市场公开信息，本人不保证该等信息的准确性或完整性。分析逻辑基于作者的职业理解，清晰准确地反映了作者的研究观点，结论不受任何第三方的授意或影响，特此声明。",
    "labels": []
  },
  {
    "id": 201,
    "text": "我们从需求端、供给端和供应链参与度三个方面，详细论证了 CXO 领域，尤其是国内 CDMO 领域的景气度持续性。在新冠特效药订单、在手订单增多以及产能扩建加快之外， 我们区别于市场的观点是前期受新冠疫情影响而延后的海外研发管线有望于 2022 年恢复进展， 这些因素共同坚定了我们对短中期国内 CDMO 领域景气有望向上的判断。 在研究方法上，为了更好地判断 2022 年国内 CDMO 订单能否加速，我们创新地引入了“III 期订单同比增速”这一指标，去判断导流逻辑兑现、商业化放量的节奏。同时，我们详细剖析了重点 CXO 企业资产负债表的边际变化，去判断市场将 CAPEX 计划作为 CDMO 订单放量指引的合理性。 此外，为了更好地判断国内 CDMO 供应商在全球的竞争力是否提升，并为了剔除订单结构变化、资产利用效率提升的干扰，我们创新地引入了“单吨收入”、 “单位产值”这两个指标，去判断国内 CDMO 供应商的订单附加值是否在提高。",
    "labels": [
      [
        "T0",
        "行业需求",
        3,
        6,
        "需求端"
      ],
      [
        "T1",
        "行业供给",
        7,
        10,
        "供给端"
      ],
      [
        "T2",
        "行业",
        28,
        31,
        "CXO"
      ],
      [
        "T3",
        "地点范围",
        38,
        40,
        "国内"
      ],
      [
        "T4",
        "行业",
        41,
        45,
        "CDMO"
      ],
      [
        "T5",
        "在手订单",
        65,
        69,
        "在手订单"
      ],
      [
        "T6",
        "属性值",
        75,
        79,
        "扩建加快"
      ],
      [
        "T7",
        "产能",
        73,
        75,
        "产能"
      ],
      [
        "T8",
        "时间范围",
        117,
        123,
        "2022 年"
      ],
      [
        "T9",
        "时间范围",
        141,
        144,
        "短中期"
      ],
      [
        "T10",
        "地点范围",
        144,
        146,
        "国内"
      ],
      [
        "T11",
        "行业",
        147,
        151,
        "CDMO"
      ],
      [
        "T12",
        "属性值",
        154,
        160,
        "景气有望向上"
      ],
      [
        "T13",
        "属性值",
        69,
        71,
        "增多"
      ],
      [
        "T14",
        "时间范围",
        180,
        186,
        "2022 年"
      ],
      [
        "T15",
        "地点范围",
        186,
        188,
        "国内"
      ],
      [
        "T16",
        "行业",
        189,
        193,
        "CDMO"
      ],
      [
        "T17",
        "行业公司",
        259,
        265,
        "CXO 企业"
      ],
      [
        "T18",
        "行业",
        294,
        298,
        "CDMO"
      ],
      [
        "T19",
        "地点范围",
        321,
        323,
        "国内"
      ],
      [
        "T20",
        "行业",
        324,
        328,
        "CDMO"
      ],
      [
        "T21",
        "地点范围",
        333,
        335,
        "全球"
      ],
      [
        "T22",
        "地点范围",
        399,
        401,
        "国内"
      ],
      [
        "T23",
        "行业",
        402,
        406,
        "CDMO"
      ],
      [
        "T24",
        "在手订单",
        411,
        413,
        "订单"
      ],
      [
        "T25",
        "在手订单",
        194,
        196,
        "订单"
      ]
    ]
  },
  {
    "id": 202,
    "text": "图表1:CRO服务内容及投入资金、时间图表2:全球医药研发投入金额及增速，2016-2020图表3.全球研发管线，2015-2019图表4:中国医药CXO行业市场规模，2013-2025年预测图表5:CXO主要公司排名情况（按市值）图表6:康龙化成业务领域图表7:Top20CXO企业收入及业务布局图表8.康龙化成商业模式图表9:康龙化成融资并购发展不qn图表10:康龙化成与其他公司毛利率对比，2014-2020图表11:康龙化成各项业务毛利率，2015-2020图表12:公司营业收入结构，2015-2020图表13:公司营业收入结构增速，2016-2020图表14:康龙化成实验室服务主要业务图表15:康龙化成实验室服务具体业务拆分，2016-2020图表16:康龙化成与药明康德实验室服务毛利率对比，2016-2020图表17:康龙化成实验室服务具体业务毛利占比，2016-2019图表18:康龙化成实验室服务毛利率对比，2015-2020图表19:可比公司CDMO收入对比，2014-2020图表20:可比公司CDMO毛利率对比，2014-2020头豹",
    "labels": [
      [
        "T0",
        "行业",
        4,
        7,
        "CRO"
      ],
      [
        "T1",
        "地点范围",
        23,
        25,
        "全球"
      ],
      [
        "T2",
        "行业",
        25,
        27,
        "医药"
      ],
      [
        "T3",
        "研发费用",
        27,
        31,
        "研发投入"
      ],
      [
        "T4",
        "时间范围",
        37,
        46,
        "2016-2020"
      ],
      [
        "T5",
        "地点范围",
        50,
        52,
        "全球"
      ],
      [
        "T6",
        "时间范围",
        57,
        66,
        "2015-2019"
      ],
      [
        "T7",
        "地点范围",
        70,
        72,
        "中国"
      ],
      [
        "T8",
        "行业",
        72,
        77,
        "医药CXO"
      ],
      [
        "T9",
        "市场规模",
        79,
        83,
        "市场规模"
      ],
      [
        "T10",
        "时间范围",
        84,
        94,
        "2013-2025年"
      ],
      [
        "T11",
        "行业公司",
        100,
        107,
        "CXO主要公司"
      ],
      [
        "T12",
        "市值",
        113,
        115,
        "市值"
      ],
      [
        "T13",
        "公司",
        120,
        124,
        "康龙化成"
      ],
      [
        "T14",
        "主营业务",
        124,
        128,
        "业务领域"
      ],
      [
        "T15",
        "行业公司",
        132,
        142,
        "Top20CXO企业"
      ],
      [
        "T16",
        "营业收入",
        142,
        144,
        "收入"
      ],
      [
        "T17",
        "公司",
        153,
        157,
        "康龙化成"
      ],
      [
        "T18",
        "公司",
        165,
        169,
        "康龙化成"
      ],
      [
        "T19",
        "投融资情况",
        169,
        171,
        "融资"
      ],
      [
        "T20",
        "公司",
        183,
        187,
        "康龙化成"
      ],
      [
        "T21",
        "毛利",
        192,
        195,
        "毛利率"
      ],
      [
        "T22",
        "时间范围",
        198,
        207,
        "2014-2020"
      ],
      [
        "T23",
        "公司",
        212,
        216,
        "康龙化成"
      ],
      [
        "T24",
        "毛利",
        220,
        223,
        "毛利率"
      ],
      [
        "T25",
        "时间范围",
        224,
        233,
        "2015-2020"
      ],
      [
        "T26",
        "营业收入",
        240,
        244,
        "营业收入"
      ],
      [
        "T27",
        "时间范围",
        247,
        256,
        "2015-2020"
      ],
      [
        "T28",
        "营业收入",
        263,
        267,
        "营业收入"
      ],
      [
        "T29",
        "时间范围",
        272,
        281,
        "2016-2020"
      ],
      [
        "T30",
        "公司",
        286,
        290,
        "康龙化成"
      ],
      [
        "T31",
        "公司",
        304,
        308,
        "康龙化成"
      ],
      [
        "T32",
        "行业",
        290,
        295,
        "实验室服务"
      ],
      [
        "T33",
        "行业",
        308,
        313,
        "实验室服务"
      ],
      [
        "T34",
        "时间范围",
        320,
        329,
        "2016-2020"
      ],
      [
        "T35",
        "公司",
        334,
        338,
        "康龙化成"
      ],
      [
        "T36",
        "公司",
        339,
        343,
        "药明康德"
      ],
      [
        "T37",
        "行业",
        343,
        348,
        "实验室服务"
      ],
      [
        "T38",
        "毛利",
        348,
        351,
        "毛利率"
      ],
      [
        "T39",
        "时间范围",
        354,
        363,
        "2016-2020"
      ],
      [
        "T40",
        "公司",
        368,
        372,
        "康龙化成"
      ],
      [
        "T41",
        "行业",
        372,
        377,
        "实验室服务"
      ],
      [
        "T42",
        "毛利",
        381,
        383,
        "毛利"
      ],
      [
        "T43",
        "时间范围",
        386,
        395,
        "2016-2019"
      ],
      [
        "T44",
        "公司",
        400,
        404,
        "康龙化成"
      ],
      [
        "T45",
        "行业",
        404,
        409,
        "实验室服务"
      ],
      [
        "T46",
        "毛利",
        409,
        412,
        "毛利率"
      ],
      [
        "T47",
        "时间范围",
        415,
        424,
        "2015-2020"
      ],
      [
        "T48",
        "行业",
        433,
        437,
        "CDMO"
      ],
      [
        "T49",
        "营业收入",
        437,
        439,
        "收入"
      ],
      [
        "T50",
        "时间范围",
        442,
        451,
        "2014-2020"
      ],
      [
        "T51",
        "行业",
        460,
        464,
        "CDMO"
      ],
      [
        "T52",
        "毛利",
        464,
        467,
        "毛利率"
      ],
      [
        "T53",
        "时间范围",
        470,
        479,
        "2014-2020"
      ]
    ]
  },
  {
    "id": 203,
    "text": "从基金持股比例来看，呈现分化表现，持股比例分别有提升和下降个股。其中，基金持股比例提升的有：博腾股份（32%，提升5pct）＞九洲药业（22%，提升 4pct），基金持股比例下降的前3名分别是：药石科技 （9%，下降16pct）＞美迪西（18%，下降11pct）＞ 药明康德（21%，下降9pct）",
    "labels": [
      [
        "T0",
        "公司",
        46,
        50,
        "博腾股份"
      ],
      [
        "T1",
        "公司",
        63,
        67,
        "九洲药业"
      ],
      [
        "T2",
        "公司",
        97,
        101,
        "药石科技"
      ],
      [
        "T3",
        "公司",
        115,
        118,
        "美迪西"
      ],
      [
        "T4",
        "公司",
        133,
        137,
        "药明康德"
      ]
    ]
  },
  {
    "id": 204,
    "text": "比增长 36%、53%、61%，业绩符合预期。20Q1-Q4单季度收入同比增长 28%、35%、 43%、38%，归母净利润同比增长 42%、45%、67%、63%。由于 H2国内疫情稳定，国内的肾病和肝病产品需求明显恢复，并且因灌流器在新冠治疗中的作用，20H2 海外收入增加较多，另外，19Q3因发货波动导致基数较低，综合以上因素，20Q4业绩增长环比小幅降速。",
    "labels": [
      [
        "T0",
        "业绩",
        16,
        18,
        "业绩"
      ],
      [
        "T1",
        "时间范围",
        23,
        30,
        "20Q1-Q4"
      ],
      [
        "T2",
        "营业收入",
        33,
        35,
        "收入"
      ],
      [
        "T3",
        "归母净利润",
        57,
        62,
        "归母净利润"
      ],
      [
        "T4",
        "时间范围",
        86,
        88,
        "H2"
      ],
      [
        "T5",
        "地点范围",
        88,
        90,
        "国内"
      ],
      [
        "T6",
        "地点范围",
        95,
        97,
        "国内"
      ],
      [
        "T7",
        "行业",
        98,
        100,
        "肾病"
      ],
      [
        "T8",
        "行业",
        101,
        103,
        "肝病"
      ],
      [
        "T9",
        "行业需求",
        105,
        107,
        "需求"
      ],
      [
        "T10",
        "属性值",
        107,
        111,
        "明显恢复"
      ],
      [
        "T11",
        "时间范围",
        128,
        132,
        "20H2"
      ],
      [
        "T12",
        "地点范围",
        133,
        135,
        "海外"
      ],
      [
        "T13",
        "营业收入",
        135,
        137,
        "收入"
      ],
      [
        "T14",
        "时间范围",
        145,
        149,
        "19Q3"
      ],
      [
        "T15",
        "时间范围",
        168,
        172,
        "20Q4"
      ],
      [
        "T16",
        "业绩",
        172,
        174,
        "业绩"
      ]
    ]
  },
  {
    "id": 205,
    "text": "在临床 CRO 领域，2021 年上半年，临床试验服务团队累计提供了超过 170 个项目服务， 公司目前拥有国内规模最大的 SMO 公司，2021 年上半年员工人数接近 4000 人，同比增长 43%，分布在全国 147个城市的约 960家医院。",
    "labels": [
      [
        "T0",
        "行业",
        1,
        7,
        "临床 CRO"
      ],
      [
        "T1",
        "时间范围",
        11,
        20,
        "2021 年上半年"
      ],
      [
        "T2",
        "地点范围",
        54,
        56,
        "国内"
      ],
      [
        "T3",
        "时间范围",
        69,
        78,
        "2021 年上半年"
      ],
      [
        "T4",
        "员工数量",
        78,
        82,
        "员工人数"
      ],
      [
        "T5",
        "地点范围",
        104,
        106,
        "全国"
      ],
      [
        "T6",
        "行业",
        62,
        65,
        "SMO"
      ]
    ]
  },
  {
    "id": 207,
    "text": "在临床 CRO 领域，公司拥有独特的“放射性同位素化合物合成-临床-分析”一体化服务平台和临床开发服务一体化平台，可同时在中国、美国或欧洲提交药物 IND 申请。2020 年 7 月，公司控股联斯达，布局临床试验现场管理业务，2021 年 9 月，公司宣布收购德泰迈，加强临床试验药物警戒及医学服务能力，加速布局临床试验相关服务。",
    "labels": [
      [
        "T0",
        "行业",
        1,
        7,
        "临床 CRO"
      ],
      [
        "T1",
        "地点范围",
        61,
        63,
        "中国"
      ],
      [
        "T2",
        "地点范围",
        64,
        66,
        "美国"
      ],
      [
        "T3",
        "地点范围",
        67,
        69,
        "欧洲"
      ],
      [
        "T4",
        "时间范围",
        81,
        91,
        "2020 年 7 月"
      ],
      [
        "T5",
        "公司",
        96,
        99,
        "联斯达"
      ],
      [
        "T6",
        "行业",
        102,
        110,
        "临床试验现场管理"
      ],
      [
        "T7",
        "时间范围",
        113,
        123,
        "2021 年 9 月"
      ],
      [
        "T8",
        "公司",
        130,
        133,
        "德泰迈"
      ],
      [
        "T9",
        "行业",
        136,
        149,
        "临床试验药物警戒及医学服务"
      ],
      [
        "T10",
        "行业",
        156,
        160,
        "临床试验"
      ]
    ]
  },
  {
    "id": 208,
    "text": "2021年力口化学企業調查報告書",
    "labels": [
      [
        "T0",
        "时间范围",
        0,
        5,
        "2021年"
      ],
      [
        "T1",
        "公司",
        5,
        9,
        "力口化学"
      ]
    ]
  },
  {
    "id": 209,
    "text": " CXO行业产能转移不及预期风险；CXO企业订单不及预期风险；CXO企业订单波动风险；汇率波动风险；其他医药行业政策风险等。",
    "labels": [
      [
        "T0",
        "行业",
        2,
        5,
        "CXO"
      ],
      [
        "T1",
        "产能",
        7,
        9,
        "产能"
      ],
      [
        "T2",
        "行业公司",
        18,
        23,
        "CXO企业"
      ],
      [
        "T3",
        "行业公司",
        32,
        37,
        "CXO企业"
      ],
      [
        "T4",
        "行业",
        53,
        55,
        "医药"
      ]
    ]
  },
  {
    "id": 210,
    "text": "具体配置思路：1）中药领域：建议关注佐力药业、济川药业、东阿阿胶，推荐片仔癀等；2）仿制药 CXO领域：推荐百诚医药，建议关注阳光诺和等；3）创新药及产业链领域：九洲药业、药明康德、凯莱英等；4） BIOTECH类创新药：信达生物、亚盛医药等，建议关注康方生物；5）原料药领域：同和药业、司太立，建议关注普洛药业、天宇股份等；6）疫苗领域：智飞生物、康泰生物、万泰生物等；7）生长激素领域：安科生物等，建议关注长春高新；8）医疗服务领域：爱尔眼科、通策医疗、信邦制药等，建议关注三星医疗、海吉亚；8）血制品领域：天坛生物等， 建议关注博雅生物；9）医美领域：爱美客、华东医药、华熙生物、昊海生科等；10）医疗器械领域：鱼跃医疗、海泰新光、迈瑞医疗等。",
    "labels": [
      [
        "T0",
        "行业",
        9,
        11,
        "中药"
      ],
      [
        "T1",
        "公司",
        18,
        22,
        "佐力药业"
      ],
      [
        "T2",
        "公司",
        23,
        27,
        "济川药业"
      ],
      [
        "T3",
        "公司",
        28,
        32,
        "东阿阿胶"
      ],
      [
        "T4",
        "公司",
        35,
        38,
        "片仔癀"
      ],
      [
        "T5",
        "行业",
        42,
        49,
        "仿制药 CXO"
      ],
      [
        "T6",
        "公司",
        54,
        58,
        "百诚医药"
      ],
      [
        "T7",
        "公司",
        63,
        67,
        "阳光诺和"
      ],
      [
        "T8",
        "行业",
        71,
        78,
        "创新药及产业链"
      ],
      [
        "T9",
        "公司",
        81,
        85,
        "九洲药业"
      ],
      [
        "T10",
        "公司",
        86,
        90,
        "药明康德"
      ],
      [
        "T11",
        "公司",
        91,
        94,
        "凯莱英"
      ],
      [
        "T12",
        "行业",
        99,
        110,
        "BIOTECH类创新药"
      ],
      [
        "T13",
        "公司",
        111,
        115,
        "信达生物"
      ],
      [
        "T14",
        "公司",
        116,
        120,
        "亚盛医药"
      ],
      [
        "T15",
        "公司",
        126,
        130,
        "康方生物"
      ],
      [
        "T16",
        "行业",
        133,
        136,
        "原料药"
      ],
      [
        "T17",
        "公司",
        139,
        143,
        "同和药业"
      ],
      [
        "T18",
        "公司",
        144,
        147,
        "司太立"
      ],
      [
        "T19",
        "公司",
        152,
        156,
        "普洛药业"
      ],
      [
        "T20",
        "公司",
        157,
        161,
        "天宇股份"
      ],
      [
        "T21",
        "行业",
        165,
        167,
        "疫苗"
      ],
      [
        "T22",
        "公司",
        170,
        174,
        "智飞生物"
      ],
      [
        "T23",
        "公司",
        175,
        179,
        "康泰生物"
      ],
      [
        "T24",
        "公司",
        180,
        184,
        "万泰生物"
      ],
      [
        "T25",
        "行业",
        188,
        192,
        "生长激素"
      ],
      [
        "T26",
        "公司",
        195,
        199,
        "安科生物"
      ],
      [
        "T27",
        "公司",
        205,
        209,
        "长春高新"
      ],
      [
        "T28",
        "行业",
        212,
        216,
        "医疗服务"
      ],
      [
        "T29",
        "公司",
        219,
        223,
        "爱尔眼科"
      ],
      [
        "T30",
        "公司",
        224,
        228,
        "通策医疗"
      ],
      [
        "T31",
        "公司",
        229,
        233,
        "信邦制药"
      ],
      [
        "T32",
        "公司",
        239,
        243,
        "三星医疗"
      ],
      [
        "T33",
        "公司",
        244,
        247,
        "海吉亚"
      ],
      [
        "T34",
        "行业",
        250,
        253,
        "血制品"
      ],
      [
        "T35",
        "公司",
        256,
        260,
        "天坛生物"
      ],
      [
        "T36",
        "公司",
        267,
        271,
        "博雅生物"
      ],
      [
        "T37",
        "行业",
        274,
        276,
        "医美"
      ],
      [
        "T38",
        "公司",
        279,
        282,
        "爱美客"
      ],
      [
        "T39",
        "公司",
        283,
        287,
        "华东医药"
      ],
      [
        "T40",
        "公司",
        288,
        292,
        "华熙生物"
      ],
      [
        "T41",
        "公司",
        293,
        297,
        "昊海生科"
      ],
      [
        "T42",
        "行业",
        302,
        306,
        "医疗器械"
      ],
      [
        "T43",
        "公司",
        309,
        313,
        "鱼跃医疗"
      ],
      [
        "T44",
        "公司",
        314,
        318,
        "海泰新光"
      ],
      [
        "T45",
        "公司",
        319,
        323,
        "迈瑞医疗"
      ]
    ]
  },
  {
    "id": 211,
    "text": "▍后疫情时代国内 CXO企业加速全球化扩张和产业一体化整合，进一步抢夺市场份额。一方面，行业高景气度下国内 CXO公司的业绩加速增长和全球市占率不断提升，带来估值水平的水涨船高（相比海外成熟 CXO龙头的估值水平有明显差异）；另一方面，国内 CXO企业利用高的估值杠杆以及 A/H两个上市平台， 加速全球化扩张和一体化产业整合，全产业链布局得到加强——正向循环促进",
    "labels": [
      [
        "T0",
        "地点范围",
        6,
        8,
        "国内"
      ],
      [
        "T1",
        "行业公司",
        9,
        14,
        "CXO企业"
      ],
      [
        "T2",
        "市场份额",
        35,
        39,
        "市场份额"
      ],
      [
        "T3",
        "时间范围",
        1,
        6,
        "后疫情时代"
      ],
      [
        "T4",
        "地点范围",
        51,
        53,
        "国内"
      ],
      [
        "T5",
        "行业公司",
        54,
        59,
        "CXO公司"
      ],
      [
        "T6",
        "业绩",
        60,
        62,
        "业绩"
      ],
      [
        "T7",
        "属性值",
        62,
        66,
        "加速增长"
      ],
      [
        "T8",
        "地点范围",
        67,
        69,
        "全球"
      ],
      [
        "T9",
        "市场份额",
        69,
        72,
        "市占率"
      ],
      [
        "T10",
        "属性值",
        72,
        76,
        "不断提升"
      ],
      [
        "T11",
        "行业公司",
        96,
        101,
        "CXO龙头"
      ],
      [
        "T12",
        "地点范围",
        91,
        93,
        "海外"
      ],
      [
        "T13",
        "地点范围",
        118,
        120,
        "国内"
      ],
      [
        "T14",
        "行业公司",
        121,
        126,
        "CXO企业"
      ]
    ]
  },
  {
    "id": 212,
    "text": "CXO行业2021年中报跟踪报告",
    "labels": [
      [
        "T0",
        "行业",
        0,
        3,
        "CXO"
      ],
      [
        "T1",
        "时间范围",
        5,
        12,
        "2021年中报"
      ]
    ]
  },
  {
    "id": 213,
    "text": " 核心CXO公司CDMO业务均保持高速增长：在疫情对CDMO业务 2020年略有冲击的情况下，CDMO业务继续保持高速增长。  核心CDMO公司管线数量继续呈现高速增长：CDMO企业服务的管线数量在过去3年中均呈现高速增长，例如药明康德、凯莱英、博腾股份、九洲药业、康龙化成2020年合计管线数量同比增速分别为27%/44%/41%/25%/50%。",
    "labels": [
      [
        "T0",
        "行业公司",
        4,
        9,
        "CXO公司"
      ],
      [
        "T1",
        "行业",
        9,
        13,
        "CDMO"
      ],
      [
        "T2",
        "属性值",
        18,
        22,
        "高速增长"
      ],
      [
        "T3",
        "行业",
        27,
        31,
        "CDMO"
      ],
      [
        "T4",
        "时间范围",
        34,
        39,
        "2020年"
      ],
      [
        "T5",
        "行业",
        48,
        52,
        "CDMO"
      ],
      [
        "T6",
        "属性值",
        58,
        62,
        "高速增长"
      ],
      [
        "T7",
        "行业公司",
        68,
        74,
        "CDMO公司"
      ],
      [
        "T8",
        "行业公司",
        87,
        93,
        "CDMO企业"
      ],
      [
        "T9",
        "公司",
        116,
        120,
        "药明康德"
      ],
      [
        "T10",
        "公司",
        121,
        124,
        "凯莱英"
      ],
      [
        "T11",
        "公司",
        125,
        129,
        "博腾股份"
      ],
      [
        "T12",
        "公司",
        130,
        134,
        "九洲药业"
      ],
      [
        "T13",
        "公司",
        135,
        139,
        "康龙化成"
      ],
      [
        "T14",
        "时间范围",
        139,
        144,
        "2020年"
      ]
    ]
  },
  {
    "id": 215,
    "text": "致力于全球制药工艺的企业、生物技术企业提供药物研发、 布局中国市场，目前已仿制药一致性评价、临方位服务体系。公司坚原料药领域，服务默沙内外大中型制药公司，形成与制药巨",
    "labels": [
      [
        "T0",
        "公司",
        65,
        67,
        "默沙"
      ],
      [
        "T1",
        "行业公司",
        72,
        76,
        "制药公司"
      ],
      [
        "T2",
        "地点范围",
        3,
        5,
        "全球"
      ],
      [
        "T3",
        "行业",
        5,
        9,
        "制药工艺"
      ],
      [
        "T4",
        "行业公司",
        13,
        19,
        "生物技术企业"
      ],
      [
        "T5",
        "地点范围",
        29,
        31,
        "中国"
      ],
      [
        "T6",
        "行业",
        57,
        60,
        "原料药"
      ]
    ]
  },
  {
    "id": 216,
    "text": "口康龙化成CMC服务处于上升阶段，潜在利润空间较大。康龙化成2016年开始布局CMC服务（小分子CDMO）起步较晚，但在2017年康龙化成CMC服务已经达50.5万元/人，接近行业平均水平，略低于凯莱英人均创收53.0万元/人。博腾股份与药明康德人均创收均处于较高水准，同时维持在75万元/人，说明博腾股份与药明康德CDMO服务，订单数量较为稳定，处于CDMIO业务稳定期。康龙化成CMC业务处于上升期，人均创收还有较大上升空间口康龙化成CMC服务已经具备规模化效应。康龙化成在2016年人均创利已经超过博腾股份，同时人均创利水平与药明康德、凯莱英几乎A一致达到29万元／人，说明康龙化成CMC服务成本端更具有优势，在人均创收低于凯莱英、药明康德与博腾股份的状况下，人均创利在2020年达到相似水平。康龙化成CMC服务已经具备规模化效应，从成本端放大人均创利",
    "labels": [
      [
        "T0",
        "公司",
        1,
        5,
        "康龙化成"
      ],
      [
        "T1",
        "行业",
        5,
        10,
        "CMC服务"
      ],
      [
        "T2",
        "属性值",
        21,
        25,
        "空间较大"
      ],
      [
        "T3",
        "利润",
        19,
        21,
        "利润"
      ],
      [
        "T4",
        "公司",
        26,
        30,
        "康龙化成"
      ],
      [
        "T5",
        "时间范围",
        30,
        35,
        "2016年"
      ],
      [
        "T6",
        "行业",
        39,
        44,
        "CMC服务"
      ],
      [
        "T7",
        "行业",
        45,
        52,
        "小分子CDMO"
      ],
      [
        "T8",
        "时间范围",
        60,
        65,
        "2017年"
      ],
      [
        "T9",
        "公司",
        65,
        69,
        "康龙化成"
      ],
      [
        "T10",
        "行业",
        69,
        74,
        "CMC服务"
      ],
      [
        "T11",
        "属性值",
        77,
        85,
        "50.5万元/人"
      ],
      [
        "T12",
        "公司",
        98,
        101,
        "凯莱英"
      ],
      [
        "T13",
        "属性值",
        105,
        113,
        "53.0万元/人"
      ],
      [
        "T14",
        "人均收入",
        101,
        105,
        "人均创收"
      ],
      [
        "T15",
        "公司",
        114,
        118,
        "博腾股份"
      ],
      [
        "T16",
        "公司",
        119,
        123,
        "药明康德"
      ],
      [
        "T17",
        "人均收入",
        123,
        127,
        "人均创收"
      ],
      [
        "T18",
        "属性值",
        128,
        134,
        "处于较高水准"
      ],
      [
        "T19",
        "属性值",
        140,
        146,
        "75万元/人"
      ],
      [
        "T20",
        "公司",
        149,
        153,
        "博腾股份"
      ],
      [
        "T21",
        "公司",
        154,
        158,
        "药明康德"
      ],
      [
        "T22",
        "行业",
        158,
        164,
        "CDMO服务"
      ],
      [
        "T23",
        "属性值",
        169,
        173,
        "较为稳定"
      ],
      [
        "T24",
        "在手订单",
        165,
        167,
        "订单"
      ],
      [
        "T25",
        "行业",
        176,
        181,
        "CDMIO"
      ],
      [
        "T26",
        "公司",
        187,
        191,
        "康龙化成"
      ],
      [
        "T27",
        "行业",
        191,
        194,
        "CMC"
      ],
      [
        "T28",
        "属性值",
        196,
        201,
        "处于上升期"
      ],
      [
        "T29",
        "属性值",
        206,
        214,
        "还有较大上升空间"
      ],
      [
        "T30",
        "人均收入",
        202,
        206,
        "人均创收"
      ],
      [
        "T31",
        "公司",
        215,
        219,
        "康龙化成"
      ],
      [
        "T32",
        "行业",
        219,
        224,
        "CMC服务"
      ],
      [
        "T33",
        "公司",
        234,
        238,
        "康龙化成"
      ],
      [
        "T34",
        "时间范围",
        239,
        244,
        "2016年"
      ],
      [
        "T35",
        "人均利润",
        244,
        248,
        "人均创利"
      ],
      [
        "T36",
        "人均利润",
        259,
        263,
        "人均创利"
      ],
      [
        "T37",
        "公司",
        266,
        270,
        "药明康德"
      ],
      [
        "T38",
        "公司",
        271,
        274,
        "凯莱英"
      ],
      [
        "T39",
        "属性值",
        281,
        287,
        "29万元／人"
      ],
      [
        "T40",
        "公司",
        290,
        294,
        "康龙化成"
      ],
      [
        "T41",
        "行业",
        294,
        299,
        "CMC服务"
      ],
      [
        "T42",
        "人均收入",
        309,
        313,
        "人均创收"
      ],
      [
        "T43",
        "公司",
        315,
        318,
        "凯莱英"
      ],
      [
        "T44",
        "公司",
        319,
        323,
        "药明康德"
      ],
      [
        "T45",
        "公司",
        324,
        328,
        "博腾股份"
      ],
      [
        "T46",
        "人均利润",
        333,
        337,
        "人均创利"
      ],
      [
        "T47",
        "时间范围",
        338,
        343,
        "2020年"
      ],
      [
        "T48",
        "公司",
        350,
        354,
        "康龙化成"
      ],
      [
        "T49",
        "行业",
        354,
        359,
        "CMC服务"
      ],
      [
        "T50",
        "公司",
        252,
        256,
        "博腾股份"
      ]
    ]
  },
  {
    "id": 217,
    "text": "5月 27日，Myovant Sciences公司和辉瑞（Pfizer）宣布，美国 FDA已批准 Myfembree（relugolix 40 mg、雌二醇 1 mg和醋酸炔诺酮 0.5 mg）上市。新闻稿指出，这是首个每日一次，治疗绝经前女性子宫肌瘤相关月经大量出血的药物，治疗持续时间可长达 24个月。此次批准得到了发表在《新英格兰医学杂志》 上的 3期临床试验 LIBERTY 1和 LIBERTY 2的疗效和安全性数据的支持。子宫肌瘤是生长在子宫内壁或子宫壁上的非恶性肿瘤，它是女性中最为常见的生殖系统肿瘤之一。除遗传因素之外，雌激素水平是调控肌瘤生长的重要因子。 Relugolix组合疗法每片包含 relugolix（40 mg），雌二醇（1.0 mg），以及醋酸炔诺酮（0.5 mg）。作为一款促性腺激素释放激素（GnRH）受体拮抗剂， relugolix能降低卵巢生成的雌激素水平，从而缓解子宫肌瘤的一系列症状。 https://www.globenewswire.com",
    "labels": [
      [
        "T0",
        "时间范围",
        0,
        6,
        "5月 27日"
      ],
      [
        "T1",
        "公司",
        7,
        23,
        "Myovant Sciences"
      ],
      [
        "T2",
        "公司",
        26,
        36,
        "辉瑞（Pfizer）"
      ]
    ]
  },
  {
    "id": 218,
    "text": " CDMO：高成长新兴赛道给予更高估值溢价。海外Lonza和三星生物是CDMO中估值最高的前两位，Lonza因为其总是领先对手10年布局下一个风口赛道，小分子化药、大分子生物药和细胞基因治疗一应俱全；而三星生物则拥有全球最大的生物药产能。国内生物药CDMO绝对龙头药明生物也是估值最高的。",
    "labels": [
      [
        "T0",
        "行业",
        2,
        6,
        "CDMO"
      ],
      [
        "T1",
        "地点范围",
        23,
        25,
        "海外"
      ],
      [
        "T2",
        "公司",
        25,
        30,
        "Lonza"
      ],
      [
        "T3",
        "公司",
        31,
        35,
        "三星生物"
      ],
      [
        "T4",
        "行业",
        36,
        40,
        "CDMO"
      ],
      [
        "T5",
        "公司",
        50,
        55,
        "Lonza"
      ],
      [
        "T6",
        "行业",
        77,
        82,
        "小分子化药"
      ],
      [
        "T7",
        "行业",
        83,
        89,
        "大分子生物药"
      ],
      [
        "T8",
        "行业",
        90,
        96,
        "细胞基因治疗"
      ],
      [
        "T9",
        "公司",
        102,
        106,
        "三星生物"
      ],
      [
        "T10",
        "地点范围",
        109,
        111,
        "全球"
      ],
      [
        "T11",
        "行业",
        114,
        117,
        "生物药"
      ],
      [
        "T12",
        "产能",
        117,
        119,
        "产能"
      ],
      [
        "T13",
        "属性值",
        111,
        113,
        "最大"
      ],
      [
        "T14",
        "地点范围",
        120,
        122,
        "国内"
      ],
      [
        "T15",
        "行业",
        122,
        129,
        "生物药CDMO"
      ],
      [
        "T16",
        "公司",
        133,
        137,
        "药明生物"
      ],
      [
        "T17",
        "龙头企业",
        131,
        133,
        "龙头"
      ]
    ]
  },
  {
    "id": 219,
    "text": "新冠疫苗推动公司业绩高速增长，海外市场逐步打开。新冠疫苗于 3月被国内纳入紧急使用，实现销售，推动公司业绩实现高速增长，2021年前三季度公司实现营业收入 218.29亿元，同比增长 97.55%；实现归母净利润 84.04亿元，同比增长 239.05%，实现扣非后归母净利润 84.18亿元，同比增长 239.06%。根据 Ⅲ期临床试验数据，公司新冠疫苗对于任何严重程度的 COVID-19的保护效力为 81.76%，达到 WHO要求的新冠疫苗有效性标准，其中对于 COVID-19重症及以上病例、死亡病例的保护效力均为 100%；对 Alpha 变异株的保护效力为 92.93%；对 Delta变异株的保护效力为 77.54%。该疫苗具有良好的安全性和防病效果， 生产无需病原体，对生产车间生物安全等级要求低，产量高，成本低，在满足国内产能的同时，海外市场也已逐步打开，目前已在印尼、哥伦比亚等地获批紧急使用。",
    "labels": [
      [
        "T0",
        "业绩",
        8,
        10,
        "业绩"
      ],
      [
        "T1",
        "地点范围",
        15,
        17,
        "海外"
      ],
      [
        "T2",
        "时间范围",
        30,
        32,
        "3月"
      ],
      [
        "T3",
        "地点范围",
        33,
        35,
        "国内"
      ],
      [
        "T4",
        "业绩",
        51,
        53,
        "业绩"
      ],
      [
        "T5",
        "时间范围",
        60,
        69,
        "2021年前三季度"
      ],
      [
        "T6",
        "营业收入",
        73,
        77,
        "营业收入"
      ],
      [
        "T7",
        "归母净利润",
        101,
        106,
        "归母净利润"
      ],
      [
        "T8",
        "扣非净利润",
        130,
        138,
        "扣非后归母净利润"
      ],
      [
        "T9",
        "地点范围",
        368,
        370,
        "国内"
      ],
      [
        "T10",
        "产能",
        370,
        372,
        "产能"
      ],
      [
        "T11",
        "地点范围",
        376,
        378,
        "海外"
      ],
      [
        "T12",
        "地点范围",
        391,
        393,
        "印尼"
      ],
      [
        "T13",
        "地点范围",
        394,
        398,
        "哥伦比亚"
      ]
    ]
  },
  {
    "id": 220,
    "text": "截至 1H19，公司共计对 55家企业进行风险投资，同时拥有 10家联合营企业，风投标的与联合营企业公允价值的变动将直接影响公司净利润，造成利润端的较大波动，故我们建议以收入口径来衡量公司业务的实际增长。考虑到公司具有深厚的项目储备和极具远见的管理团队，我们认为 VC业务将继续为公司医疗保健生态系统创造价值。",
    "labels": [
      [
        "T0",
        "时间范围",
        0,
        7,
        "截至 1H19"
      ],
      [
        "T1",
        "行业",
        132,
        134,
        "VC"
      ],
      [
        "T2",
        "行业",
        142,
        146,
        "医疗保健"
      ],
      [
        "T3",
        "归母净利润",
        64,
        67,
        "净利润"
      ],
      [
        "T4",
        "利润",
        70,
        73,
        "利润端"
      ],
      [
        "T5",
        "营业收入",
        85,
        87,
        "收入"
      ]
    ]
  },
  {
    "id": 221,
    "text": "康龙化成近几年营业收入和净利润均处于持续高速增长状态，2021 年上半年实现营业收入 32.86 亿元，同比增长 49.81%，归母净利润 5.65亿元，同比增长 17.93%，扣非归母净利润 5.83亿元，同比增长 61.16%，高速增长的营业收入贡献良好的现金流，2021年上半年实现经营活动现金流 8.45 亿元，同比增长 36.75%。",
    "labels": [
      [
        "T0",
        "公司",
        0,
        4,
        "康龙化成"
      ],
      [
        "T1",
        "时间范围",
        4,
        7,
        "近几年"
      ],
      [
        "T2",
        "营业收入",
        7,
        11,
        "营业收入"
      ],
      [
        "T3",
        "归母净利润",
        12,
        15,
        "净利润"
      ],
      [
        "T4",
        "属性值",
        20,
        24,
        "高速增长"
      ],
      [
        "T5",
        "时间范围",
        27,
        36,
        "2021 年上半年"
      ],
      [
        "T6",
        "营业收入",
        38,
        42,
        "营业收入"
      ],
      [
        "T7",
        "属性值",
        43,
        51,
        "32.86 亿元"
      ],
      [
        "T8",
        "属性值",
        57,
        63,
        "49.81%"
      ],
      [
        "T9",
        "归母净利润",
        64,
        69,
        "归母净利润"
      ],
      [
        "T10",
        "属性值",
        70,
        88,
        "5.65亿元，同比增长 17.93%"
      ],
      [
        "T11",
        "扣非净利润",
        89,
        96,
        "扣非归母净利润"
      ],
      [
        "T12",
        "属性值",
        97,
        115,
        "5.83亿元，同比增长 61.16%"
      ],
      [
        "T13",
        "营业收入",
        121,
        125,
        "营业收入"
      ],
      [
        "T14",
        "属性值",
        116,
        120,
        "高速增长"
      ],
      [
        "T15",
        "属性值",
        127,
        129,
        "良好"
      ],
      [
        "T16",
        "现金流",
        130,
        133,
        "现金流"
      ],
      [
        "T17",
        "时间范围",
        134,
        142,
        "2021年上半年"
      ],
      [
        "T18",
        "现金流",
        148,
        151,
        "现金流"
      ],
      [
        "T19",
        "属性值",
        152,
        171,
        "8.45 亿元，同比增长 36.75%"
      ]
    ]
  },
  {
    "id": 223,
    "text": "口大分子药物已经成为业务发展趋势：2019年全球销售TOP20药品，其中12种是大分子生物制药。因此，小分子药物企业面对竞争激烈的小分子市场，需要考虑顺应大分子药品的趋势，企业进行业务转型增加业务营收",
    "labels": [
      [
        "T0",
        "行业",
        1,
        6,
        "大分子药物"
      ],
      [
        "T1",
        "时间范围",
        17,
        22,
        "2019年"
      ],
      [
        "T2",
        "地点范围",
        22,
        24,
        "全球"
      ],
      [
        "T3",
        "行业公司",
        51,
        58,
        "小分子药物企业"
      ],
      [
        "T4",
        "属性值",
        62,
        64,
        "激烈"
      ],
      [
        "T5",
        "竞争格局",
        60,
        62,
        "竞争"
      ],
      [
        "T6",
        "行业",
        77,
        82,
        "大分子药品"
      ],
      [
        "T7",
        "营业收入",
        98,
        100,
        "营收"
      ],
      [
        "T8",
        "行业",
        65,
        68,
        "小分子"
      ]
    ]
  },
  {
    "id": 224,
    "text": "部分疫情较严重的国家的疫苗接种情况为：  印度：截至 2021.5.27，接种总量 2.01亿剂次，每百人接种 14.58剂次，每日接种量 190.23万剂次；",
    "labels": [
      [
        "T0",
        "地点范围",
        22,
        24,
        "印度"
      ],
      [
        "T1",
        "时间范围",
        25,
        37,
        "截至 2021.5.27"
      ]
    ]
  },
  {
    "id": 225,
    "text": "公司为国内 CMO/CDMO的行业标杆（多次零缺陷通过 FDA审查；首个获批 MAH合作的 CMO/CDMO），服务项目数量持续上升（9M19：900+ vs 2012： 228），收入实现快速增长（2012-2018CAGR=25.8%）。截至 9M19，公司共计拥有约 843个临床早期项目，40个 III期项目和 17个商业化项目，晚期项目（III期和商业化）正处于迅速转化并放量的阶段。CMO/CDMO板块提速 （19/20/21三年收入 CAGR=33.1%），有望成为公司整体增长的重磅引擎。",
    "labels": [
      [
        "T0",
        "地点范围",
        3,
        5,
        "国内"
      ],
      [
        "T1",
        "行业",
        6,
        14,
        "CMO/CDMO"
      ],
      [
        "T2",
        "营业收入",
        91,
        93,
        "收入"
      ],
      [
        "T3",
        "时间范围",
        100,
        109,
        "2012-2018"
      ],
      [
        "T4",
        "CAGR",
        109,
        113,
        "CAGR"
      ],
      [
        "T5",
        "时间范围",
        121,
        128,
        "截至 9M19"
      ],
      [
        "T6",
        "行业",
        197,
        205,
        "CMO/CDMO"
      ],
      [
        "T7",
        "时间范围",
        211,
        219,
        "19/20/21"
      ],
      [
        "T8",
        "营业收入",
        221,
        223,
        "收入"
      ],
      [
        "T9",
        "CAGR",
        224,
        228,
        "CAGR"
      ],
      [
        "T10",
        "时间范围",
        67,
        71,
        "9M19"
      ],
      [
        "T11",
        "时间范围",
        80,
        84,
        "2012"
      ]
    ]
  },
  {
    "id": 226,
    "text": " CMO：扩产提速的背景下，CDMO 高端产能仍然是稀缺的。",
    "labels": [
      [
        "T0",
        "行业",
        2,
        5,
        "CMO"
      ],
      [
        "T1",
        "行业",
        15,
        19,
        "CDMO"
      ],
      [
        "T2",
        "属性值",
        27,
        29,
        "稀缺"
      ],
      [
        "T3",
        "产能",
        22,
        24,
        "产能"
      ],
      [
        "T4",
        "属性值",
        6,
        10,
        "扩产提速"
      ]
    ]
  },
  {
    "id": 227,
    "text": "医药研发外包服务行业竞争较为激烈，存在 IQVIA、LabCorp、Charles River 等多个国际龙头公司和药明康德、泰格、康龙化成等多个国内龙头公司，属于充分竞争市场，行业竞争加剧会影响中小型 CXO公司。",
    "labels": [
      [
        "T0",
        "行业",
        0,
        8,
        "医药研发外包服务"
      ],
      [
        "T1",
        "属性值",
        12,
        16,
        "较为激烈"
      ],
      [
        "T2",
        "竞争格局",
        10,
        12,
        "竞争"
      ],
      [
        "T3",
        "公司",
        20,
        25,
        "IQVIA"
      ],
      [
        "T4",
        "公司",
        26,
        33,
        "LabCorp"
      ],
      [
        "T5",
        "公司",
        34,
        47,
        "Charles River"
      ],
      [
        "T6",
        "地点范围",
        51,
        53,
        "国际"
      ],
      [
        "T7",
        "公司",
        58,
        62,
        "药明康德"
      ],
      [
        "T8",
        "公司",
        63,
        65,
        "泰格"
      ],
      [
        "T9",
        "公司",
        66,
        70,
        "康龙化成"
      ],
      [
        "T10",
        "地点范围",
        73,
        75,
        "国内"
      ],
      [
        "T11",
        "龙头企业",
        75,
        79,
        "龙头公司"
      ],
      [
        "T12",
        "龙头企业",
        53,
        57,
        "龙头公司"
      ],
      [
        "T13",
        "属性值",
        82,
        88,
        "充分竞争市场"
      ],
      [
        "T14",
        "行业公司",
        102,
        107,
        "CXO公司"
      ],
      [
        "T15",
        "属性值",
        93,
        95,
        "加剧"
      ],
      [
        "T16",
        "竞争格局",
        91,
        93,
        "竞争"
      ]
    ]
  },
  {
    "id": 228,
    "text": " 临床前CRO：能力边际拓展驱动估值提升。 海外Charles River从安评起家，逐步拓展业务版图至药物发现、CMC及细胞基因治疗领域，享受一定估值溢价。国内美迪西和昭衍新药由于业绩的超高增长，带来估值的提升。",
    "labels": [
      [
        "T0",
        "行业",
        2,
        8,
        "临床前CRO"
      ],
      [
        "T1",
        "地点范围",
        23,
        25,
        "海外"
      ],
      [
        "T2",
        "公司",
        25,
        38,
        "Charles River"
      ],
      [
        "T3",
        "行业",
        39,
        41,
        "安评"
      ],
      [
        "T4",
        "行业",
        53,
        57,
        "药物发现"
      ],
      [
        "T5",
        "行业",
        58,
        61,
        "CMC"
      ],
      [
        "T6",
        "行业",
        62,
        68,
        "细胞基因治疗"
      ],
      [
        "T7",
        "地点范围",
        80,
        82,
        "国内"
      ],
      [
        "T8",
        "公司",
        82,
        85,
        "美迪西"
      ],
      [
        "T9",
        "公司",
        86,
        90,
        "昭衍新药"
      ],
      [
        "T10",
        "业绩",
        92,
        94,
        "业绩"
      ],
      [
        "T11",
        "属性值",
        95,
        99,
        "超高增长"
      ]
    ]
  },
  {
    "id": 229,
    "text": "三、CXO企业先行指标跟踪",
    "labels": [
      [
        "T0",
        "行业公司",
        2,
        7,
        "CXO企业"
      ]
    ]
  },
  {
    "id": 230,
    "text": " A股：医药生物（申万，下同）指数上涨 0.90%，跑输沪深 300指数 2.74pp， 跑输创业板综指 3.03pp，在 28个子行业中排名第 23，表现较弱，主要是前期连续上涨后，部分子板块略有调整。  H股：港股恒生医疗健康指数收跌 0.3%，跑输恒生国企指数 1.2pp，在 11 个 Wind香港行业板块中，排名第 9位。 分子板块来看：  A股：涨幅最大的是中药，上涨 3.84%，主要是近期中药政策利好的催化；跌幅最大的是化学原料药，下跌 2.15%，主要是人民币升值影响及前期连续上涨后有所回调。  H股：生物科技 III涨幅最大，达到 2.91%；医疗保健技术 III跌幅最大，为 7.05%。 个股层面：  A股：涨幅较大的多为医美或新冠疫苗相关概念，跌幅较大的多为个股性原因。  H股：普华和顺涨幅最大，达 34.72%；现代健康科技跌幅最大，达 23.19%。",
    "labels": [
      [
        "T0",
        "行业",
        5,
        9,
        "医药生物"
      ],
      [
        "T1",
        "地点范围",
        153,
        155,
        "香港"
      ],
      [
        "T2",
        "公司",
        149,
        153,
        "Wind"
      ],
      [
        "T3",
        "行业",
        188,
        190,
        "中药"
      ],
      [
        "T4",
        "行业",
        205,
        207,
        "中药"
      ],
      [
        "T5",
        "行业",
        221,
        226,
        "化学原料药"
      ],
      [
        "T6",
        "行业",
        265,
        269,
        "生物科技"
      ],
      [
        "T7",
        "行业",
        287,
        293,
        "医疗保健技术"
      ],
      [
        "T8",
        "行业",
        329,
        331,
        "医美"
      ],
      [
        "T9",
        "行业",
        332,
        336,
        "新冠疫苗"
      ],
      [
        "T10",
        "公司",
        360,
        364,
        "普华和顺"
      ],
      [
        "T11",
        "公司",
        378,
        384,
        "现代健康科技"
      ]
    ]
  },
  {
    "id": 231,
    "text": " 美国区实验室：主要通过全资子公司 AppTec（药明康德美国）开展业务， 提供细胞与基因疗法 CDMO及医疗器械检测服务。AppTec在费城、圣保罗和亚特兰大三地设有实验室，并拥有成熟的细胞及基因治疗产品生产和过程控制经验。",
    "labels": [
      [
        "T0",
        "地点范围",
        2,
        5,
        "美国区"
      ],
      [
        "T1",
        "公司",
        19,
        33,
        "AppTec（药明康德美国）"
      ],
      [
        "T2",
        "属性值",
        41,
        62,
        "细胞与基因疗法 CDMO及医疗器械检测服务"
      ],
      [
        "T3",
        "公司",
        63,
        69,
        "AppTec"
      ],
      [
        "T4",
        "地点范围",
        70,
        72,
        "费城"
      ],
      [
        "T5",
        "地点范围",
        73,
        76,
        "圣保罗"
      ],
      [
        "T6",
        "地点范围",
        77,
        81,
        "亚特兰大"
      ],
      [
        "T7",
        "行业",
        95,
        102,
        "细胞及基因治疗"
      ],
      [
        "T8",
        "行业",
        5,
        8,
        "实验室"
      ]
    ]
  },
  {
    "id": 232,
    "text": "1）短期看：CXO年度行情与投融资年度增长趋势一致性弱。2）中长期看： CXO板块收益与投融资趋势一致性强。2019-2021年CXO板块相比生物医药板块（申万医药生物指数）具有显著超额收益（361%vs93%），从更长维度能够更清晰的看到CXO板块超额收益可能与全球投融资中长期高景气更强的一致性。基于正文数据分析，我们淡化月度/单年度投融资变化趋势与本土CXO 业绩和表现一致性的判断，而建议更多关注与研发投入一致性更强的多个年度投融资变化趋势。",
    "labels": [
      [
        "T0",
        "行业",
        6,
        9,
        "CXO"
      ],
      [
        "T1",
        "时间范围",
        2,
        4,
        "短期"
      ],
      [
        "T2",
        "投融资情况",
        14,
        17,
        "投融资"
      ],
      [
        "T3",
        "时间范围",
        30,
        33,
        "中长期"
      ],
      [
        "T4",
        "行业",
        36,
        39,
        "CXO"
      ],
      [
        "T5",
        "投融资情况",
        44,
        47,
        "投融资"
      ],
      [
        "T6",
        "时间范围",
        54,
        64,
        "2019-2021年"
      ],
      [
        "T7",
        "行业",
        64,
        67,
        "CXO"
      ],
      [
        "T8",
        "行业",
        71,
        75,
        "生物医药"
      ],
      [
        "T9",
        "行业",
        120,
        123,
        "CXO"
      ],
      [
        "T10",
        "地点范围",
        132,
        134,
        "全球"
      ],
      [
        "T11",
        "投融资情况",
        134,
        137,
        "投融资"
      ],
      [
        "T12",
        "投融资情况",
        217,
        220,
        "投融资"
      ],
      [
        "T13",
        "投融资情况",
        169,
        172,
        "投融资"
      ],
      [
        "T14",
        "地点范围",
        177,
        179,
        "本土"
      ],
      [
        "T15",
        "行业",
        179,
        182,
        "CXO"
      ],
      [
        "T16",
        "业绩",
        183,
        185,
        "业绩"
      ],
      [
        "T17",
        "研发费用",
        203,
        207,
        "研发投入"
      ]
    ]
  },
  {
    "id": 233,
    "text": "多利斯、IBM等41个供应商",
    "labels": [
      [
        "T0",
        "公司",
        0,
        3,
        "多利斯"
      ],
      [
        "T1",
        "公司",
        4,
        7,
        "IBM"
      ]
    ]
  },
  {
    "id": 234,
    "text": "临床前 CRO基于实验室、CDMO基于工厂，因此在建工程在一定程度上均反映出 CRO/CDMO公司对于产能的投入。近两年，基于行业景气度不断提升，订单需求持续加大，各家头部公司在建工程规模保持快速增长的状态。2020 年和 2021Q1，大部分公司的在建工程投入维持较快增长趋势，例如药明康德、康龙化成、药石科技、美迪西、凯莱英、博腾股份等公司呈现高速增长。这体现出一方面订单需求仍较为旺盛，在产能较为饱和的情况下需要建设新产能，另一方面体现出各家公司对于行业未来发展前景的信心。",
    "labels": [
      [
        "T0",
        "行业",
        0,
        7,
        "临床前 CRO"
      ],
      [
        "T1",
        "行业",
        13,
        17,
        "CDMO"
      ],
      [
        "T2",
        "产能",
        51,
        53,
        "产能"
      ],
      [
        "T3",
        "时间范围",
        57,
        60,
        "近两年"
      ],
      [
        "T4",
        "行业需求",
        75,
        77,
        "需求"
      ],
      [
        "T5",
        "属性值",
        65,
        72,
        "景气度不断提升"
      ],
      [
        "T6",
        "属性值",
        77,
        81,
        "持续加大"
      ],
      [
        "T7",
        "时间范围",
        104,
        110,
        "2020 年"
      ],
      [
        "T8",
        "时间范围",
        112,
        118,
        "2021Q1"
      ],
      [
        "T9",
        "公司",
        142,
        146,
        "药明康德"
      ],
      [
        "T10",
        "公司",
        147,
        151,
        "康龙化成"
      ],
      [
        "T11",
        "公司",
        152,
        156,
        "药石科技"
      ],
      [
        "T12",
        "公司",
        157,
        160,
        "美迪西"
      ],
      [
        "T13",
        "公司",
        161,
        164,
        "凯莱英"
      ],
      [
        "T14",
        "公司",
        165,
        169,
        "博腾股份"
      ],
      [
        "T15",
        "属性值",
        191,
        195,
        "较为旺盛"
      ],
      [
        "T16",
        "属性值",
        199,
        203,
        "较为饱和"
      ],
      [
        "T17",
        "行业公司",
        39,
        49,
        "CRO/CDMO公司"
      ],
      [
        "T18",
        "产能",
        197,
        199,
        "产能"
      ],
      [
        "T19",
        "行业需求",
        188,
        190,
        "需求"
      ]
    ]
  },
  {
    "id": 235,
    "text": "➢ “在建工程/固定资产”指标描述了企业扩张的能力与意愿。以药石科技、药明康德等为主要代表的 CDMO公司目前都在加速布局产能，以实现高速增长。从2021年底在建工程/固定资产看，和元生物、药石科技、药明康德、凯莱英、泰格医药、睿智医药、皓元医药与康龙化成引领行业。",
    "labels": [
      [
        "T0",
        "固定资产",
        8,
        12,
        "固定资产"
      ],
      [
        "T1",
        "公司",
        30,
        34,
        "药石科技"
      ],
      [
        "T2",
        "公司",
        35,
        39,
        "药明康德"
      ],
      [
        "T3",
        "行业公司",
        47,
        53,
        "CDMO公司"
      ],
      [
        "T4",
        "属性值",
        57,
        61,
        "加速布局"
      ],
      [
        "T5",
        "产能",
        61,
        63,
        "产能"
      ],
      [
        "T6",
        "时间范围",
        53,
        55,
        "目前"
      ],
      [
        "T7",
        "时间范围",
        73,
        78,
        "2021年"
      ],
      [
        "T8",
        "固定资产",
        84,
        88,
        "固定资产"
      ],
      [
        "T9",
        "公司",
        90,
        94,
        "和元生物"
      ],
      [
        "T10",
        "公司",
        95,
        99,
        "药石科技"
      ],
      [
        "T11",
        "公司",
        100,
        104,
        "药明康德"
      ],
      [
        "T12",
        "公司",
        105,
        108,
        "凯莱英"
      ],
      [
        "T13",
        "公司",
        109,
        113,
        "泰格医药"
      ],
      [
        "T14",
        "公司",
        114,
        118,
        "睿智医药"
      ],
      [
        "T15",
        "公司",
        119,
        123,
        "皓元医药"
      ],
      [
        "T16",
        "公司",
        124,
        128,
        "康龙化成"
      ]
    ]
  },
  {
    "id": 236,
    "text": "未来 3-5年推演：业务整合期，C(D)MO业务和临床 CRO初步具有行业竞争力。 我们认为，当公司的产业链布局初步完成时，公司将会通过来自临床前业务的导流，积极扩张 C(D)MO和临床 CRO业务，将这两个业务发展为拥有国内竞争力的主要业务之一。我们认为在这个阶段，临床前 CRO业务的增速将会放缓，临床 CRO和 C(D)MO 开始驱动收入及利润端的增长。",
    "labels": [
      [
        "T0",
        "时间范围",
        0,
        7,
        "未来 3-5年"
      ],
      [
        "T1",
        "行业",
        16,
        22,
        "C(D)MO"
      ],
      [
        "T2",
        "行业",
        25,
        31,
        "临床 CRO"
      ],
      [
        "T3",
        "行业",
        70,
        73,
        "临床前"
      ],
      [
        "T4",
        "行业",
        84,
        90,
        "C(D)MO"
      ],
      [
        "T5",
        "行业",
        91,
        97,
        "临床 CRO"
      ],
      [
        "T6",
        "地点范围",
        111,
        113,
        "国内"
      ],
      [
        "T7",
        "行业",
        151,
        157,
        "临床 CRO"
      ],
      [
        "T8",
        "行业",
        159,
        165,
        "C(D)MO"
      ],
      [
        "T9",
        "营业收入",
        170,
        172,
        "收入"
      ],
      [
        "T10",
        "利润",
        173,
        176,
        "利润端"
      ],
      [
        "T11",
        "行业",
        134,
        141,
        "临床前 CRO"
      ]
    ]
  },
  {
    "id": 237,
    "text": " 2月 9日，enGene宣布，基于其专有技术平台实现在粘膜组织局部给药的创新非病毒基因疗法 EG-70，在治疗对卡介苗无应答的高级别非肌层浸润性膀胱癌患者的 1/2期临床试验中获得积极结果。",
    "labels": [
      [
        "T0",
        "时间范围",
        2,
        7,
        "2月 9日"
      ],
      [
        "T1",
        "公司",
        8,
        14,
        "enGene"
      ]
    ]
  },
  {
    "id": 238,
    "text": "历史复盘：不要忽视的国内强β 核心CXO公司国内客户业务保持高速增长，全球化CXO公司持续为国内创新赋能：核心公司合计国内客户收入为116.39亿元，同比增长44.0%，继续维持高速增长。 不要忽视的国内强β：对比核心公司国内外业务增长情况，在实验室业务、CDMO业务等领域国内业务均呈现超越整体的强β属性。尤其是国内强β代表的昭衍新药、美迪西均呈现超高速增长。",
    "labels": [
      [
        "T0",
        "地点范围",
        10,
        12,
        "国内"
      ],
      [
        "T1",
        "地点范围",
        23,
        25,
        "国内"
      ],
      [
        "T2",
        "属性值",
        31,
        35,
        "高速增长"
      ],
      [
        "T3",
        "地点范围",
        47,
        49,
        "国内"
      ],
      [
        "T4",
        "地点范围",
        60,
        62,
        "国内"
      ],
      [
        "T5",
        "营业收入",
        64,
        66,
        "收入"
      ],
      [
        "T6",
        "属性值",
        67,
        75,
        "116.39亿元"
      ],
      [
        "T7",
        "属性值",
        80,
        85,
        "44.0%"
      ],
      [
        "T8",
        "属性值",
        90,
        94,
        "高速增长"
      ],
      [
        "T9",
        "地点范围",
        102,
        104,
        "国内"
      ],
      [
        "T10",
        "地点范围",
        113,
        116,
        "国内外"
      ],
      [
        "T11",
        "行业",
        124,
        127,
        "实验室"
      ],
      [
        "T12",
        "行业",
        130,
        134,
        "CDMO"
      ],
      [
        "T13",
        "地点范围",
        139,
        141,
        "国内"
      ],
      [
        "T14",
        "属性值",
        146,
        153,
        "超越整体的强β"
      ],
      [
        "T15",
        "地点范围",
        159,
        161,
        "国内"
      ],
      [
        "T16",
        "公司",
        166,
        170,
        "昭衍新药"
      ],
      [
        "T17",
        "公司",
        171,
        174,
        "美迪西"
      ],
      [
        "T18",
        "属性值",
        177,
        182,
        "超高速增长"
      ],
      [
        "T19",
        "行业公司",
        16,
        23,
        "核心CXO公司"
      ],
      [
        "T20",
        "行业公司",
        36,
        44,
        "全球化CXO公司"
      ]
    ]
  },
  {
    "id": 239,
    "text": "美迪西成立于 2004年 2月，是一家国内领先的生物医药临床前综合研发服务 CRO 公司， 公司业务聚焦于临床前 CRO 领域，主营业务分为药物发现、药学研究、临床前研究、综合服务项目等四大类，拥有国际实验动物评估和认可委员会（AAALAC） 认证、中国药品监督管理局 GLP 证书、达到美国 FDA 的 GLP 标准，公司同时具备创新药临床研究中美双报能力，在行业内具有较强的行业影响力和较高的市场地位， 2019年 11月 5日， 美迪西在上交所挂牌上市（股票代码：688202.SH）。",
    "labels": [
      [
        "T0",
        "公司",
        0,
        3,
        "美迪西"
      ],
      [
        "T1",
        "时间范围",
        7,
        15,
        "2004年 2月"
      ],
      [
        "T2",
        "地点范围",
        19,
        21,
        "国内"
      ],
      [
        "T3",
        "行业",
        53,
        60,
        "临床前 CRO"
      ],
      [
        "T4",
        "行业",
        24,
        41,
        "生物医药临床前综合研发服务 CRO"
      ],
      [
        "T5",
        "主营业务",
        64,
        68,
        "主营业务"
      ],
      [
        "T6",
        "时间范围",
        204,
        216,
        "2019年 11月 5日"
      ],
      [
        "T7",
        "地点范围",
        144,
        146,
        "美国"
      ],
      [
        "T8",
        "地点范围",
        173,
        174,
        "中"
      ],
      [
        "T9",
        "地点范围",
        174,
        175,
        "美"
      ],
      [
        "T10",
        "公司",
        218,
        221,
        "美迪西"
      ],
      [
        "T11",
        "属性值",
        70,
        96,
        "药物发现、药学研究、临床前研究、综合服务项目等四大类"
      ]
    ]
  },
  {
    "id": 240,
    "text": "博腾股份：再签大额新订单，业绩高增长具确定性。公司两大订单总额8.98亿美金（折合约57.17亿元人民币）。根据协议，订单交付时间为2022年，预计将支撑2022年实现优异的业绩表现。根据新建产能计划，我们预计到2023年底， 公司产能同比2021年增长约53%。",
    "labels": [
      [
        "T0",
        "公司",
        1,
        5,
        "博腾股份"
      ],
      [
        "T1",
        "业绩",
        14,
        16,
        "业绩"
      ],
      [
        "T2",
        "属性值",
        30,
        54,
        "总额8.98亿美金（折合约57.17亿元人民币）"
      ],
      [
        "T3",
        "业绩",
        88,
        90,
        "业绩"
      ],
      [
        "T4",
        "时间范围",
        107,
        113,
        "2023年底"
      ],
      [
        "T5",
        "产能",
        117,
        119,
        "产能"
      ],
      [
        "T6",
        "属性值",
        119,
        132,
        "同比2021年增长约53%"
      ],
      [
        "T7",
        "属性值",
        16,
        23,
        "高增长具确定性"
      ],
      [
        "T8",
        "时间范围",
        67,
        72,
        "2022年"
      ],
      [
        "T9",
        "时间范围",
        78,
        83,
        "2022年"
      ],
      [
        "T10",
        "属性值",
        85,
        87,
        "优异"
      ]
    ]
  },
  {
    "id": 241,
    "text": "CGT 发展历经三十余年发展，逐步迈入商业化的黄金时期。我们认为多重因素刺激 CGT 市场快速发展：1）技术成熟，商业化产品数量快速增加；2）单药售价高，易产生重磅炸弹；3）治疗效果好，患者接受意愿高，市占率有望快速提升；4）上游审批加速，下游保险支持，提高药物可及性。 CGT 技术日趋成熟，迎来上市产品收获期。CGT 研究由来已久，但技术不成熟导致的安全性低、疗效差等原因，促使监管机构对相关药物审批一直报有审慎态度。早在 1990 年美国 FDA 就批准全球首个人体基因治疗的临床试验，但直到 2017 年 FDA 才批准美国第一个细胞治疗产品 Kymriah 及第一个基因治疗产品 Luxturna 上市。 CGT 发展可分四大阶段：第一阶段为 1960-1980 年代，基于病毒对人类细胞进行基因改造的概念被初步提出并验证；第二阶段为 1980-2000 年，对病毒载体持续开发并进行人体试验，但因为受试者死亡导致 CGT 试验的停滞；第三阶段为 2000-2017 年，全球数款 CGT 产品陆续上市，但因定价高、疗效弱，患者接受意愿低，销售疲软；第四阶段为 2017 年至今，FDA 批准基于新技术具有良好治疗效果的 CGT 产品上市，此后 CGT 产品加速上市，且销售亮眼，增长强劲。 截至 2021 年 12 月， 全球范围内共有 19 款 CGT 产品获批在售。 根据 FDA 推测， 2020 至 2025 年 CGT 药物将迎来收获期，每年将会有 10-20 个药物获批上市， 至 2025 年全球范围将有 50 款以上 CGT 产品上市。快速增加的上市产品数将迅速打开 CGT 市场规模。 中国尽管早在 2000 年初就批准了 2 款 CGT 药物上市，但作为较早开发的产品销量一直不佳。2021 年中国首次上市了两款 CAR-T 产品，分别由复星凯特及药明巨诺与海外公司合作引进开发， 标志了新一代 CGT 药物在我国的商业化启程， 中国 CGT 市场逐步与国际接轨。",
    "labels": [
      [
        "T0",
        "行业",
        39,
        42,
        "CGT"
      ],
      [
        "T1",
        "市场份额",
        101,
        104,
        "市占率"
      ],
      [
        "T2",
        "属性值",
        106,
        110,
        "快速提升"
      ],
      [
        "T3",
        "行业",
        136,
        139,
        "CGT"
      ],
      [
        "T4",
        "行业",
        157,
        160,
        "CGT"
      ],
      [
        "T5",
        "时间范围",
        214,
        220,
        "1990 年"
      ],
      [
        "T6",
        "时间范围",
        250,
        256,
        "2017 年"
      ],
      [
        "T7",
        "行业",
        308,
        311,
        "CGT"
      ],
      [
        "T8",
        "时间范围",
        327,
        339,
        "1960-1980 年代"
      ],
      [
        "T9",
        "时间范围",
        373,
        384,
        "1980-2000 年"
      ],
      [
        "T10",
        "行业",
        413,
        416,
        "CGT"
      ],
      [
        "T11",
        "时间范围",
        429,
        440,
        "2000-2017 年"
      ],
      [
        "T12",
        "地点范围",
        441,
        443,
        "全球"
      ],
      [
        "T13",
        "行业",
        446,
        449,
        "CGT"
      ],
      [
        "T14",
        "时间范围",
        486,
        494,
        "2017 年至今"
      ],
      [
        "T15",
        "行业",
        516,
        519,
        "CGT"
      ],
      [
        "T16",
        "行业",
        528,
        531,
        "CGT"
      ],
      [
        "T17",
        "时间范围",
        551,
        565,
        "截至 2021 年 12 月"
      ],
      [
        "T18",
        "地点范围",
        567,
        569,
        "全球"
      ],
      [
        "T19",
        "行业",
        580,
        583,
        "CGT"
      ],
      [
        "T20",
        "时间范围",
        603,
        616,
        "2020 至 2025 年"
      ],
      [
        "T21",
        "时间范围",
        653,
        659,
        "2025 年"
      ],
      [
        "T22",
        "行业",
        698,
        701,
        "CGT"
      ],
      [
        "T23",
        "市场规模",
        702,
        706,
        "市场规模"
      ],
      [
        "T24",
        "地点范围",
        708,
        710,
        "中国"
      ],
      [
        "T25",
        "时间范围",
        715,
        721,
        "2000 年"
      ],
      [
        "T26",
        "行业",
        731,
        734,
        "CGT"
      ],
      [
        "T27",
        "时间范围",
        757,
        763,
        "2021 年"
      ],
      [
        "T28",
        "地点范围",
        763,
        765,
        "中国"
      ],
      [
        "T29",
        "公司",
        785,
        789,
        "复星凯特"
      ],
      [
        "T30",
        "公司",
        790,
        794,
        "药明巨诺"
      ],
      [
        "T31",
        "地点范围",
        831,
        833,
        "中国"
      ],
      [
        "T32",
        "行业",
        834,
        837,
        "CGT"
      ],
      [
        "T33",
        "行业",
        814,
        820,
        "CGT 药物"
      ],
      [
        "T34",
        "行业",
        617,
        623,
        "CGT 药物"
      ],
      [
        "T35",
        "地点范围",
        821,
        823,
        "我国"
      ]
    ]
  },
  {
    "id": 242,
    "text": "毛利率仍有提升空间，数统业务有望增厚毛利率。公司临床 CRO业务毛利率较泰格医药仍有一定差距，预计主要由于泰格医药收入中占比较高的临床试验咨询服务（数据管理与统计分析等）毛利率相比临床试验运作更高。随着公司逐步整合 Pharmapace的数统业务，并持续提升临床试验运作规模，毛利率未来有望持续提升。2020年行业普遍受疫情影响，运营效率有所下降，泰格医药毛利率保持提升预计主要由于并表范围变化、过手费下降、高毛利业务占比提高等因素影响。",
    "labels": [
      [
        "T0",
        "毛利",
        0,
        3,
        "毛利率"
      ],
      [
        "T1",
        "毛利",
        18,
        21,
        "毛利率"
      ],
      [
        "T2",
        "行业",
        24,
        30,
        "临床 CRO"
      ],
      [
        "T3",
        "毛利",
        32,
        35,
        "毛利率"
      ],
      [
        "T4",
        "公司",
        36,
        40,
        "泰格医药"
      ],
      [
        "T5",
        "公司",
        53,
        57,
        "泰格医药"
      ],
      [
        "T6",
        "营业收入",
        57,
        59,
        "收入"
      ],
      [
        "T7",
        "行业",
        65,
        71,
        "临床试验咨询"
      ],
      [
        "T8",
        "毛利",
        85,
        88,
        "毛利率"
      ],
      [
        "T9",
        "毛利",
        138,
        141,
        "毛利率"
      ],
      [
        "T10",
        "时间范围",
        150,
        155,
        "2020年"
      ],
      [
        "T11",
        "公司",
        174,
        178,
        "泰格医药"
      ],
      [
        "T12",
        "毛利",
        178,
        181,
        "毛利率"
      ],
      [
        "T13",
        "行业",
        10,
        12,
        "数统"
      ],
      [
        "T14",
        "公司",
        108,
        118,
        "Pharmapace"
      ],
      [
        "T15",
        "行业",
        119,
        121,
        "数统"
      ],
      [
        "T16",
        "属性值",
        183,
        185,
        "提升"
      ]
    ]
  },
  {
    "id": 243,
    "text": "个股方面，盘龙药业（61.08%）、华森制药（33.38%）、莱茵生物（32.64%）、 亚太药业（31.32%）、精华制药（30.93%）、益盛药业（26.75%）、京新药业（22.87%）、 赛隆药业（22.01%）、ST冠福（18.60%）、华润双鹤（17.90%）等涨幅较大。主要系新冠口服药、中药及相关防护热度较高。跌幅居前的是北大医药（-16.21%）、 海辰药业（-15.81%）、万孚生物（-13.44%）、上海凯宝（-12.96%）、长江健康 （-12.09%）、威尔药业（-10.78%）、舒泰神（-10.18%）、仟源医药（-10.12%）、 博雅生物（-10.00%）、贝瑞基因（-9.91%）、等跌幅较大，主要系部分公司股价高位回落、业绩预亏等因素。",
    "labels": [
      [
        "T0",
        "公司",
        5,
        9,
        "盘龙药业"
      ],
      [
        "T1",
        "公司",
        18,
        22,
        "华森制药"
      ],
      [
        "T2",
        "公司",
        31,
        35,
        "莱茵生物"
      ],
      [
        "T3",
        "公司",
        45,
        49,
        "亚太药业"
      ],
      [
        "T4",
        "公司",
        58,
        62,
        "精华制药"
      ],
      [
        "T5",
        "公司",
        71,
        75,
        "益盛药业"
      ],
      [
        "T6",
        "公司",
        84,
        88,
        "京新药业"
      ],
      [
        "T7",
        "公司",
        98,
        102,
        "赛隆药业"
      ],
      [
        "T8",
        "公司",
        113,
        115,
        "冠福"
      ],
      [
        "T9",
        "公司",
        124,
        128,
        "华润双鹤"
      ],
      [
        "T10",
        "行业",
        145,
        150,
        "新冠口服药"
      ],
      [
        "T11",
        "行业",
        151,
        153,
        "中药"
      ],
      [
        "T12",
        "公司",
        169,
        173,
        "北大医药"
      ],
      [
        "T13",
        "公司",
        184,
        188,
        "海辰药业"
      ],
      [
        "T14",
        "公司",
        198,
        202,
        "万孚生物"
      ],
      [
        "T15",
        "公司",
        212,
        216,
        "上海凯宝"
      ],
      [
        "T16",
        "公司",
        226,
        230,
        "长江健康"
      ],
      [
        "T17",
        "公司",
        241,
        245,
        "威尔药业"
      ],
      [
        "T18",
        "公司",
        255,
        258,
        "舒泰神"
      ],
      [
        "T19",
        "公司",
        268,
        272,
        "仟源医药"
      ],
      [
        "T20",
        "公司",
        283,
        287,
        "博雅生物"
      ],
      [
        "T21",
        "公司",
        297,
        301,
        "贝瑞基因"
      ],
      [
        "T22",
        "业绩",
        330,
        332,
        "业绩"
      ]
    ]
  },
  {
    "id": 245,
    "text": "作为行业先锋，Lonza 在 CGT 领域起步早，技术全，其特色是具有商业化 GMP 病毒及细胞产品生产能力，以及拥有独特的 CAR-T 自动化生产平台。在提供生产服务的基础上， Lonza 完善的供应链使其可以将产品直接送达病患手中， 为制药公司提供细胞采集-生产-递送的一站式服务，彰显强大商业化能力。公司技术布局全面， 产能遍布全球， 服务链条完整， 是当之无愧具备全方位 CGT CDMO 服务能力的龙头。",
    "labels": [
      [
        "T0",
        "公司",
        7,
        12,
        "Lonza"
      ],
      [
        "T1",
        "行业",
        15,
        18,
        "CGT"
      ],
      [
        "T2",
        "公司",
        90,
        95,
        "Lonza"
      ],
      [
        "T3",
        "行业公司",
        120,
        124,
        "制药公司"
      ],
      [
        "T4",
        "行业",
        190,
        198,
        "CGT CDMO"
      ],
      [
        "T5",
        "龙头企业",
        204,
        206,
        "龙头"
      ]
    ]
  },
  {
    "id": 246,
    "text": "CGT有望迎来快速爆发期，公司前瞻布局抢占先机。随着国内首个 CGT产品上市，相关研发、生产需求有望快速提升，而 CGT领域相比传统药物具有一定独特性，外包渗透率有望提升到较高水平。得益于公司前瞻性的布局，已经建立起规模化的服务能力，有望在 CGT新时代中抢占先机。",
    "labels": [
      [
        "T0",
        "行业",
        0,
        3,
        "CGT"
      ],
      [
        "T1",
        "地点范围",
        26,
        28,
        "国内"
      ],
      [
        "T2",
        "行业",
        57,
        60,
        "CGT"
      ],
      [
        "T3",
        "外包率",
        76,
        81,
        "外包渗透率"
      ],
      [
        "T4",
        "行业",
        121,
        124,
        "CGT"
      ],
      [
        "T5",
        "公司",
        13,
        15,
        "公司"
      ],
      [
        "T6",
        "行业需求",
        46,
        48,
        "需求"
      ],
      [
        "T7",
        "属性值",
        50,
        54,
        "快速提升"
      ],
      [
        "T8",
        "行业",
        31,
        34,
        "CGT"
      ],
      [
        "T9",
        "属性值",
        86,
        90,
        "较高水平"
      ]
    ]
  },
  {
    "id": 247,
    "text": "赛诺菲酶替代疗法 Xenpozyme获全球首批，诺华 2款 1类生物新药在华获批临床，BMS Rebrozyl贫血扩展标签申请遭 FDA推迟：3月 29日， 日本厚生劳动省已经批准赛诺菲的创新酶替代疗法 Xenpozyme上市， 用于治疗酸性鞘磷脂酶缺乏症成人和儿科患者的非中枢神经系统症状； 3月 29日，诺华两款 1类生物新药获得临床试验默示许可，分别为靶向 TIM-3受体的单抗 MBG453和抗 TGF-β单抗 NIS793，它们针对的适应症均为较低危骨髓增生异常综合征； 3月 27日，美国 FDA已将 Rebrozyl 贫血扩展标签的决定日期向后推迟了 3个月，因此至少要到今年夏天才能得知 Rebrozyl潜在标签能否获得批准。",
    "labels": [
      [
        "T0",
        "公司",
        0,
        3,
        "赛诺菲"
      ],
      [
        "T1",
        "公司",
        24,
        26,
        "诺华"
      ],
      [
        "T2",
        "公司",
        43,
        55,
        "BMS Rebrozyl"
      ],
      [
        "T3",
        "时间范围",
        71,
        77,
        "3月 29日"
      ],
      [
        "T4",
        "公司",
        90,
        93,
        "赛诺菲"
      ],
      [
        "T5",
        "时间范围",
        147,
        153,
        "3月 29日"
      ],
      [
        "T6",
        "公司",
        154,
        156,
        "诺华"
      ],
      [
        "T7",
        "时间范围",
        241,
        247,
        "3月 27日"
      ],
      [
        "T8",
        "地点范围",
        79,
        81,
        "日本"
      ],
      [
        "T9",
        "地点范围",
        248,
        250,
        "美国"
      ],
      [
        "T10",
        "时间范围",
        293,
        297,
        "今年夏天"
      ],
      [
        "T11",
        "地点范围",
        19,
        21,
        "全球"
      ],
      [
        "T12",
        "地点范围",
        37,
        38,
        "华"
      ]
    ]
  },
  {
    "id": 249,
    "text": "3.1 2020Q4业绩继续高增长，利润增速显著快于收入增速全年业绩实现高速增长，利润增速快于收入增速。10家CXO公司2020年收入总额增速为29.2%，归母净利润总额增速为69.9%，整体维持高速增长，利润增速快速收入增速主要与企业投资收益等较大有关。",
    "labels": [
      [
        "T0",
        "时间范围",
        4,
        10,
        "2020Q4"
      ],
      [
        "T1",
        "业绩",
        10,
        12,
        "业绩"
      ],
      [
        "T2",
        "属性值",
        14,
        17,
        "高增长"
      ],
      [
        "T3",
        "收入增速",
        26,
        30,
        "收入增速"
      ],
      [
        "T4",
        "业绩",
        32,
        34,
        "业绩"
      ],
      [
        "T5",
        "收入增速",
        47,
        51,
        "收入增速"
      ],
      [
        "T6",
        "行业公司",
        52,
        60,
        "10家CXO公司"
      ],
      [
        "T7",
        "时间范围",
        60,
        65,
        "2020年"
      ],
      [
        "T8",
        "收入增速",
        65,
        71,
        "收入总额增速"
      ],
      [
        "T9",
        "属性值",
        72,
        77,
        "29.2%"
      ],
      [
        "T10",
        "归母净利润增速",
        78,
        87,
        "归母净利润总额增速"
      ],
      [
        "T11",
        "属性值",
        88,
        93,
        "69.9%"
      ],
      [
        "T12",
        "收入增速",
        109,
        113,
        "收入增速"
      ],
      [
        "T13",
        "利润",
        18,
        20,
        "利润"
      ],
      [
        "T14",
        "利润",
        41,
        43,
        "利润"
      ],
      [
        "T15",
        "属性值",
        98,
        102,
        "高速增长"
      ],
      [
        "T16",
        "利润",
        103,
        105,
        "利润"
      ]
    ]
  },
  {
    "id": 250,
    "text": "2017 年， 药明康德成立美国高端治疗事业部， 开展细胞与基因疗法等治疗业务， 此后服务客户数量迅速增长。截至 2021 年 H1，公司美国区为 38 个 CGT 项目提供服务，其中有 16 个项目处于 II/III 期；中国区服务 12 个临床前及临床 I 期项目。2019-2021 年受新冠疫情以及美国客户临床失败影响，公司 CGT 业务增长相对平衡，但通过布局扩大中国区 CGT CDMO 服务，2021 年后相关业务有望提速。截至 21Q3 中国区业务同比增长 187%，有效对冲美国区业务疲软，公司预计 2021 年 CGTCDMO 业务收入超过 10 亿人民币。",
    "labels": [
      [
        "T0",
        "时间范围",
        0,
        6,
        "2017 年"
      ],
      [
        "T1",
        "公司",
        8,
        12,
        "药明康德"
      ],
      [
        "T2",
        "客户数量",
        45,
        49,
        "客户数量"
      ],
      [
        "T3",
        "属性值",
        49,
        53,
        "迅速增长"
      ],
      [
        "T4",
        "时间范围",
        54,
        66,
        "截至 2021 年 H1"
      ],
      [
        "T5",
        "行业",
        79,
        82,
        "CGT"
      ],
      [
        "T6",
        "时间范围",
        135,
        146,
        "2019-2021 年"
      ],
      [
        "T7",
        "行业",
        167,
        170,
        "CGT"
      ],
      [
        "T8",
        "行业",
        191,
        199,
        "CGT CDMO"
      ],
      [
        "T9",
        "时间范围",
        203,
        209,
        "2021 年"
      ],
      [
        "T10",
        "时间范围",
        219,
        226,
        "截至 21Q3"
      ],
      [
        "T11",
        "时间范围",
        259,
        265,
        "2021 年"
      ],
      [
        "T12",
        "行业",
        266,
        273,
        "CGTCDMO"
      ],
      [
        "T13",
        "营业收入",
        276,
        278,
        "收入"
      ],
      [
        "T14",
        "属性值",
        278,
        288,
        "超过 10 亿人民币"
      ],
      [
        "T15",
        "地点范围",
        69,
        72,
        "美国区"
      ],
      [
        "T16",
        "地点范围",
        112,
        115,
        "中国区"
      ],
      [
        "T17",
        "地点范围",
        153,
        155,
        "美国"
      ],
      [
        "T18",
        "地点范围",
        227,
        230,
        "中国区"
      ],
      [
        "T19",
        "属性值",
        232,
        241,
        "同比增长 187%"
      ],
      [
        "T20",
        "地点范围",
        246,
        249,
        "美国区"
      ],
      [
        "T21",
        "属性值",
        251,
        253,
        "疲软"
      ]
    ]
  },
  {
    "id": 251,
    "text": "2010年后， Biotech公司浪潮加剧，研发成本进一步增高，药企一体化外包服务需求增多， CRO行业规模进一步提升。这一时期，为满足药企的需求、扩大公司规模，一方面，大型 CRO企业不断通过收并购专业型的中小 CRO公司以快速扩大业务范围，另一方面，行业竞争加剧，大型 CRO公司间的合并案例增多，如 2015年 Labcorp 收购 Covance、2016年 Quintiles和 IMS合并成立 IQVIA、2021年 ICON 收购 PRA，跃居全球第二。这一阶段的 CRO公司除了与药企建立战略合作关系外，还开始提供定制化服务，龙头 CRO 公司还通过建立投资基金扶持小型 biotech公司，行业规模持续提升、集中度增加。",
    "labels": [
      [
        "T0",
        "时间范围",
        0,
        6,
        "2010年后"
      ],
      [
        "T1",
        "行业公司",
        8,
        17,
        "Biotech公司"
      ],
      [
        "T2",
        "行业",
        47,
        50,
        "CRO"
      ],
      [
        "T3",
        "市场规模",
        52,
        54,
        "规模"
      ],
      [
        "T4",
        "属性值",
        54,
        59,
        "进一步提升"
      ],
      [
        "T5",
        "行业公司",
        68,
        70,
        "药企"
      ],
      [
        "T6",
        "时间范围",
        153,
        158,
        "2015年"
      ],
      [
        "T7",
        "公司",
        159,
        166,
        "Labcorp"
      ],
      [
        "T8",
        "公司",
        170,
        177,
        "Covance"
      ],
      [
        "T9",
        "时间范围",
        178,
        183,
        "2016年"
      ],
      [
        "T10",
        "公司",
        184,
        193,
        "Quintiles"
      ],
      [
        "T11",
        "公司",
        195,
        198,
        "IMS"
      ],
      [
        "T12",
        "公司",
        203,
        208,
        "IQVIA"
      ],
      [
        "T13",
        "时间范围",
        209,
        214,
        "2021年"
      ],
      [
        "T14",
        "公司",
        215,
        219,
        "ICON"
      ],
      [
        "T15",
        "公司",
        223,
        226,
        "PRA"
      ],
      [
        "T16",
        "行业公司",
        240,
        245,
        "CRO公司"
      ],
      [
        "T17",
        "行业公司",
        248,
        250,
        "药企"
      ],
      [
        "T18",
        "市场规模",
        306,
        308,
        "规模"
      ],
      [
        "T19",
        "属性值",
        308,
        312,
        "持续提升"
      ],
      [
        "T20",
        "市场集中度",
        313,
        316,
        "集中度"
      ],
      [
        "T21",
        "属性值",
        316,
        318,
        "增加"
      ],
      [
        "T22",
        "行业公司",
        32,
        34,
        "药企"
      ],
      [
        "T23",
        "行业",
        34,
        41,
        "一体化外包服务"
      ],
      [
        "T24",
        "行业公司",
        88,
        93,
        "CRO企业"
      ],
      [
        "T25",
        "行业公司",
        107,
        112,
        "CRO公司"
      ],
      [
        "T26",
        "属性值",
        131,
        133,
        "加剧"
      ],
      [
        "T27",
        "竞争格局",
        129,
        131,
        "竞争"
      ],
      [
        "T28",
        "行业公司",
        137,
        142,
        "CRO公司"
      ],
      [
        "T29",
        "行业公司",
        294,
        303,
        "biotech公司"
      ],
      [
        "T30",
        "行业公司",
        274,
        280,
        "CRO 公司"
      ]
    ]
  },
  {
    "id": 252,
    "text": "公司员工人数持续增加，2021 年上半年员工总数达 1970 人，同比增长 31.86%，实现人均创收 24.62 万元，人均创利（扣非归母）5.57 万元，公司人效随公司规模扩张持续增加。",
    "labels": [
      [
        "T0",
        "员工数量",
        2,
        6,
        "员工人数"
      ],
      [
        "T1",
        "时间范围",
        11,
        20,
        "2021 年上半年"
      ],
      [
        "T2",
        "人均收入",
        47,
        51,
        "人均创收"
      ],
      [
        "T3",
        "人均利润",
        61,
        71,
        "人均创利（扣非归母）"
      ]
    ]
  },
  {
    "id": 253,
    "text": "4月中药材价格指数上升。中药材综合 200指数 2021年 04月收 2554.82点， 环比上月上升 0.12%，同比去年上升 7.04%。2020年以来中药材价格指数受疫情影响，3月-4月中药材价格指数连续上涨，5月开始下降，6-8月持续下降， 9-11月持续上升，12月再次下降，2021年 1-4月持续上升。",
    "labels": [
      [
        "T0",
        "时间范围",
        24,
        33,
        "2021年 04月"
      ],
      [
        "T1",
        "时间范围",
        60,
        62,
        "去年"
      ],
      [
        "T2",
        "时间范围",
        47,
        49,
        "上月"
      ],
      [
        "T3",
        "时间范围",
        71,
        76,
        "2020年"
      ],
      [
        "T4",
        "时间范围",
        91,
        96,
        "3月-4月"
      ],
      [
        "T5",
        "时间范围",
        0,
        2,
        "4月"
      ],
      [
        "T6",
        "时间范围",
        108,
        110,
        "5月"
      ],
      [
        "T7",
        "时间范围",
        115,
        119,
        "6-8月"
      ],
      [
        "T8",
        "时间范围",
        125,
        130,
        "9-11月"
      ],
      [
        "T9",
        "时间范围",
        135,
        138,
        "12月"
      ],
      [
        "T10",
        "时间范围",
        143,
        153,
        "2021年 1-4月"
      ]
    ]
  },
  {
    "id": 254,
    "text": "行业龙头公司，同时在投资领域深耕 ）为全球生物医药行业提供全方全球制药、生物科技和医疗 ，为患者带来突破性的治疗及基因疗法研发生产、医疗载着来自全球30多个先行优势。药明康德提科学领域进行选择变革性技术、医药领域内技术和研发 ology和华领医药了良好的投资回报加强行业领导地位 www.leadleo.com",
    "labels": [
      [
        "T0",
        "龙头企业",
        2,
        6,
        "龙头公司"
      ],
      [
        "T1",
        "行业",
        21,
        25,
        "生物医药"
      ],
      [
        "T2",
        "地点范围",
        19,
        21,
        "全球"
      ],
      [
        "T3",
        "公司",
        83,
        87,
        "药明康德"
      ],
      [
        "T4",
        "公司",
        119,
        123,
        "华领医药"
      ]
    ]
  },
  {
    "id": 255,
    "text": "随着业务范围的扩大、客户的增加、需求的高速增长，公司员工及产能持续增加，员工人数增速维持在 20%以上，2021 上半年总人数达 28542 人，同比增长 25.05%，2021 全年 2 CAPEX 有望达 86 亿元，预计 2021 年全年产能为 116 万 m ，至 2023 年公司产能有望达 2 170.0万 m 。",
    "labels": [
      [
        "T0",
        "产能",
        29,
        31,
        "产能"
      ],
      [
        "T1",
        "员工数量",
        36,
        40,
        "员工人数"
      ],
      [
        "T2",
        "时间范围",
        52,
        60,
        "2021 上半年"
      ],
      [
        "T3",
        "时间范围",
        85,
        92,
        "2021 全年"
      ],
      [
        "T4",
        "CAPEX资本开支",
        95,
        100,
        "CAPEX"
      ],
      [
        "T5",
        "时间范围",
        114,
        122,
        "2021 年全年"
      ],
      [
        "T6",
        "产能",
        122,
        124,
        "产能"
      ],
      [
        "T7",
        "行业",
        137,
        143,
        "2023 年"
      ],
      [
        "T8",
        "产能",
        145,
        147,
        "产能"
      ]
    ]
  },
  {
    "id": 256,
    "text": "7.2、 21M1-3后疫情时代医疗机构诊疗人次大幅回升 21M1-3医院累计总诊疗人次数 9.4亿人，同比增长 52%，其中三级医院 5.2亿人，同比增长 71%；二级医院 3.3亿人，同比增长 38%；一级医院 0.5亿人， 同比增长 28%；基层医疗机构 4.9亿人，同比增长 7%。21M1-2医院累计总诊疗人次数 6.0亿人，同比增长 52%，其中三级医院 3.3亿人，同比增长 71%； 二级医院 2.1亿人，同比增长 35%；一级医院 0.3亿人，同比增长 31%；基层医疗机构 3.1亿人，同比下降 40%。21年国内处于零星确诊的后疫情时代，1-3 月医疗机构总诊疗人次较去年疫情爆发期大幅回升。",
    "labels": [
      [
        "T0",
        "时间范围",
        5,
        11,
        "21M1-3"
      ],
      [
        "T1",
        "时间范围",
        29,
        35,
        "21M1-3"
      ],
      [
        "T2",
        "时间范围",
        145,
        151,
        "21M1-2"
      ],
      [
        "T3",
        "时间范围",
        262,
        265,
        "21年"
      ],
      [
        "T4",
        "地点范围",
        265,
        267,
        "国内"
      ],
      [
        "T5",
        "时间范围",
        280,
        285,
        "1-3 月"
      ],
      [
        "T6",
        "时间范围",
        295,
        297,
        "去年"
      ]
    ]
  },
  {
    "id": 257,
    "text": "无边界扩张的科研服务霸主。 Thermo Fisher 作为全球实验室耗材及设备的绝对霸主，通过持续并购不断开拓业务边界。公司最早以实验室仪器设备起家，通过 70 余次并购，发展为囊括生命科学、实验室服务及产品、诊断、分析仪器四大板块的国际化公司。 2021 年 Thermo Fisher 收购全球第五大 CRO 公司 PPD 后， 成功打通实验室-临床-商业化生产全链条服务，全年营收达 392 亿美元，净利润 77 亿美元，较 Lonza 及 Catalent 高出一个数量级。",
    "labels": [
      [
        "T0",
        "公司",
        14,
        27,
        "Thermo Fisher"
      ],
      [
        "T1",
        "行业",
        32,
        40,
        "实验室耗材及设备"
      ],
      [
        "T2",
        "时间范围",
        125,
        131,
        "2021 年"
      ],
      [
        "T3",
        "公司",
        132,
        145,
        "Thermo Fisher"
      ],
      [
        "T4",
        "公司",
        161,
        164,
        "PPD"
      ],
      [
        "T5",
        "行业公司",
        154,
        160,
        "CRO 公司"
      ],
      [
        "T6",
        "营业收入",
        192,
        194,
        "营收"
      ],
      [
        "T7",
        "属性值",
        196,
        203,
        "392 亿美元"
      ],
      [
        "T8",
        "归母净利润",
        204,
        207,
        "净利润"
      ],
      [
        "T9",
        "属性值",
        208,
        214,
        "77 亿美元"
      ],
      [
        "T10",
        "公司",
        217,
        222,
        "Lonza"
      ],
      [
        "T11",
        "公司",
        225,
        233,
        "Catalent"
      ],
      [
        "T12",
        "地点范围",
        30,
        32,
        "全球"
      ],
      [
        "T13",
        "属性值",
        92,
        117,
        "生命科学、实验室服务及产品、诊断、分析仪器四大板块"
      ],
      [
        "T14",
        "属性值",
        66,
        73,
        "实验室仪器设备"
      ]
    ]
  },
  {
    "id": 258,
    "text": "目前全球跨国TOP 20药企中18家已公告中报数据，统计来看其2021年上半年合计营业收入为3741亿美元，同比增长13.3%，我们判断主要是新冠疫苗和相关治疗药物的销售爆发，以及自疫情下逐渐恢复。 另外从研发投入的角度，统计18家跨国药企2021年上半年合计研发投入为634亿美元，同比增长16.8%，继续延续高速增长，维持高景气度。",
    "labels": [
      [
        "T0",
        "时间范围",
        32,
        40,
        "2021年上半年"
      ],
      [
        "T1",
        "营业收入",
        42,
        46,
        "营业收入"
      ],
      [
        "T2",
        "属性值",
        47,
        54,
        "3741亿美元"
      ],
      [
        "T3",
        "属性值",
        59,
        64,
        "13.3%"
      ],
      [
        "T4",
        "行业公司",
        115,
        122,
        "18家跨国药企"
      ],
      [
        "T5",
        "时间范围",
        122,
        130,
        "2021年上半年"
      ],
      [
        "T6",
        "研发费用",
        132,
        136,
        "研发投入"
      ],
      [
        "T7",
        "地点范围",
        3,
        5,
        "全球"
      ],
      [
        "T8",
        "行业公司",
        7,
        15,
        "TOP 20药企"
      ],
      [
        "T9",
        "属性值",
        137,
        153,
        "634亿美元，同比增长16.8%"
      ],
      [
        "T10",
        "属性值",
        158,
        162,
        "高速增长"
      ]
    ]
  },
  {
    "id": 259,
    "text": "▍新冠疫情可谓百年一遇，在其影响下，行业有望进一步提速。我们认为，资本热潮下叠加国内 MAH制度试行至今，众多临床前项目需求有望继续传导到临床 CRO和 CDMO公司的后期阶段项目，而国内 CXO企业作为全球竞争市场的参与者，凭借国内工程师红利和制造业的比较优势，全球份额不断提升，而 2020 年初爆发的新冠疫情则进一步加强国内 CXO企业的增长驱动力，一方面国内疫情控制相对较好，导致海外订单需求阶段性向中国转移加速，加速行业爆发式增长趋势，前两年已经不错的行业增长进一步提速，带来可观的业绩弹性——如药明康德、泰格医药、博腾股份、药石科技、昭衍新药等公司 2020 年利润端在 2019年的基础上进一步加速（凯莱英、九洲药业暂未披露 2020年年报）；另一方面，疫情加速新治疗技术的发展，如 ADC、双抗、溶瘤病毒、mRNA、多肽、核酸、PROTACS、LYTAC等分子结构愈发复杂的新技术，这类新技术需求爆发式增长的驱动下，新药研发对于 CMC/临床试验设计的要求也进一步提升，CDMO/CRO行业的远期外包率和龙头市占率天花板也有望随之提升。",
    "labels": [
      [
        "T0",
        "地点范围",
        40,
        42,
        "国内"
      ],
      [
        "T1",
        "行业",
        69,
        75,
        "临床 CRO"
      ],
      [
        "T2",
        "地点范围",
        92,
        94,
        "国内"
      ],
      [
        "T3",
        "行业公司",
        95,
        100,
        "CXO企业"
      ],
      [
        "T4",
        "地点范围",
        115,
        117,
        "国内"
      ],
      [
        "T5",
        "市场份额",
        134,
        136,
        "份额"
      ],
      [
        "T6",
        "属性值",
        136,
        140,
        "不断提升"
      ],
      [
        "T7",
        "时间范围",
        143,
        150,
        "2020 年初"
      ],
      [
        "T8",
        "地点范围",
        163,
        165,
        "国内"
      ],
      [
        "T9",
        "行业公司",
        166,
        171,
        "CXO企业"
      ],
      [
        "T10",
        "公司",
        253,
        257,
        "药明康德"
      ],
      [
        "T11",
        "公司",
        258,
        262,
        "泰格医药"
      ],
      [
        "T12",
        "公司",
        263,
        267,
        "博腾股份"
      ],
      [
        "T13",
        "公司",
        268,
        272,
        "药石科技"
      ],
      [
        "T14",
        "公司",
        273,
        277,
        "昭衍新药"
      ],
      [
        "T15",
        "时间范围",
        292,
        297,
        "2019年"
      ],
      [
        "T16",
        "公司",
        307,
        310,
        "凯莱英"
      ],
      [
        "T17",
        "公司",
        311,
        315,
        "九洲药业"
      ],
      [
        "T18",
        "行业",
        443,
        451,
        "CDMO/CRO"
      ],
      [
        "T19",
        "外包率",
        456,
        459,
        "外包率"
      ],
      [
        "T20",
        "行业公司",
        460,
        462,
        "龙头"
      ],
      [
        "T21",
        "市场份额",
        462,
        465,
        "市占率"
      ],
      [
        "T22",
        "属性值",
        473,
        475,
        "提升"
      ],
      [
        "T23",
        "行业",
        55,
        58,
        "临床前"
      ],
      [
        "T24",
        "行业",
        77,
        81,
        "CDMO"
      ],
      [
        "T25",
        "地点范围",
        103,
        104,
        "球"
      ],
      [
        "T26",
        "行业",
        123,
        126,
        "制造业"
      ],
      [
        "T27",
        "地点范围",
        132,
        134,
        "全球"
      ],
      [
        "T28",
        "地点范围",
        194,
        196,
        "海外"
      ],
      [
        "T29",
        "属性值",
        200,
        210,
        "阶段性向中国转移加速"
      ],
      [
        "T30",
        "行业需求",
        198,
        200,
        "需求"
      ],
      [
        "T31",
        "属性值",
        215,
        220,
        "爆发式增长"
      ],
      [
        "T32",
        "时间范围",
        223,
        226,
        "前两年"
      ],
      [
        "T33",
        "业绩",
        246,
        248,
        "业绩"
      ],
      [
        "T34",
        "时间范围",
        281,
        287,
        "2020 年"
      ],
      [
        "T35",
        "利润",
        287,
        290,
        "利润端"
      ],
      [
        "T36",
        "时间范围",
        320,
        325,
        "2020年"
      ],
      [
        "T37",
        "行业",
        416,
        420,
        "新药研发"
      ],
      [
        "T38",
        "行业",
        423,
        433,
        "CMC/临床试验设计"
      ],
      [
        "T39",
        "时间范围",
        454,
        456,
        "远期"
      ]
    ]
  },
  {
    "id": 260,
    "text": "公司为行业中独此一家提供全面端到端新药研发服务的平台，服务能力涵盖整个药物发现、 开发及生产价值链。通过不断的研发投入，公司平台能力持续增强（eg：构建 900亿分子片段量级别的 DNA编码数据库，大幅提升筛选效率（1-2周 vs 2-3月））。依托这一强大的平台，公司为客户赋能新药开发，并提供多种定制化组合服务，加强客户粘性，不断提升单客收入。",
    "labels": [
      [
        "T0",
        "研发费用",
        55,
        59,
        "研发投入"
      ]
    ]
  },
  {
    "id": 261,
    "text": "国内心血管介入行业正处于快速发展期。电生理领域，我国导管消融手术量持续增长。 根据国家卫健委心律失常介入质控中心数据，预计我国电生理手术量将由 2019年的 18.0 万台增长至 2024年的 37.3万台（CAGR 15.7%）。弗若斯特沙利文预计，血管介入领域， 我国血管介入器械市场（不含支架）规模将由 2019年的 107.4亿元达到 2024年的 190 亿元（CAGR 12.1%）。预计随着基层市场的拓展、国内企业研发能力增强，我国电生理和血管介入行业规模将保持较快增长，同时国产化率有望不断提升。",
    "labels": [
      [
        "T0",
        "地点范围",
        0,
        2,
        "国内"
      ],
      [
        "T1",
        "行业",
        2,
        7,
        "心血管介入"
      ],
      [
        "T2",
        "行业",
        18,
        21,
        "电生理"
      ],
      [
        "T3",
        "行业",
        63,
        66,
        "电生理"
      ],
      [
        "T4",
        "时间范围",
        72,
        77,
        "2019年"
      ],
      [
        "T5",
        "时间范围",
        90,
        95,
        "2024年"
      ],
      [
        "T6",
        "CAGR",
        104,
        108,
        "CAGR"
      ],
      [
        "T7",
        "属性值",
        109,
        114,
        "15.7%"
      ],
      [
        "T8",
        "行业",
        126,
        130,
        "血管介入"
      ],
      [
        "T9",
        "行业",
        136,
        142,
        "血管介入器械"
      ],
      [
        "T10",
        "市场规模",
        150,
        152,
        "规模"
      ],
      [
        "T11",
        "时间范围",
        155,
        160,
        "2019年"
      ],
      [
        "T12",
        "时间范围",
        172,
        177,
        "2024年"
      ],
      [
        "T13",
        "属性值",
        179,
        185,
        "190 亿元"
      ],
      [
        "T14",
        "CAGR",
        186,
        190,
        "CAGR"
      ],
      [
        "T15",
        "属性值",
        191,
        196,
        "12.1%"
      ],
      [
        "T16",
        "地点范围",
        210,
        212,
        "国内"
      ],
      [
        "T17",
        "行业",
        223,
        226,
        "电生理"
      ],
      [
        "T18",
        "行业",
        227,
        231,
        "血管介入"
      ],
      [
        "T19",
        "地点范围",
        24,
        26,
        "我国"
      ],
      [
        "T20",
        "地点范围",
        61,
        63,
        "我国"
      ],
      [
        "T21",
        "地点范围",
        134,
        136,
        "我国"
      ],
      [
        "T22",
        "属性值",
        162,
        169,
        "107.4亿元"
      ],
      [
        "T23",
        "地点范围",
        221,
        223,
        "我国"
      ],
      [
        "T24",
        "市场规模",
        231,
        235,
        "行业规模"
      ],
      [
        "T25",
        "属性值",
        238,
        242,
        "较快增长"
      ],
      [
        "T26",
        "属性值",
        66,
        69,
        "手术量"
      ]
    ]
  },
  {
    "id": 262,
    "text": "3月 22日，国家医保局办公室回复了河南省、重庆市医保局关于拟临时新增新型冠状病毒抗原检测项目及有关事项意见的函：一、临时新增新型冠状病毒抗原检测项目，总体符合“技耗分离、产出导向”的改革方向，充分考虑了抗原检测的技术特点，同时也是适应疫情防控需要、促进抗原检测公平可及、降低社会经济负担的有力举措。二、同意你局临时增设“新型冠状病毒抗原检测”价格项目，每次 5元；抗原检测试剂（含采样器具）零差率销售；公立医疗机构开展抗原检测服务按照“价格项目+检测试剂”的方式收费。三、同意你局提出的单次新型冠状病毒抗原检测服务、试剂（含采样器具）费用总和超过 15元/次的，实际收费按照 15元/次封顶；群众单纯检测抗原的，公立医疗机构免收门诊诊查费；患者自测的，公立医疗机构不得收取“新型冠状病毒抗原检测”项目费用等价格政策。四、请你局对本省份网络平台、社会药店等零售终端销售的抗原检测试剂价格开展专项价格监测，定期向价格监督检查执法部门通报抗原检测试剂的零售终端价格、公立医疗机构集中采购价格，主动向价格监督检查执法部门提供不同渠道的不公平高价线索，积极配合部门依法开展的检查执法工作。 3月 25日，为指导和规范医疗机构临床营养科建设与管理，提高临床营养诊疗能力和服务水平，国家卫生健康委组织起草了《临床营养科建设与管理指南(试行)》。《指南》提出，医疗机构内独立开展临床营养诊疗服务的临床科室，名称统一为临床营养科。其工作职责包括开展营养筛查与评估、营养诊断及治疗， 为患者提供医疗膳食、肠内、肠外营养处方，规范指导特殊医学用途食品使用， 制定本机构临床营养相关工作规范等。《指南》要求有关医疗机构加强临床营养科的建设和管理，持续提高临床营养诊疗水平，保障医疗质量与安全。明确二级以上综合医院以及肿瘤、儿童、精神等专科医院设置临床营养科，要按照相关规定进行建设和管理。鼓励有条件的其他医疗机构参照相关规定设置、建设和管理",
    "labels": [
      [
        "T0",
        "时间范围",
        0,
        6,
        "3月 22日"
      ],
      [
        "T1",
        "地点范围",
        18,
        21,
        "河南省"
      ],
      [
        "T2",
        "地点范围",
        22,
        25,
        "重庆市"
      ],
      [
        "T3",
        "时间范围",
        491,
        497,
        "3月 25日"
      ]
    ]
  },
  {
    "id": 264,
    "text": "1月 17日，阿斯利康（AstraZeneca）和第一三共（Daiichi Sankyo）宣布， 美国 FDA已接受其抗体偶联药物（ADC）Enhertu（trastuzumab deruxtecan） 的补充生物制品许可申请（sBLA），用于治疗既往接受过抗 HER2治疗方案的不可切除或转移性 HER2阳性乳腺癌成人患者。该 sBLA申请也获得了优先审评资格，PDUFA日期为 2022年的第二季度。 https://www.businesswire.com",
    "labels": [
      [
        "T0",
        "公司",
        7,
        24,
        "阿斯利康（AstraZeneca）"
      ],
      [
        "T1",
        "时间范围",
        0,
        6,
        "1月 17日"
      ],
      [
        "T2",
        "公司",
        25,
        45,
        "第一三共（Daiichi Sankyo）"
      ],
      [
        "T3",
        "时间范围",
        191,
        201,
        "2022年的第二季度"
      ],
      [
        "T4",
        "地点范围",
        49,
        51,
        "美国"
      ]
    ]
  },
  {
    "id": 265,
    "text": " 整体收入保持保持高增长，增速提升：国金医药大数据中心对所覆盖的 CXO全产业链的 29家 A+H上市公司的研发外包相关收入进行了拆分、分类汇总（剔除相关公司的非 CXO收入），上述公司 2015-2020年 CXO业务合计收入（剔除方达控股与泰格医药重复统计后）分别为 133/171/215/277/369/488 亿元 ,2016-2020 年分别同比增长 29%/25%/29%/33%/32%，收入端整体呈现加速上升趋势。2020年整体收入增速与 2019年相比略有下降（32.94%→32.38%），主要是新冠疫情影响了临床 CRO板块的病人招募、入组进度。  从收入结构上来看：2020年 CXO板块中，药物发现及临床前、临床 CRO、 小分子 CDMO和大分子 CDMO占比分别为 38%、9%、39%和 14%。该收入结构比例跟新药研发、开发过程中研发投入比例有所差异，主要是因为不同业务领域客户结构不同，对于临床前、临床 CRO和大分子 CDMO 国内客户占比较高，药物发现和小分子 CDMO海外客户占比较高；同时， 中国医药创新近五年来快速崛起，主要以 fast follow 为主，目前药物发现领域国内需求比例较小（未来 5年 first in class的药物发现需求逐渐崛起）。",
    "labels": [
      [
        "T0",
        "行业公司",
        34,
        54,
        "CXO全产业链的 29家 A+H上市公司"
      ],
      [
        "T1",
        "行业",
        83,
        86,
        "CXO"
      ],
      [
        "T2",
        "时间范围",
        95,
        105,
        "2015-2020年"
      ],
      [
        "T3",
        "行业",
        106,
        109,
        "CXO"
      ],
      [
        "T4",
        "营业收入",
        113,
        115,
        "收入"
      ],
      [
        "T5",
        "公司",
        118,
        122,
        "方达控股"
      ],
      [
        "T6",
        "公司",
        123,
        127,
        "泰格医药"
      ],
      [
        "T7",
        "时间范围",
        165,
        176,
        "2016-2020 年"
      ],
      [
        "T8",
        "属性值",
        183,
        202,
        "29%/25%/29%/33%/32%"
      ],
      [
        "T9",
        "时间范围",
        217,
        222,
        "2020年"
      ],
      [
        "T10",
        "收入增速",
        224,
        228,
        "收入增速"
      ],
      [
        "T11",
        "时间范围",
        230,
        235,
        "2019年"
      ],
      [
        "T12",
        "行业",
        270,
        273,
        "CRO"
      ],
      [
        "T13",
        "时间范围",
        298,
        303,
        "2020年"
      ],
      [
        "T14",
        "行业",
        304,
        307,
        "CXO"
      ],
      [
        "T15",
        "行业",
        311,
        315,
        "药物发现"
      ],
      [
        "T16",
        "行业",
        316,
        319,
        "临床前"
      ],
      [
        "T17",
        "行业",
        320,
        326,
        "临床 CRO"
      ],
      [
        "T18",
        "行业",
        328,
        336,
        "小分子 CDMO"
      ],
      [
        "T19",
        "行业",
        337,
        345,
        "大分子 CDMO"
      ],
      [
        "T20",
        "行业",
        416,
        419,
        "临床前"
      ],
      [
        "T21",
        "行业",
        420,
        426,
        "临床 CRO"
      ],
      [
        "T22",
        "行业",
        427,
        435,
        "大分子 CDMO"
      ],
      [
        "T23",
        "行业",
        445,
        449,
        "药物发现"
      ],
      [
        "T24",
        "行业",
        450,
        458,
        "小分子 CDMO"
      ],
      [
        "T25",
        "时间范围",
        477,
        480,
        "近五年"
      ],
      [
        "T26",
        "行业需求",
        515,
        517,
        "需求"
      ],
      [
        "T27",
        "地点范围",
        513,
        515,
        "国内"
      ],
      [
        "T28",
        "属性值",
        517,
        521,
        "比例较小"
      ],
      [
        "T29",
        "时间范围",
        522,
        527,
        "未来 5年"
      ],
      [
        "T30",
        "行业",
        473,
        477,
        "医药创新"
      ],
      [
        "T31",
        "地点范围",
        471,
        473,
        "中国"
      ],
      [
        "T32",
        "行业",
        507,
        511,
        "药物发现"
      ],
      [
        "T33",
        "行业",
        543,
        547,
        "药物发现"
      ],
      [
        "T34",
        "行业需求",
        547,
        549,
        "需求"
      ],
      [
        "T35",
        "属性值",
        549,
        553,
        "逐渐崛起"
      ],
      [
        "T36",
        "营业收入",
        4,
        6,
        "收入"
      ],
      [
        "T37",
        "行业",
        55,
        59,
        "研发外包"
      ],
      [
        "T38",
        "营业收入",
        61,
        63,
        "收入"
      ],
      [
        "T39",
        "营业收入",
        86,
        88,
        "收入"
      ],
      [
        "T40",
        "属性值",
        137,
        163,
        "133/171/215/277/369/488 亿元"
      ],
      [
        "T41",
        "营业收入",
        203,
        206,
        "收入端"
      ],
      [
        "T42",
        "属性值",
        210,
        214,
        "加速上升"
      ],
      [
        "T43",
        "属性值",
        242,
        248,
        "32.94%"
      ],
      [
        "T44",
        "属性值",
        249,
        255,
        "32.38%"
      ],
      [
        "T45",
        "营业收入",
        290,
        292,
        "收入"
      ],
      [
        "T46",
        "地点范围",
        436,
        438,
        "国内"
      ],
      [
        "T47",
        "地点范围",
        458,
        460,
        "海外"
      ]
    ]
  },
  {
    "id": 267,
    "text": "在新医改持续深化、产业技术加速迭代、专业人才不断涌现、资本支持日益加强的当前，中国医药企业面对四面而来的机遇与挑战犹如逆水行舟，唯有升级创新，方可乘风破浪，2022年，创新迭代周期更快，企业面临的挑战更大。在这争流百舸中，既有经验丰富不急不缓的巨轮，以创新为驱动不断完善业务布局加速国际化进程，如迈瑞医疗、药明康德、恒瑞医药、爱尔眼科等；亦不乏技术过人全速前进的轻舟，在部分领域优势明显并在自己擅长的赛道上一马当先，如百济神州、信达生物、南微医学、启明医疗等。因此，在投资方面，除重点关注一线大龙头企业外，也可自下而上找寻各细分领域的专精特新小龙头。",
    "labels": [
      [
        "T0",
        "行业公司",
        41,
        45,
        "医药企业"
      ],
      [
        "T1",
        "时间范围",
        78,
        83,
        "2022年"
      ],
      [
        "T2",
        "公司",
        148,
        152,
        "迈瑞医疗"
      ],
      [
        "T3",
        "公司",
        153,
        157,
        "药明康德"
      ],
      [
        "T4",
        "公司",
        158,
        162,
        "恒瑞医药"
      ],
      [
        "T5",
        "公司",
        163,
        167,
        "爱尔眼科"
      ],
      [
        "T6",
        "公司",
        209,
        213,
        "百济神州"
      ],
      [
        "T7",
        "公司",
        214,
        218,
        "信达生物"
      ],
      [
        "T8",
        "公司",
        219,
        223,
        "南微医学"
      ],
      [
        "T9",
        "公司",
        224,
        228,
        "启明医疗"
      ],
      [
        "T10",
        "龙头企业",
        247,
        251,
        "龙头企业"
      ],
      [
        "T11",
        "龙头企业",
        272,
        274,
        "龙头"
      ],
      [
        "T12",
        "地点范围",
        39,
        41,
        "中国"
      ]
    ]
  },
  {
    "id": 268,
    "text": " 2020 Review：①CXO板块保持高景气状态，订单和业绩表现持续提升。②板块性经营管理效率提升，人均单产与人均创利稳步成长。③资本开支与固定资产角度，产能加速扩张。④不同细分领域业绩表现有一定差异，CDMO板块景气度持续提升；新技术应用+产业升级+产业转移驱动外需提振，收入增速提升；预计 2021年开始，未来 3-5年中国本土医药创新需求整体增速呈上升态势。  行业驱动因素未发生变化，并且行业基本面有边际改善：①全球产业转移、海外订单流入；②产业升级；③中国医药创新崛起，加速成长。  2021展望：①中国比较优势明显，疫情或将加速全球产业转移（包括 CXO和 API板块）；②国内外需求旺盛，美国投融资高景气，海外创新需求加速，国内医药创新需求持续加速；③全年来看，药物发现 CRO、临床前 CRO和小分子 CDMO保持高增长，临床 CRO和海外业务板块恢复性增长，拉动 CXO整体增速小幅提振。  国内医药创新趋势来看，未来 5年将逐渐进入临床后期开发和落地兑现阶段，CDMO和临床 CRO细分行业或将迎来国内需求爆发。 投资建议  建议重点关注：行业内龙头公司，细分领域特色公司以及 CDMO细分领域，药明康德、凯莱英、九洲药业、美迪西、维亚生物等。 风险提示  海外疫情进一步发展的风险，新药研发失败风险，监管风险，汇率波动风险，IP保护风险，核心技术人员流失风险，解禁风险，投资风险，安全生产及环保风险，贸易纠纷风险。",
    "labels": [
      [
        "T0",
        "行业",
        15,
        18,
        "CXO"
      ],
      [
        "T1",
        "业绩",
        31,
        33,
        "业绩"
      ],
      [
        "T2",
        "属性值",
        35,
        39,
        "持续提升"
      ],
      [
        "T3",
        "行业",
        104,
        108,
        "CDMO"
      ],
      [
        "T4",
        "时间范围",
        158,
        165,
        "未来 3-5年"
      ],
      [
        "T5",
        "行业",
        169,
        173,
        "医药创新"
      ],
      [
        "T6",
        "行业需求",
        173,
        175,
        "需求"
      ],
      [
        "T7",
        "地点范围",
        221,
        223,
        "海外"
      ],
      [
        "T8",
        "地点范围",
        235,
        237,
        "中国"
      ],
      [
        "T9",
        "行业",
        237,
        241,
        "医药创新"
      ],
      [
        "T10",
        "属性值",
        244,
        248,
        "加速成长"
      ],
      [
        "T11",
        "时间范围",
        252,
        256,
        "2021"
      ],
      [
        "T12",
        "地点范围",
        260,
        262,
        "中国"
      ],
      [
        "T13",
        "行业",
        285,
        288,
        "CXO"
      ],
      [
        "T14",
        "行业",
        290,
        293,
        "API"
      ],
      [
        "T15",
        "地点范围",
        298,
        301,
        "国内外"
      ],
      [
        "T16",
        "行业需求",
        301,
        303,
        "需求"
      ],
      [
        "T17",
        "属性值",
        303,
        305,
        "旺盛"
      ],
      [
        "T18",
        "地点范围",
        306,
        308,
        "美国"
      ],
      [
        "T19",
        "投融资情况",
        308,
        311,
        "投融资"
      ],
      [
        "T20",
        "属性值",
        311,
        314,
        "高景气"
      ],
      [
        "T21",
        "地点范围",
        324,
        326,
        "国内"
      ],
      [
        "T22",
        "行业",
        326,
        330,
        "医药创新"
      ],
      [
        "T23",
        "行业需求",
        330,
        332,
        "需求"
      ],
      [
        "T24",
        "属性值",
        332,
        336,
        "持续加速"
      ],
      [
        "T25",
        "行业",
        343,
        351,
        "药物发现 CRO"
      ],
      [
        "T26",
        "行业",
        352,
        359,
        "临床前 CRO"
      ],
      [
        "T27",
        "行业",
        360,
        368,
        "小分子 CDMO"
      ],
      [
        "T28",
        "行业",
        374,
        380,
        "临床 CRO"
      ],
      [
        "T29",
        "地点范围",
        411,
        413,
        "国内"
      ],
      [
        "T30",
        "行业",
        413,
        417,
        "医药创新"
      ],
      [
        "T31",
        "时间范围",
        422,
        427,
        "未来 5年"
      ],
      [
        "T32",
        "属性值",
        430,
        445,
        "进入临床后期开发和落地兑现阶段"
      ],
      [
        "T33",
        "行业趋势",
        417,
        419,
        "趋势"
      ],
      [
        "T34",
        "行业",
        446,
        450,
        "CDMO"
      ],
      [
        "T35",
        "地点范围",
        465,
        467,
        "国内"
      ],
      [
        "T36",
        "行业需求",
        467,
        469,
        "需求"
      ],
      [
        "T37",
        "属性值",
        469,
        471,
        "爆发"
      ],
      [
        "T38",
        "龙头企业",
        490,
        494,
        "龙头公司"
      ],
      [
        "T39",
        "行业",
        506,
        510,
        "CDMO"
      ],
      [
        "T40",
        "公司",
        515,
        519,
        "药明康德"
      ],
      [
        "T41",
        "公司",
        520,
        523,
        "凯莱英"
      ],
      [
        "T42",
        "公司",
        524,
        528,
        "九洲药业"
      ],
      [
        "T43",
        "公司",
        529,
        532,
        "美迪西"
      ],
      [
        "T44",
        "公司",
        533,
        537,
        "维亚生物"
      ],
      [
        "T45",
        "人均利润",
        58,
        62,
        "人均创利"
      ],
      [
        "T46",
        "属性值",
        62,
        66,
        "稳步成长"
      ],
      [
        "T47",
        "行业",
        396,
        399,
        "CXO"
      ],
      [
        "T48",
        "在手订单",
        28,
        30,
        "订单"
      ],
      [
        "T49",
        "时间范围",
        2,
        6,
        "2020"
      ],
      [
        "T50",
        "CAPEX资本开支",
        68,
        72,
        "资本开支"
      ],
      [
        "T51",
        "固定资产",
        73,
        77,
        "固定资产"
      ],
      [
        "T52",
        "产能",
        80,
        82,
        "产能"
      ],
      [
        "T53",
        "属性值",
        82,
        86,
        "加速扩张"
      ],
      [
        "T54",
        "业绩",
        94,
        96,
        "业绩"
      ],
      [
        "T55",
        "收入增速",
        140,
        144,
        "收入增速"
      ],
      [
        "T56",
        "属性值",
        144,
        146,
        "提升"
      ],
      [
        "T57",
        "时间范围",
        150,
        157,
        "2021年开始"
      ],
      [
        "T58",
        "地点范围",
        165,
        169,
        "中国本土"
      ],
      [
        "T59",
        "属性值",
        177,
        184,
        "增速呈上升态势"
      ],
      [
        "T60",
        "地点范围",
        214,
        216,
        "全球"
      ],
      [
        "T61",
        "地点范围",
        315,
        317,
        "海外"
      ],
      [
        "T62",
        "地点范围",
        381,
        383,
        "海外"
      ],
      [
        "T63",
        "行业",
        451,
        457,
        "临床 CRO"
      ]
    ]
  },
  {
    "id": 269,
    "text": "产能分布上，CDMO 龙头公司均进行全球布局，Lonza、Catalent、Thermo Fisher、药明康德在多个大洲都有生产基地，反映出 CGT 药物生产具有地域性。",
    "labels": [
      [
        "T0",
        "行业",
        6,
        10,
        "CDMO"
      ],
      [
        "T1",
        "龙头企业",
        11,
        15,
        "龙头公司"
      ],
      [
        "T2",
        "公司",
        23,
        28,
        "Lonza"
      ],
      [
        "T3",
        "公司",
        29,
        37,
        "Catalent"
      ],
      [
        "T4",
        "公司",
        38,
        51,
        "Thermo Fisher"
      ],
      [
        "T5",
        "公司",
        52,
        56,
        "药明康德"
      ],
      [
        "T6",
        "行业",
        72,
        80,
        "CGT 药物生产"
      ],
      [
        "T7",
        "属性值",
        82,
        85,
        "地域性"
      ]
    ]
  },
  {
    "id": 270,
    "text": "国内 CRO行业竞争格局同样呈现龙头聚集效应，CDMO/CMO行业格局相对分散。药明康德、康龙化成、泰格医药等前三大龙头企业市场份额约为 26%。",
    "labels": [
      [
        "T0",
        "地点范围",
        0,
        2,
        "国内"
      ],
      [
        "T1",
        "行业",
        3,
        6,
        "CRO"
      ],
      [
        "T2",
        "竞争格局",
        8,
        12,
        "竞争格局"
      ],
      [
        "T3",
        "行业",
        23,
        31,
        "CDMO/CMO"
      ],
      [
        "T4",
        "竞争格局",
        33,
        35,
        "格局"
      ],
      [
        "T5",
        "属性值",
        35,
        39,
        "相对分散"
      ],
      [
        "T6",
        "公司",
        40,
        44,
        "药明康德"
      ],
      [
        "T7",
        "公司",
        45,
        49,
        "康龙化成"
      ],
      [
        "T8",
        "公司",
        50,
        54,
        "泰格医药"
      ],
      [
        "T9",
        "市场份额",
        62,
        66,
        "市场份额"
      ],
      [
        "T10",
        "属性值",
        16,
        20,
        "龙头聚集"
      ],
      [
        "T11",
        "行业公司",
        55,
        62,
        "前三大龙头企业"
      ],
      [
        "T12",
        "属性值",
        66,
        72,
        "约为 26%"
      ]
    ]
  },
  {
    "id": 272,
    "text": "短期股价受市场情绪明显扰动，中长期看中国CXO企业在全球供应链体系中占据重要战略性地位。3月17日-4月18日，CRO指数下跌0.84%。我们认为CXO板块当下资本市场遇冷，主要由悲观市场情绪传导所致，海外分析师团队预计辉瑞新冠口服药Q1销售或将不及预期，但其对全年销售仍维持原有预判，目前辉瑞2022年对Paxolvid销售额指引为220亿美金，市场一致性预期为282亿美金，JP Morgan上调预期至330亿美金。我们认为，1）各国均在推进Paxolvid临床试验，以扩大其使用范围，口服新冠药仍是重要治疗手段。英国卫生部开展的大规模临床试验已有1.75万人参与；中国深圳开展的小规模临床显示Paxolvi初步疗效；同时，辉瑞也启动针对6-17岁儿童的临床试验。2）市场认为若新冠口服药销售下滑或将导致相关CDMO公司业绩受影响。我们认为中长期维度看，新冠口服药虽带来较大金额订单机遇，究其本质，中国CXO企业在全球供应链体系中地位的明显提升，形成多层次且优质的客户群体和丰富项目池才是维持业绩持续增长的核心动力。",
    "labels": [
      [
        "T0",
        "地点范围",
        19,
        21,
        "中国"
      ],
      [
        "T1",
        "行业公司",
        21,
        26,
        "CXO企业"
      ],
      [
        "T2",
        "时间范围",
        45,
        56,
        "3月17日-4月18日"
      ],
      [
        "T3",
        "行业",
        74,
        77,
        "CXO"
      ],
      [
        "T4",
        "公司",
        146,
        148,
        "辉瑞"
      ],
      [
        "T5",
        "时间范围",
        148,
        153,
        "2022年"
      ],
      [
        "T6",
        "公司",
        315,
        317,
        "辉瑞"
      ],
      [
        "T7",
        "行业公司",
        357,
        363,
        "CDMO公司"
      ],
      [
        "T8",
        "地点范围",
        402,
        404,
        "中国"
      ],
      [
        "T9",
        "行业公司",
        404,
        409,
        "CXO企业"
      ],
      [
        "T10",
        "业绩",
        449,
        451,
        "业绩"
      ],
      [
        "T11",
        "时间范围",
        15,
        18,
        "中长期"
      ],
      [
        "T12",
        "地点范围",
        27,
        29,
        "全球"
      ],
      [
        "T13",
        "时间范围",
        118,
        120,
        "Q1"
      ],
      [
        "T14",
        "公司",
        111,
        113,
        "辉瑞"
      ],
      [
        "T15",
        "地点范围",
        260,
        262,
        "英国"
      ],
      [
        "T16",
        "地点范围",
        286,
        290,
        "中国深圳"
      ],
      [
        "T17",
        "业绩",
        363,
        365,
        "业绩"
      ],
      [
        "T18",
        "时间范围",
        373,
        376,
        "中长期"
      ],
      [
        "T19",
        "地点范围",
        410,
        412,
        "全球"
      ],
      [
        "T20",
        "时间范围",
        1,
        3,
        "短期"
      ]
    ]
  },
  {
    "id": 273,
    "text": "我国生物科研试剂市场规模快速扩张。生物科研试剂是生命科学相关领域研究人员进行科研活动的基础工具，主要包括免疫学试剂、分子生物学试剂、细胞生物学试剂和生化试剂等，随着生物技术的不断发展，生物科研试剂的使用范围不断扩展，已经成为科技发展和技术进步不可或缺的功能材料和基础材料。 国内生物科研试剂市场起步虽晚，但在国家相关政策和下游产业带动下，随着生命科学研究的不断投入和快速发展，市场规模迅速扩张，根据 Frost & Sullivan数据，中国生物科研试剂市场规模于 2015年达到 72 亿元，并以 17.1%的年复合增长率增长至 2019年的 136亿元，增速高于同期全球生物科研试剂市场。预计到 2024年，中国生物科研试剂市场规模将达到 260亿元，2019年-2024年复合增长率为 13.8%，高于全球的 7.1%。",
    "labels": [
      [
        "T0",
        "行业",
        2,
        8,
        "生物科研试剂"
      ],
      [
        "T1",
        "市场规模",
        8,
        12,
        "市场规模"
      ],
      [
        "T2",
        "属性值",
        12,
        16,
        "快速扩张"
      ],
      [
        "T3",
        "行业",
        17,
        23,
        "生物科研试剂"
      ],
      [
        "T4",
        "行业",
        92,
        98,
        "生物科研试剂"
      ],
      [
        "T5",
        "地点范围",
        137,
        139,
        "国内"
      ],
      [
        "T6",
        "行业",
        139,
        145,
        "生物科研试剂"
      ],
      [
        "T7",
        "市场规模",
        188,
        192,
        "市场规模"
      ],
      [
        "T8",
        "属性值",
        192,
        196,
        "迅速扩张"
      ],
      [
        "T9",
        "地点范围",
        219,
        221,
        "中国"
      ],
      [
        "T10",
        "行业",
        221,
        227,
        "生物科研试剂"
      ],
      [
        "T11",
        "市场规模",
        227,
        231,
        "市场规模"
      ],
      [
        "T12",
        "时间范围",
        233,
        238,
        "2015年"
      ],
      [
        "T13",
        "属性值",
        241,
        246,
        "72 亿元"
      ],
      [
        "T14",
        "属性值",
        250,
        255,
        "17.1%"
      ],
      [
        "T15",
        "CAGR",
        256,
        262,
        "年复合增长率"
      ],
      [
        "T16",
        "时间范围",
        266,
        271,
        "2019年"
      ],
      [
        "T17",
        "属性值",
        273,
        278,
        "136亿元"
      ],
      [
        "T18",
        "时间范围",
        300,
        305,
        "2024年"
      ],
      [
        "T19",
        "地点范围",
        306,
        308,
        "中国"
      ],
      [
        "T20",
        "行业",
        308,
        314,
        "生物科研试剂"
      ],
      [
        "T21",
        "市场规模",
        314,
        318,
        "市场规模"
      ],
      [
        "T22",
        "属性值",
        322,
        327,
        "260亿元"
      ],
      [
        "T23",
        "时间范围",
        328,
        339,
        "2019年-2024年"
      ],
      [
        "T24",
        "CAGR",
        339,
        344,
        "复合增长率"
      ],
      [
        "T25",
        "属性值",
        346,
        351,
        "13.8%"
      ],
      [
        "T26",
        "地点范围",
        0,
        2,
        "我国"
      ],
      [
        "T27",
        "地点范围",
        285,
        287,
        "全球"
      ],
      [
        "T28",
        "行业",
        287,
        293,
        "生物科研试剂"
      ],
      [
        "T29",
        "地点范围",
        354,
        356,
        "全球"
      ],
      [
        "T30",
        "属性值",
        358,
        362,
        "7.1%"
      ]
    ]
  },
  {
    "id": 274,
    "text": "仿制药 CXO领域：关注百诚医药、阳光诺和等； 创新药及产业链领域：药明康德、九洲药业、凯莱英等； BIOTECH类创新药：康方生物、信达生物、亚盛医药等； 原料药领域：同和药业、普洛药业、司太立、天宇股份等； 疫苗领域：智飞生物、康泰生物、万泰生物等； 生长激素领域：长春高新、安科生物等； 医疗服务领域：爱尔眼科、通策医疗、海吉亚医疗等； 血制品领域：博雅生物、天坛生物等； 医美领域：爱美客、华熙生物、华东医药、昊海生科等；",
    "labels": [
      [
        "T0",
        "公司",
        12,
        16,
        "百诚医药"
      ],
      [
        "T1",
        "公司",
        17,
        21,
        "阳光诺和"
      ],
      [
        "T2",
        "公司",
        34,
        38,
        "药明康德"
      ],
      [
        "T3",
        "公司",
        39,
        43,
        "九洲药业"
      ],
      [
        "T4",
        "公司",
        44,
        47,
        "凯莱英"
      ],
      [
        "T5",
        "行业",
        50,
        61,
        "BIOTECH类创新药"
      ],
      [
        "T6",
        "公司",
        62,
        66,
        "康方生物"
      ],
      [
        "T7",
        "公司",
        67,
        71,
        "信达生物"
      ],
      [
        "T8",
        "公司",
        72,
        76,
        "亚盛医药"
      ],
      [
        "T9",
        "行业",
        79,
        82,
        "原料药"
      ],
      [
        "T10",
        "公司",
        85,
        89,
        "同和药业"
      ],
      [
        "T11",
        "公司",
        90,
        94,
        "普洛药业"
      ],
      [
        "T12",
        "公司",
        95,
        98,
        "司太立"
      ],
      [
        "T13",
        "公司",
        99,
        103,
        "天宇股份"
      ],
      [
        "T14",
        "行业",
        106,
        108,
        "疫苗"
      ],
      [
        "T15",
        "公司",
        111,
        115,
        "智飞生物"
      ],
      [
        "T16",
        "公司",
        116,
        120,
        "康泰生物"
      ],
      [
        "T17",
        "公司",
        121,
        125,
        "万泰生物"
      ],
      [
        "T18",
        "行业",
        128,
        132,
        "生长激素"
      ],
      [
        "T19",
        "公司",
        135,
        139,
        "长春高新"
      ],
      [
        "T20",
        "公司",
        140,
        144,
        "安科生物"
      ],
      [
        "T21",
        "行业",
        147,
        151,
        "医疗服务"
      ],
      [
        "T22",
        "公司",
        154,
        158,
        "爱尔眼科"
      ],
      [
        "T23",
        "公司",
        159,
        163,
        "通策医疗"
      ],
      [
        "T24",
        "公司",
        164,
        169,
        "海吉亚医疗"
      ],
      [
        "T25",
        "行业",
        172,
        175,
        "血制品"
      ],
      [
        "T26",
        "公司",
        178,
        182,
        "博雅生物"
      ],
      [
        "T27",
        "公司",
        183,
        187,
        "天坛生物"
      ],
      [
        "T28",
        "行业",
        190,
        192,
        "医美"
      ],
      [
        "T29",
        "公司",
        195,
        198,
        "爱美客"
      ],
      [
        "T30",
        "公司",
        199,
        203,
        "华熙生物"
      ],
      [
        "T31",
        "公司",
        204,
        208,
        "华东医药"
      ],
      [
        "T32",
        "公司",
        209,
        213,
        "昊海生科"
      ],
      [
        "T33",
        "行业",
        0,
        7,
        "仿制药 CXO"
      ],
      [
        "T34",
        "行业",
        24,
        31,
        "创新药及产业链"
      ]
    ]
  },
  {
    "id": 275,
    "text": "3、全球化：基于基因治疗药物中、美、澳IND申报项目经验，逐步将业务拓展至全球。",
    "labels": [
      [
        "T0",
        "地点范围",
        14,
        15,
        "中"
      ],
      [
        "T1",
        "地点范围",
        16,
        17,
        "美"
      ],
      [
        "T2",
        "地点范围",
        18,
        19,
        "澳"
      ],
      [
        "T3",
        "行业",
        8,
        14,
        "基因治疗药物"
      ]
    ]
  },
  {
    "id": 276,
    "text": "▍市场回顾：上周中信医药指数下跌 0.74%，跑赢沪深 300指数 1.70 pct，医药流通涨幅最大。当前，医药板块 2021年预测市盈率约 35倍，融资余额占自由流通市值上升至 3.57%。上周 A股医药板块合计减持 0.28亿元；大宗交易合计成交金额 7.52亿元。",
    "labels": [
      [
        "T0",
        "行业",
        55,
        57,
        "医药"
      ],
      [
        "T1",
        "PE",
        67,
        70,
        "市盈率"
      ],
      [
        "T2",
        "时间范围",
        60,
        65,
        "2021年"
      ],
      [
        "T3",
        "属性值",
        72,
        75,
        "35倍"
      ],
      [
        "T4",
        "行业",
        102,
        104,
        "医药"
      ],
      [
        "T5",
        "时间范围",
        6,
        8,
        "上周"
      ],
      [
        "T6",
        "时间范围",
        97,
        99,
        "上周"
      ]
    ]
  },
  {
    "id": 277,
    "text": "医药CXO行业规模扩大，预计2018-2025年中国医药CXO行业年复合增长率11.3%2025年CXO市场规模将达到2,440亿美元",
    "labels": [
      [
        "T0",
        "行业",
        0,
        5,
        "医药CXO"
      ],
      [
        "T1",
        "市场规模",
        7,
        9,
        "规模"
      ],
      [
        "T2",
        "时间范围",
        14,
        24,
        "2018-2025年"
      ],
      [
        "T3",
        "地点范围",
        24,
        26,
        "中国"
      ],
      [
        "T4",
        "行业",
        26,
        31,
        "医药CXO"
      ],
      [
        "T5",
        "CAGR",
        33,
        39,
        "年复合增长率"
      ],
      [
        "T6",
        "属性值",
        39,
        44,
        "11.3%"
      ],
      [
        "T7",
        "时间范围",
        44,
        49,
        "2025年"
      ],
      [
        "T8",
        "行业",
        49,
        52,
        "CXO"
      ],
      [
        "T9",
        "市场规模",
        52,
        56,
        "市场规模"
      ],
      [
        "T10",
        "属性值",
        59,
        67,
        "2,440亿美元"
      ],
      [
        "T11",
        "属性值",
        9,
        11,
        "扩大"
      ]
    ]
  },
  {
    "id": 278,
    "text": "药明康德是全球领先的制药及医疗器械研发和生产服务外包企业。公司具有全产业链覆盖能力，能够提供从药物发现、临床前研发、临床试验及申报、原料药及制剂生产等全流程的研发、生产服务，覆盖领域既包括小分子药物、也包括细胞治疗、基因治疗以及医疗器械研发测试等领域。主要业务板块包括中国区实验室业务、美国区实验室业务、合同研发生产外包业务（CDMO），及临床 CRO业务。 公司历经 20余年发展，已成长为全球 CXO行业巨头。2000年 12月，药明康德在江苏无锡成立，在上海设立运营中心，最初开展小分子药物的研发外包业务，后逐步增加合成化学、工艺研发、研发型生产、生物分析、生物新药开发、 毒理与制剂服务等业务，不断扩大产业链布局。公司 2007年登陆纽交所，并于 2008 年收购了美国 AppTec 实验室服务有限公司，英文名更名为 WuXi AppTec。此后，公司历经多次并购扩张，海内外建厂扩产，目前业务覆盖地区已经扩大到全球 30多个国家，客户超过 4200家，员工总数超过 26000人。",
    "labels": [
      [
        "T0",
        "公司",
        0,
        4,
        "药明康德"
      ],
      [
        "T1",
        "行业",
        10,
        12,
        "制药"
      ],
      [
        "T2",
        "行业",
        94,
        99,
        "小分子药物"
      ],
      [
        "T3",
        "行业",
        103,
        107,
        "细胞治疗"
      ],
      [
        "T4",
        "行业",
        108,
        112,
        "基因治疗"
      ],
      [
        "T5",
        "行业",
        114,
        122,
        "医疗器械研发测试"
      ],
      [
        "T6",
        "主营业务",
        126,
        130,
        "主要业务"
      ],
      [
        "T7",
        "行业",
        199,
        202,
        "CXO"
      ],
      [
        "T8",
        "时间范围",
        207,
        216,
        "2000年 12月"
      ],
      [
        "T9",
        "公司",
        217,
        221,
        "药明康德"
      ],
      [
        "T10",
        "客户数量",
        421,
        423,
        "客户"
      ],
      [
        "T11",
        "属性值",
        423,
        431,
        "超过 4200家"
      ],
      [
        "T12",
        "员工数量",
        432,
        434,
        "员工"
      ],
      [
        "T13",
        "属性值",
        436,
        445,
        "超过 26000人"
      ],
      [
        "T14",
        "属性值",
        134,
        178,
        "中国区实验室业务、美国区实验室业务、合同研发生产外包业务（CDMO），及临床 CRO业务"
      ],
      [
        "T15",
        "行业",
        13,
        26,
        "医疗器械研发和生产服务外包"
      ],
      [
        "T16",
        "地点范围",
        5,
        7,
        "全球"
      ],
      [
        "T17",
        "地点范围",
        222,
        226,
        "江苏无锡"
      ],
      [
        "T18",
        "地点范围",
        230,
        232,
        "上海"
      ],
      [
        "T19",
        "时间范围",
        314,
        319,
        "2007年"
      ],
      [
        "T20",
        "时间范围",
        328,
        334,
        "2008 年"
      ],
      [
        "T21",
        "地点范围",
        337,
        339,
        "美国"
      ],
      [
        "T22",
        "公司",
        340,
        356,
        "AppTec 实验室服务有限公司"
      ],
      [
        "T23",
        "公司",
        364,
        375,
        "WuXi AppTec"
      ],
      [
        "T24",
        "地点范围",
        390,
        393,
        "海内外"
      ],
      [
        "T25",
        "地点范围",
        411,
        413,
        "全球"
      ]
    ]
  },
  {
    "id": 279,
    "text": "行业稳步增长叠加公司份额提升，中长期成长性较强。从中长期来看，全球研发、生产产业链重分工，市场份额向亚太地区转移的趋势将会持续，本土龙头在全球 CXO市场份额有望持续提升。我们从定量的角度对全球 CRO及 CDMO 市场规模及公司全球份额的变化进行了预估。预计未来十年公司收入体量有近 10倍的增长空间。",
    "labels": [
      [
        "T0",
        "市场份额",
        45,
        49,
        "市场份额"
      ],
      [
        "T1",
        "行业",
        72,
        75,
        "CXO"
      ],
      [
        "T2",
        "市场份额",
        75,
        79,
        "市场份额"
      ],
      [
        "T3",
        "行业",
        98,
        101,
        "CRO"
      ],
      [
        "T4",
        "行业",
        103,
        107,
        "CDMO"
      ],
      [
        "T5",
        "市场规模",
        108,
        112,
        "市场规模"
      ],
      [
        "T6",
        "时间范围",
        130,
        134,
        "未来十年"
      ],
      [
        "T7",
        "营业收入",
        136,
        138,
        "收入"
      ],
      [
        "T8",
        "地点范围",
        69,
        71,
        "全球"
      ],
      [
        "T9",
        "时间范围",
        15,
        18,
        "中长期"
      ],
      [
        "T10",
        "时间范围",
        25,
        28,
        "中长期"
      ],
      [
        "T11",
        "地点范围",
        31,
        33,
        "全球"
      ],
      [
        "T12",
        "龙头企业",
        66,
        68,
        "龙头"
      ],
      [
        "T13",
        "地点范围",
        64,
        66,
        "本土"
      ]
    ]
  },
  {
    "id": 280,
    "text": "药明康德在全球药物发现领域市场份额位居前列，且有望进一步提升份额。根据公司招股书披露，2017年公司小分子药物发现收入 32.03亿元，预计占全球药物发现 CRO市场份额的 4.8%。根据我们推算，2020年公司药物发现业务全球市场份额预计提升到 6.6%，位居全球前三。我们预计未来公司市场份额有望持续提升，主要由于：1）国内药物发现 CRO市场占全球比例的逐步提升， 公司作为国内龙头，将分享国内创新药成长红利；2）基于前沿新技术的药物发现平台将吸引更多订单；3）公司成熟的研发体系和过往的研发记录为公司建立了良好的声誉。",
    "labels": [
      [
        "T0",
        "公司",
        0,
        4,
        "药明康德"
      ],
      [
        "T1",
        "地点范围",
        5,
        7,
        "全球"
      ],
      [
        "T2",
        "行业",
        7,
        11,
        "药物发现"
      ],
      [
        "T3",
        "市场份额",
        13,
        17,
        "市场份额"
      ],
      [
        "T4",
        "属性值",
        17,
        21,
        "位居前列"
      ],
      [
        "T5",
        "时间范围",
        43,
        48,
        "2017年"
      ],
      [
        "T6",
        "行业",
        50,
        57,
        "小分子药物发现"
      ],
      [
        "T7",
        "营业收入",
        57,
        59,
        "收入"
      ],
      [
        "T8",
        "属性值",
        60,
        67,
        "32.03亿元"
      ],
      [
        "T9",
        "地点范围",
        71,
        73,
        "全球"
      ],
      [
        "T10",
        "行业",
        73,
        81,
        "药物发现 CRO"
      ],
      [
        "T11",
        "市场份额",
        81,
        85,
        "市场份额"
      ],
      [
        "T12",
        "属性值",
        87,
        91,
        "4.8%"
      ],
      [
        "T13",
        "时间范围",
        99,
        104,
        "2020年"
      ],
      [
        "T14",
        "行业",
        106,
        110,
        "药物发现"
      ],
      [
        "T15",
        "地点范围",
        112,
        114,
        "全球"
      ],
      [
        "T16",
        "市场份额",
        114,
        118,
        "市场份额"
      ],
      [
        "T17",
        "市场份额",
        144,
        148,
        "市场份额"
      ],
      [
        "T18",
        "地点范围",
        162,
        164,
        "国内"
      ],
      [
        "T19",
        "行业",
        164,
        172,
        "药物发现 CRO"
      ],
      [
        "T20",
        "龙头企业",
        192,
        194,
        "龙头"
      ],
      [
        "T21",
        "属性值",
        124,
        128,
        "6.6%"
      ],
      [
        "T22",
        "属性值",
        131,
        135,
        "全球前三"
      ],
      [
        "T23",
        "属性值",
        150,
        154,
        "持续提升"
      ],
      [
        "T24",
        "时间范围",
        140,
        142,
        "未来"
      ],
      [
        "T25",
        "属性值",
        180,
        184,
        "逐步提升"
      ],
      [
        "T26",
        "地点范围",
        175,
        177,
        "全球"
      ],
      [
        "T27",
        "地点范围",
        190,
        192,
        "国内"
      ],
      [
        "T28",
        "地点范围",
        198,
        200,
        "国内"
      ],
      [
        "T29",
        "行业",
        200,
        203,
        "创新药"
      ]
    ]
  },
  {
    "id": 281,
    "text": "个股表现来看，从3月17-4月18日，个股涨幅排名前3的分别是：药明生物（34.60%）＞康龙化成（18.69%）＞泰格医药 （13.09%）＞维亚生物（10.77%）；近1年涨幅排名前3的分别是：博腾股份（58.06%）＞美迪西（21.53%）＞九州药业 （18.53%），整体看3月份CXO个股表现较为稳定，7只个股实现正收益。",
    "labels": [
      [
        "T0",
        "公司",
        32,
        36,
        "药明生物"
      ],
      [
        "T1",
        "公司",
        45,
        49,
        "康龙化成"
      ],
      [
        "T2",
        "公司",
        58,
        62,
        "泰格医药"
      ],
      [
        "T3",
        "公司",
        72,
        76,
        "维亚生物"
      ],
      [
        "T4",
        "时间范围",
        85,
        88,
        "近1年"
      ],
      [
        "T5",
        "公司",
        99,
        103,
        "博腾股份"
      ],
      [
        "T6",
        "公司",
        112,
        115,
        "美迪西"
      ],
      [
        "T7",
        "公司",
        124,
        128,
        "九州药业"
      ],
      [
        "T8",
        "时间范围",
        141,
        144,
        "3月份"
      ],
      [
        "T9",
        "行业",
        144,
        147,
        "CXO"
      ],
      [
        "T10",
        "时间范围",
        7,
        18,
        "从3月17-4月18日"
      ]
    ]
  },
  {
    "id": 283,
    "text": " 2020 Review：①CXO板块保持高景气状态，订单和业绩表现持续提升。 ②板块性经营管理效率提升，人均单产与人均创利稳步成长。③资本开支与固定资产角度，产能加速扩张。④不同细分领域业绩表现有一定差异， CDMO板块景气度持续提升；新技术应用+产业升级+产业转移驱动外需提振，收入增速提升；预计 2021年开始，未来 3-5年中国本土医药创新需求整体增速呈上升态势。  行业驱动因素未发生变化，并且行业基本面有边际改善：①全球产业转移、 海外订单流入；②产业升级；③中国医药创新崛起，加速成长。  2021展望：①中国比较优势明显，疫情或将加速全球产业转移（包括 CXO和 API板块）；②国内外需求旺盛，美国投融资高景气，海外创新需求加速，国内医药创新需求持续加速；③全年来看，药物发现 CRO、临床前 CRO和小分子 CDMO保持高增长，临床 CRO和海外业务板块恢复性增长，拉动 CXO整体增速小幅提振。  国内医药创新趋势来看，未来 5年将逐渐进入临床后期开发和落地兑现阶段，CDMO和临床 CRO细分行业或将迎来国内需求爆发。",
    "labels": [
      [
        "T0",
        "行业",
        15,
        18,
        "CXO"
      ],
      [
        "T1",
        "业绩",
        31,
        33,
        "业绩"
      ],
      [
        "T2",
        "属性值",
        35,
        39,
        "持续提升"
      ],
      [
        "T3",
        "人均利润",
        59,
        63,
        "人均创利"
      ],
      [
        "T4",
        "属性值",
        63,
        67,
        "稳步成长"
      ],
      [
        "T5",
        "行业",
        106,
        110,
        "CDMO"
      ],
      [
        "T6",
        "收入增速",
        142,
        146,
        "收入增速"
      ],
      [
        "T7",
        "属性值",
        146,
        148,
        "提升"
      ],
      [
        "T8",
        "时间范围",
        160,
        167,
        "未来 3-5年"
      ],
      [
        "T9",
        "行业",
        171,
        175,
        "医药创新"
      ],
      [
        "T10",
        "行业需求",
        175,
        177,
        "需求"
      ],
      [
        "T11",
        "地点范围",
        238,
        240,
        "中国"
      ],
      [
        "T12",
        "行业",
        240,
        244,
        "医药创新"
      ],
      [
        "T13",
        "行业",
        288,
        291,
        "CXO"
      ],
      [
        "T14",
        "行业",
        293,
        296,
        "API"
      ],
      [
        "T15",
        "地点范围",
        301,
        304,
        "国内外"
      ],
      [
        "T16",
        "行业需求",
        304,
        306,
        "需求"
      ],
      [
        "T17",
        "属性值",
        306,
        308,
        "旺盛"
      ],
      [
        "T18",
        "地点范围",
        309,
        311,
        "美国"
      ],
      [
        "T19",
        "投融资情况",
        311,
        314,
        "投融资"
      ],
      [
        "T20",
        "属性值",
        314,
        317,
        "高景气"
      ],
      [
        "T21",
        "地点范围",
        318,
        320,
        "海外"
      ],
      [
        "T22",
        "地点范围",
        327,
        329,
        "国内"
      ],
      [
        "T23",
        "行业",
        329,
        333,
        "医药创新"
      ],
      [
        "T24",
        "行业需求",
        333,
        335,
        "需求"
      ],
      [
        "T25",
        "属性值",
        335,
        339,
        "持续加速"
      ],
      [
        "T26",
        "行业",
        346,
        354,
        "药物发现 CRO"
      ],
      [
        "T27",
        "行业",
        355,
        362,
        "临床前 CRO"
      ],
      [
        "T28",
        "行业",
        363,
        371,
        "小分子 CDMO"
      ],
      [
        "T29",
        "行业",
        377,
        383,
        "临床 CRO"
      ],
      [
        "T30",
        "行业",
        399,
        402,
        "CXO"
      ],
      [
        "T31",
        "地点范围",
        414,
        416,
        "国内"
      ],
      [
        "T32",
        "行业",
        416,
        420,
        "医药创新"
      ],
      [
        "T33",
        "行业趋势",
        420,
        422,
        "趋势"
      ],
      [
        "T34",
        "时间范围",
        425,
        430,
        "未来 5年"
      ],
      [
        "T35",
        "行业",
        449,
        453,
        "CDMO"
      ],
      [
        "T36",
        "行业",
        454,
        460,
        "临床 CRO"
      ],
      [
        "T37",
        "地点范围",
        468,
        470,
        "国内"
      ],
      [
        "T38",
        "行业需求",
        470,
        472,
        "需求"
      ],
      [
        "T39",
        "属性值",
        472,
        474,
        "爆发"
      ],
      [
        "T40",
        "在手订单",
        28,
        30,
        "订单"
      ],
      [
        "T41",
        "CAPEX资本开支",
        69,
        73,
        "资本开支"
      ],
      [
        "T42",
        "固定资产",
        74,
        78,
        "固定资产"
      ],
      [
        "T43",
        "产能",
        81,
        83,
        "产能"
      ],
      [
        "T44",
        "属性值",
        83,
        87,
        "加速扩张"
      ],
      [
        "T45",
        "时间范围",
        152,
        159,
        "2021年开始"
      ],
      [
        "T46",
        "属性值",
        179,
        186,
        "增速呈上升态势"
      ],
      [
        "T47",
        "地点范围",
        167,
        171,
        "中国本土"
      ],
      [
        "T48",
        "地点范围",
        224,
        226,
        "海外"
      ],
      [
        "T49",
        "地点范围",
        216,
        218,
        "全球"
      ],
      [
        "T50",
        "时间范围",
        255,
        259,
        "2021"
      ],
      [
        "T51",
        "地点范围",
        263,
        265,
        "中国"
      ],
      [
        "T52",
        "地点范围",
        384,
        386,
        "海外"
      ],
      [
        "T53",
        "属性值",
        433,
        448,
        "进入临床后期开发和落地兑现阶段"
      ]
    ]
  },
  {
    "id": 285,
    "text": "全球医药研发投入稳定增长，属于快速增长阶段，中国医药研发投入年均增长率高于全球，全球研发管线稳步上升，驱动CXO行业发展",
    "labels": [
      [
        "T0",
        "行业",
        2,
        4,
        "医药"
      ],
      [
        "T1",
        "研发费用",
        4,
        8,
        "研发投入"
      ],
      [
        "T2",
        "属性值",
        8,
        12,
        "稳定增长"
      ],
      [
        "T3",
        "地点范围",
        0,
        2,
        "全球"
      ],
      [
        "T4",
        "地点范围",
        22,
        24,
        "中国"
      ],
      [
        "T5",
        "行业",
        24,
        26,
        "医药"
      ],
      [
        "T6",
        "研发费用",
        26,
        30,
        "研发投入"
      ],
      [
        "T7",
        "行业",
        53,
        56,
        "CXO"
      ],
      [
        "T8",
        "属性值",
        30,
        39,
        "年均增长率高于全球"
      ]
    ]
  },
  {
    "id": 287,
    "text": "凯莱英财务数据良好，深度推进客户关系，，与多家跨国龙头药企已经建立合作关系，同时积极招揽人四分位属性 www.leadleo.com",
    "labels": [
      [
        "T0",
        "公司",
        0,
        3,
        "凯莱英"
      ],
      [
        "T1",
        "行业公司",
        27,
        29,
        "药企"
      ],
      [
        "T2",
        "属性值",
        7,
        9,
        "良好"
      ],
      [
        "T3",
        "财务情况",
        3,
        7,
        "财务数据"
      ],
      [
        "T4",
        "龙头企业",
        25,
        27,
        "龙头"
      ]
    ]
  },
  {
    "id": 288,
    "text": ".康龙化成属于CRO+CDMO共同布局的公司，主要服务有临床研究服务、CMC服务和实验室；2017-2020年，凯莱英与泰格医药毛利率略高于药明康德与康龙化成·实验室服务是康龙化成的明星业务，CMC业务增长缓慢，原因在于2020年疫情影响导致工厂停工，临床研究服务布局较晚，但增长较快",
    "labels": [
      [
        "T0",
        "公司",
        1,
        5,
        "康龙化成"
      ],
      [
        "T1",
        "行业",
        7,
        10,
        "CRO"
      ],
      [
        "T2",
        "行业",
        11,
        15,
        "CDMO"
      ],
      [
        "T3",
        "主营业务",
        23,
        27,
        "主要服务"
      ],
      [
        "T4",
        "属性值",
        28,
        44,
        "临床研究服务、CMC服务和实验室"
      ],
      [
        "T5",
        "时间范围",
        45,
        55,
        "2017-2020年"
      ],
      [
        "T6",
        "公司",
        56,
        59,
        "凯莱英"
      ],
      [
        "T7",
        "公司",
        60,
        64,
        "泰格医药"
      ],
      [
        "T8",
        "毛利",
        64,
        67,
        "毛利率"
      ],
      [
        "T9",
        "公司",
        70,
        74,
        "药明康德"
      ],
      [
        "T10",
        "公司",
        75,
        79,
        "康龙化成"
      ],
      [
        "T11",
        "公司",
        86,
        90,
        "康龙化成"
      ],
      [
        "T12",
        "时间范围",
        110,
        115,
        "2020年"
      ],
      [
        "T13",
        "行业",
        80,
        85,
        "实验室服务"
      ],
      [
        "T14",
        "行业",
        96,
        99,
        "CMC"
      ],
      [
        "T15",
        "行业",
        126,
        132,
        "临床研究服务"
      ]
    ]
  },
  {
    "id": 289,
    "text": "4.2.3、博腾股份：原料药生产商华丽转身，布局细胞基因治疗赛道跨越式发展的原料药企业。2017 年以前博腾股份以小分子原料药生产（CMO） 为主，其后加强开发能力转型小分子 CDMO。2018 博腾股份成立子公司苏州博腾生物， 跨越式进军 CGT CDMO。 苏州博腾生物已建成细胞治疗工艺平台与 GMP 生产车间，可以提供质粒、病毒载体及 CAR-T 等细胞疗法的工艺开发及生产服务，是我国少有可提供免疫细胞 CDMO 服务的公司。 作为传统小分子 CDMO 转型公司，博腾股份积极打造国际化团队建设 CGT CDMO 能力，引入了 Sander van Deventer 博士担任首席科学官。 Deventer 博士是首个 FDA 批准上市的基因药物 Glybera 主要开发人， 具备丰富的 CGT 药物开发及生产经验。 目前公司已打造具有一流水平的质粒、 病毒、 细胞培养平台， 其中基于昆虫细胞的慢病毒悬浮无血清培养工艺具有领先优势。 此外公司可以提供多类免疫细胞治疗产品 CDMO 服务，包括 CAR-T、TCR-T、CAR-NK 等，着力打造自动化密闭式的细胞生产线，并成功和南京卡提医学、博生吉医药、凯地生物等合作开发细胞疗法。",
    "labels": [
      [
        "T0",
        "公司",
        6,
        10,
        "博腾股份"
      ],
      [
        "T1",
        "行业公司",
        38,
        43,
        "原料药企业"
      ],
      [
        "T2",
        "公司",
        52,
        56,
        "博腾股份"
      ],
      [
        "T3",
        "行业",
        57,
        70,
        "小分子原料药生产（CMO）"
      ],
      [
        "T4",
        "行业",
        84,
        92,
        "小分子 CDMO"
      ],
      [
        "T5",
        "时间范围",
        93,
        97,
        "2018"
      ],
      [
        "T6",
        "公司",
        98,
        102,
        "博腾股份"
      ],
      [
        "T7",
        "公司",
        107,
        113,
        "苏州博腾生物"
      ],
      [
        "T8",
        "行业",
        121,
        129,
        "CGT CDMO"
      ],
      [
        "T9",
        "公司",
        131,
        137,
        "苏州博腾生物"
      ],
      [
        "T10",
        "行业",
        202,
        211,
        "免疫细胞 CDMO"
      ],
      [
        "T11",
        "行业",
        223,
        231,
        "小分子 CDMO"
      ],
      [
        "T12",
        "公司",
        237,
        241,
        "博腾股份"
      ],
      [
        "T13",
        "行业",
        253,
        261,
        "CGT CDMO"
      ],
      [
        "T14",
        "行业",
        443,
        447,
        "CDMO"
      ],
      [
        "T15",
        "公司",
        496,
        502,
        "南京卡提医学"
      ],
      [
        "T16",
        "公司",
        503,
        508,
        "博生吉医药"
      ],
      [
        "T17",
        "公司",
        509,
        513,
        "凯地生物"
      ],
      [
        "T18",
        "行业",
        11,
        14,
        "原料药"
      ],
      [
        "T19",
        "行业",
        24,
        30,
        "细胞基因治疗"
      ],
      [
        "T20",
        "时间范围",
        44,
        52,
        "2017 年以前"
      ],
      [
        "T21",
        "地点范围",
        195,
        197,
        "我国"
      ]
    ]
  },
  {
    "id": 291,
    "text": "收入体量国内居前，持续稳健增长。我们选取国内 CDMO/CMO行业龙头康龙化成（CMC业务）、凯莱英、博腾股份、九洲药业（仅纳入专利原料药业务收入）、药明生物（业务以生物药 CDMO为主，可比性略低，仅供列示参考）进行对比。药明康德的 CDMO业务收入体量较大，并且在高基数的情况下增速仍保持在行业前列。",
    "labels": [
      [
        "T0",
        "地点范围",
        4,
        6,
        "国内"
      ],
      [
        "T1",
        "地点范围",
        20,
        22,
        "国内"
      ],
      [
        "T2",
        "行业",
        23,
        31,
        "CDMO/CMO"
      ],
      [
        "T3",
        "龙头企业",
        33,
        35,
        "龙头"
      ],
      [
        "T4",
        "公司",
        35,
        39,
        "康龙化成"
      ],
      [
        "T5",
        "公司",
        47,
        50,
        "凯莱英"
      ],
      [
        "T6",
        "公司",
        51,
        55,
        "博腾股份"
      ],
      [
        "T7",
        "公司",
        56,
        60,
        "九洲药业"
      ],
      [
        "T8",
        "公司",
        75,
        79,
        "药明生物"
      ],
      [
        "T9",
        "行业",
        83,
        91,
        "生物药 CDMO"
      ],
      [
        "T10",
        "公司",
        112,
        116,
        "药明康德"
      ],
      [
        "T11",
        "行业",
        118,
        122,
        "CDMO"
      ],
      [
        "T12",
        "属性值",
        128,
        130,
        "较大"
      ],
      [
        "T13",
        "收入增速",
        141,
        143,
        "增速"
      ],
      [
        "T14",
        "营业收入",
        124,
        126,
        "收入"
      ],
      [
        "T15",
        "属性值",
        144,
        151,
        "保持在行业前列"
      ]
    ]
  },
  {
    "id": 292,
    "text": "东方生物：经此新冠一“疫”，奠定 POCT龙头地位，积极补强其它 IVD领域， 国内外市场双轮驱动，持续成长可期。 华大基因：华大因源新冠抗原检测试剂已获得自测资质，公司作为基因测序龙头公司，加大研发创新，借助新冠打开 IVD 全球化之路。",
    "labels": [
      [
        "T0",
        "公司",
        0,
        4,
        "东方生物"
      ],
      [
        "T1",
        "行业",
        17,
        21,
        "POCT"
      ],
      [
        "T2",
        "龙头企业",
        21,
        23,
        "龙头"
      ],
      [
        "T3",
        "公司",
        58,
        62,
        "华大基因"
      ],
      [
        "T4",
        "龙头企业",
        91,
        95,
        "龙头公司"
      ],
      [
        "T5",
        "行业",
        87,
        91,
        "基因测序"
      ],
      [
        "T6",
        "行业",
        33,
        36,
        "IVD"
      ],
      [
        "T7",
        "地点范围",
        40,
        43,
        "国内外"
      ],
      [
        "T8",
        "行业",
        110,
        113,
        "IVD"
      ]
    ]
  },
  {
    "id": 293,
    "text": "下，我们认为国内 CXO企业的头部效应未来有望进一步显现——具体来看，药明康德 2020年完成或发起了对明捷医药、BMS库威工厂和 OXGENE的收购， 继续加强在临床前研究、制剂和细胞/基因疗法 CDMO的国际化服务能力；药明生物先后完成或发起了对拜耳位于德国的两个工厂、辉瑞中国位于杭州的生物药生产基地以及苏桥生物的收购，进一步提升公司生物药原液及制剂产能；泰格医药主要完成了对北京雅信诚（医学翻译和注册）和上海谋思（早期临床/临床药理）的控股，以及通过方达收购 Biotranex和 ACME，继续加强 DMPK、药物发现和早期开发的能力；凯莱英完成收购冠勤医药，加强公司在临床前及临床的综合 CRO服务能力；昭衍新药在 2019年底完成收购 Biomere，加快推进国际化； 九洲药业在 2019 年底完成对苏州诺华工厂的收购，并进一步完成收购 PharmAgra Labs和 PharmAgra，拓展其在欧美市场的 CRO/CDMO研发业务； 维亚生物通过先后收购 SYNthesis全部股权和朗华制药 80%的股权，加强全产业链布局；成都先导 2020年收购英国 Vernalis（SBDD/FBDD）进一步完善公司的新药筛选和优化能力；药石科技则在 2021年初完成对浙江晖石（CDMO生产平台）的控股。",
    "labels": [
      [
        "T0",
        "地点范围",
        6,
        8,
        "国内"
      ],
      [
        "T1",
        "行业公司",
        9,
        14,
        "CXO企业"
      ],
      [
        "T2",
        "公司",
        35,
        39,
        "药明康德"
      ],
      [
        "T3",
        "时间范围",
        40,
        45,
        "2020年"
      ],
      [
        "T4",
        "公司",
        52,
        56,
        "明捷医药"
      ],
      [
        "T5",
        "公司",
        57,
        64,
        "BMS库威工厂"
      ],
      [
        "T6",
        "公司",
        66,
        72,
        "OXGENE"
      ],
      [
        "T7",
        "公司",
        112,
        116,
        "药明生物"
      ],
      [
        "T8",
        "公司",
        155,
        159,
        "苏桥生物"
      ],
      [
        "T9",
        "公司",
        181,
        185,
        "泰格医药"
      ],
      [
        "T10",
        "公司",
        191,
        196,
        "北京雅信诚"
      ],
      [
        "T11",
        "公司",
        206,
        210,
        "上海谋思"
      ],
      [
        "T12",
        "公司",
        234,
        243,
        "Biotranex"
      ],
      [
        "T13",
        "公司",
        245,
        249,
        "ACME"
      ],
      [
        "T14",
        "公司",
        273,
        276,
        "凯莱英"
      ],
      [
        "T15",
        "公司",
        280,
        284,
        "冠勤医药"
      ],
      [
        "T16",
        "公司",
        308,
        312,
        "昭衍新药"
      ],
      [
        "T17",
        "时间范围",
        314,
        319,
        "2019年"
      ],
      [
        "T18",
        "公司",
        325,
        332,
        "Biomere"
      ],
      [
        "T19",
        "公司",
        342,
        346,
        "九洲药业"
      ],
      [
        "T20",
        "时间范围",
        348,
        354,
        "2019 年"
      ],
      [
        "T21",
        "公司",
        377,
        391,
        "PharmAgra Labs"
      ],
      [
        "T22",
        "公司",
        393,
        402,
        "PharmAgra"
      ],
      [
        "T23",
        "公司",
        427,
        431,
        "维亚生物"
      ],
      [
        "T24",
        "公司",
        438,
        447,
        "SYNthesis"
      ],
      [
        "T25",
        "公司",
        452,
        456,
        "朗华制药"
      ],
      [
        "T26",
        "公司",
        473,
        477,
        "成都先导"
      ],
      [
        "T27",
        "时间范围",
        478,
        483,
        "2020年"
      ],
      [
        "T28",
        "公司",
        488,
        496,
        "Vernalis"
      ],
      [
        "T29",
        "公司",
        525,
        529,
        "药石科技"
      ],
      [
        "T30",
        "时间范围",
        532,
        537,
        "2021年"
      ],
      [
        "T31",
        "公司",
        541,
        545,
        "浙江晖石"
      ],
      [
        "T32",
        "公司",
        358,
        362,
        "苏州诺华"
      ],
      [
        "T33",
        "地点范围",
        407,
        409,
        "欧美"
      ],
      [
        "T34",
        "行业",
        413,
        423,
        "CRO/CDMO研发"
      ],
      [
        "T35",
        "行业",
        546,
        554,
        "CDMO生产平台"
      ],
      [
        "T36",
        "公司",
        125,
        127,
        "拜耳"
      ],
      [
        "T37",
        "地点范围",
        129,
        131,
        "德国"
      ],
      [
        "T38",
        "公司",
        137,
        141,
        "辉瑞中国"
      ],
      [
        "T39",
        "地点范围",
        143,
        145,
        "杭州"
      ],
      [
        "T40",
        "行业",
        146,
        149,
        "生物药"
      ],
      [
        "T41",
        "行业",
        197,
        204,
        "医学翻译和注册"
      ],
      [
        "T42",
        "行业",
        211,
        220,
        "早期临床/临床药理"
      ],
      [
        "T43",
        "公司",
        229,
        231,
        "方达"
      ]
    ]
  },
  {
    "id": 294,
    "text": "2020年全球Biotech研发投入占整体比例约30%，投融资占比仅14%。参考以上对全球创新药Biotech研发投入测算，我们也统计了国际上研发投入Top14的MNC巨头研发投入金额，我们发现2020年罗氏、默克、强生等研发投入Top14MNC巨头总研发投入金额高达1200亿美金，这一数值是全球Biotech研发投入金额的一倍（前文测算结果 2020年全球Biotech研发投入在586亿美元）多。如果再拆分全球创新药PE/VC融资金额（就是市场上一直跟踪最为密切的投融资数据）年化研发投入体量可以看到：2020年投融资年化的研发投入占全球创新药研发投入比例仅为13.81%，另外研发投入的15.76% 来自于Biotech寻求IPO或者上市后定增/配售带来的融资年化研发投入。",
    "labels": [
      [
        "T0",
        "时间范围",
        -1,
        5,
        ""
      ],
      [
        "T1",
        "地点范围",
        5,
        7,
        "全球"
      ],
      [
        "T2",
        "行业",
        7,
        14,
        "Biotech"
      ],
      [
        "T3",
        "研发费用",
        14,
        18,
        "研发投入"
      ],
      [
        "T4",
        "投融资情况",
        28,
        31,
        "投融资"
      ],
      [
        "T5",
        "地点范围",
        43,
        45,
        "全球"
      ],
      [
        "T6",
        "行业",
        45,
        55,
        "创新药Biotech"
      ],
      [
        "T7",
        "研发费用",
        55,
        59,
        "研发投入"
      ],
      [
        "T8",
        "研发费用",
        71,
        75,
        "研发投入"
      ],
      [
        "T9",
        "时间范围",
        97,
        102,
        "2020年"
      ],
      [
        "T10",
        "公司",
        102,
        104,
        "罗氏"
      ],
      [
        "T11",
        "公司",
        105,
        107,
        "默克"
      ],
      [
        "T12",
        "公司",
        108,
        110,
        "强生"
      ],
      [
        "T13",
        "行业公司",
        75,
        86,
        "Top14的MNC巨头"
      ],
      [
        "T14",
        "研发费用",
        111,
        115,
        "研发投入"
      ],
      [
        "T15",
        "行业公司",
        115,
        125,
        "Top14MNC巨头"
      ],
      [
        "T16",
        "研发费用",
        126,
        130,
        "研发投入"
      ],
      [
        "T17",
        "属性值",
        134,
        141,
        "1200亿美金"
      ],
      [
        "T18",
        "行业",
        149,
        156,
        "Biotech"
      ],
      [
        "T19",
        "研发费用",
        156,
        160,
        "研发投入"
      ],
      [
        "T20",
        "时间范围",
        173,
        178,
        "2020年"
      ],
      [
        "T21",
        "行业",
        180,
        187,
        "Biotech"
      ],
      [
        "T22",
        "地点范围",
        178,
        180,
        "全球"
      ],
      [
        "T23",
        "研发费用",
        187,
        191,
        "研发投入"
      ],
      [
        "T24",
        "属性值",
        192,
        198,
        "586亿美元"
      ],
      [
        "T25",
        "行业",
        208,
        211,
        "创新药"
      ],
      [
        "T26",
        "投融资金额",
        216,
        220,
        "融资金额"
      ],
      [
        "T27",
        "时间范围",
        254,
        259,
        "2020年"
      ],
      [
        "T28",
        "投融资金额",
        259,
        262,
        "投融资"
      ],
      [
        "T29",
        "行业",
        272,
        275,
        "创新药"
      ],
      [
        "T30",
        "研发费用",
        275,
        279,
        "研发投入"
      ],
      [
        "T31",
        "研发费用",
        292,
        296,
        "研发投入"
      ],
      [
        "T32",
        "行业",
        307,
        314,
        "Biotech"
      ],
      [
        "T33",
        "研发费用",
        86,
        90,
        "研发投入"
      ],
      [
        "T34",
        "地点范围",
        147,
        149,
        "全球"
      ],
      [
        "T35",
        "地点范围",
        206,
        208,
        "全球"
      ],
      [
        "T36",
        "研发费用",
        265,
        269,
        "研发投入"
      ]
    ]
  },
  {
    "id": 296,
    "text": "细分赛道龙头：如药石科技（细分领域龙头，Q1利润端超预期，砌块的高壁垒以及较快的产能释放节奏预期带来全年较快增速，创新药 CDMO 有潜在弹性催化",
    "labels": [
      [
        "T0",
        "龙头企业",
        4,
        6,
        "龙头"
      ],
      [
        "T1",
        "公司",
        8,
        12,
        "药石科技"
      ],
      [
        "T2",
        "龙头企业",
        17,
        19,
        "龙头"
      ],
      [
        "T3",
        "时间范围",
        20,
        22,
        "Q1"
      ],
      [
        "T4",
        "属性值",
        25,
        28,
        "超预期"
      ],
      [
        "T5",
        "行业",
        57,
        65,
        "创新药 CDMO"
      ],
      [
        "T6",
        "利润",
        22,
        25,
        "利润端"
      ],
      [
        "T7",
        "产能",
        40,
        42,
        "产能"
      ],
      [
        "T8",
        "属性值",
        42,
        44,
        "释放"
      ]
    ]
  },
  {
    "id": 298,
    "text": "2017年公司战略转型后，客户与产品结构呈多样化，大客户及大产品集中度得到明显改善，抗风险能力不断增强。",
    "labels": [
      [
        "T0",
        "时间范围",
        0,
        5,
        "2017年"
      ]
    ]
  },
  {
    "id": 299,
    "text": " 从中国医药研发外包服务行业整体的发展历史来看，全球产业转移、海外订单流入是中国 CXO产业快速发展的核心因素，根据国金医药大数据中心的统计，上市公司维度，CXO板块的整体收入（剔除非 CXO收入后）中， 海外收入占比超过 2/3（如前述图表 11所示）。近年来，国内医药创新迅速崛起（规模药企转型+国内 biotech兴起），来自国内的收入持续快速增长。  全球产业转移，海外订单流入：全球医药研发外包需求旺盛与欧美 CXO 产能扩张速度不匹配，带来全球 CXO产业向新兴的国家和地区转移。在产业转移的过程中，与印度、越南等其他新兴国家相比，中国具有全方位的比较优势，包括人力成本（工程师红利）、患者、政策、化工基础与基础设施建设、技术水平、质量管理体系、知识产权保护体系等全方位的优势， 成为产业转移的主要目的地。",
    "labels": [
      [
        "T0",
        "行业",
        5,
        13,
        "医药研发外包服务"
      ],
      [
        "T1",
        "地点范围",
        3,
        5,
        "中国"
      ],
      [
        "T2",
        "地点范围",
        39,
        41,
        "中国"
      ],
      [
        "T3",
        "行业",
        42,
        45,
        "CXO"
      ],
      [
        "T4",
        "行业",
        79,
        82,
        "CXO"
      ],
      [
        "T5",
        "行业",
        94,
        97,
        "CXO"
      ],
      [
        "T6",
        "时间范围",
        129,
        132,
        "近年来"
      ],
      [
        "T7",
        "地点范围",
        133,
        135,
        "国内"
      ],
      [
        "T8",
        "行业",
        135,
        139,
        "医药创新"
      ],
      [
        "T9",
        "行业公司",
        146,
        148,
        "药企"
      ],
      [
        "T10",
        "地点范围",
        151,
        153,
        "国内"
      ],
      [
        "T11",
        "地点范围",
        167,
        169,
        "国内"
      ],
      [
        "T12",
        "营业收入",
        170,
        172,
        "收入"
      ],
      [
        "T13",
        "行业",
        198,
        204,
        "医药研发外包"
      ],
      [
        "T14",
        "行业需求",
        204,
        206,
        "需求"
      ],
      [
        "T15",
        "属性值",
        206,
        208,
        "旺盛"
      ],
      [
        "T16",
        "地点范围",
        196,
        198,
        "全球"
      ],
      [
        "T17",
        "行业",
        231,
        234,
        "CXO"
      ],
      [
        "T18",
        "地点范围",
        25,
        27,
        "全球"
      ],
      [
        "T19",
        "地点范围",
        32,
        34,
        "海外"
      ],
      [
        "T20",
        "营业收入",
        87,
        89,
        "收入"
      ],
      [
        "T21",
        "营业收入",
        97,
        99,
        "收入"
      ],
      [
        "T22",
        "地点范围",
        104,
        106,
        "海外"
      ],
      [
        "T23",
        "行业",
        154,
        161,
        "biotech"
      ],
      [
        "T24",
        "属性值",
        174,
        178,
        "快速增长"
      ],
      [
        "T25",
        "地点范围",
        182,
        184,
        "全球"
      ],
      [
        "T26",
        "地点范围",
        189,
        191,
        "海外"
      ],
      [
        "T27",
        "地点范围",
        209,
        211,
        "欧美"
      ],
      [
        "T28",
        "行业",
        212,
        215,
        "CXO"
      ],
      [
        "T29",
        "产能",
        216,
        218,
        "产能"
      ],
      [
        "T30",
        "地点范围",
        228,
        230,
        "全球"
      ],
      [
        "T31",
        "属性值",
        236,
        247,
        "向新兴的国家和地区转移"
      ],
      [
        "T32",
        "地点范围",
        274,
        276,
        "中国"
      ],
      [
        "T33",
        "地点范围",
        259,
        261,
        "印度"
      ],
      [
        "T34",
        "地点范围",
        262,
        264,
        "越南"
      ]
    ]
  },
  {
    "id": 302,
    "text": "• 随着Battle Pass引领的第三次付费创新，腾讯率先在旗下中度竞技游戏中（ 《王者荣耀》《和平精英》等）广泛应用，并逐步渗透到重度品类，腾讯手游19-20年付费率逐步站上新台阶。",
    "labels": [
      [
        "T0",
        "公司",
        26,
        28,
        "腾讯"
      ],
      [
        "T1",
        "公司",
        72,
        74,
        "腾讯"
      ],
      [
        "T2",
        "行业",
        74,
        76,
        "手游"
      ],
      [
        "T3",
        "时间范围",
        76,
        82,
        "19-20年"
      ]
    ]
  },
  {
    "id": 303,
    "text": " 创新药存量逐年加大、内卷加剧，叠加医保控费的大背景下，创新出海已成大势所趋。2015年以来CDE新药审评速度明显加快，每年上市新药数量明显增多，整个市场上新药存量数量持续累积增加。然而，在医保资金相对不足的大背景下，为了保障更多的病种和覆盖更广泛的患者，通过医保谈判限制上市药物价格成为有效的政策调控手段。可以预见未来纳入集采和医保谈判的药物覆盖率将会持续扩大，为避免“医保天花板”，创新药走出国门，推动管线出海成为创新药企业最佳选择。",
    "labels": [
      [
        "T0",
        "行业",
        2,
        5,
        "创新药"
      ],
      [
        "T1",
        "行业公司",
        210,
        215,
        "创新药企业"
      ],
      [
        "T2",
        "行业",
        194,
        197,
        "创新药"
      ],
      [
        "T3",
        "时间范围",
        40,
        47,
        "2015年以来"
      ],
      [
        "T4",
        "属性值",
        29,
        33,
        "创新出海"
      ]
    ]
  },
  {
    "id": 304,
    "text": "近期国内外新冠治疗特效药不断取得突破进展。我国自去年疫情初期即开始布局疫苗+药物研发任务，2020年 2月 16日设立由科技部、卫生健康委、工信部、发改委、药监局、中医药局等部门组成的科研攻关组药物研发专班，组织全国优势专家团队，围绕临床救治需求，全力推进了有效药物和治疗技术研发工作。现有在研新冠病毒的抗病毒治疗药物主要包括中和抗体药物和小分子药物，主要围绕抑制病毒复制、阻断病毒进入细胞、调节人体免疫系统 3条技术路线，国内外临床试验正有序进展。 路线一：抑制病毒复制路线，主要靶标是病毒复制酶和蛋白酶，作用目标是宿主细胞，一般为小分子药物。国内口服新冠药阿兹夫定是由河南大学/真实生物研发的一种抗艾滋病 1类新药，属于新型核苷类逆转录酶和辅助蛋白 Vif抑制剂，已于 7月 21日有条件批准上市。临床研究发现，药物针对新冠肺炎在细胞水平和动物水平同样具有良好的抗病毒活性，目前正在中国、巴西、俄罗斯开展 III期临床试验。开拓药业是阿兹夫定原料药生产商。普克鲁胺是开拓药业自主研发的新一代雄激素受体（AR）拮抗剂和降解剂，具有竞争抑制 AR和下调 AR表达的双重药物机制。下调新冠病毒入侵宿主细胞的两个关键蛋白——ACE2和 TMPRSS2的表达水平，阻止新冠病毒入侵宿主细胞进行复制。目前正在美国、巴西、南非等国家开展治疗轻中症新冠患者的Ⅲ期全球多中心临床试验（MRCT）；正在中国、巴西、马来西亚、菲律宾等国家开展治疗轻中症新冠患者的Ⅲ期 MRCT；正在中国、美国、菲律宾、巴西等国家开展治疗重症住院新冠患者的Ⅲ 期 MRCT。另外，先声药业/中国科学院上海药物所研发的抗新冠小分子药物 SIM0417 系列， SIM0417针对新冠病毒复制必须的关键蛋白酶 3CL，由于该蛋白酶的高度保守性， SIM0417对多种新冠变异株，包括高传染性的德尔塔株，有很强的抑制作用。另外，君实生物和国内多家科研机构（上海药物所、武汉病毒所等）合作口服核苷类抗新冠病毒药物 VV116在乌兹别克斯坦获批进入临床，国内正处于临床申请阶段。 路线二：阻断病毒进入细胞，主要原理是指通过阻碍病毒 s蛋白与介导病毒进入人体细胞的关键受体结合，来阻断病毒进入细胞，作用目标是病毒粒子表面 s蛋白或宿主细胞膜受体，一般是中和抗体大分子和多肽类药物。国内 EUA获批的腾盛博药的 BRII- 196/BRII-198单抗联合疗法和美国 EUA获批的君实生物/礼来 JS016新冠中和抗体联合疗法是此技术路线代表性品种。另外，君实生物还有 JS026注射液获批临床，是一种重组全人源单克隆抗体，具有广谱抗新冠病毒能力，可覆盖德尔塔等多种变异株。中科院微生物所与翰宇药业合作的抗新型冠状病毒多肽鼻喷剂药物则是一种非中和抗体的大",
    "labels": [
      [
        "T0",
        "公司",
        291,
        295,
        "真实生物"
      ],
      [
        "T1",
        "公司",
        414,
        418,
        "开拓药业"
      ],
      [
        "T2",
        "公司",
        435,
        439,
        "开拓药业"
      ],
      [
        "T3",
        "公司",
        672,
        676,
        "先声药业"
      ],
      [
        "T4",
        "公司",
        793,
        797,
        "君实生物"
      ],
      [
        "T5",
        "公司",
        975,
        979,
        "腾盛博药"
      ],
      [
        "T6",
        "公司",
        1015,
        1019,
        "君实生物"
      ],
      [
        "T7",
        "公司",
        1053,
        1057,
        "君实生物"
      ],
      [
        "T8",
        "公司",
        1120,
        1124,
        "翰宇药业"
      ],
      [
        "T9",
        "地点范围",
        21,
        23,
        "我国"
      ],
      [
        "T10",
        "时间范围",
        24,
        26,
        "去年"
      ],
      [
        "T11",
        "时间范围",
        45,
        57,
        "2020年 2月 16日"
      ],
      [
        "T12",
        "地点范围",
        212,
        215,
        "国内外"
      ],
      [
        "T13",
        "地点范围",
        273,
        275,
        "国内"
      ],
      [
        "T14",
        "时间范围",
        337,
        343,
        "7月 21日"
      ],
      [
        "T15",
        "行业",
        423,
        426,
        "原料药"
      ],
      [
        "T16",
        "地点范围",
        550,
        552,
        "美国"
      ],
      [
        "T17",
        "地点范围",
        553,
        555,
        "巴西"
      ],
      [
        "T18",
        "地点范围",
        556,
        558,
        "南非"
      ],
      [
        "T19",
        "时间范围",
        546,
        548,
        "目前"
      ],
      [
        "T20",
        "地点范围",
        575,
        577,
        "全球"
      ],
      [
        "T21",
        "地点范围",
        593,
        595,
        "中国"
      ],
      [
        "T22",
        "地点范围",
        596,
        598,
        "巴西"
      ],
      [
        "T23",
        "地点范围",
        599,
        603,
        "马来西亚"
      ],
      [
        "T24",
        "地点范围",
        604,
        607,
        "菲律宾"
      ],
      [
        "T25",
        "地点范围",
        632,
        634,
        "中国"
      ],
      [
        "T26",
        "地点范围",
        635,
        637,
        "美国"
      ],
      [
        "T27",
        "地点范围",
        638,
        641,
        "菲律宾"
      ],
      [
        "T28",
        "地点范围",
        642,
        644,
        "巴西"
      ],
      [
        "T29",
        "地点范围",
        798,
        800,
        "国内"
      ],
      [
        "T30",
        "地点范围",
        854,
        856,
        "国内"
      ],
      [
        "T31",
        "地点范围",
        966,
        968,
        "国内"
      ],
      [
        "T32",
        "时间范围",
        0,
        2,
        "近期"
      ],
      [
        "T33",
        "地点范围",
        2,
        5,
        "国内外"
      ],
      [
        "T34",
        "行业",
        35,
        37,
        "疫苗"
      ],
      [
        "T35",
        "行业",
        38,
        42,
        "药物研发"
      ]
    ]
  },
  {
    "id": 305,
    "text": "• 2020年中国手游市场规模2097亿（yoy+32.6%)，手游规模在整体游戏市场占比75.2% （yoy+6.8pct）。 • 手游行业增长逻辑并非从一而终：1）2011-2014为用户驱动的流量红利期；2）2015-2017为端转手驱动的付费红利期；3）2018-2020一方面是政策波动（版号）+偶然性事件（疫情）驱动的增速回暖和反弹，但另一方面付费驱动的内核并没有变，2020年手游ARPU同比增长 26.5%，而用户规模仅增长4.8%。",
    "labels": [
      [
        "T0",
        "时间范围",
        2,
        7,
        "2020年"
      ],
      [
        "T1",
        "地点范围",
        7,
        9,
        "中国"
      ],
      [
        "T2",
        "行业",
        9,
        11,
        "手游"
      ],
      [
        "T3",
        "市场规模",
        11,
        15,
        "市场规模"
      ],
      [
        "T4",
        "属性值",
        15,
        20,
        "2097亿"
      ],
      [
        "T5",
        "行业",
        32,
        34,
        "手游"
      ],
      [
        "T6",
        "行业",
        67,
        69,
        "手游"
      ],
      [
        "T7",
        "时间范围",
        84,
        93,
        "2011-2014"
      ],
      [
        "T8",
        "时间范围",
        107,
        116,
        "2015-2017"
      ],
      [
        "T9",
        "时间范围",
        131,
        140,
        "2018-2020"
      ],
      [
        "T10",
        "时间范围",
        190,
        195,
        "2020年"
      ],
      [
        "T11",
        "行业",
        195,
        197,
        "手游"
      ],
      [
        "T12",
        "属性值",
        24,
        30,
        "+32.6%"
      ],
      [
        "T13",
        "行业",
        39,
        41,
        "游戏"
      ],
      [
        "T14",
        "市场规模",
        34,
        36,
        "规模"
      ],
      [
        "T15",
        "属性值",
        45,
        50,
        "75.2%"
      ]
    ]
  },
  {
    "id": 306,
    "text": "1）医药外包行业正处于全球黄金发展时期。医药外包行业紧跟最前沿的生物技术，深度参与全球药物研发和生产，协助制药企业降低研发和生产成本。凭借工程师红利，国内医药外包服务人均成本远低于海外同行；近几年国内疫情稳定， 公司可以承接更多的海外订单。",
    "labels": [
      [
        "T0",
        "行业",
        2,
        6,
        "医药外包"
      ],
      [
        "T1",
        "行业",
        20,
        24,
        "医药外包"
      ],
      [
        "T2",
        "地点范围",
        75,
        77,
        "国内"
      ],
      [
        "T3",
        "时间范围",
        95,
        98,
        "近几年"
      ],
      [
        "T4",
        "地点范围",
        98,
        100,
        "国内"
      ],
      [
        "T5",
        "新签订单",
        117,
        119,
        "订单"
      ],
      [
        "T6",
        "地点范围",
        11,
        13,
        "全球"
      ],
      [
        "T7",
        "地点范围",
        41,
        43,
        "全球"
      ],
      [
        "T8",
        "行业公司",
        53,
        57,
        "制药企业"
      ],
      [
        "T9",
        "地点范围",
        90,
        92,
        "海外"
      ],
      [
        "T10",
        "行业",
        77,
        83,
        "医药外包服务"
      ],
      [
        "T11",
        "地点范围",
        115,
        117,
        "海外"
      ]
    ]
  },
  {
    "id": 307,
    "text": "1月 18日，默沙东公布代号为 KEYNOTE-394的 III期临床试验最终结果。该项研究意在评估 Keytruda联合最佳支持治疗在先前接受过索拉非尼治疗的亚洲晚期肝细胞癌患者中的疗效。Keytruda+BSC在主要终点 OS方面表现出显著统计学和临床意义的改善，与安慰剂+BSC相比，患者死亡风险降低了 21%， 中位 OS为 14.6个月，而安慰剂+BSC组中位 OS为 13.0个月。Keytruda+BSC 组患者两年内存活的比例为 34.3%，而安慰剂+BSC组为 24.9%。",
    "labels": [
      [
        "T0",
        "时间范围",
        0,
        6,
        "1月 18日"
      ],
      [
        "T1",
        "公司",
        7,
        10,
        "默沙东"
      ]
    ]
  },
  {
    "id": 308,
    "text": "• 国内CDMO公司继续呈现高速增长、且景气度有上行趋势：核心公司CDMO业务2021年三季报合计实现营业收入127亿元，同比增长 43.9%，呈现超高速增长，其中药明康德、凯莱英、博腾股份、康龙化成继续呈现高速增长。展望2022年，伴随覆盖管线数量的增长以及产能投产的加速，国内核心CDMO供应商有望持续受益、业绩呈现加速趋势。 • 海外CDMO业务呈现快速增长，显著受益于新冠业务的增厚：5家海外CDMO公司2021年前三季度合计实现营业收入46.5亿美元，同比增长30.8%，核心供应商受益于新冠相关产品的增厚继续呈现快速增长。",
    "labels": [
      [
        "T0",
        "地点范围",
        2,
        4,
        "国内"
      ],
      [
        "T1",
        "行业公司",
        4,
        10,
        "CDMO公司"
      ],
      [
        "T2",
        "行业",
        33,
        37,
        "CDMO"
      ],
      [
        "T3",
        "时间范围",
        39,
        46,
        "2021年三季"
      ],
      [
        "T4",
        "营业收入",
        51,
        55,
        "营业收入"
      ],
      [
        "T5",
        "公司",
        82,
        86,
        "药明康德"
      ],
      [
        "T6",
        "公司",
        87,
        90,
        "凯莱英"
      ],
      [
        "T7",
        "公司",
        91,
        95,
        "博腾股份"
      ],
      [
        "T8",
        "公司",
        96,
        100,
        "康龙化成"
      ],
      [
        "T9",
        "时间范围",
        111,
        116,
        "2022年"
      ],
      [
        "T10",
        "产能",
        130,
        132,
        "产能"
      ],
      [
        "T11",
        "地点范围",
        138,
        140,
        "国内"
      ],
      [
        "T12",
        "业绩",
        156,
        158,
        "业绩"
      ],
      [
        "T13",
        "行业",
        170,
        174,
        "CDMO"
      ],
      [
        "T14",
        "行业公司",
        196,
        206,
        "5家海外CDMO公司"
      ],
      [
        "T15",
        "时间范围",
        206,
        215,
        "2021年前三季度"
      ],
      [
        "T16",
        "营业收入",
        219,
        223,
        "营业收入"
      ],
      [
        "T17",
        "属性值",
        223,
        230,
        "46.5亿美元"
      ],
      [
        "T18",
        "属性值",
        235,
        240,
        "30.8%"
      ],
      [
        "T19",
        "属性值",
        55,
        60,
        "127亿元"
      ],
      [
        "T20",
        "属性值",
        66,
        71,
        "43.9%"
      ],
      [
        "T21",
        "行业公司",
        142,
        149,
        "CDMO供应商"
      ],
      [
        "T22",
        "属性值",
        160,
        162,
        "加速"
      ],
      [
        "T23",
        "地点范围",
        168,
        170,
        "海外"
      ],
      [
        "T24",
        "属性值",
        178,
        182,
        "快速增长"
      ]
    ]
  },
  {
    "id": 312,
    "text": "腾讯投资：不只是财务投资，更是着眼于中长期抢占赛道。20年腾讯投资数量与金额创历史新高， 投资组合规模较18年翻近一倍。ToB投资更积极，次数及金额保持稳定较高水平，且分布赛道繁多。 20年腾讯于上市公司的投资粗略测算年化投资回报率为9.56%。腾讯通过投资+并购，并给予业务支持，正在催生越来越多的新巨头，同时并表公司经营良好也为公司利润表带来一定弹性。 维持盈利预测，维持“买入”评级。我们维持盈利预测，预计2021-2023年公司整体收入为 5814/6935/8166亿元，同比增长21%/19%/18%；Non-IFRS归母净利润1400/1738/2074亿元， 同比增长14%/24%/19%，对应PE 34.5/27.8/23.3x。由于腾讯2021年将主动加大投入，用部分利润扩大投资，利润率短期或有压力，因此我们用2022年各业务情况进行分部估值。给予腾讯22 年 6.51万亿人民币目标市值，目标价 822港币 /股。目标市值对应 2021-2023年 PE为 46.5/37.5/31.4x。基于34.8%的上涨空间，维持“买入”评级。 风险提示：数字内容行业监管变化，互联网金融监管变化，反垄断影响，微信电商布局进展不及预期。",
    "labels": [
      [
        "T0",
        "公司",
        29,
        31,
        "腾讯"
      ],
      [
        "T1",
        "时间范围",
        26,
        29,
        "20年"
      ],
      [
        "T2",
        "时间范围",
        52,
        55,
        "18年"
      ],
      [
        "T3",
        "时间范围",
        92,
        95,
        "20年"
      ],
      [
        "T4",
        "公司",
        95,
        97,
        "腾讯"
      ],
      [
        "T5",
        "公司",
        123,
        125,
        "腾讯"
      ],
      [
        "T6",
        "时间范围",
        206,
        216,
        "2021-2023年"
      ],
      [
        "T7",
        "营业收入",
        220,
        222,
        "收入"
      ],
      [
        "T8",
        "归母净利润",
        265,
        270,
        "归母净利润"
      ],
      [
        "T9",
        "PE",
        306,
        308,
        "PE"
      ],
      [
        "T10",
        "公司",
        327,
        329,
        "腾讯"
      ],
      [
        "T11",
        "时间范围",
        329,
        334,
        "2021年"
      ],
      [
        "T12",
        "公司",
        386,
        388,
        "腾讯"
      ],
      [
        "T13",
        "时间范围",
        427,
        437,
        "2021-2023年"
      ],
      [
        "T14",
        "PE",
        438,
        440,
        "PE"
      ],
      [
        "T15",
        "属性值",
        224,
        240,
        "5814/6935/8166亿元"
      ],
      [
        "T16",
        "属性值",
        245,
        256,
        "21%/19%/18%"
      ],
      [
        "T17",
        "属性值",
        309,
        324,
        "34.5/27.8/23.3x"
      ],
      [
        "T18",
        "属性值",
        442,
        457,
        "46.5/37.5/31.4x"
      ],
      [
        "T19",
        "时间范围",
        18,
        21,
        "中长期"
      ],
      [
        "T20",
        "利润",
        168,
        171,
        "利润表"
      ],
      [
        "T21",
        "属性值",
        270,
        303,
        "1400/1738/2074亿元， 同比增长14%/24%/19%"
      ],
      [
        "T22",
        "利润",
        345,
        347,
        "利润"
      ],
      [
        "T23",
        "利润",
        352,
        355,
        "利润率"
      ],
      [
        "T24",
        "时间范围",
        367,
        372,
        "2022年"
      ],
      [
        "T25",
        "市值",
        404,
        406,
        "市值"
      ],
      [
        "T26",
        "时间范围",
        388,
        392,
        "22 年"
      ],
      [
        "T27",
        "属性值",
        393,
        402,
        "6.51万亿人民币"
      ],
      [
        "T28",
        "市值",
        422,
        424,
        "市值"
      ],
      [
        "T29",
        "公司",
        0,
        2,
        "腾讯"
      ]
    ]
  },
  {
    "id": 314,
    "text": "2019年，血制品全行业单位运营浆站年均采浆量为35吨左右。卫光生物单采血浆站采浆能力最强，单位运营浆站年均采浆量 56.6吨，公司旗下平果浆站年采浆量达百吨以上，位全行业年采浆量前三；其次泰邦生物单位运营浆站年均采浆 52吨左右，华兰生物约 40吨，天坛生物、上海莱士、博雅生物单位运营浆站年均采浆量低于行业平均。在增量新设浆站审批和选址困难的前提下，存量浆站的采浆挖潜对企业采浆量提升提供坚实基础。",
    "labels": [
      [
        "T0",
        "公司",
        95,
        99,
        "泰邦生物"
      ],
      [
        "T1",
        "公司",
        116,
        120,
        "华兰生物"
      ],
      [
        "T2",
        "公司",
        126,
        130,
        "天坛生物"
      ],
      [
        "T3",
        "公司",
        131,
        135,
        "上海莱士"
      ],
      [
        "T4",
        "公司",
        136,
        140,
        "博雅生物"
      ],
      [
        "T5",
        "行业",
        6,
        9,
        "血制品"
      ],
      [
        "T6",
        "时间范围",
        0,
        5,
        "2019年"
      ]
    ]
  },
  {
    "id": 315,
    "text": " 2021H1板块总结：上半年疫苗板块实现收入237亿元（+54.2%），归母净利润71.2亿元（+201.5%），扣非归母净利润69.5亿元（ +208.1%）。业绩增速提升系新冠疫苗放量，智飞、康泰合计新冠疫苗收入约52亿元，归母净利润合计约35亿元。目前国内外突破性感染频发，加强针接种已经开展，我们预计新冠疫苗下半年会以出口为主贡献业绩增量。剔除新冠疫苗以外，传统疫苗板块实现收入185亿元（ +20%），归母净利润36.2亿元（+53%），增速有所放缓，主要系新冠疫苗接种带来传统疫苗接种资源紧张，下半年新冠接种有望常态化， 传统疫苗业绩增速有望恢复。  板块盈利能力在新冠疫苗拉动下实现大幅增长。从盈利能力看，上半年行业毛利率为59%（+12pp）、四费率为23%（-4pp）、净利率为 38%（+22pp），其中新冠疫苗的毛利率在80%以上，净利率在60%以上。板块盈利能力主要靠新冠疫苗品种实现大幅提升。  常规重磅品种增速放缓，下半年恢复性增长可期。HPV疫苗来看，因万泰2价HPV于2020Q2才上市销售，所以仅考虑智飞4/9价HPV疫苗， 从批签发数量来看，上半年4/9价HPV实现批签发498.6万支（-14pp），2021H1实现收入约64亿元（+11%），增速同比下降40pp，预计下半年HPV疫苗批签发量将恢复正常增速。13价肺炎疫苗因沃森生物于2020年3月底上市销售，无比较意义。传统重磅疫苗竞争格局清晰， 市场空间广阔，我们预计未来新冠疫苗接种的影响将持续减弱，传统重磅品种将恢复快速增长，同时建议关注在研管线布局中主要解决未满足需求的品种，包括联合疫苗、价次提升、生产工艺的改进等方面。  政策趋严，龙头集中度提升：在疫苗管理办法出台的背景下，对疫苗企业的生产管理等各个环节提出了较高的要求，我们认为国内疫苗行业集中度提升是必然趋势，疫苗行业先发优势将越发明显，重点看好以上市公司和中生集团为代表的疫苗龙头。  平台技术布局引领行业发展趋势。以新冠疫苗为例，拥有多技术路线的平台企业在研发伊始选择性更多，成功概率更大。面对变异较多的流感类病毒，新型技术（mRNA疫苗、DNA疫苗、病毒载体疫苗等）路线的研发速度和保护率更高。从一级市场看，平台型企业吸引的融资额也更多，我们预计国内疫苗企业有望借此次疫情契机，积极布局新技术、完善出口能力、多地区临床能力，从而迎来疫苗行业发展的黄金十年。  投资建议：康泰生物（300601）、智飞生物（300122）、康希诺（688185）、华兰生物（002007）、沃森生物（300142）、万泰生物（ 603392）、康华生物（300841）、欧林生物（688319）、金迪克（688670）、百克生物（688276）。",
    "labels": [
      [
        "T0",
        "行业",
        16,
        18,
        "疫苗"
      ],
      [
        "T1",
        "营业收入",
        22,
        24,
        "收入"
      ],
      [
        "T2",
        "属性值",
        24,
        29,
        "237亿元"
      ],
      [
        "T3",
        "属性值",
        30,
        36,
        "+54.2%"
      ],
      [
        "T4",
        "归母净利润",
        38,
        43,
        "归母净利润"
      ],
      [
        "T5",
        "扣非净利润",
        59,
        66,
        "扣非归母净利润"
      ],
      [
        "T6",
        "业绩",
        83,
        85,
        "业绩"
      ],
      [
        "T7",
        "公司",
        97,
        99,
        "智飞"
      ],
      [
        "T8",
        "公司",
        100,
        102,
        "康泰"
      ],
      [
        "T9",
        "营业收入",
        108,
        110,
        "收入"
      ],
      [
        "T10",
        "归母净利润",
        116,
        121,
        "归母净利润"
      ],
      [
        "T11",
        "行业",
        185,
        189,
        "传统疫苗"
      ],
      [
        "T12",
        "营业收入",
        193,
        195,
        "收入"
      ],
      [
        "T13",
        "属性值",
        195,
        200,
        "185亿元"
      ],
      [
        "T14",
        "属性值",
        202,
        206,
        "+20%"
      ],
      [
        "T15",
        "归母净利润",
        208,
        213,
        "归母净利润"
      ],
      [
        "T16",
        "业绩",
        273,
        275,
        "业绩"
      ],
      [
        "T17",
        "行业",
        269,
        273,
        "传统疫苗"
      ],
      [
        "T18",
        "时间范围",
        313,
        316,
        "上半年"
      ],
      [
        "T19",
        "毛利",
        318,
        321,
        "毛利率"
      ],
      [
        "T20",
        "行业",
        365,
        369,
        "新冠疫苗"
      ],
      [
        "T21",
        "毛利",
        370,
        373,
        "毛利率"
      ],
      [
        "T22",
        "属性值",
        374,
        379,
        "80%以上"
      ],
      [
        "T23",
        "公司",
        446,
        448,
        "万泰"
      ],
      [
        "T24",
        "公司",
        471,
        473,
        "智飞"
      ],
      [
        "T25",
        "时间范围",
        523,
        529,
        "2021H1"
      ],
      [
        "T26",
        "营业收入",
        531,
        533,
        "收入"
      ],
      [
        "T27",
        "属性值",
        533,
        538,
        "约64亿元"
      ],
      [
        "T28",
        "公司",
        586,
        590,
        "沃森生物"
      ],
      [
        "T29",
        "龙头企业",
        723,
        725,
        "龙头"
      ],
      [
        "T30",
        "市场集中度",
        725,
        728,
        "集中度"
      ],
      [
        "T31",
        "属性值",
        728,
        730,
        "提升"
      ],
      [
        "T32",
        "地点范围",
        773,
        775,
        "国内"
      ],
      [
        "T33",
        "行业",
        775,
        777,
        "疫苗"
      ],
      [
        "T34",
        "市场集中度",
        779,
        782,
        "集中度"
      ],
      [
        "T35",
        "属性值",
        782,
        784,
        "提升"
      ],
      [
        "T36",
        "行业",
        790,
        792,
        "疫苗"
      ],
      [
        "T37",
        "公司",
        814,
        818,
        "中生集团"
      ],
      [
        "T38",
        "行业",
        822,
        824,
        "疫苗"
      ],
      [
        "T39",
        "龙头企业",
        824,
        826,
        "龙头"
      ],
      [
        "T40",
        "行业",
        962,
        964,
        "国内"
      ],
      [
        "T41",
        "行业公司",
        964,
        968,
        "疫苗企业"
      ],
      [
        "T42",
        "行业",
        1005,
        1007,
        "疫苗"
      ],
      [
        "T43",
        "公司",
        1025,
        1029,
        "康泰生物"
      ],
      [
        "T44",
        "公司",
        1038,
        1042,
        "智飞生物"
      ],
      [
        "T45",
        "公司",
        1051,
        1054,
        "康希诺"
      ],
      [
        "T46",
        "公司",
        1063,
        1067,
        "华兰生物"
      ],
      [
        "T47",
        "公司",
        1076,
        1080,
        "沃森生物"
      ],
      [
        "T48",
        "公司",
        1089,
        1093,
        "万泰生物"
      ],
      [
        "T49",
        "公司",
        1103,
        1107,
        "康华生物"
      ],
      [
        "T50",
        "公司",
        1116,
        1120,
        "欧林生物"
      ],
      [
        "T51",
        "公司",
        1129,
        1132,
        "金迪克"
      ],
      [
        "T52",
        "公司",
        1141,
        1145,
        "百克生物"
      ],
      [
        "T53",
        "时间范围",
        2,
        8,
        "2021H1"
      ],
      [
        "T54",
        "时间范围",
        13,
        16,
        "上半年"
      ],
      [
        "T55",
        "属性值",
        43,
        58,
        "71.2亿元（+201.5%）"
      ],
      [
        "T56",
        "属性值",
        66,
        82,
        "69.5亿元（ +208.1%）"
      ],
      [
        "T57",
        "属性值",
        85,
        89,
        "增速提升"
      ],
      [
        "T58",
        "时间范围",
        160,
        163,
        "下半年"
      ],
      [
        "T59",
        "业绩",
        171,
        173,
        "业绩"
      ],
      [
        "T60",
        "属性值",
        213,
        225,
        "36.2亿元（+53%）"
      ],
      [
        "T61",
        "属性值",
        228,
        232,
        "有所放缓"
      ],
      [
        "T62",
        "时间范围",
        129,
        131,
        "目前"
      ],
      [
        "T63",
        "地点范围",
        131,
        134,
        "国内外"
      ],
      [
        "T64",
        "时间范围",
        255,
        258,
        "下半年"
      ],
      [
        "T65",
        "属性值",
        275,
        281,
        "增速有望恢复"
      ],
      [
        "T66",
        "行业",
        104,
        108,
        "新冠疫苗"
      ],
      [
        "T67",
        "行业",
        156,
        160,
        "新冠疫苗"
      ],
      [
        "T68",
        "行业",
        178,
        182,
        "新冠疫苗"
      ],
      [
        "T69",
        "属性值",
        322,
        325,
        "59%"
      ],
      [
        "T70",
        "归母净利润",
        347,
        350,
        "净利率"
      ],
      [
        "T71",
        "属性值",
        352,
        355,
        "38%"
      ],
      [
        "T72",
        "归母净利润",
        380,
        383,
        "净利率"
      ],
      [
        "T73",
        "属性值",
        384,
        389,
        "60%以上"
      ],
      [
        "T74",
        "时间范围",
        426,
        429,
        "下半年"
      ],
      [
        "T75",
        "时间范围",
        454,
        460,
        "2020Q2"
      ],
      [
        "T76",
        "时间范围",
        493,
        496,
        "上半年"
      ],
      [
        "T77",
        "属性值",
        539,
        543,
        "+11%"
      ],
      [
        "T78",
        "时间范围",
        558,
        561,
        "下半年"
      ],
      [
        "T79",
        "时间范围",
        591,
        599,
        "2020年3月底"
      ],
      [
        "T80",
        "行业",
        610,
        616,
        "传统重磅疫苗"
      ],
      [
        "T81",
        "属性值",
        620,
        622,
        "清晰"
      ],
      [
        "T82",
        "竞争格局",
        616,
        620,
        "竞争格局"
      ],
      [
        "T83",
        "属性值",
        628,
        630,
        "广阔"
      ],
      [
        "T84",
        "市场规模",
        624,
        628,
        "市场空间"
      ],
      [
        "T85",
        "时间范围",
        635,
        637,
        "未来"
      ],
      [
        "T86",
        "行业公司",
        746,
        750,
        "疫苗企业"
      ],
      [
        "T87",
        "行业",
        732,
        734,
        "疫苗"
      ]
    ]
  },
  {
    "id": 316,
    "text": "环泊酚（HSK-3486）是丙泊酚的me-better产品，有效性方面效果相当并且药物追加次数少，安全性方面注射痛、呼吸抑制发生率显著降低，临床有望替代丙泊酚。环泊酚消化内镜适应症于2020年12月获批，国内每年胃肠镜患者超过6000万人，并且全麻比例不断提高，预计到2024年环泊酚消化内镜适应症销售收入达到10亿元。麻醉诱导适应症于2021年2月获批、麻醉维持、ICU镇静等适应症也在快速推进，长远看消化内镜适应症预计占比整体销售收入的40%，环泊酚整体销售峰值预计将达30亿元。环泊酚美国麻醉诱导适应症已经开始3期临床，预计明年或将能够向FDA申报上市，根据美国丙泊酚用量估算环泊酚在美国市场空间有10亿美元。",
    "labels": [
      [
        "T0",
        "属性值",
        302,
        307,
        "10亿美元"
      ],
      [
        "T1",
        "地点范围",
        295,
        297,
        "美国"
      ],
      [
        "T2",
        "地点范围",
        282,
        284,
        "美国"
      ],
      [
        "T3",
        "行业",
        291,
        294,
        "环泊酚"
      ],
      [
        "T4",
        "市场规模",
        297,
        301,
        "市场空间"
      ],
      [
        "T5",
        "时间范围",
        91,
        99,
        "2020年12月"
      ],
      [
        "T6",
        "地点范围",
        102,
        104,
        "国内"
      ],
      [
        "T7",
        "时间范围",
        134,
        139,
        "2024年"
      ],
      [
        "T8",
        "营业收入",
        151,
        153,
        "收入"
      ],
      [
        "T9",
        "时间范围",
        168,
        175,
        "2021年2月"
      ],
      [
        "T10",
        "行业",
        202,
        209,
        "消化内镜适应症"
      ],
      [
        "T11",
        "营业收入",
        217,
        219,
        "收入"
      ],
      [
        "T12",
        "行业",
        224,
        227,
        "环泊酚"
      ],
      [
        "T13",
        "属性值",
        237,
        241,
        "30亿元"
      ],
      [
        "T14",
        "时间范围",
        265,
        267,
        "明年"
      ],
      [
        "T15",
        "属性值",
        155,
        159,
        "10亿元"
      ]
    ]
  },
  {
    "id": 317,
    "text": " 2021H1，大参林的收入和利润增速都是行业领先，从当期净增加门店数量来看，老百姓是行业中最高。  老百姓、益丰药房、大参林均发展加盟店业务，一心堂也正在探索中，加盟业务成为推动相应公司业绩增长的重要因素之一。",
    "labels": [
      [
        "T0",
        "公司",
        9,
        12,
        "大参林"
      ],
      [
        "T1",
        "营收增长",
        13,
        15,
        "收入"
      ],
      [
        "T2",
        "公司",
        40,
        43,
        "老百姓"
      ],
      [
        "T3",
        "公司",
        53,
        56,
        "老百姓"
      ],
      [
        "T4",
        "公司",
        57,
        61,
        "益丰药房"
      ],
      [
        "T5",
        "公司",
        62,
        65,
        "大参林"
      ],
      [
        "T6",
        "公司",
        74,
        77,
        "一心堂"
      ],
      [
        "T7",
        "业绩",
        96,
        98,
        "业绩"
      ],
      [
        "T8",
        "属性值",
        22,
        26,
        "行业领先"
      ],
      [
        "T9",
        "利润",
        16,
        18,
        "利润"
      ]
    ]
  },
  {
    "id": 318,
    "text": "• 2021年国内多家CXO的营收再创历史新高，增速也维持在高位。 • 药明康德管理层披露，2022Q1营收增速将在65%-68%，2022全年增速在65%-70%；",
    "labels": [
      [
        "T0",
        "时间范围",
        2,
        7,
        "2021年"
      ],
      [
        "T1",
        "地点范围",
        7,
        9,
        "国内"
      ],
      [
        "T2",
        "行业",
        11,
        14,
        "CXO"
      ],
      [
        "T3",
        "营业收入",
        15,
        17,
        "营收"
      ],
      [
        "T4",
        "营收增长",
        24,
        26,
        "增速"
      ],
      [
        "T5",
        "公司",
        36,
        40,
        "药明康德"
      ],
      [
        "T6",
        "时间范围",
        46,
        52,
        "2022Q1"
      ],
      [
        "T7",
        "属性值",
        54,
        65,
        "增速将在65%-68%"
      ],
      [
        "T8",
        "营业收入",
        52,
        54,
        "营收"
      ],
      [
        "T9",
        "属性值",
        72,
        82,
        "增速在65%-70%"
      ],
      [
        "T10",
        "时间范围",
        66,
        70,
        "2022"
      ]
    ]
  },
  {
    "id": 319,
    "text": "我国角膜塑形镜快速放量，渗透率仍有较大提升空间。在青少年近视率不断提高与日渐迫切的视力改善需求下，近年来中国角膜塑形镜销量高速增长。据中国医疗器械行业协会眼科及视光学分会统计，2015年我国角膜塑形镜销量达到 64万副， 2011-2015年 CAGR约 44.1%。到 2019年，国内角膜塑形镜销量达到 80-90万副，但市场渗透率仅为 1%；而在发达国家和地区，尤其是生理结构与中国较为类似的东亚地区，塑形镜的平均渗透率都在 5%以上（我国台湾地区 2015年角膜塑形镜已经达到 7%），因此国内角膜塑形镜市场渗透率仍有较大的发展空间。未来随着电子信息化的持续发展，人们用眼强度将大幅提升，用眼疲劳将导致屈光不正患病的几率大幅增加，屈光不正视力矫正市场需求呈现快速增长。另一方面，随着新材料、新技术和新设计的不断出现，将会有更多优质的角膜塑形镜产品进入市场，预计角膜塑形镜行业将继续保持高增长。",
    "labels": [
      [
        "T0",
        "行业",
        2,
        7,
        "角膜塑形镜"
      ],
      [
        "T1",
        "时间范围",
        49,
        52,
        "近年来"
      ],
      [
        "T2",
        "行业",
        54,
        59,
        "角膜塑形镜"
      ],
      [
        "T3",
        "行业",
        69,
        73,
        "医疗器械"
      ],
      [
        "T4",
        "地点范围",
        67,
        69,
        "中国"
      ],
      [
        "T5",
        "时间范围",
        88,
        93,
        "2015年"
      ],
      [
        "T6",
        "行业",
        95,
        100,
        "角膜塑形镜"
      ],
      [
        "T7",
        "时间范围",
        111,
        121,
        "2011-2015年"
      ],
      [
        "T8",
        "CAGR",
        122,
        126,
        "CAGR"
      ],
      [
        "T9",
        "属性值",
        126,
        133,
        "约 44.1%"
      ],
      [
        "T10",
        "时间范围",
        136,
        141,
        "2019年"
      ],
      [
        "T11",
        "地点范围",
        142,
        144,
        "国内"
      ],
      [
        "T12",
        "行业",
        144,
        149,
        "角膜塑形镜"
      ],
      [
        "T13",
        "地点范围",
        249,
        251,
        "国内"
      ],
      [
        "T14",
        "行业",
        251,
        256,
        "角膜塑形镜"
      ],
      [
        "T15",
        "行业需求",
        327,
        331,
        "市场需求"
      ],
      [
        "T16",
        "行业",
        370,
        375,
        "角膜塑形镜"
      ],
      [
        "T17",
        "行业",
        384,
        389,
        "角膜塑形镜"
      ],
      [
        "T18",
        "地点范围",
        0,
        2,
        "我国"
      ],
      [
        "T19",
        "地点范围",
        52,
        54,
        "中国"
      ],
      [
        "T20",
        "地点范围",
        93,
        95,
        "我国"
      ],
      [
        "T21",
        "地点范围",
        192,
        194,
        "中国"
      ],
      [
        "T22",
        "地点范围",
        221,
        227,
        "我国台湾地区"
      ],
      [
        "T23",
        "时间范围",
        228,
        233,
        "2015年"
      ],
      [
        "T24",
        "行业",
        204,
        207,
        "塑形镜"
      ],
      [
        "T25",
        "行业",
        233,
        238,
        "角膜塑形镜"
      ],
      [
        "T26",
        "属性值",
        333,
        337,
        "快速增长"
      ],
      [
        "T27",
        "时间范围",
        271,
        273,
        "未来"
      ],
      [
        "T28",
        "属性值",
        100,
        102,
        "销量"
      ]
    ]
  },
  {
    "id": 320,
    "text": "Ø 2021年12月24日，LabCorp宣布以4.5亿美金收购癌症领域的领导者Personal Genome Diagnostics Inc 基因组学与综合液体活检和基于组织的产品组合，以加强液体活检能力，扩展基于下一代测序 (NGS) 的基因组分析能力的肿瘤学产品组合。 Labcorp 的全球影响力也为将这项技术引入制药公司进行临床试验研究以推进癌症治疗提供了机会。",
    "labels": [
      [
        "T0",
        "时间范围",
        2,
        13,
        "2021年12月24日"
      ],
      [
        "T1",
        "公司",
        14,
        21,
        "LabCorp"
      ],
      [
        "T2",
        "公司",
        41,
        71,
        "ersonal Genome Diagnostics Inc"
      ],
      [
        "T3",
        "公司",
        138,
        145,
        "Labcorp"
      ],
      [
        "T4",
        "地点范围",
        147,
        149,
        "全球"
      ],
      [
        "T5",
        "行业公司",
        161,
        165,
        "制药公司"
      ],
      [
        "T6",
        "行业",
        32,
        34,
        "癌症"
      ]
    ]
  },
  {
    "id": 321,
    "text": " 东方生物：IVD大黑马，借疫情大幅提升国际化水平。东方生物目前新冠检测试剂中超过半数均是贴牌模式，其中过半是为西门子进行贴牌，我们认为未来有望打造IVD的CDMO商业模式。同时，疫情订单产生的现金流有望反哺公司其他内生主业，为现有业务的推广提供充足的资金支撑，亦能够加速研发项目的推进。",
    "labels": [
      [
        "T0",
        "公司",
        2,
        6,
        "东方生物"
      ],
      [
        "T1",
        "行业",
        7,
        10,
        "IVD"
      ],
      [
        "T2",
        "公司",
        27,
        31,
        "东方生物"
      ],
      [
        "T3",
        "公司",
        57,
        60,
        "西门子"
      ],
      [
        "T4",
        "时间范围",
        31,
        33,
        "目前"
      ],
      [
        "T5",
        "属性值",
        75,
        83,
        "IVD的CDMO"
      ],
      [
        "T6",
        "时间范围",
        69,
        71,
        "未来"
      ]
    ]
  },
  {
    "id": 322,
    "text": " 52家创新药及制剂公司2021Q1-3收入总额增速为10.3%、归母净利润总额下降2%；Q3单季收入同比下降0.3%，利润端同比下滑 15.3%，扣非净利润同比下降5.5%。Q3利润端有所下滑， 预计由于集采、国谈等导致公司毛利率下降所致。  从盈利水平看，受集采等政策冲击，板块整体盈利能力有所下降， 三季度行业毛利率（57.5%）下降4.8pp，销售费用率（28%）， 同比下降3pp，净利率（11.9%）下降2.1pp。",
    "labels": [
      [
        "T0",
        "行业公司",
        2,
        13,
        "52家创新药及制剂公司"
      ],
      [
        "T1",
        "时间范围",
        13,
        21,
        "2021Q1-3"
      ],
      [
        "T2",
        "收入增速",
        21,
        27,
        "收入总额增速"
      ],
      [
        "T3",
        "属性值",
        28,
        33,
        "10.3%"
      ],
      [
        "T4",
        "属性值",
        41,
        45,
        "下降2%"
      ],
      [
        "T5",
        "时间范围",
        46,
        48,
        "Q3"
      ],
      [
        "T6",
        "营业收入",
        50,
        52,
        "收入"
      ],
      [
        "T7",
        "扣非净利润",
        75,
        80,
        "扣非净利润"
      ],
      [
        "T8",
        "时间范围",
        89,
        91,
        "Q3"
      ],
      [
        "T9",
        "毛利",
        114,
        117,
        "毛利率"
      ],
      [
        "T10",
        "时间范围",
        155,
        158,
        "三季度"
      ],
      [
        "T11",
        "毛利",
        160,
        163,
        "毛利率"
      ],
      [
        "T12",
        "归母净利润",
        198,
        201,
        "净利率"
      ],
      [
        "T13",
        "归母净利润",
        34,
        39,
        "归母净利润"
      ],
      [
        "T14",
        "属性值",
        52,
        60,
        "同比下降0.3%"
      ],
      [
        "T15",
        "属性值",
        64,
        74,
        "同比下滑 15.3%"
      ],
      [
        "T16",
        "利润",
        61,
        64,
        "利润端"
      ],
      [
        "T17",
        "属性值",
        117,
        119,
        "下降"
      ],
      [
        "T18",
        "属性值",
        80,
        88,
        "同比下降5.5%"
      ],
      [
        "T19",
        "属性值",
        96,
        98,
        "下滑"
      ],
      [
        "T20",
        "利润",
        91,
        94,
        "利润端"
      ],
      [
        "T21",
        "属性值",
        201,
        215,
        "（11.9%）下降2.1pp"
      ],
      [
        "T22",
        "属性值",
        163,
        177,
        "（57.5%）下降4.8pp"
      ]
    ]
  },
  {
    "id": 323,
    "text": "A股行情回顾：医药整体跑赢大盘，IVD及原料药表现较好",
    "labels": [
      [
        "T0",
        "行业",
        7,
        9,
        "医药"
      ],
      [
        "T1",
        "行业",
        16,
        19,
        "IVD"
      ],
      [
        "T2",
        "行业",
        20,
        23,
        "原料药"
      ]
    ]
  },
  {
    "id": 325,
    "text": "2.1.CXO行业——CXO行业基本情况复盘：短期调整中、逐渐进入相对合理估值水平",
    "labels": [
      [
        "T0",
        "行业",
        4,
        7,
        "CXO"
      ],
      [
        "T1",
        "行业",
        11,
        14,
        "CXO"
      ]
    ]
  },
  {
    "id": 326,
    "text": "摘要：全球 CXO行业增长相对稳定，龙头公司业绩增长主要来源于生物药 CDMO服务。中国 CXO企业在 2021年表现出高度的景气度，存货水平、 合同负债与订单情况也为 2022年增长奠定基础。但是行业收入发展到一定规模后，行业将进入分化阶段。生物药、细胞与基因的研发热度带来了全球生物药 CDMO服务的需求，中国 CXO企业也在生物药及细胞与基因方面积极进行布局。",
    "labels": [
      [
        "T0",
        "行业",
        6,
        9,
        "CXO"
      ],
      [
        "T1",
        "地点范围",
        3,
        5,
        "全球"
      ],
      [
        "T2",
        "龙头企业",
        18,
        22,
        "龙头公司"
      ],
      [
        "T3",
        "业绩",
        22,
        24,
        "业绩"
      ],
      [
        "T4",
        "地点范围",
        42,
        44,
        "中国"
      ],
      [
        "T5",
        "时间范围",
        52,
        57,
        "2021年"
      ],
      [
        "T6",
        "存货",
        67,
        71,
        "存货水平"
      ],
      [
        "T7",
        "合同负债",
        73,
        77,
        "合同负债"
      ],
      [
        "T8",
        "在手订单",
        78,
        80,
        "订单"
      ],
      [
        "T9",
        "行业",
        122,
        125,
        "生物药"
      ],
      [
        "T10",
        "行业",
        126,
        131,
        "细胞与基因"
      ],
      [
        "T11",
        "地点范围",
        155,
        157,
        "中国"
      ],
      [
        "T12",
        "行业公司",
        158,
        163,
        "CXO企业"
      ],
      [
        "T13",
        "行业",
        165,
        168,
        "生物药"
      ],
      [
        "T14",
        "行业",
        169,
        174,
        "细胞与基因"
      ],
      [
        "T15",
        "行业公司",
        45,
        50,
        "CXO企业"
      ],
      [
        "T16",
        "时间范围",
        85,
        90,
        "2022年"
      ],
      [
        "T17",
        "营业收入",
        101,
        103,
        "收入"
      ],
      [
        "T18",
        "地点范围",
        139,
        141,
        "全球"
      ],
      [
        "T19",
        "行业",
        141,
        151,
        "生物药 CDMO服务"
      ]
    ]
  },
  {
    "id": 327,
    "text": "• 2020年药明康德、康龙化成、泰格医药、凯莱英共5个CXO企业的国内收入同比增速高于海外收入同比增速； • 避免受相关医药政策影响，我们应关注海外收入占比较高的企业；",
    "labels": [
      [
        "T0",
        "时间范围",
        2,
        7,
        "2020年"
      ],
      [
        "T1",
        "公司",
        7,
        11,
        "药明康德"
      ],
      [
        "T2",
        "公司",
        12,
        16,
        "康龙化成"
      ],
      [
        "T3",
        "公司",
        17,
        21,
        "泰格医药"
      ],
      [
        "T4",
        "公司",
        22,
        25,
        "凯莱英"
      ],
      [
        "T5",
        "地点范围",
        34,
        36,
        "国内"
      ],
      [
        "T6",
        "地点范围",
        44,
        46,
        "海外"
      ],
      [
        "T7",
        "营业收入",
        36,
        38,
        "收入"
      ],
      [
        "T8",
        "营业收入",
        46,
        48,
        "收入"
      ],
      [
        "T9",
        "地点范围",
        73,
        75,
        "海外"
      ],
      [
        "T10",
        "营业收入",
        75,
        77,
        "收入"
      ],
      [
        "T11",
        "行业公司",
        28,
        33,
        "CXO企业"
      ]
    ]
  },
  {
    "id": 329,
    "text": "Ø 从个股来看，近两周医药受美国实体清单传闻影响普遍下跌。其中天宇股份是唯一双周累计上涨标的 （+13.13%），我们认为主要受到默沙东新冠药物在美获批的影响。其余CXO公司受中美国际关系不确定性的影响均有不同程度的下跌，其中博腾股份及诺泰生物跌幅超20%。",
    "labels": [
      [
        "T0",
        "时间范围",
        8,
        11,
        "近两周"
      ],
      [
        "T1",
        "行业",
        11,
        13,
        "医药"
      ],
      [
        "T2",
        "公司",
        31,
        35,
        "天宇股份"
      ],
      [
        "T3",
        "行业公司",
        82,
        87,
        "CXO公司"
      ],
      [
        "T4",
        "公司",
        113,
        117,
        "博腾股份"
      ],
      [
        "T5",
        "公司",
        118,
        122,
        "诺泰生物"
      ],
      [
        "T6",
        "地点范围",
        88,
        89,
        "中"
      ],
      [
        "T7",
        "地点范围",
        89,
        90,
        "美"
      ]
    ]
  },
  {
    "id": 330,
    "text": "Ø 国产创新药IND申请景气度持续，国产生物药IND申报数量大幅超越进口。2021年截止至12月24日，国内1类化药 IND数量841个，生物药IND数量254个；进口5.1类化药IND数44个，进口1类化药254个，进口生物药IND数量203 个。2021年12月前26天的申请量来看，国产化药已超越2020年12月整月127%，国产生物药已超越14%。",
    "labels": [
      [
        "T0",
        "IND申报数",
        7,
        12,
        "IND申请"
      ],
      [
        "T1",
        "时间范围",
        37,
        51,
        "2021年截止至12月24日"
      ],
      [
        "T2",
        "时间范围",
        125,
        137,
        "2021年12月前26天"
      ],
      [
        "T3",
        "时间范围",
        151,
        161,
        "2020年12月整月"
      ],
      [
        "T4",
        "行业",
        2,
        7,
        "国产创新药"
      ],
      [
        "T5",
        "属性值",
        12,
        17,
        "景气度持续"
      ],
      [
        "T6",
        "行业",
        18,
        23,
        "国产生物药"
      ],
      [
        "T7",
        "IND申报数",
        23,
        30,
        "IND申报数量"
      ],
      [
        "T8",
        "属性值",
        30,
        36,
        "大幅超越进口"
      ],
      [
        "T9",
        "地点范围",
        52,
        54,
        "国内"
      ],
      [
        "T10",
        "行业",
        166,
        171,
        "国产生物药"
      ],
      [
        "T11",
        "行业",
        144,
        148,
        "国产化药"
      ]
    ]
  },
  {
    "id": 331,
    "text": "• 与全球First-in-Class越来越小的差距也使得国内创新药产品在欧美规范市场更具竞争力，越来越多的企业选择将自己的创新药中美同时临床及申报，或是在早期研发阶段即把海外权益授权给海外药企共同合作研发。以恒瑞医药研发管线来看，2014年的时候K药已经获批上市而卡瑞利珠单抗还在临床前，2020年的时候默沙东与恒瑞的PD-L1/TGF-β 双抗同处于3期临床；TLR-7、OX40等新靶点恒瑞也在早期研发阶段与全球药企差距越来越小。BTK抑制剂SHR1459、 JAK1抑制剂SHR0302分别授权给TG Therapeutics、Arcutis Pharmaceuticals在进行临床。",
    "labels": [
      [
        "T0",
        "地点范围",
        29,
        31,
        "国内"
      ],
      [
        "T1",
        "行业",
        31,
        34,
        "创新药"
      ],
      [
        "T2",
        "行业",
        62,
        65,
        "创新药"
      ],
      [
        "T3",
        "公司",
        105,
        109,
        "恒瑞医药"
      ],
      [
        "T4",
        "时间范围",
        116,
        121,
        "2014年"
      ],
      [
        "T5",
        "时间范围",
        145,
        150,
        "2020年"
      ],
      [
        "T6",
        "公司",
        153,
        156,
        "默沙东"
      ],
      [
        "T7",
        "公司",
        157,
        159,
        "恒瑞"
      ],
      [
        "T8",
        "公司",
        196,
        198,
        "恒瑞"
      ],
      [
        "T9",
        "行业公司",
        209,
        211,
        "药企"
      ],
      [
        "T10",
        "地点范围",
        3,
        5,
        "全球"
      ],
      [
        "T11",
        "地点范围",
        207,
        209,
        "全球"
      ],
      [
        "T12",
        "地点范围",
        37,
        39,
        "欧美"
      ],
      [
        "T13",
        "地点范围",
        93,
        95,
        "海外"
      ],
      [
        "T14",
        "行业公司",
        95,
        97,
        "药企"
      ]
    ]
  },
  {
    "id": 332,
    "text": "生物药  业绩持续快速恢复，2021Q1-3收入和净利润持续增长。14家生物药公司2021Q1-3收入总额增速为23.5%、归母净利润总额增速为 37.2%。生物药去年同期受疫情影响较大，目前已迎来恢复。生物药企业去年同期受疫情影响较大，业绩基数相对较低，进入到今年上半年，行业已经完全迎来恢复，三季度继续加速恢复，预计全年仍将保持较快增长。  盈利能力小幅提升，销售费用率下降较大，研发投入持续快速增加。从盈利水平看，Q1-3生物药板块整体盈利能力稳中有升，行业毛利率 （63%）基本保持平稳，销售费用率（27%）持续下降，管理费用率（8%）、研发费用率（8.4%）保持稳定，净利率（22%）同比有所提升。  生物药盈利能力好转，现金流情况良好。从ROE水平来看，近几年生物药板块ROE水平持续下降，与部分企业净利润率下降有关。 2021Q1-3，生物药板块ROE为6.93%，同比下降0.3pp，总体来看，生物药板块ROE保持在比较稳定的水平。从现金流情况来看，近几年我国生物药企业经营活动产生的现金流量净额/经营活动净收益持续提升，但2021Q1-3为79.82%，同比下降2.81pp，预计四季度现金流有望继续保持较好水平。  生长激素、粉尘螨滴剂等高景气度细分赛道增速相对较快。从细分行业来看，生长激素龙头企业长春高新、安科生物2021年前三季度均实现较快增长，粉尘螨滴剂龙头企业我武生物恢复情况也较好，预计随着黄花蒿粉滴剂的放量，四季度有望持续加速。",
    "labels": [
      [
        "T0",
        "行业",
        0,
        3,
        "生物药"
      ],
      [
        "T1",
        "业绩",
        6,
        8,
        "业绩"
      ],
      [
        "T2",
        "时间范围",
        15,
        23,
        "2021Q1-3"
      ],
      [
        "T3",
        "营业收入",
        23,
        25,
        "收入"
      ],
      [
        "T4",
        "归母净利润",
        26,
        29,
        "净利润"
      ],
      [
        "T5",
        "行业公司",
        34,
        42,
        "14家生物药公司"
      ],
      [
        "T6",
        "时间范围",
        42,
        50,
        "2021Q1-3"
      ],
      [
        "T7",
        "收入增速",
        50,
        56,
        "收入总额增速"
      ],
      [
        "T8",
        "属性值",
        57,
        62,
        "23.5%"
      ],
      [
        "T9",
        "归母净利润增速",
        63,
        72,
        "归母净利润总额增速"
      ],
      [
        "T10",
        "属性值",
        74,
        79,
        "37.2%"
      ],
      [
        "T11",
        "行业",
        80,
        83,
        "生物药"
      ],
      [
        "T12",
        "行业公司",
        103,
        108,
        "生物药企业"
      ],
      [
        "T13",
        "业绩",
        120,
        122,
        "业绩"
      ],
      [
        "T14",
        "时间范围",
        132,
        137,
        "今年上半年"
      ],
      [
        "T15",
        "时间范围",
        149,
        152,
        "三季度"
      ],
      [
        "T16",
        "时间范围",
        161,
        163,
        "全年"
      ],
      [
        "T17",
        "研发费用",
        194,
        198,
        "研发投入"
      ],
      [
        "T18",
        "时间范围",
        212,
        216,
        "Q1-3"
      ],
      [
        "T19",
        "行业",
        216,
        219,
        "生物药"
      ],
      [
        "T20",
        "毛利",
        234,
        237,
        "毛利率"
      ],
      [
        "T21",
        "行业",
        309,
        312,
        "生物药"
      ],
      [
        "T22",
        "ROE净资产回报率",
        328,
        331,
        "ROE"
      ],
      [
        "T23",
        "时间范围",
        336,
        339,
        "近几年"
      ],
      [
        "T24",
        "行业",
        339,
        342,
        "生物药"
      ],
      [
        "T25",
        "ROE净资产回报率",
        344,
        347,
        "ROE"
      ],
      [
        "T26",
        "属性值",
        349,
        353,
        "持续下降"
      ],
      [
        "T27",
        "时间范围",
        369,
        377,
        "2021Q1-3"
      ],
      [
        "T28",
        "行业",
        378,
        381,
        "生物药"
      ],
      [
        "T29",
        "ROE净资产回报率",
        383,
        386,
        "ROE"
      ],
      [
        "T30",
        "行业",
        408,
        411,
        "生物药"
      ],
      [
        "T31",
        "ROE净资产回报率",
        413,
        416,
        "ROE"
      ],
      [
        "T32",
        "时间范围",
        436,
        439,
        "近几年"
      ],
      [
        "T33",
        "地点范围",
        439,
        441,
        "我国"
      ],
      [
        "T34",
        "行业公司",
        441,
        446,
        "生物药企业"
      ],
      [
        "T35",
        "时间范围",
        473,
        481,
        "2021Q1-3"
      ],
      [
        "T36",
        "时间范围",
        502,
        505,
        "四季度"
      ],
      [
        "T37",
        "现金流",
        505,
        508,
        "现金流"
      ],
      [
        "T38",
        "行业",
        522,
        526,
        "生长激素"
      ],
      [
        "T39",
        "行业",
        527,
        532,
        "粉尘螨滴剂"
      ],
      [
        "T40",
        "行业",
        556,
        560,
        "生长激素"
      ],
      [
        "T41",
        "龙头企业",
        560,
        564,
        "龙头企业"
      ],
      [
        "T42",
        "公司",
        564,
        568,
        "长春高新"
      ],
      [
        "T43",
        "公司",
        569,
        573,
        "安科生物"
      ],
      [
        "T44",
        "时间范围",
        573,
        582,
        "2021年前三季度"
      ],
      [
        "T45",
        "行业",
        590,
        595,
        "粉尘螨滴剂"
      ],
      [
        "T46",
        "龙头企业",
        595,
        599,
        "龙头企业"
      ],
      [
        "T47",
        "公司",
        599,
        603,
        "我武生物"
      ],
      [
        "T48",
        "时间范围",
        83,
        85,
        "去年"
      ],
      [
        "T49",
        "时间范围",
        95,
        97,
        "目前"
      ],
      [
        "T50",
        "时间范围",
        108,
        110,
        "去年"
      ],
      [
        "T51",
        "属性值",
        200,
        204,
        "快速增加"
      ],
      [
        "T52",
        "属性值",
        10,
        14,
        "快速恢复"
      ],
      [
        "T53",
        "属性值",
        31,
        33,
        "增长"
      ],
      [
        "T54",
        "属性值",
        239,
        242,
        "63%"
      ],
      [
        "T55",
        "属性值",
        247,
        249,
        "平稳"
      ],
      [
        "T56",
        "研发费用",
        275,
        280,
        "研发费用率"
      ],
      [
        "T57",
        "属性值",
        281,
        285,
        "8.4%"
      ],
      [
        "T58",
        "属性值",
        288,
        290,
        "稳定"
      ],
      [
        "T59",
        "归母净利润",
        291,
        294,
        "净利率"
      ],
      [
        "T60",
        "属性值",
        295,
        298,
        "22%"
      ],
      [
        "T61",
        "属性值",
        299,
        305,
        "同比有所提升"
      ],
      [
        "T62",
        "归母净利润",
        359,
        363,
        "净利润率"
      ],
      [
        "T63",
        "属性值",
        387,
        402,
        "6.93%，同比下降0.3pp"
      ],
      [
        "T64",
        "属性值",
        419,
        423,
        "比较稳定"
      ],
      [
        "T65",
        "现金流",
        428,
        431,
        "现金流"
      ],
      [
        "T66",
        "属性值",
        467,
        471,
        "持续提升"
      ],
      [
        "T67",
        "属性值",
        482,
        499,
        "79.82%，同比下降2.81pp"
      ],
      [
        "T68",
        "属性值",
        514,
        516,
        "较好"
      ],
      [
        "T69",
        "行业",
        615,
        621,
        "黄花蒿粉滴剂"
      ],
      [
        "T70",
        "时间范围",
        625,
        628,
        "四季度"
      ]
    ]
  },
  {
    "id": 333,
    "text": "公司 CRO业务营业收入在 2014年至 2020年间由 30.7亿人民币增长至 85.5亿人民币，年均复合增长率为 18.6%，毛利在 2014年至 2020年间由 11.52亿人民币增长至 35.9亿人民币，年均复合增长率为 20.9%。2021年 H1药明康德 CRO业务实现营业收入 69.3亿人民币高达 36.9%，实现毛利 24.2亿人民币，同比增长 33.7%。 在 CDMO业务方面，药明康德目前 CDMO业务收入仍小于 CRO业务收入，但是收入增长速度较高。 公司 CDMO业务在 2014年至 2020年营业收入由 10.6亿人民币增长至 52.8亿人民币，年均复合增长率为 30.6%，毛利由 3.6亿人民币增长至 21.8亿人民币，年复合增长率为 34.8%。2021H1公司 CDMO业务实现营业收入 36.0亿人民币，同比增幅高达 66.5%，实现毛利 14.8亿人民币，同比增长 72.2%。",
    "labels": [
      [
        "T0",
        "行业",
        3,
        6,
        "CRO"
      ],
      [
        "T1",
        "营业收入",
        8,
        12,
        "营业收入"
      ],
      [
        "T2",
        "时间范围",
        14,
        26,
        "2014年至 2020年"
      ],
      [
        "T3",
        "CAGR",
        50,
        57,
        "年均复合增长率"
      ],
      [
        "T4",
        "毛利",
        65,
        67,
        "毛利"
      ],
      [
        "T5",
        "CAGR",
        106,
        113,
        "年均复合增长率"
      ],
      [
        "T6",
        "时间范围",
        121,
        129,
        "2021年 H1"
      ],
      [
        "T7",
        "公司",
        129,
        133,
        "药明康德"
      ],
      [
        "T8",
        "行业",
        134,
        137,
        "CRO"
      ],
      [
        "T9",
        "营业收入",
        141,
        145,
        "营业收入"
      ],
      [
        "T10",
        "属性值",
        146,
        154,
        "69.3亿人民币"
      ],
      [
        "T11",
        "毛利",
        165,
        167,
        "毛利"
      ],
      [
        "T12",
        "公司",
        200,
        204,
        "药明康德"
      ],
      [
        "T13",
        "行业",
        207,
        211,
        "CDMO"
      ],
      [
        "T14",
        "行业",
        219,
        222,
        "CRO"
      ],
      [
        "T15",
        "收入增速",
        229,
        235,
        "收入增长速度"
      ],
      [
        "T16",
        "属性值",
        235,
        237,
        "较高"
      ],
      [
        "T17",
        "行业",
        242,
        246,
        "CDMO"
      ],
      [
        "T18",
        "营业收入",
        262,
        266,
        "营业收入"
      ],
      [
        "T19",
        "属性值",
        268,
        276,
        "10.6亿人民币"
      ],
      [
        "T20",
        "属性值",
        280,
        288,
        "52.8亿人民币"
      ],
      [
        "T21",
        "CAGR",
        289,
        296,
        "年均复合增长率"
      ],
      [
        "T22",
        "属性值",
        298,
        303,
        "30.6%"
      ],
      [
        "T23",
        "毛利",
        304,
        306,
        "毛利"
      ],
      [
        "T24",
        "属性值",
        308,
        315,
        "3.6亿人民币"
      ],
      [
        "T25",
        "属性值",
        319,
        327,
        "21.8亿人民币"
      ],
      [
        "T26",
        "CAGR",
        328,
        334,
        "年复合增长率"
      ],
      [
        "T27",
        "属性值",
        336,
        341,
        "34.8%"
      ],
      [
        "T28",
        "时间范围",
        342,
        348,
        "2021H1"
      ],
      [
        "T29",
        "行业",
        351,
        355,
        "CDMO"
      ],
      [
        "T30",
        "营业收入",
        359,
        363,
        "营业收入"
      ],
      [
        "T31",
        "属性值",
        364,
        372,
        "36.0亿人民币"
      ],
      [
        "T32",
        "属性值",
        380,
        385,
        "66.5%"
      ],
      [
        "T33",
        "时间范围",
        250,
        255,
        "2014年"
      ],
      [
        "T34",
        "时间范围",
        257,
        262,
        "2020年"
      ],
      [
        "T35",
        "时间范围",
        69,
        82,
        "2014年至 2020年间"
      ],
      [
        "T36",
        "属性值",
        168,
        187,
        "24.2亿人民币，同比增长 33.7%"
      ],
      [
        "T37",
        "行业",
        191,
        195,
        "CDMO"
      ],
      [
        "T38",
        "营业收入",
        213,
        215,
        "收入"
      ],
      [
        "T39",
        "营业收入",
        224,
        226,
        "收入"
      ],
      [
        "T40",
        "毛利",
        388,
        390,
        "毛利"
      ],
      [
        "T41",
        "属性值",
        391,
        410,
        "14.8亿人民币，同比增长 72.2%"
      ],
      [
        "T42",
        "时间连接词",
        255,
        256,
        "至"
      ]
    ]
  },
  {
    "id": 335,
    "text": " 爱尔眼科： （1）内生增长方面，屈光、视光等业务推动消费升级，高毛利业务占比有望持续提高，提升平均客单价和整体利润水平；（2）外延增长方面，一方面推进现有核心城市医院的产能扩建，另一方面持续收购体外医院， 加快眼科医疗机构在全国范围内的布局，不断提高医疗网络布局的广度、深度和密度。",
    "labels": [
      [
        "T0",
        "公司",
        2,
        6,
        "爱尔眼科"
      ],
      [
        "T1",
        "毛利",
        34,
        36,
        "毛利"
      ],
      [
        "T2",
        "利润",
        57,
        59,
        "利润"
      ],
      [
        "T3",
        "行业",
        18,
        20,
        "屈光"
      ],
      [
        "T4",
        "行业",
        21,
        23,
        "视光"
      ],
      [
        "T5",
        "产能",
        86,
        88,
        "产能"
      ],
      [
        "T6",
        "属性值",
        88,
        90,
        "扩建"
      ]
    ]
  },
  {
    "id": 336,
    "text": " 死亡病例数维持高位。受到变异毒株传播的影响，欧洲的新增死亡人数自6月以来就有所反弹。10月以来，新增死亡病例数由于新增确诊数的快速上升而激增，死亡率未见明显上升，保持稳定。1月月均新增死亡人数为2926人，对比10月的2065人上升接近50%，增长曲线十分陡峭，但对比前两周数据已有所回落，没有恶化迹象。欧洲目前累计死亡人数1571511（死亡数据通常滞后于确诊数据）。",
    "labels": [
      [
        "T0",
        "时间范围",
        44,
        49,
        "10月以来"
      ],
      [
        "T1",
        "时间范围",
        88,
        90,
        "1月"
      ],
      [
        "T2",
        "时间范围",
        107,
        110,
        "10月"
      ],
      [
        "T3",
        "时间范围",
        33,
        38,
        "自6月以来"
      ],
      [
        "T4",
        "时间范围",
        136,
        139,
        "前两周"
      ],
      [
        "T5",
        "地点范围",
        154,
        156,
        "欧洲"
      ],
      [
        "T6",
        "地点范围",
        24,
        26,
        "欧洲"
      ]
    ]
  },
  {
    "id": 337,
    "text": "• 根据塔夫茨药物研发中心数据：研发每个环节的周期能缩短25%-40%，平均缩短 34.4%； • 制药公司更趋向外包研发支出原因：１）降低药物研发成本；２）有助于弥补药企研发能力不足问题；３）提高药物研发过程中的执行效率，缩短研发周期；４）降低药企整体药物研发过程中风险。",
    "labels": [
      [
        "T0",
        "行业公司",
        50,
        54,
        "制药公司"
      ],
      [
        "T1",
        "行业公司",
        84,
        86,
        "药企"
      ],
      [
        "T2",
        "行业公司",
        123,
        125,
        "药企"
      ]
    ]
  },
  {
    "id": 338,
    "text": " 健麾信息：（1）国内领先的智能化药品管理供应商。公司是国内最早从事智能化药品管理的先驱，先后推出智慧药房项目、智能化静配中心项目、智能化药品耗材管理项目三大板块。（2）战略性布局医药零售市场，积极探索与医药零售领域内客户的广泛合作，不断研发迭代更适合医药零售环境的针对性产品。2021年公司陆续与高济药房、益丰药房、叮当快药等全国连锁签署战略合作协议，锁定独家合作权，并通过销售分成的方式绑定双方长期利益。",
    "labels": [
      [
        "T0",
        "公司",
        2,
        6,
        "健麾信息"
      ],
      [
        "T1",
        "地点范围",
        10,
        12,
        "国内"
      ],
      [
        "T2",
        "时间范围",
        140,
        145,
        "2021年"
      ],
      [
        "T3",
        "公司",
        150,
        154,
        "高济药房"
      ],
      [
        "T4",
        "公司",
        155,
        159,
        "益丰药房"
      ],
      [
        "T5",
        "公司",
        160,
        164,
        "叮当快药"
      ],
      [
        "T6",
        "行业",
        15,
        22,
        "智能化药品管理"
      ],
      [
        "T7",
        "地点范围",
        29,
        31,
        "国内"
      ],
      [
        "T8",
        "行业",
        35,
        42,
        "智能化药品管理"
      ],
      [
        "T9",
        "行业",
        91,
        95,
        "医药零售"
      ],
      [
        "T10",
        "行业",
        103,
        107,
        "医药零售"
      ],
      [
        "T11",
        "行业",
        127,
        131,
        "医药零售"
      ]
    ]
  },
  {
    "id": 339,
    "text": " 5家连锁药店公司2021上半年收入总额增速为13.9%，其中第二季度收入增速为12.6%；归母净利润总额增速为17.8%，其中第二季度增速为13% 。从趋势来看，第二季度收入、利润增速环比继续下降。  第二季度，药店板块的毛利率维持稳中有升，同比提升2.4pp，销售费用率（24.7%）逐渐回归到疫情前的水平。",
    "labels": [
      [
        "T0",
        "行业公司",
        2,
        10,
        "5家连锁药店公司"
      ],
      [
        "T1",
        "时间范围",
        10,
        17,
        "2021上半年"
      ],
      [
        "T2",
        "属性值",
        24,
        29,
        "13.9%"
      ],
      [
        "T3",
        "时间范围",
        32,
        36,
        "第二季度"
      ],
      [
        "T4",
        "属性值",
        41,
        46,
        "12.6%"
      ],
      [
        "T5",
        "归母净利润增速",
        47,
        56,
        "归母净利润总额增速"
      ],
      [
        "T6",
        "属性值",
        57,
        62,
        "17.8%"
      ],
      [
        "T7",
        "属性值",
        72,
        75,
        "13%"
      ],
      [
        "T8",
        "时间范围",
        65,
        69,
        "第二季度"
      ],
      [
        "T9",
        "行业",
        109,
        111,
        "药店"
      ],
      [
        "T10",
        "毛利",
        114,
        117,
        "毛利率"
      ],
      [
        "T11",
        "属性值",
        117,
        133,
        "维持稳中有升，同比提升2.4pp"
      ],
      [
        "T12",
        "时间范围",
        104,
        108,
        "第二季度"
      ],
      [
        "T13",
        "收入增速",
        17,
        23,
        "收入总额增速"
      ],
      [
        "T14",
        "收入增速",
        36,
        40,
        "收入增速"
      ],
      [
        "T15",
        "时间范围",
        83,
        87,
        "第二季度"
      ],
      [
        "T16",
        "营业收入",
        87,
        89,
        "收入"
      ],
      [
        "T17",
        "利润",
        90,
        92,
        "利润"
      ],
      [
        "T18",
        "属性值",
        92,
        100,
        "增速环比继续下降"
      ]
    ]
  },
  {
    "id": 340,
    "text": "• 投资建议：预期CXO板块2022年PE将在50~70水平，建议关注药明康德（2359.HK）、凯莱英（6821.HK）等。 • 风险提示：业绩不及预期风险、国内外政策风险、新业务投资不及预期风险；",
    "labels": [
      [
        "T0",
        "行业",
        9,
        12,
        "CXO"
      ],
      [
        "T1",
        "时间范围",
        14,
        19,
        "2022年"
      ],
      [
        "T2",
        "PE",
        19,
        21,
        "PE"
      ],
      [
        "T3",
        "属性值",
        23,
        28,
        "50~70"
      ],
      [
        "T4",
        "公司",
        35,
        39,
        "药明康德"
      ],
      [
        "T5",
        "公司",
        49,
        52,
        "凯莱英"
      ]
    ]
  },
  {
    "id": 341,
    "text": "bempegaldesleukin已获得临床试验默示许可，拟开发用于头颈部鳞状细胞癌。  1月 18日，复星医药发布公告称，其控股子公司复宏汉霖收到 NMPA关于同意靶向人类 BRAF蛋白 V600E突变小分子抑制剂 HLX208单药或联合治疗晚期实体瘤开展临床试验的批准。  1月 17日，绿叶制药宣布，羟考酮纳洛酮缓释片（LY021702）的上市申请已获得 CDE受理，用于治疗非阿片类药物不能有效控制的中重度慢性疼痛，解除疼痛持续时间可达 12小时，并可防止阿片类药物引发的滥用问题以及降低该类药物引起的便秘等胃肠道不良反应。  1月 17日，九典制药发布公告称，PDX-02于近日收到 NMPA签发的《药物临床试验批准通知书》，在完成相关准备工作后将开展临床试验研究。其适应症为下列疾病及症状的镇痛、消炎：骨关节炎、肩周炎、肌腱及腱鞘炎、腱鞘周围炎、肱骨外上髁炎、肌肉痛、外伤所致肿胀、疼痛。  1月 17日，海思科发布公告称，于近日收到 NMPA下发的《受理通知书》， 注射用 HSK36273获批开展临床，拟用于血液透析及术中患者的全身抗凝。  1月 17日，CDE官网公示显示，罗氏已在中国递交了 RO7191863注射液的临床试验申请，并获得受理。RO7191863是一种肝脏指向性、靶向 PD- L1的 N-乙酰半乳糖胺修饰单链寡核苷酸候选药，拟开发治疗慢性乙肝。",
    "labels": [
      [
        "T0",
        "时间范围",
        46,
        52,
        "1月 18日"
      ],
      [
        "T1",
        "公司",
        53,
        57,
        "复星医药"
      ],
      [
        "T2",
        "公司",
        69,
        73,
        "复宏汉霖"
      ],
      [
        "T3",
        "公司",
        141,
        147,
        "1月 17日"
      ],
      [
        "T4",
        "公司",
        148,
        152,
        "绿叶制药"
      ],
      [
        "T5",
        "时间范围",
        271,
        277,
        "1月 17日"
      ],
      [
        "T6",
        "公司",
        278,
        282,
        "九典制药"
      ],
      [
        "T7",
        "时间范围",
        406,
        412,
        "1月 17日"
      ],
      [
        "T8",
        "公司",
        413,
        416,
        "海思科"
      ],
      [
        "T9",
        "时间范围",
        484,
        490,
        "1月 17日"
      ],
      [
        "T10",
        "公司",
        491,
        494,
        "CDE"
      ],
      [
        "T11",
        "时间范围",
        295,
        297,
        "近日"
      ],
      [
        "T12",
        "时间范围",
        423,
        425,
        "近日"
      ],
      [
        "T13",
        "公司",
        501,
        503,
        "罗氏"
      ],
      [
        "T14",
        "地点范围",
        505,
        507,
        "中国"
      ]
    ]
  },
  {
    "id": 342,
    "text": "化学制药、医药商业增速平稳。化学制药 2021年前三季度营收 3670亿元，在所有细分行业大类中增速最低，仅同比增 11.0%，归母净利润 387.1亿元，同比增长仅 5.7%； 另外同比负增长的企业绝对数量和比例都最多，115家企业有半数企业同比 2020年负增长，主要源于持续带量采购等政策打压影响，代表性公司恒瑞医药今年前三季度营收和归母净利润分别同比增 4.0%和-1.2%。医药商业前三季度营收 6530亿元，同比增长 18.1%，归母净利润 167.7亿元，同比增长 15.5%。",
    "labels": [
      [
        "T0",
        "行业",
        14,
        18,
        "化学制药"
      ],
      [
        "T1",
        "时间范围",
        19,
        28,
        "2021年前三季度"
      ],
      [
        "T2",
        "营业收入",
        28,
        30,
        "营收"
      ],
      [
        "T3",
        "属性值",
        31,
        37,
        "3670亿元"
      ],
      [
        "T4",
        "属性值",
        58,
        63,
        "11.0%"
      ],
      [
        "T5",
        "归母净利润",
        64,
        69,
        "归母净利润"
      ],
      [
        "T6",
        "公司",
        157,
        161,
        "恒瑞医药"
      ],
      [
        "T7",
        "时间范围",
        161,
        167,
        "今年前三季度"
      ],
      [
        "T8",
        "营业收入",
        167,
        169,
        "营收"
      ],
      [
        "T9",
        "归母净利润",
        170,
        175,
        "归母净利润"
      ],
      [
        "T10",
        "属性值",
        181,
        185,
        "4.0%"
      ],
      [
        "T11",
        "属性值",
        186,
        191,
        "-1.2%"
      ],
      [
        "T12",
        "行业",
        192,
        196,
        "医药商业"
      ],
      [
        "T13",
        "时间范围",
        196,
        200,
        "前三季度"
      ],
      [
        "T14",
        "营业收入",
        200,
        202,
        "营收"
      ],
      [
        "T15",
        "属性值",
        203,
        209,
        "6530亿元"
      ],
      [
        "T16",
        "属性值",
        215,
        220,
        "18.1%"
      ],
      [
        "T17",
        "归母净利润",
        221,
        226,
        "归母净利润"
      ],
      [
        "T18",
        "行业",
        0,
        4,
        "化学制药"
      ],
      [
        "T19",
        "行业",
        5,
        9,
        "医药商业"
      ],
      [
        "T20",
        "属性值",
        70,
        88,
        "387.1亿元，同比增长仅 5.7%"
      ],
      [
        "T21",
        "时间范围",
        125,
        130,
        "2020年"
      ],
      [
        "T22",
        "属性值",
        227,
        245,
        "167.7亿元，同比增长 15.5%"
      ]
    ]
  },
  {
    "id": 343,
    "text": "欧美留置针使用率约95%，国内由于价格等因素渗透率较低，目前国内留置针市场规模约为4亿支，集采降价下市场加速扩增。公司此前留置针销售体量较小，行业市占率不足2%，经销模式下留置针出厂价格远低于原来主流厂商，产品质量非劣下集采中标概率大幅提升，截止2021年6月，公司已中标十余个省市留置针等集采项目，其中山东、辽宁等地区已经实现续标，充分说明公司留置针等产品在临床应用上的可靠性，同时集采推动放量逐步形成规模优势，自动化投入、留置针针管自产等进一步推动单位成本降低，预期毛利率逐步提升，此外公司有望凭借集采作为新市场突破切入口，拓展西北、华北等低覆盖率区域，带动后续其他产品准入值得期待。",
    "labels": [
      [
        "T0",
        "地点范围",
        13,
        15,
        "国内"
      ],
      [
        "T1",
        "地点范围",
        30,
        32,
        "国内"
      ],
      [
        "T2",
        "行业",
        32,
        35,
        "留置针"
      ],
      [
        "T3",
        "市场规模",
        35,
        39,
        "市场规模"
      ],
      [
        "T4",
        "属性值",
        39,
        44,
        "约为4亿支"
      ],
      [
        "T5",
        "市场份额",
        73,
        76,
        "市占率"
      ],
      [
        "T6",
        "时间范围",
        121,
        130,
        "截止2021年6月"
      ],
      [
        "T7",
        "行业",
        141,
        144,
        "留置针"
      ],
      [
        "T8",
        "行业",
        173,
        176,
        "留置针"
      ],
      [
        "T9",
        "行业",
        213,
        216,
        "留置针"
      ],
      [
        "T10",
        "毛利",
        235,
        238,
        "毛利率"
      ],
      [
        "T11",
        "地点范围",
        -1,
        2,
        ""
      ],
      [
        "T12",
        "时间范围",
        28,
        30,
        "目前"
      ],
      [
        "T13",
        "地点范围",
        266,
        268,
        "西北"
      ],
      [
        "T14",
        "地点范围",
        269,
        271,
        "华北"
      ],
      [
        "T15",
        "地点范围",
        152,
        154,
        "山东"
      ],
      [
        "T16",
        "地点范围",
        155,
        157,
        "辽宁"
      ],
      [
        "T17",
        "属性值",
        52,
        56,
        "加速扩增"
      ]
    ]
  },
  {
    "id": 344,
    "text": "市场新产品上线数量有限，产品质量竞争是关键；优质产品代理权难以获取，自主研发是保比对比（%） 腾讯网易完美世界三七互娱世纪华通占比（%） 代理自主研发腾讯研发投入比远高于其他厂商，用户认可度高：2020年，腾讯研发投入比为网易的高度认可正向循环，精戏获得充沛现金流， 研发游戏比例 www.leadleo.com",
    "labels": [
      [
        "T0",
        "公司",
        47,
        49,
        "腾讯"
      ],
      [
        "T1",
        "公司",
        49,
        51,
        "网易"
      ],
      [
        "T2",
        "公司",
        51,
        55,
        "完美世界"
      ],
      [
        "T3",
        "公司",
        55,
        59,
        "三七互娱"
      ],
      [
        "T4",
        "公司",
        59,
        63,
        "世纪华通"
      ],
      [
        "T5",
        "公司",
        75,
        77,
        "腾讯"
      ],
      [
        "T6",
        "时间范围",
        97,
        102,
        "2020年"
      ],
      [
        "T7",
        "公司",
        103,
        105,
        "腾讯"
      ],
      [
        "T8",
        "公司",
        111,
        113,
        "网易"
      ],
      [
        "T9",
        "研发费用率",
        77,
        82,
        "研发投入比"
      ],
      [
        "T10",
        "属性值",
        82,
        89,
        "远高于其他厂商"
      ],
      [
        "T11",
        "行业",
        69,
        75,
        "代理自主研发"
      ],
      [
        "T12",
        "研发费用率",
        105,
        110,
        "研发投入比"
      ],
      [
        "T13",
        "现金流",
        129,
        132,
        "现金流"
      ],
      [
        "T14",
        "公司",
        123,
        125,
        "精戏"
      ],
      [
        "T15",
        "属性值",
        127,
        129,
        "充沛"
      ]
    ]
  },
  {
    "id": 345,
    "text": " 近五个季度行业热度趋于稳定。2021Q3，全市场权益基金医药持仓比例为13.13%，同期医药股在A股总市值中占比为8.75%。",
    "labels": [
      [
        "T0",
        "时间范围",
        2,
        7,
        "近五个季度"
      ],
      [
        "T1",
        "时间范围",
        16,
        22,
        "2021Q3"
      ],
      [
        "T2",
        "行业",
        30,
        32,
        "医药"
      ],
      [
        "T3",
        "行业公司",
        46,
        49,
        "医药股"
      ],
      [
        "T4",
        "市值",
        53,
        55,
        "市值"
      ]
    ]
  },
  {
    "id": 346,
    "text": "• 国内CXO公司临床CRO业务继续呈现高速增长、疫情下恢复趋势明显：核心CXO公司临床CRO业务2021年三季报合计实现营业收入 50.0亿元，同比增长45.2%，呈现超高速增长，其泰格医药实现营业收入31.3亿元，同比增长41.5%。展望2022年，疫情下临床CRO业务持续恢复、且伴随国内创新逐渐传导到临床CRO业务，我们判断未来3年临床CRO业务将持续呈现快速增长、且景气度有向上的趋势。 • 海外临床CRO业务疫情下恢复明显、呈现高速增长：6家主流临床CRO公司合计2021年前三季度实现营业收入73.96亿美元，同比增长 42.8%，其中昆泰、科文斯、Syneos、PPD、ICON Q3单季度营业收入同比增长为32.4%/17.5%/20.6%/26.0%/165.9%，疫情下呈现显著恢复。",
    "labels": [
      [
        "T0",
        "地点范围",
        2,
        4,
        "国内"
      ],
      [
        "T1",
        "行业公司",
        4,
        9,
        "CXO公司"
      ],
      [
        "T2",
        "行业",
        9,
        14,
        "临床CRO"
      ],
      [
        "T3",
        "行业",
        42,
        47,
        "临床CRO"
      ],
      [
        "T4",
        "时间范围",
        49,
        56,
        "2021年三季"
      ],
      [
        "T5",
        "营业收入",
        61,
        65,
        "营业收入"
      ],
      [
        "T6",
        "属性值",
        66,
        72,
        "50.0亿元"
      ],
      [
        "T7",
        "属性值",
        77,
        82,
        "45.2%"
      ],
      [
        "T8",
        "公司",
        92,
        96,
        "泰格医药"
      ],
      [
        "T9",
        "营业收入",
        98,
        102,
        "营业收入"
      ],
      [
        "T10",
        "属性值",
        102,
        108,
        "31.3亿元"
      ],
      [
        "T11",
        "属性值",
        113,
        118,
        "41.5%"
      ],
      [
        "T12",
        "时间范围",
        121,
        126,
        "2022年"
      ],
      [
        "T13",
        "行业",
        130,
        135,
        "临床CRO"
      ],
      [
        "T14",
        "地点范围",
        145,
        147,
        "国内"
      ],
      [
        "T15",
        "行业",
        154,
        159,
        "临床CRO"
      ],
      [
        "T16",
        "时间范围",
        166,
        170,
        "未来3年"
      ],
      [
        "T17",
        "行业",
        170,
        175,
        "临床CRO"
      ],
      [
        "T18",
        "地点范围",
        201,
        203,
        "海外"
      ],
      [
        "T19",
        "行业",
        203,
        208,
        "临床CRO"
      ],
      [
        "T20",
        "行业公司",
        225,
        236,
        "6家主流临床CRO公司"
      ],
      [
        "T21",
        "时间范围",
        238,
        247,
        "2021年前三季度"
      ],
      [
        "T22",
        "营业收入",
        249,
        253,
        "营业收入"
      ],
      [
        "T23",
        "属性值",
        253,
        261,
        "73.96亿美元"
      ],
      [
        "T24",
        "属性值",
        267,
        272,
        "42.8%"
      ],
      [
        "T25",
        "公司",
        275,
        277,
        "昆泰"
      ],
      [
        "T26",
        "公司",
        278,
        281,
        "科文斯"
      ],
      [
        "T27",
        "公司",
        282,
        288,
        "Syneos"
      ],
      [
        "T28",
        "公司",
        289,
        292,
        "PPD"
      ],
      [
        "T29",
        "公司",
        293,
        297,
        "ICON"
      ],
      [
        "T30",
        "时间范围",
        298,
        300,
        "Q3"
      ],
      [
        "T31",
        "营业收入",
        303,
        307,
        "营业收入"
      ],
      [
        "T32",
        "属性值",
        312,
        317,
        "32.4%"
      ],
      [
        "T33",
        "属性值",
        318,
        323,
        "17.5%"
      ],
      [
        "T34",
        "属性值",
        324,
        329,
        "20.6%"
      ],
      [
        "T35",
        "属性值",
        330,
        335,
        "26.0%"
      ],
      [
        "T36",
        "属性值",
        336,
        342,
        "165.9%"
      ],
      [
        "T37",
        "属性值",
        20,
        24,
        "高速增长"
      ],
      [
        "T38",
        "属性值",
        85,
        90,
        "超高速增长"
      ],
      [
        "T39",
        "行业公司",
        35,
        42,
        "核心CXO公司"
      ],
      [
        "T40",
        "属性值",
        182,
        194,
        "快速增长、且景气度有向上"
      ],
      [
        "T41",
        "属性值",
        348,
        352,
        "显著恢复"
      ]
    ]
  },
  {
    "id": 347,
    "text": " 公司是血制品行业目前规划产能最为明确的公司，预计成都永安、云南基地和兰州基地建成后，公司将拥有 4000-5000 吨的血浆处理能力，赶上国际一线血制品公司规模。  我们预计2021-2023年盈利分别为7.64、9.26和11.42亿元，同比增长19.6%、21.1%和23.4%（原预测为7.29、9.09和11.40亿元， 同比增长14.0%、24.8%和25.4%），当前股价对应2021-2023分别为52.3、43.2和35.0倍PE，维持增持评级。",
    "labels": [
      [
        "T0",
        "产能",
        80,
        82,
        "规模"
      ],
      [
        "T1",
        "时间范围",
        90,
        100,
        "2021-2023年"
      ],
      [
        "T2",
        "PE",
        224,
        226,
        "PE"
      ],
      [
        "T3",
        "行业公司",
        75,
        80,
        "血制品公司"
      ],
      [
        "T4",
        "行业",
        5,
        8,
        "血制品"
      ],
      [
        "T5",
        "时间范围",
        10,
        12,
        "目前"
      ],
      [
        "T6",
        "产能",
        14,
        16,
        "产能"
      ],
      [
        "T7",
        "地点范围",
        26,
        30,
        "成都永安"
      ],
      [
        "T8",
        "地点范围",
        31,
        33,
        "云南"
      ],
      [
        "T9",
        "地点范围",
        36,
        38,
        "兰州"
      ],
      [
        "T10",
        "地点范围",
        71,
        73,
        "国际"
      ],
      [
        "T11",
        "时间范围",
        197,
        206,
        "2021-2023"
      ]
    ]
  },
  {
    "id": 349,
    "text": "• 中度游戏上，字节跳动2020年尝试（《战争艺术》《终结战场》《热血街篮》）并不成功，MOBA产品《火力对决》 已停止开发，验证了中度品类腾讯难以撼动的逻辑。重度游戏成为字节跳动发行和代理的主攻品类，涵盖MMO、 SLG、卡牌、ARPG等。 • 字节自研体系搭建超预期。自研主要通过收购工作室和挖角来加速布局，已经分别在北京、上海、杭州、深圳建立游戏工作室。团队规模达到2000人。21年4月字节自研产品《航海王：热血航线》上线，iOS畅销榜跻身TOP3。 • 字节对腾讯重度游戏的威胁判断未改变，但其当前不论自研还是代理，头部产品预期年流水体量不超过30亿，与腾讯差距仍大，中短期不构成威胁，但长期仍需观察。",
    "labels": [
      [
        "T0",
        "公司",
        8,
        12,
        "字节跳动"
      ],
      [
        "T1",
        "时间范围",
        12,
        17,
        "2020年"
      ],
      [
        "T2",
        "公司",
        70,
        72,
        "腾讯"
      ],
      [
        "T3",
        "公司",
        86,
        90,
        "字节跳动"
      ],
      [
        "T4",
        "员工数量",
        180,
        184,
        "团队规模"
      ],
      [
        "T5",
        "属性值",
        186,
        191,
        "2000人"
      ],
      [
        "T6",
        "时间范围",
        192,
        197,
        "21年4月"
      ],
      [
        "T7",
        "公司",
        235,
        237,
        "腾讯"
      ],
      [
        "T8",
        "公司",
        282,
        284,
        "腾讯"
      ],
      [
        "T9",
        "行业",
        174,
        176,
        "游戏"
      ],
      [
        "T10",
        "行业",
        2,
        6,
        "中度游戏"
      ],
      [
        "T11",
        "行业",
        66,
        68,
        "中度"
      ],
      [
        "T12",
        "行业",
        80,
        84,
        "重度游戏"
      ],
      [
        "T13",
        "地点范围",
        161,
        163,
        "北京"
      ],
      [
        "T14",
        "地点范围",
        164,
        166,
        "上海"
      ],
      [
        "T15",
        "地点范围",
        167,
        169,
        "杭州"
      ],
      [
        "T16",
        "地点范围",
        170,
        172,
        "深圳"
      ],
      [
        "T17",
        "公司",
        197,
        199,
        "字节"
      ],
      [
        "T18",
        "公司",
        232,
        234,
        "字节"
      ],
      [
        "T19",
        "行业",
        237,
        241,
        "重度游戏"
      ],
      [
        "T20",
        "时间范围",
        289,
        292,
        "中短期"
      ],
      [
        "T21",
        "时间范围",
        299,
        301,
        "长期"
      ]
    ]
  },
  {
    "id": 350,
    "text": " 医疗服务：优选具备长期增长潜力的消费医疗赛道",
    "labels": [
      [
        "T0",
        "行业",
        2,
        6,
        "医疗服务"
      ],
      [
        "T1",
        "行业",
        18,
        22,
        "消费医疗"
      ]
    ]
  },
  {
    "id": 352,
    "text": "亿元，CAGR33%，当前股价对应2021年PE47X。 普门科技（688389）：8大产品系列、50+型号产品，光子治疗为特色，竞争优势拳头产品带动，多产品线支持，由点到面，提供各级医疗机构、各科室康复整体解决方案； 主力产品有光子治疗仪、空气波压力治疗仪、红外治疗仪、高频振动排痰仪、多功能清创仪、冲击波治疗仪等，其中光子治疗仪销售占治疗与康复器械营收 40%左右。光子治疗领域竞争优势明显，与 301医院联合开展的《中国人体表难愈合创面发生新特征与防治的创新理论与关键措施研究》获得国务院颁发的2015年国家科学技术进步奖一等奖， 终端客户以二、三级医院为主，占比 90%以上。2018年末，公司已协助400+家医疗机构建成创面治疗中心，累计装机医院 3613家。预计康复器械业务分部，2021-2023年营收 1.85亿元、2.17亿元和2.56亿元，年复合增速约17%。",
    "labels": [
      [
        "T0",
        "公司",
        29,
        33,
        "普门科技"
      ],
      [
        "T1",
        "公司",
        200,
        205,
        "301医院"
      ],
      [
        "T2",
        "时间范围",
        250,
        255,
        "2015年"
      ],
      [
        "T3",
        "时间范围",
        292,
        298,
        "2018年末"
      ],
      [
        "T4",
        "时间范围",
        346,
        356,
        "2021-2023年"
      ],
      [
        "T5",
        "营业收入",
        356,
        358,
        "营收"
      ],
      [
        "T6",
        "属性值",
        359,
        379,
        "1.85亿元、2.17亿元和2.56亿元"
      ],
      [
        "T7",
        "CAGR",
        380,
        385,
        "年复合增速"
      ],
      [
        "T8",
        "属性值",
        385,
        389,
        "约17%"
      ],
      [
        "T9",
        "行业",
        337,
        341,
        "康复器械"
      ],
      [
        "T10",
        "CAGR",
        3,
        7,
        "CAGR"
      ],
      [
        "T11",
        "时间范围",
        17,
        22,
        "2021年"
      ],
      [
        "T12",
        "PE",
        22,
        24,
        "PE"
      ],
      [
        "T13",
        "营业收入",
        176,
        178,
        "营收"
      ],
      [
        "T14",
        "行业",
        185,
        189,
        "光子治疗"
      ]
    ]
  },
  {
    "id": 353,
    "text": "• 药明康德&康龙化成实验室业务继续保持高强度增长，表征全球产业链转移下国内实验室业务继续保持高速增长：药明康德、康龙化成2021年前三季度分别实现营业收入89.3亿元和33.0亿元，分别同比增长37.5%和42.3%，延续高速增长的趋势 。 • 昭衍新药&美迪西继续呈现高速增长，表征国内临床前CRO需求继续呈现高β中：昭衍新药、美迪西2021年前三季度分别实现营业收入8.6亿元和7.9亿元，分别同比增长35.7%和81.6%，另外考虑到昭衍新药前三季度新签订单同比增长超70%，继续表征国内临床CRO需求继续呈现高β。",
    "labels": [
      [
        "T0",
        "主营业务",
        11,
        14,
        "实验室"
      ],
      [
        "T1",
        "地点范围",
        28,
        30,
        "全球"
      ],
      [
        "T2",
        "地点范围",
        36,
        38,
        "国内"
      ],
      [
        "T3",
        "行业",
        38,
        41,
        "实验室"
      ],
      [
        "T4",
        "时间范围",
        61,
        70,
        "2021年前三季度"
      ],
      [
        "T5",
        "营业收入",
        74,
        78,
        "营业收入"
      ],
      [
        "T6",
        "营收增长",
        94,
        98,
        "同比增长"
      ],
      [
        "T7",
        "地点范围",
        143,
        145,
        "国内"
      ],
      [
        "T8",
        "时间范围",
        169,
        178,
        "2021年前三季度"
      ],
      [
        "T9",
        "营业收入",
        182,
        186,
        "营业收入"
      ],
      [
        "T10",
        "公司",
        221,
        225,
        "昭衍新药"
      ],
      [
        "T11",
        "时间范围",
        225,
        229,
        "前三季度"
      ],
      [
        "T12",
        "地点范围",
        246,
        248,
        "国内"
      ],
      [
        "T13",
        "公司",
        2,
        6,
        "药明康德"
      ],
      [
        "T14",
        "公司",
        7,
        11,
        "康龙化成"
      ],
      [
        "T15",
        "属性值",
        20,
        25,
        "高强度增长"
      ],
      [
        "T16",
        "属性值",
        47,
        51,
        "高速增长"
      ],
      [
        "T17",
        "公司",
        52,
        56,
        "药明康德"
      ],
      [
        "T18",
        "公司",
        57,
        61,
        "康龙化成"
      ],
      [
        "T19",
        "属性值",
        78,
        84,
        "89.3亿元"
      ],
      [
        "T20",
        "属性值",
        85,
        91,
        "33.0亿元"
      ],
      [
        "T21",
        "属性值",
        98,
        103,
        "37.5%"
      ],
      [
        "T22",
        "属性值",
        104,
        109,
        "42.3%"
      ],
      [
        "T23",
        "公司",
        124,
        128,
        "昭衍新药"
      ],
      [
        "T24",
        "公司",
        129,
        132,
        "美迪西"
      ],
      [
        "T25",
        "属性值",
        157,
        159,
        "高β"
      ],
      [
        "T26",
        "行业",
        145,
        151,
        "临床前CRO"
      ],
      [
        "T27",
        "公司",
        161,
        165,
        "昭衍新药"
      ],
      [
        "T28",
        "公司",
        166,
        169,
        "美迪西"
      ],
      [
        "T29",
        "属性值",
        186,
        191,
        "8.6亿元"
      ],
      [
        "T30",
        "属性值",
        192,
        197,
        "7.9亿元"
      ],
      [
        "T31",
        "属性值",
        204,
        209,
        "35.7%"
      ],
      [
        "T32",
        "属性值",
        210,
        215,
        "81.6%"
      ],
      [
        "T33",
        "新签订单",
        229,
        233,
        "新签订单"
      ],
      [
        "T34",
        "属性值",
        233,
        241,
        "同比增长超70%"
      ],
      [
        "T35",
        "行业",
        248,
        253,
        "临床CRO"
      ],
      [
        "T36",
        "属性值",
        259,
        261,
        "高β"
      ],
      [
        "T37",
        "行业需求",
        151,
        153,
        "需求"
      ]
    ]
  },
  {
    "id": 354,
    "text": "型，增长率及市占率均 2014年的25.3 ；移动游戏在2018年随着市场饱和， 游、页面游戏市场份额 ，端游和页面游戏市场在移动游戏用户，特征在端游时代，腾讯便不积累大规模轻度游戏用户，为之后移动游戏的发展打下用户基础 www.leadleo.com",
    "labels": [
      [
        "T0",
        "行业",
        23,
        27,
        "移动游戏"
      ],
      [
        "T1",
        "时间范围",
        28,
        33,
        "2018年"
      ],
      [
        "T2",
        "市场份额",
        47,
        51,
        "市场份额"
      ],
      [
        "T3",
        "市场份额",
        6,
        9,
        "市占率"
      ],
      [
        "T4",
        "时间范围",
        11,
        16,
        "2014年"
      ],
      [
        "T5",
        "行业",
        43,
        47,
        "页面游戏"
      ],
      [
        "T6",
        "行业",
        97,
        101,
        "移动游戏"
      ],
      [
        "T7",
        "行业",
        87,
        91,
        "轻度游戏"
      ],
      [
        "T8",
        "公司",
        78,
        80,
        "腾讯"
      ],
      [
        "T9",
        "行业",
        73,
        75,
        "端游"
      ],
      [
        "T10",
        "行业",
        53,
        55,
        "端游"
      ],
      [
        "T11",
        "行业",
        56,
        60,
        "页面游戏"
      ],
      [
        "T12",
        "行业",
        63,
        67,
        "移动游戏"
      ]
    ]
  },
  {
    "id": 355,
    "text": " 创新药及制剂板块（52家样本公司，含科创板）2021Q1-3收入1508亿元（+10.3%），归母净利润182.6亿元（-2%），毛利率58%，四费率43%，净利率为13%，集采影响扩大、医保控费导致收入增速放缓，业绩下滑。",
    "labels": [
      [
        "T0",
        "行业",
        2,
        8,
        "创新药及制剂"
      ],
      [
        "T1",
        "行业公司",
        11,
        18,
        "52家样本公司"
      ],
      [
        "T2",
        "时间范围",
        24,
        32,
        "2021Q1-3"
      ],
      [
        "T3",
        "营业收入",
        32,
        34,
        "收入"
      ],
      [
        "T4",
        "属性值",
        34,
        40,
        "1508亿元"
      ],
      [
        "T5",
        "属性值",
        41,
        47,
        "+10.3%"
      ],
      [
        "T6",
        "归母净利润",
        49,
        54,
        "归母净利润"
      ],
      [
        "T7",
        "毛利",
        67,
        70,
        "毛利率"
      ],
      [
        "T8",
        "属性值",
        70,
        73,
        "58%"
      ],
      [
        "T9",
        "业绩",
        109,
        111,
        "业绩"
      ],
      [
        "T10",
        "收入增速",
        102,
        106,
        "收入增速"
      ],
      [
        "T11",
        "属性值",
        106,
        108,
        "放缓"
      ],
      [
        "T12",
        "属性值",
        111,
        113,
        "下滑"
      ],
      [
        "T13",
        "属性值",
        54,
        66,
        "182.6亿元（-2%）"
      ],
      [
        "T14",
        "属性值",
        85,
        88,
        "13%"
      ],
      [
        "T15",
        "归母净利润",
        81,
        84,
        "净利率"
      ]
    ]
  },
  {
    "id": 359,
    "text": "• 2.2.创新药——内卷下的国际化，与First-in-Class差距越来越小重点个股推荐——恒瑞医药（600276）：经营拐点很快到来，加速国际化",
    "labels": [
      [
        "T0",
        "公司",
        48,
        52,
        "恒瑞医药"
      ],
      [
        "T1",
        "行业",
        6,
        9,
        "创新药"
      ]
    ]
  },
  {
    "id": 360,
    "text": "• 智飞生物、康泰生物和康希诺公司的相关新冠疫苗今年陆续获得获得在国内接种使用，随着新冠疫苗大范围接种，从三季报业绩来看，新冠疫苗对公司利润贡献逐步兑现，给公司均带来了丰厚的利润回报。 • 在新冠疫苗大范围接种的同时，一些常规疫苗接种受到疾控接种资源挤兑，使得一些不含新冠疫苗业务的疫苗公司业绩增长不及预期或者出现下滑。",
    "labels": [
      [
        "T0",
        "地点范围",
        33,
        35,
        "国内"
      ],
      [
        "T1",
        "业绩",
        56,
        58,
        "业绩"
      ],
      [
        "T2",
        "利润",
        68,
        70,
        "利润"
      ],
      [
        "T3",
        "业绩",
        145,
        147,
        "业绩"
      ],
      [
        "T4",
        "属性值",
        147,
        159,
        "增长不及预期或者出现下滑"
      ],
      [
        "T5",
        "公司",
        2,
        6,
        "智飞生物"
      ],
      [
        "T6",
        "公司",
        7,
        11,
        "康泰生物"
      ],
      [
        "T7",
        "公司",
        12,
        15,
        "康希诺"
      ],
      [
        "T8",
        "时间范围",
        24,
        26,
        "今年"
      ],
      [
        "T9",
        "时间范围",
        53,
        56,
        "三季报"
      ],
      [
        "T10",
        "行业公司",
        141,
        145,
        "疫苗公司"
      ],
      [
        "T11",
        "行业",
        134,
        138,
        "新冠疫苗"
      ]
    ]
  },
  {
    "id": 362,
    "text": " 全球 CXO行业增长稳定，生物药 CDMO服务表现出较大的增长潜力。全球医药市场收入与研发投入持续稳定增长中小型药企外包需求持续，药企需要进行成本控制。新冠疫情为全球 CXO企业带来了一定的订单新增，包括化学小分子药物、抗体和疫苗。全球龙头公司在收入达到一定规模后，传统小分子业务增速放缓，主要业绩增长由生物药相关业务贡献。生物药在销售收入方面表现出较好的增长潜力，相应的 Bio-CDMO 服务表现出较大的增长潜力。目前，Bio-CDMO产能仍掌握在少数龙头企业手中，龙头企业的 Bio-CDMO业务在 2021年表现出优秀的业绩增长。  中国 CXO行业在 2021年表现出高度的业绩景气度，未来将进入分化阶段。2021年 Q1-Q3中国 CXO企业收入端与利润端表现出优秀的同比增长，截至 Q3期末的存货水平与合同负债水平也与去年同期相比有所增长，为 2022年业绩景气度奠定基础。凯莱英与博腾股份均受到来自海外药企的大额订单，对于 2022年业绩增长有所助力。中国 CXO企业在 2021 年积极进行产能建设和团队建设，进行产能释放从而提高订单承接能力。中国 CXO行业在收入达到一定规模后，整体 CXO行业预期将进入分化阶段。拥有技术与核心竞争力的龙头公司有望在化学小分子业务方面承接更多订单与更复杂的业务，并在生物大分子等新兴业务方面业绩有所增长。行业内竞争力较低的公司会面临整体增速降低的问题。投资预期将进入“精挑细选”时期，需要挑选拥有核心竞争力的 CXO企业进行投资。  生物药及细胞与基因研发热度带来相应 CXO需求，中国 CXO企业积极进行相应布局。中国 CDE一类新药 IND审批数量中的生物药数量与生物药临床实验数量均呈现出上升趋势，生物药相关的 CDMO服务增长潜力大于整体 CDMO市场。药明生物作为中国生物药 CDMO服务龙头企业，掌握 WuXiUP、WuXiBody、WuXiDAR4等优势平台，业绩表现出高景气度增长，并积极进行产能建设传统化学小分子龙头 CXO企业也在积极进行新兴领域布局。",
    "labels": [
      [
        "T0",
        "地点范围",
        2,
        4,
        "全球"
      ],
      [
        "T1",
        "行业",
        5,
        8,
        "CXO"
      ],
      [
        "T2",
        "行业",
        15,
        25,
        "生物药 CDMO服务"
      ],
      [
        "T3",
        "地点范围",
        36,
        38,
        "全球"
      ],
      [
        "T4",
        "行业",
        38,
        40,
        "医药"
      ],
      [
        "T5",
        "营业收入",
        42,
        44,
        "收入"
      ],
      [
        "T6",
        "研发费用",
        45,
        49,
        "研发投入"
      ],
      [
        "T7",
        "地点范围",
        83,
        85,
        "全球"
      ],
      [
        "T8",
        "行业公司",
        86,
        91,
        "CXO企业"
      ],
      [
        "T9",
        "新签订单",
        97,
        101,
        "订单新增"
      ],
      [
        "T10",
        "地点范围",
        118,
        120,
        "全球"
      ],
      [
        "T11",
        "龙头企业",
        120,
        124,
        "龙头公司"
      ],
      [
        "T12",
        "营业收入",
        125,
        127,
        "收入"
      ],
      [
        "T13",
        "行业",
        135,
        140,
        "传统小分子"
      ],
      [
        "T14",
        "业绩",
        149,
        151,
        "业绩"
      ],
      [
        "T15",
        "行业",
        154,
        159,
        "生物药相关"
      ],
      [
        "T16",
        "行业",
        214,
        222,
        "Bio-CDMO"
      ],
      [
        "T17",
        "行业",
        243,
        251,
        "Bio-CDMO"
      ],
      [
        "T18",
        "时间范围",
        255,
        260,
        "2021年"
      ],
      [
        "T19",
        "地点范围",
        274,
        276,
        "中国"
      ],
      [
        "T20",
        "行业",
        277,
        280,
        "CXO"
      ],
      [
        "T21",
        "时间范围",
        284,
        289,
        "2021年"
      ],
      [
        "T22",
        "时间范围",
        311,
        322,
        "2021年 Q1-Q3"
      ],
      [
        "T23",
        "地点范围",
        322,
        324,
        "中国"
      ],
      [
        "T24",
        "行业公司",
        325,
        330,
        "CXO企业"
      ],
      [
        "T25",
        "时间范围",
        348,
        355,
        "截至 Q3期末"
      ],
      [
        "T26",
        "地点范围",
        410,
        412,
        "海外"
      ],
      [
        "T27",
        "行业公司",
        412,
        414,
        "药企"
      ],
      [
        "T28",
        "业绩",
        428,
        430,
        "业绩"
      ],
      [
        "T29",
        "地点范围",
        437,
        439,
        "中国"
      ],
      [
        "T30",
        "行业公司",
        440,
        445,
        "CXO企业"
      ],
      [
        "T31",
        "时间范围",
        447,
        453,
        "2021 年"
      ],
      [
        "T32",
        "龙头企业",
        532,
        536,
        "龙头公司"
      ],
      [
        "T33",
        "行业",
        539,
        544,
        "化学小分子"
      ],
      [
        "T34",
        "行业",
        564,
        569,
        "生物大分子"
      ],
      [
        "T35",
        "业绩",
        576,
        578,
        "业绩"
      ],
      [
        "T36",
        "地点范围",
        673,
        675,
        "中国"
      ],
      [
        "T37",
        "行业公司",
        676,
        681,
        "CXO企业"
      ],
      [
        "T38",
        "地点范围",
        690,
        692,
        "中国"
      ],
      [
        "T39",
        "公司",
        763,
        767,
        "药明生物"
      ],
      [
        "T40",
        "地点范围",
        769,
        771,
        "中国"
      ],
      [
        "T41",
        "行业",
        771,
        781,
        "生物药 CDMO服务"
      ],
      [
        "T42",
        "龙头企业",
        781,
        785,
        "龙头企业"
      ],
      [
        "T43",
        "业绩",
        819,
        821,
        "业绩"
      ],
      [
        "T44",
        "属性值",
        824,
        830,
        "高景气度增长"
      ],
      [
        "T45",
        "属性值",
        51,
        55,
        "稳定增长"
      ],
      [
        "T46",
        "行业公司",
        58,
        60,
        "药企"
      ],
      [
        "T47",
        "行业",
        60,
        62,
        "外包"
      ],
      [
        "T48",
        "行业公司",
        67,
        69,
        "药企"
      ],
      [
        "T49",
        "行业",
        164,
        167,
        "生物药"
      ],
      [
        "T50",
        "营业收入",
        170,
        172,
        "收入"
      ],
      [
        "T51",
        "行业",
        189,
        200,
        "Bio-CDMO 服务"
      ],
      [
        "T52",
        "时间范围",
        211,
        213,
        "目前"
      ],
      [
        "T53",
        "产能",
        222,
        224,
        "产能"
      ],
      [
        "T54",
        "业绩",
        266,
        268,
        "业绩"
      ],
      [
        "T55",
        "属性值",
        292,
        300,
        "高度的业绩景气度"
      ],
      [
        "T56",
        "营业收入",
        330,
        333,
        "收入端"
      ],
      [
        "T57",
        "利润",
        334,
        337,
        "利润端"
      ],
      [
        "T58",
        "存货",
        356,
        358,
        "存货"
      ],
      [
        "T59",
        "合同负债",
        361,
        365,
        "合同负债"
      ],
      [
        "T60",
        "属性值",
        375,
        379,
        "有所增长"
      ],
      [
        "T61",
        "时间范围",
        382,
        387,
        "2022年"
      ],
      [
        "T62",
        "业绩",
        387,
        389,
        "业绩"
      ],
      [
        "T63",
        "属性值",
        340,
        347,
        "优秀的同比增长"
      ],
      [
        "T64",
        "公司",
        397,
        400,
        "凯莱英"
      ],
      [
        "T65",
        "公司",
        401,
        405,
        "博腾股份"
      ],
      [
        "T66",
        "时间范围",
        423,
        428,
        "2022年"
      ],
      [
        "T67",
        "产能",
        457,
        459,
        "产能"
      ],
      [
        "T68",
        "产能",
        469,
        471,
        "产能"
      ],
      [
        "T69",
        "地点范围",
        484,
        486,
        "中国"
      ],
      [
        "T70",
        "行业",
        487,
        490,
        "CXO"
      ],
      [
        "T71",
        "营业收入",
        493,
        495,
        "收入"
      ],
      [
        "T72",
        "行业",
        506,
        509,
        "CXO"
      ],
      [
        "T73",
        "行业公司",
        636,
        641,
        "CXO企业"
      ],
      [
        "T74",
        "行业",
        667,
        670,
        "CXO"
      ],
      [
        "T75",
        "行业需求",
        670,
        672,
        "需求"
      ],
      [
        "T76",
        "行业",
        734,
        747,
        "生物药相关的 CDMO服务"
      ],
      [
        "T77",
        "行业",
        756,
        760,
        "CDMO"
      ],
      [
        "T78",
        "产能",
        836,
        838,
        "产能"
      ],
      [
        "T79",
        "行业",
        840,
        847,
        "传统化学小分子"
      ],
      [
        "T80",
        "行业公司",
        850,
        855,
        "CXO企业"
      ]
    ]
  },
  {
    "id": 363,
    "text": " 振德医疗：大感控龙头即将扬帆起航，核心业务线有望保持快速增长。疫情对于振德医疗的影响具有长期性，主要表现在疫情发生后，各级医院对于自身感控体系的完善趋势是不可逆的。21H1，在国内疫情整体趋于平稳的情势下 ，振德医疗感控线依然保持了80%+的同比增速。同时，能观察到公司渠道拓展、医院覆盖率提升、人员扩增等边际向好因素。配合敷料、伤口护理等业务线，公司有望成长为大感控解决方案龙头。",
    "labels": [
      [
        "T0",
        "公司",
        2,
        6,
        "振德医疗"
      ],
      [
        "T1",
        "主营业务",
        19,
        23,
        "核心业务"
      ],
      [
        "T2",
        "龙头企业",
        10,
        12,
        "龙头"
      ],
      [
        "T3",
        "行业",
        7,
        10,
        "大感控"
      ],
      [
        "T4",
        "属性值",
        28,
        32,
        "快速增长"
      ],
      [
        "T5",
        "公司",
        37,
        41,
        "振德医疗"
      ],
      [
        "T6",
        "时间范围",
        84,
        88,
        "21H1"
      ],
      [
        "T7",
        "地点范围",
        90,
        92,
        "国内"
      ],
      [
        "T8",
        "公司",
        106,
        110,
        "振德医疗"
      ],
      [
        "T9",
        "行业",
        110,
        112,
        "感控"
      ],
      [
        "T10",
        "行业",
        164,
        166,
        "敷料"
      ],
      [
        "T11",
        "行业",
        167,
        171,
        "伤口护理"
      ],
      [
        "T12",
        "行业",
        183,
        186,
        "大感控"
      ]
    ]
  },
  {
    "id": 364,
    "text": "表：南下资金医药持股金额增加前10名",
    "labels": [
      [
        "T0",
        "行业",
        6,
        8,
        "医药"
      ]
    ]
  },
  {
    "id": 365,
    "text": "近年来中美关系的变化对于海外收入为主体的CXO的愈发敏感，以及CDE政策与ICH的逐步接轨，规范性文件频发。如何看待政策及国际关系对CXO的影响成为大家对于CXO未来景气最关注的问题。",
    "labels": [
      [
        "T0",
        "时间范围",
        0,
        3,
        "近年来"
      ],
      [
        "T1",
        "地点范围",
        12,
        14,
        "海外"
      ],
      [
        "T2",
        "营业收入",
        14,
        16,
        "收入"
      ],
      [
        "T3",
        "行业",
        20,
        23,
        "CXO"
      ],
      [
        "T4",
        "地点范围",
        3,
        4,
        "中"
      ],
      [
        "T5",
        "地点范围",
        4,
        5,
        "美"
      ],
      [
        "T6",
        "行业",
        66,
        69,
        "CXO"
      ],
      [
        "T7",
        "行业",
        78,
        81,
        "CXO"
      ]
    ]
  },
  {
    "id": 366,
    "text": "• 2021年国内多家公司各季度营收再创历史新高，2021Q3季度增速维持在30%+。 • 受全球疫情影响， 2020Q2全球海外订单涌进，致2021Q2同比增速相对有所放缓；",
    "labels": [
      [
        "T0",
        "时间范围",
        2,
        7,
        "2021年"
      ],
      [
        "T1",
        "地点范围",
        7,
        9,
        "国内"
      ],
      [
        "T2",
        "营业收入",
        16,
        18,
        "营收"
      ],
      [
        "T3",
        "时间范围",
        25,
        33,
        "2021Q3季度"
      ],
      [
        "T4",
        "收入增速",
        33,
        35,
        "增速"
      ],
      [
        "T5",
        "时间范围",
        55,
        61,
        "2020Q2"
      ],
      [
        "T6",
        "地点范围",
        61,
        63,
        "全球"
      ],
      [
        "T7",
        "地点范围",
        63,
        65,
        "海外"
      ],
      [
        "T8",
        "时间范围",
        71,
        77,
        "2021Q2"
      ]
    ]
  },
  {
    "id": 367,
    "text": "1月 19日，基石药业宣布， 舒格利单抗注射液一线治疗转移性非小细胞肺癌的 III期临床研究 GEMSTONE-302达到总生存期的研究终点。结果显示，舒格利单抗联合化疗可显著延长患者的 OS并具有临床意义。它是全球首个联合化疗显著改善鳞状和非鳞状 IV期初治非小细胞肺癌患者总生存期的 PD-L1单抗， OS等详细的研究数据将在近期召开的国际学术会议中公布。",
    "labels": [
      [
        "T0",
        "时间范围",
        0,
        6,
        "1月 19日"
      ],
      [
        "T1",
        "公司",
        7,
        11,
        "基石药业"
      ],
      [
        "T2",
        "地点范围",
        106,
        108,
        "全球"
      ],
      [
        "T3",
        "时间范围",
        165,
        167,
        "近期"
      ]
    ]
  },
  {
    "id": 368,
    "text": "• 国内疫苗接种率也达到80%以上。从今年3月以来，国内开始大范围开展新冠疫苗接种，截止2021年11月15日，中国新冠疫苗接种剂次已经接近24亿剂，新冠疫苗接种率已超过80%（按照人均2剂次计算）。不过新冠疫苗接种6个月后体内抗体水平会下降，目前国内部分地区也陆续开展新冠疫苗“加强针”接种工作。",
    "labels": [
      [
        "T0",
        "时间范围",
        42,
        55,
        "截止2021年11月15日"
      ],
      [
        "T1",
        "时间范围",
        19,
        25,
        "今年3月以来"
      ],
      [
        "T2",
        "地点范围",
        2,
        4,
        "国内"
      ],
      [
        "T3",
        "地点范围",
        26,
        28,
        "国内"
      ],
      [
        "T4",
        "地点范围",
        56,
        58,
        "中国"
      ],
      [
        "T5",
        "时间范围",
        122,
        124,
        "目前"
      ],
      [
        "T6",
        "地点范围",
        124,
        130,
        "国内部分地区"
      ]
    ]
  },
  {
    "id": 370,
    "text": " CDMO业务的核心竞争优势主要由“一体化服务能力、D端研发能力、技术平台优势、订单交付能力、体量规模优势、订单价格优势”等多个因素共同决定。以九洲药业、美诺华、普洛药业、天宇股份等为代表的API 公司在发展过程当中逐步积累和形成CDMO业务的多个核心竞争优势，逐渐实现从API往CDMO业务的转型。",
    "labels": [
      [
        "T0",
        "行业",
        2,
        6,
        "CDMO"
      ],
      [
        "T1",
        "公司",
        73,
        77,
        "九洲药业"
      ],
      [
        "T2",
        "公司",
        78,
        81,
        "美诺华"
      ],
      [
        "T3",
        "公司",
        82,
        86,
        "普洛药业"
      ],
      [
        "T4",
        "公司",
        87,
        91,
        "天宇股份"
      ],
      [
        "T5",
        "行业公司",
        96,
        102,
        "API 公司"
      ],
      [
        "T6",
        "行业",
        116,
        120,
        "CDMO"
      ],
      [
        "T7",
        "行业",
        137,
        140,
        "API"
      ],
      [
        "T8",
        "行业",
        141,
        145,
        "CDMO"
      ]
    ]
  },
  {
    "id": 371,
    "text": "表：两地上市医药格式A/H溢价情况",
    "labels": [
      [
        "T0",
        "行业",
        6,
        8,
        "医药"
      ]
    ]
  },
  {
    "id": 372,
    "text": "抗TJC4的开发和商业化达成全球战略合作，总额包括19.4亿美元的首付款和里程碑付款；2021年1月，百济神州与诺华就 PD-1单抗替雷利珠达成协议，总额包括 22亿美元的首付款和里程碑付款；2021年8月，荣昌生物与西雅图基因就 ADC药物维迪西妥单抗达成全球独家许可协议，总额包括 26亿美元的首付款和里程碑付款。",
    "labels": [
      [
        "T0",
        "时间范围",
        43,
        50,
        "2021年1月"
      ],
      [
        "T1",
        "时间范围",
        96,
        103,
        "2021年8月"
      ],
      [
        "T2",
        "地点范围",
        14,
        16,
        "全球"
      ],
      [
        "T3",
        "公司",
        51,
        55,
        "百济神州"
      ],
      [
        "T4",
        "公司",
        56,
        58,
        "诺华"
      ],
      [
        "T5",
        "公司",
        104,
        108,
        "荣昌生物"
      ],
      [
        "T6",
        "公司",
        109,
        114,
        "西雅图基因"
      ],
      [
        "T7",
        "地点范围",
        129,
        131,
        "全球"
      ]
    ]
  },
  {
    "id": 373,
    "text": "生物科研试剂主要包括分子类、蛋白类以及细胞类试剂三大类。分子类主要是核酸类试剂，主要用于核酸类相关实验例如 PCR扩增和 DNA测序中涉及到的各种工具酶、 底物等，近年来核酸药物、细胞基因治疗、PROTAC等新领域的发展赋予了核酸类试剂新的应用场景，除了可以作为研究工具被用于相关领域研究，还可以作为治疗药物的关键原料。蛋白类试剂主要是指围绕蛋白质大分子进行的实验中所需要用到的试剂类型，包括重组蛋白试剂和抗体试剂等。细胞类试主要是指围绕体外细胞进行实验中所需要用到的试剂，包括特定的细胞和用于细胞培养、转染、检测凋亡、裂解细胞的产品或试剂盒等。",
    "labels": [
      [
        "T0",
        "时间范围",
        82,
        85,
        "近年来"
      ],
      [
        "T1",
        "行业",
        85,
        89,
        "核酸药物"
      ],
      [
        "T2",
        "行业",
        90,
        96,
        "细胞基因治疗"
      ],
      [
        "T3",
        "行业",
        97,
        103,
        "PROTAC"
      ],
      [
        "T4",
        "行业",
        113,
        118,
        "核酸类试剂"
      ]
    ]
  },
  {
    "id": 374,
    "text": " 2019年影像设备超过1000亿，以X线类、CT、 超声、MRI设备为主；供给端看，影像的技术壁垒较高，国产和海外厂商差距较大，当前市场主要由GPS占据绝大份额，国产化率低；需求端看，受采购政策和采购周期影响较大，从人均保有量看离发达国家有5-10倍的差距，未来市场有望持续增长。  目前X射线、超声领域国产有望凭技术积累率先突围，后续CT、MRI也有望逐步突破。关注万东、东软、迈瑞、联影等企业。  万东医疗：2021前三季度收入8亿元（+8.7% ），归母净利润1.2亿元（-18.7%），主要因移动DR销售数量与去年上半年相比有较大幅度的降低。  迈瑞医疗：2021Q1-3公司影像业务同比增速 30~35%，比中报27%的增速进一步提升，主要因国内外台式彩超需求恢复。",
    "labels": [
      [
        "T0",
        "时间范围",
        2,
        7,
        "2019年"
      ],
      [
        "T1",
        "行业",
        7,
        11,
        "影像设备"
      ],
      [
        "T2",
        "行业供给",
        39,
        42,
        "供给端"
      ],
      [
        "T3",
        "公司",
        205,
        209,
        "万东医疗"
      ],
      [
        "T4",
        "时间范围",
        210,
        218,
        "2021前三季度"
      ],
      [
        "T5",
        "营业收入",
        218,
        220,
        "收入"
      ],
      [
        "T6",
        "属性值",
        220,
        223,
        "8亿元"
      ],
      [
        "T7",
        "属性值",
        224,
        229,
        "+8.7%"
      ],
      [
        "T8",
        "归母净利润",
        232,
        237,
        "归母净利润"
      ],
      [
        "T9",
        "公司",
        282,
        286,
        "迈瑞医疗"
      ],
      [
        "T10",
        "时间范围",
        287,
        295,
        "2021Q1-3"
      ],
      [
        "T11",
        "行业",
        297,
        299,
        "影像"
      ],
      [
        "T12",
        "属性值",
        11,
        18,
        "超过1000亿"
      ],
      [
        "T13",
        "行业",
        44,
        46,
        "影像"
      ],
      [
        "T14",
        "时间范围",
        66,
        68,
        "当前"
      ],
      [
        "T15",
        "行业需求",
        89,
        92,
        "需求端"
      ],
      [
        "T16",
        "属性值",
        137,
        141,
        "持续增长"
      ],
      [
        "T17",
        "时间范围",
        131,
        133,
        "未来"
      ],
      [
        "T18",
        "时间范围",
        145,
        147,
        "目前"
      ],
      [
        "T19",
        "行业",
        147,
        150,
        "X射线"
      ],
      [
        "T20",
        "行业",
        151,
        153,
        "超声"
      ],
      [
        "T21",
        "行业",
        171,
        173,
        "CT"
      ],
      [
        "T22",
        "行业",
        174,
        177,
        "MRI"
      ],
      [
        "T23",
        "公司",
        187,
        189,
        "万东"
      ],
      [
        "T24",
        "公司",
        190,
        192,
        "东软"
      ],
      [
        "T25",
        "公司",
        193,
        195,
        "迈瑞"
      ],
      [
        "T26",
        "公司",
        196,
        198,
        "联影"
      ],
      [
        "T27",
        "属性值",
        237,
        250,
        "1.2亿元（-18.7%）"
      ],
      [
        "T28",
        "时间范围",
        263,
        268,
        "去年上半年"
      ],
      [
        "T29",
        "地点范围",
        331,
        333,
        "国内"
      ],
      [
        "T30",
        "行业",
        333,
        338,
        "外台式彩超"
      ],
      [
        "T31",
        "行业需求",
        338,
        340,
        "需求"
      ],
      [
        "T32",
        "属性值",
        340,
        342,
        "恢复"
      ],
      [
        "T33",
        "属性值",
        301,
        312,
        "同比增速 30~35%"
      ]
    ]
  },
  {
    "id": 375,
    "text": "全球 CDMO市场仍然较为分散，存在大量的小型 CDMO竞争者，行业中存在整合增长机会。根据全球头部 CDMO Recipharm年报数据，2019年年收入在 2400万美元以下的公司在行业中数量占比高达 66%,而年收入在 2.5亿至 4.9亿美元之间的 CDMO企业数量在全行业 CDMO企业数量占比仅为 3%， 年收入大于 5亿美元的 CDMO企业数量在全行业 CDMO企业数量占比仅为 1%。在市场收入份额方面，年收入大于 5亿美元的 CDMO企业占据 31%的市场份额。 从收入规模来看，中国公司药明康德与药明生物虽然与顶尖 CDMO公司收入仍有差距，但是收入水平已到达全球第一梯队水平，凯莱英、康龙化成与博腾股份收入规模已达到第二梯队水平。",
    "labels": [
      [
        "T0",
        "地点范围",
        0,
        2,
        "全球"
      ],
      [
        "T1",
        "行业",
        3,
        7,
        "CDMO"
      ],
      [
        "T2",
        "地点范围",
        46,
        48,
        "全球"
      ],
      [
        "T3",
        "公司",
        56,
        65,
        "Recipharm"
      ],
      [
        "T4",
        "时间范围",
        70,
        75,
        "2019年"
      ],
      [
        "T5",
        "市场份额",
        201,
        207,
        "市场收入份额"
      ],
      [
        "T6",
        "地点范围",
        249,
        251,
        "中国"
      ],
      [
        "T7",
        "行业公司",
        268,
        274,
        "CDMO公司"
      ],
      [
        "T8",
        "属性值",
        11,
        15,
        "较为分散"
      ],
      [
        "T9",
        "行业",
        24,
        28,
        "CDMO"
      ],
      [
        "T10",
        "行业",
        51,
        55,
        "CDMO"
      ],
      [
        "T11",
        "营业收入",
        76,
        78,
        "收入"
      ],
      [
        "T12",
        "营业收入",
        109,
        111,
        "收入"
      ],
      [
        "T13",
        "行业公司",
        129,
        135,
        "CDMO企业"
      ],
      [
        "T14",
        "行业公司",
        142,
        148,
        "CDMO企业"
      ],
      [
        "T15",
        "行业公司",
        171,
        177,
        "CDMO企业"
      ],
      [
        "T16",
        "行业公司",
        184,
        190,
        "CDMO企业"
      ],
      [
        "T17",
        "行业公司",
        222,
        228,
        "CDMO企业"
      ],
      [
        "T18",
        "市场份额",
        235,
        239,
        "市场份额"
      ],
      [
        "T19",
        "营业收入",
        242,
        244,
        "收入"
      ],
      [
        "T20",
        "公司",
        253,
        257,
        "药明康德"
      ],
      [
        "T21",
        "公司",
        258,
        262,
        "药明生物"
      ],
      [
        "T22",
        "营业收入",
        274,
        276,
        "收入"
      ],
      [
        "T23",
        "营业收入",
        283,
        285,
        "收入"
      ],
      [
        "T24",
        "地点范围",
        290,
        292,
        "全球"
      ],
      [
        "T25",
        "公司",
        299,
        302,
        "凯莱英"
      ],
      [
        "T26",
        "公司",
        303,
        307,
        "康龙化成"
      ],
      [
        "T27",
        "公司",
        308,
        312,
        "博腾股份"
      ],
      [
        "T28",
        "营业收入",
        312,
        314,
        "收入"
      ]
    ]
  },
  {
    "id": 376,
    "text": " POCT凭借快速、简单、即时即地场景多元等优势在 IVD赛道中占比逐渐提升。2018年国内POCT市场规模100亿元，预计能够维持20%以上的增速。",
    "labels": [
      [
        "T0",
        "市场规模",
        51,
        55,
        "市场规模"
      ],
      [
        "T1",
        "时间范围",
        40,
        45,
        "2018年"
      ],
      [
        "T2",
        "地点范围",
        45,
        47,
        "国内"
      ],
      [
        "T3",
        "行业",
        47,
        51,
        "POCT"
      ],
      [
        "T4",
        "属性值",
        55,
        60,
        "100亿元"
      ],
      [
        "T5",
        "属性值",
        67,
        72,
        "20%以上"
      ],
      [
        "T6",
        "行业",
        2,
        6,
        "POCT"
      ],
      [
        "T7",
        "行业",
        27,
        30,
        "IVD"
      ],
      [
        "T8",
        "属性值",
        8,
        22,
        "快速、简单、即时即地场景多元"
      ]
    ]
  },
  {
    "id": 377,
    "text": " 从21Q1-3疫苗板块收入占比看，智飞占比50%；从21Q1-3年疫苗板块归母净利润占比看，智飞占比63%；智飞为板块收入、利润的主要贡献者。",
    "labels": [
      [
        "T0",
        "时间范围",
        3,
        9,
        "21Q1-3"
      ],
      [
        "T1",
        "行业",
        9,
        11,
        "疫苗"
      ],
      [
        "T2",
        "公司",
        19,
        21,
        "智飞"
      ],
      [
        "T3",
        "时间范围",
        28,
        35,
        "21Q1-3年"
      ],
      [
        "T4",
        "行业",
        35,
        37,
        "疫苗"
      ],
      [
        "T5",
        "归母净利润",
        39,
        44,
        "归母净利润"
      ],
      [
        "T6",
        "公司",
        56,
        58,
        "智飞"
      ],
      [
        "T7",
        "营收占比",
        13,
        17,
        "收入占比"
      ],
      [
        "T8",
        "属性值",
        23,
        26,
        "50%"
      ],
      [
        "T9",
        "公司",
        48,
        50,
        "智飞"
      ],
      [
        "T10",
        "属性值",
        50,
        55,
        "占比63%"
      ],
      [
        "T11",
        "营业收入",
        61,
        63,
        "收入"
      ],
      [
        "T12",
        "利润",
        64,
        66,
        "利润"
      ]
    ]
  },
  {
    "id": 379,
    "text": " 1月 20日，誉衡生物宣布其正在开展的抗 PD-1单抗赛帕利单抗治疗复发或转移性宫颈癌 2期临床研究，已达到方案预设主要研究终点。基于该研究的结果，CDE已同意誉衡生物提交赛帕利单抗治疗复发或转移性宫颈癌的上市申请，并同意将此次新适应症的上市申请纳入优先审评审批程序。  1月 20日，CDE官网显示，君境生物的 XPO1抑制剂 WJ01075片首次获批临床，用于晚期恶性肿瘤，这是君境生物进入临床开发的第 2款 XPO1 抑制剂。  1月 20日，奥赛康 1类新药 ASKG712注射液在国内获批临床，用于治疗新生血管性年龄相关性黄斑变性。  1月 20日，华东医药发布公告称，华东医药控股子公司道尔生物于 1月 18 日收到 NMPA核准签发的《药物临床试验批准通知书》，1类新药注射用 DR30303的 I期临床试验申请获得批准。  1月 20日，CDE官网显示，辉瑞申报的 elranatamab获得一项临床试验默示许可，拟用于以下适应症：单药或联合达雷妥尤单抗，用于既往接受过至少 1线抗多发性骨髓瘤治疗的多发性骨髓瘤患者。elranatamab是一款靶向 BCMA和 CD3的双特异性抗体药物，在全球已进入 3期临床研究阶段。  1月 19日，NMPA官网显示，华北制药 1类新药奥木替韦单抗已经进入在审批阶段，预计将在近日获批，用于狂犬病毒暴露患者的被动免疫。  1月 19日，CDE官网显示，恒瑞医药的 PD-L1单抗阿得贝利单抗上市申请获受理。这是国产第 5款申报上市的 PD-L1单抗。  1 月 18 日，CDE 公示显示，Nektar Therapeutics 申报的",
    "labels": [
      [
        "T0",
        "时间范围",
        2,
        8,
        "1月 20日"
      ],
      [
        "T1",
        "公司",
        9,
        13,
        "誉衡生物"
      ],
      [
        "T2",
        "公司",
        82,
        86,
        "誉衡生物"
      ],
      [
        "T3",
        "时间范围",
        139,
        145,
        "1月 20日"
      ],
      [
        "T4",
        "公司",
        154,
        158,
        "君境生物"
      ],
      [
        "T5",
        "公司",
        194,
        198,
        "君境生物"
      ],
      [
        "T6",
        "时间范围",
        222,
        228,
        "1月 20日"
      ],
      [
        "T7",
        "地点范围",
        249,
        251,
        "国内"
      ],
      [
        "T8",
        "公司",
        229,
        232,
        "奥赛康"
      ],
      [
        "T9",
        "时间范围",
        278,
        284,
        "1月 20日"
      ],
      [
        "T10",
        "公司",
        285,
        289,
        "华东医药"
      ],
      [
        "T11",
        "公司",
        295,
        299,
        "华东医药"
      ],
      [
        "T12",
        "公司",
        304,
        308,
        "道尔生物"
      ],
      [
        "T13",
        "时间范围",
        310,
        317,
        "1月 18 日"
      ],
      [
        "T14",
        "时间范围",
        376,
        382,
        "1月 20日"
      ],
      [
        "T15",
        "公司",
        391,
        393,
        "辉瑞"
      ],
      [
        "T16",
        "地点范围",
        510,
        512,
        "全球"
      ],
      [
        "T17",
        "时间范围",
        528,
        534,
        "1月 19日"
      ],
      [
        "T18",
        "公司",
        544,
        548,
        "华北制药"
      ],
      [
        "T19",
        "时间范围",
        597,
        603,
        "1月 19日"
      ],
      [
        "T20",
        "公司",
        612,
        616,
        "恒瑞医药"
      ],
      [
        "T21",
        "时间范围",
        664,
        672,
        "1 月 18 日"
      ],
      [
        "T22",
        "公司",
        682,
        701,
        "Nektar Therapeutics"
      ]
    ]
  },
  {
    "id": 380,
    "text": "上海医药:营业收入及利润实现快速增长，1)医药商业：加快进口准入、仓储物流等方面发展;2) 医药工业：保障原料产能供应 ，积极布局高端制剂领域，实现上游领域的快速拓展。 九州通：扣除非经常性损益后业绩仍然大幅增长。同时有效控制成本和销售回款，现金流情况持续向好。公司各项管理措施不断加强，减税降费政策成效逐步显现，融资成本降低； 国药一致：加速并购药店，拓展下游产业链。OTO和DTP双重利好零售板块，分销业务迎来拐点。",
    "labels": [
      [
        "T0",
        "公司",
        0,
        4,
        "上海医药"
      ],
      [
        "T1",
        "营业收入",
        5,
        9,
        "营业收入"
      ],
      [
        "T2",
        "利润",
        10,
        12,
        "利润"
      ],
      [
        "T3",
        "属性值",
        14,
        18,
        "快速增长"
      ],
      [
        "T4",
        "行业",
        21,
        25,
        "医药商业"
      ],
      [
        "T5",
        "行业",
        46,
        50,
        "医药工业"
      ],
      [
        "T6",
        "行业",
        65,
        69,
        "高端制剂"
      ],
      [
        "T7",
        "公司",
        85,
        88,
        "九州通"
      ],
      [
        "T8",
        "业绩",
        98,
        100,
        "业绩"
      ],
      [
        "T9",
        "属性值",
        102,
        106,
        "大幅增长"
      ],
      [
        "T10",
        "现金流",
        121,
        124,
        "现金流"
      ],
      [
        "T11",
        "属性值",
        128,
        130,
        "向好"
      ],
      [
        "T12",
        "公司",
        165,
        169,
        "国药一致"
      ],
      [
        "T13",
        "行业",
        196,
        198,
        "零售"
      ],
      [
        "T14",
        "行业",
        201,
        203,
        "分销"
      ],
      [
        "T15",
        "属性值",
        205,
        209,
        "迎来拐点"
      ]
    ]
  },
  {
    "id": 381,
    "text": "风险提示：医保控费力度超出预期；医美行业整顿风险；创新药械进展低于预期。",
    "labels": [
      [
        "T0",
        "行业",
        16,
        18,
        "医美"
      ],
      [
        "T1",
        "行业",
        25,
        29,
        "创新药械"
      ]
    ]
  },
  {
    "id": 382,
    "text": "医药行业估值水平已经合理偏低，已经具有一定安全边际。当前 SW医药生物指数 PE（TTM）34倍左右，已经低于近十年 PE（TTM）估值波动中位数 38倍，医药行业归母净利润连续两年平均增长 26.5%，PEG为 1.2左右，在当前全球疫情前景不明情况下，医药作为疫情正向刺激行业，并未体现明显估值溢价。虽然部分板块估值水平较高， 但细分行业发展仍处于高速发展阶段，具有较扎实的逻辑支撑，业绩的成长会抵消估值的波动。部分医药核心公司估值已经回落到历史估值较低分位。随着政策担忧情绪缓和， 我们认为医药战略配置时刻逐渐显现。",
    "labels": [
      [
        "T0",
        "行业",
        0,
        2,
        "医药"
      ],
      [
        "T1",
        "PE",
        38,
        40,
        "PE"
      ],
      [
        "T2",
        "PE",
        59,
        61,
        "PE"
      ],
      [
        "T3",
        "行业",
        78,
        80,
        "医药"
      ],
      [
        "T4",
        "归母净利润",
        82,
        87,
        "归母净利润"
      ],
      [
        "T5",
        "时间范围",
        87,
        91,
        "连续两年"
      ],
      [
        "T6",
        "属性值",
        91,
        101,
        "平均增长 26.5%"
      ],
      [
        "T7",
        "PEG",
        102,
        105,
        "PEG"
      ],
      [
        "T8",
        "属性值",
        107,
        112,
        "1.2左右"
      ],
      [
        "T9",
        "时间范围",
        114,
        116,
        "当前"
      ],
      [
        "T10",
        "地点范围",
        116,
        118,
        "全球"
      ],
      [
        "T11",
        "行业",
        128,
        130,
        "医药"
      ],
      [
        "T12",
        "行业公司",
        208,
        216,
        "部分医药核心公司"
      ],
      [
        "T13",
        "行业",
        248,
        250,
        "医药"
      ],
      [
        "T14",
        "行业",
        31,
        35,
        "医药生物"
      ],
      [
        "T15",
        "属性值",
        45,
        50,
        "34倍左右"
      ],
      [
        "T16",
        "时间范围",
        55,
        58,
        "近十年"
      ],
      [
        "T17",
        "属性值",
        74,
        77,
        "38倍"
      ],
      [
        "T18",
        "时间范围",
        26,
        28,
        "当前"
      ]
    ]
  },
  {
    "id": 383,
    "text": " 2022年预计国内采浆量有望加速增长，新增浆站贡献及疫情后逐步恢复是采浆增长的主要动力。其中天坛生物、博雅生物由于背靠国有央企，在浆站获取及建设上具有的天然优势。",
    "labels": [
      [
        "T0",
        "时间范围",
        2,
        7,
        "2022年"
      ],
      [
        "T1",
        "地点范围",
        9,
        11,
        "国内"
      ],
      [
        "T2",
        "公司",
        48,
        52,
        "天坛生物"
      ],
      [
        "T3",
        "公司",
        53,
        57,
        "博雅生物"
      ]
    ]
  },
  {
    "id": 386,
    "text": "纳微科技：（1）国内大分子药物研发热情持续高涨，大量项目从临床阶段进入商业化生产阶段，对分离纯化的需求逐级放大，色谱填料的采购迎来高速增长期。（2）公司的色谱填料具备性能优异、供应稳定、价格合理等优点，有望快速实现对外资厂商的进口替代，其中亲和层析介质和离子交换层析介质放量增长明显。（3）依托关键微球技术，布局检测分析色谱柱、IVD磁性微球等领域，有望打造全新增长曲线。",
    "labels": [
      [
        "T0",
        "公司",
        1,
        5,
        "纳微科技"
      ],
      [
        "T1",
        "地点范围",
        9,
        11,
        "国内"
      ],
      [
        "T2",
        "行业",
        11,
        16,
        "大分子药物"
      ],
      [
        "T3",
        "行业",
        157,
        164,
        "检测分析色谱柱"
      ],
      [
        "T4",
        "行业",
        165,
        172,
        "IVD磁性微球"
      ]
    ]
  },
  {
    "id": 387,
    "text": "从原理看：游戏是慢生意，轻/中/重度游戏在用户规模、用户画像和付费能力各不相同，各公司有自己的能力圈，流量并非是万能钥匙。",
    "labels": [
      [
        "T0",
        "行业",
        5,
        7,
        "游戏"
      ],
      [
        "T1",
        "行业",
        12,
        20,
        "轻/中/重度游戏"
      ]
    ]
  },
  {
    "id": 388,
    "text": "上游成本传递和下游库存消化等影响下，原料药有望迎来新一轮提价周期。其中，缬沙坦价格逐步见底，替米沙坦、厄贝沙坦、泛酸钙、咖啡因等品种已逐步开始提价。",
    "labels": [
      [
        "T0",
        "行业",
        19,
        22,
        "原料药"
      ]
    ]
  },
  {
    "id": 390,
    "text": "2020年中国 CDE一类新药原始生物药 IND审批数量为 339个，与上年相比增加了 133个。同年 CDE 一类新药原始化学药物 IND数量为 211个，少于生物药 IND审批数量。在临床实验数量方面，原始生物药仍少于原始化学药物，但是也表现出数量快速增长的趋势。",
    "labels": [
      [
        "T0",
        "时间范围",
        0,
        5,
        "2020年"
      ],
      [
        "T1",
        "地点范围",
        5,
        7,
        "中国"
      ],
      [
        "T2",
        "时间范围",
        36,
        38,
        "上年"
      ],
      [
        "T3",
        "行业",
        81,
        84,
        "生物药"
      ],
      [
        "T4",
        "行业",
        103,
        108,
        "原始生物药"
      ],
      [
        "T5",
        "行业",
        111,
        117,
        "原始化学药物"
      ],
      [
        "T6",
        "行业",
        15,
        20,
        "原始生物药"
      ],
      [
        "T7",
        "行业",
        60,
        66,
        "原始化学药物"
      ]
    ]
  },
  {
    "id": 391,
    "text": "• 公司毛利率和归母净利润仍呈现上市趋势。2021年毛利率为47%，归母净利率33%，均呈现持续上升状态，主要归功于期间费用率不断下降。",
    "labels": [
      [
        "T0",
        "毛利",
        4,
        7,
        "毛利率"
      ],
      [
        "T1",
        "归母净利润",
        8,
        13,
        "归母净利润"
      ],
      [
        "T2",
        "时间范围",
        21,
        26,
        "2021年"
      ],
      [
        "T3",
        "毛利",
        26,
        29,
        "毛利率"
      ],
      [
        "T4",
        "归母净利润",
        34,
        39,
        "归母净利率"
      ]
    ]
  },
  {
    "id": 394,
    "text": "• 医药行业经营常态化。2021年以来随着医药行业经营进入常态化，同时叠加2020年疫情影响造成低基数，2021年1-9月中国医药制造业营业收入及利润总额累计同比2020年分别为24%/81%，实现了高速增长。 • 销售终端持续改善。随着2021年国内疫情防控进入常态化，医药产业在政策的驱动下，正进行深刻的变革。一方面，鼓励创新、人口老龄化等因素推动了医药产业发展；另一方面，医保基金腾笼换鸟等一系列改革政策使得药品降价压力增大。在机遇与挑战的共同作用下，根据米内网发布的数据显示，2021年上半年中国公立医疗机构终端药品的销售额实现恢复性增长， 比2020年上半年增长9.77%，销售额为6174亿元。",
    "labels": [
      [
        "T0",
        "行业",
        2,
        4,
        "医药"
      ],
      [
        "T1",
        "时间范围",
        12,
        19,
        "2021年以来"
      ],
      [
        "T2",
        "行业",
        21,
        23,
        "医药"
      ],
      [
        "T3",
        "时间范围",
        37,
        42,
        "2020年"
      ],
      [
        "T4",
        "时间范围",
        52,
        61,
        "2021年1-9月"
      ],
      [
        "T5",
        "地点范围",
        61,
        63,
        "中国"
      ],
      [
        "T6",
        "时间范围",
        81,
        86,
        "2020年"
      ],
      [
        "T7",
        "属性值",
        89,
        92,
        "24%"
      ],
      [
        "T8",
        "属性值",
        93,
        96,
        "81%"
      ],
      [
        "T9",
        "营收增长",
        68,
        72,
        "营业收入"
      ],
      [
        "T10",
        "利润增长",
        73,
        77,
        "利润总额"
      ],
      [
        "T11",
        "时间范围",
        242,
        250,
        "2021年上半年"
      ],
      [
        "T12",
        "地点范围",
        250,
        252,
        "中国"
      ],
      [
        "T13",
        "行业公司",
        252,
        258,
        "公立医疗机构"
      ],
      [
        "T14",
        "行业",
        258,
        262,
        "终端药品"
      ],
      [
        "T15",
        "行业",
        63,
        68,
        "医药制造业"
      ],
      [
        "T16",
        "属性值",
        100,
        104,
        "高速增长"
      ],
      [
        "T17",
        "时间范围",
        119,
        124,
        "2021年"
      ],
      [
        "T18",
        "地点范围",
        124,
        126,
        "国内"
      ],
      [
        "T19",
        "行业",
        136,
        138,
        "医药"
      ],
      [
        "T20",
        "行业",
        177,
        179,
        "医药"
      ],
      [
        "T21",
        "时间范围",
        276,
        284,
        "2020年上半年"
      ]
    ]
  },
  {
    "id": 397,
    "text": "智飞生物：公司目前已通过代理+自研模式布局多个重磅疫苗品种。（1）代理品种：HPV疫苗供不应求，中短期竞争格局良好。（2）自主研发：在研产品涵盖肺结核、流脑、肺炎、流感等方面，目前已有多个重磅品种上市或进入3期临床实验阶段。总体而言，公司管线布局结构清晰、层次丰富，重磅品种有望实现长期良性高速增长。",
    "labels": [
      [
        "T0",
        "公司",
        1,
        5,
        "智飞生物"
      ],
      [
        "T1",
        "行业",
        24,
        28,
        "重磅疫苗"
      ],
      [
        "T2",
        "时间范围",
        8,
        10,
        "目前"
      ],
      [
        "T3",
        "属性值",
        13,
        18,
        "代理+自研"
      ],
      [
        "T4",
        "属性值",
        56,
        58,
        "良好"
      ],
      [
        "T5",
        "竞争格局",
        52,
        56,
        "竞争格局"
      ],
      [
        "T6",
        "时间范围",
        49,
        52,
        "中短期"
      ],
      [
        "T7",
        "行业",
        39,
        44,
        "HPV疫苗"
      ]
    ]
  },
  {
    "id": 398,
    "text": "生物药市场快速发展，为制药装备市场带来重要增量。根据Frost & Sullivan，预计到2030年我国生物药市场规模有望达 1.3万亿元， 2020-2030年的CAGR约13%。随着我国生物药等细分行业的迅猛发展 ，药企为提升市场竞争力将加速扩产，这将成为推动制药设备市场发展的重要驱动力。",
    "labels": [
      [
        "T0",
        "行业",
        1,
        4,
        "生物药"
      ],
      [
        "T1",
        "行业",
        12,
        16,
        "制药装备"
      ],
      [
        "T2",
        "时间范围",
        47,
        52,
        "2030年"
      ],
      [
        "T3",
        "地点范围",
        52,
        54,
        "我国"
      ],
      [
        "T4",
        "行业",
        54,
        57,
        "生物药"
      ],
      [
        "T5",
        "市场规模",
        57,
        61,
        "市场规模"
      ],
      [
        "T6",
        "属性值",
        65,
        71,
        "1.3万亿元"
      ],
      [
        "T7",
        "时间范围",
        73,
        83,
        "2020-2030年"
      ],
      [
        "T8",
        "CAGR",
        84,
        88,
        "CAGR"
      ],
      [
        "T9",
        "属性值",
        88,
        92,
        "约13%"
      ],
      [
        "T10",
        "地点范围",
        95,
        97,
        "我国"
      ],
      [
        "T11",
        "行业",
        97,
        100,
        "生物药"
      ],
      [
        "T12",
        "行业公司",
        112,
        114,
        "药企"
      ],
      [
        "T13",
        "行业",
        134,
        138,
        "制药设备"
      ],
      [
        "T14",
        "属性值",
        123,
        127,
        "加速扩产"
      ]
    ]
  },
  {
    "id": 399,
    "text": "• 2019、2020年中国出海手游收入116亿、155亿美元，同比增长21%、33%，出海手游增速高于国内手游；出海手游在海外市场快速扩张，2020年出海手游海外渗透率达1/3，仍有较大提升空间。 • 中国游戏出海收入主要来自美、日、韩、德等成熟市场。2020年我们在美国、日本等成熟市场快速增长，在东欧、东南亚、拉美等市场虽有所下滑，但整体出海收入仍实现30%+增长。",
    "labels": [
      [
        "T0",
        "地点范围",
        12,
        14,
        "中国"
      ],
      [
        "T1",
        "行业",
        14,
        18,
        "出海手游"
      ],
      [
        "T2",
        "营业收入",
        18,
        20,
        "收入"
      ],
      [
        "T3",
        "行业",
        44,
        48,
        "出海手游"
      ],
      [
        "T4",
        "收入增速",
        48,
        50,
        "增速"
      ],
      [
        "T5",
        "地点范围",
        102,
        104,
        "中国"
      ],
      [
        "T6",
        "营业收入",
        108,
        110,
        "收入"
      ],
      [
        "T7",
        "时间范围",
        127,
        132,
        "2020年"
      ],
      [
        "T8",
        "营业收入",
        174,
        176,
        "收入"
      ],
      [
        "T9",
        "地点范围",
        172,
        174,
        "出海"
      ],
      [
        "T10",
        "时间范围",
        2,
        6,
        "2019"
      ],
      [
        "T11",
        "时间范围",
        7,
        12,
        "2020年"
      ],
      [
        "T12",
        "属性值",
        20,
        24,
        "116亿"
      ],
      [
        "T13",
        "属性值",
        25,
        31,
        "155亿美元"
      ],
      [
        "T14",
        "属性值",
        36,
        39,
        "21%"
      ],
      [
        "T15",
        "属性值",
        40,
        43,
        "33%"
      ],
      [
        "T16",
        "属性值",
        50,
        56,
        "高于国内手游"
      ],
      [
        "T17",
        "行业",
        57,
        61,
        "出海手游"
      ],
      [
        "T18",
        "地点范围",
        62,
        64,
        "海外"
      ],
      [
        "T19",
        "时间范围",
        71,
        76,
        "2020年"
      ],
      [
        "T20",
        "行业",
        76,
        80,
        "出海手游"
      ],
      [
        "T21",
        "地点范围",
        80,
        82,
        "海外"
      ],
      [
        "T22",
        "行业",
        104,
        106,
        "游戏"
      ],
      [
        "T23",
        "地点范围",
        114,
        115,
        "美"
      ],
      [
        "T24",
        "地点范围",
        116,
        117,
        "日"
      ],
      [
        "T25",
        "地点范围",
        118,
        119,
        "韩"
      ],
      [
        "T26",
        "地点范围",
        120,
        121,
        "德"
      ],
      [
        "T27",
        "地点范围",
        135,
        137,
        "美国"
      ],
      [
        "T28",
        "地点范围",
        138,
        140,
        "日本"
      ],
      [
        "T29",
        "地点范围",
        151,
        153,
        "东欧"
      ],
      [
        "T30",
        "地点范围",
        154,
        157,
        "东南亚"
      ],
      [
        "T31",
        "地点范围",
        158,
        160,
        "拉美"
      ]
    ]
  },
  {
    "id": 400,
    "text": "公司位于上海金山的生物大分子研发生产中心已于 2019年启动，公司持续引入具有丰富行业经验和技术能力的人才团队，完成生物药 CDMO服务平台的搭建工作。目前该平台可提供 ADC药物生物活性细胞毒素药物部分的研发生产服务；可为一系列重组 DNA（rNDA）产品提供一站式 CMC服务，包括单克隆抗体（mAB）及其他生物制品，拥有单抗的千克级原液生产能力；在 mRNA分子的临床开发及商业化生产阶段为客户提供综合 CDMO服务，涵盖体外 mRNA转录以及酶修饰和合成，可以提供可靠的 cGMP等级 mRNA药品生产服务以及 cGMP级关键原材料，包括 DNA模板、mRNA合成及修饰的酶集群，以及 mRNA药物的其他主要成分。",
    "labels": [
      [
        "T0",
        "地点范围",
        4,
        8,
        "上海金山"
      ],
      [
        "T1",
        "时间范围",
        23,
        28,
        "2019年"
      ],
      [
        "T2",
        "行业",
        58,
        68,
        "生物药 CDMO服务"
      ],
      [
        "T3",
        "时间范围",
        76,
        78,
        "目前"
      ]
    ]
  },
  {
    "id": 401,
    "text": "随着对药物靶点认知的加深和新技术的不断成熟，全球各类新产品逐渐进入临床和上市阶段。国内自15-17年陆续发文鼓励创新药以来，大量海归人才回归国内，结合资本市场的大力支持，我国创新药从 2018年开始进入收获期，预计未来 2-3年将会有更多创新药获批。",
    "labels": [
      [
        "T0",
        "地点范围",
        41,
        43,
        "国内"
      ],
      [
        "T1",
        "时间范围",
        44,
        50,
        "15-17年"
      ],
      [
        "T2",
        "地点范围",
        85,
        87,
        "我国"
      ],
      [
        "T3",
        "行业",
        87,
        90,
        "创新药"
      ],
      [
        "T4",
        "时间范围",
        90,
        99,
        "从 2018年开始"
      ],
      [
        "T5",
        "时间范围",
        107,
        114,
        "未来 2-3年"
      ],
      [
        "T6",
        "行业",
        56,
        59,
        "创新药"
      ],
      [
        "T7",
        "地点范围",
        70,
        72,
        "国内"
      ],
      [
        "T8",
        "地点范围",
        22,
        24,
        "全球"
      ]
    ]
  },
  {
    "id": 402,
    "text": "：注射：肉毒素、玻尿酸、透明质酸等：非注射：光子嫩肤、果酸换肤，微晶磨皮、皮秒激光、射频紧致、激光脱毛等",
    "labels": []
  },
  {
    "id": 403,
    "text": "Ø 重点推荐：逻辑认知超预期推荐：泰格医药、药明康德、昭衍新药、凯莱英、康龙化成、九洲药业、博腾股份、方达控股、药石科技、美迪西等。",
    "labels": [
      [
        "T0",
        "公司",
        17,
        21,
        "泰格医药"
      ],
      [
        "T1",
        "公司",
        22,
        26,
        "药明康德"
      ],
      [
        "T2",
        "公司",
        27,
        31,
        "昭衍新药"
      ],
      [
        "T3",
        "公司",
        32,
        35,
        "凯莱英"
      ],
      [
        "T4",
        "公司",
        36,
        40,
        "康龙化成"
      ],
      [
        "T5",
        "公司",
        41,
        45,
        "九洲药业"
      ],
      [
        "T6",
        "公司",
        46,
        50,
        "博腾股份"
      ],
      [
        "T7",
        "公司",
        51,
        55,
        "方达控股"
      ],
      [
        "T8",
        "公司",
        56,
        60,
        "药石科技"
      ],
      [
        "T9",
        "公司",
        61,
        64,
        "美迪西"
      ]
    ]
  },
  {
    "id": 404,
    "text": "1月 19日，阿斯利康宣布，重磅 PD-L1抑制剂度伐利尤单抗与抗 CTLA-4抗体 tremelimumab联用，在一线治疗不可切除的肝细胞癌患者的 3期临床试验中与活性对照相比，显著延长患者的总生存期。试验结果显示，接受这一给药方案治疗的患者，与活性对照组相比，死亡风险降低 22%。中位总生存期为 16.4个月，活性对照组为 13.8个月。大约 31%的患者在接受治疗 3年后仍然活着， 对照组这一数值为 20%。Tremelimumab和 Imfinzi组合的客观缓解率为 20.1%， 高于对照组的 5.1%。",
    "labels": [
      [
        "T0",
        "公司",
        7,
        11,
        "阿斯利康"
      ],
      [
        "T1",
        "时间范围",
        0,
        6,
        "1月 19日"
      ]
    ]
  },
  {
    "id": 405,
    "text": " 截止至2021年12月3日，医药行业今年累计涨幅9.37%，位于SW一级行业分类第18位。SW医药行业PE TTM为33.33 倍，处于行业第10名。从板块对比来看，医药板块的涨幅居中，目前估值在诸多行业中处于相对较高水平。",
    "labels": [
      [
        "T0",
        "时间范围",
        2,
        15,
        "截止至2021年12月3日"
      ],
      [
        "T1",
        "行业",
        16,
        18,
        "医药"
      ],
      [
        "T2",
        "时间范围",
        20,
        22,
        "今年"
      ],
      [
        "T3",
        "行业",
        49,
        51,
        "医药"
      ],
      [
        "T4",
        "PE",
        53,
        55,
        "PE"
      ],
      [
        "T5",
        "属性值",
        60,
        67,
        "33.33 倍"
      ],
      [
        "T6",
        "行业",
        85,
        87,
        "医药"
      ],
      [
        "T7",
        "时间范围",
        95,
        97,
        "目前"
      ]
    ]
  },
  {
    "id": 406,
    "text": "1. CDE政策是加入ICH之后研发流程监管与国际接轨，本质是促进创新升级，加强临床监管国际化认可度。 综合“722”临床数据自查，仿制药一致性评价，集采，DRG/DIP等政策持续推进，我们发现国内从药品申报 （CDE，注册核查、临床自查）-支付（医保局，集采、医保谈判）-用药规范（卫健委，DRG/DIP）规范化体系逐步成型，这将成为未来我国医药行业发展的整体规范化框架。",
    "labels": [
      [
        "T0",
        "地点范围",
        97,
        99,
        "国内"
      ],
      [
        "T1",
        "地点范围",
        170,
        172,
        "我国"
      ],
      [
        "T2",
        "行业",
        172,
        174,
        "医药"
      ],
      [
        "T3",
        "时间范围",
        168,
        170,
        "未来"
      ]
    ]
  },
  {
    "id": 407,
    "text": " 原料药：中短期维度，上游成本传递和下游库存消化等影响下，特色原料药有望开启新一轮提价周期。 目前，缬沙坦价格逐步见底，替米沙坦、厄贝沙坦、泛酸钙、咖啡因等品种已逐步开始提价。中长期维度，随着大客户订单持续落地，特色原料药公司有望实现CDMO业务转型。推荐标的：普洛药业、天宇股份、美诺华、奥锐特等。",
    "labels": [
      [
        "T0",
        "行业",
        118,
        122,
        "CDMO"
      ],
      [
        "T1",
        "行业",
        2,
        5,
        "原料药"
      ],
      [
        "T2",
        "时间范围",
        6,
        9,
        "中短期"
      ],
      [
        "T3",
        "行业",
        30,
        35,
        "特色原料药"
      ],
      [
        "T4",
        "时间范围",
        48,
        50,
        "目前"
      ],
      [
        "T5",
        "时间范围",
        89,
        92,
        "中长期"
      ],
      [
        "T6",
        "行业公司",
        107,
        114,
        "特色原料药公司"
      ],
      [
        "T7",
        "公司",
        132,
        136,
        "普洛药业"
      ],
      [
        "T8",
        "公司",
        137,
        141,
        "天宇股份"
      ],
      [
        "T9",
        "公司",
        142,
        145,
        "美诺华"
      ],
      [
        "T10",
        "公司",
        146,
        149,
        "奥锐特"
      ]
    ]
  },
  {
    "id": 408,
    "text": "2021年初至九月底 Catalent实现营业收入 34.66亿美元，同比增长 28%，实现净利润 5.07亿美元，同比增长 97%。生物业务（Biologics）2021年年初至九月底实现营业收入 16.93亿美元，同比增长 72%， 表现出较高的成长性，增长部分来源于 COVID-19相关项目。产能建设方面，公司积极进行基因治疗方面产能，相关设备总投资由 1.3亿美元增长至 3.6亿美元，预期完成产能建设后 18个单元的生物反应器可达到每单元 2000L的规模。（注：Catalent原始财报财年为前一自然年 7月初至次年 6月底， 为便于比较此处已按照自然年进行核算调整）。",
    "labels": [
      [
        "T0",
        "时间范围",
        0,
        10,
        "2021年初至九月底"
      ],
      [
        "T1",
        "公司",
        11,
        19,
        "Catalent"
      ],
      [
        "T2",
        "营业收入",
        21,
        25,
        "营业收入"
      ],
      [
        "T3",
        "属性值",
        26,
        34,
        "34.66亿美元"
      ],
      [
        "T4",
        "归母净利润",
        46,
        49,
        "净利润"
      ],
      [
        "T5",
        "时间范围",
        82,
        93,
        "2021年年初至九月底"
      ],
      [
        "T6",
        "营业收入",
        95,
        99,
        "营业收入"
      ],
      [
        "T7",
        "属性值",
        100,
        108,
        "16.93亿美元"
      ],
      [
        "T8",
        "属性值",
        114,
        117,
        "72%"
      ],
      [
        "T9",
        "属性值",
        40,
        43,
        "28%"
      ],
      [
        "T10",
        "属性值",
        50,
        66,
        "5.07亿美元，同比增长 97%"
      ],
      [
        "T11",
        "行业",
        67,
        69,
        "生物"
      ],
      [
        "T12",
        "行业",
        72,
        81,
        "Biologics"
      ],
      [
        "T13",
        "公司",
        238,
        246,
        "Catalent"
      ],
      [
        "T14",
        "时间范围",
        253,
        269,
        "前一自然年 7月初至次年 6月底"
      ],
      [
        "T15",
        "产能",
        150,
        152,
        "产能"
      ],
      [
        "T16",
        "行业",
        163,
        167,
        "基因治疗"
      ],
      [
        "T17",
        "产能",
        169,
        171,
        "产能"
      ],
      [
        "T18",
        "产能",
        202,
        204,
        "产能"
      ]
    ]
  },
  {
    "id": 409,
    "text": "生物药研发涉及较高的门槛，在生产方面也涉及较为复杂的工艺生产工艺和技术。生物制品包括抗体（单克隆抗体、多特异性抗体）、抗偶联药物及 mRNA。",
    "labels": [
      [
        "T0",
        "行业",
        0,
        3,
        "生物药"
      ]
    ]
  },
  {
    "id": 410,
    "text": "5.1. 医药市盈率追踪：医药指数市盈率为 31.98倍，低于历史均值 8.97个单位",
    "labels": [
      [
        "T0",
        "PE",
        7,
        10,
        "市盈率"
      ],
      [
        "T1",
        "行业",
        5,
        7,
        "医药"
      ],
      [
        "T2",
        "属性值",
        22,
        28,
        "31.98倍"
      ],
      [
        "T3",
        "行业",
        13,
        15,
        "医药"
      ]
    ]
  },
  {
    "id": 411,
    "text": "Ø 2021年12月23日，三星生物制剂宣布将生产阿斯利康的新型冠状病毒抗体组合Evusheld 。新扩大的协议规模预计为3.8亿美元，比2020年9月签署的长期战略合作伙伴关系的初始合同高出约5000万美元。Evusheld是首个获得美国食品和药物管理局紧急使用批准的长效抗体组合。根据扩大后的协议，三星生物制剂还将从明年开始生产阿斯利康的肿瘤药物Imfinzi。 另外，食品医药品安全处已决定批准三星生物制剂公司生产的Moderna公司生产的“Spikevax”疫苗的生产和供应。",
    "labels": [
      [
        "T0",
        "时间范围",
        2,
        13,
        "2021年12月23日"
      ],
      [
        "T1",
        "公司",
        14,
        20,
        "三星生物制剂"
      ],
      [
        "T2",
        "时间范围",
        69,
        76,
        "2020年9月"
      ],
      [
        "T3",
        "公司",
        25,
        29,
        "阿斯利康"
      ],
      [
        "T4",
        "公司",
        151,
        157,
        "三星生物制剂"
      ],
      [
        "T5",
        "时间范围",
        159,
        164,
        "从明年开始"
      ],
      [
        "T6",
        "公司",
        200,
        206,
        "三星生物制剂"
      ],
      [
        "T7",
        "公司",
        211,
        218,
        "Moderna"
      ],
      [
        "T8",
        "公司",
        166,
        170,
        "阿斯利康"
      ]
    ]
  },
  {
    "id": 412,
    "text": "凯莱英持续进行产能，2020年年末公司反应釜体积超过 2800立方米，而 2021年 H1期末公司反应釜体积超过 3000立方米。公司预期于 2021年下半年继续进行产能释放，预计在天津、敦化等地区释放产能 1,390m³，按照敦化、镇江基地的工程计划进度预计将于 2022年新增产能 1,500m³。在制剂方面， 公司新建喷雾干燥车间已投入使用，有机溶剂处理量每年可以达到 200吨，已成功完成多个项目生产。新建热熔挤出技术平台，预计 2021年 9月初投入使用，可帮助客户解决难溶性药物的增溶。滴眼液车间投入 GMP使用，年产能可以达到 1000万支。生物合成技术板块具备了 5000L的 GMP级别生产能力。",
    "labels": [
      [
        "T0",
        "公司",
        0,
        3,
        "凯莱英"
      ],
      [
        "T1",
        "时间范围",
        10,
        17,
        "2020年年末"
      ],
      [
        "T2",
        "时间范围",
        37,
        47,
        "2021年 H1期末"
      ],
      [
        "T3",
        "时间范围",
        71,
        79,
        "2021年下半年"
      ],
      [
        "T4",
        "属性值",
        271,
        277,
        "1000万支"
      ],
      [
        "T5",
        "产能",
        302,
        306,
        "生产能力"
      ],
      [
        "T6",
        "属性值",
        290,
        302,
        "5000L的 GMP级别"
      ],
      [
        "T7",
        "属性值",
        85,
        87,
        "释放"
      ],
      [
        "T8",
        "产能",
        83,
        85,
        "产能"
      ],
      [
        "T9",
        "地点范围",
        91,
        93,
        "天津"
      ],
      [
        "T10",
        "地点范围",
        94,
        96,
        "敦化"
      ],
      [
        "T11",
        "地点范围",
        114,
        116,
        "敦化"
      ],
      [
        "T12",
        "地点范围",
        117,
        119,
        "镇江"
      ],
      [
        "T13",
        "地点范围",
        133,
        138,
        "2022年"
      ],
      [
        "T14",
        "行业",
        152,
        154,
        "制剂"
      ],
      [
        "T15",
        "产能",
        264,
        266,
        "产能"
      ],
      [
        "T16",
        "行业",
        278,
        284,
        "生物合成技术"
      ],
      [
        "T17",
        "产能",
        7,
        9,
        "产能"
      ],
      [
        "T18",
        "属性值",
        19,
        34,
        "反应釜体积超过 2800立方米"
      ],
      [
        "T19",
        "属性值",
        49,
        64,
        "反应釜体积超过 3000立方米"
      ],
      [
        "T20",
        "属性值",
        138,
        150,
        "新增产能 1,500m³"
      ],
      [
        "T21",
        "时间范围",
        219,
        228,
        "2021年 9月初"
      ]
    ]
  },
  {
    "id": 413,
    "text": "业取得角膜塑形镜产品注册证，欧普康视角膜塑形镜于 2005年获批上市，爱博医疗角膜塑形镜于 2019年获批上市。 国内市场共 9家产品获批，后续布局者众多，爱博医疗先发优势凸显。目前国内市场共 9家角膜塑形镜生产厂家获得了 NMPA认证，除 2家国产（大陆）企业外，其他 7 家厂家分别为：台湾亨泰光学，美国欧几里得、 C&E、 Paragon、日本 Alpha、韩国 Lucid、 荷兰 Procornea。除此之外，布局国内角膜塑形镜的公司有天津视达佳、日本美尼康、浙江天瞳、上海复罗、上海先锋、昊海生科等，预计 2024年前后会有多个角膜塑形镜产品获批上市，爱博医疗、欧普康视 2家国产企业先发优势凸显。 进口产品占据主要市场，国产品牌有望凭借优势快速放量。从 2018年角膜塑形镜验配量看，欧普康视、露晰得、欧几里得、亨泰、阿尔法的市占率分别为 24%、22%、 18%、15%、14%，CR5市占率合计为 93%，行业集中度较高。未来产品推广将继续围绕医院渠道和医生教育展开，国产品牌在供货周期、售后服务、渠道铺设等方面优势明显，在整个行业保持高速增长下，未来国产品牌市场空间广阔。",
    "labels": [
      [
        "T0",
        "公司",
        14,
        17,
        "欧普康"
      ],
      [
        "T1",
        "时间范围",
        25,
        30,
        "2005年"
      ],
      [
        "T2",
        "公司",
        35,
        39,
        "爱博医疗"
      ],
      [
        "T3",
        "时间范围",
        46,
        51,
        "2019年"
      ],
      [
        "T4",
        "地点范围",
        57,
        59,
        "国内"
      ],
      [
        "T5",
        "公司",
        78,
        82,
        "爱博医疗"
      ],
      [
        "T6",
        "地点范围",
        145,
        147,
        "台湾"
      ],
      [
        "T7",
        "公司",
        147,
        151,
        "亨泰光学"
      ],
      [
        "T8",
        "地点范围",
        152,
        154,
        "美国"
      ],
      [
        "T9",
        "公司",
        154,
        158,
        "欧几里得"
      ],
      [
        "T10",
        "公司",
        160,
        163,
        "C&E"
      ],
      [
        "T11",
        "公司",
        165,
        172,
        "Paragon"
      ],
      [
        "T12",
        "地点范围",
        173,
        175,
        "日本"
      ],
      [
        "T13",
        "公司",
        176,
        181,
        "Alpha"
      ],
      [
        "T14",
        "地点范围",
        182,
        184,
        "韩国"
      ],
      [
        "T15",
        "公司",
        185,
        190,
        "Lucid"
      ],
      [
        "T16",
        "地点范围",
        192,
        194,
        "荷兰"
      ],
      [
        "T17",
        "公司",
        195,
        204,
        "Procornea"
      ],
      [
        "T18",
        "地点范围",
        212,
        214,
        "国内"
      ],
      [
        "T19",
        "行业",
        214,
        219,
        "角膜塑形镜"
      ],
      [
        "T20",
        "地点范围",
        223,
        225,
        "天津"
      ],
      [
        "T21",
        "公司",
        225,
        228,
        "视达佳"
      ],
      [
        "T22",
        "地点范围",
        229,
        231,
        "日本"
      ],
      [
        "T23",
        "公司",
        231,
        234,
        "美尼康"
      ],
      [
        "T24",
        "地点范围",
        235,
        237,
        "浙江"
      ],
      [
        "T25",
        "公司",
        237,
        239,
        "天瞳"
      ],
      [
        "T26",
        "地点范围",
        240,
        242,
        "上海"
      ],
      [
        "T27",
        "公司",
        242,
        244,
        "复罗"
      ],
      [
        "T28",
        "地点范围",
        245,
        247,
        "上海"
      ],
      [
        "T29",
        "公司",
        247,
        249,
        "先锋"
      ],
      [
        "T30",
        "公司",
        250,
        254,
        "昊海生科"
      ],
      [
        "T31",
        "时间范围",
        334,
        339,
        "2018年"
      ],
      [
        "T32",
        "市场份额",
        370,
        373,
        "市占率"
      ],
      [
        "T33",
        "属性值",
        408,
        411,
        "93%"
      ],
      [
        "T34",
        "市场集中度",
        412,
        417,
        "行业集中度"
      ],
      [
        "T35",
        "属性值",
        417,
        419,
        "较高"
      ],
      [
        "T36",
        "时间范围",
        89,
        91,
        "目前"
      ],
      [
        "T37",
        "地点范围",
        91,
        93,
        "国内"
      ],
      [
        "T38",
        "行业",
        99,
        104,
        "角膜塑形镜"
      ],
      [
        "T39",
        "时间范围",
        259,
        266,
        "2024年前后"
      ],
      [
        "T40",
        "公司",
        282,
        286,
        "爱博医疗"
      ],
      [
        "T41",
        "公司",
        287,
        291,
        "欧普康视"
      ],
      [
        "T42",
        "公司",
        349,
        353,
        "欧普康视"
      ],
      [
        "T43",
        "公司",
        354,
        357,
        "露晰得"
      ],
      [
        "T44",
        "公司",
        358,
        362,
        "欧几里得"
      ],
      [
        "T45",
        "公司",
        363,
        365,
        "亨泰"
      ],
      [
        "T46",
        "公司",
        366,
        369,
        "阿尔法"
      ],
      [
        "T47",
        "属性值",
        377,
        380,
        "24%"
      ],
      [
        "T48",
        "属性值",
        381,
        384,
        "22%"
      ],
      [
        "T49",
        "属性值",
        386,
        389,
        "18%"
      ],
      [
        "T50",
        "属性值",
        390,
        393,
        "15%"
      ],
      [
        "T51",
        "属性值",
        394,
        397,
        "14%"
      ],
      [
        "T52",
        "CR5",
        398,
        401,
        "CR5"
      ],
      [
        "T53",
        "市场份额",
        401,
        404,
        "市占率"
      ],
      [
        "T54",
        "行业",
        339,
        344,
        "角膜塑形镜"
      ],
      [
        "T55",
        "时间范围",
        483,
        485,
        "未来"
      ]
    ]
  },
  {
    "id": 414,
    "text": " 带量采购加速行业集中度提升，现金流状况持续向好。带量采购之后，药品、耗材大幅降价，相应的配送费用也降低，对于配送企业成本控制能力要求较高。大中型配送商由于规模效应明显，成本优势突出，从而获得更多带量采购品种的配送 。因此带量采购后，集中度将会提升。带量采购均要求医保资金预付款或30天内付款，大幅缓解了配送企业的资金压力， 使得流通商腾出出更多资金去开展新业务。2021H1流通企业经营活动产生现金流量净额同比增速为12%，同比2019H1实现由负转正，并持续大幅改善。",
    "labels": [
      [
        "T0",
        "现金流",
        16,
        19,
        "现金流"
      ],
      [
        "T1",
        "市场集中度",
        8,
        13,
        "行业集中度"
      ],
      [
        "T2",
        "时间范围",
        183,
        189,
        "2021H1"
      ],
      [
        "T3",
        "行业公司",
        189,
        193,
        "流通企业"
      ],
      [
        "T4",
        "属性值",
        205,
        213,
        "同比增速为12%"
      ],
      [
        "T5",
        "时间范围",
        216,
        222,
        "2019H1"
      ],
      [
        "T6",
        "行业公司",
        56,
        60,
        "配送企业"
      ],
      [
        "T7",
        "行业公司",
        74,
        77,
        "配送商"
      ],
      [
        "T8",
        "市场集中度",
        118,
        121,
        "集中度"
      ],
      [
        "T9",
        "行业公司",
        153,
        157,
        "配送企业"
      ],
      [
        "T10",
        "行业公司",
        166,
        169,
        "流通商"
      ],
      [
        "T11",
        "现金流",
        199,
        203,
        "现金流量"
      ],
      [
        "T12",
        "属性值",
        224,
        228,
        "由负转正"
      ],
      [
        "T13",
        "属性值",
        232,
        236,
        "大幅改善"
      ]
    ]
  },
  {
    "id": 415,
    "text": "2021Q1-3累计收入增速21%，毛利增速19%，归母净利润增速约27%。盈利端超增长主要是销售费用增速低于收入增速。",
    "labels": [
      [
        "T0",
        "时间范围",
        0,
        8,
        "2021Q1-3"
      ],
      [
        "T1",
        "收入增速",
        10,
        14,
        "收入增速"
      ],
      [
        "T2",
        "毛利",
        18,
        20,
        "毛利"
      ],
      [
        "T3",
        "归母净利润增速",
        26,
        33,
        "归母净利润增速"
      ],
      [
        "T4",
        "收入增速",
        55,
        59,
        "收入增速"
      ]
    ]
  },
  {
    "id": 416,
    "text": " 4家医疗服务公司2021上半年收入约为185亿元（+63%）、归母净利润总额约为27.33亿元（+83.6%），行业上半年表观增速较高，除了金域医学上半年仍有新冠检测业务增量，板块内各项常规业务相对于2019年的复合增长率约为20~30%左右，已经回归正常水平。我们的样本公司数量较少，没有包括尚未转盈的公司，因此样本内的优质企业表现出整体毛利率保持较高水平，叠加持续的规模效应压低费率，整体盈利质量保持较高水平。",
    "labels": [
      [
        "T0",
        "行业公司",
        2,
        10,
        "4家医疗服务公司"
      ],
      [
        "T1",
        "时间范围",
        10,
        17,
        "2021上半年"
      ],
      [
        "T2",
        "营业收入",
        17,
        19,
        "收入"
      ],
      [
        "T3",
        "属性值",
        27,
        31,
        "+63%"
      ],
      [
        "T4",
        "归母净利润",
        33,
        38,
        "归母净利润"
      ],
      [
        "T5",
        "属性值",
        19,
        26,
        "约为185亿元"
      ],
      [
        "T6",
        "属性值",
        42,
        57,
        "27.33亿元（+83.6%）"
      ],
      [
        "T7",
        "时间范围",
        60,
        63,
        "上半年"
      ],
      [
        "T8",
        "公司",
        72,
        76,
        "金域医学"
      ],
      [
        "T9",
        "时间范围",
        76,
        79,
        "上半年"
      ],
      [
        "T10",
        "行业",
        81,
        85,
        "新冠检测"
      ],
      [
        "T11",
        "时间范围",
        102,
        107,
        "2019年"
      ],
      [
        "T12",
        "CAGR",
        108,
        113,
        "复合增长率"
      ],
      [
        "T13",
        "属性值",
        113,
        123,
        "约为20~30%左右"
      ],
      [
        "T14",
        "属性值",
        126,
        132,
        "回归正常水平"
      ],
      [
        "T15",
        "毛利",
        172,
        175,
        "毛利率"
      ],
      [
        "T16",
        "属性值",
        90,
        99,
        "板块内各项常规业务"
      ]
    ]
  },
  {
    "id": 418,
    "text": " 港股行情回顾：本周医药整体跑赢大盘，CXO及互联网医疗表现较好。本周恒生医疗保健上涨7.07%，恒生指数上涨3.79%，恒生医疗保健整体跑赢大盘3.28%。2022年以来，恒生医疗保健整体跑输大盘19.23%。子行业方面， 本周CXO（+13.56%）、互联网医疗（+10.61%）子行业表现较好。",
    "labels": [
      [
        "T0",
        "时间范围",
        9,
        11,
        "本周"
      ],
      [
        "T1",
        "行业",
        11,
        13,
        "医药"
      ],
      [
        "T2",
        "行业",
        20,
        23,
        "CXO"
      ],
      [
        "T3",
        "行业",
        24,
        29,
        "互联网医疗"
      ],
      [
        "T4",
        "时间范围",
        34,
        36,
        "本周"
      ],
      [
        "T5",
        "时间范围",
        80,
        87,
        "2022年以来"
      ],
      [
        "T6",
        "行业",
        116,
        119,
        "CXO"
      ],
      [
        "T7",
        "行业",
        129,
        134,
        "互联网医疗"
      ],
      [
        "T8",
        "行业",
        38,
        42,
        "医疗保健"
      ],
      [
        "T9",
        "行业",
        64,
        68,
        "医疗保健"
      ],
      [
        "T10",
        "行业",
        90,
        94,
        "医疗保健"
      ],
      [
        "T11",
        "时间范围",
        114,
        116,
        "本周"
      ]
    ]
  },
  {
    "id": 419,
    "text": "义翘神州：（1）产业管线布局全面的生物试剂龙头公司，目前拥有超过6000种重组蛋白试剂，约1.3万种抗体类试剂， 约2.8万种基因类试剂，16种培养基试剂，其中在重组蛋白领域，公司产品丰富度处于领先地位。（2）公司产品覆盖大学、科研院所、医药研发企业等国内外各类生物研发单位，累计客户数量超过5,000家，目前产品已销往全球90多个国家或地区，品牌美誉度较高，用户粘性较强。",
    "labels": [
      [
        "T0",
        "龙头企业",
        22,
        26,
        "龙头公司"
      ],
      [
        "T1",
        "行业",
        18,
        22,
        "生物试剂"
      ],
      [
        "T2",
        "客户数量",
        141,
        145,
        "客户数量"
      ],
      [
        "T3",
        "属性值",
        145,
        153,
        "超过5,000家"
      ],
      [
        "T4",
        "公司",
        1,
        5,
        "义翘神州"
      ],
      [
        "T5",
        "地点范围",
        161,
        163,
        "全球"
      ]
    ]
  },
  {
    "id": 420,
    "text": "长视频：行业从竞争走向竞合，针对中短视频的版权保护增强；爱奇艺提价后腾讯已跟进。 音乐：版权隔离继续推动在线音乐付费率提升；K歌界面改版提升变现效率。 阅读：在线阅读复苏且韧性强，免费阅读推进更积极；版权运营内部外部重新梳理提升产能。 直播：推动虎牙和斗鱼合并减少成本内耗。",
    "labels": [
      [
        "T0",
        "行业",
        0,
        3,
        "长视频"
      ],
      [
        "T1",
        "行业",
        16,
        20,
        "中短视频"
      ],
      [
        "T2",
        "公司",
        28,
        31,
        "爱奇艺"
      ],
      [
        "T3",
        "公司",
        34,
        36,
        "腾讯"
      ],
      [
        "T4",
        "行业",
        41,
        43,
        "音乐"
      ],
      [
        "T5",
        "行业",
        52,
        56,
        "在线音乐"
      ],
      [
        "T6",
        "行业",
        76,
        78,
        "阅读"
      ],
      [
        "T7",
        "行业",
        79,
        83,
        "在线阅读"
      ],
      [
        "T8",
        "行业",
        90,
        94,
        "免费阅读"
      ],
      [
        "T9",
        "行业",
        118,
        120,
        "直播"
      ],
      [
        "T10",
        "公司",
        123,
        125,
        "虎牙"
      ],
      [
        "T11",
        "公司",
        126,
        128,
        "斗鱼"
      ]
    ]
  },
  {
    "id": 421,
    "text": " 涨幅排名：在28个行业中，本周医药板块涨跌幅排在第1位，2021年涨跌幅排列在所有行业第9 位。",
    "labels": [
      [
        "T0",
        "时间范围",
        15,
        17,
        "本周"
      ],
      [
        "T1",
        "行业",
        17,
        19,
        "医药"
      ],
      [
        "T2",
        "时间范围",
        30,
        35,
        "2021年"
      ]
    ]
  },
  {
    "id": 422,
    "text": "政策无形之手提高行业进入门槛。我国对血液制品行业强监管，政策不断推动行业提高集中度。从 2001 年起不再新批血液制品企业，目前国内存量血制品企业约 31家， 但正常经营血液制品企业仅 20余家。另外，新批浆站政策方面，2016年 12月15日,卫计委和 CFDA联合出台《关于促进单采血浆站健康发展的意见》，强调严格新增单采血浆站设置审批,向研发能力强、血浆综合利用率高、单采血浆站管理规范的血液制品生产企业倾斜。",
    "labels": [
      [
        "T0",
        "地点范围",
        15,
        17,
        "我国"
      ],
      [
        "T1",
        "行业",
        18,
        22,
        "血液制品"
      ],
      [
        "T2",
        "市场集中度",
        38,
        41,
        "集中度"
      ],
      [
        "T3",
        "时间范围",
        42,
        51,
        "从 2001 年起"
      ],
      [
        "T4",
        "属性值",
        36,
        38,
        "提高"
      ],
      [
        "T5",
        "行业公司",
        55,
        61,
        "血液制品企业"
      ],
      [
        "T6",
        "时间范围",
        62,
        64,
        "目前"
      ],
      [
        "T7",
        "地点范围",
        64,
        66,
        "国内"
      ],
      [
        "T8",
        "行业公司",
        68,
        73,
        "血制品企业"
      ],
      [
        "T9",
        "行业公司",
        85,
        91,
        "血液制品企业"
      ],
      [
        "T10",
        "时间范围",
        110,
        122,
        "2016年 12月15日"
      ],
      [
        "T11",
        "行业公司",
        197,
        205,
        "血液制品生产企业"
      ]
    ]
  },
  {
    "id": 423,
    "text": "抗肿瘤、中枢神经、自身免疫三大治疗领域是公司现有业务重点收入构成板块，也是公司研发管线主要布局方向。随着恩度新适应症开发、先必新与艾得辛医保快速放量，公司未来3年是业绩快速增长阶段，公司的创新药销售收入占比也将大幅提升 （预计2021年占比约60%）。",
    "labels": [
      [
        "T0",
        "时间范围",
        77,
        81,
        "未来3年"
      ],
      [
        "T1",
        "业绩",
        82,
        84,
        "业绩"
      ],
      [
        "T2",
        "时间范围",
        113,
        118,
        "2021年"
      ],
      [
        "T3",
        "行业",
        94,
        97,
        "创新药"
      ],
      [
        "T4",
        "营收占比",
        99,
        103,
        "收入占比"
      ]
    ]
  },
  {
    "id": 424,
    "text": "生物药在治疗效果与全球收入方面均显示除了出色的潜力，中国医药研发在生物药方面目前已展现出一定的热度。",
    "labels": [
      [
        "T0",
        "行业",
        0,
        3,
        "生物药"
      ],
      [
        "T1",
        "地点范围",
        9,
        11,
        "全球"
      ],
      [
        "T2",
        "营业收入",
        11,
        13,
        "收入"
      ],
      [
        "T3",
        "地点范围",
        26,
        28,
        "中国"
      ],
      [
        "T4",
        "行业",
        28,
        30,
        "医药"
      ],
      [
        "T5",
        "行业",
        33,
        36,
        "生物药"
      ]
    ]
  },
  {
    "id": 425,
    "text": " 智飞生物：新冠疫苗快速放量，疫苗龙头长期动力充足。上半年，新冠疫苗销售量超1亿剂，在新冠加持下，公司全年有望实现100亿元净利润；2021Q4以及2022年，公司新冠疫苗产能将主要用于海外出口。传统疫苗业务上，核心产品HPV疫苗批签发总量为498.6万支（2020H1为582.4万支），同比下降14.4%，主要原因系上半年疫苗体系集中批签发与接种新冠疫苗， 影响了传统疫苗的批签发，预计2021H2将全面恢复增长，有望完成1000万支的批签发与销售。重组蛋白新冠疫苗III期临床数据优异，海外放量可期。在研管线储蓄充沛，积极布局新技术平台。  康泰生物：业绩符合预期，13价肺炎产品待获批。分季度看，Q1/Q2单季度收入2.8/7.8亿元（+56%/+12%），实现归母净利润0.25/3.12亿元（+938%/+21%）。Q2单季度业绩增速放缓的原因主要是上半年新冠疫苗接种影响常规疫苗接种资源所致，预计Q3-Q4季度常规疫苗接种将逐渐恢复正常。核心品种量价齐升，下半年业绩值得期待。按产品来看，一类苗实现收入1.8亿元（+950%），主要系10μg乙肝疫苗获得恢复性增长，实现量价齐升。以及新冠疫苗于5月底获得紧急使用批准，预计下半年将持续放量。二类苗实现收入8.7亿元（+2.28% ），23价肺炎疫苗预计全年收入6.7亿元，13价肺炎结合疫苗处于申请注册批件过程中，预计21年收入3亿元。四联苗预计全年16亿收入体量，核心品种实现量价齐升，未来可期。  康希诺：公司发布2021年中报，上半年实现营业收入20.6亿元（+51058%），实现归母净利润9.4亿元（+1017%），扣非归母净利润8.99亿元（+873%）。其中Q2季度实现收入15.9 亿元，实现归母净利润9.51亿元，实现扣非归母净利润9.19亿元，均扭亏为盈。新冠疫苗推动业绩大幅增长。2021H1公司实现新冠疫苗销量约为2140万剂，其中国内约1200万剂，海外约940万剂。预计公司21年收入约为71亿元，对应新冠疫苗销量约为7200万剂；公司发布股权激励计划增添长期增长动力。同时吸入剂型新冠疫苗临床进展迅速，有望贡献业绩。",
    "labels": [
      [
        "T0",
        "公司",
        2,
        6,
        "智飞生物"
      ],
      [
        "T1",
        "时间范围",
        27,
        30,
        "上半年"
      ],
      [
        "T2",
        "时间范围",
        52,
        54,
        "全年"
      ],
      [
        "T3",
        "属性值",
        58,
        63,
        "100亿元"
      ],
      [
        "T4",
        "归母净利润",
        63,
        66,
        "净利润"
      ],
      [
        "T5",
        "时间范围",
        67,
        80,
        "2021Q4以及2022年"
      ],
      [
        "T6",
        "时间范围",
        130,
        136,
        "2020H1"
      ],
      [
        "T7",
        "公司",
        276,
        280,
        "康泰生物"
      ],
      [
        "T8",
        "业绩",
        281,
        283,
        "业绩"
      ],
      [
        "T9",
        "属性值",
        283,
        287,
        "符合预期"
      ],
      [
        "T10",
        "营业收入",
        312,
        314,
        "收入"
      ],
      [
        "T11",
        "业绩",
        371,
        373,
        "业绩"
      ],
      [
        "T12",
        "时间范围",
        407,
        414,
        "Q3-Q4季度"
      ],
      [
        "T13",
        "属性值",
        536,
        550,
        "8.7亿元（+2.28% ）"
      ],
      [
        "T14",
        "属性值",
        564,
        569,
        "6.7亿元"
      ],
      [
        "T15",
        "时间范围",
        593,
        596,
        "21年"
      ],
      [
        "T16",
        "属性值",
        598,
        601,
        "3亿元"
      ],
      [
        "T17",
        "公司",
        636,
        639,
        "康希诺"
      ],
      [
        "T18",
        "时间范围",
        644,
        649,
        "2021年"
      ],
      [
        "T19",
        "时间范围",
        652,
        655,
        "上半年"
      ],
      [
        "T20",
        "营业收入",
        657,
        661,
        "营业收入"
      ],
      [
        "T21",
        "属性值",
        661,
        667,
        "20.6亿元"
      ],
      [
        "T22",
        "属性值",
        668,
        675,
        "+51058%"
      ],
      [
        "T23",
        "归母净利润",
        679,
        684,
        "归母净利润"
      ],
      [
        "T24",
        "扣非净利润",
        698,
        705,
        "扣非归母净利润"
      ],
      [
        "T25",
        "时间范围",
        721,
        725,
        "Q2季度"
      ],
      [
        "T26",
        "营业收入",
        727,
        729,
        "收入"
      ],
      [
        "T27",
        "归母净利润",
        739,
        744,
        "归母净利润"
      ],
      [
        "T28",
        "扣非净利润",
        753,
        760,
        "扣非归母净利润"
      ],
      [
        "T29",
        "时间范围",
        836,
        839,
        "21年"
      ],
      [
        "T30",
        "营业收入",
        839,
        841,
        "收入"
      ],
      [
        "T31",
        "属性值",
        729,
        736,
        "15.9 亿元"
      ],
      [
        "T32",
        "属性值",
        744,
        750,
        "9.51亿元"
      ],
      [
        "T33",
        "属性值",
        760,
        766,
        "9.19亿元"
      ],
      [
        "T34",
        "行业",
        16,
        18,
        "疫苗"
      ],
      [
        "T35",
        "龙头企业",
        18,
        20,
        "龙头"
      ],
      [
        "T36",
        "产能",
        87,
        89,
        "产能"
      ],
      [
        "T37",
        "行业",
        83,
        87,
        "新冠疫苗"
      ],
      [
        "T38",
        "属性值",
        90,
        98,
        "主要用于海外出口"
      ],
      [
        "T39",
        "行业",
        99,
        103,
        "传统疫苗"
      ],
      [
        "T40",
        "时间范围",
        161,
        164,
        "上半年"
      ],
      [
        "T41",
        "时间范围",
        196,
        202,
        "2021H2"
      ],
      [
        "T42",
        "属性值",
        314,
        323,
        "2.8/7.8亿元"
      ],
      [
        "T43",
        "属性值",
        324,
        333,
        "+56%/+12%"
      ],
      [
        "T44",
        "时间范围",
        304,
        309,
        "Q1/Q2"
      ],
      [
        "T45",
        "属性值",
        342,
        365,
        "0.25/3.12亿元（+938%/+21%）"
      ],
      [
        "T46",
        "归母净利润",
        337,
        342,
        "归母净利润"
      ],
      [
        "T47",
        "属性值",
        373,
        377,
        "增速放缓"
      ],
      [
        "T48",
        "时间范围",
        366,
        368,
        "Q2"
      ],
      [
        "T49",
        "时间范围",
        383,
        386,
        "上半年"
      ],
      [
        "T50",
        "时间范围",
        437,
        440,
        "下半年"
      ],
      [
        "T51",
        "业绩",
        440,
        442,
        "业绩"
      ],
      [
        "T52",
        "属性值",
        442,
        446,
        "值得期待"
      ],
      [
        "T53",
        "营业收入",
        458,
        460,
        "收入"
      ],
      [
        "T54",
        "属性值",
        460,
        465,
        "1.8亿元"
      ],
      [
        "T55",
        "属性值",
        466,
        471,
        "+950%"
      ],
      [
        "T56",
        "行业",
        453,
        456,
        "一类苗"
      ],
      [
        "T57",
        "时间范围",
        506,
        509,
        "5月底"
      ],
      [
        "T58",
        "时间范围",
        520,
        523,
        "下半年"
      ],
      [
        "T59",
        "营业收入",
        534,
        536,
        "收入"
      ],
      [
        "T60",
        "行业",
        529,
        532,
        "二类苗"
      ],
      [
        "T61",
        "时间范围",
        560,
        562,
        "全年"
      ],
      [
        "T62",
        "营业收入",
        562,
        564,
        "收入"
      ],
      [
        "T63",
        "营业收入",
        596,
        598,
        "收入"
      ],
      [
        "T64",
        "行业",
        602,
        605,
        "四联苗"
      ],
      [
        "T65",
        "时间范围",
        607,
        609,
        "全年"
      ],
      [
        "T66",
        "属性值",
        609,
        612,
        "16亿"
      ],
      [
        "T67",
        "营业收入",
        612,
        614,
        "收入"
      ],
      [
        "T68",
        "行业",
        551,
        558,
        "23价肺炎疫苗"
      ],
      [
        "T69",
        "行业",
        570,
        579,
        "13价肺炎结合疫苗"
      ],
      [
        "T70",
        "属性值",
        684,
        697,
        "9.4亿元（+1017%）"
      ],
      [
        "T71",
        "属性值",
        705,
        718,
        "8.99亿元（+873%）"
      ],
      [
        "T72",
        "业绩",
        779,
        781,
        "业绩"
      ],
      [
        "T73",
        "属性值",
        781,
        785,
        "大幅增长"
      ],
      [
        "T74",
        "时间范围",
        786,
        792,
        "2021H1"
      ],
      [
        "T75",
        "地点范围",
        813,
        815,
        "国内"
      ],
      [
        "T76",
        "地点范围",
        823,
        825,
        "海外"
      ],
      [
        "T77",
        "属性值",
        841,
        847,
        "约为71亿元"
      ],
      [
        "T78",
        "业绩",
        905,
        907,
        "业绩"
      ]
    ]
  },
  {
    "id": 426,
    "text": "口从端游时代开始培养潜在移动游戏用户，特征与手游用户重合度高：在端游时代，腾讯便不局限于核心玩家，而是积累大规模轻度游戏用户，为之后移动游戏的发展打下用户基础",
    "labels": [
      [
        "T0",
        "公司",
        37,
        39,
        "腾讯"
      ],
      [
        "T1",
        "行业",
        56,
        60,
        "轻度游戏"
      ],
      [
        "T2",
        "行业",
        66,
        70,
        "移动游戏"
      ],
      [
        "T3",
        "行业",
        2,
        4,
        "端游"
      ],
      [
        "T4",
        "行业",
        12,
        16,
        "移动游戏"
      ],
      [
        "T5",
        "行业",
        22,
        24,
        "手游"
      ],
      [
        "T6",
        "行业",
        32,
        34,
        "端游"
      ]
    ]
  },
  {
    "id": 429,
    "text": "以 2018年为分水岭，医药板块间整体同涨同跌时候已过，这几年表现的是冷热不均，医药板块间估值差异、市场表现极其迥异，但不表示冷的板块就没有机会，已经较",
    "labels": [
      [
        "T0",
        "时间范围",
        2,
        7,
        "2018年"
      ],
      [
        "T1",
        "行业",
        12,
        14,
        "医药"
      ],
      [
        "T2",
        "行业",
        40,
        42,
        "医药"
      ]
    ]
  },
  {
    "id": 430,
    "text": " 根据三季度经营数据、以往年度公司经营规律及三季度订单情况等公开数据，我们对部分重点公司进行了全年经营情况预测，其中：  CXO行业整体仍然保持了较高的景气度，建议关注业绩预告：从前三季度各家公司的在手订单情况看，预计主要上市公司仍然保持了较快增速，1月开始，各家公司开始披露业绩预告，其中：泰格医药及博腾股份超过我们此前预期。  生物制药产业链公司保持较高景气度：考虑到三季度的合同负债情况，我们预计全年新签订单及各项财务指标较大概率有上调空间。  品牌中药公司整体业绩预计符合预期：行业红利持续落地，我们建议积极关注政策对公司后续业绩的影响。",
    "labels": [
      [
        "T0",
        "行业",
        63,
        66,
        "CXO"
      ],
      [
        "T1",
        "公司",
        148,
        152,
        "泰格医药"
      ],
      [
        "T2",
        "公司",
        153,
        157,
        "博腾股份"
      ],
      [
        "T3",
        "行业公司",
        169,
        178,
        "生物制药产业链公司"
      ],
      [
        "T4",
        "时间范围",
        204,
        206,
        "全年"
      ],
      [
        "T5",
        "新签订单",
        206,
        210,
        "新签订单"
      ],
      [
        "T6",
        "行业公司",
        230,
        236,
        "品牌中药公司"
      ],
      [
        "T7",
        "业绩",
        238,
        240,
        "业绩"
      ],
      [
        "T8",
        "时间范围",
        4,
        7,
        "三季度"
      ],
      [
        "T9",
        "业绩",
        86,
        88,
        "业绩"
      ],
      [
        "T10",
        "时间范围",
        92,
        96,
        "前三季度"
      ],
      [
        "T11",
        "在手订单",
        101,
        105,
        "在手订单"
      ],
      [
        "T12",
        "属性值",
        122,
        126,
        "较快增速"
      ],
      [
        "T13",
        "时间范围",
        127,
        131,
        "1月开始"
      ],
      [
        "T14",
        "业绩",
        140,
        142,
        "业绩"
      ],
      [
        "T15",
        "时间范围",
        189,
        192,
        "三季度"
      ],
      [
        "T16",
        "合同负债",
        193,
        197,
        "合同负债"
      ],
      [
        "T17",
        "财务情况",
        213,
        217,
        "财务指标"
      ],
      [
        "T18",
        "属性值",
        221,
        226,
        "有上调空间"
      ],
      [
        "T19",
        "属性值",
        242,
        246,
        "符合预期"
      ],
      [
        "T20",
        "业绩",
        271,
        273,
        "业绩"
      ],
      [
        "T21",
        "时间范围",
        48,
        50,
        "全年"
      ],
      [
        "T22",
        "时间范围",
        23,
        26,
        "三季度"
      ],
      [
        "T23",
        "属性值",
        111,
        117,
        "主要上市公司"
      ],
      [
        "T24",
        "属性值",
        157,
        165,
        "超过我们此前预期"
      ]
    ]
  },
  {
    "id": 431,
    "text": "• 截止2021年11月19日，医药行业涨幅最高个股（剔除新股和ST公司）为美迪西（287.27%），涨幅主要受益于CXO行业高景气度及本身订单业绩高增长。此外2021年涨幅前十公司多为CXO，医疗器械，制药装备，仅拓新药业和热景生物与新冠疫情相关。",
    "labels": [
      [
        "T0",
        "时间范围",
        2,
        15,
        "截止2021年11月19日"
      ],
      [
        "T1",
        "行业",
        16,
        18,
        "医药"
      ],
      [
        "T2",
        "公司",
        38,
        41,
        "美迪西"
      ],
      [
        "T3",
        "行业",
        58,
        61,
        "CXO"
      ],
      [
        "T4",
        "时间范围",
        80,
        85,
        "2021年"
      ],
      [
        "T5",
        "业绩",
        72,
        74,
        "业绩"
      ],
      [
        "T6",
        "属性值",
        74,
        77,
        "高增长"
      ],
      [
        "T7",
        "行业",
        93,
        96,
        "CXO"
      ],
      [
        "T8",
        "行业",
        97,
        101,
        "医疗器械"
      ],
      [
        "T9",
        "行业",
        102,
        106,
        "制药装备"
      ],
      [
        "T10",
        "公司",
        108,
        112,
        "拓新药业"
      ],
      [
        "T11",
        "公司",
        113,
        117,
        "热景生物"
      ]
    ]
  },
  {
    "id": 433,
    "text": " 近年来，疫苗行业上市公司营收持续保持快速增长趋势，2020年营收同比增长49%，利润同比增长56%；而2021年受益于新冠疫情驱动，Q1-Q3疫苗行业业绩大幅增长，为未来良好发展打下基础。",
    "labels": [
      [
        "T0",
        "营业收入",
        14,
        16,
        "营收"
      ],
      [
        "T1",
        "行业公司",
        6,
        14,
        "疫苗行业上市公司"
      ],
      [
        "T2",
        "时间范围",
        27,
        32,
        "2020年"
      ],
      [
        "T3",
        "属性值",
        38,
        41,
        "49%"
      ],
      [
        "T4",
        "属性值",
        48,
        51,
        "56%"
      ],
      [
        "T5",
        "时间范围",
        68,
        73,
        "Q1-Q3"
      ],
      [
        "T6",
        "行业",
        73,
        75,
        "疫苗"
      ],
      [
        "T7",
        "时间范围",
        2,
        5,
        "近年来"
      ],
      [
        "T8",
        "属性值",
        20,
        24,
        "快速增长"
      ],
      [
        "T9",
        "营业收入",
        32,
        34,
        "营收"
      ],
      [
        "T10",
        "利润",
        42,
        44,
        "利润"
      ],
      [
        "T11",
        "时间范围",
        53,
        58,
        "2021年"
      ],
      [
        "T12",
        "业绩",
        77,
        79,
        "业绩"
      ],
      [
        "T13",
        "属性值",
        79,
        83,
        "大幅增长"
      ]
    ]
  },
  {
    "id": 437,
    "text": " 16家生物药公司2021上半年收入总额增速为23.9%、归母净利润总额增速为40.4%。生物药去年同期受疫情影响较大，目前已迎来恢复。  从盈利水平看，上半年生物药板块整体盈利能力稳中有升，行业毛利率（63%）基本保持平稳，销售费用率（27%）持续下降，管理费用率（8%）、研发费用率（9%）保持稳定，净利率（21%）同比有所提升。",
    "labels": [
      [
        "T0",
        "行业公司",
        2,
        10,
        "16家生物药公司"
      ],
      [
        "T1",
        "时间范围",
        10,
        17,
        "2021上半年"
      ],
      [
        "T2",
        "收入增速",
        17,
        23,
        "收入总额增速"
      ],
      [
        "T3",
        "属性值",
        24,
        29,
        "23.9%"
      ],
      [
        "T4",
        "属性值",
        40,
        45,
        "40.4%"
      ],
      [
        "T5",
        "归母净利润增速",
        30,
        39,
        "归母净利润总额增速"
      ],
      [
        "T6",
        "毛利",
        100,
        103,
        "毛利率"
      ],
      [
        "T7",
        "归母净利润",
        154,
        157,
        "净利率"
      ],
      [
        "T8",
        "行业",
        46,
        49,
        "生物药"
      ],
      [
        "T9",
        "时间范围",
        49,
        51,
        "去年"
      ],
      [
        "T10",
        "时间范围",
        61,
        63,
        "目前"
      ],
      [
        "T11",
        "时间范围",
        79,
        82,
        "上半年"
      ],
      [
        "T12",
        "行业",
        82,
        85,
        "生物药"
      ],
      [
        "T13",
        "属性值",
        104,
        107,
        "63%"
      ],
      [
        "T14",
        "属性值",
        146,
        148,
        "9%"
      ],
      [
        "T15",
        "研发费用率",
        140,
        145,
        "研发费用率"
      ],
      [
        "T16",
        "属性值",
        158,
        161,
        "21%"
      ],
      [
        "T17",
        "属性值",
        112,
        114,
        "平稳"
      ],
      [
        "T18",
        "属性值",
        151,
        153,
        "稳定"
      ],
      [
        "T19",
        "属性值",
        162,
        168,
        "同比有所提升"
      ]
    ]
  },
  {
    "id": 440,
    "text": "• 在汇率升值的影响下，国内CXO行业2021年三季报继续保持高速增长：  统计13家A+H CXO公司（不考虑药明生物、维亚生物以及九洲药业和普洛股份）合计实现营业收入353.5亿元，同比增长41.2%，延续超高速增长。  单季度来看，合计9家CXO公司（暂不考虑睿智生物、诺泰生物、皓元医药、阳光诺和）Q1/Q2/Q3分别实现营业收入 94.3/112.6/122.5亿元，分别同比增长53.7%/38.4%/37.4%。",
    "labels": [
      [
        "T0",
        "地点范围",
        12,
        14,
        "国内"
      ],
      [
        "T1",
        "行业",
        14,
        17,
        "CXO"
      ],
      [
        "T2",
        "行业公司",
        41,
        53,
        "13家A+H CXO公司"
      ],
      [
        "T3",
        "营业收入",
        82,
        86,
        "营业收入"
      ],
      [
        "T4",
        "属性值",
        86,
        93,
        "353.5亿元"
      ],
      [
        "T5",
        "属性值",
        98,
        103,
        "41.2%"
      ],
      [
        "T6",
        "时间范围",
        19,
        26,
        "2021年三季"
      ],
      [
        "T7",
        "行业公司",
        123,
        130,
        "9家CXO公司"
      ],
      [
        "T8",
        "营业收入",
        167,
        171,
        "营业收入"
      ],
      [
        "T9",
        "公司",
        57,
        61,
        "药明生物"
      ],
      [
        "T10",
        "公司",
        62,
        66,
        "维亚生物"
      ],
      [
        "T11",
        "公司",
        68,
        72,
        "九洲药业"
      ],
      [
        "T12",
        "公司",
        73,
        77,
        "普洛股份"
      ],
      [
        "T13",
        "公司",
        135,
        139,
        "睿智生物"
      ],
      [
        "T14",
        "公司",
        140,
        144,
        "诺泰生物"
      ],
      [
        "T15",
        "公司",
        145,
        149,
        "皓元医药"
      ],
      [
        "T16",
        "公司",
        150,
        154,
        "阳光诺和"
      ],
      [
        "T17",
        "时间范围",
        155,
        157,
        "Q1"
      ],
      [
        "T18",
        "时间范围",
        158,
        160,
        "Q2"
      ],
      [
        "T19",
        "时间范围",
        161,
        163,
        "Q3"
      ],
      [
        "T20",
        "属性值",
        172,
        176,
        "94.3"
      ],
      [
        "T21",
        "属性值",
        177,
        182,
        "112.6"
      ],
      [
        "T22",
        "属性值",
        183,
        190,
        "122.5亿元"
      ],
      [
        "T23",
        "属性值",
        197,
        202,
        "53.7%"
      ],
      [
        "T24",
        "属性值",
        203,
        208,
        "38.4%"
      ],
      [
        "T25",
        "属性值",
        209,
        214,
        "37.4%"
      ]
    ]
  },
  {
    "id": 441,
    "text": " 派林生物：上半年实现收入7.9亿元，同比增长85.1%，实现归母净利润为1.8亿元，同比增长179.6%，符合此前预期。其中广东双林实现营收5.4亿元，实现净利润1.7亿元，派斯菲科实现收入2.5亿元。实现净利润5924万元。期间公司销售费用率为10.4%，同比降低4.4个pp，销售净利率22.3%，同比提升7.9个pp，公司盈利能力显著提升。  天坛生物：上半年实现收入18.1亿元，同比增长17%；实现归母净利润3.4亿元，同比增长19%；实现扣非后归母净利润3.3亿元，同比增长 20%。上半年公司采浆874.9吨，实现恢复性增长25.5%；相比2019同期增长9.3%。公司全国在营浆站55家，上半年累计公告新增12家浆站 ，十四五期间国内浆站数量有望持续快速增长，公司受益于股东国药集团的背景，浆站拓展能力行业领先，将进一步巩固龙头地位。  华兰生物：上半年实现收入12.9亿元，同比降低7.1%；实现归母净利润4.6亿元。同比降低10.6%，扣非净利润4亿元，同比降低14.9%，上半年白蛋白、静丙收入承压，主要系去年同期基数较大所致。另一方面公司的流感疫苗销售高峰主要在下半年到来，公司产能充足，若下半年需求旺盛有望贡献可观业绩。",
    "labels": [
      [
        "T0",
        "公司",
        2,
        6,
        "派林生物"
      ],
      [
        "T1",
        "时间范围",
        7,
        10,
        "上半年"
      ],
      [
        "T2",
        "营业收入",
        12,
        14,
        "收入"
      ],
      [
        "T3",
        "属性值",
        14,
        19,
        "7.9亿元"
      ],
      [
        "T4",
        "属性值",
        24,
        29,
        "85.1%"
      ],
      [
        "T5",
        "归母净利润",
        30,
        37,
        "实现归母净利润"
      ],
      [
        "T6",
        "公司",
        64,
        68,
        "广东双林"
      ],
      [
        "T7",
        "营业收入",
        70,
        72,
        "营收"
      ],
      [
        "T8",
        "归母净利润",
        80,
        83,
        "净利润"
      ],
      [
        "T9",
        "公司",
        89,
        93,
        "派斯菲科"
      ],
      [
        "T10",
        "营业收入",
        95,
        97,
        "收入"
      ],
      [
        "T11",
        "归母净利润",
        105,
        108,
        "净利润"
      ],
      [
        "T12",
        "属性值",
        72,
        77,
        "5.4亿元"
      ],
      [
        "T13",
        "属性值",
        83,
        88,
        "1.7亿元"
      ],
      [
        "T14",
        "属性值",
        97,
        102,
        "2.5亿元"
      ],
      [
        "T15",
        "属性值",
        108,
        114,
        "5924万元"
      ],
      [
        "T16",
        "公司",
        178,
        182,
        "天坛生物"
      ],
      [
        "T17",
        "时间范围",
        183,
        186,
        "上半年"
      ],
      [
        "T18",
        "营业收入",
        188,
        190,
        "收入"
      ],
      [
        "T19",
        "属性值",
        190,
        196,
        "18.1亿元"
      ],
      [
        "T20",
        "属性值",
        201,
        204,
        "17%"
      ],
      [
        "T21",
        "时间范围",
        280,
        284,
        "2019"
      ],
      [
        "T22",
        "营收增长",
        197,
        201,
        "同比增长"
      ],
      [
        "T23",
        "扣非净利润",
        228,
        236,
        "扣非后归母净利润"
      ],
      [
        "T24",
        "归母净利润",
        207,
        212,
        "归母净利润"
      ],
      [
        "T25",
        "公司",
        381,
        385,
        "华兰生物"
      ],
      [
        "T26",
        "时间范围",
        386,
        389,
        "上半年"
      ],
      [
        "T27",
        "营业收入",
        391,
        393,
        "收入"
      ],
      [
        "T28",
        "属性值",
        393,
        399,
        "12.9亿元"
      ],
      [
        "T29",
        "归母净利润",
        409,
        416,
        "实现归母净利润"
      ],
      [
        "T30",
        "扣非净利润",
        432,
        437,
        "扣非净利润"
      ],
      [
        "T31",
        "属性值",
        38,
        54,
        "1.8亿元，同比增长179.6%"
      ],
      [
        "T32",
        "属性值",
        212,
        225,
        "3.4亿元，同比增长19%"
      ],
      [
        "T33",
        "属性值",
        236,
        250,
        "3.3亿元，同比增长 20%"
      ],
      [
        "T34",
        "时间范围",
        305,
        308,
        "上半年"
      ],
      [
        "T35",
        "时间范围",
        321,
        326,
        "十四五期间"
      ],
      [
        "T36",
        "地点范围",
        326,
        328,
        "国内"
      ],
      [
        "T37",
        "公司",
        348,
        352,
        "国药集团"
      ],
      [
        "T38",
        "属性值",
        402,
        408,
        "降低7.1%"
      ],
      [
        "T39",
        "属性值",
        416,
        431,
        "4.6亿元。同比降低10.6%"
      ],
      [
        "T40",
        "属性值",
        437,
        450,
        "4亿元，同比降低14.9%"
      ],
      [
        "T41",
        "时间范围",
        451,
        454,
        "上半年"
      ],
      [
        "T42",
        "时间范围",
        468,
        470,
        "去年"
      ],
      [
        "T43",
        "时间范围",
        511,
        514,
        "下半年"
      ],
      [
        "T44",
        "业绩",
        524,
        526,
        "业绩"
      ],
      [
        "T45",
        "产能",
        505,
        507,
        "产能"
      ],
      [
        "T46",
        "时间范围",
        497,
        500,
        "下半年"
      ],
      [
        "T47",
        "属性值",
        507,
        509,
        "充足"
      ]
    ]
  },
  {
    "id": 443,
    "text": "2.1.CXO行业——CXO行业景气度跟踪框架：全球β：美国PEVC投资延续高景气度",
    "labels": [
      [
        "T0",
        "行业",
        4,
        7,
        "CXO"
      ],
      [
        "T1",
        "行业",
        11,
        14,
        "CXO"
      ],
      [
        "T2",
        "地点范围",
        28,
        30,
        "美国"
      ]
    ]
  },
  {
    "id": 444,
    "text": "分行业来看：  CXO板块(13家)： 13家CXO公司2021Q1-3收入总额增速为43%，占全行业比例为3%、归母净利润总额增速为50%，占全行业比例为6%，整体维持高速增长。Q3收入同比增长36.6%，归母净利润同比增长47.3%，三季度收入端保持高速增长，利润端增速恢复高速增长。  创新药及制剂（52家）：52家创新药及制剂公司2021Q1-3收入总额增速为10.3%，占全行业比例为12%，归母净利润总额下降2%，占全行业比例为11% ；Q3单季收入同比下降0.3%，利润端同比下滑15.3%，扣非净利润同比下降5.5%。Q3 利润端有所下滑， 预计由于集采、国谈等导致公司毛利率下降所致。 从盈利水平看，受集采等政策冲击，板块整体盈利能力有所下降，三季度行业毛利率（57.5%）下降4.8pp，销售费用率（28%），同比下降3pp，净利率（11.9%）下降 2.1pp。  医疗器械（83家）：器械板块（83家样本公司，含科创板）2021Q1-3收入1543亿元（+27.6%），归母净利润487亿元 （+26.8%），毛利率 61%，四费率25%, 净利率 32%，盈利能力维持高位。医疗器械板块Q1/Q2/Q3单季度收入 535.1/534.7/473.2亿元（+118%/+9.4%/-0.4%）,单季度净利润185.5/174.1/127.5亿元（+259%/+1.6%/-20.9%）, 高基数下板块Q3单季度业绩有所承压。  医疗服务（4家）：4家医疗服务公司2021Q1-3收入约为291亿元（+40.2%），占全行业比例为2% ，归母净利润总额约为46.2亿元（+43%），占全行业比例为3% 。  疫苗（9家）：21Q1-3疫苗板块实现收入405亿元，占全行业比例为3%，5家样本公司收入实现正增长，4家公司收入增速均超过50%增长。归母净利润占全行业比例为8%。6家公司净利润增速超过50%增长,。从21Q1-3疫苗板块收入占比看 ，智飞占比50%；从21Q1-3年疫苗板块归母净利润占比看，智飞占比63%；智飞为板块收入、利润的主要贡献者。",
    "labels": [
      [
        "T0",
        "行业",
        9,
        12,
        "CXO"
      ],
      [
        "T1",
        "行业公司",
        21,
        29,
        "13家CXO公司"
      ],
      [
        "T2",
        "时间范围",
        29,
        37,
        "2021Q1-3"
      ],
      [
        "T3",
        "收入增速",
        37,
        43,
        "收入总额增速"
      ],
      [
        "T4",
        "属性值",
        44,
        47,
        "43%"
      ],
      [
        "T5",
        "归母净利润增速",
        58,
        67,
        "归母净利润总额增速"
      ],
      [
        "T6",
        "属性值",
        68,
        71,
        "50%"
      ],
      [
        "T7",
        "时间范围",
        91,
        93,
        "Q3"
      ],
      [
        "T8",
        "属性值",
        99,
        104,
        "36.6%"
      ],
      [
        "T9",
        "行业公司",
        160,
        171,
        "52家创新药及制剂公司"
      ],
      [
        "T10",
        "时间范围",
        171,
        179,
        "2021Q1-3"
      ],
      [
        "T11",
        "收入增速",
        179,
        185,
        "收入总额增速"
      ],
      [
        "T12",
        "属性值",
        186,
        191,
        "10.3%"
      ],
      [
        "T13",
        "归母净利润",
        203,
        210,
        "归母净利润总额"
      ],
      [
        "T14",
        "属性值",
        210,
        214,
        "下降2%"
      ],
      [
        "T15",
        "行业公司",
        639,
        647,
        "4家医疗服务公司"
      ],
      [
        "T16",
        "时间范围",
        647,
        655,
        "2021Q1-3"
      ],
      [
        "T17",
        "营业收入",
        655,
        657,
        "收入"
      ],
      [
        "T18",
        "属性值",
        665,
        671,
        "+40.2%"
      ],
      [
        "T19",
        "归母净利润",
        684,
        691,
        "归母净利润总额"
      ],
      [
        "T20",
        "时间范围",
        727,
        733,
        "21Q1-3"
      ],
      [
        "T21",
        "行业",
        733,
        735,
        "疫苗"
      ],
      [
        "T22",
        "营业收入",
        739,
        741,
        "收入"
      ],
      [
        "T23",
        "属性值",
        741,
        746,
        "405亿元"
      ],
      [
        "T24",
        "行业公司",
        757,
        763,
        "5家样本公司"
      ],
      [
        "T25",
        "行业公司",
        771,
        775,
        "4家公司"
      ],
      [
        "T26",
        "公司",
        839,
        841,
        "智飞"
      ],
      [
        "T27",
        "时间范围",
        848,
        855,
        "21Q1-3年"
      ],
      [
        "T28",
        "营业收入",
        763,
        765,
        "收入"
      ],
      [
        "T29",
        "收入增速",
        775,
        779,
        "收入增速"
      ],
      [
        "T30",
        "行业公司",
        803,
        807,
        "6家公司"
      ],
      [
        "T31",
        "归母净利润增速",
        807,
        812,
        "净利润增速"
      ],
      [
        "T32",
        "营业收入",
        93,
        95,
        "收入"
      ],
      [
        "T33",
        "归母净利润",
        105,
        110,
        "归母净利润"
      ],
      [
        "T34",
        "属性值",
        110,
        119,
        "同比增长47.3%"
      ],
      [
        "T35",
        "时间范围",
        120,
        123,
        "三季度"
      ],
      [
        "T36",
        "营业收入",
        123,
        126,
        "收入端"
      ],
      [
        "T37",
        "属性值",
        128,
        132,
        "高速增长"
      ],
      [
        "T38",
        "利润",
        133,
        136,
        "利润端"
      ],
      [
        "T39",
        "属性值",
        140,
        144,
        "高速增长"
      ],
      [
        "T40",
        "行业",
        148,
        154,
        "创新药及制剂"
      ],
      [
        "T41",
        "时间范围",
        227,
        229,
        "Q3"
      ],
      [
        "T42",
        "营业收入",
        231,
        233,
        "收入"
      ],
      [
        "T43",
        "利润",
        242,
        245,
        "利润端"
      ],
      [
        "T44",
        "扣非净利润",
        255,
        260,
        "扣非净利润"
      ],
      [
        "T45",
        "属性值",
        260,
        268,
        "同比下降5.5%"
      ],
      [
        "T46",
        "属性值",
        245,
        254,
        "同比下滑15.3%"
      ],
      [
        "T47",
        "属性值",
        235,
        241,
        "下降0.3%"
      ],
      [
        "T48",
        "时间范围",
        269,
        271,
        "Q3"
      ],
      [
        "T49",
        "利润",
        272,
        275,
        "利润端"
      ],
      [
        "T50",
        "属性值",
        277,
        279,
        "下滑"
      ],
      [
        "T51",
        "毛利",
        295,
        298,
        "毛利率"
      ],
      [
        "T52",
        "时间范围",
        333,
        336,
        "三季度"
      ],
      [
        "T53",
        "毛利",
        338,
        341,
        "毛利率"
      ],
      [
        "T54",
        "归母净利润",
        375,
        378,
        "净利率"
      ],
      [
        "T55",
        "行业",
        397,
        401,
        "医疗器械"
      ],
      [
        "T56",
        "行业",
        407,
        409,
        "器械"
      ],
      [
        "T57",
        "时间范围",
        425,
        433,
        "2021Q1-3"
      ],
      [
        "T58",
        "营业收入",
        433,
        435,
        "收入"
      ],
      [
        "T59",
        "属性值",
        435,
        441,
        "1543亿元"
      ],
      [
        "T60",
        "属性值",
        442,
        448,
        "+27.6%"
      ],
      [
        "T61",
        "归母净利润",
        450,
        455,
        "归母净利润"
      ],
      [
        "T62",
        "属性值",
        455,
        469,
        "487亿元 （+26.8%）"
      ],
      [
        "T63",
        "毛利",
        470,
        473,
        "毛利率"
      ],
      [
        "T64",
        "属性值",
        474,
        477,
        "61%"
      ],
      [
        "T65",
        "归母净利润",
        486,
        489,
        "净利率"
      ],
      [
        "T66",
        "属性值",
        490,
        493,
        "32%"
      ],
      [
        "T67",
        "行业",
        503,
        507,
        "医疗器械"
      ],
      [
        "T68",
        "时间范围",
        509,
        511,
        "Q1"
      ],
      [
        "T69",
        "时间范围",
        512,
        514,
        "Q2"
      ],
      [
        "T70",
        "时间范围",
        515,
        517,
        "Q3"
      ],
      [
        "T71",
        "营业收入",
        520,
        522,
        "收入"
      ],
      [
        "T72",
        "属性值",
        523,
        528,
        "535.1"
      ],
      [
        "T73",
        "属性值",
        529,
        534,
        "534.7"
      ],
      [
        "T74",
        "属性值",
        535,
        542,
        "473.2亿元"
      ],
      [
        "T75",
        "属性值",
        543,
        548,
        "+118%"
      ],
      [
        "T76",
        "属性值",
        549,
        554,
        "+9.4%"
      ],
      [
        "T77",
        "属性值",
        555,
        560,
        "-0.4%"
      ],
      [
        "T78",
        "归母净利润",
        565,
        568,
        "净利润"
      ],
      [
        "T79",
        "属性值",
        568,
        573,
        "185.5"
      ],
      [
        "T80",
        "属性值",
        574,
        579,
        "174.1"
      ],
      [
        "T81",
        "属性值",
        580,
        587,
        "127.5亿元"
      ],
      [
        "T82",
        "时间范围",
        615,
        617,
        "Q3"
      ],
      [
        "T83",
        "业绩",
        620,
        622,
        "业绩"
      ],
      [
        "T84",
        "属性值",
        624,
        626,
        "承压"
      ],
      [
        "T85",
        "行业",
        630,
        634,
        "医疗服务"
      ],
      [
        "T86",
        "属性值",
        378,
        393,
        "（11.9%）下降 2.1pp"
      ],
      [
        "T87",
        "属性值",
        341,
        355,
        "（57.5%）下降4.8pp"
      ],
      [
        "T88",
        "属性值",
        657,
        664,
        "约为291亿元"
      ],
      [
        "T89",
        "行业",
        720,
        722,
        "疫苗"
      ],
      [
        "T90",
        "归母净利润",
        788,
        793,
        "归母净利润"
      ],
      [
        "T91",
        "属性值",
        812,
        817,
        "超过50%"
      ],
      [
        "T92",
        "时间范围",
        822,
        828,
        "21Q1-3"
      ],
      [
        "T93",
        "行业",
        828,
        830,
        "疫苗"
      ],
      [
        "T94",
        "营收占比",
        832,
        836,
        "收入占比"
      ],
      [
        "T95",
        "属性值",
        843,
        846,
        "50%"
      ],
      [
        "T96",
        "行业",
        855,
        857,
        "疫苗"
      ],
      [
        "T97",
        "归母净利润",
        859,
        864,
        "归母净利润"
      ],
      [
        "T98",
        "公司",
        868,
        870,
        "智飞"
      ],
      [
        "T99",
        "公司",
        876,
        878,
        "智飞"
      ],
      [
        "T100",
        "属性值",
        767,
        770,
        "正增长"
      ],
      [
        "T101",
        "属性值",
        691,
        705,
        "约为46.2亿元（+43%）"
      ],
      [
        "T102",
        "属性值",
        780,
        785,
        "超过50%"
      ]
    ]
  },
  {
    "id": 445,
    "text": "穿刺输注龙头企业，质优价控获益行业集中",
    "labels": [
      [
        "T0",
        "龙头企业",
        4,
        8,
        "龙头企业"
      ],
      [
        "T1",
        "行业",
        0,
        4,
        "穿刺输注"
      ]
    ]
  },
  {
    "id": 446,
    "text": " 国内多个创新药有望在2022年实现出海，国际化征程逐步起航。目前国内已有多个创新药向美国FDA提交上市申请并获受理，其中信达生物、君实生物、百济神州的PD-1单抗均有望于2022年获FDA批准上市，此外传奇生物的CAR-T、和黄医药的索凡替尼、以及亿帆医药的长效G-CSF均有望于2022年海外获批。",
    "labels": [
      [
        "T0",
        "地点范围",
        2,
        4,
        "国内"
      ],
      [
        "T1",
        "时间范围",
        12,
        17,
        "2022年"
      ],
      [
        "T2",
        "地点范围",
        34,
        36,
        "国内"
      ],
      [
        "T3",
        "地点范围",
        44,
        46,
        "美国"
      ],
      [
        "T4",
        "公司",
        46,
        49,
        "FDA"
      ],
      [
        "T5",
        "时间范围",
        87,
        92,
        "2022年"
      ],
      [
        "T6",
        "公司",
        103,
        107,
        "传奇生物"
      ],
      [
        "T7",
        "公司",
        114,
        118,
        "和黄医药"
      ],
      [
        "T8",
        "公司",
        126,
        130,
        "亿帆医药"
      ],
      [
        "T9",
        "时间范围",
        142,
        147,
        "2022年"
      ],
      [
        "T10",
        "公司",
        62,
        66,
        "信达生物"
      ],
      [
        "T11",
        "公司",
        67,
        71,
        "君实生物"
      ],
      [
        "T12",
        "公司",
        72,
        76,
        "百济神州"
      ]
    ]
  },
  {
    "id": 448,
    "text": "• 9月23日，国务院办公厅关于印发“十四五”全民医疗保障规划的通知，提及深化药品和医用耗材集中带量采购制度改革的同时，兼顾企业合理利润，促进医药行业高质量，同时鼓励产品创新，逐步将医疗新技术、新药品、新器械应用纳入商业健康保险保障范围",
    "labels": [
      [
        "T0",
        "时间范围",
        2,
        7,
        "9月23日"
      ],
      [
        "T1",
        "行业",
        71,
        73,
        "医药"
      ]
    ]
  },
  {
    "id": 450,
    "text": "2020年年初至 2021年前三季度，CXO板块公司股价走势一路向好，近期股价波动的原因之一为市场对于美国制裁中国生物科技股的忧虑。我们认为国内龙头 CXO公司已与美国龙头药企合作多年，且承接大批小分子新冠药物订单，若美国药企更换 CXO 服务商需付出高成本，承担高风险，因此国内 CXO龙头受美国制裁的可能性不高。",
    "labels": [
      [
        "T0",
        "时间范围",
        0,
        18,
        "2020年年初至 2021年前三季度"
      ],
      [
        "T1",
        "地点范围",
        70,
        72,
        "国内"
      ],
      [
        "T2",
        "龙头企业",
        72,
        74,
        "龙头"
      ],
      [
        "T3",
        "行业公司",
        75,
        80,
        "CXO公司"
      ],
      [
        "T4",
        "地点范围",
        82,
        84,
        "美国"
      ],
      [
        "T5",
        "龙头企业",
        84,
        86,
        "龙头"
      ],
      [
        "T6",
        "行业公司",
        86,
        88,
        "药企"
      ],
      [
        "T7",
        "行业公司",
        111,
        113,
        "药企"
      ],
      [
        "T8",
        "行业",
        116,
        119,
        "CXO"
      ],
      [
        "T9",
        "地点范围",
        138,
        140,
        "国内"
      ],
      [
        "T10",
        "行业",
        141,
        144,
        "CXO"
      ],
      [
        "T11",
        "地点范围",
        51,
        53,
        "美国"
      ],
      [
        "T12",
        "地点范围",
        55,
        57,
        "中国"
      ],
      [
        "T13",
        "行业公司",
        57,
        62,
        "生物科技股"
      ],
      [
        "T14",
        "行业公司",
        19,
        26,
        "CXO板块公司"
      ],
      [
        "T15",
        "地点范围",
        109,
        111,
        "美国"
      ],
      [
        "T16",
        "地点范围",
        147,
        149,
        "美国"
      ],
      [
        "T17",
        "龙头企业",
        144,
        146,
        "龙头"
      ]
    ]
  },
  {
    "id": 451,
    "text": " 医疗服务：医疗服务指导定价改革政策对行业影响深远，民营医疗机构有望凭借精细化管理能力保持竞争优势。经过21年三轮估值回调，板块估值已基本修复至疫情前水平，建议重点关注具备长期增长潜力的消费医疗赛道，细分领域龙头公司更具投资价值。推荐标的：爱尔眼科、通策医疗、锦欣生殖、信邦制药、 健麾信息。",
    "labels": [
      [
        "T0",
        "行业",
        94,
        98,
        "消费医疗"
      ],
      [
        "T1",
        "行业",
        2,
        6,
        "医疗服务"
      ],
      [
        "T2",
        "行业",
        7,
        11,
        "医疗服务"
      ],
      [
        "T3",
        "龙头企业",
        105,
        109,
        "龙头公司"
      ],
      [
        "T4",
        "公司",
        121,
        125,
        "爱尔眼科"
      ],
      [
        "T5",
        "公司",
        126,
        130,
        "通策医疗"
      ],
      [
        "T6",
        "公司",
        131,
        135,
        "锦欣生殖"
      ],
      [
        "T7",
        "公司",
        136,
        140,
        "信邦制药"
      ],
      [
        "T8",
        "公司",
        142,
        146,
        "健麾信息"
      ],
      [
        "T9",
        "时间范围",
        53,
        56,
        "21年"
      ]
    ]
  },
  {
    "id": 452,
    "text": "《医药生物行业 2022年度策略：泡沫挤压下的  再平衡》20211206 《新冠疫情持续，加强针与高效疫苗需求提升： 2021年 mRNA疫苗技术分析深度报告之二》 20211118 《AI新药研发（AIDD）行业系列报告—洞鉴行业发展，把握投资先机：（一）AIDD概览篇： AI新药研发已走过 0到 1阶段，1到 10阶段将带来更多可能》20210902",
    "labels": [
      [
        "T0",
        "行业",
        1,
        5,
        "医药生物"
      ],
      [
        "T1",
        "时间范围",
        8,
        13,
        "2022年"
      ],
      [
        "T2",
        "时间范围",
        29,
        37,
        "20211206"
      ],
      [
        "T3",
        "时间范围",
        60,
        65,
        "2021年"
      ],
      [
        "T4",
        "行业",
        66,
        72,
        "mRNA疫苗"
      ],
      [
        "T5",
        "时间范围",
        84,
        92,
        "20211118"
      ],
      [
        "T6",
        "时间范围",
        171,
        179,
        "20210902"
      ],
      [
        "T7",
        "行业",
        46,
        49,
        "加强针"
      ],
      [
        "T8",
        "行业",
        50,
        54,
        "高效疫苗"
      ],
      [
        "T9",
        "行业需求",
        54,
        56,
        "需求"
      ],
      [
        "T10",
        "属性值",
        56,
        58,
        "提升"
      ],
      [
        "T11",
        "行业",
        94,
        106,
        "AI新药研发（AIDD）"
      ],
      [
        "T12",
        "行业",
        130,
        134,
        "AIDD"
      ],
      [
        "T13",
        "行业",
        139,
        145,
        "AI新药研发"
      ]
    ]
  },
  {
    "id": 453,
    "text": "ADC药物涉及化学小分子、连接子与生物大分子三部分，涉及的工作量较大。ADC药物的生产涉及抗体生产、毒素与连接子合成、偶联过程和纯化，以及制剂灌装等流程。偶联反应需要关注反应浓度、投料量、时间、缓冲体系、pH等因素，且过程中涉及放热反应，需要进行温度控制。",
    "labels": [
      [
        "T0",
        "行业",
        0,
        5,
        "ADC药物"
      ],
      [
        "T1",
        "行业",
        35,
        40,
        "ADC药物"
      ]
    ]
  },
  {
    "id": 454,
    "text": "生物药研发与生产均涉及较高的门槛，药明生物持续引领技术创新与技术平台构建，目前拥有 “WuXiBodyBispecific”、“WuxiHybrid”、“WuXian”、“WuXia”、“WuXiUp”等技术平台，并掌握一次性生物反应器、 机器人无菌灌装、连续细胞培养生产工艺等先进技术。同时，药明生物已从 Broad Institute获得 CRISPR / Cas9技术的研究许可，目前可用于生物药品和疫苗的研发。CRISPR/Cas9是一种功能强大，快速且有效的基因编辑技术，可广泛用于疫苗,生物药品研发以及多种产品开发过程优化。CRISPR基因编辑可广泛应用于生产细胞系或其他蛋白质表达系统，其功能可改善细胞生长，生产力，产品效价和产品质量。",
    "labels": [
      [
        "T0",
        "行业",
        0,
        3,
        "生物药"
      ],
      [
        "T1",
        "公司",
        17,
        21,
        "药明生物"
      ],
      [
        "T2",
        "公司",
        147,
        151,
        "药明生物"
      ],
      [
        "T3",
        "时间范围",
        193,
        195,
        "目前"
      ],
      [
        "T4",
        "时间范围",
        37,
        39,
        "目前"
      ]
    ]
  },
  {
    "id": 455,
    "text": " 业绩为王。根据三季度经营数据、以往年度公司经营规律及三季度订单情况等公开数据，我们对部分重点公司进行了全年经营情况预测，其中：1、CXO行业整体仍然保持了较高的景气度，建议关注业绩预告：从前三季度各家公司的在手订单情况看，预计主要上市公司仍然保持了较快增速，1月开始，各家公司开始披露业绩预告，其中：泰格医药及博腾股份超过我们此前预期。2、生物制药产业链公司保持较高景气度：考虑到三季度的合同负债情况， 我们预计全年新签订单及各项财务指标较大概率有上调空间。3、品牌中药公司整体业绩预计符合预期：行业红利持续落地，我们建议积极关注政策对公司后续业绩的影响。",
    "labels": [
      [
        "T0",
        "业绩",
        2,
        4,
        "业绩"
      ],
      [
        "T1",
        "时间范围",
        9,
        12,
        "三季度"
      ],
      [
        "T2",
        "时间范围",
        28,
        31,
        "三季度"
      ],
      [
        "T3",
        "行业",
        67,
        70,
        "CXO"
      ],
      [
        "T4",
        "在手订单",
        105,
        109,
        "在手订单"
      ],
      [
        "T5",
        "公司",
        152,
        156,
        "泰格医药"
      ],
      [
        "T6",
        "公司",
        157,
        161,
        "博腾股份"
      ],
      [
        "T7",
        "行业公司",
        172,
        181,
        "生物制药产业链公司"
      ],
      [
        "T8",
        "合同负债",
        196,
        200,
        "合同负债"
      ],
      [
        "T9",
        "新签订单",
        210,
        214,
        "新签订单"
      ],
      [
        "T10",
        "财务情况",
        217,
        221,
        "财务指标"
      ],
      [
        "T11",
        "行业公司",
        233,
        239,
        "品牌中药公司"
      ],
      [
        "T12",
        "业绩",
        241,
        243,
        "业绩"
      ],
      [
        "T13",
        "业绩",
        90,
        92,
        "业绩"
      ],
      [
        "T14",
        "时间范围",
        96,
        100,
        "前三季度"
      ],
      [
        "T15",
        "行业公司",
        115,
        121,
        "主要上市公司"
      ],
      [
        "T16",
        "属性值",
        126,
        130,
        "较快增速"
      ],
      [
        "T17",
        "时间范围",
        131,
        135,
        "1月开始"
      ],
      [
        "T18",
        "业绩",
        144,
        146,
        "业绩"
      ],
      [
        "T19",
        "时间范围",
        192,
        195,
        "三季度"
      ],
      [
        "T20",
        "属性值",
        225,
        230,
        "有上调空间"
      ],
      [
        "T21",
        "属性值",
        245,
        249,
        "符合预期"
      ],
      [
        "T22",
        "时间范围",
        208,
        210,
        "全年"
      ],
      [
        "T23",
        "业绩",
        274,
        276,
        "业绩"
      ]
    ]
  },
  {
    "id": 456,
    "text": " 当前POCT主要场景有感染类、血气/凝血类、心血管检测类、妊娠检测类、药物滥用类等。传染病类和心血管类导入期完成，将进入高速成长期。",
    "labels": [
      [
        "T0",
        "行业",
        4,
        8,
        "POCT"
      ],
      [
        "T1",
        "时间范围",
        2,
        4,
        "当前"
      ]
    ]
  },
  {
    "id": 457,
    "text": " 我们选取了52家科创板医药上市公司，上半年收入总额362亿元，归母净利润109亿元，主要剔除了在2021年1月及以后上市的公司。",
    "labels": [
      [
        "T0",
        "时间范围",
        20,
        23,
        "上半年"
      ],
      [
        "T1",
        "营业收入",
        23,
        25,
        "收入"
      ],
      [
        "T2",
        "归母净利润",
        33,
        38,
        "归母净利润"
      ],
      [
        "T3",
        "行业公司",
        7,
        19,
        "52家科创板医药上市公司"
      ],
      [
        "T4",
        "属性值",
        27,
        32,
        "362亿元"
      ],
      [
        "T5",
        "属性值",
        38,
        43,
        "109亿元"
      ],
      [
        "T6",
        "时间范围",
        50,
        60,
        "2021年1月及以后"
      ]
    ]
  },
  {
    "id": 458,
    "text": " 高基数、集采、医保控费多因素影响，2021Q1-3收入增速放缓、利润下滑：52家创新药及制剂公司2021Q1-Q3收入 1508亿元（+10.3%），归母净利润182.6亿元（-2%），毛利率58%，四费率43%，净利率为13%，创新药与制剂板块Q3单季度收入503.7亿元（-0.3%）,单季度净利润59.7亿元（-15.3%）, Q3单季度毛利率57.5%（-4.8pp），单季度四费率43.4%（-2.3pp），单季度净利率11.9%（-2.1pp）。去年三季度疫情影响导致行业产生高基数，以及集采影响扩大、医保控费等多重因素影响之下，创新药及制剂板块三季度收入端和利润端双双下滑。",
    "labels": [
      [
        "T0",
        "时间范围",
        19,
        27,
        "2021Q1-3"
      ],
      [
        "T1",
        "利润",
        34,
        36,
        "利润"
      ],
      [
        "T2",
        "时间范围",
        50,
        59,
        "2021Q1-Q3"
      ],
      [
        "T3",
        "营业收入",
        59,
        61,
        "收入"
      ],
      [
        "T4",
        "归母净利润",
        77,
        82,
        "归母净利润"
      ],
      [
        "T5",
        "毛利",
        95,
        98,
        "毛利率"
      ],
      [
        "T6",
        "行业",
        117,
        123,
        "创新药与制剂"
      ],
      [
        "T7",
        "时间范围",
        125,
        127,
        "Q3"
      ],
      [
        "T8",
        "营业收入",
        130,
        132,
        "收入"
      ],
      [
        "T9",
        "属性值",
        132,
        139,
        "503.7亿元"
      ],
      [
        "T10",
        "属性值",
        140,
        145,
        "-0.3%"
      ],
      [
        "T11",
        "归母净利润",
        150,
        153,
        "净利润"
      ],
      [
        "T12",
        "时间范围",
        169,
        171,
        "Q3"
      ],
      [
        "T13",
        "毛利",
        174,
        177,
        "毛利率"
      ],
      [
        "T14",
        "时间范围",
        231,
        236,
        "去年三季度"
      ],
      [
        "T15",
        "行业",
        273,
        279,
        "创新药及制剂"
      ],
      [
        "T16",
        "属性值",
        293,
        295,
        "下滑"
      ],
      [
        "T17",
        "收入增速",
        27,
        31,
        "收入增速"
      ],
      [
        "T18",
        "行业公司",
        39,
        50,
        "52家创新药及制剂公司"
      ],
      [
        "T19",
        "属性值",
        62,
        68,
        "1508亿元"
      ],
      [
        "T20",
        "属性值",
        69,
        75,
        "+10.3%"
      ],
      [
        "T21",
        "属性值",
        82,
        94,
        "182.6亿元（-2%）"
      ],
      [
        "T22",
        "属性值",
        98,
        101,
        "58%"
      ],
      [
        "T23",
        "归母净利润",
        109,
        112,
        "净利率"
      ],
      [
        "T24",
        "属性值",
        113,
        116,
        "13%"
      ],
      [
        "T25",
        "属性值",
        153,
        167,
        "59.7亿元（-15.3%）"
      ],
      [
        "T26",
        "属性值",
        177,
        190,
        "57.5%（-4.8pp）"
      ],
      [
        "T27",
        "归母净利润",
        214,
        217,
        "净利率"
      ],
      [
        "T28",
        "属性值",
        217,
        230,
        "11.9%（-2.1pp）"
      ],
      [
        "T29",
        "时间范围",
        281,
        284,
        "三季度"
      ],
      [
        "T30",
        "利润",
        288,
        291,
        "利润端"
      ],
      [
        "T31",
        "营业收入",
        284,
        287,
        "收入端"
      ]
    ]
  },
  {
    "id": 459,
    "text": "生物科研试剂行业行业快速增长，国内增速显著快于全球。从全球来看，生物科研试剂市场的整体规模预计将从 2015年的 832亿元增长到 2024年的 1599亿元，CAGR 为7.5%。相比国外，我国生物科研试剂行业发展较晚，但近年来保持着高速增长，整体规模预计将从 2015年的 72亿元增长到 2024年的 260亿元，CAGR为 15.3%，增速远高于同期全球生物科研试剂市场。",
    "labels": [
      [
        "T0",
        "时间范围",
        0,
        6,
        "生物科研试剂"
      ],
      [
        "T1",
        "地点范围",
        15,
        17,
        "国内"
      ],
      [
        "T2",
        "时间范围",
        50,
        55,
        "2015年"
      ],
      [
        "T3",
        "属性值",
        57,
        62,
        "832亿元"
      ],
      [
        "T4",
        "时间范围",
        66,
        71,
        "2024年"
      ],
      [
        "T5",
        "属性值",
        73,
        79,
        "1599亿元"
      ],
      [
        "T6",
        "CAGR",
        80,
        84,
        "CAGR"
      ],
      [
        "T7",
        "属性值",
        86,
        90,
        "7.5%"
      ],
      [
        "T8",
        "行业",
        98,
        104,
        "生物科研试剂"
      ],
      [
        "T9",
        "行业",
        32,
        38,
        "生物科研试剂"
      ],
      [
        "T10",
        "地点范围",
        27,
        29,
        "全球"
      ],
      [
        "T11",
        "地点范围",
        96,
        98,
        "我国"
      ],
      [
        "T12",
        "时间范围",
        132,
        137,
        "2015年"
      ],
      [
        "T13",
        "时间范围",
        147,
        152,
        "2024年"
      ],
      [
        "T14",
        "属性值",
        139,
        143,
        "72亿元"
      ],
      [
        "T15",
        "属性值",
        154,
        159,
        "260亿元"
      ],
      [
        "T16",
        "属性值",
        166,
        171,
        "15.3%"
      ],
      [
        "T17",
        "CAGR",
        160,
        164,
        "CAGR"
      ],
      [
        "T18",
        "地点范围",
        23,
        25,
        "全球"
      ],
      [
        "T19",
        "地点范围",
        93,
        95,
        "国外"
      ],
      [
        "T20",
        "时间范围",
        112,
        115,
        "近年来"
      ],
      [
        "T21",
        "属性值",
        174,
        189,
        "远高于同期全球生物科研试剂市场"
      ],
      [
        "T22",
        "属性值",
        41,
        45,
        "整体规模"
      ],
      [
        "T23",
        "属性值",
        123,
        127,
        "整体规模"
      ]
    ]
  },
  {
    "id": 460,
    "text": "2019年我国注射类医美诊疗约1418万人次，行业持续快速增长中，目前市场美容针以锐针为主且多不合规，公司报批的美容钝针相比于锐针在注射效果、安全性等方面更佳，于10月14日获批，成为国内第一款经过正规临床试验获得III类注册证的美容注射针，填补国内合规市场空白，同时公司积极开拓国际市场，在以色列、巴西、法国、美国等均有布局，双向发力，此外水光针、植发针预期明年上市，在前期医美针渠道布局下将快速放量。",
    "labels": [
      [
        "T0",
        "时间范围",
        0,
        5,
        "2019年"
      ],
      [
        "T1",
        "地点范围",
        5,
        7,
        "我国"
      ],
      [
        "T2",
        "行业",
        7,
        14,
        "注射类医美诊疗"
      ],
      [
        "T3",
        "时间范围",
        33,
        35,
        "目前"
      ],
      [
        "T4",
        "时间范围",
        81,
        87,
        "10月14日"
      ],
      [
        "T5",
        "地点范围",
        92,
        94,
        "国内"
      ],
      [
        "T6",
        "地点范围",
        123,
        125,
        "国内"
      ],
      [
        "T7",
        "地点范围",
        140,
        142,
        "国际"
      ],
      [
        "T8",
        "地点范围",
        146,
        149,
        "以色列"
      ],
      [
        "T9",
        "地点范围",
        150,
        152,
        "巴西"
      ],
      [
        "T10",
        "地点范围",
        153,
        155,
        "法国"
      ],
      [
        "T11",
        "地点范围",
        156,
        158,
        "美国"
      ],
      [
        "T12",
        "时间范围",
        180,
        182,
        "明年"
      ]
    ]
  },
  {
    "id": 461,
    "text": "中药领域：佐力药业、济川药业、东阿阿胶、片仔癀等； 仿制药 CXO领域：关注百诚医药、阳光诺和等； 创新药及产业链领域：九洲药业、药明康德、凯莱英等； BIOTECH类创新药：康方生物、信达生物、亚盛医药等； 原料药领域：同和药业、普洛药业、司太立、天宇股份等； 疫苗领域：智飞生物、康泰生物、万泰生物等； 生长激素领域：长春高新、安科生物等； 医疗服务领域：通策医疗、爱尔眼科、信邦制药等； 血制品领域：博雅生物、天坛生物等； 医美领域：爱美客、华熙生物、华东医药、昊海生科等； 医疗器械领域：鱼跃医疗、海泰新光、迈瑞医疗等。",
    "labels": [
      [
        "T0",
        "行业",
        0,
        2,
        "中药"
      ],
      [
        "T1",
        "公司",
        5,
        9,
        "佐力药业"
      ],
      [
        "T2",
        "公司",
        10,
        14,
        "济川药业"
      ],
      [
        "T3",
        "公司",
        15,
        19,
        "东阿阿胶"
      ],
      [
        "T4",
        "公司",
        20,
        23,
        "片仔癀"
      ],
      [
        "T5",
        "行业",
        26,
        33,
        "仿制药 CXO"
      ],
      [
        "T6",
        "公司",
        38,
        42,
        "百诚医药"
      ],
      [
        "T7",
        "公司",
        43,
        47,
        "阳光诺和"
      ],
      [
        "T8",
        "公司",
        60,
        64,
        "九洲药业"
      ],
      [
        "T9",
        "公司",
        65,
        69,
        "药明康德"
      ],
      [
        "T10",
        "公司",
        70,
        73,
        "凯莱英"
      ],
      [
        "T11",
        "行业",
        76,
        87,
        "BIOTECH类创新药"
      ],
      [
        "T12",
        "公司",
        88,
        92,
        "康方生物"
      ],
      [
        "T13",
        "公司",
        93,
        97,
        "信达生物"
      ],
      [
        "T14",
        "公司",
        98,
        102,
        "亚盛医药"
      ],
      [
        "T15",
        "行业",
        105,
        108,
        "原料药"
      ],
      [
        "T16",
        "公司",
        111,
        115,
        "同和药业"
      ],
      [
        "T17",
        "公司",
        116,
        120,
        "普洛药业"
      ],
      [
        "T18",
        "公司",
        121,
        124,
        "司太立"
      ],
      [
        "T19",
        "公司",
        125,
        129,
        "天宇股份"
      ],
      [
        "T20",
        "行业",
        132,
        134,
        "疫苗"
      ],
      [
        "T21",
        "公司",
        137,
        141,
        "智飞生物"
      ],
      [
        "T22",
        "公司",
        142,
        146,
        "康泰生物"
      ],
      [
        "T23",
        "公司",
        147,
        151,
        "万泰生物"
      ],
      [
        "T24",
        "行业",
        154,
        158,
        "生长激素"
      ],
      [
        "T25",
        "公司",
        161,
        165,
        "长春高新"
      ],
      [
        "T26",
        "公司",
        166,
        170,
        "安科生物"
      ],
      [
        "T27",
        "行业",
        173,
        177,
        "医疗服务"
      ],
      [
        "T28",
        "公司",
        180,
        184,
        "通策医疗"
      ],
      [
        "T29",
        "公司",
        185,
        189,
        "爱尔眼科"
      ],
      [
        "T30",
        "公司",
        190,
        194,
        "信邦制药"
      ],
      [
        "T31",
        "行业",
        197,
        200,
        "血制品"
      ],
      [
        "T32",
        "公司",
        203,
        207,
        "博雅生物"
      ],
      [
        "T33",
        "公司",
        208,
        212,
        "天坛生物"
      ],
      [
        "T34",
        "行业",
        215,
        217,
        "医美"
      ],
      [
        "T35",
        "公司",
        220,
        223,
        "爱美客"
      ],
      [
        "T36",
        "公司",
        224,
        228,
        "华熙生物"
      ],
      [
        "T37",
        "公司",
        229,
        233,
        "华东医药"
      ],
      [
        "T38",
        "公司",
        234,
        238,
        "昊海生科"
      ],
      [
        "T39",
        "行业",
        241,
        245,
        "医疗器械"
      ],
      [
        "T40",
        "公司",
        248,
        252,
        "鱼跃医疗"
      ],
      [
        "T41",
        "公司",
        253,
        257,
        "海泰新光"
      ],
      [
        "T42",
        "公司",
        258,
        262,
        "迈瑞医疗"
      ],
      [
        "T43",
        "行业",
        50,
        57,
        "创新药及产业链"
      ]
    ]
  },
  {
    "id": 463,
    "text": "• 从研发端深入绑定客户，客户粘性高； • 更适宜Biotech公司的客户模式；",
    "labels": [
      [
        "T0",
        "行业公司",
        25,
        34,
        "Biotech公司"
      ]
    ]
  },
  {
    "id": 464,
    "text": " POCT凭借快速、简单、即时即地场景多元等优势在 IVD赛道中占比逐渐提升。2018年国内POCT市场规模100亿元，预计能够维持20%以上的增速。  当前POCT主要场景有感染类、血气/凝血类、心血管检测类、妊娠检测类、药物滥用类等。传染病类和心血管类导入期完成，将进入高速成长期。  2021上半年常规业务逐步恢复，叠加部分公司新冠检测试剂仍贡献增量，总体POCT企业实现收入、利润高增长（基蛋、明德）  万孚生物：国产POCT龙头，2021上半年收入18.6 亿元（+15.5%）,归母净利润5.6亿元（+23.8%）  基蛋生物：2021年上半年收入6亿元（+58%）， 归母净利润1.7亿元（+78.1%）。主要因常规业务逐步恢复。  明德生物：2021上半年收入11.4亿元（+216.5%） ，归母净利润5.8亿元（+189.5%），主要是因新冠检测试剂贡献较大增量。",
    "labels": [
      [
        "T0",
        "行业",
        2,
        6,
        "POCT"
      ],
      [
        "T1",
        "行业",
        27,
        30,
        "IVD"
      ],
      [
        "T2",
        "时间范围",
        40,
        45,
        "2018年"
      ],
      [
        "T3",
        "地点范围",
        45,
        47,
        "国内"
      ],
      [
        "T4",
        "行业",
        47,
        51,
        "POCT"
      ],
      [
        "T5",
        "市场规模",
        51,
        55,
        "市场规模"
      ],
      [
        "T6",
        "属性值",
        55,
        60,
        "100亿元"
      ],
      [
        "T7",
        "属性值",
        67,
        72,
        "20%以上"
      ],
      [
        "T8",
        "行业",
        81,
        85,
        "POCT"
      ],
      [
        "T9",
        "时间范围",
        148,
        155,
        "2021上半年"
      ],
      [
        "T10",
        "行业公司",
        184,
        190,
        "POCT企业"
      ],
      [
        "T11",
        "营业收入",
        192,
        194,
        "收入"
      ],
      [
        "T12",
        "利润",
        195,
        197,
        "利润"
      ],
      [
        "T13",
        "公司",
        201,
        203,
        "基蛋"
      ],
      [
        "T14",
        "公司",
        204,
        206,
        "明德"
      ],
      [
        "T15",
        "公司",
        210,
        214,
        "万孚生物"
      ],
      [
        "T16",
        "龙头企业",
        221,
        223,
        "龙头"
      ],
      [
        "T17",
        "时间范围",
        224,
        231,
        "2021上半年"
      ],
      [
        "T18",
        "营业收入",
        231,
        233,
        "收入"
      ],
      [
        "T19",
        "属性值",
        233,
        240,
        "18.6 亿元"
      ],
      [
        "T20",
        "属性值",
        241,
        247,
        "+15.5%"
      ],
      [
        "T21",
        "归母净利润",
        249,
        254,
        "归母净利润"
      ],
      [
        "T22",
        "公司",
        270,
        274,
        "基蛋生物"
      ],
      [
        "T23",
        "时间范围",
        275,
        283,
        "2021年上半年"
      ],
      [
        "T24",
        "营业收入",
        283,
        285,
        "收入"
      ],
      [
        "T25",
        "属性值",
        285,
        288,
        "6亿元"
      ],
      [
        "T26",
        "属性值",
        289,
        293,
        "+58%"
      ],
      [
        "T27",
        "归母净利润",
        296,
        301,
        "归母净利润"
      ],
      [
        "T28",
        "公司",
        330,
        334,
        "明德生物"
      ],
      [
        "T29",
        "时间范围",
        335,
        342,
        "2021上半年"
      ],
      [
        "T30",
        "营业收入",
        342,
        344,
        "收入"
      ],
      [
        "T31",
        "属性值",
        344,
        350,
        "11.4亿元"
      ],
      [
        "T32",
        "属性值",
        351,
        358,
        "+216.5%"
      ],
      [
        "T33",
        "归母净利润",
        361,
        366,
        "归母净利润"
      ],
      [
        "T34",
        "属性值",
        8,
        22,
        "快速、简单、即时即地场景多元"
      ],
      [
        "T35",
        "时间范围",
        79,
        81,
        "当前"
      ],
      [
        "T36",
        "属性值",
        197,
        200,
        "高增长"
      ],
      [
        "T37",
        "行业",
        215,
        221,
        "国产POCT"
      ],
      [
        "T38",
        "属性值",
        254,
        267,
        "5.6亿元（+23.8%）"
      ],
      [
        "T39",
        "属性值",
        301,
        314,
        "1.7亿元（+78.1%）"
      ],
      [
        "T40",
        "属性值",
        366,
        380,
        "5.8亿元（+189.5%）"
      ]
    ]
  },
  {
    "id": 465,
    "text": "角膜塑形镜是近视防控的有效方法之一。近视是指在眼调节放松的状态下，无穷远处物体所成的像聚焦在视网膜前的现象。近视的治疗和矫正方式包括配戴框架眼镜、隐形眼镜、角膜塑形镜纠正、准分子激光手术等。角膜塑形镜全称为塑形用硬性角膜接触镜，其采用一种与角膜表面几何形态相逆反的特殊设计，通过戴镜产生的机械力学及流体力学作用，对角膜实施合理的、可调控的、可逆的程序化塑形，改变角膜的屈光力， 从而达到矫正近视的作用。研究表明，使用阿托品滴眼液或佩戴角膜塑形镜，对近视发展的延缓作用至少与户外活动相当。2018年国家卫健委发布的《近视防治指南》指出， 长期配戴角膜塑形镜可延缓青少年眼轴长度进展约 0.19mm/年，（眼轴与近视呈正相关： 眼轴每增长 1mm，近视增长 275~300度）；《近视管理白皮书（2019）》中也明确指出， 角膜塑形镜可有效减缓近视眼眼轴增长，减缓量约为 0.15mm/年，近视控制效力中等 （0.25～0.50D/年），延缓 35%～60%近视进展。",
    "labels": [
      [
        "T0",
        "时间范围",
        243,
        248,
        "2018年"
      ]
    ]
  },
  {
    "id": 466,
    "text": " 我们选取了311家医药上市公司（包含科创板），2021年Q1-3收入总额14054亿元，归母净利润1595亿元，分别占申万医药全成分结果比例是：85%、90%，主要剔除了在2019、2020年、2021Q1-3提取巨额商誉减值损失的企业。2021年 Q1-3全行业收入增速为21%，归母净利润增速为27.2%。2021年Q1-3实现归母净利润正增长的公司有223家，占比 72%，84%（260/311）的公司实现收入正增长。",
    "labels": [
      [
        "T0",
        "时间范围",
        25,
        34,
        "2021年Q1-3"
      ],
      [
        "T1",
        "营业收入",
        34,
        38,
        "收入总额"
      ],
      [
        "T2",
        "属性值",
        38,
        45,
        "14054亿元"
      ],
      [
        "T3",
        "归母净利润",
        46,
        51,
        "归母净利润"
      ],
      [
        "T4",
        "属性值",
        51,
        57,
        "1595亿元"
      ],
      [
        "T5",
        "时间范围",
        121,
        131,
        "2021年 Q1-3"
      ],
      [
        "T6",
        "属性值",
        139,
        142,
        "21%"
      ],
      [
        "T7",
        "归母净利润增速",
        143,
        150,
        "归母净利润增速"
      ],
      [
        "T8",
        "属性值",
        151,
        156,
        "27.2%"
      ],
      [
        "T9",
        "时间范围",
        157,
        166,
        "2021年Q1-3"
      ],
      [
        "T10",
        "归母净利润",
        168,
        173,
        "归母净利润"
      ],
      [
        "T11",
        "行业公司",
        7,
        17,
        "311家医药上市公司"
      ],
      [
        "T12",
        "行业",
        63,
        65,
        "医药"
      ],
      [
        "T13",
        "属性值",
        74,
        77,
        "85%"
      ],
      [
        "T14",
        "时间范围",
        88,
        92,
        "2019"
      ],
      [
        "T15",
        "时间范围",
        93,
        98,
        "2020年"
      ],
      [
        "T16",
        "时间范围",
        99,
        107,
        "2021Q1-3"
      ],
      [
        "T17",
        "收入增速",
        134,
        138,
        "收入增速"
      ]
    ]
  },
  {
    "id": 467,
    "text": "生物药  业绩持续快速恢复，2021H1收入和净利润持续增长。16家生物药公司2021上半年收入总额增速为23.9%、归母净利润总额增速为40.4% ，收入和利润依然保持相对较快增长。生物药企业去年同期受疫情影响较大，业绩基数相对较低，进入到今年上半年，行业已经完全迎来恢复，预计到三、四季度，行业增速将逐步放缓。  盈利能力小幅提升，销售费用率下降较大，研发投入持续快速增加。从盈利水平看，生物药板块整体盈利能力保持稳定，行业毛利率（ 63%）基本保持平稳，销售费用率（27%）持续下降，管理费用率（8%）、研发费用率（9%）保持稳定，因为销售费用率下降显著，净利率（21%）同比有所提升。  生物药盈利能力好转，现金流情况良好。从ROE水平来看，近几年生物药板块ROE水平持续下降，与部分企业净利润率下降有关。 2021H1，生物药板块ROE为4.46%，同比增长0.71pp，ROE提升主要与销售费用率下降，净利润率提升有较大关系。从现金流情况来看 ，近几年我国生物药企业经营活动产生的现金流量净额/经营活动净收益持续提升，但2021H1为93.08%，同比提升10pp，上半年提升较大主要与去年同期受疫情影响基数较低有关，预计下半年现金流有望继续保持较好水平。  生长激素、粉尘螨滴剂等高景气度细分赛道增速相对较快。从细分行业来看，生长激素龙头企业长春高新、安科生物2021年上半年均实现较快增长，粉尘螨滴剂龙头企业我武生物恢复情况也较好，预计随着黄花蒿粉滴剂的放量，下半年有望持续加速。",
    "labels": [
      [
        "T0",
        "行业",
        0,
        3,
        "生物药"
      ],
      [
        "T1",
        "业绩",
        6,
        8,
        "业绩"
      ],
      [
        "T2",
        "时间范围",
        15,
        21,
        "2021H1"
      ],
      [
        "T3",
        "营业收入",
        21,
        23,
        "收入"
      ],
      [
        "T4",
        "归母净利润",
        24,
        27,
        "净利润"
      ],
      [
        "T5",
        "时间范围",
        40,
        47,
        "2021上半年"
      ],
      [
        "T6",
        "收入增速",
        47,
        53,
        "收入总额增速"
      ],
      [
        "T7",
        "归母净利润增速",
        60,
        69,
        "归母净利润总额增速"
      ],
      [
        "T8",
        "行业公司",
        93,
        98,
        "生物药企业"
      ],
      [
        "T9",
        "业绩",
        110,
        112,
        "业绩"
      ],
      [
        "T10",
        "研发费用",
        180,
        184,
        "研发投入"
      ],
      [
        "T11",
        "行业",
        198,
        201,
        "生物药"
      ],
      [
        "T12",
        "毛利",
        216,
        219,
        "毛利率"
      ],
      [
        "T13",
        "属性值",
        221,
        224,
        "63%"
      ],
      [
        "T14",
        "现金流",
        311,
        314,
        "现金流"
      ],
      [
        "T15",
        "ROE净资产回报率",
        320,
        323,
        "ROE"
      ],
      [
        "T16",
        "时间范围",
        328,
        331,
        "近几年"
      ],
      [
        "T17",
        "行业",
        331,
        334,
        "生物药"
      ],
      [
        "T18",
        "ROE净资产回报率",
        336,
        339,
        "ROE"
      ],
      [
        "T19",
        "时间范围",
        361,
        367,
        "2021H1"
      ],
      [
        "T20",
        "行业",
        368,
        371,
        "生物药"
      ],
      [
        "T21",
        "ROE净资产回报率",
        373,
        376,
        "ROE"
      ],
      [
        "T22",
        "ROE净资产回报率",
        394,
        397,
        "ROE"
      ],
      [
        "T23",
        "现金流",
        423,
        426,
        "现金流"
      ],
      [
        "T24",
        "时间范围",
        432,
        435,
        "近几年"
      ],
      [
        "T25",
        "地点范围",
        435,
        437,
        "我国"
      ],
      [
        "T26",
        "行业公司",
        437,
        442,
        "生物药企业"
      ],
      [
        "T27",
        "时间范围",
        469,
        475,
        "2021H1"
      ],
      [
        "T28",
        "时间范围",
        520,
        523,
        "下半年"
      ],
      [
        "T29",
        "现金流",
        523,
        526,
        "现金流"
      ],
      [
        "T30",
        "行业",
        540,
        544,
        "生长激素"
      ],
      [
        "T31",
        "行业",
        545,
        550,
        "粉尘螨滴剂"
      ],
      [
        "T32",
        "行业",
        574,
        578,
        "生长激素"
      ],
      [
        "T33",
        "龙头企业",
        578,
        582,
        "龙头企业"
      ],
      [
        "T34",
        "公司",
        582,
        586,
        "长春高新"
      ],
      [
        "T35",
        "公司",
        587,
        591,
        "安科生物"
      ],
      [
        "T36",
        "时间范围",
        591,
        599,
        "2021年上半年"
      ],
      [
        "T37",
        "行业",
        607,
        612,
        "粉尘螨滴剂"
      ],
      [
        "T38",
        "龙头企业",
        612,
        616,
        "龙头企业"
      ],
      [
        "T39",
        "公司",
        616,
        620,
        "我武生物"
      ],
      [
        "T40",
        "行业公司",
        32,
        40,
        "16家生物药公司"
      ],
      [
        "T41",
        "属性值",
        54,
        59,
        "23.9%"
      ],
      [
        "T42",
        "属性值",
        70,
        75,
        "40.4%"
      ],
      [
        "T43",
        "属性值",
        86,
        92,
        "相对较快增长"
      ],
      [
        "T44",
        "营业收入",
        77,
        79,
        "收入"
      ],
      [
        "T45",
        "利润",
        80,
        82,
        "利润"
      ],
      [
        "T46",
        "时间范围",
        98,
        100,
        "去年"
      ],
      [
        "T47",
        "属性值",
        112,
        118,
        "基数相对较低"
      ],
      [
        "T48",
        "时间范围",
        122,
        127,
        "今年上半年"
      ],
      [
        "T49",
        "属性值",
        132,
        138,
        "完全迎来恢复"
      ],
      [
        "T50",
        "时间范围",
        142,
        147,
        "三、四季度"
      ],
      [
        "T51",
        "属性值",
        229,
        231,
        "平稳"
      ],
      [
        "T52",
        "归母净利润",
        283,
        286,
        "净利率"
      ],
      [
        "T53",
        "属性值",
        316,
        318,
        "良好"
      ],
      [
        "T54",
        "属性值",
        377,
        393,
        "4.46%，同比增长0.71pp"
      ],
      [
        "T55",
        "属性值",
        397,
        399,
        "提升"
      ],
      [
        "T56",
        "归母净利润",
        410,
        414,
        "净利润率"
      ],
      [
        "T57",
        "属性值",
        414,
        416,
        "提升"
      ],
      [
        "T58",
        "行业",
        301,
        304,
        "生物药"
      ],
      [
        "T59",
        "现金流",
        449,
        453,
        "现金流量"
      ],
      [
        "T60",
        "时间范围",
        492,
        495,
        "上半年"
      ],
      [
        "T61",
        "时间范围",
        502,
        504,
        "去年"
      ],
      [
        "T62",
        "属性值",
        532,
        536,
        "较好水平"
      ],
      [
        "T63",
        "时间范围",
        642,
        645,
        "下半年"
      ],
      [
        "T64",
        "属性值",
        8,
        14,
        "持续快速恢复"
      ],
      [
        "T65",
        "属性值",
        27,
        31,
        "持续增长"
      ],
      [
        "T66",
        "属性值",
        184,
        190,
        "持续快速增加"
      ],
      [
        "T67",
        "属性值",
        286,
        297,
        "（21%）同比有所提升"
      ],
      [
        "T68",
        "属性值",
        341,
        345,
        "持续下降"
      ]
    ]
  },
  {
    "id": 468,
    "text": "从 FDA历年批准的新分子实体（NME）来看，2017年后每年批准数量有整体上升趋势，抗癌药物和生物药的批准数量明显增加。从 2000年到2008年，抗癌药物（12.0%） 和生物药（7.2%）批准的数量占比基本保持不变；从2009年至2017年，抗癌药物（17.5%） 和生物药（15.6%）的批准的数量占比急剧上升；过去几年中，抗癌药物和生物药的批准数量占比进一步上升，2020年 FDA共批准53个，获批抗癌药 18个（34.0%）和生物药 13个（24.5%）。",
    "labels": [
      [
        "T0",
        "时间范围",
        23,
        29,
        "2017年后"
      ],
      [
        "T1",
        "时间范围",
        61,
        74,
        "从 2000年到2008年"
      ],
      [
        "T2",
        "行业",
        75,
        79,
        "抗癌药物"
      ],
      [
        "T3",
        "行业",
        88,
        91,
        "生物药"
      ],
      [
        "T4",
        "时间范围",
        111,
        123,
        "从2009年至2017年"
      ],
      [
        "T5",
        "行业",
        124,
        128,
        "抗癌药物"
      ],
      [
        "T6",
        "行业",
        137,
        140,
        "生物药"
      ],
      [
        "T7",
        "行业",
        166,
        170,
        "抗癌药物"
      ],
      [
        "T8",
        "时间范围",
        160,
        164,
        "过去几年"
      ],
      [
        "T9",
        "行业",
        171,
        174,
        "生物药"
      ],
      [
        "T10",
        "时间范围",
        187,
        192,
        "2020年"
      ],
      [
        "T11",
        "行业",
        205,
        208,
        "抗癌药"
      ],
      [
        "T12",
        "行业",
        220,
        223,
        "生物药"
      ],
      [
        "T13",
        "属性值",
        209,
        212,
        "18个"
      ],
      [
        "T14",
        "属性值",
        224,
        227,
        "13个"
      ]
    ]
  },
  {
    "id": 469,
    "text": " 21Q1-3全行业销售费用为1896亿元（ +13%）同比增加213亿元，主要受中药 、医疗器械板块带动。行业销售费用率呈现下降趋势。",
    "labels": [
      [
        "T0",
        "行业",
        42,
        44,
        "中药"
      ],
      [
        "T1",
        "行业",
        46,
        50,
        "医疗器械"
      ],
      [
        "T2",
        "时间范围",
        2,
        8,
        "21Q1-3"
      ]
    ]
  },
  {
    "id": 470,
    "text": " 原料药（28家）：上半年实现收入443亿元(+13.3%)，实现归母净利润78.3亿元(-0.1%)；21Q1/Q2原料药板块分别实现收入216亿元/227亿元，同比+19%/8.5% ，在利润端21Q1/Q2实现归母净利润37.4亿元/40.9亿元，同比+20%/-13.2% 。二季度板块归母净利润下滑，主要是毛利率同比去年下滑约3.8pp，同时费用端同上升1.3pp。",
    "labels": [
      [
        "T0",
        "行业",
        2,
        5,
        "原料药"
      ],
      [
        "T1",
        "时间范围",
        11,
        14,
        "上半年"
      ],
      [
        "T2",
        "营业收入",
        16,
        18,
        "收入"
      ],
      [
        "T3",
        "归母净利润",
        34,
        39,
        "归母净利润"
      ],
      [
        "T4",
        "行业",
        60,
        63,
        "原料药"
      ],
      [
        "T5",
        "营业收入",
        69,
        71,
        "收入"
      ],
      [
        "T6",
        "归母净利润",
        109,
        114,
        "归母净利润"
      ],
      [
        "T7",
        "毛利",
        159,
        162,
        "毛利率"
      ],
      [
        "T8",
        "归母净利润",
        148,
        153,
        "归母净利润"
      ],
      [
        "T9",
        "时间范围",
        143,
        146,
        "二季度"
      ],
      [
        "T10",
        "属性值",
        18,
        23,
        "443亿元"
      ],
      [
        "T11",
        "属性值",
        24,
        30,
        "+13.3%"
      ],
      [
        "T12",
        "属性值",
        39,
        52,
        "78.3亿元(-0.1%)"
      ],
      [
        "T13",
        "时间范围",
        53,
        57,
        "21Q1"
      ],
      [
        "T14",
        "时间范围",
        58,
        60,
        "Q2"
      ],
      [
        "T15",
        "属性值",
        71,
        76,
        "216亿元"
      ],
      [
        "T16",
        "属性值",
        77,
        82,
        "227亿元"
      ],
      [
        "T17",
        "属性值",
        85,
        89,
        "+19%"
      ],
      [
        "T18",
        "属性值",
        90,
        94,
        "8.5%"
      ],
      [
        "T19",
        "利润",
        97,
        100,
        "利润端"
      ],
      [
        "T20",
        "时间范围",
        100,
        104,
        "21Q1"
      ],
      [
        "T21",
        "时间范围",
        105,
        107,
        "Q2"
      ],
      [
        "T22",
        "属性值",
        114,
        120,
        "37.4亿元"
      ],
      [
        "T23",
        "属性值",
        121,
        127,
        "40.9亿元"
      ],
      [
        "T24",
        "属性值",
        153,
        155,
        "下滑"
      ],
      [
        "T25",
        "属性值",
        162,
        174,
        "同比去年下滑约3.8pp"
      ]
    ]
  },
  {
    "id": 471,
    "text": " 药品板块：政策底逐步显现，推动医药中游估值修复  疫苗板块：新冠疫情驱动行业快速发展，后疫情时代有望持续获益  器械板块：感控与新冠检测具备业绩超预期潜力，高耗估值存在回暖空间",
    "labels": [
      [
        "T0",
        "行业",
        2,
        4,
        "药品"
      ],
      [
        "T1",
        "行业",
        17,
        19,
        "医药"
      ],
      [
        "T2",
        "行业",
        28,
        30,
        "疫苗"
      ],
      [
        "T3",
        "行业",
        60,
        62,
        "器械"
      ],
      [
        "T4",
        "行业",
        65,
        67,
        "感控"
      ],
      [
        "T5",
        "行业",
        68,
        72,
        "新冠检测"
      ],
      [
        "T6",
        "业绩",
        74,
        76,
        "业绩"
      ],
      [
        "T7",
        "属性值",
        76,
        81,
        "超预期潜力"
      ]
    ]
  },
  {
    "id": 472,
    "text": "Ø 2021.12.13-2021.12.24 医药板块下跌1.95%，跑赢沪深300指数0.70pct；医药外包板块下跌10.90%，跑输医药板块8.95pct。2021年年初以来，医药板块下跌7.27%，跑输沪深300指数1.70 pct，医药外包板块上涨23.23%， 跑赢沪深300指数28.79 pct。",
    "labels": [
      [
        "T0",
        "时间范围",
        2,
        23,
        "2021.12.13-2021.12.24"
      ],
      [
        "T1",
        "行业",
        24,
        26,
        "医药"
      ],
      [
        "T2",
        "行业",
        53,
        57,
        "医药外包"
      ],
      [
        "T3",
        "行业",
        70,
        72,
        "医药"
      ],
      [
        "T4",
        "时间范围",
        82,
        91,
        "2021年年初以来"
      ],
      [
        "T5",
        "行业",
        92,
        94,
        "医药"
      ],
      [
        "T6",
        "行业",
        122,
        126,
        "医药外包"
      ]
    ]
  },
  {
    "id": 474,
    "text": "Table_Summary] ⚫ 回顾： 2021年医药是政策担忧与疫情脱敏的下行之年。医药政策引导行业历次变革，贯穿医药发展全历程，近年来医药政策主基调是降价控费。 2020-2021年是医药国采和地方联采持续深化之年，尤以 2021年为国家及地方集采频次历年最高，政策压力强于过往历年。新冠业绩增量是一把双刃剑，短期增厚当期业绩，但长期疫情受益带来的高增长难以持续， 明年部分抗疫需求相关公司业绩增长可能面临今年高基数压力。在政策担忧与疫情脱敏双重压力下，今年医药行业表现并不佳，医药生物下跌 6.93%，跑输沪深 300 指数 4个百分点，排全部 28个 SW一级行业第 22位。 ⚫ 预判：明年仍需关注的几个问题。一是适应集采新常态，但医药总需求将继续保持增长，明年集采政策将趋于温和；二是分化可能更加明显， 板块冷热不均加剧；三是新冠未来流感化特征明显，特效药相关品种值得关注。 ⚫ 2022年医药行业投资策略：集采广泛化，行业分化常态化，明年我们看好生物制品、创新药产业链、非药器械、药店和上游原辅料包材类等细分行业。 生物制品：十四五期间各地浆站规划出台，血制品行业规模瓶颈有可能解除，首推天坛和博雅；疫苗行业，今年受新冠疫苗接种挤压，传统疫苗接种受影响，明年大概率恢复正常，同时疫情又教育了国民疫苗接种重要性，明年相关公司有重大产品上市，但是要关注新冠疫苗业绩下滑带来的影响。 创新药产业链（创新药企和 CXO）：政策鼓励药械创新没有变化，药物研发需求旺盛，投融资市场持续火热；国内 CXO企业彰显国际竞争力， 持续扩产。行业大逻辑并没有变化，建议弱化估值因素，战略性长期配置 CXO行业。 性价比之选：医疗器械、连锁药店。器械重点关注眼科和康复器械，眼科赛道景气度高，关注角膜塑形镜龙头，我国康复行业发展落后，受益人口老龄化，是冉冉升起的朝阳行业。重点看好翔宇医疗等。 上游原辅料包材类：国内生命科学研发投入持续高增长，预计 2015-2024 年 CAGR为 15.3%，增速远高于同期全球；研究投入也仅次于美、欧， 全球占比达到 8.3%左右。疫情充分展现我国科研试剂尤其生物试剂企业发展前景和韧性，优选健凯科技、百普赛斯、诺唯赞、山东药玻等。 ⚫ 风险提示：集采等医药政策过于严厉，部分行业估值回调风险，系统风险。",
    "labels": [
      [
        "T0",
        "时间范围",
        21,
        26,
        "2021年"
      ],
      [
        "T1",
        "时间范围",
        84,
        94,
        "2020-2021年"
      ],
      [
        "T2",
        "时间范围",
        114,
        119,
        "2021年"
      ],
      [
        "T3",
        "业绩",
        147,
        149,
        "业绩"
      ],
      [
        "T4",
        "业绩",
        164,
        166,
        "业绩"
      ],
      [
        "T5",
        "业绩",
        198,
        200,
        "业绩"
      ],
      [
        "T6",
        "时间范围",
        230,
        232,
        "今年"
      ],
      [
        "T7",
        "行业",
        232,
        234,
        "医药"
      ],
      [
        "T8",
        "行业",
        242,
        246,
        "医药生物"
      ],
      [
        "T9",
        "时间范围",
        299,
        301,
        "明年"
      ],
      [
        "T10",
        "行业",
        322,
        324,
        "医药"
      ],
      [
        "T11",
        "行业需求",
        325,
        327,
        "需求"
      ],
      [
        "T12",
        "时间范围",
        397,
        402,
        "2022年"
      ],
      [
        "T13",
        "行业",
        402,
        404,
        "医药"
      ],
      [
        "T14",
        "行业",
        431,
        435,
        "生物制品"
      ],
      [
        "T15",
        "行业",
        443,
        447,
        "非药器械"
      ],
      [
        "T16",
        "行业",
        448,
        450,
        "药店"
      ],
      [
        "T17",
        "行业",
        466,
        469,
        "生物制"
      ],
      [
        "T18",
        "公司",
        502,
        504,
        "天坛"
      ],
      [
        "T19",
        "公司",
        505,
        507,
        "博雅"
      ],
      [
        "T20",
        "行业",
        508,
        510,
        "疫苗"
      ],
      [
        "T21",
        "行业公司",
        604,
        608,
        "创新药企"
      ],
      [
        "T22",
        "行业",
        610,
        613,
        "CXO"
      ],
      [
        "T23",
        "地点范围",
        647,
        649,
        "国内"
      ],
      [
        "T24",
        "行业公司",
        650,
        655,
        "CXO企业"
      ],
      [
        "T25",
        "行业",
        697,
        700,
        "CXO"
      ],
      [
        "T26",
        "龙头企业",
        750,
        752,
        "龙头"
      ],
      [
        "T27",
        "行业",
        745,
        750,
        "角膜塑形镜"
      ],
      [
        "T28",
        "行业",
        710,
        714,
        "医疗器械"
      ],
      [
        "T29",
        "行业",
        715,
        719,
        "连锁药店"
      ],
      [
        "T30",
        "行业",
        726,
        728,
        "眼科"
      ],
      [
        "T31",
        "行业",
        729,
        733,
        "康复器械"
      ],
      [
        "T32",
        "行业",
        734,
        736,
        "眼科"
      ],
      [
        "T33",
        "公司",
        787,
        791,
        "翔宇医疗"
      ],
      [
        "T34",
        "地点范围",
        803,
        805,
        "国内"
      ],
      [
        "T35",
        "研发费用",
        809,
        813,
        "研发投入"
      ],
      [
        "T36",
        "行业",
        805,
        809,
        "生命科学"
      ],
      [
        "T37",
        "时间范围",
        822,
        833,
        "2015-2024 年"
      ],
      [
        "T38",
        "CAGR",
        834,
        838,
        "CAGR"
      ],
      [
        "T39",
        "行业公司",
        897,
        903,
        "生物试剂企业"
      ],
      [
        "T40",
        "公司",
        913,
        917,
        "健凯科技"
      ],
      [
        "T41",
        "公司",
        918,
        922,
        "百普赛斯"
      ],
      [
        "T42",
        "公司",
        923,
        926,
        "诺唯赞"
      ],
      [
        "T43",
        "公司",
        927,
        931,
        "山东药玻"
      ],
      [
        "T44",
        "行业",
        26,
        28,
        "医药"
      ],
      [
        "T45",
        "行业",
        44,
        46,
        "医药"
      ],
      [
        "T46",
        "行业",
        59,
        61,
        "医药"
      ],
      [
        "T47",
        "时间范围",
        67,
        70,
        "近年来"
      ],
      [
        "T48",
        "行业",
        70,
        72,
        "医药"
      ],
      [
        "T49",
        "行业",
        95,
        97,
        "医药"
      ],
      [
        "T50",
        "时间范围",
        186,
        188,
        "明年"
      ],
      [
        "T51",
        "时间范围",
        206,
        208,
        "今年"
      ],
      [
        "T52",
        "属性值",
        332,
        334,
        "增长"
      ],
      [
        "T53",
        "时间范围",
        335,
        337,
        "明年"
      ],
      [
        "T54",
        "时间范围",
        425,
        427,
        "明年"
      ],
      [
        "T55",
        "行业",
        436,
        442,
        "创新药产业链"
      ],
      [
        "T56",
        "行业",
        453,
        459,
        "原辅料包材类"
      ],
      [
        "T57",
        "行业",
        485,
        488,
        "血制品"
      ],
      [
        "T58",
        "市场规模",
        490,
        492,
        "规模"
      ],
      [
        "T59",
        "属性值",
        492,
        499,
        "瓶颈有可能解除"
      ],
      [
        "T60",
        "时间范围",
        513,
        515,
        "今年"
      ],
      [
        "T61",
        "时间范围",
        535,
        537,
        "明年"
      ],
      [
        "T62",
        "时间范围",
        563,
        565,
        "明年"
      ],
      [
        "T63",
        "行业",
        582,
        586,
        "新冠疫苗"
      ],
      [
        "T64",
        "业绩",
        586,
        588,
        "业绩"
      ],
      [
        "T65",
        "属性值",
        588,
        590,
        "下滑"
      ],
      [
        "T66",
        "行业",
        597,
        603,
        "创新药产业链"
      ],
      [
        "T67",
        "投融资情况",
        637,
        640,
        "投融资"
      ],
      [
        "T68",
        "属性值",
        644,
        646,
        "火热"
      ],
      [
        "T69",
        "行业",
        628,
        632,
        "药物研发"
      ],
      [
        "T70",
        "属性值",
        634,
        636,
        "旺盛"
      ],
      [
        "T71",
        "行业需求",
        632,
        634,
        "需求"
      ],
      [
        "T72",
        "行业",
        720,
        722,
        "器械"
      ],
      [
        "T73",
        "地点范围",
        753,
        755,
        "我国"
      ],
      [
        "T74",
        "行业",
        755,
        757,
        "康复"
      ],
      [
        "T75",
        "行业",
        796,
        802,
        "原辅料包材类"
      ],
      [
        "T76",
        "属性值",
        815,
        818,
        "高增长"
      ],
      [
        "T77",
        "属性值",
        840,
        845,
        "15.3%"
      ],
      [
        "T78",
        "属性值",
        846,
        855,
        "增速远高于同期全球"
      ],
      [
        "T79",
        "地点范围",
        869,
        871,
        "全球"
      ],
      [
        "T80",
        "地点范围",
        889,
        891,
        "我国"
      ],
      [
        "T81",
        "行业",
        891,
        895,
        "科研试剂"
      ]
    ]
  },
  {
    "id": 475,
    "text": " 化学发光体量大、增速快，国产化率低，是IVD领域最具确定性的好赛道。  迈瑞医疗：2021上半年收入127.8亿元（+21%），归母净利润43.4亿元（+25.8%），其中IVD业务预计约39.6亿元，增速30.8%。2020 年化学发光试剂收入约19~20亿元，剔除海外新冠试剂约13亿元，2021上半年国内发光业务预计实现翻倍增长，国际新冠检测试剂出口贡献逐渐回落。  新产业：2021上半年收入12.3亿元（+26.3%），归母净利润4.3亿元（-9.9%）。2020年化学发光试剂收入约17亿元(+28.7%），剔除新冠检测试剂贡献的3.2亿元，预计常规试剂贡献13.9亿元，2021上半年试剂收入9.1亿元（+24.5%），主要因常规试剂恢复，受股权激励摊销影响，表观净利润增速有所承压。  安图生物：2021上半年收入16.8亿元（+39.1%）,归母净利润4.1亿元（+50.6%）。2020年化学发光收入约12~13亿元，基本持平， 2021H1在低基数逐步恢复，上半年化学发光试剂收入约7.7亿元。",
    "labels": [
      [
        "T0",
        "行业",
        21,
        24,
        "IVD"
      ],
      [
        "T1",
        "公司",
        39,
        43,
        "迈瑞医疗"
      ],
      [
        "T2",
        "时间范围",
        44,
        51,
        "2021上半年"
      ],
      [
        "T3",
        "营业收入",
        51,
        53,
        "收入"
      ],
      [
        "T4",
        "属性值",
        53,
        60,
        "127.8亿元"
      ],
      [
        "T5",
        "属性值",
        61,
        65,
        "+21%"
      ],
      [
        "T6",
        "行业",
        89,
        92,
        "IVD"
      ],
      [
        "T7",
        "属性值",
        96,
        103,
        "约39.6亿元"
      ],
      [
        "T8",
        "属性值",
        106,
        111,
        "30.8%"
      ],
      [
        "T9",
        "时间范围",
        112,
        118,
        "2020 年"
      ],
      [
        "T10",
        "行业",
        118,
        124,
        "化学发光试剂"
      ],
      [
        "T11",
        "属性值",
        126,
        134,
        "约19~20亿元"
      ],
      [
        "T12",
        "营业收入",
        124,
        126,
        "收入"
      ],
      [
        "T13",
        "地点范围",
        137,
        139,
        "海外"
      ],
      [
        "T14",
        "行业",
        139,
        143,
        "新冠试剂"
      ],
      [
        "T15",
        "属性值",
        143,
        148,
        "约13亿元"
      ],
      [
        "T16",
        "地点范围",
        156,
        158,
        "国内"
      ],
      [
        "T17",
        "行业",
        158,
        160,
        "发光"
      ],
      [
        "T18",
        "时间范围",
        195,
        202,
        "2021上半年"
      ],
      [
        "T19",
        "营业收入",
        202,
        204,
        "收入"
      ],
      [
        "T20",
        "归母净利润",
        219,
        224,
        "归母净利润"
      ],
      [
        "T21",
        "时间范围",
        237,
        242,
        "2020年"
      ],
      [
        "T22",
        "行业",
        242,
        248,
        "化学发光试剂"
      ],
      [
        "T23",
        "营业收入",
        248,
        250,
        "收入"
      ],
      [
        "T24",
        "属性值",
        250,
        255,
        "约17亿元"
      ],
      [
        "T25",
        "属性值",
        256,
        262,
        "+28.7%"
      ],
      [
        "T26",
        "时间范围",
        296,
        303,
        "2021上半年"
      ],
      [
        "T27",
        "行业",
        303,
        305,
        "试剂"
      ],
      [
        "T28",
        "营业收入",
        305,
        307,
        "收入"
      ],
      [
        "T29",
        "属性值",
        307,
        312,
        "9.1亿元"
      ],
      [
        "T30",
        "属性值",
        313,
        319,
        "+24.5%"
      ],
      [
        "T31",
        "归母净利润增速",
        343,
        348,
        "净利润增速"
      ],
      [
        "T32",
        "公司",
        356,
        360,
        "安图生物"
      ],
      [
        "T33",
        "时间范围",
        361,
        368,
        "2021上半年"
      ],
      [
        "T34",
        "营业收入",
        368,
        370,
        "收入"
      ],
      [
        "T35",
        "属性值",
        370,
        376,
        "16.8亿元"
      ],
      [
        "T36",
        "属性值",
        377,
        383,
        "+39.1%"
      ],
      [
        "T37",
        "归母净利润",
        385,
        390,
        "归母净利润"
      ],
      [
        "T38",
        "时间范围",
        404,
        409,
        "2020年"
      ],
      [
        "T39",
        "行业",
        409,
        413,
        "化学发光"
      ],
      [
        "T40",
        "营业收入",
        413,
        415,
        "收入"
      ],
      [
        "T41",
        "属性值",
        415,
        423,
        "约12~13亿元"
      ],
      [
        "T42",
        "时间范围",
        430,
        436,
        "2021H1"
      ],
      [
        "T43",
        "时间范围",
        445,
        448,
        "上半年"
      ],
      [
        "T44",
        "行业",
        448,
        454,
        "化学发光试剂"
      ],
      [
        "T45",
        "营业收入",
        454,
        456,
        "收入"
      ],
      [
        "T46",
        "行业",
        2,
        6,
        "化学发光"
      ],
      [
        "T47",
        "属性值",
        72,
        86,
        "43.4亿元（+25.8%）"
      ],
      [
        "T48",
        "归母净利润",
        67,
        72,
        "归母净利润"
      ],
      [
        "T49",
        "行业",
        283,
        287,
        "常规试剂"
      ],
      [
        "T50",
        "属性值",
        289,
        295,
        "13.9亿元"
      ],
      [
        "T51",
        "属性值",
        348,
        352,
        "有所承压"
      ],
      [
        "T52",
        "时间范围",
        149,
        156,
        "2021上半年"
      ],
      [
        "T53",
        "属性值",
        166,
        170,
        "翻倍增长"
      ],
      [
        "T54",
        "公司",
        191,
        194,
        "新产业"
      ],
      [
        "T55",
        "属性值",
        204,
        210,
        "12.3亿元"
      ],
      [
        "T56",
        "属性值",
        211,
        217,
        "+26.3%"
      ],
      [
        "T57",
        "属性值",
        224,
        236,
        "4.3亿元（-9.9%）"
      ],
      [
        "T58",
        "行业",
        266,
        272,
        "新冠检测试剂"
      ],
      [
        "T59",
        "属性值",
        275,
        280,
        "3.2亿元"
      ],
      [
        "T60",
        "属性值",
        390,
        403,
        "4.1亿元（+50.6%）"
      ],
      [
        "T61",
        "属性值",
        437,
        444,
        "低基数逐步恢复"
      ],
      [
        "T62",
        "属性值",
        456,
        462,
        "约7.7亿元"
      ]
    ]
  },
  {
    "id": 476,
    "text": "维持盈利预测，预计公司2021-2023年营业收入分别为27.53/32.50/38.20亿元，归母净利润分别为3.65/4.41/6.23亿元，EPS分别为 0.34/0.41/0.58元，对应2021年11月30日收盘价18.87元/股，PE分别为56/46/33倍，维持“买入”评级。",
    "labels": [
      [
        "T0",
        "时间范围",
        11,
        21,
        "2021-2023年"
      ],
      [
        "T1",
        "营业收入",
        21,
        25,
        "营业收入"
      ],
      [
        "T2",
        "归母净利润",
        48,
        53,
        "归母净利润"
      ],
      [
        "T3",
        "时间范围",
        98,
        109,
        "2021年11月30日"
      ],
      [
        "T4",
        "PE",
        121,
        123,
        "PE"
      ]
    ]
  },
  {
    "id": 477,
    "text": "21Q1-3业绩表现优异，板块高景气度延续  疫苗板块Q1-3收入405亿元（+51.9%），归母净利润120亿元（+154.7%），扣非归母净利润117亿元（+171.4%），盈利能力看，板块扣非归母净利率为29%，板块高景气度延续。",
    "labels": [
      [
        "T0",
        "时间范围",
        0,
        6,
        "21Q1-3"
      ],
      [
        "T1",
        "业绩",
        6,
        8,
        "业绩"
      ],
      [
        "T2",
        "行业",
        24,
        26,
        "疫苗"
      ],
      [
        "T3",
        "时间范围",
        28,
        32,
        "Q1-3"
      ],
      [
        "T4",
        "营业收入",
        32,
        34,
        "收入"
      ],
      [
        "T5",
        "属性值",
        34,
        39,
        "405亿元"
      ],
      [
        "T6",
        "属性值",
        40,
        46,
        "+51.9%"
      ],
      [
        "T7",
        "归母净利润",
        48,
        53,
        "归母净利润"
      ],
      [
        "T8",
        "扣非净利润",
        68,
        75,
        "扣非归母净利润"
      ],
      [
        "T9",
        "属性值",
        53,
        67,
        "120亿元（+154.7%）"
      ],
      [
        "T10",
        "属性值",
        75,
        89,
        "117亿元（+171.4%）"
      ],
      [
        "T11",
        "扣非净利润",
        98,
        105,
        "扣非归母净利率"
      ],
      [
        "T12",
        "属性值",
        106,
        109,
        "29%"
      ]
    ]
  },
  {
    "id": 478,
    "text": "1.5.行情回顾：医药板块涨幅靠后，跑输沪深300",
    "labels": [
      [
        "T0",
        "行业",
        9,
        11,
        "医药"
      ]
    ]
  },
  {
    "id": 479,
    "text": "新冠业绩增量是一把双刃剑。短期来看，由于新冠带来的抗疫需求集中爆发，个人防护（口罩、手套等）、IVD检测试剂（盒）、新冠疫苗等相关公司迎来业绩急剧爆发式增长；中长期来看，随着新竞争者进入、产能持续扩大和疫情峰值过去，抗疫需求产品面临需求逐步回落、价格梯次回归双降局面，如个人防护用品、新冠检测试剂等价格已经多轮降价，国内新冠疫苗从年初接近 400元/人份，多轮降价到大约 90元/人份。",
    "labels": [
      [
        "T0",
        "业绩",
        69,
        71,
        "业绩"
      ],
      [
        "T1",
        "业绩",
        2,
        4,
        "业绩"
      ],
      [
        "T2",
        "地点范围",
        158,
        160,
        "国内"
      ],
      [
        "T3",
        "时间范围",
        13,
        15,
        "短期"
      ],
      [
        "T4",
        "行业",
        34,
        38,
        "个人防护"
      ],
      [
        "T5",
        "行业",
        47,
        57,
        "IVD检测试剂（盒）"
      ],
      [
        "T6",
        "行业",
        58,
        62,
        "新冠疫苗"
      ],
      [
        "T7",
        "属性值",
        71,
        78,
        "急剧爆发式增长"
      ],
      [
        "T8",
        "时间范围",
        79,
        82,
        "中长期"
      ],
      [
        "T9",
        "产能",
        94,
        96,
        "产能"
      ],
      [
        "T10",
        "属性值",
        87,
        93,
        "新竞争者进入"
      ],
      [
        "T11",
        "行业需求",
        116,
        118,
        "需求"
      ],
      [
        "T12",
        "属性值",
        118,
        122,
        "逐步回落"
      ],
      [
        "T13",
        "属性值",
        98,
        100,
        "扩大"
      ],
      [
        "T14",
        "行业",
        108,
        112,
        "抗疫需求"
      ]
    ]
  },
  {
    "id": 480,
    "text": " 从2021年开始，医药行业各细分板块估值分化明显。医药上游、消费医疗、医药中游分别处于估值的第一梯队、第二梯队、第三梯队。  各细分板块的估值区间：从2018年-至今，医药上游PE均值、峰值、最小值分别为56倍、89倍、27倍；医药上游（剔除原料药）PE均值、峰值、最小值分别为68倍、114倍、31倍；医药中游PE均值、峰值、最小值分别为47倍、67倍、24 倍；消费医疗PE均值、峰值、最小值分别58倍、89倍、27倍。",
    "labels": [
      [
        "T0",
        "时间范围",
        3,
        8,
        "2021年"
      ],
      [
        "T1",
        "行业",
        11,
        13,
        "医药"
      ],
      [
        "T2",
        "行业",
        32,
        36,
        "消费医疗"
      ],
      [
        "T3",
        "PE",
        91,
        93,
        "PE"
      ],
      [
        "T4",
        "PE",
        128,
        130,
        "PE"
      ],
      [
        "T5",
        "PE",
        159,
        161,
        "PE"
      ],
      [
        "T6",
        "行业",
        186,
        190,
        "消费医疗"
      ],
      [
        "T7",
        "PE",
        190,
        192,
        "PE"
      ],
      [
        "T8",
        "行业",
        27,
        31,
        "医药上游"
      ],
      [
        "T9",
        "行业",
        37,
        41,
        "医药中游"
      ],
      [
        "T10",
        "时间范围",
        77,
        86,
        "从2018年-至今"
      ],
      [
        "T11",
        "行业",
        87,
        91,
        "医药上游"
      ],
      [
        "T12",
        "属性值",
        105,
        108,
        "56倍"
      ],
      [
        "T13",
        "属性值",
        109,
        112,
        "89倍"
      ],
      [
        "T14",
        "属性值",
        113,
        116,
        "27倍"
      ],
      [
        "T15",
        "行业",
        117,
        128,
        "医药上游（剔除原料药）"
      ],
      [
        "T16",
        "行业",
        155,
        159,
        "医药中游"
      ],
      [
        "T17",
        "属性值",
        142,
        145,
        "68倍"
      ],
      [
        "T18",
        "属性值",
        146,
        150,
        "114倍"
      ],
      [
        "T19",
        "属性值",
        151,
        154,
        "31倍"
      ],
      [
        "T20",
        "属性值",
        173,
        176,
        "47倍"
      ],
      [
        "T21",
        "属性值",
        177,
        180,
        "67倍"
      ],
      [
        "T22",
        "属性值",
        181,
        185,
        "24 倍"
      ],
      [
        "T23",
        "属性值",
        203,
        206,
        "58倍"
      ],
      [
        "T24",
        "属性值",
        207,
        210,
        "89倍"
      ],
      [
        "T25",
        "属性值",
        211,
        214,
        "27倍"
      ]
    ]
  },
  {
    "id": 481,
    "text": "天宇股份：（1）原料药业务：在上游成本传导和下游客户库存消化充分的背景下，公司原料药产品有望迎来新一轮提价周期，原料药业务盈利能力有望逐步提升。其中，根据Wind数据，缬沙坦价格逐步见底，替米沙坦和厄贝沙坦价格逐步回升；（2）CMO业务：公司与Merk、第一三共、武田等大型药企在CMO业务上深入合作，目前商业化和待商业化阶段产品分别有11个和13个，CMO业务已进入快速发展阶段，2021H1实现营收3.06亿元，同比增长高达2133%；（3） 制剂业务：一体化延伸布局制剂业务，目前制剂在研项目达73个，设计43个不同产品。其中，厄贝沙坦片已正式获批且实现销售。2022年开始，制剂业务有望逐步成为公司业绩增长的重要驱动力之一。",
    "labels": [
      [
        "T0",
        "公司",
        1,
        5,
        "天宇股份"
      ],
      [
        "T1",
        "行业",
        9,
        12,
        "原料药"
      ],
      [
        "T2",
        "行业",
        40,
        43,
        "原料药"
      ],
      [
        "T3",
        "公司",
        57,
        60,
        "原料药"
      ],
      [
        "T4",
        "行业",
        114,
        117,
        "CMO"
      ],
      [
        "T5",
        "公司",
        123,
        127,
        "Merk"
      ],
      [
        "T6",
        "公司",
        128,
        132,
        "第一三共"
      ],
      [
        "T7",
        "公司",
        133,
        135,
        "武田"
      ],
      [
        "T8",
        "行业",
        141,
        144,
        "CMO"
      ],
      [
        "T9",
        "行业",
        177,
        180,
        "CMO"
      ],
      [
        "T10",
        "时间范围",
        192,
        198,
        "2021H1"
      ],
      [
        "T11",
        "营业收入",
        200,
        202,
        "营收"
      ],
      [
        "T12",
        "属性值",
        202,
        208,
        "3.06亿元"
      ],
      [
        "T13",
        "属性值",
        215,
        220,
        "2133%"
      ],
      [
        "T14",
        "行业",
        225,
        227,
        "制剂"
      ],
      [
        "T15",
        "行业",
        292,
        294,
        "制剂"
      ],
      [
        "T16",
        "业绩",
        304,
        306,
        "业绩"
      ],
      [
        "T17",
        "行业公司",
        138,
        140,
        "药企"
      ],
      [
        "T18",
        "时间范围",
        152,
        154,
        "目前"
      ],
      [
        "T19",
        "时间范围",
        284,
        291,
        "2022年开始"
      ]
    ]
  },
  {
    "id": 482,
    "text": "• 国内CXO公司实验室业务继续呈现高速增长、维持高景气度：核心CXO公司实验室业务2021年三季报合计实现营业收入141亿元，同比增长41.0%，呈现超高速增长，其中药明康德实验室业务实现营业收入89.3亿元，同比增长37.5%。展望2022年， 海外创新药产业链持续转移以及叠加国内的高景气度，我们判断未来3年将持续呈现快速增长。 • 海外实验室业务呈现快速增长：查尔斯河的实验室业务（安评及药物发现等）2021年前三季度实现营业收入15.7亿元，同比增长17.2%，伴随着新冠影响逐渐消除，公司药物发现和安评业务逐渐恢复强劲增长。",
    "labels": [
      [
        "T0",
        "地点范围",
        2,
        4,
        "国内"
      ],
      [
        "T1",
        "行业公司",
        4,
        9,
        "CXO公司"
      ],
      [
        "T2",
        "时间范围",
        42,
        49,
        "2021年三季"
      ],
      [
        "T3",
        "营业收入",
        54,
        58,
        "营业收入"
      ],
      [
        "T4",
        "属性值",
        58,
        63,
        "141亿元"
      ],
      [
        "T5",
        "属性值",
        68,
        73,
        "41.0%"
      ],
      [
        "T6",
        "公司",
        84,
        88,
        "药明康德"
      ],
      [
        "T7",
        "行业",
        37,
        40,
        "实验室"
      ],
      [
        "T8",
        "行业",
        88,
        91,
        "实验室"
      ],
      [
        "T9",
        "营业收入",
        95,
        99,
        "营业收入"
      ],
      [
        "T10",
        "属性值",
        99,
        105,
        "89.3亿元"
      ],
      [
        "T11",
        "属性值",
        110,
        115,
        "37.5%"
      ],
      [
        "T12",
        "时间范围",
        118,
        123,
        "2022年"
      ],
      [
        "T13",
        "地点范围",
        125,
        127,
        "海外"
      ],
      [
        "T14",
        "行业",
        127,
        130,
        "创新药"
      ],
      [
        "T15",
        "地点范围",
        141,
        143,
        "国内"
      ],
      [
        "T16",
        "时间范围",
        153,
        157,
        "未来3年"
      ],
      [
        "T17",
        "时间范围",
        204,
        212,
        "2021年前三季"
      ],
      [
        "T18",
        "营业收入",
        215,
        219,
        "营业收入"
      ],
      [
        "T19",
        "属性值",
        219,
        225,
        "15.7亿元"
      ],
      [
        "T20",
        "属性值",
        230,
        235,
        "17.2%"
      ],
      [
        "T21",
        "行业",
        250,
        254,
        "药物发现"
      ],
      [
        "T22",
        "行业",
        255,
        257,
        "安评"
      ],
      [
        "T23",
        "行业",
        195,
        197,
        "安评"
      ],
      [
        "T24",
        "行业",
        198,
        202,
        "药物发现"
      ],
      [
        "T25",
        "属性值",
        18,
        22,
        "高速增长"
      ],
      [
        "T26",
        "行业公司",
        30,
        37,
        "核心CXO公司"
      ],
      [
        "T27",
        "地点范围",
        170,
        172,
        "海外"
      ],
      [
        "T28",
        "行业",
        172,
        175,
        "实验室"
      ],
      [
        "T29",
        "公司",
        184,
        188,
        "查尔斯河"
      ],
      [
        "T30",
        "行业",
        189,
        192,
        "实验室"
      ]
    ]
  },
  {
    "id": 483,
    "text": "• 新冠疫苗为相关公司带来了丰厚回报，但就目前而言，新冠疫苗带来的短期业绩爆发后续是否能持续具有较大不确定性。后疫情时代，我们认为疫苗行业发展的驱动力仍将回到重磅品种的放量增长，以及未来潜力品种上市后放量增长。",
    "labels": [
      [
        "T0",
        "行业",
        2,
        6,
        "新冠疫苗"
      ],
      [
        "T1",
        "行业",
        26,
        30,
        "新冠疫苗"
      ],
      [
        "T2",
        "业绩",
        35,
        37,
        "业绩"
      ],
      [
        "T3",
        "行业",
        65,
        67,
        "疫苗"
      ],
      [
        "T4",
        "时间范围",
        33,
        35,
        "短期"
      ]
    ]
  },
  {
    "id": 484,
    "text": "• 智飞生物 Q3业绩符合预期，国内常规疫苗接种业务逐步恢复",
    "labels": [
      [
        "T0",
        "公司",
        2,
        6,
        "智飞生物"
      ],
      [
        "T1",
        "时间范围",
        7,
        9,
        "Q3"
      ],
      [
        "T2",
        "业绩",
        9,
        11,
        "业绩"
      ],
      [
        "T3",
        "地点范围",
        16,
        18,
        "国内"
      ],
      [
        "T4",
        "属性值",
        11,
        15,
        "符合预期"
      ],
      [
        "T5",
        "行业",
        18,
        24,
        "常规疫苗接种"
      ],
      [
        "T6",
        "属性值",
        26,
        30,
        "逐步恢复"
      ]
    ]
  },
  {
    "id": 485,
    "text": "CXO企业仍处于高景气度，产能持续扩充彰显企业发展信心。从存货、合同负债指标的高速增长可以看出 CXO企业订单充沛，行业仍处于高景气度，从在建工程、固定资产指标的快速增长可以看出现有产能不足以满足订单需求，彰显了企业对未来发展的信心，也预示着行业的高景气度有望继续维持。",
    "labels": [
      [
        "T0",
        "行业公司",
        0,
        5,
        "CXO企业"
      ],
      [
        "T1",
        "产能",
        13,
        15,
        "产能"
      ],
      [
        "T2",
        "存货",
        29,
        31,
        "存货"
      ],
      [
        "T3",
        "合同负债",
        32,
        36,
        "合同负债"
      ],
      [
        "T4",
        "行业公司",
        48,
        53,
        "CXO企业"
      ],
      [
        "T5",
        "在手订单",
        53,
        55,
        "订单"
      ],
      [
        "T6",
        "固定资产",
        74,
        78,
        "固定资产"
      ],
      [
        "T7",
        "产能",
        91,
        93,
        "产能"
      ],
      [
        "T8",
        "属性值",
        17,
        19,
        "扩充"
      ],
      [
        "T9",
        "属性值",
        39,
        43,
        "高速增长"
      ],
      [
        "T10",
        "属性值",
        55,
        57,
        "充沛"
      ],
      [
        "T11",
        "属性值",
        81,
        85,
        "快速增长"
      ],
      [
        "T12",
        "属性值",
        93,
        102,
        "不足以满足订单需求"
      ]
    ]
  },
  {
    "id": 486,
    "text": "新增项目数再创新高，业务表现持续加速： • 未来有望每年新增2-6个商业化项目。截至2021年12月31日，新增156个综合项目；2021年全年新增7个商业化项目 （共9个项目），2022-2023年有望每年新增2-4个商业化项目，2024-2025年则有望每年新增4-6个。 • 药明生物为抗击全球新冠疫情做出卓越贡献。2021年新增4个非新冠商业化项目，新冠业务有望贡献约4.6亿美金收入，2022年有望贡献约3亿美金收入。",
    "labels": [
      [
        "T0",
        "时间范围",
        40,
        53,
        "截至2021年12月31日"
      ],
      [
        "T1",
        "时间范围",
        65,
        72,
        "2021年全年"
      ],
      [
        "T2",
        "时间范围",
        90,
        100,
        "2022-2023年"
      ],
      [
        "T3",
        "时间范围",
        116,
        126,
        "2024-2025年"
      ],
      [
        "T4",
        "公司",
        141,
        145,
        "药明生物"
      ],
      [
        "T5",
        "时间范围",
        161,
        166,
        "2021年"
      ],
      [
        "T6",
        "时间范围",
        197,
        202,
        "2022年"
      ],
      [
        "T7",
        "时间范围",
        22,
        24,
        "未来"
      ],
      [
        "T8",
        "属性值",
        188,
        194,
        "4.6亿美金"
      ],
      [
        "T9",
        "营业收入",
        194,
        196,
        "收入"
      ],
      [
        "T10",
        "属性值",
        206,
        211,
        "约3亿美金"
      ],
      [
        "T11",
        "营业收入",
        211,
        213,
        "收入"
      ],
      [
        "T12",
        "行业",
        179,
        181,
        "新冠"
      ]
    ]
  },
  {
    "id": 487,
    "text": "中国 CXO行业在 2021年表现出高度的业绩景气度，未来将进入分化阶段。2021年 Q1-Q3中国 CXO企业收入端与利润端表现出优秀的同比增长，截至 Q3期末的存货水平与合同负债水平也与去年同期相比有所增长，为 2022年业绩景气度奠定基础。凯莱英与博腾股份均受到来自海外药企的大额订单，对于 2022年业绩增长有所助力。中国 CXO企业在 2021 年积极进行产能建设和团队建设，进行产能释放从而提高订单承接能力。中国 CXO行业在收入达到一定规模后，整体 CXO行业预期将进入分化阶段。拥有技术与核心竞争力的龙头公司有望在化学小分子业务方面承接更多订单与更复杂的业务，并在生物大分子等新兴业务方面业绩有所增长。行业内竞争力较低的公司会面临整体增速降低的问题。投资预期将进入“精挑细选”时期，需要挑选拥有核心竞争力的 CXO企业进行投",
    "labels": [
      [
        "T0",
        "地点范围",
        0,
        2,
        "中国"
      ],
      [
        "T1",
        "行业",
        3,
        6,
        "CXO"
      ],
      [
        "T2",
        "时间范围",
        10,
        15,
        "2021年"
      ],
      [
        "T3",
        "时间范围",
        37,
        48,
        "2021年 Q1-Q3"
      ],
      [
        "T4",
        "地点范围",
        48,
        50,
        "中国"
      ],
      [
        "T5",
        "业绩",
        113,
        115,
        "业绩"
      ],
      [
        "T6",
        "公司",
        123,
        126,
        "凯莱英"
      ],
      [
        "T7",
        "公司",
        127,
        131,
        "博腾股份"
      ],
      [
        "T8",
        "行业公司",
        138,
        140,
        "药企"
      ],
      [
        "T9",
        "时间范围",
        149,
        154,
        "2022年"
      ],
      [
        "T10",
        "业绩",
        154,
        156,
        "业绩"
      ],
      [
        "T11",
        "地点范围",
        163,
        165,
        "中国"
      ],
      [
        "T12",
        "行业公司",
        166,
        171,
        "CXO企业"
      ],
      [
        "T13",
        "地点范围",
        210,
        212,
        "中国"
      ],
      [
        "T14",
        "行业",
        213,
        216,
        "CXO"
      ],
      [
        "T15",
        "行业",
        232,
        235,
        "CXO"
      ],
      [
        "T16",
        "龙头企业",
        258,
        262,
        "龙头公司"
      ],
      [
        "T17",
        "业绩",
        302,
        304,
        "业绩"
      ],
      [
        "T18",
        "行业公司",
        362,
        367,
        "CXO企业"
      ],
      [
        "T19",
        "属性值",
        18,
        26,
        "高度的业绩景气度"
      ],
      [
        "T20",
        "时间范围",
        27,
        29,
        "未来"
      ],
      [
        "T21",
        "营业收入",
        56,
        59,
        "收入端"
      ],
      [
        "T22",
        "利润",
        60,
        63,
        "利润端"
      ],
      [
        "T23",
        "属性值",
        66,
        73,
        "优秀的同比增长"
      ],
      [
        "T24",
        "时间范围",
        74,
        81,
        "截至 Q3期末"
      ],
      [
        "T25",
        "属性值",
        94,
        105,
        "与去年同期相比有所增长"
      ],
      [
        "T26",
        "时间范围",
        108,
        113,
        "2022年"
      ],
      [
        "T27",
        "时间范围",
        173,
        179,
        "2021 年"
      ],
      [
        "T28",
        "营业收入",
        219,
        221,
        "收入"
      ],
      [
        "T29",
        "行业公司",
        51,
        56,
        "CXO企业"
      ],
      [
        "T30",
        "存货",
        82,
        84,
        "存货"
      ],
      [
        "T31",
        "合同负债",
        87,
        91,
        "合同负债"
      ],
      [
        "T32",
        "属性值",
        179,
        187,
        "积极进行产能建设"
      ]
    ]
  },
  {
    "id": 489,
    "text": " 主要增量贡献： • 收入：医药分销、中药、医疗器械、 • 毛利：医疗器械、中药、疫苗 • 净利润：医疗器械、疫苗、中药",
    "labels": [
      [
        "T0",
        "行业",
        15,
        19,
        "医药分销"
      ],
      [
        "T1",
        "行业",
        20,
        22,
        "中药"
      ],
      [
        "T2",
        "行业",
        23,
        27,
        "医疗器械"
      ],
      [
        "T3",
        "营业收入",
        12,
        14,
        "收入"
      ],
      [
        "T4",
        "毛利",
        31,
        33,
        "毛利"
      ],
      [
        "T5",
        "行业",
        34,
        38,
        "医疗器械"
      ],
      [
        "T6",
        "行业",
        39,
        41,
        "中药"
      ],
      [
        "T7",
        "行业",
        42,
        44,
        "疫苗"
      ],
      [
        "T8",
        "归母净利润",
        47,
        50,
        "净利润"
      ],
      [
        "T9",
        "行业",
        51,
        55,
        "医疗器械"
      ],
      [
        "T10",
        "行业",
        56,
        58,
        "疫苗"
      ],
      [
        "T11",
        "行业",
        59,
        61,
        "中药"
      ]
    ]
  },
  {
    "id": 492,
    "text": "医疗服务：行业受益于国内新冠疫情控制良好，国内医疗秩序相较去年恢复正常， 医院医疗服务行业增速较快，另外 CXO行业延续景气，保持较快增长。细分行业前三季度营收 900.7亿元，同比 2020年增长 36.7%，归母净利润 137.1亿元，同比增长 58.5%。 样本公司共 30家，有 3家公司营收同比负增长，6家公司归母净利润同比负增长。医疗服务行业不论是医院医疗服务和 CXO服务都呈现行业整体性增长，整体行业景气度较高。",
    "labels": [
      [
        "T0",
        "行业",
        0,
        4,
        "医疗服务"
      ],
      [
        "T1",
        "地点范围",
        10,
        12,
        "国内"
      ],
      [
        "T2",
        "地点范围",
        21,
        23,
        "国内"
      ],
      [
        "T3",
        "行业",
        53,
        56,
        "CXO"
      ],
      [
        "T4",
        "时间范围",
        74,
        78,
        "前三季度"
      ],
      [
        "T5",
        "营业收入",
        78,
        80,
        "营收"
      ],
      [
        "T6",
        "时间范围",
        92,
        97,
        "2020年"
      ],
      [
        "T7",
        "归母净利润",
        106,
        111,
        "归母净利润"
      ],
      [
        "T8",
        "营业收入",
        148,
        150,
        "营收"
      ],
      [
        "T9",
        "归母净利润",
        160,
        165,
        "归母净利润"
      ],
      [
        "T10",
        "行业",
        171,
        175,
        "医疗服务"
      ],
      [
        "T11",
        "行业",
        180,
        186,
        "医院医疗服务"
      ],
      [
        "T12",
        "行业",
        188,
        193,
        "CXO服务"
      ],
      [
        "T13",
        "行业",
        37,
        43,
        "医院医疗服务"
      ],
      [
        "T14",
        "行业",
        23,
        25,
        "医疗"
      ]
    ]
  },
  {
    "id": 495,
    "text": "目前全球已上市两款带状疱疹疫苗为Zostavax（减毒活疫苗技术）和Shingrix（重组蛋白疫苗技术）。虽然从技术水平上来看，重组技术更为先进，但其实上两种技术疫苗在实际应用中各具优势，减毒疫苗仍有市场空间。",
    "labels": [
      [
        "T0",
        "地点范围",
        2,
        4,
        "全球"
      ],
      [
        "T1",
        "时间范围",
        0,
        2,
        "目前"
      ],
      [
        "T2",
        "行业",
        94,
        98,
        "减毒疫苗"
      ],
      [
        "T3",
        "属性值",
        99,
        104,
        "有市场空间"
      ]
    ]
  },
  {
    "id": 496,
    "text": "近年来，随着对各类靶点理解的加深以及各类新技术的逐渐进步，创新药研发迎来了快速增长阶段，对于药物研究和生产的需求也推动着 CXO行业进入高速时期。从融资总额、研发投入、临床申报情况等维度，我们预计 CXO行业有望继续维持高景气度。 全球药物研发热情持续高涨，资本市场持续加码。全球早期临床数目持续增加， 全球药物研究在 Early Phase 1 & Phase 1的数量从 2017年的 3088个增长到2021年的4048个（截止到2021年 12月 9日）。全球资本市场持续加码药物研发，全球一级市场生物制药和化学制药融资总额从2017年的131.6亿美金增长到2020年的348.3亿美金，CAGR为38.1%，截止到2021年12月 9日，该数据已超过去年全年，达到 445.2亿美金。",
    "labels": [
      [
        "T0",
        "行业",
        61,
        64,
        "CXO"
      ],
      [
        "T1",
        "投融资金额",
        74,
        78,
        "融资总额"
      ],
      [
        "T2",
        "研发费用",
        79,
        83,
        "研发投入"
      ],
      [
        "T3",
        "行业",
        99,
        102,
        "CXO"
      ],
      [
        "T4",
        "行业",
        118,
        122,
        "药物研发"
      ],
      [
        "T5",
        "地点范围",
        138,
        140,
        "全球"
      ],
      [
        "T6",
        "地点范围",
        152,
        154,
        "全球"
      ],
      [
        "T7",
        "行业",
        154,
        158,
        "药物研究"
      ],
      [
        "T8",
        "时间范围",
        188,
        193,
        "2017年"
      ],
      [
        "T9",
        "时间范围",
        203,
        208,
        "2021年"
      ],
      [
        "T10",
        "属性值",
        209,
        214,
        "4048个"
      ],
      [
        "T11",
        "行业",
        253,
        262,
        "生物制药和化学制药"
      ],
      [
        "T12",
        "投融资金额",
        262,
        266,
        "融资总额"
      ],
      [
        "T13",
        "时间范围",
        267,
        272,
        "2017年"
      ],
      [
        "T14",
        "属性值",
        273,
        281,
        "131.6亿美金"
      ],
      [
        "T15",
        "时间范围",
        284,
        289,
        "2020年"
      ],
      [
        "T16",
        "属性值",
        290,
        298,
        "348.3亿美金"
      ],
      [
        "T17",
        "属性值",
        339,
        347,
        "445.2亿美金"
      ],
      [
        "T18",
        "时间范围",
        310,
        324,
        "截止到2021年12月 9日"
      ],
      [
        "T19",
        "CAGR",
        299,
        303,
        "CAGR"
      ],
      [
        "T20",
        "属性值",
        304,
        309,
        "38.1%"
      ],
      [
        "T21",
        "时间范围",
        0,
        3,
        "近年来"
      ],
      [
        "T22",
        "行业",
        29,
        34,
        "创新药研发"
      ],
      [
        "T23",
        "地点范围",
        116,
        118,
        "全球"
      ],
      [
        "T24",
        "时间范围",
        215,
        230,
        "截止到2021年 12月 9日"
      ],
      [
        "T25",
        "属性值",
        195,
        200,
        "3088个"
      ],
      [
        "T26",
        "行业",
        242,
        246,
        "药物研发"
      ],
      [
        "T27",
        "地点范围",
        232,
        234,
        "全球"
      ],
      [
        "T28",
        "地点范围",
        247,
        249,
        "全球"
      ],
      [
        "T29",
        "时间范围",
        331,
        333,
        "去年"
      ],
      [
        "T30",
        "属性值",
        148,
        150,
        "增加"
      ]
    ]
  },
  {
    "id": 497,
    "text": " “量”“质”齐升，同质化创新待突破。中国已经完成了创新药初始的量变过程，医药创新能力也逐步得到了国际认可 ，越来越多由中国公司开发的创新药正走向国际，从早期就开始布局全球多中心临床试验，并获得FDA的快速通道资格认定。但是，我国的研发基础相对薄弱，创研研究以跟进热点前沿为主，同质化严重。预计me too新药的开发在未来 3-5年可能会内卷到极致，me too策略会迅速失灵，以最为火热的PD-1单抗为例，恒瑞医药的PD-1单抗以降价85%进入医保，自2021年3月1号执行医保后，收入呈现环比负增长。未来，差异化、高技术壁垒的创新药才具有定价权，才能脱颖而出，引起增长浪潮。",
    "labels": [
      [
        "T0",
        "行业",
        27,
        30,
        "创新药"
      ],
      [
        "T1",
        "时间范围",
        160,
        167,
        "未来 3-5年"
      ],
      [
        "T2",
        "公司",
        205,
        209,
        "恒瑞医药"
      ],
      [
        "T3",
        "营业收入",
        243,
        245,
        "收入"
      ],
      [
        "T4",
        "属性值",
        247,
        252,
        "环比负增长"
      ],
      [
        "T5",
        "地点范围",
        20,
        22,
        "中国"
      ],
      [
        "T6",
        "行业",
        38,
        40,
        "医药"
      ],
      [
        "T7",
        "地点范围",
        61,
        63,
        "中国"
      ],
      [
        "T8",
        "地点范围",
        85,
        87,
        "全球"
      ],
      [
        "T9",
        "地点范围",
        114,
        116,
        "我国"
      ],
      [
        "T10",
        "时间范围",
        227,
        242,
        "自2021年3月1号执行医保后"
      ]
    ]
  },
  {
    "id": 498,
    "text": "人福医药：（1）执行归核化战略，核心资产业绩快速增长且资产负债结构持续优化。归核化执行方面，2021H1公司先后出售所持有的厦门蕙生健康、上海健益兴禾投资、上海安博生物等公司股权，累计收回转让款项7000万元；资产负债结构方面，公司资产负债率从2018年的59.71%下降至2021Q1-Q3的54.92%，资产负债结构持续优化；核心资产方面，宜昌人福的净利润从2016年的5.49亿元增长至2020年的15.77亿元，CAGR约为30.21%。（2）苯磺酸瑞马唑仑、 磷丙泊酚等重磅新品获批，驱动公司业绩快速增长。其中，苯磺酸瑞马唑仑可为结肠镜检查提供安全有效的镇静，其安全性优于同类竞品丙泊酚，看好其通过谈判进入医保后销售快速放量；磷丙泊酚二钠是新型短效静脉全身麻醉药， 与丙泊酚相比，使用磷丙泊酚患者血压和心率更为稳定，安全性更佳，磷丙泊酚二钠有望逐步替代丙泊酚。",
    "labels": [
      [
        "T0",
        "公司",
        1,
        5,
        "人福医药"
      ],
      [
        "T1",
        "业绩",
        21,
        23,
        "业绩"
      ],
      [
        "T2",
        "时间范围",
        47,
        53,
        "2021H1"
      ],
      [
        "T3",
        "公司",
        63,
        69,
        "厦门蕙生健康"
      ],
      [
        "T4",
        "公司",
        70,
        78,
        "上海健益兴禾投资"
      ],
      [
        "T5",
        "公司",
        79,
        85,
        "上海安博生物"
      ],
      [
        "T6",
        "公司",
        173,
        177,
        "宜昌人福"
      ],
      [
        "T7",
        "归母净利润",
        178,
        181,
        "净利润"
      ],
      [
        "T8",
        "时间范围",
        182,
        187,
        "2016年"
      ],
      [
        "T9",
        "属性值",
        188,
        194,
        "5.49亿元"
      ],
      [
        "T10",
        "属性值",
        203,
        210,
        "15.77亿元"
      ],
      [
        "T11",
        "时间范围",
        197,
        202,
        "2020年"
      ],
      [
        "T12",
        "属性值",
        217,
        223,
        "30.21%"
      ],
      [
        "T13",
        "CAGR",
        211,
        215,
        "CAGR"
      ],
      [
        "T14",
        "属性值",
        23,
        27,
        "快速增长"
      ],
      [
        "T15",
        "业绩",
        252,
        254,
        "业绩"
      ],
      [
        "T16",
        "属性值",
        254,
        258,
        "快速增长"
      ]
    ]
  },
  {
    "id": 499,
    "text": "生物药在销售与治疗领域表现出较大的潜力，对生物药的研发热度也随之提高。根据 Pharma Intelligence数据，生物药在 2015年至 2020年之间在全球研发管线中的占比从 29%提升至 40%，5年内提高了 11个百分点。生物药同时也面临较强的研发与生产门槛，生物药的表征、纯度等特质比较难确定，在生产中合成、分离也较为复杂。生物药的形态学复杂，且由于分子结构很容易在外界条件变化的情况下被改变，所以对于药物制剂的控制非常严格。同时生物大分子难以穿透细胞膜，且强免疫原性，导致生物药难以有效地穿透实体瘤。",
    "labels": [
      [
        "T0",
        "行业",
        0,
        3,
        "生物药"
      ],
      [
        "T1",
        "行业",
        21,
        24,
        "生物药"
      ],
      [
        "T2",
        "行业",
        60,
        63,
        "生物药"
      ],
      [
        "T3",
        "行业",
        117,
        120,
        "生物药"
      ],
      [
        "T4",
        "时间范围",
        65,
        79,
        "2015年至 2020年之间"
      ]
    ]
  },
  {
    "id": 500,
    "text": "昭衍新药在产能建设方面持续进行推进，并积极进行实验动物基地布局。昭衍（苏州）于 2021年启动约 7,500平米的动物房装修工程预计年底前可投入使用。昭衍（苏州）开始进行 II期工程的扩充建设工作，共计划增加建筑面积约 25,000平米，计划 2021年下半年开始动工，新建设施仍以动物饲养管理为主。昭衍新药广州项目于 2021年 9月正式开工兴建。该项目计划建设总面积为 8万平方米的设施，包括动物房及配套实验室。梧州实验动物基地在有序建设中，包括养殖区猴舍 54栋、厂区办公楼 1 栋、饲料间一栋共 56栋生产用房已全部完成主体工程并已通过主体验收，目前正在进行装饰装修工程、机电安装工程、室外工程施工等。公司已在广西梧州计划新增非人灵长类繁殖基地 565 亩用于开工建设具备 1.5万只饲养能力的灵长类动物设施。",
    "labels": [
      [
        "T0",
        "公司",
        0,
        4,
        "昭衍新药"
      ],
      [
        "T1",
        "公司",
        40,
        45,
        "2021年"
      ],
      [
        "T2",
        "时间范围",
        122,
        130,
        "2021年下半年"
      ],
      [
        "T3",
        "公司",
        150,
        154,
        "昭衍新药"
      ],
      [
        "T4",
        "时间范围",
        160,
        168,
        "2021年 9月"
      ],
      [
        "T5",
        "产能",
        5,
        7,
        "产能"
      ],
      [
        "T6",
        "属性值",
        11,
        17,
        "持续进行推进"
      ],
      [
        "T7",
        "时间范围",
        66,
        69,
        "年底前"
      ],
      [
        "T8",
        "公司",
        75,
        81,
        "昭衍（苏州）"
      ]
    ]
  },
  {
    "id": 501,
    "text": "由于去年疫情相关产品销售基数高，2021年收入增速有所减缓，估值目前已处于历史底部。四大上市零售药店门店均保持快速扩张，对未来业绩增长形成支撑。看好益丰药房、一心堂、老百姓、大参林。",
    "labels": [
      [
        "T0",
        "时间范围",
        16,
        21,
        "2021年"
      ],
      [
        "T1",
        "公司",
        74,
        78,
        "益丰药房"
      ],
      [
        "T2",
        "公司",
        79,
        82,
        "一心堂"
      ],
      [
        "T3",
        "公司",
        83,
        86,
        "老百姓"
      ],
      [
        "T4",
        "公司",
        87,
        90,
        "大参林"
      ],
      [
        "T5",
        "收入增速",
        21,
        25,
        "收入增速"
      ],
      [
        "T6",
        "行业公司",
        46,
        50,
        "零售药店"
      ],
      [
        "T7",
        "业绩",
        63,
        65,
        "业绩"
      ],
      [
        "T8",
        "时间范围",
        2,
        4,
        "去年"
      ]
    ]
  },
  {
    "id": 502,
    "text": " 老龄化助推骨科需求释放+骨科医师等资源配置提升带动骨科手术量高成长。2018年中国骨科耗材市场规模为262亿元，同比增长16.4%，预计2023年市场规模将达到509亿元。细分领域看，2018 年创伤、脊柱和关节类分别占据29%、29%和28%的市场份额，运动医学和其他领域占据15%左右的市场。从国产化角度看，创伤类国产已占据68%左右的市场，脊柱占据近39%市场，关节市场份额不到30%。  带量采购成为骨科行业主要压制因素，预计国产替代的趋势仍延续。  大博医疗：上半年收入8.5亿元（+25.8%），归母净利润3.2亿元（+19.9%）。骨科创伤类龙头+ 积极拓展其他增长点。  凯利泰：上半年收入6.4亿元（+30.9%），归母净利润1.1亿元（-4.8%）。上年同期受新冠疫情影响收入大幅下滑，而本报告期内主要产品手术量恢复正常。  三友医疗：上半年收入2.6亿元（+73.5%），归母净利润0.7亿元（+85.4%）。脊柱植入龙头，业绩回归高增长。",
    "labels": [
      [
        "T0",
        "时间范围",
        36,
        41,
        "2018年"
      ],
      [
        "T1",
        "地点范围",
        41,
        43,
        "中国"
      ],
      [
        "T2",
        "行业",
        43,
        47,
        "骨科耗材"
      ],
      [
        "T3",
        "市场规模",
        47,
        51,
        "市场规模"
      ],
      [
        "T4",
        "属性值",
        82,
        87,
        "509亿元"
      ],
      [
        "T5",
        "市场规模",
        75,
        79,
        "市场规模"
      ],
      [
        "T6",
        "时间范围",
        70,
        75,
        "2023年"
      ],
      [
        "T7",
        "市场份额",
        125,
        129,
        "市场份额"
      ],
      [
        "T8",
        "市场份额",
        188,
        192,
        "市场份额"
      ],
      [
        "T9",
        "公司",
        234,
        238,
        "大博医疗"
      ],
      [
        "T10",
        "时间范围",
        239,
        242,
        "上半年"
      ],
      [
        "T11",
        "营业收入",
        242,
        244,
        "收入"
      ],
      [
        "T12",
        "属性值",
        244,
        249,
        "8.5亿元"
      ],
      [
        "T13",
        "属性值",
        250,
        256,
        "+25.8%"
      ],
      [
        "T14",
        "公司",
        299,
        302,
        "凯利泰"
      ],
      [
        "T15",
        "时间范围",
        303,
        306,
        "上半年"
      ],
      [
        "T16",
        "营业收入",
        306,
        308,
        "收入"
      ],
      [
        "T17",
        "属性值",
        308,
        313,
        "6.4亿元"
      ],
      [
        "T18",
        "属性值",
        314,
        320,
        "+30.9%"
      ],
      [
        "T19",
        "归母净利润",
        322,
        327,
        "归母净利润"
      ],
      [
        "T20",
        "公司",
        379,
        383,
        "三友医疗"
      ],
      [
        "T21",
        "时间范围",
        384,
        387,
        "上半年"
      ],
      [
        "T22",
        "营业收入",
        387,
        389,
        "收入"
      ],
      [
        "T23",
        "属性值",
        389,
        394,
        "2.6亿元"
      ],
      [
        "T24",
        "属性值",
        395,
        401,
        "+73.5%"
      ],
      [
        "T25",
        "行业",
        422,
        426,
        "脊柱植入"
      ],
      [
        "T26",
        "龙头企业",
        426,
        428,
        "龙头"
      ],
      [
        "T27",
        "业绩",
        429,
        431,
        "业绩"
      ],
      [
        "T28",
        "行业",
        27,
        29,
        "骨科"
      ],
      [
        "T29",
        "行业",
        7,
        9,
        "骨科"
      ],
      [
        "T30",
        "属性值",
        11,
        13,
        "释放"
      ],
      [
        "T31",
        "行业需求",
        9,
        11,
        "需求"
      ],
      [
        "T32",
        "属性值",
        52,
        67,
        "262亿元，同比增长16.4%"
      ],
      [
        "T33",
        "时间范围",
        94,
        100,
        "2018 年"
      ],
      [
        "T34",
        "行业",
        100,
        102,
        "创伤"
      ],
      [
        "T35",
        "行业",
        103,
        105,
        "脊柱"
      ],
      [
        "T36",
        "行业",
        106,
        109,
        "关节类"
      ],
      [
        "T37",
        "属性值",
        113,
        116,
        "29%"
      ],
      [
        "T38",
        "属性值",
        117,
        120,
        "29%"
      ],
      [
        "T39",
        "属性值",
        121,
        124,
        "28%"
      ],
      [
        "T40",
        "行业",
        130,
        137,
        "运动医学和其他"
      ],
      [
        "T41",
        "属性值",
        141,
        146,
        "15%左右"
      ],
      [
        "T42",
        "行业",
        158,
        163,
        "创伤类国产"
      ],
      [
        "T43",
        "属性值",
        166,
        169,
        "68%"
      ],
      [
        "T44",
        "行业",
        175,
        177,
        "脊柱"
      ],
      [
        "T45",
        "属性值",
        179,
        183,
        "近39%"
      ],
      [
        "T46",
        "行业",
        186,
        188,
        "关节"
      ],
      [
        "T47",
        "属性值",
        192,
        197,
        "不到30%"
      ],
      [
        "T48",
        "行业",
        207,
        209,
        "骨科"
      ],
      [
        "T49",
        "属性值",
        220,
        224,
        "国产替代"
      ],
      [
        "T50",
        "属性值",
        263,
        276,
        "3.2亿元（+19.9%）"
      ],
      [
        "T51",
        "归母净利润",
        258,
        263,
        "归母净利润"
      ],
      [
        "T52",
        "行业",
        277,
        282,
        "骨科创伤类"
      ],
      [
        "T53",
        "龙头企业",
        282,
        284,
        "龙头"
      ],
      [
        "T54",
        "属性值",
        353,
        357,
        "大幅下滑"
      ],
      [
        "T55",
        "营业收入",
        351,
        353,
        "收入"
      ],
      [
        "T56",
        "时间范围",
        340,
        342,
        "上年"
      ],
      [
        "T57",
        "属性值",
        327,
        339,
        "1.1亿元（-4.8%）"
      ],
      [
        "T58",
        "归母净利润",
        403,
        408,
        "归母净利润"
      ],
      [
        "T59",
        "属性值",
        408,
        421,
        "0.7亿元（+85.4%）"
      ],
      [
        "T60",
        "属性值",
        433,
        436,
        "高增长"
      ]
    ]
  },
  {
    "id": 503,
    "text": "复宏汉霖 HLX208获批临床，恒瑞医药 PD-L1单抗申报上市：1月 18 日，复星医药发布公告称，其控股子公司复宏汉霖收到 NMPA关于同意靶向人类 BRAF蛋白 V600E突变小分子抑制剂 HLX208单药或联合治疗晚期实体瘤开展临床试验的批准；1月 19日，CDE官网显示，恒瑞医药的 PD-L1单抗阿得贝利单抗上市申请获受理。这是国产第 5款申报上市的 PD-L1单抗。",
    "labels": [
      [
        "T0",
        "公司",
        16,
        20,
        "恒瑞医药"
      ],
      [
        "T1",
        "公司",
        41,
        45,
        "复星医药"
      ],
      [
        "T2",
        "公司",
        0,
        4,
        "复宏汉霖"
      ],
      [
        "T3",
        "公司",
        57,
        61,
        "复宏汉霖"
      ],
      [
        "T4",
        "时间范围",
        126,
        132,
        "1月 19日"
      ],
      [
        "T5",
        "公司",
        141,
        145,
        "恒瑞医药"
      ],
      [
        "T6",
        "时间范围",
        33,
        40,
        "1月 18 日"
      ]
    ]
  },
  {
    "id": 504,
    "text": " 器械板块（45家样本公司，不含科创板）上半年收入761.8亿元（+29.3%），归母净利润230.8亿元（+37.1%），毛利率59.3%，四费率23.4%,“ 剪刀差”使得上半年净利率大幅提升至31.2%，疫情受益器械股业绩延续高增长。",
    "labels": [
      [
        "T0",
        "行业",
        2,
        4,
        "器械"
      ],
      [
        "T1",
        "时间范围",
        21,
        24,
        "上半年"
      ],
      [
        "T2",
        "营业收入",
        24,
        26,
        "收入"
      ],
      [
        "T3",
        "归母净利润",
        42,
        47,
        "归母净利润"
      ],
      [
        "T4",
        "毛利",
        63,
        66,
        "毛利率"
      ],
      [
        "T5",
        "行业",
        110,
        112,
        "器械"
      ],
      [
        "T6",
        "业绩",
        113,
        115,
        "业绩"
      ],
      [
        "T7",
        "属性值",
        26,
        33,
        "761.8亿元"
      ],
      [
        "T8",
        "属性值",
        34,
        40,
        "+29.3%"
      ],
      [
        "T9",
        "属性值",
        47,
        62,
        "230.8亿元（+37.1%）"
      ],
      [
        "T10",
        "属性值",
        66,
        71,
        "59.3%"
      ],
      [
        "T11",
        "时间范围",
        89,
        92,
        "上半年"
      ],
      [
        "T12",
        "归母净利润",
        92,
        95,
        "净利率"
      ],
      [
        "T13",
        "属性值",
        100,
        105,
        "31.2%"
      ],
      [
        "T14",
        "属性值",
        117,
        120,
        "高增长"
      ]
    ]
  },
  {
    "id": 505,
    "text": "• 2.2.创新药——内卷下的国际化，与First-in-Class差距越来越小",
    "labels": [
      [
        "T0",
        "行业",
        6,
        9,
        "创新药"
      ]
    ]
  },
  {
    "id": 506,
    "text": " 血液净化耗材市场空间大：2019年预计我国ESRD患者数量为258万，年复合增速5.2%，目前透析治疗率28%不到，假设2030年透析率80%，透析患者中使用灌流（HP）的比例为50%， 那么预计2030年血液净化耗材市场规模达到444亿，复合增速16%。  血液净化为治疗刚需，疫情期间和疫情后基本维持高增长态势。  健帆生物：上半年收入 11.9亿元（ +36.6%），归母净利润 6.2亿元（ +40.7%）。其中肾科领域实现25%左右的增长。  三鑫医疗：上半年收入 5.1亿元（ +16.6%），归母净利润0.71亿元（ +60%），2021H1血液净化业务收入 3.4亿元（+30.1%），比2019H1增长 83.7%，作为核心业务延续高增长态势。",
    "labels": [
      [
        "T0",
        "行业",
        2,
        8,
        "血液净化耗材"
      ],
      [
        "T1",
        "时间范围",
        14,
        19,
        "2019年"
      ],
      [
        "T2",
        "地点范围",
        21,
        23,
        "我国"
      ],
      [
        "T3",
        "CAGR",
        37,
        42,
        "年复合增速"
      ],
      [
        "T4",
        "时间范围",
        100,
        105,
        "2030年"
      ],
      [
        "T5",
        "行业",
        105,
        111,
        "血液净化耗材"
      ],
      [
        "T6",
        "市场规模",
        111,
        115,
        "市场规模"
      ],
      [
        "T7",
        "属性值",
        117,
        121,
        "444亿"
      ],
      [
        "T8",
        "CAGR",
        122,
        126,
        "复合增速"
      ],
      [
        "T9",
        "属性值",
        126,
        129,
        "16%"
      ],
      [
        "T10",
        "公司",
        164,
        168,
        "健帆生物"
      ],
      [
        "T11",
        "时间范围",
        169,
        172,
        "上半年"
      ],
      [
        "T12",
        "营业收入",
        172,
        174,
        "收入"
      ],
      [
        "T13",
        "属性值",
        175,
        181,
        "11.9亿元"
      ],
      [
        "T14",
        "属性值",
        183,
        189,
        "+36.6%"
      ],
      [
        "T15",
        "归母净利润",
        191,
        196,
        "归母净利润"
      ],
      [
        "T16",
        "公司",
        232,
        236,
        "三鑫医疗"
      ],
      [
        "T17",
        "时间范围",
        237,
        240,
        "上半年"
      ],
      [
        "T18",
        "营业收入",
        240,
        242,
        "收入"
      ],
      [
        "T19",
        "属性值",
        243,
        248,
        "5.1亿元"
      ],
      [
        "T20",
        "属性值",
        250,
        256,
        "+16.6%"
      ],
      [
        "T21",
        "时间范围",
        277,
        283,
        "2021H1"
      ],
      [
        "T22",
        "行业",
        283,
        287,
        "血液净化"
      ],
      [
        "T23",
        "营业收入",
        289,
        291,
        "收入"
      ],
      [
        "T24",
        "属性值",
        292,
        297,
        "3.4亿元"
      ],
      [
        "T25",
        "属性值",
        298,
        304,
        "+30.1%"
      ],
      [
        "T26",
        "属性值",
        12,
        13,
        "大"
      ],
      [
        "T27",
        "市场规模",
        8,
        12,
        "市场空间"
      ],
      [
        "T28",
        "时间范围",
        62,
        67,
        "2030年"
      ],
      [
        "T29",
        "属性值",
        197,
        211,
        "6.2亿元（ +40.7%）"
      ],
      [
        "T30",
        "属性值",
        220,
        225,
        "25%左右"
      ],
      [
        "T31",
        "行业",
        214,
        216,
        "肾科"
      ],
      [
        "T32",
        "属性值",
        263,
        276,
        "0.71亿元（ +60%）"
      ],
      [
        "T33",
        "时间范围",
        307,
        313,
        "2019H1"
      ],
      [
        "T34",
        "属性值",
        316,
        321,
        "83.7%"
      ],
      [
        "T35",
        "属性值",
        330,
        333,
        "高增长"
      ],
      [
        "T36",
        "归母净利润",
        258,
        263,
        "归母净利润"
      ]
    ]
  },
  {
    "id": 507,
    "text": " 投资建议：投资策略上，CXO全产业链战略性看好，继续推荐具有全球竞争力的龙头公司，CDMO、药物发现及临床前研究CRO和临床CRO的细分市场龙头，以及受益于行业高景气度的小而美的公司，持续推荐博腾股份、美迪西 、药明康德、九洲药业、昭衍新药、凯莱英、康龙化成、诺泰生物、维亚生物等。",
    "labels": [
      [
        "T0",
        "行业",
        13,
        16,
        "CXO"
      ],
      [
        "T1",
        "龙头企业",
        38,
        42,
        "龙头公司"
      ],
      [
        "T2",
        "行业",
        43,
        47,
        "CDMO"
      ],
      [
        "T3",
        "行业",
        48,
        52,
        "药物发现"
      ],
      [
        "T4",
        "行业",
        53,
        61,
        "临床前研究CRO"
      ],
      [
        "T5",
        "行业",
        62,
        67,
        "临床CRO"
      ],
      [
        "T6",
        "龙头企业",
        72,
        74,
        "龙头"
      ],
      [
        "T7",
        "公司",
        98,
        102,
        "博腾股份"
      ],
      [
        "T8",
        "公司",
        103,
        106,
        "美迪西"
      ],
      [
        "T9",
        "公司",
        108,
        112,
        "药明康德"
      ],
      [
        "T10",
        "公司",
        113,
        117,
        "九洲药业"
      ],
      [
        "T11",
        "公司",
        118,
        122,
        "昭衍新药"
      ],
      [
        "T12",
        "公司",
        123,
        126,
        "凯莱英"
      ],
      [
        "T13",
        "公司",
        127,
        131,
        "康龙化成"
      ],
      [
        "T14",
        "公司",
        132,
        136,
        "诺泰生物"
      ],
      [
        "T15",
        "公司",
        137,
        141,
        "维亚生物"
      ],
      [
        "T16",
        "地点范围",
        32,
        34,
        "全球"
      ]
    ]
  },
  {
    "id": 508,
    "text": " 21Q1/Q2原料药板块分别实现收入216亿元/227亿元，同比+19%/8.5% ，在利润端21Q1/Q2实现归母净利润37.4亿元/40.9亿元，同比 +20%/-13.2%。二季度板块归母净利润下滑，主要是毛利率同比去年下滑约3.8pp，同时费用端同上升1.3pp，价格和成本波动造成行业的周期性明显，建议臻选细分领域内具有成长趋势的公司，尤其是下半年业绩表现较为稳健的公司。",
    "labels": [
      [
        "T0",
        "行业",
        9,
        12,
        "原料药"
      ],
      [
        "T1",
        "营业收入",
        18,
        20,
        "收入"
      ],
      [
        "T2",
        "归母净利润",
        58,
        63,
        "归母净利润"
      ],
      [
        "T3",
        "归母净利润",
        97,
        102,
        "归母净利润"
      ],
      [
        "T4",
        "毛利",
        108,
        111,
        "毛利率"
      ],
      [
        "T5",
        "时间范围",
        2,
        6,
        "21Q1"
      ],
      [
        "T6",
        "时间范围",
        7,
        9,
        "Q2"
      ],
      [
        "T7",
        "属性值",
        20,
        25,
        "216亿元"
      ],
      [
        "T8",
        "属性值",
        26,
        31,
        "227亿元"
      ],
      [
        "T9",
        "属性值",
        34,
        38,
        "+19%"
      ],
      [
        "T10",
        "属性值",
        39,
        43,
        "8.5%"
      ],
      [
        "T11",
        "利润",
        46,
        49,
        "利润端"
      ],
      [
        "T12",
        "时间范围",
        49,
        53,
        "21Q1"
      ],
      [
        "T13",
        "时间范围",
        54,
        56,
        "Q2"
      ],
      [
        "T14",
        "属性值",
        63,
        69,
        "37.4亿元"
      ],
      [
        "T15",
        "属性值",
        70,
        76,
        "40.9亿元"
      ],
      [
        "T16",
        "时间范围",
        92,
        95,
        "二季度"
      ],
      [
        "T17",
        "属性值",
        102,
        104,
        "下滑"
      ],
      [
        "T18",
        "属性值",
        111,
        123,
        "同比去年下滑约3.8pp"
      ],
      [
        "T19",
        "时间范围",
        178,
        181,
        "下半年"
      ],
      [
        "T20",
        "业绩",
        181,
        183,
        "业绩"
      ]
    ]
  },
  {
    "id": 509,
    "text": " 板块2021Q1-3收入总额增速为20%，其中第三季度收入增速为 28.9%；2021Q1-3归母净利润总额增速为25.7%，其中第三季度增速为34.4%。 6家血液制品公司中上半年收入、利润均实现正增长。  第三季度，板块毛利率下降4.3pp，销售费用率降低3.1pp，板块净利润在28%左右，维持稳定。",
    "labels": [
      [
        "T0",
        "时间范围",
        4,
        12,
        "2021Q1-3"
      ],
      [
        "T1",
        "收入增速",
        12,
        18,
        "收入总额增速"
      ],
      [
        "T2",
        "时间范围",
        25,
        29,
        "第三季度"
      ],
      [
        "T3",
        "收入增速",
        29,
        33,
        "收入增速"
      ],
      [
        "T4",
        "时间范围",
        41,
        49,
        "2021Q1-3"
      ],
      [
        "T5",
        "归母净利润增速",
        49,
        58,
        "归母净利润总额增速"
      ],
      [
        "T6",
        "时间范围",
        67,
        71,
        "第三季度"
      ],
      [
        "T7",
        "毛利",
        115,
        118,
        "毛利率"
      ],
      [
        "T8",
        "归母净利润",
        141,
        144,
        "净利润"
      ],
      [
        "T9",
        "利润",
        96,
        98,
        "利润"
      ],
      [
        "T10",
        "营业收入",
        93,
        95,
        "收入"
      ],
      [
        "T11",
        "时间范围",
        90,
        93,
        "上半年"
      ],
      [
        "T12",
        "行业公司",
        81,
        89,
        "6家血液制品公司"
      ],
      [
        "T13",
        "属性值",
        101,
        104,
        "正增长"
      ],
      [
        "T14",
        "时间范围",
        108,
        112,
        "第三季度"
      ]
    ]
  },
  {
    "id": 511,
    "text": "• 长春高新金赛业绩持续高增长，静待广东联盟生长激素集采结果落地",
    "labels": [
      [
        "T0",
        "公司",
        2,
        8,
        "长春高新金赛"
      ],
      [
        "T1",
        "业绩",
        8,
        10,
        "业绩"
      ],
      [
        "T2",
        "属性值",
        10,
        15,
        "持续高增长"
      ]
    ]
  },
  {
    "id": 512,
    "text": "CXO行业景气度持续，预期在 2022年保持高景气度增长。2021年 Q1- Q3中国 CXO企业收入端与利润端表现出优秀的同比增长，截至 Q3期末的存货水平与合同负债水平也与去年同期相比有所增长，为 2022年业绩景气度奠定基础。凯莱英与博腾股份均受到来自海外药企的大额订单，对于 2022年业绩增长有所助力。中国 CXO企业在 2021年积极进行产能建设和团队建设，进行产能释放从而提高订单承接能力。中国 CXO行业预期增长速度仍高于全球 CXO行业，中国 CXO企业有望在全球获得更大比例的订单。生物药销售与研发的热度带来了相应的 Bio- CDMO服务，而 Bio-CDMO产能仍掌握在少数龙头企业手中。中国 CDE 一类新药 IND审批数量中的生物药数量与生物药临床实验数量均呈现出",
    "labels": [
      [
        "T0",
        "行业",
        0,
        3,
        "CXO"
      ],
      [
        "T1",
        "时间范围",
        15,
        20,
        "2022年"
      ],
      [
        "T2",
        "时间范围",
        29,
        41,
        "2021年 Q1- Q3"
      ],
      [
        "T3",
        "行业公司",
        44,
        49,
        "CXO企业"
      ],
      [
        "T4",
        "时间范围",
        101,
        106,
        "2022年"
      ],
      [
        "T5",
        "业绩",
        106,
        108,
        "业绩"
      ],
      [
        "T6",
        "公司",
        116,
        119,
        "凯莱英"
      ],
      [
        "T7",
        "公司",
        120,
        124,
        "博腾股份"
      ],
      [
        "T8",
        "行业公司",
        131,
        133,
        "药企"
      ],
      [
        "T9",
        "时间范围",
        142,
        147,
        "2022年"
      ],
      [
        "T10",
        "行业公司",
        159,
        164,
        "CXO企业"
      ],
      [
        "T11",
        "行业",
        205,
        208,
        "CXO"
      ],
      [
        "T12",
        "行业",
        222,
        225,
        "CXO"
      ],
      [
        "T13",
        "行业公司",
        231,
        236,
        "CXO企业"
      ],
      [
        "T14",
        "营业收入",
        49,
        52,
        "收入端"
      ],
      [
        "T15",
        "利润",
        53,
        56,
        "利润端"
      ],
      [
        "T16",
        "属性值",
        59,
        66,
        "优秀的同比增长"
      ],
      [
        "T17",
        "时间范围",
        67,
        74,
        "截至 Q3期末"
      ],
      [
        "T18",
        "存货",
        75,
        77,
        "存货"
      ],
      [
        "T19",
        "合同负债",
        80,
        84,
        "合同负债"
      ],
      [
        "T20",
        "属性值",
        87,
        98,
        "与去年同期相比有所增长"
      ],
      [
        "T21",
        "地点范围",
        41,
        43,
        "中国"
      ],
      [
        "T22",
        "时间范围",
        166,
        171,
        "2021年"
      ],
      [
        "T23",
        "业绩",
        147,
        149,
        "业绩"
      ],
      [
        "T24",
        "属性值",
        171,
        179,
        "积极进行产能建设"
      ],
      [
        "T25",
        "地点范围",
        156,
        158,
        "中国"
      ],
      [
        "T26",
        "地点范围",
        202,
        204,
        "中国"
      ],
      [
        "T27",
        "地点范围",
        219,
        221,
        "全球"
      ],
      [
        "T28",
        "地点范围",
        228,
        230,
        "中国"
      ],
      [
        "T29",
        "地点范围",
        239,
        241,
        "全球"
      ],
      [
        "T30",
        "行业",
        283,
        291,
        "Bio-CDMO"
      ],
      [
        "T31",
        "产能",
        291,
        293,
        "产能"
      ],
      [
        "T32",
        "属性值",
        294,
        305,
        "掌握在少数龙头企业手中"
      ],
      [
        "T33",
        "地点范围",
        306,
        308,
        "中国"
      ],
      [
        "T34",
        "临床试验数量",
        336,
        342,
        "临床实验数量"
      ],
      [
        "T35",
        "行业",
        333,
        336,
        "生物药"
      ],
      [
        "T36",
        "行业",
        269,
        280,
        "Bio- CDMO服务"
      ]
    ]
  },
  {
    "id": 513,
    "text": " 国家统计局规模以上医药制造业数据：2020年全年累计实现营业收入2.49万亿元，同比+4.5%；累计实现利润总额3506亿元，同比增加 13%。2021年1-8月医药制造营业收入同比增长26.2%，医药制造利润总额同比增长89.1%，主要系疫情加速恢复与2020年1-8月低基数两方面原因所致，根据收入和利润相比2019年的同比情况看，医药制造业基本恢复。  PDB样本医院药品销售额数据：2019年PDB样本医院药品收入同比+11.7%，比2018年提升了9个百分点，我们认为主要是众多创新品种进入医保后快速放量所致。2020年PDB样本医院药品收入2213亿元，同比下降13%，其中Q1受疫情的影响，收入下滑25%，Q2/Q3/Q4 单季度收入增速分别为-17%/-6%/-5%，降幅逐季收窄。2021Q1-3收入增速为18%，预计2022年将继续改善。  西南观点：医药工业整体增速在国家医保局成立背景下，随着带量采购执行，行业格局变化在即。宏观上医药工业收入近两年符合增速低于10%，但结构上分化愈加明显，创新药、创新器械、医药消费品等成行业主要增长动力，展望2022年，我们预计低基数和疫情进一步得到控制，医药工业整体增速将持续回暖。",
    "labels": [
      [
        "T0",
        "时间范围",
        19,
        26,
        "2020年全年"
      ],
      [
        "T1",
        "营业收入",
        30,
        34,
        "营业收入"
      ],
      [
        "T2",
        "属性值",
        34,
        40,
        "2.49万亿"
      ],
      [
        "T3",
        "属性值",
        44,
        49,
        "+4.5%"
      ],
      [
        "T4",
        "利润",
        54,
        56,
        "利润"
      ],
      [
        "T5",
        "属性值",
        58,
        64,
        "3506亿元"
      ],
      [
        "T6",
        "属性值",
        70,
        73,
        "13%"
      ],
      [
        "T7",
        "时间范围",
        74,
        83,
        "2021年1-8月"
      ],
      [
        "T8",
        "行业",
        83,
        87,
        "医药制造"
      ],
      [
        "T9",
        "营业收入",
        87,
        91,
        "营业收入"
      ],
      [
        "T10",
        "属性值",
        95,
        100,
        "26.2%"
      ],
      [
        "T11",
        "行业",
        101,
        105,
        "医药制造"
      ],
      [
        "T12",
        "利润",
        105,
        107,
        "利润"
      ],
      [
        "T13",
        "属性值",
        113,
        118,
        "89.1%"
      ],
      [
        "T14",
        "时间范围",
        129,
        138,
        "2020年1-8月"
      ],
      [
        "T15",
        "营业收入",
        151,
        153,
        "收入"
      ],
      [
        "T16",
        "利润",
        154,
        156,
        "利润"
      ],
      [
        "T17",
        "时间范围",
        198,
        203,
        "2019年"
      ],
      [
        "T18",
        "营业收入",
        212,
        214,
        "收入"
      ],
      [
        "T19",
        "时间范围",
        224,
        229,
        "2018年"
      ],
      [
        "T20",
        "时间范围",
        263,
        268,
        "2020年"
      ],
      [
        "T21",
        "营业收入",
        277,
        279,
        "收入"
      ],
      [
        "T22",
        "营业收入",
        305,
        307,
        "收入"
      ],
      [
        "T23",
        "时间范围",
        296,
        298,
        "Q1"
      ],
      [
        "T24",
        "时间范围",
        352,
        360,
        "2021Q1-3"
      ],
      [
        "T25",
        "收入增速",
        360,
        364,
        "收入增速"
      ],
      [
        "T26",
        "时间范围",
        371,
        376,
        "2022年"
      ],
      [
        "T27",
        "行业",
        390,
        394,
        "医药工业"
      ],
      [
        "T28",
        "行业",
        431,
        435,
        "医药工业"
      ],
      [
        "T29",
        "营业收入",
        435,
        437,
        "收入"
      ],
      [
        "T30",
        "行业",
        461,
        464,
        "创新药"
      ],
      [
        "T31",
        "行业",
        465,
        469,
        "创新器械"
      ],
      [
        "T32",
        "行业",
        470,
        475,
        "医药消费品"
      ],
      [
        "T33",
        "行业",
        512,
        516,
        "医药工业"
      ],
      [
        "T34",
        "时间范围",
        488,
        493,
        "2022年"
      ],
      [
        "T35",
        "时间范围",
        437,
        440,
        "近两年"
      ],
      [
        "T36",
        "行业",
        11,
        16,
        "医药制造业"
      ],
      [
        "T37",
        "属性值",
        175,
        179,
        "基本恢复"
      ],
      [
        "T38",
        "行业",
        170,
        175,
        "医药制造业"
      ],
      [
        "T39",
        "时间范围",
        313,
        315,
        "Q2"
      ],
      [
        "T40",
        "时间范围",
        316,
        318,
        "Q3"
      ],
      [
        "T41",
        "时间范围",
        319,
        321,
        "Q4"
      ],
      [
        "T42",
        "收入增速",
        325,
        329,
        "收入增速"
      ],
      [
        "T43",
        "属性值",
        332,
        336,
        "-17%"
      ],
      [
        "T44",
        "属性值",
        337,
        340,
        "-6%"
      ],
      [
        "T45",
        "属性值",
        341,
        344,
        "-5%"
      ],
      [
        "T46",
        "属性值",
        307,
        312,
        "下滑25%"
      ],
      [
        "T47",
        "行业公司",
        268,
        275,
        "PDB样本医院"
      ],
      [
        "T48",
        "行业",
        275,
        277,
        "药品"
      ],
      [
        "T49",
        "属性值",
        279,
        285,
        "2213亿元"
      ],
      [
        "T50",
        "属性值",
        288,
        293,
        "下降13%"
      ],
      [
        "T51",
        "属性值",
        423,
        427,
        "变化在即"
      ],
      [
        "T52",
        "属性值",
        442,
        449,
        "增速低于10%"
      ],
      [
        "T53",
        "时间范围",
        158,
        163,
        "2019年"
      ],
      [
        "T54",
        "行业公司",
        183,
        190,
        "PDB样本医院"
      ],
      [
        "T55",
        "行业",
        190,
        192,
        "药品"
      ],
      [
        "T56",
        "行业公司",
        203,
        210,
        "PDB样本医院"
      ],
      [
        "T57",
        "行业",
        210,
        212,
        "药品"
      ],
      [
        "T58",
        "属性值",
        216,
        222,
        "+11.7%"
      ],
      [
        "T59",
        "属性值",
        232,
        237,
        "9个百分点"
      ],
      [
        "T60",
        "属性值",
        365,
        368,
        "18%"
      ],
      [
        "T61",
        "属性值",
        377,
        381,
        "继续改善"
      ],
      [
        "T62",
        "竞争格局",
        421,
        423,
        "格局"
      ]
    ]
  },
  {
    "id": 514,
    "text": "原料药：特色原料药需求稳定、竞争格局优化，原料药制剂一体化是传统化药必然趋势。原料药公司在板块内的估值增速性价比较高，建议关注客户结构优化、下游增速较快、掌握关键中间体环节的原料药企业，推荐华海药业、博瑞医药、美诺华， 关注天宇股份、司太立、普洛药业等。",
    "labels": [
      [
        "T0",
        "行业",
        0,
        3,
        "原料药"
      ],
      [
        "T1",
        "行业需求",
        9,
        11,
        "需求"
      ],
      [
        "T2",
        "行业",
        4,
        9,
        "特色原料药"
      ],
      [
        "T3",
        "属性值",
        11,
        13,
        "稳定"
      ],
      [
        "T4",
        "竞争格局",
        14,
        18,
        "竞争格局"
      ],
      [
        "T5",
        "行业公司",
        39,
        44,
        "原料药公司"
      ],
      [
        "T6",
        "公司",
        95,
        99,
        "华海药业"
      ],
      [
        "T7",
        "行业公司",
        87,
        92,
        "原料药企业"
      ],
      [
        "T8",
        "公司",
        100,
        104,
        "博瑞医药"
      ],
      [
        "T9",
        "公司",
        105,
        108,
        "美诺华"
      ],
      [
        "T10",
        "公司",
        112,
        116,
        "天宇股份"
      ],
      [
        "T11",
        "公司",
        117,
        120,
        "司太立"
      ],
      [
        "T12",
        "公司",
        121,
        125,
        "普洛药业"
      ],
      [
        "T13",
        "属性值",
        18,
        20,
        "优化"
      ],
      [
        "T14",
        "属性值",
        21,
        29,
        "原料药制剂一体化"
      ],
      [
        "T15",
        "行业",
        30,
        34,
        "传统化药"
      ]
    ]
  },
  {
    "id": 515,
    "text": "• 国内生物医药PEVC投融资活动继续保持高强度：2018年以来国内生物医药投融资金额持续保持高强度，尤其是2020年达到历史高点667亿元。 2021年前10月，国内发生161个PEVC投融资案例、合计融资金额达到522亿元，延续高强度。 • Biotech企业2021年上市继续保持高强度：继2018年中国香港放开非盈利生物科技企业上市政策、2019年科创板允许非盈利生物科技企业上市， 2020年迎来生物科技企业融资高峰，合计融资金额达到527亿元。2021年前9月在港交所和科创板实现16家企业的IPO、合计融资金额达到275亿元，继续保持高强度。",
    "labels": [
      [
        "T0",
        "地点范围",
        2,
        4,
        "国内"
      ],
      [
        "T1",
        "行业",
        4,
        8,
        "生物医药"
      ],
      [
        "T2",
        "时间范围",
        25,
        32,
        "2018年以来"
      ],
      [
        "T3",
        "地点范围",
        32,
        34,
        "国内"
      ],
      [
        "T4",
        "行业",
        34,
        38,
        "生物医药"
      ],
      [
        "T5",
        "投融资金额",
        38,
        43,
        "投融资金额"
      ],
      [
        "T6",
        "时间范围",
        54,
        59,
        "2020年"
      ],
      [
        "T7",
        "属性值",
        65,
        70,
        "667亿元"
      ],
      [
        "T8",
        "时间范围",
        72,
        81,
        "2021年前10月"
      ],
      [
        "T9",
        "地点范围",
        82,
        84,
        "国内"
      ],
      [
        "T10",
        "投融资金额",
        102,
        106,
        "融资金额"
      ],
      [
        "T11",
        "属性值",
        108,
        113,
        "522亿元"
      ],
      [
        "T12",
        "行业公司",
        123,
        132,
        "Biotech企业"
      ],
      [
        "T13",
        "时间范围",
        132,
        137,
        "2021年"
      ],
      [
        "T14",
        "行业公司",
        162,
        168,
        "生物科技企业"
      ],
      [
        "T15",
        "行业公司",
        186,
        192,
        "生物科技企业"
      ],
      [
        "T16",
        "行业公司",
        203,
        209,
        "生物科技企业"
      ],
      [
        "T17",
        "投融资情况",
        209,
        211,
        "融资"
      ],
      [
        "T18",
        "投融资金额",
        216,
        220,
        "融资金额"
      ],
      [
        "T19",
        "属性值",
        222,
        227,
        "527亿元"
      ],
      [
        "T20",
        "时间范围",
        228,
        236,
        "2021年前9月"
      ],
      [
        "T21",
        "投融资金额",
        258,
        262,
        "融资金额"
      ],
      [
        "T22",
        "属性值",
        264,
        269,
        "275亿元"
      ],
      [
        "T23",
        "投融资情况",
        12,
        15,
        "投融资"
      ],
      [
        "T24",
        "属性值",
        21,
        24,
        "高强度"
      ],
      [
        "T25",
        "属性值",
        47,
        50,
        "高强度"
      ],
      [
        "T26",
        "投融资事件数",
        94,
        99,
        "投融资案例"
      ],
      [
        "T27",
        "属性值",
        86,
        90,
        "161个"
      ],
      [
        "T28",
        "时间范围",
        148,
        153,
        "2018年"
      ],
      [
        "T29",
        "地点范围",
        153,
        157,
        "中国香港"
      ],
      [
        "T30",
        "时间范围",
        173,
        178,
        "2019年"
      ],
      [
        "T31",
        "时间范围",
        196,
        201,
        "2020年"
      ],
      [
        "T32",
        "属性值",
        211,
        213,
        "高峰"
      ]
    ]
  },
  {
    "id": 516,
    "text": ".中国游戏人口趋于饱和，进入存量市场。加强游戏质量和进军海外游戏市场是腾讯游戏未来发展趋势。精品化路线上，腾讯研发投入巨大且投入产出比高，有利于形成正向循环，加大出品优势。游戏出海上，腾讯拳头产品常年霸榜，口碑和利润双丰收，未来前景良好",
    "labels": [
      [
        "T0",
        "公司",
        35,
        37,
        "腾讯"
      ],
      [
        "T1",
        "行业",
        3,
        5,
        "游戏"
      ],
      [
        "T2",
        "公司",
        53,
        55,
        "腾讯"
      ],
      [
        "T3",
        "公司",
        92,
        94,
        "腾讯"
      ],
      [
        "T4",
        "利润",
        106,
        108,
        "利润"
      ],
      [
        "T5",
        "地点范围",
        1,
        3,
        "中国"
      ],
      [
        "T6",
        "行业",
        37,
        39,
        "游戏"
      ],
      [
        "T7",
        "地点范围",
        28,
        30,
        "海外"
      ],
      [
        "T8",
        "行业",
        30,
        32,
        "游戏"
      ],
      [
        "T9",
        "研发费用",
        55,
        59,
        "研发投入"
      ],
      [
        "T10",
        "属性值",
        59,
        61,
        "巨大"
      ],
      [
        "T11",
        "行业",
        86,
        90,
        "游戏出海"
      ],
      [
        "T12",
        "属性值",
        109,
        111,
        "丰收"
      ]
    ]
  },
  {
    "id": 517,
    "text": " 全行业销售费用同比增加158亿元，主要受中药、创新药及制剂板块带动。尽管销售费用录得同比增长，但增速低于行业营收增速，预计未来行业销售费用率将持续下行。",
    "labels": [
      [
        "T0",
        "行业",
        22,
        24,
        "中药"
      ],
      [
        "T1",
        "行业",
        25,
        28,
        "创新药"
      ],
      [
        "T2",
        "行业",
        29,
        31,
        "制剂"
      ],
      [
        "T3",
        "收入增速",
        56,
        60,
        "营收增速"
      ]
    ]
  },
  {
    "id": 518,
    "text": "华东医药：（1）医美管线：公司通过代理韩国LG玻尿酸、收购英国公司Sinclair、参股美国公司R2、与韩国公司 Jetema合作等方式全面布局医美管线，目前公司医美产品管线已全面覆盖玻尿酸、少女针、埋线、肉毒素、光电医美等核心品种。其中，根据公司公告，少女针2021年4月国内正式获批，目前签约合作医院数量超过120家，实现预收款超过1亿元，预计有望超额完成全年销售目标。（2）工业板块：考虑到阿卡波糖2020年集采失标负面影响逐步消退、 百令胶囊再次大幅降价可能性较小、他克莫司胶囊/吗替麦考酚酯分散片销售稳定增长、利拉鲁肽的减肥和糖尿病适应症的III期临床进展顺利，2022年医药工业板块销售有望保持稳定增长。",
    "labels": [
      [
        "T0",
        "公司",
        1,
        5,
        "华东医药"
      ],
      [
        "T1",
        "公司",
        22,
        24,
        "LG"
      ],
      [
        "T2",
        "行业",
        9,
        11,
        "医美"
      ],
      [
        "T3",
        "公司",
        34,
        42,
        "Sinclair"
      ],
      [
        "T4",
        "公司",
        49,
        51,
        "R2"
      ],
      [
        "T5",
        "公司",
        58,
        64,
        "Jetema"
      ],
      [
        "T6",
        "行业",
        73,
        75,
        "医美"
      ],
      [
        "T7",
        "行业",
        292,
        296,
        "医药工业"
      ],
      [
        "T8",
        "时间范围",
        287,
        292,
        "2022年"
      ],
      [
        "T9",
        "地点范围",
        30,
        32,
        "英国"
      ],
      [
        "T10",
        "地点范围",
        20,
        22,
        "韩国"
      ],
      [
        "T11",
        "地点范围",
        45,
        47,
        "美国"
      ],
      [
        "T12",
        "地点范围",
        53,
        55,
        "韩国"
      ],
      [
        "T13",
        "时间范围",
        78,
        80,
        "目前"
      ],
      [
        "T14",
        "行业",
        82,
        84,
        "医美"
      ],
      [
        "T15",
        "时间范围",
        131,
        138,
        "2021年4月"
      ],
      [
        "T16",
        "地点范围",
        138,
        140,
        "国内"
      ],
      [
        "T17",
        "行业",
        191,
        193,
        "工业"
      ],
      [
        "T18",
        "时间范围",
        203,
        208,
        "2020年"
      ]
    ]
  },
  {
    "id": 519,
    "text": "全球医药市场保持稳定增长，根据 Frost&Sullivan数据全球医药市场 2021年市场收入预期为 13.93千亿美元，2016年-2021年年均复合增长率为 3.9%，预期 2025年全球医药市场收入将达到 17.11千亿美元， 2021年-2025年预期年均复合增长率为 5.3%。其中，2021年全球创新药市场收入预期为 9.61千亿美元， 2016年-2021年年均复合增长率为 3.8%。全球创新药市场收入预期将于 2025年达到 12.17千亿美元， 预期 2021年-2015年预期年均复合增长率为 6.1%。",
    "labels": [
      [
        "T0",
        "行业",
        2,
        4,
        "医药"
      ],
      [
        "T1",
        "地点范围",
        0,
        2,
        "全球"
      ],
      [
        "T2",
        "行业",
        34,
        36,
        "医药"
      ],
      [
        "T3",
        "地点范围",
        32,
        34,
        "全球"
      ],
      [
        "T4",
        "时间范围",
        39,
        44,
        "2021年"
      ],
      [
        "T5",
        "营业收入",
        46,
        48,
        "收入"
      ],
      [
        "T6",
        "属性值",
        52,
        61,
        "13.93千亿美元"
      ],
      [
        "T7",
        "时间范围",
        62,
        73,
        "2016年-2021年"
      ],
      [
        "T8",
        "CAGR",
        73,
        80,
        "年均复合增长率"
      ],
      [
        "T9",
        "时间范围",
        90,
        95,
        "2025年"
      ],
      [
        "T10",
        "地点范围",
        95,
        97,
        "全球"
      ],
      [
        "T11",
        "行业",
        97,
        99,
        "医药"
      ],
      [
        "T12",
        "营业收入",
        101,
        103,
        "收入"
      ],
      [
        "T13",
        "属性值",
        107,
        116,
        "17.11千亿美元"
      ],
      [
        "T14",
        "时间范围",
        118,
        129,
        "2021年-2025年"
      ],
      [
        "T15",
        "CAGR",
        131,
        138,
        "年均复合增长率"
      ],
      [
        "T16",
        "属性值",
        140,
        144,
        "5.3%"
      ],
      [
        "T17",
        "时间范围",
        148,
        153,
        "2021年"
      ],
      [
        "T18",
        "地点范围",
        153,
        155,
        "全球"
      ],
      [
        "T19",
        "行业",
        155,
        158,
        "创新药"
      ],
      [
        "T20",
        "营业收入",
        160,
        162,
        "收入"
      ],
      [
        "T21",
        "属性值",
        166,
        174,
        "9.61千亿美元"
      ],
      [
        "T22",
        "时间范围",
        176,
        187,
        "2016年-2021年"
      ],
      [
        "T23",
        "CAGR",
        187,
        194,
        "年均复合增长率"
      ],
      [
        "T24",
        "属性值",
        196,
        200,
        "3.8%"
      ],
      [
        "T25",
        "行业",
        203,
        206,
        "创新药"
      ],
      [
        "T26",
        "地点范围",
        201,
        203,
        "全球"
      ],
      [
        "T27",
        "时间范围",
        215,
        220,
        "2025年"
      ],
      [
        "T28",
        "时间范围",
        237,
        248,
        "2021年-2015年"
      ],
      [
        "T29",
        "CAGR",
        250,
        257,
        "年均复合增长率"
      ],
      [
        "T30",
        "属性值",
        259,
        263,
        "6.1%"
      ],
      [
        "T31",
        "营业收入",
        208,
        210,
        "收入"
      ],
      [
        "T32",
        "属性值",
        8,
        12,
        "稳定增长"
      ],
      [
        "T33",
        "属性值",
        82,
        86,
        "3.9%"
      ],
      [
        "T34",
        "属性值",
        223,
        232,
        "12.17千亿美元"
      ]
    ]
  },
  {
    "id": 520,
    "text": "中国 CXO企业在 2021年存货水平与上年相比有显著提升。药明康德截至 2021年 9月 30日存货为 45.2 亿人民币，同比增长 91%。凯莱英截至 2021年 9月 30日存货为 10.08亿人民币，同比增长 61%。康龙化成截至 2021年 9月 30日存货为 5.7亿人民币，同比增长 121%。博腾股份截至 2021年 9月 30日存货水平达到 26.3亿人民币，同比增长 55%。中国 CRO龙头企业昭衍新药截至 2021年 9月 30日存货为 6.9亿人民币，同比增长 101%。",
    "labels": [
      [
        "T0",
        "地点范围",
        0,
        2,
        "中国"
      ],
      [
        "T1",
        "行业公司",
        3,
        8,
        "CXO企业"
      ],
      [
        "T2",
        "时间范围",
        10,
        15,
        "2021年"
      ],
      [
        "T3",
        "属性值",
        19,
        29,
        "与上年相比有显著提升"
      ],
      [
        "T4",
        "公司",
        30,
        34,
        "药明康德"
      ],
      [
        "T5",
        "时间范围",
        34,
        49,
        "截至 2021年 9月 30日"
      ],
      [
        "T6",
        "存货",
        49,
        51,
        "存货"
      ],
      [
        "T7",
        "公司",
        72,
        75,
        "凯莱英"
      ],
      [
        "T8",
        "时间范围",
        75,
        90,
        "截至 2021年 9月 30日"
      ],
      [
        "T9",
        "存货",
        90,
        92,
        "存货"
      ],
      [
        "T10",
        "公司",
        113,
        117,
        "康龙化成"
      ],
      [
        "T11",
        "时间范围",
        117,
        132,
        "截至 2021年 9月 30日"
      ],
      [
        "T12",
        "存货",
        132,
        134,
        "存货"
      ],
      [
        "T13",
        "公司",
        154,
        158,
        "博腾股份"
      ],
      [
        "T14",
        "时间范围",
        158,
        173,
        "截至 2021年 9月 30日"
      ],
      [
        "T15",
        "存货",
        173,
        175,
        "存货"
      ],
      [
        "T16",
        "地点范围",
        198,
        200,
        "中国"
      ],
      [
        "T17",
        "行业",
        201,
        204,
        "CRO"
      ],
      [
        "T18",
        "龙头企业",
        204,
        208,
        "龙头企业"
      ],
      [
        "T19",
        "公司",
        208,
        212,
        "昭衍新药"
      ],
      [
        "T20",
        "时间范围",
        212,
        226,
        "截至 2021年 9月 30"
      ],
      [
        "T21",
        "存货",
        227,
        229,
        "存货"
      ],
      [
        "T22",
        "存货",
        15,
        17,
        "存货"
      ],
      [
        "T23",
        "属性值",
        53,
        71,
        "45.2 亿人民币，同比增长 91%"
      ],
      [
        "T24",
        "属性值",
        94,
        112,
        "10.08亿人民币，同比增长 61%"
      ],
      [
        "T25",
        "属性值",
        180,
        197,
        "26.3亿人民币，同比增长 55%"
      ],
      [
        "T26",
        "属性值",
        136,
        153,
        "5.7亿人民币，同比增长 121%"
      ],
      [
        "T27",
        "属性值",
        231,
        248,
        "6.9亿人民币，同比增长 101%"
      ]
    ]
  },
  {
    "id": 521,
    "text": "在团队建设方面，龙头 CXO公司持续进行人才引入与团队建设，康龙化成截至 2021H1期末员工人数同比增长高达 40%；美迪西截至 2021H1期末员工人数同比增长超过 30%；药明康德、凯莱英与昭衍新药截至 2021H1期末员工人数同比增长均超过 20%。 药明康德截至 2021H1期末公司共拥有 28,542名员工，同比增长 25%，相比上年年末团队人数增加 8%。 公司团队中 9,179名获得硕士或以上学位，1,149名获得博士或同等学位，获得硕士或以上学位人数占比为 32.2%，博士或同等学位人员占比 4%。 凯莱英 2021年 H1共引进博士人才 31人，硕士人才 165人。公司截至 2021年 6月 30日拥有员工超过 5,600人，同比增长 23%，其中研发及分析人员超过 2,600人。 博腾股份截至 2021H1期末公司全球团队已发展至 3,054人，较 2020年底增加 419人，较 2020年同期末增加 681人，同比增长 29%。公司团队中研发技术人员规模从 2020年底的 714人增加至 909人，研发技术人员占比已达 30%。 昭衍新药人员规模稳定增长，截至 2021年 H1期末公司已形成了近 1600人的规模化人才队伍，可以同时开展近千个试验项目。2021年 H1期间公司人才团队扩容 100人左右，团队人数同比增长 23%。",
    "labels": [
      [
        "T0",
        "龙头企业",
        8,
        10,
        "龙头"
      ],
      [
        "T1",
        "行业公司",
        11,
        16,
        "CXO公司"
      ],
      [
        "T2",
        "公司",
        30,
        34,
        "康龙化成"
      ],
      [
        "T3",
        "员工数量",
        45,
        49,
        "员工人数"
      ],
      [
        "T4",
        "公司",
        60,
        63,
        "美迪西"
      ],
      [
        "T5",
        "员工数量",
        74,
        78,
        "员工人数"
      ],
      [
        "T6",
        "公司",
        89,
        93,
        "药明康德"
      ],
      [
        "T7",
        "公司",
        94,
        97,
        "凯莱英"
      ],
      [
        "T8",
        "公司",
        98,
        102,
        "昭衍新药"
      ],
      [
        "T9",
        "员工数量",
        113,
        117,
        "员工人数"
      ],
      [
        "T10",
        "公司",
        130,
        134,
        "药明康德"
      ],
      [
        "T11",
        "员工数量",
        176,
        180,
        "团队人数"
      ],
      [
        "T12",
        "公司",
        262,
        265,
        "凯莱英"
      ],
      [
        "T13",
        "时间范围",
        298,
        313,
        "截至 2021年 6月 30日"
      ],
      [
        "T14",
        "员工数量",
        315,
        317,
        "员工"
      ],
      [
        "T15",
        "公司",
        356,
        360,
        "博腾股份"
      ],
      [
        "T16",
        "时间范围",
        34,
        45,
        "截至 2021H1期末"
      ],
      [
        "T17",
        "属性值",
        49,
        59,
        "同比增长高达 40%"
      ],
      [
        "T18",
        "时间范围",
        63,
        74,
        "截至 2021H1期末"
      ],
      [
        "T19",
        "属性值",
        78,
        88,
        "同比增长超过 30%"
      ],
      [
        "T20",
        "时间范围",
        102,
        113,
        "截至 2021H1期末"
      ],
      [
        "T21",
        "属性值",
        117,
        128,
        "同比增长均超过 20%"
      ],
      [
        "T22",
        "时间范围",
        134,
        145,
        "截至 2021H1期末"
      ],
      [
        "T23",
        "属性值",
        151,
        169,
        "28,542名员工，同比增长 25%"
      ],
      [
        "T24",
        "属性值",
        180,
        185,
        "增加 8%"
      ],
      [
        "T25",
        "时间范围",
        266,
        274,
        "2021年 H1"
      ],
      [
        "T26",
        "属性值",
        317,
        335,
        "超过 5,600人，同比增长 23%"
      ],
      [
        "T27",
        "时间范围",
        360,
        371,
        "截至 2021H1期末"
      ],
      [
        "T28",
        "地点范围",
        373,
        375,
        "全球"
      ],
      [
        "T29",
        "公司",
        484,
        488,
        "昭衍新药"
      ],
      [
        "T30",
        "属性值",
        492,
        496,
        "稳定增长"
      ],
      [
        "T31",
        "员工数量",
        488,
        492,
        "人员规模"
      ],
      [
        "T32",
        "时间范围",
        497,
        510,
        "截至 2021年 H1期末"
      ],
      [
        "T33",
        "属性值",
        516,
        523,
        "近 1600人"
      ],
      [
        "T34",
        "时间范围",
        546,
        556,
        "2021年 H1期间"
      ],
      [
        "T35",
        "属性值",
        562,
        571,
        "扩容 100人左右"
      ],
      [
        "T36",
        "属性值",
        576,
        584,
        "同比增长 23%"
      ],
      [
        "T37",
        "时间范围",
        172,
        176,
        "上年年末"
      ],
      [
        "T38",
        "属性值",
        382,
        388,
        "3,054人"
      ],
      [
        "T39",
        "属性值",
        397,
        404,
        "增加 419人"
      ],
      [
        "T40",
        "属性值",
        415,
        422,
        "增加 681人"
      ],
      [
        "T41",
        "属性值",
        423,
        431,
        "同比增长 29%"
      ],
      [
        "T42",
        "时间范围",
        391,
        397,
        "2020年底"
      ],
      [
        "T43",
        "时间范围",
        407,
        412,
        "2020年"
      ]
    ]
  },
  {
    "id": 522,
    "text": "在上次周报中我们提到，CXO两条投资主线下市场对需求端的过度担忧及对供给端能力升级的忽视是最大的预期差。从技术能力上药明康德、凯莱英、博腾股份等公司在连续流、酶催化、结晶等产学研能力闭环中不断升级，结合工程师红利及成本优势，在全球产业链中地位不断攀升。",
    "labels": [
      [
        "T0",
        "行业",
        11,
        14,
        "CXO"
      ],
      [
        "T1",
        "行业需求",
        24,
        27,
        "需求端"
      ],
      [
        "T2",
        "行业供给",
        34,
        37,
        "供给端"
      ],
      [
        "T3",
        "公司",
        58,
        62,
        "药明康德"
      ],
      [
        "T4",
        "公司",
        63,
        66,
        "凯莱英"
      ],
      [
        "T5",
        "公司",
        67,
        71,
        "博腾股份"
      ],
      [
        "T6",
        "地点范围",
        113,
        115,
        "全球"
      ]
    ]
  },
  {
    "id": 523,
    "text": "强调供给端能力的提升对前端CRO的量价齐升及后端CDMO在全球参与度的增强。我们重点推荐关注：泰格医药、 2 药明康德、昭衍新药、凯莱英、康龙化成、九洲药业、博腾股份、方达控股、药石科技、美迪西等。",
    "labels": [
      [
        "T0",
        "行业",
        13,
        16,
        "CRO"
      ],
      [
        "T1",
        "行业",
        24,
        28,
        "CDMO"
      ],
      [
        "T2",
        "公司",
        47,
        51,
        "泰格医药"
      ],
      [
        "T3",
        "公司",
        55,
        59,
        "药明康德"
      ],
      [
        "T4",
        "公司",
        60,
        64,
        "昭衍新药"
      ],
      [
        "T5",
        "公司",
        65,
        68,
        "凯莱英"
      ],
      [
        "T6",
        "公司",
        69,
        73,
        "康龙化成"
      ],
      [
        "T7",
        "公司",
        74,
        78,
        "九洲药业"
      ],
      [
        "T8",
        "公司",
        79,
        83,
        "博腾股份"
      ],
      [
        "T9",
        "公司",
        84,
        88,
        "方达控股"
      ],
      [
        "T10",
        "公司",
        89,
        93,
        "药石科技"
      ],
      [
        "T11",
        "公司",
        94,
        97,
        "美迪西"
      ],
      [
        "T12",
        "行业供给",
        2,
        5,
        "供给端"
      ],
      [
        "T13",
        "地点范围",
        29,
        31,
        "全球"
      ]
    ]
  },
  {
    "id": 525,
    "text": "中国 CXO行业在收入达到一定规模后，整体 CXO行业预期将进入分化阶段。根据 Frost&Sullivan数据，中国 CDMO收入在 2024年和 2025年预期增长速度为 28.6%和 26.1%，化学药 CDMO服务市场收入在 2024年和 2025年预期增长速度为 25.8%和 23.5%，生物药 CDMO服务市场收入在 2024年和 2025 年预期增长速度为 34.1%和 30.9%。中国 CRO市场收入在 2024年预期增长速度为 30.6%，其中药物发现、临床前研究和临床研究三部分在 2024年的预期增长速度分别为 26.5%，17.7%和 34.3%。 行业投资预期将进入“精挑细选”时期，需要挑选拥有核心竞争力的 CXO企业进行投资。拥有核心技术的龙头公司有望凭借优势承接更多订单，而行业内竞争力较低的公司会面临整体增速降低的问题。",
    "labels": [
      [
        "T0",
        "地点范围",
        0,
        2,
        "中国"
      ],
      [
        "T1",
        "行业",
        3,
        6,
        "CXO"
      ],
      [
        "T2",
        "行业",
        22,
        25,
        "CXO"
      ],
      [
        "T3",
        "地点范围",
        57,
        59,
        "中国"
      ],
      [
        "T4",
        "行业",
        60,
        64,
        "CDMO"
      ],
      [
        "T5",
        "时间范围",
        68,
        73,
        "2024年"
      ],
      [
        "T6",
        "行业",
        101,
        111,
        "化学药 CDMO服务"
      ],
      [
        "T7",
        "时间范围",
        117,
        122,
        "2024年"
      ],
      [
        "T8",
        "时间范围",
        124,
        129,
        "2025年"
      ],
      [
        "T9",
        "行业",
        150,
        160,
        "生物药 CDMO服务"
      ],
      [
        "T10",
        "时间范围",
        166,
        171,
        "2024年"
      ],
      [
        "T11",
        "时间范围",
        173,
        179,
        "2025 年"
      ],
      [
        "T12",
        "行业",
        203,
        206,
        "CRO"
      ],
      [
        "T13",
        "时间范围",
        253,
        258,
        "2024年"
      ],
      [
        "T14",
        "行业公司",
        320,
        325,
        "CXO企业"
      ],
      [
        "T15",
        "龙头企业",
        337,
        341,
        "龙头公司"
      ],
      [
        "T16",
        "营业收入",
        9,
        11,
        "收入"
      ],
      [
        "T17",
        "营业收入",
        64,
        66,
        "收入"
      ],
      [
        "T18",
        "时间范围",
        75,
        80,
        "2025年"
      ],
      [
        "T19",
        "属性值",
        88,
        93,
        "28.6%"
      ],
      [
        "T20",
        "属性值",
        95,
        100,
        "26.1%"
      ],
      [
        "T21",
        "营业收入",
        113,
        115,
        "收入"
      ],
      [
        "T22",
        "属性值",
        137,
        142,
        "25.8%"
      ],
      [
        "T23",
        "属性值",
        144,
        149,
        "23.5%"
      ],
      [
        "T24",
        "营业收入",
        162,
        164,
        "收入"
      ],
      [
        "T25",
        "属性值",
        187,
        192,
        "34.1%"
      ],
      [
        "T26",
        "属性值",
        194,
        199,
        "30.9%"
      ],
      [
        "T27",
        "地点范围",
        200,
        202,
        "中国"
      ],
      [
        "T28",
        "营业收入",
        208,
        210,
        "收入"
      ],
      [
        "T29",
        "时间范围",
        212,
        217,
        "2024年"
      ],
      [
        "T30",
        "属性值",
        225,
        230,
        "30.6%"
      ],
      [
        "T31",
        "行业",
        233,
        237,
        "药物发现"
      ],
      [
        "T32",
        "行业",
        238,
        243,
        "临床前研究"
      ],
      [
        "T33",
        "行业",
        244,
        248,
        "临床研究"
      ],
      [
        "T34",
        "属性值",
        269,
        274,
        "26.5%"
      ],
      [
        "T35",
        "属性值",
        275,
        280,
        "17.7%"
      ],
      [
        "T36",
        "属性值",
        282,
        287,
        "34.3%"
      ]
    ]
  },
  {
    "id": 526,
    "text": " CXO：创新药投融资高速增长，CXO行业持续高景气  生命科学服务：证券化加速，产业链各环节都有了上市公司  原料药：中期提价周期开启，长期CDMO转型可期  制药装备：延续高景气度，关注估值性价比高的个股",
    "labels": [
      [
        "T0",
        "行业",
        2,
        5,
        "CXO"
      ],
      [
        "T1",
        "行业",
        6,
        9,
        "创新药"
      ],
      [
        "T2",
        "投融资情况",
        9,
        12,
        "投融资"
      ],
      [
        "T3",
        "属性值",
        12,
        16,
        "高速增长"
      ],
      [
        "T4",
        "行业",
        17,
        20,
        "CXO"
      ],
      [
        "T5",
        "行业",
        30,
        34,
        "生命科学"
      ],
      [
        "T6",
        "行业",
        59,
        62,
        "原料药"
      ],
      [
        "T7",
        "行业",
        85,
        87,
        "制药"
      ],
      [
        "T8",
        "行业",
        74,
        78,
        "CDMO"
      ],
      [
        "T9",
        "时间范围",
        72,
        74,
        "长期"
      ],
      [
        "T10",
        "时间范围",
        63,
        65,
        "中期"
      ]
    ]
  },
  {
    "id": 528,
    "text": " 上半年器械板块（45家样本，不含科创板）收入实现正增长的有34家， 占比76%，超过50%增长有14家，占比31%；  上半年器械板块（45家样本，不含科创板）归母净利润实现正增长的有 31家，占比69%，超过50%增长有18家，占比40%；  从收入贡献看，前五名迈瑞、英科、乐普、华大、鱼跃贡献了48.8%的板块收入；  从归母净利润贡献看，前五名英科、迈瑞、乐普、达安、华大贡献了 63.4%的板块净利润。",
    "labels": [
      [
        "T0",
        "行业",
        5,
        7,
        "器械"
      ],
      [
        "T1",
        "营业收入",
        22,
        24,
        "收入"
      ],
      [
        "T2",
        "行业",
        66,
        68,
        "器械"
      ],
      [
        "T3",
        "归母净利润",
        83,
        88,
        "归母净利润"
      ],
      [
        "T4",
        "营业收入",
        128,
        130,
        "收入"
      ],
      [
        "T5",
        "公司",
        137,
        139,
        "迈瑞"
      ],
      [
        "T6",
        "公司",
        140,
        142,
        "英科"
      ],
      [
        "T7",
        "公司",
        143,
        145,
        "乐普"
      ],
      [
        "T8",
        "公司",
        146,
        148,
        "华大"
      ],
      [
        "T9",
        "公司",
        149,
        151,
        "鱼跃"
      ],
      [
        "T10",
        "归母净利润",
        169,
        174,
        "归母净利润"
      ],
      [
        "T11",
        "公司",
        181,
        183,
        "英科"
      ],
      [
        "T12",
        "公司",
        184,
        186,
        "迈瑞"
      ],
      [
        "T13",
        "公司",
        187,
        189,
        "乐普"
      ],
      [
        "T14",
        "公司",
        190,
        192,
        "达安"
      ],
      [
        "T15",
        "公司",
        193,
        195,
        "华大"
      ],
      [
        "T16",
        "归母净利润",
        207,
        210,
        "净利润"
      ],
      [
        "T17",
        "时间范围",
        2,
        5,
        "上半年"
      ],
      [
        "T18",
        "时间范围",
        63,
        66,
        "上半年"
      ]
    ]
  },
  {
    "id": 529,
    "text": "• 新药研发的投资回报率从2010年的10.1%下降至2020年的2.5%； • 新上市药物的研发成本从2010年的11.9亿美元上升至2020年的25.1亿美元；",
    "labels": [
      [
        "T0",
        "时间范围",
        52,
        57,
        "2010年"
      ],
      [
        "T1",
        "时间范围",
        68,
        73,
        "2020年"
      ],
      [
        "T2",
        "行业",
        2,
        6,
        "新药研发"
      ],
      [
        "T3",
        "时间范围",
        13,
        18,
        "2010年"
      ],
      [
        "T4",
        "时间范围",
        27,
        32,
        "2020年"
      ]
    ]
  },
  {
    "id": 530,
    "text": " 季度波动较大，21Q1-3板块业绩同比略有下滑。原料药板块2021Q1-3同比增长14.2%，归母净利润下降0.4%；单三季度收入、归母净利分别为250亿元、37亿元，分别同比+14.5%、-2.6%。",
    "labels": [
      [
        "T0",
        "时间范围",
        9,
        15,
        "21Q1-3"
      ],
      [
        "T1",
        "业绩",
        17,
        19,
        "业绩"
      ],
      [
        "T2",
        "行业",
        26,
        29,
        "原料药"
      ],
      [
        "T3",
        "时间范围",
        31,
        39,
        "2021Q1-3"
      ],
      [
        "T4",
        "归母净利润",
        49,
        54,
        "归母净利润"
      ],
      [
        "T5",
        "属性值",
        54,
        60,
        "下降0.4%"
      ],
      [
        "T6",
        "营业收入",
        65,
        67,
        "收入"
      ],
      [
        "T7",
        "归母净利润",
        68,
        72,
        "归母净利"
      ],
      [
        "T8",
        "属性值",
        75,
        80,
        "250亿元"
      ],
      [
        "T9",
        "属性值",
        81,
        85,
        "37亿元"
      ],
      [
        "T10",
        "属性值",
        90,
        96,
        "+14.5%"
      ],
      [
        "T11",
        "时间范围",
        62,
        65,
        "三季度"
      ]
    ]
  },
  {
    "id": 531,
    "text": " 2019年影像设备超过1000亿，以X线类、CT、 超声、MRI设备为主；供给端看，影像的技术壁垒较高，国产和海外厂商差距较大，当前市场主要由GPS占据绝大份额，国产化率低；需求端看，受采购政策和采购周期影响较大，从人均保有量看离发达国家有5-10倍的差距，未来市场有望持续增长。  目前X射线、超声领域国产有望凭技术积累率先突围，后续CT、MRI也有望逐步突破。关注万东、东软、迈瑞、联影等企业。  万东医疗：2021上半年收入下降1.6%，归母净利润下降20.9%，主要因移动DR销售数量与去年上半年相比有较大幅度的降低。  迈瑞医疗：公司影像业务上半年同比增长26.9% ，主要因国内外台式彩超需求恢复。",
    "labels": [
      [
        "T0",
        "时间范围",
        2,
        7,
        "2019年"
      ],
      [
        "T1",
        "行业",
        7,
        11,
        "影像设备"
      ],
      [
        "T2",
        "行业供给",
        39,
        42,
        "供给端"
      ],
      [
        "T3",
        "市场份额",
        80,
        82,
        "份额"
      ],
      [
        "T4",
        "行业需求",
        89,
        92,
        "需求端"
      ],
      [
        "T5",
        "行业",
        147,
        150,
        "X射线"
      ],
      [
        "T6",
        "行业",
        20,
        23,
        "X线类"
      ],
      [
        "T7",
        "行业",
        24,
        26,
        "CT"
      ],
      [
        "T8",
        "行业",
        28,
        30,
        "超声"
      ],
      [
        "T9",
        "行业",
        31,
        34,
        "MRI"
      ],
      [
        "T10",
        "行业",
        73,
        76,
        "GPS"
      ],
      [
        "T11",
        "行业",
        151,
        153,
        "超声"
      ],
      [
        "T12",
        "行业",
        171,
        173,
        "CT"
      ],
      [
        "T13",
        "行业",
        174,
        177,
        "MRI"
      ],
      [
        "T14",
        "公司",
        187,
        189,
        "万东"
      ],
      [
        "T15",
        "公司",
        190,
        192,
        "东软"
      ],
      [
        "T16",
        "公司",
        193,
        195,
        "迈瑞"
      ],
      [
        "T17",
        "公司",
        196,
        198,
        "联影"
      ],
      [
        "T18",
        "公司",
        205,
        209,
        "万东医疗"
      ],
      [
        "T19",
        "时间范围",
        210,
        217,
        "2021上半年"
      ],
      [
        "T20",
        "营业收入",
        217,
        219,
        "收入"
      ],
      [
        "T21",
        "属性值",
        219,
        225,
        "下降1.6%"
      ],
      [
        "T22",
        "归母净利润",
        226,
        231,
        "归母净利润"
      ],
      [
        "T23",
        "属性值",
        231,
        238,
        "下降20.9%"
      ],
      [
        "T24",
        "公司",
        270,
        274,
        "迈瑞医疗"
      ],
      [
        "T25",
        "行业需求",
        305,
        307,
        "需求"
      ],
      [
        "T26",
        "行业",
        301,
        305,
        "台式彩超"
      ],
      [
        "T27",
        "时间范围",
        66,
        68,
        "当前"
      ],
      [
        "T28",
        "时间范围",
        145,
        147,
        "目前"
      ],
      [
        "T29",
        "行业",
        277,
        279,
        "影像"
      ],
      [
        "T30",
        "时间范围",
        281,
        284,
        "上半年"
      ],
      [
        "T31",
        "属性值",
        284,
        293,
        "同比增长26.9%"
      ],
      [
        "T32",
        "地点范围",
        298,
        301,
        "国内外"
      ],
      [
        "T33",
        "属性值",
        307,
        309,
        "恢复"
      ]
    ]
  },
  {
    "id": 532,
    "text": " CXO板块(10家)： CXO公司2021年上半年收入总额为229亿元，同比增速为45.6%，归母净利润总额为60亿元，同比增速为49.7%，Q2收入同比增长37.7%，龙头药明康德上半年收入占板块超过46%，净利润占比超过45%，带动行业稳健增长。  疫苗（6家）：上半年疫苗板块实现收入237亿元，同比+54.2%，归母净利润71亿元，同比+201.5%；从分公司占比看，智飞上半年收入占整个板块的55.6%，归母净利润占比77.1%。智飞为板块收入、利润的主要贡献者。  医疗服务（4家）：上半年收入185亿元，同比+63%，归母净利润总额27亿元，同比+84%。去年Q1受疫情影响，医疗服务板块业绩基数较低，预计下半年行业将重回正常增长轨道。  医疗器械（45家）：上半年收入762亿元（+29.3%），归母净利润231亿元（+37.1%），前五名英科、迈瑞、乐普、达安、华大贡献了 63.4%的板块净利润。Q1/Q2/单季度收入增速分别为+94.9%/-4.6%,单季度净利润+196.7%/-13.6%）,抗疫需求仍然支撑着器械板块业绩的高水位运行。",
    "labels": [
      [
        "T0",
        "行业",
        2,
        5,
        "CXO"
      ],
      [
        "T1",
        "行业公司",
        14,
        19,
        "CXO公司"
      ],
      [
        "T2",
        "时间范围",
        19,
        27,
        "2021年上半年"
      ],
      [
        "T3",
        "营业收入",
        27,
        29,
        "收入"
      ],
      [
        "T4",
        "归母净利润",
        49,
        54,
        "归母净利润"
      ],
      [
        "T5",
        "归母净利润增速",
        64,
        66,
        "增速"
      ],
      [
        "T6",
        "时间范围",
        73,
        75,
        "Q2"
      ],
      [
        "T7",
        "营业收入",
        75,
        77,
        "收入"
      ],
      [
        "T8",
        "龙头企业",
        87,
        89,
        "龙头"
      ],
      [
        "T9",
        "公司",
        89,
        93,
        "药明康德"
      ],
      [
        "T10",
        "时间范围",
        93,
        96,
        "上半年"
      ],
      [
        "T11",
        "营收占比",
        96,
        98,
        "收入"
      ],
      [
        "T12",
        "归母净利润",
        107,
        110,
        "净利润"
      ],
      [
        "T13",
        "行业",
        130,
        132,
        "疫苗"
      ],
      [
        "T14",
        "行业",
        140,
        142,
        "疫苗"
      ],
      [
        "T15",
        "时间范围",
        137,
        140,
        "上半年"
      ],
      [
        "T16",
        "营业收入",
        146,
        148,
        "收入"
      ],
      [
        "T17",
        "归母净利润",
        163,
        168,
        "归母净利润"
      ],
      [
        "T18",
        "公司",
        191,
        193,
        "智飞"
      ],
      [
        "T19",
        "时间范围",
        193,
        196,
        "上半年"
      ],
      [
        "T20",
        "营收占比",
        196,
        198,
        "收入"
      ],
      [
        "T21",
        "归母净利润",
        210,
        215,
        "归母净利润"
      ],
      [
        "T22",
        "公司",
        223,
        225,
        "智飞"
      ],
      [
        "T23",
        "利润",
        231,
        233,
        "利润"
      ],
      [
        "T24",
        "营业收入",
        228,
        230,
        "收入"
      ],
      [
        "T25",
        "行业",
        243,
        247,
        "医疗服务"
      ],
      [
        "T26",
        "时间范围",
        252,
        255,
        "上半年"
      ],
      [
        "T27",
        "营业收入",
        255,
        257,
        "收入"
      ],
      [
        "T28",
        "归母净利润",
        270,
        275,
        "归母净利润"
      ],
      [
        "T29",
        "行业",
        299,
        303,
        "医疗服务"
      ],
      [
        "T30",
        "业绩",
        305,
        307,
        "业绩"
      ],
      [
        "T31",
        "属性值",
        307,
        311,
        "基数较低"
      ],
      [
        "T32",
        "时间范围",
        314,
        317,
        "下半年"
      ],
      [
        "T33",
        "行业",
        332,
        336,
        "医疗器械"
      ],
      [
        "T34",
        "时间范围",
        342,
        345,
        "上半年"
      ],
      [
        "T35",
        "营业收入",
        345,
        347,
        "收入"
      ],
      [
        "T36",
        "归母净利润",
        361,
        366,
        "归母净利润"
      ],
      [
        "T37",
        "公司",
        383,
        385,
        "英科"
      ],
      [
        "T38",
        "公司",
        386,
        388,
        "迈瑞"
      ],
      [
        "T39",
        "公司",
        389,
        391,
        "乐普"
      ],
      [
        "T40",
        "公司",
        392,
        394,
        "达安"
      ],
      [
        "T41",
        "公司",
        395,
        397,
        "华大"
      ],
      [
        "T42",
        "归母净利润",
        409,
        412,
        "净利润"
      ],
      [
        "T43",
        "收入增速",
        422,
        426,
        "收入增速"
      ],
      [
        "T44",
        "归母净利润",
        445,
        448,
        "净利润"
      ],
      [
        "T45",
        "属性值",
        32,
        37,
        "229亿元"
      ],
      [
        "T46",
        "属性值",
        43,
        48,
        "45.6%"
      ],
      [
        "T47",
        "属性值",
        57,
        61,
        "60亿元"
      ],
      [
        "T48",
        "属性值",
        67,
        72,
        "49.7%"
      ],
      [
        "T49",
        "属性值",
        81,
        86,
        "37.7%"
      ],
      [
        "T50",
        "属性值",
        101,
        106,
        "超过46%"
      ],
      [
        "T51",
        "属性值",
        110,
        117,
        "占比超过45%"
      ],
      [
        "T52",
        "属性值",
        148,
        153,
        "237亿元"
      ],
      [
        "T53",
        "属性值",
        156,
        162,
        "+54.2%"
      ],
      [
        "T54",
        "属性值",
        168,
        182,
        "71亿元，同比+201.5%"
      ],
      [
        "T55",
        "属性值",
        204,
        209,
        "55.6%"
      ],
      [
        "T56",
        "属性值",
        215,
        222,
        "占比77.1%"
      ],
      [
        "T57",
        "属性值",
        257,
        262,
        "185亿元"
      ],
      [
        "T58",
        "属性值",
        265,
        269,
        "+63%"
      ],
      [
        "T59",
        "属性值",
        277,
        288,
        "27亿元，同比+84%"
      ],
      [
        "T60",
        "时间范围",
        289,
        293,
        "去年Q1"
      ],
      [
        "T61",
        "属性值",
        347,
        352,
        "762亿元"
      ],
      [
        "T62",
        "属性值",
        353,
        359,
        "+29.3%"
      ],
      [
        "T63",
        "属性值",
        366,
        379,
        "231亿元（+37.1%）"
      ],
      [
        "T64",
        "行业",
        473,
        475,
        "器械"
      ],
      [
        "T65",
        "业绩",
        477,
        479,
        "业绩"
      ],
      [
        "T66",
        "属性值",
        480,
        485,
        "高水位运行"
      ]
    ]
  },
  {
    "id": 533,
    "text": "博腾股份在生物 CDMO服务方面目前已已搭建质粒 CDMO平台、病毒载体 CDMO平台与细胞治疗 CDMO平台。公司基因细胞治疗 CDMO服务主要由二级控股子公司苏州博腾承接，2020年苏州博腾位于苏州腾飞创新园的研发中心及临床生产基地已投入使用。2021年上半年，苏州博腾在品牌推广、 市场开拓、硬件设施建设、技术平台能力建设、项目交付、团队扩充等方面持续开展各项工作，获得 9个新项目订单，涉及金额约 5.47千万人民币。2021年 5月，苏州博腾与南凯地生物达成战略合作，苏州博腾将作为独家 CDMO合作伙伴为凯地生物提供多个 CAR-T项目的 CMC研究开发服务，包括质粒、病毒载体和 CAR-T细胞的工艺开发与生产及 CMC部分的 IND注册申报支持等服务。",
    "labels": [
      [
        "T0",
        "公司",
        0,
        4,
        "博腾股份"
      ],
      [
        "T1",
        "公司",
        81,
        85,
        "苏州博腾"
      ],
      [
        "T2",
        "时间范围",
        88,
        93,
        "2020年"
      ],
      [
        "T3",
        "公司",
        93,
        97,
        "苏州博腾"
      ],
      [
        "T4",
        "时间范围",
        124,
        132,
        "2021年上半年"
      ],
      [
        "T5",
        "公司",
        133,
        137,
        "苏州博腾"
      ],
      [
        "T6",
        "新签订单",
        194,
        196,
        "订单"
      ],
      [
        "T7",
        "属性值",
        189,
        191,
        "9个"
      ],
      [
        "T8",
        "时间范围",
        213,
        221,
        "2021年 5月"
      ],
      [
        "T9",
        "公司",
        222,
        226,
        "苏州博腾"
      ],
      [
        "T10",
        "公司",
        227,
        232,
        "南凯地生物"
      ],
      [
        "T11",
        "公司",
        239,
        243,
        "苏州博腾"
      ],
      [
        "T12",
        "公司",
        258,
        262,
        "凯地生物"
      ],
      [
        "T13",
        "行业",
        5,
        14,
        "生物 CDMO服务"
      ],
      [
        "T14",
        "行业",
        58,
        71,
        "基因细胞治疗 CDMO服务"
      ],
      [
        "T15",
        "属性值",
        201,
        212,
        "约 5.47千万人民币"
      ]
    ]
  },
  {
    "id": 536,
    "text": "创新型高耗赛道长期成长性逻辑不变。根据沙利文、产业信息网、前瞻产业研究院、公司公告等信息来源，我国介入性术式渗透率仍然较低，其中：主动脉夹层、主动脉瘤手术渗透率<2%，PCI手术开展率≈美国的20%，胃镜、肠镜开展率<发达国家的10%，外周介入渗透率约为0.2%（不及美国同比率的4%）…渗透率的提升有望持续驱动有关介入类高值耗材厂商成长。",
    "labels": [
      [
        "T0",
        "行业",
        1,
        6,
        "创新型高耗"
      ],
      [
        "T1",
        "时间范围",
        8,
        10,
        "长期"
      ],
      [
        "T2",
        "地点范围",
        48,
        50,
        "我国"
      ],
      [
        "T3",
        "行业",
        50,
        55,
        "介入性术式"
      ],
      [
        "T4",
        "行业公司",
        159,
        168,
        "介入类高值耗材厂商"
      ]
    ]
  },
  {
    "id": 540,
    "text": "Catalent为全球龙头 CDMO企业，公司营业收入在 2012财年至 2017财年之间由 16.9亿美元增长至 20.8 亿美元。公司传统化学小分子业务相对成熟，且公司整体收入规模高，增速相对缓慢。（注：Catalent 原始财报财年为前一自然年 7月初至次年 6月底）",
    "labels": [
      [
        "T0",
        "公司",
        0,
        8,
        "Catalent"
      ],
      [
        "T1",
        "地点范围",
        9,
        11,
        "全球"
      ],
      [
        "T2",
        "龙头企业",
        11,
        13,
        "龙头"
      ],
      [
        "T3",
        "行业",
        14,
        18,
        "CDMO"
      ],
      [
        "T4",
        "营业收入",
        23,
        27,
        "营业收入"
      ],
      [
        "T5",
        "时间范围",
        29,
        35,
        "2012财年"
      ],
      [
        "T6",
        "时间范围",
        37,
        43,
        "2017财年"
      ],
      [
        "T7",
        "属性值",
        47,
        54,
        "16.9亿美元"
      ],
      [
        "T8",
        "属性值",
        58,
        66,
        "20.8 亿美元"
      ],
      [
        "T9",
        "行业",
        71,
        76,
        "化学小分子"
      ],
      [
        "T10",
        "营业收入",
        88,
        90,
        "收入"
      ],
      [
        "T11",
        "属性值",
        96,
        100,
        "相对缓慢"
      ],
      [
        "T12",
        "公司",
        104,
        112,
        "Catalent"
      ],
      [
        "T13",
        "属性值",
        90,
        93,
        "规模高"
      ]
    ]
  },
  {
    "id": 541,
    "text": " 下游医疗服务等出现质量问题；",
    "labels": [
      [
        "T0",
        "行业",
        4,
        8,
        "医疗服务"
      ]
    ]
  },
  {
    "id": 542,
    "text": " 血制品（6家）：上半年收入总额增速为13.5%，归母净利润总额增速为19.8%；其中单二季度收入增速为22.2%，归母净利润增速为19.2%，二季度板块收入增速提升明显。21Q2板块毛利率略降低1.5pp，主要系部分收入增量贡献大的公司调整产品结构所致，销售费用率降低1.9pp，板块净利润在29%左右，维持稳定。  创新药及制剂（46家）：上半年收入总额增速为16.7%、归母净利润总额增速为12.4%；Q2单季收入同比增长12.7%，利润端同比下滑7.3%，扣非净利润基本持平。Q2利润端有所下滑， 预计由于集采、国谈等导致公司毛利率下降所致。  零售药店（5家）：上半年收入总额增速为13.8%，其中第二季度收入增速为12.6%；归母净利润总额增速为17.8%，其中第二季度增速为13%。从趋势来看，第二季度收入、利润增速环比继续下降。利润端的增速快于收入端，主要系产品结构恢复到疫情前水平，低毛利率的抗疫产品占比下降，毛利率明显提升。预计Q3和Q4利润端将逐季改善，看好下半年药店内生增长，带动利润端逐季改善。  医药分销（16家）：上半年收入总额增速为29.5%，归母净利润总额增速为42.1%，扣非后归母净利润增速为17.8%，上半年快速增长主要系去年同期受疫情影响形成低基数。毛利率为10%，下降1pp，主要系带量采购带来毛利率的下降。Q2 实现了加速增长，单二季度实现归母净利润的同比增速为45.5%。二季度费用率环比略有下降。销售费用率同比下降 0.4pp，财务费用率下降0.1pp，管理费用率同比下降0.1pp。  原料药（28家）：上半年实现收入443亿元(+13.3%)，实现归母净利润78.3亿元(-0.1%)；21Q1/Q2原料药板块分别实现收入216亿元/227亿元，同比+19%/8.5% ，在利润端21Q1/Q2实现归母净利润37.4亿元/40.9亿元，同比+20%/-13.2% 。二季度板块归母净利润下滑，主要是毛利率同比去年下滑约3.8pp，同时费用端同上升1.3pp。",
    "labels": [
      [
        "T0",
        "行业",
        2,
        5,
        "血制品"
      ],
      [
        "T1",
        "时间范围",
        10,
        13,
        "上半年"
      ],
      [
        "T2",
        "收入增速",
        13,
        19,
        "收入总额增速"
      ],
      [
        "T3",
        "归母净利润增速",
        26,
        35,
        "归母净利润总额增速"
      ],
      [
        "T4",
        "时间范围",
        45,
        48,
        "二季度"
      ],
      [
        "T5",
        "收入增速",
        48,
        52,
        "收入增速"
      ],
      [
        "T6",
        "归母净利润增速",
        59,
        66,
        "归母净利润增速"
      ],
      [
        "T7",
        "时间范围",
        73,
        76,
        "二季度"
      ],
      [
        "T8",
        "收入增速",
        78,
        82,
        "收入增速"
      ],
      [
        "T9",
        "时间范围",
        87,
        91,
        "21Q2"
      ],
      [
        "T10",
        "毛利",
        93,
        96,
        "毛利率"
      ],
      [
        "T11",
        "归母净利润",
        144,
        147,
        "净利润"
      ],
      [
        "T12",
        "行业",
        162,
        168,
        "创新药及制剂"
      ],
      [
        "T13",
        "时间范围",
        174,
        177,
        "上半年"
      ],
      [
        "T14",
        "收入增速",
        177,
        183,
        "收入总额增速"
      ],
      [
        "T15",
        "归母净利润增速",
        190,
        199,
        "归母净利润总额增速"
      ],
      [
        "T16",
        "时间范围",
        206,
        208,
        "Q2"
      ],
      [
        "T17",
        "营业收入",
        210,
        212,
        "收入"
      ],
      [
        "T18",
        "扣非净利润",
        234,
        239,
        "扣非净利润"
      ],
      [
        "T19",
        "时间范围",
        244,
        246,
        "Q2"
      ],
      [
        "T20",
        "毛利",
        269,
        272,
        "毛利率"
      ],
      [
        "T21",
        "行业",
        280,
        284,
        "零售药店"
      ],
      [
        "T22",
        "时间范围",
        289,
        292,
        "上半年"
      ],
      [
        "T23",
        "收入增速",
        292,
        298,
        "收入总额增速"
      ],
      [
        "T24",
        "时间范围",
        307,
        311,
        "第二季度"
      ],
      [
        "T25",
        "收入增速",
        311,
        315,
        "收入增速"
      ],
      [
        "T26",
        "归母净利润增速",
        322,
        331,
        "归母净利润总额增速"
      ],
      [
        "T27",
        "时间范围",
        340,
        344,
        "第二季度"
      ],
      [
        "T28",
        "时间范围",
        357,
        361,
        "第二季度"
      ],
      [
        "T29",
        "营业收入",
        361,
        363,
        "收入"
      ],
      [
        "T30",
        "利润",
        375,
        378,
        "利润端"
      ],
      [
        "T31",
        "毛利",
        404,
        407,
        "毛利率"
      ],
      [
        "T32",
        "毛利",
        417,
        420,
        "毛利率"
      ],
      [
        "T33",
        "时间范围",
        427,
        429,
        "Q3"
      ],
      [
        "T34",
        "时间范围",
        430,
        432,
        "Q4"
      ],
      [
        "T35",
        "利润",
        432,
        435,
        "利润端"
      ],
      [
        "T36",
        "时间范围",
        443,
        446,
        "下半年"
      ],
      [
        "T37",
        "利润",
        455,
        458,
        "利润端"
      ],
      [
        "T38",
        "行业",
        466,
        470,
        "医药分销"
      ],
      [
        "T39",
        "时间范围",
        476,
        479,
        "上半年"
      ],
      [
        "T40",
        "收入增速",
        479,
        485,
        "收入总额增速"
      ],
      [
        "T41",
        "归母净利润增速",
        492,
        501,
        "归母净利润总额增速"
      ],
      [
        "T42",
        "扣非净利润增速",
        508,
        518,
        "扣非后归母净利润增速"
      ],
      [
        "T43",
        "时间范围",
        525,
        528,
        "上半年"
      ],
      [
        "T44",
        "毛利",
        550,
        553,
        "毛利率"
      ],
      [
        "T45",
        "毛利",
        573,
        576,
        "毛利率"
      ],
      [
        "T46",
        "归母净利润",
        597,
        602,
        "归母净利润"
      ],
      [
        "T47",
        "时间范围",
        683,
        686,
        "上半年"
      ],
      [
        "T48",
        "营业收入",
        688,
        690,
        "收入"
      ],
      [
        "T49",
        "归母净利润",
        706,
        711,
        "归母净利润"
      ],
      [
        "T50",
        "时间范围",
        725,
        729,
        "21Q1"
      ],
      [
        "T51",
        "时间范围",
        730,
        732,
        "Q2"
      ],
      [
        "T52",
        "行业",
        732,
        735,
        "原料药"
      ],
      [
        "T53",
        "营业收入",
        741,
        743,
        "收入"
      ],
      [
        "T54",
        "属性值",
        743,
        748,
        "216亿元"
      ],
      [
        "T55",
        "属性值",
        749,
        754,
        "227亿元"
      ],
      [
        "T56",
        "属性值",
        757,
        761,
        "+19%"
      ],
      [
        "T57",
        "属性值",
        762,
        766,
        "8.5%"
      ],
      [
        "T58",
        "利润",
        769,
        772,
        "利润端"
      ],
      [
        "T59",
        "时间范围",
        772,
        776,
        "21Q1"
      ],
      [
        "T60",
        "时间范围",
        777,
        779,
        "Q2"
      ],
      [
        "T61",
        "归母净利润",
        781,
        786,
        "归母净利润"
      ],
      [
        "T62",
        "属性值",
        786,
        792,
        "37.4亿元"
      ],
      [
        "T63",
        "属性值",
        793,
        799,
        "40.9亿元"
      ],
      [
        "T64",
        "时间范围",
        815,
        818,
        "二季度"
      ],
      [
        "T65",
        "归母净利润",
        820,
        825,
        "归母净利润"
      ],
      [
        "T66",
        "毛利",
        831,
        834,
        "毛利率"
      ],
      [
        "T67",
        "行业",
        674,
        677,
        "原料药"
      ],
      [
        "T68",
        "属性值",
        690,
        695,
        "443亿元"
      ],
      [
        "T69",
        "属性值",
        696,
        702,
        "+13.3%"
      ],
      [
        "T70",
        "属性值",
        20,
        25,
        "13.5%"
      ],
      [
        "T71",
        "属性值",
        36,
        41,
        "19.8%"
      ],
      [
        "T72",
        "属性值",
        53,
        58,
        "22.2%"
      ],
      [
        "T73",
        "属性值",
        67,
        72,
        "19.2%"
      ],
      [
        "T74",
        "属性值",
        82,
        86,
        "提升明显"
      ],
      [
        "T75",
        "属性值",
        96,
        104,
        "略降低1.5pp"
      ],
      [
        "T76",
        "属性值",
        148,
        153,
        "29%左右"
      ],
      [
        "T77",
        "属性值",
        184,
        189,
        "16.7%"
      ],
      [
        "T78",
        "属性值",
        200,
        205,
        "12.4%"
      ],
      [
        "T79",
        "属性值",
        216,
        221,
        "12.7%"
      ],
      [
        "T80",
        "属性值",
        239,
        243,
        "基本持平"
      ],
      [
        "T81",
        "属性值",
        249,
        253,
        "有所下滑"
      ],
      [
        "T82",
        "属性值",
        299,
        304,
        "13.8%"
      ],
      [
        "T83",
        "属性值",
        316,
        321,
        "12.6%"
      ],
      [
        "T84",
        "属性值",
        332,
        337,
        "17.8%"
      ],
      [
        "T85",
        "属性值",
        347,
        350,
        "13%"
      ],
      [
        "T86",
        "利润",
        222,
        225,
        "利润端"
      ],
      [
        "T87",
        "利润",
        246,
        249,
        "利润端"
      ],
      [
        "T88",
        "属性值",
        225,
        233,
        "同比下滑7.3%"
      ],
      [
        "T89",
        "利润",
        364,
        366,
        "利润"
      ],
      [
        "T90",
        "属性值",
        366,
        374,
        "增速环比继续下降"
      ],
      [
        "T91",
        "行业",
        446,
        448,
        "药店"
      ],
      [
        "T92",
        "属性值",
        436,
        440,
        "逐季改善"
      ],
      [
        "T93",
        "属性值",
        379,
        386,
        "增速快于收入端"
      ],
      [
        "T94",
        "属性值",
        420,
        424,
        "明显提升"
      ],
      [
        "T95",
        "属性值",
        458,
        462,
        "逐季改善"
      ],
      [
        "T96",
        "属性值",
        486,
        491,
        "29.5%"
      ],
      [
        "T97",
        "属性值",
        502,
        507,
        "42.1%"
      ],
      [
        "T98",
        "属性值",
        519,
        524,
        "17.8%"
      ],
      [
        "T99",
        "时间范围",
        535,
        537,
        "去年"
      ],
      [
        "T100",
        "属性值",
        554,
        563,
        "10%，下降1pp"
      ],
      [
        "T101",
        "时间范围",
        580,
        582,
        "Q2"
      ],
      [
        "T102",
        "时间范围",
        592,
        595,
        "二季度"
      ],
      [
        "T103",
        "属性值",
        608,
        613,
        "45.5%"
      ],
      [
        "T104",
        "时间范围",
        614,
        617,
        "二季度"
      ],
      [
        "T105",
        "属性值",
        711,
        724,
        "78.3亿元(-0.1%)"
      ],
      [
        "T106",
        "属性值",
        825,
        827,
        "下滑"
      ],
      [
        "T107",
        "属性值",
        834,
        846,
        "同比去年下滑约3.8pp"
      ]
    ]
  },
  {
    "id": 543,
    "text": " 从收入贡献看，前五名迈瑞、英科、乐普、华大、鱼跃贡献了48.8%的板块收入；  从归母净利润贡献看，前五名英科、迈瑞、乐普、达安、华大贡献了63.4%的板块净利润。。",
    "labels": [
      [
        "T0",
        "营业收入",
        3,
        5,
        "收入"
      ],
      [
        "T1",
        "公司",
        12,
        14,
        "迈瑞"
      ],
      [
        "T2",
        "公司",
        15,
        17,
        "英科"
      ],
      [
        "T3",
        "公司",
        18,
        20,
        "乐普"
      ],
      [
        "T4",
        "公司",
        21,
        23,
        "华大"
      ],
      [
        "T5",
        "公司",
        24,
        26,
        "鱼跃"
      ],
      [
        "T6",
        "营业收入",
        37,
        39,
        "收入"
      ],
      [
        "T7",
        "归母净利润",
        44,
        49,
        "归母净利润"
      ],
      [
        "T8",
        "公司",
        56,
        58,
        "英科"
      ],
      [
        "T9",
        "公司",
        59,
        61,
        "迈瑞"
      ],
      [
        "T10",
        "公司",
        62,
        64,
        "乐普"
      ],
      [
        "T11",
        "公司",
        65,
        67,
        "达安"
      ],
      [
        "T12",
        "公司",
        68,
        70,
        "华大"
      ],
      [
        "T13",
        "归母净利润",
        81,
        84,
        "净利润"
      ]
    ]
  },
  {
    "id": 544,
    "text": "博腾股份在 2018年至 2020年营业收入由 11.8亿人民币增长至 20.7亿人民币，年均复合增长率为 32.44%，归母净利润由 1.2亿人民币增长至 3.2亿人民币，年均复合 63.3%。公司 2021年 Q1-Q3实现营业收入 20.3亿人民币，同比增长 36%，实现归母净利润 3.6亿人民币，同比增长 51%，收入端与利润端均保持高速增长。",
    "labels": [
      [
        "T0",
        "公司",
        0,
        4,
        "博腾股份"
      ],
      [
        "T1",
        "时间范围",
        6,
        11,
        "2018年"
      ],
      [
        "T2",
        "时间范围",
        13,
        18,
        "2020年"
      ],
      [
        "T3",
        "营业收入",
        18,
        22,
        "营业收入"
      ],
      [
        "T4",
        "属性值",
        24,
        32,
        "11.8亿人民币"
      ],
      [
        "T5",
        "属性值",
        36,
        44,
        "20.7亿人民币"
      ],
      [
        "T6",
        "CAGR",
        45,
        52,
        "年均复合增长率"
      ],
      [
        "T7",
        "属性值",
        54,
        60,
        "32.44%"
      ],
      [
        "T8",
        "归母净利润",
        61,
        66,
        "归母净利润"
      ],
      [
        "T9",
        "属性值",
        68,
        75,
        "1.2亿人民币"
      ],
      [
        "T10",
        "属性值",
        79,
        86,
        "3.2亿人民币"
      ],
      [
        "T11",
        "CAGR",
        87,
        91,
        "年均复合"
      ],
      [
        "T12",
        "属性值",
        92,
        97,
        "63.3%"
      ],
      [
        "T13",
        "时间范围",
        101,
        112,
        "2021年 Q1-Q3"
      ],
      [
        "T14",
        "营业收入",
        114,
        118,
        "营业收入"
      ],
      [
        "T15",
        "属性值",
        119,
        127,
        "20.3亿人民币"
      ],
      [
        "T16",
        "属性值",
        133,
        136,
        "36%"
      ],
      [
        "T17",
        "归母净利润",
        139,
        144,
        "归母净利润"
      ],
      [
        "T18",
        "营业收入",
        162,
        165,
        "收入端"
      ],
      [
        "T19",
        "利润",
        166,
        169,
        "利润端"
      ],
      [
        "T20",
        "属性值",
        172,
        176,
        "高速增长"
      ],
      [
        "T21",
        "属性值",
        145,
        161,
        "3.6亿人民币，同比增长 51%"
      ],
      [
        "T22",
        "时间连接词",
        11,
        12,
        "至"
      ]
    ]
  },
  {
    "id": 545,
    "text": "从 2001年开始，我国就不再批准新设血液制品企业；同时 2008年卫生部颁布的 《单采血浆站管理办法》第十一条规定，血液制品生产单位注册的血液制品少于 6个品种的，承担国家计划免疫任务的血液制品生产单位少于5个品种的，不予批准新设浆站， 2012年《单采血浆站管理办法》（修订版）进一步收紧审批，在前述满足品种数量的基础上，要求同时包含人血白蛋白、人免疫球蛋白和人凝血因子类制品三大类。仅从近年来凝血类批签发数据来判断，全行业不到十家血制品企业有相关产品上市，绝大多数血制品企业由于政策限制失去新设浆站能力。 我国血制品行业寡头垄断格局已经形成。目前，国内血制行业已经形成以天坛生物、 华兰生物、上海莱士和泰邦生物为主的寡头垄断格局，四大血制企业采浆量占全行业达 52.4%。大型血液制品企业由于浆站资源多，采浆量大，血浆利用率高，相对中小型血液制品企业能攫取更多市场份额和利润，强者恒强。 行业形成寡头垄断格局的两大推手：政策无形之手，并购有形之手。 政策无形之手提高行业进入门槛。我国对血液制品行业强监管，政策不断推动行业提高集中度。从 2001 年起不再新批血液制品企业，目前国内存量血制品企业约 31家， 但正常经营血液制品企业仅 20余家。另外，新批浆站政策方面，2016年 12月15日,卫计委和 CFDA联合出台《关于促进单采血浆站健康发展的意见》，强调严格新增单采血浆站设置审批,向研发能力强、血浆综合利用率高、单采血浆站管理规范的血液制品生产企业倾斜。 并购整合促行业企业存量优化。头部企业并购重组活跃，上海莱士相继收购整合郑州莱士、同路生物、浙江海康；天坛生物以成都蓉生为平台整合集团血制资产；派林生物并购哈尔滨派斯菲科，连横新疆德源。血制企业间并购整合，进一步优化存量血制企业，血制企业数量从90年代 70多家企业下降到目前 20余家（正常经营企业数）。",
    "labels": [
      [
        "T0",
        "行业公司",
        19,
        25,
        "血液制品企业"
      ],
      [
        "T1",
        "行业公司",
        218,
        223,
        "血制品企业"
      ],
      [
        "T2",
        "行业公司",
        235,
        240,
        "血制品企业"
      ],
      [
        "T3",
        "行业",
        258,
        261,
        "血制品"
      ],
      [
        "T4",
        "地点范围",
        256,
        258,
        "我国"
      ],
      [
        "T5",
        "地点范围",
        277,
        279,
        "国内"
      ],
      [
        "T6",
        "行业",
        279,
        281,
        "血制"
      ],
      [
        "T7",
        "公司",
        288,
        292,
        "天坛生物"
      ],
      [
        "T8",
        "公司",
        294,
        298,
        "华兰生物"
      ],
      [
        "T9",
        "公司",
        299,
        303,
        "上海莱士"
      ],
      [
        "T10",
        "公司",
        304,
        308,
        "泰邦生物"
      ],
      [
        "T11",
        "行业公司",
        341,
        347,
        "血液制品企业"
      ],
      [
        "T12",
        "市场份额",
        383,
        387,
        "市场份额"
      ],
      [
        "T13",
        "利润",
        388,
        390,
        "利润"
      ],
      [
        "T14",
        "行业",
        446,
        450,
        "血液制品"
      ],
      [
        "T15",
        "地点范围",
        492,
        494,
        "国内"
      ],
      [
        "T16",
        "行业公司",
        496,
        501,
        "血制品企业"
      ],
      [
        "T17",
        "行业公司",
        513,
        519,
        "血液制品企业"
      ],
      [
        "T18",
        "公司",
        662,
        666,
        "上海莱士"
      ],
      [
        "T19",
        "公司",
        672,
        676,
        "郑州莱士"
      ],
      [
        "T20",
        "公司",
        677,
        681,
        "同路生物"
      ],
      [
        "T21",
        "公司",
        682,
        686,
        "浙江海康"
      ],
      [
        "T22",
        "公司",
        687,
        691,
        "天坛生物"
      ],
      [
        "T23",
        "公司",
        692,
        696,
        "成都蓉生"
      ],
      [
        "T24",
        "公司",
        708,
        712,
        "派林生物"
      ],
      [
        "T25",
        "公司",
        714,
        721,
        "哈尔滨派斯菲科"
      ],
      [
        "T26",
        "公司",
        724,
        728,
        "新疆德源"
      ],
      [
        "T27",
        "行业公司",
        729,
        733,
        "血制企业"
      ],
      [
        "T28",
        "行业公司",
        751,
        755,
        "血制企业"
      ],
      [
        "T29",
        "时间范围",
        0,
        9,
        "从 2001年开始"
      ],
      [
        "T30",
        "地点范围",
        10,
        12,
        "我国"
      ],
      [
        "T31",
        "时间范围",
        29,
        34,
        "2008年"
      ],
      [
        "T32",
        "行业",
        59,
        63,
        "血液制品"
      ],
      [
        "T33",
        "时间范围",
        120,
        125,
        "2012年"
      ],
      [
        "T34",
        "时间范围",
        196,
        199,
        "近年来"
      ],
      [
        "T35",
        "属性值",
        263,
        267,
        "寡头垄断"
      ],
      [
        "T36",
        "属性值",
        311,
        315,
        "寡头垄断"
      ],
      [
        "T37",
        "行业公司",
        318,
        324,
        "四大血制企业"
      ],
      [
        "T38",
        "属性值",
        401,
        405,
        "寡头垄断"
      ],
      [
        "T39",
        "地点范围",
        443,
        445,
        "我国"
      ],
      [
        "T40",
        "市场集中度",
        466,
        469,
        "集中度"
      ],
      [
        "T41",
        "属性值",
        464,
        466,
        "提高"
      ],
      [
        "T42",
        "时间范围",
        490,
        492,
        "目前"
      ],
      [
        "T43",
        "时间范围",
        470,
        479,
        "从 2001 年起"
      ],
      [
        "T44",
        "行业公司",
        483,
        489,
        "血液制品企业"
      ],
      [
        "T45",
        "时间范围",
        538,
        550,
        "2016年 12月15日"
      ],
      [
        "T46",
        "行业公司",
        746,
        750,
        "血制企业"
      ]
    ]
  },
  {
    "id": 546,
    "text": "近年来，随着我国人口老龄化不断加深，协调发展与之相适应的康复产业愈显重要。 我国出台一系列扶持和推动康复产业链发展的方针政策，鼓励市场化运作，鼓励康复中心、护理中心集团化、连锁化运营；加大医保支付力度，2016年，新增 20项康复项目医保支持，累计医保康复项目上升到 29项。 2021年，国家卫健委联合医保局、发改委、民政部、财政部、中医药管理局、残联和教育部等八部委共同制定发布《关于加快推进康复医疗工作发展的意见》，增加康复医疗服务供给，明确设立 2025年发展目标（康复师、康复治疗师等人才队伍，不同人口级别城市康复医疗机构设置等），支持和引导社会力量，全方位补充康复医疗供给缺口。 鼓励和推动康复产业发展，康复辅助器具产业发展先行。2016年，国务院发布《关于加快发展康复辅助器具产业的若干意见》(国发〔2016〕60号)，2020年，民政部、科技部等七部委联合印发《关于开展康复辅助器具产业第二批国家综合创新试点的通知》 (民发〔2020〕149号，以下简称《通知》)，启动了康复辅助器具产业第二批国家综合创新试点，将在全国选择 15个地市级行政区域(包含副省级城市)，在最大限度利用现有资源的基础上，开展康复辅助器具产业综合创新试点，通过试点，将康复辅助器具产业打造成为助力经济转型升级的先导产业。",
    "labels": [
      [
        "T0",
        "时间范围",
        0,
        3,
        "近年来"
      ],
      [
        "T1",
        "地点范围",
        6,
        8,
        "我国"
      ],
      [
        "T2",
        "地点范围",
        38,
        40,
        "我国"
      ],
      [
        "T3",
        "行业",
        50,
        55,
        "康复产业链"
      ],
      [
        "T4",
        "时间范围",
        101,
        106,
        "2016年"
      ],
      [
        "T5",
        "时间范围",
        139,
        144,
        "2021年"
      ],
      [
        "T6",
        "行业",
        213,
        219,
        "康复医疗服务"
      ],
      [
        "T7",
        "时间范围",
        227,
        232,
        "2025年"
      ],
      [
        "T8",
        "行业",
        286,
        290,
        "康复医疗"
      ],
      [
        "T9",
        "行业",
        301,
        303,
        "康复"
      ],
      [
        "T10",
        "行业",
        308,
        314,
        "康复辅助器具"
      ],
      [
        "T11",
        "时间范围",
        321,
        326,
        "2016年"
      ],
      [
        "T12",
        "时间范围",
        367,
        372,
        "2020年"
      ],
      [
        "T13",
        "行业",
        444,
        450,
        "康复辅助器具"
      ],
      [
        "T14",
        "地点范围",
        466,
        468,
        "全国"
      ],
      [
        "T15",
        "行业",
        509,
        515,
        "康复辅助器具"
      ],
      [
        "T16",
        "行业",
        530,
        536,
        "康复辅助器具"
      ],
      [
        "T17",
        "行业",
        339,
        345,
        "康复辅助器具"
      ]
    ]
  },
  {
    "id": 548,
    "text": "本周受到广东集采等政策影响，医药指数大跌 7.2%，我们总体上认为市场可能过于恐慌，尤其是血制品最高申报价远高于广东最低价，尽管最终中标价很可能选择前两个价格的孰低价，但其较高的最高申报价远说明血制品供不应求、对血制品的保护等。另外 CXO 公司纷纷披露 2021年年报预告，总体上看该领域业绩仍较好，2022年其板块高增长仍将延续，一季报前后股价很可能走强；中药、仿制药 CXO及原料药板块等仍持续看好。",
    "labels": [
      [
        "T0",
        "时间范围",
        0,
        2,
        "本周"
      ],
      [
        "T1",
        "行业",
        45,
        48,
        "血制品"
      ],
      [
        "T2",
        "行业",
        106,
        109,
        "血制品"
      ],
      [
        "T3",
        "行业公司",
        117,
        123,
        "CXO 公司"
      ],
      [
        "T4",
        "业绩",
        145,
        147,
        "业绩"
      ],
      [
        "T5",
        "时间范围",
        128,
        133,
        "2021年"
      ],
      [
        "T6",
        "时间范围",
        151,
        156,
        "2022年"
      ],
      [
        "T7",
        "行业",
        180,
        182,
        "中药"
      ],
      [
        "T8",
        "行业",
        183,
        186,
        "仿制药"
      ],
      [
        "T9",
        "行业",
        187,
        190,
        "CXO"
      ],
      [
        "T10",
        "行业",
        191,
        194,
        "原料药"
      ],
      [
        "T11",
        "属性值",
        148,
        150,
        "较好"
      ],
      [
        "T12",
        "时间范围",
        167,
        170,
        "一季报"
      ]
    ]
  },
  {
    "id": 549,
    "text": "中国市场红利下，国内需求驱动的CRO公司，增长驱动方面有量也有价。我们强调，政策驱动的创新能力提升或带来板块向龙头集中度增强，而CRO公司不断增强的一体化能力有望带来未来业绩增长及盈利能力提升的超预期。",
    "labels": [
      [
        "T0",
        "行业需求",
        10,
        12,
        "需求"
      ],
      [
        "T1",
        "地点范围",
        8,
        10,
        "国内"
      ],
      [
        "T2",
        "地点范围",
        0,
        2,
        "中国"
      ],
      [
        "T3",
        "行业公司",
        15,
        20,
        "CRO公司"
      ],
      [
        "T4",
        "龙头企业",
        55,
        57,
        "龙头"
      ],
      [
        "T5",
        "市场集中度",
        57,
        60,
        "集中度"
      ],
      [
        "T6",
        "行业公司",
        64,
        69,
        "CRO公司"
      ],
      [
        "T7",
        "业绩",
        85,
        87,
        "业绩"
      ],
      [
        "T8",
        "属性值",
        60,
        62,
        "增强"
      ],
      [
        "T9",
        "时间范围",
        83,
        85,
        "未来"
      ],
      [
        "T10",
        "属性值",
        87,
        89,
        "增长"
      ]
    ]
  },
  {
    "id": 550,
    "text": "3. 增值服务：游戏仍是增长确定性保证",
    "labels": [
      [
        "T0",
        "行业",
        8,
        10,
        "游戏"
      ]
    ]
  },
  {
    "id": 551,
    "text": "中国龙头 CXO企业在 2018-2021年表现出持续优秀的增长，其中药明康德收入水平已到达全球 CDMO 企业第一梯队（5亿美元以上）的收入规模，利润端与收入端均持续表现出优秀的增长。凯莱英与博腾股份收入规模均已超过 2.5亿美元，达到全球 CDMO企业收入规模第二梯队水平。凯莱英在 2018-2021 年持续表现优秀的收入端增长。",
    "labels": [
      [
        "T0",
        "地点范围",
        0,
        2,
        "中国"
      ],
      [
        "T1",
        "龙头企业",
        2,
        4,
        "龙头"
      ],
      [
        "T2",
        "行业公司",
        5,
        10,
        "CXO企业"
      ],
      [
        "T3",
        "时间范围",
        12,
        22,
        "2018-2021年"
      ],
      [
        "T4",
        "公司",
        35,
        39,
        "药明康德"
      ],
      [
        "T5",
        "营业收入",
        39,
        41,
        "收入"
      ],
      [
        "T6",
        "行业公司",
        49,
        56,
        "CDMO 企业"
      ],
      [
        "T7",
        "利润",
        74,
        77,
        "利润端"
      ],
      [
        "T8",
        "营业收入",
        78,
        81,
        "收入端"
      ],
      [
        "T9",
        "公司",
        93,
        96,
        "凯莱英"
      ],
      [
        "T10",
        "公司",
        97,
        101,
        "博腾股份"
      ],
      [
        "T11",
        "营业收入",
        101,
        103,
        "收入"
      ],
      [
        "T12",
        "行业公司",
        122,
        128,
        "CDMO企业"
      ],
      [
        "T13",
        "公司",
        139,
        142,
        "凯莱英"
      ],
      [
        "T14",
        "时间范围",
        144,
        155,
        "2018-2021 年"
      ],
      [
        "T15",
        "营业收入",
        162,
        165,
        "收入端"
      ],
      [
        "T16",
        "地点范围",
        46,
        48,
        "全球"
      ],
      [
        "T17",
        "属性值",
        61,
        67,
        "5亿美元以上"
      ],
      [
        "T18",
        "属性值",
        87,
        92,
        "优秀的增长"
      ],
      [
        "T19",
        "属性值",
        107,
        116,
        "超过 2.5亿美元"
      ],
      [
        "T20",
        "地点范围",
        119,
        121,
        "全球"
      ],
      [
        "T21",
        "属性值",
        165,
        167,
        "增长"
      ]
    ]
  },
  {
    "id": 552,
    "text": " 从下游客户来看，生命科学服务可以同时覆盖科研客户和工业客户两部分：科研客户是指从事基础科学研究的高等院校和科研院所，包括但不限于分子生物学、细胞生物学、生物工程、制药工程、遗传学、基础医学、生物医学工程等研究方向，通常以课题组为单位进行采购；工业客户是指从事生命科学研究的各类企业，包括但不限于抗体药物研发企业、细胞/基因治疗企业、疫苗企业、体外诊断企业等，产品应用覆盖从研发到生产的各个环节。受益于下游需求的不断提升，生命科学服务行业作为产业链“卖水人”可持续享受高景气度。",
    "labels": [
      [
        "T0",
        "行业公司",
        149,
        157,
        "抗体药物研发企业"
      ],
      [
        "T1",
        "行业公司",
        158,
        167,
        "细胞/基因治疗企业"
      ],
      [
        "T2",
        "行业公司",
        168,
        172,
        "疫苗企业"
      ],
      [
        "T3",
        "行业公司",
        173,
        179,
        "体外诊断企业"
      ],
      [
        "T4",
        "行业需求",
        204,
        206,
        "需求"
      ],
      [
        "T5",
        "行业",
        212,
        218,
        "生命科学服务"
      ],
      [
        "T6",
        "行业",
        10,
        16,
        "生命科学服务"
      ]
    ]
  },
  {
    "id": 553,
    "text": "• 8月19日，安徽省发布公立医疗机构临床检验试剂集中带量采购谈判议价公告，对化学发光试剂5大类23小类产品开展集采； • 8月27日，安徽省医药集中采购服务中心公布化学发光集采结果，相关产品价格平均降幅达到47.02%，预计每年可为医疗机构节约采购资金1.73亿元。 • 11月4日，安徽医保局公布执行安徽省公立医疗机构临床检验试剂集中带量采购谈判议价结果的通知。集采自2021年11月11日起执行 ，原则上采购周期为2年；采购量为上年度采购量的80%作为协议采购量，和企业或进口产品全国总代理签订带量购销合同；对属于 《公告》采购产品范围，未纳入谈判议价的同类产品，将价格联动到不高于谈判成功产品价格水平；对不参加谈判议价、谈判不成功及不确认带量联动价格的产品，调整到备案交易目录。备案采购金额占该范围产品采购总金额比例不得高于10%，否则纪委约谈。",
    "labels": [
      [
        "T0",
        "时间范围",
        2,
        7,
        "8月19日"
      ],
      [
        "T1",
        "地点范围",
        8,
        11,
        "安徽省"
      ],
      [
        "T2",
        "时间范围",
        62,
        67,
        "8月27日"
      ],
      [
        "T3",
        "地点范围",
        68,
        71,
        "安徽省"
      ],
      [
        "T4",
        "行业公司",
        117,
        121,
        "医疗机构"
      ],
      [
        "T5",
        "时间范围",
        137,
        142,
        "11月4日"
      ],
      [
        "T6",
        "地点范围",
        143,
        145,
        "安徽"
      ],
      [
        "T7",
        "时间范围",
        185,
        198,
        "自2021年11月11日起"
      ]
    ]
  },
  {
    "id": 554,
    "text": "国内二级市场药企研发投入持续增加。A股样本上市药企研发费用总支出从 2017 年的 214.6亿元增长到 2020年的 440.6亿元，CAGR为 27%；港股样本上市药企研发费用总支出从2018年的154.7亿元增长到 2020年的243.0亿元，CAGR为25%。",
    "labels": [
      [
        "T0",
        "地点范围",
        0,
        2,
        "国内"
      ],
      [
        "T1",
        "行业公司",
        6,
        8,
        "药企"
      ],
      [
        "T2",
        "研发费用",
        8,
        12,
        "研发投入"
      ],
      [
        "T3",
        "行业公司",
        21,
        25,
        "上市药企"
      ],
      [
        "T4",
        "CAGR",
        68,
        72,
        "CAGR"
      ],
      [
        "T5",
        "CAGR",
        125,
        129,
        "CAGR"
      ],
      [
        "T6",
        "属性值",
        14,
        16,
        "增加"
      ],
      [
        "T7",
        "时间范围",
        34,
        40,
        "2017 年"
      ],
      [
        "T8",
        "属性值",
        42,
        49,
        "214.6亿元"
      ],
      [
        "T9",
        "时间范围",
        53,
        58,
        "2020年"
      ],
      [
        "T10",
        "属性值",
        60,
        67,
        "440.6亿元"
      ],
      [
        "T11",
        "属性值",
        74,
        77,
        "27%"
      ],
      [
        "T12",
        "行业公司",
        84,
        86,
        "药企"
      ],
      [
        "T13",
        "时间范围",
        94,
        99,
        "2018年"
      ],
      [
        "T14",
        "时间范围",
        111,
        116,
        "2020年"
      ],
      [
        "T15",
        "属性值",
        100,
        107,
        "154.7亿元"
      ],
      [
        "T16",
        "属性值",
        117,
        124,
        "243.0亿元"
      ],
      [
        "T17",
        "属性值",
        130,
        133,
        "25%"
      ],
      [
        "T18",
        "属性值",
        25,
        32,
        "研发费用总支出"
      ],
      [
        "T19",
        "属性值",
        86,
        93,
        "研发费用总支出"
      ]
    ]
  },
  {
    "id": 555,
    "text": "1.3 今年国家及地方集采频次历年最高，政策压力强于过往历年 2020-2021年是医药国采和地方联采持续深化之年，尤以 2021年为国家及地方集采频次历年最高，政策压力强于过往历年。 首先，国采频率历年最高。2020年克服新冠疫情影响，药品集采频率上升到一年两次，如果算上冠脉支架高值耗材集采则一年三次；2021年包括刚刚出炉的第六轮国家集采（胰岛素专项）在内，当年已经开展了三轮药品国家集采，如果包含关节等骨科高值耗材集采，今年国家层面共进行了四次药械集采。集采品种从此前仿制药拓展到胰岛素生物药、冠脉支架和人工关节等高值耗材。 其次，地方省级和省际联采从 2020年开始如雨后春笋般迅速在全国铺开，绝大部分省际联采从 2020年开始展开，其中 2021年有 8个省际联盟采购，采购的药品通用名数量也较为庞大，最新的广东 16省联盟采购涉及药品通用名 256个，涵盖化药、中成药和生物药全品种。 1.4 明年涉及集采政策将趋于稳定和温和我们认为明年国采、联采政策将趋于稳定和温和。",
    "labels": [
      [
        "T0",
        "时间范围",
        4,
        6,
        "今年"
      ],
      [
        "T1",
        "时间范围",
        31,
        41,
        "2020-2021年"
      ],
      [
        "T2",
        "时间范围",
        61,
        66,
        "2021年"
      ],
      [
        "T3",
        "时间范围",
        105,
        110,
        "2020年"
      ],
      [
        "T4",
        "时间范围",
        153,
        158,
        "2021年"
      ],
      [
        "T5",
        "时间范围",
        214,
        216,
        "今年"
      ],
      [
        "T6",
        "时间范围",
        279,
        288,
        "从 2020年开始"
      ],
      [
        "T7",
        "时间范围",
        325,
        330,
        "2021年"
      ],
      [
        "T8",
        "时间范围",
        404,
        406,
        "明年"
      ],
      [
        "T9",
        "时间范围",
        424,
        426,
        "明年"
      ],
      [
        "T10",
        "地点范围",
        360,
        362,
        "广东"
      ],
      [
        "T11",
        "时间范围",
        310,
        319,
        "从 2020年开始"
      ],
      [
        "T12",
        "地点范围",
        297,
        299,
        "全国"
      ]
    ]
  },
  {
    "id": 556,
    "text": "我们发现近年来国内承接的全球多中心临床数量快速增长，可能与海外药企对中国本土较强的临床需求以及未来较大的市场前景的逐渐重视相关。另外随着本土创新药企业能力的不断增强，本土企业国际化加速。我们认为在国内未满足临床需求逐步被满足、本土创新研发能力持续验证后，会有越来越多的创新药企业参与国际化竞争， 占据更大市场份额。同时，有望带动本土CXO的国际化突破。",
    "labels": [
      [
        "T0",
        "地点范围",
        7,
        9,
        "国内"
      ],
      [
        "T1",
        "地点范围",
        29,
        31,
        "海外"
      ],
      [
        "T2",
        "行业公司",
        31,
        33,
        "药企"
      ],
      [
        "T3",
        "行业公司",
        70,
        75,
        "创新药企业"
      ],
      [
        "T4",
        "地点范围",
        98,
        100,
        "国内"
      ],
      [
        "T5",
        "行业公司",
        134,
        139,
        "创新药企业"
      ],
      [
        "T6",
        "市场份额",
        152,
        156,
        "市场份额"
      ],
      [
        "T7",
        "行业",
        166,
        169,
        "CXO"
      ],
      [
        "T8",
        "时间范围",
        4,
        7,
        "近年来"
      ],
      [
        "T9",
        "地点范围",
        12,
        14,
        "全球"
      ],
      [
        "T10",
        "地点范围",
        34,
        38,
        "中国本土"
      ]
    ]
  },
  {
    "id": 557,
    "text": " 创新药及制剂板块Q1/Q2/Q3单季度收入514.1/489.8/503.7亿元（+21.7%/+11.3%/-0.3%）,单季度净利润66.4/56.5/59.7亿元（ +24.4%/-9.5%/-15.3%）, 高基数，集采影响扩大，医保控费等多重因素影响之下，创新药及制剂板块三季度收入端和利润端双双下滑。  Q3单季度毛利率57.5%（-4.8pp），单季度四费率43.4%（-2.3pp），单季度净利率11.9%（-2.1pp）。",
    "labels": [
      [
        "T0",
        "行业",
        2,
        8,
        "创新药及制剂"
      ],
      [
        "T1",
        "时间范围",
        10,
        12,
        "Q1"
      ],
      [
        "T2",
        "时间范围",
        13,
        15,
        "Q2"
      ],
      [
        "T3",
        "时间范围",
        16,
        18,
        "Q3"
      ],
      [
        "T4",
        "营业收入",
        21,
        23,
        "收入"
      ],
      [
        "T5",
        "属性值",
        23,
        28,
        "514.1"
      ],
      [
        "T6",
        "属性值",
        29,
        34,
        "489.8"
      ],
      [
        "T7",
        "属性值",
        35,
        42,
        "503.7亿元"
      ],
      [
        "T8",
        "属性值",
        43,
        49,
        "+21.7%"
      ],
      [
        "T9",
        "属性值",
        50,
        56,
        "+11.3%"
      ],
      [
        "T10",
        "属性值",
        57,
        62,
        "-0.3%"
      ],
      [
        "T11",
        "归母净利润",
        67,
        70,
        "净利润"
      ],
      [
        "T12",
        "属性值",
        70,
        74,
        "66.4"
      ],
      [
        "T13",
        "属性值",
        75,
        79,
        "56.5"
      ],
      [
        "T14",
        "属性值",
        80,
        86,
        "59.7亿元"
      ],
      [
        "T15",
        "行业",
        135,
        141,
        "创新药及制剂"
      ],
      [
        "T16",
        "营业收入",
        146,
        149,
        "收入端"
      ],
      [
        "T17",
        "利润",
        150,
        153,
        "利润端"
      ],
      [
        "T18",
        "时间范围",
        161,
        163,
        "Q3"
      ],
      [
        "T19",
        "毛利",
        166,
        169,
        "毛利率"
      ],
      [
        "T20",
        "属性值",
        155,
        157,
        "下滑"
      ],
      [
        "T21",
        "时间范围",
        143,
        146,
        "三季度"
      ],
      [
        "T22",
        "属性值",
        169,
        182,
        "57.5%（-4.8pp）"
      ],
      [
        "T23",
        "归母净利润",
        206,
        209,
        "净利率"
      ],
      [
        "T24",
        "属性值",
        209,
        222,
        "11.9%（-2.1pp）"
      ]
    ]
  },
  {
    "id": 558,
    "text": " 18家医药流通股21Q1-3收入总额增速为22.6%，归母净利润总额增速为20.3%。  从盈利水平来看，单三季度毛利率为10.4%，同比下降0.2pp。  三季度费用率均环比保持稳定。销售费用率同比增加0.1pp，财务费用率增加0.1pp，管理费用率同比无变化。",
    "labels": [
      [
        "T0",
        "时间范围",
        10,
        16,
        "21Q1-3"
      ],
      [
        "T1",
        "收入增速",
        16,
        22,
        "收入总额增速"
      ],
      [
        "T2",
        "归母净利润增速",
        29,
        38,
        "归母净利润总额增速"
      ],
      [
        "T3",
        "毛利",
        60,
        63,
        "毛利率"
      ],
      [
        "T4",
        "行业公司",
        2,
        10,
        "18家医药流通股"
      ],
      [
        "T5",
        "属性值",
        23,
        28,
        "22.6%"
      ],
      [
        "T6",
        "属性值",
        39,
        44,
        "20.3%"
      ],
      [
        "T7",
        "时间范围",
        57,
        60,
        "三季度"
      ],
      [
        "T8",
        "属性值",
        64,
        79,
        "10.4%，同比下降0.2pp"
      ],
      [
        "T9",
        "时间范围",
        83,
        86,
        "三季度"
      ]
    ]
  },
  {
    "id": 559,
    "text": " 46家创新药及制剂公司2021上半年收入总额增速为16.7%、归母净利润总额增速为12.4%；Q2单季收入同比增长12.7%，利润端同比下滑7.3%，扣非净利润基本持平。Q2利润端有所下滑， 预计由于集采、国谈等导致公司毛利率下降所致。  从盈利水平看，受集采等政策冲击，板块整体盈利能力有所下降， 二季度行业毛利率（54.2%）下降3.5pp，销售费用率（26.9%） ，同比下降0.9pp，净利率（10.2%）下降2.2pp。",
    "labels": [
      [
        "T0",
        "时间范围",
        13,
        20,
        "2021上半年"
      ],
      [
        "T1",
        "收入增速",
        20,
        26,
        "收入总额增速"
      ],
      [
        "T2",
        "归母净利润增速",
        33,
        42,
        "归母净利润总额增速"
      ],
      [
        "T3",
        "业务指标情况",
        53,
        55,
        "收入"
      ],
      [
        "T4",
        "时间范围",
        49,
        51,
        "Q2"
      ],
      [
        "T5",
        "利润",
        65,
        68,
        "利润端"
      ],
      [
        "T6",
        "扣非净利润",
        77,
        82,
        "扣非净利润"
      ],
      [
        "T7",
        "时间范围",
        87,
        89,
        "Q2"
      ],
      [
        "T8",
        "利润",
        89,
        92,
        "利润端"
      ],
      [
        "T9",
        "毛利",
        112,
        115,
        "毛利率"
      ],
      [
        "T10",
        "毛利",
        158,
        161,
        "毛利率"
      ],
      [
        "T11",
        "行业公司",
        2,
        13,
        "46家创新药及制剂公司"
      ],
      [
        "T12",
        "属性值",
        27,
        32,
        "16.7%"
      ],
      [
        "T13",
        "属性值",
        43,
        48,
        "12.4%"
      ],
      [
        "T14",
        "属性值",
        59,
        64,
        "12.7%"
      ],
      [
        "T15",
        "属性值",
        70,
        76,
        "下滑7.3%"
      ],
      [
        "T16",
        "属性值",
        82,
        86,
        "基本持平"
      ],
      [
        "T17",
        "属性值",
        94,
        96,
        "下滑"
      ],
      [
        "T18",
        "时间范围",
        153,
        156,
        "二季度"
      ],
      [
        "T19",
        "属性值",
        161,
        175,
        "（54.2%）下降3.5pp"
      ]
    ]
  },
  {
    "id": 560,
    "text": "生物药及细胞与基因研发热度带来相应 CXO需求，中国 CXO企业积极进行相应布局。中国 CDE一类新药 IND审批数量中的生物药数量与生物药临床实验数量均呈现出上升趋势，生物药相关的 CDMO服务增长潜力大于整体 CDMO市场。药明生物作为中国生物药 CDMO服务龙头企业，掌握 WuXiUP、WuXiBody、WuXiDAR4等优势平台，业绩表现出高景气度增长，并积极进行产能建设传统化学小分子龙头 CXO企业也在积极进行新兴领域布局。",
    "labels": [
      [
        "T0",
        "行业需求",
        21,
        23,
        "需求"
      ],
      [
        "T1",
        "地点范围",
        24,
        26,
        "中国"
      ],
      [
        "T2",
        "行业公司",
        27,
        32,
        "CXO企业"
      ],
      [
        "T3",
        "行业",
        92,
        96,
        "CDMO"
      ],
      [
        "T4",
        "行业",
        107,
        111,
        "CDMO"
      ],
      [
        "T5",
        "公司",
        114,
        118,
        "药明生物"
      ],
      [
        "T6",
        "行业",
        122,
        130,
        "生物药 CDMO"
      ],
      [
        "T7",
        "龙头企业",
        132,
        136,
        "龙头企业"
      ],
      [
        "T8",
        "业绩",
        170,
        172,
        "业绩"
      ],
      [
        "T9",
        "属性值",
        175,
        181,
        "高景气度增长"
      ],
      [
        "T10",
        "龙头企业",
        198,
        200,
        "龙头"
      ],
      [
        "T11",
        "行业公司",
        201,
        206,
        "CXO企业"
      ],
      [
        "T12",
        "行业",
        18,
        21,
        "CXO"
      ],
      [
        "T13",
        "属性值",
        183,
        191,
        "积极进行产能建设"
      ],
      [
        "T14",
        "行业",
        191,
        198,
        "传统化学小分子"
      ],
      [
        "T15",
        "临床试验数量",
        70,
        76,
        "临床实验数量"
      ],
      [
        "T16",
        "属性值",
        80,
        82,
        "上升"
      ],
      [
        "T17",
        "行业",
        67,
        70,
        "生物药"
      ]
    ]
  },
  {
    "id": 562,
    "text": "• 目前全球跨国TOP 20药企中16家已公告数据，统计来看其2021年前三季度合计营业收入为5024亿美元，同比增长15.1% ，我们判断主要是新冠疫苗和相关治疗药物的销售爆发，以及自疫情下逐渐恢复。 • 另外从研发投入的角度，统计15家跨国药企（相对收入，无罗氏数据）2021年前三季度合计研发投入为784亿美元，同比增长12.9%，延续高速增长，维持高景气度。",
    "labels": [
      [
        "T0",
        "时间范围",
        31,
        40,
        "2021年前三季度"
      ],
      [
        "T1",
        "营业收入",
        42,
        46,
        "营业收入"
      ],
      [
        "T2",
        "时间范围",
        136,
        145,
        "2021年前三季度"
      ],
      [
        "T3",
        "研发费用",
        147,
        151,
        "研发投入"
      ],
      [
        "T4",
        "地点范围",
        4,
        6,
        "全球"
      ],
      [
        "T5",
        "时间范围",
        2,
        4,
        "目前"
      ],
      [
        "T6",
        "属性值",
        47,
        54,
        "5024亿美元"
      ],
      [
        "T7",
        "属性值",
        59,
        64,
        "15.1%"
      ],
      [
        "T8",
        "研发费用",
        107,
        111,
        "研发投入"
      ],
      [
        "T9",
        "行业公司",
        117,
        124,
        "15家跨国药企"
      ],
      [
        "T10",
        "属性值",
        152,
        168,
        "784亿美元，同比增长12.9%"
      ],
      [
        "T11",
        "属性值",
        171,
        175,
        "高速增长"
      ],
      [
        "T12",
        "行业公司",
        6,
        16,
        "跨国TOP 20药企"
      ]
    ]
  },
  {
    "id": 563,
    "text": " 信邦制药：（1）聚焦医疗服务主业，以贵阳市为中心向省内辐射扩展，打造肿瘤医院、白云医院、乌当医院等核心医院资产，战略下沉基层市场，逐步构建分级诊疗网络，坚持“一体化管理、同质化发展”的思路，临床落实首席专家制，后台部门落实中心化管理。（2）股权激励落地，发展目标明确。2021年8月发布上市以来的第一次股权激励计划，2021-2023年的净利润目标值分别为2.8亿元、3.5亿元、4.3亿元，有望推动集团长期高质量发展。",
    "labels": [
      [
        "T0",
        "公司",
        2,
        6,
        "信邦制药"
      ],
      [
        "T1",
        "时间范围",
        160,
        170,
        "2021-2023年"
      ],
      [
        "T2",
        "归母净利润",
        171,
        174,
        "净利润"
      ],
      [
        "T3",
        "属性值",
        180,
        197,
        "2.8亿元、3.5亿元、4.3亿元"
      ],
      [
        "T4",
        "行业",
        12,
        16,
        "医疗服务"
      ],
      [
        "T5",
        "地点范围",
        20,
        23,
        "贵阳市"
      ]
    ]
  },
  {
    "id": 564,
    "text": "我国创新药企业通过 License-out实现出海第一步，提高了国际知名度的同时也获得了现金流补充。随着国内新药研发水平不断提高，国内产品逐渐展现出优异的国际竞争力，对外授权的项目呈现出逐年上升和授权大金额项目增加的双重趋势。对外授权项目数从 2015-2019年每年有不到 10项，到2020年和 2021年的每年30项左右。交易金额屡创纪录：2006年，微芯生物以 2800万美元将其在研产品西达本胺授权给 HUYA， 开创中国创新药海外 License-out的先河；2020年9月，天境生物与艾伯维就CD47单",
    "labels": [
      [
        "T0",
        "地点范围",
        0,
        2,
        "我国"
      ],
      [
        "T1",
        "行业公司",
        2,
        7,
        "创新药企业"
      ],
      [
        "T2",
        "地点范围",
        52,
        54,
        "国内"
      ],
      [
        "T3",
        "公司",
        179,
        183,
        "微芯生物"
      ],
      [
        "T4",
        "行业",
        216,
        219,
        "创新药"
      ],
      [
        "T5",
        "公司",
        245,
        249,
        "天境生物"
      ],
      [
        "T6",
        "公司",
        250,
        253,
        "艾伯维"
      ],
      [
        "T7",
        "时间范围",
        150,
        155,
        "2021年"
      ],
      [
        "T8",
        "时间范围",
        173,
        178,
        "2006年"
      ],
      [
        "T9",
        "时间范围",
        237,
        244,
        "2020年9月"
      ],
      [
        "T10",
        "现金流",
        44,
        47,
        "现金流"
      ],
      [
        "T11",
        "时间范围",
        122,
        132,
        "2015-2019年"
      ],
      [
        "T12",
        "时间范围",
        143,
        148,
        "2020年"
      ],
      [
        "T13",
        "地点范围",
        214,
        216,
        "中国"
      ],
      [
        "T14",
        "地点范围",
        219,
        221,
        "海外"
      ]
    ]
  },
  {
    "id": 566,
    "text": " Pharma转型加速，Biotech展现国际化竞争实力。pharma的优势在于研发资金充裕、具有成熟的营销推广团队，关键需要产品加持，白马龙头恒瑞今年9月连续引进2款国内biotech产品，树立积极、开放参与创新的风向标。信达和百济的PD-1单抗国内获批肝癌和肺癌大适应症，康方和誉衡两款新PD-1获批上市，泽布替尼、恩沙替尼、阿美替尼等表现优异，荣昌HER2-ADC和百济PD-1刷新license-out单药交易金额，创新实力逐步得到国际化认可。",
    "labels": [
      [
        "T0",
        "行业",
        13,
        20,
        "Biotech"
      ],
      [
        "T1",
        "公司",
        2,
        8,
        "Pharma"
      ],
      [
        "T2",
        "公司",
        30,
        36,
        "pharma"
      ],
      [
        "T3",
        "龙头企业",
        71,
        73,
        "龙头"
      ],
      [
        "T4",
        "公司",
        73,
        75,
        "恒瑞"
      ],
      [
        "T5",
        "公司",
        113,
        115,
        "信达"
      ],
      [
        "T6",
        "公司",
        116,
        118,
        "百济"
      ],
      [
        "T7",
        "公司",
        139,
        141,
        "康方"
      ],
      [
        "T8",
        "公司",
        142,
        144,
        "誉衡"
      ],
      [
        "T9",
        "公司",
        176,
        178,
        "荣昌"
      ],
      [
        "T10",
        "公司",
        187,
        189,
        "百济"
      ],
      [
        "T11",
        "时间范围",
        75,
        79,
        "今年9月"
      ],
      [
        "T12",
        "地点范围",
        85,
        87,
        "国内"
      ],
      [
        "T13",
        "行业",
        87,
        94,
        "biotech"
      ]
    ]
  },
  {
    "id": 568,
    "text": "2019年我国零售药店销售额 CR5、CR10、CR100集中度分别为 13%、20%、46%， 远低于美国零售药销售额 CR3的 77%、日本药妆店销售额 CR5的 31%，行业集中度将确定性提升，龙头连锁药店发展空间广阔。近年来，头部连锁药店新开和并购门店速度加快，今年前三季度四大龙头门店数均净增加 1000家以上，预计全年新增门店占比 15- 25%。",
    "labels": [
      [
        "T0",
        "时间范围",
        0,
        5,
        "2019年"
      ],
      [
        "T1",
        "地点范围",
        5,
        7,
        "我国"
      ],
      [
        "T2",
        "行业",
        7,
        11,
        "零售药店"
      ],
      [
        "T3",
        "CR5",
        15,
        18,
        "CR5"
      ],
      [
        "T4",
        "CR10",
        19,
        23,
        "CR10"
      ],
      [
        "T5",
        "市场集中度",
        29,
        32,
        "集中度"
      ],
      [
        "T6",
        "属性值",
        36,
        39,
        "13%"
      ],
      [
        "T7",
        "属性值",
        40,
        43,
        "20%"
      ],
      [
        "T8",
        "地点范围",
        52,
        54,
        "美国"
      ],
      [
        "T9",
        "行业",
        54,
        57,
        "零售药"
      ],
      [
        "T10",
        "市场集中度",
        88,
        93,
        "行业集中度"
      ],
      [
        "T11",
        "龙头企业",
        100,
        102,
        "龙头"
      ],
      [
        "T12",
        "时间范围",
        135,
        141,
        "今年前三季度"
      ],
      [
        "T13",
        "地点范围",
        70,
        72,
        "日本"
      ],
      [
        "T14",
        "行业",
        72,
        75,
        "药妆店"
      ],
      [
        "T15",
        "CR5",
        79,
        82,
        "CR5"
      ],
      [
        "T16",
        "属性值",
        84,
        87,
        "31%"
      ],
      [
        "T17",
        "属性值",
        94,
        99,
        "确定性提升"
      ],
      [
        "T18",
        "时间范围",
        113,
        116,
        "近年来"
      ]
    ]
  },
  {
    "id": 570,
    "text": "• CXO领域：博腾股份、美迪西、药明康德、九洲药业、昭衍新药、凯莱英、康龙化成、诺泰生物、维亚生物； • 医美领域：爱美客、华东医药； • 疫苗：智飞生物、百克生物、康泰生物； • 生长激素： 长春高新； • 创新药及制剂出口领域：恒瑞医药、先声药业、海思科； • 医疗器械领域：维力医疗、康德莱。",
    "labels": [
      [
        "T0",
        "行业",
        2,
        5,
        "CXO"
      ],
      [
        "T1",
        "公司",
        8,
        12,
        "博腾股份"
      ],
      [
        "T2",
        "公司",
        13,
        16,
        "美迪西"
      ],
      [
        "T3",
        "公司",
        17,
        21,
        "药明康德"
      ],
      [
        "T4",
        "公司",
        22,
        26,
        "九洲药业"
      ],
      [
        "T5",
        "公司",
        27,
        31,
        "昭衍新药"
      ],
      [
        "T6",
        "公司",
        32,
        35,
        "凯莱英"
      ],
      [
        "T7",
        "公司",
        36,
        40,
        "康龙化成"
      ],
      [
        "T8",
        "公司",
        41,
        45,
        "诺泰生物"
      ],
      [
        "T9",
        "公司",
        46,
        50,
        "维亚生物"
      ],
      [
        "T10",
        "行业",
        54,
        56,
        "医美"
      ],
      [
        "T11",
        "公司",
        59,
        62,
        "爱美客"
      ],
      [
        "T12",
        "公司",
        63,
        67,
        "华东医药"
      ],
      [
        "T13",
        "行业",
        71,
        73,
        "疫苗"
      ],
      [
        "T14",
        "公司",
        74,
        78,
        "智飞生物"
      ],
      [
        "T15",
        "公司",
        79,
        83,
        "百克生物"
      ],
      [
        "T16",
        "公司",
        84,
        88,
        "康泰生物"
      ],
      [
        "T17",
        "行业",
        92,
        96,
        "生长激素"
      ],
      [
        "T18",
        "行业",
        106,
        114,
        "创新药及制剂出口"
      ],
      [
        "T19",
        "公司",
        117,
        121,
        "恒瑞医药"
      ],
      [
        "T20",
        "公司",
        122,
        126,
        "先声药业"
      ],
      [
        "T21",
        "公司",
        127,
        130,
        "海思科"
      ],
      [
        "T22",
        "行业",
        134,
        138,
        "医疗器械"
      ],
      [
        "T23",
        "公司",
        141,
        145,
        "维力医疗"
      ],
      [
        "T24",
        "公司",
        146,
        149,
        "康德莱"
      ],
      [
        "T25",
        "公司",
        98,
        102,
        "长春高新"
      ]
    ]
  },
  {
    "id": 571,
    "text": "CXO年报预告与回顾：需求不减，景气依旧：截至 2022年 1月 21日，共计 8家企业发布年度业绩预告，整体略超市场预期，其中昭衍新药、博腾股份业绩超市场预期，药明康德、泰格医药、康龙化成略超市场预期。 2020年年初至 2021年前三季度，CXO板块公司股价走势一路向好，近期股价波动的原因之一为市场对于美国制裁中国生物科技股的忧虑。我们认为国内龙头 CXO公司已与美国龙头药企合作多年，且承接大批小分子新冠药物订单，若美国药企更换 CXO服务商需付出高成本，承担高风险， 因此国内 CXO龙头受美国制裁的可能性不高。",
    "labels": [
      [
        "T0",
        "行业",
        0,
        3,
        "CXO"
      ],
      [
        "T1",
        "行业需求",
        11,
        13,
        "需求"
      ],
      [
        "T2",
        "时间范围",
        21,
        36,
        "截至 2022年 1月 21日"
      ],
      [
        "T3",
        "公司",
        64,
        68,
        "昭衍新药"
      ],
      [
        "T4",
        "公司",
        69,
        73,
        "博腾股份"
      ],
      [
        "T5",
        "业绩",
        73,
        75,
        "业绩"
      ],
      [
        "T6",
        "公司",
        81,
        85,
        "药明康德"
      ],
      [
        "T7",
        "公司",
        86,
        90,
        "泰格医药"
      ],
      [
        "T8",
        "公司",
        91,
        95,
        "康龙化成"
      ],
      [
        "T9",
        "行业",
        122,
        125,
        "CXO"
      ],
      [
        "T10",
        "地点范围",
        173,
        175,
        "国内"
      ],
      [
        "T11",
        "龙头企业",
        175,
        177,
        "龙头"
      ],
      [
        "T12",
        "行业公司",
        178,
        183,
        "CXO公司"
      ],
      [
        "T13",
        "地点范围",
        185,
        187,
        "美国"
      ],
      [
        "T14",
        "龙头企业",
        187,
        189,
        "龙头"
      ],
      [
        "T15",
        "行业公司",
        189,
        191,
        "药企"
      ],
      [
        "T16",
        "行业公司",
        214,
        216,
        "药企"
      ],
      [
        "T17",
        "地点范围",
        241,
        243,
        "国内"
      ],
      [
        "T18",
        "行业",
        244,
        247,
        "CXO"
      ],
      [
        "T19",
        "龙头企业",
        247,
        249,
        "龙头"
      ],
      [
        "T20",
        "属性值",
        13,
        15,
        "不减"
      ],
      [
        "T21",
        "业绩",
        48,
        50,
        "业绩"
      ],
      [
        "T22",
        "时间范围",
        103,
        121,
        "2020年年初至 2021年前三季度"
      ],
      [
        "T23",
        "地点范围",
        154,
        156,
        "美国"
      ],
      [
        "T24",
        "地点范围",
        158,
        160,
        "中国"
      ],
      [
        "T25",
        "行业公司",
        160,
        165,
        "生物科技股"
      ],
      [
        "T26",
        "地点范围",
        212,
        214,
        "美国"
      ],
      [
        "T27",
        "行业公司",
        219,
        225,
        "CXO服务商"
      ],
      [
        "T28",
        "地点范围",
        250,
        252,
        "美国"
      ]
    ]
  },
  {
    "id": 572,
    "text": "《凯莱英：业绩稳定增长，持续建设产能服务  能力》20211027 《凯莱英：业绩稳定增长，服务能力与产能持续提升》20210816 《凯莱英：兼顾“做深”与“做广”，业绩实现稳定增长》20210416",
    "labels": [
      [
        "T0",
        "公司",
        1,
        4,
        "凯莱英"
      ],
      [
        "T1",
        "业绩",
        5,
        7,
        "业绩"
      ],
      [
        "T2",
        "属性值",
        7,
        11,
        "稳定增长"
      ],
      [
        "T3",
        "公司",
        35,
        38,
        "凯莱英"
      ],
      [
        "T4",
        "业绩",
        39,
        41,
        "业绩"
      ],
      [
        "T5",
        "属性值",
        41,
        45,
        "稳定增长"
      ],
      [
        "T6",
        "时间范围",
        25,
        33,
        "20211027"
      ],
      [
        "T7",
        "时间范围",
        58,
        66,
        "20210816"
      ],
      [
        "T8",
        "时间范围",
        93,
        101,
        "20210416"
      ],
      [
        "T9",
        "公司",
        68,
        71,
        "凯莱英"
      ],
      [
        "T10",
        "产能",
        51,
        53,
        "产能"
      ],
      [
        "T11",
        "业绩",
        84,
        86,
        "业绩"
      ],
      [
        "T12",
        "属性值",
        88,
        92,
        "稳定增长"
      ],
      [
        "T13",
        "属性值",
        53,
        57,
        "持续提升"
      ],
      [
        "T14",
        "属性值",
        12,
        16,
        "持续建设"
      ]
    ]
  },
  {
    "id": 573,
    "text": " CXO板块(10家)： CXO公司2021年上半年收入总额为229亿元，同比增速为45.6%，归母净利润总额为60亿元，同比增速为49.7%，Q2收入同比增长37.7%，龙头药明康德上半年收入占板块超过46%，净利润占比超过45%，带动行业稳健增长。",
    "labels": [
      [
        "T0",
        "行业",
        2,
        5,
        "CXO"
      ],
      [
        "T1",
        "行业公司",
        14,
        19,
        "CXO公司"
      ],
      [
        "T2",
        "时间范围",
        19,
        27,
        "2021年上半年"
      ],
      [
        "T3",
        "营业收入",
        27,
        31,
        "收入总额"
      ],
      [
        "T4",
        "营收增长",
        40,
        42,
        "增速"
      ],
      [
        "T5",
        "时间范围",
        73,
        75,
        "Q2"
      ],
      [
        "T6",
        "营业收入",
        75,
        77,
        "收入"
      ],
      [
        "T7",
        "龙头企业",
        87,
        89,
        "龙头"
      ],
      [
        "T8",
        "公司",
        89,
        93,
        "药明康德"
      ],
      [
        "T9",
        "时间范围",
        93,
        96,
        "上半年"
      ],
      [
        "T10",
        "营业收入",
        96,
        98,
        "收入"
      ],
      [
        "T11",
        "归母净利润",
        107,
        110,
        "净利润"
      ],
      [
        "T12",
        "属性值",
        32,
        37,
        "229亿元"
      ],
      [
        "T13",
        "属性值",
        43,
        48,
        "45.6%"
      ],
      [
        "T14",
        "属性值",
        57,
        61,
        "60亿元"
      ],
      [
        "T15",
        "归母净利润",
        49,
        54,
        "归母净利润"
      ],
      [
        "T16",
        "属性值",
        67,
        72,
        "49.7%"
      ],
      [
        "T17",
        "属性值",
        81,
        86,
        "37.7%"
      ],
      [
        "T18",
        "属性值",
        101,
        106,
        "超过46%"
      ]
    ]
  },
  {
    "id": 574,
    "text": "我们发现近年来头部CXO国际化产能布局加速。药明康德收购百时美施贵宝位于瑞士库威（Couvet）的生产基地以加快切入全球API 和制剂供应链体系。康龙化成以1.187亿美元现金收购艾伯维旗下位于英国利物浦的 ABL及美国Absorption Systems，旨在打造从临床前研究、产品开发到商业化生产的CGT服务大平台。博腾股份加强美国子公司J-STAR服务能力，从导流本土到local-for-local的战略转变均体现了头部CXO公司在技术能力提升的同时不断加强海外产能布局，以应对不确定的国际关系风险。",
    "labels": [
      [
        "T0",
        "行业",
        9,
        12,
        "CXO"
      ],
      [
        "T1",
        "时间范围",
        4,
        7,
        "近年来"
      ],
      [
        "T2",
        "公司",
        22,
        26,
        "药明康德"
      ],
      [
        "T3",
        "公司",
        28,
        34,
        "百时美施贵宝"
      ],
      [
        "T4",
        "公司",
        73,
        77,
        "康龙化成"
      ],
      [
        "T5",
        "公司",
        90,
        93,
        "艾伯维"
      ],
      [
        "T6",
        "公司",
        104,
        107,
        "ABL"
      ],
      [
        "T7",
        "公司",
        110,
        128,
        "Absorption Systems"
      ],
      [
        "T8",
        "公司",
        160,
        164,
        "博腾股份"
      ],
      [
        "T9",
        "公司",
        171,
        177,
        "J-STAR"
      ],
      [
        "T10",
        "行业公司",
        214,
        219,
        "CXO公司"
      ],
      [
        "T11",
        "属性值",
        17,
        21,
        "布局加速"
      ],
      [
        "T12",
        "地点范围",
        36,
        48,
        "瑞士库威（Couvet）"
      ],
      [
        "T13",
        "地点范围",
        58,
        60,
        "全球"
      ],
      [
        "T14",
        "行业",
        60,
        70,
        "API 和制剂供应链"
      ],
      [
        "T15",
        "地点范围",
        97,
        102,
        "英国利物浦"
      ],
      [
        "T16",
        "地点范围",
        108,
        110,
        "美国"
      ],
      [
        "T17",
        "属性值",
        231,
        239,
        "加强海外产能布局"
      ]
    ]
  },
  {
    "id": 575,
    "text": "催化剂三：创新药海外进展，阿帕替尼+PD1全球多中心一线肝癌预期2022年BLA，吡咯替尼肺癌预期2022年NDA。氟唑帕利、IL-17单抗、 JAK1等多个产品海外关键性临床3期。",
    "labels": [
      [
        "T0",
        "行业",
        5,
        8,
        "创新药"
      ],
      [
        "T1",
        "地点范围",
        8,
        10,
        "海外"
      ],
      [
        "T2",
        "地点范围",
        81,
        83,
        "海外"
      ]
    ]
  },
  {
    "id": 576,
    "text": "我们认为 CXO赛道当前发展趋势不变。头部公司随着业务布局的逐渐完善， 行业市占率稳步提升，业绩快速增长趋势不变；细分赛道龙头受益于创新药市场景气度，订单保持较快增长。我们建议投资人关注：一线产业龙头：如药明康德、凯莱英、泰格医药、康龙化成、药明生物等。细分赛道龙头：如博腾股份、美迪西、昭衍新药、九洲药业、药石科技等。",
    "labels": [
      [
        "T0",
        "行业",
        4,
        8,
        " CXO"
      ],
      [
        "T1",
        "市场份额",
        38,
        41,
        "市占率"
      ],
      [
        "T2",
        "业绩",
        46,
        48,
        "业绩"
      ],
      [
        "T3",
        "龙头企业",
        98,
        100,
        "龙头"
      ],
      [
        "T4",
        "公司",
        102,
        106,
        "药明康德"
      ],
      [
        "T5",
        "公司",
        107,
        110,
        "凯莱英"
      ],
      [
        "T6",
        "公司",
        111,
        115,
        "泰格医药"
      ],
      [
        "T7",
        "公司",
        116,
        120,
        "康龙化成"
      ],
      [
        "T8",
        "公司",
        121,
        125,
        "药明生物"
      ],
      [
        "T9",
        "龙头企业",
        131,
        133,
        "龙头"
      ],
      [
        "T10",
        "公司",
        135,
        139,
        "博腾股份"
      ],
      [
        "T11",
        "公司",
        140,
        143,
        "美迪西"
      ],
      [
        "T12",
        "公司",
        144,
        148,
        "昭衍新药"
      ],
      [
        "T13",
        "公司",
        149,
        153,
        "九洲药业"
      ],
      [
        "T14",
        "公司",
        154,
        158,
        "药石科技"
      ],
      [
        "T15",
        "属性值",
        16,
        18,
        "不变"
      ],
      [
        "T16",
        "行业",
        66,
        69,
        "创新药"
      ]
    ]
  },
  {
    "id": 577,
    "text": "同时，行业因素和估值等是前期扰动 CXO板块的重要因素，当前我们认为其对板块的压制正在边际缓和。一方面，复盘海外市场来看，我们认为海外流动性收紧（联储收紧）对全球投融资数据、CXO公司业绩及股价表现并不会产生太强的负面影响。另一方面，从估值角度来看，随着前期板块下跌消化估值溢价，当前 CXO板块估值处在相对低位水平。此外，虽然短期新冠小分子药物重磅订单催化我国小分子 CDMO行业产能快速释放，但根据我们分析和测算行业需求后续仍有较大提升空间，且全球订单向中国转移和集中的趋势可持续。",
    "labels": [
      [
        "T0",
        "行业",
        17,
        20,
        "CXO"
      ],
      [
        "T1",
        "时间范围",
        28,
        30,
        "当前"
      ],
      [
        "T2",
        "地点范围",
        54,
        56,
        "海外"
      ],
      [
        "T3",
        "地点范围",
        65,
        67,
        "海外"
      ],
      [
        "T4",
        "投融资情况",
        81,
        86,
        "投融资数据"
      ],
      [
        "T5",
        "地点范围",
        79,
        81,
        "全球"
      ],
      [
        "T6",
        "行业公司",
        87,
        92,
        "CXO公司"
      ],
      [
        "T7",
        "业绩",
        92,
        94,
        "业绩"
      ],
      [
        "T8",
        "时间范围",
        140,
        142,
        "当前"
      ],
      [
        "T9",
        "行业",
        143,
        146,
        "CXO"
      ],
      [
        "T10",
        "地点范围",
        179,
        181,
        "我国"
      ],
      [
        "T11",
        "行业",
        181,
        189,
        "小分子 CDMO"
      ],
      [
        "T12",
        "产能",
        191,
        193,
        "产能"
      ],
      [
        "T13",
        "属性值",
        193,
        197,
        "快速释放"
      ],
      [
        "T14",
        "行业需求",
        208,
        212,
        "行业需求"
      ],
      [
        "T15",
        "属性值",
        215,
        222,
        "有较大提升空间"
      ],
      [
        "T16",
        "属性值",
        224,
        236,
        "全球订单向中国转移和集中"
      ]
    ]
  },
  {
    "id": 579,
    "text": "估值角度来看，随着过去几个月板块持续下跌消化估值溢价，当前 CXO板块估值已进入低位水平，多数公司 2022年 PE估值在 40倍以下。基于 2022年部分 CDMO公司有重磅订单贡献业绩弹性，我们考虑 2022-2023年两年复合增速，当前 CXO板块多数公司 PEG小于 1。以药明康德为例，根据我们最新盈利预测， 预计其 2021-2023年 EPS分别为 1.69/2.75/3.53元（同比增长 69%/63%/28%）， 2022年 3月 8日股价对应 PE分别为 58X/36X/28X，2022-2023年归母净利润复合增长率约为 44%，PEG小于 1。",
    "labels": [
      [
        "T0",
        "行业",
        30,
        33,
        "CXO"
      ],
      [
        "T1",
        "时间范围",
        49,
        55,
        " 2022年"
      ],
      [
        "T2",
        "PE",
        56,
        58,
        "PE"
      ],
      [
        "T3",
        "时间范围",
        71,
        76,
        "2022年"
      ],
      [
        "T4",
        "行业公司",
        79,
        85,
        "CDMO公司"
      ],
      [
        "T5",
        "时间范围",
        102,
        114,
        "2022-2023年两年"
      ],
      [
        "T6",
        "行业公司",
        122,
        131,
        "CXO板块多数公司"
      ],
      [
        "T7",
        "PEG",
        132,
        135,
        "PEG"
      ],
      [
        "T8",
        "属性值",
        135,
        139,
        "小于 1"
      ],
      [
        "T9",
        "公司",
        141,
        145,
        "药明康德"
      ],
      [
        "T10",
        "时间范围",
        164,
        175,
        "2021-2023年 "
      ],
      [
        "T11",
        "时间范围",
        216,
        228,
        " 2022年 3月 8日"
      ],
      [
        "T12",
        "PE",
        232,
        235,
        " PE"
      ],
      [
        "T13",
        "属性值",
        239,
        250,
        "58X/36X/28X"
      ],
      [
        "T14",
        "时间范围",
        251,
        261,
        "2022-2023年"
      ],
      [
        "T15",
        "归母净利润",
        261,
        266,
        "归母净利润"
      ],
      [
        "T16",
        "CAGR",
        266,
        271,
        "复合增长率"
      ],
      [
        "T17",
        "属性值",
        271,
        277,
        "约为 44%"
      ],
      [
        "T18",
        "PEG",
        278,
        281,
        "PEG"
      ],
      [
        "T19",
        "属性值",
        281,
        285,
        "小于 1"
      ],
      [
        "T20",
        "时间范围",
        119,
        121,
        "当前"
      ],
      [
        "T21",
        "时间范围",
        9,
        14,
        "过去几个月"
      ],
      [
        "T22",
        "时间范围",
        27,
        29,
        "当前"
      ]
    ]
  },
  {
    "id": 581,
    "text": "具体对比历史两轮联储紧缩周期及 2008年金融危机海外 CXO公司及纳斯达克指数涨跌幅，可以看到在联储紧缩周期中，CXO公司股价实现上涨，且涨幅均值显著超过纳斯达克指数（期间存在波动，但总体呈现上涨），而在金融危机阶段 CXO公司呈现出大幅下跌状态。基于此，我们认为除开重大金融事件扰动全球市场，海外流动性收紧（联储收紧）对 CXO公司业绩及股价表现并未产生太强的负面影响。",
    "labels": [
      [
        "T0",
        "时间范围",
        16,
        21,
        "2008年"
      ],
      [
        "T1",
        "地点范围",
        25,
        27,
        "海外"
      ],
      [
        "T2",
        "行业公司",
        28,
        33,
        "CXO公司"
      ],
      [
        "T3",
        "行业公司",
        57,
        62,
        "CXO公司"
      ],
      [
        "T4",
        "行业公司",
        110,
        115,
        "CXO公司"
      ],
      [
        "T5",
        "行业公司",
        163,
        168,
        "CXO公司"
      ],
      [
        "T6",
        "业绩",
        168,
        170,
        "业绩"
      ],
      [
        "T7",
        "地点范围",
        148,
        150,
        "海外"
      ]
    ]
  },
  {
    "id": 587,
    "text": "影响亦是相对有限。同时，无论是全球还是国内，继 2020年之后，2021年医药产业的融资金额又是高速增长，全球同比增速约 59.5%、国内同比增速约 38.8%。这为中短期内我国 CXO公司的订单来源和业绩增长提供有力支撑。",
    "labels": [
      [
        "T0",
        "地点范围",
        15,
        17,
        "全球"
      ],
      [
        "T1",
        "地点范围",
        19,
        21,
        "国内"
      ],
      [
        "T2",
        "时间范围",
        24,
        31,
        "2020年之后"
      ],
      [
        "T3",
        "时间范围",
        32,
        37,
        "2021年"
      ],
      [
        "T4",
        "行业",
        37,
        39,
        "医药"
      ],
      [
        "T5",
        "投融资金额",
        42,
        46,
        "融资金额"
      ],
      [
        "T6",
        "属性值",
        48,
        52,
        "高速增长"
      ],
      [
        "T7",
        "地点范围",
        53,
        55,
        "全球"
      ],
      [
        "T8",
        "属性值",
        55,
        66,
        "同比增速约 59.5%"
      ],
      [
        "T9",
        "属性值",
        69,
        80,
        "同比增速约 38.8%"
      ],
      [
        "T10",
        "地点范围",
        67,
        69,
        "国内"
      ],
      [
        "T11",
        "行业公司",
        90,
        95,
        "CXO公司"
      ],
      [
        "T12",
        "业绩",
        101,
        103,
        "业绩"
      ],
      [
        "T13",
        "时间范围",
        83,
        86,
        "中短期"
      ],
      [
        "T14",
        "地点范围",
        87,
        89,
        "我国"
      ]
    ]
  },
  {
    "id": 588,
    "text": "此外，除了投融资外，big pharma的研发费用作为创新研发资金的“基本盘”， 其稳定的增长也是 CXO维持景气度的重要驱动力。复盘历史来看，big pharma 的营收总体保持着稳定增长。虽然全球新药研发难度处于持续提升状态，但研发费用率总体保持稳步上行趋势。从研发费用角度来看，2013年后 big pharma研发费用重新回归增长趋势。",
    "labels": [
      [
        "T0",
        "行业",
        10,
        20,
        "big pharma"
      ],
      [
        "T1",
        "研发费用",
        21,
        25,
        "研发费用"
      ],
      [
        "T2",
        "属性值",
        42,
        47,
        "稳定的增长"
      ],
      [
        "T3",
        "行业",
        50,
        53,
        "CXO"
      ],
      [
        "T4",
        "行业",
        72,
        82,
        "big pharma"
      ],
      [
        "T5",
        "营业收入",
        84,
        86,
        "营收"
      ],
      [
        "T6",
        "属性值",
        91,
        95,
        "稳定增长"
      ],
      [
        "T7",
        "地点范围",
        98,
        100,
        "全球"
      ],
      [
        "T8",
        "研发费用率",
        116,
        121,
        "研发费用率"
      ],
      [
        "T9",
        "行业",
        100,
        104,
        "新药研发"
      ],
      [
        "T10",
        "研发费用",
        133,
        137,
        "研发费用"
      ],
      [
        "T11",
        "时间范围",
        142,
        148,
        "2013年后"
      ],
      [
        "T12",
        "行业",
        149,
        159,
        "big pharma"
      ],
      [
        "T13",
        "研发费用",
        159,
        163,
        "研发费用"
      ],
      [
        "T14",
        "属性值",
        167,
        169,
        "增长"
      ],
      [
        "T15",
        "属性值",
        125,
        129,
        "稳步上行"
      ]
    ]
  },
  {
    "id": 593,
    "text": "源于海外 CXO龙头公司的持续外延布局和调整经营战略，导致这些公司的业绩存在一定的波动性。回顾来看，海外 CXO龙头公司业绩增速的承压，除了金融危机等行业因素外，大多源于重组或资产剥离等带来的负面影响。但总体来看，海外 CXO龙头公司的业绩是保持稳定较快增长的。以 Charles River、 Parexel、Lonza为例，在 2008年金融危机之后，Charles River 2009-2021年净利润复合增长率为 10.8%；Lonza 2009-2020年净利润复合增长率为 16.5%；Parexel 2009-2016年（2017年退市）净利润复合增长率为 21.6%。",
    "labels": [
      [
        "T0",
        "地点范围",
        2,
        4,
        "海外"
      ],
      [
        "T1",
        "行业",
        4,
        8,
        " CXO"
      ],
      [
        "T2",
        "龙头企业",
        8,
        12,
        "龙头公司"
      ],
      [
        "T3",
        "业绩",
        34,
        36,
        "业绩"
      ],
      [
        "T4",
        "地点范围",
        50,
        53,
        "海外 "
      ],
      [
        "T5",
        "业绩",
        60,
        62,
        "业绩"
      ],
      [
        "T6",
        "地点范围",
        107,
        109,
        "海外"
      ],
      [
        "T7",
        "业绩",
        118,
        120,
        "业绩"
      ],
      [
        "T8",
        "公司",
        133,
        146,
        "Charles River"
      ],
      [
        "T9",
        "公司",
        148,
        155,
        "Parexel"
      ],
      [
        "T10",
        "公司",
        156,
        161,
        "Lonza"
      ],
      [
        "T11",
        "公司",
        178,
        191,
        "Charles River"
      ],
      [
        "T12",
        "时间范围",
        192,
        202,
        "2009-2021年"
      ],
      [
        "T13",
        "归母净利润",
        202,
        205,
        "净利润"
      ],
      [
        "T14",
        "CAGR",
        205,
        210,
        "复合增长率"
      ],
      [
        "T15",
        "属性值",
        211,
        217,
        " 10.8%"
      ],
      [
        "T16",
        "公司",
        218,
        224,
        "Lonza "
      ],
      [
        "T17",
        "时间范围",
        224,
        234,
        "2009-2020年"
      ],
      [
        "T18",
        "归母净利润",
        234,
        237,
        "净利润"
      ],
      [
        "T19",
        "CAGR",
        237,
        242,
        "复合增长率"
      ],
      [
        "T20",
        "属性值",
        244,
        249,
        "16.5%"
      ],
      [
        "T21",
        "公司",
        250,
        258,
        "Parexel "
      ],
      [
        "T22",
        "时间范围",
        258,
        268,
        "2009-2016年"
      ],
      [
        "T23",
        "归母净利润",
        277,
        280,
        "净利润"
      ],
      [
        "T24",
        "CAGR",
        280,
        285,
        "复合增长率"
      ],
      [
        "T25",
        "属性值",
        287,
        292,
        "21.6%"
      ],
      [
        "T26",
        "属性值",
        62,
        67,
        "增速的承压"
      ],
      [
        "T27",
        "行业公司",
        110,
        117,
        "CXO龙头公司"
      ],
      [
        "T28",
        "属性值",
        123,
        129,
        "稳定较快增长"
      ],
      [
        "T29",
        "行业公司",
        53,
        60,
        "CXO龙头公司"
      ],
      [
        "T30",
        "时间范围",
        166,
        171,
        "2008年"
      ],
      [
        "T31",
        "时间范围",
        269,
        274,
        "2017年"
      ]
    ]
  },
  {
    "id": 594,
    "text": "分析估值，除近两年外，海外 CXO头部公司的 PE总体落在 20-40倍之间，对比复合增速来看，其 PEG基本处在 1.5-2.5之间，存在一定的估值溢价。而近两年基于海外 CXO板块的优异表现，估值随着业绩增速一同上行。",
    "labels": [
      [
        "T0",
        "时间范围",
        6,
        9,
        "近两年"
      ],
      [
        "T1",
        "地点范围",
        11,
        13,
        "海外"
      ],
      [
        "T2",
        "PE",
        22,
        25,
        " PE"
      ],
      [
        "T3",
        "PEG",
        50,
        53,
        "PEG"
      ],
      [
        "T4",
        "时间范围",
        79,
        82,
        "近两年"
      ],
      [
        "T5",
        "行业",
        87,
        90,
        "CXO"
      ],
      [
        "T6",
        "业绩",
        102,
        104,
        "业绩"
      ],
      [
        "T7",
        "属性值",
        30,
        38,
        "20-40倍之间"
      ],
      [
        "T8",
        "行业公司",
        14,
        21,
        "CXO头部公司"
      ],
      [
        "T9",
        "属性值",
        58,
        67,
        "1.5-2.5之间"
      ],
      [
        "T10",
        "地点范围",
        84,
        86,
        "海外"
      ]
    ]
  },
  {
    "id": 596,
    "text": "而针对以国内业务为主的 CXO公司，我们认为当前国内创新药市场有些类似于 1980-1990年代的海外创新药市场，创新需求蓬勃发展，但竞争也在持续加剧， 开始加大对 CXO的需求。以昭衍新药为例，临床前 CRO可以间接体现国内创新药市场的繁荣度，可以看到昭衍新药在 2016年后收入增速开始显著加速。",
    "labels": [
      [
        "T0",
        "地点范围",
        4,
        6,
        "国内"
      ],
      [
        "T1",
        "行业公司",
        12,
        17,
        "CXO公司"
      ],
      [
        "T2",
        "地点范围",
        24,
        26,
        "国内"
      ],
      [
        "T3",
        "行业",
        26,
        29,
        "创新药"
      ],
      [
        "T4",
        "时间范围",
        37,
        48,
        "1980-1990年代"
      ],
      [
        "T5",
        "地点范围",
        49,
        51,
        "海外"
      ],
      [
        "T6",
        "行业",
        51,
        54,
        "创新药"
      ],
      [
        "T7",
        "行业需求",
        59,
        61,
        "需求"
      ],
      [
        "T8",
        "属性值",
        61,
        65,
        "蓬勃发展"
      ],
      [
        "T9",
        "竞争格局",
        67,
        69,
        "竞争"
      ],
      [
        "T10",
        "属性值",
        71,
        75,
        "持续加剧"
      ],
      [
        "T11",
        "行业",
        83,
        86,
        "CXO"
      ],
      [
        "T12",
        "公司",
        91,
        95,
        "昭衍新药"
      ],
      [
        "T13",
        "行业",
        98,
        105,
        "临床前 CRO"
      ],
      [
        "T14",
        "地点范围",
        111,
        113,
        "国内"
      ],
      [
        "T15",
        "行业",
        113,
        116,
        "创新药"
      ],
      [
        "T16",
        "公司",
        127,
        131,
        "昭衍新药"
      ],
      [
        "T17",
        "时间范围",
        133,
        139,
        "2016年后"
      ],
      [
        "T18",
        "收入增速",
        139,
        143,
        "收入增速"
      ],
      [
        "T19",
        "属性值",
        145,
        149,
        "显著加速"
      ],
      [
        "T20",
        "时间范围",
        22,
        24,
        "当前"
      ]
    ]
  },
  {
    "id": 599,
    "text": "Charles River代表临床前 CRO、Catalent代表 CDMO、IQVIA代表临床 CRO， 可以看到，Charles River和 Catalent走势总体趋同，在 2020年 3月后显著跑赢纳斯达克指数，其反映出临床前 CRO和 CDMO在疫情短期冲击后快速复苏，业绩实现加速增长。而临床 CRO受疫情影响程度相对更高，且恢复相对更慢，因此 IQVIA的走势在 2021年 3月前总体和纳斯达克指数趋同，2021年一季报体现出 IQVIA业绩也开始复苏及加速，其后续走势和纳斯达克指数出现分化。",
    "labels": [
      [
        "T0",
        "公司",
        0,
        13,
        "Charles River"
      ],
      [
        "T1",
        "行业",
        15,
        22,
        "临床前 CRO"
      ],
      [
        "T2",
        "公司",
        23,
        31,
        "Catalent"
      ],
      [
        "T3",
        "行业",
        34,
        38,
        "CDMO"
      ],
      [
        "T4",
        "公司",
        39,
        44,
        "IQVIA"
      ],
      [
        "T5",
        "行业",
        46,
        52,
        "临床 CRO"
      ],
      [
        "T6",
        "公司",
        59,
        72,
        "Charles River"
      ],
      [
        "T7",
        "公司",
        74,
        82,
        "Catalent"
      ],
      [
        "T8",
        "行业",
        115,
        122,
        "临床前 CRO"
      ],
      [
        "T9",
        "行业",
        124,
        128,
        "CDMO"
      ],
      [
        "T10",
        "业绩",
        141,
        143,
        "业绩"
      ],
      [
        "T11",
        "行业",
        151,
        157,
        "临床 CRO"
      ],
      [
        "T12",
        "公司",
        180,
        185,
        "IQVIA"
      ],
      [
        "T13",
        "时间范围",
        190,
        198,
        "2021年 3月"
      ],
      [
        "T14",
        "时间范围",
        211,
        218,
        "2021年一季"
      ],
      [
        "T15",
        "公司",
        223,
        228,
        "IQVIA"
      ],
      [
        "T16",
        "业绩",
        228,
        230,
        "业绩"
      ],
      [
        "T17",
        "时间范围",
        91,
        100,
        "2020年 3月后"
      ],
      [
        "T18",
        "属性值",
        145,
        149,
        "加速增长"
      ],
      [
        "T19",
        "属性值",
        233,
        238,
        "复苏及加速"
      ]
    ]
  },
  {
    "id": 600,
    "text": "从需求端分析，我们在上文图 10中分析 big pharma研发费用逐年稳步增长的趋势。从全球 IND数量角度来看，回顾 FDA CDER药物和非生物仿制药 IND数据，其中商业类项目数近年保持加速增长趋势，尤其是 2020年增长尤为明显。 从全球创新药市场规模来看，根据 Frost & Sullivan数据，全球创新药市场规模保持着稳定增长。基于这些数据，考虑 CDMO渗透率继续保持提升，我们认为全球市场对 CDMO订单需求总量整体保持稳定增长趋势。",
    "labels": [
      [
        "T0",
        "研发费用",
        30,
        34,
        "研发费用"
      ],
      [
        "T1",
        "行业",
        20,
        30,
        "big pharma"
      ],
      [
        "T2",
        "地点范围",
        122,
        124,
        "全球"
      ],
      [
        "T3",
        "行业",
        124,
        127,
        "创新药"
      ],
      [
        "T4",
        "市场规模",
        127,
        131,
        "市场规模"
      ],
      [
        "T5",
        "地点范围",
        156,
        158,
        "全球"
      ],
      [
        "T6",
        "行业",
        158,
        161,
        "创新药"
      ],
      [
        "T7",
        "市场规模",
        161,
        165,
        "市场规模"
      ],
      [
        "T8",
        "行业",
        183,
        187,
        "CDMO"
      ],
      [
        "T9",
        "行业",
        207,
        211,
        "CDMO"
      ],
      [
        "T10",
        "属性值",
        168,
        172,
        "稳定增长"
      ],
      [
        "T11",
        "属性值",
        36,
        40,
        "稳步增长"
      ],
      [
        "T12",
        "地点范围",
        45,
        47,
        "全球"
      ],
      [
        "T13",
        "时间范围",
        108,
        113,
        "2020年"
      ],
      [
        "T14",
        "地点范围",
        201,
        203,
        "全球"
      ],
      [
        "T15",
        "属性值",
        221,
        225,
        "稳定增长"
      ]
    ]
  },
  {
    "id": 605,
    "text": "值得一提的是，诚然基于新冠小分子药物重磅订单催化，我国小分子 CDMO行业产能快速释放，但增量产能主要针对新冠药物增量订单，抛开这部分不考虑我国小分子 CDMO市场的订单和全球市占率仍处在稳步上行的轨道。虽然后续新冠药物销售较难推测和演绎，但大概率是在短期爆发后，后续针对这类项目的产能慢慢回归于其他项目。在这一结构变化的过程中，我们预计我国小分子 CDMO市场发展将逐步回归到如图 29所预测的轨迹，后续全球市占率仍有望回归到稳定较快提升。",
    "labels": [
      [
        "T0",
        "地点范围",
        25,
        27,
        "我国"
      ],
      [
        "T1",
        "公司",
        27,
        35,
        "小分子 CDMO"
      ],
      [
        "T2",
        "地点范围",
        70,
        72,
        "我国"
      ],
      [
        "T3",
        "行业",
        72,
        80,
        "小分子 CDMO"
      ],
      [
        "T4",
        "新签订单",
        83,
        85,
        "订单"
      ],
      [
        "T5",
        "市场份额",
        88,
        91,
        "市占率"
      ],
      [
        "T6",
        "地点范围",
        169,
        171,
        "我国"
      ],
      [
        "T7",
        "行业",
        171,
        179,
        "小分子 CDMO"
      ],
      [
        "T8",
        "属性值",
        39,
        43,
        "快速释放"
      ],
      [
        "T9",
        "产能",
        37,
        39,
        "产能"
      ],
      [
        "T10",
        "地点范围",
        86,
        88,
        "全球"
      ],
      [
        "T11",
        "属性值",
        94,
        98,
        "稳步上行"
      ],
      [
        "T12",
        "地点范围",
        203,
        205,
        "全球"
      ],
      [
        "T13",
        "市场份额",
        205,
        208,
        "市占率"
      ],
      [
        "T14",
        "属性值",
        209,
        220,
        "有望回归到稳定较快提升"
      ]
    ]
  },
  {
    "id": 606,
    "text": "从全球产能建设角度，我们列举国内部分重点小分子 CDMO公司和海外部分 CDMO公司近年固定资产同比增长率和在建工程同比增长率。分析国内来看， 我国 CDMO企业产能建设和投入均处在较快增长状态，其中 2018-2020年在建工程复合增长率较为显著加速，体现出近年来我国小分子 CDMO产能的加速建设状态。分析海外来看，以 Lonza和 Catalent代表海外 CDMO龙头公司，可以看到两家龙头公司近年在建工程在加速增长；而以 Recipharm和 Siegfried代表中型规模的海外小分子 CDMO公司，其在建工程增长则相对不快。",
    "labels": [
      [
        "T0",
        "地点范围",
        1,
        3,
        "全球"
      ],
      [
        "T1",
        "产能",
        3,
        5,
        "产能"
      ],
      [
        "T2",
        "地点范围",
        14,
        16,
        "国内"
      ],
      [
        "T3",
        "行业公司",
        20,
        30,
        "小分子 CDMO公司"
      ],
      [
        "T4",
        "地点范围",
        31,
        33,
        "海外"
      ],
      [
        "T5",
        "行业公司",
        36,
        42,
        "CDMO公司"
      ],
      [
        "T6",
        "固定资产",
        44,
        48,
        "固定资产"
      ],
      [
        "T7",
        "地点范围",
        66,
        68,
        "国内"
      ],
      [
        "T8",
        "地点范围",
        72,
        74,
        "我国"
      ],
      [
        "T9",
        "行业公司",
        75,
        81,
        "CDMO企业"
      ],
      [
        "T10",
        "产能",
        81,
        83,
        "产能"
      ],
      [
        "T11",
        "属性值",
        91,
        95,
        "较快增长"
      ],
      [
        "T12",
        "时间范围",
        101,
        111,
        "2018-2020年"
      ],
      [
        "T13",
        "时间范围",
        130,
        133,
        "近年来"
      ],
      [
        "T14",
        "地点范围",
        133,
        135,
        "我国"
      ],
      [
        "T15",
        "行业",
        135,
        143,
        "小分子 CDMO"
      ],
      [
        "T16",
        "产能",
        143,
        145,
        "产能"
      ],
      [
        "T17",
        "属性值",
        146,
        150,
        "加速建设"
      ],
      [
        "T18",
        "地点范围",
        155,
        157,
        "海外"
      ],
      [
        "T19",
        "公司",
        162,
        167,
        "Lonza"
      ],
      [
        "T20",
        "公司",
        169,
        177,
        "Catalent"
      ],
      [
        "T21",
        "地点范围",
        179,
        181,
        "海外"
      ],
      [
        "T22",
        "行业",
        182,
        186,
        "CDMO"
      ],
      [
        "T23",
        "龙头企业",
        186,
        190,
        "龙头公司"
      ],
      [
        "T24",
        "公司",
        216,
        225,
        "Recipharm"
      ],
      [
        "T25",
        "公司",
        227,
        236,
        "Siegfried"
      ],
      [
        "T26",
        "地点范围",
        243,
        245,
        "海外"
      ],
      [
        "T27",
        "行业公司",
        245,
        255,
        "小分子 CDMO公司"
      ]
    ]
  },
  {
    "id": 608,
    "text": "分析 CAPEX，Lonza和 Catalent这类头部 CDMO公司，其 CAPEX增长和在建工程增长相对匹配，均处于加速增长状态，体现其对产能的加快建设。而 Recipharm和 Siegfried这类中型规模的海外小分子 CDMO公司，其近年的 CAPEX增速并不快，更趋近于全球 CDMO市场规模的增长水平。进一步聚焦于 Lonza和 Catalent 近年 CAPEX的拆分，其主要的投入方向是生物药 CDMO（包含 CGT），小分子 CDMO占比相对较小且增速相对平稳。基于此，我们认为头部 CDMO企业产能建设相对较快，但主要重心不在小分子 CDMO；中型小分子 CDMO企业产能建设保持相对平稳增长。总体来看，海外小分子 CDMO产能处于稳步增长趋势。在我国小分子 CDMO行业产能快速释放的基础下，全球订单向中国转移和集中的趋势可持续。",
    "labels": [
      [
        "T0",
        "公司",
        9,
        14,
        "Lonza"
      ],
      [
        "T1",
        "公司",
        16,
        24,
        "Catalent"
      ],
      [
        "T2",
        "龙头企业",
        26,
        28,
        "头部"
      ],
      [
        "T3",
        "行业公司",
        29,
        35,
        "CDMO公司"
      ],
      [
        "T4",
        "公司",
        81,
        90,
        "Recipharm"
      ],
      [
        "T5",
        "公司",
        92,
        101,
        "Siegfried"
      ],
      [
        "T6",
        "地点范围",
        108,
        110,
        "海外"
      ],
      [
        "T7",
        "行业公司",
        110,
        120,
        "小分子 CDMO公司"
      ],
      [
        "T8",
        "CAPEX资本开支",
        3,
        8,
        "CAPEX"
      ],
      [
        "T9",
        "CAPEX资本开支",
        37,
        43,
        " CAPEX"
      ],
      [
        "T10",
        "CAPEX资本开支",
        126,
        131,
        "CAPEX"
      ],
      [
        "T11",
        "属性值",
        131,
        136,
        "增速并不快"
      ],
      [
        "T12",
        "行业",
        144,
        148,
        "CDMO"
      ],
      [
        "T13",
        "市场规模",
        148,
        152,
        "市场规模"
      ],
      [
        "T14",
        "公司",
        165,
        170,
        "Lonza"
      ],
      [
        "T15",
        "公司",
        172,
        180,
        "Catalent"
      ],
      [
        "T16",
        "CAPEX资本开支",
        184,
        189,
        "CAPEX"
      ],
      [
        "T17",
        "行业",
        202,
        210,
        "生物药 CDMO"
      ],
      [
        "T18",
        "行业",
        219,
        227,
        "小分子 CDMO"
      ],
      [
        "T19",
        "行业",
        274,
        282,
        "小分子 CDMO"
      ],
      [
        "T20",
        "行业",
        315,
        323,
        "小分子 CDMO"
      ],
      [
        "T21",
        "地点范围",
        313,
        315,
        "海外"
      ],
      [
        "T22",
        "地点范围",
        335,
        337,
        "我国"
      ],
      [
        "T23",
        "行业",
        337,
        345,
        "小分子 CDMO"
      ],
      [
        "T24",
        "属性值",
        60,
        64,
        "加速增长"
      ],
      [
        "T25",
        "产能",
        71,
        73,
        "产能"
      ],
      [
        "T26",
        "属性值",
        74,
        78,
        "加快建设"
      ],
      [
        "T27",
        "时间范围",
        122,
        124,
        "近年"
      ],
      [
        "T28",
        "地点范围",
        141,
        143,
        "全球"
      ],
      [
        "T29",
        "时间范围",
        181,
        183,
        "近年"
      ],
      [
        "T30",
        "行业",
        214,
        217,
        "CGT"
      ],
      [
        "T31",
        "产能",
        258,
        260,
        "产能"
      ],
      [
        "T32",
        "属性值",
        260,
        266,
        "建设相对较快"
      ],
      [
        "T33",
        "行业公司",
        249,
        258,
        "头部 CDMO企业"
      ],
      [
        "T34",
        "行业公司",
        283,
        295,
        "中型小分子 CDMO企业"
      ],
      [
        "T35",
        "产能",
        295,
        297,
        "产能"
      ],
      [
        "T36",
        "属性值",
        297,
        307,
        "建设保持相对平稳增长"
      ],
      [
        "T37",
        "产能",
        323,
        325,
        "产能"
      ],
      [
        "T38",
        "属性值",
        327,
        331,
        "稳步增长"
      ],
      [
        "T39",
        "产能",
        347,
        349,
        "产能"
      ],
      [
        "T40",
        "属性值",
        349,
        353,
        "快速释放"
      ],
      [
        "T41",
        "地点范围",
        358,
        360,
        "全球"
      ],
      [
        "T42",
        "地点范围",
        363,
        365,
        "中国"
      ]
    ]
  },
  {
    "id": 611,
    "text": "我们认为 CXO赛道当前发展趋势不变。头部公司随着业务布局的逐渐完善，行业市占率稳步提升，业绩快速增长趋势不变；细分赛道龙头受益于创新药市场景气度，订单保持较快增长。我们建议投资人关注：",
    "labels": [
      [
        "T0",
        "行业",
        4,
        8,
        " CXO"
      ],
      [
        "T1",
        "市场份额",
        37,
        40,
        "市占率"
      ],
      [
        "T2",
        "业绩",
        45,
        47,
        "业绩"
      ],
      [
        "T3",
        "行业",
        65,
        68,
        "创新药"
      ],
      [
        "T4",
        "属性值",
        16,
        18,
        "不变"
      ]
    ]
  },
  {
    "id": 612,
    "text": "CRO/CDMO行业发展为顺周期，经济进入下行周期或行业下行，则需要引起重视。同时，中国的人口红利逐步减小，工程师红利尚存，其维持时间也需要持续跟踪。",
    "labels": [
      [
        "T0",
        "行业",
        0,
        8,
        "CRO/CDMO"
      ],
      [
        "T1",
        "地点范围",
        42,
        44,
        "中国"
      ]
    ]
  },
  {
    "id": 617,
    "text": "2）国内：创新药研发外包市场逐步进入收获期。比如，凯莱英2021年国内收入同比增长64%，且在手NDA订单数量超过30个，随着NDA及商业化项目数量的逐步落地，将推动国内市场持续快速增长。",
    "labels": [
      [
        "T0",
        "地点范围",
        2,
        4,
        "国内"
      ],
      [
        "T1",
        "行业",
        5,
        12,
        "创新药研发外包"
      ],
      [
        "T2",
        "公司",
        25,
        28,
        "凯莱英"
      ],
      [
        "T3",
        "时间范围",
        28,
        33,
        "2021年"
      ],
      [
        "T4",
        "地点范围",
        33,
        35,
        "国内"
      ],
      [
        "T5",
        "营业收入",
        35,
        37,
        "收入"
      ],
      [
        "T6",
        "在手订单",
        46,
        53,
        "在手NDA订单"
      ],
      [
        "T7",
        "属性值",
        55,
        60,
        "超过30个"
      ],
      [
        "T8",
        "属性值",
        41,
        44,
        "64%"
      ],
      [
        "T9",
        "地点范围",
        83,
        85,
        "国内"
      ]
    ]
  },
  {
    "id": 629,
    "text": "康龙化成业务包括实验室服务、CMC（小分子 CDMO） 服务、临床研究服务、大分子和细胞与基因治疗服务四大模块，公司业务源于小分子药物发现服务，在药物发现、临床前及早期临床研究方面处于领先地位，目前积极布局临床试验服务、大分子和细胞与基因治疗服务两大业务，打造多疗法、一体化的药物研发服务全球领军企业。",
    "labels": [
      [
        "T0",
        "公司",
        0,
        4,
        "康龙化成"
      ],
      [
        "T1",
        "主营业务",
        4,
        6,
        "业务"
      ],
      [
        "T2",
        "属性值",
        8,
        51,
        "实验室服务、CMC（小分子 CDMO） 服务、临床研究服务、大分子和细胞与基因治疗服务"
      ],
      [
        "T3",
        "行业",
        62,
        71,
        "小分子药物发现服务"
      ],
      [
        "T4",
        "行业",
        73,
        77,
        "药物发现"
      ],
      [
        "T5",
        "行业",
        78,
        88,
        "临床前及早期临床研究"
      ],
      [
        "T6",
        "行业",
        103,
        109,
        "临床试验服务"
      ],
      [
        "T7",
        "行业",
        110,
        113,
        "大分子"
      ],
      [
        "T8",
        "行业",
        114,
        123,
        "细胞与基因治疗服务"
      ],
      [
        "T9",
        "地点范围",
        144,
        146,
        "全球"
      ],
      [
        "T10",
        "行业",
        138,
        144,
        "药物研发服务"
      ],
      [
        "T11",
        "时间范围",
        97,
        99,
        "目前"
      ]
    ]
  },
  {
    "id": 635,
    "text": "康龙化成：2021年实现营收 74.44亿元，同比增长 45.00%；归母净利润 16.61亿元，同比增长 41.68%；扣非归母净利润 13.41亿元，同比增长 67.46%。",
    "labels": [
      [
        "T0",
        "公司",
        0,
        4,
        "康龙化成"
      ],
      [
        "T1",
        "时间范围",
        5,
        10,
        "2021年"
      ],
      [
        "T2",
        "营业收入",
        12,
        14,
        "营收"
      ],
      [
        "T3",
        "属性值",
        15,
        22,
        "74.44亿元"
      ],
      [
        "T4",
        "归母净利润",
        35,
        40,
        "归母净利润"
      ],
      [
        "T5",
        "扣非净利润",
        61,
        68,
        "扣非归母净利润"
      ],
      [
        "T6",
        "属性值",
        28,
        34,
        "45.00%"
      ],
      [
        "T7",
        "属性值",
        41,
        60,
        "16.61亿元，同比增长 41.68%"
      ],
      [
        "T8",
        "属性值",
        69,
        88,
        "13.41亿元，同比增长 67.46%"
      ]
    ]
  },
  {
    "id": 636,
    "text": "口目前，临床CRO行业市场集中度较高，初创公司难以抢占市场份额，IQVIA、Covance、LabCorp、Parexel等龙头公司地位已经形成。根据Frost&Sullivan，全球2019年临床CRO市场集中度CR10为64.9%，泰格医药是唯一进入Top10的中国企业，全球市场份额为0.8%。在中国临床CRO市场中，泰格医药和药明康德占据领先地位",
    "labels": [
      [
        "T0",
        "时间范围",
        1,
        3,
        "目前"
      ],
      [
        "T1",
        "行业",
        4,
        9,
        "临床CRO"
      ],
      [
        "T2",
        "属性值",
        16,
        18,
        "较高"
      ],
      [
        "T3",
        "市场集中度",
        11,
        16,
        "市场集中度"
      ],
      [
        "T4",
        "市场份额",
        27,
        31,
        "市场份额"
      ],
      [
        "T5",
        "公司",
        32,
        37,
        "IQVIA"
      ],
      [
        "T6",
        "公司",
        38,
        45,
        "Covance"
      ],
      [
        "T7",
        "公司",
        46,
        53,
        "LabCorp"
      ],
      [
        "T8",
        "公司",
        54,
        61,
        "Parexel"
      ],
      [
        "T9",
        "龙头企业",
        62,
        66,
        "龙头公司"
      ],
      [
        "T10",
        "地点范围",
        90,
        92,
        "全球"
      ],
      [
        "T11",
        "时间范围",
        92,
        97,
        "2019年"
      ],
      [
        "T12",
        "行业",
        97,
        102,
        "临床CRO"
      ],
      [
        "T13",
        "CR10",
        107,
        111,
        "CR10"
      ],
      [
        "T14",
        "市场集中度",
        102,
        107,
        "市场集中度"
      ],
      [
        "T15",
        "属性值",
        112,
        117,
        "64.9%"
      ],
      [
        "T16",
        "公司",
        118,
        122,
        "泰格医药"
      ],
      [
        "T17",
        "地点范围",
        133,
        135,
        "中国"
      ],
      [
        "T18",
        "地点范围",
        138,
        140,
        "全球"
      ],
      [
        "T19",
        "市场份额",
        140,
        144,
        "市场份额"
      ],
      [
        "T20",
        "属性值",
        145,
        149,
        "0.8%"
      ],
      [
        "T21",
        "地点范围",
        151,
        153,
        "中国"
      ],
      [
        "T22",
        "行业",
        153,
        158,
        "临床CRO"
      ],
      [
        "T23",
        "公司",
        162,
        166,
        "泰格医药"
      ],
      [
        "T24",
        "公司",
        167,
        171,
        "药明康德"
      ]
    ]
  },
  {
    "id": 641,
    "text": "➢ 全球新药在研管线饱满。根据Pharmaprojects统计，全球在研活跃药物管线数量2022年1月达到了20109个（数据截止2021.1），其中以处于临床前阶段的占比最大，占比为56%，临床I期和II期的管线合计占比30%。丰富的研发管线使得CXO公司上游的外包需求较为旺盛。",
    "labels": [
      [
        "T0",
        "行业公司",
        124,
        129,
        "CXO公司"
      ],
      [
        "T1",
        "行业需求",
        134,
        136,
        "需求"
      ],
      [
        "T2",
        "地点范围",
        2,
        4,
        "全球"
      ],
      [
        "T3",
        "地点范围",
        32,
        34,
        "全球"
      ],
      [
        "T4",
        "时间范围",
        65,
        71,
        "2021.1"
      ],
      [
        "T5",
        "行业",
        132,
        134,
        "外包"
      ],
      [
        "T6",
        "属性值",
        136,
        140,
        "较为旺盛"
      ],
      [
        "T7",
        "时间范围",
        44,
        51,
        "2022年1月"
      ]
    ]
  },
  {
    "id": 646,
    "text": "➢ 如前所述，CXO产业的空间主要来自全球创新药研发投入与医药健康领域融资规模，以及外包渗透率的提升 。根据当前全球新药研发产业链各环节的外包渗透率，CXO行业还有较大增长空间。",
    "labels": [
      [
        "T0",
        "行业",
        7,
        10,
        "CXO"
      ],
      [
        "T1",
        "地点范围",
        19,
        21,
        "全球"
      ],
      [
        "T2",
        "行业",
        21,
        24,
        "创新药"
      ],
      [
        "T3",
        "研发费用",
        24,
        28,
        "研发投入"
      ],
      [
        "T4",
        "行业",
        29,
        33,
        "医药健康"
      ],
      [
        "T5",
        "投融资情况",
        35,
        39,
        "融资规模"
      ],
      [
        "T6",
        "外包率",
        42,
        47,
        "外包渗透率"
      ],
      [
        "T7",
        "属性值",
        48,
        50,
        "提升"
      ],
      [
        "T8",
        "时间范围",
        54,
        56,
        "当前"
      ],
      [
        "T9",
        "地点范围",
        56,
        58,
        "全球"
      ],
      [
        "T10",
        "行业",
        58,
        62,
        "新药研发"
      ],
      [
        "T11",
        "外包率",
        69,
        74,
        "外包渗透率"
      ],
      [
        "T12",
        "行业",
        75,
        78,
        "CXO"
      ]
    ]
  },
  {
    "id": 647,
    "text": "◼ 为什么我们说未来最大的全球CXO公司大概率出现在中国？ ➢ 中国具备造就全球最大的CXO的天时、地利、人和的土壤：天时方面，中国和全球都迎来了创新药研发热潮， 中国公司CXO企业能力经过多年研发投入和重资本开支，企业能力得到较大提升，软硬实力兼备；地利方面， MAH政策激发国内Biotech公司研发投入、中国具备全球最为完善的工业产业链、旺盛的内生需求、便利的融资途径，助力国内CXO公司发展壮大；人和方面，中国具备工程师红利，国内CXO公司可以招募到大量高素质低成本的人员，过去20年的留学人员归国创业潮为中国CXO行业注入更多活力，使得企业管理体系与技术平台具有更广阔的国际化视野。以上三大因素，是中国CXO企业发展壮大的三大基石。 ➢ 我们测算了中国CXO领域几大细分龙头，2019-2029年各家公司有望达到8~12倍的收入空间，药明生物、药明康德届时将成为全球最大的CXO公司。",
    "labels": [
      [
        "T0",
        "行业公司",
        15,
        20,
        "CXO公司"
      ],
      [
        "T1",
        "行业",
        43,
        46,
        "CXO"
      ],
      [
        "T2",
        "龙头企业",
        86,
        91,
        "CXO企业"
      ],
      [
        "T3",
        "地点范围",
        139,
        141,
        "国内"
      ],
      [
        "T4",
        "行业公司",
        141,
        150,
        "Biotech公司"
      ],
      [
        "T5",
        "行业需求",
        177,
        179,
        "需求"
      ],
      [
        "T6",
        "行业公司",
        192,
        197,
        "CXO公司"
      ],
      [
        "T7",
        "地点范围",
        217,
        219,
        "国内"
      ],
      [
        "T8",
        "地点范围",
        190,
        192,
        "国内"
      ],
      [
        "T9",
        "行业公司",
        219,
        224,
        "CXO公司"
      ],
      [
        "T10",
        "地点范围",
        257,
        259,
        "中国"
      ],
      [
        "T11",
        "行业",
        259,
        262,
        "CXO"
      ],
      [
        "T12",
        "行业公司",
        306,
        311,
        "CXO企业"
      ],
      [
        "T13",
        "行业",
        331,
        334,
        "CXO"
      ],
      [
        "T14",
        "地点范围",
        329,
        331,
        "中国"
      ],
      [
        "T15",
        "龙头企业",
        340,
        342,
        "龙头"
      ],
      [
        "T16",
        "时间范围",
        343,
        353,
        "2019-2029年"
      ],
      [
        "T17",
        "公司",
        372,
        376,
        "药明生物"
      ],
      [
        "T18",
        "公司",
        377,
        381,
        "药明康德"
      ],
      [
        "T19",
        "行业公司",
        391,
        396,
        "CXO公司"
      ],
      [
        "T20",
        "时间范围",
        8,
        10,
        "未来"
      ],
      [
        "T21",
        "地点范围",
        13,
        15,
        "全球"
      ],
      [
        "T22",
        "地点范围",
        26,
        28,
        "中国"
      ],
      [
        "T23",
        "地点范围",
        32,
        34,
        "中国"
      ],
      [
        "T24",
        "地点范围",
        38,
        40,
        "全球"
      ],
      [
        "T25",
        "地点范围",
        64,
        66,
        "中国"
      ],
      [
        "T26",
        "地点范围",
        67,
        69,
        "全球"
      ],
      [
        "T27",
        "地点范围",
        82,
        84,
        "中国"
      ],
      [
        "T28",
        "属性值",
        102,
        103,
        "重"
      ],
      [
        "T29",
        "CAPEX资本开支",
        103,
        107,
        "资本开支"
      ],
      [
        "T30",
        "地点范围",
        155,
        157,
        "中国"
      ],
      [
        "T31",
        "地点范围",
        159,
        161,
        "全球"
      ],
      [
        "T32",
        "行业",
        166,
        168,
        "工业"
      ],
      [
        "T33",
        "地点范围",
        207,
        209,
        "中国"
      ],
      [
        "T34",
        "时间范围",
        241,
        246,
        "过去20年"
      ],
      [
        "T35",
        "地点范围",
        304,
        306,
        "中国"
      ],
      [
        "T36",
        "地点范围",
        386,
        388,
        "全球"
      ],
      [
        "T37",
        "行业",
        73,
        76,
        "创新药"
      ],
      [
        "T38",
        "研发费用",
        97,
        101,
        "研发投入"
      ],
      [
        "T39",
        "研发费用",
        150,
        154,
        "研发投入"
      ],
      [
        "T40",
        "属性值",
        172,
        174,
        "旺盛"
      ],
      [
        "T41",
        "营业收入",
        367,
        369,
        "收入"
      ]
    ]
  },
  {
    "id": 648,
    "text": "从年报来看， 2020年 CXO板块多数公司保持稳步扩增趋势，增速区间为 20-30%。 部分公司基于其业务拓展节奏和产能释放节奏实现加速增长，为其业绩的快速增长奠定基础，如康龙化成、美迪西和凯莱英等。从 2021Q1来看，虽然披露员工数量的公司较少，但以药明康德为例，可以看到其稳定的员工增速水平，且基于其今年的员工数量规划预计全年将呈现加速趋势。",
    "labels": [
      [
        "T0",
        "时间范围",
        7,
        12,
        "2020年"
      ],
      [
        "T1",
        "行业公司",
        13,
        22,
        "CXO板块多数公司"
      ],
      [
        "T2",
        "产能",
        59,
        61,
        "产能"
      ],
      [
        "T3",
        "业绩",
        74,
        76,
        "业绩"
      ],
      [
        "T4",
        "公司",
        87,
        91,
        "康龙化成"
      ],
      [
        "T5",
        "公司",
        92,
        95,
        "美迪西"
      ],
      [
        "T6",
        "公司",
        96,
        99,
        "凯莱英"
      ],
      [
        "T7",
        "时间范围",
        103,
        109,
        "2021Q1"
      ],
      [
        "T8",
        "员工数量",
        116,
        120,
        "员工数量"
      ],
      [
        "T9",
        "公司",
        128,
        132,
        "药明康德"
      ],
      [
        "T10",
        "属性值",
        170,
        172,
        "加速"
      ],
      [
        "T11",
        "员工数量",
        157,
        161,
        "员工数量"
      ],
      [
        "T12",
        "时间范围",
        154,
        156,
        "今年"
      ],
      [
        "T13",
        "属性值",
        140,
        149,
        "稳定的员工增速水平"
      ],
      [
        "T14",
        "属性值",
        77,
        81,
        "快速增长"
      ]
    ]
  },
  {
    "id": 658,
    "text": "我国单抗市场将迎来快速发展时期。单抗具备特异性强、灵敏度高、副作用小的独特优势，是生物药的最大类别，2018年销售额占全球生物药市场比重高达 55.3%。2020年全球销售额前二十的药品中，13个生物药中单抗就占据 9席，单抗目前是全球制药市场最重要的细分领域之一。而随着国内需求端及支付能力的持续提升，医保覆盖面及上市品种的持续扩大，我国单抗市场迎来快速发展时期，依据弗若斯特沙利文数据，预计到 2025年，中国单克隆抗体市场将增长到 1,810亿元人民币，2020年到 2025年的年复合增长率为 34.6%。到 2030年，我国市场规模将增长到 4,091亿元， 2025年到 2030年的年复合增长率为 17.7%。",
    "labels": [
      [
        "T0",
        "时间范围",
        199,
        204,
        "2025年"
      ],
      [
        "T1",
        "地点范围",
        205,
        207,
        "中国"
      ],
      [
        "T2",
        "行业",
        207,
        212,
        "单克隆抗体"
      ],
      [
        "T3",
        "属性值",
        219,
        229,
        "1,810亿元人民币"
      ],
      [
        "T4",
        "时间范围",
        230,
        242,
        "2020年到 2025年"
      ],
      [
        "T5",
        "CAGR",
        243,
        249,
        "年复合增长率"
      ],
      [
        "T6",
        "属性值",
        251,
        256,
        "34.6%"
      ],
      [
        "T7",
        "时间范围",
        259,
        264,
        "2030年"
      ],
      [
        "T8",
        "地点范围",
        265,
        267,
        "我国"
      ],
      [
        "T9",
        "市场规模",
        267,
        271,
        "市场规模"
      ],
      [
        "T10",
        "属性值",
        276,
        283,
        "4,091亿元"
      ],
      [
        "T11",
        "时间范围",
        285,
        297,
        "2025年到 2030年"
      ],
      [
        "T12",
        "CAGR",
        298,
        304,
        "年复合增长率"
      ],
      [
        "T13",
        "属性值",
        306,
        311,
        "17.7%"
      ],
      [
        "T14",
        "地点范围",
        168,
        170,
        "我国"
      ],
      [
        "T15",
        "行业",
        170,
        172,
        "单抗"
      ],
      [
        "T16",
        "时间范围",
        77,
        82,
        "2020年"
      ],
      [
        "T17",
        "地点范围",
        82,
        84,
        "全球"
      ],
      [
        "T18",
        "时间范围",
        113,
        115,
        "目前"
      ],
      [
        "T19",
        "行业",
        111,
        113,
        "单抗"
      ],
      [
        "T20",
        "地点范围",
        116,
        118,
        "全球"
      ],
      [
        "T21",
        "行业",
        118,
        120,
        "制药"
      ],
      [
        "T22",
        "地点范围",
        136,
        138,
        "国内"
      ],
      [
        "T23",
        "行业需求",
        138,
        141,
        "需求端"
      ],
      [
        "T24",
        "属性值",
        147,
        151,
        "持续提升"
      ],
      [
        "T25",
        "时间范围",
        50,
        55,
        "2018年"
      ],
      [
        "T26",
        "地点范围",
        59,
        61,
        "全球"
      ],
      [
        "T27",
        "行业",
        61,
        64,
        "生物药"
      ],
      [
        "T28",
        "行业",
        41,
        44,
        "生物药"
      ],
      [
        "T29",
        "行业",
        2,
        4,
        "单抗"
      ],
      [
        "T30",
        "地点范围",
        0,
        2,
        "我国"
      ],
      [
        "T31",
        "行业",
        16,
        18,
        "单抗"
      ]
    ]
  },
  {
    "id": 660,
    "text": "短期看：CXO年度收益与投融资年度增长趋势一致性弱。回顾2011-2020年CXO 市场表现与上一年投融资增长趋势一致性较弱。2015年是A股牛市，并非主要是因为2014 年全球投融资同比增速较高催化CXO股价大幅上涨。2015年全球投融资金额同比增长 43%，但是2016年CXO平均收益率为-14%，2017年投融资YOY61%但2018年CXO 下跌4%，2019年投融资YOY3%但2020年CXO上涨135%，从这些年度数据看不出明显的一致性。",
    "labels": [
      [
        "T0",
        "时间范围",
        0,
        2,
        "短期"
      ],
      [
        "T1",
        "行业",
        4,
        7,
        "CXO"
      ],
      [
        "T2",
        "投融资情况",
        12,
        15,
        "投融资"
      ],
      [
        "T3",
        "时间范围",
        28,
        38,
        "2011-2020年"
      ],
      [
        "T4",
        "行业",
        38,
        41,
        "CXO"
      ],
      [
        "T5",
        "投融资情况",
        50,
        53,
        "投融资"
      ],
      [
        "T6",
        "时间范围",
        63,
        68,
        "2015年"
      ],
      [
        "T7",
        "时间范围",
        81,
        87,
        "2014 年"
      ],
      [
        "T8",
        "地点范围",
        87,
        89,
        "全球"
      ],
      [
        "T9",
        "投融资情况",
        89,
        92,
        "投融资"
      ],
      [
        "T10",
        "属性值",
        92,
        98,
        "同比增速较高"
      ],
      [
        "T11",
        "行业",
        100,
        103,
        "CXO"
      ],
      [
        "T12",
        "时间范围",
        110,
        115,
        "2015年"
      ],
      [
        "T13",
        "地点范围",
        115,
        117,
        "全球"
      ],
      [
        "T14",
        "投融资金额",
        117,
        122,
        "投融资金额"
      ],
      [
        "T15",
        "属性值",
        122,
        130,
        "同比增长 43%"
      ],
      [
        "T16",
        "时间范围",
        133,
        138,
        "2016年"
      ],
      [
        "T17",
        "行业",
        138,
        141,
        "CXO"
      ],
      [
        "T18",
        "时间范围",
        152,
        157,
        "2017年"
      ],
      [
        "T19",
        "投融资情况",
        157,
        160,
        "投融资"
      ],
      [
        "T20",
        "时间范围",
        167,
        172,
        "2018年"
      ],
      [
        "T21",
        "行业",
        172,
        175,
        "CXO"
      ],
      [
        "T22",
        "时间范围",
        181,
        186,
        "2019年"
      ],
      [
        "T23",
        "投融资情况",
        186,
        189,
        "投融资"
      ],
      [
        "T24",
        "时间范围",
        195,
        200,
        "2020年"
      ],
      [
        "T25",
        "行业",
        200,
        203,
        "CXO"
      ]
    ]
  },
  {
    "id": 665,
    "text": "Thermo Fisher 在 2017 年通过 72 亿美元收购 Patheon 进入小分子及大分子 CDMO 行业，在 2019 年以 17 亿美元收购 Brammar Bio 开始布局细胞基因治疗 CDMO 服务。Brammar Bio 是一家专注于制造细胞基因治疗病毒载体的 CDMO 公司，支持了首个基因治疗临床试验。收购完成后，Thermo Fisher 具备了完善的质粒 DNA、病毒载体、细胞疗法生产以及相关供应链服务能力。发展至今， Thermo Fisher 细胞基因治疗 CDMO 业务已在美国、 欧洲拥有 650,000 平方英尺工厂，超过 3500 名科学家及技术人员，其主要服务包括：",
    "labels": [
      [
        "T0",
        "公司",
        0,
        14,
        "Thermo Fisher "
      ],
      [
        "T1",
        "时间范围",
        15,
        22,
        " 2017 年"
      ],
      [
        "T2",
        "公司",
        34,
        41,
        "Patheon"
      ],
      [
        "T3",
        "时间范围",
        62,
        68,
        "2019 年"
      ],
      [
        "T4",
        "公司",
        78,
        90,
        " Brammar Bio"
      ],
      [
        "T5",
        "公司",
        110,
        122,
        "Brammar Bio "
      ],
      [
        "T6",
        "行业",
        142,
        147,
        "CDMO "
      ],
      [
        "T7",
        "公司",
        170,
        183,
        "Thermo Fisher"
      ],
      [
        "T8",
        "公司",
        225,
        240,
        " Thermo Fisher "
      ],
      [
        "T9",
        "行业",
        240,
        251,
        "细胞基因治疗 CDMO"
      ],
      [
        "T10",
        "行业",
        44,
        56,
        "小分子及大分子 CDMO"
      ],
      [
        "T11",
        "行业",
        95,
        109,
        "细胞基因治疗 CDMO 服务"
      ],
      [
        "T12",
        "属性值",
        128,
        140,
        "制造细胞基因治疗病毒载体"
      ],
      [
        "T13",
        "地点范围",
        256,
        258,
        "美国"
      ],
      [
        "T14",
        "地点范围",
        260,
        262,
        "欧洲"
      ]
    ]
  },
  {
    "id": 671,
    "text": "业毛利率较高，主营业务收入较高， 其他",
    "labels": [
      [
        "T0",
        "毛利",
        1,
        4,
        "毛利率"
      ],
      [
        "T1",
        "主营业务",
        7,
        11,
        "主营业务"
      ],
      [
        "T2",
        "营业收入",
        11,
        13,
        "收入"
      ]
    ]
  },
  {
    "id": 677,
    "text": "·大分子药品占据全球TOP20主要销售药品，小分子药品销售规模占比逐年降低，导致药企销售意愿降低，同时小分子药品业内竞争激烈，多数小分子药品研发企业需要进行业务转型",
    "labels": [
      [
        "T0",
        "行业",
        1,
        6,
        "大分子药品"
      ],
      [
        "T1",
        "行业",
        22,
        27,
        "小分子药品"
      ],
      [
        "T2",
        "行业公司",
        40,
        42,
        "药企"
      ],
      [
        "T3",
        "行业",
        51,
        56,
        "小分子药品"
      ],
      [
        "T4",
        "行业",
        65,
        70,
        "小分子药品"
      ],
      [
        "T5",
        "地点范围",
        8,
        10,
        "全球"
      ],
      [
        "T6",
        "属性值",
        60,
        62,
        "激烈"
      ]
    ]
  },
  {
    "id": 683,
    "text": "开路先锋，引领未来。公司前瞻性的进入细胞与基因疗法、医疗器械检测等新兴领域并确立起领导地位（2017年公司细胞与基因疗法在美国市场份额排名第二，为 18.2%）。截至 9M19，公司为 24个临床 I期项目及 9个临床 II-III期的项目提供 CDMO服务。",
    "labels": [
      [
        "T0",
        "时间范围",
        46,
        51,
        "2017年"
      ],
      [
        "T1",
        "行业",
        53,
        60,
        "细胞与基因疗法"
      ],
      [
        "T2",
        "地点范围",
        61,
        63,
        "美国"
      ],
      [
        "T3",
        "市场份额",
        63,
        67,
        "市场份额"
      ],
      [
        "T4",
        "时间范围",
        81,
        88,
        "截至 9M19"
      ],
      [
        "T5",
        "行业",
        26,
        32,
        "医疗器械检测"
      ],
      [
        "T6",
        "行业",
        18,
        25,
        "细胞与基因疗法"
      ]
    ]
  },
  {
    "id": 684,
    "text": "康龙化成主要业务领域包括实验室服务、CMC服务、临床开发服务，临床开发服务输属于公司业务最大部分，占营业收入64%",
    "labels": [
      [
        "T0",
        "公司",
        0,
        4,
        "康龙化成"
      ],
      [
        "T1",
        "属性值",
        12,
        30,
        "实验室服务、CMC服务、临床开发服务"
      ],
      [
        "T2",
        "主营业务",
        4,
        8,
        "主要业务"
      ],
      [
        "T3",
        "行业",
        31,
        37,
        "临床开发服务"
      ],
      [
        "T4",
        "营业收入",
        50,
        54,
        "营业收入"
      ],
      [
        "T5",
        "属性值",
        54,
        57,
        "64%"
      ]
    ]
  },
  {
    "id": 689,
    "text": "目前 CDMO行业内存在缺乏有经验丰富的人才的问题，如何建立机制吸引人才加入并留住人才，是建立核心竞争力的关键。上市至今，公司共进行多次股权激励计划奖励高级管理和技术人员（其中第一期由于国内证券市场环境发生较大变化被终止），近 3年考核趋于常态化，彰显了业绩增长信心。",
    "labels": [
      [
        "T0",
        "行业",
        3,
        7,
        "CDMO"
      ],
      [
        "T1",
        "时间范围",
        112,
        116,
        "近 3年"
      ],
      [
        "T2",
        "业绩",
        127,
        129,
        "业绩"
      ],
      [
        "T3",
        "时间范围",
        0,
        2,
        "目前"
      ]
    ]
  },
  {
    "id": 691,
    "text": "我们统计了2014-2020年药明康德、药明生物、凯莱英、康龙化成、泰格医药、博腾股份、药石科技、美迪西、昭衍新药等9家本土CXO龙头国内收入加和数据，我们发现其收入加和同比增速与中国医疗健康投融资YOY趋势具有较强的一致性。我们认为这体现了本土CXO国内收入中Biotech客户占据主导地位。同时也意味着我们将中国医疗健康投融资YOY作为本土CXO企业国内订单景气度前瞻指标具有一定参考价值。",
    "labels": [
      [
        "T0",
        "时间范围",
        5,
        15,
        "2014-2020年"
      ],
      [
        "T1",
        "公司",
        15,
        19,
        "药明康德"
      ],
      [
        "T2",
        "公司",
        20,
        24,
        "药明生物"
      ],
      [
        "T3",
        "公司",
        25,
        28,
        "凯莱英"
      ],
      [
        "T4",
        "公司",
        29,
        33,
        "康龙化成"
      ],
      [
        "T5",
        "公司",
        34,
        38,
        "泰格医药"
      ],
      [
        "T6",
        "公司",
        39,
        43,
        "博腾股份"
      ],
      [
        "T7",
        "公司",
        44,
        48,
        "药石科技"
      ],
      [
        "T8",
        "公司",
        49,
        52,
        "美迪西"
      ],
      [
        "T9",
        "公司",
        53,
        57,
        "昭衍新药"
      ],
      [
        "T10",
        "行业公司",
        58,
        67,
        "9家本土CXO龙头"
      ],
      [
        "T11",
        "地点范围",
        67,
        69,
        "国内"
      ],
      [
        "T12",
        "营业收入",
        69,
        71,
        "收入"
      ],
      [
        "T13",
        "地点范围",
        90,
        92,
        "中国"
      ],
      [
        "T14",
        "行业",
        92,
        96,
        "医疗健康"
      ],
      [
        "T15",
        "投融资情况",
        96,
        99,
        "投融资"
      ],
      [
        "T16",
        "营业收入",
        81,
        83,
        "收入"
      ],
      [
        "T17",
        "地点范围",
        121,
        123,
        "本土"
      ],
      [
        "T18",
        "行业",
        123,
        126,
        "CXO"
      ],
      [
        "T19",
        "地点范围",
        126,
        128,
        "国内"
      ],
      [
        "T20",
        "营业收入",
        128,
        130,
        "收入"
      ],
      [
        "T21",
        "行业",
        131,
        138,
        "Biotech"
      ],
      [
        "T22",
        "地点范围",
        156,
        158,
        "中国"
      ],
      [
        "T23",
        "行业",
        158,
        162,
        "医疗健康"
      ],
      [
        "T24",
        "投融资情况",
        162,
        165,
        "投融资"
      ],
      [
        "T25",
        "地点范围",
        170,
        172,
        "本土"
      ],
      [
        "T26",
        "行业公司",
        172,
        177,
        "CXO企业"
      ],
      [
        "T27",
        "地点范围",
        177,
        179,
        "国内"
      ],
      [
        "T28",
        "在手订单",
        179,
        181,
        "订单"
      ]
    ]
  },
  {
    "id": 697,
    "text": "中国区实验室是药明康德最核心业务，其收入贡献占比超过 50%。中国区实验室服务主要包括：小分子药物发现服务、药物分析及测试服务、细胞和基因治疗 CDMO服务。中国区实验室业务 2020年收入 85.46亿元（+32.0%），其中小分子药物发现服务、药物分析与测试服务是主要的收入来源，细胞基因/治疗方面，无锡基地 2019年开始投入运营，能够为国内客户提供细胞和基因治疗产品的 CDMO/CMO服务。",
    "labels": [
      [
        "T0",
        "公司",
        7,
        11,
        "药明康德"
      ],
      [
        "T1",
        "地点范围",
        0,
        3,
        "中国区"
      ],
      [
        "T2",
        "行业",
        3,
        6,
        "实验室"
      ],
      [
        "T3",
        "行业",
        34,
        39,
        "实验室服务"
      ],
      [
        "T4",
        "地点范围",
        31,
        34,
        "中国区"
      ],
      [
        "T5",
        "行业",
        44,
        53,
        "小分子药物发现服务"
      ],
      [
        "T6",
        "行业",
        54,
        58,
        "药物分析"
      ],
      [
        "T7",
        "行业",
        59,
        63,
        "测试服务"
      ],
      [
        "T8",
        "行业",
        64,
        78,
        "细胞和基因治疗 CDMO服务"
      ],
      [
        "T9",
        "地点范围",
        79,
        82,
        "中国区"
      ],
      [
        "T10",
        "行业",
        82,
        85,
        "实验室"
      ],
      [
        "T11",
        "时间范围",
        88,
        93,
        "2020年"
      ],
      [
        "T12",
        "属性值",
        96,
        103,
        "85.46亿元"
      ],
      [
        "T13",
        "营业收入",
        93,
        95,
        "收入"
      ],
      [
        "T14",
        "属性值",
        104,
        110,
        "+32.0%"
      ],
      [
        "T15",
        "行业",
        114,
        123,
        "小分子药物发现服务"
      ],
      [
        "T16",
        "行业",
        124,
        128,
        "药物分析"
      ],
      [
        "T17",
        "行业",
        129,
        133,
        "测试服务"
      ],
      [
        "T18",
        "行业",
        142,
        149,
        "细胞基因/治疗"
      ],
      [
        "T19",
        "时间范围",
        156,
        162,
        " 2019年"
      ],
      [
        "T20",
        "地点范围",
        172,
        174,
        "国内"
      ],
      [
        "T21",
        "行业",
        178,
        185,
        "细胞和基因治疗"
      ],
      [
        "T22",
        "营收占比",
        18,
        24,
        "收入贡献占比"
      ],
      [
        "T23",
        "属性值",
        24,
        30,
        "超过 50%"
      ]
    ]
  },
  {
    "id": 719,
    "text": "50.07/67.22/89.53 亿元，分别同比增长 69.2%/34.2%/32.2%，对应 21-23 年 EPS 为 1.69/2.27/3.03 元。 A 股对应 21-23 年 PE 为 62/47/35 倍， 维持“买入” 评级；H 股对应 21-23 年 PE 为 55/41/31 倍，维持“买入”评级。 风险提示：疫情持续风险；药企研发投入不及预期；竞争加剧。",
    "labels": [
      [
        "T0",
        "行业公司",
        174,
        176,
        "药企"
      ],
      [
        "T1",
        "研发费用",
        176,
        180,
        "研发投入"
      ],
      [
        "T2",
        "PE",
        136,
        139,
        "PE "
      ],
      [
        "T3",
        "时间范围",
        49,
        56,
        "21-23 年"
      ],
      [
        "T4",
        "时间范围",
        128,
        135,
        "21-23 年"
      ],
      [
        "T5",
        "PE",
        95,
        97,
        "PE"
      ]
    ]
  },
  {
    "id": 721,
    "text": "公司临床 CRO业务处于起步阶段，成长空间广阔。公司于 2016-2017年先后收购 Quotient（康龙英国）、Xceleron（康龙美国）切入临床 CRO业务，起步较晚，但增长势头较好。以国内临床 CRO龙头泰格医药为例，2019年收入达到 27.93亿元，毛利率长期稳定在 45%左右。2019年，公司临床 CRO业务收入 4.56亿元，3年 CAGR达 45.46%；2020H1收入 2.43亿元，同比增速 27.51%。早年公司临床 CRO收入来源于",
    "labels": [
      [
        "T0",
        "地点范围",
        97,
        99,
        "国内"
      ],
      [
        "T1",
        "行业",
        99,
        105,
        "临床 CRO"
      ],
      [
        "T2",
        "龙头企业",
        105,
        107,
        "龙头"
      ],
      [
        "T3",
        "公司",
        107,
        111,
        "泰格医药"
      ],
      [
        "T4",
        "时间范围",
        114,
        119,
        "2019年"
      ],
      [
        "T5",
        "营业收入",
        119,
        121,
        "收入"
      ],
      [
        "T6",
        "属性值",
        124,
        131,
        "27.93亿元"
      ],
      [
        "T7",
        "毛利",
        132,
        135,
        "毛利率"
      ],
      [
        "T8",
        "属性值",
        141,
        146,
        "45%左右"
      ],
      [
        "T9",
        "时间范围",
        147,
        152,
        "2019年"
      ],
      [
        "T10",
        "行业",
        155,
        161,
        "临床 CRO"
      ],
      [
        "T11",
        "营业收入",
        163,
        165,
        "收入"
      ],
      [
        "T12",
        "CAGR",
        176,
        180,
        "CAGR"
      ],
      [
        "T13",
        "时间范围",
        189,
        195,
        "2020H1"
      ],
      [
        "T14",
        "营业收入",
        195,
        197,
        "收入"
      ],
      [
        "T15",
        "行业",
        221,
        227,
        "临床 CRO"
      ],
      [
        "T16",
        "营业收入",
        227,
        229,
        "收入"
      ],
      [
        "T17",
        "公司",
        43,
        57,
        "Quotient（康龙英国）"
      ],
      [
        "T18",
        "公司",
        58,
        72,
        "Xceleron（康龙美国）"
      ],
      [
        "T19",
        "行业",
        74,
        80,
        "临床 CRO"
      ],
      [
        "T20",
        "时间范围",
        28,
        38,
        "2016-2017年"
      ],
      [
        "T21",
        "行业",
        2,
        8,
        "临床 CRO"
      ]
    ]
  },
  {
    "id": 722,
    "text": "子公司合全药业为国内 CMO/CDMO 行业的绝对领军者（2018 年市场份额为 7.3%）， 2016-2018销售收入实现 28.4%的复合增速，远超行业平均水平（中国行业 17.1%）。我们预计 19/20/21三年公司 CMO/CDMO业务增速中枢有望提升至 33.1%左右，基于：1） 晚期项目（III期及商业化）加速转化（截至 9M19有 17个项目进入商业化阶段 vs 1H18 的 13个）；2）丰厚的早期项目池（截至 9M19有 40个 3期临床项目及 900+早期项目）， 有望持续向后期临床及商业化生产推进；3）获益国内 MAH政策红利（合全药业为首个获批 MAH合作的 CMO/CDMO）；4）新三板退市，收购少数股权，进一步理清业务结构， 夯实 CRO/CMO全产业链战略。",
    "labels": [
      [
        "T0",
        "公司",
        3,
        7,
        "合全药业"
      ],
      [
        "T1",
        "地点范围",
        8,
        10,
        "国内"
      ],
      [
        "T2",
        "行业",
        11,
        20,
        "CMO/CDMO "
      ],
      [
        "T3",
        "时间范围",
        29,
        35,
        "2018 年"
      ],
      [
        "T4",
        "市场份额",
        35,
        39,
        "市场份额"
      ],
      [
        "T5",
        "属性值",
        40,
        45,
        " 7.3%"
      ],
      [
        "T6",
        "CAGR",
        70,
        74,
        "复合增速"
      ],
      [
        "T7",
        "时间范围",
        48,
        57,
        "2016-2018"
      ],
      [
        "T8",
        "假设情形",
        98,
        100,
        "预计"
      ],
      [
        "T9",
        "时间范围",
        101,
        111,
        "19/20/21三年"
      ],
      [
        "T10",
        "行业",
        114,
        122,
        "CMO/CDMO"
      ],
      [
        "T11",
        "时间范围",
        167,
        174,
        "截至 9M19"
      ],
      [
        "T12",
        "时间范围",
        215,
        222,
        "截至 9M19"
      ],
      [
        "T13",
        "公司",
        280,
        284,
        "合全药业"
      ],
      [
        "T14",
        "行业",
        297,
        305,
        "CMO/CDMO"
      ],
      [
        "T15",
        "行业",
        336,
        343,
        "CRO/CMO"
      ],
      [
        "T16",
        "属性值",
        64,
        69,
        "28.4%"
      ],
      [
        "T17",
        "地点范围",
        84,
        86,
        "中国"
      ],
      [
        "T18",
        "属性值",
        89,
        94,
        "17.1%"
      ],
      [
        "T19",
        "地点范围",
        269,
        271,
        "国内"
      ],
      [
        "T20",
        "属性值",
        57,
        61,
        "销售收入"
      ]
    ]
  },
  {
    "id": 725,
    "text": "➢ Biotech公司逐步发力。随着Biotech公司的成长，其产品管线前移使得更多产品获批进入市场，Biotech公司产品在整个药物市场的销售比重也在逐步增多，预计到2026年其产品销售额占比将占市场的37%。Biotech公司的外包意愿",
    "labels": [
      [
        "T0",
        "行业公司",
        2,
        11,
        "Biotech公司"
      ],
      [
        "T1",
        "行业公司",
        18,
        27,
        "Biotech公司"
      ],
      [
        "T2",
        "行业公司",
        51,
        60,
        "Biotech公司"
      ],
      [
        "T3",
        "时间范围",
        84,
        89,
        "2026年"
      ],
      [
        "T4",
        "行业公司",
        106,
        115,
        "Biotech公司"
      ]
    ]
  },
  {
    "id": 729,
    "text": "国内 CMO/CDMO行业增速仍将提升。根据 Frost & Sullivan数据，2018年国内小分子 CDMO/CMO行业规模达 55亿美元，同比增长 15%，预计到 2023 年市场规模有望达到 140亿美元，2018~2023年 CAGR有望达到 20.6%。",
    "labels": [
      [
        "T0",
        "地点范围",
        0,
        2,
        "国内"
      ],
      [
        "T1",
        "行业",
        3,
        11,
        "CMO/CDMO"
      ],
      [
        "T2",
        "时间范围",
        42,
        47,
        "2018年"
      ],
      [
        "T3",
        "地点范围",
        47,
        49,
        "国内"
      ],
      [
        "T4",
        "行业",
        49,
        61,
        "小分子 CDMO/CMO"
      ],
      [
        "T5",
        "市场规模",
        61,
        65,
        "行业规模"
      ],
      [
        "T6",
        "属性值",
        67,
        81,
        "55亿美元，同比增长 15%"
      ],
      [
        "T7",
        "时间范围",
        86,
        92,
        "2023 年"
      ],
      [
        "T8",
        "市场规模",
        92,
        96,
        "市场规模"
      ],
      [
        "T9",
        "属性值",
        101,
        107,
        "140亿美元"
      ],
      [
        "T10",
        "时间范围",
        108,
        118,
        "2018~2023年"
      ],
      [
        "T11",
        "CAGR",
        119,
        123,
        "CAGR"
      ],
      [
        "T12",
        "属性值",
        128,
        133,
        "20.6%"
      ]
    ]
  },
  {
    "id": 731,
    "text": "口大分子药品销售规模占比扩大，但小分子药品占据主要市场：从FDA批准的新药构成来看，小分子药物目前仍占主要市场。2019年，FDA批准上市的药物中，小分子占比77%。但是销售规模角度分析，年小分子药物销售70%相比，销售规模占比收缩，2019年小分子药物销售规模占比为63.81%，与2015并且逐年下降。说明小分子药物业内竞争加剧，药物新品种增多，但单药物销售数量下降，反映出制药企业小分子药物销售意愿降低。会导致制药企业对小分子药物研发生产外包的需求减少，进而制约小分子药物的发展",
    "labels": [
      [
        "T0",
        "时间范围",
        56,
        61,
        "2019年"
      ],
      [
        "T1",
        "时间范围",
        117,
        122,
        "2019年"
      ],
      [
        "T2",
        "时间范围",
        142,
        146,
        "2015"
      ],
      [
        "T3",
        "行业",
        155,
        160,
        "小分子药物"
      ],
      [
        "T4",
        "行业",
        122,
        127,
        "小分子药物"
      ],
      [
        "T5",
        "行业",
        16,
        21,
        "小分子药品"
      ],
      [
        "T6",
        "行业",
        42,
        47,
        "小分子药物"
      ],
      [
        "T7",
        "行业",
        95,
        100,
        "小分子药物"
      ],
      [
        "T8",
        "行业公司",
        189,
        193,
        "制药企业"
      ],
      [
        "T9",
        "行业",
        193,
        198,
        "小分子药物"
      ],
      [
        "T10",
        "行业公司",
        208,
        212,
        "制药企业"
      ],
      [
        "T11",
        "行业",
        234,
        239,
        "小分子药物"
      ],
      [
        "T12",
        "时间范围",
        47,
        49,
        "目前"
      ],
      [
        "T13",
        "行业",
        74,
        77,
        "小分子"
      ],
      [
        "T14",
        "属性值",
        164,
        166,
        "加剧"
      ],
      [
        "T15",
        "行业",
        213,
        224,
        "小分子药物研发生产外包"
      ],
      [
        "T16",
        "行业",
        1,
        6,
        "大分子药品"
      ],
      [
        "T17",
        "属性值",
        227,
        229,
        "减少"
      ],
      [
        "T18",
        "行业需求",
        225,
        227,
        "需求"
      ]
    ]
  },
  {
    "id": 737,
    "text": " 投资建议：投资策略上，CXO全产业链战略性看好，继续推荐具有全球竞争力的龙头公司，CDMO、药物发现及临床前研究 CRO和临床CRO的细分市场龙头，以及受益于行业高景气度的小而美的公司，持续推荐药明康德、博腾股份、美迪西、九洲药业、昭衍新药、凯莱英、药明生物等。",
    "labels": [
      [
        "T0",
        "行业",
        13,
        16,
        "CXO"
      ],
      [
        "T1",
        "龙头企业",
        38,
        42,
        "龙头公司"
      ],
      [
        "T2",
        "行业",
        43,
        47,
        "CDMO"
      ],
      [
        "T3",
        "行业",
        48,
        52,
        "药物发现"
      ],
      [
        "T4",
        "行业",
        53,
        62,
        "临床前研究 CRO"
      ],
      [
        "T5",
        "行业",
        63,
        68,
        "临床CRO"
      ],
      [
        "T6",
        "龙头企业",
        73,
        75,
        "龙头"
      ],
      [
        "T7",
        "公司",
        99,
        103,
        "药明康德"
      ],
      [
        "T8",
        "公司",
        104,
        108,
        "博腾股份"
      ],
      [
        "T9",
        "公司",
        109,
        112,
        "美迪西"
      ],
      [
        "T10",
        "公司",
        113,
        117,
        "九洲药业"
      ],
      [
        "T11",
        "公司",
        118,
        122,
        "昭衍新药"
      ],
      [
        "T12",
        "公司",
        123,
        126,
        "凯莱英"
      ],
      [
        "T13",
        "公司",
        127,
        131,
        "药明生物"
      ],
      [
        "T14",
        "地点范围",
        32,
        34,
        "全球"
      ]
    ]
  },
  {
    "id": 749,
    "text": "CRO 行业包括临床前 CRO 和临床 CRO 两大部分，均为医药外包服务行业的重要板块， 该板块诞生了多家全球排名前十的 CXO公司，如 IQVIA、Labcorp、ICON、Charles River 等。目前，临床前及临床阶段的外包服务基本贯穿药物研发的全流程，业务种类丰富。",
    "labels": [
      [
        "T0",
        "行业",
        0,
        3,
        "CRO"
      ],
      [
        "T1",
        "行业",
        8,
        15,
        "临床前 CRO"
      ],
      [
        "T2",
        "行业",
        17,
        24,
        "临床 CRO "
      ],
      [
        "T3",
        "行业",
        31,
        37,
        "医药外包服务"
      ],
      [
        "T4",
        "行业公司",
        61,
        67,
        " CXO公司"
      ],
      [
        "T5",
        "公司",
        70,
        75,
        "IQVIA"
      ],
      [
        "T6",
        "公司",
        76,
        83,
        "Labcorp"
      ],
      [
        "T7",
        "公司",
        84,
        88,
        "ICON"
      ],
      [
        "T8",
        "公司",
        89,
        103,
        "Charles River "
      ],
      [
        "T9",
        "时间范围",
        105,
        107,
        "目前"
      ],
      [
        "T10",
        "地点范围",
        54,
        56,
        "全球"
      ]
    ]
  },
  {
    "id": 751,
    "text": " 产能的扩建依靠资本开支，当期资本开支反映了未来几年收入规模上限。  相较2018年，药明康德、凯莱英、博腾股份、康龙化成、普洛药业的资本性支出在2020年均实现快速增长。我们认为随着产能逐渐放量，未来几年会实现收入的快速提升。  在建工程：2020年药明康德、康龙化成、凯莱英等CDMO公司的在建工程处于领先水平。",
    "labels": [
      [
        "T0",
        "产能",
        2,
        4,
        "产能"
      ],
      [
        "T1",
        "公司",
        45,
        49,
        "药明康德"
      ],
      [
        "T2",
        "CAPEX资本开支",
        9,
        13,
        "资本开支"
      ],
      [
        "T3",
        "主要玩家",
        16,
        20,
        "资本开支"
      ],
      [
        "T4",
        "公司",
        50,
        53,
        "凯莱英"
      ],
      [
        "T5",
        "公司",
        54,
        58,
        "博腾股份"
      ],
      [
        "T6",
        "公司",
        59,
        63,
        "康龙化成"
      ],
      [
        "T7",
        "公司",
        64,
        68,
        "普洛药业"
      ],
      [
        "T8",
        "CAPEX资本开支",
        69,
        74,
        "资本性支出"
      ],
      [
        "T9",
        "时间范围",
        75,
        80,
        "2020年"
      ],
      [
        "T10",
        "时间范围",
        101,
        105,
        "未来几年"
      ],
      [
        "T11",
        "营业收入",
        108,
        110,
        "收入"
      ],
      [
        "T12",
        "时间范围",
        124,
        129,
        "2020年"
      ],
      [
        "T13",
        "公司",
        129,
        133,
        "药明康德"
      ],
      [
        "T14",
        "公司",
        134,
        138,
        "康龙化成"
      ],
      [
        "T15",
        "公司",
        139,
        142,
        "凯莱英"
      ],
      [
        "T16",
        "行业公司",
        143,
        149,
        "CDMO公司"
      ],
      [
        "T17",
        "时间范围",
        23,
        27,
        "未来几年"
      ],
      [
        "T18",
        "营业收入",
        27,
        29,
        "收入"
      ],
      [
        "T19",
        "时间范围",
        39,
        44,
        "2018年"
      ],
      [
        "T20",
        "属性值",
        83,
        87,
        "快速增长"
      ],
      [
        "T21",
        "产能",
        94,
        96,
        "产能"
      ],
      [
        "T22",
        "属性值",
        96,
        100,
        "逐渐放量"
      ],
      [
        "T23",
        "属性值",
        111,
        115,
        "快速提升"
      ]
    ]
  },
  {
    "id": 752,
    "text": "金斯瑞生物科技（1548.HK）：全球基因合成龙头，其子公司南京传奇在细胞免疫治疗领域也在全球范围走在创新前列，CART产品即将美国获批上市。蓬勃生物已建立整合的创新生物药CDMO平台，主要包括两大服务领域治疗性抗体药和基因与细胞治疗，目前处于高速发展期。高瓴合计投资超过80亿港币，有助于公司的研发投入和生产建设。",
    "labels": [
      [
        "T0",
        "公司",
        0,
        7,
        "金斯瑞生物科技"
      ],
      [
        "T1",
        "行业",
        19,
        23,
        "基因合成"
      ],
      [
        "T2",
        "龙头企业",
        23,
        25,
        "龙头"
      ],
      [
        "T3",
        "公司",
        30,
        34,
        "南京传奇"
      ],
      [
        "T4",
        "行业",
        35,
        41,
        "细胞免疫治疗"
      ],
      [
        "T5",
        "行业",
        81,
        90,
        "创新生物药CDMO"
      ],
      [
        "T6",
        "公司",
        128,
        130,
        "高瓴"
      ],
      [
        "T7",
        "投融资金额",
        132,
        134,
        "投资"
      ],
      [
        "T8",
        "研发费用",
        148,
        152,
        "研发投入"
      ],
      [
        "T9",
        "地点范围",
        17,
        19,
        "全球"
      ],
      [
        "T10",
        "地点范围",
        45,
        47,
        "全球"
      ],
      [
        "T11",
        "地点范围",
        64,
        66,
        "美国"
      ],
      [
        "T12",
        "公司",
        71,
        75,
        "蓬勃生物"
      ],
      [
        "T13",
        "行业",
        103,
        109,
        "治疗性抗体药"
      ],
      [
        "T14",
        "行业",
        110,
        117,
        "基因与细胞治疗"
      ],
      [
        "T15",
        "地点范围",
        118,
        120,
        "目前"
      ]
    ]
  },
  {
    "id": 755,
    "text": "近年来，药明康德、康龙化成等临床前CRO公司纷纷布局DEL、PROTAC等药物早筛技术平台。我们认为：①药物早筛平台可以解决传统药物发现中的痛点，为客户创造更高的价值。DEL相比传统的 HTS可以将筛选时间从一年缩短至4周； PROTAC技术则有克服以往难以成药的靶点以及避免靶蛋白突变产生的耐药性等优势。高附加价值业务更具议价权，因此药物早筛公司成都先导、维亚生物、药石科技相比传统的临床前CRO公司具有更高的毛利率。②药物早筛平台可以有效聚焦流量，为下游业务打开增长空间。药明康德的HitS平台在2020年创立以后新增客户超过500名，占公司当年1300名新增客户的 38%，获取流量效果明显。",
    "labels": [
      [
        "T0",
        "公司",
        4,
        8,
        "药明康德"
      ],
      [
        "T1",
        "公司",
        9,
        13,
        "康龙化成"
      ],
      [
        "T2",
        "行业公司",
        14,
        22,
        "临床前CRO公司"
      ],
      [
        "T3",
        "行业公司",
        168,
        174,
        "药物早筛公司"
      ],
      [
        "T4",
        "公司",
        174,
        178,
        "成都先导"
      ],
      [
        "T5",
        "公司",
        179,
        183,
        "维亚生物"
      ],
      [
        "T6",
        "公司",
        184,
        188,
        "药石科技"
      ],
      [
        "T7",
        "行业公司",
        193,
        201,
        "临床前CRO公司"
      ],
      [
        "T8",
        "毛利",
        206,
        209,
        "毛利率"
      ],
      [
        "T9",
        "公司",
        238,
        242,
        "药明康德"
      ],
      [
        "T10",
        "时间范围",
        0,
        3,
        "近年来"
      ],
      [
        "T11",
        "行业",
        37,
        45,
        "药物早筛技术平台"
      ],
      [
        "T12",
        "属性值",
        203,
        205,
        "更高"
      ],
      [
        "T13",
        "时间范围",
        250,
        255,
        "2020年"
      ]
    ]
  },
  {
    "id": 756,
    "text": "国内 9-45 岁适龄女性约 3.6亿人（城市适龄女性约 1.2 亿人），从 2017 年国内引进 HPV 产品至今，批签发总量约 6500万支，折合约 2000 万人份，整体人群渗透率约 5.5%（城市适龄女性渗透率约 16.5%）处于低位。以 3针免疫程序、300元/支价格及 50%存量渗透率计算，存量市场规模达 1500亿。国产HPV 企业崛起，多个 9价管线推进至 ph3临床，携手智飞生物代理默沙东高端品种， 分享国内存量市场。",
    "labels": [
      [
        "T0",
        "地点范围",
        0,
        2,
        "国内"
      ],
      [
        "T1",
        "时间范围",
        39,
        45,
        "2017 年"
      ],
      [
        "T2",
        "地点范围",
        45,
        47,
        "国内"
      ],
      [
        "T3",
        "市场规模",
        154,
        158,
        "市场规模"
      ],
      [
        "T4",
        "属性值",
        160,
        165,
        "1500亿"
      ],
      [
        "T5",
        "公司",
        196,
        200,
        "智飞生物"
      ],
      [
        "T6",
        "公司",
        202,
        205,
        "默沙东"
      ],
      [
        "T7",
        "地点范围",
        213,
        215,
        "国内"
      ],
      [
        "T8",
        "行业公司",
        166,
        174,
        "国产HPV 企业"
      ],
      [
        "T9",
        "行业",
        50,
        53,
        "HPV"
      ]
    ]
  },
  {
    "id": 759,
    "text": "口医药CXO行业由CRO、CDMO、CMO三个细分行业共同构成，医药CXO行业市场规模由大分子CDMO/CMO、小分子CDMO/CMO、CRO（药物临床前、发现、临床外外包）多个市场规模叠加组成口2013-2017年，中国医药CXO行业年复合增长率为10.3%，2017年市场规模104,1亿美元。2018年至2025年，年复合增长率11.3%，预计2025年市场规模2,440.0亿美元口在医药CXO行业中，大分子CDMO/CMO行业占比最少，每年以2%的速度增加，2025年预计大分子CDMO/CMO行业占比2.6%，临床前外包行业占比3.8%，发现外包行业占比8.5%，临床外包行业占比28%，小分子CDMO行业占比58%",
    "labels": [
      [
        "T0",
        "行业",
        1,
        6,
        "医药CXO"
      ],
      [
        "T1",
        "行业",
        9,
        12,
        "CRO"
      ],
      [
        "T2",
        "行业",
        13,
        17,
        "CDMO"
      ],
      [
        "T3",
        "行业",
        18,
        21,
        "CMO"
      ],
      [
        "T4",
        "行业",
        32,
        37,
        "医药CXO"
      ],
      [
        "T5",
        "市场规模",
        39,
        43,
        "市场规模"
      ],
      [
        "T6",
        "行业",
        44,
        55,
        "大分子CDMO/CMO"
      ],
      [
        "T7",
        "行业",
        56,
        67,
        "小分子CDMO/CMO"
      ],
      [
        "T8",
        "行业",
        68,
        71,
        "CRO"
      ],
      [
        "T9",
        "行业",
        72,
        77,
        "药物临床前"
      ],
      [
        "T10",
        "行业",
        78,
        80,
        "发现"
      ],
      [
        "T11",
        "行业",
        81,
        86,
        "临床外外包"
      ],
      [
        "T12",
        "市场规模",
        89,
        93,
        "市场规模"
      ],
      [
        "T13",
        "时间范围",
        98,
        108,
        "2013-2017年"
      ],
      [
        "T14",
        "地点范围",
        109,
        111,
        "中国"
      ],
      [
        "T15",
        "行业",
        111,
        116,
        "医药CXO"
      ],
      [
        "T16",
        "CAGR",
        118,
        124,
        "年复合增长率"
      ],
      [
        "T17",
        "属性值",
        125,
        130,
        "10.3%"
      ],
      [
        "T18",
        "时间范围",
        131,
        136,
        "2017年"
      ],
      [
        "T19",
        "市场规模",
        136,
        140,
        "市场规模"
      ],
      [
        "T20",
        "属性值",
        140,
        148,
        "104,1亿美元"
      ],
      [
        "T21",
        "时间范围",
        149,
        160,
        "2018年至2025年"
      ],
      [
        "T22",
        "CAGR",
        161,
        167,
        "年复合增长率"
      ],
      [
        "T23",
        "属性值",
        167,
        172,
        "11.3%"
      ],
      [
        "T24",
        "时间范围",
        175,
        180,
        "2025年"
      ],
      [
        "T25",
        "市场规模",
        180,
        184,
        "市场规模"
      ],
      [
        "T26",
        "属性值",
        184,
        194,
        "2,440.0亿美元"
      ],
      [
        "T27",
        "行业",
        196,
        201,
        "医药CXO"
      ],
      [
        "T28",
        "行业",
        205,
        216,
        "大分子CDMO/CMO"
      ],
      [
        "T29",
        "时间范围",
        234,
        239,
        "2025年"
      ],
      [
        "T30",
        "行业",
        241,
        252,
        "大分子CDMO/CMO"
      ],
      [
        "T31",
        "属性值",
        256,
        260,
        "2.6%"
      ],
      [
        "T32",
        "行业",
        261,
        266,
        "临床前外包"
      ],
      [
        "T33",
        "属性值",
        270,
        274,
        "3.8%"
      ],
      [
        "T34",
        "属性值",
        220,
        222,
        "最少"
      ],
      [
        "T35",
        "行业",
        275,
        279,
        "发现外包"
      ],
      [
        "T36",
        "属性值",
        283,
        287,
        "8.5%"
      ],
      [
        "T37",
        "行业",
        288,
        292,
        "临床外包"
      ],
      [
        "T38",
        "属性值",
        296,
        299,
        "28%"
      ],
      [
        "T39",
        "行业",
        300,
        307,
        "小分子CDMO"
      ],
      [
        "T40",
        "属性值",
        311,
        314,
        "58%"
      ]
    ]
  },
  {
    "id": 761,
    "text": " 分版块 4，生物大分子 CRO/CDMO业务保持高速增长，未来高增长可期： 2015-2020年上述 29家公司中的大分子 CRO/CDMO相关业务整体收入规模分别为 6/13/20/33/50/68亿元，2016-2020年分别同比增长 136%/47% /66% /53%/35%，2020年及之前，生物大分子 CRO/CDMO板块绝大部分收入来自于临床前及临床阶段项目（2020年只有药明生物有 2个商业化项目），2020年受到新冠疫情的影响，海外客户的大分子临床项目进度有所延迟，生物大分子 CRO/CDMO板块收入增速受到一定影响。考虑到生物大分子领域的市场增速较快，目前国内 CDMO企业的所服务的项目大多处在早期临床阶段，未来随着客户项目的不断推进，会逐渐出现大体量的商业化 CMO订单，参考小分子 CDMO的商业模式（商业化项目占比 60%左右，公司业绩仍能保持 20-30%增长），生物大分子 CRO/CDMO业务领域的成长空间和成长性巨大。",
    "labels": [
      [
        "T0",
        "行业",
        8,
        22,
        "生物大分子 CRO/CDMO"
      ],
      [
        "T1",
        "行业",
        60,
        72,
        "大分子 CRO/CDMO"
      ],
      [
        "T2",
        "营业收入",
        78,
        80,
        "收入"
      ],
      [
        "T3",
        "时间范围",
        105,
        115,
        "2016-2020年"
      ],
      [
        "T4",
        "时间范围",
        145,
        153,
        "2020年及之前"
      ],
      [
        "T5",
        "行业",
        154,
        168,
        "生物大分子 CRO/CDMO"
      ],
      [
        "T6",
        "时间范围",
        190,
        195,
        "2020年"
      ],
      [
        "T7",
        "公司",
        197,
        201,
        "药明生物"
      ],
      [
        "T8",
        "时间范围",
        212,
        217,
        "2020年"
      ],
      [
        "T9",
        "行业",
        246,
        260,
        "生物大分子 CRO/CDMO"
      ],
      [
        "T10",
        "地点范围",
        293,
        295,
        "国内"
      ],
      [
        "T11",
        "行业公司",
        296,
        302,
        "CDMO企业"
      ],
      [
        "T12",
        "行业",
        355,
        363,
        "小分子 CDMO"
      ],
      [
        "T13",
        "业绩",
        385,
        387,
        "业绩"
      ],
      [
        "T14",
        "行业",
        402,
        416,
        "生物大分子 CRO/CDMO"
      ],
      [
        "T15",
        "属性值",
        421,
        431,
        "成长空间和成长性巨大"
      ],
      [
        "T16",
        "属性值",
        26,
        30,
        "高速增长"
      ],
      [
        "T17",
        "时间范围",
        40,
        50,
        "2015-2020年"
      ]
    ]
  },
  {
    "id": 767,
    "text": "公司从中间体到 API到制剂 CDMO面临了不同的挑战，中间体向 API的延伸主要是体系层面的变革，而制剂 CDMO对技术提出了更高的要求。公司重点发展创新药，另布局有技术优势和市场优势的仿制药产品，建立创新药+仿制药一站式制药服务平台，充分利用原料药 CDMO的技术和产能优势，为创新药客户提供从原料药到制剂的端到端服务。截至 2020年，制剂 CDMO业务已拥有员工近 70人。",
    "labels": [
      [
        "T0",
        "行业",
        3,
        6,
        "中间体"
      ],
      [
        "T1",
        "行业",
        8,
        11,
        "API"
      ],
      [
        "T2",
        "行业",
        12,
        19,
        "制剂 CDMO"
      ],
      [
        "T3",
        "行业",
        28,
        31,
        "中间体"
      ],
      [
        "T4",
        "行业",
        33,
        36,
        "API"
      ],
      [
        "T5",
        "行业",
        51,
        58,
        "制剂 CDMO"
      ],
      [
        "T6",
        "行业",
        123,
        131,
        "原料药 CDMO"
      ],
      [
        "T7",
        "时间范围",
        162,
        170,
        "截至 2020年"
      ],
      [
        "T8",
        "行业",
        171,
        178,
        "制剂 CDMO"
      ],
      [
        "T9",
        "员工数量",
        183,
        185,
        "员工"
      ],
      [
        "T10",
        "行业",
        76,
        79,
        "创新药"
      ],
      [
        "T11",
        "行业",
        141,
        144,
        "创新药"
      ]
    ]
  },
  {
    "id": 779,
    "text": "➢ 2021年全年CDE审评中心受理11569个受理号，其中化药受理8174个，中药1371个，生物制品2022个。2021年受理数量相比于 2020年有明显增加，总量增加1322个，其中中药受理数量大幅增加，相比于2020年增加了899个。2022年1-3月CDE共承办3043个， 其中化药受理2150个，中药383个，生物制品486个。 ➢ 2022年1-3月各类申报类型为：补充申请为主，占比54.26%，其次申请生产，占比为21.36%，申请临床占比17.88%。其中，补充申请所占比例与2021年基本持平。",
    "labels": [
      [
        "T0",
        "时间范围",
        2,
        9,
        "2021年全年"
      ],
      [
        "T1",
        "时间范围",
        58,
        63,
        "2021年"
      ],
      [
        "T2",
        "时间范围",
        71,
        76,
        "2020年"
      ],
      [
        "T3",
        "时间范围",
        108,
        113,
        "2020年"
      ],
      [
        "T4",
        "时间范围",
        121,
        130,
        "2022年1-3月"
      ],
      [
        "T5",
        "时间范围",
        174,
        183,
        "2022年1-3月"
      ],
      [
        "T6",
        "时间范围",
        249,
        254,
        "2021年"
      ]
    ]
  },
  {
    "id": 780,
    "text": "对比来看，扣非净利润 2021Q1加速趋势和收入端基本相仿，在增速上普遍高于收入端。由于利润端影响因素相对较多，因此在复合增速上也相对体现出更大的差异性。一方面，部分中小型市值标的相对较大的业绩弹性驱动其较好的股价表现。另一方面，考虑利润端较多的影响因素，例如在剔除非经营性影响因素的经调整口径上，药明康德和泰格医药的利润增速表现更为突出；在不考虑汇兑损益影响下，凯莱英利润增速也有更好的表现；药石科技也存在股权激励费用等因素影响。",
    "labels": [
      [
        "T0",
        "公司",
        149,
        153,
        "药明康德"
      ],
      [
        "T1",
        "公司",
        154,
        158,
        "泰格医药"
      ],
      [
        "T2",
        "公司",
        182,
        185,
        "凯莱英"
      ],
      [
        "T3",
        "公司",
        197,
        201,
        "药石科技"
      ],
      [
        "T4",
        "时间范围",
        11,
        17,
        "2021Q1"
      ],
      [
        "T5",
        "扣非净利润",
        5,
        10,
        "扣非净利润"
      ],
      [
        "T6",
        "营业收入",
        22,
        25,
        "收入端"
      ],
      [
        "T7",
        "营业收入",
        38,
        41,
        "收入端"
      ],
      [
        "T8",
        "利润",
        44,
        47,
        "利润端"
      ],
      [
        "T9",
        "市值",
        86,
        88,
        "市值"
      ],
      [
        "T10",
        "业绩",
        95,
        97,
        "业绩"
      ],
      [
        "T11",
        "利润",
        117,
        120,
        "利润端"
      ],
      [
        "T12",
        "属性值",
        161,
        169,
        "增速表现更为突出"
      ],
      [
        "T13",
        "属性值",
        187,
        196,
        "增速也有更好的表现"
      ],
      [
        "T14",
        "利润",
        159,
        161,
        "利润"
      ],
      [
        "T15",
        "利润",
        185,
        187,
        "利润"
      ]
    ]
  },
  {
    "id": 781,
    "text": "➢ 外部驱动因素未变，看好CXO行业景气度。2021年全球医疗健康融资额同比增长约70%，达8194亿元；融资事件数为3591起， 同比增长64%。 2021年中国医疗健康产业融资总额达2192亿元人民币，同比增长39%，共有1362起融资事件，同比增长83%。 2022Q1全球和中国医疗健康融资额均出现回落，分别为1553.62亿元和392.11亿元，分别同比下降28.50%和33.73%；全球医疗健康产业融资事件数与去年同期基本持平，为856起。全球医药研发支出继续保持增长，创新药产品管线丰富，带动上游CXO需求。随着外包意愿更强的Biotech公司逐渐发力，将继续推动CXO行业的发展。我们认为全球创新药研发热情并未消退，制药企业对CXO的外包需求还将保持增长。",
    "labels": [
      [
        "T0",
        "时间范围",
        22,
        27,
        "2021年"
      ],
      [
        "T1",
        "行业",
        13,
        16,
        "CXO"
      ],
      [
        "T2",
        "地点范围",
        27,
        29,
        "全球"
      ],
      [
        "T3",
        "行业",
        29,
        33,
        "医疗健康"
      ],
      [
        "T4",
        "投融资金额",
        33,
        36,
        "融资额"
      ],
      [
        "T5",
        "属性值",
        36,
        52,
        "同比增长约70%，达8194亿元"
      ],
      [
        "T6",
        "投融资事件数",
        53,
        58,
        "融资事件数"
      ],
      [
        "T7",
        "属性值",
        59,
        73,
        "3591起， 同比增长64%"
      ],
      [
        "T8",
        "时间范围",
        75,
        80,
        "2021年"
      ],
      [
        "T9",
        "地点范围",
        80,
        82,
        "中国"
      ],
      [
        "T10",
        "行业",
        82,
        86,
        "医疗健康"
      ],
      [
        "T11",
        "投融资金额",
        88,
        92,
        "融资总额"
      ],
      [
        "T12",
        "属性值",
        93,
        110,
        "2192亿元人民币，同比增长39%"
      ],
      [
        "T13",
        "属性值",
        113,
        118,
        "1362起"
      ],
      [
        "T14",
        "投融资事件数",
        118,
        122,
        "融资事件"
      ],
      [
        "T15",
        "属性值",
        123,
        130,
        "同比增长83%"
      ],
      [
        "T16",
        "时间范围",
        132,
        138,
        "2022Q1"
      ],
      [
        "T17",
        "地点范围",
        138,
        140,
        "全球"
      ],
      [
        "T18",
        "地点范围",
        141,
        143,
        "中国"
      ],
      [
        "T19",
        "行业",
        143,
        147,
        "医疗健康"
      ],
      [
        "T20",
        "投融资金额",
        147,
        150,
        "融资额"
      ],
      [
        "T21",
        "属性值",
        153,
        155,
        "回落"
      ],
      [
        "T22",
        "属性值",
        159,
        168,
        "1553.62亿元"
      ],
      [
        "T23",
        "属性值",
        169,
        177,
        "392.11亿元"
      ],
      [
        "T24",
        "地点范围",
        198,
        200,
        "全球"
      ],
      [
        "T25",
        "行业",
        200,
        204,
        "医疗健康"
      ],
      [
        "T26",
        "投融资事件数",
        206,
        211,
        "融资事件数"
      ],
      [
        "T27",
        "属性值",
        222,
        226,
        "856起"
      ],
      [
        "T28",
        "地点范围",
        227,
        229,
        "全球"
      ],
      [
        "T29",
        "行业",
        229,
        231,
        "医药"
      ],
      [
        "T30",
        "研发费用",
        231,
        235,
        "研发支出"
      ],
      [
        "T31",
        "属性值",
        239,
        241,
        "增长"
      ],
      [
        "T32",
        "行业",
        242,
        245,
        "创新药"
      ],
      [
        "T33",
        "行业",
        256,
        259,
        "CXO"
      ],
      [
        "T34",
        "行业公司",
        271,
        280,
        "Biotech公司"
      ],
      [
        "T35",
        "行业",
        290,
        293,
        "CXO"
      ],
      [
        "T36",
        "地点范围",
        303,
        305,
        "全球"
      ],
      [
        "T37",
        "行业",
        305,
        308,
        "创新药"
      ],
      [
        "T38",
        "行业公司",
        317,
        321,
        "制药企业"
      ],
      [
        "T39",
        "行业",
        322,
        325,
        "CXO"
      ],
      [
        "T40",
        "行业需求",
        328,
        330,
        "需求"
      ],
      [
        "T41",
        "属性值",
        334,
        336,
        "增长"
      ],
      [
        "T42",
        "属性值",
        216,
        220,
        "基本持平"
      ],
      [
        "T43",
        "时间范围",
        212,
        214,
        "去年"
      ]
    ]
  },
  {
    "id": 782,
    "text": "从事临床前实验室服务的 CRO企业中，公司收入体量高居首位。我们以药明康德的中国区实验室业务与康龙化成实验室业务、方达控股临床前业务（生物分析、DMPK、安全性评价）、昭衍新药临床前业务。药明康德的收入规模巨大， 行业龙头地位显著。 毛利率相对较高，过去 3年基本保持稳定。公司相比可比公司毛利率居于较高水平。一方面由于公司收入占比较高的药物发现服务相对于临床前实验室业务毛利率较高，另一方面也体现出公司较强的行业竞争力。昭衍新药的主营业务以安全性评价为主，因而毛利率相对更高。",
    "labels": [
      [
        "T0",
        "行业公司",
        11,
        17,
        " CRO企业"
      ],
      [
        "T1",
        "营业收入",
        21,
        23,
        "收入"
      ],
      [
        "T2",
        "公司",
        33,
        37,
        "药明康德"
      ],
      [
        "T3",
        "公司",
        47,
        51,
        "康龙化成"
      ],
      [
        "T4",
        "公司",
        57,
        61,
        "方达控股"
      ],
      [
        "T5",
        "公司",
        84,
        88,
        "昭衍新药"
      ],
      [
        "T6",
        "公司",
        94,
        98,
        "药明康德"
      ],
      [
        "T7",
        "营业收入",
        99,
        101,
        "收入"
      ],
      [
        "T8",
        "属性值",
        101,
        105,
        "规模巨大"
      ],
      [
        "T9",
        "龙头企业",
        109,
        111,
        "龙头"
      ],
      [
        "T10",
        "毛利",
        117,
        120,
        "毛利率"
      ],
      [
        "T11",
        "属性值",
        120,
        124,
        "相对较高"
      ],
      [
        "T12",
        "毛利",
        145,
        148,
        "毛利率"
      ],
      [
        "T13",
        "属性值",
        148,
        154,
        "居于较高水平"
      ],
      [
        "T14",
        "毛利",
        186,
        189,
        "毛利率"
      ],
      [
        "T15",
        "公司",
        211,
        215,
        "昭衍新药"
      ],
      [
        "T16",
        "主营业务",
        216,
        220,
        "主营业务"
      ],
      [
        "T17",
        "毛利",
        231,
        234,
        "毛利率"
      ],
      [
        "T18",
        "属性值",
        234,
        238,
        "相对更高"
      ],
      [
        "T19",
        "时间范围",
        125,
        130,
        "过去 3年"
      ],
      [
        "T20",
        "属性值",
        221,
        226,
        "安全性评价"
      ],
      [
        "T21",
        "营收占比",
        162,
        166,
        "收入占比"
      ],
      [
        "T22",
        "属性值",
        166,
        168,
        "较高"
      ],
      [
        "T23",
        "行业",
        169,
        175,
        "药物发现服务"
      ],
      [
        "T24",
        "行业",
        178,
        184,
        "临床前实验室"
      ],
      [
        "T25",
        "属性值",
        189,
        191,
        "较高"
      ],
      [
        "T26",
        "行业",
        88,
        91,
        "临床前"
      ],
      [
        "T27",
        "行业",
        61,
        64,
        "临床前"
      ],
      [
        "T28",
        "地点范围",
        38,
        41,
        "中国区"
      ],
      [
        "T29",
        "行业",
        41,
        44,
        "实验室"
      ],
      [
        "T30",
        "行业",
        51,
        54,
        "实验室"
      ],
      [
        "T31",
        "行业",
        2,
        10,
        "临床前实验室服务"
      ]
    ]
  },
  {
    "id": 785,
    "text": "自主疫苗快速放量，HPV疫苗供不应求。智飞生物是国内综合实力最强的上市民营生物疫苗供应和服务商之一，主营业务包括自主与代理疫苗。自主疫苗产品持续快速放量，上半年 ACYW135、AC结合疫苗各批签发 401.33万支（+123.67%）、315.57万支（+115.12%），另微卡和 EC诊断试剂市场推广工作持续推进中，即将实现放量；核心代理产品四价及九价 HPV疫苗目前为国内独家品种，覆盖病毒亚型种类多，价格高，国内接受度高，市场空间大，仍供不应求。公司已与默沙东签订 2021-2023H1的代理产品采购协议， HPV疫苗采购额大幅增长，进一步增强公司业绩确定性。我们推测随着全国新冠疫苗接种压力的释放， HPV 疫苗等产品批签发已逐步实现恢复。",
    "labels": [
      [
        "T0",
        "行业",
        9,
        14,
        "HPV疫苗"
      ],
      [
        "T1",
        "公司",
        19,
        23,
        "智飞生物"
      ],
      [
        "T2",
        "地点范围",
        24,
        26,
        "国内"
      ],
      [
        "T3",
        "主营业务",
        50,
        54,
        "主营业务"
      ],
      [
        "T4",
        "属性值",
        56,
        63,
        "自主与代理疫苗"
      ],
      [
        "T5",
        "时间范围",
        77,
        81,
        "上半年 "
      ],
      [
        "T6",
        "公司",
        232,
        235,
        "默沙东"
      ],
      [
        "T7",
        "业绩",
        280,
        282,
        "业绩"
      ],
      [
        "T8",
        "时间范围",
        237,
        249,
        " 2021-2023H1"
      ],
      [
        "T9",
        "行业",
        0,
        4,
        "自主疫苗"
      ],
      [
        "T10",
        "行业",
        37,
        41,
        "生物疫苗"
      ],
      [
        "T11",
        "行业",
        64,
        68,
        "自主疫苗"
      ],
      [
        "T12",
        "行业",
        143,
        149,
        "EC诊断试剂"
      ]
    ]
  },
  {
    "id": 791,
    "text": "构建一体化药物发现平台，打造下游流量入口。2020年公司将 DNA编码化合物库（DEL）、蛋白生产和基于结构的药物发现平台（SBDD）进行整合，构建一体化靶标到命中化合物发现平台（HitS）。目前公司的 DNA编码化合物库（DEL） 包含超过 900亿种分子结构，2016年收购的德国药物发现服务企业 Crelux能够提供包括蛋白生产、生物物理分析、片段筛选以及 X-射线晶体结构解析在内的药物发现服务。通过建设 HitS平台，公司能够进一步优化资源配置，充分赋能早期小分子新药研发客户，将其建设成为下游的“流量入口”，充分发挥全产业链平台优势。2020年公司 HitS平台赋能超过 500家全球客户，收入 1.96亿元，同比增长 43%。",
    "labels": [
      [
        "T0",
        "时间范围",
        21,
        26,
        "2020年"
      ],
      [
        "T1",
        "公司",
        132,
        137,
        "2016年"
      ],
      [
        "T2",
        "公司",
        151,
        157,
        "Crelux"
      ],
      [
        "T3",
        "时间范围",
        273,
        278,
        "2020年"
      ],
      [
        "T4",
        "营业收入",
        301,
        303,
        "收入"
      ],
      [
        "T5",
        "地点范围",
        140,
        142,
        "德国"
      ],
      [
        "T6",
        "行业",
        142,
        148,
        "药物发现服务"
      ],
      [
        "T7",
        "地点范围",
        296,
        298,
        "全球"
      ],
      [
        "T8",
        "时间范围",
        96,
        98,
        "目前"
      ]
    ]
  },
  {
    "id": 794,
    "text": "考虑到杨子江药业、齐鲁制药等国内龙头较大的营业收入体量和创新能力，我们假设2016-2020年国内传统药企整体研发投入是Top7（恒瑞医药、复星医药、石药集团、 中国生物制药、上海医药、科伦药业、翰森制药）上市传统药企研发投入的一倍。依此测算2020年国内Biotech投融资（PE/VC）年化研发投入占比达32%，IPO和上市后再融资年化研发投入占比高达47%，传统药企研发投入占比仅为21%。",
    "labels": [
      [
        "T0",
        "公司",
        3,
        8,
        "杨子江药业"
      ],
      [
        "T1",
        "公司",
        9,
        13,
        "齐鲁制药"
      ],
      [
        "T2",
        "地点范围",
        14,
        16,
        "国内"
      ],
      [
        "T3",
        "龙头企业",
        16,
        18,
        "龙头"
      ],
      [
        "T4",
        "营业收入",
        21,
        25,
        "营业收入"
      ],
      [
        "T5",
        "时间范围",
        37,
        47,
        "2016-2020年"
      ],
      [
        "T6",
        "地点范围",
        47,
        49,
        "国内"
      ],
      [
        "T7",
        "研发费用",
        55,
        59,
        "研发投入"
      ],
      [
        "T8",
        "公司",
        65,
        69,
        "恒瑞医药"
      ],
      [
        "T9",
        "公司",
        70,
        74,
        "复星医药"
      ],
      [
        "T10",
        "公司",
        75,
        79,
        "石药集团"
      ],
      [
        "T11",
        "公司",
        81,
        87,
        "中国生物制药"
      ],
      [
        "T12",
        "公司",
        88,
        92,
        "上海医药"
      ],
      [
        "T13",
        "公司",
        93,
        97,
        "科伦药业"
      ],
      [
        "T14",
        "公司",
        98,
        102,
        "翰森制药"
      ],
      [
        "T15",
        "研发费用",
        109,
        113,
        "研发投入"
      ],
      [
        "T16",
        "时间范围",
        121,
        126,
        "2020年"
      ],
      [
        "T17",
        "地点范围",
        126,
        128,
        "国内"
      ],
      [
        "T18",
        "行业",
        128,
        135,
        "Biotech"
      ],
      [
        "T19",
        "投融资情况",
        165,
        168,
        "再融资"
      ],
      [
        "T20",
        "研发费用",
        170,
        174,
        "研发投入"
      ],
      [
        "T21",
        "行业公司",
        103,
        109,
        "上市传统药企"
      ],
      [
        "T22",
        "行业公司",
        49,
        53,
        "传统药企"
      ],
      [
        "T23",
        "投融资情况",
        135,
        138,
        "投融资"
      ],
      [
        "T24",
        "行业公司",
        182,
        186,
        "传统药企"
      ],
      [
        "T25",
        "研发费用率",
        186,
        192,
        "研发投入占比"
      ],
      [
        "T26",
        "属性值",
        194,
        197,
        "21%"
      ],
      [
        "T27",
        "属性值",
        178,
        181,
        "47%"
      ],
      [
        "T28",
        "属性值",
        154,
        157,
        "32%"
      ],
      [
        "T29",
        "研发费用率",
        147,
        153,
        "研发投入占比"
      ]
    ]
  },
  {
    "id": 797,
    "text": "我国的两款 CAR-T 产品尽管定价高， 尚未进入医保， 但使用人数依旧快速增长。 接受 CAR-T 治疗的患者均为末线患者，在经历前线疗法无效或复发的情况下， 考虑两款产品疗效好，对其有较高接受度。复星医药的益基利仑赛注射液与药明巨诺的瑞基奥仑赛注射液分别在 2021 年 6 月份与 9 月份获批，截至 21 年底接受两款产品治疗的人数分别达到 100 余人与 90 余人， 平均每月有 20-30 名患者分别接受治疗，这将推动两款产品在上市一年内销售额即突破亿元大关。",
    "labels": [
      [
        "T0",
        "公司",
        100,
        104,
        "复星医药"
      ],
      [
        "T1",
        "公司",
        114,
        118,
        "药明巨诺"
      ],
      [
        "T2",
        "时间范围",
        151,
        159,
        "截至 21 年底"
      ],
      [
        "T3",
        "地点范围",
        0,
        2,
        "我国"
      ],
      [
        "T4",
        "时间范围",
        131,
        142,
        "2021 年 6 月份"
      ],
      [
        "T5",
        "时间范围",
        144,
        148,
        "9 月份"
      ]
    ]
  },
  {
    "id": 798,
    "text": "在 CGT 领域， 金斯瑞生物科技上游布局耗材与设备， 中游布局 CDMO 技术与产能，下游布局 CGT 药物，打造一体化闭环服务。2021 年公司 CGT CDMO 营收快速增长，商业化生产能力得到认可，且产能进一步扩充，有望在未来维持行业领先地位，并快速提高营收水平。 风险提示：中国 CGT 行业发展不及预期；公司抗体生产产能建设不及预期；传奇生物产品研发失败。",
    "labels": [
      [
        "T0",
        "行业",
        2,
        5,
        "CGT"
      ],
      [
        "T1",
        "公司",
        10,
        17,
        "金斯瑞生物科技"
      ],
      [
        "T2",
        "行业",
        21,
        23,
        "耗材"
      ],
      [
        "T3",
        "行业",
        24,
        26,
        "设备"
      ],
      [
        "T4",
        "行业",
        33,
        37,
        "CDMO"
      ],
      [
        "T5",
        "行业",
        49,
        55,
        "CGT 药物"
      ],
      [
        "T6",
        "时间范围",
        66,
        72,
        "2021 年"
      ],
      [
        "T7",
        "行业",
        75,
        83,
        "CGT CDMO"
      ],
      [
        "T8",
        "营业收入",
        84,
        86,
        "营收"
      ],
      [
        "T9",
        "属性值",
        86,
        90,
        "快速增长"
      ],
      [
        "T10",
        "属性值",
        109,
        111,
        "扩充"
      ],
      [
        "T11",
        "产能",
        104,
        106,
        "产能"
      ],
      [
        "T12",
        "时间范围",
        115,
        117,
        "未来"
      ],
      [
        "T13",
        "属性值",
        127,
        131,
        "快速提高"
      ],
      [
        "T14",
        "营业收入",
        131,
        133,
        "营收"
      ]
    ]
  },
  {
    "id": 803,
    "text": "MPP公布Paxlovid授权仿制名单，国内五家药企获授权。2022年3月17日晚，药品专利池组织（MPP）宣布已与35家药企签订协议，允许全球95个中低收入国家或地区获得辉瑞新冠口服治疗药物Paxlovid的仿制权。本次 MMP授权的35家药企中，有5家为中国药企，分别为复星医药、普洛药业、 九洲药业、上海迪赛诺和华海药业。其中九洲药业仅生产原料药，其余可以同时生产原料药和制剂。",
    "labels": [
      [
        "T0",
        "地点范围",
        20,
        22,
        "国内"
      ],
      [
        "T1",
        "时间范围",
        30,
        41,
        "2022年3月17日晚"
      ],
      [
        "T2",
        "公司",
        86,
        88,
        "辉瑞"
      ],
      [
        "T3",
        "行业公司",
        131,
        133,
        "药企"
      ],
      [
        "T4",
        "公司",
        137,
        141,
        "复星医药"
      ],
      [
        "T5",
        "公司",
        142,
        146,
        "普洛药业"
      ],
      [
        "T6",
        "公司",
        148,
        152,
        "九洲药业"
      ],
      [
        "T7",
        "公司",
        153,
        158,
        "上海迪赛诺"
      ],
      [
        "T8",
        "公司",
        159,
        163,
        "华海药业"
      ],
      [
        "T9",
        "公司",
        166,
        170,
        "九洲药业"
      ],
      [
        "T10",
        "行业公司",
        22,
        26,
        "五家药企"
      ],
      [
        "T11",
        "行业公司",
        58,
        63,
        "35家药企"
      ],
      [
        "T12",
        "地点范围",
        70,
        72,
        "全球"
      ],
      [
        "T13",
        "行业公司",
        118,
        123,
        "35家药企"
      ],
      [
        "T14",
        "地点范围",
        129,
        131,
        "中国"
      ]
    ]
  },
  {
    "id": 827,
    "text": "Y提升、传播”这一核心目标，头豹打～头豹是中国领先的原创行企研究内容平台和新型企业服务提供商。围绕“协助企业加速资本价值的挖掘造了一系列产品及解决方案，包括：报告/数据库服务、行企研报服务、微估值及微尽调自动化产品财务顾问服务、PR及IR服务，以及其他企业为基础，围绕产业焦点、热点问题，基于丰富案例和海量数据，通过开放合作的增长咨利用大数据、区块链和人工智能等技术，询服务等－头豹致力于以优质商业资源共享研究平台，汇集各界智慧，推动产业健康、有序、可持续发展",
    "labels": [
      [
        "T0",
        "公司",
        18,
        20,
        "头豹"
      ],
      [
        "T1",
        "公司",
        14,
        16,
        "头豹"
      ],
      [
        "T2",
        "公司",
        189,
        191,
        "头豹"
      ],
      [
        "T3",
        "地点范围",
        21,
        23,
        "中国"
      ],
      [
        "T4",
        "行业",
        26,
        36,
        "原创行企研究内容平台"
      ],
      [
        "T5",
        "行业",
        39,
        43,
        "企业服务"
      ],
      [
        "T6",
        "属性值",
        79,
        121,
        "报告/数据库服务、行企研报服务、微估值及微尽调自动化产品财务顾问服务、PR及IR服务"
      ]
    ]
  },
  {
    "id": 833,
    "text": "IQVIA经过近 40年的发展，目前已经成为全球最大的生物制药开发服务和商业外包服务提供商之一，纵观其发展路径，可以将其总结为“全面覆盖、优势业务、信息技术、创新模式”四大要点。",
    "labels": [
      [
        "T0",
        "公司",
        0,
        5,
        "IQVIA"
      ],
      [
        "T1",
        "地点范围",
        22,
        24,
        "全球"
      ],
      [
        "T2",
        "时间范围",
        16,
        18,
        "目前"
      ],
      [
        "T3",
        "行业",
        27,
        33,
        "生物制药开发"
      ]
    ]
  },
  {
    "id": 834,
    "text": "CXO行业百舸争流，优质人才、稀缺平台、前沿技术构建公司三大核心竞争力。 中长期来看创新药研发投入强度有望维持稳定增长，作为创新药产业链中业绩确定性最高的环节，CXO板块吸引诸多玩家参与竞争。面对日趋激烈的行业竞争态势，我们认为公司行业龙头的地位有望持续稳固，并有望实现强者恒强。 主要由于公司已在人才、平台和技术三个层面建立起较强护城河：  优质人才：高素质人才带来的工程师红利是国内 CXO在全球竞争中占得优势的基础，公司的品牌地位、研发经验、平台优势将对团队扩张和招募带来集聚效应；  稀缺平台：CXO行业虽然玩家众多，但真正拥有端到端的全产业链服务能力的企业具有较强稀缺性，而这一平台优势有望持续转化为客户粘性优势和流量变现优势；  前沿技术：近年来药物发现的新机制和新技术迭出，公司通过布局创新性技术平台建立起丰富的流量入口，有望获得更多全球长尾客户订单，为后续增长提供持续动力。",
    "labels": [
      [
        "T0",
        "行业",
        0,
        3,
        "CXO"
      ],
      [
        "T1",
        "时间范围",
        37,
        40,
        "中长期"
      ],
      [
        "T2",
        "行业",
        42,
        45,
        "创新药"
      ],
      [
        "T3",
        "研发费用",
        45,
        49,
        "研发投入"
      ],
      [
        "T4",
        "属性值",
        55,
        59,
        "稳定增长"
      ],
      [
        "T5",
        "行业",
        62,
        68,
        "创新药产业链"
      ],
      [
        "T6",
        "业绩",
        69,
        71,
        "业绩"
      ],
      [
        "T7",
        "行业",
        80,
        83,
        "CXO"
      ],
      [
        "T8",
        "属性值",
        71,
        76,
        "确定性最高"
      ],
      [
        "T9",
        "属性值",
        98,
        102,
        "日趋激烈"
      ],
      [
        "T10",
        "地点范围",
        192,
        194,
        "国内"
      ],
      [
        "T11",
        "行业",
        195,
        198,
        "CXO"
      ],
      [
        "T12",
        "地点范围",
        199,
        201,
        "全球"
      ],
      [
        "T13",
        "行业",
        253,
        256,
        "CXO"
      ],
      [
        "T14",
        "时间范围",
        329,
        332,
        "近年来"
      ],
      [
        "T15",
        "行业",
        332,
        336,
        "药物发现"
      ],
      [
        "T16",
        "地点范围",
        377,
        379,
        "全球"
      ]
    ]
  },
  {
    "id": 835,
    "text": "全球 CRO行业保持稳健增长。根据 Frost & Sullivan统计，全球 2019年全球 CRO行业市场规模达到 626亿美元，同比增长 8.3%，其中药物发现阶段市场规模 129亿美元，临床前 CRO市场规模 91亿美元，临床 CRO市场规模 406 亿美元，近年来按研发流程分类的三大细分领域市场规模占比基本保持稳定。 预计到 2024年，CRO行业规模将达到 961亿美元，2019~2024年 CAGR达到 8.9%。",
    "labels": [
      [
        "T0",
        "地点范围",
        0,
        2,
        "全球"
      ],
      [
        "T1",
        "行业",
        3,
        6,
        "CRO"
      ],
      [
        "T2",
        "地点范围",
        37,
        39,
        "全球"
      ],
      [
        "T3",
        "时间范围",
        40,
        45,
        "2019年"
      ],
      [
        "T4",
        "地点范围",
        45,
        47,
        "全球"
      ],
      [
        "T5",
        "行业",
        48,
        51,
        "CRO"
      ],
      [
        "T6",
        "市场规模",
        53,
        57,
        "市场规模"
      ],
      [
        "T7",
        "行业",
        79,
        85,
        "药物发现阶段"
      ],
      [
        "T8",
        "市场规模",
        85,
        89,
        "市场规模"
      ],
      [
        "T9",
        "属性值",
        90,
        96,
        "129亿美元"
      ],
      [
        "T10",
        "行业",
        97,
        104,
        "临床前 CRO"
      ],
      [
        "T11",
        "市场规模",
        104,
        108,
        "市场规模"
      ],
      [
        "T12",
        "属性值",
        109,
        114,
        "91亿美元"
      ],
      [
        "T13",
        "行业",
        115,
        121,
        "临床 CRO"
      ],
      [
        "T14",
        "市场规模",
        121,
        125,
        "市场规模"
      ],
      [
        "T15",
        "属性值",
        126,
        133,
        "406 亿美元"
      ],
      [
        "T16",
        "时间范围",
        134,
        137,
        "近年来"
      ],
      [
        "T17",
        "时间范围",
        169,
        174,
        "2024年"
      ],
      [
        "T18",
        "行业",
        175,
        178,
        "CRO"
      ],
      [
        "T19",
        "市场规模",
        180,
        182,
        "规模"
      ],
      [
        "T20",
        "属性值",
        186,
        192,
        "961亿美元"
      ],
      [
        "T21",
        "时间范围",
        193,
        203,
        "2019~2024年"
      ],
      [
        "T22",
        "CAGR",
        204,
        208,
        "CAGR"
      ],
      [
        "T23",
        "属性值",
        211,
        215,
        "8.9%"
      ],
      [
        "T24",
        "市场规模",
        151,
        155,
        "市场规模"
      ],
      [
        "T25",
        "属性值",
        60,
        76,
        "626亿美元，同比增长 8.3%"
      ]
    ]
  },
  {
    "id": 840,
    "text": " 股权激励呈现常态化：2020年实施股权激励的CXO公司有药明康德、康龙化成、凯莱英、博腾股份、九洲药业、昭衍新药、 美迪西，实现员工利益和公司及股东利益的绑定。  核心CXO公司人均薪酬呈现上升趋势，但工程师红利优势短期不会发生变化：在人均薪酬逐渐上涨和股权激励的双重作用下 ，人均薪酬均呈现上升趋势，即大部分公司人均薪酬已达到20万元以上。",
    "labels": [
      [
        "T0",
        "时间范围",
        12,
        17,
        "2020年"
      ],
      [
        "T1",
        "行业公司",
        24,
        29,
        "CXO公司"
      ],
      [
        "T2",
        "公司",
        30,
        34,
        "药明康德"
      ],
      [
        "T3",
        "公司",
        35,
        39,
        "康龙化成"
      ],
      [
        "T4",
        "公司",
        40,
        43,
        "凯莱英"
      ],
      [
        "T5",
        "公司",
        44,
        48,
        "博腾股份"
      ],
      [
        "T6",
        "公司",
        49,
        53,
        "九洲药业"
      ],
      [
        "T7",
        "公司",
        54,
        58,
        "昭衍新药"
      ],
      [
        "T8",
        "公司",
        60,
        63,
        "美迪西"
      ],
      [
        "T9",
        "行业公司",
        85,
        92,
        "核心CXO公司"
      ],
      [
        "T10",
        "时间范围",
        111,
        113,
        "短期"
      ]
    ]
  },
  {
    "id": 845,
    "text": "业毛利率较高，主营业务收入较高，泰格医",
    "labels": [
      [
        "T0",
        "毛利",
        1,
        4,
        "毛利率"
      ],
      [
        "T1",
        "主营业务",
        7,
        11,
        "主营业务"
      ],
      [
        "T2",
        "营业收入",
        11,
        13,
        "收入"
      ],
      [
        "T3",
        "公司",
        16,
        19,
        "泰格医"
      ]
    ]
  },
  {
    "id": 852,
    "text": "【通策医疗】①2020年度业绩：营业收入 20.88亿元（+8.12%），归母净利润 4.93 亿元（+5.69%）；②2021年 Q1业绩：营业收入 6.31亿元（+221.59%），归母净利润 9394.26 万元（+11.35%）。",
    "labels": [
      [
        "T0",
        "公司",
        1,
        5,
        "通策医疗"
      ],
      [
        "T1",
        "业绩",
        13,
        15,
        "业绩"
      ],
      [
        "T2",
        "时间范围",
        7,
        13,
        "2020年度"
      ],
      [
        "T3",
        "营业收入",
        16,
        20,
        "营业收入"
      ],
      [
        "T4",
        "属性值",
        21,
        28,
        "20.88亿元"
      ],
      [
        "T5",
        "属性值",
        29,
        35,
        "+8.12%"
      ],
      [
        "T6",
        "归母净利润",
        37,
        42,
        "归母净利润"
      ],
      [
        "T7",
        "属性值",
        43,
        58,
        "4.93 亿元（+5.69%）"
      ],
      [
        "T8",
        "时间范围",
        60,
        68,
        "2021年 Q1"
      ],
      [
        "T9",
        "业绩",
        68,
        70,
        "业绩"
      ],
      [
        "T10",
        "营业收入",
        71,
        75,
        "营业收入"
      ],
      [
        "T11",
        "属性值",
        76,
        82,
        "6.31亿元"
      ],
      [
        "T12",
        "属性值",
        83,
        91,
        "+221.59%"
      ],
      [
        "T13",
        "归母净利润",
        93,
        98,
        "归母净利润"
      ],
      [
        "T14",
        "属性值",
        99,
        118,
        "9394.26 万元（+11.35%）"
      ]
    ]
  },
  {
    "id": 857,
    "text": "药明康德深耕新药研发领域多年，对行业发展趋势有着深刻理解和前瞻判断。 公司基于多年来在药物研发领域的经验，能够更为前瞻性地布局创新药前沿领域。一方面能够通过搭建以 PROTAC等新技术为基础的药物研发平台为客户赋",
    "labels": [
      [
        "T0",
        "公司",
        0,
        4,
        "药明康德"
      ],
      [
        "T1",
        "行业",
        6,
        10,
        "新药研发"
      ],
      [
        "T2",
        "行业",
        43,
        47,
        "药物研发"
      ],
      [
        "T3",
        "行业",
        63,
        66,
        "创新药"
      ]
    ]
  },
  {
    "id": 860,
    "text": "◆ 生命科学服务市场扩容迅速，景气度持续高涨生命科学服务主要包括科研试剂、模式生物、实验室设备与耗材、测序与建库服务等细分赛道。在不考虑实验室设备（国产化率极低）的情况下，我们估计2020年总体市场规模超过600亿元，2020-2024年CAGR约为20%，行业增长驱动力主要为： ➢ 生物药产业蓬勃发展：全球生物药市场规模超万亿美元，带来生命科学服务需求持续增长, mRNA疫苗、细胞与基因治疗等新兴领域有望带来额外增量； ➢ 生命科学研发支出高速增长：全球生物企业、高校科研机构研发支出持续高速增长（中国医药行业规模以上工业企业2020年同比增长28.7%），新冠疫情进一步拉动行业景气度； ◆ 国产替代空间广阔，新冠疫情提供难得窗口期科研服务行业多学科交叉，具备较高壁垒，国际巨头长期垄断市场，中国市场每年约占其总营收的10%，疫情之后迎来国产替代加速期： ➢ 国内产品质量逐渐接近国际水平：国内部分企业经过十余年技术积累，主流产品性能逐渐媲美进口品牌，为国产替代奠定基础；且国内产品价格约为进口50%-80%，响应速度快，服务优质，存在本土优势；相较之下科研试剂、实验室设备与耗材具备更大的国产替代空间（70%-90%）； ➢ 上游企业降本需求提升：生命科学服务在部分生物企业成本中占比可达60%以上，医保谈判、集采等逐渐成为常态化，价格降幅大，企业利润端承压，存在强烈的降成本需求； ➢ 新冠疫情催化剂：新冠疫情下的物流货运、疫情防控等问题为国内企业带来难得窗口期，大大推动了国产替代进程；同时疫情催生了全球生命科学领域的新需求，为国内企业出海提供优良契机，短期带来营收增量，长期利好品牌建设； ➢ 政策引导支持：疫情前后出台的一系列政策强调上游供应链安全稳定，为国产替代保驾护航。",
    "labels": [
      [
        "T0",
        "市场规模",
        8,
        10,
        "市场"
      ],
      [
        "T1",
        "属性值",
        10,
        14,
        "扩容迅速"
      ],
      [
        "T2",
        "行业",
        22,
        26,
        "生命科学"
      ],
      [
        "T3",
        "时间范围",
        90,
        95,
        "2020年"
      ],
      [
        "T4",
        "市场规模",
        97,
        101,
        "市场规模"
      ],
      [
        "T5",
        "属性值",
        101,
        108,
        "超过600亿元"
      ],
      [
        "T6",
        "属性值",
        123,
        128,
        "约为20%"
      ],
      [
        "T7",
        "CAGR",
        119,
        123,
        "CAGR"
      ],
      [
        "T8",
        "时间范围",
        109,
        119,
        "2020-2024年"
      ],
      [
        "T9",
        "行业",
        32,
        36,
        "科研试剂"
      ],
      [
        "T10",
        "行业",
        37,
        41,
        "模式生物"
      ],
      [
        "T11",
        "行业",
        42,
        50,
        "实验室设备与耗材"
      ],
      [
        "T12",
        "行业",
        51,
        58,
        "测序与建库服务"
      ],
      [
        "T13",
        "行业",
        143,
        146,
        "生物药"
      ],
      [
        "T14",
        "地点范围",
        153,
        155,
        "全球"
      ],
      [
        "T15",
        "行业",
        155,
        158,
        "生物药"
      ],
      [
        "T16",
        "市场规模",
        158,
        162,
        "市场规模"
      ],
      [
        "T17",
        "属性值",
        162,
        167,
        "超万亿美元"
      ],
      [
        "T18",
        "行业需求",
        176,
        178,
        "需求"
      ],
      [
        "T19",
        "属性值",
        178,
        182,
        "持续增长"
      ],
      [
        "T20",
        "行业",
        184,
        190,
        "mRNA疫苗"
      ],
      [
        "T21",
        "行业",
        191,
        198,
        "细胞与基因治疗"
      ],
      [
        "T22",
        "行业",
        215,
        219,
        "生命科学"
      ],
      [
        "T23",
        "研发费用",
        219,
        223,
        "研发支出"
      ],
      [
        "T24",
        "属性值",
        223,
        227,
        "高速增长"
      ],
      [
        "T25",
        "地点范围",
        228,
        230,
        "全球"
      ],
      [
        "T26",
        "行业公司",
        230,
        234,
        "生物企业"
      ],
      [
        "T27",
        "地点范围",
        252,
        254,
        "中国"
      ],
      [
        "T28",
        "时间范围",
        266,
        271,
        "2020年"
      ],
      [
        "T29",
        "研发费用",
        241,
        245,
        "研发支出"
      ],
      [
        "T30",
        "营业收入",
        360,
        362,
        "营收"
      ],
      [
        "T31",
        "行业",
        481,
        485,
        "科研试剂"
      ],
      [
        "T32",
        "行业",
        486,
        494,
        "实验室设备与耗材"
      ],
      [
        "T33",
        "利润",
        579,
        582,
        "利润端"
      ],
      [
        "T34",
        "行业",
        659,
        663,
        "生命科学"
      ],
      [
        "T35",
        "行业需求",
        667,
        669,
        "需求"
      ],
      [
        "T36",
        "地点范围",
        671,
        673,
        "国内"
      ],
      [
        "T37",
        "营业收入",
        688,
        690,
        "营收"
      ],
      [
        "T38",
        "行业",
        2,
        8,
        "生命科学服务"
      ],
      [
        "T39",
        "行业",
        68,
        73,
        "实验室设备"
      ],
      [
        "T40",
        "行业",
        170,
        176,
        "生命科学服务"
      ],
      [
        "T41",
        "属性值",
        245,
        251,
        "持续高速增长"
      ],
      [
        "T42",
        "地点范围",
        350,
        352,
        "中国"
      ],
      [
        "T43",
        "地点范围",
        657,
        659,
        "全球"
      ],
      [
        "T44",
        "时间范围",
        684,
        686,
        "短期"
      ],
      [
        "T45",
        "地点范围",
        626,
        628,
        "国内"
      ],
      [
        "T46",
        "行业",
        529,
        535,
        "生命科学服务"
      ],
      [
        "T47",
        "行业公司",
        538,
        542,
        "生物企业"
      ],
      [
        "T48",
        "地点范围",
        472,
        474,
        "本土"
      ],
      [
        "T49",
        "地点范围",
        399,
        401,
        "国内"
      ],
      [
        "T50",
        "地点范围",
        384,
        386,
        "国内"
      ],
      [
        "T51",
        "行业公司",
        254,
        266,
        "医药行业规模以上工业企业"
      ],
      [
        "T52",
        "属性值",
        271,
        280,
        "同比增长28.7%"
      ]
    ]
  },
  {
    "id": 861,
    "text": "从根治愈，细胞基因治疗（CGT）开启商业化黄金时代。与传统小分子、大分子药物相比，CGT 药物靶向生物遗传信息传递的上游，理论上可以治疗一切因蛋白质异常引发的疾病。通过对基因进行修复治疗，其适应症范围广阔，并具有一针治愈、从根解决的特性。CGT 药物单价高、疗效好，且受益于上游审批加速、 下游保险支持，正在进入商业化放量的黄金时代。据 FDA 预测，2020 至 2025 年每年将会有 10-20 个 CGT 药物获批上市。预计 2025 年全球 CGT 市场规模突破 300 亿美元（2020-25 年 CAGR=71%） ，中国市场达 25.9 亿美元（2020-25 年 CAGR=287%）。",
    "labels": [
      [
        "T0",
        "时间范围",
        217,
        223,
        "2025 年"
      ],
      [
        "T1",
        "地点范围",
        223,
        225,
        "全球"
      ],
      [
        "T2",
        "行业",
        226,
        229,
        "CGT"
      ],
      [
        "T3",
        "市场规模",
        230,
        234,
        "市场规模"
      ],
      [
        "T4",
        "属性值",
        234,
        244,
        "突破 300 亿美元"
      ],
      [
        "T5",
        "时间范围",
        245,
        254,
        "2020-25 年"
      ],
      [
        "T6",
        "CAGR",
        255,
        259,
        "CAGR"
      ],
      [
        "T7",
        "属性值",
        260,
        263,
        "71%"
      ],
      [
        "T8",
        "地点范围",
        266,
        268,
        "中国"
      ],
      [
        "T9",
        "属性值",
        272,
        280,
        "25.9 亿美元"
      ],
      [
        "T10",
        "时间范围",
        281,
        290,
        "2020-25 年"
      ],
      [
        "T11",
        "CAGR",
        291,
        295,
        "CAGR"
      ],
      [
        "T12",
        "属性值",
        296,
        300,
        "287%"
      ],
      [
        "T13",
        "行业",
        5,
        16,
        "细胞基因治疗（CGT）"
      ],
      [
        "T14",
        "行业",
        119,
        122,
        "CGT"
      ],
      [
        "T15",
        "时间范围",
        176,
        189,
        "2020 至 2025 年"
      ],
      [
        "T16",
        "行业",
        203,
        206,
        "CGT"
      ],
      [
        "T17",
        "属性值",
        195,
        202,
        "10-20 个"
      ]
    ]
  },
  {
    "id": 869,
    "text": "诺思格近四年营业收入保持持续增长状态， 2020年实现营收 4.84亿元， 同比增长 13.87%， 2018 年至 2020 年年均复合增长率达 21.82%，因新冠疫情影响，2020 年收入增速较低； 公司净利润主要来源于主营业务，2018 年、2019 年，公司业务规模和类型不断扩大，营业收入增加，拉动净利润同比高速增长，2020年，因新冠疫情影响净利润增速下降，实现归母净利润 0.84亿元， 同比增长 1.46%，实现扣非归母净利润 0.73亿元，同比降低 7.32%。",
    "labels": [
      [
        "T0",
        "公司",
        0,
        3,
        "诺思格"
      ],
      [
        "T1",
        "时间范围",
        3,
        6,
        "近四年"
      ],
      [
        "T2",
        "营业收入",
        6,
        10,
        "营业收入"
      ],
      [
        "T3",
        "时间范围",
        20,
        25,
        "2020年"
      ],
      [
        "T4",
        "营业收入",
        27,
        29,
        "营收"
      ],
      [
        "T5",
        "属性值",
        30,
        36,
        "4.84亿元"
      ],
      [
        "T6",
        "时间范围",
        50,
        65,
        " 2018 年至 2020 年"
      ],
      [
        "T7",
        "CAGR",
        65,
        72,
        "年均复合增长率"
      ],
      [
        "T8",
        "属性值",
        74,
        80,
        "21.82%"
      ],
      [
        "T9",
        "时间范围",
        89,
        95,
        "2020 年"
      ],
      [
        "T10",
        "收入增速",
        95,
        99,
        "收入增速"
      ],
      [
        "T11",
        "属性值",
        99,
        101,
        "较低"
      ],
      [
        "T12",
        "归母净利润",
        105,
        108,
        "净利润"
      ],
      [
        "T13",
        "主营业务",
        113,
        117,
        "主营业务"
      ],
      [
        "T14",
        "时间范围",
        118,
        124,
        "2018 年"
      ],
      [
        "T15",
        "时间范围",
        125,
        131,
        "2019 年"
      ],
      [
        "T16",
        "营业收入",
        146,
        150,
        "营业收入"
      ],
      [
        "T17",
        "归母净利润",
        155,
        158,
        "净利润"
      ],
      [
        "T18",
        "属性值",
        158,
        164,
        "同比高速增长"
      ],
      [
        "T19",
        "时间范围",
        165,
        170,
        "2020年"
      ],
      [
        "T20",
        "归母净利润增速",
        178,
        183,
        "净利润增速"
      ],
      [
        "T21",
        "属性值",
        183,
        185,
        "下降"
      ],
      [
        "T22",
        "归母净利润",
        188,
        193,
        "归母净利润"
      ],
      [
        "T23",
        "扣非净利润",
        215,
        222,
        "扣非归母净利润"
      ],
      [
        "T24",
        "属性值",
        14,
        16,
        "增长"
      ],
      [
        "T25",
        "属性值",
        43,
        49,
        "13.87%"
      ],
      [
        "T26",
        "属性值",
        150,
        152,
        "增加"
      ],
      [
        "T27",
        "属性值",
        194,
        212,
        "0.84亿元， 同比增长 1.46%"
      ],
      [
        "T28",
        "属性值",
        223,
        240,
        "0.73亿元，同比降低 7.32%"
      ]
    ]
  },
  {
    "id": 872,
    "text": "2.2 国内医药企业研发投入高增长，创新药IND和NDA数量保持高位 A股医药企业研发投入快速增长。我国A股医药企业研发投入保持高增长，2019年研发投入额达到 530亿元，2020研发投入额达到689亿元，同比增长30%，仍然保持在较高水平，高速增长的研发投入为CXO行业的发展奠定基础。 我国一级市场创新药企业融资额和融资事件快速增加。大型药企转型研发的同时，创业型的创新药企业数量快速增加，逐步成为我国创新药研发的主力，2018年我国一级市场创新药企业融资额快速增加，2020年融资额仍然超过680亿元，融资事件数量也保持在较高水平，biotech融资额以及研发投入的快速增加，成为推动我国CDMO行业发展的重要动力。",
    "labels": [
      [
        "T0",
        "地点范围",
        4,
        6,
        "国内"
      ],
      [
        "T1",
        "行业公司",
        6,
        10,
        "医药企业"
      ],
      [
        "T2",
        "研发费用",
        10,
        14,
        "研发投入"
      ],
      [
        "T3",
        "属性值",
        14,
        17,
        "高增长"
      ],
      [
        "T4",
        "IND申报数",
        18,
        24,
        "创新药IND"
      ],
      [
        "T5",
        "研发费用",
        41,
        45,
        "研发投入"
      ],
      [
        "T6",
        "地点范围",
        50,
        52,
        "我国"
      ],
      [
        "T7",
        "研发费用",
        58,
        62,
        "研发投入"
      ],
      [
        "T8",
        "时间范围",
        68,
        73,
        "2019年"
      ],
      [
        "T9",
        "研发费用",
        73,
        77,
        "研发投入"
      ],
      [
        "T10",
        "属性值",
        81,
        86,
        "530亿元"
      ],
      [
        "T11",
        "时间范围",
        87,
        91,
        "2020"
      ],
      [
        "T12",
        "研发费用",
        91,
        95,
        "研发投入"
      ],
      [
        "T13",
        "属性值",
        98,
        111,
        "689亿元，同比增长30%"
      ],
      [
        "T14",
        "研发费用",
        127,
        131,
        "研发投入"
      ],
      [
        "T15",
        "行业",
        132,
        135,
        "CXO"
      ],
      [
        "T16",
        "地点范围",
        146,
        148,
        "我国"
      ],
      [
        "T17",
        "投融资金额",
        157,
        160,
        "融资额"
      ],
      [
        "T18",
        "投融资事件数",
        161,
        165,
        "融资事件"
      ],
      [
        "T19",
        "属性值",
        165,
        169,
        "快速增加"
      ],
      [
        "T20",
        "行业公司",
        170,
        174,
        "大型药企"
      ],
      [
        "T21",
        "行业公司",
        182,
        191,
        "创业型的创新药企业"
      ],
      [
        "T22",
        "时间范围",
        213,
        218,
        "2018年"
      ],
      [
        "T23",
        "地点范围",
        218,
        220,
        "我国"
      ],
      [
        "T24",
        "投融资金额",
        229,
        232,
        "融资额"
      ],
      [
        "T25",
        "属性值",
        232,
        236,
        "快速增加"
      ],
      [
        "T26",
        "投融资金额",
        242,
        245,
        "融资额"
      ],
      [
        "T27",
        "属性值",
        247,
        254,
        "超过680亿元"
      ],
      [
        "T28",
        "时间范围",
        237,
        242,
        "2020年"
      ],
      [
        "T29",
        "投融资事件数",
        255,
        261,
        "融资事件数量"
      ],
      [
        "T30",
        "行业",
        270,
        277,
        "biotech"
      ],
      [
        "T31",
        "投融资金额",
        277,
        280,
        "融资额"
      ],
      [
        "T32",
        "研发费用",
        282,
        286,
        "研发投入"
      ],
      [
        "T33",
        "属性值",
        287,
        291,
        "快速增加"
      ],
      [
        "T34",
        "行业",
        298,
        302,
        "CDMO"
      ],
      [
        "T35",
        "行业公司",
        54,
        58,
        "医药企业"
      ],
      [
        "T36",
        "属性值",
        64,
        67,
        "高增长"
      ],
      [
        "T37",
        "属性值",
        122,
        126,
        "高速增长"
      ],
      [
        "T38",
        "行业公司",
        152,
        157,
        "创新药企业"
      ],
      [
        "T39",
        "地点范围",
        202,
        204,
        "我国"
      ],
      [
        "T40",
        "行业",
        204,
        207,
        "创新药"
      ],
      [
        "T41",
        "行业公司",
        224,
        229,
        "创新药企业"
      ],
      [
        "T42",
        "属性值",
        265,
        269,
        "较高水平"
      ],
      [
        "T43",
        "地点范围",
        296,
        298,
        "我国"
      ]
    ]
  },
  {
    "id": 887,
    "text": "国内二类疫苗市场规模持续扩大。我国疫苗市场规模在二类疫苗市场的拉动下持续增长，已从 2013年的 169亿元增长至 2019年的 394亿元，年均复合增长率高达 18.45%。未来随着国家政策对疫苗行业的大力扶持、居民可支配收入的增长和防病意识的不断增强、疫苗研发和生产投入不断增加、产品的升级换代， 国内疫苗产业仍将高速增长，预计 2025年我国疫苗市场规模可达 950亿元。",
    "labels": [
      [
        "T0",
        "地点范围",
        0,
        2,
        "国内"
      ],
      [
        "T1",
        "行业",
        2,
        6,
        "二类疫苗"
      ],
      [
        "T2",
        "市场规模",
        6,
        10,
        "市场规模"
      ],
      [
        "T3",
        "属性值",
        10,
        14,
        "持续扩大"
      ],
      [
        "T4",
        "行业",
        17,
        19,
        "疫苗"
      ],
      [
        "T5",
        "市场规模",
        19,
        23,
        "市场规模"
      ],
      [
        "T6",
        "属性值",
        34,
        38,
        "持续增长"
      ],
      [
        "T7",
        "时间范围",
        42,
        47,
        "2013年"
      ],
      [
        "T8",
        "属性值",
        49,
        54,
        "169亿元"
      ],
      [
        "T9",
        "属性值",
        65,
        70,
        "394亿元"
      ],
      [
        "T10",
        "属性值",
        81,
        87,
        "18.45%"
      ],
      [
        "T11",
        "时间范围",
        58,
        63,
        "2019年"
      ],
      [
        "T12",
        "CAGR",
        71,
        78,
        "年均复合增长率"
      ],
      [
        "T13",
        "行业",
        97,
        99,
        "疫苗"
      ],
      [
        "T14",
        "地点范围",
        151,
        153,
        "国内"
      ],
      [
        "T15",
        "行业",
        153,
        155,
        "疫苗"
      ],
      [
        "T16",
        "属性值",
        183,
        188,
        "950亿元"
      ],
      [
        "T17",
        "市场规模",
        176,
        180,
        "市场规模"
      ],
      [
        "T18",
        "行业",
        174,
        176,
        "疫苗"
      ],
      [
        "T19",
        "地点范围",
        172,
        174,
        "我国"
      ],
      [
        "T20",
        "地点范围",
        15,
        17,
        "我国"
      ],
      [
        "T21",
        "时间范围",
        167,
        172,
        "2025年"
      ]
    ]
  },
  {
    "id": 893,
    "text": "泰格医药成立于 2004年 12月，是国内最大、全球第九的临床 CRO公司，分别于 2012年 8 月 17 日在深交所挂牌上市（股票代码：300347.SZ），2020 年 8 月 7 日在香港联交所挂牌上市（股票代码：3347.HK）。",
    "labels": [
      [
        "T0",
        "公司",
        0,
        4,
        "泰格医药"
      ],
      [
        "T1",
        "地点范围",
        19,
        21,
        "国内"
      ],
      [
        "T2",
        "时间范围",
        8,
        17,
        "2004年 12月"
      ],
      [
        "T3",
        "地点范围",
        24,
        26,
        "全球"
      ],
      [
        "T4",
        "行业公司",
        29,
        37,
        "临床 CRO公司"
      ],
      [
        "T5",
        "时间范围",
        42,
        56,
        "2012年 8 月 17 日"
      ],
      [
        "T6",
        "时间范围",
        81,
        95,
        "2020 年 8 月 7 日"
      ]
    ]
  },
  {
    "id": 894,
    "text": "合全药业在国内 CDMO行业中龙头地位稳固，业务能力覆盖全产业链，订单储备丰富，随着过往积累的临床前期业务将不断向临床后期和商业化业务转化， 未来收入有望持续稳健增长。同时随着产能释放及技术提升也将促进盈利能力的增强。预计未来三年收入端保持 30%以上增速。",
    "labels": [
      [
        "T0",
        "公司",
        0,
        4,
        "合全药业"
      ],
      [
        "T1",
        "地点范围",
        5,
        7,
        "国内"
      ],
      [
        "T2",
        "行业",
        8,
        12,
        "CDMO"
      ],
      [
        "T3",
        "龙头企业",
        15,
        17,
        "龙头"
      ],
      [
        "T4",
        "营业收入",
        73,
        75,
        "收入"
      ],
      [
        "T5",
        "时间范围",
        71,
        73,
        "未来"
      ],
      [
        "T6",
        "产能",
        88,
        90,
        "产能"
      ],
      [
        "T7",
        "属性值",
        90,
        92,
        "释放"
      ],
      [
        "T8",
        "时间范围",
        111,
        115,
        "未来三年"
      ],
      [
        "T9",
        "营业收入",
        115,
        118,
        "收入端"
      ],
      [
        "T10",
        "属性值",
        121,
        126,
        "30%以上"
      ],
      [
        "T11",
        "属性值",
        77,
        83,
        "持续稳健增长"
      ]
    ]
  },
  {
    "id": 899,
    "text": "对标全球 CRO龙头，收入体量有 5~6倍差距。昆泰、 PPD、科文斯等全球 CRO 巨头多成立于 20世纪 70年代，相比之下，本土 CRO公司起步于 2000年前后， 有近 30年的差距。国内 CRO龙头在近 20年来随着服务能力的提升和成本优势的凸显，逐步抢占全球市场份额，增速远高于全球平均水平。但从收入体量上来看，这一追赶进程仍任重道远。 2020年 LabCorp（科文斯母公司）及 IQVIA （昆泰与 IMS合并后成立）收入规模分别达到 978亿和 795亿元，相比之下， 药明康德收入规模仅有 165亿元，虽然在本土 CRO中优势明显，但较全球龙头仍有 5~6倍增长空间。",
    "labels": [
      [
        "T0",
        "行业",
        5,
        8,
        "CRO"
      ],
      [
        "T1",
        "龙头企业",
        8,
        10,
        "龙头"
      ],
      [
        "T2",
        "营业收入",
        11,
        13,
        "收入"
      ],
      [
        "T3",
        "公司",
        24,
        26,
        "昆泰"
      ],
      [
        "T4",
        "公司",
        28,
        31,
        "PPD"
      ],
      [
        "T5",
        "公司",
        32,
        35,
        "科文斯"
      ],
      [
        "T6",
        "行业",
        38,
        42,
        " CRO"
      ],
      [
        "T7",
        "行业公司",
        68,
        73,
        "CRO公司"
      ],
      [
        "T8",
        "地点范围",
        96,
        99,
        "国内 "
      ],
      [
        "T9",
        "行业",
        99,
        102,
        "CRO"
      ],
      [
        "T10",
        "龙头企业",
        102,
        104,
        "龙头"
      ],
      [
        "T11",
        "时间范围",
        105,
        110,
        "近 20年"
      ],
      [
        "T12",
        "市场份额",
        135,
        139,
        "市场份额"
      ],
      [
        "T13",
        "营业收入",
        154,
        156,
        "收入"
      ],
      [
        "T14",
        "时间范围",
        175,
        181,
        "2020年 "
      ],
      [
        "T15",
        "公司",
        181,
        188,
        "LabCorp"
      ],
      [
        "T16",
        "公司",
        197,
        203,
        " IQVIA"
      ],
      [
        "T17",
        "营业收入",
        218,
        220,
        "收入"
      ],
      [
        "T18",
        "属性值",
        227,
        231,
        "978亿"
      ],
      [
        "T19",
        "属性值",
        233,
        238,
        "795亿元"
      ],
      [
        "T20",
        "公司",
        244,
        249,
        " 药明康德"
      ],
      [
        "T21",
        "营业收入",
        249,
        251,
        "收入"
      ],
      [
        "T22",
        "属性值",
        256,
        261,
        "165亿元"
      ],
      [
        "T23",
        "行业",
        268,
        271,
        "CRO"
      ],
      [
        "T24",
        "龙头企业",
        281,
        283,
        "龙头"
      ],
      [
        "T25",
        "地点范围",
        2,
        4,
        "全球"
      ],
      [
        "T26",
        "时间范围",
        50,
        59,
        "20世纪 70年代"
      ],
      [
        "T27",
        "地点范围",
        65,
        67,
        "本土"
      ],
      [
        "T28",
        "时间范围",
        77,
        84,
        "2000年前后"
      ],
      [
        "T29",
        "地点范围",
        133,
        135,
        "全球"
      ],
      [
        "T30",
        "公司",
        189,
        192,
        "科文斯"
      ],
      [
        "T31",
        "公司",
        205,
        207,
        "昆泰"
      ],
      [
        "T32",
        "公司",
        209,
        212,
        "IMS"
      ],
      [
        "T33",
        "地点范围",
        265,
        267,
        "本土"
      ],
      [
        "T34",
        "地点范围",
        279,
        281,
        "全球"
      ]
    ]
  },
  {
    "id": 900,
    "text": "国内 SMO行业起步较晚，但近年来持续较高增速。国内临床试验需求快速增长，逐步暴露临床医生时间与精力有限、临床项目管理能力不足等问题。近年来 SMO市场规模快速扩大，2019年达到 2.62亿美元，2015~2019年复合增长率达到 61%。预计未来五年仍将维持 30~50%的高速增长。",
    "labels": [
      [
        "T0",
        "地点范围",
        0,
        2,
        "国内"
      ],
      [
        "T1",
        "行业",
        3,
        6,
        "SMO"
      ],
      [
        "T2",
        "时间范围",
        14,
        17,
        "近年来"
      ],
      [
        "T3",
        "地点范围",
        24,
        26,
        "国内"
      ],
      [
        "T4",
        "行业",
        26,
        30,
        "临床试验"
      ],
      [
        "T5",
        "行业需求",
        30,
        32,
        "需求"
      ],
      [
        "T6",
        "属性值",
        32,
        36,
        "快速增长"
      ],
      [
        "T7",
        "时间范围",
        67,
        70,
        "近年来"
      ],
      [
        "T8",
        "行业",
        71,
        74,
        "SMO"
      ],
      [
        "T9",
        "市场规模",
        74,
        78,
        "市场规模"
      ],
      [
        "T10",
        "属性值",
        78,
        82,
        "快速扩大"
      ],
      [
        "T11",
        "时间范围",
        83,
        88,
        "2019年"
      ],
      [
        "T12",
        "属性值",
        91,
        98,
        "2.62亿美元"
      ],
      [
        "T13",
        "时间范围",
        99,
        109,
        "2015~2019年"
      ],
      [
        "T14",
        "CAGR",
        109,
        114,
        "复合增长率"
      ],
      [
        "T15",
        "属性值",
        117,
        120,
        "61%"
      ],
      [
        "T16",
        "时间范围",
        123,
        127,
        "未来五年"
      ],
      [
        "T17",
        "属性值",
        132,
        138,
        "30~50%"
      ]
    ]
  },
  {
    "id": 905,
    "text": "康龙化成实验室服务对营业收入影响最大，主要由实验室化学、生物科学、安全评估三部分构成，实验室服务中的主要收入来源是实验室化学，生物科学存在较大的利润空间",
    "labels": [
      [
        "T0",
        "公司",
        0,
        4,
        "康龙化成"
      ],
      [
        "T1",
        "营业收入",
        10,
        14,
        "营业收入"
      ],
      [
        "T2",
        "营业收入",
        52,
        54,
        "收入"
      ],
      [
        "T3",
        "利润",
        72,
        74,
        "利润"
      ],
      [
        "T4",
        "行业",
        4,
        9,
        "实验室服务"
      ]
    ]
  },
  {
    "id": 906,
    "text": "当前 CXO行业需求景气度较高，且全球订单持续向亚太等低成本地区转移。短期内预计行业景气度与趋势将得以持续，但若因内外部因素导致行业需求出现下滑，可能对公司业务增长带来较大影响。CXO行业需求收到上游医药研发投入、跨国药企外包渗透率、Biotech公司融资情况等影响较大，若相关因素发生消极变化，可能对行业景气度带来较大影响。",
    "labels": [
      [
        "T0",
        "行业",
        3,
        6,
        "CXO"
      ],
      [
        "T1",
        "属性值",
        10,
        15,
        "景气度较高"
      ],
      [
        "T2",
        "行业需求",
        8,
        10,
        "需求"
      ],
      [
        "T3",
        "地点范围",
        17,
        19,
        "全球"
      ],
      [
        "T4",
        "时间范围",
        35,
        38,
        "短期内"
      ],
      [
        "T5",
        "行业需求",
        66,
        68,
        "需求"
      ],
      [
        "T6",
        "行业",
        89,
        92,
        "CXO"
      ],
      [
        "T7",
        "行业需求",
        94,
        96,
        "需求"
      ],
      [
        "T8",
        "行业",
        100,
        102,
        "医药"
      ],
      [
        "T9",
        "研发费用",
        102,
        106,
        "研发投入"
      ],
      [
        "T10",
        "行业公司",
        109,
        111,
        "药企"
      ],
      [
        "T11",
        "行业公司",
        117,
        126,
        "Biotech公司"
      ],
      [
        "T12",
        "投融资情况",
        126,
        130,
        "融资情况"
      ],
      [
        "T13",
        "时间范围",
        0,
        2,
        "当前"
      ]
    ]
  },
  {
    "id": 911,
    "text": "➢ 4月 1日，国家药品监督管理局药品审评中心（CDE）组织发布《胰岛素类产品生物类似药药学研究与评价技术指导原则》，为规范和指导胰岛素类产品生物类似药的研发、生产和注册，进一步明确技术评价标准。",
    "labels": [
      [
        "T0",
        "时间范围",
        2,
        7,
        "4月 1日"
      ]
    ]
  },
  {
    "id": 912,
    "text": "基于上述测算的市场规模，我们按照保守、中性、积极三种情境下分析公司 2030 年达到的规模与利润。",
    "labels": [
      [
        "T0",
        "时间范围",
        34,
        40,
        "2030 年"
      ],
      [
        "T1",
        "假设情形",
        16,
        18,
        "保守"
      ],
      [
        "T2",
        "假设情形",
        19,
        21,
        "中性"
      ],
      [
        "T3",
        "假设情形",
        22,
        24,
        "积极"
      ],
      [
        "T4",
        "市场规模",
        43,
        45,
        "规模"
      ],
      [
        "T5",
        "利润",
        46,
        48,
        "利润"
      ],
      [
        "T6",
        "市场规模",
        7,
        11,
        "市场规模"
      ]
    ]
  },
  {
    "id": 924,
    "text": "➢ 从融资规模看，全球医疗健康产业领域投资方兴未艾，2021年全球融资总额处于历史高位。根据动脉网数据，2021年全球医疗健康融资额同比增长约70%，达8194亿元；融资事件数为3591起，同比增长 64%。融资金额与融资事件数均创历史新高。",
    "labels": [
      [
        "T0",
        "时间范围",
        52,
        57,
        "2021年"
      ],
      [
        "T1",
        "地点范围",
        57,
        59,
        "全球"
      ],
      [
        "T2",
        "行业",
        59,
        63,
        "医疗健康"
      ],
      [
        "T3",
        "投融资金额",
        63,
        66,
        "融资额"
      ],
      [
        "T4",
        "属性值",
        66,
        82,
        "同比增长约70%，达8194亿元"
      ],
      [
        "T5",
        "投融资事件数",
        83,
        88,
        "融资事件数"
      ],
      [
        "T6",
        "属性值",
        89,
        103,
        "3591起，同比增长 64%"
      ],
      [
        "T7",
        "投融资金额",
        104,
        108,
        "融资金额"
      ],
      [
        "T8",
        "投融资事件数",
        109,
        114,
        "融资事件数"
      ],
      [
        "T9",
        "属性值",
        115,
        120,
        "创历史新高"
      ],
      [
        "T10",
        "地点范围",
        9,
        11,
        "全球"
      ],
      [
        "T11",
        "行业",
        11,
        15,
        "医疗健康"
      ],
      [
        "T12",
        "时间范围",
        26,
        31,
        "2021年"
      ],
      [
        "T13",
        "地点范围",
        31,
        33,
        "全球"
      ],
      [
        "T14",
        "投融资金额",
        33,
        37,
        "融资总额"
      ],
      [
        "T15",
        "属性值",
        39,
        43,
        "历史高位"
      ]
    ]
  },
  {
    "id": 929,
    "text": "1月 20日，美国 ImmPACT Bio公司宣布已完成 1.11亿美元的Ｂ轮融资。此外， ImmPACT Bio公布了其靶向 CD19和 CD20的双特异性 CAR-T疗法，治疗复发 /难治性 B细胞非霍奇金淋巴瘤的 1期临床试验的最新结果。迄今为止，共 8例患者接受治疗，中位随访期为 12个月时，7例患者达到并保持完全缓解（CR）。 https://immpact-bio.com",
    "labels": [
      [
        "T0",
        "时间范围",
        0,
        6,
        "1月 20日"
      ],
      [
        "T1",
        "地点范围",
        7,
        10,
        "美国 "
      ],
      [
        "T2",
        "公司",
        10,
        21,
        "ImmPACT Bio"
      ],
      [
        "T3",
        "公司",
        45,
        57,
        " ImmPACT Bio"
      ],
      [
        "T4",
        "时间范围",
        122,
        126,
        "迄今为止"
      ]
    ]
  },
  {
    "id": 930,
    "text": "国内CXO公司实验室业务继续呈现高速增长、维持高景气度：核心公司实验室业务2021年中报合计实现营业收入99.52亿元，同比增长46.93%，呈现超高速增长，其中药明康德中国区实验室业务实现营业收入54.87亿元 ，同比增长45.17%。展望2021年下半年和2022年，海外创新药产业链持续转移以及叠加国内的高景气度，我们判断未来3年将持续呈现快速增长。 海外实验室业务呈现快速增长：查尔斯河的实验室业务（安评及药物发现等）2021年上半年实现营业收入 10.41亿元，同比增长18.2%，伴随着新冠影响逐渐消除，公司药物发现和安评业务逐渐恢复强劲增长。",
    "labels": [
      [
        "T0",
        "地点范围",
        1,
        3,
        "国内"
      ],
      [
        "T1",
        "行业公司",
        3,
        8,
        "CXO公司"
      ],
      [
        "T2",
        "行业",
        8,
        11,
        "实验室"
      ],
      [
        "T3",
        "属性值",
        17,
        21,
        "高速增长"
      ],
      [
        "T4",
        "属性值",
        24,
        28,
        "高景气度"
      ],
      [
        "T5",
        "行业公司",
        29,
        33,
        "核心公司"
      ],
      [
        "T6",
        "行业",
        33,
        36,
        "实验室"
      ],
      [
        "T7",
        "时间范围",
        38,
        43,
        "2021年"
      ],
      [
        "T8",
        "营业收入",
        49,
        53,
        "营业收入"
      ],
      [
        "T9",
        "属性值",
        53,
        60,
        "99.52亿元"
      ],
      [
        "T10",
        "属性值",
        65,
        71,
        "46.93%"
      ],
      [
        "T11",
        "属性值",
        74,
        79,
        "超高速增长"
      ],
      [
        "T12",
        "公司",
        82,
        86,
        "药明康德"
      ],
      [
        "T13",
        "地点范围",
        86,
        89,
        "中国区"
      ],
      [
        "T14",
        "行业",
        89,
        92,
        "实验室"
      ],
      [
        "T15",
        "营业收入",
        96,
        100,
        "营业收入"
      ],
      [
        "T16",
        "属性值",
        100,
        107,
        "54.87亿元"
      ],
      [
        "T17",
        "属性值",
        113,
        119,
        "45.17%"
      ],
      [
        "T18",
        "时间范围",
        122,
        130,
        "2021年下半年"
      ],
      [
        "T19",
        "时间范围",
        131,
        136,
        "2022年"
      ],
      [
        "T20",
        "地点范围",
        137,
        139,
        "海外"
      ],
      [
        "T21",
        "行业",
        139,
        142,
        "创新药"
      ],
      [
        "T22",
        "时间范围",
        165,
        169,
        "未来3年"
      ],
      [
        "T23",
        "地点范围",
        153,
        155,
        "国内"
      ],
      [
        "T24",
        "地点范围",
        181,
        183,
        "海外"
      ],
      [
        "T25",
        "行业",
        183,
        186,
        "实验室"
      ],
      [
        "T26",
        "公司",
        195,
        199,
        "查尔斯河"
      ],
      [
        "T27",
        "行业",
        200,
        203,
        "实验室"
      ],
      [
        "T28",
        "行业",
        206,
        208,
        "安评"
      ],
      [
        "T29",
        "行业",
        209,
        213,
        "药物发现"
      ],
      [
        "T30",
        "时间范围",
        215,
        223,
        "2021年上半年"
      ],
      [
        "T31",
        "营业收入",
        225,
        229,
        "营业收入"
      ],
      [
        "T32",
        "属性值",
        230,
        237,
        "10.41亿元"
      ],
      [
        "T33",
        "属性值",
        242,
        247,
        "18.2%"
      ],
      [
        "T34",
        "行业",
        262,
        266,
        "药物发现"
      ],
      [
        "T35",
        "行业",
        267,
        269,
        "安评"
      ],
      [
        "T36",
        "属性值",
        275,
        279,
        "强劲增长"
      ]
    ]
  },
  {
    "id": 934,
    "text": "行业处于快速发展阶段， CGT市场规模有望爆发。根据 Frost & Sullivan数据， 2020 年全球细胞基因治疗市场规模达到 20.75亿美元，到 2025年有望达到 305.39亿美元，2020~2025年 CAGR达到 71.2%；2020年中国 CGT市场规模仅 2380万元，但随着 CAR-T等产品在国内有望陆续获批，未来几年有望呈爆发式增长，根据 Frost & Sullivan预测，2025年中国 CGT市场规模有望达到 178.85亿元， 2020~2025年 CAGR达到 276%。",
    "labels": [
      [
        "T0",
        "行业",
        12,
        15,
        "CGT"
      ],
      [
        "T1",
        "市场规模",
        15,
        19,
        "市场规模"
      ],
      [
        "T2",
        "属性值",
        19,
        23,
        "有望爆发"
      ],
      [
        "T3",
        "时间范围",
        47,
        53,
        "2020 年"
      ],
      [
        "T4",
        "地点范围",
        53,
        55,
        "全球"
      ],
      [
        "T5",
        "行业",
        55,
        61,
        "细胞基因治疗"
      ],
      [
        "T6",
        "市场规模",
        61,
        65,
        "市场规模"
      ],
      [
        "T7",
        "属性值",
        68,
        76,
        "20.75亿美元"
      ],
      [
        "T8",
        "时间范围",
        79,
        84,
        "2025年"
      ],
      [
        "T9",
        "属性值",
        89,
        98,
        "305.39亿美元"
      ],
      [
        "T10",
        "时间范围",
        99,
        109,
        "2020~2025年"
      ],
      [
        "T11",
        "CAGR",
        110,
        114,
        "CAGR"
      ],
      [
        "T12",
        "属性值",
        117,
        122,
        "71.2%"
      ],
      [
        "T13",
        "时间范围",
        123,
        128,
        "2020年"
      ],
      [
        "T14",
        "地点范围",
        128,
        130,
        "中国"
      ],
      [
        "T15",
        "行业",
        131,
        134,
        "CGT"
      ],
      [
        "T16",
        "市场规模",
        134,
        138,
        "市场规模"
      ],
      [
        "T17",
        "属性值",
        140,
        146,
        "2380万元"
      ],
      [
        "T18",
        "时间范围",
        169,
        173,
        "未来几年"
      ],
      [
        "T19",
        "时间范围",
        204,
        209,
        "2025年"
      ],
      [
        "T20",
        "地点范围",
        209,
        211,
        "中国"
      ],
      [
        "T21",
        "行业",
        212,
        215,
        "CGT"
      ],
      [
        "T22",
        "市场规模",
        215,
        219,
        "市场规模"
      ],
      [
        "T23",
        "属性值",
        224,
        232,
        "178.85亿元"
      ],
      [
        "T24",
        "时间范围",
        234,
        244,
        "2020~2025年"
      ],
      [
        "T25",
        "CAGR",
        245,
        249,
        "CAGR"
      ],
      [
        "T26",
        "属性值",
        252,
        256,
        "276%"
      ]
    ]
  },
  {
    "id": 939,
    "text": "药物发现阶段研发外包渗透率有望持续提升。未来 5年全球药物发现阶段研发投入预计保持 4.4%的年复合增长率，而由于外包渗透率的提升，药物发现 CRO 市场仍有望维持 9.6%的增长。药物发现作为新药研发的起点，是药物知识产权与专利开发的关键阶段，大型药企过往出于保密考虑，相比于临床前和临床阶段，外包渗透率相对较低，但随着 DNA编码数据库（DEL）、SBDD（基于结构的药物发现）、CADD（计算机辅助药物设计）等新技术平台的出现，药物发现 CRO公司积累起更为丰富的化合物数据库和药物发现技术经验，吸引更多大型药企与中小客户。",
    "labels": [
      [
        "T0",
        "行业",
        0,
        6,
        "药物发现阶段"
      ],
      [
        "T1",
        "外包率",
        8,
        13,
        "外包渗透率"
      ],
      [
        "T2",
        "属性值",
        15,
        19,
        "持续提升"
      ],
      [
        "T3",
        "时间范围",
        20,
        25,
        "未来 5年"
      ],
      [
        "T4",
        "地点范围",
        25,
        27,
        "全球"
      ],
      [
        "T5",
        "行业",
        27,
        33,
        "药物发现阶段"
      ],
      [
        "T6",
        "研发费用",
        33,
        37,
        "研发投入"
      ],
      [
        "T7",
        "属性值",
        42,
        46,
        "4.4%"
      ],
      [
        "T8",
        "CAGR",
        47,
        53,
        "年复合增长率"
      ],
      [
        "T9",
        "外包率",
        57,
        62,
        "外包渗透率"
      ],
      [
        "T10",
        "属性值",
        63,
        65,
        "提升"
      ],
      [
        "T11",
        "行业",
        66,
        74,
        "药物发现 CRO"
      ],
      [
        "T12",
        "行业",
        91,
        95,
        "药物发现"
      ],
      [
        "T13",
        "行业",
        97,
        101,
        "新药研发"
      ],
      [
        "T14",
        "行业公司",
        123,
        127,
        "大型药企"
      ],
      [
        "T15",
        "行业",
        139,
        142,
        "临床前"
      ],
      [
        "T16",
        "行业",
        143,
        147,
        "临床阶段"
      ],
      [
        "T17",
        "外包率",
        148,
        153,
        "外包渗透率"
      ],
      [
        "T18",
        "属性值",
        153,
        157,
        "相对较低"
      ],
      [
        "T19",
        "行业公司",
        217,
        227,
        "药物发现 CRO公司"
      ],
      [
        "T20",
        "行业公司",
        255,
        259,
        "大型药企"
      ]
    ]
  },
  {
    "id": 941,
    "text": "国内单抗上市速度加快。目前国产单抗品种共上市 19种，涉及商品 32个，其中 12种为原研，1种为改良型新药。依据 Insight数据（数据截止 2022年 1月 12日），2006年-2017年仅批准上市 3种单抗，而",
    "labels": [
      [
        "T0",
        "地点范围",
        0,
        2,
        "国内"
      ],
      [
        "T1",
        "行业",
        2,
        4,
        "单抗"
      ],
      [
        "T2",
        "行业",
        15,
        17,
        "单抗"
      ],
      [
        "T3",
        "时间范围",
        70,
        85,
        "截止 2022年 1月 12日"
      ],
      [
        "T4",
        "时间范围",
        87,
        98,
        "2006年-2017年"
      ],
      [
        "T5",
        "时间范围",
        11,
        13,
        "目前"
      ]
    ]
  },
  {
    "id": 943,
    "text": "博腾十分重视技术团队的搭建和建设，致力于高效交付和灵活的研发及生产配置能力， 且持续通过加大研发投入、扩大研发团队规模等方式提升技术创新能力，将每项技术“做深，做实”。2020年，公司研发投入金额为 1.58亿元，占营业收入 7.62%，研发技术团队规模已扩大至 714人，其中国内研发团队约 500人，国外研发团队近 100人，其他技术人员近 110人。",
    "labels": [
      [
        "T0",
        "公司",
        0,
        2,
        "博腾"
      ],
      [
        "T1",
        "属性值",
        44,
        46,
        "加大"
      ],
      [
        "T2",
        "研发费用",
        46,
        50,
        "研发投入"
      ],
      [
        "T3",
        "时间范围",
        84,
        89,
        "2020年"
      ],
      [
        "T4",
        "研发费用",
        92,
        96,
        "研发投入"
      ],
      [
        "T5",
        "属性值",
        100,
        106,
        "1.58亿元"
      ],
      [
        "T6",
        "营业收入",
        108,
        112,
        "营业收入"
      ],
      [
        "T7",
        "地点范围",
        138,
        141,
        "中国内"
      ],
      [
        "T8",
        "地点范围",
        152,
        154,
        "国外"
      ]
    ]
  },
  {
    "id": 946,
    "text": "假设 1：全球药品销售规模及研发投入规模均保持 4.0~4.6%的增长水平。根据 Frost & Sullivan 数据，2019 年全球药品销售额约 13244 亿美元，预计 2019~2024年 CAGR为 4.4%，其中创新药与仿制药比例约 2:1。2019年全球医药研发投入约 1823亿美元，2019~2024年 CAGR为 4.5%。据此我们假设到 2030年，全球药品销售额达到 20760亿美元，研发投入达到 2880亿美元， 2020~2030年 CAGR分别为 4.14%和 4.19%。",
    "labels": [
      [
        "T0",
        "时间范围",
        128,
        133,
        "2019年"
      ],
      [
        "T1",
        "地点范围",
        133,
        135,
        "全球"
      ],
      [
        "T2",
        "行业",
        135,
        137,
        "医药"
      ],
      [
        "T3",
        "研发费用",
        137,
        141,
        "研发投入"
      ],
      [
        "T4",
        "属性值",
        141,
        150,
        "约 1823亿美元"
      ],
      [
        "T5",
        "时间范围",
        151,
        161,
        "2019~2024年"
      ],
      [
        "T6",
        "CAGR",
        162,
        166,
        "CAGR"
      ],
      [
        "T7",
        "属性值",
        168,
        172,
        "4.5%"
      ],
      [
        "T8",
        "时间范围",
        181,
        186,
        "2030年"
      ],
      [
        "T9",
        "地点范围",
        187,
        189,
        "全球"
      ],
      [
        "T10",
        "行业",
        189,
        191,
        "药品"
      ],
      [
        "T11",
        "研发费用",
        206,
        210,
        "研发投入"
      ],
      [
        "T12",
        "属性值",
        213,
        220,
        "2880亿美元"
      ],
      [
        "T13",
        "时间范围",
        222,
        232,
        "2020~2030年"
      ],
      [
        "T14",
        "CAGR",
        233,
        237,
        "CAGR"
      ],
      [
        "T15",
        "属性值",
        248,
        253,
        "4.19%"
      ],
      [
        "T16",
        "属性值",
        241,
        246,
        "4.14%"
      ],
      [
        "T17",
        "时间范围",
        61,
        67,
        "2019 年"
      ],
      [
        "T18",
        "地点范围",
        67,
        69,
        "全球"
      ],
      [
        "T19",
        "行业",
        69,
        71,
        "药品"
      ],
      [
        "T20",
        "时间范围",
        89,
        99,
        "2019~2024年"
      ],
      [
        "T21",
        "CAGR",
        100,
        104,
        "CAGR"
      ],
      [
        "T22",
        "属性值",
        106,
        110,
        "4.4%"
      ],
      [
        "T23",
        "行业",
        113,
        116,
        "创新药"
      ],
      [
        "T24",
        "行业",
        117,
        120,
        "仿制药"
      ],
      [
        "T25",
        "地点范围",
        5,
        7,
        "全球"
      ],
      [
        "T26",
        "行业",
        7,
        9,
        "药品"
      ],
      [
        "T27",
        "研发费用",
        14,
        18,
        "研发投入"
      ],
      [
        "T28",
        "属性值",
        24,
        37,
        "4.0~4.6%的增长水平"
      ],
      [
        "T29",
        "属性值",
        71,
        74,
        "销售额"
      ],
      [
        "T30",
        "属性值",
        191,
        194,
        "销售额"
      ]
    ]
  },
  {
    "id": 947,
    "text": "产业升级，经营效率提升，固定资产周转及人均单产稳步提升： CXO板块 2016-2020年固定资产周转率稳步提升（1.19→1.56），经营管理效率不断提升。同时 2015-2020 年人均单产也呈现稳步上升态势，分别为 46/53/54/55/59/61万元。我们认为，主要原因有：①产业升级，简单科研开发任务→复杂研究赋能；②经营管理效率提升；③CMO/CDMO收入占比提升，这部分业务有一定规模效应，特别是 CMO，对人力资源需求较小。",
    "labels": [
      [
        "T0",
        "行业",
        29,
        32,
        "CXO"
      ],
      [
        "T1",
        "时间范围",
        35,
        45,
        "2016-2020年"
      ],
      [
        "T2",
        "时间范围",
        82,
        92,
        "2015-2020 "
      ],
      [
        "T3",
        "人均收入",
        93,
        97,
        "人均单产"
      ],
      [
        "T4",
        "行业",
        175,
        183,
        "CMO/CDMO"
      ],
      [
        "T5",
        "属性值",
        100,
        104,
        "稳步上升"
      ],
      [
        "T6",
        "属性值",
        111,
        130,
        "46/53/54/55/59/61万元"
      ],
      [
        "T7",
        "行业",
        207,
        210,
        "CMO"
      ],
      [
        "T8",
        "营收占比",
        183,
        187,
        "收入占比"
      ],
      [
        "T9",
        "属性值",
        187,
        189,
        "提升"
      ]
    ]
  },
  {
    "id": 958,
    "text": "2020年公司 CRO和 CDMO业务的全球市占率分别为 2.4%和 0.9%。 LabCorp 与 IQVIA收入规模分别为 140亿美元和 114亿美元，对应全球 CRO市场份额为 20.8%和 16.9%，Lonza、Catalent收入规模为 51亿美元和 31亿美元，对应全球 CDMO市场份额为 6.4%和 3.9%。药明康德在 2030年有望进入全球 CXO行业第一梯队，中性假设下我们认为公司 CRO份额有望提升到 15%， CDMO份额达到 5%（关于市场规模及份额的详细测算详见正文第九章“成长性分析”部分）。",
    "labels": [
      [
        "T0",
        "公司",
        41,
        48,
        "LabCorp"
      ],
      [
        "T1",
        "公司",
        51,
        56,
        "IQVIA"
      ],
      [
        "T2",
        "营业收入",
        56,
        58,
        "收入"
      ],
      [
        "T3",
        "属性值",
        64,
        70,
        "140亿美元"
      ],
      [
        "T4",
        "属性值",
        72,
        78,
        "114亿美元"
      ],
      [
        "T5",
        "地点范围",
        81,
        83,
        "全球"
      ],
      [
        "T6",
        "行业",
        84,
        87,
        "CRO"
      ],
      [
        "T7",
        "市场份额",
        87,
        91,
        "市场份额"
      ],
      [
        "T8",
        "属性值",
        93,
        98,
        "20.8%"
      ],
      [
        "T9",
        "属性值",
        100,
        105,
        "16.9%"
      ],
      [
        "T10",
        "公司",
        106,
        111,
        "Lonza"
      ],
      [
        "T11",
        "公司",
        112,
        120,
        "Catalent"
      ],
      [
        "T12",
        "营业收入",
        120,
        122,
        "收入"
      ],
      [
        "T13",
        "属性值",
        126,
        131,
        "51亿美元"
      ],
      [
        "T14",
        "属性值",
        133,
        138,
        "31亿美元"
      ],
      [
        "T15",
        "地点范围",
        141,
        143,
        "全球"
      ],
      [
        "T16",
        "行业",
        144,
        148,
        "CDMO"
      ],
      [
        "T17",
        "市场份额",
        148,
        152,
        "市场份额"
      ],
      [
        "T18",
        "属性值",
        154,
        158,
        "6.4%"
      ],
      [
        "T19",
        "属性值",
        160,
        164,
        "3.9%"
      ],
      [
        "T20",
        "公司",
        165,
        169,
        "药明康德"
      ],
      [
        "T21",
        "时间范围",
        171,
        176,
        "2030年"
      ],
      [
        "T22",
        "地点范围",
        180,
        182,
        "全球"
      ],
      [
        "T23",
        "行业",
        183,
        186,
        "CXO"
      ],
      [
        "T24",
        "假设情形",
        193,
        197,
        "中性假设"
      ],
      [
        "T25",
        "行业",
        205,
        208,
        "CRO"
      ],
      [
        "T26",
        "行业",
        221,
        225,
        "CDMO"
      ],
      [
        "T27",
        "时间范围",
        0,
        5,
        "2020年"
      ],
      [
        "T28",
        "行业",
        8,
        11,
        "CRO"
      ],
      [
        "T29",
        "行业",
        13,
        17,
        "CDMO"
      ],
      [
        "T30",
        "地点范围",
        20,
        22,
        "全球"
      ],
      [
        "T31",
        "市场份额",
        22,
        25,
        "市占率"
      ],
      [
        "T32",
        "市场份额",
        208,
        210,
        "份额"
      ],
      [
        "T33",
        "属性值",
        216,
        219,
        "15%"
      ],
      [
        "T34",
        "属性值",
        230,
        232,
        "5%"
      ],
      [
        "T35",
        "市场份额",
        225,
        227,
        "份额"
      ]
    ]
  },
  {
    "id": 959,
    "text": " OXGENE：药明生基于 2021年 3月完成收购，是公司在欧洲的第一个细胞和基因疗法 CTDMO设施，为细胞和基因治疗公司提供从创新候选药物发现、开发、测试到规模化生产的端到端服务。",
    "labels": [
      [
        "T0",
        "公司",
        1,
        8,
        " OXGENE"
      ],
      [
        "T1",
        "行业",
        38,
        51,
        "细胞和基因疗法 CTDMO"
      ],
      [
        "T2",
        "公司",
        9,
        13,
        "药明生基"
      ],
      [
        "T3",
        "时间范围",
        15,
        23,
        "2021年 3月"
      ],
      [
        "T4",
        "地点范围",
        32,
        34,
        "欧洲"
      ],
      [
        "T5",
        "行业公司",
        55,
        64,
        "细胞和基因治疗公司"
      ]
    ]
  },
  {
    "id": 960,
    "text": "具体来看，药明康德 2020年完成或发起了对明捷医药、BMS库威工厂和 OXGENE 的收购，继续加强在临床前研究、制剂和细胞/基因疗法 CDMO的国际化服务能力；药明生物先后完成或发起了对拜耳位于德国的两个工厂、辉瑞中国位于杭州的生物药生产基地以及苏桥生物的收购，进一步提升公司生物药原液及制剂产能；泰格医药主要完成了对北京雅信诚（医学翻译和注册）和上海谋思（早期临床/临床药理）的控股，以及通过方达收购 Biotranex和 ACME，继续加强 DMPK、药物发现和早期开发的能力；凯莱英完成收购冠勤医药，加强公司在临床前及临床的综合 CRO服务能力；昭衍新药在 2019年底完成收购 Biomere，加快推进国际化；九洲药业在 2019年底完成对苏州诺华工厂的收购，并进一步完成收购 PharmAgra Labs和 PharmAgra，拓展其在欧美市场的 CRO/CDMO研发业务；维亚生物通过先后收购 SYNthesis全部股权和朗华制药 80%的股权，加强全产业链布局；成都先导 2020年收购英国 Vernalis（SBDD/FBDD）进一步完善公司的新药筛选和优化能力；药石科技则在 2021年初完成对浙江晖石（CDMO生产平台）的控股。",
    "labels": [
      [
        "T0",
        "公司",
        5,
        9,
        "药明康德"
      ],
      [
        "T1",
        "时间范围",
        10,
        15,
        "2020年"
      ],
      [
        "T2",
        "公司",
        22,
        26,
        "明捷医药"
      ],
      [
        "T3",
        "公司",
        27,
        34,
        "BMS库威工厂"
      ],
      [
        "T4",
        "公司",
        36,
        42,
        "OXGENE"
      ],
      [
        "T5",
        "行业",
        52,
        57,
        "临床前研究"
      ],
      [
        "T6",
        "行业",
        58,
        60,
        "制剂"
      ],
      [
        "T7",
        "行业",
        61,
        73,
        "细胞/基因疗法 CDMO"
      ],
      [
        "T8",
        "公司",
        82,
        86,
        "药明生物"
      ],
      [
        "T9",
        "公司",
        95,
        97,
        "拜耳"
      ],
      [
        "T10",
        "地点范围",
        99,
        101,
        "德国"
      ],
      [
        "T11",
        "公司",
        107,
        111,
        "辉瑞中国"
      ],
      [
        "T12",
        "地点范围",
        113,
        115,
        "杭州"
      ],
      [
        "T13",
        "行业",
        116,
        119,
        "生物药"
      ],
      [
        "T14",
        "公司",
        125,
        129,
        "苏桥生物"
      ],
      [
        "T15",
        "行业",
        140,
        148,
        "生物药原液及制剂"
      ],
      [
        "T16",
        "产能",
        148,
        150,
        "产能"
      ],
      [
        "T17",
        "属性值",
        136,
        138,
        "提升"
      ],
      [
        "T18",
        "公司",
        151,
        155,
        "泰格医药"
      ],
      [
        "T19",
        "公司",
        161,
        166,
        "北京雅信诚"
      ],
      [
        "T20",
        "行业",
        167,
        174,
        "医学翻译和注册"
      ],
      [
        "T21",
        "公司",
        176,
        180,
        "上海谋思"
      ],
      [
        "T22",
        "行业",
        181,
        185,
        "早期临床"
      ],
      [
        "T23",
        "行业",
        186,
        190,
        "临床药理"
      ],
      [
        "T24",
        "公司",
        199,
        201,
        "方达"
      ],
      [
        "T25",
        "公司",
        204,
        213,
        "Biotranex"
      ],
      [
        "T26",
        "公司",
        215,
        219,
        "ACME"
      ],
      [
        "T27",
        "行业",
        225,
        229,
        "DMPK"
      ],
      [
        "T28",
        "行业",
        230,
        234,
        "药物发现"
      ],
      [
        "T29",
        "行业",
        235,
        239,
        "早期开发"
      ],
      [
        "T30",
        "公司",
        243,
        246,
        "凯莱英"
      ],
      [
        "T31",
        "公司",
        250,
        254,
        "冠勤医药"
      ],
      [
        "T32",
        "行业",
        260,
        275,
        "临床前及临床的综合 CRO服务"
      ],
      [
        "T33",
        "公司",
        278,
        282,
        "昭衍新药"
      ],
      [
        "T34",
        "时间范围",
        283,
        290,
        " 2019年底"
      ],
      [
        "T35",
        "公司",
        295,
        302,
        "Biomere"
      ],
      [
        "T36",
        "公司",
        311,
        315,
        "九洲药业"
      ],
      [
        "T37",
        "时间范围",
        317,
        323,
        "2019年底"
      ],
      [
        "T38",
        "公司",
        326,
        330,
        "苏州诺华"
      ],
      [
        "T39",
        "公司",
        345,
        359,
        "PharmAgra Labs"
      ],
      [
        "T40",
        "公司",
        361,
        370,
        "PharmAgra"
      ],
      [
        "T41",
        "地点范围",
        375,
        377,
        "欧美"
      ],
      [
        "T42",
        "行业",
        381,
        391,
        "CRO/CDMO研发"
      ],
      [
        "T43",
        "公司",
        394,
        398,
        "维亚生物"
      ],
      [
        "T44",
        "公司",
        405,
        414,
        "SYNthesis"
      ],
      [
        "T45",
        "公司",
        419,
        423,
        "朗华制药"
      ],
      [
        "T46",
        "公司",
        440,
        444,
        "成都先导"
      ],
      [
        "T47",
        "时间范围",
        445,
        450,
        "2020年"
      ],
      [
        "T48",
        "地点范围",
        452,
        454,
        "英国"
      ],
      [
        "T49",
        "公司",
        455,
        463,
        "Vernalis"
      ],
      [
        "T50",
        "行业",
        464,
        468,
        "SBDD"
      ],
      [
        "T51",
        "行业",
        469,
        473,
        "FBDD"
      ],
      [
        "T52",
        "公司",
        492,
        496,
        "药石科技"
      ],
      [
        "T53",
        "时间范围",
        499,
        505,
        "2021年初"
      ],
      [
        "T54",
        "公司",
        508,
        512,
        "浙江晖石"
      ],
      [
        "T55",
        "行业",
        513,
        521,
        "CDMO生产平台"
      ]
    ]
  },
  {
    "id": 965,
    "text": " 将药明康德、康龙化成、泰格医药、凯莱英、博腾股份、美迪西、睿智医药共17家已上市或正在申报上市的CXO公司收入进行分业务归类，CDMO板块收入从2018年的104.1亿元增长至2020年的204.5亿元，无论是收入体量还是 CAGR都要明显高于临床前CRO及临床CRO板块。结合各家企业近年在CDMO业务的资本投入及项目承接状况， 我们认为CDMO仍将是未来2-3年增速最为强劲的板块。",
    "labels": [
      [
        "T0",
        "公司",
        3,
        7,
        "药明康德"
      ],
      [
        "T1",
        "公司",
        8,
        12,
        "康龙化成"
      ],
      [
        "T2",
        "公司",
        13,
        17,
        "泰格医药"
      ],
      [
        "T3",
        "公司",
        18,
        21,
        "凯莱英"
      ],
      [
        "T4",
        "公司",
        22,
        26,
        "博腾股份"
      ],
      [
        "T5",
        "公司",
        27,
        30,
        "美迪西"
      ],
      [
        "T6",
        "公司",
        31,
        35,
        "睿智医药"
      ],
      [
        "T7",
        "行业公司",
        50,
        55,
        "CXO公司"
      ],
      [
        "T8",
        "营业收入",
        55,
        57,
        "收入"
      ],
      [
        "T9",
        "行业",
        65,
        69,
        "CDMO"
      ],
      [
        "T10",
        "营业收入",
        71,
        73,
        "收入"
      ],
      [
        "T11",
        "时间范围",
        74,
        79,
        "2018年"
      ],
      [
        "T12",
        "属性值",
        80,
        87,
        "104.1亿元"
      ],
      [
        "T13",
        "时间范围",
        90,
        95,
        "2020年"
      ],
      [
        "T14",
        "属性值",
        96,
        103,
        "204.5亿元"
      ],
      [
        "T15",
        "营业收入",
        107,
        109,
        "收入"
      ],
      [
        "T16",
        "CAGR",
        114,
        118,
        "CAGR"
      ],
      [
        "T17",
        "行业",
        124,
        130,
        "临床前CRO"
      ],
      [
        "T18",
        "行业",
        131,
        136,
        "临床CRO"
      ],
      [
        "T19",
        "行业",
        148,
        152,
        "CDMO"
      ],
      [
        "T20",
        "行业",
        172,
        176,
        "CDMO"
      ],
      [
        "T21",
        "时间范围",
        179,
        185,
        "未来2-3年"
      ],
      [
        "T22",
        "属性值",
        185,
        191,
        "增速最为强劲"
      ]
    ]
  },
  {
    "id": 971,
    "text": "关注CXO、抗原检测及细分赛道龙头相关标的。本周生物医药板块整体上涨 0.54%，跑赢沪深3002.68个百分点，表现强于整体市场。申万一级行业中排第6位，较上周下降3名，弱于房地产、有色金属、纺服等周期板块。本周成交额达7713亿元，占A股总成交额16.2%，较上周提高1.4%。2022年初至今，医药生物下跌12.05%，跑赢沪深3003.45个百分点，医药生物市盈率（TTM，整体法，剔除负值）31.05x，处于近五年历史估值14.12%分位数，处于历史低位。建议关注：恒瑞医药、迈瑞医疗、药明康德、药明生物、 惠泰医疗、东方生物、华大基因、金斯瑞生物科技、普洛药业、康宁杰瑞制药-B、归创通桥-B等。",
    "labels": [
      [
        "T0",
        "行业",
        2,
        5,
        "CXO"
      ],
      [
        "T1",
        "行业",
        6,
        10,
        "抗原检测"
      ],
      [
        "T2",
        "龙头企业",
        15,
        17,
        "龙头"
      ],
      [
        "T3",
        "行业",
        24,
        28,
        "生物医药"
      ],
      [
        "T4",
        "时间范围",
        22,
        24,
        "本周"
      ],
      [
        "T5",
        "行业",
        88,
        91,
        "房地产"
      ],
      [
        "T6",
        "行业",
        92,
        96,
        "有色金属"
      ],
      [
        "T7",
        "行业",
        97,
        99,
        "纺服"
      ],
      [
        "T8",
        "时间范围",
        105,
        107,
        "本周"
      ],
      [
        "T9",
        "时间范围",
        132,
        134,
        "上周"
      ],
      [
        "T10",
        "时间范围",
        141,
        149,
        "2022年初至今"
      ],
      [
        "T11",
        "行业",
        150,
        154,
        "医药生物"
      ],
      [
        "T12",
        "行业",
        179,
        183,
        "医药生物"
      ],
      [
        "T13",
        "PE",
        183,
        186,
        "市盈率"
      ],
      [
        "T14",
        "属性值",
        200,
        206,
        "31.05x"
      ],
      [
        "T15",
        "公司",
        238,
        242,
        "恒瑞医药"
      ],
      [
        "T16",
        "公司",
        243,
        247,
        "迈瑞医疗"
      ],
      [
        "T17",
        "公司",
        248,
        252,
        "药明康德"
      ],
      [
        "T18",
        "公司",
        253,
        257,
        "药明生物"
      ],
      [
        "T19",
        "公司",
        259,
        263,
        "惠泰医疗"
      ],
      [
        "T20",
        "公司",
        264,
        268,
        "东方生物"
      ],
      [
        "T21",
        "公司",
        269,
        273,
        "华大基因"
      ],
      [
        "T22",
        "公司",
        274,
        281,
        "金斯瑞生物科技"
      ],
      [
        "T23",
        "公司",
        282,
        286,
        "普洛药业"
      ],
      [
        "T24",
        "公司",
        287,
        295,
        "康宁杰瑞制药-B"
      ],
      [
        "T25",
        "公司",
        296,
        302,
        "归创通桥-B"
      ],
      [
        "T26",
        "时间范围",
        209,
        212,
        "近五年"
      ]
    ]
  },
  {
    "id": 983,
    "text": "美国、英国子公司，国内临床 CRO业务于 2019年才刚刚开展，团队建设不够成熟， 无论是收入端还是利润端都有很大的成长空间。",
    "labels": [
      [
        "T0",
        "地点范围",
        9,
        11,
        "国内"
      ],
      [
        "T1",
        "行业",
        11,
        17,
        "临床 CRO"
      ],
      [
        "T2",
        "时间范围",
        21,
        26,
        "2019年"
      ],
      [
        "T3",
        "营业收入",
        45,
        48,
        "收入端"
      ],
      [
        "T4",
        "利润",
        50,
        53,
        "利润端"
      ],
      [
        "T5",
        "地点范围",
        0,
        2,
        "美国"
      ],
      [
        "T6",
        "地点范围",
        3,
        5,
        "英国"
      ]
    ]
  },
  {
    "id": 984,
    "text": "口药企研发费用巨大，然而投资收益率极低。2019年创新药平均研发成本19.8亿美元，IRR仅有1.8%，说明在2019年投资收益率极低，专业医药研发所以需要进行医药外包服务降低资金成本，催生出CRO公司进行",
    "labels": [
      [
        "T0",
        "行业公司",
        1,
        3,
        "药企"
      ],
      [
        "T1",
        "研发费用",
        3,
        7,
        "研发费用"
      ],
      [
        "T2",
        "属性值",
        7,
        9,
        "巨大"
      ],
      [
        "T3",
        "时间范围",
        20,
        25,
        "2019年"
      ],
      [
        "T4",
        "行业",
        25,
        28,
        "创新药"
      ],
      [
        "T5",
        "时间范围",
        55,
        60,
        "2019年"
      ],
      [
        "T6",
        "行业公司",
        96,
        101,
        "CRO公司"
      ]
    ]
  },
  {
    "id": 986,
    "text": "口全球医药研发投入稳定增长，驱动CXO行业发展。2020年全球医药研发投入204.8亿元，增速已达到12.3%，属于快速增长阶段，中国医药研发投入29.8亿元，美国医药研发投入89.8亿元2016年-2020年中国医药研发投入年均复合增长率20.0%，美国医药研发年均复合增长率7.4%，全球医药研发增长率6.9%，中国医药研发年均增长率高于全球，中国医药研发投入增长迅速，驱动CXO行业发展口全球研发管线稳步上升，驱动CXO行业发展。全球医药研发管线不断增加，2019年医药管线达到16181个，中国CXO研发管线占全球研发管线的17.5%。2015年医改以后，创新药审评速度加快、医保常态七政策出台推动国内创新药研发持续少热，研发管线持续高增长",
    "labels": [
      [
        "T0",
        "地点范围",
        1,
        3,
        "全球"
      ],
      [
        "T1",
        "行业",
        3,
        5,
        "医药"
      ],
      [
        "T2",
        "研发费用",
        5,
        9,
        "研发投入"
      ],
      [
        "T3",
        "属性值",
        9,
        13,
        "稳定增长"
      ],
      [
        "T4",
        "行业",
        16,
        19,
        "CXO"
      ],
      [
        "T5",
        "时间范围",
        24,
        29,
        "2020年"
      ],
      [
        "T6",
        "地点范围",
        29,
        31,
        "全球"
      ],
      [
        "T7",
        "行业",
        31,
        33,
        "医药"
      ],
      [
        "T8",
        "研发费用",
        33,
        37,
        "研发投入"
      ],
      [
        "T9",
        "属性值",
        37,
        44,
        "204.8亿元"
      ],
      [
        "T10",
        "地点范围",
        65,
        67,
        "中国"
      ],
      [
        "T11",
        "行业",
        67,
        69,
        "医药"
      ],
      [
        "T12",
        "研发费用",
        69,
        73,
        "研发投入"
      ],
      [
        "T13",
        "属性值",
        73,
        79,
        "29.8亿元"
      ],
      [
        "T14",
        "地点范围",
        80,
        82,
        "美国"
      ],
      [
        "T15",
        "行业",
        82,
        84,
        "医药"
      ],
      [
        "T16",
        "研发费用",
        84,
        88,
        "研发投入"
      ],
      [
        "T17",
        "属性值",
        88,
        94,
        "89.8亿元"
      ],
      [
        "T18",
        "时间范围",
        94,
        105,
        "2016年-2020年"
      ],
      [
        "T19",
        "地点范围",
        105,
        107,
        "中国"
      ],
      [
        "T20",
        "行业",
        107,
        109,
        "医药"
      ],
      [
        "T21",
        "研发费用",
        109,
        113,
        "研发投入"
      ],
      [
        "T22",
        "CAGR",
        113,
        120,
        "年均复合增长率"
      ],
      [
        "T23",
        "属性值",
        120,
        125,
        "20.0%"
      ],
      [
        "T24",
        "地点范围",
        126,
        128,
        "美国"
      ],
      [
        "T25",
        "CAGR",
        132,
        139,
        "年均复合增长率"
      ],
      [
        "T26",
        "属性值",
        139,
        143,
        "7.4%"
      ],
      [
        "T27",
        "地点范围",
        144,
        146,
        "全球"
      ],
      [
        "T28",
        "地点范围",
        158,
        160,
        "中国"
      ],
      [
        "T29",
        "地点范围",
        174,
        176,
        "中国"
      ],
      [
        "T30",
        "行业",
        176,
        178,
        "医药"
      ],
      [
        "T31",
        "研发费用",
        178,
        182,
        "研发投入"
      ],
      [
        "T32",
        "属性值",
        182,
        186,
        "增长迅速"
      ],
      [
        "T33",
        "行业",
        189,
        192,
        "CXO"
      ],
      [
        "T34",
        "行业",
        210,
        213,
        "CXO"
      ],
      [
        "T35",
        "行业",
        220,
        222,
        "医药"
      ],
      [
        "T36",
        "时间范围",
        231,
        236,
        "2019年"
      ],
      [
        "T37",
        "行业",
        251,
        254,
        "CXO"
      ],
      [
        "T38",
        "地点范围",
        218,
        220,
        "全球"
      ],
      [
        "T39",
        "地点范围",
        249,
        251,
        "中国"
      ],
      [
        "T40",
        "时间范围",
        272,
        277,
        "2015年"
      ],
      [
        "T41",
        "行业",
        282,
        285,
        "创新药"
      ],
      [
        "T42",
        "行业",
        305,
        308,
        "创新药"
      ],
      [
        "T43",
        "地点范围",
        303,
        305,
        "国内"
      ],
      [
        "T44",
        "CAGR",
        164,
        169,
        "年均增长率"
      ],
      [
        "T45",
        "地点范围",
        197,
        199,
        "全球"
      ],
      [
        "T46",
        "地点范围",
        259,
        261,
        "全球"
      ],
      [
        "T47",
        "属性值",
        169,
        173,
        "高于全球"
      ],
      [
        "T48",
        "属性值",
        153,
        157,
        "6.9%"
      ],
      [
        "T49",
        "行业",
        146,
        150,
        "医药研发"
      ],
      [
        "T50",
        "行业",
        128,
        132,
        "医药研发"
      ],
      [
        "T51",
        "行业",
        160,
        164,
        "医药研发"
      ]
    ]
  },
  {
    "id": 989,
    "text": "看好业绩提速企业，关注产能和订单匹配情况。从微观角度看，预收账款与合同负债持续增长彰显国内 CXO行业高景气，人员扩张、加大在建工程投入为订单交付提供生产保证。在手订单充裕，保证交付最为关键。1）对于 CRO企业，核心资产为相关人员数量。以 CRO业务为主的公司如康龙化成、凯莱英、美迪西、泰格医药、 药明康德和昭衍新药等，其研发人员的扩张增速均保持在 20%以上。2）对于 CDMO 企业，产能利用率持续处于高位，资本性支出与在建工程情况则是影响公司未来业绩的主要因素。泰格医药、美迪西、康龙化成、药石科技等企业的资本开支与在建工程均实现了快速增长。",
    "labels": [
      [
        "T0",
        "业绩",
        2,
        4,
        "业绩"
      ],
      [
        "T1",
        "合同负债",
        33,
        37,
        "合同负债"
      ],
      [
        "T2",
        "地点范围",
        43,
        45,
        "国内"
      ],
      [
        "T3",
        "行业",
        45,
        49,
        " CXO"
      ],
      [
        "T4",
        "在手订单",
        80,
        84,
        "在手订单"
      ],
      [
        "T5",
        "行业公司",
        101,
        106,
        "CRO企业"
      ],
      [
        "T6",
        "行业",
        121,
        124,
        "CRO"
      ],
      [
        "T7",
        "公司",
        132,
        136,
        "康龙化成"
      ],
      [
        "T8",
        "公司",
        137,
        140,
        "凯莱英"
      ],
      [
        "T9",
        "公司",
        141,
        144,
        "美迪西"
      ],
      [
        "T10",
        "公司",
        145,
        149,
        "泰格医药"
      ],
      [
        "T11",
        "公司",
        151,
        155,
        "药明康德"
      ],
      [
        "T12",
        "公司",
        156,
        160,
        "昭衍新药"
      ],
      [
        "T13",
        "行业公司",
        188,
        195,
        "CDMO 企业"
      ],
      [
        "T14",
        "业绩",
        228,
        230,
        "业绩"
      ],
      [
        "T15",
        "公司",
        236,
        240,
        "泰格医药"
      ],
      [
        "T16",
        "公司",
        241,
        244,
        "美迪西"
      ],
      [
        "T17",
        "公司",
        245,
        249,
        "康龙化成"
      ],
      [
        "T18",
        "公司",
        250,
        254,
        "药石科技"
      ],
      [
        "T19",
        "CAPEX资本开支",
        258,
        262,
        "资本开支"
      ],
      [
        "T20",
        "属性值",
        271,
        275,
        "快速增长"
      ],
      [
        "T21",
        "产能",
        11,
        13,
        "产能"
      ],
      [
        "T22",
        "在手订单",
        14,
        16,
        "订单"
      ],
      [
        "T23",
        "员工数量",
        114,
        118,
        "人员数量"
      ],
      [
        "T24",
        "CAPEX资本开支",
        208,
        213,
        "资本性支出"
      ]
    ]
  },
  {
    "id": 995,
    "text": "中国制药行业研发投入预计将由 2019 年的 211亿美元增长至 2024年的 476亿美元，增速远超全球平均增速。",
    "labels": [
      [
        "T0",
        "地点范围",
        0,
        2,
        "中国"
      ],
      [
        "T1",
        "行业",
        2,
        4,
        "制药"
      ],
      [
        "T2",
        "研发费用",
        6,
        10,
        "研发投入"
      ],
      [
        "T3",
        "时间范围",
        14,
        21,
        " 2019 年"
      ],
      [
        "T4",
        "时间范围",
        32,
        38,
        " 2024年"
      ],
      [
        "T5",
        "属性值",
        23,
        29,
        "211亿美元"
      ],
      [
        "T6",
        "属性值",
        40,
        46,
        "476亿美元"
      ]
    ]
  },
  {
    "id": 1001,
    "text": "展望中长期，行业利空因素较少，确定性较强。我们认为全球 CRO产业链向中国转移趋势受阻的可能性较小，叠加我们创新药市场有望长期维持较高的繁荣度， 我国 CXO行业保持快速增长将是大概率事件。",
    "labels": [
      [
        "T0",
        "行业",
        28,
        31,
        "CRO"
      ],
      [
        "T1",
        "地点范围",
        25,
        27,
        "全球"
      ],
      [
        "T2",
        "行业",
        54,
        57,
        "创新药"
      ],
      [
        "T3",
        "地点范围",
        73,
        75,
        "我国"
      ],
      [
        "T4",
        "行业",
        75,
        79,
        " CXO"
      ],
      [
        "T5",
        "地点范围",
        35,
        37,
        "中国"
      ],
      [
        "T6",
        "属性值",
        83,
        87,
        "快速增长"
      ]
    ]
  },
  {
    "id": 1007,
    "text": "API策略是公司 2020年的一场“大仗”，旨在不断提升商业化 API能力，为未来承接更多商业化 API订单打下基础。目前公司服务的 API订单主要是依托 J-STAR及国内 CRO平台获得的临床早期项目，项目价值渗透率上仍有提升空间。2020年，公司 API 业务销售收入为 1.87亿元，同比增长 91.56%。",
    "labels": [
      [
        "T0",
        "时间范围",
        118,
        123,
        "2020年"
      ],
      [
        "T1",
        "时间范围",
        9,
        14,
        "2020年"
      ],
      [
        "T2",
        "行业",
        127,
        130,
        "API"
      ],
      [
        "T3",
        "行业",
        32,
        35,
        "API"
      ],
      [
        "T4",
        "行业",
        49,
        52,
        "API"
      ],
      [
        "T5",
        "行业",
        67,
        70,
        "API"
      ],
      [
        "T6",
        "在手订单",
        70,
        72,
        "订单"
      ],
      [
        "T7",
        "行业",
        88,
        91,
        "CRO"
      ],
      [
        "T8",
        "营业收入",
        135,
        137,
        "收入"
      ],
      [
        "T9",
        "时间范围",
        59,
        61,
        "目前"
      ],
      [
        "T10",
        "地点范围",
        85,
        87,
        "国内"
      ]
    ]
  },
  {
    "id": 1008,
    "text": "从根治愈，细胞基因治疗（CGT）开启商业化黄金时代。与传统小分子、大分子药物相比，CGT 药物靶向生物遗传信息传递的上游，理论上可以治疗一切因蛋白质异常引发的疾病。通过对基因进行修复治疗，其适应症范围广阔，并具有一针治愈、从根解决的特性。CGT 药物单价高、疗效好，且受益于上游审批加速、 下游保险支持，正在进入商业化放量的黄金时代。据 FDA 预测，2020 至 2025 年每年将会有 10-20 个 CGT 药物获批上市。预计 2025 年全球 CGT 市场规模突破 300 亿美元（2020-25 年 CAGR=71%） ，中国市场达 25.9 亿美元（2020-25 年 CAGR=287%）。 需求旺盛，CGT CDMO 蓄势待发。快速增加的商业化产品，以及积极旺盛的研发需求，将极大地推动 CGT CDMO 发展。CGT 产品商业化，对产能的需求将从百人级提升至千人或万人级，增加药企对 CDMO 产能的依赖。此外，CGT 临床研发管线处于快速扩张周期，CDMO 可以协助研发生产。据 ARM 报告预测，截至 2026 年，全球 CGT 临床项目数将达 3500 项（包含干细胞疗法） ，较 2020 年翻 2 倍。受益于终端 CGT 市场的快速发展，全球 CGT CDMO 市场规模将在 2025 年达到近 100 亿美元（2020-25 年 CAGR=34.9%） ，中国 CGT CDMO 市场规模达 107 亿元（2020-25 年 CAGR=51.5%）。 制造复杂，CGT 生产外包意愿强。CGT 药物生产步骤多、难度大、成本高，生产外包率远高于小分子或大分子药物，达 65%以上。以 CAR-T 为例，其生产涉及质粒、病毒、细胞等多个步骤，每一步均涉及复杂的生产、纯化、分析等。高技术壁垒、 高生产成本， 导致 CGT 产能短缺， 促使药企与 CDMO 企业进行合作。 CDMO 专注于生产工艺开发，优化生产流程，提高药企研发效率，降低开发成本，增加药企依赖度。我们认为 CGT 技术（如通用型 CAR-T）及生产技术（病毒悬浮培养）不断革新，将快速降低药物生产成本，推动 CGT 及 CDMO 行业迅猛发展。 投资建议：2021 年是中国 CGT 商业化元年，复星凯特与药明巨诺的细胞治疗产品相继获批上市，正式开启中国 CGT 药物市场。受益于终端 CGT 行业进入成长期，国内 CGT CDMO 产业得以加速，有望于 2025 年突破百亿规模。考虑 CGT 企业高度依赖 CDMO 的特质，资金涌入 CGT 赛道将持续利好上游 CDMO 企业。 因此，我们认为 CGT CDMO 将伴随 CGT 管线的持续推进而迅速成长，看好提前布局产能并已搭建核心技术平台的 CDMO 公司，重点推荐药明康德、康龙化成、 博腾股份，建议关注金斯瑞生物科技、和元生物。 风险分析：CGT 药物在国内市场接受度不及预期、CGT 相关融资热度下降、 CGT CDMO 产能建设不及预期的风险。",
    "labels": [
      [
        "T0",
        "行业",
        5,
        16,
        "细胞基因治疗（CGT）"
      ],
      [
        "T1",
        "时间范围",
        176,
        189,
        "2020 至 2025 年"
      ],
      [
        "T2",
        "属性值",
        195,
        202,
        "10-20 个"
      ],
      [
        "T3",
        "行业",
        203,
        209,
        "CGT 药物"
      ],
      [
        "T4",
        "时间范围",
        217,
        223,
        "2025 年"
      ],
      [
        "T5",
        "地点范围",
        223,
        225,
        "全球"
      ],
      [
        "T6",
        "行业",
        226,
        229,
        "CGT"
      ],
      [
        "T7",
        "市场规模",
        230,
        234,
        "市场规模"
      ],
      [
        "T8",
        "属性值",
        234,
        244,
        "突破 300 亿美元"
      ],
      [
        "T9",
        "时间范围",
        245,
        254,
        "2020-25 年"
      ],
      [
        "T10",
        "CAGR",
        255,
        259,
        "CAGR"
      ],
      [
        "T11",
        "属性值",
        260,
        263,
        "71%"
      ],
      [
        "T12",
        "地点范围",
        266,
        268,
        "中国"
      ],
      [
        "T13",
        "属性值",
        272,
        280,
        "25.9 亿美元"
      ],
      [
        "T14",
        "时间范围",
        281,
        290,
        "2020-25 年"
      ],
      [
        "T15",
        "CAGR",
        291,
        295,
        "CAGR"
      ],
      [
        "T16",
        "属性值",
        296,
        300,
        "287%"
      ],
      [
        "T17",
        "行业需求",
        303,
        305,
        "需求"
      ],
      [
        "T18",
        "属性值",
        305,
        307,
        "旺盛"
      ],
      [
        "T19",
        "行业",
        308,
        316,
        "CGT CDMO"
      ],
      [
        "T20",
        "行业",
        352,
        360,
        "CGT CDMO"
      ],
      [
        "T21",
        "行业",
        364,
        367,
        "CGT"
      ],
      [
        "T22",
        "产能",
        375,
        377,
        "产能"
      ],
      [
        "T23",
        "行业公司",
        397,
        399,
        "药企"
      ],
      [
        "T24",
        "行业",
        401,
        405,
        "CDMO"
      ],
      [
        "T25",
        "产能",
        406,
        408,
        "产能"
      ],
      [
        "T26",
        "行业",
        415,
        418,
        "CGT"
      ],
      [
        "T27",
        "行业",
        434,
        438,
        "CDMO"
      ],
      [
        "T28",
        "时间范围",
        459,
        468,
        "截至 2026 年"
      ],
      [
        "T29",
        "地点范围",
        469,
        471,
        "全球"
      ],
      [
        "T30",
        "行业",
        472,
        475,
        "CGT"
      ],
      [
        "T31",
        "属性值",
        484,
        490,
        "3500 项"
      ],
      [
        "T32",
        "临床试验数量",
        476,
        481,
        "临床项目数"
      ],
      [
        "T33",
        "时间范围",
        503,
        509,
        "2020 年"
      ],
      [
        "T34",
        "属性值",
        509,
        514,
        "翻 2 倍"
      ],
      [
        "T35",
        "行业",
        518,
        524,
        "终端 CGT"
      ],
      [
        "T36",
        "地点范围",
        533,
        535,
        "全球"
      ],
      [
        "T37",
        "行业",
        536,
        544,
        "CGT CDMO"
      ],
      [
        "T38",
        "市场规模",
        545,
        549,
        "市场规模"
      ],
      [
        "T39",
        "时间范围",
        552,
        558,
        "2025 年"
      ],
      [
        "T40",
        "属性值",
        560,
        569,
        "近 100 亿美元"
      ],
      [
        "T41",
        "时间范围",
        570,
        579,
        "2020-25 年"
      ],
      [
        "T42",
        "CAGR",
        580,
        584,
        "CAGR"
      ],
      [
        "T43",
        "属性值",
        585,
        590,
        "34.9%"
      ],
      [
        "T44",
        "地点范围",
        593,
        595,
        "中国"
      ],
      [
        "T45",
        "行业",
        596,
        604,
        "CGT CDMO"
      ],
      [
        "T46",
        "市场规模",
        605,
        609,
        "市场规模"
      ],
      [
        "T47",
        "属性值",
        611,
        617,
        "107 亿元"
      ],
      [
        "T48",
        "时间范围",
        618,
        627,
        "2020-25 年"
      ],
      [
        "T49",
        "CAGR",
        628,
        632,
        "CAGR"
      ],
      [
        "T50",
        "属性值",
        633,
        638,
        "51.5%"
      ],
      [
        "T51",
        "行业",
        646,
        649,
        "CGT"
      ],
      [
        "T52",
        "行业",
        658,
        664,
        "CGT 药物"
      ],
      [
        "T53",
        "属性值",
        666,
        677,
        "步骤多、难度大、成本高"
      ],
      [
        "T54",
        "外包率",
        680,
        683,
        "外包率"
      ],
      [
        "T55",
        "属性值",
        698,
        703,
        "65%以上"
      ],
      [
        "T56",
        "行业",
        706,
        711,
        "CAR-T"
      ],
      [
        "T57",
        "行业",
        770,
        773,
        "CGT"
      ],
      [
        "T58",
        "产能",
        774,
        776,
        "产能"
      ],
      [
        "T59",
        "属性值",
        776,
        778,
        "短缺"
      ],
      [
        "T60",
        "属性值",
        753,
        765,
        "高技术壁垒、 高生产成本"
      ],
      [
        "T61",
        "行业公司",
        782,
        784,
        "药企"
      ],
      [
        "T62",
        "行业公司",
        786,
        793,
        "CDMO 企业"
      ],
      [
        "T63",
        "行业",
        799,
        803,
        "CDMO"
      ],
      [
        "T64",
        "行业公司",
        839,
        841,
        "药企"
      ],
      [
        "T65",
        "行业",
        901,
        904,
        "CGT"
      ],
      [
        "T66",
        "行业",
        907,
        911,
        "CDMO"
      ],
      [
        "T67",
        "时间范围",
        925,
        931,
        "2021 年"
      ],
      [
        "T68",
        "地点范围",
        932,
        934,
        "中国"
      ],
      [
        "T69",
        "行业",
        935,
        939,
        "CGT "
      ],
      [
        "T70",
        "公司",
        945,
        949,
        "复星凯特"
      ],
      [
        "T71",
        "公司",
        950,
        954,
        "药明巨诺"
      ],
      [
        "T72",
        "行业",
        955,
        959,
        "细胞治疗"
      ],
      [
        "T73",
        "地点范围",
        972,
        974,
        "中国"
      ],
      [
        "T74",
        "行业",
        975,
        981,
        "CGT 药物"
      ],
      [
        "T75",
        "行业",
        987,
        993,
        "终端 CGT"
      ],
      [
        "T76",
        "地点范围",
        1002,
        1004,
        "国内"
      ],
      [
        "T77",
        "行业",
        1005,
        1013,
        "CGT CDMO"
      ],
      [
        "T78",
        "时间范围",
        1025,
        1031,
        "2025 年"
      ],
      [
        "T79",
        "属性值",
        1031,
        1035,
        "突破百亿"
      ],
      [
        "T80",
        "行业公司",
        1041,
        1047,
        "CGT 企业"
      ],
      [
        "T81",
        "行业",
        1052,
        1057,
        "CDMO "
      ],
      [
        "T82",
        "市场规模",
        1035,
        1037,
        "规模"
      ],
      [
        "T83",
        "行业",
        1066,
        1069,
        "CGT"
      ],
      [
        "T84",
        "行业公司",
        1080,
        1087,
        "CDMO 企业"
      ],
      [
        "T85",
        "行业",
        1097,
        1105,
        "CGT CDMO"
      ],
      [
        "T86",
        "产能",
        1133,
        1135,
        "产能"
      ],
      [
        "T87",
        "行业公司",
        1147,
        1154,
        "CDMO 公司"
      ],
      [
        "T88",
        "公司",
        1159,
        1163,
        "药明康德"
      ],
      [
        "T89",
        "公司",
        1164,
        1168,
        "康龙化成"
      ],
      [
        "T90",
        "公司",
        1170,
        1174,
        "博腾股份"
      ],
      [
        "T91",
        "公司",
        1179,
        1186,
        "金斯瑞生物科技"
      ],
      [
        "T92",
        "公司",
        1187,
        1191,
        "和元生物"
      ]
    ]
  },
  {
    "id": 1009,
    "text": "药明康德近几年的营业收入和净利润处于持续高速增长状态，2021 上半年实现营业收入 105.37亿元，同比增长 45.70%，归母净利润 26.75亿元，同比增长 55.79%，扣非归母净利润 21.27 亿元，同比增长 88.05%，稳定增长的业绩带来良好的现金流，2021 年上半年实现经营活动现金流 21.43亿元，同比增长 49.25%。",
    "labels": [
      [
        "T0",
        "公司",
        0,
        4,
        "药明康德"
      ],
      [
        "T1",
        "时间范围",
        4,
        7,
        "近几年"
      ],
      [
        "T2",
        "营业收入",
        8,
        12,
        "营业收入"
      ],
      [
        "T3",
        "归母净利润",
        13,
        16,
        "净利润"
      ],
      [
        "T4",
        "属性值",
        18,
        24,
        "持续高速增长"
      ],
      [
        "T5",
        "时间范围",
        27,
        35,
        "2021 上半年"
      ],
      [
        "T6",
        "营业收入",
        37,
        41,
        "营业收入"
      ],
      [
        "T7",
        "属性值",
        42,
        50,
        "105.37亿元"
      ],
      [
        "T8",
        "属性值",
        56,
        62,
        "45.70%"
      ],
      [
        "T9",
        "归母净利润",
        63,
        68,
        "归母净利润"
      ],
      [
        "T10",
        "属性值",
        69,
        88,
        "26.75亿元，同比增长 55.79%"
      ],
      [
        "T11",
        "扣非净利润",
        89,
        96,
        "扣非归母净利润"
      ],
      [
        "T12",
        "属性值",
        97,
        117,
        "21.27 亿元，同比增长 88.05%"
      ],
      [
        "T13",
        "业绩",
        123,
        125,
        "业绩"
      ],
      [
        "T14",
        "属性值",
        118,
        122,
        "稳定增长"
      ],
      [
        "T15",
        "属性值",
        127,
        129,
        "良好"
      ],
      [
        "T16",
        "现金流",
        130,
        133,
        "现金流"
      ],
      [
        "T17",
        "时间范围",
        134,
        143,
        "2021 年上半年"
      ],
      [
        "T18",
        "现金流",
        149,
        152,
        "现金流"
      ],
      [
        "T19",
        "属性值",
        153,
        172,
        "21.43亿元，同比增长 49.25%"
      ]
    ]
  },
  {
    "id": 1019,
    "text": "全球 CRO龙头市盈率水平在 20~40倍之间。除疫情爆发初期美股市场大跌时期造成的短期回调，海外龙头 CRO 公司估值水平多在 20~40 倍之间（其中 IQVIA和 PRA对应的利润口径为 non-GAAP净利润）。这与其已经处于发展成熟期，行业竞争优势正逐步向东亚地区倾斜有关。因当前国内 CXO所处发展阶段与全球龙头不同，因而不宜直接比较市盈率水平。假设药明康德等中国 CXO 龙头在 2030年前后进入全球市场份额的第一梯队，彼时再使用 20~40倍的市盈率水平进行估值可能更为合适。",
    "labels": [
      [
        "T0",
        "地点范围",
        0,
        2,
        "全球"
      ],
      [
        "T1",
        "行业",
        3,
        6,
        "CRO"
      ],
      [
        "T2",
        "龙头企业",
        6,
        8,
        "龙头"
      ],
      [
        "T3",
        "PE",
        8,
        11,
        "市盈率"
      ],
      [
        "T4",
        "地点范围",
        47,
        49,
        "海外"
      ],
      [
        "T5",
        "龙头企业",
        49,
        52,
        "龙头 "
      ],
      [
        "T6",
        "行业公司",
        52,
        58,
        "CRO 公司"
      ],
      [
        "T7",
        "公司",
        78,
        83,
        "IQVIA"
      ],
      [
        "T8",
        "公司",
        84,
        88,
        " PRA"
      ],
      [
        "T9",
        "利润",
        91,
        93,
        "利润"
      ],
      [
        "T10",
        "归母净利润",
        105,
        108,
        "净利润"
      ],
      [
        "T11",
        "地点范围",
        145,
        147,
        "国内"
      ],
      [
        "T12",
        "行业",
        147,
        151,
        " CXO"
      ],
      [
        "T13",
        "地点范围",
        158,
        160,
        "全球"
      ],
      [
        "T14",
        "龙头企业",
        160,
        162,
        "龙头"
      ],
      [
        "T15",
        "PE",
        173,
        176,
        "市盈率"
      ],
      [
        "T16",
        "公司",
        181,
        185,
        "药明康德"
      ],
      [
        "T17",
        "地点范围",
        186,
        188,
        "中国"
      ],
      [
        "T18",
        "行业",
        188,
        192,
        " CXO"
      ],
      [
        "T19",
        "龙头企业",
        193,
        195,
        "龙头"
      ],
      [
        "T20",
        "时间范围",
        197,
        204,
        "2030年前后"
      ],
      [
        "T21",
        "地点范围",
        206,
        208,
        "全球"
      ],
      [
        "T22",
        "市场份额",
        208,
        212,
        "市场份额"
      ],
      [
        "T23",
        "PE",
        231,
        234,
        "市盈率"
      ],
      [
        "T24",
        "属性值",
        224,
        230,
        "20~40倍"
      ],
      [
        "T25",
        "属性值",
        15,
        23,
        "20~40倍之间"
      ],
      [
        "T26",
        "时间范围",
        143,
        145,
        "当前"
      ]
    ]
  },
  {
    "id": 1025,
    "text": " 端到端企业 CDMO 业务的成长性持续性更强，例如，药明康德小分子 CDMO 业务的 2020 年收入 53 亿元、2018-2020 年收入 CAGR 为 40%。",
    "labels": [
      [
        "T0",
        "公司",
        28,
        32,
        "药明康德"
      ],
      [
        "T1",
        "行业",
        32,
        41,
        "小分子 CDMO "
      ],
      [
        "T2",
        "时间范围",
        44,
        51,
        " 2020 年"
      ],
      [
        "T3",
        "营业收入",
        51,
        53,
        "收入"
      ],
      [
        "T4",
        "属性值",
        53,
        59,
        " 53 亿元"
      ],
      [
        "T5",
        "CAGR",
        74,
        78,
        "CAGR"
      ],
      [
        "T6",
        "营业收入",
        71,
        73,
        "收入"
      ],
      [
        "T7",
        "时间范围",
        60,
        71,
        "2018-2020 年"
      ],
      [
        "T8",
        "属性值",
        81,
        84,
        "40%"
      ],
      [
        "T9",
        "行业",
        2,
        12,
        "端到端企业 CDMO"
      ]
    ]
  },
  {
    "id": 1026,
    "text": "历史复盘：全球化产业链转移持续，尤其是在疫情催化下，实验室业务、CDMO业务有望加速转移  CXO公司区域结构：海外为基本盘、国内为增量 核心CXO公司海外客户业务保持高速增长，全球化创新药产业链转移持续：核心公司合计海外客户收入为 184.77亿元，同比增长61.83%，扣除维亚生物的并表影响，同比增长为56.71%，若再扣除药明生物（中和抗体和疫苗放量等因素）的影响，同比增长为42.04%，继续延续高速增长。",
    "labels": [
      [
        "T0",
        "行业公司",
        71,
        78,
        "核心CXO公司"
      ],
      [
        "T1",
        "行业公司",
        105,
        109,
        "核心公司"
      ],
      [
        "T2",
        "地点范围",
        111,
        113,
        "海外"
      ],
      [
        "T3",
        "营业收入",
        115,
        117,
        "收入"
      ],
      [
        "T4",
        "属性值",
        119,
        127,
        "184.77亿元"
      ],
      [
        "T5",
        "属性值",
        132,
        138,
        "61.83%"
      ],
      [
        "T6",
        "公司",
        141,
        145,
        "维亚生物"
      ],
      [
        "T7",
        "属性值",
        156,
        162,
        "56.71%"
      ],
      [
        "T8",
        "公司",
        167,
        171,
        "药明生物"
      ],
      [
        "T9",
        "属性值",
        194,
        200,
        "42.04%"
      ],
      [
        "T10",
        "属性值",
        205,
        209,
        "高速增长"
      ],
      [
        "T11",
        "属性值",
        86,
        90,
        "高速增长"
      ],
      [
        "T12",
        "地点范围",
        78,
        80,
        "海外"
      ],
      [
        "T13",
        "行业",
        94,
        97,
        "创新药"
      ],
      [
        "T14",
        "行业公司",
        47,
        52,
        "CXO公司"
      ],
      [
        "T15",
        "地点范围",
        57,
        59,
        "海外"
      ],
      [
        "T16",
        "地点范围",
        64,
        66,
        "国内"
      ],
      [
        "T17",
        "行业",
        32,
        36,
        "CDMO"
      ],
      [
        "T18",
        "行业",
        26,
        29,
        "实验室"
      ]
    ]
  },
  {
    "id": 1027,
    "text": " 国内医药不同阶段的需求，我们预计 2020年的情况如下： ① 医药创新产业链最前端药物发现类 CRO服务因为目前国内医药创新的主体思路仍为 fast follow，收入占比较低，低基数的背景下收入增速波",
    "labels": [
      [
        "T0",
        "地点范围",
        2,
        4,
        "国内"
      ],
      [
        "T1",
        "行业",
        4,
        6,
        "医药"
      ],
      [
        "T2",
        "行业需求",
        11,
        13,
        "需求"
      ],
      [
        "T3",
        "时间范围",
        19,
        24,
        "2020年"
      ],
      [
        "T4",
        "行业",
        43,
        54,
        "药物发现类 CRO服务"
      ],
      [
        "T5",
        "行业",
        33,
        37,
        "医药创新"
      ],
      [
        "T6",
        "地点范围",
        56,
        58,
        "目前"
      ],
      [
        "T7",
        "地点范围",
        58,
        60,
        "国内"
      ],
      [
        "T8",
        "行业",
        60,
        64,
        "医药创新"
      ],
      [
        "T9",
        "营收占比",
        84,
        88,
        "收入占比"
      ],
      [
        "T10",
        "属性值",
        88,
        90,
        "较低"
      ],
      [
        "T11",
        "收入增速",
        98,
        102,
        "收入增速"
      ]
    ]
  },
  {
    "id": 1031,
    "text": "生物药的快速发展，其底层驱动力来自于源源不断上市的品种，及良好疗效带来的渗透率快速提升。根据 Nature Reviews 文章统计，2000-2014 年间 FDA 每年平均批准约两款生物药上市，而此后每年平均获批数约为 8 款。同时，全球前十大畅销药物中，生物药的个数及销量均在不断提升，其中修美乐销售额更是自 2012 年起就持续占据榜首，反映市场对生物药的迫切需求。 诸多生物药 CDMO 公司也伴随着生物药市场扩大而快速成长。如三星生物和药明生物，二者营收在过去几年实现了数倍增长，从 2015 年 10-20 亿人民币级别迅速增长至 2021 年的百亿人民币规模， 市值也突破 2000 亿人民币规模，较 IPO 时市值各增长近 4 倍与 7 倍。而老牌小分子 CDMO 龙头 Lonza 在转型生物药 CDMO 后，其股价也在 2014 年前后伴随生物药快速发展而迅速上涨，其 2021 年全年营收近 50%来自于生物药 CDMO。 我们认为，CGT CDMO 的发展将重现生物药 CDMO 发展历程，并涌现诸如三星生物、药明生物的 CGT CDMO 明星企业。立足当下，正如生物药井喷期，CGT 药物将进入密集上市阶段，且药品以其优异效果迅速渗透患者，因此 CGT 市场的快速成熟有利于 CGT CDMO 的高速发展。 我们认为 CGT CDMO 的增长主要受两方面影响：  CGT 市场快速发展带来的外部影响，包括：1）CGT 快速商业化导致的产能不足； 2） CGT 在研管线快速扩增带来的研发生产需求； 3） 资金持续涌入， 支撑药企与 CDMO 企业合作。  CGT 高外包率行业特性的内部影响，包括：1）CGT 生产难度高，药企无法独立完成；2）CGT 研发以 Biotech 为主，外包意愿强；3）CGT 生产监管复杂，CDMO 具有丰富应对经验。 根据弗若斯特沙利文数据，2016-2020 年，全球 CGT CDMO 市场规模的 CAGR 为 22.3%， 其中 2020 年全球市场规模约 23 亿美元； 中国市场则更不成熟， 2020 年市场规模仅为 13 亿人民币。 但随着 CGT 管线的增长及产业的成熟，预计全球的 CGT CDMO 市场规模将在 2025 年达到 101 亿美元，2020-2025 年 CAGR 将",
    "labels": [
      [
        "T0",
        "行业",
        0,
        3,
        "生物药"
      ],
      [
        "T1",
        "时间范围",
        67,
        79,
        "2000-2014 年间"
      ],
      [
        "T2",
        "地点范围",
        119,
        121,
        "全球"
      ],
      [
        "T3",
        "行业",
        130,
        133,
        "生物药"
      ],
      [
        "T4",
        "行业",
        178,
        181,
        "生物药"
      ],
      [
        "T5",
        "行业需求",
        184,
        186,
        "需求"
      ],
      [
        "T6",
        "行业公司",
        190,
        201,
        "生物药 CDMO 公司"
      ],
      [
        "T7",
        "公司",
        219,
        223,
        "三星生物"
      ],
      [
        "T8",
        "公司",
        224,
        228,
        "药明生物"
      ],
      [
        "T9",
        "营业收入",
        231,
        233,
        "营收"
      ],
      [
        "T10",
        "时间范围",
        234,
        238,
        "过去几年"
      ],
      [
        "T11",
        "时间范围",
        248,
        254,
        "2015 年"
      ],
      [
        "T12",
        "时间范围",
        273,
        279,
        "2021 年"
      ],
      [
        "T13",
        "属性值",
        280,
        285,
        "百亿人民币"
      ],
      [
        "T14",
        "行业",
        333,
        342,
        "小分子 CDMO "
      ],
      [
        "T15",
        "龙头企业",
        342,
        344,
        "龙头"
      ],
      [
        "T16",
        "公司",
        345,
        351,
        "Lonza "
      ],
      [
        "T17",
        "行业",
        354,
        362,
        "生物药 CDMO"
      ],
      [
        "T18",
        "时间范围",
        371,
        379,
        "2014 年前后"
      ],
      [
        "T19",
        "行业",
        381,
        384,
        "生物药"
      ],
      [
        "T20",
        "时间范围",
        395,
        404,
        " 2021 年全年"
      ],
      [
        "T21",
        "营业收入",
        404,
        406,
        "营收"
      ],
      [
        "T22",
        "属性值",
        406,
        411,
        "近 50%"
      ],
      [
        "T23",
        "行业",
        414,
        422,
        "生物药 CDMO"
      ],
      [
        "T24",
        "行业",
        430,
        437,
        "GT CDMO"
      ],
      [
        "T25",
        "行业",
        444,
        453,
        "生物药 CDMO "
      ],
      [
        "T26",
        "公司",
        463,
        467,
        "三星生物"
      ],
      [
        "T27",
        "公司",
        468,
        472,
        "药明生物"
      ],
      [
        "T28",
        "行业",
        474,
        482,
        "CGT CDMO"
      ],
      [
        "T29",
        "行业",
        495,
        498,
        "生物药"
      ],
      [
        "T30",
        "行业",
        552,
        561,
        "CGT CDMO "
      ],
      [
        "T31",
        "行业",
        572,
        581,
        " CGT CDMO"
      ],
      [
        "T32",
        "行业公司",
        677,
        679,
        "药企"
      ],
      [
        "T33",
        "行业公司",
        681,
        688,
        "CDMO 企业"
      ],
      [
        "T34",
        "行业",
        597,
        600,
        "CGT"
      ],
      [
        "T35",
        "行业",
        537,
        541,
        "CGT "
      ],
      [
        "T36",
        "行业",
        620,
        624,
        "CGT "
      ],
      [
        "T37",
        "行业",
        641,
        645,
        "CGT "
      ],
      [
        "T38",
        "行业",
        694,
        697,
        "CGT"
      ],
      [
        "T39",
        "外包率",
        699,
        702,
        "外包率"
      ],
      [
        "T40",
        "属性值",
        698,
        699,
        "高"
      ],
      [
        "T41",
        "行业",
        717,
        721,
        "CGT "
      ],
      [
        "T42",
        "行业公司",
        727,
        729,
        "药企"
      ],
      [
        "T43",
        "行业",
        738,
        741,
        "CGT"
      ],
      [
        "T44",
        "行业",
        745,
        754,
        " Biotech "
      ],
      [
        "T45",
        "行业",
        765,
        768,
        "CGT"
      ],
      [
        "T46",
        "行业",
        776,
        780,
        "CDMO"
      ],
      [
        "T47",
        "时间范围",
        803,
        814,
        "2016-2020 年"
      ],
      [
        "T48",
        "地点范围",
        815,
        818,
        "全球 "
      ],
      [
        "T49",
        "行业",
        818,
        827,
        "CGT CDMO "
      ],
      [
        "T50",
        "市场规模",
        827,
        831,
        "市场规模"
      ],
      [
        "T51",
        "CAGR",
        833,
        837,
        "CAGR"
      ],
      [
        "T52",
        "属性值",
        839,
        845,
        " 22.3%"
      ],
      [
        "T53",
        "属性值",
        895,
        903,
        " 13 亿人民币"
      ],
      [
        "T54",
        "市场规模",
        889,
        893,
        "市场规模"
      ],
      [
        "T55",
        "时间范围",
        882,
        889,
        " 2020 年"
      ],
      [
        "T56",
        "时间范围",
        850,
        856,
        "2020 年"
      ],
      [
        "T57",
        "地点范围",
        856,
        858,
        "全球"
      ],
      [
        "T58",
        "市场规模",
        858,
        862,
        "市场规模"
      ],
      [
        "T59",
        "属性值",
        862,
        870,
        "约 23 亿美元"
      ],
      [
        "T60",
        "地点范围",
        872,
        874,
        "中国"
      ],
      [
        "T61",
        "行业",
        909,
        913,
        "CGT "
      ],
      [
        "T62",
        "地点范围",
        927,
        929,
        "全球"
      ],
      [
        "T63",
        "行业",
        931,
        939,
        "CGT CDMO"
      ],
      [
        "T64",
        "市场规模",
        939,
        944,
        " 市场规模"
      ],
      [
        "T65",
        "时间范围",
        946,
        953,
        " 2025 年"
      ],
      [
        "T66",
        "属性值",
        956,
        963,
        "101 亿美元"
      ],
      [
        "T67",
        "时间范围",
        964,
        975,
        "2020-2025 年"
      ],
      [
        "T68",
        "CAGR",
        976,
        980,
        "CAGR"
      ],
      [
        "T69",
        "属性值",
        241,
        245,
        "数倍增长"
      ],
      [
        "T70",
        "属性值",
        255,
        265,
        "10-20 亿人民币"
      ],
      [
        "T71",
        "行业",
        205,
        208,
        "生物药"
      ],
      [
        "T72",
        "时间范围",
        156,
        165,
        "自 2012 年起"
      ],
      [
        "T73",
        "市值",
        289,
        291,
        "市值"
      ],
      [
        "T74",
        "属性值",
        292,
        306,
        "突破 2000 亿人民币规模"
      ]
    ]
  },
  {
    "id": 1037,
    "text": "医美：伴随消费升级大趋势，医美行业蓬勃发展，医美赛道资产证券化加速且备受青睐。展望未来，我们看好医美板块，主要原因包括：1）我国医美渗透率提升空间大， 医美接受水平不断改善；2）医美产品呈现多样化，国内品牌份额趋于提升；3）医美行业市场逐步规范化，将利于正规持证品牌获取存量市场份额。推荐：爱美客、华熙生物、 昊海生科、华东医药等。",
    "labels": [
      [
        "T0",
        "行业",
        0,
        2,
        "医美"
      ],
      [
        "T1",
        "行业",
        13,
        15,
        "医美"
      ],
      [
        "T2",
        "行业",
        22,
        24,
        "医美"
      ],
      [
        "T3",
        "行业",
        48,
        50,
        "医美"
      ],
      [
        "T4",
        "地点范围",
        62,
        64,
        "我国"
      ],
      [
        "T5",
        "行业",
        64,
        66,
        "医美"
      ],
      [
        "T6",
        "行业",
        76,
        78,
        "医美"
      ],
      [
        "T7",
        "行业",
        89,
        91,
        "医美"
      ],
      [
        "T8",
        "地点范围",
        99,
        101,
        "国内"
      ],
      [
        "T9",
        "行业",
        112,
        114,
        "医美"
      ],
      [
        "T10",
        "市场份额",
        137,
        141,
        "市场份额"
      ],
      [
        "T11",
        "公司",
        145,
        148,
        "爱美客"
      ],
      [
        "T12",
        "公司",
        149,
        153,
        "华熙生物"
      ],
      [
        "T13",
        "公司",
        155,
        159,
        "昊海生科"
      ],
      [
        "T14",
        "公司",
        160,
        164,
        "华东医药"
      ],
      [
        "T15",
        "属性值",
        5,
        9,
        "消费升级"
      ]
    ]
  },
  {
    "id": 1039,
    "text": "2022年1-2月订单和收入同比增速均创历史新高，CXO仍是业绩确定性最高子版块。目前药明康德、凯莱英和泰格医药均披露2022年1-2月双月报数据，优异的业绩表现印证CXO强劲基本面。其中，药明康德和凯莱英预计一季度收入同比增速分别是65%-68%和150%+，泰格医药1-2月收入端增速100%+，高增长态势持续。",
    "labels": [
      [
        "T0",
        "行业",
        25,
        28,
        "CXO"
      ],
      [
        "T1",
        "业绩",
        30,
        32,
        "业绩"
      ],
      [
        "T2",
        "属性值",
        32,
        37,
        "确定性最高"
      ],
      [
        "T3",
        "时间范围",
        0,
        9,
        "2022年1-2月"
      ],
      [
        "T4",
        "在手订单",
        9,
        11,
        "订单"
      ],
      [
        "T5",
        "收入增速",
        12,
        18,
        "收入同比增速"
      ],
      [
        "T6",
        "属性值",
        19,
        24,
        "创历史新高"
      ],
      [
        "T7",
        "公司",
        43,
        47,
        "药明康德"
      ],
      [
        "T8",
        "时间范围",
        41,
        43,
        "目前"
      ],
      [
        "T9",
        "公司",
        48,
        51,
        "凯莱英"
      ],
      [
        "T10",
        "公司",
        52,
        56,
        "泰格医药"
      ],
      [
        "T11",
        "时间范围",
        59,
        68,
        "2022年1-2月"
      ],
      [
        "T12",
        "业绩",
        77,
        79,
        "业绩"
      ],
      [
        "T13",
        "属性值",
        74,
        76,
        "优异"
      ],
      [
        "T14",
        "行业",
        83,
        86,
        "CXO"
      ],
      [
        "T15",
        "公司",
        95,
        99,
        "药明康德"
      ],
      [
        "T16",
        "公司",
        100,
        103,
        "凯莱英"
      ],
      [
        "T17",
        "时间范围",
        105,
        108,
        "一季度"
      ],
      [
        "T18",
        "收入增速",
        108,
        114,
        "收入同比增速"
      ],
      [
        "T19",
        "属性值",
        117,
        124,
        "65%-68%"
      ],
      [
        "T20",
        "属性值",
        125,
        130,
        "150%+"
      ],
      [
        "T21",
        "公司",
        131,
        135,
        "泰格医药"
      ],
      [
        "T22",
        "时间范围",
        135,
        139,
        "1-2月"
      ],
      [
        "T23",
        "收入增速",
        139,
        144,
        "收入端增速"
      ],
      [
        "T24",
        "属性值",
        144,
        149,
        "100%+"
      ]
    ]
  },
  {
    "id": 1049,
    "text": "国内CXO企业2021年资本开支加速趋势明显，按增速来看，阳光诺和同比增长214%，位居首位；之后分别是：美迪西147%、泰格医药136%、普洛药业121%和博腾股份 97%。2021年大部分国内CXO企业资本开支均呈现翻倍式增长，2020年同比增幅约67%，加速趋势非常明显。",
    "labels": [
      [
        "T0",
        "地点范围",
        0,
        2,
        "国内"
      ],
      [
        "T1",
        "行业公司",
        2,
        7,
        "CXO企业"
      ],
      [
        "T2",
        "时间范围",
        7,
        12,
        "2021年"
      ],
      [
        "T3",
        "公司",
        29,
        33,
        "阳光诺和"
      ],
      [
        "T4",
        "公司",
        53,
        56,
        "美迪西"
      ],
      [
        "T5",
        "公司",
        61,
        65,
        "泰格医药"
      ],
      [
        "T6",
        "公司",
        70,
        74,
        "普洛药业"
      ],
      [
        "T7",
        "公司",
        79,
        83,
        "博腾股份"
      ],
      [
        "T8",
        "时间范围",
        88,
        93,
        "2021年"
      ],
      [
        "T9",
        "行业公司",
        98,
        103,
        "CXO企业"
      ],
      [
        "T10",
        "地点范围",
        96,
        98,
        "国内"
      ],
      [
        "T11",
        "时间范围",
        116,
        121,
        "2020年"
      ],
      [
        "T12",
        "CAPEX资本开支",
        12,
        16,
        "资本开支"
      ],
      [
        "T13",
        "属性值",
        16,
        18,
        "加速"
      ],
      [
        "T14",
        "CAPEX资本开支",
        103,
        107,
        "资本开支"
      ],
      [
        "T15",
        "属性值",
        110,
        115,
        "翻倍式增长"
      ],
      [
        "T16",
        "属性值",
        121,
        129,
        "同比增幅约67%"
      ],
      [
        "T17",
        "属性值",
        33,
        41,
        "同比增长214%"
      ]
    ]
  },
  {
    "id": 1052,
    "text": "研发投入持续加大，研发费用率持续提升。CXO公司越来越重视研发，研发费用提升显著，2021Q1 研发费用率超过5%，预计未来仍将继续提提升。",
    "labels": [
      [
        "T0",
        "研发费用",
        0,
        4,
        "研发投入"
      ],
      [
        "T1",
        "行业公司",
        19,
        24,
        "CXO公司"
      ],
      [
        "T2",
        "研发费用",
        32,
        36,
        "研发费用"
      ],
      [
        "T3",
        "属性值",
        36,
        40,
        "提升显著"
      ],
      [
        "T4",
        "时间范围",
        41,
        48,
        "2021Q1 "
      ],
      [
        "T5",
        "时间范围",
        60,
        62,
        "未来"
      ],
      [
        "T6",
        "研发费用率",
        48,
        53,
        "研发费用率"
      ],
      [
        "T7",
        "属性值",
        53,
        57,
        "超过5%"
      ],
      [
        "T8",
        "属性值",
        67,
        69,
        "提升"
      ],
      [
        "T9",
        "研发费用率",
        9,
        14,
        "研发费用率"
      ],
      [
        "T10",
        "属性值",
        4,
        8,
        "持续加大"
      ],
      [
        "T11",
        "属性值",
        14,
        18,
        "持续提升"
      ]
    ]
  },
  {
    "id": 1061,
    "text": "美国FDA新药在近几年都呈现较高强度：2020年获批新药53个品种，其中38个小分子创新药、15个生物药。 另外2021年01-08月获批36个创新药，相对2019和2020年同期的26和38个继续保持高强度； 另外我们观察clinicaltrials上的美国新开展临床I期的数量继续保持稳健增长，此数据也表征IND申报数量，继续保持向上增长。",
    "labels": [
      [
        "T0",
        "时间范围",
        9,
        12,
        "近几年"
      ],
      [
        "T1",
        "时间范围",
        20,
        25,
        "2020年"
      ],
      [
        "T2",
        "行业",
        40,
        46,
        "小分子创新药"
      ],
      [
        "T3",
        "行业",
        50,
        53,
        "生物药"
      ],
      [
        "T4",
        "时间范围",
        57,
        68,
        "2021年01-08月"
      ],
      [
        "T5",
        "属性值",
        37,
        40,
        "38个"
      ],
      [
        "T6",
        "属性值",
        47,
        50,
        "15个"
      ],
      [
        "T7",
        "行业",
        73,
        76,
        "创新药"
      ],
      [
        "T8",
        "属性值",
        70,
        73,
        "36个"
      ],
      [
        "T9",
        "时间范围",
        79,
        83,
        "2019"
      ],
      [
        "T10",
        "时间范围",
        84,
        89,
        "2020年"
      ],
      [
        "T11",
        "地点范围",
        130,
        132,
        "美国"
      ]
    ]
  },
  {
    "id": 1066,
    "text": "C(D)MO行业正处于高速增长期，产能是业务开展的关键。我们认为，随着新药结构的日趋复杂和药企对于成本管控要求的不断提升，具备高附加值的 C(D)MO服务成为药企优化生产流程、降低成本和提高生产效率的首要选择。欧美医药市场规模大，研发与生产分离制度实施较早，使得欧美 C(D)MO占据着全球市场大多数份额。近年受益于显著的成本优势，全球产能正逐步向中国和印度等发展中地区转移。在国内市场，MA H制度为药企的药品生产提供了政策便利，实现药物研发与生产的分离，一方面促进国内创新药行业的发展，另一方面也有助于提升 C(D)MO行业市场空间，形成正向循环。 国内 C(D)MO行业正处于高速增长期，我们认为对于企业而言，产能是业务开展的关键， 只有提前进行产能扩建和相关认证工作，才能获得订单。自 2015年到 2019年，国内 C (D)MO企业资本开支稳定在一个较高水平，固定资产原值持续攀升反映了产能的加速扩建。",
    "labels": [
      [
        "T0",
        "行业",
        0,
        6,
        "C(D)MO"
      ],
      [
        "T1",
        "产能",
        17,
        19,
        "产能"
      ],
      [
        "T2",
        "行业公司",
        45,
        47,
        "药企"
      ],
      [
        "T3",
        "行业",
        68,
        75,
        " C(D)MO"
      ],
      [
        "T4",
        "行业公司",
        79,
        81,
        "药企"
      ],
      [
        "T5",
        "市场规模",
        109,
        113,
        "市场规模"
      ],
      [
        "T6",
        "行业",
        134,
        140,
        "C(D)MO"
      ],
      [
        "T7",
        "市场份额",
        150,
        152,
        "份额"
      ],
      [
        "T8",
        "产能",
        168,
        170,
        "产能"
      ],
      [
        "T9",
        "地点范围",
        189,
        191,
        "国内"
      ],
      [
        "T10",
        "行业公司",
        201,
        203,
        "药企"
      ],
      [
        "T11",
        "地点范围",
        234,
        236,
        "国内"
      ],
      [
        "T12",
        "行业",
        236,
        239,
        "创新药"
      ],
      [
        "T13",
        "行业",
        256,
        262,
        "C(D)MO"
      ],
      [
        "T14",
        "地点范围",
        277,
        280,
        "国内 "
      ],
      [
        "T15",
        "行业",
        280,
        286,
        "C(D)MO"
      ],
      [
        "T16",
        "产能",
        308,
        310,
        "产能"
      ],
      [
        "T17",
        "时间范围",
        345,
        359,
        "自 2015年到 2019年"
      ],
      [
        "T18",
        "地点范围",
        360,
        362,
        "国内"
      ],
      [
        "T19",
        "行业公司",
        363,
        372,
        "C (D)MO企业"
      ],
      [
        "T20",
        "CAPEX资本开支",
        372,
        376,
        "资本开支"
      ],
      [
        "T21",
        "属性值",
        376,
        385,
        "稳定在一个较高水平"
      ],
      [
        "T22",
        "固定资产",
        386,
        390,
        "固定资产"
      ],
      [
        "T23",
        "产能",
        399,
        401,
        "产能"
      ],
      [
        "T24",
        "属性值",
        402,
        406,
        "加速扩建"
      ],
      [
        "T25",
        "属性值",
        392,
        396,
        "持续攀升"
      ],
      [
        "T26",
        "地点范围",
        105,
        107,
        "欧美"
      ],
      [
        "T27",
        "行业",
        107,
        109,
        "医药"
      ],
      [
        "T28",
        "属性值",
        113,
        114,
        "大"
      ],
      [
        "T29",
        "地点范围",
        131,
        133,
        "欧美"
      ],
      [
        "T30",
        "地点范围",
        143,
        145,
        "全球"
      ],
      [
        "T31",
        "时间范围",
        153,
        155,
        "近年"
      ],
      [
        "T32",
        "地点范围",
        166,
        168,
        "全球"
      ],
      [
        "T33",
        "地点范围",
        174,
        176,
        "中国"
      ],
      [
        "T34",
        "地点范围",
        177,
        179,
        "印度"
      ],
      [
        "T35",
        "产能",
        326,
        328,
        "产能"
      ]
    ]
  },
  {
    "id": 1067,
    "text": "高值耗材全国带量采购落地，加速进口替代及国产创新。自 2019年国务院印发《治理高值医用耗材改革方案》的通知后，地方高值耗材带量采购就已进入常态化，全国各省份独立或者省级联盟持续对人工晶体、冠脉球囊等耗材进行带量采购。全国集采则自 2020年 10月正式拉开序幕后，已实施两次，均降幅明显。未来随着耗材统一编码的完成、各省份及全国采购经验的累积等前期工作的梳理，全国高值耗材带量采购有望加速开展。高值耗材带量采购短期内会对行业造成一定压力，但长期来看会：1）持续加速进口替代。目前骨骼、神经介入等高值耗材国内主要市场仍被外企占据，国产价格相对进口低，且降价接受程度较高，在带量采购过程中占据明显优势，市场占有率有望得到持续提升；（2）促进行业集中度的提升。带量采购的实施有助于产品线丰富、生产及成本控制能力的企业获取更大的市场份额。（3）加速国内医疗器械创新。带量采购导致企业产品价格降低，利润空间被压缩，创新能力较强的企业可以通过丰富产品和升级技术来获得较好的成长空间。",
    "labels": [
      [
        "T0",
        "地点范围",
        252,
        254,
        "国内"
      ],
      [
        "T1",
        "市场份额",
        300,
        305,
        "市场占有率"
      ],
      [
        "T2",
        "行业",
        0,
        4,
        "高值耗材"
      ],
      [
        "T3",
        "行业",
        58,
        62,
        "高值耗材"
      ],
      [
        "T4",
        "行业",
        183,
        187,
        "高值耗材"
      ],
      [
        "T5",
        "行业",
        198,
        202,
        "高值耗材"
      ],
      [
        "T6",
        "行业",
        248,
        252,
        "高值耗材"
      ],
      [
        "T7",
        "市场集中度",
        319,
        324,
        "行业集中度"
      ],
      [
        "T8",
        "市场份额",
        361,
        365,
        "市场份额"
      ],
      [
        "T9",
        "地点范围",
        371,
        373,
        "国内"
      ],
      [
        "T10",
        "行业",
        373,
        377,
        "医疗器械"
      ],
      [
        "T11",
        "地点范围",
        4,
        6,
        "全国"
      ],
      [
        "T12",
        "时间范围",
        25,
        32,
        "自 2019年"
      ],
      [
        "T13",
        "地点范围",
        74,
        76,
        "全国"
      ],
      [
        "T14",
        "地点范围",
        109,
        111,
        "全国"
      ],
      [
        "T15",
        "时间范围",
        114,
        125,
        "自 2020年 10月"
      ],
      [
        "T16",
        "地点范围",
        181,
        183,
        "全国"
      ],
      [
        "T17",
        "时间范围",
        145,
        147,
        "未来"
      ],
      [
        "T18",
        "行业",
        240,
        242,
        "骨骼"
      ],
      [
        "T19",
        "行业",
        243,
        247,
        "神经介入"
      ],
      [
        "T20",
        "时间范围",
        238,
        240,
        "目前"
      ],
      [
        "T21",
        "属性值",
        311,
        313,
        "提升"
      ],
      [
        "T22",
        "利润",
        395,
        397,
        "利润"
      ]
    ]
  },
  {
    "id": 1073,
    "text": "三星以145.6亿元收购渤健所持Bioepis股份。三星 Bioepis于2012年由三星生物制剂和百健共同投资成立。三星 Bioepis主要研发管线主要为生物类似药，已有6款生物类似药获批上市（雷珠单抗、贝伐珠单抗、曲妥珠单抗、阿达木单抗、英夫利西单抗和依那西普），还有1款甘精胰岛素已申报上市。",
    "labels": [
      [
        "T0",
        "公司",
        1,
        3,
        "三星"
      ],
      [
        "T1",
        "公司",
        17,
        24,
        "Bioepis"
      ],
      [
        "T2",
        "公司",
        27,
        37,
        "三星 Bioepis"
      ],
      [
        "T3",
        "公司",
        44,
        48,
        "三星生物"
      ],
      [
        "T4",
        "公司",
        51,
        53,
        "百健"
      ],
      [
        "T5",
        "公司",
        60,
        70,
        "三星 Bioepis"
      ],
      [
        "T6",
        "时间范围",
        38,
        43,
        "2012年"
      ],
      [
        "T7",
        "公司",
        13,
        15,
        "渤健"
      ]
    ]
  },
  {
    "id": 1079,
    "text": "➢ 2021年以来CXO板块出现分化并波动明显：2021年1月至8月，CXO板块公司股价走势一路向好，行业受疫情影响较小，甚至受益订单转移表现出逆势上涨；在2021年8月至今，CXO板块公司股价出现波动并逐渐下行，主要系市场对CXO行业未来景气度的担忧与疫情带动新冠相关业务需求的相互对冲，同时CXO行业也受到国际政治形势变化的影响，国际贸易环境变化对CXO行业也形成一部分冲击，板块内部分个股跑赢大盘与行业指数。 ➢ 行业基本面扎实，保持高景气度发展：18家CXO公司2021年收入总额为567.30亿元，同比增速42.71%；扣非归母净利润总额为 99.31亿元，同比增速为57.02%；2022Q1收入总额为196.29亿元，同比增速72.18%；扣非归母净利润总额为38.94亿元，同比增速102.44%；2022年CXO行业开局业绩亮眼，延续既往高景气度表现。 ➢ 外部驱动因素未变，看好CXO行业景气度。2021年全球医疗健康融资额同比增长约70%，达8194亿元；融资事件数为3591起， 同比增长64%。 2021年中国医疗健康产业融资总额达2192亿元人民币，同比增长39%，共有1362起融资事件，同比增长83%。 2022Q1全球和中国医疗健康融资额均出现回落，分别为1553.62亿元和392.11亿元，分别同比下降28.50%和33.73%；全球医疗健康产业融资事件数与去年同期基本持平，为856起。全球医药研发支出继续保持增长，创新药产品管线丰富，带动上游CXO需求。随着外包意愿更强的Biotech公司逐渐发力，将继续推动CXO行业的发展。我们认为全球创新药研发热情并未消退，制药企业对CXO的外包需求还将保持增长。 ➢ 从国内CXO企业先行指标看，企业扩张趋势显著：选取预收账款+合同负债、企业人员数量、在手订单金额以及固定资产和在建工程/固定资产等，我们发现国内CXO企业上述指标的2021年的高位提示企业仍处于快速扩张期，尤其是龙头公司扩张意愿明显。 在上游订单饱满的情况下，企业人员增长、产能增加配合运营效率和能力的提升使得中国CXO企业综合竞争力不断加强。 ➢ 长期看，我们认为未来全球最大的CXO公司大概率出现在中国。中国具备造就全球最大的CXO的天时、地利、人和的土壤，我们测算了中国CXO领域几大细分龙头，细分龙头标的将进一步提升市占率，届时药明康德和药明生物很可能成为全球最大的CXO公司。从发展阶段来看，中国CXO企业已进入产业链延伸、重资产投入、深度绑定客户需求的阶段，未来依靠对医药研发的理解、 合成发酵等技术的领先不断提升自身能力，中国特色CXO成长之路明晰。 ➢ 投资建议：综上所述，我们推荐（1）CXO一体化龙头药明康德、凯莱英、康龙化成，关注药明生物、泰格医药；（2）各细分领域优势企业九洲药业、昭衍新药、药石科技、博腾股份、和元生物，关注美迪西。 ➢ 风险提示：逆全球化风险；竞争加剧导致盈利能力下降；行业景气度受外部冲击导致不及预期。",
    "labels": [
      [
        "T0",
        "时间范围",
        2,
        7,
        "2021年"
      ],
      [
        "T1",
        "行业",
        9,
        12,
        "CXO"
      ],
      [
        "T2",
        "时间范围",
        24,
        34,
        "2021年1月至8月"
      ],
      [
        "T3",
        "行业",
        35,
        38,
        "CXO"
      ],
      [
        "T4",
        "时间范围",
        78,
        87,
        "2021年8月至今"
      ],
      [
        "T5",
        "行业",
        88,
        91,
        "CXO"
      ],
      [
        "T6",
        "行业",
        113,
        116,
        "CXO"
      ],
      [
        "T7",
        "行业",
        147,
        150,
        "CXO"
      ],
      [
        "T8",
        "行业",
        176,
        179,
        "CXO"
      ],
      [
        "T9",
        "时间范围",
        235,
        240,
        "2021年"
      ],
      [
        "T10",
        "时间范围",
        296,
        302,
        "2022Q1"
      ],
      [
        "T11",
        "时间范围",
        357,
        362,
        "2022年"
      ],
      [
        "T12",
        "行业",
        362,
        365,
        "CXO"
      ],
      [
        "T13",
        "业绩",
        369,
        371,
        "业绩"
      ],
      [
        "T14",
        "行业",
        399,
        402,
        "CXO"
      ],
      [
        "T15",
        "时间范围",
        408,
        413,
        "2021年"
      ],
      [
        "T16",
        "地点范围",
        413,
        415,
        "全球"
      ],
      [
        "T17",
        "行业",
        415,
        419,
        "医疗健康"
      ],
      [
        "T18",
        "投融资金额",
        419,
        422,
        "融资额"
      ],
      [
        "T19",
        "属性值",
        422,
        438,
        "同比增长约70%，达8194亿元"
      ],
      [
        "T20",
        "投融资事件数",
        439,
        444,
        "融资事件数"
      ],
      [
        "T21",
        "属性值",
        445,
        459,
        "3591起， 同比增长64%"
      ],
      [
        "T22",
        "时间范围",
        461,
        466,
        "2021年"
      ],
      [
        "T23",
        "地点范围",
        466,
        468,
        "中国"
      ],
      [
        "T24",
        "行业",
        468,
        472,
        "医疗健康"
      ],
      [
        "T25",
        "投融资金额",
        474,
        478,
        "融资总额"
      ],
      [
        "T26",
        "属性值",
        479,
        496,
        "2192亿元人民币，同比增长39%"
      ],
      [
        "T27",
        "属性值",
        499,
        504,
        "1362起"
      ],
      [
        "T28",
        "投融资事件数",
        504,
        508,
        "融资事件"
      ],
      [
        "T29",
        "时间范围",
        517,
        524,
        " 2022Q1"
      ],
      [
        "T30",
        "行业",
        529,
        533,
        "医疗健康"
      ],
      [
        "T31",
        "投融资金额",
        533,
        536,
        "融资额"
      ],
      [
        "T32",
        "属性值",
        545,
        554,
        "1553.62亿元"
      ],
      [
        "T33",
        "属性值",
        555,
        563,
        "392.11亿元"
      ],
      [
        "T34",
        "地点范围",
        524,
        526,
        "全球"
      ],
      [
        "T35",
        "地点范围",
        527,
        529,
        "中国"
      ],
      [
        "T36",
        "地点范围",
        584,
        586,
        "全球"
      ],
      [
        "T37",
        "行业",
        586,
        590,
        "医疗健康"
      ],
      [
        "T38",
        "投融资事件数",
        592,
        597,
        "融资事件数"
      ],
      [
        "T39",
        "地点范围",
        613,
        615,
        "全球"
      ],
      [
        "T40",
        "行业",
        615,
        617,
        "医药"
      ],
      [
        "T41",
        "研发费用",
        617,
        621,
        "研发支出"
      ],
      [
        "T42",
        "行业",
        642,
        645,
        "CXO"
      ],
      [
        "T43",
        "行业需求",
        645,
        647,
        "需求"
      ],
      [
        "T44",
        "行业公司",
        657,
        666,
        "Biotech公司"
      ],
      [
        "T45",
        "行业",
        676,
        679,
        "CXO"
      ],
      [
        "T46",
        "行业公司",
        703,
        707,
        "制药企业"
      ],
      [
        "T47",
        "行业",
        708,
        711,
        "CXO"
      ],
      [
        "T48",
        "行业需求",
        712,
        716,
        "外包需求"
      ],
      [
        "T49",
        "地点范围",
        727,
        729,
        "国内"
      ],
      [
        "T50",
        "行业公司",
        729,
        734,
        "CXO企业"
      ],
      [
        "T51",
        "合同负债",
        756,
        760,
        "合同负债"
      ],
      [
        "T52",
        "员工数量",
        761,
        767,
        "企业人员数量"
      ],
      [
        "T53",
        "在手订单",
        768,
        772,
        "在手订单"
      ],
      [
        "T54",
        "固定资产",
        776,
        780,
        "固定资产"
      ],
      [
        "T55",
        "地点范围",
        796,
        798,
        "国内"
      ],
      [
        "T56",
        "行业公司",
        798,
        803,
        "CXO企业"
      ],
      [
        "T57",
        "时间范围",
        808,
        813,
        "2021年"
      ],
      [
        "T58",
        "龙头企业",
        832,
        836,
        "龙头公司"
      ],
      [
        "T59",
        "在手订单",
        847,
        849,
        "订单"
      ],
      [
        "T60",
        "地点范围",
        881,
        883,
        "中国"
      ],
      [
        "T61",
        "行业公司",
        883,
        888,
        "CXO企业"
      ],
      [
        "T62",
        "行业公司",
        916,
        921,
        "CXO公司"
      ],
      [
        "T63",
        "行业",
        941,
        944,
        "CXO"
      ],
      [
        "T64",
        "行业",
        964,
        967,
        "CXO"
      ],
      [
        "T65",
        "龙头企业",
        973,
        975,
        "龙头"
      ],
      [
        "T66",
        "龙头企业",
        978,
        980,
        "龙头"
      ],
      [
        "T67",
        "市场份额",
        988,
        991,
        "市占率"
      ],
      [
        "T68",
        "公司",
        994,
        998,
        "药明康德"
      ],
      [
        "T69",
        "公司",
        999,
        1003,
        "药明生物"
      ],
      [
        "T70",
        "行业公司",
        1013,
        1018,
        "CXO公司"
      ],
      [
        "T71",
        "行业公司",
        1029,
        1034,
        "CXO企业"
      ],
      [
        "T72",
        "行业",
        1098,
        1101,
        "CXO"
      ],
      [
        "T73",
        "行业",
        1128,
        1131,
        "CXO"
      ],
      [
        "T74",
        "龙头企业",
        1134,
        1136,
        "龙头"
      ],
      [
        "T75",
        "公司",
        1136,
        1140,
        "药明康德"
      ],
      [
        "T76",
        "公司",
        1141,
        1144,
        "凯莱英"
      ],
      [
        "T77",
        "公司",
        1145,
        1149,
        "康龙化成"
      ],
      [
        "T78",
        "公司",
        1152,
        1156,
        "药明生物"
      ],
      [
        "T79",
        "公司",
        1157,
        1161,
        "泰格医药"
      ],
      [
        "T80",
        "公司",
        1174,
        1178,
        "九洲药业"
      ],
      [
        "T81",
        "公司",
        1179,
        1183,
        "昭衍新药"
      ],
      [
        "T82",
        "公司",
        1184,
        1188,
        "药石科技"
      ],
      [
        "T83",
        "公司",
        1189,
        1193,
        "博腾股份"
      ],
      [
        "T84",
        "公司",
        1194,
        1198,
        "和元生物"
      ],
      [
        "T85",
        "公司",
        1201,
        1204,
        "美迪西"
      ],
      [
        "T86",
        "行业公司",
        227,
        235,
        "18家CXO公司"
      ],
      [
        "T87",
        "属性值",
        245,
        253,
        "567.30亿元"
      ],
      [
        "T88",
        "属性值",
        258,
        264,
        "42.71%"
      ],
      [
        "T89",
        "属性值",
        276,
        283,
        "99.31亿元"
      ],
      [
        "T90",
        "属性值",
        289,
        295,
        "57.02%"
      ],
      [
        "T91",
        "属性值",
        307,
        315,
        "196.29亿元"
      ],
      [
        "T92",
        "属性值",
        320,
        326,
        "72.18%"
      ],
      [
        "T93",
        "属性值",
        337,
        344,
        "38.94亿元"
      ],
      [
        "T94",
        "属性值",
        349,
        356,
        "102.44%"
      ],
      [
        "T95",
        "属性值",
        371,
        373,
        "亮眼"
      ],
      [
        "T96",
        "属性值",
        509,
        516,
        "同比增长83%"
      ],
      [
        "T97",
        "属性值",
        539,
        541,
        "回落"
      ],
      [
        "T98",
        "属性值",
        625,
        627,
        "增长"
      ],
      [
        "T99",
        "属性值",
        602,
        606,
        "基本持平"
      ],
      [
        "T100",
        "属性值",
        608,
        612,
        "856起"
      ],
      [
        "T101",
        "时间范围",
        598,
        600,
        "去年"
      ],
      [
        "T102",
        "地点范围",
        689,
        691,
        "全球"
      ],
      [
        "T103",
        "行业",
        691,
        694,
        "创新药"
      ],
      [
        "T104",
        "属性值",
        720,
        722,
        "增长"
      ],
      [
        "T105",
        "地点范围",
        911,
        913,
        "全球"
      ],
      [
        "T106",
        "时间范围",
        909,
        911,
        "未来"
      ],
      [
        "T107",
        "地点范围",
        927,
        929,
        "中国"
      ],
      [
        "T108",
        "地点范围",
        930,
        932,
        "中国"
      ],
      [
        "T109",
        "地点范围",
        936,
        938,
        "全球"
      ],
      [
        "T110",
        "地点范围",
        962,
        964,
        "中国"
      ],
      [
        "T111",
        "地点范围",
        1008,
        1010,
        "全球"
      ],
      [
        "T112",
        "时间范围",
        1061,
        1063,
        "未来"
      ],
      [
        "T113",
        "地点范围",
        1094,
        1096,
        "中国"
      ],
      [
        "T114",
        "地点范围",
        1027,
        1029,
        "中国"
      ],
      [
        "T115",
        "营业收入",
        240,
        242,
        "收入"
      ],
      [
        "T116",
        "扣非净利润",
        265,
        272,
        "扣非归母净利润"
      ],
      [
        "T117",
        "营业收入",
        302,
        304,
        "收入"
      ],
      [
        "T118",
        "扣非净利润",
        327,
        334,
        "扣非归母净利润"
      ]
    ]
  },
  {
    "id": 1085,
    "text": "5月 27日，传奇生物宣布，美国 FDA已接受杨森（Janssen）公司为靶向 B细胞成熟抗原（BCMA）的 CAR-T疗法 ciltacabtagene autoleucel（cilta-cel） 提交的生物制品许可申请（BLA）。FDA同时授予其优先审评资格，预计在今年 11月 29日之前做出回复。 Cilta-cel是一种具有差异性结构的 CAR-T细胞疗法， 包含一个 4-1BB共刺激结构域和两个靶向 BCMA的抗体结构域，具有促进 CD8 阳性 T细胞扩增的能力。BCMA是一种在骨髓瘤细胞上高度表达的蛋白。2017 年 12月，杨森生物技术有限公司与传奇生物达成全球独家许可和合作协议，共同开发和商业化 cilta-cel。迄今为止的研究结果显示，cilta-cel在治疗经过多种前期疗法治疗的多发性骨髓瘤患者方面显示出巨大的前景。",
    "labels": [
      [
        "T0",
        "时间范围",
        0,
        6,
        "5月 27日"
      ],
      [
        "T1",
        "公司",
        7,
        11,
        "传奇生物"
      ],
      [
        "T2",
        "时间范围",
        135,
        147,
        "今年 11月 29日之前"
      ],
      [
        "T3",
        "时间范围",
        261,
        271,
        "2017 年 12月"
      ],
      [
        "T4",
        "公司",
        272,
        282,
        "杨森生物技术有限公司"
      ],
      [
        "T5",
        "公司",
        283,
        287,
        "传奇生物"
      ],
      [
        "T6",
        "地点范围",
        14,
        16,
        "美国"
      ],
      [
        "T7",
        "公司",
        23,
        34,
        "杨森（Janssen）"
      ],
      [
        "T8",
        "地点范围",
        289,
        291,
        "全球"
      ]
    ]
  },
  {
    "id": 1090,
    "text": "海外、国内双轮驱动下，中国CXO企业收入和利润增速远超行业平均增速，2021年创历史新高。根据弗若斯特沙利文的数据， 2017-2021年全球CR(D)MO市场规模年均复合增长率为11.4%，中国为26%。根据我们整理测算，2021年，19家中国CXO企业实现收入713亿元，同比增长46%；实现归母净利润175亿元，同比增长71%；2017-2021年，收入年均复合增长率为32.5%，利润为 56.5%，远超行业平均增速。",
    "labels": [
      [
        "T0",
        "时间范围",
        60,
        70,
        "2017-2021年"
      ],
      [
        "T1",
        "地点范围",
        70,
        72,
        "全球"
      ],
      [
        "T2",
        "行业",
        72,
        79,
        "CR(D)MO"
      ],
      [
        "T3",
        "市场规模",
        79,
        83,
        "市场规模"
      ],
      [
        "T4",
        "CAGR",
        83,
        90,
        "年均复合增长率"
      ],
      [
        "T5",
        "属性值",
        91,
        96,
        "11.4%"
      ],
      [
        "T6",
        "地点范围",
        97,
        99,
        "中国"
      ],
      [
        "T7",
        "属性值",
        100,
        103,
        "26%"
      ],
      [
        "T8",
        "时间范围",
        35,
        40,
        "2021年"
      ],
      [
        "T9",
        "地点范围",
        12,
        14,
        "中国"
      ],
      [
        "T10",
        "行业公司",
        14,
        19,
        "CXO企业"
      ],
      [
        "T11",
        "营业收入",
        19,
        21,
        "收入"
      ],
      [
        "T12",
        "利润",
        22,
        24,
        "利润"
      ],
      [
        "T13",
        "属性值",
        26,
        34,
        "远超行业平均增速"
      ],
      [
        "T14",
        "地点范围",
        1,
        3,
        "海外"
      ],
      [
        "T15",
        "地点范围",
        4,
        6,
        "国内"
      ],
      [
        "T16",
        "时间范围",
        113,
        118,
        "2021年"
      ],
      [
        "T17",
        "行业公司",
        119,
        129,
        "19家中国CXO企业"
      ],
      [
        "T18",
        "营业收入",
        131,
        133,
        "收入"
      ],
      [
        "T19",
        "属性值",
        133,
        138,
        "713亿元"
      ],
      [
        "T20",
        "属性值",
        143,
        146,
        "46%"
      ],
      [
        "T21",
        "归母净利润",
        149,
        154,
        "归母净利润"
      ],
      [
        "T22",
        "属性值",
        154,
        167,
        "175亿元，同比增长71%"
      ],
      [
        "T23",
        "时间范围",
        168,
        178,
        "2017-2021年"
      ],
      [
        "T24",
        "营业收入",
        179,
        181,
        "收入"
      ],
      [
        "T25",
        "CAGR",
        181,
        188,
        "年均复合增长率"
      ],
      [
        "T26",
        "属性值",
        189,
        194,
        "32.5%"
      ],
      [
        "T27",
        "属性值",
        199,
        204,
        "56.5%"
      ],
      [
        "T28",
        "利润",
        195,
        197,
        "利润"
      ],
      [
        "T29",
        "属性值",
        205,
        213,
        "远超行业平均增速"
      ]
    ]
  },
  {
    "id": 1091,
    "text": "公司员工持续增加， 2021年上半年公司员工总数达 7208人，同比增长 35.69%，实现人均创收 28.5 万元，人均创利（扣非归母）7.5万元。员工人数的高增长提升了公司承接项目的能力，随着受疫情影响的业务的进一步复苏，公司人效有望进一步上升。",
    "labels": [
      [
        "T0",
        "时间范围",
        10,
        18,
        "2021年上半年"
      ],
      [
        "T1",
        "员工数量",
        20,
        24,
        "员工总数"
      ],
      [
        "T2",
        "人均收入",
        46,
        50,
        "人均创收"
      ],
      [
        "T3",
        "人均利润",
        59,
        63,
        "人均创利"
      ]
    ]
  },
  {
    "id": 1096,
    "text": "默克完成收购生物制药CDMO公司Exelead，并计划投资逾5亿欧元提升技术能力。Exelead系一家生物制药 CDMO企业，专注于研发聚乙二醇化(PEGylated)产品和高端复杂的可注射制剂，包括基于脂质纳米颗粒 (LNP)的药物递送技术，这项技术是用于开发Covid-19 和其他诸多适应症mRNA疫苗及药物的关键。",
    "labels": [
      [
        "T0",
        "公司",
        1,
        3,
        "默克"
      ],
      [
        "T1",
        "行业公司",
        7,
        17,
        "生物制药CDMO公司"
      ],
      [
        "T2",
        "公司",
        17,
        24,
        "Exelead"
      ],
      [
        "T3",
        "公司",
        42,
        49,
        "Exelead"
      ],
      [
        "T4",
        "行业公司",
        52,
        63,
        "生物制药 CDMO企业"
      ]
    ]
  },
  {
    "id": 1097,
    "text": "通过 FCFF法及敏感性分析计算得到的公司合理估值在 5208~5996亿元，对应合理股价水平在 176~203元，对应 2022年 PE倍数 97~112X。",
    "labels": [
      [
        "T0",
        "时间范围",
        61,
        67,
        "2022年 "
      ],
      [
        "T1",
        "PE",
        67,
        69,
        "PE"
      ]
    ]
  },
  {
    "id": 1099,
    "text": " CDMO板块增长强劲：按公司业务进行拆分，CDMO以2018-2020年细分板块收入CAGR40.2%远超临床前CRO （34.5%）及临床CRO板块（18.8%）。结合各家企业近年在CDMO业务的资本投入及项目承接情况，我们认为 CDMO仍将是未来2-3年增速最为强劲的板块。",
    "labels": [
      [
        "T0",
        "行业",
        2,
        6,
        "CDMO"
      ],
      [
        "T1",
        "行业",
        23,
        27,
        "CDMO"
      ],
      [
        "T2",
        "时间范围",
        28,
        38,
        "2018-2020年"
      ],
      [
        "T3",
        "营业收入",
        42,
        44,
        "收入"
      ],
      [
        "T4",
        "CAGR",
        44,
        48,
        "CAGR"
      ],
      [
        "T5",
        "属性值",
        48,
        53,
        "40.2%"
      ],
      [
        "T6",
        "行业",
        55,
        61,
        "临床前CRO"
      ],
      [
        "T7",
        "属性值",
        63,
        68,
        "34.5%"
      ],
      [
        "T8",
        "行业",
        70,
        75,
        "临床CRO"
      ],
      [
        "T9",
        "属性值",
        78,
        83,
        "18.8%"
      ],
      [
        "T10",
        "时间范围",
        91,
        93,
        "近年"
      ],
      [
        "T11",
        "行业",
        94,
        98,
        "CDMO"
      ],
      [
        "T12",
        "CAPEX资本开支",
        101,
        105,
        "资本投入"
      ],
      [
        "T13",
        "行业",
        118,
        122,
        "CDMO"
      ],
      [
        "T14",
        "时间范围",
        125,
        131,
        "未来2-3年"
      ],
      [
        "T15",
        "属性值",
        8,
        12,
        "增长强劲"
      ]
    ]
  },
  {
    "id": 1100,
    "text": "基于上述测算的市场规模，我们按照保守、中性、积极三种情境下分析公司 2030 年达到的规模与利润。 保守假设：药明康德全球 CRO市占率提升至 10%， CDMO市占率提升至 3%。 2019年公司 CRO业务全球市占率仅 2.1%，CDMO业务全球市占率仅 0.7%， 但相比于 2016年 CRO市占率 1.3%，CDMO市占率 0.4%已经有显著提升。 我们预计随着公司业务规模持续扩张，全球市占率提升速度会不断加快，保守测算到 2030年 CRO和 CDMO全球市占率有望分别达到 10%和 3%。 保守测算下 2030年收入规模有望达到 1377亿元，经调整 Non-IFRS净利润达到 317亿元。基于以上假设测算，公司 2030年 CRO和 CDMO业务收入分别达到 1000亿元和 376亿元，2020~2030年 CAGR分别为 24.4%和 21.7%。 对应总收入体量达到 1377亿元（2020~2030年 CAGR为 23.6%），按照 23% 的经调整 Non-IFRS净利率计算， 2030年经调整 Non-IFRS净利润约为 317亿元（2020~2030年 CAGR为 24.4%）。",
    "labels": [
      [
        "T0",
        "市场规模",
        7,
        11,
        "市场规模"
      ],
      [
        "T1",
        "时间范围",
        34,
        40,
        "2030 年"
      ],
      [
        "T2",
        "公司",
        55,
        59,
        "药明康德"
      ],
      [
        "T3",
        "行业",
        62,
        65,
        "CRO"
      ],
      [
        "T4",
        "地点范围",
        59,
        61,
        "全球"
      ],
      [
        "T5",
        "市场份额",
        65,
        68,
        "市占率"
      ],
      [
        "T6",
        "属性值",
        72,
        75,
        "10%"
      ],
      [
        "T7",
        "行业",
        76,
        81,
        " CDMO"
      ],
      [
        "T8",
        "市场份额",
        81,
        84,
        "市占率"
      ],
      [
        "T9",
        "属性值",
        88,
        90,
        "3%"
      ],
      [
        "T10",
        "时间范围",
        92,
        97,
        "2019年"
      ],
      [
        "T11",
        "行业",
        100,
        103,
        "CRO"
      ],
      [
        "T12",
        "市场份额",
        107,
        110,
        "市占率"
      ],
      [
        "T13",
        "属性值",
        112,
        116,
        "2.1%"
      ],
      [
        "T14",
        "行业",
        117,
        121,
        "CDMO"
      ],
      [
        "T15",
        "地点范围",
        105,
        107,
        "全球"
      ],
      [
        "T16",
        "地点范围",
        123,
        125,
        "全球"
      ],
      [
        "T17",
        "市场份额",
        125,
        128,
        "市占率"
      ],
      [
        "T18",
        "属性值",
        130,
        134,
        "0.7%"
      ],
      [
        "T19",
        "时间范围",
        141,
        147,
        "2016年 "
      ],
      [
        "T20",
        "行业",
        147,
        150,
        "CRO"
      ],
      [
        "T21",
        "市场份额",
        150,
        153,
        "市占率"
      ],
      [
        "T22",
        "属性值",
        154,
        158,
        "1.3%"
      ],
      [
        "T23",
        "行业",
        159,
        163,
        "CDMO"
      ],
      [
        "T24",
        "市场份额",
        163,
        166,
        "市占率"
      ],
      [
        "T25",
        "属性值",
        167,
        171,
        "0.4%"
      ],
      [
        "T26",
        "市场份额",
        199,
        202,
        "市占率"
      ],
      [
        "T27",
        "时间范围",
        218,
        223,
        "2030年"
      ],
      [
        "T28",
        "行业",
        224,
        227,
        "CRO"
      ],
      [
        "T29",
        "行业",
        228,
        233,
        " CDMO"
      ],
      [
        "T30",
        "地点范围",
        233,
        235,
        "全球"
      ],
      [
        "T31",
        "市场份额",
        235,
        238,
        "市占率"
      ],
      [
        "T32",
        "属性值",
        245,
        248,
        "10%"
      ],
      [
        "T33",
        "属性值",
        249,
        252,
        " 3%"
      ],
      [
        "T34",
        "时间范围",
        259,
        265,
        " 2030年"
      ],
      [
        "T35",
        "属性值",
        274,
        280,
        "1377亿元"
      ],
      [
        "T36",
        "归母净利润",
        293,
        296,
        "净利润"
      ],
      [
        "T37",
        "属性值",
        299,
        304,
        "317亿元"
      ],
      [
        "T38",
        "时间范围",
        317,
        322,
        "2030年"
      ],
      [
        "T39",
        "行业",
        322,
        326,
        " CRO"
      ],
      [
        "T40",
        "行业",
        328,
        332,
        "CDMO"
      ],
      [
        "T41",
        "营业收入",
        334,
        336,
        "收入"
      ],
      [
        "T42",
        "属性值",
        341,
        347,
        "1000亿元"
      ],
      [
        "T43",
        "属性值",
        349,
        354,
        "376亿元"
      ],
      [
        "T44",
        "时间范围",
        355,
        365,
        "2020~2030年"
      ],
      [
        "T45",
        "CAGR",
        366,
        370,
        "CAGR"
      ],
      [
        "T46",
        "属性值",
        373,
        379,
        " 24.4%"
      ],
      [
        "T47",
        "属性值",
        380,
        386,
        " 21.7%"
      ],
      [
        "T48",
        "属性值",
        398,
        404,
        "1377亿元"
      ],
      [
        "T49",
        "时间范围",
        405,
        415,
        "2020~2030年"
      ],
      [
        "T50",
        "CAGR",
        415,
        420,
        " CAGR"
      ],
      [
        "T51",
        "属性值",
        422,
        427,
        "23.6%"
      ],
      [
        "T52",
        "时间范围",
        456,
        461,
        "2030年"
      ],
      [
        "T53",
        "属性值",
        476,
        484,
        "约为 317亿元"
      ],
      [
        "T54",
        "时间范围",
        485,
        496,
        "2020~2030年 "
      ],
      [
        "T55",
        "CAGR",
        496,
        500,
        "CAGR"
      ],
      [
        "T56",
        "属性值",
        502,
        507,
        "24.4%"
      ],
      [
        "T57",
        "市场规模",
        43,
        45,
        "规模"
      ],
      [
        "T58",
        "利润",
        46,
        48,
        "利润"
      ],
      [
        "T59",
        "假设情形",
        50,
        54,
        "保守假设"
      ],
      [
        "T60",
        "地点范围",
        197,
        199,
        "全球"
      ],
      [
        "T61",
        "假设情形",
        212,
        216,
        "保守测算"
      ],
      [
        "T62",
        "假设情形",
        254,
        258,
        "保守测算"
      ],
      [
        "T63",
        "营业收入",
        265,
        267,
        "收入"
      ],
      [
        "T64",
        "属性值",
        390,
        393,
        "总收入"
      ],
      [
        "T65",
        "属性值",
        461,
        476,
        "经调整 Non-IFRS净利润"
      ],
      [
        "T66",
        "属性值",
        202,
        211,
        "提升速度会不断加快"
      ]
    ]
  },
  {
    "id": 1112,
    "text": "口医药CXO行业由CRO、CDMO、CMO三个细分行业共同构成，医药CXO行业市场规模由大分子CDMO/CMO、小分子CDMO/CMO、CRO市场规模叠加组成（药物临床前、药物发现、临床外外包）多个口2013-2017年，中国医药CXO行业年复合增长率为10.3%，2017年市场规模1,041亿美元。2018年至2025年，年复合增长率11.3%，预计2025年市场规模2,440亿美元口在医药CXO行业中，大分子CDMO/CMO行业占比最少，每年以2%的速度增加，2025年预计大分子CDMO/CMO行业占比2.6%，临床前外包行业占比3.8%，发现外包行业占比8.5%，临床外包行业占比28%，小分子CDMO行业占比58%",
    "labels": [
      [
        "T0",
        "行业",
        1,
        6,
        "医药CXO"
      ],
      [
        "T1",
        "行业",
        9,
        12,
        "CRO"
      ],
      [
        "T2",
        "行业",
        13,
        17,
        "CDMO"
      ],
      [
        "T3",
        "行业",
        18,
        21,
        "CMO"
      ],
      [
        "T4",
        "行业",
        32,
        37,
        "医药CXO"
      ],
      [
        "T5",
        "市场规模",
        39,
        43,
        "市场规模"
      ],
      [
        "T6",
        "行业",
        44,
        55,
        "大分子CDMO/CMO"
      ],
      [
        "T7",
        "行业",
        56,
        67,
        "小分子CDMO/CMO"
      ],
      [
        "T8",
        "行业",
        68,
        71,
        "CRO"
      ],
      [
        "T9",
        "市场规模",
        71,
        75,
        "市场规模"
      ],
      [
        "T10",
        "时间范围",
        100,
        110,
        "2013-2017年"
      ],
      [
        "T11",
        "地点范围",
        111,
        113,
        "中国"
      ],
      [
        "T12",
        "行业",
        113,
        118,
        "医药CXO"
      ],
      [
        "T13",
        "属性值",
        127,
        132,
        "10.3%"
      ],
      [
        "T14",
        "时间范围",
        133,
        138,
        "2017年"
      ],
      [
        "T15",
        "市场规模",
        138,
        142,
        "市场规模"
      ],
      [
        "T16",
        "属性值",
        142,
        150,
        "1,041亿美元"
      ],
      [
        "T17",
        "时间范围",
        151,
        162,
        "2018年至2025年"
      ],
      [
        "T18",
        "CAGR",
        163,
        169,
        "年复合增长率"
      ],
      [
        "T19",
        "属性值",
        169,
        174,
        "11.3%"
      ],
      [
        "T20",
        "时间范围",
        177,
        182,
        "2025年"
      ],
      [
        "T21",
        "市场规模",
        182,
        186,
        "市场规模"
      ],
      [
        "T22",
        "属性值",
        186,
        194,
        "2,440亿美元"
      ],
      [
        "T23",
        "行业",
        196,
        201,
        "医药CXO"
      ],
      [
        "T24",
        "行业",
        205,
        216,
        "大分子CDMO/CMO"
      ],
      [
        "T25",
        "时间范围",
        234,
        239,
        "2025年"
      ],
      [
        "T26",
        "行业",
        241,
        252,
        "大分子CDMO/CMO"
      ],
      [
        "T27",
        "行业",
        261,
        266,
        "临床前外包"
      ],
      [
        "T28",
        "行业",
        275,
        279,
        "发现外包"
      ],
      [
        "T29",
        "行业",
        288,
        294,
        "临床外包行业"
      ],
      [
        "T30",
        "行业",
        300,
        307,
        "小分子CDMO"
      ],
      [
        "T31",
        "行业",
        80,
        85,
        "药物临床前"
      ],
      [
        "T32",
        "行业",
        86,
        90,
        "药物发现"
      ],
      [
        "T33",
        "行业",
        91,
        96,
        "临床外外包"
      ],
      [
        "T34",
        "属性值",
        256,
        260,
        "2.6%"
      ],
      [
        "T35",
        "属性值",
        270,
        274,
        "3.8%"
      ],
      [
        "T36",
        "属性值",
        283,
        287,
        "8.5%"
      ],
      [
        "T37",
        "属性值",
        296,
        299,
        "28%"
      ],
      [
        "T38",
        "属性值",
        311,
        314,
        "58%"
      ],
      [
        "T39",
        "属性值",
        220,
        222,
        "最少"
      ],
      [
        "T40",
        "CAGR",
        120,
        126,
        "年复合增长率"
      ]
    ]
  },
  {
    "id": 1121,
    "text": " 客户和业务拓展驱动高增长。1）订单类型：商业化阶段收入增速35.58%，占比52.63%，技术服务收入增速31.61%，临床阶段收入增速稍慢，达到17.82%；2）客户层面：国内客户收入快速增长达到69.05%，收入占比提高到11.77%；海外中小客户收入增速30.22%，收入占比22.19%，海外大客户收入稳健增长，收入占比仍有66.02%；3）业务层面：新业务包括化学大分子、制剂、生物酶、 临床研究服务等，收入2.18亿，增长91.74%，收入占比6.92%。",
    "labels": [
      [
        "T0",
        "营收占比",
        226,
        230,
        "收入占比"
      ],
      [
        "T1",
        "营业收入",
        209,
        211,
        "收入"
      ],
      [
        "T2",
        "行业",
        187,
        192,
        "化学大分子"
      ],
      [
        "T3",
        "行业",
        193,
        195,
        "制剂"
      ],
      [
        "T4",
        "行业",
        196,
        199,
        "生物酶"
      ],
      [
        "T5",
        "行业",
        201,
        205,
        "临床研究"
      ],
      [
        "T6",
        "收入增速",
        27,
        31,
        "收入增速"
      ],
      [
        "T7",
        "收入增速",
        51,
        55,
        "收入增速"
      ],
      [
        "T8",
        "收入增速",
        66,
        70,
        "收入增速"
      ],
      [
        "T9",
        "收入增速",
        93,
        97,
        "收入快速"
      ],
      [
        "T10",
        "营收占比",
        108,
        112,
        "收入占比"
      ],
      [
        "T11",
        "收入增速",
        128,
        132,
        "收入增速"
      ],
      [
        "T12",
        "营收占比",
        139,
        143,
        "收入占比"
      ],
      [
        "T13",
        "营业收入",
        155,
        157,
        "收入"
      ],
      [
        "T14",
        "营收占比",
        162,
        166,
        "收入占比"
      ],
      [
        "T15",
        "地点范围",
        122,
        124,
        "海外"
      ],
      [
        "T16",
        "地点范围",
        150,
        152,
        "海外"
      ]
    ]
  },
  {
    "id": 1127,
    "text": "重点推荐业绩有望进入新一轮加速期的CDMO：1）进入漏斗效应兑现期 CDMO龙头药明康德和凯莱英。2）能力持续搭建，盈利能力有望持续提升的 CDMO：康龙化成（CMC向CDMO拓展）、博腾股份（CRO向CMO延伸）、 九洲药业（CDMO占比持续提升）、药石科技（由CRO向CDMO延伸）等。 临床CRO：处于国际化能力跃迁的临床CRO龙头泰格医药。 临床前CRO：受益中国市场红利以及更高盈利能力业务占比提升：药明康德 （安评和生物分析业务）、康龙化成（生物科学业务）、昭衍新药（安评）、美迪西、方达控股等。",
    "labels": [
      [
        "T0",
        "业绩",
        4,
        6,
        "业绩"
      ],
      [
        "T1",
        "行业",
        17,
        21,
        "CDMO"
      ],
      [
        "T2",
        "行业",
        34,
        38,
        "CDMO"
      ],
      [
        "T3",
        "龙头企业",
        38,
        40,
        "龙头"
      ],
      [
        "T4",
        "公司",
        40,
        44,
        "药明康德"
      ],
      [
        "T5",
        "公司",
        45,
        48,
        "凯莱英"
      ],
      [
        "T6",
        "行业",
        70,
        74,
        "CDMO"
      ],
      [
        "T7",
        "公司",
        75,
        79,
        "康龙化成"
      ],
      [
        "T8",
        "公司",
        92,
        96,
        "博腾股份"
      ],
      [
        "T9",
        "公司",
        109,
        113,
        "九洲药业"
      ],
      [
        "T10",
        "公司",
        126,
        130,
        "药石科技"
      ],
      [
        "T11",
        "行业",
        132,
        135,
        "CRO"
      ],
      [
        "T12",
        "行业",
        136,
        140,
        "CDMO"
      ],
      [
        "T13",
        "行业",
        97,
        100,
        "CRO"
      ],
      [
        "T14",
        "行业",
        101,
        104,
        "CMO"
      ],
      [
        "T15",
        "行业",
        80,
        83,
        "CMC"
      ],
      [
        "T16",
        "行业",
        84,
        88,
        "CDMO"
      ],
      [
        "T17",
        "行业",
        114,
        118,
        "CDMO"
      ],
      [
        "T18",
        "行业",
        146,
        151,
        "临床CRO"
      ],
      [
        "T19",
        "行业",
        162,
        167,
        "临床CRO"
      ],
      [
        "T20",
        "龙头企业",
        167,
        169,
        "龙头"
      ],
      [
        "T21",
        "公司",
        169,
        173,
        "泰格医药"
      ],
      [
        "T22",
        "行业",
        175,
        181,
        "临床前CRO"
      ],
      [
        "T23",
        "公司",
        205,
        210,
        "药明康德 "
      ],
      [
        "T24",
        "公司",
        222,
        226,
        "康龙化成"
      ],
      [
        "T25",
        "公司",
        235,
        239,
        "昭衍新药"
      ],
      [
        "T26",
        "公司",
        244,
        247,
        "美迪西"
      ],
      [
        "T27",
        "公司",
        248,
        252,
        "方达控股"
      ],
      [
        "T28",
        "行业",
        211,
        213,
        "安评"
      ],
      [
        "T29",
        "行业",
        214,
        218,
        "生物分析"
      ],
      [
        "T30",
        "行业",
        227,
        231,
        "生物科学"
      ],
      [
        "T31",
        "行业",
        240,
        242,
        "安评"
      ],
      [
        "T32",
        "属性值",
        10,
        16,
        "新一轮加速期"
      ]
    ]
  },
  {
    "id": 1130,
    "text": "整体来看，医药行业研发投入仍将持续加大、对研发效率的要求持续提升、外包渗透率持续提高的长期逻辑并未发生改变。新药研发竞争格局有望向头部集中，研发型企业的立项、布局更加多元、更加前瞻。“去伪存真”之后，创新药行业将有更多“真创新”企业在 CXO的帮助下加速对海外医药龙头的追赶。",
    "labels": [
      [
        "T0",
        "行业",
        5,
        7,
        "医药"
      ],
      [
        "T1",
        "研发费用",
        9,
        13,
        "研发投入"
      ],
      [
        "T2",
        "外包率",
        33,
        38,
        "外包渗透率"
      ],
      [
        "T3",
        "属性值",
        38,
        42,
        "持续提高"
      ],
      [
        "T4",
        "竞争格局",
        58,
        62,
        "竞争格局"
      ],
      [
        "T5",
        "行业",
        100,
        103,
        "创新药"
      ],
      [
        "T6",
        "行业",
        118,
        121,
        "CXO"
      ],
      [
        "T7",
        "地点范围",
        128,
        130,
        "海外"
      ],
      [
        "T8",
        "行业",
        130,
        132,
        "医药"
      ],
      [
        "T9",
        "龙头企业",
        132,
        134,
        "龙头"
      ],
      [
        "T10",
        "属性值",
        15,
        19,
        "持续加大"
      ],
      [
        "T11",
        "行业",
        54,
        58,
        "新药研发"
      ],
      [
        "T12",
        "属性值",
        64,
        69,
        "向头部集中"
      ]
    ]
  },
  {
    "id": 1133,
    "text": "1.6 医药制造业数据2022年明显回落 ➢ 国家统计局规模以上医药制造业数据：2022年2月我国医药制造业实现营业收入和利润总额分别为4295.1亿元（+2.3%），683.0 亿元（-17.6%），可以看到医药制造业增速有所放缓，利润总额出现明显下降。 ➢ 根据医药魔方的样本医院药品数据，2021年整体从疫情中恢复，2021全年样本医院用药金额达2617.2亿元，同比增长8.0%，基本恢复到疫情前水平；2021Q4再次受到国内疫情多点爆发影响，样本医院用药金额达615.4亿元，同比下降11.3%。",
    "labels": [
      [
        "T0",
        "时间范围",
        11,
        16,
        "2022年"
      ],
      [
        "T1",
        "时间范围",
        40,
        47,
        "2022年2月"
      ],
      [
        "T2",
        "地点范围",
        47,
        49,
        "我国"
      ],
      [
        "T3",
        "营业收入",
        56,
        60,
        "营业收入"
      ],
      [
        "T4",
        "利润",
        61,
        63,
        "利润"
      ],
      [
        "T5",
        "属性值",
        68,
        76,
        "4295.1亿元"
      ],
      [
        "T6",
        "属性值",
        77,
        82,
        "+2.3%"
      ],
      [
        "T7",
        "属性值",
        84,
        92,
        "683.0 亿元"
      ],
      [
        "T8",
        "属性值",
        93,
        99,
        "-17.6%"
      ],
      [
        "T9",
        "时间范围",
        147,
        152,
        "2021年"
      ],
      [
        "T10",
        "时间范围",
        161,
        167,
        "2021全年"
      ],
      [
        "T11",
        "时间范围",
        205,
        211,
        "2021Q4"
      ],
      [
        "T12",
        "行业",
        4,
        9,
        "医药制造业"
      ],
      [
        "T13",
        "行业",
        32,
        37,
        "医药制造业"
      ],
      [
        "T14",
        "行业",
        49,
        54,
        "医药制造业"
      ],
      [
        "T15",
        "行业",
        105,
        110,
        "医药制造业"
      ],
      [
        "T16",
        "利润",
        117,
        119,
        "利润"
      ],
      [
        "T17",
        "属性值",
        123,
        127,
        "明显下降"
      ]
    ]
  },
  {
    "id": 1139,
    "text": "上海：5月 26日，上海市公布了 2021年第四批一致性评价过评仿制药挂网采购的通知，主要包括山东润泽制药的注射用头孢曲松钠、华北制药的注射用哌拉西林钠他唑巴坦钠等 80个品规。 浙江：5月 26日，浙江省公布了第十八批一致性评价过评仿制药和 1类新药挂网采购的通知。其中，一致性评价过评品种主要包括河北仁合益康药业的氨溴特罗口服溶液、北京天衡药物研究院南阳天衡制药厂的奥氮平片等 76个品规；优先挂网采购产品包括广东百科制药的阿托伐他汀钙分散片、广东嘉博制药有限公司的丙泊酚中/长链脂肪乳注射液等 30个品规； 1类新药挂网采购产品包括北京诺诚健华的奥布替尼片等 5个品规。",
    "labels": [
      [
        "T0",
        "公司",
        47,
        53,
        "山东润泽制药"
      ],
      [
        "T1",
        "公司",
        63,
        67,
        "华北制药"
      ],
      [
        "T2",
        "公司",
        150,
        158,
        "河北仁合益康药业"
      ],
      [
        "T3",
        "公司",
        168,
        177,
        "北京天衡药物研究院"
      ],
      [
        "T4",
        "公司",
        177,
        184,
        "南阳天衡制药厂"
      ],
      [
        "T5",
        "公司",
        207,
        213,
        "广东百科制药"
      ],
      [
        "T6",
        "公司",
        224,
        234,
        "广东嘉博制药有限公司"
      ],
      [
        "T7",
        "公司",
        269,
        275,
        "北京诺诚健华"
      ],
      [
        "T8",
        "地点范围",
        0,
        2,
        "上海"
      ],
      [
        "T9",
        "时间范围",
        3,
        9,
        "5月 26日"
      ],
      [
        "T10",
        "地点范围",
        10,
        13,
        "上海市"
      ],
      [
        "T11",
        "时间范围",
        17,
        22,
        "2021年"
      ],
      [
        "T12",
        "地点范围",
        90,
        92,
        "浙江"
      ],
      [
        "T13",
        "时间范围",
        93,
        99,
        "5月 26日"
      ],
      [
        "T14",
        "地点范围",
        100,
        103,
        "浙江省"
      ]
    ]
  },
  {
    "id": 1145,
    "text": "我们参考弗若斯特沙利文相关全球CRO市场规模同比增长数据以及全球医疗健康投融资金额（这个是市场上跟踪CXO订单景气度认可度较高的前瞻指标）同比增速还有 top14MNC研发投入同比增速数据，可以看到全球CRO市场规模同比增速与top14MNC 研发投入增速变化趋势一致性较强，跟全球医疗健康投融资金额同比增速趋势一致性较弱。我们认为这主要是因为top14MNC研发投入占全球生物医药研发投入比例较高导致 （2020年top14MNC研发投入1200亿美元，2020年全球医药研发投入2048亿美元，top14 MNC研发投入占比58.59%）。",
    "labels": [
      [
        "T0",
        "地点范围",
        13,
        15,
        "全球"
      ],
      [
        "T1",
        "行业",
        15,
        18,
        "CRO"
      ],
      [
        "T2",
        "市场规模",
        18,
        22,
        "市场规模"
      ],
      [
        "T3",
        "地点范围",
        30,
        32,
        "全球"
      ],
      [
        "T4",
        "行业",
        32,
        36,
        "医疗健康"
      ],
      [
        "T5",
        "投融资金额",
        36,
        41,
        "投融资金额"
      ],
      [
        "T6",
        "研发费用",
        84,
        88,
        "研发投入"
      ],
      [
        "T7",
        "地点范围",
        99,
        101,
        "全球"
      ],
      [
        "T8",
        "行业",
        101,
        104,
        "CRO"
      ],
      [
        "T9",
        "市场规模",
        104,
        108,
        "市场规模"
      ],
      [
        "T10",
        "研发费用",
        122,
        126,
        "研发投入"
      ],
      [
        "T11",
        "地点范围",
        139,
        141,
        "全球"
      ],
      [
        "T12",
        "行业",
        141,
        145,
        "医疗健康"
      ],
      [
        "T13",
        "投融资金额",
        145,
        150,
        "投融资金额"
      ],
      [
        "T14",
        "研发费用",
        180,
        184,
        "研发投入"
      ],
      [
        "T15",
        "地点范围",
        185,
        187,
        "全球"
      ],
      [
        "T16",
        "行业",
        187,
        191,
        "生物医药"
      ],
      [
        "T17",
        "研发费用",
        191,
        195,
        "研发投入"
      ],
      [
        "T18",
        "时间范围",
        228,
        233,
        "2020年"
      ],
      [
        "T19",
        "地点范围",
        233,
        235,
        "全球"
      ],
      [
        "T20",
        "行业",
        235,
        237,
        "医药"
      ],
      [
        "T21",
        "研发费用",
        237,
        241,
        "研发投入"
      ],
      [
        "T22",
        "属性值",
        241,
        248,
        "2048亿美元"
      ],
      [
        "T23",
        "行业",
        50,
        53,
        "CXO"
      ],
      [
        "T24",
        "时间范围",
        203,
        208,
        "2020年"
      ],
      [
        "T25",
        "行业公司",
        208,
        216,
        "top14MNC"
      ],
      [
        "T26",
        "研发费用",
        216,
        220,
        "研发投入"
      ],
      [
        "T27",
        "属性值",
        220,
        227,
        "1200亿美元"
      ],
      [
        "T28",
        "行业公司",
        172,
        180,
        "top14MNC"
      ],
      [
        "T29",
        "行业公司",
        113,
        122,
        "top14MNC "
      ],
      [
        "T30",
        "行业公司",
        76,
        84,
        "top14MNC"
      ],
      [
        "T31",
        "行业公司",
        249,
        258,
        "top14 MNC"
      ],
      [
        "T32",
        "属性值",
        264,
        270,
        "58.59%"
      ],
      [
        "T33",
        "研发费用率",
        258,
        264,
        "研发投入占比"
      ]
    ]
  },
  {
    "id": 1149,
    "text": "生物创新药是未来新药研发的主要方向。随着生物科技的快速发展及研发投入的不断增加，生物药已成为制药行业近年来发展最快的子行业之一。依据 EvaluatePharma数据，全球生物药市场销售额已从 2012 年的 1,490亿美元增加到 2019年的 2,660亿美元，年均复合增长率为 8.63%，远高于传统药物的 0.82%，占全球药品销售额的比重也从 2012年的 20%快速提升到 2018年的 29%。此外，2020年全球销售额前二十的药品中，生物药就占据 13席。 PD-1抑制剂帕博利珠单抗（Pembrolizumab， Keytruda）和纳武单抗（Nivolumab， Opdivo）自 2014年在国外上市以来短短几年已经分别成为年销售 143.80亿和 78.10亿美元的大品种。生物创新药将是未来新药研发的主要方向，生物制药产业是目前医药产业中发展最快、活力最强、技术壁垒最高的领域之一。",
    "labels": [
      [
        "T0",
        "地点范围",
        84,
        86,
        "全球"
      ],
      [
        "T1",
        "行业",
        86,
        89,
        "生物药"
      ],
      [
        "T2",
        "行业",
        0,
        5,
        "生物创新药"
      ],
      [
        "T3",
        "时间范围",
        6,
        8,
        "未来"
      ],
      [
        "T4",
        "行业",
        8,
        12,
        "新药研发"
      ],
      [
        "T5",
        "行业",
        20,
        24,
        "生物科技"
      ],
      [
        "T6",
        "研发费用",
        30,
        34,
        "研发投入"
      ],
      [
        "T7",
        "属性值",
        35,
        39,
        "不断增加"
      ],
      [
        "T8",
        "行业",
        40,
        43,
        "生物药"
      ],
      [
        "T9",
        "行业",
        46,
        48,
        "制药"
      ],
      [
        "T10",
        "时间范围",
        50,
        53,
        "近年来"
      ],
      [
        "T11",
        "时间范围",
        97,
        103,
        "2012 年"
      ],
      [
        "T12",
        "时间范围",
        117,
        122,
        "2019年"
      ],
      [
        "T13",
        "CAGR",
        133,
        140,
        "年均复合增长率"
      ],
      [
        "T14",
        "属性值",
        142,
        147,
        "8.63%"
      ],
      [
        "T15",
        "行业",
        151,
        155,
        "传统药物"
      ],
      [
        "T16",
        "属性值",
        157,
        162,
        "0.82%"
      ],
      [
        "T17",
        "地点范围",
        164,
        166,
        "全球"
      ],
      [
        "T18",
        "行业",
        166,
        168,
        "药品"
      ],
      [
        "T19",
        "时间范围",
        177,
        182,
        "2012年"
      ],
      [
        "T20",
        "时间范围",
        193,
        198,
        "2018年"
      ],
      [
        "T21",
        "时间范围",
        207,
        212,
        "2020年"
      ],
      [
        "T22",
        "地点范围",
        212,
        214,
        "全球"
      ],
      [
        "T23",
        "时间范围",
        301,
        306,
        "2014年"
      ],
      [
        "T24",
        "地点范围",
        307,
        309,
        "国外"
      ],
      [
        "T25",
        "行业",
        349,
        354,
        "生物创新药"
      ],
      [
        "T26",
        "时间范围",
        356,
        358,
        "未来"
      ],
      [
        "T27",
        "行业",
        358,
        362,
        "新药研发"
      ],
      [
        "T28",
        "行业",
        368,
        372,
        "生物制药"
      ],
      [
        "T29",
        "时间范围",
        375,
        377,
        "目前"
      ],
      [
        "T30",
        "行业",
        377,
        379,
        "医药"
      ],
      [
        "T31",
        "属性值",
        91,
        94,
        "销售额"
      ]
    ]
  },
  {
    "id": 1150,
    "text": "研发投入持续加大，研发费用率持续提升。CXO公司越来越重视研发，研发费用提升显著，2020年研发费用率接近5%，预计未来仍将继续提提升。",
    "labels": [
      [
        "T0",
        "行业公司",
        19,
        24,
        "CXO公司"
      ],
      [
        "T1",
        "研发费用",
        32,
        36,
        "研发费用"
      ],
      [
        "T2",
        "属性值",
        36,
        40,
        "提升显著"
      ],
      [
        "T3",
        "时间范围",
        41,
        46,
        "2020年"
      ],
      [
        "T4",
        "属性值",
        51,
        55,
        "接近5%"
      ],
      [
        "T5",
        "研发费用率",
        46,
        51,
        "研发费用率"
      ],
      [
        "T6",
        "研发费用",
        0,
        4,
        "研发投入"
      ],
      [
        "T7",
        "属性值",
        4,
        8,
        "持续加大"
      ],
      [
        "T8",
        "研发费用率",
        9,
        14,
        "研发费用率"
      ],
      [
        "T9",
        "属性值",
        14,
        18,
        "持续提升"
      ],
      [
        "T10",
        "时间范围",
        58,
        60,
        "未来"
      ],
      [
        "T11",
        "属性值",
        65,
        67,
        "提升"
      ]
    ]
  },
  {
    "id": 1157,
    "text": "【长春高新】公司向特定对象发行 270.80万的可转换债券于 2021年 4月 13日以 86.35元/张价格解锁。",
    "labels": [
      [
        "T0",
        "公司",
        1,
        5,
        "长春高新"
      ],
      [
        "T1",
        "时间范围",
        30,
        43,
        " 2021年 4月 13日"
      ]
    ]
  },
  {
    "id": 1169,
    "text": "行业整体发展良好，传统仿制药产业持续承压，创新仍是发展的主旋律。全球及国内创新药研发火热，新发现、新技术、新领域不断涌现，加速产业及产业链快速发展，我们挖掘出以下赛道供投资者参考，建议积极关注产业政策边际变化，相关企业产品竞争格局的变化以及研发管线的价值。",
    "labels": [
      [
        "T0",
        "行业",
        9,
        14,
        "传统仿制药"
      ],
      [
        "T1",
        "地点范围",
        32,
        34,
        "全球"
      ],
      [
        "T2",
        "地点范围",
        35,
        37,
        "国内"
      ],
      [
        "T3",
        "行业",
        37,
        40,
        "创新药"
      ],
      [
        "T4",
        "竞争格局",
        111,
        115,
        "竞争格局"
      ]
    ]
  },
  {
    "id": 1179,
    "text": "千亿美元市场。 全球 CRO行业经过 40余年的发展，已经与药企形成战略合作或定制化合作关系，深度参与新药研发过程。目前，政策推动药物创新、人口老龄化、新兴技术的涌现持续推动新药研发投入上升，据 Frost & Sullivan预测，全球制药行业研发投入将在 2024年达到 2270 亿美元，中国制药研发投入将在 2024年达到 476亿美元。但在新药研发过程中，存在周期长、失败率高、投资回报比下降、 “专利悬崖” 、监管严格等多种不利因素，为降本增效，药企对 CRO的需求旺盛，驱动 CRO 行业蓬勃发展，据 Frost & Sullivan预测，2024 年全球 CRO 行业市场规模可达 960亿美元，有望成长为全球千亿美元规模的市场。",
    "labels": [
      [
        "T0",
        "地点范围",
        117,
        119,
        "全球"
      ],
      [
        "T1",
        "行业",
        119,
        121,
        "制药"
      ],
      [
        "T2",
        "研发费用",
        123,
        127,
        "研发投入"
      ],
      [
        "T3",
        "时间范围",
        130,
        135,
        "2024年"
      ],
      [
        "T4",
        "属性值",
        138,
        146,
        "2270 亿美元"
      ],
      [
        "T5",
        "地点范围",
        147,
        149,
        "中国"
      ],
      [
        "T6",
        "行业",
        149,
        151,
        "制药"
      ],
      [
        "T7",
        "研发费用",
        151,
        155,
        "研发投入"
      ],
      [
        "T8",
        "时间范围",
        158,
        163,
        "2024年"
      ],
      [
        "T9",
        "属性值",
        166,
        172,
        "476亿美元"
      ],
      [
        "T10",
        "行业公司",
        229,
        231,
        "药企"
      ],
      [
        "T11",
        "行业",
        233,
        236,
        "CRO"
      ],
      [
        "T12",
        "行业需求",
        237,
        239,
        "需求"
      ],
      [
        "T13",
        "属性值",
        239,
        241,
        "旺盛"
      ],
      [
        "T14",
        "行业",
        245,
        248,
        "CRO"
      ],
      [
        "T15",
        "时间范围",
        277,
        283,
        "2024 年"
      ],
      [
        "T16",
        "地点范围",
        283,
        285,
        "全球"
      ],
      [
        "T17",
        "行业",
        286,
        289,
        "CRO"
      ],
      [
        "T18",
        "市场规模",
        292,
        296,
        "市场规模"
      ],
      [
        "T19",
        "属性值",
        299,
        305,
        "960亿美元"
      ],
      [
        "T20",
        "地点范围",
        311,
        313,
        "全球"
      ],
      [
        "T21",
        "地点范围",
        8,
        10,
        "全球"
      ],
      [
        "T22",
        "行业",
        11,
        14,
        "CRO"
      ],
      [
        "T23",
        "行业公司",
        30,
        32,
        "药企"
      ],
      [
        "T24",
        "时间范围",
        58,
        60,
        "目前"
      ],
      [
        "T25",
        "研发费用",
        89,
        93,
        "研发投入"
      ],
      [
        "T26",
        "行业",
        87,
        89,
        "新药"
      ],
      [
        "T27",
        "属性值",
        93,
        95,
        "上升"
      ]
    ]
  },
  {
    "id": 1181,
    "text": "CRO是中国医药产业研发创新的实践者与助推者，CDMO是中国医药先进制造产业升级的标杆。前者从起步开始就面向全球市场，通过为大型药企提供研发外包服务，不断提升研发经验、拓宽能力边界，也为国内原创新药提供了成长的沃土。后者从最初的大宗与特色原料药，到承接专利原料药 CMO订单， 再到技术赋能的 CDMO模式，在不断的转型中实现了中国医药产业先进制造能力的升级。而药明康德无疑在这些成长与转型的进程中走在前列。 诚然当前国内 CRO/CDMO（简称 CXO）公司的估值已然处于历史高位，但这背后亦有其高估值的合理性。我们能够看到创新药研发需求的高景气度，也能够看到 CXO公司切实提升了研发过程的效率，降低了成本，而 CXO的“卖水人”的商业模式更是为行业注入了更高的成长确定性。高景气度带来的高成长性与高确定性，成为了高估值背后的基础。 面向未来，本土 CXO公司还有极高的天花板。目前作为公司的 CRO和 CDMO 业务在全球市场的份额预计仅有 2.4%和 0.9%，而全球一线龙头目前在两大市场的份额已经达到约 18%和 6%。在中国医药产业开始全面国际化的时代，我们有理由相信，作为国内 CXO的龙头代表，公司未来有望对标一线龙头的全球市场份额。 厚积薄发廿余载，药明康德已然从一家创业企业成长为覆盖药物研发/生产全流程的 CXO航母旗舰。一站式的研发平台为大型药企带来了优质高效的服务，也为广大 Biotech提供了参与创新药研发的机会，更为新药更快上市、病人更早得到治疗提供了希望。 “让天下没有难做的药，难治的病”，这是药明康德的愿景，也是医药人共同的期盼。",
    "labels": [
      [
        "T0",
        "行业",
        0,
        3,
        "CRO"
      ],
      [
        "T1",
        "地点范围",
        4,
        6,
        "中国"
      ],
      [
        "T2",
        "行业",
        6,
        8,
        "医药"
      ],
      [
        "T3",
        "行业",
        23,
        27,
        "CDMO"
      ],
      [
        "T4",
        "地点范围",
        28,
        30,
        "中国"
      ],
      [
        "T5",
        "地点范围",
        93,
        95,
        "国内"
      ],
      [
        "T6",
        "行业",
        128,
        135,
        "原料药 CMO"
      ],
      [
        "T7",
        "地点范围",
        164,
        166,
        "中国"
      ],
      [
        "T8",
        "行业",
        166,
        168,
        "医药"
      ],
      [
        "T9",
        "公司",
        181,
        185,
        "药明康德"
      ],
      [
        "T10",
        "地点范围",
        209,
        211,
        "国内"
      ],
      [
        "T11",
        "行业",
        211,
        220,
        " CRO/CDMO"
      ],
      [
        "T12",
        "行业",
        223,
        227,
        " CXO"
      ],
      [
        "T13",
        "行业需求",
        268,
        270,
        "需求"
      ],
      [
        "T14",
        "属性值",
        271,
        275,
        "高景气度"
      ],
      [
        "T15",
        "行业公司",
        282,
        287,
        "CXO公司"
      ],
      [
        "T16",
        "行业",
        307,
        311,
        " CXO"
      ],
      [
        "T17",
        "行业公司",
        377,
        382,
        "CXO公司"
      ],
      [
        "T18",
        "行业",
        398,
        402,
        " CRO"
      ],
      [
        "T19",
        "行业",
        404,
        409,
        "CDMO "
      ],
      [
        "T20",
        "地点范围",
        412,
        414,
        "全球"
      ],
      [
        "T21",
        "龙头企业",
        440,
        442,
        "龙头"
      ],
      [
        "T22",
        "属性值",
        423,
        428,
        " 2.4%"
      ],
      [
        "T23",
        "属性值",
        429,
        434,
        " 0.9%"
      ],
      [
        "T24",
        "地点范围",
        467,
        469,
        "中国"
      ],
      [
        "T25",
        "行业",
        469,
        471,
        "医药"
      ],
      [
        "T26",
        "地点范围",
        494,
        497,
        "国内 "
      ],
      [
        "T27",
        "行业",
        497,
        500,
        "CXO"
      ],
      [
        "T28",
        "龙头企业",
        501,
        503,
        "龙头"
      ],
      [
        "T29",
        "市场份额",
        521,
        525,
        "市场份额"
      ],
      [
        "T30",
        "公司",
        535,
        539,
        "药明康德"
      ],
      [
        "T31",
        "行业",
        565,
        568,
        "CXO"
      ],
      [
        "T32",
        "行业",
        602,
        609,
        "Biotech"
      ],
      [
        "T33",
        "公司",
        666,
        670,
        "药明康德"
      ],
      [
        "T34",
        "行业",
        30,
        36,
        "医药先进制造"
      ],
      [
        "T35",
        "地点范围",
        54,
        56,
        "全球"
      ],
      [
        "T36",
        "行业公司",
        64,
        66,
        "药企"
      ],
      [
        "T37",
        "行业",
        263,
        266,
        "创新药"
      ],
      [
        "T38",
        "属性值",
        312,
        317,
        "“卖水人”"
      ],
      [
        "T39",
        "时间范围",
        391,
        393,
        "目前"
      ],
      [
        "T40",
        "地点范围",
        374,
        376,
        "本土"
      ],
      [
        "T41",
        "时间范围",
        371,
        373,
        "未来"
      ],
      [
        "T42",
        "地点范围",
        519,
        521,
        "全球"
      ],
      [
        "T43",
        "行业",
        95,
        99,
        "原创新药"
      ]
    ]
  },
  {
    "id": 1182,
    "text": "口临床CRO是CRO行业中市场规模最大，研发投入最大的细分领域。2019年中国临床CRO市场规模为37亿美元，占中国CRO市场总额的54.4%。CRO行业研发支出中，药物发现支出占比21%，临床前研发支出占比11%，临床研发支出占比68%，临床研发支出占据最大比例",
    "labels": [
      [
        "T0",
        "行业",
        1,
        6,
        "临床CRO"
      ],
      [
        "T1",
        "行业",
        7,
        10,
        "CRO"
      ],
      [
        "T2",
        "市场规模",
        13,
        17,
        "市场规模"
      ],
      [
        "T3",
        "属性值",
        17,
        19,
        "最大"
      ],
      [
        "T4",
        "研发费用",
        20,
        24,
        "研发投入"
      ],
      [
        "T5",
        "属性值",
        24,
        26,
        "最大"
      ],
      [
        "T6",
        "时间范围",
        32,
        37,
        "2019年"
      ],
      [
        "T7",
        "地点范围",
        37,
        39,
        "中国"
      ],
      [
        "T8",
        "行业",
        39,
        44,
        "临床CRO"
      ],
      [
        "T9",
        "市场规模",
        44,
        48,
        "市场规模"
      ],
      [
        "T10",
        "属性值",
        49,
        54,
        "37亿美元"
      ],
      [
        "T11",
        "地点范围",
        56,
        58,
        "中国"
      ],
      [
        "T12",
        "行业",
        58,
        61,
        "CRO"
      ],
      [
        "T13",
        "属性值",
        66,
        71,
        "54.4%"
      ],
      [
        "T14",
        "行业",
        72,
        75,
        "CRO"
      ],
      [
        "T15",
        "研发费用",
        77,
        81,
        "研发支出"
      ],
      [
        "T16",
        "行业",
        83,
        87,
        "药物发现"
      ],
      [
        "T17",
        "行业",
        95,
        98,
        "临床前"
      ],
      [
        "T18",
        "研发费用",
        98,
        102,
        "研发支出"
      ],
      [
        "T19",
        "行业",
        108,
        110,
        "临床"
      ],
      [
        "T20",
        "研发费用",
        110,
        114,
        "研发支出"
      ],
      [
        "T21",
        "行业",
        120,
        122,
        "临床"
      ],
      [
        "T22",
        "研发费用",
        122,
        126,
        "研发支出"
      ],
      [
        "T23",
        "属性值",
        126,
        132,
        "占据最大比例"
      ],
      [
        "T24",
        "属性值",
        114,
        119,
        "占比68%"
      ],
      [
        "T25",
        "属性值",
        102,
        107,
        "占比11%"
      ],
      [
        "T26",
        "属性值",
        89,
        94,
        "占比21%"
      ]
    ]
  },
  {
    "id": 1187,
    "text": "医药创新整体地域差异：外需占比高，内需增速快。国金医药大数据中心对所覆盖的 CXO全产业链的 29家 A+H上市公司的研发外包相关收入进行了相应的客户来源拆分和分类汇总（剔除相关公司的非 CXO收入），上述公司 2015-2020 年 CXO 业务海外收入占比分别为 78%/78%/75% /70%/71%/69%，整个 CXO板块按照客户来源进行划分，外需仍为主要的订单来源。2015-2020年上述公司的国内客户收入复合增速为 39%，海外客户收入复合增速为 27%。",
    "labels": [
      [
        "T0",
        "行业",
        0,
        4,
        "医药创新"
      ],
      [
        "T1",
        "行业",
        38,
        41,
        "CXO"
      ],
      [
        "T2",
        "时间范围",
        106,
        117,
        "2015-2020 年"
      ],
      [
        "T3",
        "营收占比",
        126,
        130,
        "收入占比"
      ],
      [
        "T4",
        "行业",
        161,
        165,
        " CXO"
      ],
      [
        "T5",
        "时间范围",
        190,
        200,
        "2015-2020年"
      ],
      [
        "T6",
        "CAGR",
        211,
        215,
        "复合增速"
      ],
      [
        "T7",
        "CAGR",
        227,
        231,
        "复合增速"
      ],
      [
        "T8",
        "地点范围",
        221,
        223,
        "海外"
      ],
      [
        "T9",
        "行业公司",
        47,
        58,
        "29家 A+H上市公司"
      ],
      [
        "T10",
        "行业",
        118,
        121,
        "CXO"
      ],
      [
        "T11",
        "属性值",
        134,
        158,
        "78%/78%/75% /70%/71%/69%"
      ],
      [
        "T12",
        "地点范围",
        124,
        126,
        "海外"
      ],
      [
        "T13",
        "属性值",
        217,
        220,
        "39%"
      ],
      [
        "T14",
        "属性值",
        233,
        236,
        "27%"
      ],
      [
        "T15",
        "营业收入",
        65,
        67,
        "收入"
      ],
      [
        "T16",
        "营业收入",
        97,
        99,
        "收入"
      ],
      [
        "T17",
        "地点范围",
        205,
        207,
        "国内"
      ],
      [
        "T18",
        "属性值",
        207,
        211,
        "客户收入"
      ],
      [
        "T19",
        "属性值",
        223,
        227,
        "客户收入"
      ]
    ]
  },
  {
    "id": 1193,
    "text": "➢ Q4保持高增长，全年各业务板块齐头并进。公司2020年Q4单季度实现营业收入15.48亿元，同比增长 36.88%，实现归母净利润3.83亿元，同比增长75.19%，全年业绩符合我们的预期。分业务看，2020年公司实验室服务（实验室化学）实现营收32.63亿元，同比增长37.12%，主要增长动力来自客户订单的增长以及生物科学服务的快速发展（实验室服务中收入占比提升至41.33%）。实验室服务业务全年为国内医药及生物科技公司开展58个IND或NDA临床试验申报，其中多国同时申报项目46个；CMC服务实现营收12.22亿元，同比增长35.54%，主要增长动力来自前期积累的众多药物发现项目进入药物开发阶段，同时公司产能配合不断扩张。2020年，公司化学工艺开发及生产服务共涉及药物分子或中间体 739个，其中临床前487个、临床I-II期202个、III期47个、商业化3个，制剂开发团队则完成26个GMP项目；临床研究服务业务实现营收6.29亿元，同比增长37.94%，主要业绩增长动力来自独特的“放射性同位素化合物合成-临床-分析”平台，以及海外临床服务的稳健增长。2020年，公司完成对北京联斯达的收购，打造了临床CRO+SMO的一体化服务平台，临床服务人员增加1652人至2208人。 ➢ 一体化平台优势凸显，毛利率不断提升，产能与人员持续扩张。康龙化成拥有业内少有的一体化、端到端新药研发平台，业务间协同效应持续体现。2020年公司分别实现毛利率37.47%（+1.95pt）与扣非归母净利率15.6%（+2.16pt），其中实验室服务毛利率提升2.48pt至42.74%，CMC业务毛利率提升 4.96pt至32.73%，体现了公司盈利能力的不断提升。同时公司产能与人员持续扩张，产能方面绍兴工厂 8.1万平米一期工程、北京地区2.25万平米实验室服务设施、天津工厂4万平米工程建设及宁波园区实验室与工厂扩建均推进良好，人员方面2020年公司员工增加3619人至11012人。2020年公司服务全球超 1500家客户，新增客户721家，客户资源及订单充裕配合产能人员扩张，未来业绩可期。 ➢ 布局大分子CDMO+外延式收购扩张，打开长期成长空间。2020年，公司加快大分子及细胞和基因疗法等研发服务能力的建设，通过收购（收购美国Absorption Systems与艾伯维旗下Allergan Biologics）的方式加速外延扩张，进入增速更快的大分子CDMO赛道，打开长期成长空间。 ➢ 盈利预测与投资评级：由于公司毛利率的提升带动盈利能力不断加强，我们调整2021-2022年EPS至 1.92(+0.30)/2.53(+0.41)，预计2023年EPS为3.35元，当前市值对应2021-2023年PE分别为73/55/42倍。考虑到公司小分子一体化平台优势持续凸显，大分子加剧布局，未来三年盈利复合增速有望超30%，维持“买入”评级。 ➢ 风险提示：订单获取不及预期；新项目研发不及预期；汇兑损益风险等",
    "labels": [
      [
        "T0",
        "时间范围",
        2,
        4,
        "Q4"
      ],
      [
        "T1",
        "时间范围",
        24,
        31,
        "2020年Q4"
      ],
      [
        "T2",
        "营业收入",
        36,
        40,
        "营业收入"
      ],
      [
        "T3",
        "归母净利润",
        62,
        67,
        "归母净利润"
      ],
      [
        "T4",
        "业绩",
        87,
        89,
        "业绩"
      ],
      [
        "T5",
        "时间范围",
        102,
        107,
        "2020年"
      ],
      [
        "T6",
        "营业收入",
        123,
        125,
        "营收"
      ],
      [
        "T7",
        "营收占比",
        179,
        183,
        "收入占比"
      ],
      [
        "T8",
        "行业",
        248,
        251,
        "CMC"
      ],
      [
        "T9",
        "营业收入",
        255,
        257,
        "营收"
      ],
      [
        "T10",
        "时间范围",
        319,
        324,
        "2020年"
      ],
      [
        "T11",
        "营业收入",
        419,
        421,
        "营收"
      ],
      [
        "T12",
        "业绩",
        441,
        443,
        "业绩"
      ],
      [
        "T13",
        "时间范围",
        488,
        493,
        "2020年"
      ],
      [
        "T14",
        "公司",
        499,
        504,
        "北京联斯达"
      ],
      [
        "T15",
        "毛利",
        562,
        565,
        "毛利率"
      ],
      [
        "T16",
        "公司",
        580,
        584,
        "康龙化成"
      ],
      [
        "T17",
        "时间范围",
        617,
        622,
        "2020年"
      ],
      [
        "T18",
        "毛利",
        628,
        631,
        "毛利率"
      ],
      [
        "T19",
        "行业",
        671,
        676,
        "实验室服务"
      ],
      [
        "T20",
        "毛利",
        676,
        679,
        "毛利率"
      ],
      [
        "T21",
        "行业",
        695,
        698,
        "CMC"
      ],
      [
        "T22",
        "毛利",
        700,
        703,
        "毛利率"
      ],
      [
        "T23",
        "属性值",
        713,
        719,
        "32.73%"
      ],
      [
        "T24",
        "员工数量",
        830,
        832,
        "员工"
      ],
      [
        "T25",
        "属性值",
        840,
        846,
        "11012人"
      ],
      [
        "T26",
        "时间范围",
        847,
        852,
        "2020年"
      ],
      [
        "T27",
        "客户数量",
        865,
        867,
        "客户"
      ],
      [
        "T28",
        "属性值",
        858,
        865,
        "超 1500家"
      ],
      [
        "T29",
        "在手订单",
        882,
        884,
        "订单"
      ],
      [
        "T30",
        "业绩",
        897,
        899,
        "业绩"
      ],
      [
        "T31",
        "行业",
        907,
        914,
        "大分子CDMO"
      ],
      [
        "T32",
        "时间范围",
        932,
        937,
        "2020年"
      ],
      [
        "T33",
        "公司",
        973,
        991,
        "Absorption Systems"
      ],
      [
        "T34",
        "公司",
        992,
        995,
        "艾伯维"
      ],
      [
        "T35",
        "公司",
        997,
        1015,
        "Allergan Biologics"
      ],
      [
        "T36",
        "行业",
        1033,
        1040,
        "大分子CDMO"
      ],
      [
        "T37",
        "毛利",
        1069,
        1072,
        "毛利率"
      ],
      [
        "T38",
        "时间范围",
        1090,
        1100,
        "2021-2022年"
      ],
      [
        "T39",
        "时间范围",
        1152,
        1162,
        "2021-2023年"
      ],
      [
        "T40",
        "PE",
        1162,
        1164,
        "PE"
      ],
      [
        "T41",
        "属性值",
        1167,
        1176,
        "73/55/42倍"
      ],
      [
        "T42",
        "时间范围",
        823,
        828,
        "2020年"
      ],
      [
        "T43",
        "行业",
        409,
        415,
        "临床研究服务"
      ],
      [
        "T44",
        "行业",
        511,
        520,
        "临床CRO+SMO"
      ],
      [
        "T45",
        "行业",
        529,
        533,
        "临床服务"
      ],
      [
        "T46",
        "产能",
        570,
        572,
        "产能"
      ],
      [
        "T47",
        "属性值",
        631,
        646,
        "37.47%（+1.95pt）"
      ],
      [
        "T48",
        "扣非净利润",
        647,
        654,
        "扣非归母净利率"
      ],
      [
        "T49",
        "属性值",
        654,
        668,
        "15.6%（+2.16pt）"
      ],
      [
        "T50",
        "属性值",
        688,
        694,
        "42.74%"
      ],
      [
        "T51",
        "属性值",
        744,
        748,
        "持续扩张"
      ],
      [
        "T52",
        "地点范围",
        856,
        858,
        "全球"
      ],
      [
        "T53",
        "属性值",
        899,
        901,
        "可期"
      ],
      [
        "T54",
        "市值",
        1148,
        1150,
        "市值"
      ],
      [
        "T55",
        "时间范围",
        1205,
        1209,
        "未来三年"
      ],
      [
        "T56",
        "CAGR",
        1211,
        1215,
        "复合增速"
      ],
      [
        "T57",
        "属性值",
        1217,
        1221,
        "超30%"
      ],
      [
        "T58",
        "产能",
        739,
        741,
        "产能"
      ],
      [
        "T59",
        "时间范围",
        895,
        897,
        "未来"
      ],
      [
        "T60",
        "时间范围",
        1131,
        1136,
        "2023年"
      ],
      [
        "T61",
        "行业",
        109,
        114,
        "实验室服务"
      ],
      [
        "T62",
        "行业",
        115,
        120,
        "实验室化学"
      ],
      [
        "T63",
        "行业",
        194,
        199,
        "实验室服务"
      ],
      [
        "T64",
        "地点范围",
        204,
        206,
        "国内"
      ],
      [
        "T65",
        "行业公司",
        206,
        215,
        "医药及生物科技公司"
      ],
      [
        "T66",
        "属性值",
        1209,
        1211,
        "盈利"
      ],
      [
        "T67",
        "属性值",
        884,
        886,
        "充裕"
      ]
    ]
  },
  {
    "id": 1199,
    "text": "本周(2022.2.7-2022.2.11)生物医药指数下跌 2.73%，板块表现不及沪深 300的 0.82% 的涨幅；子板块中，表现最佳的生物制品板块上涨 2.17%，最弱势的医疗服务板块下跌 11.1%。2022年至今，表现最佳的子板块为医药商业跌幅为 10.04%，优于医药指数 17.27%的跌幅，表现不及沪深 300指数 6.86%的跌幅。",
    "labels": [
      [
        "T0",
        "行业",
        22,
        26,
        "生物医药"
      ],
      [
        "T1",
        "行业",
        71,
        75,
        "生物制品"
      ],
      [
        "T2",
        "行业",
        90,
        94,
        "医疗服务"
      ],
      [
        "T3",
        "时间范围",
        105,
        112,
        "2022年至今"
      ],
      [
        "T4",
        "行业",
        122,
        126,
        "医药商业"
      ],
      [
        "T5",
        "行业",
        139,
        141,
        "医药"
      ],
      [
        "T6",
        "时间范围",
        0,
        2,
        "本周"
      ],
      [
        "T7",
        "时间范围",
        3,
        21,
        "2022.2.7-2022.2.11"
      ]
    ]
  },
  {
    "id": 1205,
    "text": " 2020年在全球疫情持续肆虐的大背景下，20家跨国药企的合计营业收入依然呈现正增长，即同比增长3.2%。 跨国药企研发投入继续呈现高景气度、研发费用率呈现持续提升：2020年20家跨国药企研发投入合计为1362 亿美元，同比增长9.6%，其中仅有个别几家公司呈现负增长。另外从研发费用率角度来看，跨国药企整体研发费用率依然呈现上升趋势，2020年达到19.07%。",
    "labels": [
      [
        "T0",
        "时间范围",
        2,
        7,
        "2020年"
      ],
      [
        "T1",
        "营业收入",
        32,
        36,
        "营业收入"
      ],
      [
        "T2",
        "研发费用",
        60,
        64,
        "研发投入"
      ],
      [
        "T3",
        "研发费用率",
        73,
        78,
        "研发费用率"
      ],
      [
        "T4",
        "时间范围",
        85,
        90,
        "2020年"
      ],
      [
        "T5",
        "研发费用",
        97,
        101,
        "研发投入"
      ],
      [
        "T6",
        "研发费用率",
        157,
        162,
        "研发费用率"
      ],
      [
        "T7",
        "时间范围",
        171,
        176,
        "2020年"
      ],
      [
        "T8",
        "行业公司",
        22,
        29,
        "20家跨国药企"
      ],
      [
        "T9",
        "地点范围",
        8,
        10,
        "全球"
      ],
      [
        "T10",
        "属性值",
        40,
        43,
        "正增长"
      ],
      [
        "T11",
        "属性值",
        49,
        53,
        "3.2%"
      ],
      [
        "T12",
        "属性值",
        68,
        72,
        "高景气度"
      ],
      [
        "T13",
        "属性值",
        80,
        84,
        "持续提升"
      ],
      [
        "T14",
        "行业公司",
        90,
        97,
        "20家跨国药企"
      ],
      [
        "T15",
        "属性值",
        104,
        121,
        "1362 亿美元，同比增长9.6%"
      ],
      [
        "T16",
        "研发费用率",
        141,
        146,
        "研发费用率"
      ],
      [
        "T17",
        "属性值",
        166,
        168,
        "上升"
      ],
      [
        "T18",
        "属性值",
        178,
        184,
        "19.07%"
      ],
      [
        "T19",
        "行业公司",
        56,
        60,
        "跨国药企"
      ],
      [
        "T20",
        "行业公司",
        151,
        155,
        "跨国药企"
      ]
    ]
  },
  {
    "id": 1211,
    "text": "诚然当前国内 CRO/CDMO（简称 CXO）公司的估值已然处于历史高位，但这背后亦有其高估值的合理性。我们能够看到创新药研发需求的高景气度，也能够看到 CXO公司切实提升了研发过程的效率，降低了成本，而 CXO的“卖水人”的商业模式更是为行业注入了更高的成长确定性。高景气度带来的高成长性与高确定性，成为了高估值背后的基础。",
    "labels": [
      [
        "T0",
        "地点范围",
        4,
        6,
        "国内"
      ],
      [
        "T1",
        "行业",
        7,
        15,
        "CRO/CDMO"
      ],
      [
        "T2",
        "行业",
        19,
        22,
        "CXO"
      ],
      [
        "T3",
        "行业需求",
        63,
        65,
        "需求"
      ],
      [
        "T4",
        "行业公司",
        77,
        82,
        "CXO公司"
      ],
      [
        "T5",
        "行业",
        103,
        106,
        "CXO"
      ],
      [
        "T6",
        "行业",
        58,
        61,
        "创新药"
      ],
      [
        "T7",
        "属性值",
        66,
        70,
        "高景气度"
      ],
      [
        "T8",
        "属性值",
        107,
        112,
        "“卖水人”"
      ]
    ]
  },
  {
    "id": 1217,
    "text": "盈利预测、估值与评级：随着公司小分子 CDMO 产能布局完善，相关业务有望快速放量；同时大分子及 CGT 业务也在持续规划建设，落地后形成小分子-大分子-CGT 全产业链端到端服务能力，打造全方位一体化 CDMO 公司。我们维持公司 21-23 年归母净利润预测为 16.07/21.50/29.41 亿元，EPS 分别为 2.02/2.71/3.70 元，分别同比增长 37.06%/33.80%/36.79%，对应 21-23 年 PE 为 62/46/34 倍，维持“买入”评级。",
    "labels": [
      [
        "T0",
        "行业",
        15,
        24,
        "小分子 CDMO "
      ],
      [
        "T1",
        "行业",
        44,
        47,
        "大分子"
      ],
      [
        "T2",
        "行业",
        49,
        53,
        "CGT "
      ],
      [
        "T3",
        "行业",
        102,
        106,
        "CDMO"
      ],
      [
        "T4",
        "时间范围",
        117,
        124,
        "21-23 年"
      ],
      [
        "T5",
        "归母净利润",
        124,
        129,
        "归母净利润"
      ],
      [
        "T6",
        "时间范围",
        209,
        217,
        " 21-23 年"
      ],
      [
        "T7",
        "PE",
        218,
        220,
        "PE"
      ]
    ]
  },
  {
    "id": 1223,
    "text": "中国医药CXO（研发及生产外包服务） China's pharmaceutical CXO (R&D and production outsourcing) industry 中国の製薬研究開発および生産アウトソーシングサービス産業の概要",
    "labels": [
      [
        "T0",
        "地点范围",
        0,
        2,
        "中国"
      ],
      [
        "T1",
        "行业",
        2,
        7,
        "医药CXO"
      ],
      [
        "T2",
        "行业",
        8,
        17,
        "研发及生产外包服务"
      ]
    ]
  },
  {
    "id": 1224,
    "text": "人均创收位于国内前列，距离海外龙头仍有差距。CRO是人才密集型行业，人效水平体现了公司的运营管理能力。2019年公司人均创收达 65万元（员工人数以年初年末均值计算），在国内 CRO公司中位居前列。但对比海外前 10大 CRO公司，仍然有 1-2倍的提升空间。",
    "labels": [
      [
        "T0",
        "行业",
        22,
        25,
        "CRO"
      ],
      [
        "T1",
        "属性值",
        26,
        31,
        "人才密集型"
      ],
      [
        "T2",
        "时间范围",
        51,
        56,
        "2019年"
      ],
      [
        "T3",
        "人均收入",
        58,
        62,
        "人均创收"
      ],
      [
        "T4",
        "人均收入",
        0,
        4,
        "人均创收"
      ],
      [
        "T5",
        "地点范围",
        85,
        87,
        "国内"
      ],
      [
        "T6",
        "行业公司",
        88,
        93,
        "CRO公司"
      ],
      [
        "T7",
        "地点范围",
        102,
        104,
        "海外"
      ],
      [
        "T8",
        "行业公司",
        104,
        115,
        "前 10大 CRO公司"
      ],
      [
        "T9",
        "地点范围",
        13,
        15,
        "海外"
      ]
    ]
  },
  {
    "id": 1229,
    "text": "同比增长 28%/26%/25%/26%/34%，整体维持 26%复合增长，2020年加速成长。我们分析该板块保持快速增长的主要原因：①新冠疫情下，中国 CXO优势凸显，加速产业转移；②新技术的应用，如 DEL、PROTAC、 虚拟筛选等；③毛利率相对较高的 DMPK、毒理学业务的快速发展。",
    "labels": [
      [
        "T0",
        "地点范围",
        74,
        77,
        "中国 "
      ],
      [
        "T1",
        "行业",
        77,
        80,
        "CXO"
      ],
      [
        "T2",
        "毛利",
        121,
        124,
        "毛利率"
      ],
      [
        "T3",
        "时间范围",
        38,
        43,
        "2020年"
      ]
    ]
  },
  {
    "id": 1240,
    "text": "中国 CMO市场方兴未艾。全球医药生产外包服务市场规模巨大但极为分散（CR5=10%）， 2018年全球小分子 CMO市场规模达 650亿美元（2013-2018 CAGR=11.3%），其中中国等新兴市场发展迅猛（2013-2018 CAGR=16.0 %），未来在成本、人才、技术等因素作用下，全球市场有望进一步向中国等新兴市场转移（中国 2018-2021E CAGR=22.2%）。",
    "labels": [
      [
        "T0",
        "地点范围",
        0,
        2,
        "中国"
      ],
      [
        "T1",
        "行业",
        3,
        6,
        "CMO"
      ],
      [
        "T2",
        "地点范围",
        13,
        15,
        "全球"
      ],
      [
        "T3",
        "行业",
        15,
        23,
        "医药生产外包服务"
      ],
      [
        "T4",
        "市场规模",
        23,
        27,
        "市场规模"
      ],
      [
        "T5",
        "属性值",
        27,
        29,
        "巨大"
      ],
      [
        "T6",
        "属性值",
        30,
        34,
        "极为分散"
      ],
      [
        "T7",
        "CR5",
        35,
        38,
        "CR5"
      ],
      [
        "T8",
        "属性值",
        39,
        42,
        "10%"
      ],
      [
        "T9",
        "时间范围",
        45,
        50,
        "2018年"
      ],
      [
        "T10",
        "地点范围",
        50,
        52,
        "全球"
      ],
      [
        "T11",
        "行业",
        52,
        59,
        "小分子 CMO"
      ],
      [
        "T12",
        "市场规模",
        59,
        63,
        "市场规模"
      ],
      [
        "T13",
        "属性值",
        65,
        71,
        "650亿美元"
      ],
      [
        "T14",
        "时间范围",
        72,
        81,
        "2013-2018"
      ],
      [
        "T15",
        "CAGR",
        82,
        86,
        "CAGR"
      ],
      [
        "T16",
        "属性值",
        87,
        92,
        "11.3%"
      ],
      [
        "T17",
        "地点范围",
        96,
        98,
        "中国"
      ],
      [
        "T18",
        "时间范围",
        108,
        117,
        "2013-2018"
      ],
      [
        "T19",
        "CAGR",
        118,
        122,
        "CAGR"
      ],
      [
        "T20",
        "属性值",
        123,
        129,
        "16.0 %"
      ],
      [
        "T21",
        "地点范围",
        149,
        151,
        "全球"
      ],
      [
        "T22",
        "地点范围",
        159,
        161,
        "中国"
      ],
      [
        "T23",
        "地点范围",
        169,
        171,
        "中国"
      ],
      [
        "T24",
        "时间范围",
        172,
        182,
        "2018-2021E"
      ],
      [
        "T25",
        "CAGR",
        183,
        187,
        "CAGR"
      ],
      [
        "T26",
        "属性值",
        188,
        193,
        "22.2%"
      ]
    ]
  },
  {
    "id": 1241,
    "text": "CRO公司与药企已建立起多种形式的合作方式，实现“风险共担、利益共享”。 全球 CRO 行业龙头昆泰（IQVIA）首创了风险共担的合作模式，不同于早期 CRO公司于药企之间以单纯的购买服务方式进行合作，昆泰通过对医药企业提供投资、技术、销售等支持建立更为密切的战略合作关系。经历多年来的实践检验，里程碑收益、服务换股权、股权投资等多种形式的合作方式已经被行业所接受，成为 CRO公司创新商业模式，提高盈利能力的重要手段。",
    "labels": [
      [
        "T0",
        "行业公司",
        0,
        5,
        "CRO公司"
      ],
      [
        "T1",
        "行业公司",
        6,
        8,
        "药企"
      ],
      [
        "T2",
        "行业",
        40,
        43,
        "CRO"
      ],
      [
        "T3",
        "龙头企业",
        46,
        48,
        "龙头"
      ],
      [
        "T4",
        "公司",
        48,
        57,
        "昆泰（IQVIA）"
      ],
      [
        "T5",
        "行业公司",
        76,
        81,
        "CRO公司"
      ],
      [
        "T6",
        "行业公司",
        82,
        84,
        "药企"
      ],
      [
        "T7",
        "公司",
        101,
        103,
        "昆泰"
      ],
      [
        "T8",
        "行业公司",
        106,
        110,
        "医药企业"
      ],
      [
        "T9",
        "行业公司",
        186,
        191,
        "CRO公司"
      ],
      [
        "T10",
        "地点范围",
        37,
        39,
        "全球"
      ]
    ]
  },
  {
    "id": 1247,
    "text": "疫苗：疫苗行业未来需要重点关注能把握住疫苗新技术和新方向的优质公司，关注智飞生物（渠道力极强+产品布局持续改善）、复星医药、万泰生物、康泰生物、康希诺等。",
    "labels": [
      [
        "T0",
        "行业",
        0,
        2,
        "疫苗"
      ],
      [
        "T1",
        "行业",
        3,
        5,
        "疫苗"
      ],
      [
        "T2",
        "公司",
        36,
        40,
        "智飞生物"
      ],
      [
        "T3",
        "公司",
        57,
        61,
        "复星医药"
      ],
      [
        "T4",
        "公司",
        62,
        66,
        "万泰生物"
      ],
      [
        "T5",
        "公司",
        67,
        71,
        "康泰生物"
      ],
      [
        "T6",
        "公司",
        72,
        75,
        "康希诺"
      ]
    ]
  },
  {
    "id": 1253,
    "text": "3.3 临床前CRO：整体呈现加速趋势，企业间业绩增速差异较大临床前CRO业务整体呈现加速趋势。受到疫情影响，海外产能进一步加速向我国转移，从而带动我国 CXO企业临床前CRO业务迎来快速增长。 企业间业绩增速差异较大。龙头药明康德的临床前CRO业务基数较高，保持稳健增长，康龙化成、昭衍新药和美迪西等因基数较低，加之产能扩建从而实现较高速增长。临床前CRO业务整体相对成熟， 各家毛利率也均保持在较高的水平。",
    "labels": [
      [
        "T0",
        "行业",
        4,
        10,
        "临床前CRO"
      ],
      [
        "T1",
        "业绩",
        23,
        25,
        "业绩"
      ],
      [
        "T2",
        "行业",
        31,
        37,
        "临床前CRO"
      ],
      [
        "T3",
        "行业",
        82,
        88,
        "临床前CRO"
      ],
      [
        "T4",
        "业绩",
        101,
        103,
        "业绩"
      ],
      [
        "T5",
        "龙头企业",
        110,
        112,
        "龙头"
      ],
      [
        "T6",
        "公司",
        112,
        116,
        "药明康德"
      ],
      [
        "T7",
        "行业",
        117,
        123,
        "临床前CRO"
      ],
      [
        "T8",
        "公司",
        137,
        141,
        "康龙化成"
      ],
      [
        "T9",
        "公司",
        142,
        146,
        "昭衍新药"
      ],
      [
        "T10",
        "公司",
        147,
        150,
        "美迪西"
      ],
      [
        "T11",
        "行业",
        173,
        179,
        "临床前CRO"
      ],
      [
        "T12",
        "毛利",
        191,
        194,
        "毛利率"
      ],
      [
        "T13",
        "属性值",
        15,
        17,
        "加速"
      ],
      [
        "T14",
        "地点范围",
        55,
        57,
        "海外"
      ],
      [
        "T15",
        "产能",
        57,
        59,
        "产能"
      ],
      [
        "T16",
        "地点范围",
        65,
        67,
        "我国"
      ],
      [
        "T17",
        "行业公司",
        77,
        82,
        "CXO企业"
      ],
      [
        "T18",
        "属性值",
        92,
        96,
        "快速增长"
      ],
      [
        "T19",
        "地点范围",
        74,
        76,
        "我国"
      ],
      [
        "T20",
        "产能",
        159,
        161,
        "产能"
      ],
      [
        "T21",
        "属性值",
        161,
        163,
        "扩建"
      ],
      [
        "T22",
        "属性值",
        103,
        109,
        "增速差异较大"
      ],
      [
        "T23",
        "属性值",
        132,
        136,
        "稳健增长"
      ],
      [
        "T24",
        "属性值",
        167,
        172,
        "较高速增长"
      ]
    ]
  },
  {
    "id": 1259,
    "text": "电生理和血管介入领域领先企业。公司是我国电生理和血管介入医疗器械领域龙头， 形成了以冠脉通路和电生理医疗器械为主导、以外周血管和神经介入为重点发展方向的业务布局。2019年公司的电生理和冠脉通路业务在国产品牌中分别排名第一和第三，领先地位明显。根据其业绩快报，2020年公司实现营业收入 4.79亿元，同比增长 18.68%， 归母与扣非净利润分别为 1.11亿/0.97亿元，同比分别增长 34.20%/20.85%。从 2017-2020 年的复合增速来看，公司营业收入、归母净利润和扣非净利润分别实现 46.28%/47.57%/108.75%的高速增长。",
    "labels": [
      [
        "T0",
        "行业",
        0,
        8,
        "电生理和血管介入"
      ],
      [
        "T1",
        "龙头企业",
        34,
        36,
        "龙头"
      ],
      [
        "T2",
        "地点范围",
        18,
        20,
        "我国"
      ],
      [
        "T3",
        "时间范围",
        81,
        86,
        "2019年"
      ],
      [
        "T4",
        "业绩",
        125,
        127,
        "业绩"
      ],
      [
        "T5",
        "时间范围",
        130,
        135,
        "2020年"
      ],
      [
        "T6",
        "营业收入",
        139,
        143,
        "营业收入"
      ],
      [
        "T7",
        "归母净利润",
        164,
        166,
        "归母"
      ],
      [
        "T8",
        "扣非净利润",
        167,
        172,
        "扣非净利润"
      ],
      [
        "T9",
        "时间范围",
        211,
        223,
        " 2017-2020 年"
      ],
      [
        "T10",
        "CAGR",
        224,
        228,
        "复合增速"
      ],
      [
        "T11",
        "营业收入",
        233,
        237,
        "营业收入"
      ],
      [
        "T12",
        "归母净利润",
        238,
        243,
        "归母净利润"
      ],
      [
        "T13",
        "扣非净利润",
        244,
        249,
        "扣非净利润"
      ],
      [
        "T14",
        "行业",
        20,
        32,
        "电生理和血管介入医疗器械"
      ]
    ]
  },
  {
    "id": 1264,
    "text": "2016年开始，众多CXO龙头企业凯莱英（2016年）、药明生物（2017年，H股）、 昭衍新药（2017年）、药石科技（2017年）、药明康德（2018年）、康龙化成（2019年）、 美迪西（2019年）等开始陆续实现A/H股首次上市。2018年药明康德上市后不久，CXO 板块也迎来了浩浩荡荡的行情，多支股票实现了上市后最高20倍以上超额收益。 投资者也开始关心能够指引CXO行业景气度的前瞻性高频数据指标，而全球医疗健康行业的投融资数据（月度、季度和年度）也被认为是对创新药行业未来景气度以及CXO 订单景气度前瞻指标。通过我们分析后发现： 1）全球投融资：趋势与全球CRO市场规模增长趋势和本土CXO海外收入增长趋势一致性均较弱； 2）国内投融资：与国内CRO市场规模增长趋势和本土CXO国内收入增长趋势一致性较强。CXO业绩更细化前瞻指标可以参考资本开支和订单趋势； 3）本土CXO行情：短期与投融资年度增长趋势一致性不强，中长期板块超额收益与投融资趋势一致性强。 4）展望：中长期CXO仍有加速可能，投资价值凸显。估值受政策+投融资扰动，回归历史低位。2021-2024年CXO收入端仍有望加速，投资价值凸显。",
    "labels": [
      [
        "T0",
        "公司",
        17,
        20,
        "凯莱英"
      ],
      [
        "T1",
        "时间范围",
        21,
        26,
        "2016年"
      ],
      [
        "T2",
        "行业",
        10,
        13,
        "CXO"
      ],
      [
        "T3",
        "时间范围",
        0,
        7,
        "2016年开始"
      ],
      [
        "T4",
        "公司",
        28,
        32,
        "药明生物"
      ],
      [
        "T5",
        "时间范围",
        33,
        38,
        "2017年"
      ],
      [
        "T6",
        "公司",
        44,
        48,
        "昭衍新药"
      ],
      [
        "T7",
        "时间范围",
        49,
        54,
        "2017年"
      ],
      [
        "T8",
        "公司",
        56,
        60,
        "药石科技"
      ],
      [
        "T9",
        "时间范围",
        61,
        66,
        "2017年"
      ],
      [
        "T10",
        "公司",
        68,
        72,
        "药明康德"
      ],
      [
        "T11",
        "时间范围",
        73,
        78,
        "2018年"
      ],
      [
        "T12",
        "公司",
        80,
        84,
        "康龙化成"
      ],
      [
        "T13",
        "时间范围",
        85,
        90,
        "2019年"
      ],
      [
        "T14",
        "公司",
        93,
        96,
        "美迪西"
      ],
      [
        "T15",
        "时间范围",
        97,
        102,
        "2019年"
      ],
      [
        "T16",
        "时间范围",
        119,
        124,
        "2018年"
      ],
      [
        "T17",
        "公司",
        124,
        128,
        "药明康德"
      ],
      [
        "T18",
        "行业",
        134,
        137,
        "CXO"
      ],
      [
        "T19",
        "行业",
        187,
        190,
        "CXO"
      ],
      [
        "T20",
        "地点范围",
        207,
        209,
        "全球"
      ],
      [
        "T21",
        "行业",
        209,
        213,
        "医疗健康"
      ],
      [
        "T22",
        "投融资情况",
        216,
        221,
        "投融资数据"
      ],
      [
        "T23",
        "行业",
        237,
        240,
        "创新药"
      ],
      [
        "T24",
        "行业",
        249,
        252,
        "CXO"
      ],
      [
        "T25",
        "地点范围",
        276,
        278,
        "全球"
      ],
      [
        "T26",
        "投融资情况",
        278,
        281,
        "投融资"
      ],
      [
        "T27",
        "地点范围",
        285,
        287,
        "全球"
      ],
      [
        "T28",
        "行业",
        287,
        290,
        "CRO"
      ],
      [
        "T29",
        "市场规模",
        290,
        294,
        "市场规模"
      ],
      [
        "T30",
        "地点范围",
        299,
        301,
        "本土"
      ],
      [
        "T31",
        "行业",
        301,
        304,
        "CXO"
      ],
      [
        "T32",
        "地点范围",
        304,
        306,
        "海外"
      ],
      [
        "T33",
        "营收增长",
        306,
        310,
        "收入增长"
      ],
      [
        "T34",
        "在手订单",
        253,
        255,
        "订单"
      ],
      [
        "T35",
        "时间范围",
        482,
        492,
        "2021-2024年"
      ],
      [
        "T36",
        "行业",
        492,
        495,
        "CXO"
      ],
      [
        "T37",
        "营业收入",
        495,
        498,
        "收入端"
      ],
      [
        "T38",
        "属性值",
        499,
        503,
        "有望加速"
      ],
      [
        "T39",
        "时间范围",
        443,
        446,
        "中长期"
      ],
      [
        "T40",
        "行业",
        446,
        449,
        "CXO"
      ],
      [
        "T41",
        "地点范围",
        391,
        393,
        "本土"
      ],
      [
        "T42",
        "行业",
        393,
        396,
        "CXO"
      ],
      [
        "T43",
        "时间范围",
        399,
        401,
        "短期"
      ],
      [
        "T44",
        "投融资情况",
        402,
        405,
        "投融资"
      ],
      [
        "T45",
        "时间范围",
        417,
        420,
        "中长期"
      ],
      [
        "T46",
        "行业",
        362,
        365,
        "CXO"
      ],
      [
        "T47",
        "CAPEX资本开支",
        378,
        382,
        "资本开支"
      ],
      [
        "T48",
        "在手订单",
        383,
        385,
        "订单"
      ],
      [
        "T49",
        "业绩",
        365,
        367,
        "业绩"
      ],
      [
        "T50",
        "地点范围",
        343,
        345,
        "本土"
      ],
      [
        "T51",
        "行业",
        345,
        348,
        "CXO"
      ],
      [
        "T52",
        "地点范围",
        348,
        350,
        "国内"
      ],
      [
        "T53",
        "营收增长",
        350,
        354,
        "收入增长"
      ],
      [
        "T54",
        "地点范围",
        329,
        331,
        "国内"
      ],
      [
        "T55",
        "行业",
        331,
        334,
        "CRO"
      ],
      [
        "T56",
        "市场规模",
        334,
        338,
        "市场规模"
      ],
      [
        "T57",
        "地点范围",
        322,
        324,
        "国内"
      ],
      [
        "T58",
        "投融资情况",
        324,
        327,
        "投融资"
      ]
    ]
  },
  {
    "id": 1268,
    "text": "国内 CRO市场持续高景气度，保持较高增速。根据 Frost & Sullivan数据， 2019 年国内 CRO市场规模接近 69亿美元，其中药物发现市场规模 14亿美元，临床前 CRO市场 18亿美元，临床 CRO市场 37亿美元。受益于全球医药外包订单向亚太区转移，以及国内工程师红利带来的成本优势，近年来国内 CRO行业保持了较高的增长，2015~2019年 CAGR达到 27.3%。预计到 2024年市场规模能达到 221亿美元，2019~2024年 CAGR预计能够达到 26.5%。",
    "labels": [
      [
        "T0",
        "地点范围",
        0,
        2,
        "国内"
      ],
      [
        "T1",
        "行业",
        3,
        6,
        "CRO"
      ],
      [
        "T2",
        "时间范围",
        45,
        51,
        "2019 年"
      ],
      [
        "T3",
        "地点范围",
        51,
        53,
        "国内"
      ],
      [
        "T4",
        "行业",
        53,
        57,
        " CRO"
      ],
      [
        "T5",
        "市场规模",
        57,
        61,
        "市场规模"
      ],
      [
        "T6",
        "属性值",
        61,
        69,
        "接近 69亿美元"
      ],
      [
        "T7",
        "行业",
        72,
        76,
        "药物发现"
      ],
      [
        "T8",
        "市场规模",
        76,
        80,
        "市场规模"
      ],
      [
        "T9",
        "属性值",
        80,
        86,
        " 14亿美元"
      ],
      [
        "T10",
        "行业",
        87,
        94,
        "临床前 CRO"
      ],
      [
        "T11",
        "属性值",
        97,
        102,
        "18亿美元"
      ],
      [
        "T12",
        "行业",
        103,
        109,
        "临床 CRO"
      ],
      [
        "T13",
        "属性值",
        112,
        117,
        "37亿美元"
      ],
      [
        "T14",
        "时间范围",
        153,
        156,
        "近年来"
      ],
      [
        "T15",
        "地点范围",
        156,
        159,
        "国内 "
      ],
      [
        "T16",
        "行业",
        159,
        162,
        "CRO"
      ],
      [
        "T17",
        "CAGR",
        184,
        188,
        "CAGR"
      ],
      [
        "T18",
        "属性值",
        190,
        196,
        " 27.3%"
      ],
      [
        "T19",
        "时间范围",
        201,
        206,
        "2024年"
      ],
      [
        "T20",
        "市场规模",
        206,
        210,
        "市场规模"
      ],
      [
        "T21",
        "属性值",
        214,
        220,
        "221亿美元"
      ],
      [
        "T22",
        "属性值",
        243,
        248,
        "26.5%"
      ],
      [
        "T23",
        "CAGR",
        232,
        236,
        "CAGR"
      ],
      [
        "T24",
        "时间范围",
        221,
        231,
        "2019~2024年"
      ],
      [
        "T25",
        "地点范围",
        121,
        123,
        "全球"
      ],
      [
        "T26",
        "行业",
        123,
        127,
        "医药外包"
      ],
      [
        "T27",
        "地点范围",
        138,
        140,
        "国内"
      ],
      [
        "T28",
        "时间范围",
        173,
        183,
        "2015~2019年"
      ]
    ]
  },
  {
    "id": 1271,
    "text": "2021Q1年国内CXO行业继续保持高速增长：统计9家CXO公司合计实现营业收入94.3亿元，同比增长53.7%，继续延续超高速增长。 分公司来看，除泰格医药、成都先导等受疫情影响严重的公司，均保持高速增长。考虑到2020Q1受到疫情影响，相对2019Q1 增速较快的公司有昭衍新药、美迪西、康龙化成、药石科技、药明康德等。 图：核心公司营业收入继续呈现高速增长（亿元）",
    "labels": [
      [
        "T0",
        "时间范围",
        1,
        7,
        "2021Q1"
      ],
      [
        "T1",
        "地点范围",
        8,
        10,
        "国内"
      ],
      [
        "T2",
        "行业",
        10,
        13,
        "CXO"
      ],
      [
        "T3",
        "营业收入",
        37,
        41,
        "营业收入"
      ],
      [
        "T4",
        "公司",
        77,
        81,
        "泰格医药"
      ],
      [
        "T5",
        "公司",
        82,
        86,
        "成都先导"
      ],
      [
        "T6",
        "时间范围",
        109,
        115,
        "2020Q1"
      ],
      [
        "T7",
        "时间范围",
        124,
        131,
        "2019Q1 "
      ],
      [
        "T8",
        "公司",
        139,
        143,
        "昭衍新药"
      ],
      [
        "T9",
        "公司",
        144,
        147,
        "美迪西"
      ],
      [
        "T10",
        "公司",
        148,
        152,
        "康龙化成"
      ],
      [
        "T11",
        "公司",
        153,
        157,
        "药石科技"
      ],
      [
        "T12",
        "公司",
        158,
        162,
        "药明康德"
      ],
      [
        "T13",
        "营业收入",
        171,
        175,
        "营业收入"
      ],
      [
        "T14",
        "属性值",
        19,
        23,
        "高速增长"
      ],
      [
        "T15",
        "行业公司",
        26,
        33,
        "9家CXO公司"
      ],
      [
        "T16",
        "属性值",
        41,
        47,
        "94.3亿元"
      ],
      [
        "T17",
        "属性值",
        52,
        57,
        "53.7%"
      ],
      [
        "T18",
        "属性值",
        62,
        67,
        "超高速增长"
      ],
      [
        "T19",
        "行业公司",
        167,
        171,
        "核心公司"
      ],
      [
        "T20",
        "属性值",
        179,
        183,
        "高速增长"
      ]
    ]
  },
  {
    "id": 1277,
    "text": " Lonza完成中国API产能工厂的实验室扩建项目，实验室占地面积增加了250㎡。包括增加新的分析和制造设备，新增项目扩展了实验室的能力和产能，以及HPAPI 的公斤级生产能力。这是Lonza在高需求推动下小分子开发管道的重要组成部分。",
    "labels": [
      [
        "T0",
        "公司",
        2,
        7,
        "Lonza"
      ],
      [
        "T1",
        "公司",
        92,
        97,
        "Lonza"
      ],
      [
        "T2",
        "地点范围",
        9,
        11,
        "中国"
      ],
      [
        "T3",
        "行业",
        11,
        14,
        "API"
      ],
      [
        "T4",
        "产能",
        14,
        16,
        "产能"
      ],
      [
        "T5",
        "属性值",
        19,
        24,
        "实验室扩建"
      ]
    ]
  },
  {
    "id": 1283,
    "text": "部分偏绝对收益的低估资产：这部分企业虽然“主题性”不强，但经营稳健，所在领域具有相当看点，且本身估值较为合理，适合投资人作为绝对收益标的长期布局，如石药集团、中国生物制药、健康元/丽珠集团、恩华药业、博瑞医药等。",
    "labels": [
      [
        "T0",
        "公司",
        74,
        78,
        "石药集团"
      ],
      [
        "T1",
        "公司",
        79,
        85,
        "中国生物制药"
      ],
      [
        "T2",
        "公司",
        86,
        94,
        "健康元/丽珠集团"
      ],
      [
        "T3",
        "公司",
        95,
        99,
        "恩华药业"
      ],
      [
        "T4",
        "公司",
        100,
        104,
        "博瑞医药"
      ]
    ]
  },
  {
    "id": 1295,
    "text": ".康龙化成实际控制人是楼柏良、楼小强、郑北，三人合计持有公司18.31%的股份，康龙化成其余控股人多为专业机构投资者·康龙化成创新药研发能力深受海外客户的认可，对于行业抗风险能力较强，然而会造成公司的议价能力较低，同时海外客户居多会给康龙化成带来汇率风险康龙化成员工基数较大，订单交付能力较强，研发人数也具有较·为专业的研发背景，研究能力较强，管理层也具有较为深厚的背景",
    "labels": [
      [
        "T0",
        "公司",
        1,
        5,
        "康龙化成"
      ],
      [
        "T1",
        "公司",
        40,
        44,
        "康龙化成"
      ],
      [
        "T2",
        "公司",
        59,
        63,
        "康龙化成"
      ],
      [
        "T3",
        "公司",
        117,
        121,
        "康龙化成"
      ],
      [
        "T4",
        "地点范围",
        109,
        111,
        "海外"
      ],
      [
        "T5",
        "行业",
        63,
        66,
        "创新药"
      ]
    ]
  },
  {
    "id": 1301,
    "text": "我们认为行业长期发展趋势不变，头部公司业绩加速趋势明显，行业始终维持在高景气度。2021Q1业绩高速增长虽有去年同期低基数效应影响， 但相较 2019Q1 的复合增速亦表现靓丽，全年业绩表现值得期待。展望 2021Q2，虽然去年同期基数开始上行，但我们预计从环比角度来看多数公司 Q2将继续保持较好增长趋势。",
    "labels": [
      [
        "T0",
        "龙头企业",
        15,
        19,
        "头部公司"
      ],
      [
        "T1",
        "业绩",
        19,
        21,
        "业绩"
      ],
      [
        "T2",
        "时间范围",
        40,
        46,
        "2021Q1"
      ],
      [
        "T3",
        "业绩",
        46,
        48,
        "业绩"
      ],
      [
        "T4",
        "时间范围",
        70,
        78,
        " 2019Q1 "
      ],
      [
        "T5",
        "业绩",
        91,
        93,
        "业绩"
      ],
      [
        "T6",
        "时间范围",
        103,
        109,
        "2021Q2"
      ],
      [
        "T7",
        "时间范围",
        140,
        142,
        "Q2"
      ]
    ]
  },
  {
    "id": 1307,
    "text": "5月 28日，百时美施贵宝宣布，美国 FDA批准 Zeposia（ozanimod）0.92 mg 用于治疗成人中重度活动性溃疡性结肠炎（UC）。新闻稿指出，这是首个获批用于治疗中重度活动性 UC患者的口服 S1P受体调节剂。Zeposia（ozanimod） 是一种口服 S1P受体调节剂，以高亲和力与 S1P受体 1和 5结合，Zeposia降低淋巴细胞离开淋巴结的能力，减少外周血中循环淋巴细胞的数量。它已经获得 FDA批准用于治疗多发性硬化。目前 Zeposia治疗溃疡性结肠炎的机制尚未完全得到澄清，但可能涉及减少迁移至发炎肠粘膜中的淋巴细胞数量。",
    "labels": [
      [
        "T0",
        "时间范围",
        0,
        6,
        "5月 28日"
      ],
      [
        "T1",
        "公司",
        7,
        13,
        "百时美施贵宝"
      ],
      [
        "T2",
        "地点范围",
        16,
        18,
        "美国"
      ],
      [
        "T3",
        "时间范围",
        225,
        227,
        "目前"
      ]
    ]
  },
  {
    "id": 1311,
    "text": "假设 2：CRO及 CDMO在研发阶段渗透率持续提升。根据 Frost & Sullivan数据，2019年全球医药研发投入总额的 1823亿中，药物发现阶段投入约 381亿美元，临床前阶段投入约 206 亿美元，临床阶段投入约 1236 亿美元。假设 2019~2030年，药物发现阶段 CRO渗透率从 34%提升至 51%；临床前阶段",
    "labels": [
      [
        "T0",
        "时间范围",
        49,
        54,
        "2019年"
      ],
      [
        "T1",
        "地点范围",
        54,
        56,
        "全球"
      ],
      [
        "T2",
        "行业",
        56,
        58,
        "医药"
      ],
      [
        "T3",
        "研发费用",
        58,
        62,
        "研发投入"
      ],
      [
        "T4",
        "属性值",
        66,
        71,
        "1823亿"
      ],
      [
        "T5",
        "行业",
        73,
        79,
        "药物发现阶段"
      ],
      [
        "T6",
        "研发费用",
        79,
        81,
        "投入"
      ],
      [
        "T7",
        "属性值",
        81,
        89,
        "约 381亿美元"
      ],
      [
        "T8",
        "行业",
        90,
        95,
        "临床前阶段"
      ],
      [
        "T9",
        "研发费用",
        95,
        97,
        "投入"
      ],
      [
        "T10",
        "属性值",
        97,
        106,
        "约 206 亿美元"
      ],
      [
        "T11",
        "行业",
        107,
        111,
        "临床阶段"
      ],
      [
        "T12",
        "研发费用",
        111,
        113,
        "投入"
      ],
      [
        "T13",
        "属性值",
        113,
        123,
        "约 1236 亿美元"
      ],
      [
        "T14",
        "时间范围",
        127,
        137,
        "2019~2030年"
      ],
      [
        "T15",
        "行业",
        138,
        148,
        "药物发现阶段 CRO"
      ],
      [
        "T16",
        "行业",
        5,
        8,
        "CRO"
      ],
      [
        "T17",
        "行业",
        10,
        14,
        "CDMO"
      ]
    ]
  },
  {
    "id": 1313,
    "text": "临床 CRO布局加速进行，业务范围拓宽+地域覆盖更广。基于全球唯一的“放射性同位素化合物合成-临床-分析”一体化服务平台，公司早期收入主要来源于欧美地区， 且主要覆盖 I/II期临床。2019年，通过控股南京思睿及其子公司希麦迪、战略入股联斯达，公司实现了国内业务在临床试验服务、SMO、数统、生物分析等方面的覆盖。预计随着公司临床 CRO布局的持续进行，国外与国内业务的协同性不断增强，收入有望迎来爆发增长、毛利率也将持续改善。",
    "labels": [
      [
        "T0",
        "行业",
        0,
        6,
        "临床 CRO"
      ],
      [
        "T1",
        "营业收入",
        65,
        67,
        "收入"
      ],
      [
        "T2",
        "时间范围",
        92,
        97,
        "2019年"
      ],
      [
        "T3",
        "公司",
        102,
        106,
        "南京思睿"
      ],
      [
        "T4",
        "公司",
        111,
        114,
        "希麦迪"
      ],
      [
        "T5",
        "公司",
        119,
        122,
        "联斯达"
      ],
      [
        "T6",
        "行业",
        164,
        170,
        "临床 CRO"
      ],
      [
        "T7",
        "营业收入",
        194,
        196,
        "收入"
      ],
      [
        "T8",
        "毛利",
        205,
        208,
        "毛利率"
      ],
      [
        "T9",
        "地点范围",
        72,
        74,
        "欧美"
      ],
      [
        "T10",
        "地点范围",
        128,
        130,
        "国内"
      ],
      [
        "T11",
        "行业",
        133,
        139,
        "临床试验服务"
      ],
      [
        "T12",
        "行业",
        140,
        143,
        "SMO"
      ],
      [
        "T13",
        "行业",
        144,
        146,
        "数统"
      ],
      [
        "T14",
        "行业",
        147,
        151,
        "生物分析"
      ],
      [
        "T15",
        "地点范围",
        178,
        180,
        "国外"
      ],
      [
        "T16",
        "地点范围",
        181,
        183,
        "国内"
      ],
      [
        "T17",
        "地点范围",
        29,
        31,
        "全球"
      ]
    ]
  },
  {
    "id": 1315,
    "text": "我们认为CXO板块仍是未来3-5年极具投资价值板块。1）展望短中期：参考2021 年资本开支、存货、合同负债、人员、在手订单等变化趋势，我们认为本土CXO企业收入端短中期高增长仍有较强确定性。2）展望中长期：CGTCDMO、大分子CDMO等新增量业务、国际化业务拓展进入兑现期，有望为CXO企业长期收入可持续性稳增长提供保障。",
    "labels": [
      [
        "T0",
        "行业公司",
        142,
        147,
        "CXO企业"
      ],
      [
        "T1",
        "营业收入",
        149,
        151,
        "收入"
      ],
      [
        "T2",
        "属性值",
        151,
        158,
        "可持续性稳增长"
      ],
      [
        "T3",
        "行业",
        104,
        111,
        "CGTCDMO"
      ],
      [
        "T4",
        "行业",
        112,
        119,
        "大分子CDMO"
      ],
      [
        "T5",
        "行业",
        4,
        7,
        "CXO"
      ],
      [
        "T6",
        "时间范围",
        11,
        17,
        "未来3-5年"
      ],
      [
        "T7",
        "时间范围",
        30,
        33,
        "短中期"
      ],
      [
        "T8",
        "时间范围",
        36,
        42,
        "2021 年"
      ],
      [
        "T9",
        "CAPEX资本开支",
        42,
        46,
        "资本开支"
      ],
      [
        "T10",
        "存货",
        47,
        49,
        "存货"
      ],
      [
        "T11",
        "合同负债",
        50,
        54,
        "合同负债"
      ],
      [
        "T12",
        "员工数量",
        55,
        57,
        "人员"
      ],
      [
        "T13",
        "在手订单",
        58,
        62,
        "在手订单"
      ],
      [
        "T14",
        "地点范围",
        72,
        74,
        "本土"
      ],
      [
        "T15",
        "行业公司",
        74,
        79,
        "CXO企业"
      ],
      [
        "T16",
        "营业收入",
        79,
        82,
        "收入端"
      ],
      [
        "T17",
        "时间范围",
        82,
        85,
        "短中期"
      ],
      [
        "T18",
        "属性值",
        85,
        88,
        "高增长"
      ]
    ]
  },
  {
    "id": 1325,
    "text": "口BMS、辉瑞、阿斯利康等大型药企均与AI技术公司展开合作，而中国CXO龙头公司药明康德和InsilicoMedicine、博腾股份和晶泰科技均已合作，在药物智能开发领域的合作已经走在世界前列",
    "labels": [
      [
        "T0",
        "公司",
        1,
        4,
        "BMS"
      ],
      [
        "T1",
        "公司",
        5,
        7,
        "辉瑞"
      ],
      [
        "T2",
        "公司",
        8,
        12,
        "阿斯利康"
      ],
      [
        "T3",
        "行业公司",
        19,
        25,
        "AI技术公司"
      ],
      [
        "T4",
        "地点范围",
        31,
        33,
        "中国"
      ],
      [
        "T5",
        "行业",
        33,
        36,
        "CXO"
      ],
      [
        "T6",
        "龙头企业",
        36,
        40,
        "龙头公司"
      ],
      [
        "T7",
        "公司",
        40,
        44,
        "药明康德"
      ],
      [
        "T8",
        "公司",
        45,
        61,
        "InsilicoMedicine"
      ],
      [
        "T9",
        "公司",
        62,
        66,
        "博腾股份"
      ],
      [
        "T10",
        "公司",
        67,
        71,
        "晶泰科技"
      ],
      [
        "T11",
        "行业",
        77,
        83,
        "药物智能开发"
      ],
      [
        "T12",
        "行业公司",
        15,
        17,
        "药企"
      ]
    ]
  },
  {
    "id": 1327,
    "text": " CXO板块进入较低估值分位，行业需求不减，具备配备价值：2022年国内主流 CXO公司平均市盈率为 41倍，PEG均值 0.93，与国外 CXO公司相比，我们认为 A股 CXO估值已经大幅消化。国内龙头 CXO公司已与美国龙头药企合作多年，且承接大批新冠药物订单，若美国药企更换 CXO服务商需付出高成本，承担高风险，所以我们仍然认为国内 CXO龙头公司被列入实体清单可能性不高。药明生物被列入 UVL对公司及行业影响也极为有限，且有望未来数月内移出清单。回顾 2021年全球及中国药企研发投入、新药管线数量、医疗健康产业融资额与融资数，我们认为 CXO需求不减，仍具备充足动能。国内 CXO公司 2021年业绩预告也展现出 CXO业绩能见度从未改变，我们认为具备配备价值。",
    "labels": [
      [
        "T0",
        "时间范围",
        30,
        35,
        "2022年"
      ],
      [
        "T1",
        "地点范围",
        35,
        37,
        "国内"
      ],
      [
        "T2",
        "行业公司",
        37,
        45,
        "主流 CXO公司"
      ],
      [
        "T3",
        "PE",
        47,
        50,
        "市盈率"
      ],
      [
        "T4",
        "属性值",
        52,
        55,
        "41倍"
      ],
      [
        "T5",
        "PEG",
        56,
        59,
        "PEG"
      ],
      [
        "T6",
        "属性值",
        62,
        66,
        "0.93"
      ],
      [
        "T7",
        "地点范围",
        68,
        70,
        "国外"
      ],
      [
        "T8",
        "行业公司",
        71,
        76,
        "CXO公司"
      ],
      [
        "T9",
        "行业",
        87,
        90,
        "CXO"
      ],
      [
        "T10",
        "地点范围",
        99,
        101,
        "国内"
      ],
      [
        "T11",
        "龙头企业",
        101,
        103,
        "龙头"
      ],
      [
        "T12",
        "行业公司",
        104,
        109,
        "CXO公司"
      ],
      [
        "T13",
        "地点范围",
        111,
        113,
        "美国"
      ],
      [
        "T14",
        "龙头企业",
        113,
        115,
        "龙头"
      ],
      [
        "T15",
        "行业公司",
        115,
        117,
        "药企"
      ],
      [
        "T16",
        "地点范围",
        135,
        137,
        "美国"
      ],
      [
        "T17",
        "行业公司",
        137,
        139,
        "药企"
      ],
      [
        "T18",
        "公司",
        192,
        196,
        "药明生物"
      ],
      [
        "T19",
        "时间范围",
        220,
        225,
        "未来数月内"
      ],
      [
        "T20",
        "时间范围",
        233,
        238,
        "2021年"
      ],
      [
        "T21",
        "地点范围",
        238,
        240,
        "全球"
      ],
      [
        "T22",
        "地点范围",
        241,
        243,
        "中国"
      ],
      [
        "T23",
        "行业公司",
        243,
        245,
        "药企"
      ],
      [
        "T24",
        "研发费用",
        245,
        249,
        "研发投入"
      ],
      [
        "T25",
        "行业",
        257,
        261,
        "医疗健康"
      ],
      [
        "T26",
        "投融资金额",
        263,
        266,
        "融资额"
      ],
      [
        "T27",
        "投融资事件数",
        267,
        270,
        "融资数"
      ],
      [
        "T28",
        "行业",
        276,
        279,
        "CXO"
      ],
      [
        "T29",
        "行业需求",
        279,
        281,
        "需求"
      ],
      [
        "T30",
        "属性值",
        281,
        283,
        "不减"
      ],
      [
        "T31",
        "地点范围",
        292,
        294,
        "国内"
      ],
      [
        "T32",
        "行业公司",
        295,
        300,
        "CXO公司"
      ],
      [
        "T33",
        "时间范围",
        301,
        306,
        "2021年"
      ],
      [
        "T34",
        "业绩",
        306,
        308,
        "业绩"
      ],
      [
        "T35",
        "行业",
        315,
        318,
        "CXO"
      ],
      [
        "T36",
        "业绩",
        318,
        320,
        "业绩"
      ],
      [
        "T37",
        "属性值",
        320,
        327,
        "能见度从未改变"
      ],
      [
        "T38",
        "行业",
        2,
        5,
        "CXO"
      ],
      [
        "T39",
        "行业需求",
        16,
        20,
        "行业需求"
      ],
      [
        "T40",
        "属性值",
        20,
        22,
        "不减"
      ]
    ]
  },
  {
    "id": 1328,
    "text": "口CXO企业并购优势有两种，（1）扩充业务领域：CXO作为一站式服务平台，业务服务范围越广利润越高，通过收购有技术优势的企业，可以补充自身业务空白，如查尔斯河在2016年完成收购后，ROIC提升至10.4%；　（2）扩张产能：收购大型药企的闲置产能，提升生产实力，同时可以通过收购当地产能进入新市场。如Avara相继收购阿斯利康、安斯泰来、优时比、默沙东、辉瑞、GSK等大型药企的工厂，市场版图持续扩大",
    "labels": [
      [
        "T0",
        "行业公司",
        1,
        6,
        "CXO企业"
      ],
      [
        "T1",
        "行业",
        24,
        27,
        "CXO"
      ],
      [
        "T2",
        "利润",
        45,
        47,
        "利润"
      ],
      [
        "T3",
        "行业公司",
        115,
        119,
        "大型药企"
      ],
      [
        "T4",
        "公司",
        151,
        156,
        "Avara"
      ],
      [
        "T5",
        "公司",
        160,
        164,
        "阿斯利康"
      ],
      [
        "T6",
        "公司",
        165,
        169,
        "安斯泰来"
      ],
      [
        "T7",
        "公司",
        170,
        173,
        "优时比"
      ],
      [
        "T8",
        "公司",
        174,
        177,
        "默沙东"
      ],
      [
        "T9",
        "公司",
        178,
        180,
        "辉瑞"
      ],
      [
        "T10",
        "公司",
        181,
        184,
        "GSK"
      ],
      [
        "T11",
        "行业公司",
        185,
        189,
        "大型药企"
      ],
      [
        "T12",
        "公司",
        75,
        79,
        "查尔斯河"
      ],
      [
        "T13",
        "时间范围",
        80,
        85,
        "2016年"
      ],
      [
        "T14",
        "ROIC资本回报率",
        91,
        95,
        "ROIC"
      ],
      [
        "T15",
        "属性值",
        98,
        103,
        "10.4%"
      ]
    ]
  },
  {
    "id": 1331,
    "text": "人均创收居于 CDMO与综合类 CRO公司之间，团队素质与竞争力较高。相比于 CRO行业，CDMO行业更偏向重资产，因而人均创收相对较高。药明康德由于兼具 CRO与 CDMO业务，团队人效居于两类公司之间。较高的人均创收体现出公司较强的团队素质与行业竞争力。",
    "labels": [
      [
        "T0",
        "人均收入",
        0,
        4,
        "人均创收"
      ],
      [
        "T1",
        "行业",
        7,
        11,
        "CDMO"
      ],
      [
        "T2",
        "行业公司",
        15,
        21,
        " CRO公司"
      ],
      [
        "T3",
        "行业",
        39,
        42,
        "CRO"
      ],
      [
        "T4",
        "行业",
        45,
        49,
        "CDMO"
      ],
      [
        "T5",
        "人均收入",
        60,
        64,
        "人均创收"
      ],
      [
        "T6",
        "属性值",
        64,
        68,
        "相对较高"
      ],
      [
        "T7",
        "公司",
        69,
        73,
        "药明康德"
      ],
      [
        "T8",
        "行业",
        78,
        81,
        "CRO"
      ],
      [
        "T9",
        "行业",
        82,
        87,
        " CDMO"
      ],
      [
        "T10",
        "人均收入",
        106,
        110,
        "人均创收"
      ],
      [
        "T11",
        "属性值",
        103,
        105,
        "较高"
      ],
      [
        "T12",
        "属性值",
        54,
        57,
        "重资产"
      ]
    ]
  },
  {
    "id": 1337,
    "text": "全球 CDMO/CMO市场稳健增长增速有望提升。根据 Frost & Sullivan统计， 全球 2018年全球小分子 CDMO/CMO行业规模达到 646亿美元，细胞基因治疗 CDMO/CMO市场规模 15亿美元，预计到 2023年二者规模分别增长至 1072 亿美元和 48亿美元，2018~2023年 CAGR分别为 11%和 26%。",
    "labels": [
      [
        "T0",
        "地点范围",
        0,
        2,
        "全球"
      ],
      [
        "T1",
        "行业",
        3,
        11,
        "CDMO/CMO"
      ],
      [
        "T2",
        "地点范围",
        47,
        49,
        "全球"
      ],
      [
        "T3",
        "时间范围",
        50,
        55,
        "2018年"
      ],
      [
        "T4",
        "地点范围",
        55,
        57,
        "全球"
      ],
      [
        "T5",
        "行业",
        57,
        69,
        "小分子 CDMO/CMO"
      ],
      [
        "T6",
        "市场规模",
        69,
        73,
        "行业规模"
      ],
      [
        "T7",
        "属性值",
        75,
        82,
        " 646亿美元"
      ],
      [
        "T8",
        "行业",
        83,
        98,
        "细胞基因治疗 CDMO/CMO"
      ],
      [
        "T9",
        "市场规模",
        98,
        102,
        "市场规模"
      ],
      [
        "T10",
        "属性值",
        103,
        108,
        "15亿美元"
      ],
      [
        "T11",
        "时间范围",
        113,
        118,
        "2023年"
      ],
      [
        "T12",
        "属性值",
        128,
        136,
        "1072 亿美元"
      ],
      [
        "T13",
        "属性值",
        138,
        143,
        "48亿美元"
      ],
      [
        "T14",
        "属性值",
        162,
        166,
        " 11%"
      ],
      [
        "T15",
        "属性值",
        168,
        171,
        "26%"
      ],
      [
        "T16",
        "CAGR",
        155,
        159,
        "CAGR"
      ],
      [
        "T17",
        "时间范围",
        144,
        154,
        "2018~2023年"
      ],
      [
        "T18",
        "属性值",
        120,
        122,
        "规模"
      ],
      [
        "T19",
        "属性值",
        13,
        23,
        "稳健增长增速有望提升"
      ]
    ]
  },
  {
    "id": 1343,
    "text": "➢ 公司业绩符合预期，毛利率稍有下降。2021年，药物临床前研究服务收入14.83亿元（+40.83%），占总营收的97.75%；临床服务收入0.31亿元（+45.47%）；实验动物供应收入355万元，较去年同期增长 63.68%，快于整体业务增速。2021年公司主营业务毛利率为48.73%，较去年同期降低2.65pct，主要系动物采购价格上涨及临床服务业务成本上涨。考虑到公司产能在国内创新药产业链中的稀缺性，同时动物成本会向客户端转移，公司盈利能力有望保持稳定。 ➢ 产能扩张助力订单增长。公司不断扩增产能以满足订单增长需求，截至2021年底，公司在手订单金额约 29亿元，较去年同期增长70.59%。昭衍（苏州）于2021年启动约7500平米的动物房装修工程，已于2021 年年底完工并投入使用。苏州昭衍计划2022年完成II期2万平米的设施建设，公司预计2022年下半年正式投入使用；子公司昭衍易创计划租赁9000平米实验室，开展药物筛选、药效学试验；无锡昭衍3000平米的试验设施预计2022年下半年投入使用。公司人员增长快速，2021年公司研发技术人员1590人，同比增长46%。在公司订单充足的前提下、产能释放有望形成规模效应，同时公司不断拓展的业务之间有望发挥协同作用，进一步带动订单增长。 ➢ 坚持国际化战略，海外布局见成效。公司于2021年2月26日H股上市后，深化海外业务布局，提升全球医药研发服务能力，海外销售订单持续提升。2021年，海外子公司BIOMERE承接订单约2.8亿元，同比增长超过75%，实现高速增长；同时，BIOMERE 的客户可以将其他CRO 环节的服务委托至国内昭衍进行 ，与国内实验室形成中美联动，2021年昭衍国内公司承接海外订单约1.6 亿元，同比增长超过100%，延续高增长趋势。昭衍加州于2021年新装修投入约6000平米的试验设施，缓解了BIOMERE的产能紧张，同时有利于开拓美国西海岸业务。另外，公司和子公司苏州昭衍均通过了日本PMDA 史上第一次对中国非临床CRO 进行的GLP 检查，体现了公司海外服务的能力，国际化布局有望助力公司长期业绩增长。 ➢ 盈利预测与投资评级：考虑到公司是安评领域龙头之一，享受行业高增红利，同时产能扩建，订单充足 ，我们将公司2022-2023 年归母净利润从6.14/8.17亿元上调至7.07/9.09亿元，预计2024年归母净利润为 10.84亿元，对应2022-2024年PE 分别为60/47/39倍，维持“买入”评级。 ➢ 风险提示：市场竞争风险，新业务拓展风险，新冠疫情及其他不可抗力风险，汇兑损益风险等。",
    "labels": [
      [
        "T0",
        "业绩",
        4,
        6,
        "业绩"
      ],
      [
        "T1",
        "毛利",
        11,
        14,
        "毛利率"
      ],
      [
        "T2",
        "时间范围",
        19,
        24,
        "2021年"
      ],
      [
        "T3",
        "营业收入",
        34,
        36,
        "收入"
      ],
      [
        "T4",
        "行业",
        65,
        69,
        "临床服务"
      ],
      [
        "T5",
        "营业收入",
        69,
        71,
        "收入"
      ],
      [
        "T6",
        "行业",
        87,
        93,
        "实验动物供应"
      ],
      [
        "T7",
        "营业收入",
        93,
        95,
        "收入"
      ],
      [
        "T8",
        "时间范围",
        125,
        130,
        "2021年"
      ],
      [
        "T9",
        "主营业务",
        132,
        136,
        "主营业务"
      ],
      [
        "T10",
        "毛利",
        136,
        139,
        "毛利率"
      ],
      [
        "T11",
        "新签订单",
        259,
        261,
        "订单"
      ],
      [
        "T12",
        "时间范围",
        266,
        274,
        "截至2021年底"
      ],
      [
        "T13",
        "在手订单",
        277,
        281,
        "在手订单"
      ],
      [
        "T14",
        "在手订单",
        500,
        502,
        "订单"
      ],
      [
        "T15",
        "时间范围",
        470,
        475,
        "2021年"
      ],
      [
        "T16",
        "新签订单",
        549,
        551,
        "订单"
      ],
      [
        "T17",
        "时间范围",
        625,
        630,
        "2021年"
      ],
      [
        "T18",
        "公司",
        636,
        643,
        "BIOMERE"
      ],
      [
        "T19",
        "公司",
        674,
        682,
        "BIOMERE "
      ],
      [
        "T20",
        "行业",
        690,
        693,
        "CRO"
      ],
      [
        "T21",
        "时间范围",
        723,
        728,
        "2021年"
      ],
      [
        "T22",
        "公司",
        728,
        730,
        "昭衍"
      ],
      [
        "T23",
        "在手订单",
        738,
        740,
        "订单"
      ],
      [
        "T24",
        "属性值",
        740,
        747,
        "约1.6 亿元"
      ],
      [
        "T25",
        "公司",
        798,
        805,
        "BIOMERE"
      ],
      [
        "T26",
        "公司",
        767,
        769,
        "昭衍"
      ],
      [
        "T27",
        "公司",
        837,
        839,
        "昭衍"
      ],
      [
        "T28",
        "行业",
        925,
        927,
        "安评"
      ],
      [
        "T29",
        "龙头企业",
        929,
        931,
        "龙头"
      ],
      [
        "T30",
        "时间范围",
        961,
        972,
        "2022-2023 年"
      ],
      [
        "T31",
        "归母净利润",
        972,
        977,
        "归母净利润"
      ],
      [
        "T32",
        "属性值",
        992,
        1003,
        "7.07/9.09亿元"
      ],
      [
        "T33",
        "假设情形",
        1004,
        1006,
        "预计"
      ],
      [
        "T34",
        "时间范围",
        1006,
        1011,
        "2024年"
      ],
      [
        "T35",
        "归母净利润",
        1011,
        1016,
        "归母净利润"
      ],
      [
        "T36",
        "属性值",
        1018,
        1025,
        "10.84亿元"
      ],
      [
        "T37",
        "时间范围",
        1028,
        1038,
        "2022-2024年"
      ],
      [
        "T38",
        "PE",
        1038,
        1040,
        "PE"
      ],
      [
        "T39",
        "属性值",
        1044,
        1053,
        "60/47/39倍"
      ],
      [
        "T40",
        "公司",
        704,
        706,
        "昭衍"
      ],
      [
        "T41",
        "行业",
        25,
        34,
        "药物临床前研究服务"
      ],
      [
        "T42",
        "地点范围",
        631,
        633,
        "海外"
      ],
      [
        "T43",
        "属性值",
        647,
        663,
        "约2.8亿元，同比增长超过75%"
      ],
      [
        "T44",
        "地点范围",
        702,
        704,
        "国内"
      ],
      [
        "T45",
        "地点范围",
        711,
        713,
        "国内"
      ],
      [
        "T46",
        "地点范围",
        718,
        719,
        "中"
      ],
      [
        "T47",
        "地点范围",
        719,
        720,
        "美"
      ],
      [
        "T48",
        "地点范围",
        730,
        732,
        "国内"
      ],
      [
        "T49",
        "营业收入",
        55,
        57,
        "营收"
      ],
      [
        "T50",
        "产能",
        237,
        239,
        "产能"
      ],
      [
        "T51",
        "产能",
        509,
        511,
        "产能"
      ],
      [
        "T52",
        "产能",
        254,
        256,
        "产能"
      ],
      [
        "T53",
        "公司",
        304,
        310,
        "昭衍（苏州）"
      ],
      [
        "T54",
        "时间范围",
        311,
        316,
        "2021年"
      ],
      [
        "T55",
        "时间范围",
        336,
        344,
        "2021 年年底"
      ],
      [
        "T56",
        "公司",
        352,
        356,
        "苏州昭衍"
      ],
      [
        "T57",
        "时间范围",
        358,
        363,
        "2022年"
      ],
      [
        "T58",
        "公司",
        400,
        404,
        "昭衍易创"
      ],
      [
        "T59",
        "产能",
        190,
        192,
        "产能"
      ]
    ]
  },
  {
    "id": 1349,
    "text": "1）海外：商业模式落地兑现，形成多层次且优质客户群体。凭借20余年的经验累积和高交付质量的项目记录，国内CXO企业已获得海外大药企高度认可，比如，凯莱英参与美国五大跨国制药公司临床后期项目管线比例超过 30%，其中一家该比例达到50%。同时，也在加速开发中小型biotech客户。",
    "labels": [
      [
        "T0",
        "地点范围",
        50,
        52,
        "国内"
      ],
      [
        "T1",
        "行业公司",
        52,
        57,
        "CXO企业"
      ],
      [
        "T2",
        "行业公司",
        63,
        65,
        "药企"
      ],
      [
        "T3",
        "公司",
        73,
        76,
        "凯莱英"
      ],
      [
        "T4",
        "行业公司",
        84,
        88,
        "制药公司"
      ],
      [
        "T5",
        "行业",
        130,
        137,
        "biotech"
      ],
      [
        "T6",
        "地点范围",
        2,
        4,
        "海外"
      ],
      [
        "T7",
        "地点范围",
        60,
        62,
        "海外"
      ],
      [
        "T8",
        "地点范围",
        78,
        80,
        "美国"
      ]
    ]
  },
  {
    "id": 1355,
    "text": "2 2 公司现有约 1000m 的基因治疗产品中试平台， 约 7000m 的基因治疗产品 GMP 生产平台，包括质粒生产线 1 条、病毒载体生产线 3 条、CAR-T 细胞生产线 2 条、建库生产线 3 条、灌装线 1 条。为了应对快速增长的基因治疗 CDMO 市场 2 需求，公司加快产能扩张，在上海临港建设近 80,000m 的精准医疗产业基地， 设计 GMP 生产线 33 条，反应器规模最大可达 2,000L。其中，I 期 11 条生产线计划于 2023 年初投产，II 期 22 条生产线计划于 2025 年初投产。 作为产业后起之秀，和元生物与其他业内同行差异化竞争，专注于基因治疗的病毒载体开发，形成基础研究-基因治疗孵化-临床/商业化生产的商业模式，打造一站式基因治疗 CDMO 服务平台。 风险提示：公司产能建设不及预期；全球基因药物研发投入降低；公司商业化订单获取不及预期。",
    "labels": [
      [
        "T0",
        "行业",
        121,
        130,
        "基因治疗 CDMO"
      ],
      [
        "T1",
        "产能",
        195,
        197,
        "规模"
      ],
      [
        "T2",
        "公司",
        273,
        277,
        "和元生物"
      ],
      [
        "T3",
        "行业",
        338,
        347,
        "基因治疗 CDMO"
      ],
      [
        "T4",
        "属性值",
        307,
        327,
        "基础研究-基因治疗孵化-临床/商业化生产"
      ],
      [
        "T5",
        "属性值",
        116,
        120,
        "快速增长"
      ],
      [
        "T6",
        "地点范围",
        149,
        151,
        "上海"
      ],
      [
        "T7",
        "行业",
        166,
        170,
        "精准医疗"
      ],
      [
        "T8",
        "时间范围",
        253,
        259,
        "2025 年"
      ]
    ]
  },
  {
    "id": 1361,
    "text": "CXO企业业绩能见度从未改变。12家CXO公司2020年收入总额同比增速 29.1%、 归母净利润总额同比增速为 67.4%，扣非归母净利润总额同比增速为 33.4%；2021年前三季度扣非归母净利润总额进一步大幅增长至 69.27亿元，同比增长 71.84%。我们认为 CXO行业景气度不变，具备配备价值。",
    "labels": [
      [
        "T0",
        "行业公司",
        0,
        5,
        "CXO企业"
      ],
      [
        "T1",
        "时间范围",
        23,
        28,
        "2020年"
      ],
      [
        "T2",
        "收入增速",
        28,
        36,
        "收入总额同比增速"
      ],
      [
        "T3",
        "归母净利润增速",
        44,
        55,
        "归母净利润总额同比增速"
      ],
      [
        "T4",
        "扣非净利润增速",
        63,
        76,
        "扣非归母净利润总额同比增速"
      ],
      [
        "T5",
        "时间范围",
        84,
        93,
        "2021年前三季度"
      ],
      [
        "T6",
        "行业",
        136,
        139,
        "CXO"
      ],
      [
        "T7",
        "业绩",
        5,
        7,
        "业绩"
      ],
      [
        "T8",
        "行业公司",
        15,
        23,
        "12家CXO公司"
      ],
      [
        "T9",
        "属性值",
        37,
        42,
        "29.1%"
      ],
      [
        "T10",
        "属性值",
        57,
        62,
        "67.4%"
      ],
      [
        "T11",
        "属性值",
        78,
        83,
        "33.4%"
      ],
      [
        "T12",
        "属性值",
        111,
        130,
        "69.27亿元，同比增长 71.84%"
      ],
      [
        "T13",
        "扣非净利润",
        93,
        100,
        "扣非归母净利润"
      ]
    ]
  },
  {
    "id": 1362,
    "text": "在 IQVIA的发展过程中，除了不断提升既有业务服务能力、探索新的业务模式，公司还进行了多项收并购，以快速拓展服务边界。 2011年至 2014年，公司分别收购了 Outcome、 Advion BioService、Expression Analysis、Novella、Encore等公司，提高了真实世界服务能力、生物标志物、基因测序能力，拓展了医疗器械临床服务业务和电子健康档案管理业务； 2015 年，公司与 Quest 成立合资公司，拓展临床试验实验室服务能力；2016 年，公司与医药商业资讯龙头公司 IMS 合并，成立 Quintiles IMS Holdings，并于 2017年正式更名为 IQVIA。",
    "labels": [
      [
        "T0",
        "公司",
        2,
        7,
        "IQVIA"
      ],
      [
        "T1",
        "时间范围",
        60,
        73,
        " 2011年至 2014年"
      ],
      [
        "T2",
        "公司",
        82,
        89,
        "Outcome"
      ],
      [
        "T3",
        "公司",
        91,
        108,
        "Advion BioService"
      ],
      [
        "T4",
        "公司",
        109,
        128,
        "Expression Analysis"
      ],
      [
        "T5",
        "公司",
        129,
        136,
        "Novella"
      ],
      [
        "T6",
        "公司",
        137,
        143,
        "Encore"
      ],
      [
        "T7",
        "行业",
        175,
        183,
        "医疗器械临床服务"
      ],
      [
        "T8",
        "行业",
        186,
        194,
        "电子健康档案管理"
      ],
      [
        "T9",
        "时间范围",
        198,
        204,
        "2015 年"
      ],
      [
        "T10",
        "公司",
        209,
        214,
        "Quest"
      ],
      [
        "T11",
        "时间范围",
        236,
        242,
        "2016 年"
      ],
      [
        "T12",
        "行业",
        246,
        252,
        "医药商业资讯"
      ],
      [
        "T13",
        "公司",
        257,
        260,
        "IMS"
      ],
      [
        "T14",
        "龙头企业",
        252,
        256,
        "龙头公司"
      ],
      [
        "T15",
        "公司",
        267,
        289,
        "Quintiles IMS Holdings"
      ],
      [
        "T16",
        "时间范围",
        293,
        298,
        "2017年"
      ],
      [
        "T17",
        "公司",
        304,
        309,
        "IQVIA"
      ]
    ]
  },
  {
    "id": 1373,
    "text": " 药明康德是我国最早全方位布局大分子 CDMO（后被拆分为药明生物独立上市）、小分子 CDMO、CGT CDMO 的企业。药明康德发展历程与 Lonza 相似，始终牢牢跟随药物发展风口，成为我国最大的 CXO 公司。公司是我国最早介入 CGT CDMO 业务的企业之一，目前 CGT 产能布局欧、美、亚三大洲，CDMO 业务覆盖质粒、病毒、免疫细胞三大类，与全球客户建立良好合作。其中欧美地区提供病毒与细胞治疗 CDMO，中国提供质粒与病毒 CDMO。  金斯瑞生物科技以科研服务起家，跨界进入 CGT CDMO，这一发展路径可对标 Thermo Fisher。金斯瑞生物科技最初以基因合成业务为核心，专注实验室服务， 在孵化细胞治疗公司传奇生物后积累充分 CGT 药物开发经验， 顺利进入 CGT CDMO 领域。由于具备上游实验室服务能力，金斯瑞生物科技积极开发 CGT 相关设备、耗材等产品，打造一体化产业链供应能力，与 Thermo Fisher 布局相近，有望成为我国科研服务-工业生产一体化龙头。 由于金斯瑞生物科技具备丰富的实验室级别质粒供应经验，在完成工业级别产能扩张后，迅速成为我国 GMP 质粒龙头生产商。目前公司主要提供质粒与病毒 CDMO 服务，不涉及免疫细胞业务。  博腾股份起初专注于小分子 CDMO，进军 CGT CDMO 领域略晚于前二者， 但公司快速扩建免疫细胞生产产能实现弯道超车，与 Catalent 发展历程相近。公司在中国布局质粒、病毒、免疫细胞 CDMO 产能，是国内少有的具备免疫细胞 CDMO 服务能力的公司。作为海外对标公司，Catalent 正是通过收购快速切入 CGT CDMO 赛道， 并专长于免疫细胞 CDMO， 可服务 CAR-T、 TCR=T、CAR-NK 等多类细胞，而博腾股份也具备各类免疫细胞生产能力。  和元生物是相对年轻且专长于病毒 CDMO 的公司， 海外可比公司为 Oxford BioMedic，后者是全球病毒载体 CDMO 先驱，擅长慢病毒与腺相关病毒载体生产。和元生物也具备质粒、病毒、细胞的全方位生产，但其特色是具有多种病毒载体的 CRO 工艺开发与放大生产的能力和经验，其中溶瘤病毒的开发与生产是公司一大亮点，处于业内顶尖技术之列。公司提出“基因药，中国造”的愿景，要在上海临港打造全球最大基因药生产基地。  康龙化成介入 CGT CDMO 的方式与国内同行策略不同，目前公司仅在海外提供服务，可以提供质粒生产与基因药物开发。公司通过收购海外标的， 获得了 CGT 分析测试与 CDMO 能力，目前专注与国际领先的基因药物（病毒类为主）开发团队进行合作，打造公司基因药物的开发能力。",
    "labels": [
      [
        "T0",
        "公司",
        2,
        6,
        "药明康德"
      ],
      [
        "T1",
        "行业",
        16,
        24,
        "大分子 CDMO"
      ],
      [
        "T2",
        "公司",
        30,
        34,
        "药明生物"
      ],
      [
        "T3",
        "行业",
        40,
        48,
        "小分子 CDMO"
      ],
      [
        "T4",
        "行业",
        49,
        57,
        "CGT CDMO"
      ],
      [
        "T5",
        "公司",
        62,
        66,
        "药明康德"
      ],
      [
        "T6",
        "公司",
        72,
        78,
        "Lonza "
      ],
      [
        "T7",
        "地点范围",
        96,
        98,
        "我国"
      ],
      [
        "T8",
        "行业公司",
        102,
        108,
        "CXO 公司"
      ],
      [
        "T9",
        "行业",
        119,
        128,
        "CGT CDMO "
      ],
      [
        "T10",
        "行业",
        139,
        142,
        "CGT"
      ],
      [
        "T11",
        "行业",
        199,
        211,
        "病毒与细胞治疗 CDMO"
      ],
      [
        "T12",
        "行业",
        216,
        226,
        "质粒与病毒 CDMO"
      ],
      [
        "T13",
        "公司",
        230,
        237,
        "金斯瑞生物科技"
      ],
      [
        "T14",
        "行业",
        249,
        258,
        " CGT CDMO"
      ],
      [
        "T15",
        "公司",
        268,
        282,
        " Thermo Fisher"
      ],
      [
        "T16",
        "公司",
        283,
        290,
        "金斯瑞生物科技"
      ],
      [
        "T17",
        "公司",
        321,
        325,
        "传奇生物"
      ],
      [
        "T18",
        "行业",
        330,
        334,
        " CGT"
      ],
      [
        "T19",
        "行业",
        347,
        357,
        " CGT CDMO "
      ],
      [
        "T20",
        "公司",
        374,
        381,
        "金斯瑞生物科技"
      ],
      [
        "T21",
        "行业",
        386,
        390,
        "CGT "
      ],
      [
        "T22",
        "公司",
        416,
        430,
        "Thermo Fisher "
      ],
      [
        "T23",
        "龙头企业",
        453,
        455,
        "龙头"
      ],
      [
        "T24",
        "地点范围",
        439,
        441,
        "我国"
      ],
      [
        "T25",
        "公司",
        459,
        466,
        "金斯瑞生物科技"
      ],
      [
        "T26",
        "地点范围",
        500,
        502,
        "我国"
      ],
      [
        "T27",
        "行业",
        503,
        509,
        "GMP 质粒"
      ],
      [
        "T28",
        "龙头企业",
        509,
        511,
        "龙头"
      ],
      [
        "T29",
        "公司",
        550,
        554,
        "博腾股份"
      ],
      [
        "T30",
        "行业",
        559,
        567,
        "小分子 CDMO"
      ],
      [
        "T31",
        "行业",
        571,
        579,
        "CGT CDMO"
      ],
      [
        "T32",
        "公司",
        613,
        622,
        " Catalent"
      ],
      [
        "T33",
        "行业",
        664,
        673,
        "免疫细胞 CDMO"
      ],
      [
        "T34",
        "公司",
        691,
        700,
        "Catalent "
      ],
      [
        "T35",
        "行业",
        711,
        719,
        "CGT CDMO"
      ],
      [
        "T36",
        "行业",
        728,
        737,
        "免疫细胞 CDMO"
      ],
      [
        "T37",
        "公司",
        770,
        774,
        "博腾股份"
      ],
      [
        "T38",
        "公司",
        791,
        795,
        "和元生物"
      ],
      [
        "T39",
        "行业",
        804,
        811,
        "病毒 CDMO"
      ],
      [
        "T40",
        "公司",
        825,
        840,
        "Oxford BioMedic"
      ],
      [
        "T41",
        "行业",
        846,
        855,
        "病毒载体 CDMO"
      ],
      [
        "T42",
        "公司",
        875,
        879,
        "和元生物"
      ],
      [
        "T43",
        "行业",
        912,
        915,
        "CRO"
      ],
      [
        "T44",
        "公司",
        1003,
        1007,
        "康龙化成"
      ],
      [
        "T45",
        "行业",
        1009,
        1018,
        " CGT CDMO"
      ],
      [
        "T46",
        "行业",
        1076,
        1085,
        " CGT 分析测试"
      ],
      [
        "T47",
        "行业",
        1087,
        1091,
        "CDMO"
      ],
      [
        "T48",
        "地点范围",
        7,
        9,
        "我国"
      ],
      [
        "T49",
        "行业",
        87,
        89,
        "药物"
      ],
      [
        "T50",
        "地点范围",
        112,
        114,
        "我国"
      ],
      [
        "T51",
        "时间范围",
        136,
        138,
        "目前"
      ],
      [
        "T52",
        "产能",
        143,
        145,
        "产能"
      ],
      [
        "T53",
        "属性值",
        145,
        155,
        "布局欧、美、亚三大洲"
      ],
      [
        "T54",
        "地点范围",
        180,
        182,
        "全球"
      ],
      [
        "T55",
        "地点范围",
        193,
        195,
        "欧美"
      ],
      [
        "T56",
        "地点范围",
        212,
        214,
        "中国"
      ],
      [
        "T57",
        "行业",
        441,
        453,
        "科研服务-工业生产一体化"
      ],
      [
        "T58",
        "属性值",
        486,
        494,
        "工业级别产能扩张"
      ],
      [
        "T59",
        "时间范围",
        515,
        517,
        "目前"
      ],
      [
        "T60",
        "属性值",
        593,
        603,
        "快速扩建免疫细胞生产"
      ],
      [
        "T61",
        "属性值",
        635,
        655,
        "布局质粒、病毒、免疫细胞 CDMO 产能"
      ],
      [
        "T62",
        "地点范围",
        657,
        659,
        "国内"
      ],
      [
        "T63",
        "地点范围",
        633,
        635,
        "中国"
      ],
      [
        "T64",
        "地点范围",
        684,
        686,
        "海外"
      ],
      [
        "T65",
        "产能",
        603,
        605,
        "产能"
      ],
      [
        "T66",
        "时间范围",
        1032,
        1034,
        "目前"
      ],
      [
        "T67",
        "地点范围",
        1038,
        1040,
        "海外"
      ],
      [
        "T68",
        "地点范围",
        1023,
        1025,
        "国内"
      ],
      [
        "T69",
        "时间范围",
        1095,
        1097,
        "目前"
      ],
      [
        "T70",
        "地点范围",
        1100,
        1102,
        "国际"
      ],
      [
        "T71",
        "地点范围",
        982,
        984,
        "上海"
      ],
      [
        "T72",
        "地点范围",
        988,
        990,
        "全球"
      ],
      [
        "T73",
        "地点范围",
        1067,
        1069,
        "海外"
      ]
    ]
  },
  {
    "id": 1374,
    "text": "在新冠特效药订单、在手订单增多以及产能扩建加快之外，我们区别于市场的观点是前期受新冠疫情影响而延后的海外研发管线有望于 2022年恢复进展，这些因素共同坚定了我们对短中期国内 CDMO领域景气有望向上的判断。在此背景下，我们重点看好：  平台型企业，药明康德动态市盈率在 77x，历史均值为 90x；  CDMO主导型企业，凯莱英、博腾股份的 2022年预测 PEG分别为 1.17倍、 0.96倍；  CRO+CDMO型企业，康龙化成动态市盈率在 69x，历史均值为 95x；药石科技动态市盈率在 43x，历史均值为 90x。",
    "labels": [
      [
        "T0",
        "在手订单",
        9,
        13,
        "在手订单"
      ],
      [
        "T1",
        "时间范围",
        59,
        65,
        " 2022年"
      ],
      [
        "T2",
        "地点范围",
        85,
        87,
        "国内"
      ],
      [
        "T3",
        "行业",
        88,
        92,
        "CDMO"
      ],
      [
        "T4",
        "属性值",
        94,
        100,
        "景气有望向上"
      ],
      [
        "T5",
        "时间范围",
        82,
        85,
        "短中期"
      ],
      [
        "T6",
        "公司",
        126,
        130,
        "药明康德"
      ],
      [
        "T7",
        "PE",
        132,
        135,
        "市盈率"
      ],
      [
        "T8",
        "属性值",
        137,
        140,
        "77x"
      ],
      [
        "T9",
        "行业",
        154,
        158,
        "CDMO"
      ],
      [
        "T10",
        "公司",
        164,
        167,
        "凯莱英"
      ],
      [
        "T11",
        "公司",
        168,
        172,
        "博腾股份"
      ],
      [
        "T12",
        "时间范围",
        174,
        179,
        "2022年"
      ],
      [
        "T13",
        "PEG",
        182,
        185,
        "PEG"
      ],
      [
        "T14",
        "属性值",
        189,
        194,
        "1.17倍"
      ],
      [
        "T15",
        "属性值",
        196,
        201,
        "0.96倍"
      ],
      [
        "T16",
        "行业",
        204,
        208,
        " CRO"
      ],
      [
        "T17",
        "行业",
        209,
        213,
        "CDMO"
      ],
      [
        "T18",
        "公司",
        217,
        221,
        "康龙化成"
      ],
      [
        "T19",
        "PE",
        223,
        226,
        "市盈率"
      ],
      [
        "T20",
        "属性值",
        227,
        231,
        " 69x"
      ],
      [
        "T21",
        "公司",
        242,
        246,
        "药石科技"
      ],
      [
        "T22",
        "PE",
        248,
        251,
        "市盈率"
      ],
      [
        "T23",
        "属性值",
        253,
        256,
        "43x"
      ],
      [
        "T24",
        "属性值",
        147,
        150,
        "90x"
      ],
      [
        "T25",
        "时间范围",
        141,
        143,
        "历史"
      ],
      [
        "T26",
        "属性值",
        238,
        241,
        "95x"
      ],
      [
        "T27",
        "时间范围",
        232,
        234,
        "历史"
      ],
      [
        "T28",
        "属性值",
        263,
        266,
        "90x"
      ],
      [
        "T29",
        "时间范围",
        257,
        259,
        "历史"
      ],
      [
        "T30",
        "地点范围",
        50,
        52,
        "海外"
      ]
    ]
  },
  {
    "id": 1379,
    "text": "三、 2022年04月医药行业投资策略及标的",
    "labels": [
      [
        "T0",
        "时间范围",
        3,
        11,
        "2022年04月"
      ],
      [
        "T1",
        "行业",
        11,
        13,
        "医药"
      ]
    ]
  },
  {
    "id": 1380,
    "text": "口康龙化成实验室服务主要由实验室化学、生物科学、安全评估三部分构成。公司的主要收入和利润来源于实验室化学，收入占比维持在60%左右，同时生物科学的占比提升较快，2016年生物科学占实验室服务收入的17.3%，2020年生物科学占实验室服务收入的41.3%，增速较快，未来收入弹性较大。康龙化成预计2021年完成形成CGT疗法的临床前研究-工艺开发（CMC）-cGMP生产（CDMO）服务体系，将会给生物科学业务带来导流，形成更大的利润空间。安全评估占实验服务业务的比重较小，且逐步降低，原因在于CMC服务逐渐发展，财报并表时可能将安全评估业务并入CMC服务口康龙化成的实验室服务毛利率一直呈上升趋势，同时增速较快。对比药明康德实验室服务，2020年已经和CXO行业龙头药明康德中国区实验室服务毛利率几乎一致，说明实验室服务业务是维持康龙化成营业收入稳定的基石。2016年康龙化成实验室服务毛利率32.7%，2020年康龙化成实验室服务毛利率42.7%，5年时间毛利率上升了10%，增速较快预计进入毛利率稳定阶段",
    "labels": [
      [
        "T0",
        "公司",
        1,
        5,
        "康龙化成"
      ],
      [
        "T1",
        "营收占比",
        53,
        57,
        "收入占比"
      ],
      [
        "T2",
        "行业",
        47,
        52,
        "实验室化学"
      ],
      [
        "T3",
        "营业收入",
        39,
        41,
        "收入"
      ],
      [
        "T4",
        "利润",
        42,
        44,
        "利润"
      ],
      [
        "T5",
        "行业",
        68,
        72,
        "生物科学"
      ],
      [
        "T6",
        "时间范围",
        80,
        85,
        "2016年"
      ],
      [
        "T7",
        "行业",
        85,
        89,
        "生物科学"
      ],
      [
        "T8",
        "时间范围",
        104,
        109,
        "2020年"
      ],
      [
        "T9",
        "行业",
        109,
        113,
        "生物科学"
      ],
      [
        "T10",
        "行业",
        114,
        119,
        "实验室服务"
      ],
      [
        "T11",
        "行业",
        90,
        95,
        "实验室服务"
      ],
      [
        "T12",
        "营业收入",
        119,
        121,
        "收入"
      ],
      [
        "T13",
        "营业收入",
        95,
        97,
        "收入"
      ],
      [
        "T14",
        "营业收入",
        135,
        137,
        "收入"
      ],
      [
        "T15",
        "时间范围",
        133,
        135,
        "未来"
      ],
      [
        "T16",
        "公司",
        142,
        146,
        "康龙化成"
      ],
      [
        "T17",
        "时间范围",
        148,
        153,
        "2021年"
      ],
      [
        "T18",
        "行业",
        199,
        203,
        "生物科学"
      ],
      [
        "T19",
        "利润",
        215,
        217,
        "利润"
      ],
      [
        "T20",
        "行业",
        220,
        224,
        "安全评估"
      ],
      [
        "T21",
        "行业",
        225,
        229,
        "实验服务"
      ],
      [
        "T22",
        "行业",
        247,
        252,
        "CMC服务"
      ],
      [
        "T23",
        "行业",
        265,
        269,
        "安全评估"
      ],
      [
        "T24",
        "行业",
        273,
        278,
        "CMC服务"
      ],
      [
        "T25",
        "公司",
        279,
        283,
        "康龙化成"
      ],
      [
        "T26",
        "行业",
        284,
        289,
        "实验室服务"
      ],
      [
        "T27",
        "毛利",
        289,
        292,
        "毛利率"
      ],
      [
        "T28",
        "属性值",
        295,
        297,
        "上升"
      ],
      [
        "T29",
        "属性值",
        302,
        306,
        "增速较快"
      ],
      [
        "T30",
        "公司",
        309,
        313,
        "药明康德"
      ],
      [
        "T31",
        "行业",
        313,
        318,
        "实验室服务"
      ],
      [
        "T32",
        "时间范围",
        319,
        324,
        "2020年"
      ],
      [
        "T33",
        "行业",
        327,
        330,
        "CXO"
      ],
      [
        "T34",
        "龙头企业",
        332,
        334,
        "龙头"
      ],
      [
        "T35",
        "公司",
        334,
        338,
        "药明康德"
      ],
      [
        "T36",
        "地点范围",
        338,
        341,
        "中国区"
      ],
      [
        "T37",
        "行业",
        341,
        346,
        "实验室服务"
      ],
      [
        "T38",
        "毛利",
        346,
        349,
        "毛利率"
      ],
      [
        "T39",
        "行业",
        356,
        361,
        "实验室服务"
      ],
      [
        "T40",
        "公司",
        366,
        370,
        "康龙化成"
      ],
      [
        "T41",
        "营业收入",
        370,
        374,
        "营业收入"
      ],
      [
        "T42",
        "时间范围",
        380,
        385,
        "2016年"
      ],
      [
        "T43",
        "公司",
        385,
        389,
        "康龙化成"
      ],
      [
        "T44",
        "行业",
        389,
        394,
        "实验室服务"
      ],
      [
        "T45",
        "毛利",
        394,
        397,
        "毛利率"
      ],
      [
        "T46",
        "属性值",
        397,
        402,
        "32.7%"
      ],
      [
        "T47",
        "时间范围",
        403,
        408,
        "2020年"
      ],
      [
        "T48",
        "公司",
        408,
        412,
        "康龙化成"
      ],
      [
        "T49",
        "行业",
        412,
        417,
        "实验室服务"
      ],
      [
        "T50",
        "毛利",
        417,
        420,
        "毛利率"
      ],
      [
        "T51",
        "属性值",
        420,
        425,
        "42.7%"
      ],
      [
        "T52",
        "毛利",
        430,
        433,
        "毛利率"
      ],
      [
        "T53",
        "属性值",
        433,
        439,
        "上升了10%"
      ],
      [
        "T54",
        "属性值",
        440,
        444,
        "增速较快"
      ],
      [
        "T55",
        "毛利",
        448,
        451,
        "毛利率"
      ],
      [
        "T56",
        "属性值",
        60,
        65,
        "60%左右"
      ]
    ]
  },
  {
    "id": 1385,
    "text": "业毛利率较高，主营业务收入较高，",
    "labels": [
      [
        "T0",
        "毛利",
        1,
        4,
        "毛利率"
      ],
      [
        "T1",
        "主营业务",
        7,
        11,
        "主营业务"
      ],
      [
        "T2",
        "营业收入",
        11,
        13,
        "收入"
      ]
    ]
  },
  {
    "id": 1391,
    "text": "创始人担任董事长、总裁、首席执行官，具有前瞻性战略眼光。公司创始人李革（Ge Li）博士毕业于美国哥伦比亚大学，取得有机化学博士学位，曾在 Pharmacopeia Inc.作为创始科学家并担任科研总监，2000年 12月创立了公司前身无锡药明康德新药开发有限公司，并担任董事长、总裁兼首席执行官。李革博士具有极强的前瞻性战略布局眼光，在 20 余年前创立公司，引领了国内 CRO行业发展浪潮，此后又在生物药 CDMO领域培育了药明生物（2269.HK）， 其于 2017年在港股独立上市。在小分子 CDMO领域培育的子公司合全药业， 也已经成为行业绝对龙头。在李革博士的带领下，公司有望继续抓住行业发展机遇，延续快速成长的路径。",
    "labels": [
      [
        "T0",
        "地点范围",
        184,
        186,
        "国内"
      ],
      [
        "T1",
        "行业",
        186,
        190,
        " CRO"
      ],
      [
        "T2",
        "行业",
        201,
        209,
        "生物药 CDMO"
      ],
      [
        "T3",
        "公司",
        214,
        218,
        "药明生物"
      ],
      [
        "T4",
        "时间范围",
        232,
        237,
        "2017年"
      ],
      [
        "T5",
        "行业",
        246,
        254,
        "小分子 CDMO"
      ],
      [
        "T6",
        "公司",
        262,
        266,
        "合全药业"
      ],
      [
        "T7",
        "龙头企业",
        277,
        279,
        "龙头"
      ],
      [
        "T8",
        "公司",
        118,
        132,
        "无锡药明康德新药开发有限公司"
      ],
      [
        "T9",
        "时间范围",
        102,
        111,
        "2000年 12月"
      ],
      [
        "T10",
        "公司",
        70,
        87,
        "Pharmacopeia Inc."
      ],
      [
        "T11",
        "时间范围",
        170,
        176,
        "20 余年前"
      ]
    ]
  },
  {
    "id": 1392,
    "text": "美国 J-STAR：该公司主要专注于临床前至临床早期 API，同时在晶体技术上具备优势，博腾获得了其优秀的技术、团队、客户、以及工艺化学 CRO业务平台。但是 J-STAR在放大能力上略有不足，这恰好是博腾的一个优势，若美国技术中心和 J-STAR 顺利整合，将形成“1+1＞2”的效应。2017年，J-STAR为 CRO业务贡献了约 7000万元的收入， 2020年已达到 2.13亿元， CAGR达 45%。 2020年， J-STAR 向国内导流项目 50个，协同效应持续显现。",
    "labels": [
      [
        "T0",
        "公司",
        3,
        9,
        "J-STAR"
      ],
      [
        "T1",
        "地点范围",
        0,
        2,
        "美国"
      ],
      [
        "T2",
        "属性值",
        18,
        30,
        "临床前至临床早期 API"
      ],
      [
        "T3",
        "公司",
        44,
        46,
        "博腾"
      ],
      [
        "T4",
        "行业",
        64,
        72,
        "工艺化学 CRO"
      ],
      [
        "T5",
        "公司",
        80,
        86,
        "J-STAR"
      ],
      [
        "T6",
        "公司",
        101,
        103,
        "博腾"
      ],
      [
        "T7",
        "地点范围",
        110,
        112,
        "美国"
      ],
      [
        "T8",
        "公司",
        118,
        124,
        "J-STAR"
      ],
      [
        "T9",
        "时间范围",
        144,
        149,
        "2017年"
      ],
      [
        "T10",
        "公司",
        150,
        156,
        "J-STAR"
      ],
      [
        "T11",
        "行业",
        158,
        161,
        "CRO"
      ],
      [
        "T12",
        "属性值",
        166,
        174,
        "约 7000万元"
      ],
      [
        "T13",
        "时间范围",
        179,
        184,
        "2020年"
      ],
      [
        "T14",
        "属性值",
        188,
        194,
        "2.13亿元"
      ],
      [
        "T15",
        "CAGR",
        196,
        200,
        "CAGR"
      ],
      [
        "T16",
        "属性值",
        202,
        205,
        "45%"
      ],
      [
        "T17",
        "时间范围",
        207,
        212,
        "2020年"
      ],
      [
        "T18",
        "公司",
        214,
        220,
        "J-STAR"
      ],
      [
        "T19",
        "地点范围",
        222,
        224,
        "国内"
      ],
      [
        "T20",
        "属性值",
        175,
        177,
        "收入"
      ]
    ]
  },
  {
    "id": 1394,
    "text": "ROE整体呈现出增长趋势，未来仍有一定提升空间。从ROE水平来看，2020年昭衍新药、药明康德 、博腾股份和九洲药业等几家企业提升显著，ROE提升主要与企业净利润率提升有关，另外如凯莱英 、康龙化成和泰格医药等CXO企业ROE水平小幅下降，主要因扩产速度较快，周转率下降有关，另外泰格医药作为临床CRO龙头，疫情中受影响相对较大，ROE出现明显下降。",
    "labels": [
      [
        "T0",
        "ROE净资产回报率",
        0,
        3,
        "ROE"
      ],
      [
        "T1",
        "ROE净资产回报率",
        25,
        28,
        "ROE"
      ],
      [
        "T2",
        "时间范围",
        33,
        38,
        "2020年"
      ],
      [
        "T3",
        "公司",
        38,
        42,
        "昭衍新药"
      ],
      [
        "T4",
        "公司",
        43,
        47,
        "药明康德"
      ],
      [
        "T5",
        "公司",
        49,
        53,
        "博腾股份"
      ],
      [
        "T6",
        "公司",
        54,
        58,
        "九洲药业"
      ],
      [
        "T7",
        "属性值",
        63,
        67,
        "提升显著"
      ],
      [
        "T8",
        "ROE净资产回报率",
        68,
        71,
        "ROE"
      ],
      [
        "T9",
        "公司",
        90,
        93,
        "凯莱英"
      ],
      [
        "T10",
        "公司",
        95,
        99,
        "康龙化成"
      ],
      [
        "T11",
        "公司",
        100,
        104,
        "泰格医药"
      ],
      [
        "T12",
        "行业公司",
        105,
        110,
        "CXO企业"
      ],
      [
        "T13",
        "ROE净资产回报率",
        110,
        113,
        "ROE"
      ],
      [
        "T14",
        "属性值",
        115,
        119,
        "小幅下降"
      ],
      [
        "T15",
        "公司",
        140,
        144,
        "泰格医药"
      ],
      [
        "T16",
        "行业",
        146,
        151,
        "临床CRO"
      ],
      [
        "T17",
        "龙头企业",
        151,
        153,
        "龙头"
      ],
      [
        "T18",
        "属性值",
        170,
        174,
        "明显下降"
      ],
      [
        "T19",
        "ROE净资产回报率",
        165,
        168,
        "ROE"
      ]
    ]
  },
  {
    "id": 1403,
    "text": "中国 CXO 领域王者。药明康德成立于 2000 年，历经 20 余年发展，成为我国第一，全球第七的 CRO 公司。公司主营业务覆盖实验室服务、临床 CRO、小分子 CDMO 及 CGT CDMO 等， 提供除了大分子 CDMO （剥离成为药明生物独立上市） 外的全方位研发外包服务。",
    "labels": [
      [
        "T0",
        "地点范围",
        0,
        2,
        "中国"
      ],
      [
        "T1",
        "行业",
        2,
        6,
        " CXO"
      ],
      [
        "T2",
        "公司",
        12,
        16,
        "药明康德"
      ],
      [
        "T3",
        "行业公司",
        51,
        57,
        "CRO 公司"
      ],
      [
        "T4",
        "主营业务",
        60,
        64,
        "主营业务"
      ],
      [
        "T5",
        "属性值",
        66,
        98,
        "实验室服务、临床 CRO、小分子 CDMO 及 CGT CDMO"
      ],
      [
        "T6",
        "行业",
        106,
        114,
        "大分子 CDMO"
      ],
      [
        "T7",
        "公司",
        120,
        124,
        "药明生物"
      ],
      [
        "T8",
        "时间范围",
        20,
        26,
        "2000 年"
      ],
      [
        "T9",
        "地点范围",
        40,
        42,
        "我国"
      ],
      [
        "T10",
        "地点范围",
        45,
        47,
        "全球"
      ]
    ]
  },
  {
    "id": 1409,
    "text": "国内 CRO行业集中度较低，综合型企业少，有待进一步发展。据前瞻产业研究院 2019年统计，我国主要 CRO公司市场份额占比仅 31.86%，行业集中度较全球平均水平低。从公司类型看， 50%为临床 CRO 公司， 47%为临床前 CRO 公司，仅有 3%的公司为综合型 CRO 公司，企业规模和综合能力有待进一步发展。",
    "labels": [
      [
        "T0",
        "地点范围",
        0,
        2,
        "国内"
      ],
      [
        "T1",
        "行业",
        3,
        6,
        "CRO"
      ],
      [
        "T2",
        "市场集中度",
        6,
        11,
        "行业集中度"
      ],
      [
        "T3",
        "属性值",
        11,
        13,
        "较低"
      ],
      [
        "T4",
        "时间范围",
        38,
        43,
        "2019年"
      ],
      [
        "T5",
        "市场份额",
        56,
        60,
        "市场份额"
      ],
      [
        "T6",
        "地点范围",
        46,
        48,
        "我国"
      ],
      [
        "T7",
        "市场集中度",
        71,
        76,
        "行业集中度"
      ],
      [
        "T8",
        "行业公司",
        97,
        106,
        "临床 CRO 公司"
      ],
      [
        "T9",
        "行业公司",
        112,
        122,
        "临床前 CRO 公司"
      ],
      [
        "T10",
        "行业公司",
        132,
        142,
        "综合型 CRO 公司"
      ],
      [
        "T11",
        "属性值",
        83,
        84,
        "低"
      ],
      [
        "T12",
        "地点范围",
        77,
        79,
        "全球"
      ]
    ]
  },
  {
    "id": 1410,
    "text": "康龙化成CMC服务对营业收入影响适中，同比其他公司CDMO营业收入、毛利率较低，但预计2021年CMC业务产能释放，营业收入以及毛利率将会迎来较大提升",
    "labels": [
      [
        "T0",
        "公司",
        0,
        4,
        "康龙化成"
      ],
      [
        "T1",
        "行业",
        4,
        9,
        "CMC服务"
      ],
      [
        "T2",
        "营业收入",
        10,
        14,
        "营业收入"
      ],
      [
        "T3",
        "行业",
        25,
        29,
        "CDMO"
      ],
      [
        "T4",
        "营业收入",
        29,
        33,
        "营业收入"
      ],
      [
        "T5",
        "毛利",
        34,
        37,
        "毛利率"
      ],
      [
        "T6",
        "时间范围",
        43,
        48,
        "2021年"
      ],
      [
        "T7",
        "行业",
        48,
        51,
        "CMC"
      ],
      [
        "T8",
        "属性值",
        37,
        39,
        "较低"
      ],
      [
        "T9",
        "属性值",
        55,
        57,
        "释放"
      ],
      [
        "T10",
        "产能",
        53,
        55,
        "产能"
      ],
      [
        "T11",
        "营业收入",
        58,
        62,
        "营业收入"
      ],
      [
        "T12",
        "毛利",
        64,
        67,
        "毛利率"
      ],
      [
        "T13",
        "属性值",
        71,
        75,
        "较大提升"
      ]
    ]
  },
  {
    "id": 1417,
    "text": "可比公司对比：收入体量较高，盈利能力仍有增长空间。我们对比了药明康德与可比公司在 2020年的财务数据，公司在收入体量上显著高于可比公司，体现了稳固的行业地位。从盈利能力来看，公司毛利率与净利率水平略低于行业平均水平，一方面公司净利率水平受非经常性损益影响存在一定波动，另一方面，美国区实验室、细胞生物治疗 CDMO等业务仍处于业务拓展阶段，预计利润率水平仍有较大提升空间。从成长性来看，受益于行业高景气度，CXO龙头公司普遍保持较高增速水平。从 ROE水平来看，公司 ROE处于可比公司中游位置，较泰格医药、凯莱英等公司相比仍有提升空间，差距主要由于 EBIT margin 相对较低所致，未来盈利能力仍有提升空间。",
    "labels": [
      [
        "T0",
        "营业收入",
        7,
        9,
        "收入"
      ],
      [
        "T1",
        "公司",
        30,
        34,
        "药明康德"
      ],
      [
        "T2",
        "时间范围",
        41,
        46,
        "2020年"
      ],
      [
        "T3",
        "财务情况",
        47,
        51,
        "财务数据"
      ],
      [
        "T4",
        "营业收入",
        55,
        57,
        "收入"
      ],
      [
        "T5",
        "毛利",
        90,
        93,
        "毛利率"
      ],
      [
        "T6",
        "属性值",
        99,
        108,
        "略低于行业平均水平"
      ],
      [
        "T7",
        "行业",
        147,
        158,
        "细胞生物治疗 CDMO"
      ],
      [
        "T8",
        "行业",
        204,
        207,
        "CXO"
      ],
      [
        "T9",
        "龙头企业",
        207,
        211,
        "龙头公司"
      ],
      [
        "T10",
        "ROE净资产回报率",
        224,
        227,
        "ROE"
      ],
      [
        "T11",
        "ROE净资产回报率",
        235,
        238,
        "ROE"
      ],
      [
        "T12",
        "公司",
        250,
        254,
        "泰格医药"
      ],
      [
        "T13",
        "公司",
        255,
        258,
        "凯莱英"
      ],
      [
        "T14",
        "属性值",
        60,
        68,
        "显著高于可比公司"
      ],
      [
        "T15",
        "归母净利润",
        94,
        97,
        "净利率"
      ],
      [
        "T16",
        "属性值",
        128,
        134,
        "存在一定波动"
      ],
      [
        "T17",
        "归母净利润",
        114,
        117,
        "净利率"
      ],
      [
        "T18",
        "利润",
        173,
        176,
        "利润率"
      ],
      [
        "T19",
        "属性值",
        179,
        186,
        "有较大提升空间"
      ],
      [
        "T20",
        "属性值",
        238,
        248,
        "处于可比公司中游位置"
      ],
      [
        "T21",
        "属性值",
        264,
        269,
        "有提升空间"
      ]
    ]
  },
  {
    "id": 1418,
    "text": "估值方面，自 2021年 10月起，由于 2021年 9月全球医疗健康产业投融资金额环比下滑，《抗肿瘤药物临床研发指导原则》正式发布，以及市场对地缘政治风险的担忧，A股 CXO公司的估值持续消化。除了凯莱英和博腾股份由于大订单催化外，药明康德、康龙化成、泰格医药和昭衍新药的动态市盈率已处于过去三年的均值或者历史低位。值得注意的是，重点 CXO公司 2022年预测 PEG均值为 1.20倍，相较于三季报末的 2.01倍（2021年 10月 30日），估值已经大幅消化。",
    "labels": [
      [
        "T0",
        "时间范围",
        5,
        17,
        "自 2021年 10月起"
      ],
      [
        "T1",
        "时间范围",
        20,
        29,
        " 2021年 9月"
      ],
      [
        "T2",
        "地点范围",
        29,
        31,
        "全球"
      ],
      [
        "T3",
        "行业",
        31,
        35,
        "医疗健康"
      ],
      [
        "T4",
        "投融资金额",
        37,
        42,
        "投融资金额"
      ],
      [
        "T5",
        "属性值",
        42,
        46,
        "环比下滑"
      ],
      [
        "T6",
        "行业公司",
        85,
        90,
        "CXO公司"
      ],
      [
        "T7",
        "公司",
        100,
        103,
        "凯莱英"
      ],
      [
        "T8",
        "公司",
        104,
        108,
        "博腾股份"
      ],
      [
        "T9",
        "公司",
        117,
        121,
        "药明康德"
      ],
      [
        "T10",
        "公司",
        122,
        126,
        "康龙化成"
      ],
      [
        "T11",
        "公司",
        127,
        131,
        "泰格医药"
      ],
      [
        "T12",
        "公司",
        132,
        136,
        "昭衍新药"
      ],
      [
        "T13",
        "时间范围",
        175,
        180,
        "2022年"
      ],
      [
        "T14",
        "PEG",
        182,
        186,
        " PEG"
      ],
      [
        "T15",
        "属性值",
        190,
        195,
        "1.20倍"
      ],
      [
        "T16",
        "假设情形",
        180,
        182,
        "预测"
      ],
      [
        "T17",
        "行业公司",
        166,
        174,
        "重点 CXO公司"
      ],
      [
        "T18",
        "时间范围",
        199,
        203,
        "三季报末"
      ],
      [
        "T19",
        "属性值",
        205,
        210,
        "2.01倍"
      ],
      [
        "T20",
        "时间范围",
        211,
        224,
        "2021年 10月 30日"
      ],
      [
        "T21",
        "PE",
        139,
        142,
        "市盈率"
      ],
      [
        "T22",
        "属性值",
        142,
        158,
        "已处于过去三年的均值或者历史低位"
      ]
    ]
  },
  {
    "id": 1427,
    "text": "通过对比全球的中国制药企业、CRO公司的人均成本，可以看出：CRO 公司人均成本更低，国内 CRO 更具成本优势。目前，CRO 公司承担了近 1/3 的新药研发工作，近 2/3 的中后期研究工作，医药研发服务外包已经成为全球医药研发的主要形式。",
    "labels": [
      [
        "T0",
        "行业公司",
        9,
        13,
        "制药企业"
      ],
      [
        "T1",
        "行业公司",
        14,
        19,
        "CRO公司"
      ],
      [
        "T2",
        "行业公司",
        30,
        36,
        "CRO 公司"
      ],
      [
        "T3",
        "地点范围",
        43,
        46,
        "国内 "
      ],
      [
        "T4",
        "行业",
        46,
        49,
        "CRO"
      ],
      [
        "T5",
        "行业公司",
        60,
        66,
        "CRO 公司"
      ],
      [
        "T6",
        "行业",
        98,
        106,
        "医药研发服务外包"
      ],
      [
        "T7",
        "行业",
        112,
        116,
        "医药研发"
      ],
      [
        "T8",
        "地点范围",
        4,
        6,
        "全球"
      ],
      [
        "T9",
        "地点范围",
        7,
        9,
        "中国"
      ],
      [
        "T10",
        "时间范围",
        57,
        59,
        "目前"
      ],
      [
        "T11",
        "地点范围",
        110,
        112,
        "全球"
      ]
    ]
  },
  {
    "id": 1439,
    "text": "注：临床前板块包括：药明康德、康龙化成、美迪西、睿智医药、药石科技、成都先导、昭衍新药、维亚生物； 临床板块包括：泰格医药、药明康德、康龙化成、诺思格、普蕊斯、博济医药、凯莱英； CDMO板块包括：药明康德、凯莱英、博腾股份、康龙化成、九洲药业、药明生物、普洛药业、药石科技。",
    "labels": [
      [
        "T0",
        "行业",
        2,
        5,
        "临床前"
      ],
      [
        "T1",
        "公司",
        10,
        14,
        "药明康德"
      ],
      [
        "T2",
        "公司",
        15,
        19,
        "康龙化成"
      ],
      [
        "T3",
        "公司",
        20,
        23,
        "美迪西"
      ],
      [
        "T4",
        "公司",
        24,
        28,
        "睿智医药"
      ],
      [
        "T5",
        "公司",
        29,
        33,
        "药石科技"
      ],
      [
        "T6",
        "公司",
        34,
        38,
        "成都先导"
      ],
      [
        "T7",
        "公司",
        39,
        43,
        "昭衍新药"
      ],
      [
        "T8",
        "公司",
        44,
        48,
        "维亚生物"
      ],
      [
        "T9",
        "行业",
        50,
        52,
        "临床"
      ],
      [
        "T10",
        "公司",
        57,
        61,
        "泰格医药"
      ],
      [
        "T11",
        "公司",
        62,
        66,
        "药明康德"
      ],
      [
        "T12",
        "公司",
        67,
        71,
        "康龙化成"
      ],
      [
        "T13",
        "公司",
        72,
        75,
        "诺思格"
      ],
      [
        "T14",
        "公司",
        76,
        79,
        "普蕊斯"
      ],
      [
        "T15",
        "公司",
        80,
        84,
        "博济医药"
      ],
      [
        "T16",
        "公司",
        85,
        88,
        "凯莱英"
      ],
      [
        "T17",
        "行业",
        89,
        94,
        " CDMO"
      ],
      [
        "T18",
        "公司",
        99,
        103,
        "药明康德"
      ],
      [
        "T19",
        "公司",
        104,
        107,
        "凯莱英"
      ],
      [
        "T20",
        "公司",
        108,
        112,
        "博腾股份"
      ],
      [
        "T21",
        "公司",
        113,
        117,
        "康龙化成"
      ],
      [
        "T22",
        "公司",
        118,
        122,
        "九洲药业"
      ],
      [
        "T23",
        "公司",
        123,
        127,
        "药明生物"
      ],
      [
        "T24",
        "公司",
        128,
        132,
        "普洛药业"
      ],
      [
        "T25",
        "公司",
        133,
        137,
        "药石科技"
      ]
    ]
  },
  {
    "id": 1440,
    "text": "根据3月16日收盘价，部分重点CXO 个股动态市盈率已到历史平均值之下。药明康德动态PE为78x（历史平均PE 121x）＞药明生物动态PE为75x （历史平均PE 205x）＞泰格医药动态 PE为74x（历史平均PE 141x）＞康龙化成动态PE73x（历史平均PE 136x）。我们认为，在基本面逻辑没有变化的情况下，CXO板块迎来适配区。",
    "labels": [
      [
        "T0",
        "行业公司",
        15,
        21,
        "CXO 个股"
      ],
      [
        "T1",
        "PE",
        23,
        26,
        "市盈率"
      ],
      [
        "T2",
        "公司",
        36,
        40,
        "药明康德"
      ],
      [
        "T3",
        "时间范围",
        2,
        7,
        "3月16日"
      ],
      [
        "T4",
        "PE",
        42,
        44,
        "PE"
      ],
      [
        "T5",
        "属性值",
        45,
        48,
        "78x"
      ],
      [
        "T6",
        "PE",
        53,
        55,
        "PE"
      ],
      [
        "T7",
        "公司",
        62,
        66,
        "药明生物"
      ],
      [
        "T8",
        "PE",
        68,
        70,
        "PE"
      ],
      [
        "T9",
        "属性值",
        71,
        74,
        "75x"
      ],
      [
        "T10",
        "时间范围",
        49,
        51,
        "历史"
      ],
      [
        "T11",
        "时间范围",
        76,
        78,
        "历史"
      ],
      [
        "T12",
        "PE",
        80,
        82,
        "PE"
      ],
      [
        "T13",
        "属性值",
        83,
        87,
        "205x"
      ],
      [
        "T14",
        "公司",
        89,
        93,
        "泰格医药"
      ],
      [
        "T15",
        "PE",
        96,
        98,
        "PE"
      ],
      [
        "T16",
        "属性值",
        99,
        102,
        "74x"
      ],
      [
        "T17",
        "PE",
        107,
        109,
        "PE"
      ],
      [
        "T18",
        "时间范围",
        103,
        105,
        "历史"
      ],
      [
        "T19",
        "公司",
        116,
        120,
        "康龙化成"
      ],
      [
        "T20",
        "属性值",
        110,
        114,
        "141x"
      ],
      [
        "T21",
        "PE",
        122,
        124,
        "PE"
      ],
      [
        "T22",
        "属性值",
        124,
        127,
        "73x"
      ],
      [
        "T23",
        "时间范围",
        128,
        130,
        "历史"
      ],
      [
        "T24",
        "PE",
        132,
        134,
        "PE"
      ],
      [
        "T25",
        "属性值",
        135,
        139,
        "136x"
      ],
      [
        "T26",
        "行业",
        161,
        164,
        "CXO"
      ],
      [
        "T27",
        "属性值",
        56,
        60,
        "121x"
      ]
    ]
  },
  {
    "id": 1451,
    "text": "保守假设：药明康德全球 CRO市占率提升至 10%， CDMO市占率提升至 3%。 2019年公司 CRO业务全球市占率仅 2.1%，CDMO业务全球市占率仅 0.7%， 但相比于 2016年 CRO市占率 1.3%，CDMO市占率 0.4%已经有显著提升。 我们预计随着公司业务规模持续扩张，全球市占率提升速度会不断加快，保守测算到 2030年 CRO和 CDMO全球市占率有望分别达到 10%和 3%。",
    "labels": [
      [
        "T0",
        "公司",
        5,
        9,
        "药明康德"
      ],
      [
        "T1",
        "地点范围",
        9,
        11,
        "全球"
      ],
      [
        "T2",
        "行业",
        12,
        15,
        "CRO"
      ],
      [
        "T3",
        "市场份额",
        15,
        18,
        "市占率"
      ],
      [
        "T4",
        "属性值",
        21,
        25,
        " 10%"
      ],
      [
        "T5",
        "行业",
        27,
        31,
        "CDMO"
      ],
      [
        "T6",
        "市场份额",
        31,
        34,
        "市占率"
      ],
      [
        "T7",
        "属性值",
        38,
        40,
        "3%"
      ],
      [
        "T8",
        "时间范围",
        42,
        47,
        "2019年"
      ],
      [
        "T9",
        "行业",
        50,
        53,
        "CRO"
      ],
      [
        "T10",
        "地点范围",
        55,
        57,
        "全球"
      ],
      [
        "T11",
        "市场份额",
        57,
        60,
        "市占率"
      ],
      [
        "T12",
        "属性值",
        61,
        66,
        " 2.1%"
      ],
      [
        "T13",
        "行业",
        67,
        71,
        "CDMO"
      ],
      [
        "T14",
        "地点范围",
        73,
        75,
        "全球"
      ],
      [
        "T15",
        "市场份额",
        75,
        78,
        "市占率"
      ],
      [
        "T16",
        "属性值",
        80,
        84,
        "0.7%"
      ],
      [
        "T17",
        "时间范围",
        91,
        96,
        "2016年"
      ],
      [
        "T18",
        "行业",
        97,
        100,
        "CRO"
      ],
      [
        "T19",
        "市场份额",
        100,
        103,
        "市占率"
      ],
      [
        "T20",
        "属性值",
        104,
        108,
        "1.3%"
      ],
      [
        "T21",
        "行业",
        109,
        113,
        "CDMO"
      ],
      [
        "T22",
        "市场份额",
        113,
        116,
        "市占率"
      ],
      [
        "T23",
        "属性值",
        117,
        121,
        "0.4%"
      ],
      [
        "T24",
        "地点范围",
        147,
        149,
        "全球"
      ],
      [
        "T25",
        "市场份额",
        149,
        152,
        "市占率"
      ],
      [
        "T26",
        "时间范围",
        167,
        173,
        " 2030年"
      ],
      [
        "T27",
        "行业",
        173,
        177,
        " CRO"
      ],
      [
        "T28",
        "行业",
        179,
        183,
        "CDMO"
      ],
      [
        "T29",
        "地点范围",
        183,
        185,
        "全球"
      ],
      [
        "T30",
        "市场份额",
        185,
        188,
        "市占率"
      ],
      [
        "T31",
        "属性值",
        195,
        198,
        "10%"
      ],
      [
        "T32",
        "属性值",
        200,
        202,
        "3%"
      ],
      [
        "T33",
        "假设情形",
        0,
        4,
        "保守假设"
      ],
      [
        "T34",
        "假设情形",
        162,
        166,
        "保守测算"
      ]
    ]
  },
  {
    "id": 1452,
    "text": "特色CDMO：包括康龙化成、药石科技、皓元医药及维亚生物，这4家公司均是以早期实验室服务蓄积客户流量，从临床前阶段就切入客户管线，客户粘性强， 通过自建产能或者收购现有产能，打造研发-生产一体化服务产业链。因此，前端业务积蓄客户流量，后端生产逐步放量，特色CDMO弹性最大。",
    "labels": [
      [
        "T0",
        "行业",
        1,
        7,
        "特色CDMO"
      ],
      [
        "T1",
        "公司",
        10,
        14,
        "康龙化成"
      ],
      [
        "T2",
        "公司",
        15,
        19,
        "药石科技"
      ],
      [
        "T3",
        "公司",
        20,
        24,
        "皓元医药"
      ],
      [
        "T4",
        "公司",
        25,
        29,
        "维亚生物"
      ],
      [
        "T5",
        "行业",
        38,
        45,
        "早期实验室服务"
      ]
    ]
  },
  {
    "id": 1457,
    "text": "我们预计未来三年公司临床前 CRO 业务将保持稳健增长，其中中国实验室业务实现 20/18/16%的增长，美国实验室业务实现 30/30/25%的增长，基于：1）中国新药创新需求与日增加、公司业务条线持续扩张（加速发展安评等业务），以及不断发展长尾客户； 2） 引领新技术领域，拓展新热点（比如 Protac业务拉动小分子新药研发的广泛需求）；以及 3）细胞&基因疗法市场的蓬勃兴起。",
    "labels": [
      [
        "T0",
        "时间范围",
        4,
        8,
        "未来三年"
      ],
      [
        "T1",
        "行业",
        10,
        18,
        "临床前 CRO "
      ],
      [
        "T2",
        "地点范围",
        81,
        83,
        "中国"
      ],
      [
        "T3",
        "行业需求",
        87,
        89,
        "需求"
      ],
      [
        "T4",
        "行业",
        177,
        184,
        "细胞&基因疗法"
      ],
      [
        "T5",
        "地点范围",
        30,
        32,
        "中国"
      ],
      [
        "T6",
        "行业",
        83,
        87,
        "新药创新"
      ],
      [
        "T7",
        "属性值",
        89,
        93,
        "与日增加"
      ]
    ]
  },
  {
    "id": 1463,
    "text": "个股表现来看，从1月6-2月6日，近1个月跌幅排名前3的分别是：方达控股（-3.3%）＞百诚医药（-4.34%）＞博腾股份（-8.18%）；近1年涨幅排名前3的分别是：博腾股份 （86.03%）＞美迪西（48.17%）＞普洛药业 （19.98%），整体看博腾股份股价表现较为坚挺。",
    "labels": [
      [
        "T0",
        "时间范围",
        8,
        16,
        "1月6-2月6日"
      ],
      [
        "T1",
        "时间范围",
        17,
        21,
        "近1个月"
      ],
      [
        "T2",
        "公司",
        32,
        36,
        "方达控股"
      ],
      [
        "T3",
        "公司",
        44,
        48,
        "百诚医药"
      ],
      [
        "T4",
        "公司",
        57,
        61,
        "博腾股份"
      ],
      [
        "T5",
        "时间范围",
        70,
        73,
        "近1年"
      ],
      [
        "T6",
        "公司",
        84,
        88,
        "博腾股份"
      ],
      [
        "T7",
        "公司",
        98,
        101,
        "美迪西"
      ],
      [
        "T8",
        "公司",
        110,
        115,
        "普洛药业 "
      ],
      [
        "T9",
        "公司",
        127,
        131,
        "博腾股份"
      ]
    ]
  },
  {
    "id": 1469,
    "text": "细胞基因治疗CXO市场规模保持稳健增长。 2020年全球CGT领域CRO和CDMO 市场规模分别达到 7.05亿美元和 17.19亿美元。随着终端产品市场规模的快速扩大，CXO市场有望水涨船高。预计到 2025年全球 CGT领域的 CRO和 CDMO 市场规模分别达到 17.41亿和 78.55亿美元，CAGR分别达到 19.8%和 35.5%。",
    "labels": [
      [
        "T0",
        "行业",
        0,
        9,
        "细胞基因治疗CXO"
      ],
      [
        "T1",
        "市场规模",
        9,
        13,
        "市场规模"
      ],
      [
        "T2",
        "地点范围",
        26,
        28,
        "全球"
      ],
      [
        "T3",
        "行业",
        28,
        31,
        "CGT"
      ],
      [
        "T4",
        "行业",
        33,
        36,
        "CRO"
      ],
      [
        "T5",
        "行业",
        37,
        41,
        "CDMO"
      ],
      [
        "T6",
        "市场规模",
        42,
        46,
        "市场规模"
      ],
      [
        "T7",
        "属性值",
        51,
        58,
        "7.05亿美元"
      ],
      [
        "T8",
        "属性值",
        60,
        68,
        "17.19亿美元"
      ],
      [
        "T9",
        "市场规模",
        75,
        79,
        "市场规模"
      ],
      [
        "T10",
        "行业",
        85,
        88,
        "CXO"
      ],
      [
        "T11",
        "时间范围",
        101,
        106,
        "2025年"
      ],
      [
        "T12",
        "行业",
        108,
        112,
        " CGT"
      ],
      [
        "T13",
        "行业",
        116,
        119,
        "CRO"
      ],
      [
        "T14",
        "行业",
        121,
        125,
        "CDMO"
      ],
      [
        "T15",
        "市场规模",
        126,
        130,
        "市场规模"
      ],
      [
        "T16",
        "属性值",
        134,
        141,
        " 17.41亿"
      ],
      [
        "T17",
        "CAGR",
        152,
        156,
        "CAGR"
      ],
      [
        "T18",
        "属性值",
        161,
        166,
        "19.8%"
      ],
      [
        "T19",
        "属性值",
        168,
        173,
        "35.5%"
      ],
      [
        "T20",
        "地点范围",
        106,
        108,
        "全球"
      ],
      [
        "T21",
        "属性值",
        15,
        19,
        "稳健增长"
      ],
      [
        "T22",
        "时间范围",
        21,
        26,
        "2020年"
      ],
      [
        "T23",
        "属性值",
        143,
        151,
        "78.55亿美元"
      ]
    ]
  },
  {
    "id": 1481,
    "text": "1、《凯莱英 2021年报点评：产能加速释放，小分子和新兴业务均维持高增长！》2022-03-31 2、《康德莱 2021年业绩快报及 2022Q1业绩预告点评：产品线持续拓展，穿刺龙头成长空间广阔！》2022-03-31 3、《康龙化成 2021年报点评： 业绩超出预期，股权激励带动新一轮增长！》2022-03-31 4、《昊海生科 2021年报点评： 收入端稳健增长，新产品继续贡献增量！》2022-03-31 5、《心通医疗 2021年年报点评： 疫情拖累行业增速，看好公司中长期发展！》2022-04-01 6、《昭衍新药 2021年年报点评： 业绩符合预期，产能扩张+海外布局助力业绩增长！》 2022-04-01",
    "labels": [
      [
        "T0",
        "公司",
        3,
        6,
        "凯莱英"
      ],
      [
        "T1",
        "时间范围",
        7,
        12,
        "2021年"
      ],
      [
        "T2",
        "公司",
        53,
        56,
        "康德莱"
      ],
      [
        "T3",
        "时间范围",
        57,
        62,
        "2021年"
      ],
      [
        "T4",
        "业绩",
        62,
        64,
        "业绩"
      ],
      [
        "T5",
        "时间范围",
        68,
        74,
        "2022Q1"
      ],
      [
        "T6",
        "业绩",
        74,
        76,
        "业绩"
      ],
      [
        "T7",
        "龙头企业",
        91,
        93,
        "龙头"
      ],
      [
        "T8",
        "时间范围",
        101,
        111,
        "2022-03-31"
      ],
      [
        "T9",
        "公司",
        115,
        119,
        "康龙化成"
      ],
      [
        "T10",
        "业绩",
        130,
        132,
        "业绩"
      ],
      [
        "T11",
        "属性值",
        132,
        136,
        "超出预期"
      ],
      [
        "T12",
        "时间范围",
        150,
        160,
        "2022-03-31"
      ],
      [
        "T13",
        "公司",
        164,
        168,
        "昊海生科"
      ],
      [
        "T14",
        "时间范围",
        169,
        174,
        "2021年"
      ],
      [
        "T15",
        "营业收入",
        178,
        182,
        " 收入端"
      ],
      [
        "T16",
        "属性值",
        182,
        186,
        "稳健增长"
      ],
      [
        "T17",
        "时间范围",
        198,
        208,
        "2022-03-31"
      ],
      [
        "T18",
        "公司",
        212,
        216,
        "心通医疗"
      ],
      [
        "T19",
        "时间范围",
        217,
        222,
        "2021年"
      ],
      [
        "T20",
        "时间范围",
        248,
        258,
        "2022-04-01"
      ],
      [
        "T21",
        "公司",
        262,
        266,
        "昭衍新药"
      ],
      [
        "T22",
        "时间范围",
        267,
        272,
        "2021年"
      ],
      [
        "T23",
        "业绩",
        278,
        280,
        "业绩"
      ],
      [
        "T24",
        "属性值",
        18,
        22,
        "加速释放"
      ],
      [
        "T25",
        "产能",
        16,
        18,
        "产能"
      ],
      [
        "T26",
        "时间范围",
        39,
        49,
        "2022-03-31"
      ],
      [
        "T27",
        "行业",
        89,
        91,
        "穿刺"
      ],
      [
        "T28",
        "时间范围",
        120,
        125,
        "2021年"
      ],
      [
        "T29",
        "属性值",
        280,
        284,
        "符合预期"
      ],
      [
        "T30",
        "属性值",
        287,
        289,
        "扩张"
      ],
      [
        "T31",
        "产能",
        285,
        287,
        "产能"
      ],
      [
        "T32",
        "地点范围",
        290,
        292,
        "海外"
      ],
      [
        "T33",
        "属性值",
        298,
        300,
        "增长"
      ],
      [
        "T34",
        "业绩",
        296,
        298,
        "业绩"
      ],
      [
        "T35",
        "时间范围",
        303,
        313,
        "2022-04-01"
      ]
    ]
  },
  {
    "id": 1489,
    "text": "自上周三（5月 26日）开始，普洛药业股价经历了 3天比较大的调整，主要由于大家对印度疫情蔓延和人民币升值的担心；随后在上周最后一个交易日，CXO 板块均经历了比较大幅度的调整，市场上甚至产生了对 CXO行业成长性的担忧。 我们认为，不论是从短期还是中期看来，CXO 行业仍是医药行业内景气度最为确定的赛道，其行业景气度最高点和公司市值最高点都还未到达。 1）人民币升值预期减弱，CXO公司业绩影响有限。人民币短期呈现快速升值趋势，但我们认为随着美国经济下半年的全面反弹，美元指数有望随之走强，人民币汇率上涨预期减弱。据我们草根调研了解到，以海外收入为主的国内 CXO公司均采用了相应的锁汇政策，同时 CXO公司的订单报价采取价格协商机制，汇率变动和原材料价格变动等因素均可以适当向下游客户传导，总体压力可控。 2）前瞻性指标提示行业景气度仍处在上行阶段，行业景气度高点还未到达。动脉网数据显示，2021Q1，全球医疗健康一级市场融资总额达到 1954亿人民币， 实现翻倍级增长；国内医疗健康一级市场融资总额达到 494亿人民币，单季融资金额均创下历史新高。我们认为，医疗健康行业的一级市场融资为未来 2-3年创新药企的研发支出提供充足的资金来源，全球新药研发热度不减，CXO 行业仍处在景气周期上行阶段，行业景气度高点还未到达。",
    "labels": [
      [
        "T0",
        "时间范围",
        0,
        14,
        "自上周三（5月 26日）开始"
      ],
      [
        "T1",
        "公司",
        15,
        19,
        "普洛药业"
      ],
      [
        "T2",
        "行业",
        70,
        73,
        "CXO"
      ],
      [
        "T3",
        "时间范围",
        60,
        62,
        "上周"
      ],
      [
        "T4",
        "行业",
        99,
        102,
        "CXO"
      ],
      [
        "T5",
        "时间范围",
        121,
        123,
        "短期"
      ],
      [
        "T6",
        "时间范围",
        125,
        127,
        "中期"
      ],
      [
        "T7",
        "行业",
        130,
        133,
        "CXO"
      ],
      [
        "T8",
        "行业",
        138,
        140,
        "医药"
      ],
      [
        "T9",
        "行业公司",
        190,
        195,
        "CXO公司"
      ],
      [
        "T10",
        "业绩",
        195,
        197,
        "业绩"
      ],
      [
        "T11",
        "行业公司",
        281,
        286,
        "CXO公司"
      ],
      [
        "T12",
        "地点范围",
        278,
        280,
        "国内"
      ],
      [
        "T13",
        "地点范围",
        271,
        273,
        "海外"
      ],
      [
        "T14",
        "行业公司",
        301,
        306,
        "CXO公司"
      ],
      [
        "T15",
        "时间范围",
        398,
        404,
        "2021Q1"
      ],
      [
        "T16",
        "地点范围",
        405,
        407,
        "全球"
      ],
      [
        "T17",
        "行业",
        407,
        411,
        "医疗健康"
      ],
      [
        "T18",
        "投融资金额",
        415,
        419,
        "融资总额"
      ],
      [
        "T19",
        "属性值",
        422,
        430,
        "1954亿人民币"
      ],
      [
        "T20",
        "地点范围",
        440,
        442,
        "国内"
      ],
      [
        "T21",
        "行业",
        442,
        446,
        "医疗健康"
      ],
      [
        "T22",
        "投融资金额",
        450,
        454,
        "融资总额"
      ],
      [
        "T23",
        "属性值",
        457,
        464,
        "494亿人民币"
      ],
      [
        "T24",
        "行业",
        484,
        488,
        "医疗健康"
      ],
      [
        "T25",
        "时间范围",
        498,
        505,
        "未来 2-3年"
      ],
      [
        "T26",
        "行业公司",
        505,
        509,
        "创新药企"
      ],
      [
        "T27",
        "研发费用",
        510,
        514,
        "研发支出"
      ],
      [
        "T28",
        "属性值",
        516,
        523,
        "充足的资金来源"
      ],
      [
        "T29",
        "地点范围",
        524,
        526,
        "全球"
      ],
      [
        "T30",
        "行业",
        526,
        530,
        "新药研发"
      ],
      [
        "T31",
        "行业",
        535,
        538,
        "CXO"
      ],
      [
        "T32",
        "地点范围",
        223,
        225,
        "美国"
      ],
      [
        "T33",
        "时间范围",
        227,
        230,
        "下半年"
      ]
    ]
  },
  {
    "id": 1499,
    "text": "以合全药业、凯莱英价格为参考，我们预计 21-25年 CMC业务收入将以 30%以上的增速增长，25年临床 III期、商业化项目数将分别达到 79、18个，公司 CMC收入首次突破 50亿元。",
    "labels": [
      [
        "T0",
        "公司",
        1,
        5,
        "合全药业"
      ],
      [
        "T1",
        "公司",
        6,
        9,
        "凯莱英"
      ],
      [
        "T2",
        "时间范围",
        19,
        26,
        " 21-25年"
      ],
      [
        "T3",
        "行业",
        27,
        30,
        "CMC"
      ],
      [
        "T4",
        "营业收入",
        32,
        34,
        "收入"
      ],
      [
        "T5",
        "行业",
        81,
        84,
        "CMC"
      ],
      [
        "T6",
        "营业收入",
        84,
        86,
        "收入"
      ]
    ]
  },
  {
    "id": 1505,
    "text": "以美国为例，美国医疗保险和医疗补助服务中心（CMS）针对诺华的 CAR-T 产品 Kymriah 提出了基于疗效的医保支付方式，患者只有在第一个月对治疗有应答，医保才会在月末给诺华进行补偿。吉利徳则进行了商业保险的探索，保险公司可以与患者签订个性化合同，在符合条件的情况下患者可以得到全额赔付。对于 Zolegensma 这种天价药物，多家商业保险公司也有覆盖，但相应地提出更多限制条件，诸如患者年龄、疾病症状、治疗历史等方面有所要求，需满足标准方可赔付。",
    "labels": [
      [
        "T0",
        "公司",
        28,
        30,
        "诺华"
      ],
      [
        "T1",
        "公司",
        88,
        90,
        "诺华"
      ],
      [
        "T2",
        "公司",
        95,
        98,
        "吉利徳"
      ],
      [
        "T3",
        "地点范围",
        1,
        3,
        "美国"
      ],
      [
        "T4",
        "地点范围",
        6,
        8,
        "美国"
      ]
    ]
  },
  {
    "id": 1506,
    "text": " 行业继续维持高景气度：参照核心跟踪指标（美国FDA新药获批数量、国内CDE受理新药临床申报数量，以及全球TOP 20跨国药企研发投入及美国一级医疗健康投融资增长情况、国内A股存量药企研发投入，及核心Biotech企业研发投入），整体维持判断全球及国内医疗健康研发投入继续维持高景气度。  A+H核心CXO公司2020年报财务数据分析：行业高景气度延续，不容忽视的国内强β  核心CXO公司继续呈现高景气度：统计15家A+H CXO公司2020年合计实现营业收入438.7亿元，同比增长42.0%，且统计 9家CXO公司2021Q1合计实现营业收入94.3亿元，同比增长53.7%，继续延续超高速增长。  工程师红利下带来全球产业链转移和国内高β，共同驱动行业估值中枢上移： • 全球化产业链转移持续，尤其是在疫情催化下，实验室业务、CDMO业务有望加速转移：CXO公司海外客户收入合计为274.58亿元，同比增长28.5%，继续延续高速增长的趋势； • 不要忽视的国内强β，全球化CXO公司持续为国内创新赋能：CXO公司国内客户收入合计为116.39亿元，同比增长 44.0%，尤其是国内强β代表的昭衍新药、美迪西均呈现超高速增长。 • 估值中枢呈现逐渐上移：受业绩高速增长和确定性增长影响，核心CXO公司估值中枢上移过程中。  分业务来看，CDMO业务景气度最高：CDMO业务2020年处于固定资产呈现快速增长与单位固定资产产值双重提升中， 营业收入达到219.4亿元，同比增长40.1%；实验室业务（药物发现&临床前研究）2020年处于员工数量呈现高速增长以及单人产值双重提升中，营业收入达到157.8亿元，同比增长32.2% ；临床CRO业务2020年受疫情影响较大，营业收入达到42.4亿元，同比增长15.4%。  投资建议：投资策略上，CXO全产业链战略性看好，继续推荐具有全球竞争力的龙头公司，CDMO、药物发现及临床前研究 CRO和临床CRO的细分市场龙头，以及受益于行业高景气度的小而美的公司，持续推荐药明康德、博腾股份、美迪西、九洲药业、昭衍新药、凯莱英、药明生物等。  风险提示：新冠疫情进展具有不确定性；相关公司海外并购及业务拓展具有不确定性；核心管理层及核心技术人员流失的风 2",
    "labels": [
      [
        "T0",
        "行业公司",
        209,
        221,
        "15家A+H CXO公司"
      ],
      [
        "T1",
        "时间范围",
        221,
        226,
        "2020年"
      ],
      [
        "T2",
        "营业收入",
        230,
        234,
        "营业收入"
      ],
      [
        "T3",
        "属性值",
        234,
        241,
        "438.7亿元"
      ],
      [
        "T4",
        "属性值",
        246,
        251,
        "42.0%"
      ],
      [
        "T5",
        "行业公司",
        256,
        263,
        "9家CXO公司"
      ],
      [
        "T6",
        "时间范围",
        263,
        269,
        "2021Q1"
      ],
      [
        "T7",
        "营业收入",
        273,
        277,
        "营业收入"
      ],
      [
        "T8",
        "属性值",
        277,
        283,
        "94.3亿元"
      ],
      [
        "T9",
        "属性值",
        288,
        293,
        "53.7%"
      ],
      [
        "T10",
        "属性值",
        298,
        303,
        "超高速增长"
      ],
      [
        "T11",
        "地点范围",
        323,
        325,
        "国内"
      ],
      [
        "T12",
        "地点范围",
        315,
        317,
        "全球"
      ],
      [
        "T13",
        "行业",
        365,
        368,
        "实验室"
      ],
      [
        "T14",
        "行业",
        371,
        375,
        "CDMO"
      ],
      [
        "T15",
        "行业公司",
        384,
        389,
        "CXO公司"
      ],
      [
        "T16",
        "地点范围",
        389,
        391,
        "海外"
      ],
      [
        "T17",
        "营业收入",
        393,
        395,
        "收入"
      ],
      [
        "T18",
        "属性值",
        398,
        406,
        "274.58亿元"
      ],
      [
        "T19",
        "属性值",
        411,
        416,
        "28.5%"
      ],
      [
        "T20",
        "属性值",
        421,
        425,
        "高速增长"
      ],
      [
        "T21",
        "地点范围",
        437,
        439,
        "国内"
      ],
      [
        "T22",
        "行业公司",
        445,
        450,
        "CXO公司"
      ],
      [
        "T23",
        "地点范围",
        453,
        455,
        "国内"
      ],
      [
        "T24",
        "行业公司",
        460,
        465,
        "CXO公司"
      ],
      [
        "T25",
        "地点范围",
        465,
        467,
        "国内"
      ],
      [
        "T26",
        "营业收入",
        469,
        471,
        "收入"
      ],
      [
        "T27",
        "属性值",
        474,
        482,
        "116.39亿元"
      ],
      [
        "T28",
        "属性值",
        488,
        493,
        "44.0%"
      ],
      [
        "T29",
        "地点范围",
        497,
        499,
        "国内"
      ],
      [
        "T30",
        "公司",
        504,
        508,
        "昭衍新药"
      ],
      [
        "T31",
        "公司",
        509,
        512,
        "美迪西"
      ],
      [
        "T32",
        "业绩",
        536,
        538,
        "业绩"
      ],
      [
        "T33",
        "行业公司",
        551,
        558,
        "核心CXO公司"
      ],
      [
        "T34",
        "行业",
        577,
        581,
        "CDMO"
      ],
      [
        "T35",
        "行业",
        589,
        593,
        "CDMO"
      ],
      [
        "T36",
        "时间范围",
        595,
        600,
        "2020年"
      ],
      [
        "T37",
        "固定资产",
        602,
        606,
        "固定资产"
      ],
      [
        "T38",
        "属性值",
        608,
        612,
        "快速增长"
      ],
      [
        "T39",
        "营业收入",
        628,
        632,
        "营业收入"
      ],
      [
        "T40",
        "属性值",
        634,
        641,
        "219.4亿元"
      ],
      [
        "T41",
        "属性值",
        646,
        651,
        "40.1%"
      ],
      [
        "T42",
        "行业",
        652,
        655,
        "实验室"
      ],
      [
        "T43",
        "行业",
        658,
        662,
        "药物发现"
      ],
      [
        "T44",
        "行业",
        663,
        668,
        "临床前研究"
      ],
      [
        "T45",
        "时间范围",
        669,
        674,
        "2020年"
      ],
      [
        "T46",
        "员工数量",
        676,
        680,
        "员工数量"
      ],
      [
        "T47",
        "属性值",
        682,
        686,
        "高速增长"
      ],
      [
        "T48",
        "营业收入",
        698,
        702,
        "营业收入"
      ],
      [
        "T49",
        "属性值",
        704,
        711,
        "157.8亿元"
      ],
      [
        "T50",
        "属性值",
        716,
        721,
        "32.2%"
      ],
      [
        "T51",
        "行业",
        723,
        728,
        "临床CRO"
      ],
      [
        "T52",
        "时间范围",
        730,
        735,
        "2020年"
      ],
      [
        "T53",
        "营业收入",
        743,
        747,
        "营业收入"
      ],
      [
        "T54",
        "属性值",
        749,
        755,
        "42.4亿元"
      ],
      [
        "T55",
        "属性值",
        760,
        765,
        "15.4%"
      ],
      [
        "T56",
        "行业",
        780,
        783,
        "CXO"
      ],
      [
        "T57",
        "地点范围",
        799,
        801,
        "全球"
      ],
      [
        "T58",
        "行业",
        810,
        814,
        "CDMO"
      ],
      [
        "T59",
        "行业",
        815,
        819,
        "药物发现"
      ],
      [
        "T60",
        "行业",
        820,
        829,
        "临床前研究 CRO"
      ],
      [
        "T61",
        "行业",
        830,
        835,
        "临床CRO"
      ],
      [
        "T62",
        "公司",
        866,
        870,
        "药明康德"
      ],
      [
        "T63",
        "公司",
        871,
        875,
        "博腾股份"
      ],
      [
        "T64",
        "公司",
        876,
        879,
        "美迪西"
      ],
      [
        "T65",
        "公司",
        880,
        884,
        "九洲药业"
      ],
      [
        "T66",
        "公司",
        885,
        889,
        "昭衍新药"
      ],
      [
        "T67",
        "公司",
        890,
        893,
        "凯莱英"
      ],
      [
        "T68",
        "公司",
        894,
        898,
        "药明生物"
      ],
      [
        "T69",
        "行业公司",
        147,
        157,
        "A+H核心CXO公司"
      ],
      [
        "T70",
        "时间范围",
        157,
        162,
        "2020年"
      ],
      [
        "T71",
        "财务情况",
        163,
        167,
        "财务数据"
      ],
      [
        "T72",
        "地点范围",
        85,
        87,
        "国内"
      ],
      [
        "T73",
        "地点范围",
        52,
        54,
        "全球"
      ],
      [
        "T74",
        "行业公司",
        54,
        64,
        "TOP 20跨国药企"
      ],
      [
        "T75",
        "研发费用",
        64,
        68,
        "研发投入"
      ],
      [
        "T76",
        "地点范围",
        69,
        71,
        "美国"
      ],
      [
        "T77",
        "行业",
        73,
        77,
        "医疗健康"
      ],
      [
        "T78",
        "投融资情况",
        77,
        80,
        "投融资"
      ],
      [
        "T79",
        "地点范围",
        22,
        24,
        "美国"
      ],
      [
        "T80",
        "FDA新药获批数",
        24,
        33,
        "FDA新药获批数量"
      ],
      [
        "T81",
        "地点范围",
        34,
        36,
        "国内"
      ],
      [
        "T82",
        "行业公司",
        91,
        93,
        "药企"
      ],
      [
        "T83",
        "研发费用",
        93,
        97,
        "研发投入"
      ],
      [
        "T84",
        "行业公司",
        99,
        110,
        "核心Biotech企业"
      ],
      [
        "T85",
        "研发费用",
        110,
        114,
        "研发投入"
      ],
      [
        "T86",
        "地点范围",
        122,
        124,
        "全球"
      ],
      [
        "T87",
        "地点范围",
        125,
        127,
        "国内"
      ],
      [
        "T88",
        "行业",
        127,
        131,
        "医疗健康"
      ],
      [
        "T89",
        "研发费用",
        131,
        135,
        "研发投入"
      ],
      [
        "T90",
        "属性值",
        139,
        143,
        "高景气度"
      ],
      [
        "T91",
        "行业公司",
        191,
        198,
        "核心CXO公司"
      ],
      [
        "T92",
        "地点范围",
        184,
        186,
        "国内"
      ]
    ]
  },
  {
    "id": 1508,
    "text": "需求旺盛，CGT CDMO 蓄势待发。快速增加的商业化产品，以及积极旺盛的研发需求，将极大地推动 CGT CDMO 发展。CGT 产品商业化，对产能的需求将从百人级提升至千人或万人级，增加药企对 CDMO 产能的依赖。此外，CGT 临床研发管线处于快速扩张周期，CDMO 可以协助研发生产。据 ARM 报告预测，截至 2026 年，全球 CGT 临床项目数将达 3500 项（包含干细胞疗法） ，较 2020 年翻 2 倍。受益于终端 CGT 市场的快速发展，全球 CGT CDMO 市场规模将在 2025 年达到近 100 亿美元（2020-25 年 CAGR=34.9%） ，中国 CGT CDMO 市场规模达 107 亿元（2020-25 年 CAGR=51.5%）。",
    "labels": [
      [
        "T0",
        "行业需求",
        0,
        2,
        "需求"
      ],
      [
        "T1",
        "行业",
        5,
        14,
        "CGT CDMO "
      ],
      [
        "T2",
        "行业",
        49,
        58,
        "CGT CDMO "
      ],
      [
        "T3",
        "行业",
        61,
        64,
        "CGT"
      ],
      [
        "T4",
        "行业公司",
        94,
        96,
        "药企"
      ],
      [
        "T5",
        "行业",
        98,
        103,
        "CDMO "
      ],
      [
        "T6",
        "行业",
        112,
        115,
        "CGT"
      ],
      [
        "T7",
        "行业",
        131,
        135,
        "CDMO"
      ],
      [
        "T8",
        "时间范围",
        156,
        165,
        "截至 2026 年"
      ],
      [
        "T9",
        "地点范围",
        166,
        168,
        "全球"
      ],
      [
        "T10",
        "行业",
        169,
        172,
        "CGT"
      ],
      [
        "T11",
        "临床试验数量",
        173,
        178,
        "临床项目数"
      ],
      [
        "T12",
        "地点范围",
        230,
        232,
        "全球"
      ],
      [
        "T13",
        "行业",
        233,
        242,
        "CGT CDMO "
      ],
      [
        "T14",
        "市场规模",
        242,
        246,
        "市场规模"
      ],
      [
        "T15",
        "时间范围",
        248,
        255,
        " 2025 年"
      ],
      [
        "T16",
        "属性值",
        257,
        266,
        "近 100 亿美元"
      ],
      [
        "T17",
        "属性值",
        282,
        287,
        "34.9%"
      ],
      [
        "T18",
        "CAGR",
        277,
        281,
        "CAGR"
      ],
      [
        "T19",
        "时间范围",
        267,
        276,
        "2020-25 年"
      ],
      [
        "T20",
        "地点范围",
        290,
        292,
        "中国"
      ],
      [
        "T21",
        "行业",
        293,
        301,
        "CGT CDMO"
      ],
      [
        "T22",
        "市场规模",
        302,
        306,
        "市场规模"
      ],
      [
        "T23",
        "属性值",
        308,
        314,
        "107 亿元"
      ],
      [
        "T24",
        "属性值",
        330,
        335,
        "51.5%"
      ],
      [
        "T25",
        "CAGR",
        325,
        329,
        "CAGR"
      ],
      [
        "T26",
        "时间范围",
        315,
        325,
        "2020-25 年 "
      ],
      [
        "T27",
        "属性值",
        2,
        4,
        "旺盛"
      ],
      [
        "T28",
        "产能",
        72,
        74,
        "产能"
      ],
      [
        "T29",
        "产能",
        103,
        105,
        "产能"
      ],
      [
        "T30",
        "属性值",
        181,
        187,
        "3500 项"
      ],
      [
        "T31",
        "时间范围",
        200,
        206,
        "2020 年"
      ],
      [
        "T32",
        "属性值",
        206,
        211,
        "翻 2 倍"
      ],
      [
        "T33",
        "行业",
        215,
        221,
        "终端 CGT"
      ]
    ]
  },
  {
    "id": 1511,
    "text": "历史悠长的老牌 CDMO 公司。公司成立于 1897 年，在 1965 年进入医药化工中间体业务，并发展小分子 CDMO 业务起家，成为全球小分子 CDMO 巨头；在上世纪九十年代至 2000 年初积极布局大分子业务，目前是全球拥有最多商业化大分子 CDMO 项目数的公司； 于 2015 年公司正式布局细胞基因治疗 CDMO 服务， 并成为最早实现 2000L AAV 商业化生产的 CDMO 公司。 公司始终紧随时代步伐， 把握住每一个新型治疗方式的风口，成为制药界 CDMO 龙头公司。 2017 年，Lonza 通过收购 PharmaCell BV 奠定其细胞基因治疗生产领先地位， 后者为当时仅有的两款获批细胞治疗产品提供商业化生产。至今 Lonza 累计服务超过 120 个细胞基因治疗项目，提供细胞和基因治疗的临床前、临床和商业化开发和生产端到端服务，主要包括：1）自体和异体细胞疗法生产服务；2） 用于基因治疗的病毒载体生产；3）工艺开发和生物分析服务；4）符合 cGMP 规范的生产制造；5）流程监督与管理支持；6）原材料采购服务。 产能方面，Lonza 在美洲、欧洲、亚洲均有布局，其中位于休斯顿的 30 万平方英尺 CGT 生产园区是全球最大 CGT 生产基地，在 2018 年正式投产，并且现在已获得 FDA 批准进行商业化生产。厂区洁净室采用模块化设计建设，可以根据客户需求有效快速改造，以满足不同规模的生产需求，帮助药品获批上市以及商业化生产。",
    "labels": [
      [
        "T0",
        "行业",
        39,
        46,
        "医药化工中间体"
      ],
      [
        "T1",
        "行业",
        52,
        60,
        "小分子 CDMO"
      ],
      [
        "T2",
        "地点范围",
        68,
        70,
        "全球"
      ],
      [
        "T3",
        "行业",
        70,
        79,
        "小分子 CDMO "
      ],
      [
        "T4",
        "行业",
        103,
        106,
        "大分子"
      ],
      [
        "T5",
        "行业",
        121,
        129,
        "大分子 CDMO"
      ],
      [
        "T6",
        "行业",
        152,
        163,
        "细胞基因治疗 CDMO"
      ],
      [
        "T7",
        "行业公司",
        193,
        200,
        "CDMO 公司"
      ],
      [
        "T8",
        "行业",
        232,
        240,
        "制药界 CDMO"
      ],
      [
        "T9",
        "龙头企业",
        241,
        245,
        "龙头公司"
      ],
      [
        "T10",
        "时间范围",
        246,
        253,
        " 2017 年"
      ],
      [
        "T11",
        "公司",
        254,
        259,
        "Lonza"
      ],
      [
        "T12",
        "公司",
        265,
        278,
        "PharmaCell BV"
      ],
      [
        "T13",
        "行业",
        282,
        288,
        "细胞基因治疗"
      ],
      [
        "T14",
        "公司",
        324,
        330,
        " Lonza"
      ],
      [
        "T15",
        "产能",
        475,
        478,
        " 产能"
      ],
      [
        "T16",
        "公司",
        481,
        486,
        "Lonza"
      ],
      [
        "T17",
        "行业",
        533,
        537,
        "CGT "
      ],
      [
        "T18",
        "行业公司",
        8,
        15,
        "CDMO 公司"
      ],
      [
        "T19",
        "时间范围",
        22,
        28,
        "1897 年"
      ],
      [
        "T20",
        "时间范围",
        31,
        37,
        "1965 年"
      ],
      [
        "T21",
        "时间范围",
        140,
        146,
        "2015 年"
      ],
      [
        "T22",
        "属性值",
        487,
        500,
        "在美洲、欧洲、亚洲均有布局"
      ],
      [
        "T23",
        "地点范围",
        505,
        508,
        "休斯顿"
      ],
      [
        "T24",
        "地点范围",
        528,
        530,
        "全球"
      ],
      [
        "T25",
        "时间范围",
        544,
        550,
        "2018 年"
      ]
    ]
  },
  {
    "id": 1517,
    "text": "短期在手订单预计较为饱满，受益于海外订单持续转移、漏斗效应下订单规模放大，未来 3年高增长的确定性较强；中期来看，人才、平台、技术三大核心竞争力支撑其在国内同行中保持领先地位，与海外企业竞争中发挥成本优势，前瞻布局细胞基因治疗领域 CTDMO使得公司有望在新一波药物研发浪潮中抢占先机；长期看行业天花板较高， 静态比较公司当前与全球 CRO龙头的收入体量有 5~6倍差距，以 10 年期维度测算，公司 CRO与 CDMO全球市占率有望提升至 15%和 5% （2020年市占率预计为 2.4%和 0.9%），对应 10倍以上的成长空间。",
    "labels": [
      [
        "T0",
        "在手订单",
        2,
        6,
        "在手订单"
      ],
      [
        "T1",
        "时间范围",
        37,
        42,
        "未来 3年"
      ],
      [
        "T2",
        "行业",
        166,
        170,
        " CRO"
      ],
      [
        "T3",
        "龙头企业",
        170,
        172,
        "龙头"
      ],
      [
        "T4",
        "行业",
        201,
        204,
        "CRO"
      ],
      [
        "T5",
        "行业",
        206,
        210,
        "CDMO"
      ],
      [
        "T6",
        "市场份额",
        212,
        215,
        "市占率"
      ],
      [
        "T7",
        "地点范围",
        210,
        212,
        "全球"
      ],
      [
        "T8",
        "时间范围",
        230,
        235,
        "2020年"
      ],
      [
        "T9",
        "市场份额",
        235,
        238,
        "市占率"
      ],
      [
        "T10",
        "地点范围",
        16,
        18,
        "海外"
      ],
      [
        "T11",
        "行业",
        107,
        121,
        "细胞基因治疗领域 CTDMO"
      ],
      [
        "T12",
        "行业",
        131,
        135,
        "药物研发"
      ],
      [
        "T13",
        "时间范围",
        143,
        145,
        "长期"
      ],
      [
        "T14",
        "时间范围",
        161,
        163,
        "当前"
      ],
      [
        "T15",
        "地点范围",
        164,
        166,
        "全球"
      ],
      [
        "T16",
        "营业收入",
        173,
        175,
        "收入"
      ],
      [
        "T17",
        "时间范围",
        0,
        2,
        "短期"
      ],
      [
        "T18",
        "时间范围",
        52,
        54,
        "中期"
      ],
      [
        "T19",
        "地点范围",
        89,
        91,
        "海外"
      ],
      [
        "T20",
        "地点范围",
        76,
        78,
        "国内"
      ]
    ]
  },
  {
    "id": 1518,
    "text": "口2016-2020年康龙化成人效目前波动较大，疫情恢复后有望逐步回归正常。通过对比康龙化成与泰格医药、药明康德临床CRO服务人均创收来看，2018年康龙化成人均创收人均创利均处于较高水平，康龙化成临床研究服务2018年人均创收126.6万元/人，高于同年泰格医药59.0万元/人。2018年康龙化成人均创利32.1万元/人高于泰格医药25.5万元/人口康龙化成人效状况下降是因为疫情对海外临床业务造成影响以及2020年研发人员增长较快。2020年药明康德和康龙化成的临床CRO服务的毛利率、人均创收和人均创利水平均出现明显下降，药明康德主要是疫情影响下2020年临床订单的执行受到明显影响，康龙化成主要是因为疫情对海外临床业务造成一定影响以及2020年人员增长较快（同比2019年增长197%）导致人均创收和创利出现短暂下降，后续疫情恢复人员稳定，人均创收创利有望稳定提升",
    "labels": [
      [
        "T0",
        "时间范围",
        1,
        11,
        "2016-2020年"
      ],
      [
        "T1",
        "公司",
        11,
        15,
        "康龙化成"
      ],
      [
        "T2",
        "公司",
        42,
        46,
        "康龙化成"
      ],
      [
        "T3",
        "公司",
        47,
        51,
        "泰格医药"
      ],
      [
        "T4",
        "公司",
        52,
        56,
        "药明康德"
      ],
      [
        "T5",
        "行业",
        56,
        63,
        "临床CRO服务"
      ],
      [
        "T6",
        "人均收入",
        63,
        67,
        "人均创收"
      ],
      [
        "T7",
        "时间范围",
        70,
        75,
        "2018年"
      ],
      [
        "T8",
        "公司",
        75,
        79,
        "康龙化成"
      ],
      [
        "T9",
        "人均收入",
        79,
        83,
        "人均创收"
      ],
      [
        "T10",
        "人均利润",
        83,
        87,
        "人均创利"
      ],
      [
        "T11",
        "属性值",
        90,
        94,
        "较高水平"
      ],
      [
        "T12",
        "公司",
        95,
        99,
        "康龙化成"
      ],
      [
        "T13",
        "行业",
        99,
        105,
        "临床研究服务"
      ],
      [
        "T14",
        "时间范围",
        105,
        110,
        "2018年"
      ],
      [
        "T15",
        "人均收入",
        110,
        114,
        "人均创收"
      ],
      [
        "T16",
        "属性值",
        114,
        123,
        "126.6万元/人"
      ],
      [
        "T17",
        "公司",
        128,
        132,
        "泰格医药"
      ],
      [
        "T18",
        "属性值",
        132,
        140,
        "59.0万元/人"
      ],
      [
        "T19",
        "时间范围",
        141,
        146,
        "2018年"
      ],
      [
        "T20",
        "公司",
        146,
        150,
        "康龙化成"
      ],
      [
        "T21",
        "人均利润",
        150,
        154,
        "人均创利"
      ],
      [
        "T22",
        "属性值",
        154,
        162,
        "32.1万元/人"
      ],
      [
        "T23",
        "公司",
        164,
        168,
        "泰格医药"
      ],
      [
        "T24",
        "属性值",
        168,
        176,
        "25.5万元/人"
      ],
      [
        "T25",
        "公司",
        177,
        181,
        "康龙化成"
      ],
      [
        "T26",
        "地点范围",
        193,
        195,
        "海外"
      ],
      [
        "T27",
        "行业",
        195,
        197,
        "临床"
      ],
      [
        "T28",
        "时间范围",
        205,
        210,
        "2020年"
      ],
      [
        "T29",
        "时间范围",
        219,
        224,
        "2020年"
      ],
      [
        "T30",
        "公司",
        224,
        228,
        "药明康德"
      ],
      [
        "T31",
        "公司",
        229,
        233,
        "康龙化成"
      ],
      [
        "T32",
        "行业",
        234,
        241,
        "临床CRO服务"
      ],
      [
        "T33",
        "毛利",
        242,
        245,
        "毛利率"
      ],
      [
        "T34",
        "人均收入",
        246,
        250,
        "人均创收"
      ],
      [
        "T35",
        "人均利润",
        251,
        255,
        "人均创利"
      ],
      [
        "T36",
        "属性值",
        260,
        264,
        "明显下降"
      ],
      [
        "T37",
        "公司",
        265,
        269,
        "药明康德"
      ],
      [
        "T38",
        "时间范围",
        277,
        282,
        "2020年"
      ],
      [
        "T39",
        "公司",
        296,
        300,
        "康龙化成"
      ],
      [
        "T40",
        "地点范围",
        308,
        310,
        "海外"
      ],
      [
        "T41",
        "行业",
        310,
        312,
        "临床"
      ],
      [
        "T42",
        "时间范围",
        322,
        327,
        "2020年"
      ],
      [
        "T43",
        "时间范围",
        336,
        341,
        "2019年"
      ],
      [
        "T44",
        "属性值",
        329,
        333,
        "增长较快"
      ],
      [
        "T45",
        "人均收入",
        350,
        354,
        "人均创收"
      ],
      [
        "T46",
        "属性值",
        359,
        363,
        "短暂下降"
      ],
      [
        "T47",
        "属性值",
        372,
        374,
        "稳定"
      ],
      [
        "T48",
        "人均收入",
        375,
        379,
        "人均创收"
      ],
      [
        "T49",
        "属性值",
        383,
        387,
        "稳定提升"
      ]
    ]
  },
  {
    "id": 1523,
    "text": "Medpace，全球TOP10的临床CRO公司，1992年成立以来，专注于全方位I-IV期临床CRO服务。 图表11：Medpace成长轨迹图表12：Medpace近一年股价复盘图",
    "labels": [
      [
        "T0",
        "公司",
        0,
        7,
        "Medpace"
      ],
      [
        "T1",
        "地点范围",
        8,
        10,
        "全球"
      ],
      [
        "T2",
        "行业公司",
        16,
        23,
        "临床CRO公司"
      ],
      [
        "T3",
        "行业",
        45,
        50,
        "临床CRO"
      ],
      [
        "T4",
        "公司",
        59,
        66,
        "Medpace"
      ],
      [
        "T5",
        "公司",
        75,
        82,
        "Medpace"
      ],
      [
        "T6",
        "时间范围",
        82,
        85,
        "近一年"
      ],
      [
        "T7",
        "时间范围",
        24,
        29,
        "1992年"
      ]
    ]
  },
  {
    "id": 1535,
    "text": "本周医药板块调整明显，市场因素偏多、行业基本面因素变化不大，尤其是周五信达生物的 PD1的非麟非小细胞肺癌适应症在 FDA暂时被否。本周跌幅较大主要集中 CXO板块，主要原因经历过去三年牛市筹码结构过于集中，再加上药明生物暂时列入 UVL清单引发恐慌情绪。总体上看，康明康德、凯莱英、博腾股份等 CXO龙头估值 PEG等于 1或小于 1， CXO板块已处于估值底部。从行业景气度及筹码结构看，中药板块、设备自主可控、血制品及疫苗板块等比较具有吸引力。另外创新药股价从 2021 年下半年开始下跌，跌幅超过 60-70%，再加上信达事件最后一击，创新药收益大于风险，建议战略性配置创新药。",
    "labels": [
      [
        "T0",
        "时间范围",
        0,
        2,
        "本周"
      ],
      [
        "T1",
        "行业",
        2,
        4,
        "医药"
      ],
      [
        "T2",
        "时间范围",
        33,
        35,
        "周五"
      ],
      [
        "T3",
        "公司",
        35,
        39,
        "信达生物"
      ],
      [
        "T4",
        "时间范围",
        66,
        68,
        "本周"
      ],
      [
        "T5",
        "行业",
        76,
        80,
        " CXO"
      ],
      [
        "T6",
        "时间范围",
        89,
        93,
        "过去三年"
      ],
      [
        "T7",
        "公司",
        107,
        111,
        "药明生物"
      ],
      [
        "T8",
        "公司",
        133,
        137,
        "康明康德"
      ],
      [
        "T9",
        "公司",
        138,
        141,
        "凯莱英"
      ],
      [
        "T10",
        "公司",
        142,
        146,
        "博腾股份"
      ],
      [
        "T11",
        "行业",
        148,
        151,
        "CXO"
      ],
      [
        "T12",
        "龙头企业",
        151,
        153,
        "龙头"
      ],
      [
        "T13",
        "PEG",
        156,
        159,
        "PEG"
      ],
      [
        "T14",
        "属性值",
        159,
        168,
        "等于 1或小于 1"
      ],
      [
        "T15",
        "行业",
        170,
        173,
        "CXO"
      ],
      [
        "T16",
        "行业",
        196,
        198,
        "中药"
      ],
      [
        "T17",
        "行业",
        201,
        207,
        "设备自主可控"
      ],
      [
        "T18",
        "行业",
        208,
        211,
        "血制品"
      ],
      [
        "T19",
        "行业",
        212,
        214,
        "疫苗"
      ],
      [
        "T20",
        "行业",
        227,
        230,
        "创新药"
      ],
      [
        "T21",
        "行业",
        272,
        275,
        "创新药"
      ],
      [
        "T22",
        "行业",
        289,
        292,
        "创新药"
      ],
      [
        "T23",
        "时间范围",
        232,
        245,
        "从 2021 年下半年开始"
      ]
    ]
  },
  {
    "id": 1540,
    "text": "假设 3：商业化阶段创新药毛利率平均水平以 85%计算，其中原料药占成本比重以 60%计算，原料药与制剂的 CDMO渗透率均持续提升。据此我们测算商业化阶段制剂 CDMO市场规模到 2030年有望达到 412亿美元，原料药 CDMO 市场规模达到 877 亿美元。商业化阶段 CDMO 规模合计 1289 亿美元， 2020~2030年 CAGR为 8.71%。2030年研发阶段与商业化阶段 CDMO规模合计达到 1777亿美元，2020~2030年 CAGR为 8.24%。",
    "labels": [
      [
        "T0",
        "毛利",
        13,
        16,
        "毛利率"
      ],
      [
        "T1",
        "行业",
        30,
        33,
        "原料药"
      ],
      [
        "T2",
        "行业",
        46,
        49,
        "原料药"
      ],
      [
        "T3",
        "行业",
        50,
        58,
        "制剂的 CDMO"
      ],
      [
        "T4",
        "行业",
        73,
        85,
        "商业化阶段制剂 CDMO"
      ],
      [
        "T5",
        "行业",
        5,
        13,
        "商业化阶段创新药"
      ],
      [
        "T6",
        "市场规模",
        85,
        89,
        "市场规模"
      ],
      [
        "T7",
        "时间范围",
        91,
        96,
        "2030年"
      ],
      [
        "T8",
        "属性值",
        101,
        107,
        "412亿美元"
      ],
      [
        "T9",
        "行业",
        108,
        116,
        "原料药 CDMO"
      ],
      [
        "T10",
        "市场规模",
        117,
        121,
        "市场规模"
      ],
      [
        "T11",
        "属性值",
        124,
        131,
        "877 亿美元"
      ],
      [
        "T12",
        "行业",
        132,
        142,
        "商业化阶段 CDMO"
      ],
      [
        "T13",
        "市场规模",
        143,
        145,
        "规模"
      ],
      [
        "T14",
        "属性值",
        148,
        156,
        "1289 亿美元"
      ],
      [
        "T15",
        "时间范围",
        158,
        168,
        "2020~2030年"
      ],
      [
        "T16",
        "CAGR",
        169,
        173,
        "CAGR"
      ],
      [
        "T17",
        "属性值",
        175,
        180,
        "8.71%"
      ],
      [
        "T18",
        "时间范围",
        181,
        186,
        "2030年"
      ],
      [
        "T19",
        "行业",
        186,
        201,
        "研发阶段与商业化阶段 CDMO"
      ],
      [
        "T20",
        "市场规模",
        201,
        203,
        "规模"
      ],
      [
        "T21",
        "属性值",
        208,
        215,
        "1777亿美元"
      ],
      [
        "T22",
        "时间范围",
        216,
        226,
        "2020~2030年"
      ],
      [
        "T23",
        "CAGR",
        227,
        231,
        "CAGR"
      ],
      [
        "T24",
        "属性值",
        233,
        238,
        "8.24%"
      ]
    ]
  },
  {
    "id": 1541,
    "text": "新药研发时间紧、投入高，CRO成为价廉物美的优选。研究表明，与 CRO合作，可将新药研发时间缩短 1/4~1/3，并且节省 30%~70%的研发费用。 CRO公司凭借丰富的项目经验将医药研发流程模块化，同时进行多部分工作，提升协同效应、提高效率；在临床申请和临床阶段，CRO 公司可简化流程，直接对接试验机构以及审评机构，缩短研发时间。 通过对比全球的中国制药企业、CRO公司的人均成本，可以看出：CRO 公司人均成本更低，国内 CRO 更具成本优势。目前，CRO 公司承担了近 1/3 的新药研发工作，近 2/3 的中后期研究工作，医药研发服务外包已经成为全球医药研发的主要形式。",
    "labels": [
      [
        "T0",
        "行业",
        12,
        15,
        "CRO"
      ],
      [
        "T1",
        "行业",
        32,
        35,
        "CRO"
      ],
      [
        "T2",
        "研发费用",
        70,
        74,
        "研发费用"
      ],
      [
        "T3",
        "行业公司",
        76,
        81,
        "CRO公司"
      ],
      [
        "T4",
        "行业公司",
        134,
        140,
        "CRO 公司"
      ],
      [
        "T5",
        "行业公司",
        178,
        182,
        "制药企业"
      ],
      [
        "T6",
        "行业公司",
        183,
        188,
        "CRO公司"
      ],
      [
        "T7",
        "行业公司",
        199,
        205,
        "CRO 公司"
      ],
      [
        "T8",
        "地点范围",
        212,
        214,
        "国内"
      ],
      [
        "T9",
        "行业",
        215,
        218,
        "CRO"
      ],
      [
        "T10",
        "行业公司",
        229,
        235,
        "CRO 公司"
      ],
      [
        "T11",
        "行业",
        267,
        275,
        "医药研发服务外包"
      ],
      [
        "T12",
        "行业",
        281,
        285,
        "医药研发"
      ],
      [
        "T13",
        "地点范围",
        279,
        281,
        "全球"
      ],
      [
        "T14",
        "行业",
        91,
        93,
        "医药"
      ],
      [
        "T15",
        "地点范围",
        173,
        175,
        "全球"
      ],
      [
        "T16",
        "地点范围",
        176,
        178,
        "中国"
      ],
      [
        "T17",
        "时间范围",
        226,
        228,
        "目前"
      ]
    ]
  },
  {
    "id": 1542,
    "text": "个股表现来看，从2月1-3月16日，个股涨幅排名前3的分别是：诺泰生物（20.64%）＞普洛药业（18.46%）＞百诚医药 （16.53%）；近1年涨幅排名前3的分别是：博腾股份 （120.59%）＞美迪西（60.80%）＞九洲药业（59.01%）， 整体看2月份CXO个股出现结构性反弹，10只个股实现正收益。",
    "labels": [
      [
        "T0",
        "公司",
        31,
        35,
        "诺泰生物"
      ],
      [
        "T1",
        "公司",
        44,
        48,
        "普洛药业"
      ],
      [
        "T2",
        "公司",
        57,
        61,
        "百诚医药"
      ],
      [
        "T3",
        "公司",
        85,
        89,
        "博腾股份"
      ],
      [
        "T4",
        "公司",
        100,
        103,
        "美迪西"
      ],
      [
        "T5",
        "公司",
        112,
        116,
        "九洲药业"
      ],
      [
        "T6",
        "时间范围",
        129,
        132,
        "2月份"
      ],
      [
        "T7",
        "行业公司",
        132,
        137,
        "CXO个股"
      ],
      [
        "T8",
        "时间范围",
        7,
        17,
        "从2月1-3月16日"
      ],
      [
        "T9",
        "时间范围",
        71,
        74,
        "近1年"
      ]
    ]
  },
  {
    "id": 1544,
    "text": "药物发现行业快速成长，公司全球市占率位居前列。根据 Frost & Sullivan数据， 2019年全球药物发现 CRO市场规模约 129亿美元，其中中国市场规模约 14 亿美元，占比仅为 11%。药物发现位于产业链上游，对技术积累要求较高，研发风险相对较大，国内企业药物研发策略仍以 fast-follow策略为主，基于新靶点的研发需求相对有限。但随着本土创新药企业的发展，对于 first-in-class药物的研发需求将带动国内药物发现 CRO市场的快速增长。",
    "labels": [
      [
        "T0",
        "行业",
        0,
        4,
        "药物发现"
      ],
      [
        "T1",
        "地点范围",
        13,
        15,
        "全球"
      ],
      [
        "T2",
        "市场份额",
        15,
        18,
        "市占率"
      ],
      [
        "T3",
        "时间范围",
        46,
        51,
        "2019年"
      ],
      [
        "T4",
        "地点范围",
        51,
        53,
        "全球"
      ],
      [
        "T5",
        "行业",
        53,
        61,
        "药物发现 CRO"
      ],
      [
        "T6",
        "市场规模",
        61,
        65,
        "市场规模"
      ],
      [
        "T7",
        "属性值",
        65,
        73,
        "约 129亿美元"
      ],
      [
        "T8",
        "属性值",
        82,
        90,
        "约 14 亿美元"
      ],
      [
        "T9",
        "地点范围",
        76,
        78,
        "中国"
      ],
      [
        "T10",
        "市场规模",
        78,
        82,
        "市场规模"
      ],
      [
        "T11",
        "行业",
        100,
        104,
        "药物发现"
      ],
      [
        "T12",
        "地点范围",
        131,
        133,
        "国内"
      ],
      [
        "T13",
        "行业公司",
        180,
        185,
        "创新药企业"
      ],
      [
        "T14",
        "地点范围",
        216,
        218,
        "国内"
      ],
      [
        "T15",
        "行业",
        218,
        226,
        "药物发现 CRO"
      ],
      [
        "T16",
        "地点范围",
        178,
        180,
        "本土"
      ]
    ]
  },
  {
    "id": 1547,
    "text": "海外个股表现来看，近1个月跌幅排名前3的分别是：Lonza（-1.18%） ＞Syneos（-1.20%）＞Charles River（-1.59%）；近1年涨幅排名前3的分别是：ICON（19.55%） ＞Lonza（17.83%）＞＞IQVIA （8.40%）。",
    "labels": [
      [
        "T0",
        "地点范围",
        0,
        2,
        "海外"
      ],
      [
        "T1",
        "时间范围",
        9,
        13,
        "近1个月"
      ],
      [
        "T2",
        "公司",
        24,
        29,
        "Lonza"
      ],
      [
        "T3",
        "公司",
        39,
        45,
        "Syneos"
      ],
      [
        "T4",
        "公司",
        54,
        67,
        "Charles River"
      ],
      [
        "T5",
        "时间范围",
        76,
        79,
        "近1年"
      ],
      [
        "T6",
        "公司",
        90,
        94,
        "ICON"
      ],
      [
        "T7",
        "公司",
        104,
        109,
        "Lonza"
      ],
      [
        "T8",
        "公司",
        119,
        124,
        "IQVIA"
      ]
    ]
  },
  {
    "id": 1559,
    "text": "零售业务兑现高增长，门店扩张大幅加速。报告期内国大药房实现营收 194.38亿元， 同比增长 44.04%；实现净利润 4.77亿，同比增长 54.81%，显著加速。截至 2020年底公司门店总数达 7660家，其中直营及加盟店分别净增 2468/171家达到 6212家和 1448家 （其中并购成大方圆增加超过 1500家）。成大方圆 2019年实现营收 29.37亿元（占国大药房的 23%），直营及加盟店遍布 5省 19市，覆盖辽宁、吉林、内蒙古、山东和河北部分重点城市，布局区域为公司战略推进重点范围，有望加强公司北方市场竞争力。假设成大方圆 2021-2022年实现 25%/20%的业绩增速，我们测算有望增厚国药一致 2021-2022年业绩 3.7%/3.8%。长期看成大方圆有望通过引进国大药房的集采优势品种、DTP独家品种从而丰富商品品类并优化商品结构。本次重大收购有望成为公司战略扩张加速起点。",
    "labels": [
      [
        "T0",
        "公司",
        23,
        27,
        "国大药房"
      ],
      [
        "T1",
        "营业收入",
        29,
        32,
        "营收 "
      ],
      [
        "T2",
        "属性值",
        32,
        40,
        "194.38亿元"
      ],
      [
        "T3",
        "归母净利润",
        56,
        59,
        "净利润"
      ],
      [
        "T4",
        "时间范围",
        83,
        92,
        "截至 2020年底"
      ],
      [
        "T5",
        "公司",
        149,
        153,
        "成大方圆"
      ],
      [
        "T6",
        "公司",
        165,
        169,
        "成大方圆"
      ],
      [
        "T7",
        "时间范围",
        170,
        175,
        "2019年"
      ],
      [
        "T8",
        "营业收入",
        177,
        180,
        "营收 "
      ],
      [
        "T9",
        "属性值",
        180,
        187,
        "29.37亿元"
      ],
      [
        "T10",
        "公司",
        189,
        193,
        "国大药房"
      ],
      [
        "T11",
        "公司",
        272,
        276,
        "成大方圆"
      ],
      [
        "T12",
        "时间范围",
        277,
        287,
        "2021-2022年"
      ],
      [
        "T13",
        "时间范围",
        316,
        326,
        "2021-2022年"
      ],
      [
        "T14",
        "公司",
        342,
        346,
        "成大方圆"
      ],
      [
        "T15",
        "公司",
        352,
        356,
        "国大药房"
      ],
      [
        "T16",
        "属性值",
        47,
        53,
        "44.04%"
      ],
      [
        "T17",
        "属性值",
        60,
        77,
        "4.77亿，同比增长 54.81%"
      ],
      [
        "T18",
        "公司",
        311,
        315,
        "国药一致"
      ]
    ]
  },
  {
    "id": 1564,
    "text": "全球药物研发投入稳健增长，外包服务产业链持续转移。我们此前发布的 CXO 行业深度《药物研发史波澜壮阔，外包服务业立于潮头》中指出，CXO行业伴随药物研发产业而出现，而兴盛，新药研发难度的提升、竞争的加剧、回报的下降促使外包渗透率持续提升。全球药物研发投入持续稳健增长的情况下， CXO 行业需求有望维持高景气度。从全球产业链转移的视角来看，国内的工程师红利、广大的患者基数、基建配套优势带来了成本竞争力，国内 CXO企业在全球份额有望持续提升，作为国内绝对龙头的药明康德有望对标乃至超越全球一线龙头的市场份额。",
    "labels": [
      [
        "T0",
        "地点范围",
        0,
        2,
        "全球"
      ],
      [
        "T1",
        "行业",
        2,
        4,
        "药物"
      ],
      [
        "T2",
        "研发费用",
        4,
        8,
        "研发投入"
      ],
      [
        "T3",
        "属性值",
        8,
        12,
        "稳健增长"
      ],
      [
        "T4",
        "行业",
        13,
        17,
        "外包服务"
      ],
      [
        "T5",
        "行业",
        33,
        36,
        "CXO"
      ],
      [
        "T6",
        "行业",
        52,
        57,
        "外包服务业"
      ],
      [
        "T7",
        "行业",
        66,
        69,
        "CXO"
      ],
      [
        "T8",
        "行业",
        73,
        77,
        "药物研发"
      ],
      [
        "T9",
        "外包率",
        110,
        115,
        "外包渗透率"
      ],
      [
        "T10",
        "属性值",
        115,
        119,
        "持续提升"
      ],
      [
        "T11",
        "行业",
        87,
        91,
        "新药研发"
      ],
      [
        "T12",
        "竞争格局",
        97,
        99,
        "竞争"
      ],
      [
        "T13",
        "属性值",
        100,
        102,
        "加剧"
      ],
      [
        "T14",
        "地点范围",
        120,
        122,
        "全球"
      ],
      [
        "T15",
        "行业",
        122,
        124,
        "药物"
      ],
      [
        "T16",
        "研发费用",
        124,
        128,
        "研发投入"
      ],
      [
        "T17",
        "属性值",
        128,
        134,
        "持续稳健增长"
      ],
      [
        "T18",
        "行业",
        140,
        143,
        "CXO"
      ],
      [
        "T19",
        "行业需求",
        144,
        148,
        "行业需求"
      ],
      [
        "T20",
        "属性值",
        152,
        156,
        "高景气度"
      ],
      [
        "T21",
        "地点范围",
        158,
        160,
        "全球"
      ],
      [
        "T22",
        "地点范围",
        171,
        173,
        "国内"
      ],
      [
        "T23",
        "地点范围",
        203,
        205,
        "国内"
      ],
      [
        "T24",
        "行业公司",
        206,
        211,
        "CXO企业"
      ],
      [
        "T25",
        "地点范围",
        212,
        214,
        "全球"
      ],
      [
        "T26",
        "市场份额",
        214,
        216,
        "份额"
      ],
      [
        "T27",
        "属性值",
        218,
        222,
        "持续提升"
      ],
      [
        "T28",
        "地点范围",
        225,
        227,
        "国内"
      ],
      [
        "T29",
        "龙头企业",
        229,
        231,
        "龙头"
      ],
      [
        "T30",
        "公司",
        232,
        236,
        "药明康德"
      ],
      [
        "T31",
        "地点范围",
        244,
        246,
        "全球"
      ],
      [
        "T32",
        "市场份额",
        251,
        255,
        "市场份额"
      ],
      [
        "T33",
        "龙头企业",
        248,
        250,
        "龙头"
      ]
    ]
  },
  {
    "id": 1565,
    "text": "➢ 造影剂原料药奠定全球龙头地位。碘造影剂全球制剂和原料药公司重合度较高，实现了一体化，其中GEHealthcare占全球造影剂原料药销量最大市场份额。司太立深耕行业多年，长期为行业龙头恒瑞医药、正大天晴等供货，2018年收购国内产能第二名的海神制药，2020年定增扩产产能翻倍。国际四大龙头近年来新增产能不多，国内其他几家新增厂家难以顺利进入其供应链，而司太立新增产能较多且技术、产品皆优，国际巨头对司太立可能从竞争为主转向合作，一方面奠定行业长期格局，提升企业估值，一方面公司的新增产能也得到了充分消化。我们预计公司2020- 2022年的原料药销量（含自用）分别为960、1400、2000吨，价格和毛利率保持平稳或有所上升，预计收入端有40%以上的复合增长。 ➢ 制剂端开始业绩持续提速。2020年仙居工厂爆炸产能恢复爬坡需要时间，2021年Q3要对国采备货，公司2021年前几个季度业绩并不理想。 2021年Q4开始，公司2021年6月中标的碘海醇、碘克沙醇注射剂开始执标，约定量是每年200万瓶，按照前四轮国采试剂量有约定量两倍有余。 我们假定2021年Q4、2022年全年量分别为50万、400万瓶，则新增收入分别为5000万元、4亿元，新增利润约为1000、8000万元，带来显著的利润增量。同时考虑到近一倍的原料药和中间体产能释放，我们预计公司2021年Q4归母净利润约为1.1亿元，单季度同比增长超150%。",
    "labels": [
      [
        "T0",
        "行业",
        2,
        8,
        "造影剂原料药"
      ],
      [
        "T1",
        "龙头企业",
        12,
        14,
        "龙头"
      ],
      [
        "T2",
        "行业",
        17,
        21,
        "碘造影剂"
      ],
      [
        "T3",
        "公司",
        46,
        58,
        "GEHealthcare"
      ],
      [
        "T4",
        "地点范围",
        59,
        61,
        "全球"
      ],
      [
        "T5",
        "行业",
        61,
        67,
        "造影剂原料药"
      ],
      [
        "T6",
        "市场份额",
        71,
        75,
        "市场份额"
      ],
      [
        "T7",
        "属性值",
        69,
        71,
        "最大"
      ],
      [
        "T8",
        "公司",
        76,
        79,
        "司太立"
      ],
      [
        "T9",
        "龙头企业",
        91,
        93,
        "龙头"
      ],
      [
        "T10",
        "公司",
        93,
        97,
        "恒瑞医药"
      ],
      [
        "T11",
        "公司",
        98,
        102,
        "正大天晴"
      ],
      [
        "T12",
        "时间范围",
        106,
        111,
        "2018年"
      ],
      [
        "T13",
        "公司",
        121,
        125,
        "海神制药"
      ],
      [
        "T14",
        "时间范围",
        126,
        131,
        "2020年"
      ],
      [
        "T15",
        "产能",
        135,
        137,
        "产能"
      ],
      [
        "T16",
        "属性值",
        137,
        139,
        "翻倍"
      ],
      [
        "T17",
        "公司",
        178,
        181,
        "司太立"
      ],
      [
        "T18",
        "公司",
        201,
        204,
        "司太立"
      ],
      [
        "T19",
        "时间范围",
        260,
        271,
        "2020- 2022年"
      ],
      [
        "T20",
        "行业",
        272,
        275,
        "原料药"
      ],
      [
        "T21",
        "毛利",
        303,
        306,
        "毛利率"
      ],
      [
        "T22",
        "营业收入",
        318,
        321,
        "收入端"
      ],
      [
        "T23",
        "属性值",
        322,
        327,
        "40%以上"
      ],
      [
        "T24",
        "CAGR",
        328,
        332,
        "复合增长"
      ],
      [
        "T25",
        "业绩",
        341,
        343,
        "业绩"
      ],
      [
        "T26",
        "时间范围",
        348,
        353,
        "2020年"
      ],
      [
        "T27",
        "时间范围",
        370,
        377,
        "2021年Q3"
      ],
      [
        "T28",
        "时间范围",
        386,
        396,
        "2021年前几个季度"
      ],
      [
        "T29",
        "业绩",
        396,
        398,
        "业绩"
      ],
      [
        "T30",
        "时间范围",
        404,
        413,
        "2021年Q4开始"
      ],
      [
        "T31",
        "时间范围",
        478,
        485,
        "2021年Q4"
      ],
      [
        "T32",
        "时间范围",
        486,
        493,
        "2022年全年"
      ],
      [
        "T33",
        "营业收入",
        510,
        512,
        "收入"
      ],
      [
        "T34",
        "利润",
        528,
        530,
        "利润"
      ],
      [
        "T35",
        "利润",
        549,
        551,
        "利润"
      ],
      [
        "T36",
        "时间范围",
        581,
        588,
        "2021年Q4"
      ],
      [
        "T37",
        "归母净利润",
        588,
        593,
        "归母净利润"
      ],
      [
        "T38",
        "地点范围",
        21,
        23,
        "全球"
      ],
      [
        "T39",
        "地点范围",
        113,
        115,
        "国内"
      ],
      [
        "T40",
        "产能",
        115,
        117,
        "产能"
      ],
      [
        "T41",
        "属性值",
        117,
        120,
        "第二名"
      ],
      [
        "T42",
        "地点范围",
        156,
        158,
        "国内"
      ],
      [
        "T43",
        "属性值",
        181,
        187,
        "新增产能较多"
      ],
      [
        "T44",
        "地点范围",
        196,
        198,
        "国际"
      ],
      [
        "T45",
        "属性值",
        308,
        315,
        "平稳或有所上升"
      ],
      [
        "T46",
        "行业",
        336,
        339,
        "制剂端"
      ],
      [
        "T47",
        "属性值",
        345,
        347,
        "提速"
      ],
      [
        "T48",
        "属性值",
        398,
        402,
        "并不理想"
      ],
      [
        "T49",
        "时间范围",
        416,
        423,
        "2021年6月"
      ],
      [
        "T50",
        "属性值",
        515,
        521,
        "5000万元"
      ],
      [
        "T51",
        "属性值",
        522,
        525,
        "4亿元"
      ],
      [
        "T52",
        "属性值",
        532,
        536,
        "1000"
      ],
      [
        "T53",
        "属性值",
        537,
        543,
        "8000万元"
      ],
      [
        "T54",
        "行业",
        563,
        566,
        "原料药"
      ],
      [
        "T55",
        "行业",
        567,
        570,
        "中间体"
      ],
      [
        "T56",
        "属性值",
        572,
        574,
        "释放"
      ],
      [
        "T57",
        "产能",
        570,
        572,
        "产能"
      ],
      [
        "T58",
        "属性值",
        593,
        613,
        "约为1.1亿元，单季度同比增长超150%"
      ],
      [
        "T59",
        "地点范围",
        10,
        12,
        "全球"
      ],
      [
        "T60",
        "时间范围",
        146,
        149,
        "近年来"
      ]
    ]
  },
  {
    "id": 1577,
    "text": "“聚焦+放大”打开成长空间。药石科技是全球领先的药物分子砌块供应商，通过“聚焦+放大”打开了成长空间。（1）聚焦：基于分子砌块优势，强化药物发现业务。基于分子砌块库优势，延伸并强化药物发现服务业务，建设基于碎片分子片段的药物发现（FBDD）技术、DNA 编码化合物库（DEL）技术、超大容量特色虚拟化合物库筛选技术等多个关键药物发现技术平台；（2）放大：中间体→原料药→制剂，全产业链布局促进分子砌块产品的放量。建设符合 FDA 标准的制剂 CDMO 产能，将公司服务阶段从中间体、API，延伸到制剂，提高价值量的同时，将进一步绑定客户。 受大订单波动影响，2021Q3 业绩低于市场预期。2021Q3，实现营业收入 2.82 亿元（+5.86% YOY），实现归母净利润 0.61 亿元（+11.16% YOY），实现扣非归母净利润 0.56 亿元（+5.72% YOY），低于市场预期。预计主要是公司处于由前端药物分子砌块向后端 CDMO 的转型期，单季度收入受大订单确认周期影响而出现波动。 分子砌块导流+M 端能力升级，CDMO 漏斗效应强化。订单结构方面，2021H1， 分子砌块及 CDMO 项目中，有 320 余个项目在临床前至临床 II 期，29 个在临床 III 期至商业化阶段，另有 350 余个公斤级以上项目。产能方面，浙江晖石生产基地已启用 3 个车间，501 车间（商业化多功能 GMP 生产车间）预计 2021H2 投入使用，502、503 车间预计 2022H1 投入使用。我们认为得益于公司新颖性、 高成药性分子砌块对早期客户的绑定， 随着 GMP 产能逐步释放、 M 端能力升级， 公司 CDMO 业务的漏斗效应将继续强化，有望带来持续盈利高增长。 借力新药发现平台，分子砌块远期延伸价值值得期待。基于分子砌块核心资源， 公司搭建 DEL-T、 FBDD、 超大容量特色虚拟化合物库筛选技术等新药发现平台， 2021H1 完成超过 30 个新靶点的筛选。 药物发现业务从源头促进创新合作， 2020 年实现自研创新药 TT-01025 的对外授权，未来“风险共担、利益共享”模式的复制值得期待。 盈利预测、估值与评级：公司是分子砌块龙头，2021Q3 起分子砌块业务突破实验室产能瓶颈，CDMO 业务漏斗效应强化，业绩将持续较高增长。我们维持公司 21-23 年归母净利润预测为 5.02/4.02/5.59 亿元，分别同比增长 +173%/-20%/+39%（扣除 2021H1 浙江晖石 2.22 亿元投资收益，2022 年经调整净利润增速 44%），现价对应 21-23 年 PE 为 61/76/54 倍，维持“买入”评级。",
    "labels": [
      [
        "T0",
        "公司",
        14,
        18,
        "药石科技"
      ],
      [
        "T1",
        "时间范围",
        279,
        286,
        "2021Q3 "
      ],
      [
        "T2",
        "业绩",
        286,
        288,
        "业绩"
      ],
      [
        "T3",
        "属性值",
        288,
        294,
        "低于市场预期"
      ],
      [
        "T4",
        "时间范围",
        295,
        301,
        "2021Q3"
      ],
      [
        "T5",
        "营业收入",
        304,
        308,
        "营业收入"
      ],
      [
        "T6",
        "属性值",
        309,
        316,
        "2.82 亿元"
      ],
      [
        "T7",
        "归母净利润",
        331,
        336,
        "归母净利润"
      ],
      [
        "T8",
        "扣非净利润",
        360,
        368,
        "扣非归母净利润 "
      ],
      [
        "T9",
        "行业",
        711,
        715,
        "CDMO"
      ],
      [
        "T10",
        "行业",
        845,
        849,
        "药物发现"
      ],
      [
        "T11",
        "行业",
        929,
        933,
        "分子砌块"
      ],
      [
        "T12",
        "龙头企业",
        933,
        935,
        "龙头"
      ],
      [
        "T13",
        "时间范围",
        936,
        943,
        "2021Q3 "
      ],
      [
        "T14",
        "行业",
        944,
        948,
        "分子砌块"
      ],
      [
        "T15",
        "行业",
        960,
        965,
        "CDMO "
      ],
      [
        "T16",
        "业绩",
        974,
        976,
        "业绩"
      ],
      [
        "T17",
        "属性值",
        977,
        983,
        "持续较高增长"
      ],
      [
        "T18",
        "时间范围",
        991,
        998,
        "21-23 年"
      ],
      [
        "T19",
        "归母净利润",
        998,
        1003,
        "归母净利润"
      ],
      [
        "T20",
        "属性值",
        1007,
        1024,
        "5.02/4.02/5.59 亿元"
      ],
      [
        "T21",
        "时间范围",
        1075,
        1081,
        "2022 年"
      ],
      [
        "T22",
        "归母净利润增速",
        1084,
        1089,
        "净利润增速"
      ],
      [
        "T23",
        "属性值",
        1089,
        1093,
        " 44%"
      ],
      [
        "T24",
        "时间范围",
        1100,
        1108,
        "21-23 年 "
      ],
      [
        "T25",
        "PE",
        1108,
        1111,
        "PE "
      ],
      [
        "T26",
        "属性值",
        1113,
        1123,
        "61/76/54 倍"
      ],
      [
        "T27",
        "地点范围",
        19,
        21,
        "全球"
      ],
      [
        "T28",
        "行业",
        24,
        30,
        "药物分子砌块"
      ],
      [
        "T29",
        "属性值",
        317,
        323,
        "+5.86%"
      ],
      [
        "T30",
        "属性值",
        337,
        357,
        "0.61 亿元（+11.16% YOY）"
      ],
      [
        "T31",
        "属性值",
        368,
        387,
        "0.56 亿元（+5.72% YOY）"
      ],
      [
        "T32",
        "时间范围",
        483,
        489,
        "2021H1"
      ],
      [
        "T33",
        "产能",
        566,
        568,
        "产能"
      ],
      [
        "T34",
        "时间范围",
        615,
        621,
        "2021H2"
      ],
      [
        "T35",
        "时间范围",
        640,
        646,
        "2022H1"
      ],
      [
        "T36",
        "产能",
        691,
        693,
        "产能"
      ],
      [
        "T37",
        "时间范围",
        821,
        827,
        "2021H1"
      ],
      [
        "T38",
        "时间范围",
        862,
        868,
        "2020 年"
      ],
      [
        "T39",
        "产能",
        955,
        957,
        "产能"
      ],
      [
        "T40",
        "时间范围",
        1051,
        1057,
        "2021H1"
      ],
      [
        "T41",
        "公司",
        1058,
        1062,
        "浙江晖石"
      ]
    ]
  },
  {
    "id": 1583,
    "text": "2021 年公司收购了欧洲的 OXGENE，进一步丰富技术平台与全球化布局，成为在欧、美、亚均有布局的全球性 CGT CDMO 公司，能有效服务全球客户。收购完成后，公司整合成立三大平台，可以全方位提供 CTDMO 服务：  质粒 DNA 生产平台：独立的质粒开发实验室、质粒菌种 GMP 建库生产线和 GMP 质粒生产线，有自动化的纯化、收集、端到端的测试放行及上市资料准备，能在 5 天内提供高产量（1-10g）高质量的质粒生产服务。 2  病毒载体生产平台：４条独立的病毒载体 GMP 生产线（2,100ｍ ），具有独特的生产平台。 10 11 -XAAV 悬浮瞬转平台，能在 30 天内交付高产量（2x10 -2x10 GC/ml） 高质量的 AAV 载体， 从 DNA 到 IND 仅需 15 个月， 已为 8 个客户提供服务。 7 -XLenti 贴壁和悬浮瞬转平台，能在 20 天内交付高产量（1x10 TU/ml） 高质量的慢病毒载体，是传统技术产量的 2-5 倍。 -Tessa AAV 生产平台，比传统质粒转染方式产量平均提高约 15 倍。 与传统方式相比，200L 生产规模的 Tessa 平台可以生产至少服务 10 倍病人的药剂量。Tessa 平台已经为 2 家大型制药公司、10 家 Biotech 公司以及 2 所大学提供服务。  细胞治疗平台：平台工艺适用于各种来源的细胞（如外周血、脐带血、骨髓、脂肪等），业务范围包括 CAR-T，TCR-T，NK，DC 等免疫细胞治疗产品以及多种干细胞的大规模扩增及检定等。",
    "labels": [
      [
        "T0",
        "时间范围",
        0,
        6,
        "2021 年"
      ],
      [
        "T1",
        "公司",
        15,
        21,
        "OXGENE"
      ],
      [
        "T2",
        "行业公司",
        55,
        66,
        "CGT CDMO 公司"
      ],
      [
        "T3",
        "地点范围",
        11,
        13,
        "欧洲"
      ],
      [
        "T4",
        "地点范围",
        41,
        42,
        "欧"
      ],
      [
        "T5",
        "地点范围",
        43,
        44,
        "美"
      ],
      [
        "T6",
        "地点范围",
        45,
        46,
        "亚"
      ],
      [
        "T7",
        "行业",
        102,
        107,
        "CTDMO"
      ],
      [
        "T8",
        "行业公司",
        552,
        567,
        "10 家 Biotech 公司"
      ],
      [
        "T9",
        "行业公司",
        542,
        551,
        "2 家大型制药公司"
      ]
    ]
  },
  {
    "id": 1584,
    "text": "客户覆盖率： J-STAR 在服务中小创新药企客户方面具有优势，公司将北美 Biotech 公司作为 2018年业务开拓的重点，同年获得北美 20家生物技术企业的业务订单， 来自北美中小客户收入超过 5000万元。2020年，博腾累计服务客户近 500家， 活跃客户超 200家，已覆盖 80%的全球前 20大制药公司及 100余家全球新兴 Biotech，未来客户覆盖率有望进一步提升。",
    "labels": [
      [
        "T0",
        "公司",
        7,
        13,
        "J-STAR"
      ],
      [
        "T1",
        "地点范围",
        35,
        37,
        "北美"
      ],
      [
        "T2",
        "行业公司",
        38,
        48,
        "Biotech 公司"
      ],
      [
        "T3",
        "时间范围",
        51,
        56,
        "2018年"
      ],
      [
        "T4",
        "地点范围",
        68,
        70,
        "北美"
      ],
      [
        "T5",
        "行业公司",
        71,
        80,
        "20家生物技术企业"
      ],
      [
        "T6",
        "地点范围",
        89,
        91,
        "北美"
      ],
      [
        "T7",
        "营业收入",
        95,
        97,
        "收入"
      ],
      [
        "T8",
        "时间范围",
        107,
        112,
        "2020年"
      ],
      [
        "T9",
        "公司",
        113,
        115,
        "博腾"
      ],
      [
        "T10",
        "属性值",
        121,
        127,
        "近 500家"
      ],
      [
        "T11",
        "地点范围",
        148,
        150,
        "全球"
      ],
      [
        "T12",
        "行业公司",
        155,
        159,
        "制药公司"
      ],
      [
        "T13",
        "地点范围",
        166,
        168,
        "全球"
      ],
      [
        "T14",
        "行业",
        171,
        178,
        "Biotech"
      ]
    ]
  },
  {
    "id": 1589,
    "text": "3.1. 创新药/改良药研发进展（获批上市/申报上市/获批临床）  2月 11日，亚辉龙宣布，其日本合作伙伴株式会社医学生物学研究所的新型冠状病毒抗原检测试剂盒于北京时间 2022 年 2 月 10 日取得了由日本 PMDA签发的《体外诊断产品生产销售许可书》。  2月 11日，诺华飞尼妥（依维莫司片）获国家药品监督管理局批准新增适应症，联合依西美坦用于治疗来曲唑或阿那曲唑治疗失败后的激素受体阳性、表皮生长因子受体-2阴性、绝经后晚期女性乳腺癌患者。  2月 11日，上海健信生物医药宣布，其自主研发的序列特异 IgG-like双特异抗体平台产品 Bis5，获得 CDE临床试验默示许可，拟用于晚期恶性肿瘤。 Bis5是一款注射用重组抗 PD-1/TIM3人源化双特异抗体。  2月 10日，再生元和赛诺菲宣布，美国 FDA已授予度普利尤单抗的补充生物制品许可申请优先审评资格，作为 6个月至 5岁中重度特应性皮炎儿童患者的添加维持治疗。度普利尤单抗将成为首个获批治疗这一群体不受控制中重度特应性皮炎的生物制品。  2月 10日，信达/礼来 PD-1抗体信迪利单抗迎来 FDA获批审议会议。在关于“是否需要额外的适用于美国病人和美国医疗临床试验证明？”的投票环节中，赞成与反对结果为 14:1，信达/礼来 PD-1不被建议直接获批。  2月 10日，君实生物旗下产品特瑞普利单抗联合标准化疗作为胃或食管胃结合部腺癌根治术后的辅助治疗 III 期临床研究已完成首例患者给药。  2月 10日，艾伯维申请的乌帕替尼缓释片新药上市申请已进入：在审批， 该产品有望近期在中国获批。此次乌帕替尼缓释片有望在中国获批的适应症为：用于适合系统性治疗的成人和 12岁及 12岁以上青少年中重度特应性皮炎患者。  2月 10日，安斯泰来申报的注射用 zolbetuximab在中国获得一项临床试验",
    "labels": [
      [
        "T0",
        "时间范围",
        35,
        41,
        "2月 11日"
      ],
      [
        "T1",
        "公司",
        42,
        45,
        "亚辉龙"
      ],
      [
        "T2",
        "公司",
        55,
        67,
        "株式会社医学生物学研究所"
      ],
      [
        "T3",
        "时间范围",
        87,
        102,
        "2022 年 2 月 10 日"
      ],
      [
        "T4",
        "时间范围",
        135,
        141,
        "2月 11日"
      ],
      [
        "T5",
        "时间范围",
        232,
        238,
        "2月 11日"
      ],
      [
        "T6",
        "公司",
        239,
        247,
        "上海健信生物医药"
      ],
      [
        "T7",
        "时间范围",
        345,
        351,
        "2月 10日"
      ],
      [
        "T8",
        "公司",
        352,
        355,
        "再生元"
      ],
      [
        "T9",
        "公司",
        356,
        359,
        "赛诺菲"
      ],
      [
        "T10",
        "时间范围",
        465,
        471,
        "2月 10日"
      ],
      [
        "T11",
        "公司",
        472,
        474,
        "信达"
      ],
      [
        "T12",
        "时间范围",
        575,
        582,
        " 2月 10日"
      ],
      [
        "T13",
        "公司",
        583,
        587,
        "君实生物"
      ],
      [
        "T14",
        "时间范围",
        647,
        653,
        "2月 10日"
      ],
      [
        "T15",
        "公司",
        654,
        657,
        "艾伯维"
      ],
      [
        "T16",
        "时间范围",
        758,
        764,
        "2月 10日"
      ],
      [
        "T17",
        "公司",
        765,
        769,
        "安斯泰来"
      ],
      [
        "T18",
        "地点范围",
        49,
        51,
        "日本"
      ],
      [
        "T19",
        "地点范围",
        106,
        108,
        "日本"
      ],
      [
        "T20",
        "公司",
        475,
        477,
        "礼来"
      ],
      [
        "T21",
        "地点范围",
        516,
        518,
        "美国"
      ],
      [
        "T22",
        "地点范围",
        521,
        523,
        "美国"
      ],
      [
        "T23",
        "公司",
        554,
        556,
        "信达"
      ],
      [
        "T24",
        "公司",
        557,
        559,
        "礼来"
      ],
      [
        "T25",
        "地点范围",
        789,
        791,
        "中国"
      ]
    ]
  },
  {
    "id": 1590,
    "text": "21M1-11医药制造业累计收入同比增速有所放缓。21M1-11医药制造业累计收入 26094.60亿元，同比增长 20.9%；营业成本和利润总额同比增加 13.2%和 70.8%，与 20M1-11同期相比收入、成本和利润增速提升了 17.0pp、8.3pp和 58.9pp。以上为增速公布值，若计算公布绝对值相比上年同期的增速，则营业收入、营业成本和利润总额分别同比提升 18.6%、11.0%和 71.8%。我们认为， 21M1-11医药制造业经营情况持续改善，但是增速有所放缓。",
    "labels": [
      [
        "T0",
        "时间范围",
        0,
        7,
        "21M1-11"
      ],
      [
        "T1",
        "行业",
        7,
        12,
        "医药制造业"
      ],
      [
        "T2",
        "属性值",
        20,
        24,
        "有所放缓"
      ],
      [
        "T3",
        "收入增速",
        14,
        20,
        "收入同比增速"
      ],
      [
        "T4",
        "时间范围",
        25,
        32,
        "21M1-11"
      ],
      [
        "T5",
        "行业",
        32,
        37,
        "医药制造业"
      ],
      [
        "T6",
        "营业收入",
        39,
        41,
        "收入"
      ],
      [
        "T7",
        "属性值",
        42,
        52,
        "26094.60亿元"
      ],
      [
        "T8",
        "属性值",
        58,
        63,
        "20.9%"
      ],
      [
        "T9",
        "利润",
        69,
        71,
        "利润"
      ],
      [
        "T10",
        "属性值",
        85,
        90,
        "70.8%"
      ],
      [
        "T11",
        "时间范围",
        93,
        100,
        "20M1-11"
      ],
      [
        "T12",
        "属性值",
        118,
        124,
        "17.0pp"
      ],
      [
        "T13",
        "营业收入",
        167,
        171,
        "营业收入"
      ],
      [
        "T14",
        "利润",
        177,
        179,
        "利润"
      ],
      [
        "T15",
        "属性值",
        188,
        193,
        "18.6%"
      ],
      [
        "T16",
        "属性值",
        201,
        206,
        "71.8%"
      ],
      [
        "T17",
        "时间范围",
        213,
        220,
        "21M1-11"
      ],
      [
        "T18",
        "行业",
        220,
        225,
        "医药制造业"
      ]
    ]
  },
  {
    "id": 1595,
    "text": "根据医药魔方数据，2022年1-3月化学创新药IND申请数量为169 个，同比上升12%；生物创新药 IND申请数量为152个，同比上升 37%。可以看到，国内创新申报延续火热趋势。",
    "labels": [
      [
        "T0",
        "时间范围",
        9,
        18,
        "2022年1-3月"
      ],
      [
        "T1",
        "地点范围",
        78,
        80,
        "国内"
      ],
      [
        "T2",
        "行业",
        18,
        23,
        "化学创新药"
      ],
      [
        "T3",
        "IND申报数",
        23,
        30,
        "IND申请数量"
      ],
      [
        "T4",
        "属性值",
        31,
        44,
        "169 个，同比上升12%"
      ],
      [
        "T5",
        "属性值",
        59,
        72,
        "152个，同比上升 37%"
      ],
      [
        "T6",
        "行业",
        45,
        50,
        "生物创新药"
      ],
      [
        "T7",
        "IND申报数",
        51,
        58,
        "IND申请数量"
      ]
    ]
  },
  {
    "id": 1601,
    "text": "CDMO行业由订单驱动，公司需要预留富余产能以便接受新订单。近几年博腾的产能利用率处在逐步爬坡的阶段，2020全年达到约 70%，2021年一季度达到约 77%，随着生产运营效率提升、工艺流程和产品结构不断优化，2021全年产能利用率相比往年有望进一步提升。",
    "labels": [
      [
        "T0",
        "行业",
        0,
        4,
        "CDMO"
      ],
      [
        "T1",
        "时间范围",
        30,
        33,
        "近几年"
      ],
      [
        "T2",
        "公司",
        33,
        35,
        "博腾"
      ],
      [
        "T3",
        "时间范围",
        51,
        57,
        "2020全年"
      ],
      [
        "T4",
        "时间范围",
        65,
        73,
        "2021年一季度"
      ],
      [
        "T5",
        "时间范围",
        106,
        112,
        "2021全年"
      ]
    ]
  },
  {
    "id": 1607,
    "text": " 分版块 2，疫情影响，临床 CRO业务增速有所下降；看好 3-5年细分行业前景，国际竞争力有望提升，细分领域增速有望提升：2015-2020年上述 29家公司中的临床 CRO相关业务整体收入规模（剔除方达控股与泰格医药重复计算部分）分别为 12/13/20/31/41/46亿元，2016-2020年分别同比增长 9%/59%/54%/32%/13%，收入增速小幅下降。  我们认为临床 CRO板块 2019年收入增速下降的主要原因有四点： ①2015-2016年受到 722核查的影响，行业处于规则重塑、规范化的变革， 整体临床 CRO业务承压，2017-2018年恢复性增长。 ②2019年仿制药一致性评价业务需求有所变化，我们预计尤其 2019年下半年相关业务收入增速下降较为明显；但该因素对版块整体增速影响相对有限，我们预计在统计范围内的仿制药一致性评价业务收入占比在 10%左右，利润占比低于收入占比。 ③业务口径发生一定变化，主要包括创新药临床业务中的过手费收入占比下降，以及并表口径的变化（权重占比较大的泰格医药 2019年剥离了低毛利的上海晟通）。 ④中国医药研发创新浪潮，从早期临床开发阶段过渡到临床中后期开发阶段，申报临床的窗口期可能影响到了 2019年临床 CRO板块收入增速。  2020年临床 CRO板块增速下降的主要原因是新冠疫情影响了医院端病人招募、入组和临床试验的推进的进度，特别是 2020年上半年，2020年下半年进度逐渐恢复正常。  中长期来看，我们认为临床 CRO板块发展即将进入上升通道：①后续板块重点公司的战略布局逐渐聚焦国际业务，潜在的国际并购将加速中国临床 CRO企业的国际竞争力。②国内创新药临床 CRO需求即将进入爆发期， 大量国内创新药研发项目进入临床后期开发阶段，带来较大的国内需求提振。",
    "labels": [
      [
        "T0",
        "行业",
        13,
        19,
        "临床 CRO"
      ],
      [
        "T1",
        "时间范围",
        31,
        35,
        "3-5年"
      ],
      [
        "T2",
        "时间范围",
        63,
        73,
        "2015-2020年"
      ],
      [
        "T3",
        "行业",
        83,
        89,
        "临床 CRO"
      ],
      [
        "T4",
        "营业收入",
        95,
        97,
        "收入"
      ],
      [
        "T5",
        "公司",
        102,
        106,
        "方达控股"
      ],
      [
        "T6",
        "公司",
        107,
        111,
        "泰格医药"
      ],
      [
        "T7",
        "时间范围",
        142,
        152,
        "2016-2020年"
      ],
      [
        "T8",
        "收入增速",
        178,
        182,
        "收入增速"
      ],
      [
        "T9",
        "行业",
        194,
        200,
        "临床 CRO"
      ],
      [
        "T10",
        "时间范围",
        203,
        208,
        "2019年"
      ],
      [
        "T11",
        "收入增速",
        208,
        212,
        "收入增速"
      ],
      [
        "T12",
        "时间范围",
        225,
        235,
        "2015-2016年"
      ],
      [
        "T13",
        "行业",
        266,
        272,
        "临床 CRO"
      ],
      [
        "T14",
        "时间范围",
        277,
        287,
        "2017-2018年"
      ],
      [
        "T15",
        "时间范围",
        295,
        300,
        "2019年"
      ],
      [
        "T16",
        "时间范围",
        324,
        332,
        "2019年下半年"
      ],
      [
        "T17",
        "收入增速",
        336,
        340,
        "收入增速"
      ],
      [
        "T18",
        "利润",
        398,
        400,
        "利润"
      ],
      [
        "T19",
        "营收占比",
        404,
        408,
        "收入占比"
      ],
      [
        "T20",
        "行业",
        426,
        431,
        "创新药临床"
      ],
      [
        "T21",
        "营收占比",
        438,
        442,
        "收入占比"
      ],
      [
        "T22",
        "公司",
        462,
        467,
        "泰格医药 "
      ],
      [
        "T23",
        "时间范围",
        467,
        472,
        "2019年"
      ],
      [
        "T24",
        "毛利",
        476,
        478,
        "毛利"
      ],
      [
        "T25",
        "公司",
        479,
        483,
        "上海晟通"
      ],
      [
        "T26",
        "时间范围",
        535,
        540,
        "2019年"
      ],
      [
        "T27",
        "行业",
        540,
        546,
        "临床 CRO"
      ],
      [
        "T28",
        "收入增速",
        548,
        552,
        "收入增速"
      ],
      [
        "T29",
        "时间范围",
        556,
        561,
        "2020年"
      ],
      [
        "T30",
        "行业",
        561,
        567,
        "临床 CRO"
      ],
      [
        "T31",
        "时间范围",
        612,
        620,
        "2020年上半年"
      ],
      [
        "T32",
        "时间范围",
        621,
        629,
        "2020年下半年"
      ],
      [
        "T33",
        "行业",
        651,
        657,
        "临床 CRO"
      ],
      [
        "T34",
        "行业公司",
        705,
        713,
        "临床 CRO企业"
      ],
      [
        "T35",
        "地点范围",
        721,
        723,
        "国内"
      ],
      [
        "T36",
        "行业",
        723,
        732,
        "创新药临床 CRO"
      ],
      [
        "T37",
        "行业需求",
        732,
        734,
        "需求"
      ],
      [
        "T38",
        "属性值",
        734,
        741,
        "即将进入爆发期"
      ],
      [
        "T39",
        "地点范围",
        770,
        772,
        "国内"
      ],
      [
        "T40",
        "行业需求",
        772,
        774,
        "需求"
      ],
      [
        "T41",
        "属性值",
        21,
        27,
        "增速有所下降"
      ],
      [
        "T42",
        "地点范围",
        487,
        489,
        "中国"
      ],
      [
        "T43",
        "行业",
        489,
        493,
        "医药研发"
      ],
      [
        "T44",
        "地点范围",
        703,
        705,
        "中国"
      ],
      [
        "T45",
        "地点范围",
        745,
        747,
        "国内"
      ],
      [
        "T46",
        "行业",
        747,
        750,
        "创新药"
      ],
      [
        "T47",
        "行业公司",
        76,
        81,
        "29家公司"
      ],
      [
        "T48",
        "属性值",
        212,
        214,
        "下降"
      ],
      [
        "T49",
        "属性值",
        122,
        141,
        "12/13/20/31/41/46亿元"
      ],
      [
        "T50",
        "属性值",
        159,
        177,
        "9%/59%/54%/32%/13%"
      ],
      [
        "T51",
        "属性值",
        182,
        186,
        "小幅下降"
      ],
      [
        "T52",
        "属性值",
        774,
        776,
        "提振"
      ],
      [
        "T53",
        "行业",
        300,
        308,
        "仿制药一致性评价"
      ],
      [
        "T54",
        "行业需求",
        310,
        312,
        "需求"
      ],
      [
        "T55",
        "属性值",
        312,
        316,
        "有所变化"
      ],
      [
        "T56",
        "属性值",
        340,
        346,
        "下降较为明显"
      ],
      [
        "T57",
        "行业",
        376,
        384,
        "仿制药一致性评价"
      ],
      [
        "T58",
        "营收占比",
        386,
        390,
        "收入占比"
      ],
      [
        "T59",
        "属性值",
        392,
        397,
        "10%左右"
      ]
    ]
  },
  {
    "id": 1608,
    "text": " 受疫情影响，2020年临床CRO业务同比增速有所下滑（康龙化成20年临床CRO业务+37.94%，主要由于当年6月完成联斯达并购）。  2020年收入规模排名：泰格医药31.92亿＞药明康德11.69亿＞康龙化成6.29亿。强者恒强，泰格医药2014-2020年收入CAGR达到31.25%。",
    "labels": [
      [
        "T0",
        "时间范围",
        8,
        13,
        "2020年"
      ],
      [
        "T1",
        "行业",
        13,
        18,
        "临床CRO"
      ],
      [
        "T2",
        "公司",
        29,
        33,
        "康龙化成"
      ],
      [
        "T3",
        "时间范围",
        33,
        36,
        "20年"
      ],
      [
        "T4",
        "行业",
        36,
        41,
        "临床CRO"
      ],
      [
        "T5",
        "时间范围",
        71,
        76,
        "2020年"
      ],
      [
        "T6",
        "营业收入",
        76,
        78,
        "收入"
      ],
      [
        "T7",
        "公司",
        83,
        87,
        "泰格医药"
      ],
      [
        "T8",
        "属性值",
        87,
        93,
        "31.92亿"
      ],
      [
        "T9",
        "属性值",
        98,
        104,
        "11.69亿"
      ],
      [
        "T10",
        "属性值",
        109,
        114,
        "6.29亿"
      ],
      [
        "T11",
        "属性值",
        142,
        148,
        "31.25%"
      ],
      [
        "T12",
        "CAGR",
        136,
        140,
        "CAGR"
      ],
      [
        "T13",
        "营业收入",
        134,
        136,
        "收入"
      ],
      [
        "T14",
        "时间范围",
        124,
        134,
        "2014-2020年"
      ],
      [
        "T15",
        "公司",
        120,
        124,
        "泰格医药"
      ],
      [
        "T16",
        "公司",
        94,
        98,
        "药明康德"
      ],
      [
        "T17",
        "公司",
        105,
        109,
        "康龙化成"
      ],
      [
        "T18",
        "时间范围",
        55,
        59,
        "当年6月"
      ],
      [
        "T19",
        "公司",
        61,
        64,
        "联斯达"
      ]
    ]
  },
  {
    "id": 1613,
    "text": "近十年，公司毛利率由 25%逐渐上升并稳定至 34%左右，净利率稳定至 2%左右，2020年实现毛利率 33.97%，归母净利率 2.47%。",
    "labels": [
      [
        "T0",
        "时间范围",
        0,
        3,
        "近十年"
      ],
      [
        "T1",
        "毛利",
        6,
        9,
        "毛利率"
      ],
      [
        "T2",
        "时间范围",
        41,
        46,
        "2020年"
      ],
      [
        "T3",
        "毛利",
        48,
        51,
        "毛利率"
      ]
    ]
  },
  {
    "id": 1618,
    "text": "本土CXO海外收入增速趋势与Biotech投融资增长趋势一致性较弱，我们估计主要是因为：1）相比全球医药行业研发投入本土CXO企业海外收入体量仍然偏小（占比仅 2%附近：2020年海外收入加和269亿人民币vs2020年全球医药研发投入2048亿美元， 2020年生物医药投融资（PE/VC）金额2547亿人民币，2020年美股医疗保健IPO和再融资金额582亿美元），全球投融资、IPO/再融资和MNC研发投入较小波动可能会给本土CXO海外收入YOY带来较大波动。2）另一方面通过拆分本土CXO企业海外收入中 MNC和Biotech收入占比发现，两者在本土CXO海外收入贡献占比可能相当（2020年和2021H1药明康德海外收入中top20MNC占比高达44%和37%，康龙化成top20MNC 收入占比分别为27%和24%，2020年凯莱英前五大客户收入占比高为58%，预计主要为 top20MNC），整体来看减弱了收入与MNC研发投入和全球投融资增长趋势一致性。",
    "labels": [
      [
        "T0",
        "行业公司",
        60,
        65,
        "CXO企业"
      ],
      [
        "T1",
        "地点范围",
        58,
        60,
        "本土"
      ],
      [
        "T2",
        "营业收入",
        67,
        69,
        "收入"
      ],
      [
        "T3",
        "属性值",
        80,
        84,
        "2%附近"
      ],
      [
        "T4",
        "地点范围",
        65,
        67,
        "海外"
      ],
      [
        "T5",
        "时间范围",
        85,
        90,
        "2020年"
      ],
      [
        "T6",
        "地点范围",
        90,
        92,
        "海外"
      ],
      [
        "T7",
        "营业收入",
        92,
        94,
        "收入"
      ],
      [
        "T8",
        "属性值",
        96,
        103,
        "269亿人民币"
      ],
      [
        "T9",
        "时间范围",
        105,
        110,
        "2020年"
      ],
      [
        "T10",
        "地点范围",
        110,
        112,
        "全球"
      ],
      [
        "T11",
        "行业",
        112,
        114,
        "医药"
      ],
      [
        "T12",
        "研发费用",
        114,
        118,
        "研发投入"
      ],
      [
        "T13",
        "属性值",
        118,
        125,
        "2048亿美元"
      ],
      [
        "T14",
        "时间范围",
        127,
        132,
        "2020年"
      ],
      [
        "T15",
        "行业",
        132,
        136,
        "生物医药"
      ],
      [
        "T16",
        "投融资金额",
        136,
        148,
        "投融资（PE/VC）金额"
      ],
      [
        "T17",
        "属性值",
        148,
        156,
        "2547亿人民币"
      ],
      [
        "T18",
        "时间范围",
        157,
        162,
        "2020年"
      ],
      [
        "T19",
        "行业",
        164,
        168,
        "医疗保健"
      ],
      [
        "T20",
        "属性值",
        177,
        183,
        "582亿美元"
      ],
      [
        "T21",
        "研发费用",
        202,
        206,
        "研发投入"
      ],
      [
        "T22",
        "行业公司",
        199,
        202,
        "MNC"
      ],
      [
        "T23",
        "地点范围",
        185,
        187,
        "全球"
      ],
      [
        "T24",
        "投融资情况",
        187,
        198,
        "投融资、IPO/再融资"
      ],
      [
        "T25",
        "投融资金额",
        168,
        177,
        "IPO和再融资金额"
      ],
      [
        "T26",
        "属性值",
        206,
        210,
        "较小波动"
      ],
      [
        "T27",
        "地点范围",
        214,
        216,
        "本土"
      ],
      [
        "T28",
        "行业",
        216,
        219,
        "CXO"
      ],
      [
        "T29",
        "地点范围",
        219,
        221,
        "海外"
      ],
      [
        "T30",
        "营业收入",
        221,
        223,
        "收入"
      ],
      [
        "T31",
        "属性值",
        228,
        232,
        "较大波动"
      ],
      [
        "T32",
        "地点范围",
        243,
        245,
        "本土"
      ],
      [
        "T33",
        "行业公司",
        245,
        250,
        "CXO企业"
      ],
      [
        "T34",
        "地点范围",
        250,
        252,
        "海外"
      ],
      [
        "T35",
        "营业收入",
        252,
        254,
        "收入"
      ],
      [
        "T36",
        "行业公司",
        256,
        259,
        "MNC"
      ],
      [
        "T37",
        "行业",
        260,
        267,
        "Biotech"
      ],
      [
        "T38",
        "营收占比",
        267,
        271,
        "收入占比"
      ],
      [
        "T39",
        "行业",
        2,
        5,
        "CXO"
      ],
      [
        "T40",
        "地点范围",
        277,
        279,
        "本土"
      ],
      [
        "T41",
        "行业",
        279,
        282,
        "CXO"
      ],
      [
        "T42",
        "地点范围",
        282,
        284,
        "海外"
      ],
      [
        "T43",
        "营收占比",
        284,
        290,
        "收入贡献占比"
      ],
      [
        "T44",
        "时间范围",
        295,
        300,
        "2020年"
      ],
      [
        "T45",
        "收入增速",
        7,
        11,
        "收入增速"
      ],
      [
        "T46",
        "时间范围",
        301,
        307,
        "2021H1"
      ],
      [
        "T47",
        "公司",
        307,
        311,
        "药明康德"
      ],
      [
        "T48",
        "地点范围",
        311,
        313,
        "海外"
      ],
      [
        "T49",
        "营业收入",
        313,
        315,
        "收入"
      ],
      [
        "T50",
        "行业公司",
        316,
        324,
        "top20MNC"
      ],
      [
        "T51",
        "公司",
        336,
        340,
        "康龙化成"
      ],
      [
        "T52",
        "行业公司",
        340,
        348,
        "top20MNC"
      ],
      [
        "T53",
        "营收占比",
        349,
        353,
        "收入占比"
      ],
      [
        "T54",
        "属性值",
        356,
        359,
        "27%"
      ],
      [
        "T55",
        "属性值",
        360,
        363,
        "24%"
      ],
      [
        "T56",
        "属性值",
        328,
        331,
        "44%"
      ],
      [
        "T57",
        "属性值",
        332,
        335,
        "37%"
      ],
      [
        "T58",
        "时间范围",
        364,
        369,
        "2020年"
      ],
      [
        "T59",
        "公司",
        369,
        372,
        "凯莱英"
      ],
      [
        "T60",
        "营收占比",
        377,
        381,
        "收入占比"
      ],
      [
        "T61",
        "属性值",
        383,
        386,
        "58%"
      ],
      [
        "T62",
        "行业公司",
        393,
        401,
        "top20MNC"
      ],
      [
        "T63",
        "营业收入",
        410,
        412,
        "收入"
      ],
      [
        "T64",
        "行业公司",
        413,
        416,
        "MNC"
      ],
      [
        "T65",
        "研发费用",
        416,
        420,
        "研发投入"
      ],
      [
        "T66",
        "地点范围",
        421,
        423,
        "全球"
      ],
      [
        "T67",
        "投融资情况",
        423,
        426,
        "投融资"
      ],
      [
        "T68",
        "地点范围",
        48,
        50,
        "全球"
      ],
      [
        "T69",
        "行业",
        50,
        52,
        "医药"
      ],
      [
        "T70",
        "研发费用",
        54,
        58,
        "研发投入"
      ],
      [
        "T71",
        "行业",
        14,
        21,
        "Biotech"
      ],
      [
        "T72",
        "投融资情况",
        21,
        24,
        "投融资"
      ],
      [
        "T73",
        "地点范围",
        0,
        2,
        "本土"
      ],
      [
        "T74",
        "地点范围",
        5,
        7,
        "海外"
      ]
    ]
  },
  {
    "id": 1620,
    "text": "【山河药辅】2020年度业绩：营业收入 5.31亿元（+14.47%），归母净利润 4.93亿元（+5.69%）。",
    "labels": [
      [
        "T0",
        "公司",
        1,
        5,
        "山河药辅"
      ],
      [
        "T1",
        "时间范围",
        6,
        11,
        "2020年"
      ],
      [
        "T2",
        "业绩",
        12,
        14,
        "业绩"
      ],
      [
        "T3",
        "营业收入",
        15,
        19,
        "营业收入"
      ],
      [
        "T4",
        "属性值",
        19,
        26,
        " 5.31亿元"
      ],
      [
        "T5",
        "属性值",
        27,
        34,
        "+14.47%"
      ],
      [
        "T6",
        "归母净利润",
        36,
        41,
        "归母净利润"
      ],
      [
        "T7",
        "属性值",
        42,
        56,
        "4.93亿元（+5.69%）"
      ]
    ]
  },
  {
    "id": 1631,
    "text": "我国创新药研发靶点、适应症等集中，同质化较为严重，同类药品市场较为拥挤。以热门的靶点 PD-1 为例，依据 Insight数据，截止 2022年 1月 12日，国内有 8款产品上市，4款产品正在申请上市中，另多达 346项临床试验正在进行中。 图 19我国抗肿瘤药物研发管线概况",
    "labels": [
      [
        "T0",
        "地点范围",
        0,
        2,
        "我国"
      ],
      [
        "T1",
        "行业",
        2,
        5,
        "创新药"
      ],
      [
        "T2",
        "时间范围",
        64,
        79,
        "截止 2022年 1月 12日"
      ],
      [
        "T3",
        "地点范围",
        80,
        82,
        "国内"
      ],
      [
        "T4",
        "属性值",
        107,
        111,
        "346项"
      ],
      [
        "T5",
        "地点范围",
        126,
        128,
        "我国"
      ],
      [
        "T6",
        "行业",
        128,
        133,
        "抗肿瘤药物"
      ]
    ]
  },
  {
    "id": 1637,
    "text": "21M1-11期末参保人数同比增长 0.4%，环比增长 0.1%。据国家医保局披露， 21M11期末基本医疗保险参保人数达 13.63亿人，参保覆盖面稳定在 95%以上， 参保人数同比增长 0.4%，环比增长 0.1%。需要注意的是，自 2020年起，不再单列生育保险基金收入，在职工基本医疗保险统筹基金待遇支出中设置生育待遇支出项目。",
    "labels": [
      [
        "T0",
        "时间范围",
        0,
        7,
        "21M1-11"
      ],
      [
        "T1",
        "时间范围",
        43,
        48,
        "21M11"
      ],
      [
        "T2",
        "时间范围",
        119,
        124,
        "2020年"
      ]
    ]
  },
  {
    "id": 1645,
    "text": "1. 医药CXO行业细分市场 • 临床 64.9 球药物发现CRO行业增速 • 中国生物业务 2. 未来医药CXO行业市场空间大 2013 • 模104,1亿美医药CXO行业市场规模2,440亿 3.一站式服务平台是行业发展趋势",
    "labels": [
      [
        "T0",
        "行业",
        3,
        8,
        "医药CXO"
      ],
      [
        "T1",
        "行业",
        26,
        33,
        "药物发现CRO"
      ],
      [
        "T2",
        "地点范围",
        40,
        42,
        "中国"
      ],
      [
        "T3",
        "行业",
        42,
        44,
        "生物"
      ],
      [
        "T4",
        "时间范围",
        50,
        52,
        "未来"
      ],
      [
        "T5",
        "行业",
        52,
        57,
        "医药CXO"
      ],
      [
        "T6",
        "市场规模",
        59,
        63,
        "市场空间"
      ],
      [
        "T7",
        "属性值",
        63,
        64,
        "大"
      ],
      [
        "T8",
        "行业",
        80,
        85,
        "医药CXO"
      ],
      [
        "T9",
        "市场规模",
        87,
        91,
        "市场规模"
      ],
      [
        "T10",
        "属性值",
        91,
        97,
        "2,440亿"
      ],
      [
        "T11",
        "属性值",
        100,
        107,
        "一站式服务平台"
      ]
    ]
  },
  {
    "id": 1649,
    "text": "公司细胞/基因治疗研发生产经验丰富，技术能力全面。AppTec已有 27年的细胞储库构建历史，具备全面的细胞系构建、等能力。随着产能逐步释放、客户持续增加以及服务项目由临床早期向后期不断推进，未来收入有望实现加速增长。截止 2021年 Q1末，公司美国区实验室为 36个临床阶段细胞和基因治疗项目提供 CTDMO服务，包括 22个 I期临床试验项目和 14个 II/III期临床试验项目。 细胞治疗：高标准的生产基地，丰富的细胞库构建经验。AppTec能够提供自体或异体细胞疗法的开发、测试和 cGMP生产。公司的细胞库构建工厂全部按照 GMP和 GLP法规进行，生产工厂通过了 ISO认证。工厂建有七个独立配套车间，各车间均设有 ISO5级层流生物安全柜。 基因治疗：技术平台覆盖多种病毒载体，有序扩充产能。公司能提供不同形式的基因疗法的开发、测试和生产服务，病毒载体覆盖慢病毒、逆转录酶病毒、 腺相关病毒（AAV）、腺病毒等类型载体。AppTec配备内部动物设施和分子生物学实验室，可用于开展生物分布和毒理学研究，并制定了完善的 GMP车间清洁验证和环境监控方案。2020年 1月，公司扩建位于美国费城的腺相关病毒",
    "labels": [
      [
        "T0",
        "营业收入",
        98,
        100,
        "收入"
      ],
      [
        "T1",
        "时间范围",
        109,
        121,
        "截止 2021年 Q1末"
      ],
      [
        "T2",
        "时间范围",
        484,
        492,
        "2020年 1月"
      ],
      [
        "T3",
        "时间范围",
        96,
        98,
        "未来"
      ],
      [
        "T4",
        "地点范围",
        124,
        127,
        "美国区"
      ],
      [
        "T5",
        "公司",
        25,
        31,
        "AppTec"
      ],
      [
        "T6",
        "产能",
        64,
        66,
        "产能"
      ],
      [
        "T7",
        "属性值",
        68,
        70,
        "释放"
      ],
      [
        "T8",
        "属性值",
        104,
        108,
        "加速增长"
      ],
      [
        "T9",
        "属性值",
        73,
        77,
        "持续增加"
      ]
    ]
  },
  {
    "id": 1655,
    "text": "龙头公司理应享有一定估值溢价，高基数基础上有望继续维持高增长。公司作为本土 CXO中绝对的行业龙头，已经在业务体量、品牌形象、服务记录等方面建立起优势地位，理应享有一定的龙头溢价。部分观点认为公司收入基数较高， 未来增长弹性可能不及中小规模 CXO企业，但我们认为公司未来的持续高增长是建立在人才、平台、技术三大核心竞争力的基础之上，在高基数的基础上仍然有望维持高增长。有关公司三大竞争力的详细论述请见后文第九章“成长性分析”部分。  优质人才：高素质人才带来的工程师红利是国内 CXO在全球竞争中占得优势的基础，公司的品牌地位、研发经验、平台优势将对团队扩张和招募带来集聚效应，进而与公司业务高质量发展形成正反馈；  稀缺平台：CXO行业虽然玩家众多，但真正拥有端到端的全产业链服务能力的企业具有较强稀缺性，全产业链平台能够带来极高的客户转化率和客户粘性，形成协同效应；  前沿技术：近年来药物发现的新机制和新技术迭出，通过前瞻性布局创新性技术平台，公司有望获得更多全球长尾客户订单，为后续增长提供持续动力。",
    "labels": [
      [
        "T0",
        "龙头企业",
        0,
        4,
        "龙头公司"
      ],
      [
        "T1",
        "龙头企业",
        47,
        49,
        "龙头"
      ],
      [
        "T2",
        "营业收入",
        98,
        100,
        "收入"
      ],
      [
        "T3",
        "行业公司",
        121,
        126,
        "CXO企业"
      ],
      [
        "T4",
        "地点范围",
        238,
        240,
        "国内"
      ],
      [
        "T5",
        "行业",
        241,
        244,
        "CXO"
      ],
      [
        "T6",
        "行业",
        317,
        320,
        "CXO"
      ],
      [
        "T7",
        "行业",
        399,
        403,
        "药物发现"
      ],
      [
        "T8",
        "行业",
        38,
        41,
        "CXO"
      ],
      [
        "T9",
        "地点范围",
        35,
        37,
        "本土"
      ],
      [
        "T10",
        "地点范围",
        245,
        247,
        "全球"
      ],
      [
        "T11",
        "时间范围",
        396,
        399,
        "近年来"
      ],
      [
        "T12",
        "地点范围",
        437,
        439,
        "全球"
      ]
    ]
  },
  {
    "id": 1656,
    "text": "·CXO即医药合同外包服务，包括CRO、CMO、CDMO三个细分行业，其中CRO专注于药物发现研究服务，CMO、CDMO专注于药物生产服务·医药CXO行业规模持续扩大，预计2018-2025年中国医药CXO行·医药CXO行业上游主要负责医药原材料与生产设备供应；中游是业年复合增长率10.3%，2025年CXO市场规模将达到2,440亿美元药品生产服务环节主要包括CRO、CDMO、CMO，下游是制药企业，主要负责购买药品再销往医疗服务机构",
    "labels": [
      [
        "T0",
        "行业",
        1,
        4,
        "CXO"
      ],
      [
        "T1",
        "行业",
        5,
        13,
        "医药合同外包服务"
      ],
      [
        "T2",
        "行业",
        16,
        19,
        "CRO"
      ],
      [
        "T3",
        "行业",
        20,
        23,
        "CMO"
      ],
      [
        "T4",
        "行业",
        24,
        28,
        "CDMO"
      ],
      [
        "T5",
        "行业",
        37,
        40,
        "CRO"
      ],
      [
        "T6",
        "行业",
        52,
        55,
        "CMO"
      ],
      [
        "T7",
        "行业",
        56,
        60,
        "CDMO"
      ],
      [
        "T8",
        "行业",
        63,
        69,
        "药物生产服务"
      ],
      [
        "T9",
        "行业",
        43,
        51,
        "药物发现研究服务"
      ],
      [
        "T10",
        "行业",
        70,
        75,
        "医药CXO"
      ],
      [
        "T11",
        "市场规模",
        77,
        79,
        "规模"
      ],
      [
        "T12",
        "属性值",
        79,
        83,
        "持续扩大"
      ],
      [
        "T13",
        "时间范围",
        86,
        96,
        "2018-2025年"
      ],
      [
        "T14",
        "地点范围",
        96,
        98,
        "中国"
      ],
      [
        "T15",
        "行业",
        98,
        103,
        "医药CXO"
      ],
      [
        "T16",
        "行业",
        105,
        110,
        "医药CXO"
      ],
      [
        "T17",
        "时间范围",
        147,
        152,
        "2025年"
      ],
      [
        "T18",
        "行业",
        152,
        155,
        "CXO"
      ],
      [
        "T19",
        "市场规模",
        155,
        159,
        "市场规模"
      ],
      [
        "T20",
        "属性值",
        162,
        170,
        "2,440亿美元"
      ],
      [
        "T21",
        "行业",
        170,
        176,
        "药品生产服务"
      ],
      [
        "T22",
        "行业",
        182,
        185,
        "CRO"
      ],
      [
        "T23",
        "行业",
        186,
        190,
        "CDMO"
      ],
      [
        "T24",
        "行业",
        191,
        194,
        "CMO"
      ],
      [
        "T25",
        "行业公司",
        198,
        202,
        "制药企业"
      ],
      [
        "T26",
        "行业公司",
        214,
        220,
        "医疗服务机构"
      ]
    ]
  },
  {
    "id": 1667,
    "text": "注：药明康德、康龙化成、九州药业、普洛药业的坪效反映的是整个企业的产能利用效率，不单单包括CDMO业务",
    "labels": [
      [
        "T0",
        "公司",
        2,
        6,
        "药明康德"
      ],
      [
        "T1",
        "公司",
        7,
        11,
        "康龙化成"
      ],
      [
        "T2",
        "公司",
        12,
        16,
        "九州药业"
      ],
      [
        "T3",
        "公司",
        17,
        21,
        "普洛药业"
      ],
      [
        "T4",
        "行业",
        45,
        49,
        "CDMO"
      ]
    ]
  },
  {
    "id": 1668,
    "text": "➢ 从科研投入和医药市场规模情况看，全球与中国市场的体量均在稳步提升。需求端的高景气将持续带动科研服务行业发展。2020年全球药企研发费用1878亿美元，2020-2025年CAGR约为3.8%，中国生物医药行业规模以上企业2020年研发费用785亿元，同比增长28.7%。",
    "labels": [
      [
        "T0",
        "行业",
        8,
        10,
        "医药"
      ],
      [
        "T1",
        "市场规模",
        10,
        14,
        "市场规模"
      ],
      [
        "T2",
        "地点范围",
        18,
        20,
        "全球"
      ],
      [
        "T3",
        "地点范围",
        21,
        23,
        "中国"
      ],
      [
        "T4",
        "行业需求",
        35,
        38,
        "需求端"
      ],
      [
        "T5",
        "行业",
        47,
        51,
        "科研服务"
      ],
      [
        "T6",
        "时间范围",
        56,
        61,
        "2020年"
      ],
      [
        "T7",
        "地点范围",
        61,
        63,
        "全球"
      ],
      [
        "T8",
        "行业公司",
        63,
        65,
        "药企"
      ],
      [
        "T9",
        "研发费用",
        65,
        69,
        "研发费用"
      ],
      [
        "T10",
        "属性值",
        69,
        76,
        "1878亿美元"
      ],
      [
        "T11",
        "时间范围",
        77,
        87,
        "2020-2025年"
      ],
      [
        "T12",
        "CAGR",
        87,
        91,
        "CAGR"
      ],
      [
        "T13",
        "属性值",
        91,
        97,
        "约为3.8%"
      ],
      [
        "T14",
        "地点范围",
        98,
        100,
        "中国"
      ],
      [
        "T15",
        "时间范围",
        112,
        117,
        "2020年"
      ],
      [
        "T16",
        "研发费用",
        117,
        121,
        "研发费用"
      ],
      [
        "T17",
        "行业公司",
        100,
        112,
        "生物医药行业规模以上企业"
      ],
      [
        "T18",
        "属性值",
        30,
        34,
        "稳步提升"
      ],
      [
        "T19",
        "属性值",
        121,
        136,
        "785亿元，同比增长28.7%"
      ],
      [
        "T20",
        "属性值",
        39,
        42,
        "高景气"
      ]
    ]
  },
  {
    "id": 1676,
    "text": "海外CXO企业中，2020年，Catalent和龙沙的资本开支增速位居前两位，同比增速分别为113.57%和24.21%。",
    "labels": [
      [
        "T0",
        "地点范围",
        0,
        2,
        "海外"
      ],
      [
        "T1",
        "行业公司",
        2,
        7,
        "CXO企业"
      ],
      [
        "T2",
        "时间范围",
        9,
        14,
        "2020年"
      ],
      [
        "T3",
        "公司",
        15,
        23,
        "Catalent"
      ],
      [
        "T4",
        "公司",
        24,
        26,
        "龙沙"
      ],
      [
        "T5",
        "CAPEX资本开支",
        27,
        31,
        "资本开支"
      ],
      [
        "T6",
        "属性值",
        31,
        38,
        "增速位居前两位"
      ]
    ]
  },
  {
    "id": 1679,
    "text": "但是需要特别说明的是，虽然2016-2020年Top14MNC研发投入复合增速只有6.83%， 但是本土CXO龙头企业（包括药明康德、药明生物、康龙化成、泰格医药、凯莱英、博腾股份、九洲药业、药石科技、昭衍新药、美迪西、睿智医药等11家CXO龙头）收入加和复合增速高达29.98%，远超MNC研发投入增速，可能主要是本土CXO龙头低基数、 全球产业链转移加速以及外包率持续提升等多方面因素导致。",
    "labels": [
      [
        "T0",
        "时间范围",
        13,
        23,
        "2016-2020年"
      ],
      [
        "T1",
        "研发费用",
        31,
        35,
        "研发投入"
      ],
      [
        "T2",
        "CAGR",
        35,
        39,
        "复合增速"
      ],
      [
        "T3",
        "行业",
        52,
        55,
        "CXO"
      ],
      [
        "T4",
        "龙头企业",
        55,
        59,
        "龙头企业"
      ],
      [
        "T5",
        "公司",
        62,
        66,
        "药明康德"
      ],
      [
        "T6",
        "公司",
        67,
        71,
        "药明生物"
      ],
      [
        "T7",
        "公司",
        72,
        76,
        "康龙化成"
      ],
      [
        "T8",
        "公司",
        77,
        81,
        "泰格医药"
      ],
      [
        "T9",
        "公司",
        82,
        85,
        "凯莱英"
      ],
      [
        "T10",
        "公司",
        86,
        90,
        "博腾股份"
      ],
      [
        "T11",
        "公司",
        91,
        95,
        "九洲药业"
      ],
      [
        "T12",
        "公司",
        96,
        100,
        "药石科技"
      ],
      [
        "T13",
        "公司",
        101,
        105,
        "昭衍新药"
      ],
      [
        "T14",
        "公司",
        106,
        109,
        "美迪西"
      ],
      [
        "T15",
        "公司",
        110,
        114,
        "睿智医药"
      ],
      [
        "T16",
        "行业",
        118,
        121,
        "CXO"
      ],
      [
        "T17",
        "龙头企业",
        121,
        123,
        "龙头"
      ],
      [
        "T18",
        "研发费用",
        146,
        150,
        "研发投入"
      ],
      [
        "T19",
        "行业",
        160,
        163,
        "CXO"
      ],
      [
        "T20",
        "地点范围",
        50,
        52,
        "本土"
      ],
      [
        "T21",
        "行业公司",
        23,
        31,
        "Top14MNC"
      ],
      [
        "T22",
        "属性值",
        41,
        46,
        "6.83%"
      ],
      [
        "T23",
        "地点范围",
        158,
        160,
        "本土"
      ],
      [
        "T24",
        "属性值",
        134,
        140,
        "29.98%"
      ],
      [
        "T25",
        "地点范围",
        170,
        172,
        "全球"
      ],
      [
        "T26",
        "外包率",
        181,
        184,
        "外包率"
      ],
      [
        "T27",
        "属性值",
        124,
        128,
        "收入加和"
      ],
      [
        "T28",
        "属性值",
        184,
        188,
        "持续提升"
      ]
    ]
  },
  {
    "id": 1681,
    "text": "中国企业全球份额持续提升。2020年中国细胞和基因治疗领域 CRO和 CDMO规模分别达到 3.07亿和 13.34亿元，预计到 2025年分别达到 12.03亿和 197.39亿元，2020~2025年 CAGR分别达到 31.4%和 43.3%，此处市场规模口径包括了中国 CXO企业在全球范围内的业务收入。从中国企业在细胞基因治疗 CRO和 CDMO领域的全球份额来看，预计分别从 2020年的 6%和 12%提升到 2025年的 10%和 20%。",
    "labels": [
      [
        "T0",
        "时间范围",
        13,
        18,
        "2020年"
      ],
      [
        "T1",
        "地点范围",
        18,
        20,
        "中国"
      ],
      [
        "T2",
        "地点范围",
        0,
        2,
        "中国"
      ],
      [
        "T3",
        "地点范围",
        4,
        6,
        "全球"
      ],
      [
        "T4",
        "市场份额",
        6,
        8,
        "份额"
      ],
      [
        "T5",
        "行业",
        20,
        33,
        "细胞和基因治疗领域 CRO"
      ],
      [
        "T6",
        "行业",
        35,
        39,
        "CDMO"
      ],
      [
        "T7",
        "市场规模",
        39,
        41,
        "规模"
      ],
      [
        "T8",
        "属性值",
        46,
        51,
        "3.07亿"
      ],
      [
        "T9",
        "属性值",
        53,
        60,
        "13.34亿元"
      ],
      [
        "T10",
        "时间范围",
        65,
        70,
        "2025年"
      ],
      [
        "T11",
        "属性值",
        75,
        81,
        "12.03亿"
      ],
      [
        "T12",
        "属性值",
        83,
        91,
        "197.39亿元"
      ],
      [
        "T13",
        "时间范围",
        92,
        102,
        "2020~2025年"
      ],
      [
        "T14",
        "CAGR",
        103,
        107,
        "CAGR"
      ],
      [
        "T15",
        "属性值",
        112,
        117,
        "31.4%"
      ],
      [
        "T16",
        "属性值",
        119,
        124,
        "43.3%"
      ],
      [
        "T17",
        "市场规模",
        127,
        131,
        "市场规模"
      ],
      [
        "T18",
        "地点范围",
        136,
        138,
        "中国"
      ],
      [
        "T19",
        "行业公司",
        139,
        144,
        "CXO企业"
      ],
      [
        "T20",
        "地点范围",
        145,
        147,
        "全球"
      ],
      [
        "T21",
        "营业收入",
        153,
        155,
        "收入"
      ],
      [
        "T22",
        "地点范围",
        157,
        159,
        "中国"
      ],
      [
        "T23",
        "行业",
        162,
        172,
        "细胞基因治疗 CRO"
      ],
      [
        "T24",
        "行业",
        174,
        178,
        "CDMO"
      ],
      [
        "T25",
        "地点范围",
        181,
        183,
        "全球"
      ],
      [
        "T26",
        "市场份额",
        183,
        185,
        "份额"
      ],
      [
        "T27",
        "时间范围",
        194,
        199,
        "2020年"
      ],
      [
        "T28",
        "属性值",
        201,
        203,
        "6%"
      ],
      [
        "T29",
        "属性值",
        205,
        208,
        "12%"
      ],
      [
        "T30",
        "时间范围",
        212,
        217,
        "2025年"
      ],
      [
        "T31",
        "属性值",
        219,
        222,
        "10%"
      ],
      [
        "T32",
        "属性值",
        224,
        227,
        "20%"
      ]
    ]
  },
  {
    "id": 1685,
    "text": "行情回顾：上周， A股医药生物指数下跌上涨 0.90%，跑输沪深 300指数 2.74pp， 跑输创业板综指 3.03pp，排名 23/28，表现较弱，主要是前期连续上涨后，部分子板块略有调整。港股恒生医疗健康指数收跌 0.3%，跑赢恒生国企指数 1.2pp，排名 9/11。 上市公司研发进度跟踪：上周，恒瑞医药的 HR18034注射液、HRS9432注射液和 HR19003贴剂的 IND申请新进承办，百济神州的 BGB-15025胶囊的 IND申请新进承办，华兰生物的乙型肝炎人免疫球蛋白注射剂的上市申请新进承办。新基医药的 Ozanimod胶囊剂正在进行三期临床；豪森药业的培化西海马肽注射剂正在进行二期临床；信达生物的 IBI321、海思科的 HSK21542注射剂、石药集团的 SKLB1028胶囊剂、正大天晴的 TQ05105片剂正在进行一期临床。 本周观点：汇率影响有限，CXO行业景气度仍处于上行阶段。主要基于三点理由：1）人民币升值预期减弱，CXO公司业绩影响有限；2）前瞻性指标提示行业景气度仍处在上行阶段，行业景气度高点还未到达；3）国内 CXO公司的成长之路仍未走完，公司市值最高点仍未到达。我们继续强调 CDMO在整个医药外包产业链中的结构性机会，我们仍然认为，下一阶段在 500-1000亿市值区间有望诞生多家 CDMO公司。同时，我们认为在短期外部环境（海外疫情和人民币升值）复杂的背景下，应当多关注具有较强执行力的公司，如药明康德。重点推荐药明康德（A+H）、凯莱英、博腾股份、维亚生物（H），建议关注普洛药业、 方达控股等。 2021年投资策略：1）内需大市场主线，建议关注疫苗、血制品、民营医疗服务、 药店与互联网新零售等强劲内需拉动的细分方向，推荐康华生物、智飞生物、派林生物、爱尔眼科、欧普康视、老百姓等。2）国内国际双发力主线，建议关注创新药械、CXO 产业链、防护类耗材赛道等有望受益于国际市场供应链变化的细分方向，推荐信达生物(H)、恒瑞医药、艾德生物、药石科技、九洲药业、康德莱、英科医疗等。 风险分析：药品/耗材降价风险；行业“黑天鹅”事件；研发失败风险。",
    "labels": [
      [
        "T0",
        "时间范围",
        5,
        7,
        "上周"
      ],
      [
        "T1",
        "行业",
        11,
        15,
        "医药生物"
      ],
      [
        "T2",
        "行业",
        101,
        105,
        "医疗健康"
      ],
      [
        "T3",
        "时间范围",
        150,
        152,
        "上周"
      ],
      [
        "T4",
        "公司",
        153,
        157,
        "恒瑞医药"
      ],
      [
        "T5",
        "公司",
        203,
        207,
        "百济神州"
      ],
      [
        "T6",
        "公司",
        232,
        236,
        "华兰生物"
      ],
      [
        "T7",
        "公司",
        260,
        264,
        "新基医药"
      ],
      [
        "T8",
        "公司",
        286,
        290,
        "豪森药业"
      ],
      [
        "T9",
        "公司",
        309,
        313,
        "信达生物"
      ],
      [
        "T10",
        "公司",
        322,
        325,
        "海思科"
      ],
      [
        "T11",
        "公司",
        339,
        343,
        "石药集团"
      ],
      [
        "T12",
        "公司",
        357,
        361,
        "正大天晴"
      ],
      [
        "T13",
        "时间范围",
        381,
        384,
        " 本周"
      ],
      [
        "T14",
        "行业",
        394,
        397,
        "CXO"
      ],
      [
        "T15",
        "行业公司",
        431,
        436,
        "CXO公司"
      ],
      [
        "T16",
        "业绩",
        436,
        438,
        "业绩"
      ],
      [
        "T17",
        "地点范围",
        479,
        481,
        "国内"
      ],
      [
        "T18",
        "行业公司",
        482,
        487,
        "CXO公司"
      ],
      [
        "T19",
        "行业",
        516,
        520,
        "CDMO"
      ],
      [
        "T20",
        "行业",
        523,
        527,
        "医药外包"
      ],
      [
        "T21",
        "行业公司",
        571,
        577,
        "CDMO公司"
      ],
      [
        "T22",
        "公司",
        628,
        632,
        "药明康德"
      ],
      [
        "T23",
        "公司",
        637,
        641,
        "药明康德"
      ],
      [
        "T24",
        "公司",
        647,
        650,
        "凯莱英"
      ],
      [
        "T25",
        "公司",
        651,
        655,
        "博腾股份"
      ],
      [
        "T26",
        "公司",
        656,
        660,
        "维亚生物"
      ],
      [
        "T27",
        "公司",
        668,
        672,
        "普洛药业"
      ],
      [
        "T28",
        "公司",
        674,
        678,
        "方达控股"
      ],
      [
        "T29",
        "时间范围",
        681,
        686,
        "2021年"
      ],
      [
        "T30",
        "行业",
        705,
        707,
        "疫苗"
      ],
      [
        "T31",
        "行业",
        708,
        711,
        "血制品"
      ],
      [
        "T32",
        "行业",
        712,
        716,
        "民营医疗"
      ],
      [
        "T33",
        "行业",
        720,
        722,
        "药店"
      ],
      [
        "T34",
        "行业",
        723,
        729,
        "互联网新零售"
      ],
      [
        "T35",
        "公司",
        744,
        748,
        "康华生物"
      ],
      [
        "T36",
        "公司",
        749,
        753,
        "智飞生物"
      ],
      [
        "T37",
        "公司",
        754,
        758,
        "派林生物"
      ],
      [
        "T38",
        "公司",
        759,
        763,
        "爱尔眼科"
      ],
      [
        "T39",
        "公司",
        764,
        768,
        "欧普康视"
      ],
      [
        "T40",
        "公司",
        769,
        772,
        "老百姓"
      ],
      [
        "T41",
        "行业",
        790,
        794,
        "创新药械"
      ],
      [
        "T42",
        "行业",
        803,
        808,
        "防护类耗材"
      ],
      [
        "T43",
        "公司",
        833,
        837,
        "信达生物"
      ],
      [
        "T44",
        "公司",
        841,
        845,
        "恒瑞医药"
      ],
      [
        "T45",
        "公司",
        846,
        850,
        "艾德生物"
      ],
      [
        "T46",
        "公司",
        851,
        855,
        "药石科技"
      ],
      [
        "T47",
        "公司",
        856,
        860,
        "九洲药业"
      ],
      [
        "T48",
        "公司",
        861,
        864,
        "康德莱"
      ],
      [
        "T49",
        "公司",
        865,
        869,
        "英科医疗"
      ],
      [
        "T50",
        "地点范围",
        776,
        778,
        "国内"
      ],
      [
        "T51",
        "地点范围",
        778,
        780,
        "国际"
      ],
      [
        "T52",
        "行业",
        795,
        802,
        "CXO 产业链"
      ]
    ]
  },
  {
    "id": 1691,
    "text": "➢ 2021年以来CXO板块出现分化并波动明显：2021年1月至8月，CXO板块公司股价走势一路向好，行业受疫情影响较小，甚至受益订单转移表现出逆势上涨；在2021年8月至今，CXO板块公司股价出现波动并逐渐下行，主要系市场对CXO行业未来景气度的担忧与疫情带动新冠相关业务需求的相互对冲，同时CXO行业也受到国际政治形势变化的影响，国际贸易环境变化对CXO行业也形成一部分冲击，板块内部分个股跑赢大盘与行业指数。",
    "labels": [
      [
        "T0",
        "行业",
        9,
        12,
        "CXO"
      ],
      [
        "T1",
        "时间范围",
        24,
        34,
        "2021年1月至8月"
      ],
      [
        "T2",
        "行业",
        35,
        38,
        "CXO"
      ],
      [
        "T3",
        "时间范围",
        78,
        87,
        "2021年8月至今"
      ],
      [
        "T4",
        "行业",
        88,
        91,
        "CXO"
      ],
      [
        "T5",
        "行业",
        113,
        116,
        "CXO"
      ],
      [
        "T6",
        "行业",
        147,
        150,
        "CXO"
      ],
      [
        "T7",
        "行业",
        176,
        179,
        "CXO"
      ],
      [
        "T8",
        "时间范围",
        2,
        9,
        "2021年以来"
      ]
    ]
  },
  {
    "id": 1709,
    "text": "对比国内外 CMO/CDMO龙头公司的主要业务我们发现，国外龙头公司基本聚焦在制剂与高级原料药业务，而国内公司大多从事中间体生产业务，行业壁垒主要在于：1）稳定的质量控制体系；2）后期阶段的工艺开发能力；3）符合 cGMP标准的生产能力（合全药业是中国首个通过美国，欧盟和加拿大监管机构审查的小分子 CMO平台）；4）工艺验证能力；5）行业声誉及客户忠诚度。合全药业凭借其强大的技术水平和优秀的质量控制能力率先进入制剂业务领域，进一步巩固其国内市场龙头地位。",
    "labels": [
      [
        "T0",
        "行业",
        5,
        14,
        " CMO/CDMO"
      ],
      [
        "T1",
        "龙头企业",
        14,
        18,
        "龙头公司"
      ],
      [
        "T2",
        "主营业务",
        19,
        23,
        "主要业务"
      ],
      [
        "T3",
        "地点范围",
        28,
        30,
        "国外"
      ],
      [
        "T4",
        "龙头企业",
        30,
        34,
        "龙头公司"
      ],
      [
        "T5",
        "地点范围",
        51,
        53,
        "国内"
      ],
      [
        "T6",
        "公司",
        119,
        123,
        "合全药业"
      ],
      [
        "T7",
        "行业",
        146,
        153,
        "小分子 CMO"
      ],
      [
        "T8",
        "公司",
        179,
        183,
        "合全药业"
      ],
      [
        "T9",
        "地点范围",
        220,
        222,
        "国内"
      ],
      [
        "T10",
        "龙头企业",
        224,
        226,
        "龙头"
      ],
      [
        "T11",
        "行业",
        207,
        209,
        "制剂"
      ],
      [
        "T12",
        "地点范围",
        2,
        5,
        "国内外"
      ],
      [
        "T13",
        "属性值",
        39,
        47,
        "制剂与高级原料药"
      ],
      [
        "T14",
        "属性值",
        59,
        64,
        "中间体生产"
      ],
      [
        "T15",
        "地点范围",
        124,
        126,
        "中国"
      ]
    ]
  },
  {
    "id": 1727,
    "text": "全球 CRO行业集中度高，竞争激烈。全球 CRO行业竞争激烈，约有 1000多家从事医药外包服务的公司，大型 CRO 公司主要集中于欧美地区。前瞻产业研究院数据显示，2018 年全球前八大 CRO 公司市场份额占比约为 43%，前三大公司占比约 31%，全球 CRO 行业市场集中度高。",
    "labels": [
      [
        "T0",
        "地点范围",
        0,
        2,
        "全球"
      ],
      [
        "T1",
        "行业",
        3,
        6,
        "CRO"
      ],
      [
        "T2",
        "市场集中度",
        6,
        11,
        "行业集中度"
      ],
      [
        "T3",
        "属性值",
        11,
        12,
        "高"
      ],
      [
        "T4",
        "地点范围",
        18,
        20,
        "全球"
      ],
      [
        "T5",
        "行业",
        21,
        24,
        "CRO"
      ],
      [
        "T6",
        "行业",
        42,
        48,
        "医药外包服务"
      ],
      [
        "T7",
        "时间范围",
        83,
        89,
        "2018 年"
      ],
      [
        "T8",
        "地点范围",
        89,
        91,
        "全球"
      ],
      [
        "T9",
        "行业公司",
        91,
        101,
        "前八大 CRO 公司"
      ],
      [
        "T10",
        "市场份额",
        101,
        105,
        "市场份额"
      ],
      [
        "T11",
        "属性值",
        107,
        113,
        "约为 43%"
      ],
      [
        "T12",
        "行业公司",
        114,
        119,
        "前三大公司"
      ],
      [
        "T13",
        "属性值",
        121,
        126,
        "约 31%"
      ],
      [
        "T14",
        "属性值",
        141,
        142,
        "高"
      ],
      [
        "T15",
        "市场集中度",
        136,
        141,
        "市场集中度"
      ],
      [
        "T16",
        "行业",
        130,
        134,
        "CRO "
      ],
      [
        "T17",
        "地点范围",
        127,
        129,
        "全球"
      ],
      [
        "T18",
        "属性值",
        15,
        17,
        "激烈"
      ],
      [
        "T19",
        "行业公司",
        52,
        61,
        "大型 CRO 公司"
      ]
    ]
  },
  {
    "id": 1732,
    "text": "值得重视的是我们也通过测算发现2013-2020年Biotech投融资以及IPO和上市后再融资转化为研发投入占比持续提升，意味着Biotech研发投入对全球医药研发投入以及CXO 订单指引价值边际上在变强。",
    "labels": [
      [
        "T0",
        "时间范围",
        15,
        25,
        "2013-2020年"
      ],
      [
        "T1",
        "行业",
        25,
        32,
        "Biotech"
      ],
      [
        "T2",
        "投融资情况",
        32,
        35,
        "投融资"
      ],
      [
        "T3",
        "属性值",
        56,
        60,
        "持续提升"
      ],
      [
        "T4",
        "研发费用率",
        50,
        56,
        "研发投入占比"
      ],
      [
        "T5",
        "行业",
        64,
        71,
        "Biotech"
      ],
      [
        "T6",
        "研发费用",
        71,
        75,
        "研发投入"
      ],
      [
        "T7",
        "地点范围",
        76,
        78,
        "全球"
      ],
      [
        "T8",
        "行业",
        78,
        80,
        "医药"
      ],
      [
        "T9",
        "研发费用",
        80,
        84,
        "研发投入"
      ],
      [
        "T10",
        "行业",
        86,
        89,
        "CXO"
      ],
      [
        "T11",
        "在手订单",
        90,
        92,
        "订单"
      ]
    ]
  },
  {
    "id": 1734,
    "text": "截止至 2021 年 6 月 30 日，公司累计为全球超过 5220 家客户提供服务，其中，来自“长尾”及中国客户的销售贡献增速高于全球前 20 大药企（除 2020 年因疫情影响外），2021 年上半年“长尾”及中国客户贡献收入 75.70亿元，同比增长 53.67%，增速显著高于全球前 20大药企客户（2021H1，营收 29.67亿元，同比+ 28.72%）。",
    "labels": [
      [
        "T0",
        "时间范围",
        0,
        19,
        "截止至 2021 年 6 月 30 日"
      ],
      [
        "T1",
        "时间范围",
        93,
        102,
        "2021 年上半年"
      ],
      [
        "T2",
        "营业收入",
        113,
        115,
        "收入"
      ],
      [
        "T3",
        "时间范围",
        154,
        160,
        "2021H1"
      ],
      [
        "T4",
        "营业收入",
        161,
        163,
        "营收"
      ],
      [
        "T5",
        "属性值",
        164,
        171,
        "29.67亿元"
      ],
      [
        "T6",
        "属性值",
        174,
        182,
        "+ 28.72%"
      ],
      [
        "T7",
        "地点范围",
        25,
        27,
        "全球"
      ],
      [
        "T8",
        "时间范围",
        79,
        85,
        "2020 年"
      ],
      [
        "T9",
        "行业公司",
        68,
        76,
        "前 20 大药企"
      ],
      [
        "T10",
        "地点范围",
        66,
        68,
        "全球"
      ],
      [
        "T11",
        "地点范围",
        142,
        144,
        "全球"
      ],
      [
        "T12",
        "行业公司",
        144,
        151,
        "前 20大药企"
      ]
    ]
  },
  {
    "id": 1740,
    "text": "根据动脉网不完全统计，截至 2021 年，国内经营 CGT CDMO 业务的企业共 16 家。 与欧美市场相比， 国内 CGTCDMO 行业处于发展初期， 但近年来加快成长， 市场规模快速扩大，增长态势良好。国内主要从事 CGT CDMO 业务的公司包括药明康德、金斯瑞生物科技、康龙化成、博腾股份、和元生物。",
    "labels": [
      [
        "T0",
        "时间范围",
        11,
        20,
        "截至 2021 年"
      ],
      [
        "T1",
        "地点范围",
        21,
        23,
        "国内"
      ],
      [
        "T2",
        "行业",
        26,
        34,
        "CGT CDMO"
      ],
      [
        "T3",
        "地点范围",
        49,
        51,
        "欧美"
      ],
      [
        "T4",
        "地点范围",
        57,
        59,
        "国内"
      ],
      [
        "T5",
        "行业",
        60,
        67,
        "CGTCDMO"
      ],
      [
        "T6",
        "时间范围",
        79,
        82,
        "近年来"
      ],
      [
        "T7",
        "市场规模",
        88,
        92,
        "市场规模"
      ],
      [
        "T8",
        "属性值",
        92,
        96,
        "快速扩大"
      ],
      [
        "T9",
        "地点范围",
        104,
        106,
        "国内"
      ],
      [
        "T10",
        "行业",
        111,
        119,
        "CGT CDMO"
      ],
      [
        "T11",
        "公司",
        127,
        131,
        "药明康德"
      ],
      [
        "T12",
        "公司",
        132,
        139,
        "金斯瑞生物科技"
      ],
      [
        "T13",
        "公司",
        140,
        144,
        "康龙化成"
      ],
      [
        "T14",
        "公司",
        145,
        149,
        "博腾股份"
      ],
      [
        "T15",
        "公司",
        150,
        154,
        "和元生物"
      ]
    ]
  },
  {
    "id": 1741,
    "text": "根据Evaluate Pharma数据，全球细胞及基因治疗的市场规模将从2017年的13亿美元增长至2024年的437亿美元，年复合增长率达到65%",
    "labels": [
      [
        "T0",
        "地点范围",
        20,
        22,
        "全球"
      ],
      [
        "T1",
        "行业",
        22,
        29,
        "细胞及基因治疗"
      ],
      [
        "T2",
        "市场规模",
        30,
        34,
        "市场规模"
      ],
      [
        "T3",
        "时间范围",
        36,
        41,
        "2017年"
      ],
      [
        "T4",
        "属性值",
        42,
        47,
        "13亿美元"
      ],
      [
        "T5",
        "时间范围",
        50,
        55,
        "2024年"
      ],
      [
        "T6",
        "属性值",
        56,
        62,
        "437亿美元"
      ],
      [
        "T7",
        "CAGR",
        63,
        69,
        "年复合增长率"
      ],
      [
        "T8",
        "属性值",
        71,
        74,
        "65%"
      ]
    ]
  },
  {
    "id": 1751,
    "text": "此外，我们也统计了国内top7上市传统药企研发投入数据，发现其绝对值相比Biotech 融资年化研发投入金额相差6.4倍（2020年top7传统药企192亿vsBiotech1424亿），这一现象与全球MNC/Biotech创新药研发投入数据完全不同。我们预计主要是因为本土创新药研发起步较晚导致Biotech和传统药企发展并没有明显时间差，以及国内药企并购事件较少有关。这也表明Biotech融资数据（PE/VC投融资+IPO/定增）等对国内创新药行业景气度和本土CXO行业订单景气度指引价值较大。但是需要注意的是Biotech研发投入更多的是来自于IPO和上市后再融资，而并非PE/VC等一级市场投融资。",
    "labels": [
      [
        "T0",
        "地点范围",
        9,
        11,
        "国内"
      ],
      [
        "T1",
        "行业公司",
        11,
        21,
        "top7上市传统药企"
      ],
      [
        "T2",
        "研发费用",
        21,
        25,
        "研发投入"
      ],
      [
        "T3",
        "行业",
        36,
        44,
        "Biotech "
      ],
      [
        "T4",
        "研发费用",
        48,
        52,
        "研发投入"
      ],
      [
        "T5",
        "时间范围",
        61,
        66,
        "2020年"
      ],
      [
        "T6",
        "行业公司",
        66,
        74,
        "top7传统药企"
      ],
      [
        "T7",
        "属性值",
        74,
        78,
        "192亿"
      ],
      [
        "T8",
        "行业",
        80,
        87,
        "Biotech"
      ],
      [
        "T9",
        "属性值",
        87,
        92,
        "1424亿"
      ],
      [
        "T10",
        "研发费用",
        115,
        119,
        "研发投入"
      ],
      [
        "T11",
        "行业",
        137,
        140,
        "创新药"
      ],
      [
        "T12",
        "行业",
        148,
        155,
        "Biotech"
      ],
      [
        "T13",
        "行业公司",
        156,
        160,
        "传统药企"
      ],
      [
        "T14",
        "行业公司",
        175,
        177,
        "药企"
      ],
      [
        "T15",
        "行业",
        190,
        197,
        "Biotech"
      ],
      [
        "T16",
        "地点范围",
        220,
        222,
        "国内"
      ],
      [
        "T17",
        "行业",
        222,
        225,
        "创新药"
      ],
      [
        "T18",
        "行业",
        233,
        236,
        "CXO"
      ],
      [
        "T19",
        "行业",
        258,
        265,
        "Biotech"
      ],
      [
        "T20",
        "研发费用",
        265,
        269,
        "研发投入"
      ],
      [
        "T21",
        "地点范围",
        99,
        101,
        "全球"
      ],
      [
        "T22",
        "行业",
        101,
        115,
        "MNC/Biotech创新药"
      ],
      [
        "T23",
        "地点范围",
        135,
        137,
        "本土"
      ],
      [
        "T24",
        "地点范围",
        173,
        175,
        "国内"
      ],
      [
        "T25",
        "投融资情况",
        197,
        201,
        "融资数据"
      ],
      [
        "T26",
        "地点范围",
        231,
        233,
        "本土"
      ]
    ]
  },
  {
    "id": 1763,
    "text": "创新药和创新器械受政策影响调整较多，已经进入估值合理区间，建议自下而上筛选优质标的。创新药：在创新药中我们一方面关注已经从 Biotech向 Biopharma进军并取得一定成效的企业，如恒瑞医药、信达生物、贝达药业、君实生物、康方生物、再鼎医药、博瑞医药等；同时也关注在研发上有靓丽表现， 产品未来具备一定国际化可能性的优秀生物技术公司，如天境生物、诺诚健华、 康宁杰瑞、亚盛医药等。医疗器械：这其中 A股标的中我们关注高成长估值业绩总体匹配，细分领域不断进行进口替代的优质公司，如迈瑞医疗、鱼跃医疗、 惠泰医疗、艾德生物、健帆生物、南微医学、心脉医疗、爱博医疗、乐普医疗等；港股中则关注技术具有一定优势，具有 Biotech属性的创新医疗器械公司， 如诺辉健康、启明医疗、心通医疗、沛嘉医疗、归创通桥等。",
    "labels": [
      [
        "T0",
        "行业",
        0,
        3,
        "创新药"
      ],
      [
        "T1",
        "行业",
        4,
        8,
        "创新器械"
      ],
      [
        "T2",
        "行业",
        42,
        45,
        "创新药"
      ],
      [
        "T3",
        "行业",
        47,
        50,
        "创新药"
      ],
      [
        "T4",
        "行业",
        62,
        69,
        "Biotech"
      ],
      [
        "T5",
        "行业",
        71,
        80,
        "Biopharma"
      ],
      [
        "T6",
        "公司",
        94,
        98,
        "恒瑞医药"
      ],
      [
        "T7",
        "公司",
        99,
        103,
        "信达生物"
      ],
      [
        "T8",
        "公司",
        104,
        108,
        "贝达药业"
      ],
      [
        "T9",
        "公司",
        109,
        113,
        "君实生物"
      ],
      [
        "T10",
        "公司",
        114,
        118,
        "康方生物"
      ],
      [
        "T11",
        "公司",
        119,
        123,
        "再鼎医药"
      ],
      [
        "T12",
        "公司",
        124,
        128,
        "博瑞医药"
      ],
      [
        "T13",
        "行业公司",
        163,
        169,
        "生物技术公司"
      ],
      [
        "T14",
        "公司",
        171,
        175,
        "天境生物"
      ],
      [
        "T15",
        "公司",
        176,
        180,
        "诺诚健华"
      ],
      [
        "T16",
        "公司",
        182,
        186,
        "康宁杰瑞"
      ],
      [
        "T17",
        "公司",
        187,
        191,
        "亚盛医药"
      ],
      [
        "T18",
        "行业",
        193,
        197,
        "医疗器械"
      ],
      [
        "T19",
        "业绩",
        216,
        218,
        "业绩"
      ],
      [
        "T20",
        "公司",
        242,
        246,
        "迈瑞医疗"
      ],
      [
        "T21",
        "公司",
        247,
        251,
        "鱼跃医疗"
      ],
      [
        "T22",
        "公司",
        253,
        257,
        "惠泰医疗"
      ],
      [
        "T23",
        "公司",
        258,
        262,
        "艾德生物"
      ],
      [
        "T24",
        "公司",
        263,
        267,
        "健帆生物"
      ],
      [
        "T25",
        "公司",
        268,
        272,
        "南微医学"
      ],
      [
        "T26",
        "公司",
        273,
        277,
        "心脉医疗"
      ],
      [
        "T27",
        "公司",
        278,
        282,
        "爱博医疗"
      ],
      [
        "T28",
        "公司",
        283,
        287,
        "乐普医疗"
      ],
      [
        "T29",
        "行业",
        307,
        314,
        "Biotech"
      ],
      [
        "T30",
        "行业公司",
        317,
        325,
        "创新医疗器械公司"
      ],
      [
        "T31",
        "公司",
        328,
        332,
        "诺辉健康"
      ],
      [
        "T32",
        "公司",
        333,
        337,
        "启明医疗"
      ],
      [
        "T33",
        "公司",
        338,
        342,
        "心通医疗"
      ],
      [
        "T34",
        "公司",
        343,
        347,
        "沛嘉医疗"
      ],
      [
        "T35",
        "公司",
        348,
        352,
        "归创通桥"
      ]
    ]
  },
  {
    "id": 1765,
    "text": "“中国策略”为公司的主要发展战略之一。中国作为全球第二大医药市场（2018 年占比全球市场 18.3%，2018-2023E CAGR=6.8%），当前正在经历由低端仿制药到高端创新药的行业变革，一方面国内企业对创新型药物的需求强烈，且持续加大研发投入，另一方面国内企业研发经验和技术相对缺乏，这一矛盾持续推升医药外包行业景气度，催化出繁荣发展的蓝海市场。公司作为国内 CRO龙头，有望凭借其品牌、技术和客户优势，进一步提升市场份额，创造利润。",
    "labels": [
      [
        "T0",
        "地点范围",
        19,
        21,
        "中国"
      ],
      [
        "T1",
        "地点范围",
        23,
        25,
        "全球"
      ],
      [
        "T2",
        "行业",
        28,
        30,
        "医药"
      ],
      [
        "T3",
        "时间范围",
        33,
        39,
        "2018 年"
      ],
      [
        "T4",
        "地点范围",
        41,
        43,
        "全球"
      ],
      [
        "T5",
        "属性值",
        46,
        51,
        "18.3%"
      ],
      [
        "T6",
        "时间范围",
        52,
        62,
        "2018-2023E"
      ],
      [
        "T7",
        "CAGR",
        63,
        67,
        "CAGR"
      ],
      [
        "T8",
        "属性值",
        68,
        72,
        "6.8%"
      ],
      [
        "T9",
        "时间范围",
        74,
        76,
        "当前"
      ],
      [
        "T10",
        "行业",
        81,
        86,
        "低端仿制药"
      ],
      [
        "T11",
        "行业",
        87,
        92,
        "高端创新药"
      ],
      [
        "T12",
        "地点范围",
        101,
        103,
        "国内"
      ],
      [
        "T13",
        "行业",
        106,
        111,
        "创新型药物"
      ],
      [
        "T14",
        "行业需求",
        112,
        114,
        "需求"
      ],
      [
        "T15",
        "属性值",
        114,
        116,
        "强烈"
      ],
      [
        "T16",
        "属性值",
        118,
        122,
        "持续加大"
      ],
      [
        "T17",
        "研发费用",
        122,
        126,
        "研发投入"
      ],
      [
        "T18",
        "地点范围",
        131,
        133,
        "国内"
      ],
      [
        "T19",
        "行业",
        155,
        159,
        "医药外包"
      ],
      [
        "T20",
        "地点范围",
        182,
        184,
        "国内"
      ],
      [
        "T21",
        "行业",
        185,
        188,
        "CRO"
      ],
      [
        "T22",
        "龙头企业",
        188,
        190,
        "龙头"
      ],
      [
        "T23",
        "市场份额",
        212,
        216,
        "市场份额"
      ],
      [
        "T24",
        "利润",
        219,
        221,
        "利润"
      ]
    ]
  },
  {
    "id": 1769,
    "text": "战略转型阶段（2017二季度至今）：公司于 2017年面临两大客户大品种的需求冲击，积极推动 CMO向“CRO + CDMO一体化”转型。以 2017年成功收购美国 J-STAR公司为契机，CRO业务一方面给公司带来了业务收入，另一方面也起到了客户与订单的引流作用，为转化为后期 CMO项目提供储备。同时，公司在制剂 CDMO和生物 CDMO等新领域积极布局，并将作为未来三年重点发展的业务。",
    "labels": [
      [
        "T0",
        "时间范围",
        7,
        16,
        "2017二季度至今"
      ],
      [
        "T1",
        "时间范围",
        22,
        27,
        "2017年"
      ],
      [
        "T2",
        "行业",
        47,
        50,
        "CMO"
      ],
      [
        "T3",
        "行业",
        52,
        56,
        "CRO "
      ],
      [
        "T4",
        "行业",
        58,
        62,
        "CDMO"
      ],
      [
        "T5",
        "时间范围",
        71,
        76,
        "2017年"
      ],
      [
        "T6",
        "公司",
        83,
        89,
        "J-STAR"
      ],
      [
        "T7",
        "行业",
        95,
        98,
        "CRO"
      ],
      [
        "T8",
        "营业收入",
        111,
        113,
        "收入"
      ],
      [
        "T9",
        "行业",
        140,
        143,
        "CMO"
      ],
      [
        "T10",
        "行业",
        156,
        163,
        "制剂 CDMO"
      ],
      [
        "T11",
        "行业",
        164,
        171,
        "生物 CDMO"
      ],
      [
        "T12",
        "地点范围",
        80,
        82,
        "美国"
      ],
      [
        "T13",
        "时间范围",
        184,
        188,
        "未来三年"
      ]
    ]
  },
  {
    "id": 1775,
    "text": "政策面变化带来市场较大波动，长期逻辑并未改变，无需过度担忧。2021年 7 月 2日，国家药监局药品审评中心（CDE）发布《以临床价值为导向的抗肿瘤药物临床研发指导原则（征求意见稿）》，其中提出“当选择阳性药作为对照时， 应关注阳性对照药是否反映和代表了目标适应症患者最佳用药情况；当计划选择安慰剂或 BSC（最佳支持治疗）作为对照药时，则应确保该适应症在临床中确无标准治疗；当有 BSC时，应优选 BSC作为对照，而非安慰剂。”市场担忧这一政策将导致国内“me-too”类药物上市难度加大，立项减少，从而导致 CXO 行业需求下降。",
    "labels": [
      [
        "T0",
        "时间范围",
        30,
        42,
        "2021年 7 月 2日"
      ],
      [
        "T1",
        "行业",
        255,
        260,
        " CXO "
      ],
      [
        "T2",
        "行业需求",
        262,
        264,
        "需求"
      ],
      [
        "T3",
        "属性值",
        264,
        266,
        "下降"
      ],
      [
        "T4",
        "地点范围",
        226,
        228,
        "国内"
      ]
    ]
  },
  {
    "id": 1780,
    "text": "21M1-4医药制造业同比增速有所放缓。 21M1-4医药制造业累计收入 8774亿元， 同比增长 28.5%；营业成本和利润总额同比增加 20.8%和 80.2%，与 20Q1同期相比收入、成本和利润增速提升了 34.1pp、22.9pp和 87.6pp。以上为增速公布值，若计算公布绝对值相比上年同期的增速，则营业收入，营业成本和利润总额分别同比提升 26.4%、20.8%和 80.2%。我们认为，21M1-4医药制造业经营情况持续改善，但是增速有所放缓。",
    "labels": [
      [
        "T0",
        "时间范围",
        0,
        6,
        "21M1-4"
      ],
      [
        "T1",
        "行业",
        6,
        11,
        "医药制造业"
      ],
      [
        "T2",
        "时间范围",
        21,
        27,
        "21M1-4"
      ],
      [
        "T3",
        "行业",
        27,
        32,
        "医药制造业"
      ],
      [
        "T4",
        "营业收入",
        34,
        36,
        "收入"
      ],
      [
        "T5",
        "属性值",
        37,
        43,
        "8774亿元"
      ],
      [
        "T6",
        "属性值",
        50,
        55,
        "28.5%"
      ],
      [
        "T7",
        "利润",
        61,
        63,
        "利润"
      ],
      [
        "T8",
        "时间范围",
        85,
        89,
        "20Q1"
      ],
      [
        "T9",
        "营业收入",
        93,
        95,
        "收入"
      ],
      [
        "T10",
        "利润",
        99,
        101,
        "利润"
      ],
      [
        "T11",
        "属性值",
        103,
        113,
        "提升了 34.1pp"
      ],
      [
        "T12",
        "营业收入",
        157,
        161,
        "营业收入"
      ],
      [
        "T13",
        "利润",
        167,
        169,
        "利润"
      ],
      [
        "T14",
        "属性值",
        178,
        183,
        "26.4%"
      ],
      [
        "T15",
        "时间范围",
        202,
        208,
        "21M1-4"
      ],
      [
        "T16",
        "行业",
        208,
        213,
        "医药制造业"
      ]
    ]
  },
  {
    "id": 1781,
    "text": "➢ 4月 1日，亚太药业发布公告称，公司于近日收到国家药监局核准签发的关于注射用奥美拉唑钠的《药品补充申请批准通知书》，该药品通过仿",
    "labels": [
      [
        "T0",
        "时间范围",
        2,
        7,
        "4月 1日"
      ],
      [
        "T1",
        "公司",
        8,
        12,
        "亚太药业"
      ]
    ]
  },
  {
    "id": 1787,
    "text": "利润快速增长，主营业务净利率持续提升：剔除部分其他业务带来的较大波动（金斯瑞生物科技、*ST百花）、及部分重复统计口径（泰格医药&方达控股）的后， CXO 板块 2015-2020整体表观利润分别为 13/22/31/52 /64/99亿元，2016-2020年分别同比增长 68%/40%/69%/25%/53%，表观净利率整体呈持续改善趋势，2015-2020 年上述公司净利率分别为 8%/ 14%/15%/17% /18%。",
    "labels": [
      [
        "T0",
        "利润",
        0,
        2,
        "利润"
      ],
      [
        "T1",
        "主营业务",
        7,
        11,
        "主营业务"
      ],
      [
        "T2",
        "公司",
        35,
        42,
        "金斯瑞生物科技"
      ],
      [
        "T3",
        "公司",
        43,
        48,
        "*ST百花"
      ],
      [
        "T4",
        "公司",
        60,
        64,
        "泰格医药"
      ],
      [
        "T5",
        "公司",
        65,
        69,
        "方达控股"
      ],
      [
        "T6",
        "行业",
        74,
        77,
        "CXO"
      ],
      [
        "T7",
        "时间范围",
        81,
        90,
        "2015-2020"
      ],
      [
        "T8",
        "利润",
        94,
        96,
        "利润"
      ],
      [
        "T9",
        "时间范围",
        173,
        184,
        "2015-2020 年"
      ],
      [
        "T10",
        "时间范围",
        121,
        131,
        "2016-2020年"
      ],
      [
        "T11",
        "归母净利润",
        11,
        14,
        "净利率"
      ],
      [
        "T12",
        "属性值",
        100,
        120,
        "13/22/31/52 /64/99亿元"
      ],
      [
        "T13",
        "属性值",
        138,
        157,
        "68%/40%/69%/25%/53%"
      ],
      [
        "T14",
        "归母净利润",
        160,
        163,
        "净利率"
      ],
      [
        "T15",
        "归母净利润",
        188,
        191,
        "净利率"
      ],
      [
        "T16",
        "属性值",
        195,
        215,
        "8%/ 14%/15%/17% /18%"
      ],
      [
        "T17",
        "属性值",
        166,
        170,
        "持续改善"
      ]
    ]
  },
  {
    "id": 1793,
    "text": "乐观假设下 2030年收入规模有望达到 2797亿元，经调整 Non-IFRS净利润达到 671亿元。基于以上假设测算，公司 2030年 CRO和 CDMO业务收入分别达到 1799亿元和 998亿元，2020~2030年 CAGR分别为 32.0%和 34.2%。 对应总收入体量达到 2797亿元（2020~2030年 CAGR为 32.7%），按照 24% 的经调整 Non-IFRS净利率计算， 2030年经调整 Non-IFRS净利润约为 671亿元（2020~2030年 CAGR为 34.1%）。",
    "labels": [
      [
        "T0",
        "时间范围",
        6,
        11,
        "2030年"
      ],
      [
        "T1",
        "营业收入",
        11,
        15,
        "收入规模"
      ],
      [
        "T2",
        "归母净利润",
        39,
        42,
        "净利润"
      ],
      [
        "T3",
        "时间范围",
        63,
        68,
        "2030年"
      ],
      [
        "T4",
        "行业",
        68,
        72,
        " CRO"
      ],
      [
        "T5",
        "行业",
        74,
        78,
        "CDMO"
      ],
      [
        "T6",
        "时间范围",
        101,
        111,
        "2020~2030年"
      ],
      [
        "T7",
        "CAGR",
        111,
        116,
        " CAGR"
      ],
      [
        "T8",
        "营业收入",
        137,
        139,
        "收入"
      ],
      [
        "T9",
        "时间范围",
        151,
        161,
        "2020~2030年"
      ],
      [
        "T10",
        "CAGR",
        162,
        166,
        "CAGR"
      ],
      [
        "T11",
        "时间范围",
        202,
        207,
        "2030年"
      ],
      [
        "T12",
        "归母净利润",
        219,
        222,
        "净利润"
      ],
      [
        "T13",
        "时间范围",
        231,
        241,
        "2020~2030年"
      ],
      [
        "T14",
        "CAGR",
        242,
        246,
        "CAGR"
      ],
      [
        "T15",
        "假设情形",
        0,
        4,
        "乐观假设"
      ]
    ]
  },
  {
    "id": 1796,
    "text": "CGT 药物市场规模的快速增长，将推动 CDMO 行业进入快车道，正如过去生物药市场需求催生了生物药 CDMO 龙头公司的快速成长一样。",
    "labels": [
      [
        "T0",
        "市场规模",
        6,
        10,
        "市场规模"
      ],
      [
        "T1",
        "属性值",
        11,
        15,
        "快速增长"
      ],
      [
        "T2",
        "行业",
        20,
        25,
        "CDMO "
      ],
      [
        "T3",
        "行业",
        37,
        40,
        "生物药"
      ],
      [
        "T4",
        "行业需求",
        42,
        44,
        "需求"
      ],
      [
        "T5",
        "行业",
        47,
        56,
        "生物药 CDMO "
      ],
      [
        "T6",
        "龙头企业",
        56,
        60,
        "龙头公司"
      ],
      [
        "T7",
        "行业",
        0,
        6,
        "CGT 药物"
      ]
    ]
  },
  {
    "id": 1799,
    "text": "2021Q4公募基金医药重仓比例为 5.26%，环比下降 0.12个百分点，配置处于 2016年以来历史最低水平。截止 2021年 12月 31日，医药（申万）市值占比约为 8.73%，环比下降 0.13个百分点。个股方面，从持有基金数、持股总市值等不同指标来看，药明康德、泰格医药、凯莱英等医疗外包服务上市公司为基金重仓股。",
    "labels": [
      [
        "T0",
        "时间范围",
        0,
        6,
        "2021Q4"
      ],
      [
        "T1",
        "时间范围",
        43,
        48,
        "2016年"
      ],
      [
        "T2",
        "时间范围",
        57,
        73,
        "截止 2021年 12月 31日"
      ],
      [
        "T3",
        "行业",
        74,
        76,
        "医药"
      ],
      [
        "T4",
        "公司",
        132,
        136,
        "药明康德"
      ],
      [
        "T5",
        "公司",
        137,
        141,
        "泰格医药"
      ],
      [
        "T6",
        "公司",
        142,
        145,
        "凯莱英"
      ],
      [
        "T7",
        "行业公司",
        146,
        156,
        "医疗外包服务上市公司"
      ],
      [
        "T8",
        "市值",
        80,
        82,
        "市值"
      ]
    ]
  },
  {
    "id": 1805,
    "text": "国内 CXO公司呈现多、小、散的格局，头部效应明显。据弗若斯特沙利文数据，2020年中国小分子 CDMO药物市场中，前五名公司市场占比过半，其中药明康德市占率第一，占比高达 23%，具备大规模的研发服务及生产能力，业务模式较广的综合性或细分龙头竞争优势明显。预计未来随着全球生物技术及医药行业的发展，国际及国内药品质量标准的提升，国内创新药研发持续升级等，作为新药研发的重要参与者，CXO行业结构化进程或将加速。",
    "labels": [
      [
        "T0",
        "地点范围",
        0,
        2,
        "国内"
      ],
      [
        "T1",
        "行业公司",
        3,
        8,
        "CXO公司"
      ],
      [
        "T2",
        "时间范围",
        37,
        42,
        "2020年"
      ],
      [
        "T3",
        "地点范围",
        42,
        44,
        "中国"
      ],
      [
        "T4",
        "行业",
        44,
        52,
        "小分子 CDMO"
      ],
      [
        "T5",
        "公司",
        72,
        76,
        "药明康德"
      ],
      [
        "T6",
        "市场份额",
        76,
        79,
        "市占率"
      ],
      [
        "T7",
        "属性值",
        79,
        90,
        "第一，占比高达 23%"
      ],
      [
        "T8",
        "龙头企业",
        120,
        122,
        "龙头"
      ],
      [
        "T9",
        "行业",
        142,
        144,
        "医药"
      ],
      [
        "T10",
        "地点范围",
        165,
        167,
        "国内"
      ],
      [
        "T11",
        "行业",
        167,
        170,
        "创新药"
      ],
      [
        "T12",
        "行业",
        191,
        194,
        "CXO"
      ],
      [
        "T13",
        "属性值",
        10,
        15,
        "多、小、散"
      ],
      [
        "T14",
        "属性值",
        19,
        25,
        "头部效应明显"
      ],
      [
        "T15",
        "时间范围",
        131,
        133,
        "未来"
      ],
      [
        "T16",
        "地点范围",
        135,
        137,
        "全球"
      ],
      [
        "T17",
        "地点范围",
        150,
        152,
        "国际"
      ],
      [
        "T18",
        "地点范围",
        153,
        155,
        "国内"
      ]
    ]
  },
  {
    "id": 1812,
    "text": "截至 9M19，公司累计助力客户完成 71个 IND申报（1-3Q19：申报 16个），共计 54个获得 CTA批准（1-3Q19：获批 20个），目前尚未有项目进入商业化阶段（进度最快的项目已进入关键性上市实验）。目前新增项目的服务费收入已基本趋稳，未来随着新药研发项目逐步进入里程碑和专利费收入阶段，DDSU业务有望大幅贡献利润增量。",
    "labels": [
      [
        "T0",
        "时间范围",
        0,
        7,
        "截至 9M19"
      ],
      [
        "T1",
        "时间范围",
        29,
        35,
        "1-3Q19"
      ],
      [
        "T2",
        "时间范围",
        59,
        65,
        "1-3Q19"
      ]
    ]
  },
  {
    "id": 1817,
    "text": "◼ 龙头公司的alpha来自哪里？ ➢ 第一，专业性。在医药研发高度分工的背景下，龙头公司有着更为深厚的客户资源和人才优势，可以更为效率地精进自身能力，帮助药企在研发过程中减少费用和加快进度。龙头公司的订单整体会比较饱和，一方面保障了企业的高增速，另一方面，CXO龙头公司可以选取承接自己利润更为丰厚的单子，提升自己的盈利性。除了行业龙头之外，CXO企业通过高研发投入可形成自身较为特色竞争领域，利用专业性服务能力构建护城河。 ➢ 第二，规模优势。CRO企业是人力密集型行业，在企业做大后，往往面临管理边界扩大的人员管理难题，人均创收不一定向好。相反，CDMO公司可在生产交付订单的过程中不断优化工艺，从而一方面扩大产能，另一方面获取更多高附加值的订单，体现了CDMO企业与单纯专利药合同生产企业（CMO）的区别。按照规模优势的从高到底，CXO中各细分子版块的排序为CDMO>临床前CRO>药物发现>临床CRO。 ➢ 第三，龙头公司在平台化下商业模式的多样性。CXO在新药研发生产中，对服务药品和客户往往具备更深的理解，在龙头公司可以衍生出较多的商业模式。比如说，药明康德DDSU业务部门，对于新药研发的过程中除了按照里程碑方式收费外，也降低了药企的研发服务费用，转而拿到药品上市后部分权益分成。这给企业的盈利带来了更大的弹性。",
    "labels": [
      [
        "T0",
        "龙头企业",
        2,
        6,
        "龙头公司"
      ],
      [
        "T1",
        "龙头企业",
        41,
        45,
        "龙头公司"
      ],
      [
        "T2",
        "行业公司",
        78,
        80,
        "药企"
      ],
      [
        "T3",
        "龙头企业",
        96,
        100,
        "龙头公司"
      ],
      [
        "T4",
        "行业",
        129,
        132,
        "CXO"
      ],
      [
        "T5",
        "龙头企业",
        132,
        136,
        "龙头公司"
      ],
      [
        "T6",
        "利润",
        144,
        146,
        "利润"
      ],
      [
        "T7",
        "龙头企业",
        167,
        169,
        "龙头"
      ],
      [
        "T8",
        "行业公司",
        172,
        177,
        "CXO企业"
      ],
      [
        "T9",
        "研发费用",
        180,
        184,
        "研发投入"
      ],
      [
        "T10",
        "行业公司",
        224,
        229,
        "CRO企业"
      ],
      [
        "T11",
        "人均收入",
        263,
        267,
        "人均创收"
      ],
      [
        "T12",
        "行业公司",
        276,
        282,
        "CDMO公司"
      ],
      [
        "T13",
        "行业公司",
        330,
        336,
        "CDMO企业"
      ],
      [
        "T14",
        "行业公司",
        339,
        348,
        "专利药合同生产企业"
      ],
      [
        "T15",
        "行业",
        369,
        372,
        "CXO"
      ],
      [
        "T16",
        "行业",
        383,
        387,
        "CDMO"
      ],
      [
        "T17",
        "行业",
        388,
        394,
        "临床前CRO"
      ],
      [
        "T18",
        "行业",
        395,
        399,
        "药物发现"
      ],
      [
        "T19",
        "行业",
        400,
        405,
        "临床CRO"
      ],
      [
        "T20",
        "龙头企业",
        412,
        416,
        "龙头公司"
      ],
      [
        "T21",
        "行业",
        430,
        433,
        "CXO"
      ],
      [
        "T22",
        "龙头企业",
        461,
        465,
        "龙头公司"
      ],
      [
        "T23",
        "公司",
        482,
        486,
        "药明康德"
      ],
      [
        "T24",
        "属性值",
        230,
        235,
        "人力密集型"
      ]
    ]
  },
  {
    "id": 1823,
    "text": "国内行业景气度指标主要跟踪：历史后验指标（A&港股上市公司研发投入）&创新药IND受理情况 国内CDE新药临床受理品种数量依然处于上升中、2020年呈现高速增长、凸显国内β：2020年有235个1类化学药和159个1类治疗性生物制品申报临床试验，整体相对2019年同期增长30.0%，依然处于上升趋势，尤其是生物药品种上升明显。 2021年01-08月 CDE的IND数量继续呈现高速增长：2021年01-08月有238个1类化学药、 196个1类治疗性生物制品申报临床，整体同比增长68.9%，继续呈现高速增长。",
    "labels": [
      [
        "T0",
        "地点范围",
        0,
        2,
        "国内"
      ],
      [
        "T1",
        "地点范围",
        47,
        49,
        "国内"
      ],
      [
        "T2",
        "时间范围",
        70,
        75,
        "2020年"
      ],
      [
        "T3",
        "地点范围",
        84,
        86,
        "国内"
      ],
      [
        "T4",
        "时间范围",
        88,
        93,
        "2020年"
      ],
      [
        "T5",
        "时间范围",
        128,
        135,
        "2019年同期"
      ],
      [
        "T6",
        "时间范围",
        167,
        178,
        "2021年01-08月"
      ],
      [
        "T7",
        "IND申报数",
        183,
        188,
        "IND数量"
      ],
      [
        "T8",
        "时间范围",
        197,
        208,
        "2021年01-08月"
      ],
      [
        "T9",
        "行业",
        35,
        38,
        "创新药"
      ],
      [
        "T10",
        "行业",
        155,
        158,
        "生物药"
      ],
      [
        "T11",
        "属性值",
        94,
        98,
        "235个"
      ],
      [
        "T12",
        "属性值",
        104,
        108,
        "159个"
      ],
      [
        "T13",
        "属性值",
        209,
        213,
        "238个"
      ],
      [
        "T14",
        "属性值",
        220,
        224,
        "196个"
      ]
    ]
  },
  {
    "id": 1829,
    "text": "医药研发外包服务行业依附于医药行业存在，若医药研发投入降低，或医药企业自建团队开展业务，外包服务率降低，行业市场空间和景气度均会受到较大影响。",
    "labels": [
      [
        "T0",
        "行业",
        0,
        8,
        "医药研发外包服务"
      ],
      [
        "T1",
        "行业",
        13,
        15,
        "医药"
      ],
      [
        "T2",
        "行业",
        21,
        23,
        "医药"
      ],
      [
        "T3",
        "研发费用",
        23,
        27,
        "研发投入"
      ],
      [
        "T4",
        "外包率",
        44,
        49,
        "外包服务率"
      ]
    ]
  },
  {
    "id": 1835,
    "text": " CXO方面，医药创新研发热度不减，CXO行业创新化景气度持续提升。进入到产业链竞争时代，CXO企业进军高技术壁垒服务品类，开始逐步具备全球竞争力。推荐药明生物（H）、康龙化成、皓元医药、药石科技。",
    "labels": [
      [
        "T0",
        "行业",
        2,
        5,
        "CXO"
      ],
      [
        "T1",
        "行业",
        19,
        22,
        "CXO"
      ],
      [
        "T2",
        "行业公司",
        46,
        51,
        "CXO企业"
      ],
      [
        "T3",
        "公司",
        77,
        81,
        "药明生物"
      ],
      [
        "T4",
        "公司",
        85,
        89,
        "康龙化成"
      ],
      [
        "T5",
        "公司",
        90,
        94,
        "皓元医药"
      ],
      [
        "T6",
        "公司",
        95,
        99,
        "药石科技"
      ],
      [
        "T7",
        "行业",
        8,
        12,
        "医药创新"
      ],
      [
        "T8",
        "地点范围",
        69,
        71,
        "全球"
      ]
    ]
  },
  {
    "id": 1837,
    "text": "在新药研发愈加复杂、困难，新药需求不断增加的情况下，CRO 行业持续蓬勃发展。据 Frost & Sullivan 统计，2019 年全球 CRO 行业市场规模为 626亿美元，预计 2024 年可达 960 亿美元，有望成长为全球千亿美元规模的市场。",
    "labels": [
      [
        "T0",
        "行业",
        26,
        29,
        "CRO"
      ],
      [
        "T1",
        "行业",
        13,
        15,
        "新药"
      ],
      [
        "T2",
        "行业需求",
        15,
        17,
        "需求"
      ],
      [
        "T3",
        "属性值",
        17,
        21,
        "不断增加"
      ],
      [
        "T4",
        "时间范围",
        61,
        67,
        "2019 年"
      ],
      [
        "T5",
        "地点范围",
        67,
        69,
        "全球"
      ],
      [
        "T6",
        "行业",
        70,
        73,
        "CRO"
      ],
      [
        "T7",
        "市场规模",
        76,
        80,
        "市场规模"
      ],
      [
        "T8",
        "属性值",
        82,
        88,
        "626亿美元"
      ],
      [
        "T9",
        "时间范围",
        92,
        98,
        "2024 年"
      ],
      [
        "T10",
        "属性值",
        101,
        108,
        "960 亿美元"
      ],
      [
        "T11",
        "地点范围",
        114,
        116,
        "全球"
      ]
    ]
  },
  {
    "id": 1841,
    "text": "3）外包市场扩容：FDA预计到2025年，将会每年批准10-20个 CGT产品，商业化爆发时期明确，外包市场规模加速扩容。",
    "labels": [
      [
        "T0",
        "时间范围",
        15,
        20,
        "2025年"
      ],
      [
        "T1",
        "行业",
        2,
        4,
        "外包"
      ],
      [
        "T2",
        "行业",
        50,
        52,
        "外包"
      ],
      [
        "T3",
        "属性值",
        56,
        60,
        "加速扩容"
      ],
      [
        "T4",
        "市场规模",
        52,
        56,
        "市场规模"
      ]
    ]
  },
  {
    "id": 1847,
    "text": "对于国内 CRO 公司而言，需要不断更新迭代、增强综合服务能力，协助解决国内新药创新难点。我们预计，随着国内 CRO 行业整体水平提升，竞争加剧，集中度上升，国内 CRO 公司将持续向“一体化、差异化、信息化”三大方向发展，以增强综合竞争力。",
    "labels": [
      [
        "T0",
        "地点范围",
        2,
        4,
        "国内"
      ],
      [
        "T1",
        "行业公司",
        5,
        11,
        "CRO 公司"
      ],
      [
        "T2",
        "地点范围",
        52,
        54,
        "国内"
      ],
      [
        "T3",
        "行业",
        55,
        59,
        "CRO "
      ],
      [
        "T4",
        "市场集中度",
        73,
        76,
        "集中度"
      ],
      [
        "T5",
        "地点范围",
        79,
        81,
        "国内"
      ],
      [
        "T6",
        "行业公司",
        81,
        88,
        " CRO 公司"
      ],
      [
        "T7",
        "属性值",
        92,
        105,
        "“一体化、差异化、信息化”"
      ],
      [
        "T8",
        "属性值",
        76,
        78,
        "上升"
      ],
      [
        "T9",
        "属性值",
        70,
        72,
        "加剧"
      ],
      [
        "T10",
        "地点范围",
        36,
        38,
        "国内"
      ],
      [
        "T11",
        "行业",
        38,
        42,
        "新药创新"
      ]
    ]
  },
  {
    "id": 1853,
    "text": ".康龙化成主要业务领域包括实验室服务、CMC服务、临床开发服务，临床开发服务输属于公司业务最大部分，占营业收入64%·，一体化医药研发服务平台是公司最重要的核心竞争力之一，凭借一体化研发服务平台，一方面公司可以提供一体化研究服务，另一方面不同的业务之间可以互相导流·康龙化成2016-2020年通过并购快速搭建海外与中国一站式临床服务平台，2021年预计通过收购完成CGT疗法的CDMO业务布局·康龙化成通过投资自建发展实验室服务、CMC业务，将实验室服务作为基础业务，铺展其他海外业务，2021年计划开展生物制剂Y2业务.om",
    "labels": [
      [
        "T0",
        "公司",
        1,
        5,
        "康龙化成"
      ],
      [
        "T1",
        "属性值",
        13,
        31,
        "实验室服务、CMC服务、临床开发服务"
      ],
      [
        "T2",
        "行业",
        32,
        36,
        "临床开发"
      ],
      [
        "T3",
        "营业收入",
        51,
        55,
        "营业收入"
      ],
      [
        "T4",
        "属性值",
        55,
        58,
        "64%"
      ],
      [
        "T5",
        "公司",
        133,
        137,
        "康龙化成"
      ],
      [
        "T6",
        "时间范围",
        137,
        147,
        "2016-2020年"
      ],
      [
        "T7",
        "时间范围",
        170,
        175,
        "2021年"
      ],
      [
        "T8",
        "行业",
        189,
        193,
        "CDMO"
      ],
      [
        "T9",
        "公司",
        198,
        202,
        "康龙化成"
      ],
      [
        "T10",
        "时间范围",
        244,
        249,
        "2021年"
      ],
      [
        "T11",
        "主营业务",
        5,
        9,
        "主要业务"
      ],
      [
        "T12",
        "地点范围",
        155,
        157,
        "海外"
      ],
      [
        "T13",
        "地点范围",
        158,
        160,
        "中国"
      ],
      [
        "T14",
        "地点范围",
        239,
        241,
        "海外"
      ],
      [
        "T15",
        "行业",
        253,
        257,
        "生物制剂"
      ],
      [
        "T16",
        "行业",
        216,
        219,
        "CMC"
      ],
      [
        "T17",
        "行业",
        210,
        215,
        "实验室服务"
      ],
      [
        "T18",
        "行业",
        223,
        228,
        "实验室服务"
      ]
    ]
  },
  {
    "id": 1858,
    "text": " 行业高景气度持续：近十年FDA批准的新药数量稳步上升，全球TOP药企研发投入大，体现了全球创新需求的旺盛； 受政策和资本驱动，国内创新需求高增长。回顾2020年板块业绩表现，海外临床CRO受疫情影响较大，业绩普遍下滑；国内CXO业绩普遍优异，我们认为疫情转移逻辑并非20年业绩高增长的主要驱动因素，而主要受益于国内行业的高景气度。",
    "labels": [
      [
        "T0",
        "地点范围",
        29,
        31,
        "全球"
      ],
      [
        "T1",
        "行业公司",
        31,
        36,
        "TOP药企"
      ],
      [
        "T2",
        "研发费用",
        36,
        40,
        "研发投入"
      ],
      [
        "T3",
        "属性值",
        40,
        41,
        "大"
      ],
      [
        "T4",
        "地点范围",
        45,
        47,
        "全球"
      ],
      [
        "T5",
        "行业",
        47,
        49,
        "创新"
      ],
      [
        "T6",
        "行业需求",
        49,
        51,
        "需求"
      ],
      [
        "T7",
        "属性值",
        52,
        54,
        "旺盛"
      ],
      [
        "T8",
        "地点范围",
        65,
        67,
        "国内"
      ],
      [
        "T9",
        "行业",
        67,
        69,
        "创新"
      ],
      [
        "T10",
        "行业需求",
        69,
        71,
        "需求"
      ],
      [
        "T11",
        "属性值",
        71,
        74,
        "高增长"
      ],
      [
        "T12",
        "时间范围",
        77,
        82,
        "2020年"
      ],
      [
        "T13",
        "业绩",
        84,
        86,
        "业绩"
      ],
      [
        "T14",
        "地点范围",
        89,
        91,
        "海外"
      ],
      [
        "T15",
        "行业",
        91,
        96,
        "临床CRO"
      ],
      [
        "T16",
        "业绩",
        104,
        106,
        "业绩"
      ],
      [
        "T17",
        "属性值",
        106,
        110,
        "普遍下滑"
      ],
      [
        "T18",
        "地点范围",
        111,
        113,
        "国内"
      ],
      [
        "T19",
        "行业",
        113,
        116,
        "CXO"
      ],
      [
        "T20",
        "业绩",
        116,
        118,
        "业绩"
      ],
      [
        "T21",
        "属性值",
        118,
        122,
        "普遍优异"
      ],
      [
        "T22",
        "时间范围",
        135,
        138,
        "20年"
      ],
      [
        "T23",
        "业绩",
        138,
        140,
        "业绩"
      ],
      [
        "T24",
        "属性值",
        140,
        143,
        "高增长"
      ],
      [
        "T25",
        "地点范围",
        157,
        159,
        "国内"
      ],
      [
        "T26",
        "时间范围",
        11,
        14,
        "近十年"
      ]
    ]
  },
  {
    "id": 1859,
    "text": "5月 24日，勃林格殷格翰（Boehringer Ingelheim）宣布，美国 FDA已授予口服在研疗法 BI 425809突破性疗法认定（BTD），用于治疗与精神分裂症相关的认知障碍（CIAS）。BI 425809是一种新型甘氨酸转运体-1（GlyT1）抑制剂。 CIAS包括日常生活解决问题的能力、记忆力和注意力，是精神分裂症患者的主要负担，目前没有获批疗法。勃林格殷格翰计划启动 BI 425809的 3期临床试验， 以评估该药在改善成人精神分裂症患者认知方面的安全性和有效性。值得一提的是，今年 3月 24日，根据 CDE官网显示，它已在中国默认获批临床，拟用于治疗精神分裂症认知症状。BI 425809是勃林格殷格翰开发的一款新型 Gly-T1抑制剂，旨在通过抑制 Gly-T1改善 N-甲基-D-天冬氨酸（NMDA）受体的功能减退， 从而起到治疗作用。N-甲基-D-天冬氨酸受体功能低下导致的谷氨酸能途径异常是精神分裂症和阿尔茨海默症发病的病理原因之一。 https://www.prnewswire.com",
    "labels": [
      [
        "T0",
        "时间范围",
        0,
        6,
        "5月 24日"
      ],
      [
        "T1",
        "公司",
        7,
        35,
        "勃林格殷格翰（Boehringer Ingelheim）"
      ],
      [
        "T2",
        "地点范围",
        38,
        40,
        "美国"
      ],
      [
        "T3",
        "时间范围",
        250,
        259,
        "今年 3月 24日"
      ],
      [
        "T4",
        "地点范围",
        274,
        276,
        "中国"
      ]
    ]
  },
  {
    "id": 1861,
    "text": " CXO板块持续高景气，叠加 2020Q1低基数效应（新冠疫情影响）。一季度收入端高增长，毛利率/净利率恢复至往年正常水平，利润高增长。国金医药大数据中心统计的 15家代表性 CXO 上市公司一季度收入同比增长 49%，归母净利润同比增长 181%，扣非后归母净利润同比增长 105%。",
    "labels": [
      [
        "T0",
        "行业公司",
        82,
        97,
        "15家代表性 CXO 上市公司"
      ],
      [
        "T1",
        "时间范围",
        97,
        100,
        "一季度"
      ],
      [
        "T2",
        "营收增长",
        100,
        106,
        "收入同比增长"
      ],
      [
        "T3",
        "属性值",
        107,
        110,
        "49%"
      ],
      [
        "T4",
        "归母净利润",
        111,
        116,
        "归母净利润"
      ],
      [
        "T5",
        "属性值",
        116,
        125,
        "同比增长 181%"
      ],
      [
        "T6",
        "扣非净利润",
        126,
        134,
        "扣非后归母净利润"
      ],
      [
        "T7",
        "属性值",
        134,
        143,
        "同比增长 105%"
      ],
      [
        "T8",
        "行业",
        2,
        5,
        "CXO"
      ],
      [
        "T9",
        "时间范围",
        36,
        39,
        "一季度"
      ],
      [
        "T10",
        "营业收入",
        39,
        42,
        "收入端"
      ],
      [
        "T11",
        "属性值",
        42,
        45,
        "高增长"
      ],
      [
        "T12",
        "毛利",
        46,
        49,
        "毛利率"
      ],
      [
        "T13",
        "归母净利润",
        50,
        53,
        "净利率"
      ],
      [
        "T14",
        "利润",
        63,
        65,
        "利润"
      ],
      [
        "T15",
        "属性值",
        65,
        68,
        "高增长"
      ]
    ]
  },
  {
    "id": 1866,
    "text": "2019年相比，整体需求增速将会处于上升态势。 三驾马车共同驱动外需增速提振：新技术应用 +产业升级 +产业转移。 2016-2020年，上述 29家上市公司来源于境外客户的收入增速分别为 27%/25%/19%/36%/29%。2019年增速显著提升，我们判断主要原因如下： ①药物发现 CRO服务收入增速提振，主要受益于 DEL、PROTAC、虚拟筛选、AI药筛等新技术的应用和新靶点的开发。②临床前开发 CRO服务， 收入占比较小的离岸动物实验需求逐渐开始产业转移，增速提升明显。③ 临床 CRO服务增速小幅提升，收入占比相对较小，主要受益于新客户拓展。④小分子 CMO/CDMO服务，产业升级（中间体→原料药→制剂）和产业转移共振刺激收入增速提升。⑤大分子 CRO/CDMO服务，新客户、 新靶点、新项目类型（ADC、多抗、融合蛋白等）共同刺激增速提振。 2020年受到新冠疫情的影响，海外（主要是美国）增速略有下降。预计未来五年，海外需求平稳增长。",
    "labels": [
      [
        "T0",
        "时间范围",
        0,
        5,
        "2019年"
      ],
      [
        "T1",
        "时间范围",
        58,
        68,
        "2016-2020年"
      ],
      [
        "T2",
        "行业公司",
        72,
        79,
        "29家上市公司"
      ],
      [
        "T3",
        "地点范围",
        82,
        84,
        "境外"
      ],
      [
        "T4",
        "收入增速",
        87,
        91,
        "收入增速"
      ],
      [
        "T5",
        "属性值",
        95,
        114,
        "27%/25%/19%/36%/29%"
      ],
      [
        "T6",
        "时间范围",
        115,
        120,
        "2019年"
      ],
      [
        "T7",
        "行业",
        140,
        150,
        "药物发现 CRO服务"
      ],
      [
        "T8",
        "收入增速",
        150,
        154,
        "收入增速"
      ],
      [
        "T9",
        "属性值",
        154,
        156,
        "提振"
      ],
      [
        "T10",
        "行业",
        199,
        210,
        "临床前开发 CRO服务"
      ],
      [
        "T11",
        "行业",
        219,
        225,
        "离岸动物实验"
      ],
      [
        "T12",
        "营收占比",
        212,
        216,
        "收入占比"
      ],
      [
        "T13",
        "属性值",
        216,
        218,
        "较小"
      ],
      [
        "T14",
        "行业",
        245,
        253,
        "临床 CRO服务"
      ],
      [
        "T15",
        "营收占比",
        260,
        264,
        "收入占比"
      ],
      [
        "T16",
        "属性值",
        264,
        268,
        "相对较小"
      ],
      [
        "T17",
        "行业",
        281,
        295,
        "小分子 CMO/CDMO服务"
      ],
      [
        "T18",
        "收入增速",
        321,
        325,
        "收入增速"
      ],
      [
        "T19",
        "属性值",
        325,
        327,
        "提升"
      ],
      [
        "T20",
        "行业",
        329,
        343,
        "大分子 CRO/CDMO服务"
      ],
      [
        "T21",
        "属性值",
        378,
        380,
        "提振"
      ],
      [
        "T22",
        "时间范围",
        382,
        387,
        "2020年"
      ],
      [
        "T23",
        "地点范围",
        397,
        399,
        "海外"
      ],
      [
        "T24",
        "地点范围",
        403,
        405,
        "美国"
      ],
      [
        "T25",
        "属性值",
        408,
        412,
        "略有下降"
      ],
      [
        "T26",
        "时间范围",
        415,
        419,
        "未来五年"
      ],
      [
        "T27",
        "地点范围",
        420,
        422,
        "海外"
      ],
      [
        "T28",
        "属性值",
        424,
        428,
        "平稳增长"
      ]
    ]
  },
  {
    "id": 1871,
    "text": "风险共担、利益共享的商业模式：拥抱行业成长红利 “服务费+里程碑收费+专利费”的创新商业模式。药明康德国内新药研发服务部（DDSU）成立于 2014年，通过对公司各子平台的有机整合，采用全新的合作模式，专注于为中国药企赋能研发小分子一类新药，提供以 IND申报为目标的一站式新药研发服务。 DDSU部门与客户建立以成功为导向（Success-based）",
    "labels": [
      [
        "T0",
        "公司",
        47,
        51,
        "药明康德"
      ],
      [
        "T1",
        "地点范围",
        51,
        53,
        "国内"
      ],
      [
        "T2",
        "时间范围",
        70,
        75,
        "2014年"
      ],
      [
        "T3",
        "地点范围",
        105,
        107,
        "中国"
      ],
      [
        "T4",
        "行业公司",
        107,
        109,
        "药企"
      ]
    ]
  },
  {
    "id": 1873,
    "text": "医药CXO行业市场规模2,440亿美元",
    "labels": [
      [
        "T0",
        "行业",
        0,
        5,
        "医药CXO"
      ],
      [
        "T1",
        "市场规模",
        7,
        11,
        "市场规模"
      ],
      [
        "T2",
        "属性值",
        11,
        19,
        "2,440亿美元"
      ]
    ]
  },
  {
    "id": 1877,
    "text": "本周医药生物板块全周上涨 0.51%，沪深 300指数全周下跌 2.14%，截至 2022年 03月 25日，医药板块估值为 28.90倍（TTM整体法，剔除负值），溢价率方面， 医药板块对于沪深 300的估值溢价率为 150.51%，医药板块对于剔除银行后的全部 A股溢价率为 51.98%。近期医药生物板块上涨，医药生物板块相对沪深 300溢价率呈上升趋势。我们假设 2021年行业利润增长率为 25%左右，则整体估值水平在 23.12倍左右。",
    "labels": [
      [
        "T0",
        "时间范围",
        0,
        2,
        "本周"
      ],
      [
        "T1",
        "行业",
        2,
        6,
        "医药生物"
      ],
      [
        "T2",
        "时间范围",
        38,
        54,
        "截至 2022年 03月 25日"
      ],
      [
        "T3",
        "行业",
        55,
        57,
        "医药"
      ],
      [
        "T4",
        "行业",
        90,
        92,
        "医药"
      ],
      [
        "T5",
        "行业",
        118,
        120,
        "医药"
      ],
      [
        "T6",
        "行业",
        149,
        153,
        "医药生物"
      ],
      [
        "T7",
        "时间范围",
        147,
        149,
        "近期"
      ],
      [
        "T8",
        "行业",
        158,
        162,
        "医药生物"
      ],
      [
        "T9",
        "时间范围",
        185,
        191,
        " 2021年"
      ],
      [
        "T10",
        "利润",
        193,
        195,
        "利润"
      ]
    ]
  },
  {
    "id": 1883,
    "text": "业绩方面，正如我们在《CDMO：景气度无虞，竞争力提升——医药外包行业系列深度报告之四（20211201）》的观点，通过对在手订单以及 CAPEX计划的梳理，我们认为 CDMO公司 2022年业绩有望加速。此外，新冠口服药的销售超预期亦有望催化相关 CDMO公司业绩超预期。",
    "labels": [
      [
        "T0",
        "业绩",
        0,
        2,
        "业绩"
      ],
      [
        "T1",
        "行业",
        11,
        15,
        "CDMO"
      ],
      [
        "T2",
        "行业",
        29,
        33,
        "医药外包"
      ],
      [
        "T3",
        "在手订单",
        61,
        65,
        "在手订单"
      ],
      [
        "T4",
        "CAPEX资本开支",
        68,
        73,
        "CAPEX"
      ],
      [
        "T5",
        "行业公司",
        84,
        91,
        "CDMO公司 "
      ],
      [
        "T6",
        "时间范围",
        91,
        96,
        "2022年"
      ],
      [
        "T7",
        "业绩",
        96,
        98,
        "业绩"
      ],
      [
        "T8",
        "行业公司",
        125,
        131,
        "CDMO公司"
      ],
      [
        "T9",
        "业绩",
        131,
        133,
        "业绩"
      ],
      [
        "T10",
        "时间范围",
        44,
        52,
        "20211201"
      ],
      [
        "T11",
        "属性值",
        100,
        102,
        "加速"
      ],
      [
        "T12",
        "属性值",
        133,
        136,
        "超预期"
      ]
    ]
  },
  {
    "id": 1885,
    "text": "2020年国内Biotech研发投入金额预计为1424亿，投融资年化研发投入为581亿。 国内创新药Biotech企业融资主要方式为PE/VC、IPO以及上市后的定增配股等方式（传统药企一般依靠商业化创新药和仿制药品种销售实现研发资金的积累），2020年和2021",
    "labels": [
      [
        "T0",
        "时间范围",
        0,
        5,
        "2020年"
      ],
      [
        "T1",
        "地点范围",
        5,
        7,
        "国内"
      ],
      [
        "T2",
        "行业",
        7,
        14,
        "Biotech"
      ],
      [
        "T3",
        "研发费用",
        14,
        18,
        "研发投入"
      ],
      [
        "T4",
        "属性值",
        23,
        28,
        "1424亿"
      ],
      [
        "T5",
        "地点范围",
        45,
        47,
        "国内"
      ],
      [
        "T6",
        "行业公司",
        47,
        59,
        "创新药Biotech企业"
      ],
      [
        "T7",
        "行业公司",
        89,
        93,
        "传统药企"
      ],
      [
        "T8",
        "时间范围",
        122,
        127,
        "2020年"
      ],
      [
        "T9",
        "时间范围",
        128,
        132,
        "2021"
      ]
    ]
  },
  {
    "id": 1889,
    "text": "二线CDMO：包括九洲药业、普洛药业及诺泰生物，这3家公司都有足够的产能和丰富的生产经验，原先主营业务以大宗原料药等为主，逐步向附加值更高的 CDMO业务拓展，提升公司整体毛利率和净利率。受益产业转移的二线CDMO迎来发展新机遇。",
    "labels": [
      [
        "T0",
        "行业",
        3,
        7,
        "CDMO"
      ],
      [
        "T1",
        "公司",
        10,
        14,
        "九洲药业"
      ],
      [
        "T2",
        "公司",
        15,
        19,
        "普洛药业"
      ],
      [
        "T3",
        "公司",
        20,
        24,
        "诺泰生物"
      ],
      [
        "T4",
        "主营业务",
        48,
        52,
        "主营业务"
      ],
      [
        "T5",
        "行业",
        72,
        76,
        "CDMO"
      ],
      [
        "T6",
        "毛利",
        87,
        90,
        "毛利率"
      ],
      [
        "T7",
        "行业",
        104,
        108,
        "CDMO"
      ]
    ]
  },
  {
    "id": 1899,
    "text": "绝对估值：合理估值 5208~5996亿元公司所处的医药研发/生产外包服务行业（以下简称 CXO）受益于研发投入持续增长和全球产业链向亚太地区转移，需求景气度较高，国内企业增速普遍高于全球行业平均水平。 公司作为国内 CXO行业绝对龙头，在高质量的人才队伍、全产业链平台覆盖、 前沿技术布局等方面构建了较强优势。在与全球龙头竞争的过程中，工程师红利带来的成本和效率优势将持续体现。我们预计公司未来三年的收入增速将维持在 27~30%的水平，后续增长有望随着研发订单的持续进入和生产订单的规模维持在较高水平。 在中国新药研发快速爆发的时代，作为“卖水人”的 CXO企业具有较强的成长性和较高的确定性。未来中国原创新药（First-in-Class）必将有能力与全球跨国药企同台竞技，而中国的 CXO龙头也必将进入全球的第一梯队。因此我们认为，在 10年的维度上，公司在全球 CRO和 CDMO的市场份额有望分别提升至 15%与 5%（2020年预计为 2.4%和 0.9%，而 Covance、IQVIA当前在全球 CRO市场中份额为 20.8%和 16.9%，Lonza、Catalent在全球 CDMO市场中份额为 6.35%和 3.85%）。",
    "labels": [
      [
        "T0",
        "行业",
        26,
        37,
        "医药研发/生产外包服务"
      ],
      [
        "T1",
        "行业",
        45,
        48,
        "CXO"
      ],
      [
        "T2",
        "研发费用",
        52,
        56,
        "研发投入"
      ],
      [
        "T3",
        "属性值",
        56,
        60,
        "持续增长"
      ],
      [
        "T4",
        "行业需求",
        74,
        76,
        "需求"
      ],
      [
        "T5",
        "属性值",
        76,
        81,
        "景气度较高"
      ],
      [
        "T6",
        "地点范围",
        106,
        108,
        "国内"
      ],
      [
        "T7",
        "行业",
        109,
        112,
        "CXO"
      ],
      [
        "T8",
        "龙头企业",
        116,
        118,
        "龙头"
      ],
      [
        "T9",
        "龙头企业",
        160,
        162,
        "龙头"
      ],
      [
        "T10",
        "地点范围",
        158,
        160,
        "全球"
      ],
      [
        "T11",
        "时间范围",
        196,
        200,
        "未来三年"
      ],
      [
        "T12",
        "收入增速",
        201,
        205,
        "收入增速"
      ],
      [
        "T13",
        "行业公司",
        277,
        283,
        " CXO企业"
      ],
      [
        "T14",
        "地点范围",
        301,
        303,
        "中国"
      ],
      [
        "T15",
        "行业",
        303,
        307,
        "原创新药"
      ],
      [
        "T16",
        "行业公司",
        331,
        335,
        "跨国药企"
      ],
      [
        "T17",
        "行业",
        345,
        348,
        "CXO"
      ],
      [
        "T18",
        "龙头企业",
        348,
        350,
        "龙头"
      ],
      [
        "T19",
        "地点范围",
        383,
        385,
        "全球"
      ],
      [
        "T20",
        "行业",
        386,
        389,
        "CRO"
      ],
      [
        "T21",
        "行业",
        391,
        395,
        "CDMO"
      ],
      [
        "T22",
        "市场份额",
        396,
        400,
        "市场份额"
      ],
      [
        "T23",
        "时间范围",
        416,
        421,
        "2020年"
      ],
      [
        "T24",
        "公司",
        438,
        445,
        "Covance"
      ],
      [
        "T25",
        "公司",
        446,
        451,
        "IQVIA"
      ],
      [
        "T26",
        "地点范围",
        454,
        456,
        "全球"
      ],
      [
        "T27",
        "时间范围",
        451,
        453,
        "当前"
      ],
      [
        "T28",
        "行业",
        457,
        460,
        "CRO"
      ],
      [
        "T29",
        "市场份额",
        463,
        465,
        "份额"
      ],
      [
        "T30",
        "属性值",
        467,
        472,
        "20.8%"
      ],
      [
        "T31",
        "属性值",
        474,
        479,
        "16.9%"
      ],
      [
        "T32",
        "公司",
        480,
        485,
        "Lonza"
      ],
      [
        "T33",
        "公司",
        486,
        494,
        "Catalent"
      ],
      [
        "T34",
        "地点范围",
        495,
        498,
        "全球 "
      ],
      [
        "T35",
        "行业",
        498,
        502,
        "CDMO"
      ],
      [
        "T36",
        "市场份额",
        505,
        507,
        "份额"
      ],
      [
        "T37",
        "属性值",
        509,
        514,
        "6.35%"
      ],
      [
        "T38",
        "属性值",
        516,
        521,
        "3.85%"
      ],
      [
        "T39",
        "地点范围",
        61,
        63,
        "全球"
      ],
      [
        "T40",
        "地点范围",
        67,
        71,
        "亚太地区"
      ],
      [
        "T41",
        "地点范围",
        82,
        84,
        "国内"
      ],
      [
        "T42",
        "地点范围",
        92,
        94,
        "全球"
      ],
      [
        "T43",
        "地点范围",
        255,
        257,
        "中国"
      ],
      [
        "T44",
        "时间范围",
        299,
        301,
        "未来"
      ],
      [
        "T45",
        "地点范围",
        329,
        331,
        "全球"
      ],
      [
        "T46",
        "地点范围",
        355,
        357,
        "全球"
      ],
      [
        "T47",
        "地点范围",
        341,
        343,
        "中国"
      ]
    ]
  },
  {
    "id": 1925,
    "text": "CGT 相关临床数量稳步上升也催化 CDMO 的发展。据 ARM 年报统计， 2016-2020 年，全球由产业界赞助的 CGT 临床阶段管线从 425 个增长至 842 个。其中，临床 II 期占比最大，达到 50%左右。临床 III 期管线由 2016 的 31 个增长至 2020 年的 97 个，4 年增长超过 2 倍。至 2026 年，CGT 临床管线有望较 2020 年翻 2 倍，达到近 3500 个（包含干细胞疗法），其中 355 个将处于 III 期临床试验阶段。由于临床管线多，2021 年接受在研 CGT 药物人数大于接受商业化 CGT 药物人数，且该现象将持续数年，表明 CGT 临床试验对 CGT CDMO 发展也起了巨大的推动作用。",
    "labels": [
      [
        "T0",
        "行业",
        0,
        3,
        "CGT"
      ],
      [
        "T1",
        "行业",
        18,
        22,
        "CDMO"
      ],
      [
        "T2",
        "地点范围",
        51,
        53,
        "全球"
      ],
      [
        "T3",
        "行业",
        61,
        65,
        "CGT "
      ],
      [
        "T4",
        "时间范围",
        124,
        128,
        "2016"
      ],
      [
        "T5",
        "时间范围",
        138,
        145,
        " 2020 年"
      ],
      [
        "T6",
        "行业",
        173,
        177,
        "CGT "
      ],
      [
        "T7",
        "时间范围",
        249,
        255,
        "2021 年"
      ],
      [
        "T8",
        "行业",
        259,
        264,
        " CGT "
      ],
      [
        "T9",
        "行业",
        276,
        280,
        "CGT "
      ],
      [
        "T10",
        "行业",
        297,
        301,
        " CGT"
      ],
      [
        "T11",
        "行业",
        307,
        316,
        " CGT CDMO"
      ],
      [
        "T12",
        "时间范围",
        39,
        50,
        "2016-2020 年"
      ],
      [
        "T13",
        "时间范围",
        166,
        172,
        "2026 年"
      ]
    ]
  },
  {
    "id": 1926,
    "text": "·全球医药研发投入稳定增长，驱动CXO行业发展。2020年全球医药研发投入204.8亿元，增速已达到12.3%，属于快速增长阶段，中国医药研发投入29.8亿元，美国医药研发投入89.8亿元。2016年-2020年中国医药研发投入年均复合增长率20.0%，美国医药研发年均复合增长率7.4%，全球医药研发增长率6.9%，中国医药研发年均增长率高于全球，中国医药研发投入增长迅速，驱动CXO行业发展",
    "labels": [
      [
        "T0",
        "地点范围",
        1,
        3,
        "全球"
      ],
      [
        "T1",
        "行业",
        3,
        5,
        "医药"
      ],
      [
        "T2",
        "研发费用",
        5,
        9,
        "研发投入"
      ],
      [
        "T3",
        "属性值",
        9,
        13,
        "稳定增长"
      ],
      [
        "T4",
        "行业",
        16,
        19,
        "CXO"
      ],
      [
        "T5",
        "时间范围",
        24,
        29,
        "2020年"
      ],
      [
        "T6",
        "地点范围",
        29,
        31,
        "全球"
      ],
      [
        "T7",
        "行业",
        31,
        33,
        "医药"
      ],
      [
        "T8",
        "研发费用",
        33,
        37,
        "研发投入"
      ],
      [
        "T9",
        "属性值",
        37,
        44,
        "204.8亿元"
      ],
      [
        "T10",
        "地点范围",
        65,
        67,
        "中国"
      ],
      [
        "T11",
        "行业",
        67,
        69,
        "医药"
      ],
      [
        "T12",
        "研发费用",
        69,
        73,
        "研发投入"
      ],
      [
        "T13",
        "属性值",
        73,
        79,
        "29.8亿元"
      ],
      [
        "T14",
        "地点范围",
        80,
        82,
        "美国"
      ],
      [
        "T15",
        "行业",
        82,
        84,
        "医药"
      ],
      [
        "T16",
        "研发费用",
        84,
        88,
        "研发投入"
      ],
      [
        "T17",
        "属性值",
        88,
        94,
        "89.8亿元"
      ],
      [
        "T18",
        "时间范围",
        95,
        106,
        "2016年-2020年"
      ],
      [
        "T19",
        "地点范围",
        106,
        108,
        "中国"
      ],
      [
        "T20",
        "行业",
        108,
        110,
        "医药"
      ],
      [
        "T21",
        "研发费用",
        110,
        114,
        "研发投入"
      ],
      [
        "T22",
        "CAGR",
        114,
        121,
        "年均复合增长率"
      ],
      [
        "T23",
        "属性值",
        121,
        126,
        "20.0%"
      ],
      [
        "T24",
        "地点范围",
        127,
        129,
        "美国"
      ],
      [
        "T25",
        "行业",
        129,
        133,
        "医药研发"
      ],
      [
        "T26",
        "CAGR",
        133,
        140,
        "年均复合增长率"
      ],
      [
        "T27",
        "属性值",
        140,
        144,
        "7.4%"
      ],
      [
        "T28",
        "地点范围",
        145,
        147,
        "全球"
      ],
      [
        "T29",
        "行业",
        147,
        151,
        "医药研发"
      ],
      [
        "T30",
        "地点范围",
        159,
        161,
        "中国"
      ],
      [
        "T31",
        "行业",
        161,
        165,
        "医药研发"
      ],
      [
        "T32",
        "地点范围",
        175,
        177,
        "中国"
      ],
      [
        "T33",
        "行业",
        177,
        179,
        "医药"
      ],
      [
        "T34",
        "研发费用",
        179,
        183,
        "研发投入"
      ],
      [
        "T35",
        "属性值",
        183,
        187,
        "增长迅速"
      ],
      [
        "T36",
        "行业",
        190,
        193,
        "CXO"
      ],
      [
        "T37",
        "CAGR",
        165,
        170,
        "年均增长率"
      ],
      [
        "T38",
        "属性值",
        170,
        174,
        "高于全球"
      ],
      [
        "T39",
        "属性值",
        154,
        158,
        "6.9%"
      ]
    ]
  },
  {
    "id": 1931,
    "text": " 国内CDMO公司继续呈现高速增长、且景气度有上行趋势：核心公司CDMO业务2021年中报合计实现营业收入147.67亿元 ，同比增长65.96%，呈现超高速增长，其中药明生物受益于新冠疫苗、中和抗体等业务的放量，上半年实现营业收入44.13 亿元，同比增长126.29%。展望2021年下半年和2022年，伴随新冠疫苗、新冠中和抗体、新冠口服药等产品上市及放量，国内核心CDMO供应商有望持续受益、业绩呈现加速趋势。  海外CDMO业务呈现快速增长，显著受益于新冠业务的增厚：5家海外CDMO公司2021年上半年合计实现营业收入65.03亿美元，同比增长26.0%，其中生物药CDMO营业收入达到31.87亿美元，同比增长40.9%，核心受益于新冠相关产品的增厚。",
    "labels": [
      [
        "T0",
        "地点范围",
        2,
        4,
        "国内"
      ],
      [
        "T1",
        "行业公司",
        4,
        10,
        "CDMO公司"
      ],
      [
        "T2",
        "行业",
        33,
        37,
        "CDMO"
      ],
      [
        "T3",
        "时间范围",
        39,
        44,
        "2021年"
      ],
      [
        "T4",
        "营业收入",
        50,
        54,
        "营业收入"
      ],
      [
        "T5",
        "公司",
        85,
        89,
        "药明生物"
      ],
      [
        "T6",
        "时间范围",
        108,
        111,
        "上半年"
      ],
      [
        "T7",
        "营业收入",
        113,
        117,
        "营业收入"
      ],
      [
        "T8",
        "属性值",
        117,
        125,
        "44.13 亿元"
      ],
      [
        "T9",
        "地点范围",
        183,
        185,
        "国内"
      ],
      [
        "T10",
        "业绩",
        201,
        203,
        "业绩"
      ],
      [
        "T11",
        "地点范围",
        212,
        215,
        " 海外"
      ],
      [
        "T12",
        "行业",
        215,
        219,
        "CDMO"
      ],
      [
        "T13",
        "时间范围",
        251,
        259,
        "2021年上半年"
      ],
      [
        "T14",
        "营业收入",
        263,
        267,
        "营业收入"
      ],
      [
        "T15",
        "行业",
        288,
        295,
        "生物药CDMO"
      ],
      [
        "T16",
        "营业收入",
        295,
        299,
        "营业收入"
      ],
      [
        "T17",
        "属性值",
        14,
        26,
        "高速增长、且景气度有上行"
      ],
      [
        "T18",
        "属性值",
        130,
        137,
        "126.29%"
      ],
      [
        "T19",
        "行业公司",
        241,
        251,
        "5家海外CDMO公司"
      ],
      [
        "T20",
        "属性值",
        267,
        275,
        "65.03亿美元"
      ],
      [
        "T21",
        "属性值",
        280,
        285,
        "26.0%"
      ],
      [
        "T22",
        "属性值",
        301,
        309,
        "31.87亿美元"
      ],
      [
        "T23",
        "属性值",
        314,
        319,
        "40.9%"
      ],
      [
        "T24",
        "行业公司",
        29,
        33,
        "核心公司"
      ],
      [
        "T25",
        "属性值",
        54,
        62,
        "147.67亿元"
      ],
      [
        "T26",
        "属性值",
        68,
        74,
        "65.96%"
      ],
      [
        "T27",
        "属性值",
        77,
        82,
        "超高速增长"
      ],
      [
        "T28",
        "行业公司",
        185,
        194,
        "核心CDMO供应商"
      ],
      [
        "T29",
        "属性值",
        205,
        207,
        "加速"
      ],
      [
        "T30",
        "时间范围",
        140,
        148,
        "2021年下半年"
      ],
      [
        "T31",
        "时间范围",
        149,
        154,
        "2022年"
      ]
    ]
  },
  {
    "id": 1932,
    "text": "➢ 2022Q1全球和中国医疗健康产业融资总额出现回落。根据动脉网数据，2022Q1全球和中国医疗健康融资额均出现回落，分别为1553.62亿元和392.11亿元，同比下降分别为28.50%和33.73%；全球医疗健康产业融资事件数与去年同期基本持平，为856起。 ➢ 中国医疗健康领域投融资趋势与全球一致，保持高增长趋势。2022Q1，全球范围内共有43家医疗健康领域内企业完成IPO，总募集金额合计约348亿元，环比下降64%；完成IPO的企业中以生物医药领域企业为主，共有29家。",
    "labels": [
      [
        "T0",
        "时间范围",
        2,
        8,
        "2022Q1"
      ],
      [
        "T1",
        "地点范围",
        8,
        10,
        "全球"
      ],
      [
        "T2",
        "地点范围",
        11,
        13,
        "中国"
      ],
      [
        "T3",
        "行业",
        13,
        17,
        "医疗健康"
      ],
      [
        "T4",
        "投融资金额",
        19,
        23,
        "融资总额"
      ],
      [
        "T5",
        "属性值",
        25,
        27,
        "回落"
      ],
      [
        "T6",
        "时间范围",
        36,
        42,
        "2022Q1"
      ],
      [
        "T7",
        "地点范围",
        42,
        44,
        "全球"
      ],
      [
        "T8",
        "地点范围",
        45,
        47,
        "中国"
      ],
      [
        "T9",
        "行业",
        47,
        51,
        "医疗健康"
      ],
      [
        "T10",
        "投融资金额",
        51,
        54,
        "融资额"
      ],
      [
        "T11",
        "属性值",
        57,
        59,
        "回落"
      ],
      [
        "T12",
        "属性值",
        63,
        72,
        "1553.62亿元"
      ],
      [
        "T13",
        "属性值",
        73,
        81,
        "392.11亿元"
      ],
      [
        "T14",
        "地点范围",
        103,
        105,
        "全球"
      ],
      [
        "T15",
        "行业",
        105,
        109,
        "医疗健康"
      ],
      [
        "T16",
        "投融资事件数",
        111,
        116,
        "融资事件数"
      ],
      [
        "T17",
        "时间范围",
        117,
        119,
        "去年"
      ],
      [
        "T18",
        "属性值",
        127,
        131,
        "856起"
      ],
      [
        "T19",
        "地点范围",
        135,
        137,
        "中国"
      ],
      [
        "T20",
        "行业",
        137,
        141,
        "医疗健康"
      ],
      [
        "T21",
        "投融资情况",
        143,
        146,
        "投融资"
      ],
      [
        "T22",
        "地点范围",
        149,
        151,
        "全球"
      ],
      [
        "T23",
        "属性值",
        156,
        159,
        "高增长"
      ],
      [
        "T24",
        "时间范围",
        162,
        168,
        "2022Q1"
      ],
      [
        "T25",
        "地点范围",
        169,
        171,
        "全球"
      ],
      [
        "T26",
        "行业",
        179,
        183,
        "医疗健康"
      ],
      [
        "T27",
        "行业",
        226,
        230,
        "生物医药"
      ]
    ]
  },
  {
    "id": 1937,
    "text": "资本支出加速，以景气度最高的 CDMO代表性公司凯莱英为例： CDMO 行业高景气，凯莱英作为全球领先的一站式 CDMO企业，订单需求旺盛， 排产饱满。公司近年来加大了资本开支力度，我们预计凯莱英的固定资产复合增长从 2015-2018年的 24%提升至 2018-2021年的 35%左右，2021 年将是凯莱英固定资产投资的一个大年，预计 2021年底凯莱英的化学反应釜体积提升至 2019年的 1.8倍，研发、开发和生产产能快速扩充。",
    "labels": [
      [
        "T0",
        "行业",
        15,
        19,
        "CDMO"
      ],
      [
        "T1",
        "公司",
        24,
        27,
        "凯莱英"
      ],
      [
        "T2",
        "行业",
        31,
        35,
        "CDMO"
      ],
      [
        "T3",
        "公司",
        42,
        45,
        "凯莱英"
      ],
      [
        "T4",
        "行业公司",
        55,
        62,
        " CDMO企业"
      ],
      [
        "T5",
        "公司",
        95,
        98,
        "凯莱英"
      ],
      [
        "T6",
        "时间范围",
        109,
        119,
        "2015-2018年"
      ],
      [
        "T7",
        "属性值",
        121,
        124,
        "24%"
      ],
      [
        "T8",
        "时间范围",
        128,
        138,
        "2018-2021年"
      ],
      [
        "T9",
        "时间范围",
        146,
        152,
        "2021 年"
      ],
      [
        "T10",
        "公司",
        154,
        157,
        "凯莱英"
      ],
      [
        "T11",
        "固定资产",
        157,
        161,
        "固定资产"
      ],
      [
        "T12",
        "时间范围",
        172,
        177,
        "2021年"
      ],
      [
        "T13",
        "公司",
        178,
        181,
        "凯莱英"
      ],
      [
        "T14",
        "时间范围",
        193,
        198,
        "2019年"
      ],
      [
        "T15",
        "CAPEX资本开支",
        0,
        4,
        "资本支出"
      ],
      [
        "T16",
        "地点范围",
        47,
        49,
        "全球"
      ],
      [
        "T17",
        "时间范围",
        78,
        81,
        "近年来"
      ],
      [
        "T18",
        "CAPEX资本开支",
        84,
        88,
        "资本开支"
      ],
      [
        "T19",
        "属性值",
        81,
        83,
        "加大"
      ],
      [
        "T20",
        "固定资产",
        99,
        103,
        "固定资产"
      ],
      [
        "T21",
        "CAGR",
        103,
        107,
        "复合增长"
      ],
      [
        "T22",
        "产能",
        213,
        215,
        "产能"
      ],
      [
        "T23",
        "属性值",
        215,
        219,
        "快速扩充"
      ],
      [
        "T24",
        "属性值",
        140,
        145,
        "35%左右"
      ]
    ]
  },
  {
    "id": 1949,
    "text": "目前公司有宁波、天津和绍兴三个 C(D)MO产能基地在建，未来产能将逐步释放。 2015年公司计划在宁波投资 19.83亿元、建设期 5年，建成提供实验室服务与 CMC服务的杭州湾生命科技园区；2期工程预计在 2021年可交付使用，届时可增加科研技术人员 2500多名，实验室服务、 CMC产能可得到有效扩充。 2017年 9月，用于临床 C(D) MO业务的康龙天津 2期项目投产，C(D)MO产能由 66563L提升到 124263L；天津 3 期项目 2019年完成主体工程建设，预计 2020年底交付使用。绍兴上虞工厂于 2019年 3 破土动工，1期工程预计 2022年完成，可将公司原料药反应釜体积从约 200m 提升至 3 800m，预期年产 47吨医药中间体；2期工程完成后，绍兴工厂将年产出 200吨医药中间体及 API。预计随着天津 3期、杭州湾生命科技园以及绍兴上虞工厂的投入使用和来自 CRO业务的订单导流，公司 C(D)MO业务将会迎来高速发展期。",
    "labels": [
      [
        "T0",
        "行业",
        16,
        22,
        "C(D)MO"
      ],
      [
        "T1",
        "时间范围",
        40,
        45,
        "2015年"
      ],
      [
        "T2",
        "时间范围",
        105,
        110,
        "2021年"
      ],
      [
        "T3",
        "时间范围",
        156,
        164,
        "2017年 9月"
      ],
      [
        "T4",
        "行业",
        167,
        177,
        "临床 C(D) MO"
      ],
      [
        "T5",
        "行业",
        192,
        198,
        "C(D)MO"
      ],
      [
        "T6",
        "产能",
        198,
        200,
        "产能"
      ],
      [
        "T7",
        "时间范围",
        229,
        234,
        "2019年"
      ],
      [
        "T8",
        "时间范围",
        246,
        251,
        "2020年"
      ],
      [
        "T9",
        "时间范围",
        265,
        273,
        "2019年 3 "
      ],
      [
        "T10",
        "时间范围",
        285,
        290,
        "2022年"
      ],
      [
        "T11",
        "行业",
        405,
        408,
        "CRO"
      ],
      [
        "T12",
        "行业",
        418,
        425,
        " C(D)MO"
      ],
      [
        "T13",
        "时间范围",
        0,
        2,
        "目前"
      ],
      [
        "T14",
        "地点范围",
        5,
        7,
        "宁波"
      ],
      [
        "T15",
        "地点范围",
        8,
        10,
        "天津"
      ],
      [
        "T16",
        "地点范围",
        11,
        13,
        "绍兴"
      ],
      [
        "T17",
        "产能",
        31,
        33,
        "产能"
      ],
      [
        "T18",
        "产能",
        22,
        24,
        "产能"
      ],
      [
        "T19",
        "地点范围",
        50,
        52,
        "宁波"
      ],
      [
        "T20",
        "产能",
        145,
        147,
        "产能"
      ],
      [
        "T21",
        "行业",
        142,
        145,
        "CMC"
      ],
      [
        "T22",
        "行业",
        135,
        140,
        "实验室服务"
      ]
    ]
  },
  {
    "id": 1955,
    "text": "◼ Capacity：随长寿 109车间投产，301车间、江西东邦 II期、两江制剂 I期等建设和投入使用（预计 2022年后），公司产能进一步提升。",
    "labels": [
      [
        "T0",
        "时间范围",
        57,
        63,
        "2022年后"
      ],
      [
        "T1",
        "产能",
        2,
        10,
        "Capacity"
      ],
      [
        "T2",
        "产能",
        67,
        69,
        "产能"
      ]
    ]
  },
  {
    "id": 1956,
    "text": " 分版块 3，小分子 CMO/CDMO业务进入加速上升通道，收入增速持续显著提升：2015-2020年上述 29家公司中的小分子 CMO/CDMO相关业务整体收入规模分别为 54/66/79/103/136/189亿元，2016-2020年分别同比增长 22%/21%/30%/32%/39%， 2020年该板块收入增速继续如期大幅提升。近年来小分子 CMO/CDMO板块行业景气度持续提升，临床前 CMC 药学研究、临床阶段 CDMO订单及商业化阶段 CMO订单均实现快速增长， 研发、开发能力显著提升，尤其是临床前及临床阶段项目数量大大提升、 项目梯队日以合理，未来业绩的波动性降低、可持续性提升。随着产业持续升级（中间体→原料药→制剂）、全球产业转移，海外订单持续流入，全球市占率持续提升；中国医药创新经过过去 5-10年的发展，在未来 5年时间逐渐进入临床后期开发和落地兑现阶段，MAH制度下的 CDMO国内需求将显著增长（验证批次需求+新国产商业化 CMO订单）。",
    "labels": [
      [
        "T0",
        "行业",
        8,
        20,
        "小分子 CMO/CDMO"
      ],
      [
        "T1",
        "收入增速",
        31,
        35,
        "收入增速"
      ],
      [
        "T2",
        "属性值",
        35,
        41,
        "持续显著提升"
      ],
      [
        "T3",
        "时间范围",
        42,
        52,
        "2015-2020年"
      ],
      [
        "T4",
        "行业公司",
        55,
        60,
        "29家公司"
      ],
      [
        "T5",
        "行业",
        62,
        74,
        "小分子 CMO/CDMO"
      ],
      [
        "T6",
        "营业收入",
        80,
        82,
        "收入"
      ],
      [
        "T7",
        "属性值",
        88,
        110,
        "54/66/79/103/136/189亿元"
      ],
      [
        "T8",
        "时间范围",
        111,
        121,
        "2016-2020年"
      ],
      [
        "T9",
        "属性值",
        128,
        147,
        "22%/21%/30%/32%/39%"
      ],
      [
        "T10",
        "时间范围",
        149,
        154,
        "2020年"
      ],
      [
        "T11",
        "收入增速",
        157,
        161,
        "收入增速"
      ],
      [
        "T12",
        "属性值",
        165,
        169,
        "大幅提升"
      ],
      [
        "T13",
        "时间范围",
        170,
        173,
        "近年来"
      ],
      [
        "T14",
        "行业",
        173,
        185,
        "小分子 CMO/CDMO"
      ],
      [
        "T15",
        "行业",
        197,
        209,
        "临床前 CMC 药学研究"
      ],
      [
        "T16",
        "行业",
        210,
        219,
        "临床阶段 CDMO"
      ],
      [
        "T17",
        "行业",
        222,
        231,
        "商业化阶段 CMO"
      ],
      [
        "T18",
        "属性值",
        236,
        240,
        "快速增长"
      ],
      [
        "T19",
        "行业",
        403,
        407,
        "CDMO"
      ],
      [
        "T20",
        "地点范围",
        407,
        409,
        "国内"
      ],
      [
        "T21",
        "行业需求",
        409,
        411,
        "需求"
      ],
      [
        "T22",
        "属性值",
        412,
        416,
        "显著增长"
      ],
      [
        "T23",
        "时间范围",
        370,
        375,
        "未来 5年"
      ],
      [
        "T24",
        "时间范围",
        357,
        365,
        "过去 5-10年"
      ],
      [
        "T25",
        "地点范围",
        339,
        341,
        "全球"
      ],
      [
        "T26",
        "市场份额",
        341,
        344,
        "市占率"
      ],
      [
        "T27",
        "地点范围",
        330,
        332,
        "海外"
      ],
      [
        "T28",
        "地点范围",
        349,
        351,
        "中国"
      ],
      [
        "T29",
        "行业",
        351,
        355,
        "医药创新"
      ],
      [
        "T30",
        "业绩",
        286,
        288,
        "业绩"
      ]
    ]
  },
  {
    "id": 1961,
    "text": "▍CXO短期业绩确定性强，中长期天花板有望打开，从绝对收益/相对收益角度来看，均是值得重点配置的医药子板块。回顾 2020年各医药行业板块，医药外包服务板块是涨幅最多的子板块——2020年医药外包服务板块涨幅高达 95.67%， 大幅跑赢沪深 300指数 68.46pcts，跑赢医药指数 45.27pcts。虽然 2021年截至目前，前期涨幅较多的板块均有一些调整，但医药外包服务板块仍能取得一定的相对收益——2021年至今医药外包服务板块跑赢沪深 300指数 2.40pcts，跑赢医药指数 1.24pcts。我们认为，一方面 2020年海外疫情致全球订单向国内加速转移，推动国内 CXO企业产能利用和经营效率不断提升，业绩端呈现高速增长，海外疫情的逐渐恢复并不改变这一行业大趋势；另一方面，医疗健康领域投融额快速增长的资本热潮下，国内外新兴生物技术企业和中小型制药公司数量快速增长，研发投入加速，未来 2-3年 CXO行业的高景气度料仍将持续。因此， 我们认为，无论是从短期业绩（2021一季报到全年）高增长的确定性，或是中长期行业发展趋势来看，CXO是值得重点配置的医药子板块。",
    "labels": [
      [
        "T0",
        "行业",
        1,
        4,
        "CXO"
      ],
      [
        "T1",
        "业绩",
        6,
        8,
        "业绩"
      ],
      [
        "T2",
        "行业",
        48,
        50,
        "医药"
      ],
      [
        "T3",
        "时间范围",
        57,
        62,
        "2020年"
      ],
      [
        "T4",
        "行业",
        63,
        65,
        "医药"
      ],
      [
        "T5",
        "行业",
        70,
        76,
        "医药外包服务"
      ],
      [
        "T6",
        "时间范围",
        89,
        94,
        "2020年"
      ],
      [
        "T7",
        "行业",
        94,
        100,
        "医药外包服务"
      ],
      [
        "T8",
        "行业",
        140,
        142,
        "医药"
      ],
      [
        "T9",
        "时间范围",
        158,
        167,
        "2021年截至目前"
      ],
      [
        "T10",
        "行业",
        185,
        191,
        "医药外包服务"
      ],
      [
        "T11",
        "时间范围",
        206,
        213,
        "2021年至今"
      ],
      [
        "T12",
        "行业",
        213,
        219,
        "医药外包服务"
      ],
      [
        "T13",
        "行业",
        243,
        245,
        "医药"
      ],
      [
        "T14",
        "时间范围",
        266,
        271,
        "2020年"
      ],
      [
        "T15",
        "地点范围",
        271,
        273,
        "海外"
      ],
      [
        "T16",
        "地点范围",
        281,
        283,
        "国内"
      ],
      [
        "T17",
        "地点范围",
        290,
        292,
        "国内"
      ],
      [
        "T18",
        "行业公司",
        292,
        298,
        " CXO企业"
      ],
      [
        "T19",
        "业绩",
        312,
        314,
        "业绩"
      ],
      [
        "T20",
        "行业",
        348,
        352,
        "医疗健康"
      ],
      [
        "T21",
        "投融资金额",
        354,
        357,
        "投融额"
      ],
      [
        "T22",
        "属性值",
        357,
        361,
        "快速增长"
      ],
      [
        "T23",
        "研发费用",
        394,
        398,
        "研发投入"
      ],
      [
        "T24",
        "时间范围",
        401,
        409,
        "未来 2-3年 "
      ],
      [
        "T25",
        "行业",
        409,
        412,
        "CXO"
      ],
      [
        "T26",
        "业绩",
        440,
        442,
        "业绩"
      ],
      [
        "T27",
        "时间范围",
        443,
        453,
        "2021一季报到全年"
      ],
      [
        "T28",
        "行业",
        476,
        479,
        "CXO"
      ],
      [
        "T29",
        "行业",
        487,
        489,
        "医药"
      ],
      [
        "T30",
        "属性值",
        8,
        12,
        "确定性强"
      ],
      [
        "T31",
        "时间范围",
        4,
        6,
        "短期"
      ],
      [
        "T32",
        "时间范围",
        13,
        16,
        "中长期"
      ],
      [
        "T33",
        "属性值",
        16,
        23,
        "天花板有望打开"
      ],
      [
        "T34",
        "属性值",
        317,
        321,
        "高速增长"
      ],
      [
        "T35",
        "地点范围",
        368,
        371,
        "国内外"
      ],
      [
        "T36",
        "属性值",
        454,
        457,
        "高增长"
      ],
      [
        "T37",
        "时间范围",
        464,
        467,
        "中长期"
      ],
      [
        "T38",
        "时间范围",
        438,
        440,
        "短期"
      ],
      [
        "T39",
        "行业公司",
        373,
        379,
        "生物技术企业"
      ],
      [
        "T40",
        "属性值",
        398,
        400,
        "加速"
      ],
      [
        "T41",
        "行业公司",
        380,
        387,
        "中小型制药公司"
      ]
    ]
  },
  {
    "id": 1973,
    "text": "CXO板块将在 Q1季报窗口期表现靓丽，尤其在辉瑞口服新冠产业链受益更为明显的个股，建议重点关注凯莱英、药明康德等； CXO板块中 2023 年增长更为确定个股在下半年表现将更为明显，重点关注百诚医药、九洲药业等；如果看更长周期，药明康德、凯莱英等第一梯队个股将仍有全球较强竞争力。将是国内新冠疫苗续贯接种将是大概率、且可能持续多年，获批用于续冠智飞重复蛋白及康希诺腺病毒疫苗应该享受一定估值。",
    "labels": [
      [
        "T0",
        "行业",
        0,
        3,
        "CXO"
      ],
      [
        "T1",
        "公司",
        23,
        25,
        "辉瑞"
      ],
      [
        "T2",
        "公司",
        48,
        51,
        "凯莱英"
      ],
      [
        "T3",
        "公司",
        52,
        56,
        "药明康德"
      ],
      [
        "T4",
        "行业",
        58,
        62,
        " CXO"
      ],
      [
        "T5",
        "时间范围",
        7,
        10,
        " Q1"
      ],
      [
        "T6",
        "时间范围",
        66,
        72,
        "2023 年"
      ],
      [
        "T7",
        "时间范围",
        81,
        84,
        "下半年"
      ],
      [
        "T8",
        "公司",
        96,
        100,
        "百诚医药"
      ],
      [
        "T9",
        "公司",
        101,
        105,
        "九洲药业"
      ],
      [
        "T10",
        "公司",
        115,
        119,
        "药明康德"
      ],
      [
        "T11",
        "公司",
        120,
        123,
        "凯莱英"
      ],
      [
        "T12",
        "地点范围",
        133,
        135,
        "全球"
      ],
      [
        "T13",
        "地点范围",
        143,
        145,
        "国内"
      ],
      [
        "T14",
        "公司",
        180,
        183,
        "康希诺"
      ],
      [
        "T15",
        "公司",
        173,
        175,
        "智飞"
      ]
    ]
  },
  {
    "id": 1976,
    "text": "根据 QYResearch 分析，全球病毒载体以及质粒市场规模在 2025 年将达 13.5 亿美金，2021-2025 年 CAGR 为 18.5%。而中国地区病毒载体及质粒市场增速更快，2021-2025 年 CAGR 为 21.5%，到 25 年将达到 68.31 百万美元。",
    "labels": [
      [
        "T0",
        "行业",
        19,
        27,
        "病毒载体以及质粒"
      ],
      [
        "T1",
        "地点范围",
        17,
        19,
        "全球"
      ],
      [
        "T2",
        "市场规模",
        27,
        31,
        "市场规模"
      ],
      [
        "T3",
        "时间范围",
        33,
        39,
        "2025 年"
      ],
      [
        "T4",
        "属性值",
        42,
        50,
        "13.5 亿美金"
      ],
      [
        "T5",
        "属性值",
        70,
        75,
        "18.5%"
      ],
      [
        "T6",
        "属性值",
        114,
        119,
        "21.5%"
      ],
      [
        "T7",
        "属性值",
        129,
        140,
        " 68.31 百万美元"
      ],
      [
        "T8",
        "CAGR",
        63,
        68,
        "CAGR "
      ],
      [
        "T9",
        "CAGR",
        107,
        111,
        "CAGR"
      ],
      [
        "T10",
        "时间范围",
        51,
        62,
        "2021-2025 年"
      ],
      [
        "T11",
        "时间范围",
        95,
        106,
        "2021-2025 年"
      ],
      [
        "T12",
        "时间范围",
        122,
        126,
        "25 年"
      ],
      [
        "T13",
        "地点范围",
        77,
        81,
        "中国地区"
      ],
      [
        "T14",
        "行业",
        81,
        88,
        "病毒载体及质粒"
      ]
    ]
  },
  {
    "id": 1979,
    "text": "此外，由于多数 CDMO 企业出于保护客户 IP 的考虑不披露历年 CDMO 产品的销售量，同时鉴于主要 CDMO 企业的产能利用率处于历史高位，我们统计了这些企业 2021H1 的 CDMO 收入以及产能，来判断其单位产值。我们发现，药明康德小分子 CDMO 业务由于主要是供应 API 及制剂，且包含临床前药物发现及",
    "labels": [
      [
        "T0",
        "行业公司",
        8,
        15,
        "CDMO 企业"
      ],
      [
        "T1",
        "行业",
        33,
        39,
        " CDMO "
      ],
      [
        "T2",
        "时间范围",
        83,
        89,
        "2021H1"
      ],
      [
        "T3",
        "行业",
        92,
        97,
        "CDMO "
      ],
      [
        "T4",
        "营业收入",
        97,
        99,
        "收入"
      ],
      [
        "T5",
        "产能",
        101,
        103,
        "产能"
      ],
      [
        "T6",
        "公司",
        118,
        122,
        "药明康德"
      ],
      [
        "T7",
        "行业",
        122,
        131,
        "小分子 CDMO "
      ],
      [
        "T8",
        "行业公司",
        53,
        60,
        "CDMO 企业"
      ]
    ]
  },
  {
    "id": 1985,
    "text": "重点推荐：业绩有望进入新一轮加速期的CDMO：1）进入漏斗效应兑现期CDMO 龙头药明康德和凯莱英。2）能力持续搭建，盈利能力有望持续提升的CDMO：康龙化成 （CMC向CDMO拓展）、博腾股份（CRO向CMO延伸）、九洲药业（CDMO占比持续提升）、药石科技（由CRO向CDMO延伸）等。 临床CRO：处于国际化能力跃迁的临床CRO龙头泰格医药。 临床前CRO：受益中国市场红利以及更高盈利能力业务占比提升：药明康德（安评和生物分析业务）、康龙化成（生物科学业务）、昭衍新药（安评）、美迪西、方达控股等。 8.风险提示国内药审政策的波动性风险、一级市场投融资周期波动的风险、新业务拓展不及预期风险、汇兑风险、竞争风险。",
    "labels": [
      [
        "T0",
        "业绩",
        5,
        7,
        "业绩"
      ],
      [
        "T1",
        "行业",
        18,
        22,
        "CDMO"
      ],
      [
        "T2",
        "行业",
        34,
        38,
        "CDMO"
      ],
      [
        "T3",
        "龙头企业",
        39,
        41,
        "龙头"
      ],
      [
        "T4",
        "公司",
        41,
        45,
        "药明康德"
      ],
      [
        "T5",
        "公司",
        46,
        49,
        "凯莱英"
      ],
      [
        "T6",
        "行业",
        70,
        74,
        "CDMO"
      ],
      [
        "T7",
        "公司",
        75,
        79,
        "康龙化成"
      ],
      [
        "T8",
        "公司",
        93,
        97,
        "博腾股份"
      ],
      [
        "T9",
        "公司",
        109,
        113,
        "九洲药业"
      ],
      [
        "T10",
        "公司",
        126,
        130,
        "药石科技"
      ],
      [
        "T11",
        "行业",
        146,
        151,
        "临床CRO"
      ],
      [
        "T12",
        "行业",
        162,
        167,
        "临床CRO"
      ],
      [
        "T13",
        "龙头企业",
        167,
        169,
        "龙头"
      ],
      [
        "T14",
        "公司",
        169,
        173,
        "泰格医药"
      ],
      [
        "T15",
        "行业",
        174,
        181,
        " 临床前CRO"
      ],
      [
        "T16",
        "公司",
        205,
        209,
        "药明康德"
      ],
      [
        "T17",
        "公司",
        221,
        225,
        "康龙化成"
      ],
      [
        "T18",
        "公司",
        234,
        238,
        "昭衍新药"
      ],
      [
        "T19",
        "公司",
        243,
        246,
        "美迪西"
      ],
      [
        "T20",
        "公司",
        247,
        251,
        "方达控股"
      ],
      [
        "T21",
        "行业",
        81,
        84,
        "CMC"
      ],
      [
        "T22",
        "行业",
        85,
        89,
        "CDMO"
      ],
      [
        "T23",
        "行业",
        98,
        101,
        "CRO"
      ],
      [
        "T24",
        "行业",
        102,
        105,
        "CMO"
      ],
      [
        "T25",
        "行业",
        114,
        118,
        "CDMO"
      ],
      [
        "T26",
        "行业",
        132,
        135,
        "CRO"
      ],
      [
        "T27",
        "行业",
        136,
        140,
        "CDMO"
      ],
      [
        "T28",
        "地点范围",
        184,
        186,
        "中国"
      ],
      [
        "T29",
        "行业",
        210,
        212,
        "安评"
      ],
      [
        "T30",
        "行业",
        213,
        217,
        "生物分析"
      ],
      [
        "T31",
        "行业",
        226,
        230,
        "生物科学"
      ],
      [
        "T32",
        "行业",
        239,
        241,
        "安评"
      ]
    ]
  },
  {
    "id": 1988,
    "text": "国内CXO企业2021年Q3资本开支加速趋势明显，按增速来看，药石科技同比增长758%，位居首位；之后分别是：药明康德152%、美迪西130%和凯莱英93%。2021年Q3大部分国内CXO企业资本开支均呈现翻倍式增长，2020年同比增幅约40%，加速趋势明显。",
    "labels": [
      [
        "T0",
        "地点范围",
        0,
        2,
        "国内"
      ],
      [
        "T1",
        "行业公司",
        2,
        7,
        "CXO企业"
      ],
      [
        "T2",
        "时间范围",
        7,
        14,
        "2021年Q3"
      ],
      [
        "T3",
        "公司",
        31,
        35,
        "药石科技"
      ],
      [
        "T4",
        "公司",
        55,
        59,
        "药明康德"
      ],
      [
        "T5",
        "公司",
        64,
        67,
        "美迪西"
      ],
      [
        "T6",
        "公司",
        72,
        75,
        "凯莱英"
      ],
      [
        "T7",
        "时间范围",
        79,
        86,
        "2021年Q3"
      ],
      [
        "T8",
        "地点范围",
        89,
        91,
        "国内"
      ],
      [
        "T9",
        "行业公司",
        91,
        96,
        "CXO企业"
      ],
      [
        "T10",
        "时间范围",
        109,
        114,
        "2020年"
      ],
      [
        "T11",
        "CAPEX资本开支",
        14,
        18,
        "资本开支"
      ],
      [
        "T12",
        "属性值",
        18,
        20,
        "加速"
      ],
      [
        "T13",
        "属性值",
        35,
        43,
        "同比增长758%"
      ],
      [
        "T14",
        "CAPEX资本开支",
        96,
        100,
        "资本开支"
      ],
      [
        "T15",
        "属性值",
        103,
        108,
        "翻倍式增长"
      ],
      [
        "T16",
        "属性值",
        114,
        122,
        "同比增幅约40%"
      ]
    ]
  },
  {
    "id": 2003,
    "text": "百年一遇的新冠疫情影响深远，一方面 2020年海外疫情致全球订单向国内加速转移，另一方面疫情加速了新治疗技术的发展，医药外包行业远期外包率和龙头市占率天花板有望随之提升，国内 CXO企业短期业绩确定性强，中长期天花板有望打开；同时，后疫情时代下国内 CXO企业利用较高的估值差异（杠杆），加速全球产业化扩张和整合，一体化/全产业链平台布局得到加强，我们认为国内 CXO 企业的头部效应未来有望进一步显现。综上，我们继续强烈推荐 CXO赛道，建议积极关注药明康德、泰格医药、凯莱英、九洲药业、普洛药业、药石科技等。",
    "labels": [
      [
        "T0",
        "时间范围",
        18,
        23,
        "2020年"
      ],
      [
        "T1",
        "行业",
        58,
        62,
        "医药外包"
      ],
      [
        "T2",
        "外包率",
        66,
        69,
        "外包率"
      ],
      [
        "T3",
        "龙头企业",
        70,
        72,
        "龙头"
      ],
      [
        "T4",
        "市场份额",
        72,
        75,
        "市占率"
      ],
      [
        "T5",
        "地点范围",
        85,
        88,
        "国内 "
      ],
      [
        "T6",
        "行业公司",
        88,
        93,
        "CXO企业"
      ],
      [
        "T7",
        "业绩",
        95,
        97,
        "业绩"
      ],
      [
        "T8",
        "地点范围",
        122,
        124,
        "国内"
      ],
      [
        "T9",
        "行业公司",
        125,
        130,
        "CXO企业"
      ],
      [
        "T10",
        "地点范围",
        178,
        180,
        "国内"
      ],
      [
        "T11",
        "行业公司",
        181,
        187,
        "CXO 企业"
      ],
      [
        "T12",
        "行业",
        214,
        217,
        "CXO"
      ],
      [
        "T13",
        "公司",
        226,
        230,
        "药明康德"
      ],
      [
        "T14",
        "公司",
        231,
        235,
        "泰格医药"
      ],
      [
        "T15",
        "公司",
        236,
        239,
        "凯莱英"
      ],
      [
        "T16",
        "公司",
        240,
        244,
        "九洲药业"
      ],
      [
        "T17",
        "公司",
        245,
        249,
        "普洛药业"
      ],
      [
        "T18",
        "公司",
        250,
        254,
        "药石科技"
      ],
      [
        "T19",
        "属性值",
        82,
        84,
        "提升"
      ],
      [
        "T20",
        "时间范围",
        93,
        95,
        "短期"
      ],
      [
        "T21",
        "属性值",
        97,
        101,
        "确定性强"
      ],
      [
        "T22",
        "时间范围",
        102,
        105,
        "中长期"
      ],
      [
        "T23",
        "属性值",
        105,
        112,
        "天花板有望打开"
      ],
      [
        "T24",
        "地点范围",
        23,
        25,
        "海外"
      ],
      [
        "T25",
        "地点范围",
        28,
        30,
        "全球"
      ],
      [
        "T26",
        "地点范围",
        33,
        35,
        "国内"
      ]
    ]
  },
  {
    "id": 2009,
    "text": "根据CXO公司市值，将CXO公司分为三个梯队康龙化成处于CXO行业第二梯队，所以需要关注康龙化成业务、利润等方面在CXO行业第二梯队的位置",
    "labels": [
      [
        "T0",
        "行业公司",
        2,
        7,
        "CXO公司"
      ],
      [
        "T1",
        "行业",
        11,
        14,
        "CXO"
      ],
      [
        "T2",
        "公司",
        22,
        26,
        "康龙化成"
      ],
      [
        "T3",
        "行业",
        28,
        31,
        "CXO"
      ],
      [
        "T4",
        "公司",
        44,
        48,
        "康龙化成"
      ],
      [
        "T5",
        "利润",
        51,
        53,
        "利润"
      ],
      [
        "T6",
        "行业",
        57,
        60,
        "CXO"
      ],
      [
        "T7",
        "市值",
        7,
        9,
        "市值"
      ]
    ]
  },
  {
    "id": 2015,
    "text": "➢ 从融资规模看，全球医疗健康产业领域投资方兴未艾，2021年全球融资总额处于历史高位。根据动脉网数据，2021年全球医疗健康融资额同比增长约70%，达8194亿元；融资事件数为3591起，同比增长 64%。融资金额与融资事件数均创历史新高。 ➢ 中国医疗健康领域投融资趋势与全球一致，保持高增长趋势。2021年，中国医疗健康产业融资总额达 2192亿元人民币，共有1362起融资事件，相比2020年，中国医疗健康领域融资总额同比增长39%，融资事件数同比增长83%。中国医药健康融资保持高速增长，2018年后趋于严峻的融资环境有所缓解，新的医疗健康领域融资的持续增长趋势已然显现。",
    "labels": [
      [
        "T0",
        "地点范围",
        9,
        11,
        "全球"
      ],
      [
        "T1",
        "行业",
        11,
        15,
        "医疗健康"
      ],
      [
        "T2",
        "时间范围",
        26,
        31,
        "2021年"
      ],
      [
        "T3",
        "地点范围",
        31,
        33,
        "全球"
      ],
      [
        "T4",
        "投融资金额",
        33,
        37,
        "融资总额"
      ],
      [
        "T5",
        "时间范围",
        52,
        57,
        "2021年"
      ],
      [
        "T6",
        "地点范围",
        57,
        59,
        "全球"
      ],
      [
        "T7",
        "行业",
        59,
        63,
        "医疗健康"
      ],
      [
        "T8",
        "投融资金额",
        63,
        66,
        "融资额"
      ],
      [
        "T9",
        "属性值",
        66,
        82,
        "同比增长约70%，达8194亿元"
      ],
      [
        "T10",
        "属性值",
        89,
        94,
        "3591起"
      ],
      [
        "T11",
        "投融资事件数",
        83,
        88,
        "融资事件数"
      ],
      [
        "T12",
        "投融资金额",
        104,
        108,
        "融资金额"
      ],
      [
        "T13",
        "投融资事件数",
        109,
        114,
        "融资事件数"
      ],
      [
        "T14",
        "地点范围",
        124,
        126,
        "中国"
      ],
      [
        "T15",
        "行业",
        126,
        130,
        "医疗健康"
      ],
      [
        "T16",
        "时间范围",
        151,
        156,
        "2021年"
      ],
      [
        "T17",
        "地点范围",
        157,
        159,
        "中国"
      ],
      [
        "T18",
        "行业",
        159,
        163,
        "医疗健康"
      ],
      [
        "T19",
        "投融资金额",
        165,
        169,
        "融资总额"
      ],
      [
        "T20",
        "属性值",
        171,
        180,
        "2192亿元人民币"
      ],
      [
        "T21",
        "属性值",
        183,
        188,
        "1362起"
      ],
      [
        "T22",
        "投融资事件数",
        188,
        192,
        "融资事件"
      ],
      [
        "T23",
        "时间范围",
        195,
        200,
        "2020年"
      ],
      [
        "T24",
        "地点范围",
        201,
        203,
        "中国"
      ],
      [
        "T25",
        "行业",
        203,
        207,
        "医疗健康"
      ],
      [
        "T26",
        "投融资金额",
        209,
        213,
        "融资总额"
      ],
      [
        "T27",
        "投融资事件数",
        221,
        226,
        "融资事件数"
      ],
      [
        "T28",
        "地点范围",
        234,
        236,
        "中国"
      ],
      [
        "T29",
        "行业",
        236,
        240,
        "医药健康"
      ],
      [
        "T30",
        "时间范围",
        249,
        254,
        "2018年"
      ],
      [
        "T31",
        "行业",
        271,
        275,
        "医疗健康"
      ],
      [
        "T32",
        "属性值",
        242,
        248,
        "保持高速增长"
      ]
    ]
  },
  {
    "id": 2021,
    "text": "毛利率基本稳定，19 年略有下降主要由于新投产基地产能利用率尚低。公司 2016年以来 CDMO业务毛利率保持在 40%以上，近年来略有下降主要由于无锡新吴区的制剂商业化生产基地 2018年建成，19年承接了数个项目的注册或验证批次生产。由于制剂的商业化生产需等待监管部门批准，该基地的利用率仍处于较低水平。预计随着越来越多的制剂项目进入临床后期和商业化阶段， 无锡商业化生产基地的产能利用率将快速提升。",
    "labels": [
      [
        "T0",
        "毛利",
        0,
        3,
        "毛利率"
      ],
      [
        "T1",
        "时间范围",
        8,
        12,
        "19 年"
      ],
      [
        "T2",
        "时间范围",
        35,
        41,
        " 2016年"
      ],
      [
        "T3",
        "行业",
        44,
        48,
        "CDMO"
      ],
      [
        "T4",
        "毛利",
        50,
        53,
        "毛利率"
      ],
      [
        "T5",
        "时间范围",
        63,
        66,
        "近年来"
      ],
      [
        "T6",
        "时间范围",
        90,
        95,
        "2018年"
      ],
      [
        "T7",
        "时间范围",
        98,
        101,
        "19年"
      ]
    ]
  },
  {
    "id": 2027,
    "text": "医用耗材集采持续推进，以骨科耗材为代表的企业短期业绩具有一定不确定性，长期发展空间受到压制，但我们认为，医疗器械行业百花齐放、黄金投资时代的大趋势不变，核心原因：1）国内医疗器械消费水平远低于欧美，此次新冠疫情有望加速国内医疗建设，医疗设备显著受益；2）国内厂家技术持续向中高端突破，进口替代加速；3）术式创新带来国内创新器械公司蓬勃发展；4）科创板将加快更多优质器械公司上市。我们建议关注以下几类，1）医疗设备类企业，不受集采影响，国产替代+海外出口推动长期稳定发展，如迈瑞医疗、理邦仪器等；2）国产化低的医用耗材，如化学发光、电生理、 PCI介入耗材等领域； 3）新技术、新术式带来的新的诊疗方向，如介入瓣膜、神经介入、 癌症早筛等；4）自费产品，受益于消费升级，重点推荐眼科如角膜塑形镜领域。",
    "labels": [
      [
        "T0",
        "业绩",
        24,
        26,
        "业绩"
      ],
      [
        "T1",
        "行业",
        52,
        56,
        "医疗器械"
      ],
      [
        "T2",
        "地点范围",
        83,
        85,
        "国内"
      ],
      [
        "T3",
        "行业",
        85,
        89,
        "医疗器械"
      ],
      [
        "T4",
        "地点范围",
        109,
        111,
        "国内"
      ],
      [
        "T5",
        "行业",
        116,
        120,
        "医疗设备"
      ],
      [
        "T6",
        "地点范围",
        127,
        129,
        "国内"
      ],
      [
        "T7",
        "行业公司",
        159,
        165,
        "创新器械公司"
      ],
      [
        "T8",
        "地点范围",
        157,
        159,
        "国内"
      ],
      [
        "T9",
        "行业",
        202,
        206,
        "医疗设备"
      ],
      [
        "T10",
        "公司",
        236,
        240,
        "迈瑞医疗"
      ],
      [
        "T11",
        "公司",
        241,
        245,
        "理邦仪器"
      ],
      [
        "T12",
        "行业",
        254,
        258,
        "医用耗材"
      ],
      [
        "T13",
        "行业",
        260,
        264,
        "化学发光"
      ],
      [
        "T14",
        "行业",
        265,
        268,
        "电生理"
      ],
      [
        "T15",
        "行业",
        270,
        277,
        "PCI介入耗材"
      ],
      [
        "T16",
        "行业",
        338,
        340,
        "眼科"
      ],
      [
        "T17",
        "行业",
        341,
        346,
        "角膜塑形镜"
      ],
      [
        "T18",
        "地点范围",
        96,
        98,
        "欧美"
      ],
      [
        "T19",
        "属性值",
        63,
        69,
        "黄金投资时代"
      ],
      [
        "T20",
        "行业",
        111,
        113,
        "医疗"
      ],
      [
        "T21",
        "行业公司",
        182,
        186,
        "器械公司"
      ],
      [
        "T22",
        "行业公司",
        11,
        22,
        "以骨科耗材为代表的企业"
      ],
      [
        "T23",
        "时间范围",
        22,
        24,
        "短期"
      ],
      [
        "T24",
        "属性值",
        26,
        34,
        "具有一定不确定性"
      ]
    ]
  },
  {
    "id": 2028,
    "text": "全球产能加速转移，创新药研发火热，政策、人才推动下，近年来我国 CXO市场快速发展。依据弗若斯特沙利文数据，中国 CDMO市场快速增长，小分子药物 CDMO规模从 2016年的 80亿元快速增长至 2020 年的 226亿元，复合增长率高达 29.8%，增速是全球小分子药物 CDMO的三倍，全球占比也从约 4.85%提升至 9.46%。预计 2025年中国小分子药物 CDMO市场规模将达到 777亿元，2020-2025年复合增长率高达 28%，全球占比升至 20.13%。",
    "labels": [
      [
        "T0",
        "产能",
        2,
        4,
        "产能"
      ],
      [
        "T1",
        "地点范围",
        0,
        2,
        "全球"
      ],
      [
        "T2",
        "行业",
        9,
        12,
        "创新药"
      ],
      [
        "T3",
        "时间范围",
        26,
        29,
        "近年来"
      ],
      [
        "T4",
        "地点范围",
        29,
        31,
        "我国"
      ],
      [
        "T5",
        "行业",
        32,
        35,
        "CXO"
      ],
      [
        "T6",
        "地点范围",
        54,
        56,
        "中国"
      ],
      [
        "T7",
        "行业",
        57,
        61,
        "CDMO"
      ],
      [
        "T8",
        "行业",
        68,
        78,
        "小分子药物 CDMO"
      ],
      [
        "T9",
        "市场规模",
        78,
        80,
        "规模"
      ],
      [
        "T10",
        "时间范围",
        82,
        87,
        "2016年"
      ],
      [
        "T11",
        "属性值",
        89,
        93,
        "80亿元"
      ],
      [
        "T12",
        "时间范围",
        99,
        105,
        "2020 年"
      ],
      [
        "T13",
        "属性值",
        107,
        112,
        "226亿元"
      ],
      [
        "T14",
        "CAGR",
        113,
        118,
        "复合增长率"
      ],
      [
        "T15",
        "属性值",
        121,
        126,
        "29.8%"
      ],
      [
        "T16",
        "地点范围",
        130,
        132,
        "全球"
      ],
      [
        "T17",
        "行业",
        132,
        142,
        "小分子药物 CDMO"
      ],
      [
        "T18",
        "地点范围",
        146,
        148,
        "全球"
      ],
      [
        "T19",
        "时间范围",
        172,
        177,
        "2025年"
      ],
      [
        "T20",
        "地点范围",
        177,
        179,
        "中国"
      ],
      [
        "T21",
        "行业",
        179,
        189,
        "小分子药物 CDMO"
      ],
      [
        "T22",
        "市场规模",
        189,
        193,
        "市场规模"
      ],
      [
        "T23",
        "属性值",
        197,
        202,
        "777亿元"
      ],
      [
        "T24",
        "时间范围",
        203,
        213,
        "2020-2025年"
      ],
      [
        "T25",
        "CAGR",
        213,
        218,
        "复合增长率"
      ],
      [
        "T26",
        "属性值",
        221,
        224,
        "28%"
      ],
      [
        "T27",
        "地点范围",
        225,
        227,
        "全球"
      ],
      [
        "T28",
        "属性值",
        232,
        238,
        "20.13%"
      ],
      [
        "T29",
        "属性值",
        152,
        159,
        "约 4.85%"
      ],
      [
        "T30",
        "属性值",
        163,
        168,
        "9.46%"
      ]
    ]
  },
  {
    "id": 2033,
    "text": "根据医药魔方数据。2022年2月，海外医药融资总额约20.4亿美金，同比下滑22%，融资事件数达到46起，同比下滑12%； 国内融资总额约同比下滑65%，融资事件数达到23起，同比下滑60%。",
    "labels": [
      [
        "T0",
        "时间范围",
        9,
        16,
        "2022年2月"
      ],
      [
        "T1",
        "地点范围",
        17,
        19,
        "海外"
      ],
      [
        "T2",
        "行业",
        19,
        21,
        "医药"
      ],
      [
        "T3",
        "投融资金额",
        21,
        25,
        "融资总额"
      ],
      [
        "T4",
        "属性值",
        25,
        41,
        "约20.4亿美金，同比下滑22%"
      ],
      [
        "T5",
        "投融资事件数",
        42,
        47,
        "融资事件数"
      ],
      [
        "T6",
        "属性值",
        49,
        60,
        "46起，同比下滑12%"
      ],
      [
        "T7",
        "投融资金额",
        64,
        68,
        "融资总额"
      ],
      [
        "T8",
        "投融资事件数",
        77,
        82,
        "融资事件数"
      ],
      [
        "T9",
        "属性值",
        68,
        76,
        "约同比下滑65%"
      ],
      [
        "T10",
        "属性值",
        84,
        95,
        "23起，同比下滑60%"
      ],
      [
        "T11",
        "地点范围",
        61,
        64,
        " 国内"
      ]
    ]
  },
  {
    "id": 2037,
    "text": "潜力业务一：临床 CRO业务。Frost & Sullivan数据显示，临床 CRO为 CRO市场规模最大的子领域（2018：占比全球 CRO市场 65.6%&占比中国 CRO市场 55.4%），但在公司业务中贡献尚小（1H19收入占比 8.0%），未来潜力巨大。公司通过自建与并购的方式 （例如 2018完成收购美国临床 CRO 公司 ResearchPoint Global，2019年收购美国数统公司 pharmapace）逐步构建建国际多中心临床试验服务能力，赋能国内新药“走出去” 与海外新药“引进来”。公司计划在国内重点扩张数统团队，境内外联动打造“前店后厂” 模式，提高临床业务的净利润率。",
    "labels": [
      [
        "T0",
        "行业",
        6,
        12,
        "临床 CRO"
      ],
      [
        "T1",
        "行业",
        36,
        42,
        "临床 CRO"
      ],
      [
        "T2",
        "行业",
        44,
        47,
        "CRO"
      ],
      [
        "T3",
        "市场规模",
        47,
        51,
        "市场规模"
      ],
      [
        "T4",
        "时间范围",
        58,
        62,
        "2018"
      ],
      [
        "T5",
        "行业",
        67,
        71,
        " CRO"
      ],
      [
        "T6",
        "地点范围",
        65,
        67,
        "全球"
      ],
      [
        "T7",
        "地点范围",
        82,
        84,
        "中国"
      ],
      [
        "T8",
        "行业",
        85,
        88,
        "CRO"
      ],
      [
        "T9",
        "时间范围",
        110,
        114,
        "1H19"
      ],
      [
        "T10",
        "营收占比",
        114,
        119,
        "收入占比 "
      ],
      [
        "T11",
        "时间范围",
        149,
        153,
        "2018"
      ],
      [
        "T12",
        "行业",
        159,
        165,
        "临床 CRO"
      ],
      [
        "T13",
        "公司",
        169,
        189,
        "ResearchPoint Global"
      ],
      [
        "T14",
        "时间范围",
        190,
        195,
        "2019年"
      ],
      [
        "T15",
        "公司",
        204,
        214,
        "pharmapace"
      ],
      [
        "T16",
        "属性值",
        51,
        53,
        "最大"
      ],
      [
        "T17",
        "属性值",
        74,
        79,
        "65.6%"
      ],
      [
        "T18",
        "属性值",
        91,
        96,
        "55.4%"
      ],
      [
        "T19",
        "地点范围",
        157,
        159,
        "美国"
      ],
      [
        "T20",
        "地点范围",
        197,
        199,
        "美国"
      ],
      [
        "T21",
        "地点范围",
        262,
        264,
        "国内"
      ],
      [
        "T22",
        "行业",
        268,
        270,
        "数统"
      ],
      [
        "T23",
        "行业",
        199,
        201,
        "数统"
      ],
      [
        "T24",
        "地点范围",
        236,
        238,
        "国内"
      ],
      [
        "T25",
        "地点范围",
        247,
        249,
        "海外"
      ]
    ]
  },
  {
    "id": 2045,
    "text": " 国内CXO公司临床CRO业务继续呈现高速增长、疫情下恢复趋势明显：核心公司临床CRO业务2021年中报合计实现营业收入27.87亿元，同比增长50.46%，呈现超高速增长，其泰格医药临床CRO业务（不包括方达的实验室业务）实现营业收入 15.82亿元，同比增长42.53%。展望2021年下半年和2022年，疫情下临床CRO业务持续恢复、且伴随国内创新逐渐传导到临床CRO业务，我们判断未来3年临床CRO业务将持续呈现快速增长、且景气度有向上的趋势。  海外临床CRO业务疫情下恢复明显、呈现高速增长：7家主流临床CRO公司合计实现营业收入136.57亿美元，同比增长 32.6%，其中昆泰、科文斯、Syneos、PPD、ICON Q2单季度营业收入同比增长为53.1%/36.7%/32.6%/59.5%/37.5%，疫情下呈现显著恢复。",
    "labels": [
      [
        "T0",
        "地点范围",
        2,
        4,
        "国内"
      ],
      [
        "T1",
        "行业公司",
        4,
        9,
        "CXO公司"
      ],
      [
        "T2",
        "行业",
        9,
        14,
        "临床CRO"
      ],
      [
        "T3",
        "属性值",
        20,
        24,
        "高速增长"
      ],
      [
        "T4",
        "行业",
        39,
        44,
        "临床CRO"
      ],
      [
        "T5",
        "时间范围",
        46,
        51,
        "2021年"
      ],
      [
        "T6",
        "公司",
        89,
        93,
        "泰格医药"
      ],
      [
        "T7",
        "行业",
        93,
        98,
        "临床CRO"
      ],
      [
        "T8",
        "公司",
        104,
        106,
        "方达"
      ],
      [
        "T9",
        "属性值",
        120,
        127,
        "15.82亿元"
      ],
      [
        "T10",
        "属性值",
        132,
        138,
        "42.53%"
      ],
      [
        "T11",
        "时间范围",
        141,
        155,
        "2021年下半年和2022年"
      ],
      [
        "T12",
        "行业",
        159,
        164,
        "临床CRO"
      ],
      [
        "T13",
        "地点范围",
        174,
        176,
        "国内"
      ],
      [
        "T14",
        "行业",
        183,
        188,
        "临床CRO"
      ],
      [
        "T15",
        "时间范围",
        195,
        199,
        "未来3年"
      ],
      [
        "T16",
        "行业",
        199,
        204,
        "临床CRO"
      ],
      [
        "T17",
        "地点范围",
        230,
        232,
        "海外"
      ],
      [
        "T18",
        "行业",
        232,
        237,
        "临床CRO"
      ],
      [
        "T19",
        "行业公司",
        254,
        265,
        "7家主流临床CRO公司"
      ],
      [
        "T20",
        "属性值",
        273,
        282,
        "136.57亿美元"
      ],
      [
        "T21",
        "营收增长",
        288,
        293,
        "32.6%"
      ],
      [
        "T22",
        "公司",
        296,
        298,
        "昆泰"
      ],
      [
        "T23",
        "公司",
        299,
        302,
        "科文斯"
      ],
      [
        "T24",
        "公司",
        303,
        309,
        "Syneos"
      ],
      [
        "T25",
        "公司",
        310,
        313,
        "PPD"
      ],
      [
        "T26",
        "公司",
        314,
        318,
        "ICON"
      ],
      [
        "T27",
        "时间范围",
        319,
        321,
        "Q2"
      ],
      [
        "T28",
        "属性值",
        333,
        338,
        "53.1%"
      ],
      [
        "T29",
        "属性值",
        339,
        344,
        "36.7%"
      ],
      [
        "T30",
        "属性值",
        345,
        350,
        "32.6%"
      ],
      [
        "T31",
        "属性值",
        351,
        356,
        "59.5%"
      ],
      [
        "T32",
        "属性值",
        357,
        362,
        "37.5%"
      ],
      [
        "T33",
        "营业收入",
        324,
        328,
        "营业收入"
      ],
      [
        "T34",
        "营业收入",
        269,
        273,
        "营业收入"
      ],
      [
        "T35",
        "营业收入",
        115,
        119,
        "营业收入"
      ],
      [
        "T36",
        "营业收入",
        57,
        61,
        "营业收入"
      ],
      [
        "T37",
        "行业公司",
        35,
        39,
        "核心公司"
      ],
      [
        "T38",
        "属性值",
        61,
        68,
        "27.87亿元"
      ],
      [
        "T39",
        "属性值",
        73,
        79,
        "50.46%"
      ],
      [
        "T40",
        "属性值",
        82,
        87,
        "超高速增长"
      ]
    ]
  },
  {
    "id": 2047,
    "text": "国内 CAR-T市场迎来机遇。以 CAR-T疗法为代表的免疫疗法取得突破性进展，为癌症患者带来新的希望，特别是集采及医保目录谈判等新机制的出台，显著提升患者的支付意愿及能力，细胞免疫将逐步解决目前临床上未满足的重大需求，与此同时国内细胞免疫行业也迎来重大的市场机遇。根据弗若斯特沙利文报告推测，2025年中国 CAR-T疗法市场规模将快速达到 11.5亿美元，全球占比高达 12.71%。",
    "labels": [
      [
        "T0",
        "地点范围",
        0,
        2,
        "国内"
      ],
      [
        "T1",
        "行业",
        3,
        8,
        "CAR-T"
      ],
      [
        "T2",
        "地点范围",
        114,
        116,
        "国内"
      ],
      [
        "T3",
        "行业",
        116,
        120,
        "细胞免疫"
      ],
      [
        "T4",
        "时间范围",
        147,
        152,
        "2025年"
      ],
      [
        "T5",
        "地点范围",
        152,
        154,
        "中国"
      ],
      [
        "T6",
        "行业",
        155,
        162,
        "CAR-T疗法"
      ],
      [
        "T7",
        "市场规模",
        162,
        166,
        "市场规模"
      ],
      [
        "T8",
        "属性值",
        172,
        179,
        "11.5亿美元"
      ],
      [
        "T9",
        "地点范围",
        180,
        182,
        "全球"
      ],
      [
        "T10",
        "属性值",
        187,
        193,
        "12.71%"
      ],
      [
        "T11",
        "行业",
        17,
        24,
        "CAR-T疗法"
      ],
      [
        "T12",
        "行业",
        28,
        32,
        "免疫疗法"
      ],
      [
        "T13",
        "行业",
        87,
        91,
        "细胞免疫"
      ],
      [
        "T14",
        "时间范围",
        96,
        98,
        "目前"
      ]
    ]
  },
  {
    "id": 2053,
    "text": "全球研发投入逐年攀升，中国增速远超全球平均水平。虽然新药创新存在诸多困难，但人口老龄化、新兴技术的发现和应用、政策不断加码创新等因素持续推动新药创新发展。据 Frost & Sullivan 统计，全球制药行业的研发投入预计将由 2019 年的 1824 亿美元增长至请阅读最后一页免责声明及信息披露 http://www.cindasc.com 10",
    "labels": [
      [
        "T0",
        "地点范围",
        99,
        101,
        "全球"
      ],
      [
        "T1",
        "行业",
        101,
        103,
        "制药"
      ],
      [
        "T2",
        "研发费用",
        106,
        110,
        "研发投入"
      ],
      [
        "T3",
        "时间范围",
        115,
        121,
        "2019 年"
      ],
      [
        "T4",
        "属性值",
        123,
        131,
        "1824 亿美元"
      ],
      [
        "T5",
        "地点范围",
        11,
        13,
        "中国"
      ],
      [
        "T6",
        "地点范围",
        0,
        2,
        "全球"
      ],
      [
        "T7",
        "研发费用",
        2,
        6,
        "研发投入"
      ],
      [
        "T8",
        "地点范围",
        17,
        19,
        "全球"
      ],
      [
        "T9",
        "行业",
        26,
        30,
        "新药创新"
      ],
      [
        "T10",
        "行业",
        70,
        74,
        "新药创新"
      ]
    ]
  },
  {
    "id": 2063,
    "text": "细胞基因治疗CDMO第一股上市，新赛道带来新机会。中国细胞基因治疗第一股和元生物预计在3月下旬登陆资本市场， 历经小分子化药和大分子生物药之后，细胞基因治疗有望掀起第三次的革命浪潮，将会带来相关领域外包服务的高需求。 细胞基因治疗无论从一级市场的投融资景气度还是在研管线的顺利推进，都可以清晰认知到其爆发期将至，FDA预测 2025年将会迎来细胞基因治疗的商业化爆发期，每年预计10-20个产品获批上市。",
    "labels": [
      [
        "T0",
        "行业",
        1,
        11,
        "细胞基因治疗CDMO"
      ],
      [
        "T1",
        "地点范围",
        26,
        28,
        "中国"
      ],
      [
        "T2",
        "行业",
        28,
        34,
        "细胞基因治疗"
      ],
      [
        "T3",
        "公司",
        37,
        41,
        "和元生物"
      ],
      [
        "T4",
        "时间范围",
        44,
        48,
        "3月下旬"
      ],
      [
        "T5",
        "行业",
        73,
        79,
        "细胞基因治疗"
      ],
      [
        "T6",
        "行业",
        110,
        116,
        "细胞基因治疗"
      ],
      [
        "T7",
        "时间范围",
        163,
        168,
        "2025年"
      ],
      [
        "T8",
        "行业",
        172,
        178,
        "细胞基因治疗"
      ],
      [
        "T9",
        "行业",
        58,
        63,
        "小分子化药"
      ],
      [
        "T10",
        "行业",
        64,
        70,
        "大分子生物药"
      ],
      [
        "T11",
        "行业",
        100,
        104,
        "外包服务"
      ],
      [
        "T12",
        "属性值",
        105,
        106,
        "高"
      ],
      [
        "T13",
        "行业需求",
        106,
        108,
        "需求"
      ]
    ]
  },
  {
    "id": 2087,
    "text": "美迪西近几年营业收入和净利润持续稳定增长，2021 年上半年实现营业收入 4.85 亿元， 同比增长 86.26%，归母净利润 1.13亿元，同比增长 142.29%，扣非归母净利润 1.10亿元， 请阅读最后一页免责声明及信息披露 http://www.cindasc.com 29",
    "labels": [
      [
        "T0",
        "公司",
        0,
        3,
        "美迪西"
      ],
      [
        "T1",
        "时间范围",
        3,
        6,
        "近几年"
      ],
      [
        "T2",
        "营业收入",
        6,
        10,
        "营业收入"
      ],
      [
        "T3",
        "归母净利润",
        11,
        14,
        "净利润"
      ],
      [
        "T4",
        "时间范围",
        21,
        30,
        "2021 年上半年"
      ],
      [
        "T5",
        "营业收入",
        32,
        36,
        "营业收入"
      ],
      [
        "T6",
        "属性值",
        37,
        44,
        "4.85 亿元"
      ],
      [
        "T7",
        "属性值",
        51,
        57,
        "86.26%"
      ],
      [
        "T8",
        "归母净利润",
        58,
        63,
        "归母净利润"
      ],
      [
        "T9",
        "属性值",
        64,
        83,
        "1.13亿元，同比增长 142.29%"
      ],
      [
        "T10",
        "扣非净利润",
        84,
        91,
        "扣非归母净利润"
      ],
      [
        "T11",
        "属性值",
        92,
        98,
        "1.10亿元"
      ],
      [
        "T12",
        "属性值",
        14,
        20,
        "持续稳定增长"
      ]
    ]
  },
  {
    "id": 2093,
    "text": "数据来源：Wind，安信证券研究中心注：数据截止2021年11月16日；注：统计的CRO/CDMO公司包括药明康德、药明生物、康龙化成、昭衍新药、泰格医药、凯莱英、九洲药业、博腾股份、美迪西、药石科技、皓元医药、诺泰生物等",
    "labels": [
      [
        "T0",
        "时间范围",
        22,
        35,
        "截止2021年11月16日"
      ],
      [
        "T1",
        "行业公司",
        41,
        51,
        "CRO/CDMO公司"
      ],
      [
        "T2",
        "公司",
        53,
        57,
        "药明康德"
      ],
      [
        "T3",
        "公司",
        58,
        62,
        "药明生物"
      ],
      [
        "T4",
        "公司",
        63,
        67,
        "康龙化成"
      ],
      [
        "T5",
        "公司",
        68,
        72,
        "昭衍新药"
      ],
      [
        "T6",
        "公司",
        73,
        77,
        "泰格医药"
      ],
      [
        "T7",
        "公司",
        78,
        81,
        "凯莱英"
      ],
      [
        "T8",
        "公司",
        82,
        86,
        "九洲药业"
      ],
      [
        "T9",
        "公司",
        87,
        91,
        "博腾股份"
      ],
      [
        "T10",
        "公司",
        92,
        95,
        "美迪西"
      ],
      [
        "T11",
        "公司",
        96,
        100,
        "药石科技"
      ],
      [
        "T12",
        "公司",
        101,
        105,
        "皓元医药"
      ],
      [
        "T13",
        "公司",
        106,
        110,
        "诺泰生物"
      ]
    ]
  },
  {
    "id": 2095,
    "text": "进口产品占据主要市场，国产品牌有望凭借优势快速放量。从 2018年角膜塑形镜验配量看，欧普康视、露晰得、欧几里得、亨泰、阿尔法的市占率分别为 24%、22%、 18%、15%、14%，CR5市占率合计为 93%，行业集中度较高。未来产品推广将继续围绕医院渠道和医生教育展开，国产品牌在供货周期、售后服务、渠道铺设等方面优势明显，在整个行业保持高速增长下，未来国产品牌市场空间广阔。",
    "labels": [
      [
        "T0",
        "时间范围",
        28,
        33,
        "2018年"
      ],
      [
        "T1",
        "行业",
        33,
        38,
        "角膜塑形镜"
      ],
      [
        "T2",
        "公司",
        43,
        47,
        "欧普康视"
      ],
      [
        "T3",
        "公司",
        48,
        51,
        "露晰得"
      ],
      [
        "T4",
        "公司",
        52,
        56,
        "欧几里得"
      ],
      [
        "T5",
        "公司",
        57,
        59,
        "亨泰"
      ],
      [
        "T6",
        "公司",
        60,
        63,
        "阿尔法"
      ],
      [
        "T7",
        "市场份额",
        64,
        67,
        "市占率"
      ],
      [
        "T8",
        "属性值",
        71,
        74,
        "24%"
      ],
      [
        "T9",
        "属性值",
        75,
        78,
        "22%"
      ],
      [
        "T10",
        "属性值",
        80,
        83,
        "18%"
      ],
      [
        "T11",
        "属性值",
        84,
        87,
        "15%"
      ],
      [
        "T12",
        "属性值",
        88,
        91,
        "14%"
      ],
      [
        "T13",
        "市场份额",
        95,
        98,
        "市占率"
      ],
      [
        "T14",
        "CR5",
        92,
        95,
        "CR5"
      ],
      [
        "T15",
        "市场集中度",
        106,
        111,
        "行业集中度"
      ],
      [
        "T16",
        "属性值",
        111,
        113,
        "较高"
      ],
      [
        "T17",
        "属性值",
        102,
        105,
        "93%"
      ]
    ]
  },
  {
    "id": 2098,
    "text": "百普赛斯：（1）专注于服务生物医药客户，下游景气度驱动业绩高增长。公司是国内领先的重组蛋白试剂品牌，根据公司公告，业务范围覆盖全球60多个国家和地区，服务于4,000多家客户，全球前50大医药企业的覆盖度超过80%。 2020年常规业务收入同比增长65.41%，2021H1常规业务收入同比增长75.82%。（2）技术独具特色，全市场领先的质控体系。公司同时掌握四种表达系统，95%以上的产品都是通过HEK193系统表达，人源化优势明显，成功开发出 CD20、CD133、CCR5 GPCR等市场稀缺的高难度跨膜蛋白产品，构建了严格的质量控制体系，产品质量稳定性全市场领先。",
    "labels": [
      [
        "T0",
        "公司",
        1,
        5,
        "百普赛斯"
      ],
      [
        "T1",
        "行业",
        14,
        18,
        "生物医药"
      ],
      [
        "T2",
        "行业",
        42,
        48,
        "重组蛋白试剂"
      ],
      [
        "T3",
        "属性值",
        79,
        86,
        "4,000多家"
      ],
      [
        "T4",
        "时间范围",
        110,
        115,
        "2020年"
      ],
      [
        "T5",
        "营业收入",
        119,
        121,
        "收入"
      ],
      [
        "T6",
        "属性值",
        125,
        131,
        "65.41%"
      ],
      [
        "T7",
        "属性值",
        148,
        154,
        "75.82%"
      ],
      [
        "T8",
        "营业收入",
        142,
        144,
        "收入"
      ],
      [
        "T9",
        "时间范围",
        132,
        138,
        "2021H1"
      ],
      [
        "T10",
        "地点范围",
        37,
        39,
        "国内"
      ],
      [
        "T11",
        "业绩",
        28,
        30,
        "业绩"
      ],
      [
        "T12",
        "属性值",
        30,
        33,
        "高增长"
      ],
      [
        "T13",
        "地点范围",
        64,
        66,
        "全球"
      ],
      [
        "T14",
        "地点范围",
        89,
        91,
        "全球"
      ],
      [
        "T15",
        "行业公司",
        91,
        99,
        "前50大医药企业"
      ]
    ]
  },
  {
    "id": 2101,
    "text": " 21Q1/Q2/Q3原料药板块分别实现收入242亿元/260/250亿元，同比+19%/+9%/+14.5% ，在利润端21Q1/Q2/Q3实现归母净利润41.7亿元/46.4/36.8亿元，同比+20%/-12.4%/-2.6%。三季度板块归母净利润下滑有所缓解，主要是毛利率同比去年下滑约5.1pp，价格和成本波动造成行业的周期性明显，建议臻选细分领域内具有成长趋势的公司，尤其是Q4业绩表现较为稳健的公司。",
    "labels": [
      [
        "T0",
        "时间范围",
        1,
        6,
        " 21Q1"
      ],
      [
        "T1",
        "时间范围",
        7,
        9,
        "Q2"
      ],
      [
        "T2",
        "时间范围",
        10,
        12,
        "Q3"
      ],
      [
        "T3",
        "行业",
        12,
        15,
        "原料药"
      ],
      [
        "T4",
        "营业收入",
        21,
        23,
        "收入"
      ],
      [
        "T5",
        "属性值",
        23,
        28,
        "242亿元"
      ],
      [
        "T6",
        "属性值",
        29,
        32,
        "260"
      ],
      [
        "T7",
        "属性值",
        33,
        38,
        "250亿元"
      ],
      [
        "T8",
        "属性值",
        41,
        45,
        "+19%"
      ],
      [
        "T9",
        "属性值",
        46,
        49,
        "+9%"
      ],
      [
        "T10",
        "属性值",
        50,
        56,
        "+14.5%"
      ],
      [
        "T11",
        "利润",
        59,
        62,
        "利润端"
      ],
      [
        "T12",
        "时间范围",
        62,
        66,
        "21Q1"
      ],
      [
        "T13",
        "时间范围",
        67,
        69,
        "Q2"
      ],
      [
        "T14",
        "时间范围",
        70,
        72,
        "Q3"
      ],
      [
        "T15",
        "归母净利润",
        74,
        79,
        "归母净利润"
      ],
      [
        "T16",
        "属性值",
        79,
        85,
        "41.7亿元"
      ],
      [
        "T17",
        "属性值",
        86,
        90,
        "46.4"
      ],
      [
        "T18",
        "属性值",
        91,
        97,
        "36.8亿元"
      ],
      [
        "T19",
        "时间范围",
        118,
        121,
        "三季度"
      ],
      [
        "T20",
        "归母净利润",
        123,
        128,
        "归母净利润"
      ],
      [
        "T21",
        "属性值",
        128,
        134,
        "下滑有所缓解"
      ],
      [
        "T22",
        "毛利",
        138,
        141,
        "毛利率"
      ],
      [
        "T23",
        "属性值",
        145,
        153,
        "下滑约5.1pp"
      ],
      [
        "T24",
        "时间范围",
        143,
        145,
        "去年"
      ],
      [
        "T25",
        "时间范围",
        194,
        196,
        "Q4"
      ],
      [
        "T26",
        "业绩",
        196,
        198,
        "业绩"
      ]
    ]
  },
  {
    "id": 2104,
    "text": " CXO板块(13家)： 13家CXO公司2021Q1-3收入总额增速为43%、归母净利润总额增速为50%，整体维持高速增长。Q3收入同比增长36.6%，归母净利润同比增长47.3%，三季度收入端保持高速增长，利润端增速恢复高速增长。  疫苗（9家）：21Q1-3疫苗板块实现收入405亿元，5家样本公司收入实现正增长，4家公司收入增速均超过50%增长，6家公司净利润增速超过50%增长。从21Q1-3疫苗板块收入占比看，智飞占比50%；从21Q1-3年疫苗板块归母净利润占比看， 智飞占比63%；智飞为板块收入、利润的主要贡献者。  医疗服务（4家）：4家医疗服务公司2021Q1-3收入约为291亿元（+40.2%）、归母净利润总额约为46.2亿元（+43%）。  医疗器械（83家）：器械板块（83家样本公司，含科创板）2021Q1-3收入1543亿元（+27.6%），归母净利润487亿元（ +26.8%），毛利率 61%，四费率 25%, 净利率 32%，盈利能力维持高位。医疗器械板块 Q1/Q2/Q3单季度收入 535.1/534.7/473.2亿元（+118%/+9.4%/-0.4%），单季度净利润185.5/174.1/127.5亿元（+259%/+1.6%/-20.9%）, 高基数下板块Q3单季度业绩有所承压。",
    "labels": [
      [
        "T0",
        "行业",
        2,
        5,
        "CXO"
      ],
      [
        "T1",
        "行业公司",
        14,
        22,
        "13家CXO公司"
      ],
      [
        "T2",
        "时间范围",
        22,
        30,
        "2021Q1-3"
      ],
      [
        "T3",
        "收入增速",
        30,
        36,
        "收入总额增速"
      ],
      [
        "T4",
        "属性值",
        37,
        40,
        "43%"
      ],
      [
        "T5",
        "归母净利润增速",
        41,
        50,
        "归母净利润总额增速"
      ],
      [
        "T6",
        "属性值",
        51,
        54,
        "50%"
      ],
      [
        "T7",
        "时间范围",
        64,
        66,
        "Q3"
      ],
      [
        "T8",
        "营业收入",
        66,
        68,
        "收入"
      ],
      [
        "T9",
        "属性值",
        72,
        77,
        "36.6%"
      ],
      [
        "T10",
        "归母净利润",
        78,
        83,
        "归母净利润"
      ],
      [
        "T11",
        "属性值",
        83,
        92,
        "同比增长47.3%"
      ],
      [
        "T12",
        "时间范围",
        93,
        96,
        "三季度"
      ],
      [
        "T13",
        "营业收入",
        96,
        99,
        "收入端"
      ],
      [
        "T14",
        "属性值",
        101,
        105,
        "高速增长"
      ],
      [
        "T15",
        "利润",
        106,
        109,
        "利润端"
      ],
      [
        "T16",
        "行业",
        121,
        123,
        "疫苗"
      ],
      [
        "T17",
        "时间范围",
        128,
        134,
        "21Q1-3"
      ],
      [
        "T18",
        "行业",
        134,
        136,
        "疫苗"
      ],
      [
        "T19",
        "营业收入",
        140,
        142,
        "收入"
      ],
      [
        "T20",
        "属性值",
        142,
        147,
        "405亿元"
      ],
      [
        "T21",
        "行业公司",
        148,
        154,
        "5家样本公司"
      ],
      [
        "T22",
        "营业收入",
        154,
        156,
        "收入"
      ],
      [
        "T23",
        "属性值",
        158,
        161,
        "正增长"
      ],
      [
        "T24",
        "行业公司",
        162,
        166,
        "4家公司"
      ],
      [
        "T25",
        "收入增速",
        166,
        170,
        "收入增速"
      ],
      [
        "T26",
        "属性值",
        171,
        176,
        "超过50%"
      ],
      [
        "T27",
        "行业公司",
        179,
        183,
        "6家公司"
      ],
      [
        "T28",
        "归母净利润增速",
        183,
        188,
        "净利润增速"
      ],
      [
        "T29",
        "属性值",
        188,
        193,
        "超过50%"
      ],
      [
        "T30",
        "时间范围",
        197,
        203,
        "21Q1-3"
      ],
      [
        "T31",
        "行业",
        203,
        205,
        "疫苗"
      ],
      [
        "T32",
        "营收占比",
        207,
        211,
        "收入占比"
      ],
      [
        "T33",
        "公司",
        213,
        215,
        "智飞"
      ],
      [
        "T34",
        "属性值",
        217,
        220,
        "50%"
      ],
      [
        "T35",
        "时间范围",
        222,
        229,
        "21Q1-3年"
      ],
      [
        "T36",
        "行业",
        229,
        231,
        "疫苗"
      ],
      [
        "T37",
        "归母净利润",
        233,
        238,
        "归母净利润"
      ],
      [
        "T38",
        "公司",
        243,
        245,
        "智飞"
      ],
      [
        "T39",
        "公司",
        251,
        253,
        "智飞"
      ],
      [
        "T40",
        "营业收入",
        256,
        258,
        "收入"
      ],
      [
        "T41",
        "利润",
        259,
        261,
        "利润"
      ],
      [
        "T42",
        "行业",
        271,
        275,
        "医疗服务"
      ],
      [
        "T43",
        "行业公司",
        280,
        288,
        "4家医疗服务公司"
      ],
      [
        "T44",
        "时间范围",
        288,
        296,
        "2021Q1-3"
      ],
      [
        "T45",
        "营业收入",
        296,
        298,
        "收入"
      ],
      [
        "T46",
        "属性值",
        298,
        305,
        "约为291亿元"
      ],
      [
        "T47",
        "属性值",
        306,
        312,
        "+40.2%"
      ],
      [
        "T48",
        "归母净利润",
        314,
        319,
        "归母净利润"
      ],
      [
        "T49",
        "属性值",
        321,
        335,
        "约为46.2亿元（+43%）"
      ],
      [
        "T50",
        "行业",
        339,
        343,
        "医疗器械"
      ],
      [
        "T51",
        "行业",
        349,
        351,
        "器械"
      ],
      [
        "T52",
        "时间范围",
        367,
        375,
        "2021Q1-3"
      ],
      [
        "T53",
        "营业收入",
        375,
        377,
        "收入"
      ],
      [
        "T54",
        "行业公司",
        354,
        361,
        "83家样本公司"
      ],
      [
        "T55",
        "属性值",
        377,
        383,
        "1543亿元"
      ],
      [
        "T56",
        "属性值",
        384,
        390,
        "+27.6%"
      ],
      [
        "T57",
        "归母净利润",
        392,
        397,
        "归母净利润"
      ],
      [
        "T58",
        "属性值",
        397,
        411,
        "487亿元（ +26.8%）"
      ],
      [
        "T59",
        "毛利",
        412,
        415,
        "毛利率"
      ],
      [
        "T60",
        "属性值",
        416,
        419,
        "61%"
      ],
      [
        "T61",
        "归母净利润",
        429,
        432,
        "净利率"
      ],
      [
        "T62",
        "属性值",
        433,
        436,
        "32%"
      ],
      [
        "T63",
        "行业",
        446,
        450,
        "医疗器械"
      ],
      [
        "T64",
        "时间范围",
        453,
        455,
        "Q1"
      ],
      [
        "T65",
        "时间范围",
        456,
        458,
        "Q2"
      ],
      [
        "T66",
        "时间范围",
        459,
        461,
        "Q3"
      ],
      [
        "T67",
        "营业收入",
        464,
        466,
        "收入"
      ],
      [
        "T68",
        "属性值",
        467,
        472,
        "535.1"
      ],
      [
        "T69",
        "属性值",
        473,
        478,
        "534.7"
      ],
      [
        "T70",
        "属性值",
        479,
        486,
        "473.2亿元"
      ],
      [
        "T71",
        "属性值",
        487,
        492,
        "+118%"
      ],
      [
        "T72",
        "属性值",
        493,
        498,
        "+9.4%"
      ],
      [
        "T73",
        "属性值",
        499,
        504,
        "-0.4%"
      ],
      [
        "T74",
        "归母净利润",
        509,
        512,
        "净利润"
      ],
      [
        "T75",
        "属性值",
        512,
        517,
        "185.5"
      ],
      [
        "T76",
        "属性值",
        518,
        523,
        "174.1"
      ],
      [
        "T77",
        "属性值",
        524,
        531,
        "127.5亿元"
      ],
      [
        "T78",
        "时间范围",
        559,
        561,
        "Q3"
      ],
      [
        "T79",
        "业绩",
        564,
        566,
        "业绩"
      ],
      [
        "T80",
        "属性值",
        566,
        570,
        "有所承压"
      ],
      [
        "T81",
        "属性值",
        109,
        117,
        "增速恢复高速增长"
      ]
    ]
  },
  {
    "id": 2117,
    "text": "2.5.医疗器械&耗材——各层级医疗机构诊疗人次快速回升，但距正常水平仍有差距",
    "labels": [
      [
        "T0",
        "行业",
        4,
        8,
        "医疗器械"
      ],
      [
        "T1",
        "行业",
        9,
        11,
        "耗材"
      ]
    ]
  },
  {
    "id": 2118,
    "text": " 16家医药流通股上半年收入总额增速为29.5%，归母净利润总额增速为42.1%。  从盈利水平来看，上半年整体毛利率为10.3%，同比下降1.1pp，其中单二季度毛利率为10.6%，同比下降1.2pp，环比提升0.5pp。  二季度费用率均环比保持稳定，同比略有下降。销售费用率同比下降 0.4pp，财务费用率下降0.2pp，管理费用率同比下降0.2pp。",
    "labels": [
      [
        "T0",
        "行业公司",
        2,
        10,
        "16家医药流通股"
      ],
      [
        "T1",
        "时间范围",
        10,
        13,
        "上半年"
      ],
      [
        "T2",
        "收入增速",
        13,
        19,
        "收入总额增速"
      ],
      [
        "T3",
        "属性值",
        20,
        25,
        "29.5%"
      ],
      [
        "T4",
        "归母净利润增速",
        26,
        35,
        "归母净利润总额增速"
      ],
      [
        "T5",
        "属性值",
        36,
        41,
        "42.1%"
      ],
      [
        "T6",
        "时间范围",
        53,
        56,
        "上半年"
      ],
      [
        "T7",
        "毛利",
        58,
        61,
        "毛利率"
      ],
      [
        "T8",
        "属性值",
        62,
        77,
        "10.3%，同比下降1.1pp"
      ],
      [
        "T9",
        "时间范围",
        81,
        84,
        "二季度"
      ],
      [
        "T10",
        "毛利",
        84,
        87,
        "毛利率"
      ],
      [
        "T11",
        "属性值",
        88,
        103,
        "10.6%，同比下降1.2pp"
      ],
      [
        "T12",
        "时间范围",
        117,
        120,
        "二季度"
      ]
    ]
  },
  {
    "id": 2129,
    "text": " 中药（49家）：49家中药公司2021Q1-3收入总额增速为12%，占全行业比例为16% ，归母净利润总额增速为10.3%， 占全行业比例为15% ，Q3单季收入稳健增长，利润同比下降；收入端增速为7%，利润端下降15.5%。从盈利水平看，中药板块整体盈利能力整体稳中有升，21Q1-3，行业毛利率（43%），销售费用率（23%）保持稳定，净利率（9%）略有下滑。",
    "labels": [
      [
        "T0",
        "行业",
        2,
        4,
        "中药"
      ],
      [
        "T1",
        "行业公司",
        10,
        17,
        "49家中药公司"
      ],
      [
        "T2",
        "时间范围",
        17,
        25,
        "2021Q1-3"
      ],
      [
        "T3",
        "收入增速",
        25,
        31,
        "收入总额增速"
      ],
      [
        "T4",
        "属性值",
        32,
        35,
        "12%"
      ],
      [
        "T5",
        "归母净利润增速",
        48,
        57,
        "归母净利润总额增速"
      ],
      [
        "T6",
        "属性值",
        58,
        63,
        "10.3%"
      ],
      [
        "T7",
        "时间范围",
        77,
        79,
        "Q3"
      ],
      [
        "T8",
        "营业收入",
        81,
        83,
        "收入"
      ],
      [
        "T9",
        "属性值",
        83,
        87,
        "稳健增长"
      ],
      [
        "T10",
        "利润",
        88,
        90,
        "利润"
      ],
      [
        "T11",
        "属性值",
        90,
        94,
        "同比下降"
      ],
      [
        "T12",
        "收入增速",
        95,
        100,
        "收入端增速"
      ],
      [
        "T13",
        "属性值",
        101,
        103,
        "7%"
      ],
      [
        "T14",
        "利润",
        104,
        107,
        "利润端"
      ],
      [
        "T15",
        "属性值",
        107,
        114,
        "下降15.5%"
      ],
      [
        "T16",
        "行业",
        122,
        124,
        "中药"
      ],
      [
        "T17",
        "时间范围",
        139,
        145,
        "21Q1-3"
      ],
      [
        "T18",
        "毛利",
        148,
        151,
        "毛利率"
      ],
      [
        "T19",
        "属性值",
        152,
        155,
        "43%"
      ],
      [
        "T20",
        "归母净利润",
        172,
        175,
        "净利率"
      ],
      [
        "T21",
        "属性值",
        176,
        183,
        "9%）略有下滑"
      ]
    ]
  },
  {
    "id": 2130,
    "text": " 4家医疗服务公司2021 Q1/Q2/Q3收入分别约为89/96/107亿元（+106%/+36.4%/+13%）、归母净利润总额分别约为12.8/14.5/18.9亿元（ +810%/+8%/+8%），季度之间增速波动较大，主要是2020年一季度医院经营受疫情影响较大，同时部分需求递延到2020年二季度，我们的医疗服务板块纳入标的都有明显的固定成本属性，去年季度收入节奏的扰乱造成今年单季度利润波动较大。展望Q4来看，预计还是受到去年基数影响，尽管各项业务顺利开展，业绩表观增速仍然可能较以往偏低。",
    "labels": [
      [
        "T0",
        "行业公司",
        2,
        10,
        "4家医疗服务公司"
      ],
      [
        "T1",
        "时间范围",
        10,
        17,
        "2021 Q1"
      ],
      [
        "T2",
        "时间范围",
        18,
        20,
        "Q2"
      ],
      [
        "T3",
        "时间范围",
        21,
        23,
        "Q3"
      ],
      [
        "T4",
        "属性值",
        29,
        31,
        "89"
      ],
      [
        "T5",
        "属性值",
        32,
        34,
        "96"
      ],
      [
        "T6",
        "属性值",
        35,
        40,
        "107亿元"
      ],
      [
        "T7",
        "属性值",
        41,
        46,
        "+106%"
      ],
      [
        "T8",
        "属性值",
        47,
        53,
        "+36.4%"
      ],
      [
        "T9",
        "属性值",
        54,
        58,
        "+13%"
      ],
      [
        "T10",
        "归母净利润",
        60,
        65,
        "归母净利润"
      ],
      [
        "T11",
        "属性值",
        71,
        75,
        "12.8"
      ],
      [
        "T12",
        "属性值",
        76,
        80,
        "14.5"
      ],
      [
        "T13",
        "属性值",
        81,
        87,
        "18.9亿元"
      ],
      [
        "T14",
        "时间范围",
        118,
        126,
        "2020年一季度"
      ],
      [
        "T15",
        "时间范围",
        147,
        155,
        "2020年二季度"
      ],
      [
        "T16",
        "行业",
        159,
        163,
        "医疗服务"
      ],
      [
        "T17",
        "地点范围",
        181,
        183,
        "去年"
      ],
      [
        "T18",
        "时间范围",
        194,
        196,
        "今年"
      ],
      [
        "T19",
        "利润",
        199,
        201,
        "利润"
      ],
      [
        "T20",
        "时间范围",
        208,
        210,
        "Q4"
      ],
      [
        "T21",
        "时间范围",
        219,
        221,
        "去年"
      ],
      [
        "T22",
        "业绩",
        237,
        239,
        "业绩"
      ]
    ]
  },
  {
    "id": 2132,
    "text": " POCT凭借快速、简单、即时即地场景多元等优势在 IVD赛道中占比逐渐提升。2018年国内POCT市场规模100亿元，预计能够维持20%以上的增速。  当前POCT主要场景有感染类、血气/凝血类、心血管检测类、妊娠检测类、药物滥用类等。传染病类和心血管类导入期完成，将进入高速成长期。  2021Q1-3常规业务逐步恢复，叠加部分公司新冠检测试剂仍贡献增量，总体POCT企业实现收入、利润正增长，但增速有所分化，其中明德生物由于新冠贡献增量较多，增速较快。  万孚生物：国产POCT龙头，2021Q1-3收入25.1亿元（+15.4%）,归母净利润6.3亿元（+10.8%）， 单Q3业绩表现低于预期，主要因成本增加导致毛利率下降。  基蛋生物：2021Q1-3收入9.2亿元（+20.9%）， 归母净利润2.5亿元（+28.4%）。  明德生物：2021Q1-3收入19.4亿元（+202.8%） ，归母净利润10.1亿元（+182.2%），主要是因新冠检测试剂贡献较大增量。",
    "labels": [
      [
        "T0",
        "行业",
        1,
        6,
        " POCT"
      ],
      [
        "T1",
        "行业",
        26,
        30,
        " IVD"
      ],
      [
        "T2",
        "时间范围",
        40,
        45,
        "2018年"
      ],
      [
        "T3",
        "地点范围",
        45,
        47,
        "国内"
      ],
      [
        "T4",
        "行业",
        47,
        51,
        "POCT"
      ],
      [
        "T5",
        "市场规模",
        51,
        55,
        "市场规模"
      ],
      [
        "T6",
        "属性值",
        55,
        60,
        "100亿元"
      ],
      [
        "T7",
        "行业",
        81,
        85,
        "POCT"
      ],
      [
        "T8",
        "时间范围",
        148,
        156,
        "2021Q1-3"
      ],
      [
        "T9",
        "行业公司",
        185,
        191,
        "POCT企业"
      ],
      [
        "T10",
        "营业收入",
        193,
        195,
        "收入"
      ],
      [
        "T11",
        "利润",
        196,
        198,
        "利润"
      ],
      [
        "T12",
        "公司",
        212,
        216,
        "明德生物"
      ],
      [
        "T13",
        "公司",
        235,
        239,
        "万孚生物"
      ],
      [
        "T14",
        "龙头企业",
        246,
        248,
        "龙头"
      ],
      [
        "T15",
        "时间范围",
        249,
        257,
        "2021Q1-3"
      ],
      [
        "T16",
        "营业收入",
        257,
        259,
        "收入"
      ],
      [
        "T17",
        "属性值",
        259,
        265,
        "25.1亿元"
      ],
      [
        "T18",
        "属性值",
        266,
        272,
        "+15.4%"
      ],
      [
        "T19",
        "归母净利润",
        274,
        279,
        "归母净利润"
      ],
      [
        "T20",
        "业绩",
        297,
        299,
        "业绩"
      ],
      [
        "T21",
        "毛利",
        315,
        318,
        "毛利率"
      ],
      [
        "T22",
        "属性值",
        318,
        320,
        "下降"
      ],
      [
        "T23",
        "公司",
        324,
        328,
        "基蛋生物"
      ],
      [
        "T24",
        "时间范围",
        329,
        337,
        "2021Q1-3"
      ],
      [
        "T25",
        "营业收入",
        337,
        339,
        "收入"
      ],
      [
        "T26",
        "归母净利润",
        354,
        359,
        "归母净利润"
      ],
      [
        "T27",
        "属性值",
        339,
        344,
        "9.2亿元"
      ],
      [
        "T28",
        "属性值",
        345,
        351,
        "+20.9%"
      ],
      [
        "T29",
        "属性值",
        391,
        397,
        "19.4亿元"
      ],
      [
        "T30",
        "属性值",
        398,
        405,
        "+202.8%"
      ],
      [
        "T31",
        "公司",
        376,
        380,
        "明德生物"
      ],
      [
        "T32",
        "时间范围",
        381,
        389,
        "2021Q1-3"
      ],
      [
        "T33",
        "营业收入",
        389,
        391,
        "收入"
      ],
      [
        "T34",
        "归母净利润",
        408,
        413,
        "归母净利润"
      ],
      [
        "T35",
        "属性值",
        67,
        72,
        "20%以上"
      ],
      [
        "T36",
        "属性值",
        8,
        22,
        "快速、简单、即时即地场景多元"
      ],
      [
        "T37",
        "属性值",
        198,
        201,
        "正增长"
      ],
      [
        "T38",
        "行业",
        240,
        246,
        "国产POCT"
      ],
      [
        "T39",
        "属性值",
        279,
        292,
        "6.3亿元（+10.8%）"
      ],
      [
        "T40",
        "属性值",
        301,
        305,
        "低于预期"
      ],
      [
        "T41",
        "属性值",
        359,
        372,
        "2.5亿元（+28.4%）"
      ],
      [
        "T42",
        "属性值",
        413,
        428,
        "10.1亿元（+182.2%）"
      ],
      [
        "T43",
        "时间范围",
        295,
        297,
        "Q3"
      ]
    ]
  },
  {
    "id": 2139,
    "text": " 生物药（14家）：14家生物药公司2021Q1-3收入总额增速为23.5%，占全行业比例为4% ，归母净利润总额增速为 37.2%，占全行业比例为7% 。生物药去年同期受疫情影响较大，目前已迎来恢复。从盈利水平看，Q1-3生物药板块整体盈利能力稳中有升，行业毛利率（63%）基本保持平稳，销售费用率（27%）持续下降，管理费用率（8%）、研发费用率（8.4%）保持稳定，净利率（22%）同比有所提升。",
    "labels": [
      [
        "T0",
        "行业",
        2,
        5,
        "生物药"
      ],
      [
        "T1",
        "行业公司",
        11,
        19,
        "14家生物药公司"
      ],
      [
        "T2",
        "时间范围",
        19,
        27,
        "2021Q1-3"
      ],
      [
        "T3",
        "收入增速",
        27,
        33,
        "收入总额增速"
      ],
      [
        "T4",
        "属性值",
        34,
        39,
        "23.5%"
      ],
      [
        "T5",
        "归母净利润增速",
        51,
        60,
        "归母净利润总额增速"
      ],
      [
        "T6",
        "属性值",
        62,
        67,
        "37.2%"
      ],
      [
        "T7",
        "行业",
        79,
        82,
        "生物药"
      ],
      [
        "T8",
        "时间范围",
        109,
        113,
        "Q1-3"
      ],
      [
        "T9",
        "行业",
        113,
        116,
        "生物药"
      ],
      [
        "T10",
        "毛利",
        131,
        134,
        "毛利率"
      ],
      [
        "T11",
        "研发费用率",
        171,
        176,
        "研发费用率"
      ],
      [
        "T12",
        "属性值",
        176,
        186,
        "（8.4%）保持稳定"
      ],
      [
        "T13",
        "归母净利润",
        187,
        190,
        "净利率"
      ],
      [
        "T14",
        "属性值",
        190,
        201,
        "（22%）同比有所提升"
      ],
      [
        "T15",
        "属性值",
        134,
        145,
        "（63%）基本保持平稳"
      ],
      [
        "T16",
        "时间范围",
        94,
        96,
        "目前"
      ]
    ]
  },
  {
    "id": 2147,
    "text": "• 从A股6家血制品公司三季报情况来看，6家公司2021年Q1-Q3营业收入合计同比于2019年增长27.49%，同比于 2020年增长19.91%；2021年Q1-Q3归母净利润合计同比于2019年增长45.69%，同比于2020年增长25.65%；2021 年Q1-Q3扣非归母净利润合计同比于2019年增长47.58%，同比于2020年增长27.05%。整体而言，血制品公司业绩增长较为稳定。 • 2021年9月30日，广东省发布血制品集采规则，对人血白蛋白、人免疫球蛋白、人凝血因子、人纤维蛋白原等血制品进行集采。从此次集采分组和竞价规则来看，中标规则较为温和，预计血制品最终价格降幅有限。",
    "labels": [
      [
        "T0",
        "行业公司",
        5,
        12,
        "6家血制品公司"
      ],
      [
        "T1",
        "时间范围",
        12,
        14,
        "三季"
      ],
      [
        "T2",
        "时间范围",
        24,
        34,
        "2021年Q1-Q3"
      ],
      [
        "T3",
        "营业收入",
        34,
        38,
        "营业收入"
      ],
      [
        "T4",
        "时间范围",
        43,
        48,
        "2019年"
      ],
      [
        "T5",
        "属性值",
        50,
        56,
        "27.49%"
      ],
      [
        "T6",
        "时间范围",
        61,
        66,
        "2020年"
      ],
      [
        "T7",
        "属性值",
        68,
        74,
        "19.91%"
      ],
      [
        "T8",
        "时间范围",
        75,
        85,
        "2021年Q1-Q3"
      ],
      [
        "T9",
        "归母净利润",
        85,
        90,
        "归母净利润"
      ],
      [
        "T10",
        "时间范围",
        95,
        100,
        "2019年"
      ],
      [
        "T11",
        "时间范围",
        112,
        117,
        "2020年"
      ],
      [
        "T12",
        "时间范围",
        126,
        137,
        "2021 年Q1-Q3"
      ],
      [
        "T13",
        "扣非净利润",
        137,
        144,
        "扣非归母净利润"
      ],
      [
        "T14",
        "属性值",
        100,
        108,
        "增长45.69%"
      ],
      [
        "T15",
        "属性值",
        117,
        125,
        "增长25.65%"
      ],
      [
        "T16",
        "属性值",
        154,
        162,
        "增长47.58%"
      ],
      [
        "T17",
        "属性值",
        171,
        179,
        "增长27.05%"
      ],
      [
        "T18",
        "时间范围",
        166,
        171,
        "2020年"
      ],
      [
        "T19",
        "时间范围",
        149,
        154,
        "2019年"
      ],
      [
        "T20",
        "行业公司",
        185,
        190,
        "血制品公司"
      ],
      [
        "T21",
        "业绩",
        190,
        192,
        "业绩"
      ],
      [
        "T22",
        "属性值",
        192,
        198,
        "增长较为稳定"
      ],
      [
        "T23",
        "时间范围",
        202,
        212,
        "2021年9月30日"
      ],
      [
        "T24",
        "地点范围",
        213,
        216,
        "广东省"
      ]
    ]
  },
  {
    "id": 2153,
    "text": "CXO公司在 2021年 Q1-Q3业绩表现出高景气度增长，药明康德、凯莱英、康龙化成、博腾股份等公司在利润端与收入端均表现出优秀的增长。同时，行业内公司的存货水平与合同负债水平也与 2020 年相比有显著的增长，预期对 2022年业绩增长产生积极影响。凯莱英全资子公司已与美国某大型制药公司签订大额订单，供货时间为 2021年-2022年，将对公司业绩产能是积极影响。博腾股份也于 2021年 11月发布公告，宣布公司获得美国某大型制药的新一批《采购订单》，订单交付时间为 2021年至 2022年。",
    "labels": [
      [
        "T0",
        "行业公司",
        0,
        5,
        "CXO公司"
      ],
      [
        "T1",
        "时间范围",
        7,
        18,
        "2021年 Q1-Q3"
      ],
      [
        "T2",
        "业绩",
        18,
        20,
        "业绩"
      ],
      [
        "T3",
        "属性值",
        23,
        29,
        "高景气度增长"
      ],
      [
        "T4",
        "公司",
        30,
        34,
        "药明康德"
      ],
      [
        "T5",
        "公司",
        35,
        38,
        "凯莱英"
      ],
      [
        "T6",
        "公司",
        39,
        43,
        "康龙化成"
      ],
      [
        "T7",
        "公司",
        44,
        48,
        "博腾股份"
      ],
      [
        "T8",
        "利润",
        52,
        55,
        "利润端"
      ],
      [
        "T9",
        "营业收入",
        56,
        59,
        "收入端"
      ],
      [
        "T10",
        "属性值",
        63,
        68,
        "优秀的增长"
      ],
      [
        "T11",
        "存货",
        78,
        80,
        "存货"
      ],
      [
        "T12",
        "合同负债",
        83,
        87,
        "合同负债"
      ],
      [
        "T13",
        "时间范围",
        92,
        98,
        "2020 年"
      ],
      [
        "T14",
        "属性值",
        101,
        106,
        "显著的增长"
      ],
      [
        "T15",
        "时间范围",
        111,
        116,
        "2022年"
      ],
      [
        "T16",
        "业绩",
        116,
        118,
        "业绩"
      ],
      [
        "T17",
        "公司",
        127,
        130,
        "凯莱英"
      ],
      [
        "T18",
        "地点范围",
        137,
        139,
        "美国"
      ],
      [
        "T19",
        "行业公司",
        142,
        146,
        "制药公司"
      ],
      [
        "T20",
        "时间范围",
        159,
        170,
        "2021年-2022年"
      ],
      [
        "T21",
        "业绩",
        175,
        177,
        "业绩"
      ],
      [
        "T22",
        "产能",
        177,
        179,
        "产能"
      ],
      [
        "T23",
        "公司",
        185,
        189,
        "博腾股份"
      ],
      [
        "T24",
        "时间范围",
        192,
        201,
        "2021年 11月"
      ],
      [
        "T25",
        "地点范围",
        212,
        214,
        "美国"
      ],
      [
        "T26",
        "时间范围",
        238,
        250,
        "2021年至 2022年"
      ]
    ]
  },
  {
    "id": 2170,
    "text": " 后疫情时代，医院业务恢复推动流通企业业绩持续回暖：16家医药流通股上半年收入总额增速为29.5%，归母净利润总额增速为42.1%，扣非后归母净利润增速为17.8%，上半年快速增长主要系去年同期受疫情影响形成低基数。毛利率为10% ，下降1pp，主要系带量采购带来毛利率的下降。Q2实现了加速增长，单二季度实现归母净利润的同比增速为45.5%。二季度费用率环比略有下降。销售费用率同比下降0.4pp，财务费用率下降0.1pp，管理费用率同比下降0.1pp。",
    "labels": [
      [
        "T0",
        "行业公司",
        27,
        35,
        "16家医药流通股"
      ],
      [
        "T1",
        "时间范围",
        35,
        38,
        "上半年"
      ],
      [
        "T2",
        "收入增速",
        38,
        44,
        "收入总额增速"
      ],
      [
        "T3",
        "属性值",
        45,
        50,
        "29.5%"
      ],
      [
        "T4",
        "归母净利润增速",
        51,
        60,
        "归母净利润总额增速"
      ],
      [
        "T5",
        "属性值",
        61,
        66,
        "42.1%"
      ],
      [
        "T6",
        "扣非净利润增速",
        67,
        77,
        "扣非后归母净利润增速"
      ],
      [
        "T7",
        "属性值",
        78,
        83,
        "17.8%"
      ],
      [
        "T8",
        "时间范围",
        84,
        87,
        "上半年"
      ],
      [
        "T9",
        "时间范围",
        94,
        96,
        "去年"
      ],
      [
        "T10",
        "毛利",
        109,
        112,
        "毛利率"
      ],
      [
        "T11",
        "属性值",
        113,
        116,
        "10%"
      ],
      [
        "T12",
        "毛利",
        133,
        136,
        "毛利率"
      ],
      [
        "T13",
        "属性值",
        137,
        139,
        "下降"
      ],
      [
        "T14",
        "时间范围",
        140,
        142,
        "Q2"
      ],
      [
        "T15",
        "时间范围",
        151,
        154,
        "二季度"
      ],
      [
        "T16",
        "归母净利润",
        156,
        161,
        "归母净利润"
      ],
      [
        "T17",
        "属性值",
        167,
        172,
        "45.5%"
      ],
      [
        "T18",
        "行业公司",
        16,
        20,
        "流通企业"
      ],
      [
        "T19",
        "业绩",
        20,
        22,
        "业绩"
      ],
      [
        "T20",
        "属性值",
        22,
        26,
        "持续回暖"
      ],
      [
        "T21",
        "时间范围",
        2,
        7,
        "后疫情时代"
      ]
    ]
  },
  {
    "id": 2171,
    "text": " 我们选取了311家医药上市公司（包含科创板），2021年Q1- 3收入总额14054亿元，归母净利润1595亿元，分别占申万医药全成分结果比例是：85%、90%，主要剔除了在2019 、2020年、2021Q1-3提取巨额商誉减值损失的企业。  2021年Q1-3全行业收入增速为21%，归母净利润增速为 27.2%。  2021年Q1-3实现归母净利润正增长的公司有223家，占比 72%，84%（260/311）的公司实现收入正增长。",
    "labels": [
      [
        "T0",
        "行业公司",
        7,
        17,
        "311家医药上市公司"
      ],
      [
        "T1",
        "时间范围",
        25,
        35,
        "2021年Q1- 3"
      ],
      [
        "T2",
        "属性值",
        39,
        46,
        "14054亿元"
      ],
      [
        "T3",
        "归母净利润",
        47,
        52,
        "归母净利润"
      ],
      [
        "T4",
        "营业收入",
        35,
        37,
        "收入"
      ],
      [
        "T5",
        "属性值",
        52,
        58,
        "1595亿元"
      ],
      [
        "T6",
        "属性值",
        75,
        78,
        "85%"
      ],
      [
        "T7",
        "行业",
        64,
        66,
        "医药"
      ],
      [
        "T8",
        "时间范围",
        89,
        93,
        "2019"
      ],
      [
        "T9",
        "时间范围",
        95,
        100,
        "2020年"
      ],
      [
        "T10",
        "时间范围",
        101,
        109,
        "2021Q1-3"
      ],
      [
        "T11",
        "时间范围",
        126,
        135,
        "2021年Q1-3"
      ],
      [
        "T12",
        "收入增速",
        138,
        142,
        "收入增速"
      ],
      [
        "T13",
        "归母净利润增速",
        147,
        154,
        "归母净利润增速"
      ],
      [
        "T14",
        "时间范围",
        165,
        174,
        "2021年Q1-3"
      ],
      [
        "T15",
        "归母净利润",
        176,
        181,
        "归母净利润"
      ],
      [
        "T16",
        "营业收入",
        217,
        219,
        "收入"
      ]
    ]
  },
  {
    "id": 2173,
    "text": "受高基数影响，Q2单季度同比增速放缓  医疗器械板块Q1/Q2单季度收入391.2/370.6亿元（+94.9%/-4.6%）,单季度净利润120.3/110.5亿元（+196.7%/-13.6%）,去年二季度受疫情影响导致行业利润产生高基数。  Q2单季度毛利率58.8%（-1.8pp），单季度四费率24.2%（+3.4pp），单季度净利率29.8%（-3.1pp）。",
    "labels": [
      [
        "T0",
        "行业",
        21,
        25,
        "医疗器械"
      ],
      [
        "T1",
        "时间范围",
        27,
        29,
        "Q1"
      ],
      [
        "T2",
        "时间范围",
        30,
        32,
        "Q2"
      ],
      [
        "T3",
        "营业收入",
        35,
        37,
        "收入"
      ],
      [
        "T4",
        "属性值",
        37,
        42,
        "391.2"
      ],
      [
        "T5",
        "属性值",
        43,
        50,
        "370.6亿元"
      ],
      [
        "T6",
        "属性值",
        51,
        57,
        "+94.9%"
      ],
      [
        "T7",
        "属性值",
        58,
        63,
        "-4.6%"
      ],
      [
        "T8",
        "归母净利润",
        68,
        71,
        "净利润"
      ],
      [
        "T9",
        "属性值",
        71,
        76,
        "120.3"
      ],
      [
        "T10",
        "属性值",
        77,
        84,
        "110.5亿元"
      ],
      [
        "T11",
        "时间范围",
        101,
        106,
        "去年二季度"
      ],
      [
        "T12",
        "利润",
        115,
        117,
        "利润"
      ],
      [
        "T13",
        "属性值",
        119,
        122,
        "高基数"
      ],
      [
        "T14",
        "时间范围",
        126,
        128,
        "Q2"
      ],
      [
        "T15",
        "毛利",
        131,
        134,
        "毛利率"
      ],
      [
        "T16",
        "属性值",
        134,
        147,
        "58.8%（-1.8pp）"
      ],
      [
        "T17",
        "归母净利润",
        171,
        174,
        "净利率"
      ],
      [
        "T18",
        "属性值",
        174,
        187,
        "29.8%（-3.1pp）"
      ],
      [
        "T19",
        "时间范围",
        7,
        9,
        "Q2"
      ]
    ]
  },
  {
    "id": 2177,
    "text": "普洛药业为一家集研究、开发、生产原料药、制剂、医药中间体的大型综合性制药企业，近年公司对 CDMO板块战略布局的持续加大，可为客户提供从产品工艺开发、生产定制及全球申报等方面的“一站式”定制研发生产服务。 公司 2021年 H1期间 CDMO业务实现营业收入 7.21亿人民币，同比增长 30.65%。在 2021H1期间，公司 CDMO客户总数同比增长 51.0%，报价项目达到 355个，同比增加 157%。公司从“起始原料药+注册中间体”到“注册中间体+API”的转型升级策略取得显著成果，目前，公司已与国内 126家创新药企业签订保密协议，并与超过 30家国内创新公司开展了业务合作，上半年已签订多个吨级规模订单。",
    "labels": [
      [
        "T0",
        "公司",
        0,
        4,
        "普洛药业"
      ],
      [
        "T1",
        "属性值",
        8,
        28,
        "研究、开发、生产原料药、制剂、医药中间体"
      ],
      [
        "T2",
        "时间范围",
        39,
        41,
        "近年"
      ],
      [
        "T3",
        "行业",
        45,
        49,
        "CDMO"
      ],
      [
        "T4",
        "时间范围",
        106,
        114,
        "2021年 H1"
      ],
      [
        "T5",
        "行业",
        117,
        121,
        "CDMO"
      ],
      [
        "T6",
        "营业收入",
        125,
        129,
        "营业收入"
      ],
      [
        "T7",
        "属性值",
        130,
        138,
        "7.21亿人民币"
      ],
      [
        "T8",
        "属性值",
        144,
        150,
        "30.65%"
      ],
      [
        "T9",
        "时间范围",
        153,
        159,
        "2021H1"
      ],
      [
        "T10",
        "行业",
        165,
        169,
        "CDMO"
      ],
      [
        "T11",
        "客户数量",
        169,
        173,
        "客户总数"
      ],
      [
        "T12",
        "属性值",
        173,
        183,
        "同比增长 51.0%"
      ],
      [
        "T13",
        "地点范围",
        255,
        257,
        "国内"
      ],
      [
        "T14",
        "行业公司",
        258,
        267,
        "126家创新药企业"
      ],
      [
        "T15",
        "行业公司",
        276,
        288,
        "超过 30家国内创新公司"
      ],
      [
        "T16",
        "时间范围",
        296,
        299,
        "上半年"
      ],
      [
        "T17",
        "属性值",
        302,
        310,
        "多个吨级规模订单"
      ]
    ]
  },
  {
    "id": 2183,
    "text": " A股行情回顾：本周医药整体跑赢大盘，医药分销及医药零售表现较好。本周医药指数上涨2.41%，万得全A指数下跌1.12%，医药指数整体跑赢大盘3.53%。2022年以来，医药指数整体跑输大盘12.39%。子行业方面，本周医药分销（+1.49%）、医药零售（-1.44%）子行业表现较好。",
    "labels": [
      [
        "T0",
        "时间范围",
        9,
        11,
        "本周"
      ],
      [
        "T1",
        "行业",
        11,
        13,
        "医药"
      ],
      [
        "T2",
        "行业",
        20,
        24,
        "医药分销"
      ],
      [
        "T3",
        "行业",
        25,
        29,
        "医药零售"
      ],
      [
        "T4",
        "时间范围",
        34,
        36,
        "本周"
      ],
      [
        "T5",
        "行业",
        36,
        38,
        "医药"
      ],
      [
        "T6",
        "行业",
        62,
        64,
        "医药"
      ],
      [
        "T7",
        "时间范围",
        78,
        85,
        "2022年以来"
      ],
      [
        "T8",
        "行业",
        86,
        88,
        "医药"
      ],
      [
        "T9",
        "时间范围",
        109,
        111,
        "本周"
      ],
      [
        "T10",
        "行业",
        111,
        115,
        "医药分销"
      ],
      [
        "T11",
        "行业",
        124,
        128,
        "医药零售"
      ]
    ]
  },
  {
    "id": 2186,
    "text": " 14家生物药公司2021Q1-3收入总额增速为23.5%、归母净利润总额增速为37.2%。生物药去年同期受疫情影响较大，目前已迎来恢复。  从盈利水平看，Q1-3生物药板块整体盈利能力稳中有升，行业毛利率 （63%）基本保持平稳，销售费用率（27%）持续下降，管理费用率 （8%）、研发费用率（8.4%）保持稳定，净利率（22%）同比有所提升。",
    "labels": [
      [
        "T0",
        "行业公司",
        2,
        10,
        "14家生物药公司"
      ],
      [
        "T1",
        "时间范围",
        10,
        18,
        "2021Q1-3"
      ],
      [
        "T2",
        "收入增速",
        18,
        24,
        "收入总额增速"
      ],
      [
        "T3",
        "归母净利润增速",
        31,
        40,
        "归母净利润总额增速"
      ],
      [
        "T4",
        "属性值",
        25,
        30,
        "23.5%"
      ],
      [
        "T5",
        "属性值",
        41,
        46,
        "37.2%"
      ],
      [
        "T6",
        "行业",
        47,
        50,
        "生物药"
      ],
      [
        "T7",
        "时间范围",
        80,
        84,
        "Q1-3"
      ],
      [
        "T8",
        "行业",
        84,
        87,
        "生物药"
      ],
      [
        "T9",
        "毛利",
        102,
        106,
        "毛利率 "
      ],
      [
        "T10",
        "属性值",
        106,
        117,
        "（63%）基本保持平稳"
      ],
      [
        "T11",
        "时间范围",
        50,
        52,
        "去年"
      ],
      [
        "T12",
        "时间范围",
        62,
        64,
        "目前"
      ],
      [
        "T13",
        "研发费用率",
        144,
        149,
        "研发费用率"
      ],
      [
        "T14",
        "属性值",
        149,
        159,
        "（8.4%）保持稳定"
      ],
      [
        "T15",
        "归母净利润",
        160,
        163,
        "净利率"
      ],
      [
        "T16",
        "属性值",
        163,
        174,
        "（22%）同比有所提升"
      ]
    ]
  },
  {
    "id": 2191,
    "text": " 分子诊断近年来行业增速约25%，2019年行业规模约100亿元左右，占整个IVD板块15%，是 IVD领域增速最快的赛道。分子诊断凭借准确度高、灵敏度强、速度快等优点，未来在传染病监测、肿瘤筛查等领域具有广阔空间，本次疫情中核酸诊断为新冠筛查的“金标准”，其价值得到凸显，后续分子诊断发展有望加速。  板块：我们选取分子诊断8家企业，2021上半年收入191亿元（+169.8%），归母净利润82.4亿元（+70.8%），上半年高增长趋势主要由于新冠检测试剂出口能维持高水平。  华大基因： 2021年上半年收入 36.5亿元（ - 11.2%），归母净利润10.9亿元（-34.2%）。 新冠检测试剂出口有所下滑。  艾德生物：2021年上半年收入4亿元（+41%） ，归母净利润1.1亿元（+37.8%），低基数下重回高增长态势。伴随诊断行业成长突出，公司产品齐全，院内市占率领先，后续有望持续改善。",
    "labels": [
      [
        "T0",
        "行业",
        2,
        6,
        "分子诊断"
      ],
      [
        "T1",
        "时间范围",
        6,
        9,
        "近年来"
      ],
      [
        "T2",
        "时间范围",
        18,
        23,
        "2019年"
      ],
      [
        "T3",
        "市场规模",
        23,
        27,
        "行业规模"
      ],
      [
        "T4",
        "属性值",
        27,
        35,
        "约100亿元左右"
      ],
      [
        "T5",
        "行业",
        39,
        42,
        "IVD"
      ],
      [
        "T6",
        "行业",
        50,
        53,
        "IVD"
      ],
      [
        "T7",
        "行业",
        63,
        67,
        "分子诊断"
      ],
      [
        "T8",
        "属性值",
        69,
        82,
        "准确度高、灵敏度强、速度快"
      ],
      [
        "T9",
        "时间范围",
        86,
        88,
        "未来"
      ],
      [
        "T10",
        "行业",
        95,
        99,
        "肿瘤筛查"
      ],
      [
        "T11",
        "行业",
        89,
        94,
        "传染病监测"
      ],
      [
        "T12",
        "行业",
        140,
        144,
        "分子诊断"
      ],
      [
        "T13",
        "行业公司",
        161,
        169,
        "分子诊断8家企业"
      ],
      [
        "T14",
        "时间范围",
        170,
        177,
        "2021上半年"
      ],
      [
        "T15",
        "营业收入",
        177,
        179,
        "收入"
      ],
      [
        "T16",
        "属性值",
        179,
        184,
        "191亿元"
      ],
      [
        "T17",
        "属性值",
        185,
        192,
        "+169.8%"
      ],
      [
        "T18",
        "归母净利润",
        194,
        199,
        "归母净利润"
      ],
      [
        "T19",
        "属性值",
        199,
        213,
        "82.4亿元（+70.8%）"
      ],
      [
        "T20",
        "时间范围",
        214,
        217,
        "上半年"
      ],
      [
        "T21",
        "公司",
        244,
        248,
        "华大基因"
      ],
      [
        "T22",
        "时间范围",
        250,
        258,
        "2021年上半年"
      ],
      [
        "T23",
        "营业收入",
        258,
        260,
        "收入"
      ],
      [
        "T24",
        "属性值",
        261,
        267,
        "36.5亿元"
      ],
      [
        "T25",
        "属性值",
        268,
        276,
        " - 11.2%"
      ],
      [
        "T26",
        "归母净利润",
        278,
        283,
        "归母净利润"
      ],
      [
        "T27",
        "属性值",
        283,
        297,
        "10.9亿元（-34.2%）"
      ],
      [
        "T28",
        "公司",
        315,
        319,
        "艾德生物"
      ],
      [
        "T29",
        "时间范围",
        320,
        328,
        "2021年上半年"
      ],
      [
        "T30",
        "营业收入",
        328,
        330,
        "收入"
      ],
      [
        "T31",
        "属性值",
        330,
        333,
        "4亿元"
      ],
      [
        "T32",
        "属性值",
        334,
        338,
        "+41%"
      ],
      [
        "T33",
        "归母净利润",
        341,
        346,
        "归母净利润"
      ],
      [
        "T34",
        "属性值",
        346,
        359,
        "1.1亿元（+37.8%）"
      ],
      [
        "T35",
        "行业",
        374,
        376,
        "诊断"
      ]
    ]
  },
  {
    "id": 2199,
    "text": " 血制品（6家）：板块2021Q1-3收入总额增速为20%，占全行业比例为1% ，其中第三季度收入增速为28.9%；2021Q1- 3归母净利润总额增速为25.7%，占全行业比例为2% ，其中第三季度增速为34.4%。 6家血液制品公司中上半年收入、利润均实现正增长。第三季度，板块毛利率下降4.3pp，销售费用率降低3.1pp，板块净利润在28%左右，维持稳定。  生物药（14家）：14家生物药公司2021Q1-3收入总额增速为23.5%，占全行业比例为4% ，归母净利润总额增速为 37.2%，占全行业比例为7% 。生物药去年同期受疫情影响较大，目前已迎来恢复。从盈利水平看，Q1-3生物药板块整体盈利能力稳中有升，行业毛利率（63%）基本保持平稳，销售费用率（27%）持续下降，管理费用率（8%）、研发费用率（8.4%）保持稳定，净利率（22%）同比有所提升。  中药（49家）：49家中药公司2021Q1-3收入总额增速为12%，占全行业比例为16% ，归母净利润总额增速为10.3%， 占全行业比例为15% ，Q3单季收入稳健增长，利润同比下降；收入端增速为7%，利润端下降15.5%。从盈利水平看，中药板块整体盈利能力整体稳中有升，21Q1-3，行业毛利率（43%），销售费用率（23%）保持稳定，净利率（9%）略有下滑。  原料药（35家）：原料药板块2021Q1-3同比增长14.2%，占全行业比例为5% ，归母净利润下降0.4%，占全行业比例为 8% ；单三季度收入、归母净利分别为250亿元、37亿元，分别同比+14.5%、-2.6%。35家原料药公司中有26家公司收入实现正增长，其中7家超过30%，9家公司收入同比下滑。 22家公司实现归母净利润正增长，其中3家增速超过50%。  零售药店（6家）：6家连锁药店公司2021Q1-3收入总额增速为14.5%，占全行业比例为4% ，其中第三季度收入增速为 16.3%；归母净利润总额增速为10%，占全行业比例为2% ，其中第三季度下降8.2% 。从趋势来看，第三季度收入环比上升、净利润环比继续下降。第三季度，药店板块的毛利率为36%，销售费用率（25.5%）逐渐回归到疫情前的水平。  医药分销（18家）：18家医药流通股21Q1-3收入总额增速为22.6%，占全行业比例为40% ，归母净利润总额增速为 20.3%，占全行业比例为8% 。从盈利水平来看，单三季度毛利率为10.4%，同比下降0.2pp。三季度费用率均环比保持稳定。销售费用率同比增加0.1pp，财务费用率增加0.1pp，管理费用率同比无变化。",
    "labels": [
      [
        "T0",
        "行业",
        1,
        5,
        " 血制品"
      ],
      [
        "T1",
        "时间范围",
        12,
        20,
        "2021Q1-3"
      ],
      [
        "T2",
        "收入增速",
        20,
        26,
        "收入总额增速"
      ],
      [
        "T3",
        "属性值",
        27,
        30,
        "20%"
      ],
      [
        "T4",
        "收入增速",
        48,
        52,
        "收入增速"
      ],
      [
        "T5",
        "属性值",
        53,
        58,
        "28.9%"
      ],
      [
        "T6",
        "归母净利润增速",
        68,
        77,
        "归母净利润总额增速"
      ],
      [
        "T7",
        "属性值",
        78,
        83,
        "25.7%"
      ],
      [
        "T8",
        "属性值",
        104,
        109,
        "34.4%"
      ],
      [
        "T9",
        "行业公司",
        111,
        119,
        "6家血液制品公司"
      ],
      [
        "T10",
        "毛利",
        142,
        145,
        "毛利率"
      ],
      [
        "T11",
        "营业收入",
        123,
        125,
        "收入"
      ],
      [
        "T12",
        "利润",
        126,
        128,
        "利润"
      ],
      [
        "T13",
        "属性值",
        129,
        134,
        "实现正增长"
      ],
      [
        "T14",
        "属性值",
        145,
        152,
        "下降4.3pp"
      ],
      [
        "T15",
        "归母净利润",
        168,
        171,
        "净利润"
      ],
      [
        "T16",
        "时间范围",
        44,
        48,
        "第三季度"
      ],
      [
        "T17",
        "时间范围",
        59,
        68,
        "2021Q1- 3"
      ],
      [
        "T18",
        "时间范围",
        97,
        101,
        "第三季度"
      ],
      [
        "T19",
        "时间范围",
        135,
        139,
        "第三季度"
      ],
      [
        "T20",
        "行业",
        186,
        189,
        "生物药"
      ],
      [
        "T21",
        "行业公司",
        195,
        203,
        "14家生物药公司"
      ],
      [
        "T22",
        "时间范围",
        203,
        211,
        "2021Q1-3"
      ],
      [
        "T23",
        "收入增速",
        211,
        217,
        "收入总额增速"
      ],
      [
        "T24",
        "属性值",
        218,
        223,
        "23.5%"
      ],
      [
        "T25",
        "归母净利润增速",
        235,
        244,
        "归母净利润总额增速"
      ],
      [
        "T26",
        "属性值",
        245,
        251,
        " 37.2%"
      ],
      [
        "T27",
        "行业",
        263,
        266,
        "生物药"
      ],
      [
        "T28",
        "时间范围",
        293,
        297,
        "Q1-3"
      ],
      [
        "T29",
        "行业",
        297,
        300,
        "生物药"
      ],
      [
        "T30",
        "毛利",
        315,
        318,
        "毛利率"
      ],
      [
        "T31",
        "行业",
        389,
        391,
        "中药"
      ],
      [
        "T32",
        "行业公司",
        397,
        404,
        "49家中药公司"
      ],
      [
        "T33",
        "时间范围",
        404,
        412,
        "2021Q1-3"
      ],
      [
        "T34",
        "收入增速",
        412,
        418,
        "收入总额增速"
      ],
      [
        "T35",
        "属性值",
        419,
        422,
        "12%"
      ],
      [
        "T36",
        "归母净利润增速",
        435,
        444,
        "归母净利润总额增速"
      ],
      [
        "T37",
        "属性值",
        445,
        450,
        "10.3%"
      ],
      [
        "T38",
        "时间范围",
        464,
        466,
        "Q3"
      ],
      [
        "T39",
        "营业收入",
        468,
        470,
        "收入"
      ],
      [
        "T40",
        "利润",
        475,
        477,
        "利润"
      ],
      [
        "T41",
        "属性值",
        470,
        474,
        "稳健增长"
      ],
      [
        "T42",
        "属性值",
        477,
        481,
        "同比下降"
      ],
      [
        "T43",
        "收入增速",
        482,
        487,
        "收入端增速"
      ],
      [
        "T44",
        "属性值",
        488,
        490,
        "7%"
      ],
      [
        "T45",
        "属性值",
        494,
        501,
        "下降15.5%"
      ],
      [
        "T46",
        "行业",
        509,
        511,
        "中药"
      ],
      [
        "T47",
        "时间范围",
        526,
        532,
        "21Q1-3"
      ],
      [
        "T48",
        "毛利",
        535,
        538,
        "毛利率"
      ],
      [
        "T49",
        "属性值",
        539,
        542,
        "43%"
      ],
      [
        "T50",
        "行业",
        574,
        577,
        "原料药"
      ],
      [
        "T51",
        "行业",
        583,
        586,
        "原料药"
      ],
      [
        "T52",
        "时间范围",
        588,
        596,
        "2021Q1-3"
      ],
      [
        "T53",
        "归母净利润",
        617,
        622,
        "归母净利润"
      ],
      [
        "T54",
        "属性值",
        622,
        628,
        "下降0.4%"
      ],
      [
        "T55",
        "时间范围",
        642,
        645,
        "三季度"
      ],
      [
        "T56",
        "营业收入",
        645,
        647,
        "收入"
      ],
      [
        "T57",
        "归母净利润",
        648,
        652,
        "归母净利"
      ],
      [
        "T58",
        "属性值",
        655,
        660,
        "250亿元"
      ],
      [
        "T59",
        "属性值",
        661,
        665,
        "37亿元"
      ],
      [
        "T60",
        "属性值",
        670,
        676,
        "+14.5%"
      ],
      [
        "T61",
        "行业公司",
        683,
        691,
        "35家原料药公司"
      ],
      [
        "T62",
        "营业收入",
        698,
        700,
        "收入"
      ],
      [
        "T63",
        "营业收入",
        720,
        722,
        "收入"
      ],
      [
        "T64",
        "归母净利润",
        735,
        740,
        "归母净利润"
      ],
      [
        "T65",
        "行业",
        759,
        763,
        "零售药店"
      ],
      [
        "T66",
        "行业公司",
        768,
        776,
        "6家连锁药店公司"
      ],
      [
        "T67",
        "时间范围",
        776,
        784,
        "2021Q1-3"
      ],
      [
        "T68",
        "收入增速",
        784,
        790,
        "收入总额增速"
      ],
      [
        "T69",
        "属性值",
        791,
        796,
        "14.5%"
      ],
      [
        "T70",
        "收入增速",
        814,
        818,
        "收入增速"
      ],
      [
        "T71",
        "属性值",
        819,
        825,
        " 16.3%"
      ],
      [
        "T72",
        "归母净利润增速",
        826,
        835,
        "归母净利润总额增速"
      ],
      [
        "T73",
        "属性值",
        836,
        839,
        "10%"
      ],
      [
        "T74",
        "属性值",
        857,
        863,
        "下降8.2%"
      ],
      [
        "T75",
        "营业收入",
        875,
        877,
        "收入"
      ],
      [
        "T76",
        "属性值",
        877,
        881,
        "环比上升"
      ],
      [
        "T77",
        "归母净利润",
        882,
        885,
        "净利润"
      ],
      [
        "T78",
        "属性值",
        885,
        891,
        "环比继续下降"
      ],
      [
        "T79",
        "时间范围",
        892,
        896,
        "第三季度"
      ],
      [
        "T80",
        "行业",
        897,
        899,
        "药店"
      ],
      [
        "T81",
        "毛利",
        902,
        905,
        "毛利率"
      ],
      [
        "T82",
        "属性值",
        906,
        909,
        "36%"
      ],
      [
        "T83",
        "行业",
        937,
        941,
        "医药分销"
      ],
      [
        "T84",
        "行业公司",
        947,
        955,
        "18家医药流通股"
      ],
      [
        "T85",
        "时间范围",
        955,
        961,
        "21Q1-3"
      ],
      [
        "T86",
        "收入增速",
        961,
        967,
        "收入总额增速"
      ],
      [
        "T87",
        "属性值",
        968,
        973,
        "22.6%"
      ],
      [
        "T88",
        "归母净利润增速",
        986,
        995,
        "归母净利润总额增速"
      ],
      [
        "T89",
        "属性值",
        997,
        1002,
        "20.3%"
      ],
      [
        "T90",
        "时间范围",
        1023,
        1026,
        "三季度"
      ],
      [
        "T91",
        "毛利",
        1026,
        1029,
        "毛利率"
      ],
      [
        "T92",
        "属性值",
        1030,
        1035,
        "10.4%"
      ],
      [
        "T93",
        "时间范围",
        1046,
        1049,
        "三季度"
      ],
      [
        "T94",
        "归母净利润",
        559,
        562,
        "净利率"
      ],
      [
        "T95",
        "属性值",
        563,
        570,
        "9%）略有下滑"
      ],
      [
        "T96",
        "属性值",
        172,
        177,
        "28%左右"
      ],
      [
        "T97",
        "时间范围",
        266,
        268,
        "去年"
      ],
      [
        "T98",
        "时间范围",
        278,
        280,
        "目前"
      ],
      [
        "T99",
        "研发费用率",
        355,
        360,
        "研发费用率"
      ],
      [
        "T100",
        "属性值",
        360,
        370,
        "（8.4%）保持稳定"
      ],
      [
        "T101",
        "归母净利润",
        371,
        374,
        "净利率"
      ],
      [
        "T102",
        "属性值",
        374,
        385,
        "（22%）同比有所提升"
      ],
      [
        "T103",
        "属性值",
        318,
        329,
        "（63%）基本保持平稳"
      ],
      [
        "T104",
        "行业公司",
        693,
        698,
        "26家公司"
      ],
      [
        "T105",
        "属性值",
        702,
        705,
        "正增长"
      ],
      [
        "T106",
        "行业公司",
        716,
        720,
        "9家公司"
      ],
      [
        "T107",
        "行业公司",
        728,
        733,
        "22家公司"
      ],
      [
        "T108",
        "属性值",
        740,
        743,
        "正增长"
      ],
      [
        "T109",
        "属性值",
        722,
        726,
        "同比下滑"
      ],
      [
        "T110",
        "时间范围",
        810,
        814,
        "第三季度"
      ],
      [
        "T111",
        "时间范围",
        853,
        857,
        "第三季度"
      ],
      [
        "T112",
        "时间范围",
        871,
        875,
        "第三季度"
      ],
      [
        "T113",
        "利润",
        491,
        494,
        "利润端"
      ],
      [
        "T114",
        "时间范围",
        120,
        123,
        "上半年"
      ]
    ]
  },
  {
    "id": 2207,
    "text": " 4家医疗服务公司2021上半年收入约为185亿元（+63%）、归母净利润总额约为27.33亿元（+83.6%）。  从盈利水平看，医疗服务板块整体盈利能力稳中有升，行业毛利率（ 43%）同比提升4个pp，销售费用率（9%）保持稳定，净利率（17% ）提高3个pp。  从收入贡献看，爱尔眼科、金域医学、润达医疗、通策医疗贡献比例为 40%、30%、23%、7%；  从净利润贡献看，爱尔眼科、金域医学、通策医疗、润达医疗贡献比例为41%、39%、13%、7%。",
    "labels": [
      [
        "T0",
        "行业公司",
        2,
        10,
        "4家医疗服务公司"
      ],
      [
        "T1",
        "时间范围",
        10,
        17,
        "2021上半年"
      ],
      [
        "T2",
        "营业收入",
        17,
        19,
        "收入"
      ],
      [
        "T3",
        "属性值",
        19,
        26,
        "约为185亿元"
      ],
      [
        "T4",
        "属性值",
        27,
        31,
        "+63%"
      ],
      [
        "T5",
        "归母净利润",
        33,
        38,
        "归母净利润"
      ],
      [
        "T6",
        "属性值",
        40,
        57,
        "约为27.33亿元（+83.6%）"
      ],
      [
        "T7",
        "行业",
        68,
        72,
        "医疗服务"
      ],
      [
        "T8",
        "毛利",
        87,
        90,
        "毛利率"
      ],
      [
        "T9",
        "属性值",
        90,
        104,
        "（ 43%）同比提升4个pp"
      ],
      [
        "T10",
        "归母净利润",
        119,
        122,
        "净利率"
      ],
      [
        "T11",
        "属性值",
        122,
        134,
        "（17% ）提高3个pp"
      ],
      [
        "T12",
        "营业收入",
        139,
        141,
        "收入"
      ],
      [
        "T13",
        "公司",
        145,
        149,
        "爱尔眼科"
      ],
      [
        "T14",
        "公司",
        150,
        154,
        "金域医学"
      ],
      [
        "T15",
        "公司",
        155,
        159,
        "润达医疗"
      ],
      [
        "T16",
        "公司",
        160,
        164,
        "通策医疗"
      ],
      [
        "T17",
        "属性值",
        170,
        173,
        "40%"
      ],
      [
        "T18",
        "属性值",
        174,
        177,
        "30%"
      ],
      [
        "T19",
        "属性值",
        178,
        181,
        "23%"
      ],
      [
        "T20",
        "属性值",
        182,
        184,
        "7%"
      ],
      [
        "T21",
        "归母净利润",
        189,
        192,
        "净利润"
      ],
      [
        "T22",
        "公司",
        196,
        200,
        "爱尔眼科"
      ],
      [
        "T23",
        "公司",
        201,
        205,
        "金域医学"
      ],
      [
        "T24",
        "公司",
        206,
        210,
        "通策医疗"
      ],
      [
        "T25",
        "公司",
        211,
        215,
        "润达医疗"
      ]
    ]
  },
  {
    "id": 2208,
    "text": " 上半年板块收入、业绩增长稳健：6家血液制品公司2021上半年收入总额增速为13.5%，归母净利润总额增速为19.8%；其中单二季度收入增速为22.2%，归母净利润增速为19.2%，二季度板块收入增速提升明显。21Q2板块毛利率略降低1.5pp，主要系部分收入增量贡献大的公司调整产品结构所致，销售费用率降低1.9pp，板块净利润在29%左右，维持稳定。  目前供需处于紧平衡状态，十四五期间浆站拓展有望迈上新台阶：行业在2017~2019年经历了渠道去库存，2020年新冠疫情对供给端的带来一定压制。目前行业库存水平健康，产品供需正处于紧平衡状态，部分血制品上半年售价有小幅度提升。十四五规划背景下新增浆站批准建设有望加速。其中云南省已于2020年12月发布了《云南省单采血浆站设置规划（2020-2023） （征求意见稿）》，计划在未来三年内新增建设24个单采血浆站，对应新增占比约8%（2020年底全国共有浆站302家）。预计后续其他省份将有类似政策规划跟进，行业采浆能力有望迈上新台阶。  中国血制品企业经历多次整合并购后，第一梯队四大龙头的格局基本形成。国内血制品行业CR4=56%，相比全球市场 CR4=72%，仍有一定提升空间，未来龙头凭借浆站资源、资金、技术、效率和兼并收购有望强者恒强。血制品具备刚需属性 ，新冠疫情疫情提高了医生和患者对血制品作用的认知，尤其静丙的价值被极大挖掘（适应症拓展），长线看血制品渗透率提升有望加速。  投资建议：1）推荐派林生物（000403）：管理精细化逻辑逐渐兑现，并购派斯菲科+供浆协议落地，采浆规模快速大幅提升 ，成为千吨血制品新秀，公司现有浆站5年潜在采浆量为1500吨左右。新品上市+产品结构改善提升吨浆净利润，凝血八因子 2021年已顺利实现批签发，推进高纯静丙等在研产品以储长期提升动力。2）推荐天坛生物（600161）：浆站数量国内首位 ，规模优势显著，公司目前有56个运营浆站，2020年新增4个浆站，2021年上半年累计公告新增12家浆站，新增浆站运营成熟将持续带来成长动能。",
    "labels": [
      [
        "T0",
        "时间范围",
        2,
        5,
        "上半年"
      ],
      [
        "T1",
        "营业收入",
        7,
        9,
        "收入"
      ],
      [
        "T2",
        "业绩",
        10,
        12,
        "业绩"
      ],
      [
        "T3",
        "行业公司",
        17,
        25,
        "6家血液制品公司"
      ],
      [
        "T4",
        "时间范围",
        25,
        32,
        "2021上半年"
      ],
      [
        "T5",
        "收入增速",
        32,
        38,
        "收入总额增速"
      ],
      [
        "T6",
        "属性值",
        39,
        44,
        "13.5%"
      ],
      [
        "T7",
        "归母净利润增速",
        45,
        54,
        "归母净利润总额增速"
      ],
      [
        "T8",
        "属性值",
        55,
        60,
        "19.8%"
      ],
      [
        "T9",
        "时间范围",
        64,
        67,
        "二季度"
      ],
      [
        "T10",
        "收入增速",
        67,
        71,
        "收入增速"
      ],
      [
        "T11",
        "属性值",
        72,
        77,
        "22.2%"
      ],
      [
        "T12",
        "归母净利润增速",
        78,
        85,
        "归母净利润增速"
      ],
      [
        "T13",
        "属性值",
        86,
        91,
        "19.2%"
      ],
      [
        "T14",
        "时间范围",
        92,
        95,
        "二季度"
      ],
      [
        "T15",
        "收入增速",
        97,
        101,
        "收入增速"
      ],
      [
        "T16",
        "时间范围",
        106,
        110,
        "21Q2"
      ],
      [
        "T17",
        "毛利",
        112,
        115,
        "毛利率"
      ],
      [
        "T18",
        "归母净利润",
        163,
        166,
        "净利润"
      ],
      [
        "T19",
        "时间范围",
        232,
        237,
        "2020年"
      ],
      [
        "T20",
        "地点范围",
        452,
        454,
        "中国"
      ],
      [
        "T21",
        "行业公司",
        454,
        459,
        "血制品企业"
      ],
      [
        "T22",
        "属性值",
        469,
        477,
        "第一梯队四大龙头"
      ],
      [
        "T23",
        "竞争格局",
        478,
        480,
        "格局"
      ],
      [
        "T24",
        "地点范围",
        485,
        487,
        "国内"
      ],
      [
        "T25",
        "行业",
        487,
        490,
        "血制品"
      ],
      [
        "T26",
        "地点范围",
        502,
        504,
        "全球"
      ],
      [
        "T27",
        "行业",
        613,
        616,
        "血制品"
      ],
      [
        "T28",
        "公司",
        638,
        642,
        "派林生物"
      ],
      [
        "T29",
        "公司",
        784,
        788,
        "天坛生物"
      ],
      [
        "T30",
        "时间范围",
        746,
        751,
        "2021年"
      ],
      [
        "T31",
        "地点范围",
        801,
        803,
        "国内"
      ],
      [
        "T32",
        "时间范围",
        827,
        832,
        "2020年"
      ],
      [
        "T33",
        "时间范围",
        839,
        847,
        "2021年上半年"
      ],
      [
        "T34",
        "时间范围",
        322,
        330,
        "2020年12月"
      ],
      [
        "T35",
        "地点范围",
        317,
        320,
        "云南省"
      ],
      [
        "T36",
        "地点范围",
        334,
        337,
        "云南省"
      ],
      [
        "T37",
        "时间范围",
        347,
        356,
        "2020-2023"
      ],
      [
        "T38",
        "时间范围",
        370,
        375,
        "未来三年内"
      ],
      [
        "T39",
        "时间范围",
        213,
        223,
        "2017~2019年"
      ]
    ]
  },
  {
    "id": 2213,
    "text": "办公厅印发《治理医用高值耗材改革通知》以来，各省多批次带量采购政策加速落地， 短期虽带来终端价格压力，但中长期对于国产头部企业提升市场份额，加速国产替代提供良机；此外，《DRG/DIP 支付方式改革三年行动计划》正式发布，未来保质控费仍是医药政策的主旋律。目前，国产器械产品相对国际品牌的价格优势已逐渐显露，随着国内医械企业技术提升和成本控制，国产产品性价比优势将进一步凸显。 医疗设备是医疗器械市场规模最大、国产化平均水平最低的细分赛道。 2019年国内医疗设备市场规模达到 3560亿元，占医疗器械市场整体份额的 57%。然而由于技术壁垒较高、研发周期漫长、临床对产品质量和稳定性要求较高，MRI、CT、超声等高端医疗设备国产产品占比普遍低于 30%，内窥镜更是低于 10%；此外，由于芯片、传感器、 探测器等关键核心部件研发生产尚未成熟，国产医疗设备正处于技术补足、快速发展的阶段。 中高端设备潜在需求较大，核心部件国产化需求迫切。近年来，国产企业逐渐在超声、内窥镜等医疗设备市场展露头角，2021年上半年招投标数据显示，迈瑞超声诊断仪中标和出货数量双双第一，开立在软式内窥镜市场取得 4.7%的市场份额。随着医疗新基建持续推进，国内市场对于中高端诊疗设备需求较大，国产中高端设备有望受益基础采购快速放量；此外，新冠疫情及贸易摩擦使供应链安全的重要性进一步凸显，医疗设备核心部件优势企业有望取得充分发展。",
    "labels": [
      [
        "T0",
        "龙头企业",
        59,
        63,
        "头部企业"
      ],
      [
        "T1",
        "市场份额",
        65,
        69,
        "市场份额"
      ],
      [
        "T2",
        "地点范围",
        156,
        158,
        "国内"
      ],
      [
        "T3",
        "行业公司",
        158,
        162,
        "医械企业"
      ],
      [
        "T4",
        "行业",
        189,
        193,
        "医疗设备"
      ],
      [
        "T5",
        "行业",
        194,
        198,
        "医疗器械"
      ],
      [
        "T6",
        "市场规模",
        198,
        202,
        "市场规模"
      ],
      [
        "T7",
        "时间范围",
        221,
        226,
        "2019年"
      ],
      [
        "T8",
        "地点范围",
        226,
        228,
        "国内"
      ],
      [
        "T9",
        "行业",
        228,
        232,
        "医疗设备"
      ],
      [
        "T10",
        "市场规模",
        232,
        236,
        "市场规模"
      ],
      [
        "T11",
        "属性值",
        239,
        245,
        "3560亿元"
      ],
      [
        "T12",
        "时间范围",
        419,
        422,
        "近年来"
      ],
      [
        "T13",
        "时间范围",
        448,
        456,
        "2021年上半年"
      ],
      [
        "T14",
        "公司",
        464,
        466,
        "迈瑞"
      ],
      [
        "T15",
        "市场份额",
        501,
        505,
        "市场份额"
      ],
      [
        "T16",
        "属性值",
        495,
        500,
        " 4.7%"
      ],
      [
        "T17",
        "公司",
        483,
        485,
        "开立"
      ],
      [
        "T18",
        "行业",
        486,
        491,
        "软式内窥镜"
      ],
      [
        "T19",
        "地点范围",
        518,
        520,
        "国内"
      ],
      [
        "T20",
        "行业",
        584,
        588,
        "医疗设备"
      ],
      [
        "T21",
        "行业",
        247,
        251,
        "医疗器械"
      ],
      [
        "T22",
        "属性值",
        259,
        262,
        "57%"
      ],
      [
        "T23",
        "市场份额",
        255,
        257,
        "份额"
      ],
      [
        "T24",
        "行业",
        395,
        400,
        "中高端设备"
      ],
      [
        "T25",
        "属性值",
        404,
        406,
        "较大"
      ],
      [
        "T26",
        "行业",
        430,
        432,
        "超声"
      ],
      [
        "T27",
        "行业",
        433,
        436,
        "内窥镜"
      ],
      [
        "T28",
        "行业",
        437,
        441,
        "医疗设备"
      ],
      [
        "T29",
        "时间范围",
        39,
        41,
        "短期"
      ],
      [
        "T30",
        "时间范围",
        52,
        55,
        "中长期"
      ],
      [
        "T31",
        "时间范围",
        111,
        113,
        "未来"
      ],
      [
        "T32",
        "时间范围",
        128,
        130,
        "目前"
      ]
    ]
  },
  {
    "id": 2215,
    "text": " 10家CXO公司2021年上半年收入总额增速为45.6%、归母净利润总额增速为49.7%，整体维持高速增长。Q2收入同比增长37.7%，归母净利润同比增长4.7%，二季度收入端保持高速增长，利润端增速环比下降主要与龙头企业投资收益下降有关。  从盈利水平看，CXO板块整体盈利能力保持稳定，未受疫情影响，二季度行业毛利率（39%）保持平稳，销售费用率（3%）、财务费用率（1%）均保持平稳，扣非后净利率（21%）小幅提升主要与管理费用率（10%，-2.2pp）降低有关。",
    "labels": [
      [
        "T0",
        "行业公司",
        2,
        10,
        "10家CXO公司"
      ],
      [
        "T1",
        "时间范围",
        10,
        18,
        "2021年上半年"
      ],
      [
        "T2",
        "收入增速",
        18,
        24,
        "收入总额增速"
      ],
      [
        "T3",
        "属性值",
        25,
        30,
        "45.6%"
      ],
      [
        "T4",
        "归母净利润增速",
        31,
        40,
        "归母净利润总额增速"
      ],
      [
        "T5",
        "属性值",
        41,
        46,
        "49.7%"
      ],
      [
        "T6",
        "时间范围",
        56,
        58,
        "Q2"
      ],
      [
        "T7",
        "营业收入",
        58,
        60,
        "收入"
      ],
      [
        "T8",
        "属性值",
        64,
        69,
        "37.7%"
      ],
      [
        "T9",
        "归母净利润",
        70,
        75,
        "归母净利润"
      ],
      [
        "T10",
        "属性值",
        75,
        83,
        "同比增长4.7%"
      ],
      [
        "T11",
        "时间范围",
        84,
        87,
        "二季度"
      ],
      [
        "T12",
        "营业收入",
        87,
        90,
        "收入端"
      ],
      [
        "T13",
        "属性值",
        92,
        96,
        "高速增长"
      ],
      [
        "T14",
        "利润",
        97,
        100,
        "利润端"
      ],
      [
        "T15",
        "属性值",
        100,
        106,
        "增速环比下降"
      ],
      [
        "T16",
        "行业",
        132,
        135,
        "CXO"
      ],
      [
        "T17",
        "时间范围",
        155,
        158,
        "二季度"
      ],
      [
        "T18",
        "毛利",
        160,
        163,
        "毛利率"
      ],
      [
        "T19",
        "属性值",
        164,
        167,
        "39%"
      ],
      [
        "T20",
        "扣非净利润",
        198,
        204,
        "扣非后净利率"
      ],
      [
        "T21",
        "属性值",
        205,
        208,
        "21%"
      ]
    ]
  },
  {
    "id": 2216,
    "text": " 从ROE水平来看，近几年生物药板块ROE水平持续下降，与部分企业净利润率下降有关。2021Q1-3，生物药板块ROE为6.93%，同比下降0.3pp，总体来看，生物药板块ROE保持在比较稳定的水平。  从现金流情况来看，近几年我国生物药企业经营活动产生的现金流量净额/经营活动净收益持续提升，但2021Q1-3为79.82%，同比下降 2.81pp，预计四季度现金流有望继续保持较好水平。",
    "labels": [
      [
        "T0",
        "ROE净资产回报率",
        3,
        6,
        "ROE"
      ],
      [
        "T1",
        "时间范围",
        11,
        14,
        "近几年"
      ],
      [
        "T2",
        "行业",
        14,
        17,
        "生物药"
      ],
      [
        "T3",
        "ROE净资产回报率",
        19,
        22,
        "ROE"
      ],
      [
        "T4",
        "属性值",
        24,
        28,
        "持续下降"
      ],
      [
        "T5",
        "时间范围",
        43,
        51,
        "2021Q1-3"
      ],
      [
        "T6",
        "行业",
        52,
        55,
        "生物药"
      ],
      [
        "T7",
        "ROE净资产回报率",
        57,
        60,
        "ROE"
      ],
      [
        "T8",
        "行业",
        82,
        85,
        "生物药"
      ],
      [
        "T9",
        "ROIC资本回报率",
        87,
        90,
        "ROE"
      ],
      [
        "T10",
        "现金流",
        105,
        108,
        "现金流"
      ],
      [
        "T11",
        "时间范围",
        113,
        116,
        "近几年"
      ],
      [
        "T12",
        "地点范围",
        116,
        118,
        "我国"
      ],
      [
        "T13",
        "行业公司",
        118,
        123,
        "生物药企业"
      ],
      [
        "T14",
        "时间范围",
        150,
        158,
        "2021Q1-3"
      ],
      [
        "T15",
        "时间范围",
        180,
        183,
        "四季度"
      ],
      [
        "T16",
        "现金流",
        183,
        186,
        "现金流"
      ],
      [
        "T17",
        "属性值",
        61,
        76,
        "6.93%，同比下降0.3pp"
      ],
      [
        "T18",
        "属性值",
        93,
        97,
        "比较稳定"
      ],
      [
        "T19",
        "属性值",
        192,
        196,
        "较好水平"
      ]
    ]
  },
  {
    "id": 2225,
    "text": " 原料药板块2021Q1-3同比增长14.2%，归母净利润下降0.4%；单三季度收入、归母净利分别为250亿元、37亿元，分别同比+14.5%、 -2.6%。",
    "labels": [
      [
        "T0",
        "行业",
        2,
        5,
        "原料药"
      ],
      [
        "T1",
        "时间范围",
        7,
        15,
        "2021Q1-3"
      ],
      [
        "T2",
        "归母净利润",
        25,
        30,
        "归母净利润"
      ],
      [
        "T3",
        "属性值",
        30,
        36,
        "下降0.4%"
      ],
      [
        "T4",
        "时间范围",
        38,
        41,
        "三季度"
      ],
      [
        "T5",
        "营业收入",
        41,
        43,
        "收入"
      ],
      [
        "T6",
        "归母净利润",
        44,
        48,
        "归母净利"
      ],
      [
        "T7",
        "属性值",
        51,
        56,
        "250亿元"
      ],
      [
        "T8",
        "属性值",
        57,
        61,
        "37亿元"
      ],
      [
        "T9",
        "属性值",
        66,
        72,
        "+14.5%"
      ],
      [
        "T10",
        "属性值",
        74,
        79,
        "-2.6%"
      ]
    ]
  },
  {
    "id": 2230,
    "text": "根据 Frost&Sullivan数据，2021年中国 CDMO市场预期收入为 432亿人民币，2016-2021年年均复合增长率为 32.7%。其中，临床前项目 2021年预期收入为 26亿人民币，临床项目 2021年预期收入为 195亿人民币，商业化项目 2021年预期收入为 211亿人民币。预期 2021年-2025年中国 CDMO市场收入年均复合增长率为 30.0%，中国 CDMO市场收入将于 2025年达到 1235亿人民币。其中，临床前项目 2025 年预期收入为 63亿人民币，临床项目 2025年预期收入为 562亿人民币，商业化项目 2025年预期收入为 610亿人民币。",
    "labels": [
      [
        "T0",
        "时间范围",
        20,
        25,
        "2021年"
      ],
      [
        "T1",
        "地点范围",
        25,
        27,
        "中国"
      ],
      [
        "T2",
        "行业",
        28,
        32,
        "CDMO"
      ],
      [
        "T3",
        "营业收入",
        36,
        38,
        "收入"
      ],
      [
        "T4",
        "属性值",
        40,
        47,
        "432亿人民币"
      ],
      [
        "T5",
        "时间范围",
        48,
        58,
        "2016-2021年"
      ],
      [
        "T6",
        "CAGR",
        58,
        65,
        "年均复合增长率"
      ],
      [
        "T7",
        "属性值",
        67,
        72,
        "32.7%"
      ],
      [
        "T8",
        "行业",
        76,
        79,
        "临床前"
      ],
      [
        "T9",
        "时间范围",
        82,
        87,
        "2021年"
      ],
      [
        "T10",
        "营业收入",
        89,
        91,
        "收入"
      ],
      [
        "T11",
        "属性值",
        93,
        99,
        "26亿人民币"
      ],
      [
        "T12",
        "行业",
        100,
        102,
        "临床"
      ],
      [
        "T13",
        "时间范围",
        105,
        110,
        "2021年"
      ],
      [
        "T14",
        "营业收入",
        112,
        114,
        "收入"
      ],
      [
        "T15",
        "属性值",
        116,
        123,
        "195亿人民币"
      ],
      [
        "T16",
        "行业",
        124,
        127,
        "商业化"
      ],
      [
        "T17",
        "时间范围",
        130,
        135,
        "2021年"
      ],
      [
        "T18",
        "营业收入",
        137,
        139,
        "收入"
      ],
      [
        "T19",
        "属性值",
        141,
        148,
        "211亿人民币"
      ],
      [
        "T20",
        "时间范围",
        152,
        163,
        "2021年-2025年"
      ],
      [
        "T21",
        "地点范围",
        163,
        165,
        "中国"
      ],
      [
        "T22",
        "行业",
        166,
        170,
        "CDMO"
      ],
      [
        "T23",
        "营业收入",
        172,
        174,
        "收入"
      ],
      [
        "T24",
        "CAGR",
        174,
        181,
        "年均复合增长率"
      ],
      [
        "T25",
        "属性值",
        183,
        188,
        "30.0%"
      ],
      [
        "T26",
        "地点范围",
        189,
        191,
        "中国"
      ],
      [
        "T27",
        "行业",
        192,
        196,
        "CDMO"
      ],
      [
        "T28",
        "营业收入",
        198,
        200,
        "收入"
      ],
      [
        "T29",
        "时间范围",
        203,
        208,
        "2025年"
      ],
      [
        "T30",
        "属性值",
        211,
        219,
        "1235亿人民币"
      ],
      [
        "T31",
        "行业",
        223,
        226,
        "临床前"
      ],
      [
        "T32",
        "时间范围",
        229,
        235,
        "2025 年"
      ],
      [
        "T33",
        "营业收入",
        237,
        239,
        "收入"
      ],
      [
        "T34",
        "属性值",
        241,
        247,
        "63亿人民币"
      ],
      [
        "T35",
        "行业",
        248,
        250,
        "临床"
      ],
      [
        "T36",
        "时间范围",
        253,
        258,
        "2025年"
      ],
      [
        "T37",
        "营业收入",
        260,
        262,
        "收入"
      ],
      [
        "T38",
        "属性值",
        264,
        271,
        "562亿人民币"
      ],
      [
        "T39",
        "行业",
        272,
        275,
        "商业化"
      ],
      [
        "T40",
        "时间范围",
        278,
        283,
        "2025年"
      ],
      [
        "T41",
        "营业收入",
        285,
        287,
        "收入"
      ],
      [
        "T42",
        "属性值",
        289,
        296,
        "610亿人民币"
      ]
    ]
  },
  {
    "id": 2231,
    "text": "4）行业事件带来国内医药外包板块估值调整，业绩驱动有望让股价反弹。受乌克兰局势、美国加息预期以及药明生物被列入“UVL清单”事件影响，CXO板块近期整体回调，目前多家优质标的公司的估值处于历史低位。",
    "labels": [
      [
        "T0",
        "地点范围",
        8,
        10,
        "国内"
      ],
      [
        "T1",
        "行业",
        10,
        14,
        "医药外包"
      ],
      [
        "T2",
        "业绩",
        21,
        23,
        "业绩"
      ],
      [
        "T3",
        "公司",
        48,
        52,
        "药明生物"
      ],
      [
        "T4",
        "行业",
        67,
        70,
        "CXO"
      ],
      [
        "T5",
        "地点范围",
        34,
        37,
        "乌克兰"
      ],
      [
        "T6",
        "地点范围",
        40,
        42,
        "美国"
      ],
      [
        "T7",
        "时间范围",
        79,
        81,
        "目前"
      ]
    ]
  },
  {
    "id": 2239,
    "text": "根据 Frost&Sullivan数据，2021年全球 CDMO市场收入预期为 637亿美元，其中商业化阶段服务收入与临床阶段收入占比较高，收入预期分别为 279亿美元和 309亿美元。临床前阶段 CDMO服务在整体市场中占比较小，收入为 49亿美元。全球 CDMO市场收入 2016年-2021年年均复合增长率为 12.5%，市场收入预期将于 2025年达到 1066亿美元，2021年-2025年年均复合增长率为 13.7%。 全球药物研发投入增加，在研药物数量持续增加，制药公司在药物研发阶段及未来商业化阶段都需要更多的外包生产服务。全球药物开发的一个重要趋势是较小的公司正在开发更大比例的新分子， 这些公司越来越多地自行将其分子从临床试验到商业化，而不是在开发初期将其出售给大公司。由于资金的可用性增加以及对专业药物的关注度增加使患者群体更加明确，对大型制药销售和分销网络的需求有所降低。根据凯莱英招股书数据，小型制药公司及生物科技初创公司的研发支出从 2016 年的 92亿美元大幅增长至 2020年的 151亿美元，复合年增长率为 13.3%，预计到 2025年将进一步增长至 249亿美元，复合年增长率预计为 10.5%。小型生物技术或小型制药公司通常专注于药物发现阶段，自身不具备相应生产能力或生产能力较弱，因此需要与 CDMO公司进行合作。 全球药品管线分散化，中小型制药公司及生物科技初创公司在新药审批中占比持续增长，大型制药公司及中小型制药公司都更愿意将其部分研发及生产业务外包给 CDMO公司，从而缩短上市时间、 节省成本、确保合规性，重新分配内部资源。药企在药物开发过程的早期阶段与 CDMO合作的趋势越来越明显，而且由于高技术转移成本及合规风险，在药物研发过程后期更换 CDMO公司的可能性不高。 许多国家政府的医疗费用控制举措和专利到期后的仿制药竞争给药品价格带来了强大的下行压力。 根据 Frost&Sullivan的资料，中国医疗报销系统的近期变动带来了巨大的价格压力，仅于 2020年 12月就列入国家报销药品目录进行价格谈判期间列入国家报销药品目录的药品平均降价 50.7%。技术先进的 CDMO公司可以为制药企业提供有效的解决方案，以提高效率及降低成本，从而在市场上获得有利的竞争条件。 近期，世界各地的监管机构强烈建议制药公司确保稳定的药物生产来源，制药公司正在使用 CDMO 作为单种药物的多个制造商。",
    "labels": [
      [
        "T0",
        "时间范围",
        20,
        25,
        "2021年"
      ],
      [
        "T1",
        "地点范围",
        25,
        27,
        "全球"
      ],
      [
        "T2",
        "行业",
        28,
        32,
        "CDMO"
      ],
      [
        "T3",
        "营业收入",
        34,
        36,
        "收入"
      ],
      [
        "T4",
        "属性值",
        40,
        46,
        "637亿美元"
      ],
      [
        "T5",
        "行业",
        49,
        56,
        "商业化阶段服务"
      ],
      [
        "T6",
        "行业",
        59,
        63,
        "临床阶段"
      ],
      [
        "T7",
        "营业收入",
        70,
        72,
        "收入"
      ],
      [
        "T8",
        "属性值",
        78,
        84,
        "279亿美元"
      ],
      [
        "T9",
        "属性值",
        86,
        92,
        "309亿美元"
      ],
      [
        "T10",
        "行业",
        93,
        105,
        "临床前阶段 CDMO服务"
      ],
      [
        "T11",
        "营业收入",
        116,
        118,
        "收入"
      ],
      [
        "T12",
        "属性值",
        120,
        125,
        "49亿美元"
      ],
      [
        "T13",
        "地点范围",
        126,
        128,
        "全球"
      ],
      [
        "T14",
        "行业",
        129,
        133,
        "CDMO"
      ],
      [
        "T15",
        "营业收入",
        135,
        137,
        "收入"
      ],
      [
        "T16",
        "时间范围",
        138,
        149,
        "2016年-2021年"
      ],
      [
        "T17",
        "CAGR",
        149,
        156,
        "年均复合增长率"
      ],
      [
        "T18",
        "属性值",
        158,
        163,
        "12.5%"
      ],
      [
        "T19",
        "营业收入",
        166,
        168,
        "收入"
      ],
      [
        "T20",
        "时间范围",
        173,
        178,
        "2025年"
      ],
      [
        "T21",
        "属性值",
        181,
        188,
        "1066亿美元"
      ],
      [
        "T22",
        "时间范围",
        189,
        200,
        "2021年-2025年"
      ],
      [
        "T23",
        "CAGR",
        200,
        207,
        "年均复合增长率"
      ],
      [
        "T24",
        "属性值",
        209,
        214,
        "13.7%"
      ],
      [
        "T25",
        "地点范围",
        216,
        218,
        "全球"
      ],
      [
        "T26",
        "行业",
        218,
        220,
        "药物"
      ],
      [
        "T27",
        "研发费用",
        220,
        224,
        "研发投入"
      ],
      [
        "T28",
        "属性值",
        224,
        226,
        "增加"
      ],
      [
        "T29",
        "行业公司",
        238,
        242,
        "制药公司"
      ],
      [
        "T30",
        "地点范围",
        270,
        272,
        "全球"
      ],
      [
        "T31",
        "行业",
        272,
        276,
        "药物开发"
      ],
      [
        "T32",
        "属性值",
        284,
        301,
        "较小的公司正在开发更大比例的新分子"
      ],
      [
        "T33",
        "公司",
        400,
        403,
        "凯莱英"
      ],
      [
        "T34",
        "行业公司",
        409,
        415,
        "小型制药公司"
      ],
      [
        "T35",
        "行业公司",
        416,
        424,
        "生物科技初创公司"
      ],
      [
        "T36",
        "研发费用",
        425,
        429,
        "研发支出"
      ],
      [
        "T37",
        "时间范围",
        431,
        437,
        "2016 年"
      ],
      [
        "T38",
        "属性值",
        439,
        444,
        "92亿美元"
      ],
      [
        "T39",
        "时间范围",
        450,
        455,
        "2020年"
      ],
      [
        "T40",
        "属性值",
        457,
        463,
        "151亿美元"
      ],
      [
        "T41",
        "CAGR",
        464,
        470,
        "复合年增长率"
      ],
      [
        "T42",
        "属性值",
        472,
        477,
        "13.3%"
      ],
      [
        "T43",
        "时间范围",
        482,
        487,
        "2025年"
      ],
      [
        "T44",
        "属性值",
        495,
        501,
        "249亿美元"
      ],
      [
        "T45",
        "CAGR",
        502,
        508,
        "复合年增长率"
      ],
      [
        "T46",
        "属性值",
        512,
        517,
        "10.5%"
      ],
      [
        "T47",
        "行业公司",
        689,
        691,
        "药企"
      ],
      [
        "T48",
        "行业公司",
        652,
        658,
        "CDMO公司"
      ],
      [
        "T49",
        "行业公司",
        619,
        625,
        "大型制药公司"
      ],
      [
        "T50",
        "行业公司",
        626,
        633,
        "中小型制药公司"
      ],
      [
        "T51",
        "行业公司",
        590,
        597,
        "中小型制药公司"
      ],
      [
        "T52",
        "行业公司",
        598,
        606,
        "生物科技初创公司"
      ],
      [
        "T53",
        "地点范围",
        580,
        582,
        "全球"
      ],
      [
        "T54",
        "行业公司",
        568,
        574,
        "CDMO公司"
      ],
      [
        "T55",
        "行业公司",
        749,
        755,
        "CDMO公司"
      ],
      [
        "T56",
        "行业",
        785,
        788,
        "仿制药"
      ],
      [
        "T57",
        "地点范围",
        828,
        830,
        "中国"
      ],
      [
        "T58",
        "行业",
        830,
        836,
        "医疗报销系统"
      ],
      [
        "T59",
        "时间范围",
        855,
        864,
        "2020年 12月"
      ],
      [
        "T60",
        "行业公司",
        913,
        919,
        "CDMO公司"
      ],
      [
        "T61",
        "行业公司",
        922,
        926,
        "制药企业"
      ],
      [
        "T62",
        "时间范围",
        964,
        966,
        "近期"
      ],
      [
        "T63",
        "行业公司",
        980,
        984,
        "制药公司"
      ],
      [
        "T64",
        "行业公司",
        996,
        1000,
        "制药公司"
      ]
    ]
  },
  {
    "id": 2243,
    "text": " 通策医疗：2021Q1-Q3成功开业9个蒲公英分院，2021Q4预计开业4家，2022全年预计开业12家，同时正式筹备紫金港540张牙椅超大规模三级口腔医院，未来建成后有望将标准化的大众口腔治疗推向更广泛的居民、高水平的院区建设成功后有望实现医质进一步提升。  爱尔眼科：公司公告拟募资不超过36.50亿元（发行不超过2.06亿股）用于对七大重点省会及直辖市龙头医院的新建及迁址扩建，未来公司有望在具有消费力和辐射力重点区域持续扩大实力。  锦欣生殖：收购全国最大单体妇儿医院，加快产业价值链延申，单个患者价值提升2-3倍，达到10-15万元。公司2021年并购5个重大标的在 2021年将大幅增厚利润。  海吉亚：2021年下半年苏州永鼎和贺州广济实现并表，山东聊城预计2021年底开业，2022年将持续增厚业绩。预计到2023年通过内生“自建+ 扩建”有望达到1万张床位，至少布局18家医院。",
    "labels": [
      [
        "T0",
        "公司",
        2,
        6,
        "通策医疗"
      ],
      [
        "T1",
        "时间范围",
        7,
        16,
        "2021Q1-Q3"
      ],
      [
        "T2",
        "时间范围",
        28,
        34,
        "2021Q4"
      ],
      [
        "T3",
        "时间范围",
        41,
        47,
        "2022全年"
      ],
      [
        "T4",
        "公司",
        134,
        138,
        "爱尔眼科"
      ],
      [
        "T5",
        "公司",
        225,
        229,
        "锦欣生殖"
      ],
      [
        "T6",
        "时间范围",
        278,
        283,
        "2021年"
      ],
      [
        "T7",
        "时间范围",
        293,
        298,
        "2021年"
      ],
      [
        "T8",
        "属性值",
        299,
        303,
        "大幅增厚"
      ],
      [
        "T9",
        "利润",
        303,
        305,
        "利润"
      ],
      [
        "T10",
        "公司",
        309,
        312,
        "海吉亚"
      ],
      [
        "T11",
        "时间范围",
        313,
        321,
        "2021年下半年"
      ],
      [
        "T12",
        "公司",
        321,
        325,
        "苏州永鼎"
      ],
      [
        "T13",
        "公司",
        326,
        330,
        "贺州广济"
      ],
      [
        "T14",
        "地点范围",
        335,
        339,
        "山东聊城"
      ],
      [
        "T15",
        "时间范围",
        341,
        347,
        "2021年底"
      ],
      [
        "T16",
        "时间范围",
        350,
        355,
        "2022年"
      ],
      [
        "T17",
        "业绩",
        360,
        362,
        "业绩"
      ],
      [
        "T18",
        "时间范围",
        366,
        371,
        "2023年"
      ],
      [
        "T19",
        "时间范围",
        195,
        197,
        "未来"
      ],
      [
        "T20",
        "时间范围",
        81,
        83,
        "未来"
      ],
      [
        "T21",
        "属性值",
        356,
        360,
        "持续增厚"
      ]
    ]
  },
  {
    "id": 2249,
    "text": " 内镜市场概况：2019年全球内窥镜器械约400亿美元，其中软镜110元，占比28%，硬镜90亿，占比22%，其余为设备和附件。国内预计2019年内窥镜240亿，其中硬镜117亿， 占比49%，软镜60亿，占比25%。  硬镜和软镜格局：由于成像稳定性和清晰度离国际巨头差距过大，硬镜和软镜基本由进口厂商主导。硬镜领域关注国产龙头迈瑞医疗、海泰新光、沈阳沈大、浙江天松。软镜受益于胃镜、肠镜检查渗透率的提升，历年维持15%以上增长， 奥林巴斯、富士胶片、宾得占据中国90%以上，国产龙头开立医疗、上海澳华有望突围。  内镜诊疗耗材：由于饮食习惯，国人消化道疾病多发，但相关的内镜检测开展率较低，胃镜、肠镜检测不到发达国家的 1/5。随着内镜微创手术的成熟、国家健康战略的推行以及早筛理念的普及，未来消化科内镜手术量会有长足的提升， 带动相关耗材的增长。2018年国内内镜诊疗耗材约为30- 35亿，其中活检类5亿、手术类10亿（圈套器和注射针）、 止血类5亿（止血夹）、ERPC类11亿，且EMR/ESD等高价值产品增速更快。  南微医学：2021Q1-3收入13.9亿元（+49.2%），归母净利润2.5（+19.2%），剔除股权激励因素，归母净利润为 3.17亿元（+52%），未来可视化产品有望贡献新增长点。",
    "labels": [
      [
        "T0",
        "行业",
        2,
        4,
        "内镜"
      ],
      [
        "T1",
        "时间范围",
        9,
        14,
        "2019年"
      ],
      [
        "T2",
        "地点范围",
        14,
        16,
        "全球"
      ],
      [
        "T3",
        "行业",
        16,
        21,
        "内窥镜器械"
      ],
      [
        "T4",
        "属性值",
        21,
        28,
        "约400亿美元"
      ],
      [
        "T5",
        "行业",
        31,
        33,
        "软镜"
      ],
      [
        "T6",
        "行业",
        44,
        46,
        "硬镜"
      ],
      [
        "T7",
        "属性值",
        46,
        49,
        "90亿"
      ],
      [
        "T8",
        "地点范围",
        65,
        67,
        "国内"
      ],
      [
        "T9",
        "时间范围",
        69,
        74,
        "2019年"
      ],
      [
        "T10",
        "行业",
        74,
        77,
        "内窥镜"
      ],
      [
        "T11",
        "属性值",
        77,
        81,
        "240亿"
      ],
      [
        "T12",
        "行业",
        84,
        86,
        "硬镜"
      ],
      [
        "T13",
        "属性值",
        86,
        90,
        "117亿"
      ],
      [
        "T14",
        "行业",
        98,
        100,
        "软镜"
      ],
      [
        "T15",
        "属性值",
        100,
        103,
        "60亿"
      ],
      [
        "T16",
        "行业",
        157,
        159,
        "硬镜"
      ],
      [
        "T17",
        "龙头企业",
        165,
        167,
        "龙头"
      ],
      [
        "T18",
        "公司",
        167,
        171,
        "迈瑞医疗"
      ],
      [
        "T19",
        "公司",
        172,
        176,
        "海泰新光"
      ],
      [
        "T20",
        "公司",
        177,
        181,
        "沈阳沈大"
      ],
      [
        "T21",
        "公司",
        182,
        186,
        "浙江天松"
      ],
      [
        "T22",
        "公司",
        219,
        223,
        "奥林巴斯"
      ],
      [
        "T23",
        "公司",
        224,
        228,
        "富士胶片"
      ],
      [
        "T24",
        "公司",
        229,
        231,
        "宾得"
      ],
      [
        "T25",
        "龙头企业",
        243,
        245,
        "龙头"
      ],
      [
        "T26",
        "公司",
        245,
        249,
        "开立医疗"
      ],
      [
        "T27",
        "公司",
        250,
        254,
        "上海澳华"
      ],
      [
        "T28",
        "行业",
        187,
        189,
        "软镜"
      ],
      [
        "T29",
        "行业",
        262,
        268,
        "内镜诊疗耗材"
      ],
      [
        "T30",
        "时间范围",
        379,
        384,
        "2018年"
      ],
      [
        "T31",
        "地点范围",
        384,
        386,
        "国内"
      ],
      [
        "T32",
        "行业",
        386,
        392,
        "内镜诊疗耗材"
      ],
      [
        "T33",
        "属性值",
        392,
        401,
        "约为30- 35亿"
      ],
      [
        "T34",
        "行业",
        404,
        407,
        "活检类"
      ],
      [
        "T35",
        "行业",
        410,
        413,
        "手术类"
      ],
      [
        "T36",
        "行业",
        427,
        430,
        "止血类"
      ],
      [
        "T37",
        "行业",
        438,
        443,
        "ERPC类"
      ],
      [
        "T38",
        "公司",
        469,
        473,
        "南微医学"
      ],
      [
        "T39",
        "时间范围",
        474,
        482,
        "2021Q1-3"
      ],
      [
        "T40",
        "营业收入",
        482,
        484,
        "收入"
      ],
      [
        "T41",
        "属性值",
        407,
        409,
        "5亿"
      ],
      [
        "T42",
        "属性值",
        413,
        416,
        "10亿"
      ],
      [
        "T43",
        "属性值",
        430,
        432,
        "5亿"
      ],
      [
        "T44",
        "属性值",
        443,
        446,
        "11亿"
      ],
      [
        "T45",
        "属性值",
        484,
        490,
        "13.9亿元"
      ],
      [
        "T46",
        "属性值",
        491,
        497,
        "+49.2%"
      ],
      [
        "T47",
        "归母净利润",
        499,
        504,
        "归母净利润"
      ],
      [
        "T48",
        "归母净利润",
        525,
        530,
        "归母净利润"
      ],
      [
        "T49",
        "属性值",
        33,
        37,
        "110元"
      ],
      [
        "T50",
        "行业",
        113,
        115,
        "硬镜"
      ],
      [
        "T51",
        "行业",
        116,
        118,
        "软镜"
      ],
      [
        "T52",
        "属性值",
        149,
        156,
        "由进口厂商主导"
      ],
      [
        "T53",
        "行业",
        142,
        144,
        "硬镜"
      ],
      [
        "T54",
        "行业",
        145,
        147,
        "软镜"
      ],
      [
        "T55",
        "时间范围",
        350,
        352,
        "未来"
      ],
      [
        "T56",
        "属性值",
        504,
        515,
        "2.5（+19.2%）"
      ],
      [
        "T57",
        "属性值",
        532,
        544,
        "3.17亿元（+52%）"
      ]
    ]
  },
  {
    "id": 2254,
    "text": "单季度表观增速受2020年基数影响  4家医疗服务公司2021 Q1/Q2收入分别约为89/96亿元（+106%/36.4%）、归母净利润总额分别约为12.8/14.5亿元（+810%/+8%），季度之间增速波动较大，主要是2020年一季度医院经营受疫情影响较大，同时部分需求递延到2020年二季度，我们的医疗服务板块纳入标的都有明显的固定成本属性，去年季度收入节奏的扰乱造成今年单季度利润波动较大。展望下半年来看，预计还是受到去年基数影响，尽管各项业务顺利开展，业绩表观增速仍然可能较以往偏低。",
    "labels": [
      [
        "T0",
        "时间范围",
        8,
        13,
        "2020年"
      ],
      [
        "T1",
        "行业公司",
        20,
        28,
        "4家医疗服务公司"
      ],
      [
        "T2",
        "时间范围",
        28,
        35,
        "2021 Q1"
      ],
      [
        "T3",
        "时间范围",
        36,
        38,
        "Q2"
      ],
      [
        "T4",
        "营业收入",
        38,
        40,
        "收入"
      ],
      [
        "T5",
        "属性值",
        44,
        46,
        "89"
      ],
      [
        "T6",
        "属性值",
        47,
        51,
        "96亿元"
      ],
      [
        "T7",
        "属性值",
        52,
        57,
        "+106%"
      ],
      [
        "T8",
        "属性值",
        58,
        63,
        "36.4%"
      ],
      [
        "T9",
        "归母净利润",
        65,
        70,
        "归母净利润"
      ],
      [
        "T10",
        "属性值",
        74,
        80,
        "约为12.8"
      ],
      [
        "T11",
        "属性值",
        81,
        87,
        "14.5亿元"
      ],
      [
        "T12",
        "时间范围",
        113,
        121,
        "2020年一季度"
      ],
      [
        "T13",
        "时间范围",
        142,
        150,
        "2020年二季度"
      ],
      [
        "T14",
        "行业",
        154,
        158,
        "医疗服务"
      ],
      [
        "T15",
        "时间范围",
        176,
        178,
        "去年"
      ],
      [
        "T16",
        "时间范围",
        189,
        191,
        "今年"
      ],
      [
        "T17",
        "利润",
        194,
        196,
        "利润"
      ],
      [
        "T18",
        "属性值",
        196,
        200,
        "波动较大"
      ],
      [
        "T19",
        "时间范围",
        203,
        206,
        "下半年"
      ],
      [
        "T20",
        "时间范围",
        215,
        217,
        "去年"
      ],
      [
        "T21",
        "业绩",
        233,
        235,
        "业绩"
      ],
      [
        "T22",
        "属性值",
        235,
        248,
        "表观增速仍然可能较以往偏低"
      ]
    ]
  },
  {
    "id": 2259,
    "text": " 心血管治疗需求旺盛，带动心血管器械增长。我国心血管病现患人数高达2.9亿人，近年来心血管病患病率及死亡率处于上升阶段，其中农村地区更为显著。2019年中国心血管器械市场规模为465亿元，占器械比重7.3%，离全球11.8%还有距离，未来PCI手术稳健增长，外周、心脏节律、TAVR 增速领跑。  上半年心血管手术逐步恢复。除部分受冠脉支架集采降价影响的标的，其他心血管创新器械标的如心脉医疗、佰仁医疗、启明医疗、沛嘉医疗等表现较好。  乐普医疗：心血管药械平台型企业，2021年上半年收入65.2亿元（+53.9%），归母净利润17.3亿元（+51.3%。器械板块上半年收入41亿元（ +130.3%），毛利率61%（-10.6pp），随着冠脉支架带量采购的实施，传统金属药物支架收入显著下降，但公司介入无植入创新产品组合（可降解支架、药物球囊、切割球囊等）上半年实现收入3.6亿元（+1951.6%），在此带动下第二季度支架业务板块基本恢复到2019年水平。  心脉医疗：2021上半年收入+68.6%，归母净利润+53.2%，业绩延续高增长，公司作为主动脉及外周血管介入龙头，创新产品不断上市并放量。  佰仁医疗：2021H1收入+86.3%，归母净利润-20.6%，剔除股份支付影响，内生归母净利润0.6亿元（+82.2%）。公司动物源性植介入龙头，当前产品以外科软组织修复、先心病植介入为主和心脏瓣膜置换与修复为主，正布局介入瓣膜的研发，长期内生增长清晰。  微创医疗：心血管器械平台型企业，产品布局齐全，2021上半年低基数逐步恢复，收入24.9亿元（+25.3%）。  启明医疗：2021年上半年收入2.4亿元（+139%），TAVR放量驱动收入快速增长，全年增长可期。",
    "labels": [
      [
        "T0",
        "行业",
        14,
        19,
        "心血管器械"
      ],
      [
        "T1",
        "行业需求",
        7,
        9,
        "需求"
      ],
      [
        "T2",
        "属性值",
        9,
        11,
        "旺盛"
      ],
      [
        "T3",
        "地点范围",
        22,
        24,
        "我国"
      ],
      [
        "T4",
        "时间范围",
        40,
        43,
        "近年来"
      ],
      [
        "T5",
        "时间范围",
        72,
        77,
        "2019年"
      ],
      [
        "T6",
        "地点范围",
        77,
        79,
        "中国"
      ],
      [
        "T7",
        "行业",
        79,
        84,
        "心血管器械"
      ],
      [
        "T8",
        "市场规模",
        84,
        88,
        "市场规模"
      ],
      [
        "T9",
        "属性值",
        89,
        94,
        "465亿元"
      ],
      [
        "T10",
        "行业",
        184,
        191,
        "心血管创新器械"
      ],
      [
        "T11",
        "公司",
        194,
        198,
        "心脉医疗"
      ],
      [
        "T12",
        "公司",
        199,
        203,
        "佰仁医疗"
      ],
      [
        "T13",
        "公司",
        204,
        208,
        "启明医疗"
      ],
      [
        "T14",
        "公司",
        209,
        213,
        "沛嘉医疗"
      ],
      [
        "T15",
        "公司",
        221,
        226,
        " 乐普医疗"
      ],
      [
        "T16",
        "行业",
        227,
        232,
        "心血管药械"
      ],
      [
        "T17",
        "时间范围",
        238,
        246,
        "2021年上半年"
      ],
      [
        "T18",
        "营业收入",
        246,
        248,
        "收入"
      ],
      [
        "T19",
        "属性值",
        248,
        254,
        "65.2亿元"
      ],
      [
        "T20",
        "属性值",
        255,
        261,
        "+53.9%"
      ],
      [
        "T21",
        "行业",
        282,
        284,
        "器械"
      ],
      [
        "T22",
        "时间范围",
        286,
        289,
        "上半年"
      ],
      [
        "T23",
        "营业收入",
        289,
        291,
        "收入"
      ],
      [
        "T24",
        "毛利",
        306,
        309,
        "毛利率"
      ],
      [
        "T25",
        "属性值",
        291,
        295,
        "41亿元"
      ],
      [
        "T26",
        "属性值",
        297,
        304,
        "+130.3%"
      ],
      [
        "T27",
        "属性值",
        309,
        321,
        "61%（-10.6pp）"
      ],
      [
        "T28",
        "时间范围",
        383,
        386,
        "上半年"
      ],
      [
        "T29",
        "营业收入",
        388,
        390,
        "收入"
      ],
      [
        "T30",
        "属性值",
        390,
        395,
        "3.6亿元"
      ],
      [
        "T31",
        "属性值",
        396,
        404,
        "+1951.6%"
      ],
      [
        "T32",
        "公司",
        437,
        441,
        "心脉医疗"
      ],
      [
        "T33",
        "时间范围",
        442,
        449,
        "2021上半年"
      ],
      [
        "T34",
        "营业收入",
        449,
        451,
        "收入"
      ],
      [
        "T35",
        "属性值",
        451,
        457,
        "+68.6%"
      ],
      [
        "T36",
        "归母净利润",
        458,
        463,
        "归母净利润"
      ],
      [
        "T37",
        "属性值",
        463,
        469,
        "+53.2%"
      ],
      [
        "T38",
        "业绩",
        470,
        472,
        "业绩"
      ],
      [
        "T39",
        "龙头企业",
        492,
        494,
        "龙头"
      ],
      [
        "T40",
        "公司",
        510,
        514,
        "佰仁医疗"
      ],
      [
        "T41",
        "时间范围",
        515,
        521,
        "2021H1"
      ],
      [
        "T42",
        "营业收入",
        521,
        523,
        "收入"
      ],
      [
        "T43",
        "属性值",
        523,
        529,
        "+86.3%"
      ],
      [
        "T44",
        "归母净利润",
        530,
        535,
        "归母净利润"
      ],
      [
        "T45",
        "属性值",
        535,
        541,
        "-20.6%"
      ],
      [
        "T46",
        "归母净利润",
        553,
        558,
        "归母净利润"
      ],
      [
        "T47",
        "行业",
        574,
        581,
        "动物源性植介入"
      ],
      [
        "T48",
        "龙头企业",
        581,
        583,
        "龙头"
      ],
      [
        "T49",
        "公司",
        641,
        645,
        "微创医疗"
      ],
      [
        "T50",
        "行业",
        646,
        651,
        "心血管器械"
      ],
      [
        "T51",
        "时间范围",
        664,
        671,
        "2021上半年"
      ],
      [
        "T52",
        "营业收入",
        679,
        681,
        "收入"
      ],
      [
        "T53",
        "属性值",
        681,
        687,
        "24.9亿元"
      ],
      [
        "T54",
        "属性值",
        688,
        694,
        "+25.3%"
      ],
      [
        "T55",
        "公司",
        699,
        703,
        "启明医疗"
      ],
      [
        "T56",
        "时间范围",
        704,
        712,
        "2021年上半年"
      ],
      [
        "T57",
        "营业收入",
        712,
        714,
        "收入"
      ],
      [
        "T58",
        "属性值",
        714,
        719,
        "2.4亿元"
      ],
      [
        "T59",
        "属性值",
        720,
        725,
        "+139%"
      ],
      [
        "T60",
        "营业收入",
        735,
        737,
        "收入"
      ],
      [
        "T61",
        "行业",
        2,
        7,
        "心血管治疗"
      ],
      [
        "T62",
        "行业",
        96,
        98,
        "器械"
      ],
      [
        "T63",
        "地点范围",
        106,
        108,
        "全球"
      ],
      [
        "T64",
        "行业",
        130,
        132,
        "外周"
      ],
      [
        "T65",
        "行业",
        133,
        137,
        "心脏节律"
      ],
      [
        "T66",
        "行业",
        138,
        142,
        "TAVR"
      ],
      [
        "T67",
        "时间范围",
        151,
        154,
        "上半年"
      ],
      [
        "T68",
        "归母净利润",
        263,
        268,
        "归母净利润"
      ],
      [
        "T69",
        "属性值",
        268,
        281,
        "17.3亿元（+51.3%"
      ],
      [
        "T70",
        "时间范围",
        411,
        415,
        "第二季度"
      ],
      [
        "T71",
        "行业",
        415,
        417,
        "支架"
      ],
      [
        "T72",
        "时间范围",
        426,
        431,
        "2019年"
      ],
      [
        "T73",
        "属性值",
        474,
        477,
        "高增长"
      ],
      [
        "T74",
        "行业",
        482,
        492,
        "主动脉及外周血管介入"
      ],
      [
        "T75",
        "属性值",
        558,
        571,
        "0.6亿元（+82.2%）"
      ],
      [
        "T76",
        "行业",
        621,
        625,
        "介入瓣膜"
      ],
      [
        "T77",
        "属性值",
        737,
        741,
        "快速增长"
      ],
      [
        "T78",
        "行业",
        727,
        731,
        "TAVR"
      ]
    ]
  },
  {
    "id": 2261,
    "text": "针对不同分类的新药，其开发策略也有差异。First-in-class新药更加注重靶点机制的验证，尤其是临床前研究的夯实。而 Best-in-class、Me-better和 Me-too产品更多寻求的是分子结构的差异，也更加适合当下绝大部分药企的研发策略。因此 Fast-follow-on 是当下企业寻求价值最大化的突破口之一，应充分利用好国内创新药系列药政，尤其是肿瘤药和罕见病用药的附条件上市等加速上市策略。在个股选择方面，重视研发费用率、未来潜力品种的市场空间外，同时更要重视医学团队体系的实力及是否具备全球多中心开展和注册能力。推荐：恒瑞医药、贝达药业、亚盛医药、康宁杰瑞、诺诚健华，建议关注：信达生物、中国生物制药、石药集团、翰森制药、君实生物、康方生物、神州细胞。",
    "labels": [
      [
        "T0",
        "地点范围",
        171,
        173,
        "国内"
      ],
      [
        "T1",
        "行业",
        173,
        176,
        "创新药"
      ],
      [
        "T2",
        "研发费用",
        217,
        221,
        "研发费用"
      ],
      [
        "T3",
        "公司",
        272,
        276,
        "恒瑞医药"
      ],
      [
        "T4",
        "公司",
        277,
        281,
        "贝达药业"
      ],
      [
        "T5",
        "公司",
        282,
        286,
        "亚盛医药"
      ],
      [
        "T6",
        "公司",
        287,
        291,
        "康宁杰瑞"
      ],
      [
        "T7",
        "公司",
        292,
        296,
        "诺诚健华"
      ],
      [
        "T8",
        "公司",
        297,
        301,
        "建议关注"
      ],
      [
        "T9",
        "公司",
        302,
        306,
        "信达生物"
      ],
      [
        "T10",
        "公司",
        307,
        313,
        "中国生物制药"
      ],
      [
        "T11",
        "公司",
        314,
        318,
        "石药集团"
      ],
      [
        "T12",
        "公司",
        319,
        323,
        "翰森制药"
      ],
      [
        "T13",
        "公司",
        324,
        328,
        "君实生物"
      ],
      [
        "T14",
        "公司",
        329,
        333,
        "康方生物"
      ],
      [
        "T15",
        "公司",
        334,
        338,
        "神州细胞"
      ],
      [
        "T16",
        "地点范围",
        256,
        258,
        "全球"
      ],
      [
        "T17",
        "行业公司",
        120,
        122,
        "药企"
      ]
    ]
  },
  {
    "id": 2267,
    "text": " 分子诊断近年来行业增速约25%，2019年行业规模约100亿元左右，占整个IVD板块15%，是 IVD领域增速最快的赛道。分子诊断凭借准确度高、灵敏度强、速度快等优点，未来在传染病监测、肿瘤筛查等领域具有广阔空间，本次疫情中核酸诊断为新冠筛查的“金标准”，其价值得到凸显，后续分子诊断发展有望加速。",
    "labels": [
      [
        "T0",
        "时间范围",
        18,
        23,
        "2019年"
      ],
      [
        "T1",
        "市场规模",
        23,
        27,
        "行业规模"
      ],
      [
        "T2",
        "行业",
        2,
        6,
        "分子诊断"
      ],
      [
        "T3",
        "时间范围",
        6,
        9,
        "近年来"
      ],
      [
        "T4",
        "属性值",
        27,
        35,
        "约100亿元左右"
      ],
      [
        "T5",
        "行业",
        39,
        42,
        "IVD"
      ],
      [
        "T6",
        "行业",
        49,
        53,
        " IVD"
      ],
      [
        "T7",
        "行业",
        63,
        67,
        "分子诊断"
      ],
      [
        "T8",
        "行业",
        140,
        144,
        "分子诊断"
      ],
      [
        "T9",
        "属性值",
        144,
        150,
        "发展有望加速"
      ],
      [
        "T10",
        "时间范围",
        86,
        88,
        "未来"
      ],
      [
        "T11",
        "行业",
        89,
        94,
        "传染病监测"
      ],
      [
        "T12",
        "行业",
        95,
        99,
        "肿瘤筛查"
      ]
    ]
  },
  {
    "id": 2268,
    "text": " CXO上市公司业绩保持快速增长的态势。2021Q1-Q3国内CXO上市公司实现营收430.44亿元，同比增长38.15%，实现归母净利润97.19亿元，同比增长49.28%。得益于旺盛的全球创新药研发需求和充足的在手订单，国内CXO上市公司收入和利润均延续高增长态势。",
    "labels": [
      [
        "T0",
        "行业公司",
        2,
        9,
        "CXO上市公司"
      ],
      [
        "T1",
        "业绩",
        9,
        11,
        "业绩"
      ],
      [
        "T2",
        "属性值",
        13,
        17,
        "快速增长"
      ],
      [
        "T3",
        "时间范围",
        21,
        30,
        "2021Q1-Q3"
      ],
      [
        "T4",
        "地点范围",
        30,
        32,
        "国内"
      ],
      [
        "T5",
        "行业公司",
        32,
        39,
        "CXO上市公司"
      ],
      [
        "T6",
        "营业收入",
        41,
        43,
        "营收"
      ],
      [
        "T7",
        "属性值",
        43,
        51,
        "430.44亿元"
      ],
      [
        "T8",
        "属性值",
        56,
        62,
        "38.15%"
      ],
      [
        "T9",
        "归母净利润",
        65,
        70,
        "归母净利润"
      ],
      [
        "T10",
        "属性值",
        70,
        88,
        "97.19亿元，同比增长49.28%"
      ],
      [
        "T11",
        "地点范围",
        95,
        97,
        "全球"
      ],
      [
        "T12",
        "行业",
        97,
        102,
        "创新药研发"
      ],
      [
        "T13",
        "属性值",
        105,
        107,
        "充足"
      ],
      [
        "T14",
        "在手订单",
        108,
        112,
        "在手订单"
      ],
      [
        "T15",
        "地点范围",
        113,
        115,
        "国内"
      ],
      [
        "T16",
        "行业公司",
        115,
        122,
        "CXO上市公司"
      ],
      [
        "T17",
        "营业收入",
        122,
        124,
        "收入"
      ],
      [
        "T18",
        "利润",
        125,
        127,
        "利润"
      ],
      [
        "T19",
        "属性值",
        130,
        133,
        "高增长"
      ]
    ]
  },
  {
    "id": 2274,
    "text": " 2021Q1-3板块总结：21Q1-3疫苗板块实现收入405亿元（+52%），归母净利润120亿元（+154.7%），扣非归母净利润117亿元（ +171.4%）。业绩同比大幅增长系新冠疫苗持续放量，智飞、康泰新冠疫苗归母净利润合计实现约55亿元。目前康泰与阿斯利康合作的腺病毒新冠疫苗已经在印尼获批，智飞也取得了乌兹别克斯坦和印尼两个国家的紧急使用。预计Q4及明年海外疫苗出口将持续贡献增量业绩。传统疫苗板块实现归母净利润65亿元（+38%），增速有所放缓，主要系新冠疫苗接种以及散点疫情频发造成，预计在疫情常态化背景下，传统疫苗接种有望恢复正常增长。  行业盈利能力主要靠新冠疫苗持续提升。从盈利能力看，21Q1-3行业毛利率为58%（+7pp）、四费率为23%（-6pp）、净利率为30%（ +16pp），其中新冠疫苗的毛利率预计在80%以上，净利率预计在50%左右。板块盈利能力主要靠新冠疫苗品种实现大幅提升。  疫情常态化已成共识，加强针接种有望为企业贡献持续利润。在疫情长期与人类共存的背景下，打开国门的关键是形成“检测-预防-治疗”的全流程完善体系。目前辉瑞的口服新冠候选药物Paxlovid可以减少高达89％的新冠肺炎非住院患者的住院或死亡率，成为防疫的有效一环。 但其中疫苗仍是最为关键的一步，目前已有7种加强针接种方案在不同国家获批，同源接种与异源序贯均能产生较高的中和抗体水平，在预防重症、死亡以及突变株方面效果显著。目前我国疫苗接种已经基本完成一轮，相关企业有望凭借加强针以及海外出口持续受益。  疫情驱动行业加速发展。此次疫情一方面加快民众对疫苗的认知，另一方面资本快速涌入疫苗行业。我们认为，未来疫苗行业重点解决未满足的需求，主要有三个路径：1）暂无疫苗的严重危害性传染病疫苗研发（如HIV病毒）。2）多联多价疫苗提升保护范围、缩短免疫剂次， 制造工艺改进提高运输效率、减少企业成本。3）新型技术路线，如mRNA疫苗。目前康泰生物的13价肺炎疫苗已经上市，万泰生物的9价 HPV疫苗处于Ⅲ期临床，各大龙头企业在mRNA技术领域均展开布局，未来国产疫苗逐步进入收获期。  投资建议：康泰生物（300601）、康希诺（688185）、欧林生物（688319）、百克生物（688276）、智飞生物（300122）、康华生物（ 300841）、华兰生物（002007）。",
    "labels": [
      [
        "T0",
        "时间范围",
        2,
        10,
        "2021Q1-3"
      ],
      [
        "T1",
        "时间范围",
        15,
        21,
        "21Q1-3"
      ],
      [
        "T2",
        "行业",
        21,
        23,
        "疫苗"
      ],
      [
        "T3",
        "营业收入",
        27,
        29,
        "收入"
      ],
      [
        "T4",
        "属性值",
        29,
        34,
        "405亿元"
      ],
      [
        "T5",
        "属性值",
        35,
        39,
        "+52%"
      ],
      [
        "T6",
        "归母净利润",
        41,
        46,
        "归母净利润"
      ],
      [
        "T7",
        "属性值",
        46,
        60,
        "120亿元（+154.7%）"
      ],
      [
        "T8",
        "扣非净利润",
        61,
        68,
        "扣非归母净利润"
      ],
      [
        "T9",
        "属性值",
        68,
        83,
        "117亿元（ +171.4%）"
      ],
      [
        "T10",
        "业绩",
        84,
        86,
        "业绩"
      ],
      [
        "T11",
        "属性值",
        86,
        92,
        "同比大幅增长"
      ],
      [
        "T12",
        "公司",
        102,
        104,
        "智飞"
      ],
      [
        "T13",
        "公司",
        105,
        107,
        "康泰"
      ],
      [
        "T14",
        "归母净利润",
        111,
        116,
        "归母净利润"
      ],
      [
        "T15",
        "公司",
        128,
        130,
        "康泰"
      ],
      [
        "T16",
        "时间范围",
        126,
        128,
        "目前"
      ],
      [
        "T17",
        "地点范围",
        148,
        150,
        "印尼"
      ],
      [
        "T18",
        "公司",
        153,
        155,
        "智飞"
      ],
      [
        "T19",
        "地点范围",
        159,
        165,
        "乌兹别克斯坦"
      ],
      [
        "T20",
        "地点范围",
        166,
        168,
        "印尼"
      ],
      [
        "T21",
        "时间范围",
        180,
        182,
        "Q4"
      ],
      [
        "T22",
        "时间范围",
        183,
        185,
        "明年"
      ],
      [
        "T23",
        "地点范围",
        185,
        187,
        "海外"
      ],
      [
        "T24",
        "行业",
        187,
        191,
        "疫苗出口"
      ],
      [
        "T25",
        "属性值",
        196,
        198,
        "增量"
      ],
      [
        "T26",
        "行业",
        201,
        205,
        "传统疫苗"
      ],
      [
        "T27",
        "归母净利润",
        209,
        214,
        "归母净利润"
      ],
      [
        "T28",
        "属性值",
        214,
        224,
        "65亿元（+38%）"
      ],
      [
        "T29",
        "属性值",
        229,
        231,
        "放缓"
      ],
      [
        "T30",
        "公司",
        910,
        914,
        "康泰生物"
      ],
      [
        "T31",
        "公司",
        923,
        926,
        "康希诺"
      ],
      [
        "T32",
        "公司",
        935,
        939,
        "欧林生物"
      ],
      [
        "T33",
        "公司",
        948,
        952,
        "百克生物"
      ],
      [
        "T34",
        "公司",
        961,
        965,
        "智飞生物"
      ],
      [
        "T35",
        "公司",
        974,
        978,
        "康华生物"
      ],
      [
        "T36",
        "公司",
        988,
        992,
        "华兰生物"
      ],
      [
        "T37",
        "公司",
        830,
        834,
        "康泰生物"
      ],
      [
        "T38",
        "时间范围",
        828,
        830,
        "目前"
      ],
      [
        "T39",
        "公司",
        847,
        851,
        "万泰生物"
      ],
      [
        "T40",
        "行业",
        874,
        880,
        "mRNA技术"
      ],
      [
        "T41",
        "行业",
        890,
        894,
        "国产疫苗"
      ],
      [
        "T42",
        "行业",
        717,
        719,
        "疫苗"
      ],
      [
        "T43",
        "时间范围",
        715,
        717,
        "未来"
      ],
      [
        "T44",
        "时间范围",
        560,
        562,
        "目前"
      ],
      [
        "T45",
        "时间范围",
        624,
        626,
        "目前"
      ],
      [
        "T46",
        "地点范围",
        626,
        628,
        "我国"
      ],
      [
        "T47",
        "行业",
        705,
        707,
        "疫苗"
      ],
      [
        "T48",
        "公司",
        488,
        490,
        "辉瑞"
      ],
      [
        "T49",
        "时间范围",
        486,
        488,
        "目前"
      ],
      [
        "T50",
        "行业",
        361,
        365,
        "新冠疫苗"
      ],
      [
        "T51",
        "毛利",
        366,
        369,
        "毛利率"
      ],
      [
        "T52",
        "属性值",
        372,
        377,
        "80%以上"
      ],
      [
        "T53",
        "归母净利润",
        378,
        381,
        "净利率"
      ],
      [
        "T54",
        "属性值",
        384,
        389,
        "50%左右"
      ],
      [
        "T55",
        "时间范围",
        307,
        313,
        "21Q1-3"
      ],
      [
        "T56",
        "毛利",
        315,
        318,
        "毛利率"
      ],
      [
        "T57",
        "业绩",
        198,
        200,
        "业绩"
      ]
    ]
  },
  {
    "id": 2279,
    "text": "2021年Q1-Q3，实现营业收入259.27亿元，同比增长1.67%；实现归母净利润18.95亿元，同比下滑20.74%；实现扣非归母净利润17.62亿元， 同比下滑13.24%。Q3单季度，实现营业收入87.48亿元，同比下滑1.04%；实现归母净利润5.95亿元，同比下滑9.88%；实现扣非归母净利润 5.68亿元，同比下滑8.99%。受药品降价影响公司核心子公司中美华东业绩持续下滑，中美华东2021年Q1-Q3营收78.04亿元，同比下滑11.4% ，净利润17.2亿元，同比下滑11.1%。但中美华东Q3净利润环比已实现增长14.8%，公司Q3归母净利润和扣非归母净利润环比均实现增长，分别增长9.79%和14.02%，经营情况在恢复向好。公司在克服经营压力的同时积极推进创新转型，陆续投资、控股、孵化多家国内拥有领先技术的生物科技公司，在糖尿病、肿瘤、自免领域引进及合作多款创新药品，为公司创新发展奠定基础。",
    "labels": [
      [
        "T0",
        "公司",
        186,
        190,
        "中美华东"
      ],
      [
        "T1",
        "业绩",
        190,
        192,
        "业绩"
      ],
      [
        "T2",
        "属性值",
        194,
        196,
        "下滑"
      ],
      [
        "T3",
        "公司",
        197,
        201,
        "中美华东"
      ],
      [
        "T4",
        "时间范围",
        201,
        211,
        "2021年Q1-Q3"
      ],
      [
        "T5",
        "营业收入",
        211,
        213,
        "营收"
      ],
      [
        "T6",
        "属性值",
        213,
        220,
        "78.04亿元"
      ],
      [
        "T7",
        "属性值",
        223,
        230,
        "下滑11.4%"
      ],
      [
        "T8",
        "归母净利润",
        232,
        235,
        "净利润"
      ],
      [
        "T9",
        "属性值",
        235,
        251,
        "17.2亿元，同比下滑11.1%"
      ],
      [
        "T10",
        "公司",
        253,
        257,
        "中美华东"
      ],
      [
        "T11",
        "时间范围",
        257,
        259,
        "Q3"
      ],
      [
        "T12",
        "归母净利润",
        259,
        262,
        "净利润"
      ],
      [
        "T13",
        "属性值",
        262,
        274,
        "环比已实现增长14.8%"
      ],
      [
        "T14",
        "时间范围",
        277,
        279,
        "Q3"
      ],
      [
        "T15",
        "归母净利润",
        279,
        284,
        "归母净利润"
      ],
      [
        "T16",
        "扣非净利润",
        285,
        292,
        "扣非归母净利润"
      ],
      [
        "T17",
        "属性值",
        292,
        299,
        "环比均实现增长"
      ],
      [
        "T18",
        "属性值",
        302,
        309,
        "增长9.79%"
      ],
      [
        "T19",
        "属性值",
        310,
        316,
        "14.02%"
      ],
      [
        "T20",
        "归母净利润",
        38,
        43,
        "归母净利润"
      ],
      [
        "T21",
        "营业收入",
        13,
        17,
        "营业收入"
      ],
      [
        "T22",
        "时间范围",
        0,
        10,
        "2021年Q1-Q3"
      ],
      [
        "T23",
        "扣非净利润",
        64,
        71,
        "扣非归母净利润"
      ],
      [
        "T24",
        "时间范围",
        91,
        93,
        "Q3"
      ],
      [
        "T25",
        "营业收入",
        99,
        103,
        "营业收入"
      ],
      [
        "T26",
        "归母净利润",
        123,
        128,
        "归母净利润"
      ],
      [
        "T27",
        "扣非净利润",
        147,
        154,
        "扣非归母净利润"
      ]
    ]
  },
  {
    "id": 2285,
    "text": "2）受益于行业高景气，2021年CXO业绩维持高增长，预计未来2-3年仍可持续。通过对比多家公司数据，全球医药外包服务公司人均成本小于全球制药公司，且在毛利率较低的情况下仍可与制药公司近似的净利率。凭借工程师红利，我们国内企业的优势更加显著，预计未来公司营收仍有望维持45%+高速增长。",
    "labels": [
      [
        "T0",
        "时间范围",
        11,
        16,
        "2021年"
      ],
      [
        "T1",
        "行业",
        16,
        19,
        "CXO"
      ],
      [
        "T2",
        "业绩",
        19,
        21,
        "业绩"
      ],
      [
        "T3",
        "属性值",
        23,
        26,
        "高增长"
      ],
      [
        "T4",
        "时间范围",
        29,
        35,
        "未来2-3年"
      ],
      [
        "T5",
        "地点范围",
        51,
        53,
        "全球"
      ],
      [
        "T6",
        "行业公司",
        53,
        61,
        "医药外包服务公司"
      ],
      [
        "T7",
        "地点范围",
        67,
        69,
        "全球"
      ],
      [
        "T8",
        "行业公司",
        69,
        73,
        "制药公司"
      ],
      [
        "T9",
        "毛利",
        76,
        79,
        "毛利率"
      ],
      [
        "T10",
        "行业公司",
        88,
        92,
        "制药公司"
      ],
      [
        "T11",
        "归母净利润",
        95,
        98,
        "净利率"
      ],
      [
        "T12",
        "地点范围",
        109,
        111,
        "国内"
      ],
      [
        "T13",
        "营业收入",
        127,
        129,
        "营收"
      ],
      [
        "T14",
        "时间范围",
        123,
        125,
        "未来"
      ]
    ]
  },
  {
    "id": 2287,
    "text": "医药生物领域投融资热情持续高涨，研发投入逐年攀升，预计2022年医药外包服务行业有望延续高增长行情： • 据动脉橙数据库统计，2021年全球生物医药领域共发生投融资事件1273起（yoy34%），投融资金额3699.13 亿元（yoy32%）；中国发生投融资事件522起（yoy53%），投融资金额1113.58亿元（yoy26%）。 • 据Frost&Sullivan统计，2020年全球医药企业研发支出达2048亿美元（yoy12%）；中国医药企业研发支出达247亿美元（yoy17%）。",
    "labels": [
      [
        "T0",
        "行业",
        0,
        4,
        "医药生物"
      ],
      [
        "T1",
        "投融资情况",
        6,
        9,
        "投融资"
      ],
      [
        "T2",
        "属性值",
        11,
        15,
        "持续高涨"
      ],
      [
        "T3",
        "研发费用",
        16,
        20,
        "研发投入"
      ],
      [
        "T4",
        "属性值",
        20,
        24,
        "逐年攀升"
      ],
      [
        "T5",
        "时间范围",
        27,
        32,
        "2022年"
      ],
      [
        "T6",
        "行业",
        32,
        38,
        "医药外包服务"
      ],
      [
        "T7",
        "时间范围",
        63,
        68,
        "2021年"
      ],
      [
        "T8",
        "地点范围",
        68,
        70,
        "全球"
      ],
      [
        "T9",
        "行业",
        70,
        74,
        "生物医药"
      ],
      [
        "T10",
        "投融资事件数",
        79,
        84,
        "投融资事件"
      ],
      [
        "T11",
        "属性值",
        84,
        97,
        "1273起（yoy34%）"
      ],
      [
        "T12",
        "投融资金额",
        98,
        103,
        "投融资金额"
      ],
      [
        "T13",
        "属性值",
        103,
        121,
        "3699.13 亿元（yoy32%）"
      ],
      [
        "T14",
        "地点范围",
        122,
        124,
        "中国"
      ],
      [
        "T15",
        "投融资事件数",
        126,
        131,
        "投融资事件"
      ],
      [
        "T16",
        "属性值",
        131,
        143,
        "522起（yoy53%）"
      ],
      [
        "T17",
        "投融资金额",
        144,
        149,
        "投融资金额"
      ],
      [
        "T18",
        "属性值",
        149,
        166,
        "1113.58亿元（yoy26%）"
      ],
      [
        "T19",
        "时间范围",
        188,
        193,
        "2020年"
      ],
      [
        "T20",
        "地点范围",
        193,
        195,
        "全球"
      ],
      [
        "T21",
        "行业公司",
        195,
        199,
        "医药企业"
      ],
      [
        "T22",
        "研发费用",
        199,
        203,
        "研发支出"
      ],
      [
        "T23",
        "属性值",
        204,
        219,
        "2048亿美元（yoy12%）"
      ],
      [
        "T24",
        "地点范围",
        220,
        222,
        "中国"
      ],
      [
        "T25",
        "行业公司",
        222,
        226,
        "医药企业"
      ],
      [
        "T26",
        "研发费用",
        226,
        230,
        "研发支出"
      ],
      [
        "T27",
        "属性值",
        231,
        245,
        "247亿美元（yoy17%）"
      ]
    ]
  },
  {
    "id": 2293,
    "text": "• 根据中国医疗器械研究院数据，2018年我国医疗器械市场规模约为5304亿元，增速近20%，其中高值耗材、低值耗材市场规模份额比为1046/641亿元，IVD诊断为604亿元，均为厂家出厂口径",
    "labels": [
      [
        "T0",
        "地点范围",
        4,
        6,
        "中国"
      ],
      [
        "T1",
        "时间范围",
        16,
        21,
        "2018年"
      ],
      [
        "T2",
        "地点范围",
        21,
        23,
        "我国"
      ],
      [
        "T3",
        "行业",
        23,
        27,
        "医疗器械"
      ],
      [
        "T4",
        "市场规模",
        27,
        31,
        "市场规模"
      ],
      [
        "T5",
        "属性值",
        31,
        39,
        "约为5304亿元"
      ],
      [
        "T6",
        "属性值",
        42,
        46,
        "近20%"
      ],
      [
        "T7",
        "行业",
        49,
        53,
        "高值耗材"
      ],
      [
        "T8",
        "行业",
        54,
        58,
        "低值耗材"
      ],
      [
        "T9",
        "市场规模",
        58,
        62,
        "市场规模"
      ],
      [
        "T10",
        "属性值",
        66,
        70,
        "1046"
      ],
      [
        "T11",
        "属性值",
        71,
        76,
        "641亿元"
      ],
      [
        "T12",
        "行业",
        77,
        82,
        "IVD诊断"
      ],
      [
        "T13",
        "属性值",
        83,
        88,
        "604亿元"
      ]
    ]
  },
  {
    "id": 2297,
    "text": " 眼科器械：根据中国医疗器械行业发展报告，2014-2019年 ，我国眼科器械市场规模自111亿元增长至约267亿元，行业复合增长率达到19.2%。其中眼科高值耗材占比约1/3， 2018年市场规模为76亿元。  人工晶体：2018年全国人工晶体销量370万片，CSR（每百万人口白内障手术量）为2662例，相比美欧日10000例以上的水平还有很大提升空间。从份额看，进口品牌占据国内市场绝大多数份额，国产品牌销量占比约为20%。软性人工晶体为主要战场，多焦点和叠加附加技术的高端产品仍以进口企业为主。随着带量采购推行和国产技术突破，未来国产率有望不断提升。  角膜塑形镜：青少年近视防控需求旺盛，驱动角膜塑形镜市场持续扩容，预计2019年渗透率提升至1.1%，覆盖人群 108万人，行业出厂总规模约为16亿元。  爱博医疗：2021Q1-3收入3.3亿元（+79%），归母净利润 1.4亿元（+104.4%），预计前三季度人工晶体收入同比增长约55%，角膜塑形镜收入约8000-9000万，大幅增长。  欧普康视：2021Q1-3收入10亿元（+64.2%）, 归母净利润 4.4亿元（+59.6%），延续高增长态势。",
    "labels": [
      [
        "T0",
        "行业",
        2,
        6,
        "眼科器械"
      ],
      [
        "T1",
        "地点范围",
        9,
        11,
        "中国"
      ],
      [
        "T2",
        "行业",
        11,
        15,
        "医疗器械"
      ],
      [
        "T3",
        "地点范围",
        34,
        36,
        "我国"
      ],
      [
        "T4",
        "行业",
        36,
        40,
        "眼科器械"
      ],
      [
        "T5",
        "市场规模",
        40,
        44,
        "市场规模"
      ],
      [
        "T6",
        "CAGR",
        62,
        67,
        "复合增长率"
      ],
      [
        "T7",
        "属性值",
        69,
        74,
        "19.2%"
      ],
      [
        "T8",
        "行业",
        77,
        83,
        "眼科高值耗材"
      ],
      [
        "T9",
        "时间范围",
        91,
        96,
        "2018年"
      ],
      [
        "T10",
        "市场规模",
        96,
        100,
        "市场规模"
      ],
      [
        "T11",
        "属性值",
        101,
        105,
        "76亿元"
      ],
      [
        "T12",
        "行业",
        109,
        113,
        "人工晶体"
      ],
      [
        "T13",
        "时间范围",
        114,
        119,
        "2018年"
      ],
      [
        "T14",
        "地点范围",
        119,
        121,
        "全国"
      ],
      [
        "T15",
        "地点范围",
        158,
        159,
        "美"
      ],
      [
        "T16",
        "地点范围",
        159,
        160,
        "欧"
      ],
      [
        "T17",
        "地点范围",
        160,
        161,
        "日"
      ],
      [
        "T18",
        "地点范围",
        192,
        194,
        "国内"
      ],
      [
        "T19",
        "行业",
        217,
        223,
        "软性人工晶体"
      ],
      [
        "T20",
        "时间范围",
        269,
        271,
        "未来"
      ],
      [
        "T21",
        "行业",
        284,
        289,
        "角膜塑形镜"
      ],
      [
        "T22",
        "时间范围",
        318,
        323,
        "2019年"
      ],
      [
        "T23",
        "公司",
        362,
        366,
        "爱博医疗"
      ],
      [
        "T24",
        "时间范围",
        367,
        375,
        "2021Q1-3"
      ],
      [
        "T25",
        "营业收入",
        375,
        377,
        "收入"
      ],
      [
        "T26",
        "属性值",
        377,
        382,
        "3.3亿元"
      ],
      [
        "T27",
        "属性值",
        383,
        387,
        "+79%"
      ],
      [
        "T28",
        "归母净利润",
        389,
        394,
        "归母净利润"
      ],
      [
        "T29",
        "属性值",
        395,
        409,
        "1.4亿元（+104.4%）"
      ],
      [
        "T30",
        "时间范围",
        412,
        416,
        "前三季度"
      ],
      [
        "T31",
        "行业",
        416,
        420,
        "人工晶体"
      ],
      [
        "T32",
        "营业收入",
        420,
        422,
        "收入"
      ],
      [
        "T33",
        "属性值",
        426,
        430,
        "约55%"
      ],
      [
        "T34",
        "行业",
        431,
        436,
        "角膜塑形镜"
      ],
      [
        "T35",
        "营业收入",
        436,
        438,
        "收入"
      ],
      [
        "T36",
        "属性值",
        438,
        449,
        "约8000-9000万"
      ],
      [
        "T37",
        "公司",
        458,
        462,
        "欧普康视"
      ],
      [
        "T38",
        "时间范围",
        463,
        471,
        "2021Q1-3"
      ],
      [
        "T39",
        "营业收入",
        471,
        473,
        "收入"
      ],
      [
        "T40",
        "属性值",
        473,
        477,
        "10亿元"
      ],
      [
        "T41",
        "属性值",
        478,
        484,
        "+64.2%"
      ],
      [
        "T42",
        "归母净利润",
        487,
        492,
        "归母净利润"
      ],
      [
        "T43",
        "属性值",
        493,
        506,
        "4.4亿元（+59.6%）"
      ],
      [
        "T44",
        "时间范围",
        22,
        26,
        "2014"
      ],
      [
        "T45",
        "时间范围",
        27,
        32,
        "2019年"
      ],
      [
        "T46",
        "时间连接词",
        26,
        27,
        "-"
      ],
      [
        "T47",
        "属性值",
        45,
        50,
        "111亿元"
      ],
      [
        "T48",
        "属性值",
        53,
        59,
        "约267亿元"
      ],
      [
        "T49",
        "属性值",
        299,
        301,
        "旺盛"
      ],
      [
        "T50",
        "行业",
        304,
        309,
        "角膜塑形镜"
      ],
      [
        "T51",
        "属性值",
        311,
        315,
        "持续扩容"
      ]
    ]
  },
  {
    "id": 2301,
    "text": "我国眼科器械市场规模快速增长。根据《中国医疗器械行业发展报告》，我国眼科器械市场规模从 2014年的 111亿元增长至 2018年的 226亿元，CAGR为 19.45%，预计 2021年将达到 375亿元。从细分产品市场份额看，2017年，我国角膜塑形镜占眼科医疗器械市场约 21.6%，人工晶体占比为 17.4%。",
    "labels": [
      [
        "T0",
        "地点范围",
        0,
        2,
        "我国"
      ],
      [
        "T1",
        "行业",
        2,
        6,
        "眼科器械"
      ],
      [
        "T2",
        "市场规模",
        6,
        10,
        "市场规模"
      ],
      [
        "T3",
        "属性值",
        10,
        14,
        "快速增长"
      ],
      [
        "T4",
        "地点范围",
        18,
        20,
        "中国"
      ],
      [
        "T5",
        "行业",
        20,
        24,
        "医疗器械"
      ],
      [
        "T6",
        "地点范围",
        32,
        34,
        "我国"
      ],
      [
        "T7",
        "行业",
        34,
        38,
        "眼科器械"
      ],
      [
        "T8",
        "市场规模",
        38,
        42,
        "市场规模"
      ],
      [
        "T9",
        "时间范围",
        44,
        49,
        "2014年"
      ],
      [
        "T10",
        "属性值",
        51,
        56,
        "111亿元"
      ],
      [
        "T11",
        "时间范围",
        60,
        65,
        "2018年"
      ],
      [
        "T12",
        "属性值",
        67,
        72,
        "226亿元"
      ],
      [
        "T13",
        "CAGR",
        73,
        77,
        "CAGR"
      ],
      [
        "T14",
        "属性值",
        79,
        85,
        "19.45%"
      ],
      [
        "T15",
        "时间范围",
        89,
        94,
        "2021年"
      ],
      [
        "T16",
        "属性值",
        98,
        103,
        "375亿元"
      ],
      [
        "T17",
        "市场份额",
        109,
        113,
        "市场份额"
      ],
      [
        "T18",
        "时间范围",
        115,
        120,
        "2017年"
      ],
      [
        "T19",
        "地点范围",
        121,
        123,
        "我国"
      ],
      [
        "T20",
        "行业",
        123,
        128,
        "角膜塑形镜"
      ],
      [
        "T21",
        "行业",
        129,
        135,
        "眼科医疗器械"
      ],
      [
        "T22",
        "属性值",
        139,
        144,
        "21.6%"
      ],
      [
        "T23",
        "行业",
        145,
        149,
        "人工晶体"
      ],
      [
        "T24",
        "属性值",
        153,
        158,
        "17.4%"
      ]
    ]
  },
  {
    "id": 2308,
    "text": " 4家医疗服务公司2021Q1-3收入约为291亿元（+40%）、归母净利润总额约为46.2亿元（+43%），行业前三季度表观增速较高，除了金域医学前三季度仍有新冠检测业务增量，板块内各项常规业务相对于2019年的复合增长率约为20~30%左右，已经回归正常水平。我们的样本公司数量较少，没有包括尚未转盈的公司，因此样本内的优质企业表现出整体毛利率保持较高水平，叠加持续的规模效应压低费率，整体盈利质量保持较高水平。",
    "labels": [
      [
        "T0",
        "行业公司",
        2,
        10,
        "4家医疗服务公司"
      ],
      [
        "T1",
        "时间范围",
        10,
        18,
        "2021Q1-3"
      ],
      [
        "T2",
        "营业收入",
        18,
        20,
        "收入"
      ],
      [
        "T3",
        "属性值",
        20,
        27,
        "约为291亿元"
      ],
      [
        "T4",
        "属性值",
        28,
        32,
        "+40%"
      ],
      [
        "T5",
        "归母净利润",
        34,
        39,
        "归母净利润"
      ],
      [
        "T6",
        "属性值",
        41,
        55,
        "约为46.2亿元（+43%）"
      ],
      [
        "T7",
        "时间范围",
        58,
        62,
        "前三季度"
      ],
      [
        "T8",
        "公司",
        71,
        75,
        "金域医学"
      ],
      [
        "T9",
        "时间范围",
        75,
        79,
        "前三季度"
      ],
      [
        "T10",
        "行业",
        81,
        85,
        "新冠检测"
      ],
      [
        "T11",
        "时间范围",
        102,
        107,
        "2019年"
      ],
      [
        "T12",
        "CAGR",
        108,
        113,
        "复合增长率"
      ],
      [
        "T13",
        "属性值",
        113,
        123,
        "约为20~30%左右"
      ],
      [
        "T14",
        "属性值",
        90,
        99,
        "板块内各项常规业务"
      ]
    ]
  },
  {
    "id": 2316,
    "text": " 4家医疗服务公司2021Q1-3收入约为291亿元（+40.2%）、归母净利润总额约为46.2亿元（+43%）。  从盈利水平看，医疗服务板块整体盈利能力稳中有升，Q3季度行业毛利率（47%）同比提升2.2个pp，销售费用率（9%）保持稳定，净利率 （17.7%）下降0.8个pp。  从收入贡献看，爱尔眼科、金域医学、润达医疗、通策医疗贡献比例为 40%、30%、23%、7%；  从净利润贡献看，爱尔眼科、金域医学、通策医疗、润达医疗贡献比例为43%、36%、14%、7%。",
    "labels": [
      [
        "T0",
        "行业公司",
        2,
        10,
        "4家医疗服务公司"
      ],
      [
        "T1",
        "时间范围",
        10,
        18,
        "2021Q1-3"
      ],
      [
        "T2",
        "营业收入",
        18,
        20,
        "收入"
      ],
      [
        "T3",
        "属性值",
        20,
        27,
        "约为291亿元"
      ],
      [
        "T4",
        "属性值",
        28,
        34,
        "+40.2%"
      ],
      [
        "T5",
        "归母净利润",
        36,
        41,
        "归母净利润"
      ],
      [
        "T6",
        "行业",
        68,
        72,
        "医疗服务"
      ],
      [
        "T7",
        "时间范围",
        85,
        87,
        "Q3"
      ],
      [
        "T8",
        "毛利",
        91,
        94,
        "毛利率"
      ],
      [
        "T9",
        "属性值",
        94,
        109,
        "（47%）同比提升2.2个pp"
      ],
      [
        "T10",
        "归母净利润",
        124,
        127,
        "净利率"
      ],
      [
        "T11",
        "属性值",
        128,
        142,
        "（17.7%）下降0.8个p"
      ],
      [
        "T12",
        "公司",
        154,
        158,
        "爱尔眼科"
      ],
      [
        "T13",
        "公司",
        159,
        163,
        "金域医学"
      ],
      [
        "T14",
        "公司",
        164,
        168,
        "润达医疗"
      ],
      [
        "T15",
        "公司",
        169,
        173,
        "通策医疗"
      ],
      [
        "T16",
        "属性值",
        179,
        182,
        "40%"
      ],
      [
        "T17",
        "属性值",
        183,
        186,
        "30%"
      ],
      [
        "T18",
        "属性值",
        187,
        190,
        "23%"
      ],
      [
        "T19",
        "属性值",
        191,
        193,
        "7%"
      ],
      [
        "T20",
        "公司",
        205,
        209,
        "爱尔眼科"
      ],
      [
        "T21",
        "公司",
        210,
        214,
        "金域医学"
      ],
      [
        "T22",
        "公司",
        215,
        219,
        "通策医疗"
      ],
      [
        "T23",
        "公司",
        220,
        224,
        "润达医疗"
      ],
      [
        "T24",
        "属性值",
        43,
        57,
        "约为46.2亿元（+43%）"
      ]
    ]
  },
  {
    "id": 2321,
    "text": " 我们选取了234家医药上市公司（不包含科创板），2021年上半年收入总额8711亿元，归母净利润961亿元，分别占申万医药全成分结果比例是：80%、82%，主要剔除了在 2019、2020年提取巨额商誉减值损失的企业、在2021年1月及以后上市的公司。  2021年上半年全行业收入增速为24.7%，归母净利润增速为 34.1%。  2021年上半年实现归母净利润正增长的公司有180家，占比 77%，85%（199/233）的公司实现收入正增长。",
    "labels": [
      [
        "T0",
        "行业公司",
        7,
        17,
        "234家医药上市公司"
      ],
      [
        "T1",
        "时间范围",
        27,
        34,
        "021年上半年"
      ],
      [
        "T2",
        "营业收入",
        34,
        36,
        "收入"
      ],
      [
        "T3",
        "属性值",
        38,
        44,
        "8711亿元"
      ],
      [
        "T4",
        "归母净利润",
        45,
        50,
        "归母净利润"
      ],
      [
        "T5",
        "属性值",
        50,
        55,
        "961亿元"
      ],
      [
        "T6",
        "行业",
        61,
        63,
        "医药"
      ],
      [
        "T7",
        "属性值",
        72,
        75,
        "80%"
      ],
      [
        "T8",
        "时间范围",
        87,
        91,
        "2019"
      ],
      [
        "T9",
        "时间范围",
        92,
        97,
        "2020年"
      ],
      [
        "T10",
        "时间范围",
        112,
        119,
        "2021年1月"
      ],
      [
        "T11",
        "时间范围",
        131,
        139,
        "2021年上半年"
      ],
      [
        "T12",
        "收入增速",
        142,
        146,
        "收入增速"
      ],
      [
        "T13",
        "归母净利润增速",
        153,
        160,
        "归母净利润增速"
      ],
      [
        "T14",
        "时间范围",
        171,
        179,
        "2021年上半年"
      ],
      [
        "T15",
        "归母净利润",
        181,
        186,
        "归母净利润"
      ],
      [
        "T16",
        "营业收入",
        222,
        224,
        "收入"
      ]
    ]
  },
  {
    "id": 2322,
    "text": "康泰生物：作为疫苗行业龙头企业之一及目前疫苗销售种类最多的企业之一，公司有望在未来多个自主研发的重磅品种兑现中实现长期良性高速增长。（1）公司目前产品竞争格局良好，百白破-Hib四联苗和60μg乙肝疫苗为独家品种， 潜在市场规模较大；13价肺炎结合疫苗为国内第三家，领先后来者3-4年；人二倍体狂犬疫苗有望第二家上市，领先第三家2-3年；在研管线及临床后期重磅产品数量均居行业前列。（2）公司研发投入持续加大，研发团队不断扩容，同时积极开展国际合作项目，富集全球领先技术，共同助力推动创新管线研发。",
    "labels": [
      [
        "T0",
        "公司",
        1,
        5,
        "康泰生物"
      ],
      [
        "T1",
        "行业",
        8,
        10,
        "疫苗"
      ],
      [
        "T2",
        "龙头企业",
        12,
        16,
        "龙头企业"
      ],
      [
        "T3",
        "时间范围",
        19,
        21,
        "目前"
      ],
      [
        "T4",
        "时间范围",
        40,
        42,
        "未来"
      ],
      [
        "T5",
        "时间范围",
        72,
        74,
        "目前"
      ],
      [
        "T6",
        "竞争格局",
        76,
        80,
        "竞争格局"
      ],
      [
        "T7",
        "属性值",
        80,
        82,
        "良好"
      ],
      [
        "T8",
        "市场规模",
        111,
        115,
        "市场规模"
      ],
      [
        "T9",
        "地点范围",
        128,
        130,
        "国内"
      ],
      [
        "T10",
        "研发费用",
        197,
        201,
        "研发投入"
      ],
      [
        "T11",
        "属性值",
        201,
        205,
        "持续加大"
      ],
      [
        "T12",
        "地点范围",
        230,
        232,
        "全球"
      ]
    ]
  },
  {
    "id": 2326,
    "text": " 眼科器械：根据中国医疗器械行业发展报告，2014-2019 年，我国眼科器械市场规模自111亿元增长至约267亿元， 行业复合增长率达到19.2%。其中眼科高值耗材占比约1/3 ，2018年市场规模为76亿元。  人工晶体：2018年全国人工晶体销量370万片，CSR（每百万人口白内障手术量）为2662例，相比美欧日10000例以上的水平还有很大提升空间。从份额看，进口品牌占据国内市场绝大多数份额，国产品牌销量占比约为20%。软性人工晶体为主要战场，多焦点和叠加附加技术的高端产品仍以进口企业为主。随着带量采购推行和国产技术突破 ，未来国产率有望不断提升。  角膜塑形镜：青少年近视防控需求旺盛，驱动角膜塑形镜市场持续扩容，预计2019年渗透率提升至1.1%，覆盖人群 108万人，行业出厂总规模约为16亿元。  爱博医疗：2021上半年收入2.1亿元（+99.2%），归母净利润0.9亿元（+143.6%），2021H1人工晶体收入1.54亿元（+71.4%），2021H1角膜塑形镜收入4422万元，同比增长308.1%。  欧普康视：上半年收入5.7亿元（+91.9%）, 归母净利润 2.6亿元（+100.1%），其中角膜塑形镜收入3.3亿元（ +81.3%），延续高增长态势。",
    "labels": [
      [
        "T0",
        "行业",
        2,
        6,
        "眼科器械"
      ],
      [
        "T1",
        "地点范围",
        9,
        11,
        "中国"
      ],
      [
        "T2",
        "行业",
        11,
        15,
        "医疗器械"
      ],
      [
        "T3",
        "时间范围",
        22,
        26,
        "2014"
      ],
      [
        "T4",
        "时间范围",
        27,
        33,
        "2019 年"
      ],
      [
        "T5",
        "地点范围",
        34,
        36,
        "我国"
      ],
      [
        "T6",
        "行业",
        36,
        40,
        "眼科器械"
      ],
      [
        "T7",
        "市场规模",
        40,
        44,
        "市场规模"
      ],
      [
        "T8",
        "属性值",
        45,
        50,
        "111亿元"
      ],
      [
        "T9",
        "属性值",
        53,
        59,
        "约267亿元"
      ],
      [
        "T10",
        "CAGR",
        63,
        68,
        "复合增长率"
      ],
      [
        "T11",
        "属性值",
        70,
        75,
        "19.2%"
      ],
      [
        "T12",
        "行业",
        78,
        84,
        "眼科高值耗材"
      ],
      [
        "T13",
        "属性值",
        87,
        90,
        "1/3"
      ],
      [
        "T14",
        "时间范围",
        92,
        97,
        "2018年"
      ],
      [
        "T15",
        "市场规模",
        97,
        101,
        "市场规模"
      ],
      [
        "T16",
        "属性值",
        102,
        106,
        "76亿元"
      ],
      [
        "T17",
        "行业",
        110,
        114,
        "人工晶体"
      ],
      [
        "T18",
        "时间范围",
        115,
        120,
        "2018年"
      ],
      [
        "T19",
        "地点范围",
        120,
        122,
        "全国"
      ],
      [
        "T20",
        "行业",
        122,
        126,
        "人工晶体"
      ],
      [
        "T21",
        "地点范围",
        159,
        160,
        "美"
      ],
      [
        "T22",
        "地点范围",
        160,
        161,
        "欧"
      ],
      [
        "T23",
        "地点范围",
        161,
        162,
        "日"
      ],
      [
        "T24",
        "地点范围",
        193,
        195,
        "国内"
      ],
      [
        "T25",
        "行业",
        218,
        224,
        "软性人工晶体"
      ],
      [
        "T26",
        "行业",
        286,
        291,
        "角膜塑形镜"
      ],
      [
        "T27",
        "行业需求",
        299,
        301,
        "需求"
      ],
      [
        "T28",
        "属性值",
        301,
        303,
        "旺盛"
      ],
      [
        "T29",
        "行业",
        306,
        311,
        "角膜塑形镜"
      ],
      [
        "T30",
        "时间范围",
        320,
        325,
        "2019年"
      ],
      [
        "T31",
        "公司",
        364,
        368,
        "爱博医疗"
      ],
      [
        "T32",
        "时间范围",
        369,
        376,
        "2021上半年"
      ],
      [
        "T33",
        "营业收入",
        376,
        378,
        "收入"
      ],
      [
        "T34",
        "属性值",
        378,
        383,
        "2.1亿元"
      ],
      [
        "T35",
        "属性值",
        384,
        390,
        "+99.2%"
      ],
      [
        "T36",
        "归母净利润",
        392,
        397,
        "归母净利润"
      ],
      [
        "T37",
        "属性值",
        397,
        411,
        "0.9亿元（+143.6%）"
      ],
      [
        "T38",
        "时间范围",
        412,
        418,
        "2021H1"
      ],
      [
        "T39",
        "行业",
        418,
        422,
        "人工晶体"
      ],
      [
        "T40",
        "营业收入",
        422,
        424,
        "收入"
      ],
      [
        "T41",
        "属性值",
        424,
        430,
        "1.54亿元"
      ],
      [
        "T42",
        "属性值",
        431,
        437,
        "+71.4%"
      ],
      [
        "T43",
        "时间范围",
        439,
        445,
        "2021H1"
      ],
      [
        "T44",
        "行业",
        445,
        450,
        "角膜塑形镜"
      ],
      [
        "T45",
        "营业收入",
        450,
        452,
        "收入"
      ],
      [
        "T46",
        "属性值",
        452,
        458,
        "4422万元"
      ],
      [
        "T47",
        "属性值",
        463,
        469,
        "308.1%"
      ],
      [
        "T48",
        "公司",
        473,
        477,
        "欧普康视"
      ],
      [
        "T49",
        "时间范围",
        478,
        481,
        "上半年"
      ],
      [
        "T50",
        "营业收入",
        481,
        483,
        "收入"
      ],
      [
        "T51",
        "属性值",
        483,
        488,
        "5.7亿元"
      ],
      [
        "T52",
        "属性值",
        489,
        495,
        "+91.9%"
      ],
      [
        "T53",
        "归母净利润",
        498,
        503,
        "归母净利润"
      ],
      [
        "T54",
        "属性值",
        504,
        518,
        "2.6亿元（+100.1%）"
      ],
      [
        "T55",
        "行业",
        521,
        526,
        "角膜塑形镜"
      ],
      [
        "T56",
        "营业收入",
        526,
        528,
        "收入"
      ],
      [
        "T57",
        "属性值",
        528,
        533,
        "3.3亿元"
      ],
      [
        "T58",
        "属性值",
        535,
        541,
        "+81.3%"
      ],
      [
        "T59",
        "时间连接词",
        26,
        27,
        "-"
      ],
      [
        "T60",
        "属性值",
        313,
        317,
        "持续扩容"
      ]
    ]
  },
  {
    "id": 2333,
    "text": "2.1.CXO行业——CXO行业景气度跟踪框架：全球β：跨国药企研发投入跨国药企研发投入作为全球医药创新的主力，是全球医药创新的底层β",
    "labels": [
      [
        "T0",
        "行业",
        3,
        7,
        ".CXO"
      ],
      [
        "T1",
        "行业",
        11,
        14,
        "CXO"
      ],
      [
        "T2",
        "行业公司",
        28,
        32,
        "跨国药企"
      ],
      [
        "T3",
        "研发费用",
        32,
        36,
        "研发投入"
      ],
      [
        "T4",
        "行业公司",
        36,
        40,
        "跨国药企"
      ],
      [
        "T5",
        "研发费用",
        40,
        44,
        "研发投入"
      ],
      [
        "T6",
        "地点范围",
        57,
        59,
        "全球"
      ],
      [
        "T7",
        "地点范围",
        46,
        48,
        "全球"
      ],
      [
        "T8",
        "行业",
        48,
        52,
        "医药创新"
      ],
      [
        "T9",
        "行业",
        59,
        63,
        "医药创新"
      ]
    ]
  },
  {
    "id": 2335,
    "text": "昭衍新药在 2018至 2020年营业收入由 4.1亿人民币增长至 10.8亿人民币，年均复合增长率为 62.3%， 归母净利润由 1.1亿人民币增长至 3.2亿人民币，年均复合增长率为 70.8%。公司 2021年 Q1-Q3实现营业收入 8.57亿人民币，同比增长 36%，实现归母净利润 2.48亿人民币，收入端与利润端均保持高速增长。",
    "labels": [
      [
        "T0",
        "公司",
        0,
        4,
        "昭衍新药"
      ],
      [
        "T1",
        "时间范围",
        5,
        10,
        " 2018"
      ],
      [
        "T2",
        "时间范围",
        12,
        17,
        "2020年"
      ],
      [
        "T3",
        "营业收入",
        17,
        21,
        "营业收入"
      ],
      [
        "T4",
        "属性值",
        23,
        30,
        "4.1亿人民币"
      ],
      [
        "T5",
        "属性值",
        34,
        42,
        "10.8亿人民币"
      ],
      [
        "T6",
        "CAGR",
        43,
        50,
        "年均复合增长率"
      ],
      [
        "T7",
        "属性值",
        52,
        57,
        "62.3%"
      ],
      [
        "T8",
        "归母净利润",
        59,
        64,
        "归母净利润"
      ],
      [
        "T9",
        "属性值",
        66,
        73,
        "1.1亿人民币"
      ],
      [
        "T10",
        "属性值",
        77,
        84,
        "3.2亿人民币"
      ],
      [
        "T11",
        "CAGR",
        85,
        92,
        "年均复合增长率"
      ],
      [
        "T12",
        "属性值",
        94,
        99,
        "70.8%"
      ],
      [
        "T13",
        "时间范围",
        103,
        114,
        "2021年 Q1-Q3"
      ],
      [
        "T14",
        "营业收入",
        116,
        120,
        "营业收入"
      ],
      [
        "T15",
        "属性值",
        121,
        129,
        "8.57亿人民币"
      ],
      [
        "T16",
        "属性值",
        135,
        138,
        "36%"
      ],
      [
        "T17",
        "归母净利润",
        141,
        146,
        "归母净利润"
      ],
      [
        "T18",
        "属性值",
        147,
        155,
        "2.48亿人民币"
      ],
      [
        "T19",
        "营业收入",
        156,
        159,
        "收入端"
      ],
      [
        "T20",
        "利润",
        160,
        163,
        "利润端"
      ],
      [
        "T21",
        "属性值",
        166,
        170,
        "高速增长"
      ],
      [
        "T22",
        "时间连接词",
        10,
        12,
        "至 "
      ]
    ]
  },
  {
    "id": 2338,
    "text": " 我们选取了234家医药上市公司（不包含科创板），2021年上半年收入总额8711亿元，归母净利润961亿元，分别占申万医药全成分结果比例是：80%、82%，主要剔除了在2019、2020年提取巨额商誉减值损失的企业、在2021年1月及以后上市的公司。2021年上半年全行业收入增速为24.7%，归母净利润增速为34.1%。2021年上半年实现归母净利润正增长的公司有180家，占比77%，85%（199/233） 的公司实现收入正增长。  同时我们选取了52家科创板医药上市公司，上半年收入总额362亿元，归母净利润109亿元，主要剔除了在2021年1月及以后上市的公司 。2021年上半年收入增速109%，净利润增速250% ，扣非净利润增速267%。上半年实现业绩正增长的公司有41家，占比79%，多数公司实现收入正增长（87%，45/52）。",
    "labels": [
      [
        "T0",
        "行业公司",
        7,
        17,
        "234家医药上市公司"
      ],
      [
        "T1",
        "时间范围",
        26,
        34,
        "2021年上半年"
      ],
      [
        "T2",
        "营业收入",
        34,
        36,
        "收入"
      ],
      [
        "T3",
        "属性值",
        38,
        44,
        "8711亿元"
      ],
      [
        "T4",
        "归母净利润",
        45,
        50,
        "归母净利润"
      ],
      [
        "T5",
        "属性值",
        50,
        55,
        "961亿元"
      ],
      [
        "T6",
        "行业",
        61,
        63,
        "医药"
      ],
      [
        "T7",
        "属性值",
        72,
        75,
        "80%"
      ],
      [
        "T8",
        "时间范围",
        86,
        90,
        "2019"
      ],
      [
        "T9",
        "时间范围",
        91,
        96,
        "2020年"
      ],
      [
        "T10",
        "时间范围",
        111,
        118,
        "2021年1月"
      ],
      [
        "T11",
        "时间范围",
        127,
        135,
        "2021年上半年"
      ],
      [
        "T12",
        "收入增速",
        138,
        142,
        "收入增速"
      ],
      [
        "T13",
        "归母净利润增速",
        149,
        156,
        "归母净利润增速"
      ],
      [
        "T14",
        "时间范围",
        163,
        171,
        "2021年上半年"
      ],
      [
        "T15",
        "归母净利润",
        173,
        178,
        "归母净利润"
      ],
      [
        "T16",
        "行业公司",
        230,
        242,
        "52家科创板医药上市公司"
      ],
      [
        "T17",
        "时间范围",
        243,
        246,
        "上半年"
      ],
      [
        "T18",
        "营业收入",
        246,
        248,
        "收入"
      ],
      [
        "T19",
        "属性值",
        250,
        255,
        "362亿元"
      ],
      [
        "T20",
        "归母净利润",
        256,
        261,
        "归母净利润"
      ],
      [
        "T21",
        "属性值",
        261,
        266,
        "109亿元"
      ],
      [
        "T22",
        "时间范围",
        273,
        283,
        "2021年1月及以后"
      ],
      [
        "T23",
        "时间范围",
        290,
        298,
        "2021年上半年"
      ],
      [
        "T24",
        "收入增速",
        298,
        302,
        "收入增速"
      ],
      [
        "T25",
        "属性值",
        302,
        306,
        "109%"
      ],
      [
        "T26",
        "归母净利润增速",
        307,
        312,
        "净利润增速"
      ],
      [
        "T27",
        "属性值",
        312,
        316,
        "250%"
      ],
      [
        "T28",
        "扣非净利润增速",
        318,
        325,
        "扣非净利润增速"
      ],
      [
        "T29",
        "属性值",
        325,
        329,
        "267%"
      ],
      [
        "T30",
        "业绩",
        330,
        333,
        "上半年"
      ],
      [
        "T31",
        "营业收入",
        360,
        362,
        "收入"
      ],
      [
        "T32",
        "属性值",
        143,
        148,
        "24.7%"
      ],
      [
        "T33",
        "属性值",
        157,
        162,
        "34.1%"
      ]
    ]
  },
  {
    "id": 2341,
    "text": "在市场收入份额方面，年收入大于 5亿美元的 CDMO企业占据了高达 31%的市场份额。目前全球收入顶尖的 CDMO包括瑞士 Lonza与美国 Catalent， 2020年自然年营业收入分别为 45亿法郎和 35亿美元。 其他营业收入规模达到全球第一梯队水平即大于 5亿美元的公司包括 Patheon、Aenova、Boehringer Ingelheim、Siegfreid、三星生物、Recipharm、Curia（AMRI）、Celltrion、药明康德、药明生物。收入规模在 2.5亿美元至 5亿美元的公司包括 Jubilant、凯莱英、博腾股份和康龙化成，其中康龙化成虽然整体收入达到 5亿美元以上，但是其中 CDMO业务收入仍低于 5亿美元。从收入规模来看，中国公司药明康德与药明生物虽然与顶尖 CDMO公司收入仍有差距，但是收入水平已到达全球第一梯队水平， 凯莱英、康龙化成与博腾股份收入规模已达到第二梯队水平。（注：Catalent原始财报财年为前一自然年 7月初至次年 6月底，为便于比较此处已按照自然年进行核算调整）。",
    "labels": [
      [
        "T0",
        "公司",
        59,
        67,
        "瑞士 Lonza"
      ],
      [
        "T1",
        "公司",
        68,
        79,
        "美国 Catalent"
      ],
      [
        "T2",
        "时间范围",
        81,
        86,
        "2020年"
      ],
      [
        "T3",
        "营业收入",
        89,
        93,
        "营业收入"
      ],
      [
        "T4",
        "属性值",
        97,
        102,
        "45亿法郎"
      ],
      [
        "T5",
        "属性值",
        104,
        109,
        "35亿美元"
      ],
      [
        "T6",
        "时间范围",
        43,
        45,
        "目前"
      ],
      [
        "T7",
        "地点范围",
        45,
        47,
        "全球"
      ],
      [
        "T8",
        "营业收入",
        47,
        49,
        "收入"
      ],
      [
        "T9",
        "行业",
        53,
        57,
        "CDMO"
      ],
      [
        "T10",
        "市场份额",
        38,
        42,
        "市场份额"
      ],
      [
        "T11",
        "属性值",
        34,
        37,
        "31%"
      ],
      [
        "T12",
        "行业公司",
        10,
        28,
        "年收入大于 5亿美元的 CDMO企业"
      ],
      [
        "T13",
        "市场份额",
        3,
        7,
        "收入份额"
      ],
      [
        "T14",
        "营业收入",
        113,
        117,
        "营业收入"
      ],
      [
        "T15",
        "地点范围",
        121,
        123,
        "全球"
      ],
      [
        "T16",
        "公司",
        143,
        150,
        "Patheon"
      ],
      [
        "T17",
        "公司",
        151,
        157,
        "Aenova"
      ],
      [
        "T18",
        "公司",
        158,
        178,
        "Boehringer Ingelheim"
      ],
      [
        "T19",
        "公司",
        179,
        188,
        "Siegfreid"
      ],
      [
        "T20",
        "公司",
        189,
        193,
        "三星生物"
      ],
      [
        "T21",
        "公司",
        194,
        203,
        "Recipharm"
      ],
      [
        "T22",
        "公司",
        204,
        215,
        "Curia（AMRI）"
      ],
      [
        "T23",
        "公司",
        216,
        225,
        "Celltrion"
      ],
      [
        "T24",
        "公司",
        226,
        230,
        "药明康德"
      ],
      [
        "T25",
        "公司",
        231,
        235,
        "药明生物"
      ],
      [
        "T26",
        "属性值",
        130,
        137,
        "大于 5亿美元"
      ],
      [
        "T27",
        "营业收入",
        236,
        238,
        "收入"
      ],
      [
        "T28",
        "属性值",
        242,
        254,
        "2.5亿美元至 5亿美元"
      ],
      [
        "T29",
        "公司",
        260,
        268,
        "Jubilant"
      ],
      [
        "T30",
        "公司",
        269,
        272,
        "凯莱英"
      ],
      [
        "T31",
        "公司",
        273,
        277,
        "博腾股份"
      ],
      [
        "T32",
        "公司",
        278,
        282,
        "康龙化成"
      ],
      [
        "T33",
        "公司",
        285,
        289,
        "康龙化成"
      ],
      [
        "T34",
        "营业收入",
        293,
        295,
        "收入"
      ],
      [
        "T35",
        "属性值",
        298,
        304,
        "5亿美元以上"
      ],
      [
        "T36",
        "行业",
        310,
        314,
        "CDMO"
      ],
      [
        "T37",
        "营业收入",
        316,
        318,
        "收入"
      ],
      [
        "T38",
        "属性值",
        319,
        326,
        "低于 5亿美元"
      ],
      [
        "T39",
        "营业收入",
        328,
        330,
        "收入"
      ],
      [
        "T40",
        "地点范围",
        335,
        337,
        "中国"
      ],
      [
        "T41",
        "公司",
        339,
        343,
        "药明康德"
      ],
      [
        "T42",
        "公司",
        344,
        348,
        "药明生物"
      ],
      [
        "T43",
        "行业公司",
        354,
        360,
        "CDMO公司"
      ],
      [
        "T44",
        "营业收入",
        360,
        362,
        "收入"
      ],
      [
        "T45",
        "营业收入",
        369,
        371,
        "收入"
      ],
      [
        "T46",
        "地点范围",
        376,
        378,
        "全球"
      ],
      [
        "T47",
        "公司",
        386,
        389,
        "凯莱英"
      ],
      [
        "T48",
        "公司",
        390,
        394,
        "康龙化成"
      ],
      [
        "T49",
        "公司",
        395,
        399,
        "博腾股份"
      ],
      [
        "T50",
        "营业收入",
        399,
        401,
        "收入"
      ],
      [
        "T51",
        "公司",
        416,
        424,
        "Catalent"
      ]
    ]
  },
  {
    "id": 2345,
    "text": "港股行情回顾：医药整体跑赢大盘，CXO及互联网医疗表现较好",
    "labels": [
      [
        "T0",
        "行业",
        7,
        9,
        "医药"
      ],
      [
        "T1",
        "行业",
        16,
        19,
        "CXO"
      ],
      [
        "T2",
        "行业",
        20,
        25,
        "互联网医疗"
      ]
    ]
  },
  {
    "id": 2363,
    "text": " 2021年起国内浆站建设显著加快，其中天坛生物一家新增建设浆站15家，获批1家；华润集团入主博雅生物后，浆站建设亦大幅加快，已获批2家，新取得浆站建设县级批文19家。  新建浆站预计2022年起陆续取得单采血浆许可证，对行业采浆增长贡献预计将显著提速",
    "labels": [
      [
        "T0",
        "时间范围",
        2,
        7,
        "2021年"
      ],
      [
        "T1",
        "地点范围",
        8,
        10,
        "国内"
      ],
      [
        "T2",
        "公司",
        21,
        25,
        "天坛生物"
      ],
      [
        "T3",
        "公司",
        42,
        46,
        "华润集团"
      ],
      [
        "T4",
        "公司",
        48,
        52,
        "博雅生物"
      ],
      [
        "T5",
        "时间范围",
        94,
        99,
        "2022年"
      ]
    ]
  },
  {
    "id": 2365,
    "text": " 从ROE水平来看，2021Q1-3美迪西、九洲药业、博腾股份和药石科技等几家企业提升显著，ROE提升主要与企业净利润率提升有关，另外几家CXO企业ROE水平小幅下降，主要因扩产速度较快，周转率下降有关，另外，CXO公司公允价值变动损益以及投资收益波动较大， 对ROE造成一定波动。  从现金流情况来看，近几年我国CXO企业经营活动产生的现金流量净额/经营活动净收益持续下降，2020年大幅好转，2021Q1-3为97.8% ，同比小幅下降，预计四季度随着收入逐步确认，现金流有望继续向好。",
    "labels": [
      [
        "T0",
        "时间范围",
        11,
        19,
        "2021Q1-3"
      ],
      [
        "T1",
        "ROE净资产回报率",
        3,
        6,
        "ROE"
      ],
      [
        "T2",
        "公司",
        19,
        22,
        "美迪西"
      ],
      [
        "T3",
        "公司",
        23,
        27,
        "九洲药业"
      ],
      [
        "T4",
        "公司",
        28,
        32,
        "博腾股份"
      ],
      [
        "T5",
        "公司",
        33,
        37,
        "药石科技"
      ],
      [
        "T6",
        "属性值",
        42,
        46,
        "提升显著"
      ],
      [
        "T7",
        "行业公司",
        70,
        75,
        "CXO企业"
      ],
      [
        "T8",
        "ROE净资产回报率",
        75,
        78,
        "ROE"
      ],
      [
        "T9",
        "属性值",
        80,
        84,
        "小幅下降"
      ],
      [
        "T10",
        "行业公司",
        106,
        111,
        "CXO公司"
      ],
      [
        "T11",
        "ROE净资产回报率",
        132,
        135,
        "ROE"
      ],
      [
        "T12",
        "属性值",
        137,
        141,
        "一定波动"
      ],
      [
        "T13",
        "现金流",
        146,
        149,
        "现金流"
      ],
      [
        "T14",
        "时间范围",
        154,
        157,
        "近几年"
      ],
      [
        "T15",
        "地点范围",
        157,
        159,
        "我国"
      ],
      [
        "T16",
        "行业公司",
        159,
        164,
        "CXO企业"
      ],
      [
        "T17",
        "时间范围",
        190,
        195,
        "2020年"
      ],
      [
        "T18",
        "时间范围",
        200,
        208,
        "2021Q1-3"
      ],
      [
        "T19",
        "时间范围",
        225,
        228,
        "四季度"
      ],
      [
        "T20",
        "营业收入",
        230,
        232,
        "收入"
      ],
      [
        "T21",
        "现金流",
        237,
        240,
        "现金流"
      ],
      [
        "T22",
        "属性值",
        242,
        246,
        "继续向好"
      ]
    ]
  },
  {
    "id": 2368,
    "text": "东富龙、楚天科技等主要制药装备厂商2021年以来均实现业绩增速的显著提升，且合同负债这一先行指标截止Q3仍保持着环比增长态势。根据公司公告，东富龙2021Q1-3实现收入28.8亿元，同比增长54.6%；合同负债方面，截止 Q3末共计33亿元，相比2020年末/2021年初增长了65%，季度环比增速保持在20%左右。楚天科技2021Q1-3实现收入36.8亿元，同比增长67.2%；合同负债方面，截止Q3末共计25亿元，相比2020年末/2021年初增长了134%，季度环比增长保持在30%左右。除上述两家之外，迦南科技、新华医疗、诚益通等其他国产制药装备厂商同样获得了因市场景气度提升带来的不同程度的受益。",
    "labels": [
      [
        "T0",
        "公司",
        1,
        4,
        "东富龙"
      ],
      [
        "T1",
        "公司",
        5,
        9,
        "楚天科技"
      ],
      [
        "T2",
        "行业公司",
        10,
        18,
        "主要制药装备厂商"
      ],
      [
        "T3",
        "时间范围",
        18,
        25,
        "2021年以来"
      ],
      [
        "T4",
        "业绩",
        28,
        30,
        "业绩"
      ],
      [
        "T5",
        "属性值",
        30,
        37,
        "增速的显著提升"
      ],
      [
        "T6",
        "合同负债",
        39,
        43,
        "合同负债"
      ],
      [
        "T7",
        "时间范围",
        49,
        53,
        "截止Q3"
      ],
      [
        "T8",
        "属性值",
        57,
        61,
        "环比增长"
      ],
      [
        "T9",
        "公司",
        71,
        74,
        "东富龙"
      ],
      [
        "T10",
        "时间范围",
        74,
        82,
        "2021Q1-3"
      ],
      [
        "T11",
        "营业收入",
        84,
        86,
        "收入"
      ],
      [
        "T12",
        "属性值",
        86,
        92,
        "28.8亿元"
      ],
      [
        "T13",
        "属性值",
        97,
        102,
        "54.6%"
      ],
      [
        "T14",
        "合同负债",
        103,
        107,
        "合同负债"
      ],
      [
        "T15",
        "时间范围",
        110,
        116,
        "截止 Q3末"
      ],
      [
        "T16",
        "属性值",
        118,
        122,
        "33亿元"
      ],
      [
        "T17",
        "时间范围",
        125,
        131,
        "2020年末"
      ],
      [
        "T18",
        "时间范围",
        132,
        138,
        "2021年初"
      ],
      [
        "T19",
        "属性值",
        138,
        144,
        "增长了65%"
      ],
      [
        "T20",
        "公司",
        160,
        164,
        "楚天科技"
      ],
      [
        "T21",
        "时间范围",
        164,
        172,
        "2021Q1-3"
      ],
      [
        "T22",
        "营业收入",
        174,
        176,
        "收入"
      ],
      [
        "T23",
        "属性值",
        176,
        182,
        "36.8亿元"
      ],
      [
        "T24",
        "属性值",
        187,
        192,
        "67.2%"
      ],
      [
        "T25",
        "合同负债",
        193,
        197,
        "合同负债"
      ],
      [
        "T26",
        "时间范围",
        200,
        205,
        "截止Q3末"
      ],
      [
        "T27",
        "属性值",
        207,
        211,
        "25亿元"
      ],
      [
        "T28",
        "时间范围",
        214,
        220,
        "2020年末"
      ],
      [
        "T29",
        "时间范围",
        221,
        227,
        "2021年初"
      ],
      [
        "T30",
        "属性值",
        227,
        234,
        "增长了134%"
      ],
      [
        "T31",
        "公司",
        258,
        262,
        "迦南科技"
      ],
      [
        "T32",
        "公司",
        263,
        267,
        "新华医疗"
      ],
      [
        "T33",
        "公司",
        268,
        271,
        "诚益通"
      ],
      [
        "T34",
        "行业公司",
        274,
        282,
        "国产制药装备厂商"
      ]
    ]
  },
  {
    "id": 2375,
    "text": "• CXO行业自2018年集采落地后、悲观情绪逐渐反转、且优秀公司逐渐上市和业绩持续超预期，驱动整体CXO估值水平呈现上升趋势。 • 近期CXO估值水平已有一定幅度的系统调整，逐渐进入相对合理的估值水平：近期受到美国Q3投融资数据边际变化以及CXO个股三季报业绩波动等因素影响，目前CXO指数已有一定程度的调整，已逐渐进入相对合理的估值水平。",
    "labels": [
      [
        "T0",
        "行业",
        1,
        5,
        " CXO"
      ],
      [
        "T1",
        "时间范围",
        8,
        13,
        "2018年"
      ],
      [
        "T2",
        "行业",
        50,
        53,
        "CXO"
      ],
      [
        "T3",
        "行业",
        69,
        72,
        "CXO"
      ],
      [
        "T4",
        "时间范围",
        108,
        110,
        "Q3"
      ],
      [
        "T5",
        "地点范围",
        106,
        108,
        "美国"
      ],
      [
        "T6",
        "行业",
        141,
        144,
        "CXO"
      ],
      [
        "T7",
        "业绩",
        38,
        40,
        "业绩"
      ],
      [
        "T8",
        "属性值",
        40,
        45,
        "持续超预期"
      ],
      [
        "T9",
        "时间范围",
        67,
        69,
        "近期"
      ],
      [
        "T10",
        "投融资情况",
        110,
        115,
        "投融资数据"
      ],
      [
        "T11",
        "行业公司",
        121,
        126,
        "CXO个股"
      ],
      [
        "T12",
        "时间范围",
        126,
        128,
        "三季"
      ],
      [
        "T13",
        "业绩",
        129,
        131,
        "业绩"
      ],
      [
        "T14",
        "属性值",
        131,
        133,
        "波动"
      ],
      [
        "T15",
        "时间范围",
        139,
        141,
        "目前"
      ],
      [
        "T16",
        "时间范围",
        102,
        104,
        "近期"
      ]
    ]
  },
  {
    "id": 2376,
    "text": " 血液净化耗材市场空间大：2019年预计我国ESRD患者数量为258万，年复合增速5.2%，目前透析治疗率28%不到，假设2030年透析率80%，透析患者中使用灌流（HP）的比例为50%， 那么预计2030年血液净化耗材市场规模达到444亿，复合增速16%。  血液净化为治疗刚需，疫情期间和疫情后基本维持高增长态势。  健帆生物：前三季度收入17.8亿元（ +35.5%），归母净利润 8.6亿元（ +37.6%）。其中肾科领域实现30%左右的增长。  三鑫医疗：前三季度收入8.3亿元（ +21.2%），归母净利润1.15亿元（ +39.5%），2021Q1-3血液净化业务收入同比增长30%左右，因价格下降 、原材料成本上升等因素血液净化业务有所承压，疫苗注射剂贡献增量。",
    "labels": [
      [
        "T0",
        "公司",
        164,
        168,
        "健帆生物"
      ],
      [
        "T1",
        "时间范围",
        169,
        173,
        "前三季度"
      ],
      [
        "T2",
        "营业收入",
        173,
        175,
        "收入"
      ],
      [
        "T3",
        "属性值",
        175,
        181,
        "17.8亿元"
      ],
      [
        "T4",
        "属性值",
        183,
        189,
        "+35.5%"
      ],
      [
        "T5",
        "归母净利润",
        191,
        196,
        "归母净利润"
      ],
      [
        "T6",
        "属性值",
        196,
        211,
        " 8.6亿元（ +37.6%）"
      ],
      [
        "T7",
        "行业",
        214,
        216,
        "肾科"
      ],
      [
        "T8",
        "公司",
        232,
        236,
        "三鑫医疗"
      ],
      [
        "T9",
        "时间范围",
        237,
        241,
        "前三季度"
      ],
      [
        "T10",
        "营业收入",
        241,
        243,
        "收入"
      ],
      [
        "T11",
        "属性值",
        243,
        248,
        "8.3亿元"
      ],
      [
        "T12",
        "属性值",
        250,
        256,
        "+21.2%"
      ],
      [
        "T13",
        "归母净利润",
        258,
        263,
        "归母净利润"
      ],
      [
        "T14",
        "属性值",
        263,
        278,
        "1.15亿元（ +39.5%）"
      ],
      [
        "T15",
        "时间范围",
        279,
        287,
        "2021Q1-3"
      ],
      [
        "T16",
        "行业",
        287,
        291,
        "血液净化"
      ],
      [
        "T17",
        "营业收入",
        293,
        295,
        "收入"
      ],
      [
        "T18",
        "属性值",
        299,
        304,
        "30%左右"
      ],
      [
        "T19",
        "行业",
        322,
        326,
        "血液净化"
      ],
      [
        "T20",
        "时间范围",
        100,
        105,
        "2030年"
      ],
      [
        "T21",
        "行业",
        105,
        111,
        "血液净化耗材"
      ],
      [
        "T22",
        "市场规模",
        111,
        115,
        "市场规模"
      ],
      [
        "T23",
        "属性值",
        117,
        121,
        "444亿"
      ],
      [
        "T24",
        "CAGR",
        122,
        126,
        "复合增速"
      ],
      [
        "T25",
        "属性值",
        126,
        129,
        "16%"
      ],
      [
        "T26",
        "行业",
        133,
        137,
        "血液净化"
      ],
      [
        "T27",
        "时间范围",
        14,
        19,
        "2019年"
      ],
      [
        "T28",
        "地点范围",
        21,
        23,
        "我国"
      ],
      [
        "T29",
        "CAGR",
        37,
        42,
        "年复合增速"
      ],
      [
        "T30",
        "时间范围",
        62,
        67,
        "2030年"
      ],
      [
        "T31",
        "时间范围",
        2,
        8,
        "血液净化耗材"
      ],
      [
        "T32",
        "属性值",
        12,
        13,
        "大"
      ],
      [
        "T33",
        "市场规模",
        8,
        12,
        "市场空间"
      ]
    ]
  },
  {
    "id": 2381,
    "text": "Ø 国内行业融资活跃度回升。我国医疗产业融资额在9月份出现一定幅度下滑，而自11月以来国内市场逐渐回温， 在11月份全球投融资下滑的情况下，国内的月融资额约达29亿美元，环比增长36%，显现出国内投融资活跃度的回升。 添加标题 95%",
    "labels": [
      [
        "T0",
        "地点范围",
        2,
        4,
        "国内"
      ],
      [
        "T1",
        "地点范围",
        14,
        16,
        "我国"
      ],
      [
        "T2",
        "行业",
        16,
        18,
        "医疗"
      ],
      [
        "T3",
        "投融资金额",
        20,
        23,
        "融资额"
      ],
      [
        "T4",
        "时间范围",
        24,
        27,
        "9月份"
      ],
      [
        "T5",
        "时间范围",
        54,
        58,
        "11月份"
      ],
      [
        "T6",
        "地点范围",
        58,
        60,
        "全球"
      ],
      [
        "T7",
        "投融资金额",
        60,
        63,
        "投融资"
      ],
      [
        "T8",
        "属性值",
        63,
        65,
        "下滑"
      ],
      [
        "T9",
        "地点范围",
        70,
        72,
        "国内"
      ],
      [
        "T10",
        "属性值",
        77,
        92,
        "约达29亿美元，环比增长36%"
      ],
      [
        "T11",
        "地点范围",
        96,
        98,
        "国内"
      ],
      [
        "T12",
        "投融资金额",
        74,
        77,
        "融资额"
      ],
      [
        "T13",
        "属性值",
        101,
        107,
        "活跃度的回升"
      ],
      [
        "T14",
        "投融资情况",
        98,
        101,
        "投融资"
      ],
      [
        "T15",
        "属性值",
        29,
        35,
        "一定幅度下滑"
      ],
      [
        "T16",
        "时间范围",
        37,
        43,
        "自11月以来"
      ],
      [
        "T17",
        "地点范围",
        43,
        45,
        "国内"
      ]
    ]
  },
  {
    "id": 2382,
    "text": "① IVD：常规试剂需求逐步恢复，新冠检测试剂面临高基数压力。化学发光赛道龙头格局已成，十年进口替代大周期开启，龙头公司常规发光业务收入均已回归高增长。8家分子诊断企业2021上半年收入191亿元（+169.8%） ，归母净利润82.4亿元（+70.8%），整体能表现出高增长，但内部呈现一些分化，部分公司由于2020H1新冠检测试剂高基数导致增速放缓。POCT受常规业务逐步恢复，核心公司2021H1延续高速增长，凭借快速、简单、即时即地场景多元等优势，POCT在传染病类、心血管类市场具有广阔前景。 ② 影像设备：超声产业链恢复较好。去年受益移动DR增量的企业呈现一定同比压力，超声产业链标的如迈瑞医疗、 开立医疗、祥生医疗业务逐步恢复高增长，后续关注X射线、超声、CT、MRI等影像领域的国产突破。 ③ 心血管器械：心血管手术逐步恢复，创新器械标的业绩领涨。除部分受冠脉支架集采降价影响的标的，其他心血管创新器械标的如心脉医疗、佰仁医疗、启明医疗、沛嘉医疗等表现较好。 ④ 骨科：上半年骨科龙头企业业绩有所恢复，带量采购仍是板块压制因素。大博医疗、凯利泰、三友医疗上半年收入均实现较高增长。 ⑤ 肾科：治疗刚需品种，业绩延续高增长态势。上半年健帆生物和三鑫医疗业绩维持高速增长。 ⑥ 眼科：需求旺盛，核心公司业绩高增长。上半年爱博医疗、欧普康视收入增速均超过90%，回归高速增长。后续人工晶体国产化率有望不断提升，角膜塑形镜也有望为消费器械市场大单品，眼科龙头前景广阔。",
    "labels": [
      [
        "T0",
        "行业",
        2,
        5,
        "IVD"
      ],
      [
        "T1",
        "行业",
        6,
        10,
        "常规试剂"
      ],
      [
        "T2",
        "行业需求",
        10,
        12,
        "需求"
      ],
      [
        "T3",
        "属性值",
        14,
        16,
        "恢复"
      ],
      [
        "T4",
        "行业",
        31,
        35,
        "化学发光"
      ],
      [
        "T5",
        "属性值",
        37,
        41,
        "龙头格局"
      ],
      [
        "T6",
        "龙头企业",
        56,
        60,
        "龙头公司"
      ],
      [
        "T7",
        "行业",
        60,
        64,
        "常规发光"
      ],
      [
        "T8",
        "行业公司",
        76,
        84,
        "8家分子诊断企业"
      ],
      [
        "T9",
        "时间范围",
        84,
        91,
        "2021上半年"
      ],
      [
        "T10",
        "营业收入",
        91,
        93,
        "收入"
      ],
      [
        "T11",
        "属性值",
        93,
        98,
        "191亿元"
      ],
      [
        "T12",
        "属性值",
        99,
        106,
        "+169.8%"
      ],
      [
        "T13",
        "归母净利润",
        109,
        114,
        "归母净利润"
      ],
      [
        "T14",
        "属性值",
        114,
        128,
        "82.4亿元（+70.8%）"
      ],
      [
        "T15",
        "时间范围",
        155,
        161,
        "2020H1"
      ],
      [
        "T16",
        "行业",
        177,
        181,
        "POCT"
      ],
      [
        "T17",
        "行业公司",
        191,
        195,
        "核心公司"
      ],
      [
        "T18",
        "时间范围",
        195,
        201,
        "2021H1"
      ],
      [
        "T19",
        "行业",
        228,
        232,
        "POCT"
      ],
      [
        "T20",
        "属性值",
        210,
        224,
        "快速、简单、即时即地场景多元"
      ],
      [
        "T21",
        "行业",
        254,
        258,
        "影像设备"
      ],
      [
        "T22",
        "行业",
        259,
        264,
        "超声产业链"
      ],
      [
        "T23",
        "时间范围",
        269,
        271,
        "去年"
      ],
      [
        "T24",
        "行业",
        291,
        296,
        "超声产业链"
      ],
      [
        "T25",
        "公司",
        299,
        303,
        "迈瑞医疗"
      ],
      [
        "T26",
        "公司",
        305,
        309,
        "开立医疗"
      ],
      [
        "T27",
        "公司",
        310,
        314,
        "祥生医疗"
      ],
      [
        "T28",
        "行业",
        328,
        331,
        "X射线"
      ],
      [
        "T29",
        "行业",
        332,
        334,
        "超声"
      ],
      [
        "T30",
        "行业",
        335,
        337,
        "CT"
      ],
      [
        "T31",
        "行业",
        338,
        341,
        "MRI"
      ],
      [
        "T32",
        "行业",
        342,
        344,
        "影像"
      ],
      [
        "T33",
        "行业",
        355,
        360,
        "心血管器械"
      ],
      [
        "T34",
        "行业",
        371,
        375,
        "创新器械"
      ],
      [
        "T35",
        "业绩",
        377,
        379,
        "业绩"
      ],
      [
        "T36",
        "行业",
        402,
        409,
        "心血管创新器械"
      ],
      [
        "T37",
        "公司",
        412,
        416,
        "心脉医疗"
      ],
      [
        "T38",
        "公司",
        417,
        421,
        "佰仁医疗"
      ],
      [
        "T39",
        "公司",
        422,
        426,
        "启明医疗"
      ],
      [
        "T40",
        "公司",
        427,
        431,
        "沛嘉医疗"
      ],
      [
        "T41",
        "行业",
        440,
        442,
        "骨科"
      ],
      [
        "T42",
        "时间范围",
        443,
        446,
        "上半年"
      ],
      [
        "T43",
        "行业",
        446,
        448,
        "骨科"
      ],
      [
        "T44",
        "公司",
        472,
        476,
        "大博医疗"
      ],
      [
        "T45",
        "公司",
        477,
        480,
        "凯利泰"
      ],
      [
        "T46",
        "公司",
        481,
        485,
        "三友医疗"
      ],
      [
        "T47",
        "时间范围",
        485,
        488,
        "上半年"
      ],
      [
        "T48",
        "营业收入",
        488,
        490,
        "收入"
      ],
      [
        "T49",
        "属性值",
        493,
        497,
        "较高增长"
      ],
      [
        "T50",
        "行业",
        501,
        503,
        "肾科"
      ],
      [
        "T51",
        "业绩",
        511,
        513,
        "业绩"
      ],
      [
        "T52",
        "时间范围",
        521,
        524,
        "上半年"
      ],
      [
        "T53",
        "公司",
        524,
        528,
        "健帆生物"
      ],
      [
        "T54",
        "公司",
        529,
        533,
        "三鑫医疗"
      ],
      [
        "T55",
        "业绩",
        533,
        535,
        "业绩"
      ],
      [
        "T56",
        "属性值",
        537,
        541,
        "高速增长"
      ],
      [
        "T57",
        "行业",
        545,
        547,
        "眼科"
      ],
      [
        "T58",
        "属性值",
        550,
        552,
        "旺盛"
      ],
      [
        "T59",
        "行业需求",
        548,
        550,
        "需求"
      ],
      [
        "T60",
        "行业公司",
        553,
        557,
        "核心公司"
      ],
      [
        "T61",
        "业绩",
        557,
        559,
        "业绩"
      ],
      [
        "T62",
        "属性值",
        559,
        562,
        "高增长"
      ],
      [
        "T63",
        "时间范围",
        563,
        566,
        "上半年"
      ],
      [
        "T64",
        "公司",
        566,
        570,
        "爱博医疗"
      ],
      [
        "T65",
        "公司",
        571,
        575,
        "欧普康视"
      ],
      [
        "T66",
        "收入增速",
        575,
        579,
        "收入增速"
      ],
      [
        "T67",
        "属性值",
        580,
        585,
        "超过90%"
      ],
      [
        "T68",
        "属性值",
        588,
        592,
        "高速增长"
      ],
      [
        "T69",
        "行业",
        595,
        599,
        "人工晶体"
      ],
      [
        "T70",
        "行业",
        610,
        615,
        "角膜塑形镜"
      ],
      [
        "T71",
        "行业",
        619,
        623,
        "消费器械"
      ],
      [
        "T72",
        "行业",
        629,
        631,
        "眼科"
      ],
      [
        "T73",
        "龙头企业",
        631,
        633,
        "龙头"
      ],
      [
        "T74",
        "属性值",
        515,
        518,
        "高增长"
      ]
    ]
  },
  {
    "id": 2383,
    "text": "制药装备行业延续高景气度，市场规模快速增长。根据国家统计局& 智研咨询，2020年我国制药装备市场规模领域的规模约在200亿元左右；根据市场上几个核心龙头2021 年前三季度的财务数据，我们预计 2021年我国制药装备市场规模或将达到250亿元以上，同比增长25%+ 。其中，成长最快的是生物工程细分领域，我们预计此细分市场规模或将达到60~80亿元。",
    "labels": [
      [
        "T0",
        "行业",
        1,
        5,
        "制药装备"
      ],
      [
        "T1",
        "市场规模",
        14,
        18,
        "市场规模"
      ],
      [
        "T2",
        "属性值",
        18,
        22,
        "快速增长"
      ],
      [
        "T3",
        "时间范围",
        37,
        42,
        "2020年"
      ],
      [
        "T4",
        "地点范围",
        42,
        44,
        "我国"
      ],
      [
        "T5",
        "行业",
        44,
        48,
        "制药装备"
      ],
      [
        "T6",
        "市场规模",
        48,
        52,
        "市场规模"
      ],
      [
        "T7",
        "属性值",
        57,
        66,
        "约在200亿元左右"
      ],
      [
        "T8",
        "时间范围",
        78,
        88,
        "2021 年前三季度"
      ],
      [
        "T9",
        "时间范围",
        99,
        104,
        "2021年"
      ],
      [
        "T10",
        "地点范围",
        104,
        106,
        "我国"
      ],
      [
        "T11",
        "行业",
        106,
        110,
        "制药装备"
      ],
      [
        "T12",
        "市场规模",
        110,
        114,
        "市场规模"
      ],
      [
        "T13",
        "属性值",
        118,
        125,
        "250亿元以上"
      ],
      [
        "T14",
        "行业",
        145,
        149,
        "生物工程"
      ],
      [
        "T15",
        "市场规模",
        161,
        165,
        "市场规模"
      ],
      [
        "T16",
        "属性值",
        169,
        176,
        "60~80亿元"
      ]
    ]
  },
  {
    "id": 2386,
    "text": " 从ROE水平来看，近几年生物药板块ROE水平持续下降，与部分企业净利润率下降有关。2021H1，生物药板块ROE为4.46%，同比增长 0.71pp，ROE提升主要与销售费用率下降，净利润率提升有较大关系。  从现金流情况来看，近几年我国生物药企业经营活动产生的现金流量净额/经营活动净收益持续提升，但2021H1为93.08%，同比提升 10pp，预计下半年现金流有望继续保持较好水平。",
    "labels": [
      [
        "T0",
        "ROE净资产回报率",
        3,
        6,
        "ROE"
      ],
      [
        "T1",
        "时间范围",
        11,
        14,
        "近几年"
      ],
      [
        "T2",
        "行业",
        14,
        17,
        "生物药"
      ],
      [
        "T3",
        "ROE净资产回报率",
        19,
        22,
        "ROE"
      ],
      [
        "T4",
        "属性值",
        24,
        28,
        "持续下降"
      ],
      [
        "T5",
        "时间范围",
        43,
        49,
        "2021H1"
      ],
      [
        "T6",
        "行业",
        50,
        53,
        "生物药"
      ],
      [
        "T7",
        "ROE净资产回报率",
        55,
        58,
        "ROE"
      ],
      [
        "T8",
        "属性值",
        59,
        76,
        "4.46%，同比增长 0.71pp"
      ],
      [
        "T9",
        "ROE净资产回报率",
        77,
        80,
        "ROE"
      ],
      [
        "T10",
        "现金流",
        109,
        112,
        "现金流"
      ],
      [
        "T11",
        "时间范围",
        117,
        120,
        "近几年"
      ],
      [
        "T12",
        "地点范围",
        120,
        122,
        "我国"
      ],
      [
        "T13",
        "行业公司",
        122,
        127,
        "生物药企业"
      ],
      [
        "T14",
        "现金流",
        134,
        137,
        "现金流"
      ],
      [
        "T15",
        "时间范围",
        154,
        160,
        "2021H1"
      ],
      [
        "T16",
        "现金流",
        183,
        186,
        "现金流"
      ],
      [
        "T17",
        "时间范围",
        180,
        183,
        "下半年"
      ],
      [
        "T18",
        "属性值",
        192,
        196,
        "较好水平"
      ]
    ]
  },
  {
    "id": 2387,
    "text": " 从在建工程增速来看，2021H1康龙化成、药石科技、药明康德和凯莱英等几家企业增速较快，昭衍新药、九洲药业和博腾股份也都保持在30%的增速。从固定资产（原值）增速来看，2021H1药石科技、康龙化成、药明康德等几家企业增速较快，凯莱英和博腾股份也都保持在20%以上的增速。  整体来看，我国CXO行业固定资产和在建工程仍然保持高速增长，从侧面体现出目前行业仍处于高景气度周期，企业订单充足，业绩有望持续高速增长。",
    "labels": [
      [
        "T0",
        "时间范围",
        12,
        18,
        "2021H1"
      ],
      [
        "T1",
        "公司",
        18,
        22,
        "康龙化成"
      ],
      [
        "T2",
        "公司",
        23,
        27,
        "药石科技"
      ],
      [
        "T3",
        "公司",
        28,
        32,
        "药明康德"
      ],
      [
        "T4",
        "公司",
        33,
        36,
        "凯莱英"
      ],
      [
        "T5",
        "公司",
        46,
        50,
        "昭衍新药"
      ],
      [
        "T6",
        "公司",
        51,
        55,
        "九洲药业"
      ],
      [
        "T7",
        "公司",
        56,
        60,
        "博腾股份"
      ],
      [
        "T8",
        "固定资产增速",
        73,
        83,
        "固定资产（原值）增速"
      ],
      [
        "T9",
        "时间范围",
        86,
        92,
        "2021H1"
      ],
      [
        "T10",
        "公司",
        92,
        96,
        "药石科技"
      ],
      [
        "T11",
        "公司",
        97,
        101,
        "康龙化成"
      ],
      [
        "T12",
        "公司",
        102,
        106,
        "药明康德"
      ],
      [
        "T13",
        "公司",
        116,
        119,
        "凯莱英"
      ],
      [
        "T14",
        "公司",
        120,
        124,
        "博腾股份"
      ],
      [
        "T15",
        "地点范围",
        146,
        148,
        "我国"
      ],
      [
        "T16",
        "行业",
        148,
        151,
        "CXO"
      ],
      [
        "T17",
        "固定资产",
        153,
        157,
        "固定资产"
      ],
      [
        "T18",
        "业绩",
        198,
        200,
        "业绩"
      ],
      [
        "T19",
        "属性值",
        113,
        115,
        "较快"
      ],
      [
        "T20",
        "属性值",
        129,
        134,
        "20%以上"
      ],
      [
        "T21",
        "属性值",
        166,
        170,
        "高速增长"
      ],
      [
        "T22",
        "属性值",
        202,
        208,
        "持续高速增长"
      ],
      [
        "T23",
        "属性值",
        195,
        197,
        "充足"
      ],
      [
        "T24",
        "在手订单",
        193,
        195,
        "订单"
      ]
    ]
  },
  {
    "id": 2391,
    "text": " 从ROE水平来看，2021H1九洲药业、博腾股份和药石科技等几家企业提升显著，ROE提升主要与企业净利润率提升有关，另外几家CXO 企业ROE水平小幅下降，主要因扩产速度较快，周转率下降有关，另外，CXO公司公允价值变动损益以及投资收益波动较大，对ROE造成一定波动。  从现金流情况来看，近几年我国CXO企业经营活动产生的现金流量净额/经营活动净收益持续下降，2020年大幅好转，2021H1为106.2% ，同比持平，预计下半年随着收入逐步确认，现金流有望继续向好。",
    "labels": [
      [
        "T0",
        "ROE净资产回报率",
        3,
        6,
        "ROE"
      ],
      [
        "T1",
        "时间范围",
        11,
        17,
        "2021H1"
      ],
      [
        "T2",
        "公司",
        17,
        21,
        "九洲药业"
      ],
      [
        "T3",
        "公司",
        22,
        26,
        "博腾股份"
      ],
      [
        "T4",
        "公司",
        27,
        31,
        "药石科技"
      ],
      [
        "T5",
        "属性值",
        36,
        40,
        "提升显著"
      ],
      [
        "T6",
        "ROE净资产回报率",
        41,
        44,
        "ROE"
      ],
      [
        "T7",
        "ROE净资产回报率",
        70,
        73,
        "ROE"
      ],
      [
        "T8",
        "行业公司",
        101,
        106,
        "CXO公司"
      ],
      [
        "T9",
        "ROE净资产回报率",
        126,
        129,
        "ROE"
      ],
      [
        "T10",
        "现金流",
        140,
        143,
        "现金流"
      ],
      [
        "T11",
        "时间范围",
        148,
        151,
        "近几年"
      ],
      [
        "T12",
        "地点范围",
        151,
        153,
        "我国"
      ],
      [
        "T13",
        "行业公司",
        153,
        158,
        "CXO企业"
      ],
      [
        "T14",
        "时间范围",
        184,
        189,
        "2020年"
      ],
      [
        "T15",
        "时间范围",
        194,
        200,
        "2021H1"
      ],
      [
        "T16",
        "时间范围",
        216,
        219,
        "下半年"
      ],
      [
        "T17",
        "营业收入",
        221,
        223,
        "收入"
      ],
      [
        "T18",
        "现金流",
        228,
        231,
        "现金流"
      ],
      [
        "T19",
        "行业公司",
        60,
        70,
        "另外几家CXO 企业"
      ],
      [
        "T20",
        "属性值",
        75,
        79,
        "小幅下降"
      ],
      [
        "T21",
        "属性值",
        233,
        237,
        "继续向好"
      ]
    ]
  },
  {
    "id": 2395,
    "text": "凯莱英 2021Q1-Q3实现营业收入 29.23亿人民币（+40.34%），实现扣非归母净利润 5.96亿人民币（+30.58%）公司产能持续提升，新增大额订单助力公司未来增长。",
    "labels": [
      [
        "T0",
        "公司",
        0,
        3,
        "凯莱英"
      ],
      [
        "T1",
        "时间范围",
        4,
        13,
        "2021Q1-Q3"
      ],
      [
        "T2",
        "营业收入",
        15,
        19,
        "营业收入"
      ],
      [
        "T3",
        "属性值",
        20,
        29,
        "29.23亿人民币"
      ],
      [
        "T4",
        "属性值",
        30,
        37,
        "+40.34%"
      ],
      [
        "T5",
        "扣非净利润",
        41,
        48,
        "扣非归母净利润"
      ],
      [
        "T6",
        "属性值",
        49,
        66,
        "5.96亿人民币（+30.58%）"
      ],
      [
        "T7",
        "属性值",
        70,
        74,
        "持续提升"
      ],
      [
        "T8",
        "产能",
        68,
        70,
        "产能"
      ]
    ]
  },
  {
    "id": 2399,
    "text": "Ø 医药总成交额位于历史中枢。从成交量上看，医药行业上周成交额为4201.13亿元，占全部A股总成交额的7.75%，环比上升0.74 pct，较2018年以来的中枢水平低0.68pct。 Ø 外包标的占比有所下降。本周外包重点标的成交额443.32亿元，占全部医药总成交额的10.55%，环比下降6.65pct，较2018年以来中枢水平高2.55pct。",
    "labels": [
      [
        "T0",
        "行业",
        2,
        4,
        "医药"
      ],
      [
        "T1",
        "行业",
        22,
        24,
        "医药"
      ],
      [
        "T2",
        "时间范围",
        26,
        28,
        "上周"
      ],
      [
        "T3",
        "时间范围",
        72,
        77,
        "2018年"
      ],
      [
        "T4",
        "时间范围",
        107,
        109,
        "本周"
      ],
      [
        "T5",
        "行业",
        130,
        132,
        "医药"
      ],
      [
        "T6",
        "时间范围",
        157,
        162,
        "2018年"
      ]
    ]
  },
  {
    "id": 2407,
    "text": "2021年中国 CXO企业在业绩方面仍然表现出很高的景气度，药明康德在 2021年 Q1-Q3实现实现营业收入人民币 165.2亿人民币，同比增长 40%，实现归母净利润 3.56亿人民币，同比增长 50%。在收入规模方面，药明康德已达到全球 CDMO行业领先水平，但是业绩增长仍然保持在较高水平。康龙化成 2021年 Q1-Q3实现营业收入 35.9亿人民币，同比增长 48%，实现归母净利润 10.4亿人民币，同比增长 32%。凯莱英 2021年 Q1-Q3实现营业收入 29.2亿人民币，同比增长达到 40%，实现归母净利润 6.9亿人民币，同比增长 37%。 在 CRO企业中，昭衍新药 2021年 Q1-Q3实现营业收入 8.6亿人民币，同比增长 36%，实现归母净利润 2.5亿人民币，同比增长幅度高达 110%。美迪西 2021年 Q1-Q3实现营业收入 7.9亿人民币，同比增长 82%，实现归母净利润 1.8亿人民币，同比增长幅度高达 142%。",
    "labels": [
      [
        "T0",
        "时间范围",
        0,
        5,
        "2021年"
      ],
      [
        "T1",
        "地点范围",
        5,
        7,
        "中国"
      ],
      [
        "T2",
        "行业公司",
        8,
        13,
        "CXO企业"
      ],
      [
        "T3",
        "业绩",
        14,
        16,
        "业绩"
      ],
      [
        "T4",
        "属性值",
        23,
        29,
        "很高的景气度"
      ],
      [
        "T5",
        "公司",
        30,
        34,
        "药明康德"
      ],
      [
        "T6",
        "时间范围",
        36,
        47,
        "2021年 Q1-Q3"
      ],
      [
        "T7",
        "营业收入",
        51,
        55,
        "营业收入"
      ],
      [
        "T8",
        "属性值",
        59,
        68,
        "165.2亿人民币"
      ],
      [
        "T9",
        "属性值",
        74,
        77,
        "40%"
      ],
      [
        "T10",
        "归母净利润",
        80,
        85,
        "归母净利润"
      ],
      [
        "T11",
        "属性值",
        86,
        103,
        "3.56亿人民币，同比增长 50%"
      ],
      [
        "T12",
        "营业收入",
        105,
        107,
        "收入"
      ],
      [
        "T13",
        "公司",
        112,
        116,
        "药明康德"
      ],
      [
        "T14",
        "地点范围",
        119,
        121,
        "全球"
      ],
      [
        "T15",
        "行业",
        122,
        126,
        "CDMO"
      ],
      [
        "T16",
        "业绩",
        135,
        137,
        "业绩"
      ],
      [
        "T17",
        "属性值",
        144,
        148,
        "较高水平"
      ],
      [
        "T18",
        "公司",
        149,
        153,
        "康龙化成"
      ],
      [
        "T19",
        "时间范围",
        154,
        165,
        "2021年 Q1-Q3"
      ],
      [
        "T20",
        "营业收入",
        167,
        171,
        "营业收入"
      ],
      [
        "T21",
        "属性值",
        172,
        180,
        "35.9亿人民币"
      ],
      [
        "T22",
        "属性值",
        186,
        189,
        "48%"
      ],
      [
        "T23",
        "归母净利润",
        192,
        197,
        "归母净利润"
      ],
      [
        "T24",
        "属性值",
        198,
        215,
        "10.4亿人民币，同比增长 32%"
      ],
      [
        "T25",
        "公司",
        216,
        219,
        "凯莱英"
      ],
      [
        "T26",
        "时间范围",
        220,
        231,
        "2021年 Q1-Q3"
      ],
      [
        "T27",
        "营业收入",
        233,
        237,
        "营业收入"
      ],
      [
        "T28",
        "属性值",
        238,
        246,
        "29.2亿人民币"
      ],
      [
        "T29",
        "属性值",
        254,
        257,
        "40%"
      ],
      [
        "T30",
        "归母净利润",
        260,
        265,
        "归母净利润"
      ],
      [
        "T31",
        "属性值",
        266,
        282,
        "6.9亿人民币，同比增长 37%"
      ],
      [
        "T32",
        "行业公司",
        286,
        291,
        "CRO企业"
      ],
      [
        "T33",
        "公司",
        293,
        297,
        "昭衍新药"
      ],
      [
        "T34",
        "时间范围",
        298,
        309,
        "2021年 Q1-Q3"
      ],
      [
        "T35",
        "营业收入",
        311,
        315,
        "营业收入"
      ],
      [
        "T36",
        "属性值",
        316,
        323,
        "8.6亿人民币"
      ],
      [
        "T37",
        "属性值",
        329,
        332,
        "36%"
      ],
      [
        "T38",
        "归母净利润",
        335,
        340,
        "归母净利润"
      ],
      [
        "T39",
        "属性值",
        341,
        362,
        "2.5亿人民币，同比增长幅度高达 110%"
      ],
      [
        "T40",
        "公司",
        363,
        366,
        "美迪西"
      ],
      [
        "T41",
        "时间范围",
        367,
        378,
        "2021年 Q1-Q3"
      ],
      [
        "T42",
        "营业收入",
        380,
        384,
        "营业收入"
      ],
      [
        "T43",
        "属性值",
        385,
        392,
        "7.9亿人民币"
      ],
      [
        "T44",
        "属性值",
        398,
        401,
        "82%"
      ],
      [
        "T45",
        "归母净利润",
        404,
        409,
        "归母净利润"
      ],
      [
        "T46",
        "属性值",
        410,
        431,
        "1.8亿人民币，同比增长幅度高达 142%"
      ]
    ]
  },
  {
    "id": 2411,
    "text": "CXO企业业绩能见度从未改变。12家 CXO公司 2020年收入总额同比增速 29.1%、 归母净利润总额同比增速为 67.4%，扣非归母净利润总额同比增速为 33.4%；2021年前三季度扣非归母净利润总额进一步大幅增长至 69.27亿元，同比增长 71.84%。我们认为 CXO行业景气度不变，具备配备价值。",
    "labels": [
      [
        "T0",
        "行业公司",
        0,
        5,
        "CXO企业"
      ],
      [
        "T1",
        "业绩",
        5,
        7,
        "业绩"
      ],
      [
        "T2",
        "行业公司",
        15,
        24,
        "12家 CXO公司"
      ],
      [
        "T3",
        "时间范围",
        25,
        30,
        "2020年"
      ],
      [
        "T4",
        "属性值",
        39,
        44,
        "29.1%"
      ],
      [
        "T5",
        "归母净利润增速",
        46,
        57,
        "归母净利润总额同比增速"
      ],
      [
        "T6",
        "收入增速",
        30,
        38,
        "收入总额同比增速"
      ],
      [
        "T7",
        "属性值",
        59,
        64,
        "67.4%"
      ],
      [
        "T8",
        "扣非净利润增速",
        65,
        78,
        "扣非归母净利润总额同比增速"
      ],
      [
        "T9",
        "属性值",
        80,
        85,
        "33.4%"
      ],
      [
        "T10",
        "时间范围",
        86,
        95,
        "2021年前三季度"
      ],
      [
        "T11",
        "扣非净利润",
        95,
        102,
        "扣非归母净利润"
      ],
      [
        "T12",
        "属性值",
        113,
        132,
        "69.27亿元，同比增长 71.84%"
      ],
      [
        "T13",
        "行业",
        138,
        141,
        "CXO"
      ],
      [
        "T14",
        "属性值",
        7,
        14,
        "能见度从未改变"
      ]
    ]
  },
  {
    "id": 2421,
    "text": "在手订单充裕，保证交付最为关键。1）对于 CRO企业，核心资产为相关人员数量。以 CRO业务为主的公司如美迪西、康龙化成、药明康德等，其研发人员的扩张增速均保持在 20%以上。2）对于 CDMO企业，产能利用率持续处于高位，资本性支出与在建工程情况则是影响公司未来业绩的主要因素。泰格医药、美迪西、康龙化成、 药石科技等企业的资本开支与在建工程均实现了快速增长。",
    "labels": [
      [
        "T0",
        "在手订单",
        0,
        4,
        "在手订单"
      ],
      [
        "T1",
        "行业公司",
        20,
        26,
        " CRO企业"
      ],
      [
        "T2",
        "行业",
        41,
        44,
        "CRO"
      ],
      [
        "T3",
        "公司",
        52,
        55,
        "美迪西"
      ],
      [
        "T4",
        "公司",
        56,
        60,
        "康龙化成"
      ],
      [
        "T5",
        "公司",
        61,
        65,
        "药明康德"
      ],
      [
        "T6",
        "行业公司",
        92,
        99,
        " CDMO企业"
      ],
      [
        "T7",
        "CAPEX资本开支",
        112,
        117,
        "资本性支出"
      ],
      [
        "T8",
        "业绩",
        132,
        134,
        "业绩"
      ],
      [
        "T9",
        "公司",
        140,
        144,
        "泰格医药"
      ],
      [
        "T10",
        "公司",
        145,
        148,
        "美迪西"
      ],
      [
        "T11",
        "公司",
        149,
        153,
        "康龙化成"
      ],
      [
        "T12",
        "公司",
        155,
        159,
        "药石科技"
      ],
      [
        "T13",
        "CAPEX资本开支",
        163,
        167,
        "资本开支"
      ],
      [
        "T14",
        "属性值",
        176,
        180,
        "快速增长"
      ]
    ]
  },
  {
    "id": 2423,
    "text": "Ø 海外CXO公司的估值较为分化，截至2021.12.23，生物大分子CDMO Samsung Biologics 拥有较高估值，PE （TTM）243倍，此外一体化CDMO Lonza及临床CRO IQVIA分别为64、69倍，而LabCorp (Covance)受ICL 业务的影响，估值较低，PE（TTM）为10倍。我们认为，全球医药外包行业头部公司通过兼并收购不断延伸服务、完善产业链，临床研究及将触角逐渐探入高成长板块（生物大分子及CGT）的公司往往享受更高的估值。",
    "labels": [
      [
        "T0",
        "地点范围",
        2,
        4,
        "海外"
      ],
      [
        "T1",
        "行业公司",
        4,
        9,
        "CXO公司"
      ],
      [
        "T2",
        "时间范围",
        17,
        29,
        "截至2021.12.23"
      ],
      [
        "T3",
        "行业",
        30,
        39,
        "生物大分子CDMO"
      ],
      [
        "T4",
        "公司",
        40,
        57,
        "Samsung Biologics"
      ],
      [
        "T5",
        "PE",
        65,
        67,
        "PE"
      ],
      [
        "T6",
        "属性值",
        73,
        77,
        "243倍"
      ],
      [
        "T7",
        "行业",
        80,
        87,
        "一体化CDMO"
      ],
      [
        "T8",
        "公司",
        88,
        93,
        "Lonza"
      ],
      [
        "T9",
        "行业",
        94,
        99,
        "临床CRO"
      ],
      [
        "T10",
        "公司",
        100,
        105,
        "IQVIA"
      ],
      [
        "T11",
        "属性值",
        108,
        110,
        "64"
      ],
      [
        "T12",
        "属性值",
        111,
        114,
        "69倍"
      ],
      [
        "T13",
        "公司",
        116,
        133,
        "LabCorp (Covance)"
      ],
      [
        "T14",
        "PE",
        149,
        151,
        "PE"
      ],
      [
        "T15",
        "属性值",
        157,
        160,
        "10倍"
      ],
      [
        "T16",
        "地点范围",
        166,
        168,
        "全球"
      ],
      [
        "T17",
        "行业",
        168,
        172,
        "医药外包"
      ],
      [
        "T18",
        "行业",
        215,
        220,
        "生物大分子"
      ],
      [
        "T19",
        "行业",
        221,
        224,
        "CGT"
      ]
    ]
  },
  {
    "id": 2434,
    "text": "CXO行业内公司经过泡沫挤压估值进入再平衡时期，根据截至 2022年 1月 13日股价与盈利预期 CXO行业内主要公司基于 2022年盈利预期的预期市盈率在 60左右。 若行业内公司主要公司在 2023-2025年年均复合增长率为 20%，则 2022年-2025年预期年均复合增速在 25%左右，2022年预期 PEG在 2.5左右。若行业内主要公司在 2023-2025年年均复合增长率为 30%，则 2022年-2025年预期年均复合增速在 30%左右，2022年预期 PEG在 2左右。若行业内公司主要公司在 2023-2025年年均复合增长率可达到 40%，则 2022年-2025年预期年均复合增速可达到 35%- 40%左右，2022年预期 PEG可达到 1.5左右。",
    "labels": [
      [
        "T0",
        "行业公司",
        0,
        8,
        "CXO行业内公司"
      ],
      [
        "T1",
        "时间范围",
        26,
        41,
        "截至 2022年 1月 13日"
      ],
      [
        "T2",
        "行业公司",
        49,
        59,
        "CXO行业内主要公司"
      ],
      [
        "T3",
        "时间范围",
        62,
        67,
        "2022年"
      ],
      [
        "T4",
        "PE",
        74,
        77,
        "市盈率"
      ],
      [
        "T5",
        "属性值",
        79,
        83,
        "60左右"
      ],
      [
        "T6",
        "时间范围",
        122,
        133,
        "2022年-2025年"
      ],
      [
        "T7",
        "时间范围",
        97,
        107,
        "2023-2025年"
      ],
      [
        "T8",
        "CAGR",
        107,
        114,
        "年均复合增长率"
      ],
      [
        "T9",
        "CAGR",
        135,
        141,
        "年均复合增速"
      ],
      [
        "T10",
        "时间范围",
        149,
        154,
        "2022年"
      ],
      [
        "T11",
        "PEG",
        157,
        160,
        "PEG"
      ],
      [
        "T12",
        "时间范围",
        178,
        188,
        "2023-2025年"
      ],
      [
        "T13",
        "CAGR",
        188,
        195,
        "年均复合增长率"
      ],
      [
        "T14",
        "时间范围",
        203,
        214,
        "2022年-2025年"
      ],
      [
        "T15",
        "CAGR",
        216,
        222,
        "年均复合增速"
      ],
      [
        "T16",
        "时间范围",
        230,
        235,
        "2022年"
      ],
      [
        "T17",
        "PEG",
        238,
        241,
        "PEG"
      ],
      [
        "T18",
        "时间范围",
        259,
        269,
        "2023-2025年"
      ],
      [
        "T19",
        "CAGR",
        269,
        276,
        "年均复合增长率"
      ],
      [
        "T20",
        "时间范围",
        286,
        297,
        "2022年-2025年"
      ],
      [
        "T21",
        "CAGR",
        299,
        305,
        "年均复合增速"
      ],
      [
        "T22",
        "时间范围",
        320,
        325,
        "2022年"
      ],
      [
        "T23",
        "PEG",
        328,
        331,
        "PEG"
      ],
      [
        "T24",
        "行业公司",
        86,
        95,
        "行业内公司主要公司"
      ],
      [
        "T25",
        "属性值",
        143,
        148,
        "25%左右"
      ],
      [
        "T26",
        "属性值",
        162,
        167,
        "2.5左右"
      ],
      [
        "T27",
        "行业公司",
        169,
        176,
        "行业内主要公司"
      ],
      [
        "T28",
        "属性值",
        224,
        229,
        "30%左右"
      ],
      [
        "T29",
        "属性值",
        243,
        246,
        "2左右"
      ],
      [
        "T30",
        "行业公司",
        248,
        257,
        "行业内公司主要公司"
      ],
      [
        "T31",
        "属性值",
        309,
        319,
        "35%- 40%左右"
      ],
      [
        "T32",
        "属性值",
        335,
        340,
        "1.5左右"
      ]
    ]
  },
  {
    "id": 2435,
    "text": " 板块：我们选取分子诊断8家企业，2021Q1-3 收入 273.8亿元（ +147.1%），归母净利润 114.6亿元（+42.4%），高增长主要由于新冠检测试剂出口能维持高水平，单Q3来看，增速比上半年放缓，主要因价格下降、基数增加等因素。  华大基因：2021年前三季度收入51.5亿元（- 23.7%），归母净利润14.1亿元（-47.7%）。 新冠检测试剂出口有所下滑，常规业务恢复有机增长。  艾德生物： 2021年前三季度收入 6.5亿元（ +33.4%），归母净利润1.8亿元（+40%），低基数下重回高增长态势。伴随诊断行业成长突出 ，公司产品齐全，院内市占率领先，后续有望持续改善。",
    "labels": [
      [
        "T0",
        "行业公司",
        9,
        17,
        "分子诊断8家企业"
      ],
      [
        "T1",
        "时间范围",
        18,
        26,
        "2021Q1-3"
      ],
      [
        "T2",
        "营业收入",
        27,
        29,
        "收入"
      ],
      [
        "T3",
        "属性值",
        30,
        37,
        "273.8亿元"
      ],
      [
        "T4",
        "属性值",
        39,
        46,
        "+147.1%"
      ],
      [
        "T5",
        "归母净利润",
        48,
        53,
        "归母净利润"
      ],
      [
        "T6",
        "属性值",
        54,
        69,
        "114.6亿元（+42.4%）"
      ],
      [
        "T7",
        "时间范围",
        93,
        95,
        "Q3"
      ],
      [
        "T8",
        "时间范围",
        101,
        104,
        "上半年"
      ],
      [
        "T9",
        "公司",
        126,
        130,
        "华大基因"
      ],
      [
        "T10",
        "时间范围",
        131,
        140,
        "2021年前三季度"
      ],
      [
        "T11",
        "营业收入",
        140,
        142,
        "收入"
      ],
      [
        "T12",
        "属性值",
        142,
        148,
        "51.5亿元"
      ],
      [
        "T13",
        "属性值",
        149,
        156,
        "- 23.7%"
      ],
      [
        "T14",
        "归母净利润",
        158,
        163,
        "归母净利润"
      ],
      [
        "T15",
        "属性值",
        163,
        177,
        "14.1亿元（-47.7%）"
      ],
      [
        "T16",
        "公司",
        206,
        210,
        "艾德生物"
      ],
      [
        "T17",
        "时间范围",
        212,
        221,
        "2021年前三季度"
      ],
      [
        "T18",
        "营业收入",
        221,
        223,
        "收入"
      ],
      [
        "T19",
        "属性值",
        224,
        229,
        "6.5亿元"
      ],
      [
        "T20",
        "属性值",
        231,
        237,
        "+33.4%"
      ],
      [
        "T21",
        "归母净利润",
        239,
        244,
        "归母净利润"
      ],
      [
        "T22",
        "属性值",
        244,
        255,
        "1.8亿元（+40%）"
      ],
      [
        "T23",
        "市场份额",
        289,
        292,
        "市占率"
      ],
      [
        "T24",
        "属性值",
        292,
        294,
        "领先"
      ]
    ]
  },
  {
    "id": 2442,
    "text": " 52家中药公司2021上半年收入总额增速为14.7%、归母净利润总额增速为26.2%，Q2单季收入稳健增长，利润增速较快；收入端增速为9.9%，利润端增速为34%。  从盈利水平看，中药板块整体盈利能力整体稳中有升，21年上半年 ，行业毛利率（44%），销售费用率（23%）保持稳定，净利率（ 12%）略有提升。",
    "labels": [
      [
        "T0",
        "行业公司",
        2,
        9,
        "52家中药公司"
      ],
      [
        "T1",
        "时间范围",
        9,
        16,
        "2021上半年"
      ],
      [
        "T2",
        "收入增速",
        16,
        22,
        "收入总额增速"
      ],
      [
        "T3",
        "属性值",
        23,
        28,
        "14.7%"
      ],
      [
        "T4",
        "归母净利润增速",
        29,
        38,
        "归母净利润总额增速"
      ],
      [
        "T5",
        "属性值",
        39,
        44,
        "26.2%"
      ],
      [
        "T6",
        "时间范围",
        45,
        47,
        "Q2"
      ],
      [
        "T7",
        "营业收入",
        49,
        51,
        "收入"
      ],
      [
        "T8",
        "属性值",
        51,
        55,
        "稳健增长"
      ],
      [
        "T9",
        "利润",
        56,
        58,
        "利润"
      ],
      [
        "T10",
        "属性值",
        58,
        62,
        "增速较快"
      ],
      [
        "T11",
        "收入增速",
        63,
        68,
        "收入端增速"
      ],
      [
        "T12",
        "属性值",
        69,
        73,
        "9.9%"
      ],
      [
        "T13",
        "利润",
        74,
        77,
        "利润端"
      ],
      [
        "T14",
        "属性值",
        77,
        83,
        "增速为34%"
      ],
      [
        "T15",
        "行业",
        94,
        96,
        "中药"
      ],
      [
        "T16",
        "时间范围",
        111,
        117,
        "21年上半年"
      ],
      [
        "T17",
        "毛利",
        121,
        124,
        "毛利率"
      ],
      [
        "T18",
        "属性值",
        125,
        128,
        "44%"
      ],
      [
        "T19",
        "归母净利润",
        145,
        148,
        "净利率"
      ],
      [
        "T20",
        "属性值",
        150,
        153,
        "12%"
      ]
    ]
  },
  {
    "id": 2447,
    "text": " 季度波动较大，21Q2板块业绩同比略有下滑。原料药板块2021H1实现收入443亿元(+13.3%)，实现归母净利润78.3 亿元(-0.1%)；21Q1/Q2原料药板块分别实现收入216亿元/227亿元，同比+19%/8.5% ，在利润端21Q1/Q2实现归母净利润37.4亿元/40.9亿元，同比+20%/-13.2%。二季度板块归母净利润下滑，主要是毛利率同比去年下滑约3.8pp ，同时费用端同上升1.3pp。",
    "labels": [
      [
        "T0",
        "时间范围",
        9,
        13,
        "21Q2"
      ],
      [
        "T1",
        "业绩",
        15,
        17,
        "业绩"
      ],
      [
        "T2",
        "行业",
        24,
        27,
        "原料药"
      ],
      [
        "T3",
        "时间范围",
        29,
        35,
        "2021H1"
      ],
      [
        "T4",
        "营业收入",
        37,
        39,
        "收入"
      ],
      [
        "T5",
        "属性值",
        39,
        44,
        "443亿元"
      ],
      [
        "T6",
        "属性值",
        45,
        51,
        "+13.3%"
      ],
      [
        "T7",
        "归母净利润",
        55,
        60,
        "归母净利润"
      ],
      [
        "T8",
        "属性值",
        60,
        74,
        "78.3 亿元(-0.1%)"
      ],
      [
        "T9",
        "时间范围",
        75,
        79,
        "21Q1"
      ],
      [
        "T10",
        "时间范围",
        80,
        82,
        "Q2"
      ],
      [
        "T11",
        "行业",
        82,
        85,
        "原料药"
      ],
      [
        "T12",
        "营业收入",
        91,
        93,
        "收入"
      ],
      [
        "T13",
        "属性值",
        93,
        98,
        "216亿元"
      ],
      [
        "T14",
        "属性值",
        99,
        104,
        "227亿元"
      ],
      [
        "T15",
        "属性值",
        107,
        111,
        "+19%"
      ],
      [
        "T16",
        "属性值",
        112,
        116,
        "8.5%"
      ],
      [
        "T17",
        "利润",
        119,
        122,
        "利润端"
      ],
      [
        "T18",
        "时间范围",
        122,
        126,
        "21Q1"
      ],
      [
        "T19",
        "时间范围",
        127,
        129,
        "Q2"
      ],
      [
        "T20",
        "归母净利润",
        131,
        136,
        "归母净利润"
      ],
      [
        "T21",
        "属性值",
        136,
        142,
        "37.4亿元"
      ],
      [
        "T22",
        "属性值",
        143,
        149,
        "40.9亿元"
      ],
      [
        "T23",
        "时间范围",
        164,
        167,
        "二季度"
      ],
      [
        "T24",
        "归母净利润",
        169,
        174,
        "归母净利润"
      ],
      [
        "T25",
        "属性值",
        174,
        176,
        "下滑"
      ],
      [
        "T26",
        "毛利",
        180,
        183,
        "毛利率"
      ],
      [
        "T27",
        "时间范围",
        185,
        187,
        "去年"
      ],
      [
        "T28",
        "属性值",
        187,
        195,
        "下滑约3.8pp"
      ]
    ]
  },
  {
    "id": 2452,
    "text": " Q3受到疫情反复影响，业绩环比回落：18家医药流通股Q1-Q3收入总额增速为22.6%，归母净利润总额增速为20.3%， 扣非后归母净利润增速为11.4%。单Q3实现收入同比增速为11.2%，归母净利润的同比增速为-16.8%，扣非归母净利润同比增速为0.6%。三季度费用率均环比保持稳定。销售费用率同比增加0.1pp，财务费用率增加0.1pp，管理费用率同比无变化。  带量采购加速行业集中度提升，现金流状况持续向好。带量采购之后，药品、耗材大幅降价，相应的配送费用也降低，对于配送企业成本控制能力要求较高。大中型配送商由于规模效应明显，成本优势突出，从而获得更多带量采购品种的配送 。因此带量采购后，集中度将会提升。带量采购均要求医保资金预付款或30天内付款，大幅缓解了配送企业的资金压力， 使得流通商腾出出更多资金去开展新业务。2021Q1-3流通企业经营活动产生现金流量净额同比增速为12%，同比 2019Q1-3实现由负转正，并持续大幅改善。  上下游延申产业链成为未来发展趋势。大型医药流通企业的产业链条不断延申，从上游来看，通过医药工业板块发力，实现“研-产-销”全产业布局。从下游产业链来看，通过自建与收购实现药店零售的快速扩张。国大药房旗下拥有药店8439 家，并延续快速增长趋势。流通企业借助和医院和药企紧密联系，积极布局DTP药房，未来在承接处方药外流上具有核心优势。上海医药Q3创新药研发投入持续加大，与HUYABIO达成一项license out交易，并license in两项重磅单品。  估值处于历史地位，性价比凸显。药品分销领域由于整体增速不高，且受到带量采购降价的影响，受到投资者的关注度不高。我们认为之前药品分销板块的估值压制因素已经在股价上体现，目前该板块处于历史低位，性价比凸显。即使将来扩大范围带量采购，新药的上市也将弥补这一缺口，同时总代总销品种，流通企业的业绩仍将维持稳健增长。部分经营能力强的公司，借助集采品种重新选择供应商的机会，获得更多上游品种，建议积极关注业绩增速远超行业增速的企业。",
    "labels": [
      [
        "T0",
        "行业公司",
        20,
        28,
        "18家医药流通股"
      ],
      [
        "T1",
        "时间范围",
        28,
        33,
        "Q1-Q3"
      ],
      [
        "T2",
        "收入增速",
        33,
        39,
        "收入总额增速"
      ],
      [
        "T3",
        "属性值",
        40,
        45,
        "22.6%"
      ],
      [
        "T4",
        "归母净利润增速",
        46,
        55,
        "归母净利润总额增速"
      ],
      [
        "T5",
        "属性值",
        56,
        61,
        "20.3%"
      ],
      [
        "T6",
        "扣非净利润增速",
        63,
        73,
        "扣非后归母净利润增速"
      ],
      [
        "T7",
        "属性值",
        74,
        79,
        "11.4%"
      ],
      [
        "T8",
        "业绩",
        13,
        15,
        "业绩"
      ],
      [
        "T9",
        "时间范围",
        2,
        4,
        "Q3"
      ],
      [
        "T10",
        "时间范围",
        81,
        83,
        "Q3"
      ],
      [
        "T11",
        "收入增速",
        85,
        91,
        "收入同比增速"
      ],
      [
        "T12",
        "属性值",
        92,
        97,
        "11.2%"
      ],
      [
        "T13",
        "归母净利润增速",
        98,
        108,
        "归母净利润的同比增速"
      ],
      [
        "T14",
        "属性值",
        109,
        115,
        "-16.8%"
      ],
      [
        "T15",
        "扣非净利润增速",
        116,
        127,
        "扣非归母净利润同比增速"
      ],
      [
        "T16",
        "属性值",
        128,
        132,
        "0.6%"
      ],
      [
        "T17",
        "时间范围",
        133,
        136,
        "三季度"
      ],
      [
        "T18",
        "现金流",
        203,
        206,
        "现金流"
      ],
      [
        "T19",
        "市场集中度",
        195,
        200,
        "行业集中度"
      ],
      [
        "T20",
        "行业公司",
        243,
        247,
        "配送企业"
      ],
      [
        "T21",
        "市场集中度",
        305,
        308,
        "集中度"
      ],
      [
        "T22",
        "行业公司",
        340,
        344,
        "配送企业"
      ],
      [
        "T23",
        "时间范围",
        370,
        378,
        "2021Q1-3"
      ],
      [
        "T24",
        "行业公司",
        378,
        382,
        "流通企业"
      ],
      [
        "T25",
        "时间范围",
        406,
        414,
        "2019Q1-3"
      ],
      [
        "T26",
        "属性值",
        416,
        420,
        "由负转正"
      ],
      [
        "T27",
        "属性值",
        422,
        428,
        "持续大幅改善"
      ],
      [
        "T28",
        "行业公司",
        449,
        457,
        "大型医药流通企业"
      ],
      [
        "T29",
        "行业",
        475,
        479,
        "医药工业"
      ],
      [
        "T30",
        "公司",
        527,
        531,
        "国大药房"
      ],
      [
        "T31",
        "行业公司",
        554,
        558,
        "流通企业"
      ],
      [
        "T32",
        "行业公司",
        564,
        566,
        "药企"
      ],
      [
        "T33",
        "公司",
        599,
        603,
        "上海医药"
      ],
      [
        "T34",
        "时间范围",
        603,
        605,
        "Q3"
      ],
      [
        "T35",
        "行业",
        605,
        608,
        "创新药"
      ],
      [
        "T36",
        "研发费用",
        608,
        612,
        "研发投入"
      ],
      [
        "T37",
        "属性值",
        612,
        616,
        "持续加大"
      ],
      [
        "T38",
        "公司",
        618,
        625,
        "HUYABIO"
      ],
      [
        "T39",
        "行业",
        725,
        729,
        "药品分销"
      ],
      [
        "T40",
        "时间范围",
        747,
        749,
        "目前"
      ],
      [
        "T41",
        "行业",
        778,
        780,
        "新药"
      ],
      [
        "T42",
        "行业公司",
        801,
        805,
        "流通企业"
      ],
      [
        "T43",
        "业绩",
        806,
        808,
        "业绩"
      ],
      [
        "T44",
        "属性值",
        812,
        816,
        "稳健增长"
      ],
      [
        "T45",
        "业绩",
        860,
        862,
        "业绩"
      ]
    ]
  },
  {
    "id": 2453,
    "text": " 2021Q1-3常规业务逐步恢复，叠加部分公司新冠检测试剂仍贡献增量，总体POCT企业实现收入、利润正增长，但增速有所分化，其中明德生物由于新冠贡献增量较多，增速较快。",
    "labels": [
      [
        "T0",
        "时间范围",
        2,
        10,
        "2021Q1-3"
      ],
      [
        "T1",
        "行业公司",
        39,
        45,
        "POCT企业"
      ],
      [
        "T2",
        "营业收入",
        47,
        49,
        "收入"
      ],
      [
        "T3",
        "利润",
        50,
        52,
        "利润"
      ],
      [
        "T4",
        "属性值",
        52,
        55,
        "正增长"
      ],
      [
        "T5",
        "公司",
        66,
        70,
        "明德生物"
      ]
    ]
  },
  {
    "id": 2454,
    "text": " Q3业绩承压，看好Q4毛利改善：5家连锁药店公司2021Q1-Q3总额为525亿元，增速为14.5%，其中Q3收入增速为 16.3%；归母净利润总额为31.2亿元，增速为9.6%，其中Q3增速为-8.2%。Q3利润端受到全国各地疫情散发影响，同时 2020Q3存在高基数，导致利润端增速同比有所回落，部分药店同店增速有所下降。从毛利端来看，单Q3毛利率36.4%， 环比下滑，主要系高毛利感冒药限售，处方药占比提升等因素影响。预计Q4利润端将逐季改善，日化、中药等高毛利产品有望持续改善产品结构，提升毛利率水平, 带动利润端逐季改善。  多因素促进处方外流，大型连锁药店成主力承接方。集采、DRGs、“双通道”等政策加速处方药流向院外市场，从长期看处方药外流市场有望带来2000亿增量市场。大型连锁药店对客户覆盖面广，具有更强的承接能力，因此吸引众多新增上游厂家、医院、处方平台、流量平台合作。从四家上市公司2020年报显示，处方药销售占比均呈上升趋势。  大连锁持续收购整合，次新店有望逐步进入盈利期。政策监管和开店限制趋严，倒逼小连锁和单体药店逐步淘汰出局，留给大连锁更多收购空间和开店机会。2021上半年，五家上市药店均维持高速增长步伐，上半年大参林、一心堂、老百姓、 益丰药房新增门店数量为958家、933家、1147家、847家，我们预计全年仍将维持较高的扩张速度，五家上市公司药店具有充足的现金流支持扩张。截至2021Q3末，随着2020年并购加速，各大连锁药店的次新店占比提升，有望在2022-2023 年步入盈利期。  互联网销售处方药打开市场空间。《药品网络销售监督管理办法（送审稿）》明确网络销售处方药主体，并且规定处方药审核细则。未来线下零售可在保证处方真实性基础上通过线上出售处方药，此外线下药店具有医保、会员管理、慢病管理等优势，在O2O市场具有先天优势。大参林、一心堂、老百姓、益丰药房同比增长分别为100%、78%、200%、140%， 线上业务实现快速发展。  投资建议：我国连锁药店集中度仍在持续提升，大连锁收购&自建门店空间大；处方外流才起步，尚有千亿规模可持续流向药店。两大因素均利好大型连锁药店。推荐大参林（603233）、一心堂（002727）、老百姓（603883） 、益丰药房（ 603939） 。",
    "labels": [
      [
        "T0",
        "行业公司",
        18,
        26,
        "5家连锁药店公司"
      ],
      [
        "T1",
        "时间范围",
        26,
        35,
        "2021Q1-Q3"
      ],
      [
        "T2",
        "时间范围",
        55,
        57,
        "Q3"
      ],
      [
        "T3",
        "收入增速",
        57,
        61,
        "收入增速"
      ],
      [
        "T4",
        "属性值",
        63,
        68,
        "16.3%"
      ],
      [
        "T5",
        "归母净利润",
        69,
        74,
        "归母净利润"
      ],
      [
        "T6",
        "属性值",
        77,
        83,
        "31.2亿元"
      ],
      [
        "T7",
        "属性值",
        87,
        91,
        "9.6%"
      ],
      [
        "T8",
        "时间范围",
        94,
        96,
        "Q3"
      ],
      [
        "T9",
        "属性值",
        99,
        104,
        "-8.2%"
      ],
      [
        "T10",
        "时间范围",
        105,
        107,
        "Q3"
      ],
      [
        "T11",
        "利润",
        107,
        110,
        "利润端"
      ],
      [
        "T12",
        "时间范围",
        126,
        132,
        "2020Q3"
      ],
      [
        "T13",
        "利润",
        140,
        143,
        "利润端"
      ],
      [
        "T14",
        "属性值",
        143,
        151,
        "增速同比有所回落"
      ],
      [
        "T15",
        "毛利",
        166,
        169,
        "毛利端"
      ],
      [
        "T16",
        "时间范围",
        173,
        175,
        "Q3"
      ],
      [
        "T17",
        "毛利",
        175,
        178,
        "毛利率"
      ],
      [
        "T18",
        "属性值",
        178,
        183,
        "36.4%"
      ],
      [
        "T19",
        "时间范围",
        217,
        219,
        "Q4"
      ],
      [
        "T20",
        "利润",
        219,
        222,
        "利润端"
      ],
      [
        "T21",
        "属性值",
        223,
        227,
        "逐季改善"
      ],
      [
        "T22",
        "地点范围",
        858,
        860,
        "我国"
      ],
      [
        "T23",
        "行业",
        860,
        864,
        "连锁药店"
      ],
      [
        "T24",
        "市场集中度",
        864,
        867,
        "集中度"
      ],
      [
        "T25",
        "属性值",
        869,
        873,
        "持续提升"
      ],
      [
        "T26",
        "行业",
        907,
        909,
        "药店"
      ],
      [
        "T27",
        "行业",
        917,
        923,
        "大型连锁药店"
      ],
      [
        "T28",
        "公司",
        926,
        929,
        "大参林"
      ],
      [
        "T29",
        "公司",
        938,
        941,
        "一心堂"
      ],
      [
        "T30",
        "公司",
        950,
        953,
        "老百姓"
      ],
      [
        "T31",
        "公司",
        963,
        967,
        "益丰药房"
      ],
      [
        "T32",
        "公司",
        796,
        799,
        "大参林"
      ],
      [
        "T33",
        "公司",
        800,
        803,
        "一心堂"
      ],
      [
        "T34",
        "公司",
        804,
        807,
        "老百姓"
      ],
      [
        "T35",
        "公司",
        808,
        812,
        "益丰药房"
      ],
      [
        "T36",
        "行业",
        784,
        787,
        "O2O"
      ],
      [
        "T37",
        "时间范围",
        731,
        733,
        "未来"
      ],
      [
        "T38",
        "时间范围",
        613,
        622,
        "截至2021Q3末"
      ],
      [
        "T39",
        "时间范围",
        653,
        664,
        "2022-2023 年"
      ],
      [
        "T40",
        "行业",
        673,
        681,
        "互联网销售处方药"
      ],
      [
        "T41",
        "属性值",
        681,
        683,
        "打开"
      ],
      [
        "T42",
        "市场规模",
        683,
        687,
        "市场空间"
      ],
      [
        "T43",
        "时间范围",
        526,
        529,
        "上半年"
      ],
      [
        "T44",
        "公司",
        529,
        532,
        "大参林"
      ],
      [
        "T45",
        "公司",
        533,
        536,
        "一心堂"
      ],
      [
        "T46",
        "公司",
        537,
        540,
        "老百姓"
      ],
      [
        "T47",
        "公司",
        542,
        546,
        "益丰药房"
      ],
      [
        "T48",
        "属性值",
        602,
        604,
        "充足"
      ],
      [
        "T49",
        "现金流",
        605,
        608,
        "现金流"
      ],
      [
        "T50",
        "行业公司",
        592,
        600,
        "五家上市公司药店"
      ],
      [
        "T51",
        "时间范围",
        502,
        509,
        "2021上半年"
      ],
      [
        "T52",
        "行业公司",
        510,
        516,
        "五家上市药店"
      ],
      [
        "T53",
        "行业",
        327,
        332,
        "处方药外流"
      ],
      [
        "T54",
        "时间范围",
        324,
        326,
        "长期"
      ],
      [
        "T55",
        "行业公司",
        401,
        407,
        "四家上市公司"
      ],
      [
        "T56",
        "时间范围",
        407,
        412,
        "2020年"
      ],
      [
        "T57",
        "时间范围",
        2,
        4,
        "Q3"
      ],
      [
        "T58",
        "时间范围",
        11,
        13,
        "Q4"
      ],
      [
        "T59",
        "业绩",
        4,
        6,
        "业绩"
      ],
      [
        "T60",
        "毛利",
        13,
        15,
        "毛利"
      ]
    ]
  },
  {
    "id": 2456,
    "text": "从研发投入角度来看，国内存量制药企业继续保持较快增长，另外非盈利的长尾客户继续保持高速增长。 • 统计成规模的A股已上市公司研发投入：2020年合计研发投入为477亿元，同比增长14.2%，继续维持较快增长；另外2021Q1-3合计研发投入为 335亿元，同比增长28.5%，其中恒瑞医药、复星医药、上海医药、健康元、白云山等保持高速增长。 • 已上市的Biotech企业研发投入继续保持高速增长：统计42家已公布财务数据的A/H Biotech企业，2021年上半年合计研发投入172亿元，同比增长40.7%，继续保持高速增长。（若扣除百济神州的扰动影响，41家Biotech合计研发投入为129亿元，同比增长59.4%）。",
    "labels": [
      [
        "T0",
        "研发费用",
        1,
        5,
        "研发投入"
      ],
      [
        "T1",
        "地点范围",
        10,
        12,
        "国内"
      ],
      [
        "T2",
        "行业公司",
        14,
        18,
        "制药企业"
      ],
      [
        "T3",
        "研发费用",
        62,
        66,
        "研发投入"
      ],
      [
        "T4",
        "行业公司",
        55,
        62,
        "A股已上市公司"
      ],
      [
        "T5",
        "时间范围",
        67,
        72,
        "2020年"
      ],
      [
        "T6",
        "研发费用",
        74,
        78,
        "研发投入"
      ],
      [
        "T7",
        "属性值",
        122,
        137,
        "335亿元，同比增长28.5%"
      ],
      [
        "T8",
        "时间范围",
        106,
        114,
        "2021Q1-3"
      ],
      [
        "T9",
        "研发费用",
        116,
        120,
        "研发投入"
      ],
      [
        "T10",
        "公司",
        140,
        144,
        "恒瑞医药"
      ],
      [
        "T11",
        "公司",
        145,
        149,
        "复星医药"
      ],
      [
        "T12",
        "公司",
        150,
        154,
        "上海医药"
      ],
      [
        "T13",
        "公司",
        155,
        158,
        "健康元"
      ],
      [
        "T14",
        "公司",
        159,
        162,
        "白云山"
      ],
      [
        "T15",
        "行业公司",
        177,
        186,
        "Biotech企业"
      ],
      [
        "T16",
        "研发费用",
        186,
        190,
        "研发投入"
      ],
      [
        "T17",
        "行业公司",
        201,
        225,
        "42家已公布财务数据的A/H Biotech企业"
      ],
      [
        "T18",
        "时间范围",
        226,
        234,
        "2021年上半年"
      ],
      [
        "T19",
        "研发费用",
        236,
        240,
        "研发投入"
      ],
      [
        "T20",
        "行业公司",
        279,
        289,
        "41家Biotech"
      ],
      [
        "T21",
        "研发费用",
        291,
        295,
        "研发投入"
      ],
      [
        "T22",
        "属性值",
        296,
        311,
        "129亿元，同比增长59.4%"
      ],
      [
        "T23",
        "公司",
        269,
        273,
        "百济神州"
      ],
      [
        "T24",
        "属性值",
        22,
        26,
        "较快增长"
      ],
      [
        "T25",
        "属性值",
        79,
        94,
        "477亿元，同比增长14.2%"
      ],
      [
        "T26",
        "属性值",
        194,
        198,
        "高速增长"
      ],
      [
        "T27",
        "属性值",
        240,
        255,
        "172亿元，同比增长40.7%"
      ],
      [
        "T28",
        "属性值",
        99,
        103,
        "较快增长"
      ],
      [
        "T29",
        "属性值",
        29,
        45,
        "非盈利的长尾客户继续保持高速增长"
      ],
      [
        "T30",
        "属性值",
        260,
        264,
        "高速增长"
      ],
      [
        "T31",
        "属性值",
        165,
        169,
        "高速增长"
      ]
    ]
  },
  {
    "id": 2459,
    "text": "• 创新药械进展低于预期：当前医药行业已转向以创新为主的大趋势，若是创新器械、药品研发进度不及预期，可能对市场带来冲击。",
    "labels": [
      [
        "T0",
        "行业",
        2,
        6,
        "创新药械"
      ],
      [
        "T1",
        "行业",
        15,
        17,
        "医药"
      ],
      [
        "T2",
        "行业",
        34,
        38,
        "创新器械"
      ],
      [
        "T3",
        "时间范围",
        13,
        15,
        "当前"
      ],
      [
        "T4",
        "属性值",
        22,
        27,
        "以创新为主"
      ],
      [
        "T5",
        "行业",
        39,
        43,
        "药品研发"
      ]
    ]
  },
  {
    "id": 2460,
    "text": " 上半年疫苗板块实现收入237亿元，五家样本公司收入实现正增长，3家公司收入、净利润增速均超过50%增长。",
    "labels": [
      [
        "T0",
        "时间范围",
        2,
        5,
        "上半年"
      ],
      [
        "T1",
        "行业",
        5,
        7,
        "疫苗"
      ],
      [
        "T2",
        "营业收入",
        11,
        13,
        "收入"
      ],
      [
        "T3",
        "属性值",
        13,
        18,
        "237亿元"
      ],
      [
        "T4",
        "行业公司",
        19,
        25,
        "五家样本公司"
      ],
      [
        "T5",
        "营业收入",
        25,
        27,
        "收入"
      ],
      [
        "T6",
        "属性值",
        29,
        32,
        "正增长"
      ],
      [
        "T7",
        "营业收入",
        37,
        39,
        "收入"
      ],
      [
        "T8",
        "归母净利润增速",
        40,
        45,
        "净利润增速"
      ],
      [
        "T9",
        "行业公司",
        33,
        37,
        "3家公司"
      ],
      [
        "T10",
        "属性值",
        46,
        53,
        "超过50%增长"
      ]
    ]
  },
  {
    "id": 2464,
    "text": "• 药明康德收入水平已到达全球 CDMO企业第一梯队收入规模，利润端与收入端均持续表现出优秀的增长； • 凯莱英凭借工艺优势，极大缩短生产时间和原材料成本；药明生物拥有业内最为复杂的生物药产品管线。",
    "labels": [
      [
        "T0",
        "公司",
        2,
        6,
        "药明康德"
      ],
      [
        "T1",
        "营业收入",
        6,
        8,
        "收入"
      ],
      [
        "T2",
        "地点范围",
        13,
        15,
        "全球"
      ],
      [
        "T3",
        "行业",
        16,
        20,
        "CDMO"
      ],
      [
        "T4",
        "营业收入",
        26,
        28,
        "收入"
      ],
      [
        "T5",
        "利润",
        31,
        34,
        "利润端"
      ],
      [
        "T6",
        "营业收入",
        35,
        38,
        "收入端"
      ],
      [
        "T7",
        "属性值",
        44,
        49,
        "优秀的增长"
      ],
      [
        "T8",
        "公司",
        53,
        56,
        "凯莱英"
      ],
      [
        "T9",
        "公司",
        78,
        82,
        "药明生物"
      ]
    ]
  },
  {
    "id": 2465,
    "text": "CXO  收入端继续加速，利润端受投资收益等影响放缓。10家CXO公司2021年上半年收入总额增速为45.6%、归母净利润总额增速为49.7%，整体维持高速增长。Q2收入同比增长37.7%，归母净利润同比增长4.7%，二季度收入端增速同比增加，利润端增速下降主要与龙头企业投资收益等下降有关。  盈利能力保持稳定，财务费用率保持相对在较低水平。从盈利水平看，CXO板块整体盈利能力保持稳定，二季度行业毛利率（39%）保持平稳，销售费用率（3%）、财务费用率（1%）均保持平稳，扣非后净利率（21%）小幅提升主要与管理费用率（10%，-2.2pp）降低有关。CXO企业收入主要以美元结算，2020年5月开始，人民币持续升值，导致我国CXO企业汇兑损益较大，进入2021H1，人民币汇率基本保持平稳，我们预计后续人民币升值进一步升值空间较小，CXO企业财务费用有望持续保持在较低水平。  在建工程和固定资产高速增长，验证行业仍处于高景气度周期。从在建工程增速来看，2021H1康龙化成、药石科技、药明康德和凯莱英等几家企业增速较快，昭衍新药、九洲药业和博腾股份也都保持在30%的增速。从固定资产（原值）增速来看，2021H1药石科技、康龙化成、药明康德等几家企业增速较快，凯莱英和博腾股份也都保持在20%以上的增速。整体来看，我国CXO行业固定资产和在建工程仍然保持高速增长，从侧面体现出目前行业仍处于高景气度周期，企业订单充足，业绩有望持续高速增长。  ROE持续提升，现金流逐步向好。从ROE水平来看，2021H1九洲药业、博腾股份和药石科技等几家企业提升显著，ROE提升主要与企业净利润率提升有关，另外几家CXO企业ROE水平小幅下降，主要因扩产速度较快，周转率下降有关，另外，CXO公司公允价值变动损益以及投资收益波动较大，对ROE造成一定波动。从现金流情况来看，近几年我国CXO企业经营活动产生的现金流量净额/经营活动净收益持续下降，2020年大幅好转，2021H1为106.2%，同比持平，预计下半年随着收入逐步确认，现金流有望继续向好。  非经营性影响逐步加大。目前我国CXO企业持续打造创新生态圈，投资企业逐步增加，公允价值变动净收益和投资净收益持续上涨，随着部分投资标的的上市，公允价值变动收益快速增加，预计未来公允价值变动净收益和投资净收益对利润影响将逐步增大。",
    "labels": [
      [
        "T0",
        "行业",
        0,
        3,
        "CXO"
      ],
      [
        "T1",
        "营业收入",
        6,
        9,
        "收入端"
      ],
      [
        "T2",
        "利润",
        14,
        17,
        "利润端"
      ],
      [
        "T3",
        "属性值",
        11,
        13,
        "加速"
      ],
      [
        "T4",
        "属性值",
        25,
        27,
        "放缓"
      ],
      [
        "T5",
        "行业公司",
        28,
        36,
        "10家CXO公司"
      ],
      [
        "T6",
        "时间范围",
        36,
        44,
        "2021年上半年"
      ],
      [
        "T7",
        "收入增速",
        44,
        50,
        "收入总额增速"
      ],
      [
        "T8",
        "属性值",
        51,
        56,
        "45.6%"
      ],
      [
        "T9",
        "归母净利润增速",
        57,
        66,
        "归母净利润总额增速"
      ],
      [
        "T10",
        "属性值",
        67,
        72,
        "49.7%"
      ],
      [
        "T11",
        "时间范围",
        82,
        84,
        "Q2"
      ],
      [
        "T12",
        "营业收入",
        84,
        86,
        "收入"
      ],
      [
        "T13",
        "属性值",
        90,
        95,
        "37.7%"
      ],
      [
        "T14",
        "归母净利润",
        96,
        101,
        "归母净利润"
      ],
      [
        "T15",
        "属性值",
        101,
        109,
        "同比增长4.7%"
      ],
      [
        "T16",
        "时间范围",
        110,
        113,
        "二季度"
      ],
      [
        "T17",
        "收入增速",
        113,
        118,
        "收入端增速"
      ],
      [
        "T18",
        "属性值",
        118,
        122,
        "同比增加"
      ],
      [
        "T19",
        "利润",
        123,
        126,
        "利润端"
      ],
      [
        "T20",
        "属性值",
        126,
        130,
        "增速下降"
      ],
      [
        "T21",
        "行业",
        181,
        184,
        "CXO"
      ],
      [
        "T22",
        "时间范围",
        197,
        200,
        "二季度"
      ],
      [
        "T23",
        "毛利",
        202,
        205,
        "毛利率"
      ],
      [
        "T24",
        "属性值",
        205,
        214,
        "（39%）保持平稳"
      ],
      [
        "T25",
        "扣非净利润",
        240,
        246,
        "扣非后净利率"
      ],
      [
        "T26",
        "属性值",
        246,
        255,
        "（21%）小幅提升"
      ],
      [
        "T27",
        "行业公司",
        280,
        285,
        "CXO企业"
      ],
      [
        "T28",
        "营业收入",
        285,
        287,
        "收入"
      ],
      [
        "T29",
        "时间范围",
        295,
        304,
        "2020年5月开始"
      ],
      [
        "T30",
        "地点范围",
        315,
        317,
        "我国"
      ],
      [
        "T31",
        "行业公司",
        317,
        322,
        "CXO企业"
      ],
      [
        "T32",
        "时间范围",
        331,
        337,
        "2021H1"
      ],
      [
        "T33",
        "行业公司",
        371,
        376,
        "CXO企业"
      ],
      [
        "T34",
        "固定资产",
        400,
        404,
        "固定资产"
      ],
      [
        "T35",
        "属性值",
        404,
        408,
        "高速增长"
      ],
      [
        "T36",
        "时间范围",
        433,
        439,
        "2021H1"
      ],
      [
        "T37",
        "公司",
        439,
        443,
        "康龙化成"
      ],
      [
        "T38",
        "公司",
        444,
        448,
        "药石科技"
      ],
      [
        "T39",
        "公司",
        449,
        453,
        "药明康德"
      ],
      [
        "T40",
        "公司",
        454,
        457,
        "凯莱英"
      ],
      [
        "T41",
        "公司",
        467,
        471,
        "昭衍新药"
      ],
      [
        "T42",
        "公司",
        472,
        476,
        "九洲药业"
      ],
      [
        "T43",
        "公司",
        477,
        481,
        "博腾股份"
      ],
      [
        "T44",
        "固定资产增速",
        494,
        504,
        "固定资产（原值）增速"
      ],
      [
        "T45",
        "时间范围",
        507,
        513,
        "2021H1"
      ],
      [
        "T46",
        "公司",
        513,
        517,
        "药石科技"
      ],
      [
        "T47",
        "公司",
        518,
        522,
        "康龙化成"
      ],
      [
        "T48",
        "公司",
        523,
        527,
        "药明康德"
      ],
      [
        "T49",
        "属性值",
        534,
        536,
        "较快"
      ],
      [
        "T50",
        "公司",
        537,
        540,
        "凯莱英"
      ],
      [
        "T51",
        "公司",
        541,
        545,
        "博腾股份"
      ],
      [
        "T52",
        "属性值",
        550,
        555,
        "20%以上"
      ],
      [
        "T53",
        "地点范围",
        564,
        566,
        "我国"
      ],
      [
        "T54",
        "行业",
        566,
        569,
        "CXO"
      ],
      [
        "T55",
        "固定资产",
        571,
        575,
        "固定资产"
      ],
      [
        "T56",
        "属性值",
        584,
        588,
        "高速增长"
      ],
      [
        "T57",
        "时间范围",
        595,
        597,
        "目前"
      ],
      [
        "T58",
        "业绩",
        616,
        618,
        "业绩"
      ],
      [
        "T59",
        "ROE净资产回报率",
        630,
        633,
        "ROE"
      ],
      [
        "T60",
        "现金流",
        638,
        641,
        "现金流"
      ],
      [
        "T61",
        "ROE净资产回报率",
        647,
        650,
        "ROE"
      ],
      [
        "T62",
        "时间范围",
        655,
        661,
        "2021H1"
      ],
      [
        "T63",
        "公司",
        661,
        665,
        "九洲药业"
      ],
      [
        "T64",
        "公司",
        666,
        670,
        "博腾股份"
      ],
      [
        "T65",
        "公司",
        671,
        675,
        "药石科技"
      ],
      [
        "T66",
        "属性值",
        680,
        684,
        "提升显著"
      ],
      [
        "T67",
        "ROE净资产回报率",
        685,
        688,
        "ROE"
      ],
      [
        "T68",
        "归母净利润",
        695,
        699,
        "净利润率"
      ],
      [
        "T69",
        "行业公司",
        708,
        713,
        "CXO企业"
      ],
      [
        "T70",
        "ROE净资产回报率",
        713,
        716,
        "ROE"
      ],
      [
        "T71",
        "属性值",
        718,
        722,
        "小幅下降"
      ],
      [
        "T72",
        "行业公司",
        744,
        749,
        "CXO公司"
      ],
      [
        "T73",
        "ROE净资产回报率",
        769,
        772,
        "ROE"
      ],
      [
        "T74",
        "现金流",
        780,
        783,
        "现金流"
      ],
      [
        "T75",
        "时间范围",
        788,
        791,
        "近几年"
      ],
      [
        "T76",
        "地点范围",
        791,
        793,
        "我国"
      ],
      [
        "T77",
        "行业公司",
        793,
        798,
        "CXO企业"
      ],
      [
        "T78",
        "时间范围",
        824,
        829,
        "2020年"
      ],
      [
        "T79",
        "时间范围",
        834,
        840,
        "2021H1"
      ],
      [
        "T80",
        "时间范围",
        855,
        858,
        "下半年"
      ],
      [
        "T81",
        "现金流",
        867,
        870,
        "现金流"
      ],
      [
        "T82",
        "时间范围",
        891,
        893,
        "目前"
      ],
      [
        "T83",
        "地点范围",
        893,
        895,
        "我国"
      ],
      [
        "T84",
        "行业公司",
        895,
        900,
        "CXO企业"
      ],
      [
        "T85",
        "时间范围",
        966,
        968,
        "未来"
      ],
      [
        "T86",
        "利润",
        984,
        986,
        "利润"
      ]
    ]
  },
  {
    "id": 2469,
    "text": "近年来医美行业处于高速发展阶段，国内医美市场规模从2016年的776亿元增长至2020年的1549亿元，CAGR为18.9%。在行业高速发展下，2021年6月国家卫健委等八部委联合发布《打击非法医疗美容服务专项整治工作方案》等政策出台规范行业发展，对于医美上游企业而言，行业规范发展更利于合规医美产品销售推广，头部企业有望进一步扩大市场份额。",
    "labels": [
      [
        "T0",
        "地点范围",
        16,
        18,
        "国内"
      ],
      [
        "T1",
        "行业",
        18,
        20,
        "医美"
      ],
      [
        "T2",
        "市场规模",
        20,
        24,
        "市场规模"
      ],
      [
        "T3",
        "时间范围",
        25,
        30,
        "2016年"
      ],
      [
        "T4",
        "属性值",
        31,
        36,
        "776亿元"
      ],
      [
        "T5",
        "时间范围",
        39,
        44,
        "2020年"
      ],
      [
        "T6",
        "属性值",
        45,
        51,
        "1549亿元"
      ],
      [
        "T7",
        "行业",
        3,
        5,
        "医美"
      ],
      [
        "T8",
        "时间范围",
        0,
        3,
        "近年来"
      ],
      [
        "T9",
        "CAGR",
        52,
        56,
        "CAGR"
      ],
      [
        "T10",
        "属性值",
        57,
        62,
        "18.9%"
      ],
      [
        "T11",
        "时间范围",
        72,
        79,
        "2021年6月"
      ],
      [
        "T12",
        "行业公司",
        126,
        132,
        "医美上游企业"
      ],
      [
        "T13",
        "市场份额",
        166,
        170,
        "市场份额"
      ]
    ]
  },
  {
    "id": 2471,
    "text": "康方生物：公司为国内双抗药物行业头部企业之一。（1）主要品种方面，公司PD-1/CTLA-4双抗预计2022年获批上市，有望成为国内首款获批上市的国产双抗药物；（2）其他品种方面，多个创新药品种，包括肿瘤领域的TIGIT、 CD47、CD73等，以及非肿瘤领域的PCSK9、 IL-4R、IL-17、 IL-12/ IL-23等均有望于2022年公布临床数据。",
    "labels": [
      [
        "T0",
        "公司",
        1,
        5,
        "康方生物"
      ],
      [
        "T1",
        "地点范围",
        9,
        11,
        "国内"
      ],
      [
        "T2",
        "行业",
        11,
        15,
        "双抗药物"
      ],
      [
        "T3",
        "龙头企业",
        17,
        21,
        "头部企业"
      ],
      [
        "T4",
        "时间范围",
        51,
        56,
        "2022年"
      ],
      [
        "T5",
        "地点范围",
        65,
        67,
        "国内"
      ],
      [
        "T6",
        "时间范围",
        169,
        174,
        "2022年"
      ],
      [
        "T7",
        "行业",
        101,
        103,
        "肿瘤"
      ],
      [
        "T8",
        "行业",
        126,
        129,
        "非肿瘤"
      ]
    ]
  },
  {
    "id": 2477,
    "text": "全球龙头 CDMO在 2021年业绩仍表现出了一定的成长性，尤其是生物 CDMO服务表现出较大的增长潜力，积极进行生物 CDMO服务方面布局与产能建设。 龙头 CDMO公司 Lonza业务以生物 CDMO业务及细胞与基因治疗相关 CDMO服务为主，公司 2021年上半年整体营业收入为 25.42亿法郎，同比增长 13.3%。2021H1公司生物药 CDMO业务收入 12.8亿美元，同比增长 16.7%，细胞与基因 CDMO业务收入 2.74亿美元，同比增长达 20.7%。 生物 CDMO Samsung Biologics(三星生物)为行业内生物药 CDMO龙头，主要为基于哺乳动物细胞的抗体药物提供服务，并于 2021年 5月宣布与 Moderna签约为其提供 COVID-19生产服务。公司 2021年上半年实现营业收入 6.72千亿韩元，同比增长 30.7%，实现净利润 1.82千亿韩元，同比增长 105.8%。公司 2021年 H1期末资产负债表存货数额为 8.80千亿韩元，同比增长 77%，合同负债数额为 2.27千亿韩元， 同比增长 39.2%。公司于 2018年开始 180,000L的产能建设，于 2021H1期末产能达到 364,000L，并将继续进行产能建设，预期将于 2023年完成 256,000L产能的建设。",
    "labels": [
      [
        "T0",
        "地点范围",
        0,
        2,
        "全球"
      ],
      [
        "T1",
        "行业",
        5,
        9,
        "CDMO"
      ],
      [
        "T2",
        "时间范围",
        11,
        16,
        "2021年"
      ],
      [
        "T3",
        "业绩",
        16,
        18,
        "业绩"
      ],
      [
        "T4",
        "行业",
        33,
        42,
        "生物 CDMO服务"
      ],
      [
        "T5",
        "行业",
        57,
        66,
        "生物 CDMO服务"
      ],
      [
        "T6",
        "行业公司",
        80,
        86,
        "CDMO公司"
      ],
      [
        "T7",
        "龙头企业",
        77,
        79,
        "龙头"
      ],
      [
        "T8",
        "公司",
        87,
        92,
        "Lonza"
      ],
      [
        "T9",
        "行业",
        95,
        102,
        "生物 CDMO"
      ],
      [
        "T10",
        "行业",
        105,
        121,
        "细胞与基因治疗相关 CDMO服务"
      ],
      [
        "T11",
        "时间范围",
        127,
        135,
        "2021年上半年"
      ],
      [
        "T12",
        "营业收入",
        137,
        141,
        "营业收入"
      ],
      [
        "T13",
        "属性值",
        143,
        151,
        "25.42亿法郎"
      ],
      [
        "T14",
        "属性值",
        157,
        162,
        "13.3%"
      ],
      [
        "T15",
        "时间范围",
        163,
        169,
        "2021H1"
      ],
      [
        "T16",
        "行业",
        171,
        179,
        "生物药 CDMO"
      ],
      [
        "T17",
        "营业收入",
        181,
        183,
        "收入"
      ],
      [
        "T18",
        "属性值",
        184,
        191,
        "12.8亿美元"
      ],
      [
        "T19",
        "属性值",
        197,
        202,
        "16.7%"
      ],
      [
        "T20",
        "行业",
        203,
        213,
        "细胞与基因 CDMO"
      ],
      [
        "T21",
        "营业收入",
        215,
        217,
        "收入"
      ],
      [
        "T22",
        "属性值",
        218,
        225,
        "2.74亿美元"
      ],
      [
        "T23",
        "属性值",
        232,
        237,
        "20.7%"
      ],
      [
        "T24",
        "行业",
        239,
        246,
        "生物 CDMO"
      ],
      [
        "T25",
        "公司",
        247,
        270,
        "Samsung Biologics(三星生物)"
      ],
      [
        "T26",
        "行业",
        274,
        282,
        "生物药 CDMO"
      ],
      [
        "T27",
        "龙头企业",
        282,
        284,
        "龙头"
      ],
      [
        "T28",
        "时间范围",
        309,
        317,
        "2021年 5月"
      ],
      [
        "T29",
        "公司",
        321,
        328,
        "Moderna"
      ],
      [
        "T30",
        "时间范围",
        351,
        359,
        "2021年上半年"
      ],
      [
        "T31",
        "营业收入",
        361,
        365,
        "营业收入"
      ],
      [
        "T32",
        "属性值",
        366,
        374,
        "6.72千亿韩元"
      ],
      [
        "T33",
        "属性值",
        380,
        385,
        "30.7%"
      ],
      [
        "T34",
        "归母净利润",
        388,
        391,
        "净利润"
      ],
      [
        "T35",
        "属性值",
        392,
        412,
        "1.82千亿韩元，同比增长 105.8%"
      ],
      [
        "T36",
        "时间范围",
        416,
        424,
        "2021年 H1"
      ],
      [
        "T37",
        "存货",
        431,
        433,
        "存货"
      ],
      [
        "T38",
        "属性值",
        437,
        454,
        "8.80千亿韩元，同比增长 77%"
      ],
      [
        "T39",
        "合同负债",
        455,
        459,
        "合同负债"
      ],
      [
        "T40",
        "属性值",
        463,
        483,
        "2.27千亿韩元， 同比增长 39.2%"
      ],
      [
        "T41",
        "时间范围",
        488,
        493,
        "2018年"
      ],
      [
        "T42",
        "时间范围",
        512,
        518,
        "2021H1"
      ],
      [
        "T43",
        "产能",
        520,
        522,
        "产能"
      ],
      [
        "T44",
        "属性值",
        525,
        533,
        "364,000L"
      ],
      [
        "T45",
        "产能",
        540,
        542,
        "产能"
      ],
      [
        "T46",
        "时间范围",
        550,
        555,
        "2023年"
      ],
      [
        "T47",
        "属性值",
        558,
        566,
        "256,000L"
      ],
      [
        "T48",
        "产能",
        566,
        568,
        "产能"
      ],
      [
        "T49",
        "属性值",
        23,
        29,
        "一定的成长性"
      ]
    ]
  },
  {
    "id": 2481,
    "text": "国内 R&D和生命科学研发投入持续高增长。根据国家统计局数据，近年来全国研究与试验发展（R&D）经费投入力度持续加大，由 2010 年的 7,062.6 亿元增长到 2019 年的 21,737.0 亿元，年均复合增长率达到 13.3%。生命科学领域的研究资金投入迅猛增长，由 2015年的 434亿元增长至 2019年的 866亿元，年复合增长率高达 18.8%，增速远高于全球 6.7%的复合增速。据 Frost & Sullivan统计数据，我国生命科学研究投入也仅次于美、欧，全球占比达到 8.3%左右。",
    "labels": [
      [
        "T0",
        "地点范围",
        0,
        2,
        "国内"
      ],
      [
        "T1",
        "行业",
        7,
        11,
        "生命科学"
      ],
      [
        "T2",
        "研发费用",
        11,
        15,
        "研发投入"
      ],
      [
        "T3",
        "属性值",
        15,
        20,
        "持续高增长"
      ],
      [
        "T4",
        "时间范围",
        31,
        34,
        "近年来"
      ],
      [
        "T5",
        "地点范围",
        34,
        36,
        "全国"
      ],
      [
        "T6",
        "时间范围",
        61,
        67,
        "2010 年"
      ],
      [
        "T7",
        "时间范围",
        83,
        89,
        "2019 年"
      ],
      [
        "T8",
        "CAGR",
        103,
        110,
        "年均复合增长率"
      ],
      [
        "T9",
        "行业",
        119,
        123,
        "生命科学"
      ],
      [
        "T10",
        "研发费用",
        126,
        132,
        "研究资金投入"
      ],
      [
        "T11",
        "属性值",
        132,
        136,
        "迅猛增长"
      ],
      [
        "T12",
        "时间范围",
        139,
        144,
        "2015年"
      ],
      [
        "T13",
        "属性值",
        146,
        151,
        "434亿元"
      ],
      [
        "T14",
        "时间范围",
        155,
        160,
        "2019年"
      ],
      [
        "T15",
        "属性值",
        162,
        167,
        "866亿元"
      ],
      [
        "T16",
        "CAGR",
        168,
        174,
        "年复合增长率"
      ],
      [
        "T17",
        "属性值",
        177,
        182,
        "18.8%"
      ],
      [
        "T18",
        "属性值",
        191,
        195,
        "6.7%"
      ],
      [
        "T19",
        "地点范围",
        188,
        190,
        "全球"
      ],
      [
        "T20",
        "CAGR",
        196,
        200,
        "复合增速"
      ],
      [
        "T21",
        "地点范围",
        224,
        226,
        "我国"
      ],
      [
        "T22",
        "行业",
        226,
        230,
        "生命科学"
      ],
      [
        "T23",
        "研发费用",
        230,
        234,
        "研究投入"
      ],
      [
        "T24",
        "属性值",
        235,
        241,
        "仅次于美、欧"
      ],
      [
        "T25",
        "地点范围",
        242,
        244,
        "全球"
      ]
    ]
  },
  {
    "id": 2488,
    "text": "在 CDMO市场中，生物药 CDMO服务目前收入低于化学药 CDMO服务，但是增长潜力较大。根据 Frost&Sullivan数据， 2021年化学药 CDMO收入预期为 420亿美元，在整体 CDMO市场收入中占比为 66%。 预期全球化学药 CDMO服务收入 2016年-2021年年均复合增长率为 9.6%，将于 2025年达到 606亿美元。 生物药 CDMO服务全球收入 2016年-2021年由 94亿美元增长至 218亿美元，年均复合增长率为 18.3%。 预期 2025年全球生物药 CDMO服务收入将达到 460亿美元，在整体 CDMO服务收入中占比达到 43%， 2021年-2025年年均复合增长率为 20.5%，增速高于整体 CDMO服务市场。",
    "labels": [
      [
        "T0",
        "行业",
        2,
        6,
        "CDMO"
      ],
      [
        "T1",
        "行业",
        10,
        20,
        "生物药 CDMO服务"
      ],
      [
        "T2",
        "营业收入",
        22,
        24,
        "收入"
      ],
      [
        "T3",
        "时间范围",
        20,
        22,
        "目前"
      ],
      [
        "T4",
        "行业",
        26,
        36,
        "化学药 CDMO服务"
      ],
      [
        "T5",
        "属性值",
        41,
        45,
        "潜力较大"
      ],
      [
        "T6",
        "时间范围",
        67,
        72,
        "2021年"
      ],
      [
        "T7",
        "行业",
        72,
        80,
        "化学药 CDMO"
      ],
      [
        "T8",
        "营业收入",
        80,
        82,
        "收入"
      ],
      [
        "T9",
        "属性值",
        86,
        92,
        "420亿美元"
      ],
      [
        "T10",
        "行业",
        97,
        101,
        "CDMO"
      ],
      [
        "T11",
        "营业收入",
        103,
        105,
        "收入"
      ],
      [
        "T12",
        "属性值",
        110,
        113,
        "66%"
      ],
      [
        "T13",
        "地点范围",
        117,
        119,
        "全球"
      ],
      [
        "T14",
        "行业",
        119,
        129,
        "化学药 CDMO服务"
      ],
      [
        "T15",
        "营业收入",
        129,
        131,
        "收入"
      ],
      [
        "T16",
        "时间范围",
        132,
        143,
        "2016年-2021年"
      ],
      [
        "T17",
        "CAGR",
        143,
        150,
        "年均复合增长率"
      ],
      [
        "T18",
        "属性值",
        152,
        156,
        "9.6%"
      ],
      [
        "T19",
        "时间范围",
        160,
        165,
        "2025年"
      ],
      [
        "T20",
        "属性值",
        168,
        174,
        "606亿美元"
      ],
      [
        "T21",
        "行业",
        176,
        186,
        "生物药 CDMO服务"
      ],
      [
        "T22",
        "地点范围",
        186,
        188,
        "全球"
      ],
      [
        "T23",
        "营业收入",
        188,
        190,
        "收入"
      ],
      [
        "T24",
        "时间范围",
        191,
        196,
        "2016年"
      ],
      [
        "T25",
        "时间范围",
        197,
        202,
        "2021年"
      ],
      [
        "T26",
        "属性值",
        204,
        209,
        "94亿美元"
      ],
      [
        "T27",
        "属性值",
        213,
        219,
        "218亿美元"
      ],
      [
        "T28",
        "CAGR",
        220,
        227,
        "年均复合增长率"
      ],
      [
        "T29",
        "属性值",
        229,
        234,
        "18.3%"
      ],
      [
        "T30",
        "时间范围",
        239,
        244,
        "2025年"
      ],
      [
        "T31",
        "地点范围",
        244,
        246,
        "全球"
      ],
      [
        "T32",
        "行业",
        246,
        256,
        "生物药 CDMO服务"
      ],
      [
        "T33",
        "营业收入",
        256,
        258,
        "收入"
      ],
      [
        "T34",
        "属性值",
        262,
        268,
        "460亿美元"
      ],
      [
        "T35",
        "行业",
        273,
        279,
        "CDMO服务"
      ],
      [
        "T36",
        "营业收入",
        279,
        281,
        "收入"
      ],
      [
        "T37",
        "属性值",
        287,
        290,
        "43%"
      ],
      [
        "T38",
        "时间范围",
        292,
        303,
        "2021年-2025年"
      ],
      [
        "T39",
        "CAGR",
        303,
        310,
        "年均复合增长率"
      ],
      [
        "T40",
        "属性值",
        312,
        317,
        "20.5%"
      ],
      [
        "T41",
        "行业",
        325,
        331,
        "CDMO服务"
      ]
    ]
  },
  {
    "id": 2498,
    "text": " 收入端继续加速，利润端增速恢复高增长。13家CXO公司2021Q1-3收入总额增速为43%、归母净利润总额增速为50%，整体维持高速增长。Q3收入同比增长36.6%，归母净利润同比增长47.3%，三季度收入端保持高速增长，利润端增速恢复高速增长。  盈利能力保持稳定，财务费用率保持相对在较低水平。从盈利水平看，CXO板块整体盈利能力保持稳定，未受疫情影响，三季度行业毛利率（40%）保持平稳，销售费用率（2.4%）、财务费用率（-0.6%）均保持平稳，扣非后净利率（17.8%）小幅提升主要与管理费用率（ 10.3%，-0.7pp）降低有关。CXO企业收入主要以美元结算，2020年5月开始，人民币持续升值，导致我国CXO企业汇兑损益较大，进入 2021Q1-3，人民币汇率基本保持平稳，我们预计后续人民币升值进一步升值空间较小，CXO企业财务费用有望持续保持在较低水平。  在建工程和固定资产高速增长，验证行业仍处于高景气度周期。从在建工程增速来看，2021Q1-3康龙化成、药石科技、药明康德和凯莱英等几家企业增速较快，昭衍新药、九洲药业和博腾股份也都保持在30%的增速。从固定资产（原值）增速来看，2021H1药石科技、康龙化成、药明康德等几家企业增速较快，凯莱英和博腾股份也都保持在20%以上的增速。整体来看，我国CXO行业固定资产和在建工程仍然保持高速增长，从侧面体现出目前行业仍处于高景气度周期，企业订单充足，业绩有望持续高速增长。  ROE持续提升，现金流有望向好。从ROE水平来看，2021Q1-3美迪西、九洲药业、博腾股份和药石科技等几家企业提升显著，ROE提升主要与企业净利润率提升有关，另外几家CXO企业ROE水平小幅下降，主要因扩产速度较快，周转率下降有关，另外，CXO公司公允价值变动损益以及投资收益波动较大，对ROE造成一定波动。从现金流情况来看，近几年我国CXO企业经营活动产生的现金流量净额/经营活动净收益持续下降，2020年大幅好转，2021Q1-3为97.8%，同比小幅下降，预计四季度随着收入逐步确认，现金流有望继续向好。  非经营性影响逐步加大。目前我国CXO企业持续打造创新生态圈，投资企业逐步增加，公允价值变动净收益和投资净收益持续上涨，随着部分投资标的的上市，公允价值变动收益快速增加，预计未来公允价值变动净收益和投资净收益对利润影响将逐步增大。",
    "labels": [
      [
        "T0",
        "营业收入",
        2,
        5,
        "收入端"
      ],
      [
        "T1",
        "利润",
        10,
        13,
        "利润端"
      ],
      [
        "T2",
        "行业公司",
        21,
        29,
        "13家CXO公司"
      ],
      [
        "T3",
        "时间范围",
        29,
        37,
        "2021Q1-3"
      ],
      [
        "T4",
        "收入增速",
        37,
        43,
        "收入总额增速"
      ],
      [
        "T5",
        "属性值",
        44,
        47,
        "43%"
      ],
      [
        "T6",
        "归母净利润增速",
        48,
        57,
        "归母净利润总额增速"
      ],
      [
        "T7",
        "属性值",
        58,
        61,
        "50%"
      ],
      [
        "T8",
        "时间范围",
        71,
        73,
        "Q3"
      ],
      [
        "T9",
        "营业收入",
        73,
        75,
        "收入"
      ],
      [
        "T10",
        "归母净利润",
        85,
        90,
        "归母净利润"
      ],
      [
        "T11",
        "属性值",
        90,
        99,
        "同比增长47.3%"
      ],
      [
        "T12",
        "时间范围",
        100,
        103,
        "三季度"
      ],
      [
        "T13",
        "行业",
        159,
        162,
        "CXO"
      ],
      [
        "T14",
        "时间范围",
        182,
        185,
        "三季度"
      ],
      [
        "T15",
        "毛利",
        187,
        190,
        "毛利率"
      ],
      [
        "T16",
        "行业公司",
        275,
        280,
        "CXO企业"
      ],
      [
        "T17",
        "营业收入",
        280,
        282,
        "收入"
      ],
      [
        "T18",
        "地点范围",
        310,
        312,
        "我国"
      ],
      [
        "T19",
        "行业公司",
        312,
        317,
        "CXO企业"
      ],
      [
        "T20",
        "时间范围",
        326,
        335,
        " 2021Q1-3"
      ],
      [
        "T21",
        "行业公司",
        369,
        374,
        "CXO企业"
      ],
      [
        "T22",
        "固定资产",
        398,
        402,
        "固定资产"
      ],
      [
        "T23",
        "时间范围",
        431,
        439,
        "2021Q1-3"
      ],
      [
        "T24",
        "公司",
        439,
        443,
        "康龙化成"
      ],
      [
        "T25",
        "公司",
        444,
        448,
        "药石科技"
      ],
      [
        "T26",
        "公司",
        449,
        453,
        "药明康德"
      ],
      [
        "T27",
        "公司",
        454,
        457,
        "凯莱英"
      ],
      [
        "T28",
        "公司",
        467,
        471,
        "昭衍新药"
      ],
      [
        "T29",
        "公司",
        472,
        476,
        "九洲药业"
      ],
      [
        "T30",
        "公司",
        477,
        481,
        "博腾股份"
      ],
      [
        "T31",
        "固定资产增速",
        494,
        504,
        "固定资产（原值）增速"
      ],
      [
        "T32",
        "时间范围",
        507,
        513,
        "2021H1"
      ],
      [
        "T33",
        "公司",
        513,
        517,
        "药石科技"
      ],
      [
        "T34",
        "公司",
        518,
        522,
        "康龙化成"
      ],
      [
        "T35",
        "公司",
        523,
        527,
        "药明康德"
      ],
      [
        "T36",
        "公司",
        537,
        540,
        "凯莱英"
      ],
      [
        "T37",
        "公司",
        541,
        545,
        "博腾股份"
      ],
      [
        "T38",
        "地点范围",
        564,
        566,
        "我国"
      ],
      [
        "T39",
        "行业",
        566,
        569,
        "CXO"
      ],
      [
        "T40",
        "固定资产",
        571,
        575,
        "固定资产"
      ],
      [
        "T41",
        "业绩",
        616,
        618,
        "业绩"
      ],
      [
        "T42",
        "ROE净资产回报率",
        629,
        633,
        " ROE"
      ],
      [
        "T43",
        "现金流",
        638,
        641,
        "现金流"
      ],
      [
        "T44",
        "ROE净资产回报率",
        647,
        650,
        "ROE"
      ],
      [
        "T45",
        "时间范围",
        655,
        663,
        "2021Q1-3"
      ],
      [
        "T46",
        "公司",
        663,
        666,
        "美迪西"
      ],
      [
        "T47",
        "公司",
        667,
        671,
        "九洲药业"
      ],
      [
        "T48",
        "公司",
        672,
        676,
        "博腾股份"
      ],
      [
        "T49",
        "公司",
        677,
        681,
        "药石科技"
      ],
      [
        "T50",
        "ROE净资产回报率",
        691,
        694,
        "ROE"
      ],
      [
        "T51",
        "ROE净资产回报率",
        719,
        722,
        "ROE"
      ],
      [
        "T52",
        "行业公司",
        750,
        755,
        "CXO公司"
      ],
      [
        "T53",
        "ROE净资产回报率",
        775,
        778,
        "ROE"
      ],
      [
        "T54",
        "现金流",
        786,
        789,
        "现金流"
      ],
      [
        "T55",
        "时间范围",
        794,
        797,
        "近几年"
      ],
      [
        "T56",
        "地点范围",
        797,
        799,
        "我国"
      ],
      [
        "T57",
        "时间范围",
        830,
        835,
        "2020年"
      ],
      [
        "T58",
        "时间范围",
        840,
        848,
        "2021Q1-3"
      ],
      [
        "T59",
        "时间范围",
        864,
        867,
        "四季度"
      ],
      [
        "T60",
        "营业收入",
        869,
        871,
        "收入"
      ],
      [
        "T61",
        "现金流",
        876,
        879,
        "现金流"
      ],
      [
        "T62",
        "地点范围",
        902,
        904,
        "我国"
      ],
      [
        "T63",
        "行业公司",
        904,
        909,
        "CXO企业"
      ],
      [
        "T64",
        "属性值",
        79,
        84,
        "36.6%"
      ],
      [
        "T65",
        "属性值",
        108,
        112,
        "高速增长"
      ],
      [
        "T66",
        "营业收入",
        103,
        106,
        "收入端"
      ],
      [
        "T67",
        "利润",
        113,
        116,
        "利润端"
      ],
      [
        "T68",
        "属性值",
        116,
        124,
        "增速恢复高速增长"
      ],
      [
        "T69",
        "属性值",
        190,
        199,
        "（40%）保持平稳"
      ],
      [
        "T70",
        "属性值",
        236,
        247,
        "（17.8%）小幅提升"
      ],
      [
        "T71",
        "扣非净利润",
        230,
        236,
        "扣非后净利率"
      ],
      [
        "T72",
        "时间范围",
        290,
        299,
        "2020年5月开始"
      ],
      [
        "T73",
        "属性值",
        402,
        406,
        "高速增长"
      ],
      [
        "T74",
        "属性值",
        534,
        536,
        "较快"
      ],
      [
        "T75",
        "属性值",
        550,
        555,
        "20%以上"
      ],
      [
        "T76",
        "属性值",
        584,
        588,
        "高速增长"
      ],
      [
        "T77",
        "在手订单",
        611,
        613,
        "订单"
      ],
      [
        "T78",
        "属性值",
        613,
        615,
        "充足"
      ],
      [
        "T79",
        "属性值",
        620,
        626,
        "持续高速增长"
      ],
      [
        "T80",
        "属性值",
        633,
        637,
        "持续提升"
      ],
      [
        "T81",
        "属性值",
        643,
        645,
        "向好"
      ],
      [
        "T82",
        "属性值",
        686,
        690,
        "提升显著"
      ],
      [
        "T83",
        "属性值",
        724,
        728,
        "小幅下降"
      ],
      [
        "T84",
        "行业公司",
        799,
        804,
        "CXO企业"
      ],
      [
        "T85",
        "属性值",
        881,
        885,
        "继续向好"
      ],
      [
        "T86",
        "时间范围",
        900,
        902,
        "目前"
      ],
      [
        "T87",
        "行业公司",
        710,
        719,
        "另外几家CXO企业"
      ]
    ]
  },
  {
    "id": 2501,
    "text": " 国内在疫情发生后，血制品重视程度显著提高，此前白蛋白严重依赖进口的问题得到高度重视，浆站建设和采浆有望大幅提升。2020年12月，云南省卫健委公布《云南省单采血浆站设置规划（2020-2023）（征求意见稿）》，拟在前期规划 4个县试点的基础上，在全省规划新增设置20个单采血浆站，累计设置24个，我们预计未来将有更多省份披露新建采浆站计划，未来行业采浆量增速有望提速。",
    "labels": [
      [
        "T0",
        "地点范围",
        2,
        4,
        "国内"
      ],
      [
        "T1",
        "行业",
        11,
        14,
        "血制品"
      ],
      [
        "T2",
        "时间范围",
        58,
        66,
        "2020年12月"
      ],
      [
        "T3",
        "时间范围",
        89,
        98,
        "2020-2023"
      ],
      [
        "T4",
        "地点范围",
        67,
        70,
        "云南省"
      ],
      [
        "T5",
        "时间范围",
        155,
        157,
        "未来"
      ],
      [
        "T6",
        "地点范围",
        76,
        79,
        "云南省"
      ]
    ]
  },
  {
    "id": 2503,
    "text": " 收入端全面恢复经营，更应关注常规业务真实增速。2021年上半年，受疫情影响的医疗服务如专科医院公司恢复较好，贡献板块增量。 4家医疗服务公司2021上半年收入约为185亿元（+63%）、归母净利润总额约为27.33亿元（+83.6%）。我们选取了经营较为稳健成熟的样本公司，2020年受到疫情扰动影响，下半年堆积的业务带来基数效应，造成今年板块业绩波动性较大，因此更应该关注公司常规业务的真实增速，多关注以2019年同期为基数的复合增长率。  新院区落地开花，民营医疗服务质量有望不断提升。今年上半年国内疫情防控有力，医疗服务公司经营扩张进展顺利。1）通策医疗上半年成功开业7个蒲公英分院，预计全年新开数量达到20家，同时正式筹备紫金港540张牙椅超大规模三级口腔医院，未来建成后有望将标准化的大众口腔治疗推向更广泛的居民、高水平的院区建设成功后有望实现医质进一步提升。2）爱尔眼科上半年新并入医院9家， 门诊部19个，截止2021年中报，公司共拥有境内医院155家，门诊部107家。同时上半年公司公告拟募资不超过36.50亿元（发行不超过2.06亿股）用于对七大重点省会及直辖市龙头医院的新建及迁址扩建，未来公司有望在具有消费力和辐射力重点区域持续扩大实力。  我国医疗服务资源供应不足，政策支持打开行业成长期。1）改革开放至2018年以来，我国卫生费用复合增速达到17%，但同期从业人员数量增速仅为1.12%。其中结构失衡更加严重，三甲医院超负荷，8%医院接诊占比达到54%；并且存在结构性不平衡逐年加剧中，经济相对不发达、人口密集中的省份医疗服务缺口更大。医疗服务行业整体供不应求，在三四线城市更加明显，行业供需决定长期优质赛道，填补空间巨大。2）政策支持社会办医，有力补充我国医疗服务供给市场。2021年8月31日，八部委联合印发了《深化医疗服务价格改革试点方案》的通知，政策的逐步试点、调整、正式实施，有利于我国公立医院的深化改革，提高医保基金的支付效率，最终的目的是为居民提供更广泛、优质的医疗服务。  复制性+消费属性两个维度精选专科医院赛道。从细分赛道来看，我们最看好眼科、口腔的商业模式，在整体医疗服务资源供不应求的大背景下，眼科与口腔具备独立科室、消费属性而非医保属性的特质，在商业模式上具备从综合医院独立的优势。  建议重点关注：通策医疗（600763）、爱尔眼科（300015）。",
    "labels": [
      [
        "T0",
        "行业公司",
        64,
        72,
        "4家医疗服务公司"
      ],
      [
        "T1",
        "时间范围",
        72,
        79,
        "2021上半年"
      ],
      [
        "T2",
        "营业收入",
        79,
        81,
        "收入"
      ],
      [
        "T3",
        "属性值",
        81,
        88,
        "约为185亿元"
      ],
      [
        "T4",
        "属性值",
        89,
        93,
        "+63%"
      ],
      [
        "T5",
        "归母净利润",
        95,
        100,
        "归母净利润"
      ],
      [
        "T6",
        "属性值",
        102,
        119,
        "约为27.33亿元（+83.6%）"
      ],
      [
        "T7",
        "公司",
        279,
        283,
        "通策医疗"
      ],
      [
        "T8",
        "时间范围",
        283,
        286,
        "上半年"
      ],
      [
        "T9",
        "公司",
        390,
        394,
        "爱尔眼科"
      ],
      [
        "T10",
        "时间范围",
        394,
        397,
        "上半年"
      ],
      [
        "T11",
        "时间范围",
        413,
        422,
        "截止2021年中报"
      ],
      [
        "T12",
        "时间范围",
        447,
        450,
        "上半年"
      ],
      [
        "T13",
        "时间范围",
        506,
        508,
        "未来"
      ],
      [
        "T14",
        "地点范围",
        536,
        538,
        "我国"
      ],
      [
        "T15",
        "行业",
        538,
        542,
        "医疗服务"
      ],
      [
        "T16",
        "时间范围",
        563,
        575,
        "改革开放至2018年以来"
      ],
      [
        "T17",
        "地点范围",
        576,
        578,
        "我国"
      ],
      [
        "T18",
        "营业收入",
        2,
        5,
        "收入端"
      ],
      [
        "T19",
        "时间范围",
        25,
        33,
        "2021年上半年"
      ],
      [
        "T20",
        "行业",
        40,
        44,
        "医疗服务"
      ],
      [
        "T21",
        "行业公司",
        45,
        51,
        "专科医院公司"
      ],
      [
        "T22",
        "时间范围",
        139,
        144,
        "2020年"
      ],
      [
        "T23",
        "时间范围",
        153,
        156,
        "下半年"
      ],
      [
        "T24",
        "时间范围",
        170,
        172,
        "今年"
      ],
      [
        "T25",
        "业绩",
        174,
        176,
        "业绩"
      ],
      [
        "T26",
        "时间范围",
        205,
        210,
        "2019年"
      ],
      [
        "T27",
        "时间范围",
        248,
        253,
        "今年上半年"
      ],
      [
        "T28",
        "地点范围",
        253,
        255,
        "国内"
      ],
      [
        "T29",
        "行业公司",
        262,
        268,
        "医疗服务公司"
      ],
      [
        "T30",
        "行业",
        676,
        680,
        "医疗服务"
      ],
      [
        "T31",
        "行业",
        685,
        689,
        "医疗服务"
      ],
      [
        "T32",
        "地点范围",
        699,
        704,
        "三四线城市"
      ],
      [
        "T33",
        "地点范围",
        744,
        746,
        "我国"
      ],
      [
        "T34",
        "行业",
        746,
        750,
        "医疗服务"
      ],
      [
        "T35",
        "时间范围",
        755,
        765,
        "2021年8月31日"
      ],
      [
        "T36",
        "行业",
        777,
        781,
        "医疗服务"
      ],
      [
        "T37",
        "地点范围",
        813,
        815,
        "我国"
      ],
      [
        "T38",
        "行业",
        877,
        881,
        "专科医院"
      ],
      [
        "T39",
        "属性值",
        863,
        871,
        "复制性+消费属性"
      ],
      [
        "T40",
        "行业",
        911,
        915,
        "医疗服务"
      ],
      [
        "T41",
        "行业",
        927,
        929,
        "眼科"
      ],
      [
        "T42",
        "行业",
        930,
        932,
        "口腔"
      ],
      [
        "T43",
        "属性值",
        934,
        943,
        "独立科室、消费属性"
      ],
      [
        "T44",
        "属性值",
        961,
        968,
        "从综合医院独立"
      ],
      [
        "T45",
        "公司",
        982,
        986,
        "通策医疗"
      ],
      [
        "T46",
        "公司",
        995,
        999,
        "爱尔眼科"
      ]
    ]
  },
  {
    "id": 2507,
    "text": "维持盈利预测，预计2021-2023年营业收入为111.43/136.92/160.28亿元，归母净利润为41.00/51.00/61.38亿元，EPS为10.13/12.61/15.17 元，对应2021年11月30日收盘价283.38元/股，PE分别为28/22/19倍，维持“买入”评级。",
    "labels": [
      [
        "T0",
        "时间范围",
        9,
        19,
        "2021-2023年"
      ],
      [
        "T1",
        "营业收入",
        19,
        23,
        "营业收入"
      ],
      [
        "T2",
        "归母净利润",
        47,
        52,
        "归母净利润"
      ],
      [
        "T3",
        "时间范围",
        100,
        110,
        "021年11月30日"
      ],
      [
        "T4",
        "PE",
        123,
        125,
        "PE"
      ]
    ]
  },
  {
    "id": 2513,
    "text": " 通策医疗：上半年收入同比+75%，净利润同比+141%。分医院来看，杭口改革持续兑现，今年将是杭口有效推进团队模式元年，2021H1 实现收入3.6亿元，同比+59%，2019 H1~2021H1复合增速约为12%；城西分院继续保持高效运营，21H1实现收入2.7亿元，同比+53% ，2019H1~2021H1复合增速约为23%，年初城西分院新增约20张牙椅，扣除量约10%的增长，团队模式仍在提升城西分院效益；宁口上半年实现收入约8千万元，其中6月收入估计超1600万元，期待下半年老院区取得医保资质后迎来快速增长。  爱尔眼科：2021H1公司实现营收、归母净利润、扣非归母净利润73.5/11.2/12.3亿元，分别同比增长76.5%/65%/112%（较2019年分别增长54.7%/65%/76.5%），分别实现门诊量479万人次和手术量40万例，分别同比增长81.38%/71.57%。眼科巨舰“新十年” 起航，持续深化分级诊疗体系。公司公告拟募资不超过36.50亿元（发行不超过2.06亿股）用于对七大重点省会及直辖市龙头医院的新建及迁址扩建，未来公司有望在具有消费力和辐射力重点区域持续扩大实力。  金域医学：上半年公司实现收入54.6亿元（+57%），归母利润10.6亿元（+90.5%），扣非归母净利润10.3亿元（+91.4%），经营活动现金流6.2亿元（+157.2%）。疫情加强公司在ICL领域龙头地位，品牌影响力得到进一步提升；2019年国内ICL市场规模370亿左右，占医学检验市场约8%，对标美国、欧洲、日本等成熟市场35%、50%、67%的渗透率，未来还有很大的提升空间，同时LDT规范化管理、不合理医疗检查专项行动、DRG等各种政策将将持续利好“检测外流”。",
    "labels": [
      [
        "T0",
        "公司",
        2,
        6,
        "通策医疗"
      ],
      [
        "T1",
        "时间范围",
        7,
        10,
        "上半年"
      ],
      [
        "T2",
        "营业收入",
        10,
        12,
        "收入"
      ],
      [
        "T3",
        "属性值",
        14,
        18,
        "+75%"
      ],
      [
        "T4",
        "归母净利润",
        19,
        22,
        "净利润"
      ],
      [
        "T5",
        "属性值",
        22,
        29,
        "同比+141%"
      ],
      [
        "T6",
        "时间范围",
        45,
        47,
        "今年"
      ],
      [
        "T7",
        "时间范围",
        62,
        68,
        "2021H1"
      ],
      [
        "T8",
        "公司",
        36,
        38,
        "杭口"
      ],
      [
        "T9",
        "公司",
        49,
        51,
        "杭口"
      ],
      [
        "T10",
        "属性值",
        73,
        78,
        "3.6亿元"
      ],
      [
        "T11",
        "属性值",
        81,
        85,
        "+59%"
      ],
      [
        "T12",
        "营业收入",
        71,
        73,
        "收入"
      ],
      [
        "T13",
        "时间范围",
        86,
        100,
        "2019 H1~2021H1"
      ],
      [
        "T14",
        "CAGR",
        100,
        104,
        "复合增速"
      ],
      [
        "T15",
        "属性值",
        104,
        109,
        "约为12%"
      ],
      [
        "T16",
        "时间范围",
        123,
        127,
        "21H1"
      ],
      [
        "T17",
        "时间范围",
        145,
        158,
        "2019H1~2021H1"
      ],
      [
        "T18",
        "公司",
        209,
        211,
        "宁口"
      ],
      [
        "T19",
        "时间范围",
        211,
        214,
        "上半年"
      ],
      [
        "T20",
        "营业收入",
        216,
        218,
        "收入"
      ],
      [
        "T21",
        "属性值",
        218,
        223,
        "约8千万元"
      ],
      [
        "T22",
        "时间范围",
        226,
        228,
        "6月"
      ],
      [
        "T23",
        "属性值",
        232,
        239,
        "超1600万元"
      ],
      [
        "T24",
        "营业收入",
        228,
        230,
        "收入"
      ],
      [
        "T25",
        "时间范围",
        242,
        245,
        "下半年"
      ],
      [
        "T26",
        "公司",
        265,
        269,
        "爱尔眼科"
      ],
      [
        "T27",
        "时间范围",
        270,
        276,
        "2021H1"
      ],
      [
        "T28",
        "营业收入",
        280,
        282,
        "营收"
      ],
      [
        "T29",
        "归母净利润",
        283,
        288,
        "归母净利润"
      ],
      [
        "T30",
        "扣非净利润",
        289,
        296,
        "扣非归母净利润"
      ],
      [
        "T31",
        "属性值",
        296,
        300,
        "73.5"
      ],
      [
        "T32",
        "属性值",
        301,
        305,
        "11.2"
      ],
      [
        "T33",
        "属性值",
        306,
        312,
        "12.3亿元"
      ],
      [
        "T34",
        "属性值",
        319,
        324,
        "76.5%"
      ],
      [
        "T35",
        "时间范围",
        335,
        340,
        "2019年"
      ],
      [
        "T36",
        "属性值",
        344,
        349,
        "54.7%"
      ],
      [
        "T37",
        "公司",
        513,
        517,
        "金域医学"
      ],
      [
        "T38",
        "时间范围",
        518,
        521,
        "上半年"
      ],
      [
        "T39",
        "营业收入",
        525,
        527,
        "收入"
      ],
      [
        "T40",
        "属性值",
        527,
        533,
        "54.6亿元"
      ],
      [
        "T41",
        "属性值",
        534,
        538,
        "+57%"
      ],
      [
        "T42",
        "归母净利润",
        540,
        544,
        "归母利润"
      ],
      [
        "T43",
        "属性值",
        544,
        558,
        "10.6亿元（+90.5%）"
      ],
      [
        "T44",
        "扣非净利润",
        559,
        566,
        "扣非归母净利润"
      ],
      [
        "T45",
        "属性值",
        566,
        580,
        "10.3亿元（+91.4%）"
      ],
      [
        "T46",
        "现金流",
        585,
        588,
        "现金流"
      ],
      [
        "T47",
        "属性值",
        588,
        602,
        "6.2亿元（+157.2%）"
      ],
      [
        "T48",
        "行业",
        610,
        613,
        "ICL"
      ],
      [
        "T49",
        "时间范围",
        633,
        638,
        "2019年"
      ],
      [
        "T50",
        "地点范围",
        638,
        640,
        "国内"
      ],
      [
        "T51",
        "行业",
        640,
        643,
        "ICL"
      ],
      [
        "T52",
        "市场规模",
        643,
        647,
        "市场规模"
      ],
      [
        "T53",
        "属性值",
        647,
        653,
        "370亿左右"
      ],
      [
        "T54",
        "行业",
        655,
        659,
        "医学检验"
      ],
      [
        "T55",
        "地点范围",
        667,
        669,
        "美国"
      ],
      [
        "T56",
        "地点范围",
        670,
        672,
        "欧洲"
      ],
      [
        "T57",
        "地点范围",
        673,
        675,
        "日本"
      ],
      [
        "T58",
        "属性值",
        661,
        664,
        "约8%"
      ]
    ]
  },
  {
    "id": 2515,
    "text": " 疫情与高基数导致收入端环比回落。4家医疗服务公司2021Q1-Q3收入同比增速为40.2%，归母净利润同比增速为43%。单Q3收入同比增速13%，归母净利润同比增速为8.3%，环比有所回落。主要的原因是：其一、2020年下半年疫情逐渐恢复，各位患者集中问诊， 形成2020Q3相对的高基数；其二、国内2021Q3疫情反复影响各地医院门诊量；其三、种植牙集采导致口腔患者推迟问诊。  新院区落地开花，民营医疗服务质量有望不断提升。今年上半年国内疫情防控有力，医疗服务公司经营扩张进展顺利。1）通策医疗： 2021Q1-Q3成功开业9个蒲公英分院，2021Q4预计开业4家，2022全年预计开业12家，同时正式筹备紫金港540张牙椅超大规模三级口腔医院，未来建成后有望将标准化的大众口腔治疗推向更广泛的居民、高水平的院区建设成功后有望实现医质进一步提升。2）爱尔眼科：公司公告拟募资不超过36.50亿元（发行不超过2.06亿股）用于对七大重点省会及直辖市龙头医院的新建及迁址扩建，未来公司有望在具有消费力和辐射力重点区域持续扩大实力。3）锦欣生殖：收购全国最大单体妇儿医院，加快产业价值链延申，单个患者价值提升2-3倍，达到10-15万元。公司2021年并购5个重大标的在2021年将大幅增厚利润。4）海吉亚：2021年下半年苏州永鼎和贺州广济实现并表，山东聊城预计2021年底开业，2022年将持续增厚业绩。预计到2023年通过内生“自建+扩建”有望达到1万张床位，至少布局18家医院。  政策支持民营医疗服务，医疗服务价格体系调整值得期待。政策鼓励社会力量依法举办医疗卫生机构，民营医院通过聚焦专科，能够提供差异化的服务，与公立医院形成互补，同时也能缓解公立医疗资源供给不足现状。民营医疗服务提供差异化的服务并且享受自主定价权，医院运营效率更高。医保局发布《深化医疗服务价格改革试点方案》，预计未来医疗服务价格将有升有降，总体而言未来民营医疗服务价格水平有望借助差异化服务将得到提升。依托口碑、技术、人才和资金的优势，民营医疗服务ROE和净利润率持续提升。  从三个维度精选优质赛道，1）盈利能力：牙科、眼科、辅助生殖等行业龙头企业具有医生、品牌、技术壁垒，具有较好的竞争格局， 在成熟门店的净利润率上通常更高；2）复制性：眼科、辅助生殖、康复等相对具有较好的可复制性；3）政策风险：辅助生殖、体检、 眼科、口腔对于医保的依赖程度更低，消费属性更强。建议关注细分领域龙头标的，如通策医疗、爱尔眼科、锦欣生殖、海吉亚医疗。  建议重点关注：关注“盈利能力+可复制性+医保风险”，精选专科医院赛道，建议关注细分领域龙头标的，如通策医疗、爱尔眼科、锦欣生殖、海吉亚医疗等。",
    "labels": [
      [
        "T0",
        "行业公司",
        18,
        26,
        "4家医疗服务公司"
      ],
      [
        "T1",
        "时间范围",
        26,
        35,
        "2021Q1-Q3"
      ],
      [
        "T2",
        "收入增速",
        35,
        41,
        "收入同比增速"
      ],
      [
        "T3",
        "属性值",
        42,
        47,
        "40.2%"
      ],
      [
        "T4",
        "归母净利润增速",
        48,
        57,
        "归母净利润同比增速"
      ],
      [
        "T5",
        "属性值",
        58,
        61,
        "43%"
      ],
      [
        "T6",
        "时间范围",
        63,
        65,
        "Q3"
      ],
      [
        "T7",
        "收入增速",
        65,
        71,
        "收入同比增速"
      ],
      [
        "T8",
        "属性值",
        71,
        74,
        "13%"
      ],
      [
        "T9",
        "归母净利润增速",
        75,
        84,
        "归母净利润同比增速"
      ],
      [
        "T10",
        "属性值",
        85,
        89,
        "8.3%"
      ],
      [
        "T11",
        "时间范围",
        107,
        115,
        "2020年下半年"
      ],
      [
        "T12",
        "时间范围",
        134,
        140,
        "2020Q3"
      ],
      [
        "T13",
        "地点范围",
        150,
        152,
        "国内"
      ],
      [
        "T14",
        "时间范围",
        152,
        158,
        "2021Q3"
      ],
      [
        "T15",
        "时间范围",
        217,
        222,
        "今年上半年"
      ],
      [
        "T16",
        "地点范围",
        222,
        224,
        "国内"
      ],
      [
        "T17",
        "行业公司",
        231,
        237,
        "医疗服务公司"
      ],
      [
        "T18",
        "公司",
        248,
        252,
        "通策医疗"
      ],
      [
        "T19",
        "时间范围",
        254,
        263,
        "2021Q1-Q3"
      ],
      [
        "T20",
        "时间范围",
        275,
        281,
        "2021Q4"
      ],
      [
        "T21",
        "时间范围",
        288,
        294,
        "2022全年"
      ],
      [
        "T22",
        "时间范围",
        328,
        330,
        "未来"
      ],
      [
        "T23",
        "公司",
        380,
        384,
        "爱尔眼科"
      ],
      [
        "T24",
        "公司",
        1044,
        1048,
        "通策医疗"
      ],
      [
        "T25",
        "公司",
        1049,
        1053,
        "爱尔眼科"
      ],
      [
        "T26",
        "公司",
        1054,
        1058,
        "锦欣生殖"
      ],
      [
        "T27",
        "公司",
        1059,
        1064,
        "海吉亚医疗"
      ],
      [
        "T28",
        "公司",
        1117,
        1121,
        "通策医疗"
      ],
      [
        "T29",
        "公司",
        1122,
        1126,
        "爱尔眼科"
      ],
      [
        "T30",
        "公司",
        1127,
        1131,
        "锦欣生殖"
      ],
      [
        "T31",
        "公司",
        1132,
        1137,
        "海吉亚医疗"
      ],
      [
        "T32",
        "竞争格局",
        939,
        943,
        "竞争格局"
      ],
      [
        "T33",
        "属性值",
        936,
        938,
        "较好"
      ],
      [
        "T34",
        "行业",
        863,
        869,
        "民营医疗服务"
      ],
      [
        "T35",
        "ROE净资产回报率",
        869,
        872,
        "ROE"
      ],
      [
        "T36",
        "归母净利润",
        873,
        877,
        "净利润率"
      ],
      [
        "T37",
        "属性值",
        877,
        881,
        "持续提升"
      ],
      [
        "T38",
        "行业",
        904,
        906,
        "牙科"
      ],
      [
        "T39",
        "行业",
        907,
        909,
        "眼科"
      ],
      [
        "T40",
        "行业",
        910,
        914,
        "辅助生殖"
      ],
      [
        "T41",
        "行业",
        967,
        969,
        "眼科"
      ],
      [
        "T42",
        "行业",
        970,
        974,
        "辅助生殖"
      ],
      [
        "T43",
        "行业",
        975,
        977,
        "康复"
      ],
      [
        "T44",
        "行业",
        997,
        1001,
        "辅助生殖"
      ],
      [
        "T45",
        "行业",
        1002,
        1004,
        "体检"
      ],
      [
        "T46",
        "行业",
        1006,
        1008,
        "眼科"
      ],
      [
        "T47",
        "行业",
        1009,
        1011,
        "口腔"
      ],
      [
        "T48",
        "属性值",
        1023,
        1029,
        "消费属性更强"
      ],
      [
        "T49",
        "公司",
        552,
        555,
        "海吉亚"
      ],
      [
        "T50",
        "时间范围",
        556,
        564,
        "2021年下半年"
      ],
      [
        "T51",
        "公司",
        564,
        568,
        "苏州永鼎"
      ],
      [
        "T52",
        "公司",
        569,
        573,
        "贺州广济"
      ],
      [
        "T53",
        "公司",
        578,
        582,
        "山东聊城"
      ],
      [
        "T54",
        "时间范围",
        584,
        590,
        "2021年底"
      ],
      [
        "T55",
        "时间范围",
        593,
        598,
        "2022年"
      ],
      [
        "T56",
        "属性值",
        599,
        603,
        "持续增厚"
      ],
      [
        "T57",
        "业绩",
        603,
        605,
        "业绩"
      ],
      [
        "T58",
        "时间范围",
        609,
        614,
        "2023年"
      ],
      [
        "T59",
        "行业",
        652,
        658,
        "民营医疗服务"
      ],
      [
        "T60",
        "行业",
        659,
        663,
        "医疗服务"
      ],
      [
        "T61",
        "行业",
        744,
        750,
        "民营医疗服务"
      ],
      [
        "T62",
        "行业",
        785,
        789,
        "医疗服务"
      ],
      [
        "T63",
        "时间范围",
        801,
        803,
        "未来"
      ],
      [
        "T64",
        "行业",
        803,
        807,
        "医疗服务"
      ],
      [
        "T65",
        "行业",
        821,
        827,
        "民营医疗服务"
      ],
      [
        "T66",
        "公司",
        470,
        474,
        "锦欣生殖"
      ],
      [
        "T67",
        "地点范围",
        477,
        479,
        "全国"
      ],
      [
        "T68",
        "时间范围",
        523,
        528,
        "2021年"
      ],
      [
        "T69",
        "时间范围",
        537,
        542,
        "2021年"
      ],
      [
        "T70",
        "属性值",
        543,
        547,
        "大幅增厚"
      ],
      [
        "T71",
        "利润",
        547,
        549,
        "利润"
      ],
      [
        "T72",
        "时间范围",
        441,
        443,
        "未来"
      ]
    ]
  },
  {
    "id": 2519,
    "text": "三季度营收 1.61万亿，同比 2020年（1.36万亿）增长 18.1%（2020年同比 2019年仅微增 2.9%），同比 2019年（1.33万亿）增长 21.5%；归母净利润端保持 25%以上的较快增长，2021年归母净利润 1689.8亿元，同比 2020年（1322.2亿元）增长 27.8%，同比增速较 2020年（2020年同比 2019年增速 25.2%）略微加快 2.6pct，两年平均增长 26.5%。扣非归母净利润同比增速更快，2021年前三季度达到 30.8%。 细分行业：行业分化加剧，生物制品、服务和器械快速增长，化学制药增速垫底我们观察到，医药行业内部细分行业分化加剧，行业整体业绩增长主要归因于生物制品行业、医疗服务和部分抗疫医疗器械公司业绩大幅增长，化学制药、医药商业增速平稳，化学制药行业在所有细分行业大类中增速最低，前三季度仅同比增 5.7%，且同比负增长的企业绝对数量和比例都更多，115家企业有半数企业同比 2020年负增长。中药行业恢复性增长，但仅恢复到 2019年正常年份水平。 生物制品：今年新冠疫苗业绩兑现，非新冠疫苗生物制品公司业绩持续快速增长， 共同支撑细分行业业绩快速增长。细分行业前三季度营收 893.0亿元，同比 2020年增长 40.3%，归母净利润 71.9亿元，同比增长 35.4%。样本公司共 36家，仅 1家公司营收同比负增长，有 14家公司归母净利润同比负增长，头部公司业绩绝对数和增速都明显。 智飞生物、康泰生物、康希诺业绩受益新冠疫苗业绩兑现，业绩绝对数和同比增幅都较大，另外部分非新冠的生物制品公司业绩延续快速增长，如长春高新、安科生物、上海莱士、通化东宝、甘李药业等。 医疗服务：行业受益于国内新冠疫情控制良好，国内医疗秩序相较去年恢复正常， 医院医疗服务行业增速较快，另外 CXO行业延续景气，保持较快增长。细分行业前三季度营收 900.7亿元，同比 2020年增长 36.7%，归母净利润 137.1亿元，同比增长 58.5%。 样本公司共 30家，有 3家公司营收同比负增长，6家公司归母净利润同比负增长。医疗服务行业不论是医院医疗服务和 CXO服务都呈现行业整体性增长，整体行业景气度较高。 医疗器械：抗疫器械前三季度增速亮眼，新冠检测试剂盒 IVD、手套等企业主要需求在国外，海外疫情持续紧张奠定业绩高增长基础。细分行业前三季度营收 1680.0亿元，同比 2020年增长 27.2%，归母净利润 503.1亿元，同比增长 30.2%。样本公司共 83 家，有 15家公司营收同比负增长，26家公司归母净利润同比负增长。新冠检测试剂盒 IVD企业如热景生物、达安基因、科华生物、东方生物、之江生物、圣湘生物，手套类英科医疗、蓝帆医疗等持续受益海外抗疫需求，另外器械头部企业迈瑞医疗在 2020年业绩高基数基础上，延续快速增长，营收 193.9亿元，同比增长 20.7%，归母净利润 66.6 亿元，同比增长 24.2%。 化学制药、医药商业增速平稳。化学制药 2021年前三季度营收 3670亿元，在所有细分行业大类中增速最低，仅同比增 11.0%，归母净利润 387.1亿元，同比增长仅 5.7%； 另外同比负增长的企业绝对数量和比例都最多，115家企业有半数企业同比 2020年负增长，主要源于持续带量采购等政策打压影响，代表性公司恒瑞医药今年前三季度营收和归母净利润分别同比增 4.0%和-1.2%。医药商业前三季度营收 6530亿元，同比增长 18.1%，归母净利润 167.7亿元，同比增长 15.5%。 中药行业：恢复到 2019年正常年份水平。中药行业 68家样本公司，其中 14家公司营收负增长，18家公司归母净利润负增长；细分行业整体营收 2474.1亿元，归母净利润 250亿元，分别同比增 11.1%和 20.6%，但是仅恢复到 2019年正常年份水平，今年对比 2019年同期数据，营收和归母净利润增速都是全行业最低，只有 3.2%和 1.2%。 年前三季度医药各细分行业营收和（扣非）归母净利润同比增速一览营业收入归母净利润扣非归母净利润 019年同比 2020年同比 2019年同比 2020年同比 2019年同比 2020年 21.5% 18.1% 60.1% 27.8% 66.8% 30.8%",
    "labels": [
      [
        "T0",
        "时间范围",
        0,
        3,
        "三季度"
      ],
      [
        "T1",
        "营业收入",
        3,
        5,
        "营收"
      ],
      [
        "T2",
        "时间范围",
        16,
        21,
        "2020年"
      ],
      [
        "T3",
        "时间范围",
        38,
        43,
        "2020年"
      ],
      [
        "T4",
        "时间范围",
        46,
        51,
        "2019年"
      ],
      [
        "T5",
        "时间范围",
        64,
        69,
        "2019年"
      ],
      [
        "T6",
        "归母净利润",
        86,
        92,
        "归母净利润端"
      ],
      [
        "T7",
        "时间范围",
        106,
        111,
        "2021年"
      ],
      [
        "T8",
        "归母净利润",
        111,
        116,
        "归母净利润"
      ],
      [
        "T9",
        "时间范围",
        129,
        134,
        "2020年"
      ],
      [
        "T10",
        "时间范围",
        159,
        164,
        "2020年"
      ],
      [
        "T11",
        "时间范围",
        165,
        170,
        "2020年"
      ],
      [
        "T12",
        "扣非净利润增速",
        212,
        223,
        "扣非归母净利润同比增速"
      ],
      [
        "T13",
        "时间范围",
        173,
        178,
        "2019年"
      ],
      [
        "T14",
        "时间范围",
        226,
        235,
        "2021年前三季度"
      ],
      [
        "T15",
        "行业",
        257,
        261,
        "生物制品"
      ],
      [
        "T16",
        "行业",
        262,
        264,
        "服务"
      ],
      [
        "T17",
        "行业",
        265,
        267,
        "器械"
      ],
      [
        "T18",
        "行业",
        272,
        276,
        "化学制药"
      ],
      [
        "T19",
        "行业",
        286,
        288,
        "医药"
      ],
      [
        "T20",
        "业绩",
        305,
        307,
        "业绩"
      ],
      [
        "T21",
        "属性值",
        307,
        309,
        "增长"
      ],
      [
        "T22",
        "行业",
        314,
        318,
        "生物制品"
      ],
      [
        "T23",
        "行业",
        321,
        325,
        "医疗服务"
      ],
      [
        "T24",
        "行业",
        328,
        336,
        "抗疫医疗器械公司"
      ],
      [
        "T25",
        "业绩",
        336,
        338,
        "业绩"
      ],
      [
        "T26",
        "属性值",
        338,
        342,
        "大幅增长"
      ],
      [
        "T27",
        "行业",
        343,
        347,
        "化学制药"
      ],
      [
        "T28",
        "行业",
        348,
        352,
        "医药商业"
      ],
      [
        "T29",
        "行业",
        357,
        361,
        "化学制药"
      ],
      [
        "T30",
        "时间范围",
        378,
        382,
        "前三季度"
      ],
      [
        "T31",
        "时间范围",
        426,
        431,
        "2020年"
      ],
      [
        "T32",
        "行业",
        435,
        437,
        "中药"
      ],
      [
        "T33",
        "时间范围",
        451,
        456,
        "2019年"
      ],
      [
        "T34",
        "行业",
        464,
        468,
        "生物制品"
      ],
      [
        "T35",
        "时间范围",
        469,
        471,
        "今年"
      ],
      [
        "T36",
        "业绩",
        475,
        477,
        "业绩"
      ],
      [
        "T37",
        "属性值",
        477,
        479,
        "兑现"
      ],
      [
        "T38",
        "行业公司",
        480,
        491,
        "非新冠疫苗生物制品公司"
      ],
      [
        "T39",
        "业绩",
        491,
        493,
        "业绩"
      ],
      [
        "T40",
        "属性值",
        495,
        499,
        "快速增长"
      ],
      [
        "T41",
        "业绩",
        509,
        511,
        "业绩"
      ],
      [
        "T42",
        "时间范围",
        520,
        524,
        "前三季度"
      ],
      [
        "T43",
        "营业收入",
        524,
        526,
        "营收"
      ],
      [
        "T44",
        "时间范围",
        538,
        543,
        "2020年"
      ],
      [
        "T45",
        "归母净利润",
        552,
        557,
        "归母净利润"
      ],
      [
        "T46",
        "营业收入",
        592,
        594,
        "营收"
      ],
      [
        "T47",
        "归母净利润",
        607,
        612,
        "归母净利润"
      ],
      [
        "T48",
        "业绩",
        622,
        624,
        "业绩"
      ],
      [
        "T49",
        "公司",
        634,
        639,
        " 智飞生物"
      ],
      [
        "T50",
        "公司",
        640,
        644,
        "康泰生物"
      ],
      [
        "T51",
        "公司",
        645,
        648,
        "康希诺"
      ],
      [
        "T52",
        "业绩",
        648,
        651,
        "业绩受"
      ],
      [
        "T53",
        "业绩",
        656,
        658,
        "业绩"
      ],
      [
        "T54",
        "属性值",
        658,
        660,
        "兑现"
      ],
      [
        "T55",
        "业绩",
        661,
        663,
        "业绩"
      ],
      [
        "T56",
        "属性值",
        669,
        674,
        "增幅都较大"
      ],
      [
        "T57",
        "行业公司",
        679,
        689,
        "非新冠的生物制品公司"
      ],
      [
        "T58",
        "业绩",
        689,
        691,
        "业绩"
      ],
      [
        "T59",
        "属性值",
        693,
        697,
        "快速增长"
      ],
      [
        "T60",
        "公司",
        699,
        703,
        "长春高新"
      ],
      [
        "T61",
        "公司",
        704,
        708,
        "安科生物"
      ],
      [
        "T62",
        "公司",
        709,
        713,
        "上海莱士"
      ],
      [
        "T63",
        "公司",
        714,
        718,
        "通化东宝"
      ],
      [
        "T64",
        "公司",
        719,
        723,
        "甘李药业"
      ],
      [
        "T65",
        "行业",
        726,
        730,
        "医疗服务"
      ],
      [
        "T66",
        "地点范围",
        736,
        738,
        "国内"
      ],
      [
        "T67",
        "地点范围",
        747,
        749,
        "国内"
      ],
      [
        "T68",
        "时间范围",
        749,
        751,
        "医疗"
      ],
      [
        "T69",
        "时间范围",
        755,
        757,
        "去年"
      ],
      [
        "T70",
        "行业",
        763,
        769,
        "医院医疗服务"
      ],
      [
        "T71",
        "行业",
        779,
        782,
        "CXO"
      ],
      [
        "T72",
        "时间范围",
        800,
        804,
        "前三季度"
      ],
      [
        "T73",
        "营业收入",
        804,
        806,
        "营收"
      ],
      [
        "T74",
        "时间范围",
        818,
        823,
        "2020年"
      ],
      [
        "T75",
        "归母净利润",
        832,
        837,
        "归母净利润"
      ],
      [
        "T76",
        "营业收入",
        874,
        876,
        "营收"
      ],
      [
        "T77",
        "归母净利润",
        886,
        891,
        "归母净利润"
      ],
      [
        "T78",
        "行业",
        897,
        901,
        "医疗服务"
      ],
      [
        "T79",
        "行业",
        906,
        912,
        "医院医疗服务"
      ],
      [
        "T80",
        "行业",
        914,
        919,
        "CXO服务"
      ],
      [
        "T81",
        "行业",
        941,
        945,
        "医疗器械"
      ],
      [
        "T82",
        "行业",
        946,
        950,
        "抗疫器械"
      ],
      [
        "T83",
        "时间范围",
        950,
        954,
        "前三季度"
      ],
      [
        "T84",
        "行业",
        959,
        970,
        "新冠检测试剂盒 IVD"
      ],
      [
        "T85",
        "行业",
        971,
        973,
        "手套"
      ],
      [
        "T86",
        "地点范围",
        984,
        986,
        "海外"
      ],
      [
        "T87",
        "业绩",
        994,
        996,
        "业绩"
      ],
      [
        "T88",
        "属性值",
        996,
        999,
        "高增长"
      ],
      [
        "T89",
        "时间范围",
        1006,
        1010,
        "前三季度"
      ],
      [
        "T90",
        "时间范围",
        1025,
        1030,
        "2020年"
      ],
      [
        "T91",
        "归母净利润",
        1039,
        1044,
        "归母净利润"
      ],
      [
        "T92",
        "营业收入",
        1082,
        1084,
        "营收"
      ],
      [
        "T93",
        "归母净利润",
        1095,
        1100,
        "归母净利润"
      ],
      [
        "T94",
        "行业公司",
        1106,
        1119,
        "新冠检测试剂盒 IVD企业"
      ],
      [
        "T95",
        "公司",
        1120,
        1124,
        "热景生物"
      ],
      [
        "T96",
        "公司",
        1125,
        1129,
        "达安基因"
      ],
      [
        "T97",
        "公司",
        1130,
        1134,
        "科华生物"
      ],
      [
        "T98",
        "公司",
        1135,
        1139,
        "东方生物"
      ],
      [
        "T99",
        "公司",
        1140,
        1144,
        "之江生物"
      ],
      [
        "T100",
        "公司",
        1145,
        1149,
        "圣湘生物"
      ],
      [
        "T101",
        "行业",
        1150,
        1153,
        "手套类"
      ],
      [
        "T102",
        "公司",
        1153,
        1157,
        "英科医疗"
      ],
      [
        "T103",
        "公司",
        1158,
        1162,
        "蓝帆医疗"
      ],
      [
        "T104",
        "地点范围",
        1167,
        1169,
        "海外"
      ],
      [
        "T105",
        "行业",
        1176,
        1178,
        "器械"
      ],
      [
        "T106",
        "公司",
        1182,
        1186,
        "迈瑞医疗"
      ],
      [
        "T107",
        "时间范围",
        1188,
        1193,
        "2020年"
      ],
      [
        "T108",
        "业绩",
        1193,
        1195,
        "业绩"
      ],
      [
        "T109",
        "属性值",
        1195,
        1198,
        "高基数"
      ],
      [
        "T110",
        "属性值",
        1204,
        1208,
        "快速增长"
      ],
      [
        "T111",
        "营业收入",
        1209,
        1211,
        "营收"
      ],
      [
        "T112",
        "属性值",
        1212,
        1219,
        "193.9亿元"
      ],
      [
        "T113",
        "属性值",
        1225,
        1230,
        "20.7%"
      ],
      [
        "T114",
        "归母净利润",
        1231,
        1236,
        "归母净利润"
      ],
      [
        "T115",
        "属性值",
        1237,
        1255,
        "66.6 亿元，同比增长 24.2%"
      ],
      [
        "T116",
        "行业",
        1257,
        1261,
        "化学制药"
      ],
      [
        "T117",
        "行业",
        1262,
        1266,
        "医药商业"
      ],
      [
        "T118",
        "行业",
        1271,
        1275,
        "化学制药"
      ],
      [
        "T119",
        "营业收入",
        1285,
        1287,
        "营收"
      ],
      [
        "T120",
        "属性值",
        1288,
        1294,
        "3670亿元"
      ],
      [
        "T121",
        "属性值",
        1315,
        1320,
        "11.0%"
      ],
      [
        "T122",
        "归母净利润",
        1321,
        1326,
        "归母净利润"
      ],
      [
        "T123",
        "属性值",
        1327,
        1345,
        "387.1亿元，同比增长仅 5.7%"
      ],
      [
        "T124",
        "时间范围",
        1382,
        1387,
        "2020年"
      ],
      [
        "T125",
        "公司",
        1414,
        1418,
        "恒瑞医药"
      ],
      [
        "T126",
        "营业收入",
        1424,
        1426,
        "营收"
      ],
      [
        "T127",
        "归母净利润",
        1427,
        1432,
        "归母净利润"
      ],
      [
        "T128",
        "属性值",
        1438,
        1442,
        "4.0%"
      ],
      [
        "T129",
        "行业",
        1449,
        1453,
        "医药商业"
      ],
      [
        "T130",
        "时间范围",
        1453,
        1457,
        "前三季度"
      ],
      [
        "T131",
        "营业收入",
        1457,
        1459,
        "营收"
      ],
      [
        "T132",
        "属性值",
        1460,
        1466,
        "6530亿元"
      ],
      [
        "T133",
        "属性值",
        1472,
        1477,
        "18.1%"
      ],
      [
        "T134",
        "归母净利润",
        1478,
        1483,
        "归母净利润"
      ],
      [
        "T135",
        "属性值",
        1484,
        1502,
        "167.7亿元，同比增长 15.5%"
      ],
      [
        "T136",
        "行业",
        1504,
        1506,
        "中药"
      ],
      [
        "T137",
        "时间范围",
        1513,
        1518,
        "2019年"
      ],
      [
        "T138",
        "行业",
        1525,
        1527,
        "中药"
      ],
      [
        "T139",
        "营业收入",
        1546,
        1548,
        "营收"
      ],
      [
        "T140",
        "归母净利润",
        1557,
        1562,
        "归母净利润"
      ],
      [
        "T141",
        "营业收入",
        1572,
        1574,
        "营收"
      ],
      [
        "T142",
        "归母净利润",
        1584,
        1589,
        "归母净利润"
      ],
      [
        "T143",
        "时间范围",
        1622,
        1627,
        "2019年"
      ],
      [
        "T144",
        "时间范围",
        1634,
        1636,
        "今年"
      ],
      [
        "T145",
        "时间范围",
        1639,
        1644,
        "2019年"
      ],
      [
        "T146",
        "营业收入",
        1649,
        1651,
        "营收"
      ],
      [
        "T147",
        "归母净利润增速",
        1652,
        1659,
        "归母净利润增速"
      ],
      [
        "T148",
        "时间范围",
        1682,
        1687,
        "年前三季度"
      ],
      [
        "T149",
        "行业",
        1687,
        1689,
        "医药"
      ],
      [
        "T150",
        "营业收入",
        1694,
        1696,
        "营收"
      ],
      [
        "T151",
        "扣非净利润",
        1697,
        1706,
        "（扣非）归母净利润"
      ],
      [
        "T152",
        "营业收入",
        1712,
        1716,
        "营业收入"
      ],
      [
        "T153",
        "归母净利润",
        1716,
        1721,
        "归母净利润"
      ],
      [
        "T154",
        "扣非净利润",
        1721,
        1728,
        "扣非归母净利润"
      ],
      [
        "T155",
        "时间范围",
        1729,
        1733,
        "019年"
      ],
      [
        "T156",
        "时间范围",
        1736,
        1741,
        "2020年"
      ],
      [
        "T157",
        "时间范围",
        1744,
        1749,
        "2019年"
      ],
      [
        "T158",
        "时间范围",
        1752,
        1757,
        "2020年"
      ],
      [
        "T159",
        "时间范围",
        1760,
        1765,
        "2019年"
      ],
      [
        "T160",
        "时间范围",
        1768,
        1773,
        "2020年"
      ],
      [
        "T161",
        "时间范围",
        1418,
        1424,
        "今年前三季度"
      ],
      [
        "T162",
        "时间范围",
        1276,
        1285,
        "2021年前三季度"
      ]
    ]
  },
  {
    "id": 2530,
    "text": "医疗设备是医疗器械市场规模最大、国产化平均水平最低的细分赛道。 2019年国内医疗设备市场规模达到 3560亿元，占医疗器械市场整体份额的 57%。然而由于技术壁垒较高、研发周期漫长、临床对产品质量和稳定性要求较高，MRI、CT、超声等高端医疗设备国产产品占比普遍低于 30%，内窥镜更是低于 10%；此外，由于芯片、传感器、 探测器等关键核心部件研发生产尚未成熟，国产医疗设备正处于技术补足、快速发展的阶段。",
    "labels": [
      [
        "T0",
        "行业",
        0,
        4,
        "医疗设备"
      ],
      [
        "T1",
        "行业",
        5,
        9,
        "医疗器械"
      ],
      [
        "T2",
        "市场规模",
        9,
        13,
        "市场规模"
      ],
      [
        "T3",
        "属性值",
        13,
        15,
        "最大"
      ],
      [
        "T4",
        "时间范围",
        32,
        37,
        "2019年"
      ],
      [
        "T5",
        "地点范围",
        37,
        39,
        "国内"
      ],
      [
        "T6",
        "行业",
        39,
        43,
        "医疗设备"
      ],
      [
        "T7",
        "市场规模",
        43,
        47,
        "市场规模"
      ],
      [
        "T8",
        "属性值",
        50,
        56,
        "3560亿元"
      ],
      [
        "T9",
        "行业",
        58,
        62,
        "医疗器械"
      ],
      [
        "T10",
        "属性值",
        70,
        73,
        "57%"
      ],
      [
        "T11",
        "市场份额",
        62,
        68,
        "市场整体份额"
      ],
      [
        "T12",
        "行业",
        118,
        124,
        "高端医疗设备"
      ],
      [
        "T13",
        "行业",
        108,
        111,
        "MRI"
      ],
      [
        "T14",
        "行业",
        112,
        114,
        "CT"
      ],
      [
        "T15",
        "行业",
        115,
        117,
        "超声"
      ],
      [
        "T16",
        "行业",
        139,
        142,
        "内窥镜"
      ],
      [
        "T17",
        "行业",
        183,
        189,
        "国产医疗设备"
      ]
    ]
  },
  {
    "id": 2531,
    "text": " 2021Q1-3器械板块（83家样本，含科创板）收入实现正增长的有70家 ，占比84%，超过50%增长有23家，占比28%；  2021Q1-3器械板块（83家样本，含科创板）归母净利润实现正增长的有60家，占比72%，超过50%增长有28家，占比34%；  从收入贡献看，前五名迈瑞、英科、乐普、东方生物、达安基因贡献了 36%的板块收入；  从归母净利润贡献看，前五名英科、迈瑞、东方生物、达安、中红贡献了46%的板块净利润。",
    "labels": [
      [
        "T0",
        "时间范围",
        2,
        10,
        "2021Q1-3"
      ],
      [
        "T1",
        "行业",
        10,
        12,
        "器械"
      ],
      [
        "T2",
        "营业收入",
        26,
        28,
        "收入"
      ],
      [
        "T3",
        "时间范围",
        67,
        75,
        "2021Q1-3"
      ],
      [
        "T4",
        "行业",
        75,
        77,
        "器械"
      ],
      [
        "T5",
        "归母净利润",
        91,
        96,
        "归母净利润"
      ],
      [
        "T6",
        "营业收入",
        135,
        137,
        "收入"
      ],
      [
        "T7",
        "公司",
        144,
        146,
        "迈瑞"
      ],
      [
        "T8",
        "公司",
        147,
        149,
        "英科"
      ],
      [
        "T9",
        "公司",
        150,
        152,
        "乐普"
      ],
      [
        "T10",
        "公司",
        153,
        157,
        "东方生物"
      ],
      [
        "T11",
        "公司",
        158,
        162,
        "达安基因"
      ],
      [
        "T12",
        "营业收入",
        172,
        174,
        "收入"
      ],
      [
        "T13",
        "归母净利润",
        179,
        184,
        "归母净利润"
      ],
      [
        "T14",
        "公司",
        191,
        193,
        "英科"
      ],
      [
        "T15",
        "公司",
        194,
        196,
        "迈瑞"
      ],
      [
        "T16",
        "公司",
        197,
        201,
        "东方生物"
      ],
      [
        "T17",
        "公司",
        202,
        204,
        "达安"
      ],
      [
        "T18",
        "公司",
        205,
        207,
        "中红"
      ],
      [
        "T19",
        "归母净利润",
        216,
        219,
        "净利润"
      ]
    ]
  },
  {
    "id": 2532,
    "text": " 疫苗板块 Q1/Q2/Q3单季度收入分别为 87.5/157.1/160.2亿元（ +49.1%/+52.8%/52.7%），归母净利润分别为 14/58.8/47.3亿元（ +85%/+228%/118%）。",
    "labels": [
      [
        "T0",
        "行业",
        2,
        4,
        "疫苗"
      ],
      [
        "T1",
        "时间范围",
        7,
        9,
        "Q1"
      ],
      [
        "T2",
        "时间范围",
        10,
        12,
        "Q2"
      ],
      [
        "T3",
        "时间范围",
        13,
        15,
        "Q3"
      ],
      [
        "T4",
        "营业收入",
        18,
        20,
        "收入"
      ],
      [
        "T5",
        "属性值",
        24,
        28,
        "87.5"
      ],
      [
        "T6",
        "属性值",
        29,
        34,
        "157.1"
      ],
      [
        "T7",
        "属性值",
        35,
        42,
        "160.2亿元"
      ],
      [
        "T8",
        "属性值",
        44,
        50,
        "+49.1%"
      ],
      [
        "T9",
        "属性值",
        51,
        57,
        "+52.8%"
      ],
      [
        "T10",
        "属性值",
        58,
        63,
        "52.7%"
      ],
      [
        "T11",
        "归母净利润",
        65,
        70,
        "归母净利润"
      ],
      [
        "T12",
        "属性值",
        74,
        76,
        "14"
      ],
      [
        "T13",
        "属性值",
        77,
        81,
        "58.8"
      ],
      [
        "T14",
        "属性值",
        82,
        88,
        "47.3亿元"
      ]
    ]
  },
  {
    "id": 2533,
    "text": "药物根据分子特征可分为化学药物与生物制品，化学药物包括化学小分子药物、寡核苷酸、多肽、 多糖等，生物制品包括抗体、抗偶联药物及 mRNA。化学药物收入在全球医药市场收入中仍保持高占比，全球化学药物 2020年市场收入为 10.01千亿美元，在整体全球医药市场中占比为 77%。全球化学药物市场 2016年-2021年年均复合增长率为 2.5%，预期 2021年-2025年预期年均复合增长率为 2.8%， 预期将在 2025年达到 11.81千亿美元，在整体市场中占比为 69%。 根据 Frost&Sullivan数据，全球生物制品 2020年收入为 2.98千亿美元，在全球医药市场总收入中占比为 23%，与 2016年相比提高了 4个百分点。生物制品 2021年预期全球收入为 3.37千亿美元，2016年 -2021年年均复合增长率为 8.9%。2025年全球医药市场生物制品预期收入将达到 5.30千亿美元，在整体医药市场中占比增长至 31%，2021-2025年预期年均复合增长率为 12.0%，增速高于整体医药市场。",
    "labels": [
      [
        "T0",
        "行业",
        69,
        73,
        "化学药物"
      ],
      [
        "T1",
        "营业收入",
        73,
        75,
        "收入"
      ],
      [
        "T2",
        "地点范围",
        76,
        78,
        "全球"
      ],
      [
        "T3",
        "行业",
        78,
        80,
        "医药"
      ],
      [
        "T4",
        "营业收入",
        82,
        84,
        "收入"
      ],
      [
        "T5",
        "属性值",
        88,
        91,
        "高占比"
      ],
      [
        "T6",
        "地点范围",
        92,
        94,
        "全球"
      ],
      [
        "T7",
        "行业",
        94,
        98,
        "化学药物"
      ],
      [
        "T8",
        "时间范围",
        99,
        104,
        "2020年"
      ],
      [
        "T9",
        "营业收入",
        106,
        108,
        "收入"
      ],
      [
        "T10",
        "属性值",
        110,
        119,
        "10.01千亿美元"
      ],
      [
        "T11",
        "地点范围",
        123,
        125,
        "全球"
      ],
      [
        "T12",
        "行业",
        125,
        127,
        "医药"
      ],
      [
        "T13",
        "属性值",
        134,
        137,
        "77%"
      ],
      [
        "T14",
        "地点范围",
        138,
        140,
        "全球"
      ],
      [
        "T15",
        "行业",
        140,
        144,
        "化学药物"
      ],
      [
        "T16",
        "时间范围",
        147,
        158,
        "2016年-2021年"
      ],
      [
        "T17",
        "CAGR",
        158,
        165,
        "年均复合增长率"
      ],
      [
        "T18",
        "属性值",
        167,
        171,
        "2.5%"
      ],
      [
        "T19",
        "时间范围",
        175,
        186,
        "2021年-2025年"
      ],
      [
        "T20",
        "CAGR",
        188,
        195,
        "年均复合增长率"
      ],
      [
        "T21",
        "属性值",
        197,
        201,
        "2.8%"
      ],
      [
        "T22",
        "时间范围",
        208,
        213,
        "2025年"
      ],
      [
        "T23",
        "属性值",
        216,
        225,
        "11.81千亿美元"
      ],
      [
        "T24",
        "属性值",
        236,
        239,
        "69%"
      ],
      [
        "T25",
        "地点范围",
        261,
        263,
        "全球"
      ],
      [
        "T26",
        "行业",
        263,
        267,
        "生物制品"
      ],
      [
        "T27",
        "时间范围",
        268,
        273,
        "2020年"
      ],
      [
        "T28",
        "营业收入",
        273,
        275,
        "收入"
      ],
      [
        "T29",
        "属性值",
        277,
        285,
        "2.98千亿美元"
      ],
      [
        "T30",
        "地点范围",
        287,
        289,
        "全球"
      ],
      [
        "T31",
        "行业",
        289,
        291,
        "医药"
      ],
      [
        "T32",
        "营业收入",
        294,
        296,
        "收入"
      ],
      [
        "T33",
        "属性值",
        301,
        304,
        "23%"
      ],
      [
        "T34",
        "时间范围",
        307,
        312,
        "2016年"
      ],
      [
        "T35",
        "属性值",
        314,
        323,
        "提高了 4个百分点"
      ],
      [
        "T36",
        "行业",
        324,
        328,
        "生物制品"
      ],
      [
        "T37",
        "时间范围",
        329,
        334,
        "2021年"
      ],
      [
        "T38",
        "地点范围",
        336,
        338,
        "全球"
      ],
      [
        "T39",
        "营业收入",
        338,
        340,
        "收入"
      ],
      [
        "T40",
        "属性值",
        342,
        350,
        "3.37千亿美元"
      ],
      [
        "T41",
        "时间范围",
        351,
        363,
        "2016年 -2021年"
      ],
      [
        "T42",
        "CAGR",
        363,
        370,
        "年均复合增长率"
      ],
      [
        "T43",
        "属性值",
        372,
        376,
        "8.9%"
      ],
      [
        "T44",
        "时间范围",
        377,
        382,
        "2025年"
      ],
      [
        "T45",
        "地点范围",
        382,
        384,
        "全球"
      ],
      [
        "T46",
        "行业",
        384,
        386,
        "医药"
      ],
      [
        "T47",
        "行业",
        388,
        392,
        "生物制品"
      ],
      [
        "T48",
        "营业收入",
        394,
        396,
        "收入"
      ],
      [
        "T49",
        "属性值",
        400,
        408,
        "5.30千亿美元"
      ],
      [
        "T50",
        "行业",
        412,
        414,
        "医药"
      ],
      [
        "T51",
        "属性值",
        423,
        426,
        "31%"
      ],
      [
        "T52",
        "时间范围",
        427,
        437,
        "2021-2025年"
      ],
      [
        "T53",
        "CAGR",
        439,
        446,
        "年均复合增长率"
      ],
      [
        "T54",
        "属性值",
        448,
        453,
        "12.0%"
      ],
      [
        "T55",
        "行业",
        460,
        462,
        "医药"
      ]
    ]
  },
  {
    "id": 2539,
    "text": " 上半年增速相对放缓，利润端好于收入端：5家连锁药店公司2021上半年收入总额增速为13.8%，其中第二季度收入增速为 12.6%；归母净利润总额增速为17.8%，其中第二季度增速为13%。从趋势来看，第二季度收入、利润增速环比继续下降。 利润端的增速快于收入端，主要系产品结构恢复到疫情前水平，低毛利率的抗疫产品占比下降，毛利率明显提升。预计Q3 和Q4利润端将逐季改善，看好下半年药店内生增长，带动利润端逐季改善。  多因素促进处方外流，大型连锁药店成主力承接方。院边店、DTP药房、慢病资质医保药店、带量采购相关品种流向药店 、互联网+线下药店等多因素均助力处方流向线下药店。大型连锁药店对客户覆盖面广，具有更强的承接能力，因此吸引众多新增上游厂家、医院、处方平台、流量平台合作。四家上市公司处方药销售占比均呈上升趋势。  大连锁持续收购整合，促进集中度提升。政策监管和开店限制趋严，倒逼小连锁和单体药店逐步淘汰出局，留给大连锁更多收购空间和开店机会。2021上半年，五家上市药店均维持高速增长步伐，上半年大参林、一心堂、老百姓、益丰药房新增门店数量为958家、933家、1147家、847家，我们预计全年仍将维持较高的扩张速度，五家上市公司药店具有充足的现金流支持扩张。  互联网销售处方药打开市场空间。《药品网络销售监督管理办法（送审稿）》明确网络销售处方药主体，并且规定处方药审核细则。未来线下零售可在保证处方真实性基础上通过线上出售处方药，此外线下药店具有医保、会员管理、慢病管理等优势，在O2O市场具有先天优势。大参林、一心堂、老百姓、益丰药房同比增长分别为100%、78%、200%、140%， 线上业务实现快速发展。  投资建议：我国连锁药店集中度仍在持续提升，大连锁收购&自建门店空间大；处方外流才起步，尚有千亿规模可持续流向药店。两大因素均利好大型连锁药店。推荐大参林（603233）、一心堂（002727）、老百姓（603883） 、益丰药房（ 603939） 。",
    "labels": [
      [
        "T0",
        "行业公司",
        21,
        29,
        "5家连锁药店公司"
      ],
      [
        "T1",
        "时间范围",
        29,
        36,
        "2021上半年"
      ],
      [
        "T2",
        "收入增速",
        36,
        42,
        "收入总额增速"
      ],
      [
        "T3",
        "属性值",
        43,
        48,
        "13.8%"
      ],
      [
        "T4",
        "时间范围",
        51,
        55,
        "第二季度"
      ],
      [
        "T5",
        "收入增速",
        55,
        59,
        "收入增速"
      ],
      [
        "T6",
        "属性值",
        61,
        66,
        "12.6%"
      ],
      [
        "T7",
        "归母净利润增速",
        67,
        76,
        "归母净利润总额增速"
      ],
      [
        "T8",
        "属性值",
        77,
        82,
        "17.8%"
      ],
      [
        "T9",
        "时间范围",
        85,
        89,
        "第二季度"
      ],
      [
        "T10",
        "属性值",
        92,
        95,
        "13%"
      ],
      [
        "T11",
        "时间范围",
        102,
        106,
        "第二季度"
      ],
      [
        "T12",
        "营业收入",
        106,
        108,
        "收入"
      ],
      [
        "T13",
        "利润",
        109,
        111,
        "利润"
      ],
      [
        "T14",
        "属性值",
        111,
        119,
        "增速环比继续下降"
      ],
      [
        "T15",
        "利润",
        121,
        124,
        "利润端"
      ],
      [
        "T16",
        "营业收入",
        129,
        132,
        "收入端"
      ],
      [
        "T17",
        "毛利",
        163,
        166,
        "毛利率"
      ],
      [
        "T18",
        "属性值",
        166,
        170,
        "明显提升"
      ],
      [
        "T19",
        "时间范围",
        173,
        175,
        "Q3"
      ],
      [
        "T20",
        "时间范围",
        177,
        179,
        "Q4"
      ],
      [
        "T21",
        "利润",
        179,
        182,
        "利润端"
      ],
      [
        "T22",
        "属性值",
        183,
        187,
        "逐季改善"
      ],
      [
        "T23",
        "时间范围",
        190,
        193,
        "下半年"
      ],
      [
        "T24",
        "行业公司",
        193,
        195,
        "药店"
      ],
      [
        "T25",
        "利润",
        202,
        205,
        "利润端"
      ],
      [
        "T26",
        "属性值",
        205,
        209,
        "逐季改善"
      ],
      [
        "T27",
        "行业公司",
        225,
        229,
        "连锁药店"
      ],
      [
        "T28",
        "地点范围",
        730,
        732,
        "我国"
      ],
      [
        "T29",
        "行业",
        732,
        736,
        "连锁药店"
      ],
      [
        "T30",
        "市场集中度",
        736,
        739,
        "集中度"
      ],
      [
        "T31",
        "属性值",
        741,
        745,
        "持续提升"
      ],
      [
        "T32",
        "行业公司",
        779,
        781,
        "药店"
      ],
      [
        "T33",
        "公司",
        798,
        801,
        "大参林"
      ],
      [
        "T34",
        "公司",
        810,
        813,
        "一心堂"
      ],
      [
        "T35",
        "公司",
        822,
        825,
        "老百姓"
      ],
      [
        "T36",
        "公司",
        835,
        839,
        "益丰药房"
      ],
      [
        "T37",
        "行业",
        789,
        795,
        "大型连锁药店"
      ],
      [
        "T38",
        "公司",
        668,
        671,
        "大参林"
      ],
      [
        "T39",
        "公司",
        672,
        675,
        "一心堂"
      ],
      [
        "T40",
        "公司",
        676,
        679,
        "老百姓"
      ],
      [
        "T41",
        "公司",
        680,
        684,
        "益丰药房"
      ],
      [
        "T42",
        "行业",
        656,
        659,
        "O2O"
      ],
      [
        "T43",
        "行业",
        633,
        637,
        "线下药店"
      ],
      [
        "T44",
        "属性值",
        639,
        651,
        "医保、会员管理、慢病管理"
      ],
      [
        "T45",
        "行业",
        605,
        609,
        "线下零售"
      ],
      [
        "T46",
        "公司",
        471,
        475,
        "益丰药房"
      ],
      [
        "T47",
        "公司",
        459,
        462,
        "大参林"
      ],
      [
        "T48",
        "公司",
        463,
        466,
        "一心堂"
      ],
      [
        "T49",
        "公司",
        467,
        470,
        "老百姓"
      ],
      [
        "T50",
        "时间范围",
        456,
        459,
        "上半年"
      ],
      [
        "T51",
        "行业公司",
        521,
        529,
        "五家上市公司药店"
      ],
      [
        "T52",
        "属性值",
        531,
        533,
        "充足"
      ],
      [
        "T53",
        "现金流",
        534,
        537,
        "现金流"
      ],
      [
        "T54",
        "时间范围",
        432,
        439,
        "2021上半年"
      ],
      [
        "T55",
        "行业公司",
        440,
        446,
        "五家上市药店"
      ],
      [
        "T56",
        "行业公司",
        345,
        351,
        "四家上市公司"
      ]
    ]
  },
  {
    "id": 2543,
    "text": "皓元医药：（1）前端业务：国内分子砌块和工具化合物行业正处于快速增长阶段，公司位于行业TOP 3的位置，充分享受细分行业红利，前端业务有望保持快速增长。（2）后端业务：原料药方面，公司向欧美、日本、印度等国家销售艾日布林、曲贝替定、艾地骨化醇、卡泊三醇、巴洛沙韦酯等高难度原料药和中间体，艾日布林、曲贝替定、 巴洛沙韦酯等项目有望获得下游销售分成；CDMO项目储备丰富，未来漏斗效应有望逐步显现。公司通过推进安徽皓元药业原料药和中间体建设项目强化供给能力，驱动订单的加速兑现。",
    "labels": [
      [
        "T0",
        "公司",
        1,
        5,
        "皓元医药"
      ],
      [
        "T1",
        "地点范围",
        14,
        16,
        "国内"
      ],
      [
        "T2",
        "行业",
        16,
        20,
        "分子砌块"
      ],
      [
        "T3",
        "行业",
        21,
        26,
        "工具化合物"
      ],
      [
        "T4",
        "行业",
        85,
        88,
        "原料药"
      ],
      [
        "T5",
        "行业",
        137,
        140,
        "原料药"
      ],
      [
        "T6",
        "行业",
        175,
        179,
        "CDMO"
      ],
      [
        "T7",
        "公司",
        205,
        211,
        "安徽皓元药业"
      ],
      [
        "T8",
        "行业",
        211,
        214,
        "原料药"
      ],
      [
        "T9",
        "地点范围",
        94,
        96,
        "欧美"
      ],
      [
        "T10",
        "地点范围",
        97,
        99,
        "日本"
      ],
      [
        "T11",
        "地点范围",
        100,
        102,
        "印度"
      ]
    ]
  },
  {
    "id": 2545,
    "text": "全球 CDMO市场仍然较为分散，存在大量的小型 CDMO竞争者。CRO行业也曾处于高度分散状态， 根据全球龙头 CDMO公司 Recipharm年报数据 CRO行业经历近年整合后市场集中度有大幅提升，收入规模前五名 CRO公司的市场份额已达到 70%。CDMO行业中存在整合增长机会，但是行业整合需要一定的时间，且公司在进行并购整合的过程中面临一定的不确定性。",
    "labels": [
      [
        "T0",
        "地点范围",
        0,
        2,
        "全球"
      ],
      [
        "T1",
        "行业",
        3,
        7,
        "CDMO"
      ],
      [
        "T2",
        "属性值",
        11,
        15,
        "较为分散"
      ],
      [
        "T3",
        "行业",
        24,
        28,
        "CDMO"
      ],
      [
        "T4",
        "行业",
        32,
        35,
        "CRO"
      ],
      [
        "T5",
        "属性值",
        41,
        45,
        "高度分散"
      ],
      [
        "T6",
        "地点范围",
        51,
        53,
        "全球"
      ],
      [
        "T7",
        "龙头企业",
        53,
        55,
        "龙头"
      ],
      [
        "T8",
        "公司",
        63,
        72,
        "Recipharm"
      ],
      [
        "T9",
        "行业",
        56,
        60,
        "CDMO"
      ],
      [
        "T10",
        "行业",
        77,
        80,
        "CRO"
      ],
      [
        "T11",
        "时间范围",
        84,
        86,
        "近年"
      ],
      [
        "T12",
        "市场集中度",
        89,
        94,
        "市场集中度"
      ],
      [
        "T13",
        "属性值",
        95,
        99,
        "大幅提升"
      ],
      [
        "T14",
        "行业公司",
        100,
        113,
        "收入规模前五名 CRO公司"
      ],
      [
        "T15",
        "市场份额",
        114,
        118,
        "市场份额"
      ],
      [
        "T16",
        "属性值",
        122,
        125,
        "70%"
      ],
      [
        "T17",
        "行业",
        126,
        130,
        "CDMO"
      ]
    ]
  },
  {
    "id": 2550,
    "text": "根据 Frost&Sullivan数据，全球 CRO服务收入在 2015年至 2020年间由 443亿美元增长至 672亿美元， 年均复合增长率为 8.7%。全球 CRO服务收入预期将于 2024年达到 960亿美元，2020年-2024年年均复合增长率为 9.3%。药物发现、临床前研究服务和临床研究服务市场预期 2024年收入分别为 204亿， 135亿和 622亿，在整体 CRO中收入占比为 21%，14%和 65%，药物发现、临床前研究服务和临床研究服务三部分市场收入 2020年-2024年预期年均复合增长率分别为 9.5%，8.3%和 9.5%。",
    "labels": [
      [
        "T0",
        "地点范围",
        20,
        22,
        "全球"
      ],
      [
        "T1",
        "行业",
        23,
        28,
        "CRO服务"
      ],
      [
        "T2",
        "营业收入",
        28,
        30,
        "收入"
      ],
      [
        "T3",
        "时间范围",
        32,
        37,
        "2015年"
      ],
      [
        "T4",
        "时间范围",
        39,
        44,
        "2020年"
      ],
      [
        "T5",
        "属性值",
        47,
        53,
        "443亿美元"
      ],
      [
        "T6",
        "属性值",
        57,
        63,
        "672亿美元"
      ],
      [
        "T7",
        "CAGR",
        65,
        72,
        "年均复合增长率"
      ],
      [
        "T8",
        "属性值",
        74,
        78,
        "8.7%"
      ],
      [
        "T9",
        "地点范围",
        79,
        81,
        "全球"
      ],
      [
        "T10",
        "行业",
        82,
        87,
        "CRO服务"
      ],
      [
        "T11",
        "营业收入",
        87,
        89,
        "收入"
      ],
      [
        "T12",
        "时间范围",
        94,
        99,
        "2024年"
      ],
      [
        "T13",
        "属性值",
        102,
        108,
        "960亿美元"
      ],
      [
        "T14",
        "时间范围",
        109,
        120,
        "2020年-2024年"
      ],
      [
        "T15",
        "CAGR",
        120,
        127,
        "年均复合增长率"
      ],
      [
        "T16",
        "属性值",
        129,
        133,
        "9.3%"
      ],
      [
        "T17",
        "行业",
        134,
        138,
        "药物发现"
      ],
      [
        "T18",
        "行业",
        139,
        146,
        "临床前研究服务"
      ],
      [
        "T19",
        "行业",
        147,
        153,
        "临床研究服务"
      ],
      [
        "T20",
        "时间范围",
        158,
        163,
        "2024年"
      ],
      [
        "T21",
        "营业收入",
        163,
        165,
        "收入"
      ],
      [
        "T22",
        "属性值",
        169,
        173,
        "204亿"
      ],
      [
        "T23",
        "属性值",
        175,
        179,
        "135亿"
      ],
      [
        "T24",
        "属性值",
        181,
        185,
        "622亿"
      ],
      [
        "T25",
        "行业",
        190,
        193,
        "CRO"
      ],
      [
        "T26",
        "营收占比",
        194,
        198,
        "收入占比"
      ],
      [
        "T27",
        "属性值",
        200,
        203,
        "21%"
      ],
      [
        "T28",
        "属性值",
        204,
        207,
        "14%"
      ],
      [
        "T29",
        "属性值",
        209,
        212,
        "65%"
      ],
      [
        "T30",
        "行业",
        213,
        217,
        "药物发现"
      ],
      [
        "T31",
        "行业",
        218,
        225,
        "临床前研究服务"
      ],
      [
        "T32",
        "行业",
        226,
        232,
        "临床研究服务"
      ],
      [
        "T33",
        "时间范围",
        240,
        251,
        "2020年-2024年"
      ],
      [
        "T34",
        "CAGR",
        253,
        260,
        "年均复合增长率"
      ],
      [
        "T35",
        "属性值",
        264,
        268,
        "9.5%"
      ],
      [
        "T36",
        "属性值",
        269,
        273,
        "8.3%"
      ],
      [
        "T37",
        "属性值",
        275,
        279,
        "9.5%"
      ],
      [
        "T38",
        "营业收入",
        237,
        239,
        "收入"
      ],
      [
        "T39",
        "时间连接词",
        37,
        39,
        "至 "
      ]
    ]
  },
  {
    "id": 2561,
    "text": "综合医院康复科新设推动，康复器具潜在市场规模 600-1200亿元。近年来，国家出台多项标准引导和鼓励康复医学体系建设，并且规定二级及以上综合医院设立老年医学科、康复医学科，配备标准化康复医疗器械。2019年，国家卫健委健康中国行动明确提出，到 2030年，二级以上综合医院老年医学科、康复科设置率不得低于 90%。2019 年末，我国二级以上医院 12436家（二级医院 9687家、三级医院 2749家），假设按二级以上综合医院 50%新设康复科需求，二级医院新设康复科康复器具采购额 500-1000 万，我们测算二级以上综合医院新设康复科带来康复器具市场规模 300-600亿元，如果考虑康复科设置比例更低的一级医院新设需求，预计总市场规模在 600-1200亿元。",
    "labels": [
      [
        "T0",
        "市场规模",
        18,
        22,
        "市场规模"
      ],
      [
        "T1",
        "属性值",
        23,
        33,
        "600-1200亿元"
      ],
      [
        "T2",
        "时间范围",
        34,
        37,
        "近年来"
      ],
      [
        "T3",
        "行业",
        92,
        98,
        "康复医疗器械"
      ],
      [
        "T4",
        "时间范围",
        99,
        104,
        "2019年"
      ],
      [
        "T5",
        "时间范围",
        123,
        128,
        "2030年"
      ],
      [
        "T6",
        "时间范围",
        158,
        165,
        "2019 年末"
      ],
      [
        "T7",
        "行业",
        275,
        279,
        "康复器具"
      ],
      [
        "T8",
        "行业",
        12,
        16,
        "康复器具"
      ],
      [
        "T9",
        "市场规模",
        279,
        283,
        "市场规模"
      ],
      [
        "T10",
        "市场规模",
        320,
        324,
        "市场规模"
      ],
      [
        "T11",
        "地点范围",
        112,
        114,
        "中国"
      ],
      [
        "T12",
        "行业",
        51,
        55,
        "康复医学"
      ],
      [
        "T13",
        "地点范围",
        166,
        168,
        "我国"
      ],
      [
        "T14",
        "属性值",
        284,
        293,
        "300-600亿元"
      ],
      [
        "T15",
        "属性值",
        326,
        336,
        "600-1200亿元"
      ]
    ]
  },
  {
    "id": 2567,
    "text": "受高基数影响，Q3单季度同比增速下滑  医疗器械板块Q1/Q2/Q3单季度收入535.1/534.7/473.2亿元（+118%/+9.4%/-0.4%）,单季度净利润185.5/174.1/127.5亿元（+259%/+1.6%/- 20.9%）,高基数下板块Q3单季度业绩有所承压。  Q3单季度毛利率58.6%（-4.9pp），单季度四费率27.6%（+2.9pp），单季度净利率26.9%（-2.1pp）。",
    "labels": [
      [
        "T0",
        "时间范围",
        7,
        9,
        "Q3"
      ],
      [
        "T1",
        "行业",
        21,
        25,
        "医疗器械"
      ],
      [
        "T2",
        "时间范围",
        27,
        29,
        "Q1"
      ],
      [
        "T3",
        "时间范围",
        30,
        32,
        "Q2"
      ],
      [
        "T4",
        "时间范围",
        33,
        35,
        "Q3"
      ],
      [
        "T5",
        "营业收入",
        38,
        40,
        "收入"
      ],
      [
        "T6",
        "属性值",
        40,
        45,
        "535.1"
      ],
      [
        "T7",
        "属性值",
        46,
        51,
        "534.7"
      ],
      [
        "T8",
        "属性值",
        52,
        59,
        "473.2亿元"
      ],
      [
        "T9",
        "属性值",
        60,
        65,
        "+118%"
      ],
      [
        "T10",
        "属性值",
        66,
        71,
        "+9.4%"
      ],
      [
        "T11",
        "属性值",
        72,
        77,
        "-0.4%"
      ],
      [
        "T12",
        "归母净利润",
        82,
        85,
        "净利润"
      ],
      [
        "T13",
        "属性值",
        85,
        90,
        "185.5"
      ],
      [
        "T14",
        "属性值",
        91,
        96,
        "174.1"
      ],
      [
        "T15",
        "属性值",
        97,
        104,
        "127.5亿元"
      ],
      [
        "T16",
        "时间范围",
        132,
        134,
        "Q3"
      ],
      [
        "T17",
        "业绩",
        137,
        139,
        "业绩"
      ],
      [
        "T18",
        "属性值",
        139,
        143,
        "有所承压"
      ],
      [
        "T19",
        "时间范围",
        147,
        149,
        "Q3"
      ],
      [
        "T20",
        "毛利",
        152,
        155,
        "毛利率"
      ],
      [
        "T21",
        "属性值",
        155,
        168,
        "58.6%（-4.9pp）"
      ],
      [
        "T22",
        "归母净利润",
        192,
        195,
        "净利率"
      ],
      [
        "T23",
        "属性值",
        195,
        208,
        "26.9%（-2.1pp）"
      ]
    ]
  },
  {
    "id": 2570,
    "text": "根据 Frost&Sullivan数据，中国 2021年医药市场规模预期为 17.29千亿人民币，2016年-2021年年均复合增长率为 5.4%。预期 2021年-2025年中国医药市场收入年均复合增长率为 7.2%，医药市场收入将于 2025年达到 22.87千亿人民币。 其中化学药物 2021年预期市场收入 8.47千亿人民币，在整体市场收入中占比为 48.96%，预期 2021 年-2025年化学药物市场收入年均复合增长率为 3.6%，市场收入将于 2025年达到 9.75千亿人民币。 目前生物药在市场收入中占比相比化学药仍然较少，但是收入增长潜力大于化学药。中国生物药预期 2021年市场收入为 4.25千亿人民币，在中国医药市场中占比为 24.57%。中国医药市场中生物药收入 2016年-2021年年均复合增长率为 18.3%，增长速度高于中国整体医药市场收入增长速度。预期生物药市场收入将持续以较高速度增长，预期 2021年-2015年市场收入增长速度为 17.6%，市场收入将于 2025年达到 8.12千亿人民币。",
    "labels": [
      [
        "T0",
        "地点范围",
        20,
        22,
        "中国"
      ],
      [
        "T1",
        "时间范围",
        22,
        28,
        " 2021年"
      ],
      [
        "T2",
        "行业",
        28,
        30,
        "医药"
      ],
      [
        "T3",
        "市场规模",
        30,
        34,
        "市场规模"
      ],
      [
        "T4",
        "属性值",
        38,
        48,
        "17.29千亿人民币"
      ],
      [
        "T5",
        "时间范围",
        49,
        60,
        "2016年-2021年"
      ],
      [
        "T6",
        "CAGR",
        60,
        67,
        "年均复合增长率"
      ],
      [
        "T7",
        "属性值",
        69,
        73,
        "5.4%"
      ],
      [
        "T8",
        "时间范围",
        77,
        88,
        "2021年-2025年"
      ],
      [
        "T9",
        "地点范围",
        88,
        90,
        "中国"
      ],
      [
        "T10",
        "行业",
        90,
        92,
        "医药"
      ],
      [
        "T11",
        "营业收入",
        94,
        96,
        "收入"
      ],
      [
        "T12",
        "CAGR",
        96,
        103,
        "年均复合增长率"
      ],
      [
        "T13",
        "属性值",
        105,
        109,
        "7.2%"
      ],
      [
        "T14",
        "行业",
        110,
        112,
        "医药"
      ],
      [
        "T15",
        "营业收入",
        114,
        116,
        "收入"
      ],
      [
        "T16",
        "时间范围",
        118,
        124,
        " 2025年"
      ],
      [
        "T17",
        "属性值",
        127,
        137,
        "22.87千亿人民币"
      ],
      [
        "T18",
        "行业",
        141,
        146,
        "化学药物 "
      ],
      [
        "T19",
        "时间范围",
        146,
        151,
        "2021年"
      ],
      [
        "T20",
        "营业收入",
        155,
        157,
        "收入"
      ],
      [
        "T21",
        "属性值",
        158,
        167,
        "8.47千亿人民币"
      ],
      [
        "T22",
        "属性值",
        180,
        186,
        "48.96%"
      ],
      [
        "T23",
        "属性值",
        218,
        223,
        " 3.6%"
      ],
      [
        "T24",
        "属性值",
        239,
        248,
        "9.75千亿人民币"
      ],
      [
        "T25",
        "属性值",
        306,
        315,
        "4.25千亿人民币"
      ],
      [
        "T26",
        "属性值",
        328,
        334,
        "24.57%"
      ],
      [
        "T27",
        "属性值",
        368,
        373,
        "18.3%"
      ],
      [
        "T28",
        "属性值",
        438,
        444,
        " 17.6%"
      ],
      [
        "T29",
        "属性值",
        460,
        469,
        "8.12千亿人民币"
      ],
      [
        "T30",
        "营收占比",
        173,
        178,
        "收入中占比"
      ],
      [
        "T31",
        "时间范围",
        190,
        202,
        "2021 年-2025年"
      ],
      [
        "T32",
        "行业",
        202,
        206,
        "化学药物"
      ],
      [
        "T33",
        "营业收入",
        208,
        210,
        "收入"
      ],
      [
        "T34",
        "CAGR",
        210,
        217,
        "年均复合增长率"
      ],
      [
        "T35",
        "营业收入",
        226,
        228,
        "收入"
      ],
      [
        "T36",
        "时间范围",
        230,
        236,
        " 2025年"
      ],
      [
        "T37",
        "行业",
        252,
        255,
        "生物药"
      ],
      [
        "T38",
        "营业收入",
        258,
        260,
        "收入"
      ],
      [
        "T39",
        "行业",
        265,
        268,
        "化学药"
      ],
      [
        "T40",
        "营收增长",
        275,
        279,
        "收入增长"
      ],
      [
        "T41",
        "行业",
        283,
        286,
        "化学药"
      ],
      [
        "T42",
        "地点范围",
        287,
        289,
        "中国"
      ],
      [
        "T43",
        "行业",
        289,
        292,
        "生物药"
      ],
      [
        "T44",
        "时间范围",
        294,
        300,
        " 2021年"
      ],
      [
        "T45",
        "营业收入",
        302,
        304,
        "收入"
      ],
      [
        "T46",
        "地点范围",
        317,
        319,
        "中国"
      ],
      [
        "T47",
        "行业",
        319,
        321,
        "医药"
      ],
      [
        "T48",
        "地点范围",
        335,
        337,
        "中国"
      ],
      [
        "T49",
        "行业",
        337,
        339,
        "医药"
      ],
      [
        "T50",
        "行业",
        342,
        345,
        "生物药"
      ],
      [
        "T51",
        "营业收入",
        345,
        348,
        "收入 "
      ],
      [
        "T52",
        "时间范围",
        348,
        359,
        "2016年-2021年"
      ],
      [
        "T53",
        "CAGR",
        359,
        366,
        "年均复合增长率"
      ],
      [
        "T54",
        "行业",
        397,
        400,
        "生物药"
      ],
      [
        "T55",
        "时间范围",
        418,
        429,
        "2021年-2015年"
      ],
      [
        "T56",
        "收入增速",
        431,
        437,
        "收入增长速度"
      ],
      [
        "T57",
        "营业收入",
        447,
        449,
        "收入"
      ],
      [
        "T58",
        "时间范围",
        452,
        457,
        "2025年"
      ],
      [
        "T59",
        "行业",
        384,
        386,
        "医药"
      ],
      [
        "T60",
        "地点范围",
        380,
        382,
        "中国"
      ],
      [
        "T61",
        "收入增速",
        388,
        394,
        "收入增长速度"
      ],
      [
        "T62",
        "时间范围",
        250,
        252,
        "目前"
      ],
      [
        "T63",
        "营业收入",
        402,
        404,
        "收入"
      ],
      [
        "T64",
        "属性值",
        405,
        414,
        "持续以较高速度增长"
      ]
    ]
  },
  {
    "id": 2574,
    "text": "• 医美按照介入手段，可分为手术类和非手术类。手术类项目旨在从根本上改变面部、胸部以及身体其他部位外观；非手术类项目又称为轻医美、微整形，主要包括注射疗项目和非注射项目。轻医美项目与手术类医美项目相比，具有创伤低、安全性高、恢复快等优点，减轻了消费者心理压力，因此目前广受青睐。根据新氧APP发布的《2019医美行业白皮书》显示，2018年中国医美疗程消费量为2059万次，其中轻医美疗程数在整个医美项目中占比近70%，远超手术类医美项目。 • 根据Frost&Sullivan数据，轻医美项目（主要是注射、光电类项目）增速较快，2019年市场规模约600亿元，预计到2024年将达到1450亿元，2019-2024年复合增长率达到19.2%。",
    "labels": [
      [
        "T0",
        "行业",
        242,
        245,
        "轻医美"
      ],
      [
        "T1",
        "时间范围",
        265,
        270,
        "2019年"
      ],
      [
        "T2",
        "市场规模",
        270,
        274,
        "市场规模"
      ],
      [
        "T3",
        "属性值",
        274,
        280,
        "约600亿元"
      ],
      [
        "T4",
        "时间范围",
        284,
        289,
        "2024年"
      ],
      [
        "T5",
        "属性值",
        292,
        298,
        "1450亿元"
      ],
      [
        "T6",
        "时间范围",
        299,
        309,
        "2019-2024年"
      ],
      [
        "T7",
        "CAGR",
        309,
        314,
        "复合增长率"
      ],
      [
        "T8",
        "属性值",
        316,
        321,
        "19.2%"
      ],
      [
        "T9",
        "行业",
        189,
        192,
        "轻医美"
      ],
      [
        "T10",
        "行业",
        198,
        200,
        "医美"
      ],
      [
        "T11",
        "行业",
        212,
        217,
        "手术类医美"
      ],
      [
        "T12",
        "时间范围",
        165,
        170,
        "2018年"
      ],
      [
        "T13",
        "地点范围",
        170,
        172,
        "中国"
      ],
      [
        "T14",
        "行业",
        172,
        174,
        "医美"
      ],
      [
        "T15",
        "时间范围",
        150,
        154,
        "2019"
      ],
      [
        "T16",
        "行业",
        154,
        156,
        "医美"
      ],
      [
        "T17",
        "行业",
        85,
        88,
        "轻医美"
      ],
      [
        "T18",
        "行业",
        91,
        96,
        "手术类医美"
      ],
      [
        "T19",
        "地点范围",
        132,
        134,
        "目前"
      ],
      [
        "T20",
        "行业",
        2,
        4,
        "医美"
      ],
      [
        "T21",
        "行业",
        14,
        17,
        "手术类"
      ],
      [
        "T22",
        "行业",
        18,
        22,
        "非手术类"
      ],
      [
        "T23",
        "行业",
        23,
        26,
        "手术类"
      ],
      [
        "T24",
        "行业",
        52,
        56,
        "非手术类"
      ],
      [
        "T25",
        "行业",
        61,
        64,
        "轻医美"
      ],
      [
        "T26",
        "行业",
        65,
        68,
        "微整形"
      ],
      [
        "T27",
        "行业",
        73,
        76,
        "注射疗"
      ],
      [
        "T28",
        "行业",
        79,
        82,
        "非注射"
      ]
    ]
  },
  {
    "id": 2576,
    "text": " 2021年上半年板块总结：器械板块（45家样本公司，不含科创板）上半年收入761.8亿元（+29.3%），归母净利润230.8亿元（+37.1%） ，毛利率59.3%，四费率23.4%,净利率为31.2%，医疗器械板块Q1/Q2单季度收入391.2/370.6亿元（+94.9%/-4.6%）,单季度净利润 120.3/110.5亿元（+197.%/-13.6%）, Q2单季度毛利率58.8%（-1.8pp），单季度四费率24.2%（+3.4pp），单季度净利率29.8%（- 3.1pp），去年二季度疫情影响导致行业利润产生高基数。  消费升级和国产替代共振。一方面，随着全国卫生投入增长、老龄化加剧、分级诊疗推进，中国器械市场规模突破6000亿，长期看中国医疗器械空间巨大；另一方面，当前大部分赛道国产化率不足40%（高端更低），技术突破+性价比+渠道优势促进国产化率持续提升，未来十年器械板块仍将是消费升级和国产替代共振的十年。  带量采购成为耗材招采新常态，龙头有望以价换量。人工晶体、支架、骨科、补片等产品在众多省份成为带量采购试点品种，未来高值耗材集采有望常态化。当前建议密切关注降价幅度和品种格局，一方面降价将带来经销商渠道利润和中标者费用的大幅减少，考虑到出厂价往往是终端价的30-40%，适当降价不会影响到企业出厂净价，另一方面，品种格局较好、国产化率较低的品种的，中标者量的增长的将弥补价格的下降，同时低价将带动国内高值耗材渗透率的长期提升，于企业而言，中选是最优结果。  国产创新器械扬帆起航。国产企业研发能力持续提升，在中高端医疗器械领域不断推出产品，打破了外资长期垄断的局面，例如大型医学影像、内窥镜、化学发光分析仪、手术机器人等，并在某些领域开始率先推出新产品，例如可降解支架、介入瓣膜等。集采时代，创新器械有望像创新药一样走出独立的长牛行情。  投资建议。一方面，随着全国卫生投入增长、老龄化加剧、分级诊疗推进，中国器械市场规模空间巨大，另一方面，当前大部分器械赛道国产化率较低，消费升级&进口替代有望推动国产器械迎来黄金十年。同时，以全国集采和各省试点相结合的耗材带量采购模式有望常态化进行 ，格局良好、国产化率低的耗材龙头有望以价换量加速进口替代。建议关注1）集采避风港领域：医疗设备（迈瑞医疗）、消费性器械（欧普康视、爱博医疗、伟思医疗、鱼跃医疗）；2）创新器械领域：TAVR（佰仁医疗、启明医疗）、外周介入（心脉医疗）、神经介入、电生理 （惠泰医疗）、内镜诊疗（南微医学）等；3）产业链上游公司：药机设备（东富龙、楚天科技）、药房自动化（健麾信息）、耗材生产设备 （迈得医疗）。",
    "labels": [
      [
        "T0",
        "时间范围",
        2,
        10,
        "2021年上半年"
      ],
      [
        "T1",
        "行业",
        15,
        17,
        "器械"
      ],
      [
        "T2",
        "时间范围",
        34,
        37,
        "上半年"
      ],
      [
        "T3",
        "营业收入",
        37,
        39,
        "收入"
      ],
      [
        "T4",
        "归母净利润",
        55,
        60,
        "归母净利润"
      ],
      [
        "T5",
        "毛利",
        77,
        80,
        "毛利率"
      ],
      [
        "T6",
        "行业",
        105,
        109,
        "医疗器械"
      ],
      [
        "T7",
        "营业收入",
        119,
        121,
        "收入"
      ],
      [
        "T8",
        "毛利",
        191,
        193,
        "毛利"
      ],
      [
        "T9",
        "时间范围",
        186,
        188,
        "Q2"
      ],
      [
        "T10",
        "时间范围",
        249,
        254,
        "去年二季度"
      ],
      [
        "T11",
        "利润",
        262,
        264,
        "利润"
      ],
      [
        "T12",
        "地点范围",
        313,
        315,
        "中国"
      ],
      [
        "T13",
        "行业",
        315,
        317,
        "器械"
      ],
      [
        "T14",
        "市场规模",
        317,
        321,
        "市场规模"
      ],
      [
        "T15",
        "属性值",
        321,
        328,
        "突破6000亿"
      ],
      [
        "T16",
        "地点范围",
        332,
        334,
        "中国"
      ],
      [
        "T17",
        "行业",
        334,
        338,
        "医疗器械"
      ],
      [
        "T18",
        "时间范围",
        395,
        399,
        "未来十年"
      ],
      [
        "T19",
        "行业",
        399,
        401,
        "器械"
      ],
      [
        "T20",
        "龙头企业",
        438,
        440,
        "龙头"
      ],
      [
        "T21",
        "利润",
        524,
        526,
        "利润"
      ],
      [
        "T22",
        "行业",
        770,
        774,
        "创新器械"
      ],
      [
        "T23",
        "行业",
        777,
        780,
        "创新药"
      ],
      [
        "T24",
        "地点范围",
        828,
        830,
        "中国"
      ],
      [
        "T25",
        "行业",
        830,
        832,
        "器械"
      ],
      [
        "T26",
        "市场规模",
        832,
        836,
        "市场规模"
      ],
      [
        "T27",
        "行业",
        962,
        966,
        "医疗设备"
      ],
      [
        "T28",
        "公司",
        967,
        971,
        "迈瑞医疗"
      ],
      [
        "T29",
        "行业",
        973,
        978,
        "消费性器械"
      ],
      [
        "T30",
        "公司",
        979,
        983,
        "欧普康视"
      ],
      [
        "T31",
        "公司",
        984,
        988,
        "爱博医疗"
      ],
      [
        "T32",
        "公司",
        989,
        993,
        "伟思医疗"
      ],
      [
        "T33",
        "公司",
        994,
        998,
        "鱼跃医疗"
      ],
      [
        "T34",
        "行业",
        1002,
        1006,
        "创新器械"
      ],
      [
        "T35",
        "公司",
        1019,
        1023,
        "启明医疗"
      ],
      [
        "T36",
        "行业",
        1025,
        1029,
        "外周介入"
      ],
      [
        "T37",
        "公司",
        1030,
        1034,
        "心脉医疗"
      ],
      [
        "T38",
        "行业",
        1036,
        1040,
        "神经介入"
      ],
      [
        "T39",
        "行业",
        1041,
        1044,
        "电生理"
      ],
      [
        "T40",
        "公司",
        1046,
        1050,
        "惠泰医疗"
      ],
      [
        "T41",
        "行业",
        1052,
        1056,
        "内镜诊疗"
      ],
      [
        "T42",
        "公司",
        1057,
        1061,
        "南微医学"
      ],
      [
        "T43",
        "行业",
        1074,
        1078,
        "药机设备"
      ],
      [
        "T44",
        "公司",
        1079,
        1082,
        "东富龙"
      ],
      [
        "T45",
        "公司",
        1083,
        1087,
        "楚天科技"
      ],
      [
        "T46",
        "行业",
        1089,
        1094,
        "药房自动化"
      ],
      [
        "T47",
        "公司",
        1095,
        1099,
        "健麾信息"
      ],
      [
        "T48",
        "行业",
        1101,
        1107,
        "耗材生产设备"
      ],
      [
        "T49",
        "公司",
        1109,
        1113,
        "迈得医疗"
      ],
      [
        "T50",
        "行业公司",
        20,
        27,
        "45家样本公司"
      ],
      [
        "T51",
        "属性值",
        39,
        46,
        "761.8亿元"
      ],
      [
        "T52",
        "属性值",
        47,
        53,
        "+29.3%"
      ],
      [
        "T53",
        "属性值",
        60,
        75,
        "230.8亿元（+37.1%）"
      ],
      [
        "T54",
        "属性值",
        80,
        85,
        "59.3%"
      ],
      [
        "T55",
        "归母净利润",
        95,
        98,
        "净利率"
      ],
      [
        "T56",
        "属性值",
        99,
        104,
        "31.2%"
      ],
      [
        "T57",
        "时间范围",
        111,
        113,
        "Q1"
      ],
      [
        "T58",
        "时间范围",
        114,
        116,
        "Q2"
      ],
      [
        "T59",
        "属性值",
        121,
        126,
        "391.2"
      ],
      [
        "T60",
        "属性值",
        127,
        134,
        "370.6亿元"
      ],
      [
        "T61",
        "属性值",
        135,
        141,
        "+94.9%"
      ],
      [
        "T62",
        "属性值",
        142,
        147,
        "-4.6%"
      ],
      [
        "T63",
        "归母净利润",
        152,
        155,
        "净利润"
      ],
      [
        "T64",
        "属性值",
        156,
        161,
        "120.3"
      ],
      [
        "T65",
        "属性值",
        162,
        169,
        "110.5亿元"
      ],
      [
        "T66",
        "属性值",
        194,
        207,
        "58.8%（-1.8pp）"
      ],
      [
        "T67",
        "归母净利润",
        231,
        234,
        "净利率"
      ],
      [
        "T68",
        "属性值",
        234,
        248,
        "29.8%（- 3.1pp）"
      ],
      [
        "T69",
        "属性值",
        266,
        269,
        "高基数"
      ],
      [
        "T70",
        "时间范围",
        329,
        331,
        "长期"
      ],
      [
        "T71",
        "属性值",
        340,
        342,
        "巨大"
      ],
      [
        "T72",
        "时间范围",
        348,
        350,
        "当前"
      ],
      [
        "T73",
        "属性值",
        838,
        840,
        "巨大"
      ],
      [
        "T74",
        "时间范围",
        846,
        848,
        "当前"
      ],
      [
        "T75",
        "行业",
        851,
        853,
        "器械"
      ],
      [
        "T76",
        "行业",
        875,
        879,
        "国产器械"
      ],
      [
        "T77",
        "行业",
        1009,
        1013,
        "TAVR"
      ],
      [
        "T78",
        "公司",
        1014,
        1018,
        "佰仁医疗"
      ],
      [
        "T79",
        "行业",
        678,
        685,
        "中高端医疗器械"
      ],
      [
        "T80",
        "行业",
        653,
        659,
        "国产创新器械"
      ]
    ]
  },
  {
    "id": 2578,
    "text": " 医药上游：主要包括CXO、科研试剂、原料药、制药装备等领域相关上市公司，从2018年-至今该领域PEG的最小值、均值 、最大值分别为0.69、1.61、3.11。  医药中游：主要包括药品、疫苗、器械、耗材等领域相关上市公司，从2018年-至今该领域PEG的最小值、均值、最大值分别为0.93、1.68、2.55。  下游消费医疗：主要包括医疗服务、品牌中药、零售药房、家用医疗器械等领域相关上市公司，从2018年-至今该领域PEG 的最小值、均值、最大值分别为1.04、2.01、3.02。",
    "labels": [
      [
        "T0",
        "行业",
        2,
        6,
        "医药上游"
      ],
      [
        "T1",
        "行业",
        11,
        14,
        "CXO"
      ],
      [
        "T2",
        "行业",
        15,
        19,
        "科研试剂"
      ],
      [
        "T3",
        "行业",
        20,
        23,
        "原料药"
      ],
      [
        "T4",
        "行业",
        24,
        28,
        "制药装备"
      ],
      [
        "T5",
        "时间范围",
        38,
        47,
        "从2018年-至今"
      ],
      [
        "T6",
        "PEG",
        50,
        53,
        "PEG"
      ],
      [
        "T7",
        "属性值",
        68,
        72,
        "0.69"
      ],
      [
        "T8",
        "属性值",
        73,
        77,
        "1.61"
      ],
      [
        "T9",
        "属性值",
        78,
        82,
        "3.11"
      ],
      [
        "T10",
        "行业",
        86,
        90,
        "医药中游"
      ],
      [
        "T11",
        "行业",
        95,
        97,
        "药品"
      ],
      [
        "T12",
        "行业",
        98,
        100,
        "疫苗"
      ],
      [
        "T13",
        "行业",
        101,
        103,
        "器械"
      ],
      [
        "T14",
        "行业",
        104,
        106,
        "耗材"
      ],
      [
        "T15",
        "时间范围",
        116,
        125,
        "从2018年-至今"
      ],
      [
        "T16",
        "PEG",
        128,
        131,
        "PEG"
      ],
      [
        "T17",
        "属性值",
        145,
        149,
        "0.93"
      ],
      [
        "T18",
        "属性值",
        150,
        154,
        "1.68"
      ],
      [
        "T19",
        "属性值",
        155,
        159,
        "2.55"
      ],
      [
        "T20",
        "行业",
        165,
        169,
        "消费医疗"
      ],
      [
        "T21",
        "行业",
        174,
        178,
        "医疗服务"
      ],
      [
        "T22",
        "行业",
        179,
        183,
        "品牌中药"
      ],
      [
        "T23",
        "行业",
        184,
        188,
        "零售药房"
      ],
      [
        "T24",
        "行业",
        189,
        195,
        "家用医疗器械"
      ],
      [
        "T25",
        "时间范围",
        205,
        214,
        "从2018年-至今"
      ],
      [
        "T26",
        "属性值",
        235,
        239,
        "1.04"
      ],
      [
        "T27",
        "属性值",
        240,
        244,
        "2.01"
      ],
      [
        "T28",
        "属性值",
        245,
        249,
        "3.02"
      ]
    ]
  },
  {
    "id": 2579,
    "text": "医药零售行业整体市场规模逐渐提升。随着人口结构的变化、疾病谱的迁移、医疗消费升级的加速以及医药行业政策的驱动，我国医药零售行业整体呈现长期增长的趋势。 我国药品终端市场从 2013年的 10984亿元增长到 2019年的 17955亿元，复合年增速 （CAGR）为 8.54%。但在两票制、药品耗材零加成、医保控费、药耗集采等政策逐渐落地，我国药品终端市场整体增速逐步放缓。2020年，受疫情影响，我国三大终端药品销售额为 16437亿元，同比下降 8.5%。2021年随着疫情影响逐步弱化，药品终端规模恢复稳健增长，上半年增速 8.8%。",
    "labels": [
      [
        "T0",
        "行业",
        0,
        4,
        "医药零售"
      ],
      [
        "T1",
        "市场规模",
        8,
        12,
        "市场规模"
      ],
      [
        "T2",
        "属性值",
        12,
        16,
        "逐渐提升"
      ],
      [
        "T3",
        "行业",
        45,
        47,
        "医药"
      ],
      [
        "T4",
        "地点范围",
        55,
        57,
        "我国"
      ],
      [
        "T5",
        "行业",
        57,
        61,
        "医药零售"
      ],
      [
        "T6",
        "地点范围",
        76,
        78,
        "我国"
      ],
      [
        "T7",
        "行业",
        78,
        82,
        "药品终端"
      ],
      [
        "T8",
        "时间范围",
        86,
        91,
        "2013年"
      ],
      [
        "T9",
        "属性值",
        93,
        100,
        "10984亿元"
      ],
      [
        "T10",
        "时间范围",
        104,
        109,
        "2019年"
      ],
      [
        "T11",
        "属性值",
        111,
        118,
        "17955亿元"
      ],
      [
        "T12",
        "CAGR",
        119,
        131,
        "复合年增速 （CAGR）"
      ],
      [
        "T13",
        "属性值",
        132,
        138,
        " 8.54%"
      ],
      [
        "T14",
        "地点范围",
        170,
        172,
        "我国"
      ],
      [
        "T15",
        "行业",
        172,
        176,
        "药品终端"
      ],
      [
        "T16",
        "时间范围",
        187,
        192,
        "2020年"
      ],
      [
        "T17",
        "地点范围",
        199,
        201,
        "我国"
      ],
      [
        "T18",
        "时间范围",
        230,
        235,
        "2021年"
      ],
      [
        "T19",
        "行业",
        246,
        250,
        "药品终端"
      ],
      [
        "T20",
        "属性值",
        254,
        258,
        "稳健增长"
      ]
    ]
  },
  {
    "id": 2585,
    "text": "华西证券2022年资本市场峰会 ——医药行业2022年年度投资策略报告",
    "labels": [
      [
        "T0",
        "时间范围",
        4,
        9,
        "2022年"
      ],
      [
        "T1",
        "行业",
        18,
        20,
        "医药"
      ],
      [
        "T2",
        "时间范围",
        22,
        27,
        "2022年"
      ]
    ]
  },
  {
    "id": 2601,
    "text": " 老龄化助推骨科需求释放+骨科医师等资源配置提升带动骨科手术量渗透率提升。2018年中国骨科耗材市场规模为262亿元，同比增长16.4%。细分领域看，2018年创伤、脊柱和关节类分别占据29%、 29%和28%的市场份额，运动医学和其他领域占据15%左右的市场。从国产化角度看，创伤类国产已占据68%左右的市场，脊柱占据近39%市场，关节市场份额不到30%。  关节集采相比冠脉支架有所缓和。从2021年9月14日公布的关节集采中标价格来看，平均降幅在82% ，降幅总体比之前的冠脉支架小很多，国产部分产品甚至在原出厂价以上，通过减少流通商的加价，中选产品有望实现以价换量。  大博医疗：前三季度收入13.1亿元（+17.6%），归母净利润4.5亿元（+6.1%）。骨科创伤类龙头+积极拓展其他增长点。  三友医疗：前三季度收入4.2亿元（+55.8%），归母净利润1.1亿元（+42.2%）。脊柱植入龙头，业绩回归高增长。  威高骨科：2021Q1-3收入15.7亿元（+24.5%），归母净利润4.9亿元（+29%）。",
    "labels": [
      [
        "T0",
        "时间范围",
        38,
        43,
        "2018年"
      ],
      [
        "T1",
        "地点范围",
        43,
        45,
        "中国"
      ],
      [
        "T2",
        "行业",
        45,
        49,
        "骨科耗材"
      ],
      [
        "T3",
        "市场规模",
        49,
        53,
        "市场规模"
      ],
      [
        "T4",
        "属性值",
        54,
        59,
        "262亿元"
      ],
      [
        "T5",
        "时间范围",
        76,
        81,
        "2018年"
      ],
      [
        "T6",
        "行业",
        81,
        83,
        "创伤"
      ],
      [
        "T7",
        "行业",
        84,
        86,
        "脊柱"
      ],
      [
        "T8",
        "行业",
        87,
        90,
        "关节类"
      ],
      [
        "T9",
        "属性值",
        94,
        97,
        "29%"
      ],
      [
        "T10",
        "属性值",
        99,
        102,
        "29%"
      ],
      [
        "T11",
        "属性值",
        103,
        106,
        "28%"
      ],
      [
        "T12",
        "市场份额",
        107,
        111,
        "市场份额"
      ],
      [
        "T13",
        "行业",
        112,
        116,
        "运动医学"
      ],
      [
        "T14",
        "行业",
        140,
        143,
        "创伤类"
      ],
      [
        "T15",
        "行业",
        157,
        159,
        "脊柱"
      ],
      [
        "T16",
        "行业",
        168,
        170,
        "关节"
      ],
      [
        "T17",
        "市场份额",
        170,
        174,
        "市场份额"
      ],
      [
        "T18",
        "属性值",
        174,
        179,
        "不到30%"
      ],
      [
        "T19",
        "公司",
        292,
        296,
        "大博医疗"
      ],
      [
        "T20",
        "时间范围",
        297,
        301,
        "前三季度"
      ],
      [
        "T21",
        "营业收入",
        301,
        303,
        "收入"
      ],
      [
        "T22",
        "属性值",
        303,
        309,
        "13.1亿元"
      ],
      [
        "T23",
        "属性值",
        310,
        316,
        "+17.6%"
      ],
      [
        "T24",
        "归母净利润",
        318,
        323,
        "归母净利润"
      ],
      [
        "T25",
        "公司",
        356,
        361,
        " 三友医疗"
      ],
      [
        "T26",
        "时间范围",
        362,
        366,
        "前三季度"
      ],
      [
        "T27",
        "营业收入",
        366,
        368,
        "收入"
      ],
      [
        "T28",
        "属性值",
        368,
        373,
        "4.2亿元"
      ],
      [
        "T29",
        "属性值",
        374,
        380,
        "+55.8%"
      ],
      [
        "T30",
        "归母净利润",
        382,
        387,
        "归母净利润"
      ],
      [
        "T31",
        "行业",
        401,
        405,
        "脊柱植入"
      ],
      [
        "T32",
        "龙头企业",
        405,
        407,
        "龙头"
      ],
      [
        "T33",
        "业绩",
        408,
        410,
        "业绩"
      ],
      [
        "T34",
        "公司",
        419,
        423,
        "威高骨科"
      ],
      [
        "T35",
        "时间范围",
        424,
        432,
        "2021Q1-3"
      ],
      [
        "T36",
        "营业收入",
        432,
        434,
        "收入"
      ],
      [
        "T37",
        "属性值",
        434,
        440,
        "15.7亿元"
      ],
      [
        "T38",
        "属性值",
        441,
        447,
        "+24.5%"
      ],
      [
        "T39",
        "归母净利润",
        449,
        454,
        "归母净利润"
      ],
      [
        "T40",
        "属性值",
        123,
        128,
        "15%左右"
      ],
      [
        "T41",
        "时间范围",
        199,
        209,
        "2021年9月14日"
      ],
      [
        "T42",
        "属性值",
        323,
        335,
        "4.5亿元（+6.1%）"
      ],
      [
        "T43",
        "行业",
        336,
        341,
        "骨科创伤类"
      ],
      [
        "T44",
        "龙头企业",
        341,
        343,
        "龙头"
      ],
      [
        "T45",
        "属性值",
        454,
        465,
        "4.9亿元（+29%）"
      ],
      [
        "T46",
        "属性值",
        387,
        400,
        "1.1亿元（+42.2%）"
      ],
      [
        "T47",
        "属性值",
        412,
        415,
        "高增长"
      ]
    ]
  },
  {
    "id": 2607,
    "text": " 心血管治疗需求旺盛。我国心血管病现患人数高达2.9亿人，近年来心血管病患病率及死亡率处于上升阶段，其中农村地区更为显著。2019年中国心血管器械市场规模为465亿元，占器械比重7.3%，离全球11.8%还有距离，未来外周、电生理和心脏节律、TAVR增速领跑。  前三季度心血管手术逐步恢复。除部分受冠脉支架集采降价影响的标的，其他心血管创新器械标的如心脉医疗、惠泰医疗、佰仁医疗、启明医疗、 沛嘉医疗等表现较好。  乐普医疗：心血管药械平台型企业，2021Q1-3收入86.4亿元（+35.2%），归母净利润19.2亿元（-2.6%）。前三季度器械板块除COVID-19相关产品外的常规业务营业收入较2020年同期增长14.85%，传统支架业务下降，但介入无植入创新产品组合实现收入6.1亿元（+1073.2%），实现显著放量，单三季度创新器械占营收比重为13%，显著提升。  心脉医疗：2021Q1-3收入+55.4%，归母净利润+53.9%，业绩延续高增长，公司作为主动脉及外周血管介入龙头，创新产品不断上市并放量。  惠泰医疗：2021Q1-3收入+84%，归母净利润+126.4%，电生理和通路类产品持续高增长。  佰仁医疗：2021Q1-3收入+54.2%，归母净利润-9.4%，剔除股份支付影响，内生归母净利润0.87亿元（+56.4%）。公司动物源性植介入龙头， 当前产品以外科软组织修复、先心病植介入为主和心脏瓣膜置换与修复为主，正布局介入瓣膜的研发，长期内生增长清晰。  微创医疗（半年报）：心血管器械平台型企业，产品布局齐全，2021上半年低基数逐步恢复，收入24.9亿元（+25.3%）。  启明医疗（半年报）：2021年上半年收入2.4亿元（+139%），TAVR放量驱动收入快速增长，全年增长可期。",
    "labels": [
      [
        "T0",
        "行业",
        2,
        7,
        "心血管治疗"
      ],
      [
        "T1",
        "行业需求",
        7,
        9,
        "需求"
      ],
      [
        "T2",
        "属性值",
        9,
        11,
        "旺盛"
      ],
      [
        "T3",
        "地点范围",
        12,
        14,
        "我国"
      ],
      [
        "T4",
        "时间范围",
        30,
        33,
        "近年来"
      ],
      [
        "T5",
        "时间范围",
        62,
        67,
        "2019年"
      ],
      [
        "T6",
        "地点范围",
        67,
        69,
        "中国"
      ],
      [
        "T7",
        "行业",
        69,
        74,
        "心血管器械"
      ],
      [
        "T8",
        "市场规模",
        74,
        78,
        "市场规模"
      ],
      [
        "T9",
        "属性值",
        79,
        84,
        "465亿元"
      ],
      [
        "T10",
        "时间范围",
        133,
        138,
        " 前三季度"
      ],
      [
        "T11",
        "行业",
        168,
        175,
        "心血管创新器械"
      ],
      [
        "T12",
        "公司",
        178,
        182,
        "心脉医疗"
      ],
      [
        "T13",
        "公司",
        183,
        187,
        "惠泰医疗"
      ],
      [
        "T14",
        "公司",
        188,
        192,
        "佰仁医疗"
      ],
      [
        "T15",
        "公司",
        193,
        197,
        "启明医疗"
      ],
      [
        "T16",
        "公司",
        199,
        203,
        "沛嘉医疗"
      ],
      [
        "T17",
        "公司",
        212,
        216,
        "乐普医疗"
      ],
      [
        "T18",
        "行业",
        217,
        222,
        "心血管药械"
      ],
      [
        "T19",
        "时间范围",
        228,
        236,
        "2021Q1-3"
      ],
      [
        "T20",
        "营业收入",
        236,
        238,
        "收入"
      ],
      [
        "T21",
        "属性值",
        238,
        244,
        "86.4亿元"
      ],
      [
        "T22",
        "属性值",
        245,
        251,
        "+35.2%"
      ],
      [
        "T23",
        "归母净利润",
        253,
        258,
        "归母净利润"
      ],
      [
        "T24",
        "时间范围",
        272,
        276,
        "前三季度"
      ],
      [
        "T25",
        "行业",
        276,
        278,
        "器械"
      ],
      [
        "T26",
        "营业收入",
        299,
        303,
        "营业收入"
      ],
      [
        "T27",
        "时间范围",
        304,
        311,
        "2020年同期"
      ],
      [
        "T28",
        "属性值",
        311,
        319,
        "增长14.85%"
      ],
      [
        "T29",
        "行业",
        330,
        339,
        "介入无植入创新产品"
      ],
      [
        "T30",
        "营业收入",
        343,
        345,
        "收入"
      ],
      [
        "T31",
        "属性值",
        345,
        350,
        "6.1亿元"
      ],
      [
        "T32",
        "属性值",
        351,
        359,
        "+1073.2%"
      ],
      [
        "T33",
        "时间范围",
        369,
        372,
        "三季度"
      ],
      [
        "T34",
        "行业",
        372,
        376,
        "创新器械"
      ],
      [
        "T35",
        "营收占比",
        377,
        381,
        "营收比重"
      ],
      [
        "T36",
        "属性值",
        382,
        385,
        "13%"
      ],
      [
        "T37",
        "公司",
        394,
        398,
        "心脉医疗"
      ],
      [
        "T38",
        "时间范围",
        399,
        407,
        "2021Q1-3"
      ],
      [
        "T39",
        "营业收入",
        407,
        409,
        "收入"
      ],
      [
        "T40",
        "属性值",
        409,
        415,
        "+55.4%"
      ],
      [
        "T41",
        "归母净利润",
        416,
        421,
        "归母净利润"
      ],
      [
        "T42",
        "属性值",
        421,
        427,
        "+53.9%"
      ],
      [
        "T43",
        "业绩",
        428,
        430,
        "业绩"
      ],
      [
        "T44",
        "行业",
        440,
        450,
        "主动脉及外周血管介入"
      ],
      [
        "T45",
        "龙头企业",
        450,
        452,
        "龙头"
      ],
      [
        "T46",
        "公司",
        468,
        472,
        "惠泰医疗"
      ],
      [
        "T47",
        "时间范围",
        473,
        481,
        "2021Q1-3"
      ],
      [
        "T48",
        "营业收入",
        481,
        483,
        "收入"
      ],
      [
        "T49",
        "属性值",
        483,
        487,
        "+84%"
      ],
      [
        "T50",
        "归母净利润",
        488,
        493,
        "归母净利润"
      ],
      [
        "T51",
        "属性值",
        493,
        500,
        "+126.4%"
      ],
      [
        "T52",
        "公司",
        519,
        523,
        "佰仁医疗"
      ],
      [
        "T53",
        "时间范围",
        524,
        532,
        "2021Q1-3"
      ],
      [
        "T54",
        "营业收入",
        532,
        534,
        "收入"
      ],
      [
        "T55",
        "属性值",
        534,
        540,
        "+54.2%"
      ],
      [
        "T56",
        "归母净利润",
        541,
        546,
        "归母净利润"
      ],
      [
        "T57",
        "属性值",
        546,
        551,
        "-9.4%"
      ],
      [
        "T58",
        "归母净利润",
        563,
        568,
        "归母净利润"
      ],
      [
        "T59",
        "行业",
        585,
        592,
        "动物源性植介入"
      ],
      [
        "T60",
        "龙头企业",
        592,
        594,
        "龙头"
      ],
      [
        "T61",
        "公司",
        652,
        657,
        " 微创医疗"
      ],
      [
        "T62",
        "行业",
        663,
        668,
        "心血管器械"
      ],
      [
        "T63",
        "时间范围",
        681,
        688,
        "2021上半年"
      ],
      [
        "T64",
        "营业收入",
        696,
        698,
        "收入"
      ],
      [
        "T65",
        "属性值",
        698,
        704,
        "24.9亿元"
      ],
      [
        "T66",
        "属性值",
        705,
        711,
        "+25.3%"
      ],
      [
        "T67",
        "公司",
        716,
        720,
        "启明医疗"
      ],
      [
        "T68",
        "时间范围",
        726,
        734,
        "2021年上半年"
      ],
      [
        "T69",
        "营业收入",
        734,
        736,
        "收入"
      ],
      [
        "T70",
        "属性值",
        736,
        741,
        "2.4亿元"
      ],
      [
        "T71",
        "属性值",
        742,
        747,
        "+139%"
      ],
      [
        "T72",
        "营业收入",
        757,
        759,
        "收入"
      ],
      [
        "T73",
        "行业",
        86,
        88,
        "器械"
      ],
      [
        "T74",
        "地点范围",
        96,
        98,
        "全球"
      ],
      [
        "T75",
        "行业",
        110,
        112,
        "外周"
      ],
      [
        "T76",
        "行业",
        113,
        116,
        "电生理"
      ],
      [
        "T77",
        "行业",
        117,
        121,
        "心脏节律"
      ],
      [
        "T78",
        "行业",
        122,
        126,
        "TAVR"
      ],
      [
        "T79",
        "属性值",
        258,
        271,
        "19.2亿元（-2.6%）"
      ],
      [
        "T80",
        "属性值",
        432,
        435,
        "高增长"
      ],
      [
        "T81",
        "属性值",
        568,
        582,
        "0.87亿元（+56.4%）"
      ],
      [
        "T82",
        "行业",
        749,
        753,
        "TAVR"
      ],
      [
        "T83",
        "属性值",
        759,
        763,
        "快速增长"
      ]
    ]
  },
  {
    "id": 2610,
    "text": " CXO：创新药投融资高速增长，CXO行业持续高景气  生命科学服务：证券化加速，产业链各环节都有了上市公司  原料药：中期提价周期开启，长期CDMO转型可期",
    "labels": [
      [
        "T0",
        "行业",
        2,
        5,
        "CXO"
      ],
      [
        "T1",
        "行业",
        6,
        9,
        "创新药"
      ],
      [
        "T2",
        "投融资情况",
        9,
        12,
        "投融资"
      ],
      [
        "T3",
        "属性值",
        12,
        16,
        "高速增长"
      ],
      [
        "T4",
        "行业",
        17,
        20,
        "CXO"
      ],
      [
        "T5",
        "行业",
        30,
        36,
        "生命科学服务"
      ],
      [
        "T6",
        "行业",
        59,
        62,
        "原料药"
      ],
      [
        "T7",
        "时间范围",
        72,
        74,
        "长期"
      ],
      [
        "T8",
        "行业",
        74,
        78,
        "CDMO"
      ],
      [
        "T9",
        "时间范围",
        63,
        65,
        "中期"
      ]
    ]
  },
  {
    "id": 2614,
    "text": " 中药板块：利润端增速好于收入端，业绩强势反弹。52家中药公司2021上半年收入总额增速为14.7%、归母净利润总额增速为26.2%， Q2单季收入端增速为9.9%，利润端增速为34%；收入稳健增长，利润增速较快。从盈利水平看，中药板块整体盈利能力整体保持稳定 ，21年上半年，行业毛利率（44%），销售费用率（23%）保持稳定，净利率（12%）略有提升。  行业利好政策不断，国家政策鼓励导向明显。1）中药创新方面，鼓励经典名方中药复方制剂研制，鼓励应用新工艺、新剂型对已上市中药二次开发，同时夯实中医药人才基础。2）中药国际化方面，鼓励向境外人士提供中医医疗服务、加大中药及中医服务出口的支持力度。3）中药质量控制方面，强化对中药配方科技质量控制，对中医药服务强化监督，行业规范程度提升。4）中医医疗服务方面，进一步加强综合医院中医临床科室建设，推动综合医院中西医协同发展。  上游中药材迎来涨价，下游品种有望迎来新一波提价周期。2021年以来伴随着CPI的上涨，上游中药材也迎来一波价格上涨的行情，根据康美中药网，名贵中药材天然牛黄2021年4月市场价格达到480元/g，同比提价20%，其余中药品种三七、天然麝香均有不同程度提价。提价预期带来中药板块下游存货周转速度加快，前期提价品种比如片仔癀和同仁堂纷纷在2019-2020年的提价品种能快速释放业绩 。与此同时，行业整体中药产品纷纷有提价，如太极集团的二线独家中药品种均有大幅提价。  国企混改释放红利，股权激励相机落地。中药行业国企混改以及股东层面的变动在近一年加速落地，云南白药、太极集团、广誉远、中新药业在国企混改后极大释放员工积极性，上半年广誉远、太极集团、中新药业实现实际控制人变更，云南白药混改股权激励目标将提高员工积极性，国企混改红利在逐步释放。  品牌中药具有长期成长属性，大健康转型值得期待。消费类的品牌中药仍然是中药板块投资的主线，消费属性强，增长趋势稳健。比如片仔癀、云南白药等具有强品牌的中药企业将仍然维持长期成长空间。关注大健康转型中的标的，比如片仔癀、云南白药、马应龙、仁和药业等。片仔癀的日化板块已经启动分拆上市，云南白药的大健康板块将全面实现品牌价值延申。",
    "labels": [
      [
        "T0",
        "行业",
        2,
        4,
        "中药"
      ],
      [
        "T1",
        "利润",
        7,
        10,
        "利润端"
      ],
      [
        "T2",
        "营业收入",
        14,
        17,
        "收入端"
      ],
      [
        "T3",
        "业绩",
        18,
        20,
        "业绩"
      ],
      [
        "T4",
        "属性值",
        20,
        24,
        "强势反弹"
      ],
      [
        "T5",
        "行业公司",
        25,
        32,
        "52家中药公司"
      ],
      [
        "T6",
        "时间范围",
        32,
        39,
        "2021上半年"
      ],
      [
        "T7",
        "收入增速",
        39,
        45,
        "收入总额增速"
      ],
      [
        "T8",
        "属性值",
        46,
        51,
        "14.7%"
      ],
      [
        "T9",
        "归母净利润增速",
        52,
        61,
        "归母净利润总额增速"
      ],
      [
        "T10",
        "属性值",
        62,
        67,
        "26.2%"
      ],
      [
        "T11",
        "时间范围",
        69,
        71,
        "Q2"
      ],
      [
        "T12",
        "收入增速",
        73,
        78,
        "收入端增速"
      ],
      [
        "T13",
        "属性值",
        79,
        83,
        "9.9%"
      ],
      [
        "T14",
        "利润",
        84,
        87,
        "利润端"
      ],
      [
        "T15",
        "营业收入",
        94,
        96,
        "收入"
      ],
      [
        "T16",
        "属性值",
        96,
        100,
        "稳健增长"
      ],
      [
        "T17",
        "利润",
        101,
        103,
        "利润"
      ],
      [
        "T18",
        "属性值",
        103,
        107,
        "增速较快"
      ],
      [
        "T19",
        "属性值",
        87,
        93,
        "增速为34%"
      ],
      [
        "T20",
        "行业",
        115,
        117,
        "中药"
      ],
      [
        "T21",
        "时间范围",
        133,
        139,
        "21年上半年"
      ],
      [
        "T22",
        "毛利",
        142,
        145,
        "毛利率"
      ],
      [
        "T23",
        "属性值",
        146,
        149,
        "44%"
      ],
      [
        "T24",
        "归母净利润",
        166,
        169,
        "净利率"
      ],
      [
        "T25",
        "属性值",
        170,
        173,
        "12%"
      ],
      [
        "T26",
        "行业",
        204,
        208,
        "中药创新"
      ],
      [
        "T27",
        "行业",
        252,
        255,
        "中医药"
      ],
      [
        "T28",
        "行业",
        350,
        356,
        "中医医疗服务"
      ],
      [
        "T29",
        "行业",
        394,
        399,
        "上游中药材"
      ],
      [
        "T30",
        "时间范围",
        420,
        427,
        "2021年以来"
      ],
      [
        "T31",
        "行业",
        437,
        442,
        "上游中药材"
      ],
      [
        "T32",
        "时间范围",
        472,
        479,
        "2021年4月"
      ],
      [
        "T33",
        "行业",
        528,
        530,
        "中药"
      ],
      [
        "T34",
        "时间范围",
        561,
        571,
        "2019-2020年"
      ],
      [
        "T35",
        "公司",
        551,
        554,
        "片仔癀"
      ],
      [
        "T36",
        "公司",
        555,
        558,
        "同仁堂"
      ],
      [
        "T37",
        "业绩",
        581,
        583,
        "业绩"
      ],
      [
        "T38",
        "属性值",
        577,
        581,
        "快速释放"
      ],
      [
        "T39",
        "行业",
        594,
        596,
        "中药"
      ],
      [
        "T40",
        "公司",
        605,
        609,
        "太极集团"
      ],
      [
        "T41",
        "行业",
        646,
        648,
        "中药"
      ],
      [
        "T42",
        "时间范围",
        664,
        667,
        "近一年"
      ],
      [
        "T43",
        "公司",
        672,
        676,
        "云南白药"
      ],
      [
        "T44",
        "公司",
        677,
        681,
        "太极集团"
      ],
      [
        "T45",
        "公司",
        682,
        685,
        "广誉远"
      ],
      [
        "T46",
        "公司",
        686,
        690,
        "中新药业"
      ],
      [
        "T47",
        "时间范围",
        706,
        709,
        "上半年"
      ],
      [
        "T48",
        "公司",
        709,
        712,
        "广誉远"
      ],
      [
        "T49",
        "公司",
        713,
        717,
        "太极集团"
      ],
      [
        "T50",
        "公司",
        718,
        722,
        "中新药业"
      ],
      [
        "T51",
        "公司",
        732,
        736,
        "云南白药"
      ],
      [
        "T52",
        "行业",
        768,
        772,
        "品牌中药"
      ],
      [
        "T53",
        "属性值",
        774,
        780,
        "长期成长属性"
      ],
      [
        "T54",
        "行业",
        781,
        784,
        "大健康"
      ],
      [
        "T55",
        "行业",
        791,
        799,
        "消费类的品牌中药"
      ],
      [
        "T56",
        "行业",
        802,
        804,
        "中药"
      ],
      [
        "T57",
        "属性值",
        812,
        817,
        "消费属性强"
      ],
      [
        "T58",
        "公司",
        827,
        830,
        "片仔癀"
      ],
      [
        "T59",
        "公司",
        831,
        835,
        "云南白药"
      ],
      [
        "T60",
        "行业公司",
        842,
        846,
        "中药企业"
      ],
      [
        "T61",
        "行业",
        860,
        863,
        "大健康"
      ],
      [
        "T62",
        "公司",
        872,
        875,
        "片仔癀"
      ],
      [
        "T63",
        "公司",
        876,
        880,
        "云南白药"
      ],
      [
        "T64",
        "公司",
        881,
        884,
        "马应龙"
      ],
      [
        "T65",
        "公司",
        885,
        889,
        "仁和药业"
      ],
      [
        "T66",
        "公司",
        891,
        894,
        "片仔癀"
      ],
      [
        "T67",
        "行业",
        895,
        897,
        "日化"
      ],
      [
        "T68",
        "公司",
        908,
        912,
        "云南白药"
      ],
      [
        "T69",
        "行业",
        913,
        916,
        "大健康"
      ]
    ]
  },
  {
    "id": 2616,
    "text": "根据 Frost&Sullivan数据，全球 CRO服务收入预期将于 2024年达到 960亿美元，2020年-2024年年均复合增长率为 9.3%。中国 CRO市场 2020年-2024年预期年均复合增长率为 29.1%，市场收入预期将于 2024年达到 222亿人民币。其中，药物发现项目 2024年预期市场收入为 43亿人民币，预期 2020- 2014年年均复合增长率为 28.0%；临床前研究项目 2024年预期市场收入为 41亿人民币，预期 2020- 2014年年均复合增长率为 19.7%；临床研究项目 2024年预期市场收入为 137亿人民币，预期 2020- 2014年年均复合增长率为 32.8%。",
    "labels": [
      [
        "T0",
        "地点范围",
        20,
        22,
        "全球"
      ],
      [
        "T1",
        "行业",
        23,
        28,
        "CRO服务"
      ],
      [
        "T2",
        "营业收入",
        28,
        30,
        "收入"
      ],
      [
        "T3",
        "时间范围",
        35,
        40,
        "2024年"
      ],
      [
        "T4",
        "属性值",
        43,
        49,
        "960亿美元"
      ],
      [
        "T5",
        "时间范围",
        50,
        61,
        "2020年-2024年"
      ],
      [
        "T6",
        "CAGR",
        61,
        68,
        "年均复合增长率"
      ],
      [
        "T7",
        "属性值",
        70,
        74,
        "9.3%"
      ],
      [
        "T8",
        "地点范围",
        75,
        77,
        "中国"
      ],
      [
        "T9",
        "行业",
        78,
        81,
        "CRO"
      ],
      [
        "T10",
        "时间范围",
        84,
        95,
        "2020年-2024年"
      ],
      [
        "T11",
        "CAGR",
        97,
        104,
        "年均复合增长率"
      ],
      [
        "T12",
        "属性值",
        106,
        111,
        "29.1%"
      ],
      [
        "T13",
        "营业收入",
        114,
        116,
        "收入"
      ],
      [
        "T14",
        "时间范围",
        121,
        126,
        "2024年"
      ],
      [
        "T15",
        "属性值",
        129,
        136,
        "222亿人民币"
      ],
      [
        "T16",
        "行业",
        140,
        144,
        "药物发现"
      ],
      [
        "T17",
        "时间范围",
        147,
        152,
        "2024年"
      ],
      [
        "T18",
        "营业收入",
        156,
        158,
        "收入"
      ],
      [
        "T19",
        "属性值",
        160,
        166,
        "43亿人民币"
      ],
      [
        "T20",
        "时间范围",
        170,
        181,
        "2020- 2014年"
      ],
      [
        "T21",
        "CAGR",
        181,
        188,
        "年均复合增长率"
      ],
      [
        "T22",
        "属性值",
        190,
        195,
        "28.0%"
      ],
      [
        "T23",
        "行业",
        196,
        201,
        "临床前研究"
      ],
      [
        "T24",
        "时间范围",
        204,
        209,
        "2024年"
      ],
      [
        "T25",
        "营业收入",
        213,
        215,
        "收入"
      ],
      [
        "T26",
        "属性值",
        217,
        223,
        "41亿人民币"
      ],
      [
        "T27",
        "时间范围",
        227,
        238,
        "2020- 2014年"
      ],
      [
        "T28",
        "CAGR",
        238,
        245,
        "年均复合增长率"
      ],
      [
        "T29",
        "属性值",
        247,
        252,
        "19.7%"
      ],
      [
        "T30",
        "行业",
        253,
        257,
        "临床研究"
      ],
      [
        "T31",
        "时间范围",
        260,
        265,
        "2024年"
      ],
      [
        "T32",
        "营业收入",
        269,
        271,
        "收入"
      ],
      [
        "T33",
        "属性值",
        273,
        280,
        "137亿人民币"
      ],
      [
        "T34",
        "时间范围",
        284,
        295,
        "2020- 2014年"
      ],
      [
        "T35",
        "CAGR",
        295,
        302,
        "年均复合增长率"
      ],
      [
        "T36",
        "属性值",
        304,
        309,
        "32.8%"
      ]
    ]
  },
  {
    "id": 2621,
    "text": " 通过对2018年至今CXO板块的PE估值情况进行回溯，可以发现CXO板块的历史均值为68倍，最高值为126倍（发生在 2021年9月），最低值为33倍（发生在2019年1月）。截止到2021年12月1日，CXO板块对应2022年的PE为79倍，目前 CXO板块的估值低于2年以来的均值水平。",
    "labels": [
      [
        "T0",
        "时间范围",
        5,
        12,
        "2018年至今"
      ],
      [
        "T1",
        "行业",
        12,
        15,
        "CXO"
      ],
      [
        "T2",
        "PE",
        18,
        20,
        "PE"
      ],
      [
        "T3",
        "行业",
        33,
        36,
        "CXO"
      ],
      [
        "T4",
        "时间范围",
        90,
        103,
        "截止到2021年12月1日"
      ],
      [
        "T5",
        "行业",
        104,
        107,
        "CXO"
      ],
      [
        "T6",
        "时间范围",
        111,
        116,
        "2022年"
      ],
      [
        "T7",
        "PE",
        117,
        119,
        "PE"
      ],
      [
        "T8",
        "属性值",
        120,
        123,
        "79倍"
      ],
      [
        "T9",
        "行业",
        127,
        130,
        "CXO"
      ],
      [
        "T10",
        "属性值",
        44,
        47,
        "68倍"
      ],
      [
        "T11",
        "属性值",
        52,
        56,
        "126倍"
      ],
      [
        "T12",
        "时间范围",
        61,
        68,
        "2021年9月"
      ],
      [
        "T13",
        "属性值",
        74,
        77,
        "33倍"
      ],
      [
        "T14",
        "时间范围",
        81,
        88,
        "2019年1月"
      ]
    ]
  },
  {
    "id": 2629,
    "text": "上海医药:营业收入及利润实现快速增长，1)医药商业：加快进口准入、仓储物流等方面发展;2) 医药工业：保障原料产能供应 ，积极布局高端制剂领域，实现上游领域的快速拓展。上海医药Q3创新药研发投入持续加大，与HUYABIO达成一项license out交易，并license in两项重磅单品。 九州通：扣除非经常性损益后业绩仍然大幅增长。同时有效控制成本和销售回款，现金流情况持续向好。公司各项管理措施不断加强，减税降费政策成效逐步显现，融资成本降低； 国药一致：加速并购药店，拓展下游产业链。OTO和DTP双重利好零售板块，分销业务迎来拐点。",
    "labels": [
      [
        "T0",
        "公司",
        0,
        4,
        "上海医药"
      ],
      [
        "T1",
        "营业收入",
        5,
        9,
        "营业收入"
      ],
      [
        "T2",
        "利润",
        10,
        12,
        "利润"
      ],
      [
        "T3",
        "属性值",
        14,
        18,
        "快速增长"
      ],
      [
        "T4",
        "行业",
        21,
        25,
        "医药商业"
      ],
      [
        "T5",
        "行业",
        46,
        50,
        "医药工业"
      ],
      [
        "T6",
        "行业",
        65,
        69,
        "高端制剂"
      ],
      [
        "T7",
        "公司",
        84,
        88,
        "上海医药"
      ],
      [
        "T8",
        "时间范围",
        88,
        90,
        "Q3"
      ],
      [
        "T9",
        "行业",
        90,
        93,
        "创新药"
      ],
      [
        "T10",
        "研发费用",
        93,
        97,
        "研发投入"
      ],
      [
        "T11",
        "属性值",
        97,
        101,
        "持续加大"
      ],
      [
        "T12",
        "公司",
        103,
        110,
        "HUYABIO"
      ],
      [
        "T13",
        "公司",
        147,
        150,
        "九州通"
      ],
      [
        "T14",
        "业绩",
        160,
        162,
        "业绩"
      ],
      [
        "T15",
        "属性值",
        164,
        168,
        "大幅增长"
      ],
      [
        "T16",
        "现金流",
        183,
        186,
        "现金流"
      ],
      [
        "T17",
        "属性值",
        188,
        192,
        "持续向好"
      ],
      [
        "T18",
        "公司",
        227,
        231,
        "国药一致"
      ],
      [
        "T19",
        "行业",
        258,
        260,
        "零售"
      ]
    ]
  },
  {
    "id": 2631,
    "text": "预计 2025年我国角膜塑形镜市场规模将达 47亿元。根据中国医疗器械行业协会眼科及视光学分会验配量，2015年我国角膜塑形镜渗透率为 0.51%，鉴于 2011-2015年选择角膜塑形镜治疗方式的比例增长率远超过 20%，2015年后保守按照渗透率增长率为 20%/年计算，按照中国大陆地区 8-18岁青少年测算视光类产品角膜塑形镜目标患者人数及市场空间，不同档次的角膜塑形镜以 1,500元/副作为厂家或进口总代理商的平均销售价格，预计 2025年市场规模将达 46.7亿元。",
    "labels": [
      [
        "T0",
        "时间范围",
        3,
        8,
        "2025年"
      ],
      [
        "T1",
        "地点范围",
        8,
        10,
        "我国"
      ],
      [
        "T2",
        "行业",
        10,
        15,
        "角膜塑形镜"
      ],
      [
        "T3",
        "市场规模",
        15,
        19,
        "市场规模"
      ],
      [
        "T4",
        "属性值",
        22,
        26,
        "47亿元"
      ],
      [
        "T5",
        "地点范围",
        29,
        31,
        "中国"
      ],
      [
        "T6",
        "行业",
        31,
        35,
        "医疗器械"
      ],
      [
        "T7",
        "时间范围",
        51,
        56,
        "2015年"
      ],
      [
        "T8",
        "地点范围",
        56,
        58,
        "我国"
      ],
      [
        "T9",
        "行业",
        58,
        63,
        "角膜塑形镜"
      ],
      [
        "T10",
        "时间范围",
        77,
        87,
        "2011-2015年"
      ],
      [
        "T11",
        "行业",
        89,
        94,
        "角膜塑形镜"
      ],
      [
        "T12",
        "时间范围",
        112,
        118,
        "2015年后"
      ],
      [
        "T13",
        "地点范围",
        140,
        146,
        "中国大陆地区"
      ],
      [
        "T14",
        "行业",
        162,
        167,
        "角膜塑形镜"
      ],
      [
        "T15",
        "时间范围",
        221,
        226,
        "2025年"
      ],
      [
        "T16",
        "市场规模",
        226,
        230,
        "市场规模"
      ],
      [
        "T17",
        "属性值",
        233,
        239,
        "46.7亿元"
      ]
    ]
  },
  {
    "id": 2634,
    "text": "• 销售费用同比增长15.9%，低于收入增速，销售费用率同比降低约1pp。",
    "labels": [
      [
        "T0",
        "收入增速",
        18,
        22,
        "收入增速"
      ]
    ]
  },
  {
    "id": 2639,
    "text": " 从上半年疫苗板块收入占比看，智飞占比55.6%；从上半年疫苗板块归母净利润占比看，智飞占比77.1%；智飞为板块收入、利润的主要贡献者。",
    "labels": [
      [
        "T0",
        "时间范围",
        3,
        6,
        "上半年"
      ],
      [
        "T1",
        "行业",
        6,
        8,
        "疫苗"
      ],
      [
        "T2",
        "营收占比",
        10,
        14,
        "收入占比"
      ],
      [
        "T3",
        "公司",
        16,
        18,
        "智飞"
      ],
      [
        "T4",
        "属性值",
        20,
        25,
        "55.6%"
      ],
      [
        "T5",
        "时间范围",
        27,
        30,
        "上半年"
      ],
      [
        "T6",
        "行业",
        30,
        32,
        "疫苗"
      ],
      [
        "T7",
        "归母净利润",
        34,
        39,
        "归母净利润"
      ],
      [
        "T8",
        "公司",
        43,
        45,
        "智飞"
      ],
      [
        "T9",
        "公司",
        53,
        55,
        "智飞"
      ],
      [
        "T10",
        "营业收入",
        58,
        60,
        "收入"
      ],
      [
        "T11",
        "利润",
        61,
        63,
        "利润"
      ]
    ]
  },
  {
    "id": 2645,
    "text": "泡沫挤压后行业进入估值再平衡时期，投资进入精挑细选时期。CXO 行业内公司经过泡沫挤压估值进入再平衡时期，根据截至 2022年 1月 13日股价与盈利预期 CXO行业内主要公司基于 2022年盈利预期的预期市盈率在 60左右。若行业内公司主要公司在 2023-2025年年均复合增长率为 20%，则 2022年-2025年预期年均复合增速在 25%左右，2022年预期 PEG在 2.5左右。若行业内主要公司在 2023-2025年年均复合增长率为 30%，则 2022年-2025年预期年均复合增速在 30%左右，2022年预期 PEG在 2左右。若行业内公司主要公司在 2023-2025年年均复合增长率可达到 40%，则 2022年-2025年预期年均复合增速可达到 35%-40%左右，2022年预期 PEG可达到 1.5左右。行业投资预期将进入“精挑细选”时期，需要挑选拥有核心竞争力的 CXO企业进行投资。拥有核心技术的龙头公司有望凭借优势承接更多订单，而行业内竞争力较低的公司会面临整体增速降低的问题。",
    "labels": [
      [
        "T0",
        "行业",
        28,
        31,
        "CXO"
      ],
      [
        "T1",
        "时间范围",
        55,
        70,
        "截至 2022年 1月 13日"
      ],
      [
        "T2",
        "PE",
        103,
        106,
        "市盈率"
      ],
      [
        "T3",
        "时间范围",
        125,
        135,
        "2023-2025年"
      ],
      [
        "T4",
        "CAGR",
        135,
        142,
        "年均复合增长率"
      ],
      [
        "T5",
        "时间范围",
        149,
        161,
        " 2022年-2025年"
      ],
      [
        "T6",
        "时间范围",
        177,
        182,
        "2022年"
      ],
      [
        "T7",
        "PEG",
        185,
        188,
        "PEG"
      ],
      [
        "T8",
        "时间范围",
        205,
        216,
        " 2023-2025年"
      ],
      [
        "T9",
        "CAGR",
        216,
        223,
        "年均复合增长率"
      ],
      [
        "T10",
        "时间范围",
        231,
        242,
        "2022年-2025年"
      ],
      [
        "T11",
        "时间范围",
        258,
        263,
        "2022年"
      ],
      [
        "T12",
        "时间范围",
        287,
        297,
        "2023-2025年"
      ],
      [
        "T13",
        "CAGR",
        297,
        304,
        "年均复合增长率"
      ],
      [
        "T14",
        "时间范围",
        314,
        325,
        "2022年-2025年"
      ],
      [
        "T15",
        "时间范围",
        347,
        352,
        "2022年"
      ],
      [
        "T16",
        "PEG",
        355,
        358,
        "PEG"
      ],
      [
        "T17",
        "行业公司",
        399,
        404,
        "CXO企业"
      ],
      [
        "T18",
        "龙头企业",
        416,
        420,
        "龙头公司"
      ],
      [
        "T19",
        "行业公司",
        78,
        88,
        "CXO行业内主要公司"
      ],
      [
        "T20",
        "属性值",
        107,
        112,
        " 60左右"
      ],
      [
        "T21",
        "属性值",
        190,
        195,
        "2.5左右"
      ],
      [
        "T22",
        "属性值",
        270,
        274,
        " 2左右"
      ],
      [
        "T23",
        "属性值",
        362,
        367,
        "1.5左右"
      ],
      [
        "T24",
        "时间范围",
        91,
        96,
        "2022年"
      ],
      [
        "T25",
        "CAGR",
        163,
        169,
        "年均复合增速"
      ],
      [
        "T26",
        "属性值",
        171,
        176,
        "25%左右"
      ],
      [
        "T27",
        "CAGR",
        244,
        250,
        "年均复合增速"
      ],
      [
        "T28",
        "属性值",
        252,
        257,
        "30%左右"
      ],
      [
        "T29",
        "PEG",
        266,
        269,
        "PEG"
      ],
      [
        "T30",
        "CAGR",
        327,
        333,
        "年均复合增速"
      ],
      [
        "T31",
        "属性值",
        337,
        346,
        "35%-40%左右"
      ]
    ]
  },
  {
    "id": 2651,
    "text": " 中药行业投资逻辑主要聚焦于消费属性明显的公司：消费品属性强的中药企业成长持续性明显，品牌优势突出，竞争环境优。因此，我们坚持消费品属性强的品牌中药企业的推荐逻辑，重点关注：片仔癀（600436）、云南白药（000538）、同仁堂（600085）等。",
    "labels": [
      [
        "T0",
        "行业",
        2,
        4,
        "中药"
      ],
      [
        "T1",
        "行业公司",
        32,
        36,
        "中药企业"
      ],
      [
        "T2",
        "行业公司",
        73,
        77,
        "中药企业"
      ],
      [
        "T3",
        "公司",
        88,
        91,
        "片仔癀"
      ],
      [
        "T4",
        "公司",
        100,
        104,
        "云南白药"
      ],
      [
        "T5",
        "公司",
        113,
        116,
        "同仁堂"
      ]
    ]
  },
  {
    "id": 2656,
    "text": " 13家CXO公司2021Q1-3收入总额增速为43%、归母净利润总额增速为50%，整体维持高速增长。Q3收入同比增长36.6%，归母净利润同比增长47.3%，三季度收入端保持高速增长，利润端增速恢复高速增长。  从盈利水平看，CXO板块整体盈利能力保持稳定，未受疫情影响，三季度行业毛利率（40%）保持平稳，销售费用率（2.4%）、财务费用率（-0.6%）均保持平稳，扣非后净利率（17.8%）小幅提升主要与管理费用率（10.3%，-0.7pp）降低有关。",
    "labels": [
      [
        "T0",
        "行业公司",
        2,
        10,
        "13家CXO公司"
      ],
      [
        "T1",
        "时间范围",
        10,
        18,
        "2021Q1-3"
      ],
      [
        "T2",
        "收入增速",
        18,
        24,
        "收入总额增速"
      ],
      [
        "T3",
        "属性值",
        25,
        28,
        "43%"
      ],
      [
        "T4",
        "归母净利润增速",
        29,
        38,
        "归母净利润总额增速"
      ],
      [
        "T5",
        "属性值",
        39,
        42,
        "50%"
      ],
      [
        "T6",
        "时间范围",
        52,
        54,
        "Q3"
      ],
      [
        "T7",
        "属性值",
        60,
        65,
        "36.6%"
      ],
      [
        "T8",
        "营业收入",
        54,
        56,
        "收入"
      ],
      [
        "T9",
        "归母净利润",
        66,
        71,
        "归母净利润"
      ],
      [
        "T10",
        "属性值",
        71,
        80,
        "同比增长47.3%"
      ],
      [
        "T11",
        "时间范围",
        81,
        84,
        "三季度"
      ],
      [
        "T12",
        "营业收入",
        84,
        87,
        "收入端"
      ],
      [
        "T13",
        "属性值",
        89,
        93,
        "高速增长"
      ],
      [
        "T14",
        "利润",
        94,
        97,
        "利润端"
      ],
      [
        "T15",
        "属性值",
        97,
        105,
        "增速恢复高速增长"
      ],
      [
        "T16",
        "行业",
        116,
        119,
        "CXO"
      ],
      [
        "T17",
        "时间范围",
        139,
        142,
        "三季度"
      ],
      [
        "T18",
        "毛利",
        144,
        147,
        "毛利率"
      ],
      [
        "T19",
        "属性值",
        148,
        151,
        "40%"
      ],
      [
        "T20",
        "扣非净利润",
        187,
        193,
        "扣非后净利率"
      ],
      [
        "T21",
        "属性值",
        194,
        199,
        "17.8%"
      ]
    ]
  },
  {
    "id": 2657,
    "text": "全球医药研发支出稳定增长，根据 Frost&Sullivan数据全球 2021年研发支出预期为 2.24千亿美元，2016 年-2021年年均复合增长率为 7.4%。全球医药研发支出预期将于 2025年增长至 2.95千亿美元，2021 年-2025年年均复合增长率为 7.1%。",
    "labels": [
      [
        "T0",
        "地点范围",
        0,
        2,
        "全球"
      ],
      [
        "T1",
        "行业",
        2,
        4,
        "医药"
      ],
      [
        "T2",
        "研发费用",
        4,
        8,
        "研发支出"
      ],
      [
        "T3",
        "属性值",
        8,
        12,
        "稳定增长"
      ],
      [
        "T4",
        "地点范围",
        32,
        35,
        "全球 "
      ],
      [
        "T5",
        "时间范围",
        35,
        40,
        "2021年"
      ],
      [
        "T6",
        "研发费用",
        40,
        44,
        "研发支出"
      ],
      [
        "T7",
        "属性值",
        47,
        56,
        " 2.24千亿美元"
      ],
      [
        "T8",
        "时间范围",
        57,
        69,
        "2016 年-2021年"
      ],
      [
        "T9",
        "CAGR",
        69,
        76,
        "年均复合增长率"
      ],
      [
        "T10",
        "属性值",
        77,
        82,
        " 7.4%"
      ],
      [
        "T11",
        "地点范围",
        83,
        85,
        "全球"
      ],
      [
        "T12",
        "行业",
        85,
        87,
        "医药"
      ],
      [
        "T13",
        "研发费用",
        87,
        91,
        "研发支出"
      ],
      [
        "T14",
        "时间范围",
        96,
        101,
        "2025年"
      ],
      [
        "T15",
        "属性值",
        105,
        113,
        "2.95千亿美元"
      ],
      [
        "T16",
        "属性值",
        135,
        139,
        "7.1%"
      ],
      [
        "T17",
        "CAGR",
        126,
        133,
        "年均复合增长率"
      ],
      [
        "T18",
        "时间范围",
        114,
        126,
        "2021 年-2025年"
      ]
    ]
  },
  {
    "id": 2658,
    "text": " 医药上游：2018-2019年估值整体处于相对低位，PEG均值、峰值、最小值分别为1.04、1.38、0.69；2020年开始医药上游的整体估值持续上移；2021年开始，医药上游估值内部出现分化，原料药受价格波动、汇兑损益影响，估值持续下行，CXO 、科研试剂等领域估值持续提升至第一梯队，上游（不考虑原料药）的PEG均值、峰值、最小值分别为2.60、3.17、1.82；  医药中游：2018-2020年估值处于相对高位，PEG的均值和峰值分别约为1.62、2.55、0.93。2021年-至今，由于受到降价等政策压制，估值区间开始下行。尤其是2021年至今，该板块估值已持续下移至第三梯队；  下游消费医疗：2018-2020年估值处于相对高位，PEG的均值、峰值、最小值分别为1.90、3.02、1.04。2021年-至今，由于受到政策压力扰动，估值区间逐步下行至第二梯队。",
    "labels": [
      [
        "T0",
        "时间范围",
        7,
        17,
        "2018-2019年"
      ],
      [
        "T1",
        "PEG",
        28,
        31,
        "PEG"
      ],
      [
        "T2",
        "时间范围",
        79,
        86,
        "2021年开始"
      ],
      [
        "T3",
        "行业",
        100,
        103,
        "原料药"
      ],
      [
        "T4",
        "行业",
        123,
        127,
        "CXO "
      ],
      [
        "T5",
        "行业",
        128,
        132,
        "科研试剂"
      ],
      [
        "T6",
        "行业",
        153,
        156,
        "原料药"
      ],
      [
        "T7",
        "PEG",
        158,
        161,
        "PEG"
      ],
      [
        "T8",
        "时间范围",
        196,
        206,
        "2018-2020年"
      ],
      [
        "T9",
        "PEG",
        215,
        218,
        "PEG"
      ],
      [
        "T10",
        "时间范围",
        243,
        251,
        "2021年-至今"
      ],
      [
        "T11",
        "时间范围",
        276,
        283,
        "2021年至今"
      ],
      [
        "T12",
        "行业",
        305,
        309,
        "消费医疗"
      ],
      [
        "T13",
        "时间范围",
        310,
        320,
        "2018-2020年"
      ],
      [
        "T14",
        "PEG",
        329,
        332,
        "PEG"
      ],
      [
        "T15",
        "行业",
        2,
        6,
        "医药上游"
      ],
      [
        "T16",
        "属性值",
        43,
        47,
        "1.04"
      ],
      [
        "T17",
        "属性值",
        48,
        52,
        "1.38"
      ],
      [
        "T18",
        "属性值",
        53,
        57,
        "0.69"
      ],
      [
        "T19",
        "时间范围",
        58,
        65,
        "2020年开始"
      ],
      [
        "T20",
        "行业",
        65,
        69,
        "医药上游"
      ],
      [
        "T21",
        "行业",
        87,
        91,
        "医药上游"
      ],
      [
        "T22",
        "行业",
        191,
        195,
        "医药中游"
      ],
      [
        "T23",
        "属性值",
        226,
        242,
        "约为1.62、2.55、0.93"
      ],
      [
        "T24",
        "属性值",
        345,
        349,
        "1.90"
      ],
      [
        "T25",
        "属性值",
        350,
        354,
        "3.02"
      ],
      [
        "T26",
        "属性值",
        355,
        359,
        "1.04"
      ],
      [
        "T27",
        "时间范围",
        360,
        368,
        "2021年-至今"
      ]
    ]
  },
  {
    "id": 2661,
    "text": "看好业绩提速企业，关注产能和订单匹配情况。从微观角度看，预收账款与合同负债持续增长彰显国内 CXO行业高景气，人员扩张、加大在建工程投入为订单交付提供生产保证。 预收账款与合同负债持续增长，为企业提供中短期业绩保障。2021年前三季度中， 凯莱英与九洲药业增速最快，分别达 284.54%、160.45%，此外，如药石科技、成都先导等企业也保持了高速增长。充裕的在手订单能够为企业带来稳定的业绩增量，同时也再次验证了未来几年 CXO行业的高景气。 在手订单充裕，保证交付最为关键。1）对于 CRO企业，核心资产为相关人员数量。以 CRO业务为主的公司如美迪西、康龙化成、药明康德等，其研发人员的扩张增速均保持在 20%以上。2）对于 CDMO企业，产能利用率持续处于高位，资本性支出与在建工程情况则是影响公司未来业绩的主要因素。泰格医药、美迪西、康龙化成、 药石科技等企业的资本开支与在建工程均实现了快速增长。",
    "labels": [
      [
        "T0",
        "业绩",
        2,
        4,
        "业绩"
      ],
      [
        "T1",
        "产能",
        11,
        13,
        "产能"
      ],
      [
        "T2",
        "合同负债",
        33,
        37,
        "合同负债"
      ],
      [
        "T3",
        "地点范围",
        43,
        46,
        "国内 "
      ],
      [
        "T4",
        "行业",
        46,
        49,
        "CXO"
      ],
      [
        "T5",
        "合同负债",
        86,
        90,
        "合同负债"
      ],
      [
        "T6",
        "时间范围",
        108,
        117,
        "2021年前三季度"
      ],
      [
        "T7",
        "公司",
        120,
        123,
        "凯莱英"
      ],
      [
        "T8",
        "公司",
        124,
        128,
        "九洲药业"
      ],
      [
        "T9",
        "公司",
        157,
        161,
        "药石科技"
      ],
      [
        "T10",
        "公司",
        162,
        166,
        "成都先导"
      ],
      [
        "T11",
        "在手订单",
        181,
        185,
        "在手订单"
      ],
      [
        "T12",
        "业绩",
        195,
        197,
        "业绩"
      ],
      [
        "T13",
        "时间范围",
        208,
        212,
        "未来几年"
      ],
      [
        "T14",
        "行业",
        213,
        216,
        "CXO"
      ],
      [
        "T15",
        "在手订单",
        224,
        228,
        "在手订单"
      ],
      [
        "T16",
        "行业公司",
        245,
        250,
        "CRO企业"
      ],
      [
        "T17",
        "行业",
        265,
        268,
        "CRO"
      ],
      [
        "T18",
        "公司",
        276,
        279,
        "美迪西"
      ],
      [
        "T19",
        "公司",
        280,
        284,
        "康龙化成"
      ],
      [
        "T20",
        "公司",
        285,
        289,
        "药明康德"
      ],
      [
        "T21",
        "行业公司",
        317,
        323,
        "CDMO企业"
      ],
      [
        "T22",
        "CAPEX资本开支",
        336,
        341,
        "资本性支出"
      ],
      [
        "T23",
        "业绩",
        356,
        358,
        "业绩"
      ],
      [
        "T24",
        "公司",
        364,
        368,
        "泰格医药"
      ],
      [
        "T25",
        "公司",
        369,
        372,
        "美迪西"
      ],
      [
        "T26",
        "公司",
        373,
        377,
        "康龙化成"
      ],
      [
        "T27",
        "公司",
        379,
        383,
        "药石科技"
      ],
      [
        "T28",
        "CAPEX资本开支",
        387,
        391,
        "资本开支"
      ],
      [
        "T29",
        "属性值",
        400,
        404,
        "快速增长"
      ]
    ]
  },
  {
    "id": 2663,
    "text": "2.8.血制品——血制品公司业绩稳步增长，广东省血制品联盟集采预计价格降幅有限",
    "labels": [
      [
        "T0",
        "行业",
        4,
        7,
        "血制品"
      ],
      [
        "T1",
        "行业公司",
        9,
        14,
        "血制品公司"
      ],
      [
        "T2",
        "业绩",
        14,
        16,
        "业绩"
      ],
      [
        "T3",
        "属性值",
        16,
        20,
        "稳步增长"
      ]
    ]
  },
  {
    "id": 2668,
    "text": "• 全球来看，CRO市场规模从2015年的443亿美元上升到2019年的626亿美元，期间复合增长为9.0%，预期未来5年全球CRO行业也将保持8.9%以上增长；国内 CRO市场规模处于快速增长中，主要受益于全球产业转移、国内工程师红利等因素，预期未来5年国内 CRO市场将保持20%以上的复合增长，到2024年国内市场达到222亿美元。",
    "labels": [
      [
        "T0",
        "行业",
        7,
        10,
        "CRO"
      ],
      [
        "T1",
        "市场规模",
        10,
        14,
        "市场规模"
      ],
      [
        "T2",
        "地点范围",
        2,
        4,
        "全球"
      ],
      [
        "T3",
        "时间范围",
        15,
        20,
        "2015年"
      ],
      [
        "T4",
        "属性值",
        21,
        27,
        "443亿美元"
      ],
      [
        "T5",
        "时间范围",
        30,
        35,
        "2019年"
      ],
      [
        "T6",
        "属性值",
        36,
        42,
        "626亿美元"
      ],
      [
        "T7",
        "CAGR",
        45,
        49,
        "复合增长"
      ],
      [
        "T8",
        "属性值",
        50,
        54,
        "9.0%"
      ],
      [
        "T9",
        "时间范围",
        57,
        61,
        "未来5年"
      ],
      [
        "T10",
        "地点范围",
        61,
        63,
        "全球"
      ],
      [
        "T11",
        "行业",
        63,
        66,
        "CRO"
      ],
      [
        "T12",
        "属性值",
        72,
        78,
        "8.9%以上"
      ],
      [
        "T13",
        "地点范围",
        81,
        83,
        "国内"
      ],
      [
        "T14",
        "行业",
        84,
        87,
        "CRO"
      ],
      [
        "T15",
        "市场规模",
        87,
        91,
        "市场规模"
      ],
      [
        "T16",
        "属性值",
        93,
        97,
        "快速增长"
      ],
      [
        "T17",
        "地点范围",
        104,
        106,
        "全球"
      ],
      [
        "T18",
        "地点范围",
        111,
        113,
        "国内"
      ],
      [
        "T19",
        "时间范围",
        124,
        128,
        "未来5年"
      ],
      [
        "T20",
        "地点范围",
        128,
        130,
        "国内"
      ],
      [
        "T21",
        "行业",
        131,
        134,
        "CRO"
      ],
      [
        "T22",
        "属性值",
        139,
        144,
        "20%以上"
      ],
      [
        "T23",
        "CAGR",
        145,
        149,
        "复合增长"
      ],
      [
        "T24",
        "时间范围",
        151,
        156,
        "2024年"
      ],
      [
        "T25",
        "地点范围",
        156,
        158,
        "国内"
      ],
      [
        "T26",
        "属性值",
        162,
        168,
        "222亿美元"
      ]
    ]
  },
  {
    "id": 2671,
    "text": "凯莱英作为国内领先的小分子CDMO供应商，续深耕小分子“中间体+API+制剂”一体化服务能力，另外在合成大分子和生物大分子领域持续强化布局，为公司的中长期业绩增长保驾护航。 • 2021年营业收入和归母净利润增速创近五年新高。2021年营收预计45.8亿元，同比增长46%，归母净利润10.4亿元， 同比增长44%。 • 毛利率和归母净利率小幅波动，基本稳定。近些年公司毛利率持续小幅走低，基本稳定在45%左右；归母净利润率基本稳定再23%-24%区间。",
    "labels": [
      [
        "T0",
        "公司",
        0,
        3,
        "凯莱英"
      ],
      [
        "T1",
        "地点范围",
        5,
        7,
        "国内"
      ],
      [
        "T2",
        "行业",
        10,
        17,
        "小分子CDMO"
      ],
      [
        "T3",
        "行业",
        50,
        55,
        "合成大分子"
      ],
      [
        "T4",
        "行业",
        56,
        61,
        "生物大分子"
      ],
      [
        "T5",
        "时间范围",
        74,
        77,
        "中长期"
      ],
      [
        "T6",
        "业绩",
        77,
        79,
        "业绩"
      ],
      [
        "T7",
        "属性值",
        79,
        81,
        "增长"
      ],
      [
        "T8",
        "时间范围",
        89,
        94,
        "2021年"
      ],
      [
        "T9",
        "营业收入",
        94,
        98,
        "营业收入"
      ],
      [
        "T10",
        "归母净利润增速",
        99,
        106,
        "归母净利润增速"
      ],
      [
        "T11",
        "属性值",
        110,
        112,
        "新高"
      ],
      [
        "T12",
        "时间范围",
        107,
        110,
        "近五年"
      ],
      [
        "T13",
        "时间范围",
        113,
        118,
        "2021年"
      ],
      [
        "T14",
        "营业收入",
        118,
        120,
        "营收"
      ],
      [
        "T15",
        "属性值",
        122,
        128,
        "45.8亿元"
      ],
      [
        "T16",
        "属性值",
        133,
        136,
        "46%"
      ],
      [
        "T17",
        "归母净利润",
        137,
        142,
        "归母净利润"
      ],
      [
        "T18",
        "属性值",
        142,
        157,
        "10.4亿元， 同比增长44%"
      ],
      [
        "T19",
        "毛利",
        161,
        164,
        "毛利率"
      ],
      [
        "T20",
        "归母净利润",
        165,
        170,
        "归母净利率"
      ],
      [
        "T21",
        "属性值",
        170,
        174,
        "小幅波动"
      ],
      [
        "T22",
        "时间范围",
        180,
        183,
        "近些年"
      ],
      [
        "T23",
        "毛利",
        185,
        188,
        "毛利率"
      ],
      [
        "T24",
        "属性值",
        188,
        194,
        "持续小幅走低"
      ],
      [
        "T25",
        "属性值",
        200,
        205,
        "45%左右"
      ],
      [
        "T26",
        "归母净利润",
        206,
        212,
        "归母净利润率"
      ],
      [
        "T27",
        "属性值",
        217,
        224,
        "23%-24%"
      ]
    ]
  },
  {
    "id": 2681,
    "text": "药明康德在 2018年至 2020营业收入由 96.1亿人民币增长至 165.4亿人民币，营业收入增长率均高于 20%，年均复合增长率达 31.2%，归母净利润由 22.6亿人民币增长至 29.6亿人民币，年均复合增长率为 14.4%。",
    "labels": [
      [
        "T0",
        "公司",
        0,
        4,
        "药明康德"
      ],
      [
        "T1",
        "营业收入",
        17,
        21,
        "营业收入"
      ],
      [
        "T2",
        "属性值",
        23,
        31,
        "96.1亿人民币"
      ],
      [
        "T3",
        "时间范围",
        6,
        11,
        "2018年"
      ],
      [
        "T4",
        "时间范围",
        13,
        17,
        "2020"
      ],
      [
        "T5",
        "属性值",
        35,
        44,
        "165.4亿人民币"
      ],
      [
        "T6",
        "营业收入",
        45,
        49,
        "营业收入"
      ],
      [
        "T7",
        "CAGR",
        60,
        67,
        "年均复合增长率"
      ],
      [
        "T8",
        "属性值",
        69,
        74,
        "31.2%"
      ],
      [
        "T9",
        "归母净利润",
        75,
        80,
        "归母净利润"
      ],
      [
        "T10",
        "属性值",
        82,
        90,
        "22.6亿人民币"
      ],
      [
        "T11",
        "属性值",
        94,
        102,
        "29.6亿人民币"
      ],
      [
        "T12",
        "CAGR",
        103,
        110,
        "年均复合增长率"
      ],
      [
        "T13",
        "属性值",
        112,
        117,
        "14.4%"
      ],
      [
        "T14",
        "时间连接词",
        11,
        13,
        "至 "
      ]
    ]
  },
  {
    "id": 2688,
    "text": "Ø 全球医疗健康产业融资额有所下滑。在11月份，全球融资额为97亿美元，较10月份环比下降约27%。但从全年来看，2021年全球医疗健康产业融资依然十分活跃。截止2021.12.03，全球第四季度发生637起融资事件，融资额达230亿美元，占第三季度融资总额的80%%；自今年年初起至今，全球年融资金额已达1171亿，较2020年全年增长42%，融资事件发生3259例，较去年全年增长18.25%。",
    "labels": [
      [
        "T0",
        "地点范围",
        2,
        4,
        "全球"
      ],
      [
        "T1",
        "行业",
        4,
        8,
        "医疗健康"
      ],
      [
        "T2",
        "投融资金额",
        10,
        13,
        "融资额"
      ],
      [
        "T3",
        "属性值",
        15,
        17,
        "下滑"
      ],
      [
        "T4",
        "时间范围",
        19,
        23,
        "11月份"
      ],
      [
        "T5",
        "地点范围",
        24,
        26,
        "全球"
      ],
      [
        "T6",
        "投融资金额",
        26,
        29,
        "融资额"
      ],
      [
        "T7",
        "属性值",
        30,
        35,
        "97亿美元"
      ],
      [
        "T8",
        "时间范围",
        37,
        41,
        "10月份"
      ],
      [
        "T9",
        "属性值",
        41,
        49,
        "环比下降约27%"
      ],
      [
        "T10",
        "时间范围",
        57,
        62,
        "2021年"
      ],
      [
        "T11",
        "地点范围",
        62,
        64,
        "全球"
      ],
      [
        "T12",
        "行业",
        64,
        68,
        "医疗健康"
      ],
      [
        "T13",
        "投融资情况",
        70,
        72,
        "融资"
      ],
      [
        "T14",
        "属性值",
        74,
        78,
        "十分活跃"
      ],
      [
        "T15",
        "时间范围",
        79,
        91,
        "截止2021.12.03"
      ],
      [
        "T16",
        "地点范围",
        92,
        94,
        "全球"
      ],
      [
        "T17",
        "时间范围",
        94,
        98,
        "第四季度"
      ],
      [
        "T18",
        "属性值",
        100,
        104,
        "637起"
      ],
      [
        "T19",
        "投融资事件数",
        104,
        108,
        "融资事件"
      ],
      [
        "T20",
        "投融资金额",
        109,
        112,
        "融资额"
      ],
      [
        "T21",
        "属性值",
        113,
        119,
        "230亿美元"
      ],
      [
        "T22",
        "时间范围",
        121,
        125,
        "第三季度"
      ],
      [
        "T23",
        "投融资金额",
        125,
        129,
        "融资总额"
      ],
      [
        "T24",
        "时间范围",
        135,
        143,
        "自今年年初起至今"
      ],
      [
        "T25",
        "地点范围",
        144,
        146,
        "全球"
      ],
      [
        "T26",
        "投融资金额",
        147,
        151,
        "融资金额"
      ],
      [
        "T27",
        "属性值",
        153,
        158,
        "1171亿"
      ],
      [
        "T28",
        "时间范围",
        160,
        165,
        "2020年"
      ],
      [
        "T29",
        "属性值",
        167,
        172,
        "增长42%"
      ],
      [
        "T30",
        "投融资事件数",
        173,
        177,
        "融资事件"
      ],
      [
        "T31",
        "属性值",
        179,
        184,
        "3259例"
      ],
      [
        "T32",
        "时间范围",
        186,
        188,
        "去年"
      ],
      [
        "T33",
        "属性值",
        190,
        198,
        "增长18.25%"
      ]
    ]
  },
  {
    "id": 2693,
    "text": "• 随着轻医美的受欢迎度越来越高，特别是受社交媒体的影响，提升了消费者对于医美的认知和接受度，促进了医美消费快速增长。根据艾瑞咨询发布的数据显示，2018年国内医美市场规模将为1448亿元，2013-2018年 CAGR为30.81%，预计到2022年，市场规模将突破3000亿元，国内医美市场现处于高速发展阶段。",
    "labels": [
      [
        "T0",
        "行业",
        4,
        7,
        "轻医美"
      ],
      [
        "T1",
        "行业",
        37,
        39,
        "医美"
      ],
      [
        "T2",
        "行业",
        50,
        52,
        "医美"
      ],
      [
        "T3",
        "时间范围",
        73,
        78,
        "2018年"
      ],
      [
        "T4",
        "行业",
        80,
        82,
        "医美"
      ],
      [
        "T5",
        "地点范围",
        78,
        80,
        "国内"
      ],
      [
        "T6",
        "市场规模",
        82,
        86,
        "市场规模"
      ],
      [
        "T7",
        "属性值",
        88,
        94,
        "1448亿元"
      ],
      [
        "T8",
        "时间范围",
        95,
        105,
        "2013-2018年"
      ],
      [
        "T9",
        "CAGR",
        106,
        110,
        "CAGR"
      ],
      [
        "T10",
        "属性值",
        111,
        117,
        "30.81%"
      ],
      [
        "T11",
        "时间范围",
        121,
        126,
        "2022年"
      ],
      [
        "T12",
        "市场规模",
        127,
        131,
        "市场规模"
      ],
      [
        "T13",
        "属性值",
        134,
        140,
        "3000亿元"
      ],
      [
        "T14",
        "地点范围",
        141,
        143,
        "国内"
      ],
      [
        "T15",
        "行业",
        143,
        145,
        "医美"
      ]
    ]
  },
  {
    "id": 2694,
    "text": "核心观点：业绩增速放缓，重点关注品牌中药  业绩增速放缓，行业分化明显。49家中药公司2021Q1-Q3收入总额增速为12%、归母净利润总额增速为10.3%，扣非后归母净利润增速为16.6%。Q3单季收入端增速为7%，归母净利润端增速为-15.5%，扣非后归母净利润为3.6%，收入端回落主要系2020Q3疫情恢复形成高基数。从盈利水平看，中药板块整体盈利能力整体保持稳定，21年Q1-Q3，行业毛利率（44%），销售费用率（23%）保持稳定，净利率（11%）略有提升。单Q3毛利率为30.6%，环比下滑0.6pp，主要系原材料涨价带来部分中药成本上涨。  行业利好政策不断，国家政策鼓励导向明显。利好政策方面，国家在推动中药创新、中药国际化、中药质量控制和中医医疗服务方面密集出台利好政策，促进行业稳健快速发展。与此同时，湖北、广东等地中药集采苗头初显，中成药独家品种竞争格局较好，集采降价幅度有限。  上游中药材迎来涨价带来业绩分化。 2021年以来伴随着CPI的上涨，上游中药材也迎来一波价格上涨的行情，根据康美中药网，名贵中药材天然牛黄、三七、天然麝香均有不同程度提价。原材料涨价带来行业业绩分化，中成药独家品种涨价带来毛利率提升，其他普药品种成本上涨，毛利率有所下降。前期提价品种比如片仔癀和同仁堂将持续释放业绩。2021Q1-Q3片仔癀受益于产品提价以及开辟线上直营渠道，肝病用药毛利率提升至81.9%，带动整体利润端增速超过收入增速。  国企混改释放红利，股权激励相继落地。中药行业国企混改以及股东层面的变动在近一年加速落地，云南白药、太极集团、广誉远、中新药业在国企混改后极大释放员工积极性，云南白药混改股权激励目标将提高员工积极性，国企混改红利在逐步释放。云南白药推出两期管理层股权激励计划，行权条件需要达到2021-2022年ROE考核分别不低于10.5%和11%，分红比例不低于40%。截至2021Q3公司净资产为381.5亿元，ROE为6.5%，假设按照净资产不变，我们测算全年归母净利润至少需要达到40亿元，Q4主营业务有望在股权激励下实现快速增长。  品牌中药具有长期成长属性，大健康转型值得期待。消费类的品牌中药仍然是中药板块投资的主线，消费属性强，增长趋势稳健。比如片仔癀、云南白药等具有强品牌的中药企业将仍然维持长期成长空间。关注大健康转型中的标的，比如片仔癀、云南白药、马应龙、仁和药业等。片仔癀的日化板块已经启动分拆上市，云南白药的大健康板块将全面实现品牌价值延申。 投资策略  中药行业投资逻辑主要聚焦于消费属性明显的公司：消费品属性强的中药企业成长持续性明显，品牌优势突出，竞争环境优。因此，我",
    "labels": [
      [
        "T0",
        "行业",
        16,
        20,
        "品牌中药"
      ],
      [
        "T1",
        "业绩",
        5,
        7,
        "业绩"
      ],
      [
        "T2",
        "行业公司",
        37,
        44,
        "49家中药公司"
      ],
      [
        "T3",
        "时间范围",
        44,
        53,
        "2021Q1-Q3"
      ],
      [
        "T4",
        "收入增速",
        53,
        59,
        "收入总额增速"
      ],
      [
        "T5",
        "业绩",
        23,
        25,
        "业绩"
      ],
      [
        "T6",
        "属性值",
        60,
        63,
        "12%"
      ],
      [
        "T7",
        "归母净利润增速",
        64,
        73,
        "归母净利润总额增速"
      ],
      [
        "T8",
        "属性值",
        74,
        79,
        "10.3%"
      ],
      [
        "T9",
        "扣非净利润增速",
        80,
        90,
        "扣非后归母净利润增速"
      ],
      [
        "T10",
        "属性值",
        91,
        96,
        "16.6%"
      ],
      [
        "T11",
        "时间范围",
        97,
        99,
        "Q3"
      ],
      [
        "T12",
        "收入增速",
        101,
        106,
        "收入端增速"
      ],
      [
        "T13",
        "属性值",
        107,
        109,
        "7%"
      ],
      [
        "T14",
        "归母净利润增速",
        110,
        118,
        "归母净利润端增速"
      ],
      [
        "T15",
        "属性值",
        120,
        125,
        "15.5%"
      ],
      [
        "T16",
        "扣非净利润",
        126,
        134,
        "扣非后归母净利润"
      ],
      [
        "T17",
        "属性值",
        135,
        139,
        "3.6%"
      ],
      [
        "T18",
        "营业收入",
        140,
        143,
        "收入端"
      ],
      [
        "T19",
        "时间范围",
        148,
        154,
        "2020Q3"
      ],
      [
        "T20",
        "行业",
        171,
        173,
        "中药"
      ],
      [
        "T21",
        "行业",
        188,
        196,
        "21年Q1-Q3"
      ],
      [
        "T22",
        "毛利",
        199,
        202,
        "毛利率"
      ],
      [
        "T23",
        "属性值",
        203,
        206,
        "44%"
      ],
      [
        "T24",
        "归母净利润",
        223,
        226,
        "净利率"
      ],
      [
        "T25",
        "属性值",
        227,
        230,
        "11%"
      ],
      [
        "T26",
        "时间范围",
        237,
        239,
        "Q3"
      ],
      [
        "T27",
        "毛利",
        239,
        242,
        "毛利率"
      ],
      [
        "T28",
        "属性值",
        243,
        258,
        "30.6%，环比下滑0.6pp"
      ],
      [
        "T29",
        "时间范围",
        423,
        430,
        "2021年以来"
      ],
      [
        "T30",
        "属性值",
        143,
        145,
        "回落"
      ],
      [
        "T31",
        "行业",
        406,
        411,
        "上游中药材"
      ],
      [
        "T32",
        "业绩",
        417,
        419,
        "业绩"
      ],
      [
        "T33",
        "属性值",
        419,
        421,
        "分化"
      ],
      [
        "T34",
        "行业",
        440,
        445,
        "上游中药材"
      ],
      [
        "T35",
        "公司",
        550,
        553,
        "片仔癀"
      ],
      [
        "T36",
        "公司",
        554,
        557,
        "同仁堂"
      ],
      [
        "T37",
        "属性值",
        558,
        562,
        "持续释放"
      ],
      [
        "T38",
        "业绩",
        562,
        564,
        "业绩"
      ],
      [
        "T39",
        "时间范围",
        565,
        574,
        "2021Q1-Q3"
      ],
      [
        "T40",
        "公司",
        574,
        577,
        "片仔癀"
      ],
      [
        "T41",
        "毛利",
        599,
        602,
        "毛利率"
      ],
      [
        "T42",
        "行业",
        595,
        599,
        "肝病用药"
      ],
      [
        "T43",
        "属性值",
        605,
        610,
        "81.9%"
      ],
      [
        "T44",
        "利润",
        615,
        618,
        "利润端"
      ],
      [
        "T45",
        "收入增速",
        622,
        626,
        "收入增速"
      ],
      [
        "T46",
        "行业",
        648,
        650,
        "中药"
      ],
      [
        "T47",
        "公司",
        674,
        678,
        "云南白药"
      ],
      [
        "T48",
        "公司",
        679,
        683,
        "太极集团"
      ],
      [
        "T49",
        "公司",
        684,
        687,
        "广誉远"
      ],
      [
        "T50",
        "公司",
        688,
        692,
        "中新药业"
      ],
      [
        "T51",
        "公司",
        708,
        712,
        "云南白药"
      ],
      [
        "T52",
        "公司",
        741,
        745,
        "云南白药"
      ],
      [
        "T53",
        "时间范围",
        767,
        777,
        "2021-2022年"
      ],
      [
        "T54",
        "时间范围",
        808,
        816,
        "截至2021Q3"
      ],
      [
        "T55",
        "ROE净资产回报率",
        830,
        833,
        "ROE"
      ],
      [
        "T56",
        "属性值",
        834,
        838,
        "6.5%"
      ],
      [
        "T57",
        "归母净利润",
        855,
        860,
        "归母净利润"
      ],
      [
        "T58",
        "时间范围",
        871,
        873,
        "Q4"
      ],
      [
        "T59",
        "属性值",
        887,
        891,
        "快速增长"
      ],
      [
        "T60",
        "行业",
        895,
        899,
        "品牌中药"
      ],
      [
        "T61",
        "属性值",
        901,
        905,
        "长期成长"
      ],
      [
        "T62",
        "行业",
        908,
        911,
        "大健康"
      ],
      [
        "T63",
        "行业",
        922,
        926,
        "品牌中药"
      ],
      [
        "T64",
        "行业",
        929,
        931,
        "中药"
      ],
      [
        "T65",
        "属性值",
        945,
        951,
        "增长趋势稳健"
      ],
      [
        "T66",
        "公司",
        954,
        957,
        "片仔癀"
      ],
      [
        "T67",
        "公司",
        958,
        962,
        "云南白药"
      ],
      [
        "T68",
        "行业公司",
        969,
        973,
        "中药企业"
      ],
      [
        "T69",
        "行业",
        987,
        990,
        "大健康"
      ],
      [
        "T70",
        "公司",
        999,
        1002,
        "片仔癀"
      ],
      [
        "T71",
        "公司",
        1003,
        1007,
        "云南白药"
      ],
      [
        "T72",
        "公司",
        1008,
        1011,
        "马应龙"
      ],
      [
        "T73",
        "公司",
        1012,
        1016,
        "仁和药业"
      ],
      [
        "T74",
        "公司",
        1018,
        1021,
        "片仔癀"
      ],
      [
        "T75",
        "行业",
        1022,
        1024,
        "日化"
      ],
      [
        "T76",
        "公司",
        1035,
        1039,
        "云南白药"
      ],
      [
        "T77",
        "行业",
        1040,
        1043,
        "大健康"
      ],
      [
        "T78",
        "行业",
        1065,
        1067,
        "中药"
      ],
      [
        "T79",
        "行业公司",
        1095,
        1099,
        "中药企业"
      ],
      [
        "T80",
        "行业",
        313,
        315,
        "中药"
      ],
      [
        "T81",
        "行业",
        318,
        320,
        "中药"
      ],
      [
        "T82",
        "行业",
        324,
        326,
        "中药"
      ],
      [
        "T83",
        "地点范围",
        364,
        366,
        "湖北"
      ],
      [
        "T84",
        "地点范围",
        367,
        369,
        "广东"
      ],
      [
        "T85",
        "行业",
        380,
        383,
        "中成药"
      ],
      [
        "T86",
        "竞争格局",
        387,
        391,
        "竞争格局"
      ],
      [
        "T87",
        "属性值",
        391,
        393,
        "较好"
      ],
      [
        "T88",
        "主营业务",
        873,
        877,
        "主营业务"
      ]
    ]
  },
  {
    "id": 2707,
    "text": " 2021Q1-3板块收入、业绩增长稳健：6家血液制品公司2021上半年收入总额增速为19.9%，归母净利润总额增速为25.6%；其中单三季度收入增速为28.9%，归母净利润增速为34.4%，三季度板块收入增速提升明显。21Q3板块毛利率略降低4.3pp，销售费用率降低 3.1pp，板块净利润在28%左右，维持稳定。  受前期疫情影响，目前行业供需处于紧平衡状态：2020年以来新冠疫情爆发，前期国内采浆受到影响，叠加近期海外企业对我国出口血制品下滑，促进我国血制品库存加速出清，导致行业呈现平衡偏紧的供需格局，预计这一格局将在未来一年内保持稳定。  广东联盟集采规则温和，利于行业平稳有序发展：2021年9月30日，广东省联盟集采文件征求意见稿公布，意见稿未设置企业间竞争性降价规则，且中选企业可以获得全部原采购量。我们认为本次血制品集采政策较为温和，预计利好国产血制品企业的进口替代，同时对企业的渠道管控、精细化运营等方面提出了更高的要求。  投资建议：1）推荐派林生物（000403）：并购派斯菲科+供浆协议落地，采浆规模快速提升，公司现有浆站5年潜在采浆量为1500吨左右。新品上市+产品结构改善提升吨浆净利润。广东双林2个浆站通过验收概率较高，派斯菲科有9个新建及2个迁址的省级浆站批文 ，部分浆站有望于明年年完成验收。公司前三季度积极把握海外地区血制品紧缺带来的出口机遇，通过紧急使用授权获取出口订单，未来有望进一步卡位海外市场常规销售。 2）推荐华兰生物（002007）：血制品+疫苗双轮驱动，公司浆站资源丰富，年采浆量超过千吨，血制品产品种类丰富，血浆利用率较高。公司处于国内流感疫苗市场优势地位，近年来流感疫苗需求旺盛，公司产能充足，未来成长可期。 3）推荐天坛生物（600161）：浆站数量国内首位，规模优势显著，公司目前有56个运营浆站，2020年新增4个浆站，截止 2021年10月31日累计公告新增15家浆站，新增浆站运营成熟将持续带来成长动能。",
    "labels": [
      [
        "T0",
        "时间范围",
        2,
        10,
        "2021Q1-3"
      ],
      [
        "T1",
        "营业收入",
        12,
        14,
        "收入"
      ],
      [
        "T2",
        "业绩",
        15,
        17,
        "业绩"
      ],
      [
        "T3",
        "行业公司",
        22,
        30,
        "6家血液制品公司"
      ],
      [
        "T4",
        "时间范围",
        30,
        37,
        "2021上半年"
      ],
      [
        "T5",
        "收入增速",
        37,
        43,
        "收入总额增速"
      ],
      [
        "T6",
        "属性值",
        44,
        49,
        "19.9%"
      ],
      [
        "T7",
        "归母净利润增速",
        50,
        59,
        "归母净利润总额增速"
      ],
      [
        "T8",
        "属性值",
        60,
        65,
        "25.6%"
      ],
      [
        "T9",
        "时间范围",
        69,
        72,
        "三季度"
      ],
      [
        "T10",
        "收入增速",
        72,
        76,
        "收入增速"
      ],
      [
        "T11",
        "属性值",
        77,
        82,
        "28.9%"
      ],
      [
        "T12",
        "归母净利润增速",
        83,
        90,
        "归母净利润增速"
      ],
      [
        "T13",
        "属性值",
        91,
        96,
        "34.4%"
      ],
      [
        "T14",
        "时间范围",
        97,
        100,
        "三季度"
      ],
      [
        "T15",
        "收入增速",
        102,
        106,
        "收入增速"
      ],
      [
        "T16",
        "时间范围",
        111,
        115,
        "21Q3"
      ],
      [
        "T17",
        "毛利",
        117,
        120,
        "毛利率"
      ],
      [
        "T18",
        "归母净利润",
        145,
        148,
        "净利润"
      ],
      [
        "T19",
        "时间范围",
        185,
        192,
        "2020年以来"
      ],
      [
        "T20",
        "地点范围",
        171,
        173,
        "目前"
      ],
      [
        "T21",
        "地点范围",
        231,
        233,
        "我国"
      ],
      [
        "T22",
        "行业",
        233,
        236,
        "血制品"
      ],
      [
        "T23",
        "地点范围",
        219,
        221,
        "我国"
      ],
      [
        "T24",
        "地点范围",
        214,
        216,
        "海外"
      ],
      [
        "T25",
        "时间范围",
        212,
        214,
        "近期"
      ],
      [
        "T26",
        "地点范围",
        201,
        203,
        "国内"
      ],
      [
        "T27",
        "时间范围",
        267,
        272,
        "未来一年内"
      ],
      [
        "T28",
        "时间范围",
        302,
        312,
        "2021年9月30日"
      ],
      [
        "T29",
        "地点范围",
        280,
        282,
        "广东"
      ],
      [
        "T30",
        "地点范围",
        313,
        316,
        "广东省"
      ],
      [
        "T31",
        "行业",
        369,
        372,
        "血制品"
      ],
      [
        "T32",
        "行业公司",
        387,
        392,
        "血制品企业"
      ],
      [
        "T33",
        "公司",
        438,
        442,
        "派林生物"
      ],
      [
        "T34",
        "公司",
        453,
        457,
        "派斯菲科"
      ],
      [
        "T35",
        "归母净利润",
        511,
        514,
        "净利润"
      ],
      [
        "T36",
        "地点范围",
        515,
        519,
        "广东双林"
      ],
      [
        "T37",
        "公司",
        532,
        536,
        "派斯菲科"
      ],
      [
        "T38",
        "时间范围",
        562,
        564,
        "明年"
      ],
      [
        "T39",
        "时间范围",
        572,
        576,
        "前三季度"
      ],
      [
        "T40",
        "行业",
        584,
        587,
        "血制品"
      ],
      [
        "T41",
        "地点范围",
        580,
        584,
        "海外地区"
      ],
      [
        "T42",
        "地点范围",
        621,
        623,
        "海外"
      ],
      [
        "T43",
        "公司",
        635,
        639,
        "华兰生物"
      ],
      [
        "T44",
        "行业",
        648,
        651,
        "血制品"
      ],
      [
        "T45",
        "行业",
        652,
        654,
        "疫苗"
      ],
      [
        "T46",
        "地点范围",
        699,
        701,
        "国内"
      ],
      [
        "T47",
        "行业",
        701,
        705,
        "流感疫苗"
      ],
      [
        "T48",
        "时间范围",
        712,
        715,
        "近年来"
      ],
      [
        "T49",
        "行业",
        715,
        719,
        "流感疫苗"
      ],
      [
        "T50",
        "属性值",
        721,
        723,
        "旺盛"
      ],
      [
        "T51",
        "产能",
        726,
        728,
        "产能"
      ],
      [
        "T52",
        "属性值",
        728,
        730,
        "充足"
      ],
      [
        "T53",
        "公司",
        743,
        747,
        "天坛生物"
      ],
      [
        "T54",
        "时间范围",
        774,
        776,
        "目前"
      ],
      [
        "T55",
        "时间范围",
        797,
        811,
        "截止 2021年10月31日"
      ],
      [
        "T56",
        "时间范围",
        785,
        790,
        "2020年"
      ]
    ]
  },
  {
    "id": 2711,
    "text": "口中国自研游戏出海是业务新增长点：中国游戏海外市场增长迅速，规模从2015年的372亿元增长至2020年的1,082亿元，增长近两倍，且在2020年依然保持33%的高增速；从量级看，2020年海外市场规模占中国市场45%，比重逐步提升，海外业务重要性不言而喻",
    "labels": [
      [
        "T0",
        "地点范围",
        21,
        23,
        "海外"
      ],
      [
        "T1",
        "时间范围",
        33,
        38,
        "2015年"
      ],
      [
        "T2",
        "时间范围",
        47,
        52,
        "2020年"
      ],
      [
        "T3",
        "属性值",
        39,
        44,
        "372亿元"
      ],
      [
        "T4",
        "属性值",
        53,
        60,
        "1,082亿元"
      ],
      [
        "T5",
        "时间范围",
        69,
        74,
        "2020年"
      ],
      [
        "T6",
        "地点范围",
        1,
        3,
        "中国"
      ],
      [
        "T7",
        "行业",
        3,
        9,
        "自研游戏出海"
      ],
      [
        "T8",
        "地点范围",
        17,
        19,
        "中国"
      ],
      [
        "T9",
        "行业",
        19,
        21,
        "游戏"
      ],
      [
        "T10",
        "属性值",
        78,
        81,
        "33%"
      ],
      [
        "T11",
        "时间范围",
        91,
        96,
        "2020年"
      ],
      [
        "T12",
        "地点范围",
        96,
        98,
        "海外"
      ],
      [
        "T13",
        "地点范围",
        103,
        105,
        "中国"
      ]
    ]
  },
  {
    "id": 2719,
    "text": " 原料药板块2021Q1-3同比增长14.2%，归母净利润下降0.4%；单三季度收入、归母净利分别为250亿元、37亿元，分别同比+14.5%、-2.6% 。  35家原料药公司中有26家公司收入实现正增长，其中7家超过30%，9家公司收入同比下滑。 22家公司实现归母净利润正增长，其中3家增速超过50%。",
    "labels": [
      [
        "T0",
        "行业",
        2,
        5,
        "原料药"
      ],
      [
        "T1",
        "时间范围",
        7,
        15,
        "2021Q1-3"
      ],
      [
        "T2",
        "归母净利润",
        25,
        30,
        "归母净利润"
      ],
      [
        "T3",
        "时间范围",
        38,
        41,
        "三季度"
      ],
      [
        "T4",
        "营业收入",
        41,
        43,
        "收入"
      ],
      [
        "T5",
        "归母净利润",
        44,
        48,
        "归母净利"
      ],
      [
        "T6",
        "属性值",
        51,
        56,
        "250亿元"
      ],
      [
        "T7",
        "属性值",
        57,
        61,
        "37亿元"
      ],
      [
        "T8",
        "属性值",
        66,
        72,
        "+14.5%"
      ],
      [
        "T9",
        "行业公司",
        83,
        91,
        "35家原料药公司"
      ],
      [
        "T10",
        "营业收入",
        98,
        100,
        "收入"
      ],
      [
        "T11",
        "行业公司",
        116,
        120,
        "9家公司"
      ],
      [
        "T12",
        "行业公司",
        128,
        133,
        "22家公司"
      ],
      [
        "T13",
        "归母净利润",
        135,
        140,
        "归母净利润"
      ],
      [
        "T14",
        "属性值",
        140,
        143,
        "正增长"
      ],
      [
        "T15",
        "行业公司",
        93,
        98,
        "26家公司"
      ],
      [
        "T16",
        "属性值",
        102,
        105,
        "正增长"
      ],
      [
        "T17",
        "营业收入",
        120,
        122,
        "收入"
      ],
      [
        "T18",
        "属性值",
        122,
        126,
        "同比下滑"
      ],
      [
        "T19",
        "属性值",
        30,
        36,
        "下降0.4%"
      ]
    ]
  },
  {
    "id": 2729,
    "text": "• 2021Q3连锁医疗服务营收开始恢复:自新冠疫情爆发以来，国内专科医疗机构（眼科、口腔科、体检、综合等） 2020Q1营收均受到一定程度的影响；随着疫情的逐渐控制，爱尔眼科、通策医疗、美年健康、锦欣生殖等医疗机构后续营收均恢复到往年水平。",
    "labels": [
      [
        "T0",
        "公司",
        84,
        88,
        "爱尔眼科"
      ],
      [
        "T1",
        "公司",
        89,
        93,
        "通策医疗"
      ],
      [
        "T2",
        "公司",
        94,
        98,
        "美年健康"
      ],
      [
        "T3",
        "公司",
        99,
        103,
        "锦欣生殖"
      ],
      [
        "T4",
        "营业收入",
        110,
        112,
        "营收"
      ],
      [
        "T5",
        "属性值",
        113,
        120,
        "恢复到往年水平"
      ],
      [
        "T6",
        "时间范围",
        2,
        8,
        "2021Q3"
      ],
      [
        "T7",
        "时间范围",
        55,
        61,
        "2020Q1"
      ],
      [
        "T8",
        "营业收入",
        61,
        63,
        "营收"
      ],
      [
        "T9",
        "地点范围",
        31,
        33,
        "国内"
      ],
      [
        "T10",
        "行业公司",
        33,
        39,
        "专科医疗机构"
      ],
      [
        "T11",
        "属性值",
        64,
        73,
        "受到一定程度的影响"
      ]
    ]
  },
  {
    "id": 2730,
    "text": " 6家连锁药店公司2021Q1-3收入总额增速为14.5%，其中第三季度收入增速为16.3%；归母净利润总额增速为10%，其中第三季度下降8.2% 。从趋势来看，第三季度收入环比上升、净利润环比继续下降。  第三季度，药店板块的毛利率为36%，销售费用率（25.5%）逐渐回归到疫情前的水平。",
    "labels": [
      [
        "T0",
        "行业公司",
        2,
        10,
        "6家连锁药店公司"
      ],
      [
        "T1",
        "时间范围",
        10,
        18,
        "2021Q1-3"
      ],
      [
        "T2",
        "收入增速",
        18,
        24,
        "收入总额增速"
      ],
      [
        "T3",
        "属性值",
        25,
        30,
        "14.5%"
      ],
      [
        "T4",
        "时间范围",
        33,
        37,
        "第三季度"
      ],
      [
        "T5",
        "收入增速",
        37,
        41,
        "收入增速"
      ],
      [
        "T6",
        "属性值",
        42,
        47,
        "16.3%"
      ],
      [
        "T7",
        "归母净利润增速",
        48,
        57,
        "归母净利润总额增速"
      ],
      [
        "T8",
        "属性值",
        58,
        61,
        "10%"
      ],
      [
        "T9",
        "时间范围",
        64,
        68,
        "第三季度"
      ],
      [
        "T10",
        "属性值",
        68,
        74,
        "下降8.2%"
      ],
      [
        "T11",
        "时间范围",
        82,
        86,
        "第三季度"
      ],
      [
        "T12",
        "营业收入",
        86,
        88,
        "收入"
      ],
      [
        "T13",
        "属性值",
        88,
        92,
        "环比上升"
      ],
      [
        "T14",
        "归母净利润",
        93,
        96,
        "净利润"
      ],
      [
        "T15",
        "属性值",
        96,
        102,
        "环比继续下降"
      ],
      [
        "T16",
        "时间范围",
        106,
        110,
        "第三季度"
      ],
      [
        "T17",
        "行业",
        111,
        113,
        "药店"
      ],
      [
        "T18",
        "毛利",
        116,
        119,
        "毛利率"
      ],
      [
        "T19",
        "属性值",
        120,
        123,
        "36%"
      ]
    ]
  },
  {
    "id": 2735,
    "text": "2.1.CXO行业——CRO产业细分产业链价值链：受益全球产业链转移和国内创新崛起",
    "labels": [
      [
        "T0",
        "行业",
        4,
        7,
        "CXO"
      ],
      [
        "T1",
        "行业",
        11,
        14,
        "CRO"
      ],
      [
        "T2",
        "地点范围",
        35,
        37,
        "国内"
      ],
      [
        "T3",
        "地点范围",
        27,
        29,
        "全球"
      ]
    ]
  },
  {
    "id": 2736,
    "text": "药企研发投入持续提升，CXO需求不减。根据 Pharmaprojects数据，全球药物研发支出由 2012年的 1361亿美元提升至 2020年的 1878亿美元，复合增速达 4.11%。持续加大研发投入的同时，新药管线与 IND申请/受理数量也持续走高，根据 Statista数据， 在研新药数量也由 2010年的 9737个提高到 2021年的 18582个，复合增速达 4.76%。",
    "labels": [
      [
        "T0",
        "行业公司",
        0,
        2,
        "药企"
      ],
      [
        "T1",
        "研发费用",
        2,
        6,
        "研发投入"
      ],
      [
        "T2",
        "属性值",
        6,
        10,
        "持续提升"
      ],
      [
        "T3",
        "行业",
        11,
        14,
        "CXO"
      ],
      [
        "T4",
        "行业需求",
        14,
        16,
        "需求"
      ],
      [
        "T5",
        "属性值",
        16,
        18,
        "不减"
      ],
      [
        "T6",
        "地点范围",
        39,
        41,
        "全球"
      ],
      [
        "T7",
        "行业",
        41,
        43,
        "药物"
      ],
      [
        "T8",
        "研发费用",
        43,
        47,
        "研发支出"
      ],
      [
        "T9",
        "时间范围",
        49,
        54,
        "2012年"
      ],
      [
        "T10",
        "属性值",
        56,
        63,
        "1361亿美元"
      ],
      [
        "T11",
        "时间范围",
        67,
        72,
        "2020年"
      ],
      [
        "T12",
        "属性值",
        74,
        81,
        "1878亿美元"
      ],
      [
        "T13",
        "CAGR",
        82,
        86,
        "复合增速"
      ],
      [
        "T14",
        "属性值",
        88,
        93,
        "4.11%"
      ],
      [
        "T15",
        "研发费用",
        98,
        102,
        "研发投入"
      ],
      [
        "T16",
        "属性值",
        94,
        98,
        "持续加大"
      ],
      [
        "T17",
        "IND申报数",
        112,
        117,
        "IND申请"
      ],
      [
        "T18",
        "属性值",
        123,
        127,
        "持续走高"
      ],
      [
        "T19",
        "时间范围",
        152,
        157,
        "2010年"
      ],
      [
        "T20",
        "时间范围",
        168,
        173,
        "2021年"
      ],
      [
        "T21",
        "CAGR",
        182,
        186,
        "复合增速"
      ],
      [
        "T22",
        "属性值",
        188,
        193,
        "4.76%"
      ],
      [
        "T23",
        "属性值",
        143,
        149,
        "在研新药数量"
      ]
    ]
  },
  {
    "id": 2737,
    "text": "根据 Frost&Sullivan数据，中国 CRO市场收入在 2015年至 2020年由 26亿人民币增长至 80亿人民币， 年复合增长率为 25.2%。中国 CRO市场收入预期将于 2024年达到 222亿人民币，2020年-2024年年均复合增长率为 29.1%。其中，药物发现项目 2024年预期市场收入为 43亿人民币，临床前研究项目 2024 年预期市场收入为 41亿人民币，临床研究项目 2024年预期市场收入为 137亿人民币。预期在 2020 年-2024年间临床研究项目在市场收入中仍然占比较高，而药物发现项目增长潜力较大。",
    "labels": [
      [
        "T0",
        "地点范围",
        20,
        22,
        "中国"
      ],
      [
        "T1",
        "行业",
        23,
        26,
        "CRO"
      ],
      [
        "T2",
        "营业收入",
        28,
        30,
        "收入"
      ],
      [
        "T3",
        "时间范围",
        32,
        37,
        "2015年"
      ],
      [
        "T4",
        "时间范围",
        39,
        44,
        "2020年"
      ],
      [
        "T5",
        "属性值",
        46,
        52,
        "26亿人民币"
      ],
      [
        "T6",
        "属性值",
        56,
        62,
        "80亿人民币"
      ],
      [
        "T7",
        "CAGR",
        64,
        70,
        "年复合增长率"
      ],
      [
        "T8",
        "属性值",
        72,
        77,
        "25.2%"
      ],
      [
        "T9",
        "地点范围",
        78,
        80,
        "中国"
      ],
      [
        "T10",
        "行业",
        81,
        84,
        "CRO"
      ],
      [
        "T11",
        "营业收入",
        86,
        88,
        "收入"
      ],
      [
        "T12",
        "时间范围",
        93,
        98,
        "2024年"
      ],
      [
        "T13",
        "属性值",
        101,
        108,
        "222亿人民币"
      ],
      [
        "T14",
        "时间范围",
        109,
        120,
        "2020年-2024年"
      ],
      [
        "T15",
        "CAGR",
        120,
        127,
        "年均复合增长率"
      ],
      [
        "T16",
        "属性值",
        129,
        134,
        "29.1%"
      ],
      [
        "T17",
        "行业",
        138,
        142,
        "药物发现"
      ],
      [
        "T18",
        "时间范围",
        145,
        150,
        "2024年"
      ],
      [
        "T19",
        "营业收入",
        154,
        156,
        "收入"
      ],
      [
        "T20",
        "属性值",
        158,
        164,
        "43亿人民币"
      ],
      [
        "T21",
        "行业",
        165,
        170,
        "临床前研究"
      ],
      [
        "T22",
        "时间范围",
        173,
        179,
        "2024 年"
      ],
      [
        "T23",
        "营业收入",
        183,
        185,
        "收入"
      ],
      [
        "T24",
        "属性值",
        187,
        193,
        "41亿人民币"
      ],
      [
        "T25",
        "行业",
        194,
        198,
        "临床研究"
      ],
      [
        "T26",
        "时间范围",
        201,
        206,
        "2024年"
      ],
      [
        "T27",
        "营业收入",
        210,
        212,
        "收入"
      ],
      [
        "T28",
        "属性值",
        214,
        221,
        "137亿人民币"
      ],
      [
        "T29",
        "时间范围",
        226,
        238,
        "2020 年-2024年"
      ],
      [
        "T30",
        "行业",
        239,
        243,
        "临床研究"
      ],
      [
        "T31",
        "营业收入",
        248,
        250,
        "收入"
      ],
      [
        "T32",
        "属性值",
        255,
        257,
        "较高"
      ],
      [
        "T33",
        "行业",
        259,
        263,
        "药物发现"
      ],
      [
        "T34",
        "时间连接词",
        37,
        38,
        "至"
      ]
    ]
  },
  {
    "id": 2753,
    "text": " 血制品（6家）：板块2021Q1-3收入总额增速为20%，占全行业比例为1% ，其中第三季度收入增速为28.9%；2021Q1- 3归母净利润总额增速为25.7%，占全行业比例为2% ，其中第三季度增速为34.4%。 6家血液制品公司中上半年收入、利润均实现正增长。第三季度，板块毛利率下降4.3pp，销售费用率降低3.1pp，板块净利润在28%左右，维持稳定。",
    "labels": [
      [
        "T0",
        "行业",
        2,
        5,
        "血制品"
      ],
      [
        "T1",
        "时间范围",
        12,
        20,
        "2021Q1-3"
      ],
      [
        "T2",
        "收入增速",
        20,
        26,
        "收入总额增速"
      ],
      [
        "T3",
        "属性值",
        27,
        30,
        "20%"
      ],
      [
        "T4",
        "时间范围",
        44,
        48,
        "第三季度"
      ],
      [
        "T5",
        "收入增速",
        48,
        52,
        "收入增速"
      ],
      [
        "T6",
        "属性值",
        53,
        58,
        "28.9%"
      ],
      [
        "T7",
        "时间范围",
        59,
        68,
        "2021Q1- 3"
      ],
      [
        "T8",
        "归母净利润增速",
        68,
        77,
        "归母净利润总额增速"
      ],
      [
        "T9",
        "属性值",
        78,
        83,
        "25.7%"
      ],
      [
        "T10",
        "时间范围",
        97,
        101,
        "第三季度"
      ],
      [
        "T11",
        "属性值",
        104,
        109,
        "34.4%"
      ],
      [
        "T12",
        "行业公司",
        111,
        119,
        "6家血液制品公司"
      ],
      [
        "T13",
        "时间范围",
        120,
        123,
        "上半年"
      ],
      [
        "T14",
        "营业收入",
        123,
        125,
        "收入"
      ],
      [
        "T15",
        "利润",
        126,
        128,
        "利润"
      ],
      [
        "T16",
        "属性值",
        131,
        134,
        "正增长"
      ],
      [
        "T17",
        "时间范围",
        135,
        139,
        "第三季度"
      ],
      [
        "T18",
        "毛利",
        142,
        145,
        "毛利率"
      ],
      [
        "T19",
        "属性值",
        145,
        152,
        "下降4.3pp"
      ],
      [
        "T20",
        "归母净利润",
        168,
        171,
        "净利润"
      ],
      [
        "T21",
        "属性值",
        172,
        177,
        "28%左右"
      ]
    ]
  },
  {
    "id": 2759,
    "text": "九洲药业集研发、生产、销售医药原料药及中间体为一体，主要产品类别包括专利原料药及中间体合同定制研发及生产业务(CDMO)、特色原料药及中间体业务(API)。公司持续加大 CDMO业务板块布局，深耕小分子 CDMO 业务，提升全球 CDMO 研发生产服务承接能力。公司全球客户项目持续增加， 早期项目池迅速扩大，漏斗形项目管线持续向后端转化，持续提高盈利能力。公司 2021年 H1期间 CDMO业务实现营业收入 10.23亿人民币，在收入中占比以达到 54.8%。",
    "labels": [
      [
        "T0",
        "公司",
        0,
        4,
        "九洲药业"
      ],
      [
        "T1",
        "行业",
        55,
        59,
        "CDMO"
      ],
      [
        "T2",
        "行业",
        73,
        76,
        "API"
      ],
      [
        "T3",
        "行业",
        85,
        89,
        "CDMO"
      ],
      [
        "T4",
        "行业",
        98,
        106,
        "小分子 CDMO"
      ],
      [
        "T5",
        "行业",
        115,
        119,
        "CDMO"
      ],
      [
        "T6",
        "时间范围",
        182,
        190,
        "2021年 H1"
      ],
      [
        "T7",
        "行业",
        193,
        197,
        "CDMO"
      ],
      [
        "T8",
        "营业收入",
        201,
        205,
        "营业收入"
      ],
      [
        "T9",
        "属性值",
        206,
        215,
        "10.23亿人民币"
      ],
      [
        "T10",
        "属性值",
        226,
        231,
        "54.8%"
      ],
      [
        "T11",
        "营收占比",
        217,
        222,
        "收入中占比"
      ],
      [
        "T12",
        "地点范围",
        112,
        114,
        "全球"
      ],
      [
        "T13",
        "地点范围",
        133,
        135,
        "全球"
      ]
    ]
  },
  {
    "id": 2761,
    "text": " 万孚生物：国产POCT龙头，2021Q1-3收入25.1亿元（+15.4%）,归母净利润6.3亿元（+10.8%）， 单Q3业绩表现低于预期，主要因成本增加导致毛利率下降。  基蛋生物：2021Q1-3收入9.2亿元（+20.9%）， 归母净利润2.5亿元（+28.4%）。  明德生物：2021Q1-3收入19.4亿元（+202.8%） ，归母净利润10.1亿元（+182.2%），主要是因新冠检测试剂贡献较大增量。",
    "labels": [
      [
        "T0",
        "公司",
        2,
        6,
        "万孚生物"
      ],
      [
        "T1",
        "行业",
        7,
        13,
        "国产POCT"
      ],
      [
        "T2",
        "龙头企业",
        13,
        15,
        "龙头"
      ],
      [
        "T3",
        "时间范围",
        16,
        24,
        "2021Q1-3"
      ],
      [
        "T4",
        "营业收入",
        24,
        26,
        "收入"
      ],
      [
        "T5",
        "属性值",
        26,
        32,
        "25.1亿元"
      ],
      [
        "T6",
        "属性值",
        33,
        39,
        "+15.4%"
      ],
      [
        "T7",
        "归母净利润",
        41,
        46,
        "归母净利润"
      ],
      [
        "T8",
        "属性值",
        46,
        59,
        "6.3亿元（+10.8%）"
      ],
      [
        "T9",
        "时间范围",
        62,
        64,
        "Q3"
      ],
      [
        "T10",
        "业绩",
        64,
        66,
        "业绩"
      ],
      [
        "T11",
        "属性值",
        68,
        72,
        "低于预期"
      ],
      [
        "T12",
        "毛利",
        82,
        85,
        "毛利率"
      ],
      [
        "T13",
        "属性值",
        85,
        87,
        "下降"
      ],
      [
        "T14",
        "公司",
        91,
        95,
        "基蛋生物"
      ],
      [
        "T15",
        "时间范围",
        96,
        104,
        "2021Q1-3"
      ],
      [
        "T16",
        "营业收入",
        104,
        106,
        "收入"
      ],
      [
        "T17",
        "属性值",
        106,
        111,
        "9.2亿元"
      ],
      [
        "T18",
        "属性值",
        112,
        118,
        "+20.9%"
      ],
      [
        "T19",
        "归母净利润",
        121,
        126,
        "归母净利润"
      ],
      [
        "T20",
        "属性值",
        126,
        139,
        "2.5亿元（+28.4%）"
      ],
      [
        "T21",
        "公司",
        143,
        147,
        "明德生物"
      ],
      [
        "T22",
        "时间范围",
        148,
        156,
        "2021Q1-3"
      ],
      [
        "T23",
        "营业收入",
        156,
        158,
        "收入"
      ],
      [
        "T24",
        "属性值",
        158,
        164,
        "19.4亿元"
      ],
      [
        "T25",
        "属性值",
        165,
        172,
        "+202.8%"
      ],
      [
        "T26",
        "归母净利润",
        175,
        180,
        "归母净利润"
      ],
      [
        "T27",
        "属性值",
        180,
        195,
        "10.1亿元（+182.2%）"
      ],
      [
        "T28",
        "行业",
        200,
        206,
        "新冠检测试剂"
      ]
    ]
  },
  {
    "id": 2764,
    "text": "2021年Q1-Q3，公司整体实现营业收入82.39亿元，同比增长28.75%；实现归母净利润31.47亿元，同比增长39.25%；实现扣非归母净利润 31.60亿元，同比增长43.07%。2021年金赛药业业绩持续高增长，2021年第三季度，金赛药业实现收入23.70亿元，同比增长38.27%；实现净利润11.83亿元，同比增长37.56%。9月30日生长激素被纳入广东省联盟10省采购目录中，预计近期最终价格结果会正式出台。虽然此次生长激素被纳入带量采购，但是此次分组和中标规则充分考虑了生长激素当前市场药品供应稳定性，金赛药业作为国内生长激素龙头公司，产品梯队完善，预计此次集采对公司盈利水平影响有限。",
    "labels": [
      [
        "T0",
        "时间范围",
        0,
        10,
        "2021年Q1-Q3"
      ],
      [
        "T1",
        "营业收入",
        17,
        21,
        "营业收入"
      ],
      [
        "T2",
        "归母净利润",
        42,
        47,
        "归母净利润"
      ],
      [
        "T3",
        "扣非净利润",
        68,
        75,
        "扣非归母净利润"
      ],
      [
        "T4",
        "时间范围",
        95,
        100,
        "2021年"
      ],
      [
        "T5",
        "公司",
        100,
        104,
        "金赛药业"
      ],
      [
        "T6",
        "业绩",
        104,
        106,
        "业绩"
      ],
      [
        "T7",
        "属性值",
        106,
        111,
        "持续高增长"
      ],
      [
        "T8",
        "时间范围",
        112,
        121,
        "2021年第三季度"
      ],
      [
        "T9",
        "公司",
        122,
        126,
        "金赛药业"
      ],
      [
        "T10",
        "营业收入",
        128,
        130,
        "收入"
      ],
      [
        "T11",
        "属性值",
        130,
        137,
        "23.70亿元"
      ],
      [
        "T12",
        "属性值",
        142,
        148,
        "38.27%"
      ],
      [
        "T13",
        "归母净利润",
        151,
        154,
        "净利润"
      ],
      [
        "T14",
        "属性值",
        154,
        172,
        "11.83亿元，同比增长37.56%"
      ],
      [
        "T15",
        "时间范围",
        173,
        178,
        "9月30日"
      ],
      [
        "T16",
        "地点范围",
        185,
        188,
        "广东省"
      ],
      [
        "T17",
        "时间范围",
        201,
        203,
        "近期"
      ],
      [
        "T18",
        "公司",
        263,
        267,
        "金赛药业"
      ],
      [
        "T19",
        "地点范围",
        269,
        271,
        "国内"
      ],
      [
        "T20",
        "行业",
        271,
        275,
        "生长激素"
      ],
      [
        "T21",
        "龙头企业",
        275,
        279,
        "龙头公司"
      ]
    ]
  },
  {
    "id": 2765,
    "text": "新技术引领着创新药进入新时代。抗体药物自2014年来进入快速发展阶段， O药和 K 药的上市开启了肿瘤免疫治疗新篇章，也点燃了生物医药投资的热潮。 EvaluatePharma预计 2021年全球十大畅销的药物中有五个为抗体药物，随着抗体类药物技术的成熟，类型从单抗逐渐拓展到双抗、多抗、ADC，应用领域逐渐拓展到癌症、自免、代谢和传染病，治疗性抗体药物的市场预计 2050年将达到 3000亿美金。2017年， CAR-T细胞疗法Kymriah和Yescarta以及2018年基因疗法Luxturna和全球首个siRNA 药物Patisiran的上市，带动了细胞基因疗法领域的投资。2020年，突如其来的新冠让 mRNA技术被推到前所未有的高度，进一步带动了生物医药领域的投资热情。2021年， 辉瑞 20亿美元收购ARV-471开发权引发了市场对于PROTAC技术的关注。",
    "labels": [
      [
        "T0",
        "行业",
        6,
        9,
        "创新药"
      ],
      [
        "T1",
        "行业",
        15,
        19,
        "抗体药物"
      ],
      [
        "T2",
        "行业",
        63,
        67,
        "生物医药"
      ],
      [
        "T3",
        "时间范围",
        90,
        96,
        " 2021年"
      ],
      [
        "T4",
        "行业",
        117,
        122,
        "抗体类药物"
      ],
      [
        "T5",
        "行业",
        170,
        177,
        "治疗性抗体药物"
      ],
      [
        "T6",
        "时间范围",
        183,
        188,
        "2050年"
      ],
      [
        "T7",
        "属性值",
        192,
        199,
        "3000亿美金"
      ],
      [
        "T8",
        "时间范围",
        200,
        205,
        "2017年"
      ],
      [
        "T9",
        "行业",
        280,
        286,
        "细胞基因疗法"
      ],
      [
        "T10",
        "时间范围",
        292,
        297,
        "2020年"
      ],
      [
        "T11",
        "行业",
        330,
        334,
        "生物医药"
      ],
      [
        "T12",
        "时间范围",
        342,
        347,
        "2021年"
      ],
      [
        "T13",
        "公司",
        348,
        352,
        " 辉瑞 "
      ],
      [
        "T14",
        "地点范围",
        96,
        98,
        "全球"
      ],
      [
        "T15",
        "时间范围",
        19,
        26,
        "自2014年来"
      ]
    ]
  },
  {
    "id": 2771,
    "text": "本周（2022.1.17-2021.1.21）、年初至今生物医药指数涨幅分别为-7.19%、 -8.70%，相对沪指的超额收益分别为-8.30%、-5.44%；本周医疗器械、 生物制品、化药等股价较为强势，商业、中药及医疗服务等股价较为弱势；本周涨幅居前精华制药（+36.71%）、塞力医疗（+23.32%）、拓新药业（+23.13%），跌幅居前博拓生物（-46.84%）、东方生物（-41.71%）、热景生物（-40.09%）。涨跌表现特点：受到英国、美国对疫情态度的转变及柳叶刀表态疫情即将结束、与毒共存等影响，新冠检测相关标的暴跌；受到广东招标政策影响，生长激素及血制品等跌幅明显；游资偏好的小市值个股，逐步价值回归。",
    "labels": [
      [
        "T0",
        "时间范围",
        0,
        2,
        "本周"
      ],
      [
        "T1",
        "时间范围",
        3,
        22,
        "2022.1.17-2021.1.21"
      ],
      [
        "T2",
        "时间范围",
        24,
        28,
        "年初至今"
      ],
      [
        "T3",
        "行业",
        28,
        32,
        "生物医药"
      ],
      [
        "T4",
        "时间范围",
        80,
        82,
        "本周"
      ],
      [
        "T5",
        "行业",
        82,
        86,
        "医疗器械"
      ],
      [
        "T6",
        "行业",
        88,
        92,
        "生物制品"
      ],
      [
        "T7",
        "行业",
        93,
        95,
        "化药"
      ],
      [
        "T8",
        "行业",
        103,
        105,
        "商业"
      ],
      [
        "T9",
        "行业",
        106,
        108,
        "中药"
      ],
      [
        "T10",
        "行业",
        109,
        113,
        "医疗服务"
      ],
      [
        "T11",
        "公司",
        127,
        131,
        "精华制药"
      ],
      [
        "T12",
        "公司",
        141,
        145,
        "塞力医疗"
      ],
      [
        "T13",
        "公司",
        155,
        159,
        "拓新药业"
      ],
      [
        "T14",
        "公司",
        173,
        177,
        "博拓生物"
      ],
      [
        "T15",
        "公司",
        187,
        191,
        "东方生物"
      ],
      [
        "T16",
        "公司",
        201,
        205,
        "热景生物"
      ],
      [
        "T17",
        "地点范围",
        224,
        226,
        "英国"
      ],
      [
        "T18",
        "地点范围",
        227,
        229,
        "美国"
      ],
      [
        "T19",
        "地点范围",
        271,
        273,
        "广东"
      ],
      [
        "T20",
        "行业",
        280,
        284,
        "生长激素"
      ],
      [
        "T21",
        "行业",
        285,
        288,
        "血制品"
      ]
    ]
  },
  {
    "id": 2775,
    "text": " 2021年前三季度板块总结：器械板块（83家样本公司，含科创板）2021Q1-3收入1543亿元（+27.6%），归母净利润487亿元（+26.8%） ，毛利率 61%，四费率 25%, 净利率 32%，盈利能力维持高位。医疗器械板块 Q1/Q2/Q3单季度收入 535.1/534.7/473.2亿元（ +118%/+9.4%/-0.4%）,单季度净利润185.5/174.1/127.5亿元（+259%/+1.6%/-20.9%）, 高基数下板块Q3单季度业绩有所承压。Q3单季度毛利率58.6%（-4.9pp），单季度四费率27.6%（+2.9pp），单季度净利率26.9%（-2.1pp）。  器械领域带量采购有望成为招采新常态，国采降幅预期边际回归。带量采购正在医用耗材领域广泛开展，并有逐步蔓延至IVD、设备领域的趋势，未来“国家+地方”两个层面推进器械带量采购常态化，其中人工晶体、支架、骨科、补片等成为首当其冲的品种。国家组织高值耗材全国集采已经进行两批，从第二批关节集采结果看，平均降幅在82%，降幅总体比之前的冠脉支架小很多，国产部分产品甚至在原出厂价以上 ，通过减少流通商的加价，中选产品有望实现以价换量。关节集采相比冠脉支架有所缓和，也带动市场对器械集采降幅预期的边际回归。  控费背景下器械行业开启新的投资周期，关注创新性&渗透率 & 国产化率 & 抗控费属性。过去10年，随着全国卫生投入增长、老龄化加剧 、分级诊疗推进，中国器械市场规模突破6000亿，需求端消费升级不断推进，同时大部分赛道国产化率不足40%（高端更低），技术突破+ 性价比+渠道优势促进国产化率持续提升。展望未来10年（2020~2030），在控费的总基调下，市场会更加追寻创新潜力大、竞争格局优良 、渗透率低、国产率低、定价权高的赛道，而成熟产品、国产化率高、竞争激烈的赛道则将面临类仿制药集采的逻辑与业绩双杀的局面，器械板块结构性机会大于板块性机会，政策免疫/抗控费成为器械重要的投资方向。  投资建议。从产业链视角关注“两低”赛道（低渗透率、低国产化率）和器械医保免疫方向（器械上游+下游出海）方向。建议布局1）低渗透率：TAVR（启明医疗、佰仁医疗）、电生理、外周血管介入（心脉医疗）、手术机器人（微创医疗机器人）、眼科（爱博医疗、欧普康视 ）；2）低国产化率：影像领域（万东医疗）、内窥镜（开立医疗、南微医学）、 IVD领域（迈瑞医疗）等；3）医保免疫：器械上游药机设备（东富龙、楚天科技）、药房自动化（健麾信息）、耗材生产设备（迈得医疗），下游出海国际化方向（迈瑞医疗、南微医学）、家用器械（鱼跃医疗）。",
    "labels": [
      [
        "T0",
        "时间范围",
        2,
        11,
        "2021年前三季度"
      ],
      [
        "T1",
        "行业",
        16,
        18,
        "器械"
      ],
      [
        "T2",
        "时间范围",
        34,
        42,
        "2021Q1-3"
      ],
      [
        "T3",
        "营业收入",
        42,
        44,
        "收入"
      ],
      [
        "T4",
        "属性值",
        44,
        50,
        "1543亿元"
      ],
      [
        "T5",
        "属性值",
        51,
        57,
        "+27.6%"
      ],
      [
        "T6",
        "属性值",
        82,
        86,
        " 61%"
      ],
      [
        "T7",
        "归母净利润",
        59,
        64,
        "归母净利润"
      ],
      [
        "T8",
        "毛利",
        79,
        82,
        "毛利率"
      ],
      [
        "T9",
        "行业",
        113,
        117,
        "医疗器械"
      ],
      [
        "T10",
        "时间范围",
        120,
        122,
        "Q1"
      ],
      [
        "T11",
        "时间范围",
        123,
        125,
        "Q2"
      ],
      [
        "T12",
        "时间范围",
        126,
        128,
        "Q3"
      ],
      [
        "T13",
        "营业收入",
        131,
        133,
        "收入"
      ],
      [
        "T14",
        "属性值",
        134,
        139,
        "535.1"
      ],
      [
        "T15",
        "属性值",
        140,
        145,
        "534.7"
      ],
      [
        "T16",
        "属性值",
        146,
        153,
        "473.2亿元"
      ],
      [
        "T17",
        "属性值",
        155,
        160,
        "+118%"
      ],
      [
        "T18",
        "属性值",
        161,
        166,
        "+9.4%"
      ],
      [
        "T19",
        "属性值",
        167,
        172,
        "-0.4%"
      ],
      [
        "T20",
        "属性值",
        180,
        185,
        "185.5"
      ],
      [
        "T21",
        "属性值",
        186,
        191,
        "174.1"
      ],
      [
        "T22",
        "属性值",
        192,
        199,
        "127.5亿元"
      ],
      [
        "T23",
        "归母净利润",
        177,
        180,
        "净利润"
      ],
      [
        "T24",
        "时间范围",
        227,
        229,
        "Q3"
      ],
      [
        "T25",
        "业绩",
        232,
        234,
        "业绩"
      ],
      [
        "T26",
        "属性值",
        234,
        238,
        "有所承压"
      ],
      [
        "T27",
        "毛利",
        244,
        247,
        "毛利率"
      ],
      [
        "T28",
        "属性值",
        247,
        260,
        "58.6%（-4.9pp）"
      ],
      [
        "T29",
        "行业",
        304,
        306,
        "器械"
      ],
      [
        "T30",
        "行业",
        339,
        343,
        "医用耗材"
      ],
      [
        "T31",
        "行业",
        357,
        360,
        "IVD"
      ],
      [
        "T32",
        "行业",
        361,
        363,
        "设备"
      ],
      [
        "T33",
        "行业",
        560,
        562,
        "器械"
      ],
      [
        "T34",
        "时间范围",
        598,
        603,
        "过去10年"
      ],
      [
        "T35",
        "地点范围",
        629,
        631,
        "中国"
      ],
      [
        "T36",
        "行业",
        631,
        633,
        "器械"
      ],
      [
        "T37",
        "市场规模",
        633,
        637,
        "市场规模"
      ],
      [
        "T38",
        "属性值",
        637,
        644,
        "突破6000亿"
      ],
      [
        "T39",
        "时间范围",
        707,
        723,
        "未来10年（2020~2030）"
      ],
      [
        "T40",
        "行业",
        813,
        815,
        "器械"
      ],
      [
        "T41",
        "行业",
        885,
        887,
        "器械"
      ],
      [
        "T42",
        "行业",
        918,
        922,
        "TAVR"
      ],
      [
        "T43",
        "公司",
        923,
        927,
        "启明医疗"
      ],
      [
        "T44",
        "公司",
        928,
        932,
        "佰仁医疗"
      ],
      [
        "T45",
        "行业",
        934,
        937,
        "电生理"
      ],
      [
        "T46",
        "行业",
        938,
        944,
        "外周血管介入"
      ],
      [
        "T47",
        "公司",
        945,
        949,
        "心脉医疗"
      ],
      [
        "T48",
        "行业",
        951,
        956,
        "手术机器人"
      ],
      [
        "T49",
        "公司",
        957,
        964,
        "微创医疗机器人"
      ],
      [
        "T50",
        "行业",
        966,
        968,
        "眼科"
      ],
      [
        "T51",
        "公司",
        969,
        973,
        "爱博医疗"
      ],
      [
        "T52",
        "公司",
        974,
        979,
        "欧普康视 "
      ],
      [
        "T53",
        "行业",
        989,
        991,
        "影像"
      ],
      [
        "T54",
        "公司",
        994,
        998,
        "万东医疗"
      ],
      [
        "T55",
        "行业",
        1000,
        1003,
        "内窥镜"
      ],
      [
        "T56",
        "公司",
        1004,
        1008,
        "开立医疗"
      ],
      [
        "T57",
        "公司",
        1009,
        1013,
        "南微医学"
      ],
      [
        "T58",
        "行业",
        1016,
        1019,
        "IVD"
      ],
      [
        "T59",
        "公司",
        1022,
        1026,
        "迈瑞医疗"
      ],
      [
        "T60",
        "公司",
        1045,
        1048,
        "东富龙"
      ],
      [
        "T61",
        "公司",
        1049,
        1053,
        "楚天科技"
      ],
      [
        "T62",
        "行业",
        1040,
        1044,
        "药机设备"
      ],
      [
        "T63",
        "行业",
        1055,
        1060,
        "药房自动化"
      ],
      [
        "T64",
        "公司",
        1061,
        1065,
        "健麾信息"
      ],
      [
        "T65",
        "行业",
        1067,
        1073,
        "耗材生产设备"
      ],
      [
        "T66",
        "公司",
        1074,
        1078,
        "迈得医疗"
      ],
      [
        "T67",
        "公司",
        1090,
        1094,
        "迈瑞医疗"
      ],
      [
        "T68",
        "公司",
        1095,
        1099,
        "南微医学"
      ],
      [
        "T69",
        "行业",
        1101,
        1105,
        "家用器械"
      ],
      [
        "T70",
        "公司",
        1106,
        1110,
        "鱼跃医疗"
      ],
      [
        "T71",
        "行业公司",
        21,
        28,
        "83家样本公司"
      ],
      [
        "T72",
        "属性值",
        64,
        77,
        "487亿元（+26.8%）"
      ],
      [
        "T73",
        "属性值",
        100,
        103,
        "32%"
      ],
      [
        "T74",
        "归母净利润",
        96,
        99,
        "净利率"
      ],
      [
        "T75",
        "归母净利润",
        284,
        287,
        "净利率"
      ],
      [
        "T76",
        "属性值",
        287,
        300,
        "26.9%（-2.1pp）"
      ],
      [
        "T77",
        "行业需求",
        645,
        648,
        "需求端"
      ],
      [
        "T78",
        "属性值",
        648,
        652,
        "消费升级"
      ],
      [
        "T79",
        "竞争格局",
        746,
        750,
        "竞争格局"
      ],
      [
        "T80",
        "行业",
        840,
        842,
        "器械"
      ],
      [
        "T81",
        "行业",
        894,
        898,
        "器械上游"
      ],
      [
        "T82",
        "行业",
        899,
        903,
        "下游出海"
      ],
      [
        "T83",
        "时间范围",
        239,
        241,
        "Q3"
      ],
      [
        "T84",
        "行业",
        1082,
        1087,
        "出海国际化"
      ]
    ]
  },
  {
    "id": 3685,
    "text": "中国造纸行业集中度 CR10 逐年提升",
    "labels": [
      [
        "T0",
        "地点范围",
        0,
        2,
        "中国"
      ],
      [
        "T1",
        "行业",
        2,
        4,
        "造纸"
      ],
      [
        "T2",
        "市场集中度",
        6,
        9,
        "集中度"
      ],
      [
        "T3",
        "CR10",
        10,
        14,
        "CR10"
      ],
      [
        "T4",
        "属性值",
        15,
        19,
        "逐年提升"
      ]
    ]
  },
  {
    "id": 3686,
    "text": "双碳”目标稳步推进，“双控”政策加码，龙头企业将在行业整合“长跑”中胜出。环保政策促进行业加速整合，龙头市占率进一步提升，2010 年以来，环保政策落地实施后，造纸行业的 CR10 从 2012 年的 28.7%逐步上升到 2019 年的 45.7%。横向对比，美国造纸行业在经历环保立法去产能及行业并购之后，CR10 达 90%左右。中长期来看，产业和能源结构的调整势在必行，预期行业供给端格局的整合步伐都将加速。产业链布局完善、拥有自备电厂、前瞻利用清洁能源、技术优势领先、符合 ESG 标准的龙头纸企，将在行业整合“长跑”中胜出。此外，根据中国造纸年鉴，2015-2020 年我国特种纸产量 CAGR 为 8.9%，下游消费升级推动下特种纸整体需求将维持高增，仙鹤、华旺等细分龙头值得关注。",
    "labels": [
      [
        "T0",
        "时间范围",
        61,
        69,
        "2010 年以来"
      ],
      [
        "T1",
        "市场份额",
        52,
        55,
        "市占率"
      ],
      [
        "T2",
        "行业",
        80,
        82,
        "造纸"
      ],
      [
        "T3",
        "CR10",
        86,
        90,
        "CR10"
      ],
      [
        "T4",
        "时间范围",
        92,
        99,
        " 2012 年"
      ],
      [
        "T5",
        "属性值",
        101,
        106,
        "28.7%"
      ],
      [
        "T6",
        "时间范围",
        112,
        118,
        "2019 年"
      ],
      [
        "T7",
        "属性值",
        120,
        125,
        "45.7%"
      ],
      [
        "T8",
        "地点范围",
        131,
        133,
        "美国"
      ],
      [
        "T9",
        "行业",
        133,
        135,
        "造纸"
      ],
      [
        "T10",
        "CR10",
        155,
        159,
        "CR10"
      ],
      [
        "T11",
        "属性值",
        162,
        167,
        "90%左右"
      ],
      [
        "T12",
        "时间范围",
        168,
        171,
        "中长期"
      ],
      [
        "T13",
        "行业供给",
        193,
        196,
        "供给端"
      ],
      [
        "T14",
        "地点范围",
        273,
        275,
        "中国"
      ],
      [
        "T15",
        "行业",
        275,
        277,
        "造纸"
      ],
      [
        "T16",
        "时间范围",
        280,
        291,
        "2015-2020 年"
      ],
      [
        "T17",
        "地点范围",
        291,
        293,
        "我国"
      ],
      [
        "T18",
        "行业",
        293,
        296,
        "特种纸"
      ],
      [
        "T19",
        "CAGR",
        299,
        303,
        "CAGR"
      ],
      [
        "T20",
        "属性值",
        306,
        310,
        "8.9%"
      ],
      [
        "T21",
        "属性值",
        296,
        298,
        "产量"
      ],
      [
        "T22",
        "行业",
        320,
        323,
        "特种纸"
      ],
      [
        "T23",
        "行业需求",
        325,
        327,
        "需求"
      ],
      [
        "T24",
        "属性值",
        328,
        332,
        "维持高增"
      ],
      [
        "T25",
        "公司",
        333,
        335,
        "仙鹤"
      ],
      [
        "T26",
        "公司",
        336,
        338,
        "华旺"
      ],
      [
        "T27",
        "行业公司",
        251,
        253,
        "纸企"
      ]
    ]
  },
  {
    "id": 3687,
    "text": "1）高景气：投融资景气奠定超额基础。2014-2015 年开启免疫治疗时代，2017-2018 年开启细胞和基因治疗时代直接推动投融资高增长，奠定临床 CRO超额收益基础。2023-2025 年 AI 制药、异体 CAR-T 以及细胞治疗药物在实体瘤突破、基因治疗药物在大病领域突破迎来新一轮的投融资高峰期，为 CXO业绩持续增长提供需求来源。2）高集中度：临床 CRO 集中度高于药企。从集中度角度来看，2016-2020 年全球处方药销售额 CR5 维持在 17%-19%，对于临床 CRO 来讲，头部 5 家市占率已经接近 50%，这也意味着竞争壁垒较高。丰富的管理经验以及与医院（尤其是 PI）建立的紧密合作关系是临床 CRO 行业短期较难突破的壁垒所在。3）高壁垒：临床 CRO 相比下游格局更优。CXO出现大幅降低创新药物研发壁垒，然而临床 CRO 的服务壁垒并没有显著降低，我们认为恰恰相反的是壁垒在不断强化。这一点可以从 2016-2020 年临床 CRO企业临床服务业务市占率持续提升可以得到验证。",
    "labels": [
      [
        "T0",
        "时间范围",
        18,
        29,
        "2014-2015 年"
      ],
      [
        "T1",
        "投融资情况",
        6,
        9,
        "投融资"
      ],
      [
        "T2",
        "时间范围",
        38,
        49,
        "2017-2018 年"
      ],
      [
        "T3",
        "行业",
        73,
        79,
        "临床 CRO"
      ],
      [
        "T4",
        "时间范围",
        86,
        97,
        "2023-2025 年"
      ],
      [
        "T5",
        "行业",
        135,
        137,
        "大病"
      ],
      [
        "T6",
        "投融资情况",
        64,
        67,
        "投融资"
      ],
      [
        "T7",
        "属性值",
        67,
        70,
        "高增长"
      ],
      [
        "T8",
        "行业",
        156,
        159,
        "CXO"
      ],
      [
        "T9",
        "业绩",
        159,
        161,
        "业绩"
      ],
      [
        "T10",
        "属性值",
        161,
        165,
        "持续增长"
      ],
      [
        "T11",
        "行业",
        179,
        185,
        "临床 CRO"
      ],
      [
        "T12",
        "市场集中度",
        186,
        189,
        "集中度"
      ],
      [
        "T13",
        "属性值",
        189,
        193,
        "高于药企"
      ],
      [
        "T14",
        "市场集中度",
        195,
        198,
        "集中度"
      ],
      [
        "T15",
        "时间范围",
        203,
        214,
        "2016-2020 年"
      ],
      [
        "T16",
        "地点范围",
        214,
        216,
        "全球"
      ],
      [
        "T17",
        "行业",
        216,
        219,
        "处方药"
      ],
      [
        "T18",
        "CR5",
        223,
        226,
        "CR5"
      ],
      [
        "T19",
        "属性值",
        231,
        238,
        "17%-19%"
      ],
      [
        "T20",
        "行业",
        241,
        248,
        "临床 CRO "
      ],
      [
        "T21",
        "属性值",
        262,
        268,
        "接近 50%"
      ],
      [
        "T22",
        "市场份额",
        257,
        260,
        "市占率"
      ],
      [
        "T23",
        "行业",
        311,
        317,
        "临床 CRO"
      ],
      [
        "T24",
        "行业",
        338,
        344,
        "临床 CRO"
      ],
      [
        "T25",
        "竞争格局",
        349,
        351,
        "格局"
      ],
      [
        "T26",
        "属性值",
        351,
        353,
        "更优"
      ],
      [
        "T27",
        "行业",
        354,
        357,
        "CXO"
      ],
      [
        "T28",
        "行业",
        374,
        380,
        "临床 CRO"
      ],
      [
        "T29",
        "时间范围",
        419,
        430,
        "2016-2020 年"
      ],
      [
        "T30",
        "行业公司",
        430,
        438,
        "临床 CRO企业"
      ],
      [
        "T31",
        "行业",
        438,
        442,
        "临床服务"
      ],
      [
        "T32",
        "市场份额",
        444,
        447,
        "市占率"
      ],
      [
        "T33",
        "属性值",
        447,
        451,
        "持续提升"
      ]
    ]
  },
  {
    "id": 3688,
    "text": "行业集中度提升趋势下，关注具备一体化包装解决能力的龙头企业。根据中国包装联合会数据，我国纸和纸板容器行业规模以上企业数量经历了先减后增的变化，自2017 年探底上行至 2020 年 2510 家。从营业收入来看，截至 2020 年，我国纸包装行业中小企业占比超 60%，近 5 年 CR5 营收占比逐年提升，但行业整体集中度较低。对比海外成熟市场，根据世界包装组织数据，美国前四大企业市场份额达 70%以上，澳洲前两大纸包装企业市占率超过 90%。在制造能力壁垒提升、头部企业产能加速扩张、供给端环保趋严的背景下，龙头企业市场份额有望进一步提升，我国包装行业竞争格局将加速优化。",
    "labels": [
      [
        "T0",
        "地点范围",
        32,
        34,
        "中国"
      ],
      [
        "T1",
        "地点范围",
        42,
        44,
        "我国"
      ],
      [
        "T2",
        "行业公司",
        44,
        58,
        "纸和纸板容器行业规模以上企业"
      ],
      [
        "T3",
        "时间范围",
        71,
        78,
        "自2017 年"
      ],
      [
        "T4",
        "时间范围",
        84,
        90,
        "2020 年"
      ],
      [
        "T5",
        "营业收入",
        99,
        103,
        "营业收入"
      ],
      [
        "T6",
        "时间范围",
        106,
        115,
        "截至 2020 年"
      ],
      [
        "T7",
        "地点范围",
        116,
        118,
        "我国"
      ],
      [
        "T8",
        "行业",
        118,
        121,
        "纸包装"
      ],
      [
        "T9",
        "时间范围",
        135,
        140,
        "近 5 年"
      ],
      [
        "T10",
        "CR5",
        141,
        144,
        "CR5"
      ],
      [
        "T11",
        "营收占比",
        145,
        149,
        "营收占比"
      ],
      [
        "T12",
        "属性值",
        149,
        153,
        "逐年提升"
      ],
      [
        "T13",
        "市场集中度",
        159,
        162,
        "集中度"
      ],
      [
        "T14",
        "属性值",
        162,
        164,
        "较低"
      ],
      [
        "T15",
        "地点范围",
        167,
        169,
        "海外"
      ],
      [
        "T16",
        "地点范围",
        185,
        187,
        "美国"
      ],
      [
        "T17",
        "市场份额",
        192,
        196,
        "市场份额"
      ],
      [
        "T18",
        "地点范围",
        204,
        206,
        "澳洲"
      ],
      [
        "T19",
        "行业公司",
        206,
        214,
        "前两大纸包装企业"
      ],
      [
        "T20",
        "市场份额",
        214,
        217,
        "市占率"
      ],
      [
        "T21",
        "属性值",
        217,
        223,
        "超过 90%"
      ],
      [
        "T22",
        "产能",
        238,
        240,
        "产能"
      ],
      [
        "T23",
        "行业供给",
        245,
        248,
        "供给端"
      ],
      [
        "T24",
        "市场份额",
        261,
        265,
        "市场份额"
      ],
      [
        "T25",
        "地点范围",
        273,
        275,
        "我国"
      ],
      [
        "T26",
        "行业",
        275,
        277,
        "包装"
      ],
      [
        "T27",
        "竞争格局",
        279,
        283,
        "竞争格局"
      ],
      [
        "T28",
        "属性值",
        284,
        288,
        "加速优化"
      ]
    ]
  },
  {
    "id": 3689,
    "text": "横纵角度对比，中国体育服饰行业集中度均处于高位。纵向对比体育服饰和服装行业整体集中度，2020 年体育服饰行业 CR5 已达 70.7%，远高于服装行业整体 10.4%的水平。横向对比同期其他海外成熟市场集中度，中国 CR5 也明显高于美国 34.1%、英国 48.9%、日本 47.8%的水平。整体来看，中国体育服饰市场马太效应显著，市场集中度处于高位。",
    "labels": [
      [
        "T0",
        "地点范围",
        7,
        9,
        "中国"
      ],
      [
        "T1",
        "行业",
        9,
        13,
        "体育服饰"
      ],
      [
        "T2",
        "市场集中度",
        15,
        18,
        "集中度"
      ],
      [
        "T3",
        "属性值",
        19,
        23,
        "处于高位"
      ],
      [
        "T4",
        "行业",
        28,
        32,
        "体育服饰"
      ],
      [
        "T5",
        "行业",
        33,
        35,
        "服装"
      ],
      [
        "T6",
        "市场集中度",
        39,
        42,
        "集中度"
      ],
      [
        "T7",
        "时间范围",
        43,
        49,
        "2020 年"
      ],
      [
        "T8",
        "行业",
        49,
        53,
        "体育服饰"
      ],
      [
        "T9",
        "CR5",
        56,
        59,
        "CR5"
      ],
      [
        "T10",
        "属性值",
        63,
        68,
        "70.7%"
      ],
      [
        "T11",
        "行业",
        72,
        74,
        "服装"
      ],
      [
        "T12",
        "属性值",
        79,
        84,
        "10.4%"
      ],
      [
        "T13",
        "行业",
        96,
        98,
        "海外"
      ],
      [
        "T14",
        "市场集中度",
        102,
        105,
        "集中度"
      ],
      [
        "T15",
        "地点范围",
        106,
        108,
        "中国"
      ],
      [
        "T16",
        "CR5",
        109,
        112,
        "CR5"
      ],
      [
        "T17",
        "地点范围",
        118,
        120,
        "美国"
      ],
      [
        "T18",
        "地点范围",
        127,
        129,
        "英国"
      ],
      [
        "T19",
        "地点范围",
        136,
        138,
        "日本"
      ],
      [
        "T20",
        "地点范围",
        153,
        155,
        "中国"
      ],
      [
        "T21",
        "行业",
        155,
        159,
        "体育服饰"
      ],
      [
        "T22",
        "市场集中度",
        168,
        173,
        "市场集中度"
      ],
      [
        "T23",
        "属性值",
        173,
        177,
        "处于高位"
      ]
    ]
  },
  {
    "id": 3690,
    "text": "历经近百年的发展，美国家具市场已经步入相对成熟阶段，整体市场的集中度较高。截止 2018 年美国家具行业 CR5 达到 20.4%，CR10 达到 32.3%，CR25 达到 47.6%，这一水平相较于 2015 年就已经实现的 CR5 19.10%的水平而言变化不大。",
    "labels": [
      [
        "T0",
        "地点范围",
        9,
        11,
        "美国"
      ],
      [
        "T1",
        "行业",
        11,
        13,
        "家具"
      ],
      [
        "T2",
        "市场集中度",
        31,
        34,
        "集中度"
      ],
      [
        "T3",
        "属性值",
        34,
        36,
        "较高"
      ],
      [
        "T4",
        "时间范围",
        37,
        46,
        "截止 2018 年"
      ],
      [
        "T5",
        "地点范围",
        46,
        48,
        "美国"
      ],
      [
        "T6",
        "行业",
        48,
        50,
        "家具"
      ],
      [
        "T7",
        "CR5",
        53,
        57,
        "CR5 "
      ],
      [
        "T8",
        "属性值",
        60,
        65,
        "20.4%"
      ],
      [
        "T9",
        "CR10",
        66,
        70,
        "CR10"
      ],
      [
        "T10",
        "属性值",
        74,
        79,
        "32.3%"
      ],
      [
        "T11",
        "时间范围",
        102,
        108,
        "2015 年"
      ],
      [
        "T12",
        "CR5",
        115,
        118,
        "CR5"
      ],
      [
        "T13",
        "属性值",
        119,
        125,
        "19.10%"
      ]
    ]
  },
  {
    "id": 3692,
    "text": "中美市场集中度差异显著：美国市场 CR10 占据 7 成以上份额。",
    "labels": [
      [
        "T0",
        "地点范围",
        0,
        2,
        "中美"
      ],
      [
        "T1",
        "市场集中度",
        2,
        7,
        "市场集中度"
      ],
      [
        "T2",
        "地点范围",
        12,
        14,
        "美国"
      ],
      [
        "T3",
        "CR10",
        17,
        21,
        "CR10"
      ]
    ]
  },
  {
    "id": 3693,
    "text": "从 2016-2020 年来看，美国零担市场平均 CR5、CR10、CR25 分别达到 48.9%、72.5%、90.7%，2000 年美国 CR10 为 55%（按照收入计算），意味着 2000 年后美国集中度出现了持续提升，其中联邦快递以 17.5%的份额位居头名。",
    "labels": [
      [
        "T0",
        "时间范围",
        2,
        13,
        "2016-2020 年"
      ],
      [
        "T1",
        "地点范围",
        16,
        18,
        "美国"
      ],
      [
        "T2",
        "行业",
        18,
        20,
        "零担"
      ],
      [
        "T3",
        "CR5",
        25,
        28,
        "CR5"
      ],
      [
        "T4",
        "CR10",
        29,
        33,
        "CR10"
      ],
      [
        "T5",
        "属性值",
        44,
        49,
        "48.9%"
      ],
      [
        "T6",
        "属性值",
        50,
        55,
        "72.5%"
      ],
      [
        "T7",
        "时间范围",
        62,
        68,
        "2000 年"
      ],
      [
        "T8",
        "地点范围",
        68,
        70,
        "美国"
      ],
      [
        "T9",
        "CR10",
        71,
        75,
        "CR10"
      ],
      [
        "T10",
        "属性值",
        78,
        81,
        "55%"
      ],
      [
        "T11",
        "时间范围",
        94,
        101,
        "2000 年后"
      ],
      [
        "T12",
        "地点范围",
        101,
        103,
        "美国"
      ],
      [
        "T13",
        "市场集中度",
        103,
        106,
        "集中度"
      ],
      [
        "T14",
        "属性值",
        109,
        113,
        "持续提升"
      ],
      [
        "T15",
        "公司",
        116,
        120,
        "联邦快递"
      ],
      [
        "T16",
        "属性值",
        122,
        127,
        "17.5%"
      ],
      [
        "T17",
        "市场份额",
        128,
        130,
        "份额"
      ]
    ]
  },
  {
    "id": 3694,
    "text": "反观我国零担行业 CR10 占比不到 5%，市场呈现高度分散。国内零担市场的分散主要由于其产品特性决定，从业行业门槛较低，尤其对于区域及专线型企业而言。众多个体物流商或车主可以凭借绑定 1-2 个地方企业获得一定的合同订单经营特定线路。此外，零担货运主要连接服务 B 端客户，相较于快递对于服务质量（时效性、货损率等）的要求较低，中小型物流商能够在低价市场生存。",
    "labels": [
      [
        "T0",
        "地点范围",
        2,
        4,
        "我国"
      ],
      [
        "T1",
        "行业",
        4,
        6,
        "零担"
      ],
      [
        "T2",
        "CR10",
        9,
        13,
        "CR10"
      ],
      [
        "T3",
        "属性值",
        16,
        21,
        "不到 5%"
      ],
      [
        "T4",
        "属性值",
        26,
        30,
        "高度分散"
      ],
      [
        "T5",
        "地点范围",
        31,
        33,
        "国内"
      ],
      [
        "T6",
        "行业",
        33,
        35,
        "零担"
      ],
      [
        "T7",
        "属性值",
        52,
        60,
        "从业行业门槛较低"
      ],
      [
        "T8",
        "行业",
        121,
        125,
        "零担货运"
      ],
      [
        "T9",
        "行业",
        141,
        143,
        "快递"
      ],
      [
        "T10",
        "属性值",
        143,
        164,
        "对于服务质量（时效性、货损率等）的要求较低"
      ],
      [
        "T11",
        "属性值",
        38,
        40,
        "分散"
      ]
    ]
  },
  {
    "id": 3695,
    "text": "医药行业重仓市值3085.93亿：2021Q4，主动偏股型基金重仓医药行业的市值为3085.93亿元，较上个季度下降13.92%；主动偏股型基金重仓医药行业的CR5、CR10、CR20的公司的合计比重分别为48.08%、64.9%、79.31%，较上个季度分别下滑2.81pcts、下滑6.23pcts、下滑5.27pcts，环比上个季度持股集中度有所下降；本季度重仓的前5大公司分别为药明康德（516.86亿元）、迈瑞医疗（409.31亿元）、凯莱英（228.02亿元）、爱尔眼科（185.2亿元）、泰格医药（144.41亿元）。",
    "labels": [
      [
        "T0",
        "行业",
        0,
        2,
        "医药"
      ],
      [
        "T1",
        "时间范围",
        17,
        23,
        "2021Q4"
      ],
      [
        "T2",
        "行业",
        33,
        35,
        "医药"
      ],
      [
        "T3",
        "市值",
        38,
        40,
        "市值"
      ],
      [
        "T4",
        "行业",
        74,
        76,
        "医药"
      ],
      [
        "T5",
        "CR5",
        79,
        82,
        "CR5"
      ],
      [
        "T6",
        "CR10",
        83,
        87,
        "CR10"
      ],
      [
        "T7",
        "公司",
        193,
        197,
        "药明康德"
      ],
      [
        "T8",
        "公司",
        208,
        212,
        "迈瑞医疗"
      ],
      [
        "T9",
        "公司",
        223,
        226,
        "凯莱英"
      ],
      [
        "T10",
        "公司",
        237,
        241,
        "爱尔眼科"
      ],
      [
        "T11",
        "公司",
        251,
        255,
        "泰格医药"
      ],
      [
        "T12",
        "市值",
        6,
        8,
        "市值"
      ]
    ]
  },
  {
    "id": 3696,
    "text": "中国内陆珠宝行业竞争格局分散，龙头品牌有较大提升空间。2013 年后的珠宝消费低迷期，内陆珠宝行业集中度曾持续下滑，2017 年行业集中度开始回升，CR5 从 2016年的 14.3%提升到 2019 年的 19.4%。虽然我国珠宝市场 CR5 的集中度高于美国市场，但相较于香港市场 45.8%和日本 28.4%的集中度而言，仍有较大的提升空间。",
    "labels": [
      [
        "T0",
        "地点范围",
        0,
        4,
        "中国内陆"
      ],
      [
        "T1",
        "行业",
        4,
        6,
        "珠宝"
      ],
      [
        "T2",
        "竞争格局",
        8,
        12,
        "竞争格局"
      ],
      [
        "T3",
        "属性值",
        12,
        14,
        "分散"
      ],
      [
        "T4",
        "时间范围",
        27,
        34,
        "2013 年后"
      ],
      [
        "T5",
        "行业",
        35,
        37,
        "珠宝"
      ],
      [
        "T6",
        "地点范围",
        43,
        45,
        "内陆"
      ],
      [
        "T7",
        "行业",
        45,
        47,
        "珠宝"
      ],
      [
        "T8",
        "市场集中度",
        49,
        52,
        "集中度"
      ],
      [
        "T9",
        "属性值",
        53,
        57,
        "持续下滑"
      ],
      [
        "T10",
        "时间范围",
        58,
        64,
        "2017 年"
      ],
      [
        "T11",
        "市场集中度",
        64,
        69,
        "行业集中度"
      ],
      [
        "T12",
        "属性值",
        71,
        73,
        "回升"
      ],
      [
        "T13",
        "CR5",
        74,
        77,
        "CR5"
      ],
      [
        "T14",
        "时间范围",
        80,
        85,
        "2016年"
      ],
      [
        "T15",
        "属性值",
        87,
        92,
        "14.3%"
      ],
      [
        "T16",
        "时间范围",
        96,
        102,
        "2019 年"
      ],
      [
        "T17",
        "属性值",
        104,
        109,
        "19.4%"
      ],
      [
        "T18",
        "地点范围",
        112,
        114,
        "我国"
      ],
      [
        "T19",
        "行业",
        114,
        116,
        "珠宝"
      ],
      [
        "T20",
        "CR5",
        119,
        122,
        "CR5"
      ],
      [
        "T21",
        "市场集中度",
        124,
        127,
        "集中度"
      ],
      [
        "T22",
        "属性值",
        127,
        133,
        "高于美国市场"
      ],
      [
        "T23",
        "地点范围",
        138,
        140,
        "香港"
      ],
      [
        "T24",
        "属性值",
        143,
        148,
        "45.8%"
      ],
      [
        "T25",
        "地点范围",
        149,
        151,
        "日本"
      ],
      [
        "T26",
        "属性值",
        152,
        157,
        "28.4%"
      ],
      [
        "T27",
        "属性值",
        165,
        173,
        "有较大的提升空间"
      ]
    ]
  },
  {
    "id": 3698,
    "text": "包装榨菜市场集中度显著提升，涪陵榨菜市占率稳居第一。从市场竞争格局来看，我国包装榨菜市场集中度显著提升，CR5从2008年的46.15%提升至2019年的72.24%，集中度持续提升。涪陵榨菜市占率长期处于行业第一，从2008年的21%提升至2019年的36%。我们认为随着竞争加剧以及头部企业在品牌和渠道的优势，行业集中度有望进一步提升，涪陵榨菜市占率也有望提升。",
    "labels": [
      [
        "T0",
        "行业",
        0,
        4,
        "包装榨菜"
      ],
      [
        "T1",
        "市场集中度",
        4,
        9,
        "市场集中度"
      ],
      [
        "T2",
        "属性值",
        9,
        13,
        "显著提升"
      ],
      [
        "T3",
        "公司",
        14,
        18,
        "涪陵榨菜"
      ],
      [
        "T4",
        "市场份额",
        18,
        21,
        "市占率"
      ],
      [
        "T5",
        "属性值",
        21,
        25,
        "稳居第一"
      ],
      [
        "T6",
        "竞争格局",
        29,
        33,
        "竞争格局"
      ],
      [
        "T7",
        "地点范围",
        36,
        38,
        "我国"
      ],
      [
        "T8",
        "行业",
        38,
        42,
        "包装榨菜"
      ],
      [
        "T9",
        "市场集中度",
        42,
        47,
        "市场集中度"
      ],
      [
        "T10",
        "属性值",
        47,
        51,
        "显著提升"
      ],
      [
        "T11",
        "CR5",
        52,
        55,
        "CR5"
      ],
      [
        "T12",
        "时间范围",
        56,
        61,
        "2008年"
      ],
      [
        "T13",
        "属性值",
        62,
        68,
        "46.15%"
      ],
      [
        "T14",
        "时间范围",
        71,
        76,
        "2019年"
      ],
      [
        "T15",
        "属性值",
        77,
        83,
        "72.24%"
      ],
      [
        "T16",
        "市场集中度",
        84,
        87,
        "集中度"
      ],
      [
        "T17",
        "属性值",
        87,
        91,
        "持续提升"
      ],
      [
        "T18",
        "公司",
        92,
        96,
        "涪陵榨菜"
      ],
      [
        "T19",
        "市场份额",
        96,
        99,
        "市占率"
      ],
      [
        "T20",
        "属性值",
        103,
        107,
        "行业第一"
      ],
      [
        "T21",
        "时间范围",
        109,
        114,
        "2008年"
      ],
      [
        "T22",
        "属性值",
        115,
        118,
        "21%"
      ],
      [
        "T23",
        "时间范围",
        121,
        126,
        "2019年"
      ],
      [
        "T24",
        "属性值",
        127,
        130,
        "36%"
      ],
      [
        "T25",
        "市场集中度",
        159,
        162,
        "集中度"
      ],
      [
        "T26",
        "公司",
        170,
        174,
        "涪陵榨菜"
      ],
      [
        "T27",
        "市场份额",
        174,
        177,
        "市占率"
      ],
      [
        "T28",
        "属性值",
        178,
        182,
        "有望提升"
      ]
    ]
  },
  {
    "id": 3699,
    "text": "中国：2008-2013 年，地产行业集中度在波动中缓慢微升；与 2010 年相比，2013 年总资产口径下的 CR10 由 4.8%提升 0.8pct 至 5.7%，销售金额口径下的 CR10 由 10.1%提升 3.6pct至 13.7%。2014-2018 年，行业先后迎来货币和行业政策宽松周期，以及三四线城市棚改货币化的红利，行业处于销售景气度高点，集中度提升显著；在 2018 年行业集中度高点，总资产口径下的 CR10 较 2013 年提升 5.0pct 至 10.6%，销售金额口径下的 CR10 则来到了26.9%。2019 年以来，受疫情冲击，行业集中度相对稳定；2021H1，总资产口径下的 CR5、CR10、CR30、CR50 分别为 5.6%、10.2%、18.8%、22.8%，销售金额口径下则分别来到 18.0%、27.0%、45.9%、55.6%",
    "labels": [
      [
        "T0",
        "地点范围",
        0,
        2,
        "中国"
      ],
      [
        "T1",
        "时间范围",
        3,
        14,
        "2008-2013 年"
      ],
      [
        "T2",
        "行业",
        15,
        17,
        "地产"
      ],
      [
        "T3",
        "属性值",
        23,
        30,
        "波动中缓慢微升"
      ],
      [
        "T4",
        "时间范围",
        33,
        39,
        "2010 年"
      ],
      [
        "T5",
        "时间范围",
        42,
        48,
        "2013 年"
      ],
      [
        "T6",
        "CR10",
        56,
        60,
        "CR10"
      ],
      [
        "T7",
        "属性值",
        63,
        67,
        "4.8%"
      ],
      [
        "T8",
        "属性值",
        79,
        83,
        "5.7%"
      ],
      [
        "T9",
        "CR10",
        93,
        97,
        "CR10"
      ],
      [
        "T10",
        "属性值",
        100,
        105,
        "10.1%"
      ],
      [
        "T11",
        "属性值",
        116,
        121,
        "13.7%"
      ],
      [
        "T12",
        "时间范围",
        122,
        133,
        "2014-2018 年"
      ],
      [
        "T13",
        "市场集中度",
        180,
        183,
        "集中度"
      ],
      [
        "T14",
        "属性值",
        183,
        187,
        "提升显著"
      ],
      [
        "T15",
        "时间范围",
        190,
        196,
        "2018 年"
      ],
      [
        "T16",
        "市场集中度",
        196,
        201,
        "行业集中度"
      ],
      [
        "T17",
        "市场集中度",
        17,
        22,
        "行业集中度"
      ],
      [
        "T18",
        "CR10",
        212,
        216,
        "CR10"
      ],
      [
        "T19",
        "时间范围",
        219,
        225,
        "2013 年"
      ],
      [
        "T20",
        "属性值",
        237,
        242,
        "10.6%"
      ],
      [
        "T21",
        "时间范围",
        267,
        275,
        "2019 年以来"
      ],
      [
        "T22",
        "市场集中度",
        282,
        287,
        "行业集中度"
      ],
      [
        "T23",
        "属性值",
        287,
        291,
        "相对稳定"
      ],
      [
        "T24",
        "时间范围",
        292,
        298,
        "2021H1"
      ],
      [
        "T25",
        "CR5",
        307,
        310,
        "CR5"
      ],
      [
        "T26",
        "CR10",
        311,
        315,
        "CR10"
      ],
      [
        "T27",
        "属性值",
        330,
        334,
        "5.6%"
      ],
      [
        "T28",
        "属性值",
        335,
        340,
        "10.2%"
      ],
      [
        "T29",
        "属性值",
        201,
        203,
        "高点"
      ],
      [
        "T30",
        "属性值",
        366,
        371,
        "18.0%"
      ],
      [
        "T31",
        "属性值",
        372,
        377,
        "27.0%"
      ]
    ]
  },
  {
    "id": 3700,
    "text": "我们选取了便利店、酒店、药店、轻饮食、服装、健身房、汽车后市场、早教、体检机构、电影院等业态继续比较梳理，发现行业共性与特性：从盈利能力来看，运动服装和连锁酒店盈利能力较强。选取各业态部分上市公司为代表做对比，运动服装行业销售毛利率可达40%-50%，净利率为7-17%，连锁酒店行业销售毛利率范围较大为30%-90%，净利率达8%-16%，盈利能力较强。从市场集中度来看，便利店和体检机构集中度较高，药店和轻饮食市场格局分散。便利店和体检机构较集中，CR3分别为51%和39%，而连锁药店CR10仅为20%，轻饮食中热饮品行业CR5为15.7%，街边饮食为14.4%，简餐则更低，仅为10.9%。",
    "labels": [
      [
        "T0",
        "行业",
        71,
        75,
        "运动服装"
      ],
      [
        "T1",
        "行业",
        76,
        80,
        "连锁酒店"
      ],
      [
        "T2",
        "属性值",
        80,
        86,
        "盈利能力较强"
      ],
      [
        "T3",
        "行业",
        5,
        8,
        "便利店"
      ],
      [
        "T4",
        "行业",
        9,
        11,
        "酒店"
      ],
      [
        "T5",
        "行业",
        12,
        14,
        "药店"
      ],
      [
        "T6",
        "行业",
        15,
        18,
        "轻饮食"
      ],
      [
        "T7",
        "行业",
        19,
        21,
        "服装"
      ],
      [
        "T8",
        "行业",
        22,
        25,
        "健身房"
      ],
      [
        "T9",
        "行业",
        26,
        31,
        "汽车后市场"
      ],
      [
        "T10",
        "行业",
        32,
        34,
        "早教"
      ],
      [
        "T11",
        "行业",
        35,
        39,
        "体检机构"
      ],
      [
        "T12",
        "行业",
        40,
        43,
        "电影院"
      ],
      [
        "T13",
        "行业",
        105,
        109,
        "运动服装"
      ],
      [
        "T14",
        "归母净利润",
        126,
        129,
        "净利率"
      ],
      [
        "T15",
        "属性值",
        130,
        135,
        "7-17%"
      ],
      [
        "T16",
        "行业",
        136,
        140,
        "连锁酒店"
      ],
      [
        "T17",
        "归母净利润",
        160,
        163,
        "净利率"
      ],
      [
        "T18",
        "属性值",
        164,
        170,
        "8%-16%"
      ],
      [
        "T19",
        "市场集中度",
        179,
        184,
        "市场集中度"
      ],
      [
        "T20",
        "行业",
        187,
        190,
        "便利店"
      ],
      [
        "T21",
        "行业",
        191,
        195,
        "体检机构"
      ],
      [
        "T22",
        "市场集中度",
        195,
        198,
        "集中度"
      ],
      [
        "T23",
        "属性值",
        198,
        200,
        "较高"
      ],
      [
        "T24",
        "行业",
        201,
        203,
        "药店"
      ],
      [
        "T25",
        "行业",
        204,
        207,
        "轻饮食"
      ],
      [
        "T26",
        "竞争格局",
        209,
        211,
        "格局"
      ],
      [
        "T27",
        "属性值",
        211,
        213,
        "分散"
      ],
      [
        "T28",
        "行业",
        214,
        217,
        "便利店"
      ],
      [
        "T29",
        "行业",
        218,
        222,
        "体检机构"
      ],
      [
        "T30",
        "属性值",
        222,
        225,
        "较集中"
      ],
      [
        "T31",
        "行业",
        241,
        245,
        "连锁药店"
      ],
      [
        "T32",
        "CR10",
        245,
        249,
        "CR10"
      ],
      [
        "T33",
        "属性值",
        251,
        254,
        "20%"
      ],
      [
        "T34",
        "行业",
        255,
        258,
        "轻饮食"
      ],
      [
        "T35",
        "行业",
        259,
        262,
        "热饮品"
      ],
      [
        "T36",
        "CR5",
        264,
        267,
        "CR5"
      ],
      [
        "T37",
        "属性值",
        268,
        273,
        "15.7%"
      ],
      [
        "T38",
        "行业",
        274,
        278,
        "街边饮食"
      ],
      [
        "T39",
        "属性值",
        279,
        284,
        "14.4%"
      ],
      [
        "T40",
        "行业",
        285,
        287,
        "简餐"
      ],
      [
        "T41",
        "属性值",
        293,
        298,
        "10.9%"
      ],
      [
        "T42",
        "毛利",
        113,
        116,
        "毛利率"
      ],
      [
        "T43",
        "属性值",
        118,
        125,
        "40%-50%"
      ],
      [
        "T44",
        "毛利",
        144,
        147,
        "毛利率"
      ],
      [
        "T45",
        "属性值",
        152,
        159,
        "30%-90%"
      ]
    ]
  },
  {
    "id": 3701,
    "text": "软饮行业整体整体集中度较低，包装水行业CR3有望持续提升。根据弗若斯特沙利文数据，2019年软饮行业CR5为30.9%，其中农夫山泉实现营业收入624.0亿元，市占率为6.3%，排名第四。从细分品类来看，瓶装水、茶饮、功能饮料的市场集中度较高，CR5分别达56.2%、86.5%、56.8%，果汁的市场集中度最低，CR5仅有25.1%。",
    "labels": [
      [
        "T0",
        "行业",
        0,
        2,
        "软饮"
      ],
      [
        "T1",
        "市场集中度",
        8,
        11,
        "集中度"
      ],
      [
        "T2",
        "属性值",
        11,
        13,
        "较低"
      ],
      [
        "T3",
        "行业",
        14,
        17,
        "包装水"
      ],
      [
        "T4",
        "时间范围",
        41,
        46,
        "2019年"
      ],
      [
        "T5",
        "行业",
        46,
        48,
        "软饮"
      ],
      [
        "T6",
        "CR5",
        50,
        53,
        "CR5"
      ],
      [
        "T7",
        "属性值",
        54,
        59,
        "30.9%"
      ],
      [
        "T8",
        "公司",
        62,
        66,
        "农夫山泉"
      ],
      [
        "T9",
        "营业收入",
        68,
        72,
        "营业收入"
      ],
      [
        "T10",
        "属性值",
        72,
        79,
        "624.0亿元"
      ],
      [
        "T11",
        "市场份额",
        80,
        83,
        "市占率"
      ],
      [
        "T12",
        "属性值",
        84,
        88,
        "6.3%"
      ],
      [
        "T13",
        "行业",
        102,
        105,
        "瓶装水"
      ],
      [
        "T14",
        "行业",
        106,
        108,
        "茶饮"
      ],
      [
        "T15",
        "行业",
        109,
        113,
        "功能饮料"
      ],
      [
        "T16",
        "市场集中度",
        114,
        119,
        "市场集中度"
      ],
      [
        "T17",
        "属性值",
        119,
        121,
        "较高"
      ],
      [
        "T18",
        "CR5",
        122,
        125,
        "CR5"
      ],
      [
        "T19",
        "属性值",
        128,
        133,
        "56.2%"
      ],
      [
        "T20",
        "属性值",
        134,
        139,
        "86.5%"
      ],
      [
        "T21",
        "属性值",
        140,
        145,
        "56.8%"
      ],
      [
        "T22",
        "行业",
        146,
        148,
        "果汁"
      ],
      [
        "T23",
        "市场集中度",
        149,
        154,
        "市场集中度"
      ],
      [
        "T24",
        "属性值",
        154,
        156,
        "最低"
      ],
      [
        "T25",
        "CR5",
        157,
        160,
        "CR5"
      ],
      [
        "T26",
        "属性值",
        162,
        167,
        "25.1%"
      ]
    ]
  },
  {
    "id": 3703,
    "text": "近五年菲莫国际减害产品研发费用率达 8.0%，增量竞争阶段比重接近 10%。自 2017 年起，菲莫国际的对减害产品（RRPs）的研发费用占 RRPs 产品的营收的比率由维持在 5%-10%，早期在 2016 年公司 HNB 产品 IQOS 刚进入市场时研发费用率达到 42.1%。随着 2017 年 IQOS 爆发式增长，营收同比增长 396.6%至 36.4亿美元，减害产品研发费用率接近 10%。近两年随着日本 HNB 市场由增量竞争逐渐步入存量竞争，PMI 减害产品营收的快速增长使其研发费用率呈略微下降趋势，但减害产品的研发投入的绝对数额逐年增多，从 18 年的 3.4 亿美元提升至 21 年的6.1 亿美元，涨幅达到79.4%。此外，自 2016 年起菲莫国际将超过 70%的研发投入分配给新型烟草产品开发，该比例于 2018 年之后逐步上升至 99%。大量的的研发投入足见菲莫国际对推出新型烟草产品和达成无烟未来目标的信心及决心。",
    "labels": [
      [
        "T0",
        "时间范围",
        0,
        3,
        "近五年"
      ],
      [
        "T1",
        "公司",
        3,
        7,
        "菲莫国际"
      ],
      [
        "T2",
        "时间范围",
        38,
        47,
        "自 2017 年起"
      ],
      [
        "T3",
        "公司",
        48,
        52,
        "菲莫国际"
      ],
      [
        "T4",
        "时间范围",
        100,
        106,
        "2016 年"
      ],
      [
        "T5",
        "时间范围",
        144,
        150,
        "2017 年"
      ],
      [
        "T6",
        "营业收入",
        162,
        164,
        "营收"
      ],
      [
        "T7",
        "属性值",
        169,
        175,
        "396.6%"
      ],
      [
        "T8",
        "属性值",
        177,
        184,
        "36.4亿美元"
      ],
      [
        "T9",
        "时间范围",
        201,
        204,
        "近两年"
      ],
      [
        "T10",
        "营业收入",
        237,
        239,
        "营收"
      ],
      [
        "T11",
        "时间范围",
        281,
        285,
        "18 年"
      ],
      [
        "T12",
        "时间范围",
        298,
        302,
        "21 年"
      ],
      [
        "T13",
        "时间范围",
        326,
        332,
        "2016 年"
      ],
      [
        "T14",
        "公司",
        333,
        337,
        "菲莫国际"
      ],
      [
        "T15",
        "研发费用",
        345,
        349,
        "研发投入"
      ],
      [
        "T16",
        "时间范围",
        366,
        374,
        "2018 年之后"
      ],
      [
        "T17",
        "研发费用",
        388,
        392,
        "研发投入"
      ],
      [
        "T18",
        "公司",
        394,
        398,
        "菲莫国际"
      ],
      [
        "T19",
        "研发费用率",
        11,
        16,
        "研发费用率"
      ],
      [
        "T20",
        "行业",
        7,
        9,
        "减害"
      ],
      [
        "T21",
        "属性值",
        18,
        22,
        "8.0%"
      ],
      [
        "T22",
        "行业",
        54,
        56,
        "减害"
      ],
      [
        "T23",
        "行业",
        109,
        112,
        "HNB"
      ],
      [
        "T24",
        "研发费用率",
        127,
        132,
        "研发费用率"
      ],
      [
        "T25",
        "属性值",
        135,
        140,
        "42.1%"
      ],
      [
        "T26",
        "研发费用率",
        189,
        194,
        "研发费用率"
      ],
      [
        "T27",
        "行业",
        185,
        187,
        "减害"
      ],
      [
        "T28",
        "属性值",
        194,
        200,
        "接近 10%"
      ],
      [
        "T29",
        "地点范围",
        206,
        208,
        "日本"
      ],
      [
        "T30",
        "行业",
        209,
        213,
        "HNB "
      ],
      [
        "T31",
        "属性值",
        215,
        228,
        "由增量竞争逐渐步入存量竞争"
      ],
      [
        "T32",
        "行业",
        229,
        235,
        "PMI 减害"
      ],
      [
        "T33",
        "属性值",
        240,
        244,
        "快速增长"
      ],
      [
        "T34",
        "研发费用率",
        246,
        251,
        "研发费用率"
      ],
      [
        "T35",
        "属性值",
        252,
        256,
        "略微下降"
      ],
      [
        "T36",
        "行业",
        260,
        262,
        "减害"
      ],
      [
        "T37",
        "研发费用",
        265,
        269,
        "研发投入"
      ],
      [
        "T38",
        "属性值",
        270,
        278,
        "绝对数额逐年增多"
      ],
      [
        "T39",
        "属性值",
        287,
        294,
        "3.4 亿美元"
      ],
      [
        "T40",
        "属性值",
        303,
        310,
        "6.1 亿美元"
      ],
      [
        "T41",
        "行业",
        352,
        356,
        "新型烟草"
      ],
      [
        "T42",
        "行业",
        401,
        405,
        "新型烟草"
      ],
      [
        "T43",
        "属性值",
        384,
        386,
        "大量"
      ]
    ]
  },
  {
    "id": 3704,
    "text": "从资本开支角度来看，亚马逊近期资本开支增速提升。2020Q4 亚马逊资本支出132 亿美元，同比+235%，环比+35%，大部分支持 AWS 基础设施，公司预计之后会持续加大资本开支。结合 Amazon 资本开支与 AWS 营业收入增速来看，2020 年资本支出增长远大于 AWS 营收增速，我们认为随着公司资本开支的增加，AWS 营收增速也会提升。",
    "labels": [
      [
        "T0",
        "CAPEX资本开支",
        1,
        5,
        "资本开支"
      ],
      [
        "T1",
        "公司",
        10,
        13,
        "亚马逊"
      ],
      [
        "T2",
        "CAPEX资本开支",
        15,
        19,
        "资本开支"
      ],
      [
        "T3",
        "属性值",
        19,
        23,
        "增速提升"
      ],
      [
        "T4",
        "时间范围",
        24,
        30,
        "2020Q4"
      ],
      [
        "T5",
        "公司",
        31,
        34,
        "亚马逊"
      ],
      [
        "T6",
        "CAPEX资本开支",
        34,
        38,
        "资本支出"
      ],
      [
        "T7",
        "属性值",
        38,
        60,
        "132 亿美元，同比+235%，环比+35%"
      ],
      [
        "T8",
        "属性值",
        83,
        87,
        "持续加大"
      ],
      [
        "T9",
        "CAPEX资本开支",
        87,
        91,
        "资本开支"
      ],
      [
        "T10",
        "时间范围",
        80,
        82,
        "之后"
      ],
      [
        "T11",
        "公司",
        95,
        101,
        "Amazon"
      ],
      [
        "T12",
        "CAPEX资本开支",
        102,
        106,
        "资本开支"
      ],
      [
        "T13",
        "收入增速",
        112,
        118,
        "营业收入增速"
      ],
      [
        "T14",
        "时间范围",
        121,
        127,
        "2020 年"
      ],
      [
        "T15",
        "CAPEX资本开支",
        127,
        131,
        "资本支出"
      ],
      [
        "T16",
        "属性值",
        131,
        145,
        "增长远大于 AWS 营收增速"
      ],
      [
        "T17",
        "CAPEX资本开支",
        154,
        158,
        "资本开支"
      ],
      [
        "T18",
        "收入增速",
        166,
        170,
        "营收增速"
      ]
    ]
  },
  {
    "id": 3705,
    "text": "资本开支方面，微软 2019 年处于低位，2020 年开始上升。2020Q4 微软资本开支42 亿美元，同比+18%，环比-15%。公司预计未来几年资本支出将增加，以支持云服务的增长。结合微软资本开支与 Azure 营业收入增速，微软资本开支的变动趋势一定程度上影响了营收的增速，我们认为前期资本开支的增加将会带来 Azure 营收的稳步增长。",
    "labels": [
      [
        "T0",
        "CAPEX资本开支",
        0,
        4,
        "资本开支"
      ],
      [
        "T1",
        "公司",
        7,
        9,
        "微软"
      ],
      [
        "T2",
        "时间范围",
        10,
        16,
        "2019 年"
      ],
      [
        "T3",
        "属性值",
        16,
        20,
        "处于低位"
      ],
      [
        "T4",
        "时间范围",
        21,
        27,
        "2020 年"
      ],
      [
        "T5",
        "属性值",
        27,
        31,
        "开始上升"
      ],
      [
        "T6",
        "时间范围",
        32,
        38,
        "2020Q4"
      ],
      [
        "T7",
        "公司",
        39,
        41,
        "微软"
      ],
      [
        "T8",
        "CAPEX资本开支",
        41,
        45,
        "资本开支"
      ],
      [
        "T9",
        "属性值",
        45,
        65,
        "42 亿美元，同比+18%，环比-15%"
      ],
      [
        "T10",
        "CAPEX资本开支",
        74,
        78,
        "资本支出"
      ],
      [
        "T11",
        "时间范围",
        70,
        74,
        "未来几年"
      ],
      [
        "T12",
        "属性值",
        79,
        81,
        "增加"
      ],
      [
        "T13",
        "公司",
        94,
        96,
        "微软"
      ],
      [
        "T14",
        "CAPEX资本开支",
        96,
        100,
        "资本开支"
      ],
      [
        "T15",
        "公司",
        115,
        117,
        "微软"
      ],
      [
        "T16",
        "CAPEX资本开支",
        117,
        121,
        "资本开支"
      ],
      [
        "T17",
        "营业收入",
        134,
        136,
        "营收"
      ],
      [
        "T18",
        "收入增速",
        108,
        114,
        "营业收入增速"
      ],
      [
        "T19",
        "CAPEX资本开支",
        146,
        150,
        "资本开支"
      ],
      [
        "T20",
        "属性值",
        151,
        153,
        "增加"
      ],
      [
        "T21",
        "营业收入",
        164,
        166,
        "营收"
      ]
    ]
  },
  {
    "id": 3706,
    "text": "资本开支方面，谷歌 2018Q1 资本开支达 73 亿美元，随后开始下降，2020Q4 谷歌资本开支 55 亿美元，同比-9.47%，近期同、环比增速变动较小。结合谷歌云营收与谷歌资本开支增速来看，2020 年谷歌云营收保持较快增速，而资本开支增速出现下滑，主要是由于 COVID-19 对业务的持续影响不断演变且不可预测，2021 年预计公司将增加支出。",
    "labels": [
      [
        "T0",
        "CAPEX资本开支",
        0,
        4,
        "资本开支"
      ],
      [
        "T1",
        "公司",
        7,
        9,
        "谷歌"
      ],
      [
        "T2",
        "时间范围",
        10,
        16,
        "2018Q1"
      ],
      [
        "T3",
        "CAPEX资本开支",
        17,
        21,
        "资本开支"
      ],
      [
        "T4",
        "属性值",
        23,
        29,
        "73 亿美元"
      ],
      [
        "T5",
        "时间范围",
        37,
        44,
        "2020Q4 "
      ],
      [
        "T6",
        "公司",
        44,
        46,
        "谷歌"
      ],
      [
        "T7",
        "CAPEX资本开支",
        46,
        50,
        "资本开支"
      ],
      [
        "T8",
        "营业收入",
        85,
        87,
        "营收"
      ],
      [
        "T9",
        "公司",
        88,
        90,
        "谷歌"
      ],
      [
        "T10",
        "CAPEX资本开支",
        90,
        94,
        "资本开支"
      ],
      [
        "T11",
        "属性值",
        51,
        66,
        "55 亿美元，同比-9.47%"
      ],
      [
        "T12",
        "时间范围",
        99,
        105,
        "2020 年"
      ],
      [
        "T13",
        "营业收入",
        108,
        110,
        "营收"
      ],
      [
        "T14",
        "CAPEX资本开支",
        118,
        122,
        "资本开支"
      ],
      [
        "T15",
        "时间范围",
        162,
        168,
        "2021 年"
      ],
      [
        "T16",
        "属性值",
        173,
        177,
        "增加支出"
      ]
    ]
  },
  {
    "id": 3707,
    "text": "我们认为，脸书大幅增加元宇宙方面的资本开支，很大程度上验证了元宇宙对于下游芯片、服务器、流量侧产业链的刺激作用。随着 AR/VR，元宇宙生态的不断完善，以光模块、光纤光缆、交换机为代表的流量侧产业链有望迎来新一轮高速增长。",
    "labels": [
      [
        "T0",
        "公司",
        5,
        7,
        "脸书"
      ],
      [
        "T1",
        "行业",
        11,
        14,
        "元宇宙"
      ],
      [
        "T2",
        "属性值",
        7,
        11,
        "大幅增加"
      ],
      [
        "T3",
        "CAPEX资本开支",
        17,
        21,
        "资本开支"
      ],
      [
        "T4",
        "行业",
        30,
        33,
        "元宇宙"
      ],
      [
        "T5",
        "行业",
        37,
        39,
        "芯片"
      ],
      [
        "T6",
        "行业",
        40,
        43,
        "服务器"
      ],
      [
        "T7",
        "行业",
        44,
        50,
        "流量侧产业链"
      ],
      [
        "T8",
        "行业",
        59,
        64,
        "AR/VR"
      ],
      [
        "T9",
        "行业",
        65,
        68,
        "元宇宙"
      ],
      [
        "T10",
        "行业",
        77,
        80,
        "光模块"
      ],
      [
        "T11",
        "行业",
        81,
        85,
        "光纤光缆"
      ],
      [
        "T12",
        "行业",
        86,
        89,
        "交换机"
      ],
      [
        "T13",
        "行业",
        93,
        99,
        "流量侧产业链"
      ]
    ]
  },
  {
    "id": 3710,
    "text": "资本支出：SKI 提升资本开支激进扩产，其余电池企业增速放缓。为匹配动力电池需求高增，SKI 加大资本支出扩充产能，2020 年全年资本支出达 257.5 亿元、同增 25.7%；根据SKI 规划，2021/2022/2023 年底动力电池总产能将达到 40/85/125GWh；我们预计未来 3年公司资本支出将持续保持高位；其余 LG Chem/松下/三星 SDI 资本支出增速有所放缓、短期内扩产节奏减速，但 LG Chem 资本支出依然处于高位，2020 年全年达到 158.1 亿元。CATL 2020 年资本支出 133.0 亿元，落后于 SKI、LG Chem，但 1Q21 单季度达到 89.0 亿元，同比增长 329%，2021 年内合计在建产能 77.5GWh，预计年内产能将集中投放。",
    "labels": [
      [
        "T0",
        "CAPEX资本开支",
        0,
        4,
        "资本支出"
      ],
      [
        "T1",
        "公司",
        5,
        8,
        "SKI"
      ],
      [
        "T2",
        "属性值",
        9,
        11,
        "提升"
      ],
      [
        "T3",
        "CAPEX资本开支",
        11,
        15,
        "资本开支"
      ],
      [
        "T4",
        "属性值",
        15,
        19,
        "激进扩产"
      ],
      [
        "T5",
        "行业公司",
        22,
        26,
        "电池企业"
      ],
      [
        "T6",
        "行业",
        34,
        38,
        "动力电池"
      ],
      [
        "T7",
        "行业需求",
        38,
        40,
        "需求"
      ],
      [
        "T8",
        "属性值",
        40,
        42,
        "高增"
      ],
      [
        "T9",
        "公司",
        43,
        46,
        "SKI"
      ],
      [
        "T10",
        "CAPEX资本开支",
        49,
        53,
        "资本支出"
      ],
      [
        "T11",
        "属性值",
        47,
        49,
        "加大"
      ],
      [
        "T12",
        "属性值",
        53,
        55,
        "扩充"
      ],
      [
        "T13",
        "产能",
        55,
        57,
        "产能"
      ],
      [
        "T14",
        "时间范围",
        58,
        64,
        "2020 年"
      ],
      [
        "T15",
        "CAPEX资本开支",
        66,
        70,
        "资本支出"
      ],
      [
        "T16",
        "属性值",
        72,
        89,
        "257.5 亿元、同增 25.7%"
      ],
      [
        "T17",
        "公司",
        92,
        95,
        "SKI"
      ],
      [
        "T18",
        "时间范围",
        99,
        103,
        "2021"
      ],
      [
        "T19",
        "时间范围",
        104,
        108,
        "2022"
      ],
      [
        "T20",
        "时间范围",
        109,
        113,
        "2023"
      ],
      [
        "T21",
        "行业",
        116,
        120,
        "动力电池"
      ],
      [
        "T22",
        "产能",
        121,
        123,
        "产能"
      ],
      [
        "T23",
        "属性值",
        127,
        129,
        "40"
      ],
      [
        "T24",
        "属性值",
        130,
        132,
        "85"
      ],
      [
        "T25",
        "属性值",
        133,
        139,
        "125GWh"
      ],
      [
        "T26",
        "时间范围",
        144,
        149,
        "未来 3年"
      ],
      [
        "T27",
        "CAPEX资本开支",
        151,
        155,
        "资本支出"
      ],
      [
        "T28",
        "属性值",
        156,
        162,
        "持续保持高位"
      ],
      [
        "T29",
        "公司",
        166,
        173,
        "LG Chem"
      ],
      [
        "T30",
        "公司",
        174,
        176,
        "松下"
      ],
      [
        "T31",
        "公司",
        177,
        183,
        "三星 SDI"
      ],
      [
        "T32",
        "CAPEX资本开支",
        184,
        188,
        "资本支出"
      ],
      [
        "T33",
        "属性值",
        188,
        194,
        "增速有所放缓"
      ],
      [
        "T34",
        "时间范围",
        195,
        198,
        "短期内"
      ],
      [
        "T35",
        "属性值",
        198,
        204,
        "扩产节奏减速"
      ],
      [
        "T36",
        "公司",
        207,
        214,
        "LG Chem"
      ],
      [
        "T37",
        "CAPEX资本开支",
        215,
        219,
        "资本支出"
      ],
      [
        "T38",
        "属性值",
        223,
        225,
        "高位"
      ],
      [
        "T39",
        "时间范围",
        226,
        232,
        "2020 年"
      ],
      [
        "T40",
        "属性值",
        237,
        245,
        "158.1 亿元"
      ],
      [
        "T41",
        "公司",
        246,
        250,
        "CATL"
      ],
      [
        "T42",
        "时间范围",
        251,
        257,
        "2020 年"
      ],
      [
        "T43",
        "CAPEX资本开支",
        257,
        261,
        "资本支出"
      ],
      [
        "T44",
        "属性值",
        262,
        270,
        "133.0 亿元"
      ],
      [
        "T45",
        "公司",
        275,
        278,
        "SKI"
      ],
      [
        "T46",
        "公司",
        279,
        286,
        "LG Chem"
      ],
      [
        "T47",
        "时间范围",
        289,
        293,
        "1Q21"
      ],
      [
        "T48",
        "属性值",
        300,
        317,
        "89.0 亿元，同比增长 329%"
      ],
      [
        "T49",
        "时间范围",
        318,
        324,
        "2021 年"
      ],
      [
        "T50",
        "属性值",
        347,
        351,
        "集中投放"
      ],
      [
        "T51",
        "产能",
        344,
        346,
        "产能"
      ],
      [
        "T52",
        "属性值",
        327,
        339,
        "在建产能 77.5GWh"
      ]
    ]
  },
  {
    "id": 3712,
    "text": "海外云巨头 Q2 Capex 同比显著增长，云业务收入可观有望推动资本性支出持续增长。全球云巨头 capex 从 2019Q1 以来连续 9 个季度一直保持增长的态势，需求持续向好。截至 21Q2 海外四大云巨头厂商 Amazon、Facebook、Microsoft 和 Google 资本开支合计超 300 亿美元，同比涨幅近 50%，环比涨幅超 10%；其中 Amazon 资本开支占比超 45%达 143 亿美元，同比涨幅超 90%。Facebook 披露 2021 年资本开支预期为190-210 亿美元，相对 2020 年的 160 亿美元大幅提升，并表明今年的主要投入方向为数据中心、服务器、基础网络设施以及办公设施。Amazon、Microsoft 以及 Google 也在财报中披露将进一步加大基础设施投资以支撑云业务的增长。从目前市场一致预期来看，今年北美头部云厂商的资本开支有望同比增长 20%以上。从云业务收入情况来看，AWS Q2 实现营收近 150 亿美元，增速近 40%，超市场预期；Google cloud 营收涨幅也超 50%，上半年各厂商云业务收入的高增速有望驱动下半年资本支出的持续增长。",
    "labels": [
      [
        "T0",
        "地点范围",
        0,
        2,
        "海外"
      ],
      [
        "T1",
        "CAPEX资本开支",
        9,
        14,
        "Capex"
      ],
      [
        "T2",
        "时间范围",
        6,
        8,
        "Q2"
      ],
      [
        "T3",
        "行业公司",
        2,
        5,
        "云巨头"
      ],
      [
        "T4",
        "属性值",
        15,
        21,
        "同比显著增长"
      ],
      [
        "T5",
        "营业收入",
        25,
        27,
        "收入"
      ],
      [
        "T6",
        "属性值",
        27,
        29,
        "可观"
      ],
      [
        "T7",
        "行业",
        22,
        23,
        "云"
      ],
      [
        "T8",
        "CAPEX资本开支",
        33,
        38,
        "资本性支出"
      ],
      [
        "T9",
        "属性值",
        38,
        42,
        "持续增长"
      ],
      [
        "T10",
        "地点范围",
        43,
        45,
        "全球"
      ],
      [
        "T11",
        "行业公司",
        45,
        48,
        "云巨头"
      ],
      [
        "T12",
        "CAPEX资本开支",
        49,
        54,
        "capex"
      ],
      [
        "T13",
        "时间范围",
        55,
        66,
        "从 2019Q1 以来"
      ],
      [
        "T14",
        "属性值",
        78,
        80,
        "增长"
      ],
      [
        "T15",
        "行业需求",
        84,
        86,
        "需求"
      ],
      [
        "T16",
        "属性值",
        86,
        90,
        "持续向好"
      ],
      [
        "T17",
        "时间范围",
        91,
        98,
        "截至 21Q2"
      ],
      [
        "T18",
        "地点范围",
        99,
        101,
        "海外"
      ],
      [
        "T19",
        "公司",
        109,
        115,
        "Amazon"
      ],
      [
        "T20",
        "公司",
        116,
        124,
        "Facebook"
      ],
      [
        "T21",
        "公司",
        125,
        135,
        "Microsoft "
      ],
      [
        "T22",
        "公司",
        137,
        143,
        "Google"
      ],
      [
        "T23",
        "行业公司",
        101,
        108,
        "四大云巨头厂商"
      ],
      [
        "T24",
        "CAPEX资本开支",
        144,
        148,
        "资本开支"
      ],
      [
        "T25",
        "属性值",
        150,
        179,
        "超 300 亿美元，同比涨幅近 50%，环比涨幅超 10%"
      ],
      [
        "T26",
        "公司",
        183,
        189,
        "Amazon"
      ],
      [
        "T27",
        "CAPEX资本开支",
        190,
        194,
        "资本开支"
      ],
      [
        "T28",
        "属性值",
        194,
        220,
        "占比超 45%达 143 亿美元，同比涨幅超 90%"
      ],
      [
        "T29",
        "公司",
        221,
        229,
        "Facebook"
      ],
      [
        "T30",
        "时间范围",
        233,
        239,
        "2021 年"
      ],
      [
        "T31",
        "CAPEX资本开支",
        239,
        243,
        "资本开支"
      ],
      [
        "T32",
        "属性值",
        246,
        257,
        "190-210 亿美元"
      ],
      [
        "T33",
        "时间范围",
        261,
        267,
        "2020 年"
      ],
      [
        "T34",
        "属性值",
        269,
        276,
        "160 亿美元"
      ],
      [
        "T35",
        "公司",
        316,
        322,
        "Amazon"
      ],
      [
        "T36",
        "公司",
        323,
        332,
        "Microsoft"
      ],
      [
        "T37",
        "公司",
        336,
        342,
        "Google"
      ],
      [
        "T38",
        "属性值",
        354,
        362,
        "加大基础设施投资"
      ],
      [
        "T39",
        "时间范围",
        373,
        375,
        "目前"
      ],
      [
        "T40",
        "时间范围",
        384,
        386,
        "今年"
      ],
      [
        "T41",
        "地点范围",
        386,
        388,
        "北美"
      ],
      [
        "T42",
        "行业公司",
        388,
        393,
        "头部云厂商"
      ],
      [
        "T43",
        "CAPEX资本开支",
        394,
        398,
        "资本开支"
      ],
      [
        "T44",
        "属性值",
        400,
        410,
        "同比增长 20%以上"
      ],
      [
        "T45",
        "行业",
        412,
        413,
        "云"
      ],
      [
        "T46",
        "营业收入",
        415,
        417,
        "收入"
      ]
    ]
  },
  {
    "id": 3715,
    "text": "本周台积电举办了 2021Q1 法说会，此次台积电营收、利润率均贴近前次指引上线，其台积电上修 2021 年全年 Capex 至 300 亿美元用于应对 5G、HPC 等行业需求的高涨之势。",
    "labels": [
      [
        "T0",
        "时间范围",
        0,
        2,
        "本周"
      ],
      [
        "T1",
        "公司",
        2,
        5,
        "台积电"
      ],
      [
        "T2",
        "时间范围",
        8,
        16,
        " 2021Q1 "
      ],
      [
        "T3",
        "公司",
        22,
        25,
        "台积电"
      ],
      [
        "T4",
        "营业收入",
        25,
        27,
        "营收"
      ],
      [
        "T5",
        "公司",
        42,
        45,
        "台积电"
      ],
      [
        "T6",
        "时间范围",
        48,
        56,
        "2021 年全年"
      ],
      [
        "T7",
        "CAPEX资本开支",
        57,
        63,
        "Capex "
      ],
      [
        "T8",
        "属性值",
        65,
        72,
        "300 亿美元"
      ],
      [
        "T9",
        "利润",
        28,
        31,
        "利润率"
      ],
      [
        "T10",
        "行业",
        77,
        79,
        "5G"
      ],
      [
        "T11",
        "行业",
        80,
        83,
        "HPC"
      ],
      [
        "T12",
        "行业需求",
        87,
        89,
        "需求"
      ],
      [
        "T13",
        "属性值",
        90,
        92,
        "高涨"
      ]
    ]
  },
  {
    "id": 3718,
    "text": "联电：联电 2021Q1 产能利用率达 100%。联电 21Q1 营收 471 亿元新台币，yoy 增长11.4%，qoq 增长 4%。21Q1 归母净利 104 亿元新台币，同比增长 372.5%。毛利率同比提升近 7.3%至 26.5%。联电业绩高增长主要受益于消费者和计算相关应用。公司预计二季度同比美元计 ASP 将再提升 3-4%，出货量提升 2%。因此联电也持续提升 2021全年资本开支至 23 亿美元。市场的强劲需求以及与客户的紧密合作使得公司计划将原本全年 15 亿美元资本开支提升至 23 亿美元，此前 15 亿美元 capex 主要用于 12A 厂 P5的设备投入，未来三年公司计划投资 1500 亿新台币（约合 54.1 亿美元）用于台湾省 12A厂 P5、P6 的扩产，P6 预计 2023 年二季度开始生产。",
    "labels": [
      [
        "T0",
        "公司",
        0,
        2,
        "联电"
      ],
      [
        "T1",
        "公司",
        3,
        5,
        "联电"
      ],
      [
        "T2",
        "时间范围",
        6,
        12,
        "2021Q1"
      ],
      [
        "T3",
        "公司",
        25,
        27,
        "联电"
      ],
      [
        "T4",
        "时间范围",
        28,
        32,
        "21Q1"
      ],
      [
        "T5",
        "营业收入",
        33,
        35,
        "营收"
      ],
      [
        "T6",
        "属性值",
        36,
        45,
        "471 亿元新台币"
      ],
      [
        "T7",
        "时间范围",
        68,
        72,
        "21Q1"
      ],
      [
        "T8",
        "归母净利润",
        73,
        77,
        "归母净利"
      ],
      [
        "T9",
        "属性值",
        78,
        99,
        "104 亿元新台币，同比增长 372.5%"
      ],
      [
        "T10",
        "毛利",
        100,
        103,
        "毛利率"
      ],
      [
        "T11",
        "属性值",
        115,
        120,
        "26.5%"
      ],
      [
        "T12",
        "公司",
        121,
        123,
        "联电"
      ],
      [
        "T13",
        "业绩",
        123,
        125,
        "业绩"
      ],
      [
        "T14",
        "属性值",
        125,
        128,
        "高增长"
      ],
      [
        "T15",
        "时间范围",
        148,
        151,
        "二季度"
      ],
      [
        "T16",
        "公司",
        182,
        184,
        "联电"
      ],
      [
        "T17",
        "属性值",
        185,
        189,
        "持续提升"
      ],
      [
        "T18",
        "时间范围",
        190,
        196,
        "2021全年"
      ],
      [
        "T19",
        "CAPEX资本开支",
        196,
        200,
        "资本开支"
      ],
      [
        "T20",
        "属性值",
        202,
        208,
        "23 亿美元"
      ],
      [
        "T21",
        "CAPEX资本开支",
        244,
        248,
        "资本开支"
      ],
      [
        "T22",
        "时间范围",
        294,
        298,
        "未来三年"
      ],
      [
        "T23",
        "CAPEX资本开支",
        269,
        274,
        "capex"
      ],
      [
        "T24",
        "时间范围",
        354,
        363,
        "2023 年二季度"
      ]
    ]
  },
  {
    "id": 3722,
    "text": "凯莱英（002821）：资本开支持续提升，产能释放助力公司稳健增长。为匹配快速增长的市场需求，公司自 2016年上市以来逐步增加资本开支力度，2016-2019 年平均每年资本开支高达 3.98 亿元，资本开支在同类企业中名列前茅。公司的资本开支大多用于厂房扩建与改造，固定资产+在建工程规模亦保持快速增长，2016-2019 年 CAGR 为 32.5%，显示出公司产能急速扩张。2020H1公司固定资产+在建工程同比增加 27.9%，预示着公司后续订单的饱和，产能有望快速释放。",
    "labels": [
      [
        "T0",
        "公司",
        0,
        3,
        "凯莱英"
      ],
      [
        "T1",
        "CAPEX资本开支",
        12,
        16,
        "资本开支"
      ],
      [
        "T2",
        "属性值",
        16,
        20,
        "持续提升"
      ],
      [
        "T3",
        "产能",
        21,
        23,
        "产能"
      ],
      [
        "T4",
        "属性值",
        23,
        25,
        "释放"
      ],
      [
        "T5",
        "时间范围",
        49,
        60,
        "自 2016年上市以来"
      ],
      [
        "T6",
        "属性值",
        60,
        64,
        "逐步增加"
      ],
      [
        "T7",
        "CAPEX资本开支",
        64,
        68,
        "资本开支"
      ],
      [
        "T8",
        "时间范围",
        71,
        82,
        "2016-2019 年"
      ],
      [
        "T9",
        "CAPEX资本开支",
        86,
        90,
        "资本开支"
      ],
      [
        "T10",
        "属性值",
        93,
        100,
        "3.98 亿元"
      ],
      [
        "T11",
        "CAPEX资本开支",
        101,
        105,
        "资本开支"
      ],
      [
        "T12",
        "CAPEX资本开支",
        119,
        123,
        "资本开支"
      ],
      [
        "T13",
        "固定资产",
        135,
        139,
        "固定资产"
      ],
      [
        "T14",
        "属性值",
        149,
        153,
        "快速增长"
      ],
      [
        "T15",
        "时间范围",
        154,
        165,
        "2016-2019 年"
      ],
      [
        "T16",
        "CAGR",
        166,
        170,
        "CAGR"
      ],
      [
        "T17",
        "属性值",
        173,
        178,
        "32.5%"
      ],
      [
        "T18",
        "产能",
        184,
        186,
        "产能"
      ],
      [
        "T19",
        "属性值",
        186,
        190,
        "急速扩张"
      ],
      [
        "T20",
        "时间范围",
        191,
        197,
        "2020H1"
      ],
      [
        "T21",
        "固定资产",
        199,
        203,
        "固定资产"
      ],
      [
        "T22",
        "属性值",
        208,
        218,
        "同比增加 27.9%"
      ],
      [
        "T23",
        "在手订单",
        226,
        228,
        "订单"
      ],
      [
        "T24",
        "属性值",
        229,
        231,
        "饱和"
      ],
      [
        "T25",
        "产能",
        232,
        234,
        "产能"
      ],
      [
        "T26",
        "属性值",
        236,
        240,
        "快速释放"
      ],
      [
        "T27",
        "属性值",
        140,
        146,
        "在建工程规模"
      ],
      [
        "T28",
        "属性连接词",
        139,
        140,
        "+"
      ]
    ]
  },
  {
    "id": 3724,
    "text": "好的商业模式 ROIC 非常高，在 A 股也相对稀缺，基本都是各个行业龙头企业，商业模式卓越，竞争力壁垒高筑。我们统计全部 A 股，2018-2020 年连续 3 年ROIC 超过 20%的上市公司仅有 84 家，贵州茅台三年平均 ROIC 是 31%，海康威视平均 ROIC 25%，恒瑞医药 ROIC 22%，中国中免 ROIC 是 27%。",
    "labels": [
      [
        "T0",
        "ROIC资本回报率",
        7,
        11,
        "ROIC"
      ],
      [
        "T1",
        "龙头企业",
        35,
        39,
        "龙头企业"
      ],
      [
        "T2",
        "时间范围",
        66,
        77,
        "2018-2020 年"
      ],
      [
        "T3",
        "ROIC资本回报率",
        83,
        87,
        "ROIC"
      ],
      [
        "T4",
        "公司",
        107,
        111,
        "贵州茅台"
      ],
      [
        "T5",
        "时间范围",
        111,
        113,
        "三年"
      ],
      [
        "T6",
        "属性值",
        123,
        126,
        "31%"
      ],
      [
        "T7",
        "公司",
        127,
        131,
        "海康威视"
      ],
      [
        "T8",
        "ROIC资本回报率",
        134,
        138,
        "ROIC"
      ],
      [
        "T9",
        "ROIC资本回报率",
        148,
        152,
        "ROIC"
      ],
      [
        "T10",
        "ROIC资本回报率",
        162,
        166,
        "ROIC"
      ],
      [
        "T11",
        "属性值",
        168,
        172,
        " 27%"
      ],
      [
        "T12",
        "属性值",
        153,
        156,
        "22%"
      ],
      [
        "T13",
        "属性值",
        139,
        142,
        "25%"
      ],
      [
        "T14",
        "公司",
        143,
        147,
        "恒瑞医药"
      ],
      [
        "T15",
        "公司",
        157,
        161,
        "中国中免"
      ],
      [
        "T16",
        "ROIC资本回报率",
        116,
        120,
        "ROIC"
      ]
    ]
  },
  {
    "id": 3725,
    "text": "光环新网ROE和ROIC匹配，处于行业较高水平。2020前三季度，公司ROE为7.56%，ROIC为6.54%，远高于海外龙头Equinix（ROE为3.02%，ROIC为1.47%）和Digital Realty（ROE为1.69%，ROIC为1.05%），公司IDC资产均处于北京、上海及其周边核心地区，资产质量较高，单机柜收益率高于同行业，资产收益率较高。",
    "labels": [
      [
        "T0",
        "公司",
        0,
        4,
        "光环新网"
      ],
      [
        "T1",
        "ROE净资产回报率",
        4,
        7,
        "ROE"
      ],
      [
        "T2",
        "ROIC资本回报率",
        8,
        12,
        "ROIC"
      ],
      [
        "T3",
        "属性值",
        15,
        23,
        "处于行业较高水平"
      ],
      [
        "T4",
        "时间范围",
        24,
        32,
        "2020前三季度"
      ],
      [
        "T5",
        "ROE净资产回报率",
        35,
        38,
        "ROE"
      ],
      [
        "T6",
        "属性值",
        39,
        44,
        "7.56%"
      ],
      [
        "T7",
        "ROIC资本回报率",
        45,
        49,
        "ROIC"
      ],
      [
        "T8",
        "属性值",
        50,
        55,
        "6.54%"
      ],
      [
        "T9",
        "地点范围",
        59,
        61,
        "海外"
      ],
      [
        "T10",
        "龙头企业",
        61,
        63,
        "龙头"
      ],
      [
        "T11",
        "公司",
        63,
        70,
        "Equinix"
      ],
      [
        "T12",
        "ROE净资产回报率",
        71,
        74,
        "ROE"
      ],
      [
        "T13",
        "属性值",
        75,
        80,
        "3.02%"
      ],
      [
        "T14",
        "ROIC资本回报率",
        81,
        85,
        "ROIC"
      ],
      [
        "T15",
        "属性值",
        86,
        91,
        "1.47%"
      ],
      [
        "T16",
        "公司",
        93,
        107,
        "Digital Realty"
      ],
      [
        "T17",
        "ROE净资产回报率",
        108,
        111,
        "ROE"
      ],
      [
        "T18",
        "属性值",
        112,
        117,
        "1.69%"
      ],
      [
        "T19",
        "ROIC资本回报率",
        118,
        122,
        "ROIC"
      ],
      [
        "T20",
        "属性值",
        123,
        128,
        "1.05%"
      ],
      [
        "T21",
        "地点范围",
        140,
        142,
        "北京"
      ],
      [
        "T22",
        "地点范围",
        143,
        145,
        "上海"
      ],
      [
        "T23",
        "ROE净资产回报率",
        173,
        178,
        "资产收益率"
      ],
      [
        "T24",
        "属性值",
        178,
        180,
        "较高"
      ]
    ]
  },
  {
    "id": 3726,
    "text": "瑞安航空ROE与ROIC都处于行业领先水平，2020财年（2019.04-2020.03）ROIC虽然有所下滑但仍然达到10.27%。",
    "labels": [
      [
        "T0",
        "公司",
        0,
        4,
        "瑞安航空"
      ],
      [
        "T1",
        "ROE净资产回报率",
        4,
        7,
        "ROE"
      ],
      [
        "T2",
        "ROIC资本回报率",
        8,
        12,
        "ROIC"
      ],
      [
        "T3",
        "属性值",
        13,
        21,
        "处于行业领先水平"
      ],
      [
        "T4",
        "时间范围",
        22,
        45,
        "2020财年（2019.04-2020.03）"
      ],
      [
        "T5",
        "ROIC资本回报率",
        45,
        49,
        "ROIC"
      ],
      [
        "T6",
        "属性值",
        51,
        55,
        "有所下滑"
      ],
      [
        "T7",
        "属性值",
        60,
        66,
        "10.27%"
      ]
    ]
  },
  {
    "id": 3727,
    "text": "与此同时，Rational 普通股本回报率及投资资本回报维持较高水平。2010-2019 年，Rational 普通股本回报率维持在 33.5%-42.0%；投资资本回报维持在 32.0%-39.0%，投资资本回报相对较高。Rational 累计自由现金流量逐年增加。自 2005 年以来，Rational自由现金流量保持相对稳定，2005-2020 年累计自由现金流量达 13.28 亿欧元。",
    "labels": [
      [
        "T0",
        "公司",
        5,
        14,
        "Rational "
      ],
      [
        "T1",
        "ROIC资本回报率",
        22,
        28,
        "投资资本回报"
      ],
      [
        "T2",
        "时间范围",
        35,
        46,
        "2010-2019 年"
      ],
      [
        "T3",
        "公司",
        47,
        56,
        "Rational "
      ],
      [
        "T4",
        "ROIC资本回报率",
        79,
        85,
        "投资资本回报"
      ],
      [
        "T5",
        "ROIC资本回报率",
        101,
        107,
        "投资资本回报"
      ],
      [
        "T6",
        "公司",
        112,
        121,
        "Rational "
      ],
      [
        "T7",
        "时间范围",
        134,
        144,
        "自 2005 年以来"
      ],
      [
        "T8",
        "公司",
        145,
        153,
        "Rational"
      ],
      [
        "T9",
        "现金流",
        153,
        159,
        "自由现金流量"
      ],
      [
        "T10",
        "时间范围",
        166,
        177,
        "2005-2020 年"
      ],
      [
        "T11",
        "属性值",
        30,
        34,
        "较高水平"
      ],
      [
        "T12",
        "属性值",
        89,
        100,
        "32.0%-39.0%"
      ],
      [
        "T13",
        "属性值",
        107,
        111,
        "相对较高"
      ],
      [
        "T14",
        "现金流",
        125,
        129,
        "现金流量"
      ],
      [
        "T15",
        "属性值",
        129,
        133,
        "逐年增加"
      ],
      [
        "T16",
        "属性值",
        161,
        165,
        "相对稳定"
      ],
      [
        "T17",
        "属性值",
        187,
        196,
        "13.28 亿欧元"
      ],
      [
        "T18",
        "现金流",
        181,
        185,
        "现金流量"
      ]
    ]
  },
  {
    "id": 3729,
    "text": "春秋长期资本回报优异，2016-19年平均ROE接近 13%",
    "labels": [
      [
        "T0",
        "公司",
        0,
        2,
        "春秋"
      ],
      [
        "T1",
        "ROIC资本回报率",
        4,
        8,
        "资本回报"
      ],
      [
        "T2",
        "属性值",
        8,
        10,
        "优异"
      ],
      [
        "T3",
        "时间范围",
        2,
        4,
        "长期"
      ],
      [
        "T4",
        "时间范围",
        11,
        19,
        "2016-19年"
      ],
      [
        "T5",
        "ROE净资产回报率",
        21,
        24,
        "ROE"
      ],
      [
        "T6",
        "属性值",
        24,
        30,
        "接近 13%"
      ]
    ]
  }
]